<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title>Humira, INN-adalimumab;</title>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
<meta name="generator" content="pdftohtml 0.36"/>
<meta name="author" content="CHMP"/>
<meta name="keywords" content="Humira, INN-adalimumab"/>
<meta name="date" content="2022-10-06T11:14:45+00:00"/>
<meta name="subject" content="EPAR"/>
<style type="text/css">
<!--
.xflip {
    -moz-transform: scaleX(-1);
    -webkit-transform: scaleX(-1);
    -o-transform: scaleX(-1);
    transform: scaleX(-1);
    filter: fliph;
}
.yflip {
    -moz-transform: scaleY(-1);
    -webkit-transform: scaleY(-1);
    -o-transform: scaleY(-1);
    transform: scaleY(-1);
    filter: flipv;
}
.xyflip {
    -moz-transform: scaleX(-1) scaleY(-1);
    -webkit-transform: scaleX(-1) scaleY(-1);
    -o-transform: scaleX(-1) scaleY(-1);
    transform: scaleX(-1) scaleY(-1);
    filter: fliph + flipv;
}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<!-- Page 1 -->
<a name="1"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft10{font-size:12px;font-family:HORGHZ+Arial;color:#000000;}
	.ft11{font-size:17px;font-family:HORGHZ+TimesNewRoman,Bold;color:#000000;}
-->
</style>
<div id="page1-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:452px;white-space:nowrap" class="ft10">1</p>
<p style="position:absolute;top:522px;left:424px;white-space:nowrap" class="ft11"><b>ANNEX I</b></p>
<p style="position:absolute;top:560px;left:276px;white-space:nowrap" class="ft11"><b>SUMMARY OF PRODUCT CHARACTERISTICS</b></p>
</div>
<!-- Page 2 -->
<a name="2"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft22{font-size:17px;font-family:HORGHZ+TimesNewRoman;color:#000000;}
	.ft23{font-size:17px;font-family:HORGHZ+TimesNewRoman,Italic;color:#000000;}
	.ft24{font-size:17px;line-height:19px;font-family:HORGHZ+TimesNewRoman;color:#000000;}
	.ft25{font-size:17px;line-height:18px;font-family:HORGHZ+TimesNewRoman;color:#000000;}
-->
</style>
<div id="page2-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:452px;white-space:nowrap" class="ft20">2</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft21"><b>1.</b></p>
<p style="position:absolute;top:86px;left:148px;white-space:nowrap" class="ft21"><b>NAME OF THE MEDICINAL PRODUCT&#160;</b></p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft22">Humira&#160;20&#160;mg solution for injection in pre-filled syringe</p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft21"><b>2.</b></p>
<p style="position:absolute;top:181px;left:148px;white-space:nowrap" class="ft21"><b>QUALITATIVE AND QUANTITATIVE COMPOSITION&#160;</b></p>
<p style="position:absolute;top:219px;left:106px;white-space:nowrap" class="ft22">Each&#160;0.2&#160;ml single dose pre-filled syringe contains&#160;20&#160;mg&#160;of adalimumab.&#160;</p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft22">Adalimumab is a recombinant human monoclonal antibody&#160;produced&#160;in Chinese Hamster Ovary cells.</p>
<p style="position:absolute;top:295px;left:106px;white-space:nowrap" class="ft22">For&#160;the&#160;full list of excipients, see section 6.1.&#160;</p>
<p style="position:absolute;top:352px;left:106px;white-space:nowrap" class="ft21"><b>3.</b></p>
<p style="position:absolute;top:352px;left:148px;white-space:nowrap" class="ft21"><b>PHARMACEUTICAL&#160;FORM&#160;</b></p>
<p style="position:absolute;top:390px;left:106px;white-space:nowrap" class="ft22">Solution for injection.&#160;(injection)</p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft22">Clear, colourless solution.&#160;</p>
<p style="position:absolute;top:485px;left:106px;white-space:nowrap" class="ft21"><b>4.</b></p>
<p style="position:absolute;top:485px;left:148px;white-space:nowrap" class="ft21"><b>CLINICAL PARTICULARS</b></p>
<p style="position:absolute;top:522px;left:106px;white-space:nowrap" class="ft21"><b>4.1</b></p>
<p style="position:absolute;top:522px;left:148px;white-space:nowrap" class="ft21"><b>Therapeutic indications&#160;</b></p>
<p style="position:absolute;top:560px;left:106px;white-space:nowrap" class="ft22">Juvenile idiopathic arthritis</p>
<p style="position:absolute;top:598px;left:106px;white-space:nowrap" class="ft23"><i>Polyarticular juvenile idiopathic arthritis</i></p>
<p style="position:absolute;top:636px;left:106px;white-space:nowrap" class="ft24">Humira in combination with methotrexate is indicated for the treatment&#160;of active polyarticular juvenile&#160;<br/>idiopathic arthritis, in patients from the age of 2&#160;years who have had an inadequate response to one or&#160;<br/>more&#160;disease-modifying anti-rheumatic drugs (DMARDs). Humira can be given as monotherapy in case&#160;<br/>of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the&#160;<br/>efficacy in monotherapy see section 5.1). Humira has not been studied in patients aged less than 2&#160;years.</p>
<p style="position:absolute;top:750px;left:106px;white-space:nowrap" class="ft23"><i>Enthesitis-related arthritis</i></p>
<p style="position:absolute;top:788px;left:106px;white-space:nowrap" class="ft25">Humira is indicated for the treatment&#160;of active enthesitis-related arthritis in patients, 6&#160;years of age and&#160;<br/>older, who have&#160;had an inadequate response to, or who are intolerant of, conventional therapy (see section&#160;<br/>5.1).</p>
<p style="position:absolute;top:864px;left:106px;white-space:nowrap" class="ft22">Paediatric plaque psoriasis</p>
<p style="position:absolute;top:902px;left:106px;white-space:nowrap" class="ft25">Humira is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from&#160;<br/>4&#160;years of age who have had an inadequate response to or are inappropriate candidates for topical therapy&#160;<br/>and phototherapies.</p>
<p style="position:absolute;top:978px;left:106px;white-space:nowrap" class="ft22">Paediatric Crohn's disease&#160;</p>
<p style="position:absolute;top:1016px;left:106px;white-space:nowrap" class="ft25">Humira is indicated for the treatment of&#160;moderately to&#160;severely&#160;active Crohn's disease in paediatric&#160;<br/>patients (from 6&#160;years of age) who have had an inadequate response to conventional therapy including&#160;<br/>primary nutrition therapy&#160;and a corticosteroid&#160;and/or&#160;an immunomodulator, or who are intolerant to or&#160;<br/>have contraindications for such therapies.</p>
</div>
<!-- Page 3 -->
<a name="3"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page3-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:452px;white-space:nowrap" class="ft30">3</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft32">Paediatric Uveitis</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft35">Humira is indicated for the treatment of&#160;paediatric&#160;chronic non-infectious&#160;anterior uveitis in patients from&#160;<br/>2&#160;years of age who have had an inadequate response to or are intolerant to conventional therapy, or in&#160;<br/>whom conventional therapy is inappropriate.</p>
<p style="position:absolute;top:219px;left:106px;white-space:nowrap" class="ft31"><b>4.2</b></p>
<p style="position:absolute;top:219px;left:148px;white-space:nowrap" class="ft31"><b>Posology and method of administration &#160;</b></p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft35">Humira treatment should be initiated and supervised by specialist physicians experienced in the diagnosis&#160;<br/>and treatment of conditions for which Humira is indicated.&#160;Ophthalmologists are advised to consult with&#160;<br/>an appropriate specialist before initiation of&#160;treatment with Humira (see section 4.4).&#160;Patients treated with&#160;<br/>Humira should be given the&#160;Patient Reminder Card.</p>
<p style="position:absolute;top:352px;left:106px;white-space:nowrap" class="ft35">After proper training in injection technique, patients may self-inject with Humira if their physician&#160;<br/>determines that it is appropriate and with medical follow-up as necessary.&#160;</p>
<p style="position:absolute;top:409px;left:106px;white-space:nowrap" class="ft35">During treatment with Humira, other concomitant therapies (e.g., corticosteroids and/or&#160;<br/>immunomodulatory agents) should be optimised.</p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft32">Posology</p>
<p style="position:absolute;top:503px;left:106px;white-space:nowrap" class="ft32">Paediatric population</p>
<p style="position:absolute;top:541px;left:106px;white-space:nowrap" class="ft33"><i>Juvenile idiopathic arthritis</i></p>
<p style="position:absolute;top:579px;left:106px;white-space:nowrap" class="ft33"><i>Polyarticular&#160;juvenile idiopathic arthritis from 2 years of age</i></p>
<p style="position:absolute;top:617px;left:106px;white-space:nowrap" class="ft34">The recommended dose of Humira for patients with polyarticular juvenile idiopathic arthritis&#160;from 2&#160;years&#160;<br/>of age is based on body weight (Table 1). Humira is&#160;administered every other week via subcutaneous&#160;<br/>injection.</p>
<p style="position:absolute;top:693px;left:169px;white-space:nowrap" class="ft31"><b>Table 1. Humira&#160;Dose for Patients with Polyarticular Juvenile Idiopathic Arthritis&#160;</b></p>
<p style="position:absolute;top:734px;left:279px;white-space:nowrap" class="ft31"><b>Patient Weight</b></p>
<p style="position:absolute;top:734px;left:529px;white-space:nowrap" class="ft31"><b>Dosing Regimen</b></p>
<p style="position:absolute;top:759px;left:278px;white-space:nowrap" class="ft32">10 kg to &lt; 30 kg</p>
<p style="position:absolute;top:759px;left:507px;white-space:nowrap" class="ft32">20 mg every other week</p>
<p style="position:absolute;top:784px;left:307px;white-space:nowrap" class="ft32">≥ 30 kg</p>
<p style="position:absolute;top:784px;left:507px;white-space:nowrap" class="ft32">40 mg every other week</p>
<p style="position:absolute;top:825px;left:106px;white-space:nowrap" class="ft35">Available data suggest that clinical response is&#160;usually achieved&#160;within 12&#160;weeks of treatment.&#160;Continued&#160;<br/>therapy should be carefully reconsidered in a patient not responding within this time period.</p>
<p style="position:absolute;top:882px;left:106px;white-space:nowrap" class="ft32">There is no relevant use of Humira in patients aged&#160;less than&#160;2&#160;years for this indication.</p>
<p style="position:absolute;top:920px;left:106px;white-space:nowrap" class="ft34">Humira may be available in other strengths and/or presentations depending on the individual treatment&#160;<br/>needs.</p>
<p style="position:absolute;top:977px;left:106px;white-space:nowrap" class="ft33"><i>Enthesitis-related arthritis</i></p>
<p style="position:absolute;top:1015px;left:106px;white-space:nowrap" class="ft35">The recommended dose of Humira for patients with enthesitis-related arthritis&#160;from&#160;6&#160;years of age&#160;is based&#160;<br/>on body weight (Table 2).&#160;Humira is&#160;administered every other week via subcutaneous injection.</p>
</div>
<!-- Page 4 -->
<a name="4"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page4-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:452px;white-space:nowrap" class="ft40">4</p>
<p style="position:absolute;top:86px;left:221px;white-space:nowrap" class="ft41"><b>Table&#160;2. Humira Dose for Patients with Enthesitis-Related Arthritis&#160;</b></p>
<p style="position:absolute;top:127px;left:279px;white-space:nowrap" class="ft41"><b>Patient Weight</b></p>
<p style="position:absolute;top:127px;left:529px;white-space:nowrap" class="ft41"><b>Dosing Regimen</b></p>
<p style="position:absolute;top:152px;left:278px;white-space:nowrap" class="ft42">15&#160;kg to &lt; 30 kg</p>
<p style="position:absolute;top:152px;left:507px;white-space:nowrap" class="ft42">20 mg every other week</p>
<p style="position:absolute;top:176px;left:307px;white-space:nowrap" class="ft42">≥ 30 kg</p>
<p style="position:absolute;top:176px;left:507px;white-space:nowrap" class="ft42">40 mg every other week</p>
<p style="position:absolute;top:218px;left:106px;white-space:nowrap" class="ft42">Humira has not been studied in patients with enthesitis-related arthritis aged less than 6&#160;years.</p>
<p style="position:absolute;top:256px;left:106px;white-space:nowrap" class="ft45">Humira may be available in other strengths and/or presentations depending on the individual treatment&#160;<br/>needs.</p>
<p style="position:absolute;top:313px;left:106px;white-space:nowrap" class="ft43"><i>Paediatric plaque&#160;psoriasis</i></p>
<p style="position:absolute;top:351px;left:106px;white-space:nowrap" class="ft44">The recommended Humira dose&#160;for patients with plaque psoriasis from 4 to 17&#160;years of age is based on&#160;<br/>body weight (Table 3). Humira is&#160;administered&#160;via subcutaneous injection.</p>
<p style="position:absolute;top:408px;left:223px;white-space:nowrap" class="ft41"><b>Table 3. Humira Dose&#160;for&#160;Paediatric Patients with Plaque Psoriasis&#160;</b></p>
<p style="position:absolute;top:449px;left:279px;white-space:nowrap" class="ft41"><b>Patient Weight</b></p>
<p style="position:absolute;top:449px;left:529px;white-space:nowrap" class="ft41"><b>Dosing Regimen</b></p>
<p style="position:absolute;top:473px;left:278px;white-space:nowrap" class="ft42">15&#160;kg to &lt; 30 kg</p>
<p style="position:absolute;top:473px;left:474px;white-space:nowrap" class="ft42">Initial dose of 20 mg, followed by&#160;</p>
<p style="position:absolute;top:491px;left:486px;white-space:nowrap" class="ft42">20 mg given every other week&#160;</p>
<p style="position:absolute;top:509px;left:478px;white-space:nowrap" class="ft42">starting one week after the initial&#160;</p>
<p style="position:absolute;top:527px;left:571px;white-space:nowrap" class="ft42">dose</p>
<p style="position:absolute;top:552px;left:307px;white-space:nowrap" class="ft42">≥ 30 kg</p>
<p style="position:absolute;top:552px;left:474px;white-space:nowrap" class="ft42">Initial dose of 40 mg, followed by&#160;</p>
<p style="position:absolute;top:570px;left:486px;white-space:nowrap" class="ft42">40 mg given every other week&#160;</p>
<p style="position:absolute;top:588px;left:478px;white-space:nowrap" class="ft42">starting one week after the initial&#160;</p>
<p style="position:absolute;top:606px;left:571px;white-space:nowrap" class="ft42">dose</p>
<p style="position:absolute;top:648px;left:106px;white-space:nowrap" class="ft45">Continued therapy beyond 16&#160;weeks should be carefully considered in a patient not responding within this&#160;<br/>time period.</p>
<p style="position:absolute;top:705px;left:106px;white-space:nowrap" class="ft44">If retreatment with Humira is indicated, the above guidance on dose and treatment duration should be&#160;<br/>followed.</p>
<p style="position:absolute;top:761px;left:106px;white-space:nowrap" class="ft44">The safety&#160;of Humira in paediatric patients with plaque psoriasis has been assessed for a mean of&#160;<br/>13&#160;months.</p>
<p style="position:absolute;top:818px;left:106px;white-space:nowrap" class="ft42">There is no relevant use of Humira in children aged less than 4&#160;years for this indication.</p>
<p style="position:absolute;top:856px;left:106px;white-space:nowrap" class="ft44">Humira may be available in other strengths and/or presentations depending on the individual treatment&#160;<br/>needs.</p>
<p style="position:absolute;top:913px;left:106px;white-space:nowrap" class="ft43"><i>Paediatric Crohn's disease</i></p>
<p style="position:absolute;top:951px;left:106px;white-space:nowrap" class="ft44">The recommended dose of Humira for patients with&#160;Crohn’s disease from 6&#160;to 17&#160;years&#160;of age is&#160;based on&#160;<br/>body&#160;weight&#160;(Table 4).&#160;Humira is&#160;administered via subcutaneous injection.</p>
</div>
<!-- Page 5 -->
<a name="5"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft56{font-size:17px;font-family:HORGHZ+Symbol;color:#000000;}
-->
</style>
<div id="page5-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:452px;white-space:nowrap" class="ft50">5</p>
<p style="position:absolute;top:105px;left:225px;white-space:nowrap" class="ft51"><b>Table&#160;4. Humira Dose&#160;for&#160;Paediatric Patients with Crohn’s disease</b></p>
<p style="position:absolute;top:145px;left:118px;white-space:nowrap" class="ft51"><b>Patient&#160;</b></p>
<p style="position:absolute;top:164px;left:117px;white-space:nowrap" class="ft51"><b>Weight</b></p>
<p style="position:absolute;top:145px;left:382px;white-space:nowrap" class="ft51"><b>Induction Dose</b></p>
<p style="position:absolute;top:145px;left:707px;white-space:nowrap" class="ft51"><b>Maintenance&#160;</b></p>
<p style="position:absolute;top:164px;left:735px;white-space:nowrap" class="ft51"><b>Dose</b></p>
<p style="position:absolute;top:183px;left:715px;white-space:nowrap" class="ft51"><b>Starting&#160;at</b></p>
<p style="position:absolute;top:202px;left:726px;white-space:nowrap" class="ft51"><b>Week 4</b></p>
<p style="position:absolute;top:224px;left:118px;white-space:nowrap" class="ft52">&lt; 40 kg</p>
<p style="position:absolute;top:224px;left:190px;white-space:nowrap" class="ft56">&#160;40 mg at week 0 and 20 mg at&#160;week 2</p>
<p style="position:absolute;top:264px;left:192px;white-space:nowrap" class="ft55">In case there is a need for a more rapid response to therapy&#160;with the&#160;<br/>awareness that the risk for adverse events may be higher with use of the&#160;<br/>higher induction dose, the following dose may be used:</p>
<p style="position:absolute;top:320px;left:190px;white-space:nowrap" class="ft56">&#160;80 mg at week 0 and 40 mg at week 2</p>
<p style="position:absolute;top:224px;left:712px;white-space:nowrap" class="ft52">20 mg every&#160;</p>
<p style="position:absolute;top:243px;left:717px;white-space:nowrap" class="ft52">other week</p>
<p style="position:absolute;top:344px;left:118px;white-space:nowrap" class="ft52">≥ 40 kg</p>
<p style="position:absolute;top:343px;left:190px;white-space:nowrap" class="ft56">&#160;80 mg at week 0 and 40 mg at week 2</p>
<p style="position:absolute;top:383px;left:192px;white-space:nowrap" class="ft54">In case there is a need for a more rapid response to therapy&#160;with the&#160;<br/>awareness that the risk for adverse events may be higher with use of the&#160;<br/>higher induction dose, the following dose may be used:</p>
<p style="position:absolute;top:439px;left:190px;white-space:nowrap" class="ft56">&#160;160 mg at week 0 and 80 mg at week 2</p>
<p style="position:absolute;top:344px;left:713px;white-space:nowrap" class="ft52">40 mg every&#160;</p>
<p style="position:absolute;top:363px;left:717px;white-space:nowrap" class="ft52">other week</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft52">Patients&#160;who&#160;experience insufficient response may benefit from&#160;an increase in&#160;dosage:</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft56"></p>
<p style="position:absolute;top:501px;left:147px;white-space:nowrap" class="ft52">&lt; 40&#160;kg: 20&#160;mg&#160;every week</p>
<p style="position:absolute;top:520px;left:106px;white-space:nowrap" class="ft56"></p>
<p style="position:absolute;top:522px;left:147px;white-space:nowrap" class="ft52">≥ 40&#160;kg: 40&#160;mg&#160;every&#160;week&#160;or 80&#160;mg&#160;every other week</p>
<p style="position:absolute;top:560px;left:106px;white-space:nowrap" class="ft52">Continued therapy should be carefully considered in a subject not responding by&#160;week&#160;12.</p>
<p style="position:absolute;top:598px;left:106px;white-space:nowrap" class="ft52">There is no relevant use of Humira in children aged&#160;less than&#160;6&#160;years for this indication.</p>
<p style="position:absolute;top:635px;left:106px;white-space:nowrap" class="ft54">Humira may be available in other strengths and/or presentations depending on the individual treatment&#160;<br/>needs.</p>
<p style="position:absolute;top:693px;left:106px;white-space:nowrap" class="ft53"><i>Paediatric Uveitis</i></p>
<p style="position:absolute;top:730px;left:106px;white-space:nowrap" class="ft54">The recommended dose of Humira for&#160;paediatric&#160;patients with&#160;uveitis&#160;from 2&#160;years&#160;of age&#160;is based on&#160;<br/>body&#160;weight&#160;(Table 5).&#160;Humira is&#160;administered via subcutaneous injection.</p>
<p style="position:absolute;top:787px;left:106px;white-space:nowrap" class="ft54">In paediatric uveitis, there is no experience in the treatment with Humira without concomitant treatment&#160;<br/>with methotrexate.</p>
<p style="position:absolute;top:844px;left:256px;white-space:nowrap" class="ft51"><b>Table&#160;5. Humira Dose for&#160;Paediatric&#160;Patients with&#160;Uveitis</b></p>
<p style="position:absolute;top:885px;left:279px;white-space:nowrap" class="ft51"><b>Patient Weight</b></p>
<p style="position:absolute;top:885px;left:529px;white-space:nowrap" class="ft51"><b>Dosing Regimen</b></p>
<p style="position:absolute;top:910px;left:307px;white-space:nowrap" class="ft52">&lt; 30 kg</p>
<p style="position:absolute;top:910px;left:498px;white-space:nowrap" class="ft52">20 mg every other week in&#160;</p>
<p style="position:absolute;top:928px;left:483px;white-space:nowrap" class="ft52">combination with methotrexate</p>
<p style="position:absolute;top:953px;left:307px;white-space:nowrap" class="ft52">≥ 30 kg</p>
<p style="position:absolute;top:953px;left:498px;white-space:nowrap" class="ft52">40 mg every other week in&#160;</p>
<p style="position:absolute;top:971px;left:483px;white-space:nowrap" class="ft52">combination with methotrexate</p>
<p style="position:absolute;top:1012px;left:106px;white-space:nowrap" class="ft54">When Humira therapy is initiated, a loading dose of 40&#160;mg&#160;for patients &lt; 30&#160;kg&#160;or 80&#160;mg for patients&#160;<br/>≥&#160;30&#160;kg&#160;may be administered one week prior to the start of maintenance therapy.&#160;No clinical data are&#160;<br/>available on the use of a Humira loading dose&#160;in children &lt;&#160;6&#160;years of age (see section 5.2).</p>
</div>
<!-- Page 6 -->
<a name="6"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page6-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:452px;white-space:nowrap" class="ft60">6</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft62">There is no relevant use of Humira in children aged less than 2&#160;years in this indication.</p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft64">It is recommended that the benefit and risk of continued long-term&#160;treatment should be evaluated on a&#160;<br/>yearly basis&#160;(see section 5.1).</p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft64">Humira may be available in other strengths and/or presentations depending on the individual treatment&#160;<br/>needs.</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft62">Renal and/or hepatic impairment</p>
<p style="position:absolute;top:276px;left:106px;white-space:nowrap" class="ft62">Humira has not been studied in these patient populations. No dose recommendations can be made.</p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft62">Method of administration</p>
<p style="position:absolute;top:352px;left:106px;white-space:nowrap" class="ft65">Humira is administered by subcutaneous injection. Full instructions for use are provided in the package&#160;<br/>leaflet.</p>
<p style="position:absolute;top:409px;left:106px;white-space:nowrap" class="ft62">Humira is available in other strengths and presentations.</p>
<p style="position:absolute;top:446px;left:106px;white-space:nowrap" class="ft61"><b>4.3</b></p>
<p style="position:absolute;top:446px;left:148px;white-space:nowrap" class="ft61"><b>Contraindications&#160;</b></p>
<p style="position:absolute;top:485px;left:106px;white-space:nowrap" class="ft62">Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.&#160;</p>
<p style="position:absolute;top:522px;left:106px;white-space:nowrap" class="ft62">Active tuberculosis or other severe infections such as sepsis and opportunistic infections (see section 4.4).</p>
<p style="position:absolute;top:559px;left:106px;white-space:nowrap" class="ft62">Moderate to severe heart failure (NYHA class III/IV) (see section 4.4).</p>
<p style="position:absolute;top:597px;left:106px;white-space:nowrap" class="ft61"><b>4.4</b></p>
<p style="position:absolute;top:597px;left:148px;white-space:nowrap" class="ft61"><b>Special warnings and precautions for use</b></p>
<p style="position:absolute;top:634px;left:106px;white-space:nowrap" class="ft62">Traceability</p>
<p style="position:absolute;top:672px;left:106px;white-space:nowrap" class="ft64">In&#160;order to improve traceability of biological&#160;medicinal products, the name&#160;and the batch number of the&#160;<br/>administered product should be clearly recorded.</p>
<p style="position:absolute;top:729px;left:106px;white-space:nowrap" class="ft62">Infections</p>
<p style="position:absolute;top:767px;left:106px;white-space:nowrap" class="ft65">Patients&#160;taking TNF&#160;-antagonists are more susceptible to serious infections. Impaired lung function may&#160;<br/>increase the risk for developing infections. Patients must therefore be monitored closely for infections,&#160;<br/>including tuberculosis, before, during and after treatment with Humira.&#160;Because the elimination of&#160;<br/>adalimumab may take up to four months, monitoring should be continued throughout this period.</p>
<p style="position:absolute;top:862px;left:106px;white-space:nowrap" class="ft64">Treatment with Humira should not be initiated in patients with active infections including chronic or&#160;<br/>localised infections until infections are controlled. In patients who have been exposed to tuberculosis and&#160;<br/>patients who have travelled in areas of high risk of tuberculosis or endemic mycoses, such as&#160;<br/>histoplasmosis, coccidioidomycosis, or blastomycosis, the risk and benefits of treatment with Humira&#160;<br/>should be considered prior to initiating therapy (see&#160;<i>Other opportunistic infections</i>).</p>
<p style="position:absolute;top:976px;left:106px;white-space:nowrap" class="ft64">Patients who develop a new infection while undergoing treatment with Humira should be monitored&#160;<br/>closely and undergo a complete diagnostic evaluation. Administration of Humira should be discontinued if&#160;<br/>a patient develops a new serious infection or sepsis and appropriate antimicrobial or antifungal therapy&#160;<br/>should be initiated until the infection is controlled.&#160;Physicians should exercise caution when considering&#160;<br/>the use of Humira in patients with a history of recurring infection or with underlying conditions which&#160;<br/>may predispose patients to infections, including the use of concomitant immunosuppressive medications.</p>
</div>
<!-- Page 7 -->
<a name="7"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page7-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:452px;white-space:nowrap" class="ft70">7</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft73"><i>Serious infections</i></p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft75">Serious infections,&#160;including sepsis,&#160;due to bacterial, mycobacterial, invasive fungal, parasitic, viral, or&#160;<br/>other opportunistic infections&#160;such as listeriosis, legionellosis and pneumocystis&#160;have been reported in&#160;<br/>patients receiving Humira. &#160;</p>
<p style="position:absolute;top:219px;left:106px;white-space:nowrap" class="ft75">Other serious infections seen in clinical trials include pneumonia, pyelonephritis, septic arthritis and&#160;<br/>septicaemia. Hospitalisation or fatal outcomes associated with infections have been reported.&#160;</p>
<p style="position:absolute;top:276px;left:106px;white-space:nowrap" class="ft73"><i>Tuberculosis</i></p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft74">Tuberculosis, including reactivation and new onset&#160;of tuberculosis, has been reported in patients receiving&#160;<br/>Humira.&#160;Reports included cases of pulmonary and extra-pulmonary (i.e. disseminated) tuberculosis.&#160;</p>
<p style="position:absolute;top:370px;left:106px;white-space:nowrap" class="ft75">Before initiation of therapy with Humira, all patients must be evaluated for both active or inactive&#160;<br/>(“latent”) tuberculosis infection.&#160;This evaluation should include a detailed medical assessment of patient&#160;<br/>history of tuberculosis or possible previous exposure to people with active tuberculosis and previous&#160;<br/>and/or current immunosuppressive therapy.&#160;Appropriate screening tests (i.e. tuberculin skin test and chest&#160;<br/>X-ray) should be performed in all patients (local recommendations may apply). It is recommended that the&#160;<br/>conduct and results of these tests are recorded in the&#160;Patient Reminder Card. Prescribers&#160;are&#160;reminded of&#160;<br/>the risk of false negative tuberculin skin test results, especially in patients who are severely ill or&#160;<br/>immunocompromised.&#160;</p>
<p style="position:absolute;top:541px;left:106px;white-space:nowrap" class="ft72">If active tuberculosis is diagnosed, Humira therapy must not be initiated (see section 4.3).&#160;</p>
<p style="position:absolute;top:579px;left:106px;white-space:nowrap" class="ft72">In all situations described below, the benefit/risk balance of therapy should be very carefully considered.</p>
<p style="position:absolute;top:617px;left:106px;white-space:nowrap" class="ft74">If latent tuberculosis is suspected,&#160;a physician with expertise in the treatment of tuberculosis should be&#160;<br/>consulted.</p>
<p style="position:absolute;top:674px;left:106px;white-space:nowrap" class="ft75">If latent tuberculosis is diagnosed, appropriate treatment must be started with anti-tuberculosis prophylaxis&#160;<br/>treatment before the initiation of Humira and in accordance with local recommendations.&#160;</p>
<p style="position:absolute;top:731px;left:106px;white-space:nowrap" class="ft74">Use&#160;of anti-tuberculosis prophylaxis treatment should also be considered before the initiation of Humira in&#160;<br/>patients with several or significant risk factors for tuberculosis despite a negative test for tuberculosis and&#160;<br/>in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment&#160;<br/>cannot be confirmed. &#160;</p>
<p style="position:absolute;top:826px;left:106px;white-space:nowrap" class="ft74">Despite prophylactic treatment for tuberculosis, cases of reactivated tuberculosis have occurred in patients&#160;<br/>treated with Humira. Some patients who have been successfully treated for active tuberculosis have&#160;<br/>redeveloped tuberculosis while being treated with Humira.</p>
<p style="position:absolute;top:902px;left:106px;white-space:nowrap" class="ft75">Patients should be instructed to seek medical advice if signs/symptoms suggestive of a tuberculosis&#160;<br/>infection (e.g., persistent cough, wasting/weight loss, low grade fever, listlessness) occur during or after&#160;<br/>therapy with Humira.&#160;</p>
<p style="position:absolute;top:978px;left:106px;white-space:nowrap" class="ft73"><i>Other opportunistic infections</i></p>
<p style="position:absolute;top:1016px;left:106px;white-space:nowrap" class="ft74">Opportunistic infections, including invasive fungal infections have been observed in patients receiving&#160;<br/>Humira. These infections have not consistently been recognised in patients taking TNF-antagonists and&#160;<br/>this&#160;has&#160;resulted in delays in appropriate treatment, sometimes resulting in fatal outcomes.&#160;</p>
</div>
<!-- Page 8 -->
<a name="8"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page8-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:452px;white-space:nowrap" class="ft80">8</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft84">For patients who develop the signs and symptoms such as fever, malaise, weight loss, sweats, cough,&#160;<br/>dyspnoea, and/or pulmonary infiltrates or other serious systemic illness with or without concomitant shock&#160;<br/>an invasive fungal infection should be suspected and administration of Humira should be promptly&#160;<br/>discontinued. Diagnosis and administration of empiric antifungal therapy in these patients should be made&#160;<br/>in consultation with a physician with expertise in the care of patients with invasive fungal infections.&#160;</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft82">Hepatitis B reactivation</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft85">Reactivation of hepatitis B has occurred in patients receiving a TNF-antagonist including Humira, who are&#160;<br/>chronic carriers of this virus (i.e. surface antigen positive). Some cases have had a fatal outcome. Patients&#160;<br/>should be tested for HBV infection before initiating treatment with Humira. For patients who test positive&#160;<br/>for hepatitis B infection, consultation with a physician with expertise in the treatment of hepatitis B is&#160;<br/>recommended.</p>
<p style="position:absolute;top:352px;left:106px;white-space:nowrap" class="ft84">Carriers of HBV who require treatment with Humira should be closely monitored for signs and symptoms&#160;<br/>of active HBV infection throughout therapy and for several months following termination of therapy.&#160;<br/>Adequate data from treating patients who are carriers of HBV with anti-viral therapy in conjunction with&#160;<br/>TNF-antagonist therapy to prevent HBV reactivation are not available. In patients who develop HBV&#160;<br/>reactivation, Humira should be stopped and effective anti-viral therapy with appropriate supportive&#160;<br/>treatment should be initiated.&#160;</p>
<p style="position:absolute;top:485px;left:106px;white-space:nowrap" class="ft82">Neurological events&#160;</p>
<p style="position:absolute;top:522px;left:106px;white-space:nowrap" class="ft84">TNF-antagonists including Humira have been associated in rare instances with new onset or exacerbation&#160;<br/>of clinical symptoms and/or radiographic evidence of central nervous system demyelinating disease&#160;<br/>including multiple sclerosis and optic neuritis, and peripheral demyelinating disease, including Guillain-<br/>Barré syndrome. Prescribers should exercise caution in considering the use of Humira in patients with pre-<br/>existing or recent-onset central or peripheral nervous system demyelinating disorders; discontinuation of&#160;<br/>Humira should be considered if any of these disorders develop. There is a known association&#160;between&#160;<br/>intermediate uveitis and central demyelinating disorders. Neurologic evaluation should be performed in&#160;<br/>patients with non-infectious intermediate uveitis prior to the initiation of Humira&#160;therapy and regularly&#160;<br/>during treatment to assess for pre-existing or developing central demyelinating disorders.&#160;</p>
<p style="position:absolute;top:712px;left:106px;white-space:nowrap" class="ft82">Allergic reactions</p>
<p style="position:absolute;top:750px;left:106px;white-space:nowrap" class="ft85">Serious allergic reactions associated with Humira were rare during clinical trials. Non-serious allergic&#160;<br/>reactions associated with Humira were uncommon during clinical trials. Reports of serious allergic&#160;<br/>reactions including anaphylaxis have been received following Humira administration. If an anaphylactic&#160;<br/>reaction or other serious allergic reaction occurs, administration of Humira should be discontinued&#160;<br/>immediately and appropriate therapy initiated.&#160;</p>
<p style="position:absolute;top:864px;left:106px;white-space:nowrap" class="ft82">Immunosuppression</p>
<p style="position:absolute;top:902px;left:106px;white-space:nowrap" class="ft85">In a study of 64&#160;patients with rheumatoid arthritis that were treated with Humira, there was no evidence of&#160;<br/>depression of delayed-type hypersensitivity, depression of immunoglobulin levels, or change in&#160;<br/>enumeration of&#160;effector T-, B-, NK-cells, monocyte/macrophages, and neutrophils.</p>
<p style="position:absolute;top:978px;left:106px;white-space:nowrap" class="ft82">Malignancies and lymphoproliferative disorders</p>
<p style="position:absolute;top:1016px;left:106px;white-space:nowrap" class="ft85">In the controlled portions of clinical trials of TNF-antagonists, more cases of malignancies including&#160;<br/>lymphoma have been observed among&#160;patients receiving a TNF-antagonist compared with control&#160;<br/>patients. However, the occurrence was rare. In the post marketing setting, cases of&#160;leukaemia&#160;have been&#160;<br/>reported in patients treated with a TNF-antagonist. There is an increased background risk for lymphoma&#160;</p>
</div>
<!-- Page 9 -->
<a name="9"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page9-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:452px;white-space:nowrap" class="ft90">9</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft94">and&#160;leukaemia&#160;in rheumatoid arthritis patients with long-standing,&#160;highly active, inflammatory disease,&#160;<br/>which complicates the risk estimation.&#160;With the current knowledge, a possible risk for the development of&#160;<br/>lymphomas,&#160;leukaemia, and other malignancies in patients treated with a TNF-antagonist cannot be&#160;<br/>excluded.</p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft94">Malignancies, some fatal, have been reported among children, adolescents and young adults (up to&#160;<br/>22&#160;years of age) treated with TNF-antagonists (initiation of therapy&#160;≤&#160;18&#160;years of age), including&#160;<br/>adalimumab in the post marketing setting. Approximately half the cases were lymphomas. The other cases&#160;<br/>represented a variety of different malignancies and included rare malignancies usually associated with&#160;<br/>immunosuppression. A risk for the development of malignancies in children and adolescents treated with&#160;<br/>TNF-antagonists cannot be excluded.&#160;</p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft95">Rare postmarketing cases of hepatosplenic T-cell&#160;lymphoma have been identified in patients treated with&#160;<br/>adalimumab. This rare type of T-cell&#160;lymphoma has a very aggressive disease course and is usually fatal.&#160;<br/>Some of these hepatosplenic T-cell lymphomas with Humira have occurred in young adult patients on&#160;<br/>concomitant treatment with azathioprine or 6-mercaptopurine used for inflammatory bowel disease. The&#160;<br/>potential risk with the combination of azathioprine or 6-mercaptopurine and Humira should be carefully&#160;<br/>considered. A risk for the development of hepatosplenic T-cell lymphoma in patients treated with Humira&#160;<br/>cannot be excluded (see section 4.8).</p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft95">No studies have been conducted that include patients with a history of malignancy or in whom treatment&#160;<br/>with Humira is continued following development of malignancy. Thus,&#160;additional caution should be&#160;<br/>exercised in considering Humira treatment of these patients (see section 4.8).</p>
<p style="position:absolute;top:541px;left:106px;white-space:nowrap" class="ft94">All patients, and in particular patients with a medical history of extensive immunosuppressant therapy or&#160;<br/>psoriasis patients with a history&#160;of PUVA treatment should be examined for the presence of non-<br/>melanoma skin cancer prior to and during treatment with Humira. Melanoma and Merkel cell carcinoma&#160;<br/>have also been reported in patients treated with TNF-antagonists including adalimumab (see section 4.8).</p>
<p style="position:absolute;top:636px;left:106px;white-space:nowrap" class="ft94">In an exploratory clinical trial evaluating the use of another TNF-antagonist, infliximab, in patients with&#160;<br/>moderate to severe chronic obstructive pulmonary disease (COPD), more malignancies, mostly in the lung&#160;<br/>or head and neck, were reported in&#160;infliximab-treated patients compared with control patients. All patients&#160;<br/>had a history of heavy smoking. Therefore, caution should be exercised when using any TNF-antagonist in&#160;<br/>COPD patients, as well as in patients with increased risk for malignancy due to heavy smoking.</p>
<p style="position:absolute;top:750px;left:106px;white-space:nowrap" class="ft94">With current data it is not known if adalimumab treatment influences the risk for developing dysplasia or&#160;<br/>colon cancer. All patients with ulcerative colitis who are at increased risk for dysplasia or colon carcinoma&#160;<br/>(for example, patients&#160;with long-standing ulcerative colitis or primary sclerosing cholangitis), or who had&#160;<br/>a prior history of dysplasia or colon carcinoma should be screened for dysplasia at regular intervals before&#160;<br/>therapy and throughout their disease course. This evaluation&#160;should include colonoscopy and biopsies per&#160;<br/>local recommendations.</p>
<p style="position:absolute;top:883px;left:106px;white-space:nowrap" class="ft92">Haematologic reactions</p>
<p style="position:absolute;top:921px;left:106px;white-space:nowrap" class="ft95">Rare reports of&#160;pancytopenia&#160;including aplastic anaemia have been reported with TNF-antagonists. &#160;<br/>Adverse events of the haematologic system, including medically significant&#160;cytopenia&#160;(e.g.&#160;<br/>thrombocytopenia,&#160;leukopenia) have been reported with Humira. All patients should be advised to seek&#160;<br/>immediate medical attention if they develop signs and symptoms suggestive of blood dyscrasias (e.g.&#160;<br/>persistent fever, bruising, bleeding, pallor) while on Humira. Discontinuation of Humira therapy should be&#160;<br/>considered in patients with confirmed significant haematologic abnormalities.</p>
</div>
<!-- Page 10 -->
<a name="10"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page10-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft100">10</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft102">Vaccinations&#160;</p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft105">Similar antibody responses to the standard 23-valent pneumococcal vaccine and the influenza trivalent&#160;<br/>virus vaccination were observed in a study in 226&#160;adult subjects with rheumatoid arthritis who were&#160;<br/>treated with adalimumab or placebo. No data are available on the secondary transmission of infection by&#160;<br/>live vaccines in patients receiving&#160;Humira. &#160;</p>
<p style="position:absolute;top:219px;left:106px;white-space:nowrap" class="ft105">It is recommended that paediatric patients, if possible, be brought up to date with all immunisations in&#160;<br/>agreement with current immunisation guidelines prior to initiating Humira therapy.</p>
<p style="position:absolute;top:276px;left:106px;white-space:nowrap" class="ft105">Patients on Humira may receive concurrent vaccinations, except for live vaccines. Administration of live&#160;<br/>vaccines&#160;(e.g., BCG vaccine)&#160;to&#160;infants exposed to adalimumab in utero is not recommended for 5&#160;months&#160;<br/>following the mother’s last adalimumab injection&#160;during pregnancy.</p>
<p style="position:absolute;top:352px;left:106px;white-space:nowrap" class="ft102">Congestive heart failure</p>
<p style="position:absolute;top:390px;left:106px;white-space:nowrap" class="ft104">In a clinical trial with another TNF-antagonist worsening congestive heart failure and increased mortality&#160;<br/>due to congestive heart failure have been observed. Cases of worsening congestive heart failure have&#160;also&#160;<br/>been reported in patients receiving Humira. Humira should be used with caution in patients with mild&#160;<br/>heart failure (NYHA class I/II). Humira is contraindicated in moderate to severe heart failure (see section&#160;<br/>4.3). Treatment with Humira must be discontinued in patients who develop new or worsening symptoms&#160;<br/>of congestive heart failure.</p>
<p style="position:absolute;top:522px;left:106px;white-space:nowrap" class="ft102">Autoimmune processes</p>
<p style="position:absolute;top:560px;left:106px;white-space:nowrap" class="ft104">Treatment with Humira may result in the formation of autoimmune antibodies.&#160;The impact of long-term&#160;<br/>treatment with Humira on the development of autoimmune diseases is unknown.&#160;If a patient develops&#160;<br/>symptoms suggestive of a lupus-like syndrome following treatment with Humira and is positive for&#160;<br/>antibodies against double-stranded DNA, further treatment with Humira should not be given (see section&#160;<br/>4.8).</p>
<p style="position:absolute;top:674px;left:106px;white-space:nowrap" class="ft102">Concurrent administration of biologic DMARDS or TNF-antagonists</p>
<p style="position:absolute;top:712px;left:106px;white-space:nowrap" class="ft104">Serious infections were seen in clinical studies with concurrent use of anakinra and another&#160;<br/>TNF-antagonist, etanercept, with no added clinical benefit compared to etanercept alone. Because&#160;of the&#160;<br/>nature of the adverse events seen with the combination of etanercept and anakinra therapy, similar&#160;<br/>toxicities may also result from the combination of anakinra and other TNF-antagonists. Therefore, the&#160;<br/>combination of adalimumab and anakinra is not recommended. (See section 4.5).</p>
<p style="position:absolute;top:826px;left:106px;white-space:nowrap" class="ft104">Concomitant administration of adalimumab with other biologic DMARDS (e.g, anakinra and abatacept) or&#160;<br/>other TNF-antagonists is not recommended based upon the possible increased risk for infections,&#160;<br/>including serious infections and other potential pharmacological interactions. (See section 4.5).</p>
<p style="position:absolute;top:902px;left:106px;white-space:nowrap" class="ft102">Surgery</p>
<p style="position:absolute;top:940px;left:106px;white-space:nowrap" class="ft105">There is limited safety experience of surgical procedures in patients treated with Humira. The long half-<br/>life of adalimumab should be taken into consideration if a surgical procedure is planned. A patient who&#160;<br/>requires surgery while on Humira should be closely monitored for infections, and appropriate actions&#160;<br/>should be taken. There is limited safety experience in patients undergoing arthroplasty while receiving&#160;<br/>Humira.&#160;</p>
</div>
<!-- Page 11 -->
<a name="11"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page11-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft110">11</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft112">Small bowel obstruction</p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft114">Failure to respond to treatment for Crohn’s disease may indicate the presence of fixed fibrotic stricture&#160;<br/>that may require surgical treatment. Available data suggest that Humira does not worsen or cause&#160;<br/>strictures.</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft112">Elderly</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft114">The frequency&#160;of serious infections among Humira treated subjects over 65&#160;years of age (3.7%) was&#160;<br/>higher than for those under 65&#160;years of age (1.5%). Some of those had a fatal outcome. Particular attention&#160;<br/>regarding the risk for infection should be paid when treating the&#160;elderly.</p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft112">Paediatric population</p>
<p style="position:absolute;top:352px;left:106px;white-space:nowrap" class="ft112">See Vaccinations above.</p>
<p style="position:absolute;top:390px;left:106px;white-space:nowrap" class="ft111"><b>4.5</b></p>
<p style="position:absolute;top:390px;left:148px;white-space:nowrap" class="ft111"><b>Interaction with other medicinal products and other forms of interaction&#160;</b></p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft115">Humira has been studied in rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and psoriatic&#160;<br/>arthritis patients taking Humira as monotherapy and those taking concomitant methotrexate. Antibody&#160;<br/>formation was lower when Humira was given together with methotrexate in comparison with use as&#160;<br/>monotherapy. Administration of Humira without methotrexate resulted in increased formation of&#160;<br/>antibodies, increased clearance and reduced efficacy of adalimumab (see section 5.1).&#160;</p>
<p style="position:absolute;top:541px;left:106px;white-space:nowrap" class="ft115">The combination of Humira and anakinra is not recommended (see section 4.4 “Concurrent administration&#160;<br/>of biologic DMARDS or TNF-antagonists”).&#160;</p>
<p style="position:absolute;top:598px;left:106px;white-space:nowrap" class="ft115">The combination of Humira and abatacept is not recommended (see section 4.4 “Concurrent&#160;<br/>administration of biologic DMARDS or TNF-antagonists”).</p>
<p style="position:absolute;top:655px;left:106px;white-space:nowrap" class="ft111"><b>4.6</b></p>
<p style="position:absolute;top:655px;left:148px;white-space:nowrap" class="ft111"><b>Fertility, pregnancy and lactation</b></p>
<p style="position:absolute;top:693px;left:106px;white-space:nowrap" class="ft112">Women of childbearing potential</p>
<p style="position:absolute;top:731px;left:106px;white-space:nowrap" class="ft115">Women of childbearing potential&#160;should consider&#160;the&#160;use&#160;of&#160;adequate contraception to prevent pregnancy&#160;<br/>and continue its use for at least five months after the last Humira&#160;treatment.</p>
<p style="position:absolute;top:788px;left:106px;white-space:nowrap" class="ft112">Pregnancy</p>
<p style="position:absolute;top:826px;left:106px;white-space:nowrap" class="ft114">A large number (approximately 2100) of prospectively collected pregnancies exposed to adalimumab&#160;<br/>resulting in live birth with known outcomes, including more than 1500 exposed during the first trimester,&#160;<br/>does not indicate an increase&#160;in the rate of malformation in the newborn.</p>
<p style="position:absolute;top:902px;left:106px;white-space:nowrap" class="ft115">In a prospective cohort registry, 257 women with&#160;rheumatoid arthritis (RA) or Crohn’s disease (CD)<br/>treated with adalimumab at least during the first trimester and 120 women with RA or CD not treated with&#160;<br/>adalimumab were enrolled. &#160;The primary endpoint was the birth prevalence of major birth defects. The&#160;<br/>rate of&#160;pregnancies ending with at least one live&#160;born infant with a major birth defect&#160;was 6/69 (8.7%)&#160;in&#160;<br/>the adalimumab-treated women with RA&#160;and 5/74 (6.8%) in the untreated women with RA&#160;(unadjusted&#160;<br/>OR 1.31, 95% CI 0.38-4.52) and&#160;16/152 (10.5%) in the adalimumab-treated women with&#160;CD&#160;and 3/32&#160;<br/>(9.4%)&#160;in the untreated women with CD&#160;(unadjusted OR 1.14, 95% CI 0.31-4.16). The adjusted OR&#160;<br/>(accounting for baseline differences) was&#160;1.10&#160;(95% CI 0.45-2.73)&#160;with RA and CD combined.&#160;There&#160;were&#160;<br/>no distinct differences between&#160;adalimumab-treated and untreated women&#160;for the secondary&#160;endpoints&#160;<br/>spontaneous abortions, minor birth defects, preterm&#160;delivery, birth size and serious or opportunistic&#160;</p>
</div>
<!-- Page 12 -->
<a name="12"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page12-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft120">12</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft125">infections&#160;and no stillbirths or malignancies were reported.&#160;The interpretation of data&#160;may be impacted due&#160;<br/>to methodological limitations of the&#160;study, including small sample size and non-randomized design.</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft125">In a developmental toxicity study conducted in monkeys, there was no indication of maternal toxicity,&#160;<br/>embryotoxicity or teratogenicity. Preclinical data on postnatal toxicity of adalimumab are not available&#160;<br/>(see section 5.3).</p>
<p style="position:absolute;top:220px;left:106px;white-space:nowrap" class="ft122">Due to its inhibition of TNF</p>
<p style="position:absolute;top:218px;left:292px;white-space:nowrap" class="ft126">, adalimumab administered during pregnancy could affect normal immune&#160;</p>
<p style="position:absolute;top:239px;left:106px;white-space:nowrap" class="ft122">responses in the newborn.&#160;&#160;Adalimumab should only be used during pregnancy if clearly needed.</p>
<p style="position:absolute;top:277px;left:106px;white-space:nowrap" class="ft125">Adalimumab may cross the placenta into the serum of infants born to women treated with adalimumab&#160;<br/>during pregnancy. Consequently, these infants may be at increased risk for infection. Administration of&#160;<br/>live vaccines&#160;(e.g., BCG vaccine)&#160;to infants exposed to&#160;adalimumab in utero is not recommended for&#160;<br/>5&#160;months following the mother’s last adalimumab injection during pregnancy.</p>
<p style="position:absolute;top:372px;left:106px;white-space:nowrap" class="ft122">Breast-feeding</p>
<p style="position:absolute;top:410px;left:106px;white-space:nowrap" class="ft124">Limited information from the published literature indicates that adalimumab is excreted in breast milk at&#160;<br/>very low concentrations with the presence of adalimumab in human milk at concentrations of 0.1% to 1%&#160;<br/>of the maternal serum level. Given orally, immunoglobulin G proteins undergo intestinal proteolysis and&#160;<br/>have poor bioavailability. No effects on the breastfed newborns/infants are anticipated. Consequently,&#160;<br/>Humira can be used during breastfeeding.</p>
<p style="position:absolute;top:523px;left:106px;white-space:nowrap" class="ft122">Fertility</p>
<p style="position:absolute;top:562px;left:106px;white-space:nowrap" class="ft122">Preclinical data on fertility effects of adalimumab are not available.</p>
<p style="position:absolute;top:599px;left:106px;white-space:nowrap" class="ft121"><b>4.7</b></p>
<p style="position:absolute;top:599px;left:148px;white-space:nowrap" class="ft121"><b>Effects on ability to drive and use machines&#160;</b></p>
<p style="position:absolute;top:638px;left:106px;white-space:nowrap" class="ft125">Humira may have a minor influence on the&#160;ability to drive and use machines. Vertigo and visual&#160;<br/>impairment may occur following administration of Humira (see section 4.8).</p>
<p style="position:absolute;top:694px;left:106px;white-space:nowrap" class="ft121"><b>4.8</b></p>
<p style="position:absolute;top:694px;left:148px;white-space:nowrap" class="ft121"><b>Undesirable effects</b></p>
<p style="position:absolute;top:732px;left:106px;white-space:nowrap" class="ft122">Summary of the safety profile</p>
<p style="position:absolute;top:770px;left:106px;white-space:nowrap" class="ft124">Humira was studied in&#160;9,506&#160;patients in pivotal controlled and open label trials for up to 60&#160;months or&#160;<br/>more. These trials included rheumatoid arthritis patients with short term and long standing disease,&#160;<br/>juvenile idiopathic arthritis (polyarticular juvenile idiopathic arthritis and&#160;enthesitis-related arthritis) as&#160;<br/>well as axial spondyloarthritis (ankylosing spondylitis and axial spondyloarthritis without radiographic&#160;<br/>evidence of AS), psoriatic arthritis, Crohn’s disease, ulcerative colitis, psoriasis,&#160;hidradenitis suppurativa&#160;<br/>and uveitis&#160;patients. The pivotal controlled studies involved&#160;6,089&#160;patients receiving Humira and&#160;3,801<br/>patients receiving placebo or active comparator during the controlled period.</p>
<p style="position:absolute;top:922px;left:106px;white-space:nowrap" class="ft124">The proportion of patients who discontinued treatment due to adverse events during the double-blind,&#160;<br/>controlled portion of pivotal studies&#160;was&#160;5.9% for patients taking Humira and 5.4% for control treated&#160;<br/>patients.</p>
<p style="position:absolute;top:998px;left:106px;white-space:nowrap" class="ft125">The&#160;most commonly reported adverse reactions are infections (such as nasopharyngitis, upper respiratory&#160;<br/>tract infection&#160;and sinusitis), injection site reactions (erythema, itching, haemorrhage, pain or swelling),&#160;<br/>headache and musculoskeletal pain.</p>
</div>
<!-- Page 13 -->
<a name="13"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft137{font-size:17px;line-height:20px;font-family:HORGHZ+TimesNewRoman;color:#000000;}
	.ft138{font-size:17px;line-height:23px;font-family:HORGHZ+TimesNewRoman;color:#000000;}
-->
</style>
<div id="page13-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft130">13</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft134">Serious adverse reactions have been reported for Humira. TNF-antagonists, such as Humira affect the&#160;<br/>immune system and their use&#160;may affect the body’s&#160;defence&#160;against infection and cancer.<br/>Fatal and life-threatening infections (including sepsis, opportunistic infections and TB), HBV reactivation&#160;<br/>and various malignancies (including leukaemia, lymphoma and HSTCL) have also been reported with use&#160;<br/>of Humira.</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft135">Serious haematological, neurological and autoimmune reactions have also been reported. These include&#160;<br/>rare reports of pancytopenia, aplastic anaemia, central and peripheral demyelinating events and reports of&#160;<br/>lupus, lupus-related conditions and Stevens-Johnson syndrome.</p>
<p style="position:absolute;top:276px;left:106px;white-space:nowrap" class="ft132">Paediatric population</p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft134">In&#160;general, the adverse events in paediatric patients were similar in frequency and type to those seen in&#160;<br/>adult patients.</p>
<p style="position:absolute;top:370px;left:106px;white-space:nowrap" class="ft132">Tabulated list of adverse reactions</p>
<p style="position:absolute;top:409px;left:106px;white-space:nowrap" class="ft137">The following list of adverse reactions is based on experience from clinical trials and on postmarketing&#160;<br/>experience and are displayed by system organ class and frequency in Table&#160;6&#160;below: very common&#160;<br/>(</p>
<p style="position:absolute;top:446px;left:111px;white-space:nowrap" class="ft136">&#160;1/10); common (&#160;1/100&#160;to&#160;&lt;&#160;1/10); uncommon (&#160;1/1,000&#160;to&#160;&lt;&#160;1/100); rare (&#160;1/10,000 to&#160;&lt;&#160;1/1,000);&#160;</p>
<p style="position:absolute;top:467px;left:106px;white-space:nowrap" class="ft135">and not known&#160;(cannot be estimated from the available data). Within each frequency grouping,&#160;<br/>undesirable effects are presented in order of decreasing seriousness. The highest frequency seen among the&#160;<br/>various indications has been included. An asterisk (*) appears in the SOC column if further information is&#160;<br/>found elsewhere in sections 4.3, 4.4 and 4.8.</p>
<p style="position:absolute;top:562px;left:433px;white-space:nowrap" class="ft131"><b>Table&#160;6</b></p>
<p style="position:absolute;top:581px;left:390px;white-space:nowrap" class="ft131"><b>Undesirable Effects</b></p>
<p style="position:absolute;top:628px;left:132px;white-space:nowrap" class="ft131"><b>System&#160;Organ Class</b></p>
<p style="position:absolute;top:628px;left:341px;white-space:nowrap" class="ft131"><b>Frequency</b></p>
<p style="position:absolute;top:628px;left:566px;white-space:nowrap" class="ft131"><b>Adverse Reaction</b></p>
<p style="position:absolute;top:661px;left:114px;white-space:nowrap" class="ft134">Infections and&#160;<br/>infestations*</p>
<p style="position:absolute;top:661px;left:309px;white-space:nowrap" class="ft132">Very&#160;common</p>
<p style="position:absolute;top:661px;left:465px;white-space:nowrap" class="ft135">Respiratory tract infections&#160;(including lower and&#160;<br/>upper respiratory tract infection, pneumonia,&#160;<br/>sinusitis, pharyngitis, nasopharyngitis and&#160;<br/>pneumonia herpes viral)</p>
<p style="position:absolute;top:766px;left:309px;white-space:nowrap" class="ft132">Common</p>
<p style="position:absolute;top:761px;left:465px;white-space:nowrap" class="ft138">Systemic infections&#160;(including sepsis, candidiasis&#160;<br/>and influenza),<br/>intestinal infections&#160;(including gastroenteritis&#160;<br/>viral),<br/>skin and soft tissue infections (including&#160;<br/>paronychia, cellulitis, impetigo, necrotising&#160;<br/>fasciitis and herpes zoster),<br/>ear infections,<br/>oral infections&#160;(including herpes simplex, oral&#160;<br/>herpes and tooth infections),&#160;<br/>reproductive tract infections&#160;(including&#160;<br/>vulvovaginal mycotic infection),&#160;<br/>urinary tract infections&#160;(including&#160;<br/>pyelonephritis),<br/>fungal infections,<br/>joint infections</p>
</div>
<!-- Page 14 -->
<a name="14"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft149{font-size:10px;font-family:HORGHZ+TimesNewRoman;color:#000000;}
	.ft1410{font-size:10px;line-height:23px;font-family:HORGHZ+TimesNewRoman;color:#000000;}
-->
</style>
<div id="page14-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft140">14</p>
<p style="position:absolute;top:96px;left:132px;white-space:nowrap" class="ft141"><b>System&#160;Organ Class</b></p>
<p style="position:absolute;top:96px;left:341px;white-space:nowrap" class="ft141"><b>Frequency</b></p>
<p style="position:absolute;top:96px;left:566px;white-space:nowrap" class="ft141"><b>Adverse Reaction</b></p>
<p style="position:absolute;top:125px;left:309px;white-space:nowrap" class="ft142">Uncommon</p>
<p style="position:absolute;top:125px;left:465px;white-space:nowrap" class="ft144">Neurological infections (including viral&#160;<br/>meningitis),<br/>opportunistic infections and tuberculosis&#160;<br/>(including coccidioidomycosis, histoplasmosis&#160;<br/>and mycobacterium avium complex infection),&#160;<br/>bacterial infections,<br/>eye&#160;infections,<br/>diverticulitis1)</p>
<p style="position:absolute;top:300px;left:114px;white-space:nowrap" class="ft144">Neoplasms benign,&#160;<br/>malignant and unspecified&#160;<br/>(including cysts and&#160;<br/>polyps)*</p>
<p style="position:absolute;top:300px;left:309px;white-space:nowrap" class="ft142">Common</p>
<p style="position:absolute;top:300px;left:465px;white-space:nowrap" class="ft148">Skin cancer excluding melanoma (including&#160;<br/>basal cell carcinoma and squamous cell&#160;<br/>carcinoma),<br/>benign neoplasm</p>
<p style="position:absolute;top:405px;left:309px;white-space:nowrap" class="ft142">Uncommon</p>
<p style="position:absolute;top:405px;left:465px;white-space:nowrap" class="ft145">Lymphoma**,&#160;<br/>solid organ neoplasm (including breast cancer,&#160;<br/>lung neoplasm and thyroid neoplasm),&#160;<br/>melanoma**</p>
<p style="position:absolute;top:505px;left:309px;white-space:nowrap" class="ft142">Rare</p>
<p style="position:absolute;top:505px;left:465px;white-space:nowrap" class="ft142">Leukaemia1)</p>
<p style="position:absolute;top:553px;left:309px;white-space:nowrap" class="ft142">Not&#160;known</p>
<p style="position:absolute;top:553px;left:465px;white-space:nowrap" class="ft148">Hepatosplenic T-cell lymphoma1)<br/>Merkel cell carcinoma (neuroendocrine&#160;<br/>carcinoma of the skin)1),<br/>Kaposi’s sarcoma</p>
<p style="position:absolute;top:666px;left:114px;white-space:nowrap" class="ft144">Blood and the lymphatic&#160;<br/>system disorders*</p>
<p style="position:absolute;top:666px;left:309px;white-space:nowrap" class="ft142">Very common</p>
<p style="position:absolute;top:666px;left:465px;white-space:nowrap" class="ft148">Leukopenia&#160;(including&#160;neutropenia&#160;and&#160;<br/>agranulocytosis),&#160;<br/>anaemia</p>
<p style="position:absolute;top:752px;left:309px;white-space:nowrap" class="ft142">Common</p>
<p style="position:absolute;top:752px;left:465px;white-space:nowrap" class="ft144">Leucocytosis,<br/>thrombocytopenia</p>
<p style="position:absolute;top:810px;left:309px;white-space:nowrap" class="ft142">Uncommon</p>
<p style="position:absolute;top:810px;left:465px;white-space:nowrap" class="ft142">Idiopathic&#160;thrombocytopenic&#160;purpura</p>
<p style="position:absolute;top:849px;left:309px;white-space:nowrap" class="ft142">Rare</p>
<p style="position:absolute;top:849px;left:465px;white-space:nowrap" class="ft142">Pancytopenia</p>
<p style="position:absolute;top:892px;left:114px;white-space:nowrap" class="ft142">Immune system disorders*&#160;Common</p>
<p style="position:absolute;top:892px;left:465px;white-space:nowrap" class="ft148">Hypersensitivity,<br/>allergies (including seasonal allergy)</p>
<p style="position:absolute;top:963px;left:309px;white-space:nowrap" class="ft142">Uncommon</p>
<p style="position:absolute;top:963px;left:465px;white-space:nowrap" class="ft148">Sarcoidosis1),<br/>vasculitis</p>
<p style="position:absolute;top:1034px;left:309px;white-space:nowrap" class="ft142">Rare</p>
<p style="position:absolute;top:1034px;left:465px;white-space:nowrap" class="ft142">Anaphylaxis1)</p>
<p style="position:absolute;top:1082px;left:114px;white-space:nowrap" class="ft142">Metabolism and nutrition&#160;</p>
<p style="position:absolute;top:1082px;left:309px;white-space:nowrap" class="ft142">Very common</p>
<p style="position:absolute;top:1082px;left:465px;white-space:nowrap" class="ft142">Lipids increased</p>
</div>
<!-- Page 15 -->
<a name="15"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page15-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft150">15</p>
<p style="position:absolute;top:96px;left:132px;white-space:nowrap" class="ft151"><b>System&#160;Organ Class</b></p>
<p style="position:absolute;top:96px;left:341px;white-space:nowrap" class="ft151"><b>Frequency</b></p>
<p style="position:absolute;top:96px;left:566px;white-space:nowrap" class="ft151"><b>Adverse Reaction</b></p>
<p style="position:absolute;top:125px;left:114px;white-space:nowrap" class="ft152">disorders</p>
<p style="position:absolute;top:153px;left:309px;white-space:nowrap" class="ft152">Common</p>
<p style="position:absolute;top:153px;left:465px;white-space:nowrap" class="ft158">Hypokalaemia,&#160;<br/>uric acid increased,&#160;<br/>blood sodium abnormal,<br/>hypocalcaemia,<br/>hyperglycaemia,<br/>hypophosphatemia,<br/>dehydration</p>
<p style="position:absolute;top:355px;left:114px;white-space:nowrap" class="ft152">Psychiatric disorders</p>
<p style="position:absolute;top:355px;left:309px;white-space:nowrap" class="ft152">Common</p>
<p style="position:absolute;top:355px;left:465px;white-space:nowrap" class="ft158">Mood alterations (including depression),&#160;<br/>anxiety,<br/>insomnia</p>
<p style="position:absolute;top:450px;left:114px;white-space:nowrap" class="ft152">Nervous system disorders*&#160;Very common</p>
<p style="position:absolute;top:450px;left:465px;white-space:nowrap" class="ft152">Headache</p>
<p style="position:absolute;top:498px;left:309px;white-space:nowrap" class="ft152">Common</p>
<p style="position:absolute;top:498px;left:465px;white-space:nowrap" class="ft158">Paraesthesias (including&#160;hypoesthesia),<br/>migraine,<br/>nerve root compression</p>
<p style="position:absolute;top:588px;left:309px;white-space:nowrap" class="ft152">Uncommon</p>
<p style="position:absolute;top:588px;left:465px;white-space:nowrap" class="ft154">Cerebrovascular accident1),<br/>tremor,<br/>neuropathy &#160;</p>
<p style="position:absolute;top:665px;left:309px;white-space:nowrap" class="ft152">Rare</p>
<p style="position:absolute;top:665px;left:465px;white-space:nowrap" class="ft154">Multiple sclerosis,<br/>demyelinating disorders&#160;(e.g. optic neuritis,&#160;<br/>Guillain-Barré syndrome)&#160;1)</p>
<p style="position:absolute;top:755px;left:114px;white-space:nowrap" class="ft152">Eye&#160;disorders</p>
<p style="position:absolute;top:755px;left:309px;white-space:nowrap" class="ft152">Common</p>
<p style="position:absolute;top:755px;left:465px;white-space:nowrap" class="ft158">Visual impairment,<br/>conjunctivitis,<br/>blepharitis,<br/>eye swelling</p>
<p style="position:absolute;top:868px;left:309px;white-space:nowrap" class="ft152">Uncommon</p>
<p style="position:absolute;top:868px;left:465px;white-space:nowrap" class="ft152">Diplopia</p>
<p style="position:absolute;top:912px;left:114px;white-space:nowrap" class="ft154">Ear and labyrinth&#160;<br/>disorders&#160;</p>
<p style="position:absolute;top:912px;left:309px;white-space:nowrap" class="ft152">Common</p>
<p style="position:absolute;top:912px;left:465px;white-space:nowrap" class="ft152">Vertigo</p>
<p style="position:absolute;top:955px;left:309px;white-space:nowrap" class="ft152">Uncommon</p>
<p style="position:absolute;top:955px;left:465px;white-space:nowrap" class="ft154">Deafness,&#160;<br/>tinnitus</p>
<p style="position:absolute;top:1017px;left:114px;white-space:nowrap" class="ft152">Cardiac disorders*&#160;</p>
<p style="position:absolute;top:1017px;left:309px;white-space:nowrap" class="ft152">Common</p>
<p style="position:absolute;top:1017px;left:465px;white-space:nowrap" class="ft152">Tachycardia</p>
<p style="position:absolute;top:1065px;left:309px;white-space:nowrap" class="ft152">Uncommon</p>
<p style="position:absolute;top:1065px;left:465px;white-space:nowrap" class="ft152">Myocardial infarction1),</p>
</div>
<!-- Page 16 -->
<a name="16"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page16-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft160">16</p>
<p style="position:absolute;top:96px;left:132px;white-space:nowrap" class="ft161"><b>System&#160;Organ Class</b></p>
<p style="position:absolute;top:96px;left:341px;white-space:nowrap" class="ft161"><b>Frequency</b></p>
<p style="position:absolute;top:96px;left:566px;white-space:nowrap" class="ft161"><b>Adverse Reaction</b></p>
<p style="position:absolute;top:129px;left:465px;white-space:nowrap" class="ft168">arrhythmia,<br/>congestive heart failure</p>
<p style="position:absolute;top:195px;left:309px;white-space:nowrap" class="ft162">Rare</p>
<p style="position:absolute;top:195px;left:465px;white-space:nowrap" class="ft162">Cardiac arrest</p>
<p style="position:absolute;top:239px;left:114px;white-space:nowrap" class="ft162">Vascular disorders</p>
<p style="position:absolute;top:239px;left:309px;white-space:nowrap" class="ft162">Common</p>
<p style="position:absolute;top:239px;left:465px;white-space:nowrap" class="ft168">Hypertension,&#160;<br/>flushing,&#160;<br/>haematoma</p>
<p style="position:absolute;top:329px;left:309px;white-space:nowrap" class="ft162">Uncommon</p>
<p style="position:absolute;top:329px;left:465px;white-space:nowrap" class="ft164">Aortic&#160;aneurysm,<br/>vascular arterial occlusion,<br/>thrombophlebitis &#160;&#160;</p>
<p style="position:absolute;top:410px;left:114px;white-space:nowrap" class="ft164">Respiratory, thoracic and&#160;<br/>mediastinal disorders*</p>
<p style="position:absolute;top:410px;left:309px;white-space:nowrap" class="ft162">Common</p>
<p style="position:absolute;top:410px;left:465px;white-space:nowrap" class="ft168">Asthma,<br/>dyspnoea,<br/>cough</p>
<p style="position:absolute;top:500px;left:309px;white-space:nowrap" class="ft162">Uncommon</p>
<p style="position:absolute;top:500px;left:465px;white-space:nowrap" class="ft165">Pulmonary embolism1),<br/>interstitial lung disease,&#160;<br/>chronic obstructive pulmonary disease,<br/>pneumonitis,<br/>pleural effusion1)</p>
<p style="position:absolute;top:619px;left:309px;white-space:nowrap" class="ft162">Rare</p>
<p style="position:absolute;top:615px;left:465px;white-space:nowrap" class="ft162">Pulmonary fibrosis1)</p>
<p style="position:absolute;top:658px;left:114px;white-space:nowrap" class="ft162">Gastrointestinal disorders</p>
<p style="position:absolute;top:658px;left:309px;white-space:nowrap" class="ft162">Very common</p>
<p style="position:absolute;top:658px;left:465px;white-space:nowrap" class="ft168">Abdominal pain,&#160;<br/>nausea and vomiting</p>
<p style="position:absolute;top:725px;left:309px;white-space:nowrap" class="ft162">Common</p>
<p style="position:absolute;top:725px;left:465px;white-space:nowrap" class="ft164">GI haemorrhage,&#160;<br/>dyspepsia,<br/>gastroesophageal reflux disease,<br/>sicca syndrome</p>
<p style="position:absolute;top:820px;left:309px;white-space:nowrap" class="ft162">Uncommon</p>
<p style="position:absolute;top:820px;left:465px;white-space:nowrap" class="ft164">Pancreatitis,&#160;<br/>dysphagia,<br/>face oedema</p>
<p style="position:absolute;top:901px;left:309px;white-space:nowrap" class="ft162">Rare</p>
<p style="position:absolute;top:901px;left:465px;white-space:nowrap" class="ft162">Intestinal perforation1)</p>
<p style="position:absolute;top:949px;left:114px;white-space:nowrap" class="ft162">Hepato-biliary disorders*</p>
<p style="position:absolute;top:949px;left:309px;white-space:nowrap" class="ft162">Very Common</p>
<p style="position:absolute;top:949px;left:465px;white-space:nowrap" class="ft162">Elevated liver enzymes</p>
<p style="position:absolute;top:993px;left:309px;white-space:nowrap" class="ft162">Uncommon</p>
<p style="position:absolute;top:993px;left:465px;white-space:nowrap" class="ft164">Cholecystitis and cholelithiasis,<br/>hepatic steatosis,<br/>bilirubin increased</p>
<p style="position:absolute;top:1074px;left:309px;white-space:nowrap" class="ft162">Rare</p>
<p style="position:absolute;top:1074px;left:465px;white-space:nowrap" class="ft162">Hepatitis</p>
</div>
<!-- Page 17 -->
<a name="17"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page17-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft170">17</p>
<p style="position:absolute;top:96px;left:132px;white-space:nowrap" class="ft171"><b>System&#160;Organ Class</b></p>
<p style="position:absolute;top:96px;left:341px;white-space:nowrap" class="ft171"><b>Frequency</b></p>
<p style="position:absolute;top:96px;left:566px;white-space:nowrap" class="ft171"><b>Adverse Reaction</b></p>
<p style="position:absolute;top:129px;left:465px;white-space:nowrap" class="ft1710">reactivation of hepatitis B1)&#160;<br/>autoimmune&#160;hepatitis1)</p>
<p style="position:absolute;top:195px;left:309px;white-space:nowrap" class="ft172">Not known</p>
<p style="position:absolute;top:195px;left:465px;white-space:nowrap" class="ft172">Liver failure1)</p>
<p style="position:absolute;top:243px;left:114px;white-space:nowrap" class="ft174">Skin and subcutaneous&#160;<br/>tissue disorders</p>
<p style="position:absolute;top:243px;left:309px;white-space:nowrap" class="ft172">Very Common</p>
<p style="position:absolute;top:243px;left:465px;white-space:nowrap" class="ft172">Rash (including exfoliative rash)</p>
<p style="position:absolute;top:287px;left:309px;white-space:nowrap" class="ft172">Common</p>
<p style="position:absolute;top:287px;left:465px;white-space:nowrap" class="ft175">Worsening or new onset of&#160;psoriasis(including&#160;<br/>palmoplantar pustular psoriasis)1),<br/>urticaria,<br/>bruising (including purpura),&#160;<br/>dermatitis (including eczema),<br/>onychoclasis,&#160;<br/>hyperhidrosis,<br/>alopecia1),<br/>pruritus&#160;</p>
<p style="position:absolute;top:477px;left:309px;white-space:nowrap" class="ft172">Uncommon</p>
<p style="position:absolute;top:477px;left:465px;white-space:nowrap" class="ft174">Night sweats,<br/>scar</p>
<p style="position:absolute;top:539px;left:309px;white-space:nowrap" class="ft172">Rare</p>
<p style="position:absolute;top:539px;left:465px;white-space:nowrap" class="ft1710">Erythema multiforme1),<br/>Stevens-Johnson syndrome1),<br/>angioedema1),<br/>cutaneous vasculitis1)<br/>lichenoid skin&#160;reaction1)</p>
<p style="position:absolute;top:680px;left:309px;white-space:nowrap" class="ft172">Not known</p>
<p style="position:absolute;top:680px;left:465px;white-space:nowrap" class="ft172">Worsening of symptoms of dermatomyositis1)</p>
<p style="position:absolute;top:728px;left:114px;white-space:nowrap" class="ft174">Musculoskeletal and&#160;<br/>connective tissue disorders</p>
<p style="position:absolute;top:728px;left:309px;white-space:nowrap" class="ft172">Very common</p>
<p style="position:absolute;top:728px;left:465px;white-space:nowrap" class="ft172">Musculoskeletal pain</p>
<p style="position:absolute;top:776px;left:309px;white-space:nowrap" class="ft172">Common</p>
<p style="position:absolute;top:776px;left:465px;white-space:nowrap" class="ft174">Muscle spasms (including blood creatine&#160;<br/>phosphokinase increased)</p>
<p style="position:absolute;top:838px;left:309px;white-space:nowrap" class="ft172">Uncommon</p>
<p style="position:absolute;top:838px;left:465px;white-space:nowrap" class="ft175">Rhabdomyolysis,<br/>systemic lupus erythematosus</p>
<p style="position:absolute;top:896px;left:309px;white-space:nowrap" class="ft172">Rare</p>
<p style="position:absolute;top:896px;left:465px;white-space:nowrap" class="ft172">Lupus-like syndrome1)</p>
<p style="position:absolute;top:939px;left:114px;white-space:nowrap" class="ft175">Renal and urinary&#160;<br/>disorders&#160;</p>
<p style="position:absolute;top:939px;left:309px;white-space:nowrap" class="ft172">Common</p>
<p style="position:absolute;top:939px;left:465px;white-space:nowrap" class="ft178">Renal impairment,<br/>haematuria</p>
<p style="position:absolute;top:1005px;left:309px;white-space:nowrap" class="ft172">Uncommon</p>
<p style="position:absolute;top:1005px;left:465px;white-space:nowrap" class="ft172">Nocturia</p>
<p style="position:absolute;top:1049px;left:114px;white-space:nowrap" class="ft174">Reproductive system and&#160;<br/>breast disorders</p>
<p style="position:absolute;top:1049px;left:309px;white-space:nowrap" class="ft172">Uncommon</p>
<p style="position:absolute;top:1049px;left:465px;white-space:nowrap" class="ft172">Erectile dysfunction</p>
</div>
<!-- Page 18 -->
<a name="18"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page18-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft180">18</p>
<p style="position:absolute;top:96px;left:132px;white-space:nowrap" class="ft181"><b>System&#160;Organ Class</b></p>
<p style="position:absolute;top:96px;left:341px;white-space:nowrap" class="ft181"><b>Frequency</b></p>
<p style="position:absolute;top:96px;left:566px;white-space:nowrap" class="ft181"><b>Adverse Reaction</b></p>
<p style="position:absolute;top:129px;left:114px;white-space:nowrap" class="ft184">General disorders and&#160;<br/>administration site&#160;<br/>conditions*</p>
<p style="position:absolute;top:129px;left:309px;white-space:nowrap" class="ft182">Very Common</p>
<p style="position:absolute;top:129px;left:465px;white-space:nowrap" class="ft184">Injection site reaction (including injection site&#160;<br/>erythema)</p>
<p style="position:absolute;top:191px;left:309px;white-space:nowrap" class="ft182">Common</p>
<p style="position:absolute;top:191px;left:465px;white-space:nowrap" class="ft185">Chest pain,&#160;<br/>oedema,<br/>pyrexia1)</p>
<p style="position:absolute;top:268px;left:309px;white-space:nowrap" class="ft182">Uncommon</p>
<p style="position:absolute;top:268px;left:465px;white-space:nowrap" class="ft182">Inflammation</p>
<p style="position:absolute;top:311px;left:114px;white-space:nowrap" class="ft182">Investigations*</p>
<p style="position:absolute;top:311px;left:309px;white-space:nowrap" class="ft182">Common</p>
<p style="position:absolute;top:311px;left:465px;white-space:nowrap" class="ft188">Coagulation and bleeding disorders (including&#160;<br/>activated partial thromboplastin time prolonged),&#160;<br/>autoantibody test positive (including double&#160;<br/>stranded DNA antibody),&#160;<br/>blood lactate dehydrogenase increased</p>
<p style="position:absolute;top:444px;left:309px;white-space:nowrap" class="ft182">Not known</p>
<p style="position:absolute;top:444px;left:465px;white-space:nowrap" class="ft182">Weight increased2)</p>
<p style="position:absolute;top:468px;left:114px;white-space:nowrap" class="ft184">Injury, poisoning&#160;and&#160;<br/>procedural complications</p>
<p style="position:absolute;top:468px;left:309px;white-space:nowrap" class="ft182">Common</p>
<p style="position:absolute;top:468px;left:465px;white-space:nowrap" class="ft182">Impaired healing</p>
<p style="position:absolute;top:528px;left:106px;white-space:nowrap" class="ft184">*&#160;further information is found elsewhere in sections 4.3, 4.4 and 4.8<br/>**&#160;including open label extension studies</p>
<p style="position:absolute;top:565px;left:106px;white-space:nowrap" class="ft189">1)&#160;including spontaneous reporting data</p>
<p style="position:absolute;top:584px;left:106px;white-space:nowrap" class="ft184">2)&#160;The mean weight change from baseline for adalimumab ranged from 0.3&#160;kg to 1.0&#160;kg across adult&#160;<br/>indications compared to (minus)&#160;-0.4&#160;kg to 0.4&#160;kg for placebo over a treatment period of 4-6 months.&#160;<br/>Weight increase of 5-6&#160;kg has also been observed&#160;in long-term&#160;extension studies with mean exposures of&#160;<br/>approximately 1-2 years without control group,&#160;particularly in patients with Crohn’s disease and&#160;<br/>Ulcerative colitis. The mechanism behind this effect is unclear but could be associated with the&#160;<br/>anti-inflammatory effect of adalimumab.</p>
<p style="position:absolute;top:718px;left:106px;white-space:nowrap" class="ft182">Uveitis</p>
<p style="position:absolute;top:756px;left:106px;white-space:nowrap" class="ft185">The safety&#160;profile for patients with uveitis treated with Humira every other week was consistent with the&#160;<br/>known safety profile of Humira.</p>
<p style="position:absolute;top:813px;left:106px;white-space:nowrap" class="ft182">Description of selected adverse reactions</p>
<p style="position:absolute;top:851px;left:106px;white-space:nowrap" class="ft183"><i>Injection site reactions</i></p>
<p style="position:absolute;top:889px;left:106px;white-space:nowrap" class="ft184">In the pivotal controlled trials in adults and children, 12.9% of patients treated with Humira developed&#160;<br/>injection site reactions (erythema and/or itching, haemorrhage, pain or swelling), compared to&#160;7.2% of&#160;<br/>patients receiving placebo or active control. Injection site reactions generally did not necessitate&#160;<br/>discontinuation of the medicinal product.</p>
<p style="position:absolute;top:984px;left:106px;white-space:nowrap" class="ft183"><i>Infections&#160;</i></p>
<p style="position:absolute;top:1022px;left:106px;white-space:nowrap" class="ft184">In the pivotal controlled trials in adults and children, the rate of infection was 1.51 per patient year in the&#160;<br/>Humira treated patients and 1.46 per patient year in the placebo and active control-treated patients. The&#160;<br/>infections consisted primarily of&#160;nasopharyngitis, upper respiratory tract infection, and sinusitis.&#160;Most&#160;<br/>patients continued on Humira after the infection resolved. &#160;</p>
</div>
<!-- Page 19 -->
<a name="19"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page19-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft190">19</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft194">The incidence of&#160;serious infections was 0.04&#160;per patient year in Humira treated patients and 0.03&#160;per&#160;<br/>patient year in placebo and active control&#160;−&#160;treated patients. &#160;</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft194">In controlled and open label adult and paediatric studies with Humira, serious infections (including fatal&#160;<br/>infections, which occurred rarely) have been reported, which include reports of tuberculosis (including&#160;<br/>miliary and extra-pulmonary locations) and invasive opportunistic infections (e.g. disseminated&#160;or&#160;<br/>extrapulmonary&#160;histoplasmosis,&#160;blastomycosis, coccidioidomycosis, pneumocystis,&#160;candidiasis,&#160;<br/>aspergillosis and listeriosis). Most of the cases of tuberculosis occurred within the first eight months after&#160;<br/>initiation of therapy and may reflect recrudescence of latent disease.</p>
<p style="position:absolute;top:295px;left:106px;white-space:nowrap" class="ft193"><i>Malignancies and lymphoproliferative disorders</i></p>
<p style="position:absolute;top:333px;left:106px;white-space:nowrap" class="ft194">No&#160;malignancies were observed in 249 paediatric patients with an exposure of 655.6 patient years during&#160;<br/>Humira trials in patients with juvenile idiopathic arthritis (polyarticular juvenile idiopathic arthritis and&#160;<br/>enthesitis-related arthritis).&#160;In addition, no malignancies were observed in 192 paediatric patients with an&#160;<br/>exposure of&#160;498.1&#160;patient years during Humira trials&#160;in paediatric patients with Crohn’s disease. No&#160;<br/>malignancies were observed in 77 paediatric patients with an exposure of 80.0 patient years during a&#160;<br/>Humira trial in paediatric patients with chronic plaque psoriasis.&#160;No malignancies were observed in 60&#160;<br/>paediatric patients with an exposure of 58.4 patient years during a Humira trial in paediatric patients with&#160;<br/>uveitis.</p>
<p style="position:absolute;top:503px;left:106px;white-space:nowrap" class="ft195">During the controlled portions of pivotal Humira trials in adults of at least 12&#160;weeks in duration in patients&#160;<br/>with moderately to severely active rheumatoid arthritis, ankylosing spondylitis, axial spondyloarthritis&#160;<br/>without radiographic evidence of AS, psoriatic arthritis, psoriasis, hidradenitis suppurativa, Crohn’s&#160;<br/>disease,&#160;ulcerative colitis&#160;and uveitis, malignancies, other than lymphoma and non-melanoma skin cancer,&#160;<br/>were observed at a rate (95% confidence interval) of&#160;6.8 (4.4, 10.5)&#160;per 1,000 patient-years among&#160;5,291<br/>Humira treated patients&#160;<i>versus&#160;</i>a rate of&#160;6.3 (3.4, 11.8)&#160;per 1,000 patient-years among&#160;3,444&#160;control&#160;<br/>patients (median duration&#160;of treatment was 4.0 months for Humira and&#160;3.8&#160;months for control-treated&#160;<br/>patients). The rate (95% confidence interval) of non-melanoma skin cancers was&#160;8.8 (6.0, 13.0)&#160;per 1,000&#160;<br/>patient-years among Humira-treated patients and&#160;3.2 (1.3, 7.6)&#160;per 1,000&#160;patient-years among control&#160;<br/>patients. Of these skin cancers, squamous cell carcinomas occurred at rates (95% confidence interval) of&#160;<br/>2.7 (1.4, 5.4)&#160;per 1,000 patient-years among Humira-treated patients and&#160;0.6 (0.1, 4.5)&#160;per 1,000 patient-<br/>years among control patients. The rate (95% confidence interval) of lymphomas was 0.7 (0.2, 2.7) per&#160;<br/>1,000 patient-years among Humira-treated patients and&#160;0.6 (0.1, 4.5)&#160;per 1,000 patient-years among&#160;<br/>control patients.</p>
<p style="position:absolute;top:788px;left:106px;white-space:nowrap" class="ft195">When combining controlled portions of these trials and&#160;ongoing and completed open label extension&#160;<br/>studies with a median duration of approximately&#160;3.3&#160;years including&#160;6,427&#160;patients and over&#160;26,439<br/>patient-years of therapy, the observed rate of malignancies, other than lymphoma and non-melanoma skin&#160;<br/>cancers is&#160;approximately 8.5 per 1,000 patient years. The observed rate of non-melanoma skin cancers is&#160;<br/>approximately&#160;9.6&#160;per 1,000 patient years, and the observed rate of lymphomas is approximately 1.3 per&#160;<br/>1,000 patient years.</p>
<p style="position:absolute;top:921px;left:106px;white-space:nowrap" class="ft194">In post-marketing experience from January 2003 to December 2010, predominantly in patients with&#160;<br/>rheumatoid arthritis, the reported rate of malignancies is approximately 2.7 per 1,000 patient treatment&#160;<br/>years. The reported rates for non-melanoma skin cancers and lymphomas are approximately 0.2&#160;and 0.3&#160;<br/>per 1,000 patient treatment years, respectively (see section 4.4).</p>
<p style="position:absolute;top:1016px;left:106px;white-space:nowrap" class="ft194">Rare post-marketing cases of hepatosplenic T-cell&#160;lymphoma have been reported in patients treated with&#160;<br/>adalimumab (see section 4.4).</p>
<p style="position:absolute;top:1072px;left:106px;white-space:nowrap" class="ft193"><i>Autoantibodies&#160;</i></p>
</div>
<!-- Page 20 -->
<a name="20"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page20-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft200">20</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft204">Patients had serum samples&#160;tested for autoantibodies at multiple time points in rheumatoid arthritis studies&#160;<br/>I&#160;−&#160;V. In these trials, 11.9% of patients treated with Humira and 8.1% of placebo and active&#160;<br/>control&#160;−&#160;treated patients that had negative baseline anti-nuclear antibody titres reported positive titres at&#160;<br/>Week&#160;24. Two patients out of 3,441 treated with Humira in all rheumatoid arthritis and psoriatic arthritis&#160;<br/>studies developed clinical signs suggestive of new-onset lupus-like syndrome. The patients improved&#160;<br/>following discontinuation of therapy. No patients developed lupus nephritis or central nervous system&#160;<br/>symptoms.</p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft203"><i>Hepato-biliary events</i></p>
<p style="position:absolute;top:295px;left:106px;white-space:nowrap" class="ft204">In controlled Phase 3 trials of Humira in patients with rheumatoid arthritis and psoriatic arthritis with a&#160;<br/>control period duration ranging&#160;from 4 to 104&#160;weeks, ALT elevations&#160;≥&#160;3&#160;x&#160;ULN occurred in 3.7% of&#160;<br/>Humira-treated patients and 1.6% of control-treated patients.&#160;</p>
<p style="position:absolute;top:370px;left:106px;white-space:nowrap" class="ft204">In controlled Phase 3 trials of Humira in patients with polyarticular juvenile idiopathic arthritis who were&#160;<br/>4 to 17&#160;years and&#160;enthesitis-related arthritis who were 6 to 17&#160;years, ALT elevations&#160;≥&#160;3&#160;x&#160;ULN occurred&#160;<br/>in 6.1% of Humira-treated patients and 1.3% of control-treated patients. Most ALT elevations occurred&#160;<br/>with concomitant methotrexate use. No ALT elevations&#160;≥&#160;3&#160;x&#160;ULN occurred in the Phase 3 trial of Humira&#160;<br/>in patients with polyarticular juvenile idiopathic arthritis who were 2 to &lt;&#160;4&#160;years.</p>
<p style="position:absolute;top:485px;left:106px;white-space:nowrap" class="ft204">In controlled Phase 3 trials of Humira in patients with&#160;Crohn’s disease and ulcerative colitis with a control&#160;<br/>period ranging from 4&#160;to 52&#160;weeks. ALT elevations&#160;≥&#160;3&#160;x&#160;ULN occurred in 0.9% of Humira-treated&#160;<br/>patients and 0.9% of controlled-treated patients.</p>
<p style="position:absolute;top:560px;left:106px;white-space:nowrap" class="ft205">In the Phase 3 trial of Humira in patients with paediatric Crohn’s disease which evaluated efficacy and&#160;<br/>safety of two body weight&#160;adjusted maintenance dose regimens following body weight adjusted induction&#160;<br/>therapy up to 52&#160;weeks of treatment, ALT elevations&#160;≥&#160;3&#160;x&#160;ULN occurred in 2.6%&#160;(5/192)&#160;of patients&#160;of&#160;<br/>whom 4 were receiving&#160;concomitant immunosuppressants at baseline.</p>
<p style="position:absolute;top:655px;left:106px;white-space:nowrap" class="ft205">In controlled Phase 3 trials of Humira in patients with plaque&#160;psoriasis&#160;with a control period duration&#160;<br/>ranging from 12 to 24&#160;weeks, ALT elevations&#160;≥&#160;3&#160;x&#160;ULN occurred in 1.8% of Humira-treated patients and&#160;<br/>1.8% of control-treated patients.&#160;</p>
<p style="position:absolute;top:731px;left:106px;white-space:nowrap" class="ft205">No&#160;ALT elevations&#160;≥&#160;3&#160;x&#160;ULN occurred in the Phase 3 trial of Humira in paediatric patients with plaque&#160;<br/>psoriasis.</p>
<p style="position:absolute;top:788px;left:106px;white-space:nowrap" class="ft204">In controlled trials of Humira (initial doses of 80&#160;mg at Week 0 followed by 40&#160;mg&#160;every other week&#160;<br/>starting at Week 1) in&#160;adult patients with uveitis up to 80 weeks with a median exposure of 166.5 days and&#160;<br/>105.0 days in Humira-treated and control-treated patients, respectively, ALT elevations&#160;≥&#160;3&#160;x&#160;ULN&#160;<br/>occurred in 2.4% of Humira-treated patients and 2.4% of control-treated patients.&#160;</p>
<p style="position:absolute;top:883px;left:106px;white-space:nowrap" class="ft205">Across all indications&#160;in clinical trials patients with raised ALT were asymptomatic and in most cases&#160;<br/>elevations were transient and resolved on continued treatment. However, there have also been post-<br/>marketing reports of liver failure as well as less severe liver disorders that may precede liver failure, such&#160;<br/>as hepatitis including autoimmune hepatitis in patients receiving adalimumab.</p>
<p style="position:absolute;top:978px;left:106px;white-space:nowrap" class="ft202">Concurrent treatment with azathioprine/6-mercaptopurine</p>
<p style="position:absolute;top:1016px;left:106px;white-space:nowrap" class="ft204">In adult Crohn’s disease studies, higher incidences of malignant and serious infection-related adverse&#160;<br/>events were seen with the combination of Humira and azathioprine/6-mercaptopurine compared with&#160;<br/>Humira alone.</p>
</div>
<!-- Page 21 -->
<a name="21"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft2111{font-size:17px;font-family:HORGHZ+TimesNewRoman;color:#0000ff;}
-->
</style>
<div id="page21-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft210">21</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft212">Reporting of suspected adverse reactions</p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft214">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows&#160;<br/>continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are&#160;<br/>asked to report any suspected adverse reactions via&#160;<a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">the national reporting system listed in&#160;Appendix V.</a></p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft211"><b>4.9</b></p>
<p style="position:absolute;top:200px;left:160px;white-space:nowrap" class="ft211"><b>Overdose</b></p>
<p style="position:absolute;top:239px;left:106px;white-space:nowrap" class="ft214">No dose-limiting toxicity was observed during clinical trials. The highest dose level evaluated has been&#160;<br/>multiple intravenous doses of 10&#160;mg/kg, which is approximately 15&#160;times the recommended dose.&#160;</p>
<p style="position:absolute;top:315px;left:106px;white-space:nowrap" class="ft211"><b>5.</b></p>
<p style="position:absolute;top:315px;left:148px;white-space:nowrap" class="ft211"><b>PHARMACOLOGICAL PROPERTIES</b></p>
<p style="position:absolute;top:353px;left:106px;white-space:nowrap" class="ft211"><b>5.1</b></p>
<p style="position:absolute;top:353px;left:148px;white-space:nowrap" class="ft211"><b>Pharmacodynamic properties</b></p>
<p style="position:absolute;top:391px;left:106px;white-space:nowrap" class="ft214">Pharmacotherapeutic group: Immunosuppressants, Tumour Necrosis&#160;Factor alpha (TNF-α) inhibitors.&#160;<br/>ATC code: L04AB04</p>
<p style="position:absolute;top:448px;left:106px;white-space:nowrap" class="ft212">Mechanism&#160;of action</p>
<p style="position:absolute;top:486px;left:106px;white-space:nowrap" class="ft214">Adalimumab binds specifically to TNF and neutralises the biological function of TNF by blocking its&#160;<br/>interaction with the p55 and p75 cell surface TNF receptors. &#160;</p>
<p style="position:absolute;top:543px;left:106px;white-space:nowrap" class="ft214">Adalimumab also&#160;modulates biological responses that are induced or regulated by TNF, including changes&#160;<br/>in the levels of adhesion molecules responsible for leukocyte migration (ELAM-1, VCAM-1, and ICAM-1&#160;<br/>with an IC50&#160;of&#160;0.1-0.2 nM).&#160;</p>
<p style="position:absolute;top:619px;left:106px;white-space:nowrap" class="ft212">Pharmacodynamic effects&#160;</p>
<p style="position:absolute;top:657px;left:106px;white-space:nowrap" class="ft215">After&#160;treatment with Humira, a rapid decrease in levels of acute phase reactants of inflammation&#160;<br/>(C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)) and serum cytokines (IL-6) was&#160;<br/>observed, compared to baseline in patients with rheumatoid arthritis. Serum levels of matrix&#160;<br/>metalloproteinases (MMP-1 and MMP-3) that produce tissue remodelling responsible for cartilage&#160;<br/>destruction were also decreased after Humira administration. Patients treated with Humira usually&#160;<br/>experienced improvement in haematological signs of chronic inflammation.</p>
<p style="position:absolute;top:790px;left:106px;white-space:nowrap" class="ft215">A rapid decrease in CRP levels was also observed in patients with polyarticular juvenile idiopathic&#160;<br/>arthritis, Crohn’s disease, ulcerative colitis and hidradenitis suppurativa after treatment with Humira. In&#160;<br/>patients with Crohn’s disease,&#160;a reduction of the number of cells expressing inflammatory markers in the&#160;<br/>colon including a significant reduction of expression of TNFα was seen. Endoscopic studies in intestinal&#160;<br/>mucosa have shown evidence of mucosal healing in adalimumab treated patients.</p>
<p style="position:absolute;top:904px;left:106px;white-space:nowrap" class="ft212">Clinical efficacy and safety</p>
<p style="position:absolute;top:941px;left:106px;white-space:nowrap" class="ft213"><i>Adults with rheumatoid arthritis</i></p>
<p style="position:absolute;top:980px;left:106px;white-space:nowrap" class="ft214">Humira was evaluated in over 3,000 patients in all rheumatoid arthritis clinical trials. The efficacy and&#160;<br/>safety of Humira were assessed in five randomised, double-blind&#160;and well-controlled studies. Some&#160;<br/>patients were treated for up to 120&#160;months duration.&#160;</p>
<p style="position:absolute;top:1055px;left:106px;white-space:nowrap" class="ft212">RA study I evaluated 271 patients with moderately to severely active rheumatoid arthritis who were&#160;</p>
<p style="position:absolute;top:1073px;left:106px;white-space:nowrap" class="ft216">&#160;18&#160;years old, had failed therapy with at least one disease-modifying, anti&#160;rheumatic drug and had&#160;</p>
</div>
<!-- Page 22 -->
<a name="22"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page22-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft220">22</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft224">insufficient efficacy with methotrexate at doses of 12.5 to 25&#160;mg (10&#160;mg if methotrexate-intolerant) every&#160;<br/>week and whose methotrexate dose remained constant at 10 to 25&#160;mg&#160;every&#160;week. Doses of 20, 40 or&#160;<br/>80&#160;mg of Humira or&#160;placebo were given every other week for 24&#160;weeks.&#160;</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft222">RA study II evaluated 544 patients with moderately to severely active rheumatoid arthritis who were&#160;</p>
<p style="position:absolute;top:180px;left:106px;white-space:nowrap" class="ft224">&#160;18&#160;years old and had failed therapy with at least one disease-modifying, anti-rheumatic drugs. Doses of&#160;<br/>20 or 40&#160;mg of Humira were given by subcutaneous injection every other week with placebo on alternative&#160;<br/>weeks or every week for 26&#160;weeks; placebo was given every week for the same duration. No other&#160;<br/>disease-modifying anti-rheumatic drugs were allowed.</p>
<p style="position:absolute;top:277px;left:106px;white-space:nowrap" class="ft222">RA study III evaluated 619 patients with moderately to severely active rheumatoid arthritis who were&#160;</p>
<p style="position:absolute;top:295px;left:106px;white-space:nowrap" class="ft224">&#160;18&#160;years old, and who had an ineffective response to methotrexate at doses of 12.5 to 25&#160;mg or have&#160;<br/>been intolerant to 10&#160;mg of methotrexate every week. There were three&#160;groups in this study. The first&#160;<br/>received placebo injections every week for 52&#160;weeks. The second received 20&#160;mg of Humira every week&#160;<br/>for 52&#160;weeks. The third group received 40&#160;mg&#160;of Humira every other week with placebo injections on&#160;<br/>alternate&#160;weeks.&#160;Upon completion of the first 52&#160;weeks, 457 patients enrolled in an open-label extension&#160;<br/>phase in which 40&#160;mg&#160;of Humira/MTX was administered every&#160;other week up to 10&#160;years.</p>
<p style="position:absolute;top:430px;left:106px;white-space:nowrap" class="ft227">RA study IV primarily assessed safety in 636 patients with moderately to severely active rheumatoid&#160;<br/>arthritis who were&#160;</p>
<p style="position:absolute;top:448px;left:230px;white-space:nowrap" class="ft226">&#160;18&#160;years old. Patients were permitted to be either disease-modifying, anti-rheumatic&#160;</p>
<p style="position:absolute;top:469px;left:106px;white-space:nowrap" class="ft225">drug-naïve or to remain on their pre-existing rheumatologic therapy provided that therapy was stable for a&#160;<br/>minimum of 28&#160;days. These therapies include methotrexate, leflunomide, hydroxychloroquine,&#160;<br/>sulfasalazine and/or gold salts. Patients were randomised to 40&#160;mg&#160;of Humira or placebo every other week&#160;<br/>for&#160;24&#160;weeks. &#160;</p>
<p style="position:absolute;top:564px;left:106px;white-space:nowrap" class="ft224">RA study V evaluated 799 methotrexate-naïve, adult patients with moderate to severely active early&#160;<br/>rheumatoid arthritis (mean disease duration less than 9&#160;months). This study evaluated the efficacy of&#160;<br/>Humira 40&#160;mg&#160;every other week/methotrexate combination therapy, Humira&#160;40&#160;mg&#160;every other week&#160;<br/>monotherapy and methotrexate monotherapy in reducing the signs and symptoms and rate of progression&#160;<br/>of joint damage in rheumatoid arthritis for 104&#160;weeks.&#160;Upon completion of the first 104 weeks, 497&#160;<br/>patients enrolled in an open-label extension phase in which 40&#160;mg&#160;of Humira was administered every&#160;<br/>other week up to 10&#160;years.</p>
<p style="position:absolute;top:716px;left:106px;white-space:nowrap" class="ft224">The primary end point in RA studies I, II and III and the secondary endpoint in RA study IV was the&#160;<br/>percent of patients who achieved&#160;an ACR 20 response at Week&#160;24 or 26. The primary endpoint in RA&#160;<br/>study V was the percent of patients who achieved an ACR 50 response at Week&#160;52. RA studies III and V&#160;<br/>had an additional primary endpoint at 52&#160;weeks of retardation of disease progression (as detected by X-ray&#160;<br/>results). RA study III also had a primary endpoint of changes in quality of life.&#160;</p>
<p style="position:absolute;top:830px;left:106px;white-space:nowrap" class="ft223"><i>ACR response</i></p>
<p style="position:absolute;top:868px;left:106px;white-space:nowrap" class="ft224">The percent of Humira-treated patients achieving ACR 20, 50 and 70 responses was consistent across RA&#160;<br/>studies I, II and III. The results for&#160;the 40&#160;mg&#160;every other week&#160;dose are summarised in Table&#160;7.&#160;</p>
</div>
<!-- Page 23 -->
<a name="23"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft2312{font-size:10px;line-height:18px;font-family:HORGHZ+TimesNewRoman;color:#000000;}
-->
</style>
<div id="page23-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft230">23</p>
<p style="position:absolute;top:105px;left:429px;white-space:nowrap" class="ft231"><b>Table&#160;7</b></p>
<p style="position:absolute;top:124px;left:297px;white-space:nowrap" class="ft231"><b>ACR Responses in Placebo-Controlled Trials</b></p>
<p style="position:absolute;top:143px;left:383px;white-space:nowrap" class="ft231"><b>(Percent of Patients)</b></p>
<p style="position:absolute;top:182px;left:113px;white-space:nowrap" class="ft232">Response</p>
<p style="position:absolute;top:182px;left:255px;white-space:nowrap" class="ft232">RA Study Ia**</p>
<p style="position:absolute;top:182px;left:448px;white-space:nowrap" class="ft232">RA Study IIa**</p>
<p style="position:absolute;top:182px;left:643px;white-space:nowrap" class="ft232">RA Study IIIa**</p>
<p style="position:absolute;top:221px;left:217px;white-space:nowrap" class="ft232">Placebo/&#160;</p>
<p style="position:absolute;top:240px;left:224px;white-space:nowrap" class="ft232">MTXc</p>
<p style="position:absolute;top:259px;left:228px;white-space:nowrap" class="ft232">n=60</p>
<p style="position:absolute;top:221px;left:292px;white-space:nowrap" class="ft232">Humirab/ MTXc</p>
<p style="position:absolute;top:240px;left:328px;white-space:nowrap" class="ft232">n=63</p>
<p style="position:absolute;top:221px;left:426px;white-space:nowrap" class="ft232">Placebo</p>
<p style="position:absolute;top:240px;left:431px;white-space:nowrap" class="ft232">n=110</p>
<p style="position:absolute;top:221px;left:519px;white-space:nowrap" class="ft232">Humirab</p>
<p style="position:absolute;top:240px;left:526px;white-space:nowrap" class="ft232">n=113</p>
<p style="position:absolute;top:221px;left:615px;white-space:nowrap" class="ft232">Placebo/&#160;</p>
<p style="position:absolute;top:240px;left:623px;white-space:nowrap" class="ft2312">MTXc<br/>n=200</p>
<p style="position:absolute;top:221px;left:691px;white-space:nowrap" class="ft232">Humirab/ MTXc</p>
<p style="position:absolute;top:240px;left:723px;white-space:nowrap" class="ft232">n=207</p>
<p style="position:absolute;top:279px;left:113px;white-space:nowrap" class="ft232">ACR 20</p>
<p style="position:absolute;top:298px;left:124px;white-space:nowrap" class="ft232">6&#160;months</p>
<p style="position:absolute;top:298px;left:224px;white-space:nowrap" class="ft232">13.3%</p>
<p style="position:absolute;top:298px;left:324px;white-space:nowrap" class="ft232">65.1%</p>
<p style="position:absolute;top:298px;left:431px;white-space:nowrap" class="ft232">19.1%</p>
<p style="position:absolute;top:298px;left:526px;white-space:nowrap" class="ft232">46.0%</p>
<p style="position:absolute;top:298px;left:622px;white-space:nowrap" class="ft232">29.5%</p>
<p style="position:absolute;top:298px;left:724px;white-space:nowrap" class="ft232">63.3%</p>
<p style="position:absolute;top:317px;left:124px;white-space:nowrap" class="ft232">12&#160;months</p>
<p style="position:absolute;top:317px;left:233px;white-space:nowrap" class="ft232">NA</p>
<p style="position:absolute;top:317px;left:333px;white-space:nowrap" class="ft232">NA</p>
<p style="position:absolute;top:317px;left:440px;white-space:nowrap" class="ft232">NA</p>
<p style="position:absolute;top:317px;left:535px;white-space:nowrap" class="ft232">NA</p>
<p style="position:absolute;top:317px;left:622px;white-space:nowrap" class="ft232">24.0%</p>
<p style="position:absolute;top:317px;left:724px;white-space:nowrap" class="ft232">58.9%</p>
<p style="position:absolute;top:336px;left:113px;white-space:nowrap" class="ft232">ACR 50</p>
<p style="position:absolute;top:355px;left:124px;white-space:nowrap" class="ft232">6&#160;months</p>
<p style="position:absolute;top:355px;left:228px;white-space:nowrap" class="ft232">6.7%</p>
<p style="position:absolute;top:355px;left:324px;white-space:nowrap" class="ft232">52.4%</p>
<p style="position:absolute;top:355px;left:436px;white-space:nowrap" class="ft232">8.2%</p>
<p style="position:absolute;top:355px;left:526px;white-space:nowrap" class="ft232">22.1%</p>
<p style="position:absolute;top:355px;left:630px;white-space:nowrap" class="ft232">9.5%</p>
<p style="position:absolute;top:355px;left:724px;white-space:nowrap" class="ft232">39.1%</p>
<p style="position:absolute;top:374px;left:124px;white-space:nowrap" class="ft232">12&#160;months</p>
<p style="position:absolute;top:374px;left:233px;white-space:nowrap" class="ft232">NA</p>
<p style="position:absolute;top:374px;left:333px;white-space:nowrap" class="ft232">NA</p>
<p style="position:absolute;top:374px;left:440px;white-space:nowrap" class="ft232">NA</p>
<p style="position:absolute;top:374px;left:535px;white-space:nowrap" class="ft232">NA</p>
<p style="position:absolute;top:374px;left:630px;white-space:nowrap" class="ft232">9.5%</p>
<p style="position:absolute;top:374px;left:724px;white-space:nowrap" class="ft232">41.5%</p>
<p style="position:absolute;top:393px;left:113px;white-space:nowrap" class="ft232">ACR 70</p>
<p style="position:absolute;top:412px;left:124px;white-space:nowrap" class="ft232">6&#160;months</p>
<p style="position:absolute;top:412px;left:228px;white-space:nowrap" class="ft232">3.3%</p>
<p style="position:absolute;top:412px;left:324px;white-space:nowrap" class="ft232">23.8%</p>
<p style="position:absolute;top:412px;left:436px;white-space:nowrap" class="ft232">1.8%</p>
<p style="position:absolute;top:412px;left:526px;white-space:nowrap" class="ft232">12.4%</p>
<p style="position:absolute;top:412px;left:630px;white-space:nowrap" class="ft232">2.5%</p>
<p style="position:absolute;top:412px;left:724px;white-space:nowrap" class="ft232">20.8%</p>
<p style="position:absolute;top:431px;left:124px;white-space:nowrap" class="ft232">12&#160;months</p>
<p style="position:absolute;top:431px;left:233px;white-space:nowrap" class="ft232">NA</p>
<p style="position:absolute;top:431px;left:333px;white-space:nowrap" class="ft232">NA</p>
<p style="position:absolute;top:431px;left:440px;white-space:nowrap" class="ft232">NA</p>
<p style="position:absolute;top:431px;left:535px;white-space:nowrap" class="ft232">NA</p>
<p style="position:absolute;top:431px;left:630px;white-space:nowrap" class="ft232">4.5%</p>
<p style="position:absolute;top:431px;left:724px;white-space:nowrap" class="ft232">23.2%</p>
<p style="position:absolute;top:450px;left:113px;white-space:nowrap" class="ft239">a&#160;RA study I at 24&#160;weeks, RA study II at 26&#160;weeks , and RA study III at 24&#160;and 52&#160;weeks</p>
<p style="position:absolute;top:468px;left:113px;white-space:nowrap" class="ft239">b&#160;40&#160;mg Humira administered every other week</p>
<p style="position:absolute;top:487px;left:113px;white-space:nowrap" class="ft237">c&#160;MTX = methotrexate<br/>**p&#160;&lt;&#160;0.01, Humira&#160;<i>versus&#160;</i>placebo</p>
<p style="position:absolute;top:546px;left:106px;white-space:nowrap" class="ft235">In RA studies I-IV, all individual components of the ACR response criteria (number of tender and swollen&#160;<br/>joints, physician and patient assessment of disease activity and pain, disability index (HAQ) scores and&#160;<br/>CRP (mg/dl) values) improved&#160;at 24 or 26&#160;weeks compared to placebo. In RA study III, these&#160;<br/>improvements were maintained throughout 52&#160;weeks.&#160;</p>
<p style="position:absolute;top:641px;left:106px;white-space:nowrap" class="ft234">In the open-label extension for RA study III, most patients who were ACR responders maintained&#160;<br/>response when followed for up to 10&#160;years. Of 207 patients who were randomised to Humira 40&#160;mg&#160;every&#160;<br/>other week, 114 patients continued on Humira 40&#160;mg&#160;every other week for 5&#160;years. Among those, 86&#160;<br/>patients (75.4%) had ACR 20 responses; 72 patients (63.2%) had ACR 50 responses; and 41 patients&#160;<br/>(36%) had&#160;ACR 70 responses. Of 207 patients, 81 patients continued on Humira 40&#160;mg every other week&#160;<br/>for 10&#160;years. Among those, 64 patients (79.0%) had ACR 20 responses; 56 patients (69.1%) had ACR 50&#160;<br/>responses; and 43 patients (53.1%) had ACR 70 responses.</p>
<p style="position:absolute;top:792px;left:106px;white-space:nowrap" class="ft234">In RA&#160;study IV, the ACR 20 response of patients treated with Humira plus standard of care was&#160;<br/>statistically significantly better than patients treated with placebo plus standard of care (p&#160;&lt;&#160;0.001). &#160;</p>
<p style="position:absolute;top:849px;left:106px;white-space:nowrap" class="ft234">In RA studies I-IV, Humira-treated patients achieved&#160;statistically significant ACR 20 and 50 responses&#160;<br/>compared to placebo as early as one to two weeks after initiation of treatment.</p>
<p style="position:absolute;top:906px;left:106px;white-space:nowrap" class="ft234">In RA study V with early rheumatoid arthritis patients who were methotrexate naïve, combination therapy&#160;<br/>with Humira and methotrexate led to faster and significantly greater ACR responses than methotrexate&#160;<br/>monotherapy and Humira monotherapy at Week&#160;52 and responses were sustained at Week&#160;104 (see Table&#160;<br/>8).</p>
</div>
<!-- Page 24 -->
<a name="24"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft2413{font-size:10px;font-family:HORGHZ+TimesNewRoman,Bold;color:#000000;}
-->
</style>
<div id="page24-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft240">24</p>
<p style="position:absolute;top:105px;left:433px;white-space:nowrap" class="ft241"><b>Table&#160;8</b></p>
<p style="position:absolute;top:124px;left:350px;white-space:nowrap" class="ft241"><b>ACR Responses in RA Study V</b></p>
<p style="position:absolute;top:143px;left:388px;white-space:nowrap" class="ft241"><b>(percent of patients)</b></p>
<p style="position:absolute;top:191px;left:120px;white-space:nowrap" class="ft241"><b>Response</b></p>
<p style="position:absolute;top:181px;left:258px;white-space:nowrap" class="ft241"><b>MTX</b></p>
<p style="position:absolute;top:201px;left:256px;white-space:nowrap" class="ft241"><b>n=257</b></p>
<p style="position:absolute;top:181px;left:348px;white-space:nowrap" class="ft241"><b>Humira</b></p>
<p style="position:absolute;top:201px;left:355px;white-space:nowrap" class="ft241"><b>n=274</b></p>
<p style="position:absolute;top:181px;left:436px;white-space:nowrap" class="ft241"><b>Humira/MTX</b></p>
<p style="position:absolute;top:201px;left:463px;white-space:nowrap" class="ft241"><b>n=268</b></p>
<p style="position:absolute;top:191px;left:557px;white-space:nowrap" class="ft241"><b>p-valuea</b></p>
<p style="position:absolute;top:191px;left:642px;white-space:nowrap" class="ft241"><b>p-valueb</b></p>
<p style="position:absolute;top:191px;left:731px;white-space:nowrap" class="ft241"><b>p-valuec</b></p>
<p style="position:absolute;top:220px;left:120px;white-space:nowrap" class="ft242">ACR 20</p>
<p style="position:absolute;top:240px;left:162px;white-space:nowrap" class="ft242">Week&#160;</p>
<p style="position:absolute;top:259px;left:120px;white-space:nowrap" class="ft242">52</p>
<p style="position:absolute;top:240px;left:256px;white-space:nowrap" class="ft242">62.6%</p>
<p style="position:absolute;top:240px;left:355px;white-space:nowrap" class="ft242">54.4%</p>
<p style="position:absolute;top:240px;left:464px;white-space:nowrap" class="ft242">72.8%</p>
<p style="position:absolute;top:240px;left:567px;white-space:nowrap" class="ft242">0.013</p>
<p style="position:absolute;top:240px;left:645px;white-space:nowrap" class="ft242">&lt;&#160;0.001</p>
<p style="position:absolute;top:240px;left:741px;white-space:nowrap" class="ft242">0.043</p>
<p style="position:absolute;top:279px;left:162px;white-space:nowrap" class="ft242">Week&#160;</p>
<p style="position:absolute;top:298px;left:120px;white-space:nowrap" class="ft242">104</p>
<p style="position:absolute;top:279px;left:256px;white-space:nowrap" class="ft242">56.0%</p>
<p style="position:absolute;top:279px;left:355px;white-space:nowrap" class="ft242">49.3%</p>
<p style="position:absolute;top:279px;left:464px;white-space:nowrap" class="ft242">69.4%</p>
<p style="position:absolute;top:279px;left:567px;white-space:nowrap" class="ft242">0.002</p>
<p style="position:absolute;top:279px;left:645px;white-space:nowrap" class="ft242">&lt;&#160;0.001</p>
<p style="position:absolute;top:279px;left:741px;white-space:nowrap" class="ft242">0.140</p>
<p style="position:absolute;top:318px;left:120px;white-space:nowrap" class="ft242">ACR 50</p>
<p style="position:absolute;top:337px;left:162px;white-space:nowrap" class="ft242">Week&#160;</p>
<p style="position:absolute;top:356px;left:120px;white-space:nowrap" class="ft242">52</p>
<p style="position:absolute;top:337px;left:256px;white-space:nowrap" class="ft242">45.9%</p>
<p style="position:absolute;top:337px;left:355px;white-space:nowrap" class="ft242">41.2%</p>
<p style="position:absolute;top:337px;left:464px;white-space:nowrap" class="ft242">61.6%</p>
<p style="position:absolute;top:337px;left:560px;white-space:nowrap" class="ft242">&lt;&#160;0.001</p>
<p style="position:absolute;top:337px;left:645px;white-space:nowrap" class="ft242">&lt;&#160;0.001</p>
<p style="position:absolute;top:337px;left:741px;white-space:nowrap" class="ft242">0.317</p>
<p style="position:absolute;top:376px;left:162px;white-space:nowrap" class="ft242">Week&#160;</p>
<p style="position:absolute;top:395px;left:120px;white-space:nowrap" class="ft242">104</p>
<p style="position:absolute;top:376px;left:256px;white-space:nowrap" class="ft242">42.8%</p>
<p style="position:absolute;top:376px;left:355px;white-space:nowrap" class="ft242">36.9%</p>
<p style="position:absolute;top:376px;left:464px;white-space:nowrap" class="ft242">59.0%</p>
<p style="position:absolute;top:376px;left:560px;white-space:nowrap" class="ft242">&lt;&#160;0.001</p>
<p style="position:absolute;top:376px;left:645px;white-space:nowrap" class="ft242">&lt;&#160;0.001</p>
<p style="position:absolute;top:376px;left:741px;white-space:nowrap" class="ft242">0.162</p>
<p style="position:absolute;top:414px;left:120px;white-space:nowrap" class="ft242">ACR 70</p>
<p style="position:absolute;top:434px;left:162px;white-space:nowrap" class="ft242">Week&#160;</p>
<p style="position:absolute;top:453px;left:120px;white-space:nowrap" class="ft242">52</p>
<p style="position:absolute;top:434px;left:256px;white-space:nowrap" class="ft242">27.2%</p>
<p style="position:absolute;top:434px;left:355px;white-space:nowrap" class="ft242">25.9%</p>
<p style="position:absolute;top:434px;left:464px;white-space:nowrap" class="ft242">45.5%</p>
<p style="position:absolute;top:434px;left:560px;white-space:nowrap" class="ft242">&lt;&#160;0.001</p>
<p style="position:absolute;top:434px;left:645px;white-space:nowrap" class="ft242">&lt;&#160;0.001</p>
<p style="position:absolute;top:434px;left:741px;white-space:nowrap" class="ft242">0.656</p>
<p style="position:absolute;top:473px;left:162px;white-space:nowrap" class="ft242">Week&#160;</p>
<p style="position:absolute;top:492px;left:120px;white-space:nowrap" class="ft242">104</p>
<p style="position:absolute;top:473px;left:256px;white-space:nowrap" class="ft242">28.4%</p>
<p style="position:absolute;top:473px;left:355px;white-space:nowrap" class="ft242">28.1%</p>
<p style="position:absolute;top:473px;left:464px;white-space:nowrap" class="ft242">46.6%</p>
<p style="position:absolute;top:473px;left:560px;white-space:nowrap" class="ft242">&lt;&#160;0.001</p>
<p style="position:absolute;top:473px;left:645px;white-space:nowrap" class="ft242">&lt;&#160;0.001</p>
<p style="position:absolute;top:473px;left:741px;white-space:nowrap" class="ft242">0.864</p>
<p style="position:absolute;top:512px;left:121px;white-space:nowrap" class="ft242">a.&#160;p-value is from the pairwise comparison of methotrexate monotherapy and Humira/methotrexate&#160;</p>
<p style="position:absolute;top:531px;left:148px;white-space:nowrap" class="ft242">combination&#160;therapy using the Mann-Whitney U test.</p>
<p style="position:absolute;top:550px;left:121px;white-space:nowrap" class="ft242">b.&#160;p-value is from the pairwise comparison of Humira monotherapy and Humira/methotrexate&#160;</p>
<p style="position:absolute;top:568px;left:145px;white-space:nowrap" class="ft242">combination therapy using the Mann-Whitney U test</p>
<p style="position:absolute;top:588px;left:121px;white-space:nowrap" class="ft242">c. &#160; p-value is from the pairwise comparison of Humira monotherapy and methotrexate monotherapy&#160;</p>
<p style="position:absolute;top:607px;left:145px;white-space:nowrap" class="ft242">using the Mann-Whitney U test</p>
<p style="position:absolute;top:645px;left:106px;white-space:nowrap" class="ft244">In the open-label extension for RA study V, ACR&#160;response rates were&#160;maintained when followed for up to&#160;<br/>10&#160;years. Of&#160;542&#160;patients&#160;who were randomised to Humira 40&#160;mg&#160;every other week,&#160;170&#160;patients&#160;<br/>continued on Humira 40&#160;mg&#160;every other week for 10&#160;years. Among those,&#160;154&#160;patients (90.6%) had ACR&#160;<br/>20 responses;&#160;127&#160;patients (74.7%) had ACR 50 responses; and&#160;102&#160;patients (60.0%) had ACR 70&#160;<br/>responses.</p>
<p style="position:absolute;top:759px;left:106px;white-space:nowrap" class="ft244">At Week&#160;52, 42.9% of patients who received&#160;Humira/methotrexate combination therapy achieved clinical&#160;<br/>remission (DAS28&#160;(CRP)&#160;&lt;&#160;2.6) compared to 20.6% of patients receiving methotrexate monotherapy and&#160;<br/>23.4% of patients receiving Humira monotherapy. Humira/methotrexate combination therapy was&#160;<br/>clinically and statistically superior to methotrexate (p&#160;&lt;&#160;0.001) and Humira monotherapy (p&#160;&lt;&#160;0.001) in&#160;<br/>achieving a low disease state in patients with recently diagnosed moderate to severe rheumatoid arthritis.&#160;<br/>The response for the two monotherapy arms was similar (p&#160;=&#160;0.447).&#160;Of&#160;342&#160;subjects&#160;originally&#160;<br/>randomized to Humira monotherapy or Humira/methotrexate&#160;combination therapy&#160;who entered the open-<br/>label extension study, 171 subjects completed 10&#160;years of Humira treatment. Among those,&#160;109&#160;subjects&#160;<br/>(63.7%) were reported to be in remission at 10&#160;years.</p>
<p style="position:absolute;top:949px;left:106px;white-space:nowrap" class="ft243"><i>Radiographic response</i></p>
<p style="position:absolute;top:987px;left:106px;white-space:nowrap" class="ft244">In RA study III, where Humira treated patients had a mean duration of rheumatoid arthritis of&#160;<br/>approximately 11&#160;years, structural joint damage was assessed radiographically and expressed as change in&#160;<br/>modified Total Sharp Score (TSS) and its components, the erosion score and joint space narrowing score.&#160;<br/>Humira/methotrexate patients demonstrated significantly less radiographic progression than patients&#160;<br/>receiving methotrexate alone at 6 and 12&#160;months (see Table&#160;9). &#160;</p>
</div>
<!-- Page 25 -->
<a name="25"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page25-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft250">25</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft254">In the open-label extension of RA Study III, the reduction in rate of progression of structural damage is&#160;<br/>maintained for 8 and 10&#160;years in a subset of patients. At 8&#160;years, 81 of 207 patients originally treated&#160;with&#160;<br/>40&#160;mg Humira every other week were evaluated radiographically. Among those, 48 patients showed no&#160;<br/>progression of structural damage defined by a change from baseline in the mTSS of 0.5 or less. At&#160;<br/>10&#160;years, 79 of 207 patients originally treated with 40&#160;mg Humira every other week were evaluated&#160;<br/>radiographically. Among those, 40 patients showed no progression of structural damage defined by a&#160;<br/>change from baseline in the mTSS of 0.5 or less.</p>
<p style="position:absolute;top:238px;left:411px;white-space:nowrap" class="ft251"><b>Table&#160;9</b></p>
<p style="position:absolute;top:257px;left:221px;white-space:nowrap" class="ft251"><b>Radiographic Mean Changes Over 12&#160;Months in RA Study III</b></p>
<p style="position:absolute;top:296px;left:270px;white-space:nowrap" class="ft255">Placebo/<br/>MTXa</p>
<p style="position:absolute;top:296px;left:391px;white-space:nowrap" class="ft252">Humira/MTX</p>
<p style="position:absolute;top:314px;left:396px;white-space:nowrap" class="ft252">40&#160;mg&#160;every&#160;</p>
<p style="position:absolute;top:333px;left:400px;white-space:nowrap" class="ft252">other week</p>
<p style="position:absolute;top:296px;left:529px;white-space:nowrap" class="ft252">Placebo/MTX-</p>
<p style="position:absolute;top:314px;left:513px;white-space:nowrap" class="ft252">Humira/MTX (95%&#160;</p>
<p style="position:absolute;top:333px;left:541px;white-space:nowrap" class="ft252">Confidence&#160;</p>
<p style="position:absolute;top:352px;left:548px;white-space:nowrap" class="ft252">Intervalb)</p>
<p style="position:absolute;top:296px;left:687px;white-space:nowrap" class="ft252">p-value</p>
<p style="position:absolute;top:372px;left:124px;white-space:nowrap" class="ft252">Total Sharp Score</p>
<p style="position:absolute;top:372px;left:306px;white-space:nowrap" class="ft252">2.7</p>
<p style="position:absolute;top:372px;left:426px;white-space:nowrap" class="ft252">0.1</p>
<p style="position:absolute;top:372px;left:536px;white-space:nowrap" class="ft252">2.6 (1.4, 3.8)&#160;</p>
<p style="position:absolute;top:372px;left:684px;white-space:nowrap" class="ft252">&lt;&#160;0.001c</p>
<p style="position:absolute;top:392px;left:139px;white-space:nowrap" class="ft252">Erosion score</p>
<p style="position:absolute;top:392px;left:306px;white-space:nowrap" class="ft252">1.6</p>
<p style="position:absolute;top:392px;left:426px;white-space:nowrap" class="ft252">0.0</p>
<p style="position:absolute;top:392px;left:536px;white-space:nowrap" class="ft252">1.6 (0.9, 2.2)</p>
<p style="position:absolute;top:392px;left:687px;white-space:nowrap" class="ft252">&lt;&#160;0.001</p>
<p style="position:absolute;top:411px;left:148px;white-space:nowrap" class="ft252">JSNd&#160;score</p>
<p style="position:absolute;top:411px;left:306px;white-space:nowrap" class="ft252">1.0</p>
<p style="position:absolute;top:411px;left:426px;white-space:nowrap" class="ft252">0.1</p>
<p style="position:absolute;top:411px;left:536px;white-space:nowrap" class="ft252">0.9 (0.3, 1.4)</p>
<p style="position:absolute;top:411px;left:689px;white-space:nowrap" class="ft252">&#160;&#160;0.002</p>
<p style="position:absolute;top:429px;left:106px;white-space:nowrap" class="ft2513"><b>a</b>methotrexate</p>
<p style="position:absolute;top:449px;left:106px;white-space:nowrap" class="ft259">b95% confidence intervals for the differences in change scores between methotrexate and Humira.&#160;</p>
<p style="position:absolute;top:468px;left:106px;white-space:nowrap" class="ft259">cBased on rank analysis&#160;</p>
<p style="position:absolute;top:487px;left:106px;white-space:nowrap" class="ft259">dJoint Space Narrowing</p>
<p style="position:absolute;top:526px;left:106px;white-space:nowrap" class="ft254">In RA study V, structural joint damage was assessed radiographically and expressed as change in modified&#160;<br/>Total Sharp Score (see Table&#160;10).</p>
<p style="position:absolute;top:583px;left:418px;white-space:nowrap" class="ft251"><b>Table&#160;10</b></p>
<p style="position:absolute;top:602px;left:246px;white-space:nowrap" class="ft251"><b>&#160;&#160;Radiographic Mean Changes at Week&#160;52 in RA Study V</b></p>
<p style="position:absolute;top:641px;left:261px;white-space:nowrap" class="ft252">MTX</p>
<p style="position:absolute;top:660px;left:258px;white-space:nowrap" class="ft252">n=257</p>
<p style="position:absolute;top:679px;left:261px;white-space:nowrap" class="ft252">(95%&#160;</p>
<p style="position:absolute;top:698px;left:243px;white-space:nowrap" class="ft252">confidence&#160;</p>
<p style="position:absolute;top:717px;left:251px;white-space:nowrap" class="ft252">interval)</p>
<p style="position:absolute;top:641px;left:367px;white-space:nowrap" class="ft252">Humira</p>
<p style="position:absolute;top:660px;left:371px;white-space:nowrap" class="ft252">n=274</p>
<p style="position:absolute;top:679px;left:374px;white-space:nowrap" class="ft252">(95%&#160;</p>
<p style="position:absolute;top:698px;left:356px;white-space:nowrap" class="ft252">confidence&#160;</p>
<p style="position:absolute;top:717px;left:364px;white-space:nowrap" class="ft252">interval)</p>
<p style="position:absolute;top:641px;left:458px;white-space:nowrap" class="ft252">Humira/MTX</p>
<p style="position:absolute;top:660px;left:482px;white-space:nowrap" class="ft252">n=268</p>
<p style="position:absolute;top:679px;left:486px;white-space:nowrap" class="ft252">(95%&#160;</p>
<p style="position:absolute;top:698px;left:467px;white-space:nowrap" class="ft252">confidence&#160;</p>
<p style="position:absolute;top:717px;left:476px;white-space:nowrap" class="ft252">interval)</p>
<p style="position:absolute;top:679px;left:569px;white-space:nowrap" class="ft252">p-valuea</p>
<p style="position:absolute;top:679px;left:643px;white-space:nowrap" class="ft252">p-valueb</p>
<p style="position:absolute;top:679px;left:718px;white-space:nowrap" class="ft252">p-valuec</p>
<p style="position:absolute;top:736px;left:129px;white-space:nowrap" class="ft252">Total Sharp&#160;</p>
<p style="position:absolute;top:755px;left:149px;white-space:nowrap" class="ft252">Score</p>
<p style="position:absolute;top:736px;left:238px;white-space:nowrap" class="ft252">5.7 (4.2-7.3)</p>
<p style="position:absolute;top:736px;left:351px;white-space:nowrap" class="ft252">3.0 (1.7-4.3)</p>
<p style="position:absolute;top:736px;left:462px;white-space:nowrap" class="ft252">1.3 (0.5-2.1)</p>
<p style="position:absolute;top:736px;left:571px;white-space:nowrap" class="ft252">&lt;&#160;0.001</p>
<p style="position:absolute;top:736px;left:648px;white-space:nowrap" class="ft252">0.0020</p>
<p style="position:absolute;top:736px;left:720px;white-space:nowrap" class="ft252">&lt;&#160;0.001</p>
<p style="position:absolute;top:775px;left:122px;white-space:nowrap" class="ft252">Erosion score</p>
<p style="position:absolute;top:775px;left:238px;white-space:nowrap" class="ft252">3.7 (2.7-4.7)</p>
<p style="position:absolute;top:775px;left:351px;white-space:nowrap" class="ft252">1.7 (1.0-2.4)</p>
<p style="position:absolute;top:775px;left:462px;white-space:nowrap" class="ft252">0.8 (0.4-1.2)</p>
<p style="position:absolute;top:775px;left:571px;white-space:nowrap" class="ft252">&lt;&#160;0.001</p>
<p style="position:absolute;top:775px;left:648px;white-space:nowrap" class="ft252">0.0082</p>
<p style="position:absolute;top:775px;left:720px;white-space:nowrap" class="ft252">&lt;&#160;0.001</p>
<p style="position:absolute;top:795px;left:134px;white-space:nowrap" class="ft252">JSN score</p>
<p style="position:absolute;top:795px;left:238px;white-space:nowrap" class="ft252">2.0 (1.2-2.8)</p>
<p style="position:absolute;top:795px;left:351px;white-space:nowrap" class="ft252">1.3 (0.5-2.1)</p>
<p style="position:absolute;top:795px;left:468px;white-space:nowrap" class="ft252">0.5 (0-1.0)</p>
<p style="position:absolute;top:795px;left:571px;white-space:nowrap" class="ft252">&lt;&#160;0.001</p>
<p style="position:absolute;top:795px;left:648px;white-space:nowrap" class="ft252">0.0037</p>
<p style="position:absolute;top:795px;left:726px;white-space:nowrap" class="ft252">0.151</p>
<p style="position:absolute;top:813px;left:122px;white-space:nowrap" class="ft259">a&#160;p-value is from&#160;the pairwise comparison of methotrexate monotherapy and Humira/methotrexate&#160;</p>
<p style="position:absolute;top:833px;left:147px;white-space:nowrap" class="ft252">combination therapy using the Mann-Whitney U test.</p>
<p style="position:absolute;top:851px;left:122px;white-space:nowrap" class="ft259">b&#160;p-value is from the pairwise comparison of Humira monotherapy and Humira/methotrexate&#160;</p>
<p style="position:absolute;top:871px;left:149px;white-space:nowrap" class="ft252">combination therapy using the Mann-Whitney&#160;U test&#160;</p>
<p style="position:absolute;top:889px;left:122px;white-space:nowrap" class="ft259">c&#160;p-value is from the pairwise comparison of Humira monotherapy and methotrexate monotherapy&#160;</p>
<p style="position:absolute;top:909px;left:149px;white-space:nowrap" class="ft252">using the Mann-Whitney U test</p>
<p style="position:absolute;top:947px;left:106px;white-space:nowrap" class="ft257">Following 52&#160;weeks and 104&#160;weeks of treatment, the percentage of patients without progression (change&#160;<br/>from baseline in modified Total Sharp Score&#160;</p>
<p style="position:absolute;top:965px;left:404px;white-space:nowrap" class="ft256">&#160;0.5) was significantly higher with Humira/methotrexate&#160;</p>
<p style="position:absolute;top:986px;left:106px;white-space:nowrap" class="ft254">combination therapy (63.8% and 61.2% respectively) compared to methotrexate monotherapy (37.4% and&#160;<br/>33.5% respectively, p&#160;&lt;&#160;0.001) and Humira monotherapy (50.7%, p&#160;&lt;&#160;0.002 and&#160;44.5%, p&#160;&lt;&#160;0.001&#160;<br/>respectively).</p>
<p style="position:absolute;top:1062px;left:106px;white-space:nowrap" class="ft254">In the open-label extension of RA study V, the mean change from baseline at Year 10 in the modified&#160;<br/>Total Sharp Score was 10.8, 9.2 and 3.9 in patients originally randomized to&#160;methotrexate monotherapy,&#160;</p>
</div>
<!-- Page 26 -->
<a name="26"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft2614{font-size:17px;line-height:19px;font-family:HORGHZ+TimesNewRoman,Italic;color:#000000;}
-->
</style>
<div id="page26-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft260">26</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft265">Humira&#160;monotherapy&#160;and Humira/methotrexate&#160;combination therapy, respectively.&#160;The corresponding&#160;<br/>proportions of patients with no radiographic progression were 31.3%, 23.7% and 36.7% respectively.</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft263"><i>Quality of life and physical function&#160;</i></p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft264">Health-related quality of life and physical function were assessed using the disability index of the Health&#160;<br/>Assessment Questionnaire (HAQ) in the four original adequate and well-controlled trials, which was a&#160;<br/>pre-specified primary endpoint at Week&#160;52 in RA study III. All doses/schedules of Humira in all four&#160;<br/>studies showed statistically significantly greater improvement in the disability index of the HAQ from&#160;<br/>baseline to Month&#160;6 compared to placebo and in RA study III the same was seen at Week&#160;52. Results from&#160;<br/>the Short Form Health Survey (SF 36) for all doses/schedules of Humira in all four studies support these&#160;<br/>findings, with statistically significant physical component summary (PCS) scores, as well as statistically&#160;<br/>significant pain and vitality domain scores for the 40&#160;mg&#160;every other week dose. A statistically significant&#160;<br/>decrease in fatigue as measured by functional assessment of chronic illness therapy (FACIT) scores was&#160;<br/>seen in all three studies in which it was assessed (RA studies I, III, IV).</p>
<p style="position:absolute;top:390px;left:106px;white-space:nowrap" class="ft264">In RA study III, most subjects who achieved&#160;improvement in physical function and continued treatment&#160;<br/>maintained improvement through Week&#160;520 (120&#160;months) of open-label treatment. Improvement in&#160;<br/>quality of life was measured up to Week&#160;156 (36&#160;months) and improvement was maintained through that&#160;<br/>time.</p>
<p style="position:absolute;top:485px;left:106px;white-space:nowrap" class="ft265">In RA study V, the improvement in the HAQ disability index and the physical component of the SF 36&#160;<br/>showed greater improvement (p&#160;&lt;&#160;0.001) for Humira/methotrexate combination therapy&#160;<i>versus<br/></i>methotrexate monotherapy and Humira monotherapy at Week&#160;52, which&#160;was maintained through&#160;<br/>Week&#160;104.&#160;Among the 250 subjects who&#160;completed&#160;the open-label extension study, improvements in&#160;<br/>physical function were maintained through 10 years of treatment.</p>
<p style="position:absolute;top:598px;left:106px;white-space:nowrap" class="ft263"><i>Adult plaque psoriasis&#160;</i></p>
<p style="position:absolute;top:637px;left:106px;white-space:nowrap" class="ft262">The safety and efficacy of Humira were studied&#160;in adult patients with chronic plaque psoriasis (</p>
<p style="position:absolute;top:635px;left:737px;white-space:nowrap" class="ft266">&#160;10%&#160;</p>
<p style="position:absolute;top:658px;left:106px;white-space:nowrap" class="ft262">BSA involvement and&#160;PASI&#160;</p>
<p style="position:absolute;top:656px;left:296px;white-space:nowrap" class="ft266">&#160;12 or&#160;&#160;10) who were candidates for systemic therapy or phototherapy in&#160;</p>
<p style="position:absolute;top:676px;left:106px;white-space:nowrap" class="ft264">randomised, double-blind studies. 73% of patients enrolled in Psoriasis Studies I and II had received&#160;prior&#160;<br/>systemic therapy or phototherapy. The safety and efficacy of Humira were&#160;also studied in adult patients&#160;<br/>with moderate to severe&#160;chronic plaque psoriasis with concomitant hand and/or foot psoriasis who were&#160;<br/>candidates for systemic therapy in a randomised double-blind study (Psoriasis Study III). &#160;</p>
<p style="position:absolute;top:770px;left:106px;white-space:nowrap" class="ft267">Psoriasis Study I (REVEAL) evaluated 1,212 patients within three treatment periods. In period A, patients&#160;<br/>received placebo or Humira at an initial dose of 80&#160;mg&#160;followed by 40&#160;mg&#160;every other week starting one&#160;<br/>week after the initial dose. After 16&#160;weeks&#160;of therapy, patients who achieved at least a PASI 75 response&#160;<br/>(PASI score improvement of at least 75% relative to baseline), entered period B and received open-label&#160;<br/>40&#160;mg Humira every other week. Patients who&#160;maintained&#160;</p>
<p style="position:absolute;top:845px;left:494px;white-space:nowrap" class="ft266">PASI 75 response at Week&#160;33 and were&#160;</p>
<p style="position:absolute;top:866px;left:106px;white-space:nowrap" class="ft265">originally randomised to active therapy in Period A, were re-randomised in period C to receive 40&#160;mg&#160;<br/>Humira every other week or placebo for an additional 19&#160;weeks. Across all treatment groups, the mean&#160;<br/>baseline PASI score was 18.9 and the baseline&#160;PGA&#160;score ranged from “moderate” (53% of subjects&#160;<br/>included) to “severe” (41%) to “very severe” (6%).</p>
<p style="position:absolute;top:961px;left:106px;white-space:nowrap" class="ft264">Psoriasis Study II (CHAMPION) compared the efficacy and safety of Humira&#160;<i>versus&#160;</i>methotrexate and&#160;<br/>placebo in 271 patients.&#160;Patients received placebo, an initial dose of MTX 7.5&#160;mg and thereafter dose&#160;<br/>increases up to Week&#160;12, with a maximum dose of 25&#160;mg&#160;or an initial dose of 80&#160;mg Humira followed by&#160;<br/>40&#160;mg&#160;every other week (starting one week after the initial dose) for&#160;16&#160;weeks. There are no data available&#160;<br/>comparing Humira and MTX beyond 16&#160;weeks of therapy. Patients receiving MTX who achieved a&#160;</p>
<p style="position:absolute;top:1055px;left:106px;white-space:nowrap" class="ft266">PASI 50 response at Week&#160;8 and/or 12 did not receive further dose increases. Across all treatment&#160;</p>
</div>
<!-- Page 27 -->
<a name="27"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft2715{font-size:17px;line-height:18px;font-family:HORGHZ+TimesNewRoman,Bold;color:#000000;}
-->
</style>
<div id="page27-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft270">27</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft275">groups, the mean baseline&#160;PASI&#160;score was 19.7 and the baseline PGA score ranged from “mild” (&lt;1%) to&#160;<br/>“moderate” (48%) to “severe” (46%) to “very severe” (6%).</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft274">Patients participating in all Phase 2 and Phase 3 psoriasis studies were eligible to&#160;enrol&#160;into an open-label&#160;<br/>extension trial, where Humira was given for at least an additional 108&#160;weeks.</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft274">In Psoriasis Studies I and II, a primary endpoint was the proportion of patients who achieved a PASI 75&#160;<br/>response from baseline at Week&#160;16&#160;(see Tables&#160;11&#160;and&#160;12).</p>
<p style="position:absolute;top:257px;left:429px;white-space:nowrap" class="ft271"><b>Table&#160;11</b></p>
<p style="position:absolute;top:276px;left:271px;white-space:nowrap" class="ft271"><b>Ps Study I&#160;(REVEAL) &#160;-&#160;Efficacy Results at 16&#160;Weeks</b></p>
<p style="position:absolute;top:296px;left:455px;white-space:nowrap" class="ft271"><b>Placebo</b></p>
<p style="position:absolute;top:314px;left:459px;white-space:nowrap" class="ft271"><b>N=398</b></p>
<p style="position:absolute;top:333px;left:462px;white-space:nowrap" class="ft271"><b>n&#160;(%)</b></p>
<p style="position:absolute;top:296px;left:564px;white-space:nowrap" class="ft271"><b>Humira 40 mg eow</b></p>
<p style="position:absolute;top:314px;left:608px;white-space:nowrap" class="ft271"><b>N=814</b></p>
<p style="position:absolute;top:333px;left:611px;white-space:nowrap" class="ft271"><b>n&#160;(%)</b></p>
<p style="position:absolute;top:354px;left:207px;white-space:nowrap" class="ft271"><b>&#160; &#160;&#160;</b></p>
<p style="position:absolute;top:352px;left:223px;white-space:nowrap" class="ft276">&#160;<b>PASI 75a</b></p>
<p style="position:absolute;top:353px;left:456px;white-space:nowrap" class="ft272">26 (6.5)</p>
<p style="position:absolute;top:353px;left:594px;white-space:nowrap" class="ft272">578 (70.9)b</p>
<p style="position:absolute;top:374px;left:207px;white-space:nowrap" class="ft271"><b>&#160; &#160;&#160;PASI 100</b></p>
<p style="position:absolute;top:374px;left:460px;white-space:nowrap" class="ft272">3 (0.8)</p>
<p style="position:absolute;top:374px;left:594px;white-space:nowrap" class="ft272">163 (20.0)b</p>
<p style="position:absolute;top:394px;left:207px;white-space:nowrap" class="ft271"><b>&#160; &#160;&#160;PGA: Clear/minimal</b></p>
<p style="position:absolute;top:394px;left:456px;white-space:nowrap" class="ft272">17 (4.3)</p>
<p style="position:absolute;top:394px;left:594px;white-space:nowrap" class="ft272">506 (62.2)b</p>
<p style="position:absolute;top:412px;left:207px;white-space:nowrap" class="ft277">a&#160;Percent of patients achieving PASI75 response was calculated as&#160;centre-<br/>adjusted rate</p>
<p style="position:absolute;top:450px;left:207px;white-space:nowrap" class="ft279">b&#160;p&#160;&lt;&#160;0.001, Humira vs. Placebo</p>
<p style="position:absolute;top:485px;left:429px;white-space:nowrap" class="ft271"><b>Table&#160;12</b></p>
<p style="position:absolute;top:504px;left:264px;white-space:nowrap" class="ft271"><b>Ps Study II (CHAMPION) Efficacy Results at 16&#160;Weeks</b></p>
<p style="position:absolute;top:543px;left:353px;white-space:nowrap" class="ft271"><b>Placebo</b></p>
<p style="position:absolute;top:562px;left:361px;white-space:nowrap" class="ft271"><b>N=53</b></p>
<p style="position:absolute;top:581px;left:360px;white-space:nowrap" class="ft271"><b>n&#160;(%)</b></p>
<p style="position:absolute;top:543px;left:474px;white-space:nowrap" class="ft271"><b>MTX</b></p>
<p style="position:absolute;top:562px;left:470px;white-space:nowrap" class="ft271"><b>N=110</b></p>
<p style="position:absolute;top:581px;left:473px;white-space:nowrap" class="ft271"><b>n&#160;(%)</b></p>
<p style="position:absolute;top:543px;left:566px;white-space:nowrap" class="ft271"><b>Humira 40 mg eow</b></p>
<p style="position:absolute;top:562px;left:610px;white-space:nowrap" class="ft271"><b>N=108</b></p>
<p style="position:absolute;top:581px;left:613px;white-space:nowrap" class="ft271"><b>n&#160;(%)</b></p>
<p style="position:absolute;top:602px;left:203px;white-space:nowrap" class="ft271"><b>&#160; &#160;&#160;</b></p>
<p style="position:absolute;top:600px;left:220px;white-space:nowrap" class="ft276">&#160;<b>PASI 75</b></p>
<p style="position:absolute;top:600px;left:350px;white-space:nowrap" class="ft272">10 (18.9)</p>
<p style="position:absolute;top:600px;left:463px;white-space:nowrap" class="ft272">39 (35.5)</p>
<p style="position:absolute;top:600px;left:594px;white-space:nowrap" class="ft272">86 (79.6)&#160;a, b</p>
<p style="position:absolute;top:621px;left:203px;white-space:nowrap" class="ft271"><b>&#160; &#160;&#160;PASI 100</b></p>
<p style="position:absolute;top:621px;left:358px;white-space:nowrap" class="ft272">1 (1.9)</p>
<p style="position:absolute;top:621px;left:471px;white-space:nowrap" class="ft272">8 (7.3)</p>
<p style="position:absolute;top:621px;left:594px;white-space:nowrap" class="ft272">18 (16.7)&#160;c, d</p>
<p style="position:absolute;top:641px;left:203px;white-space:nowrap" class="ft2715"><b>&#160; &#160;&#160;PGA:&#160;<br/>Clear/minimal</b></p>
<p style="position:absolute;top:641px;left:354px;white-space:nowrap" class="ft272">6 (11.3)</p>
<p style="position:absolute;top:641px;left:463px;white-space:nowrap" class="ft272">33 (30.0)</p>
<p style="position:absolute;top:641px;left:594px;white-space:nowrap" class="ft272">79 (73.1)&#160;a, b</p>
<p style="position:absolute;top:678px;left:203px;white-space:nowrap" class="ft279">a&#160;p&#160;&lt;&#160;0.001 Humira vs. placebo</p>
<p style="position:absolute;top:697px;left:203px;white-space:nowrap" class="ft279">b&#160;p&#160;&lt;&#160;0.001 Humira vs. methotrexate</p>
<p style="position:absolute;top:716px;left:203px;white-space:nowrap" class="ft279">c&#160;p&#160;&lt;&#160;0.01 Humira vs. placebo</p>
<p style="position:absolute;top:735px;left:203px;white-space:nowrap" class="ft279">d&#160;p&#160;&lt;&#160;0.05 Humira vs. methotrexate</p>
<p style="position:absolute;top:775px;left:106px;white-space:nowrap" class="ft274">In&#160;Psoriasis&#160;Study I, 28% of patients who were PASI 75 responders and were re-randomised to placebo at&#160;<br/>Week&#160;33 compared to 5% continuing on Humira, p&#160;&lt;&#160;0.001, experienced “loss of adequate response”<br/>(PASI score after Week&#160;33 and on or before Week&#160;52 that resulted in a &lt;PASI 50 response relative to&#160;<br/>baseline with a minimum of a 6-point increase in PASI score relative to Week&#160;33). Of the patients who&#160;<br/>lost adequate response after re-randomisation to placebo who then enrolled into the open-label extension&#160;<br/>trial, 38% (25/66) and 55% (36/66) regained PASI 75 response after 12 and 24&#160;weeks of re-treatment,&#160;<br/>respectively.</p>
<p style="position:absolute;top:927px;left:106px;white-space:nowrap" class="ft275">A total of 233 PASI 75 responders at Week&#160;16 and Week&#160;33 received continuous Humira therapy for&#160;<br/>52&#160;weeks in Psoriasis Study I, and continued Humira in the&#160;open-label extension trial.&#160;PASI 75 and PGA&#160;<br/>of clear or minimal response rates in these patients were 74.7% and 59.0%, respectively, after an&#160;<br/>additional 108&#160;weeks of open-label therapy (total of 160&#160;weeks). In an analysis in which all patients who&#160;<br/>dropped out of the study for adverse events or lack of efficacy, or who dose-escalated, were considered&#160;<br/>non-responders, PASI 75 and PGA of clear or minimal response rates in these patients were 69.6% and&#160;<br/>55.7%, respectively, after an additional 108&#160;weeks of open-label therapy (total of 160&#160;weeks).</p>
</div>
<!-- Page 28 -->
<a name="28"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page28-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft280">28</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft284">A total of 347 stable responders participated in a withdrawal and retreatment evaluation in an open-label&#160;<br/>extension study. During the withdrawal period, symptoms of psoriasis returned over time with a median&#160;<br/>time to relapse (decline to PGA “moderate” or worse) of approximately 5&#160;months. None of these patients&#160;<br/>experienced rebound during the withdrawal period. A total of 76.5% (218/285) of patients who entered the&#160;<br/>retreatment period had a response of PGA “clear” or “minimal” after 16&#160;weeks of retreatment, irrespective&#160;<br/>of&#160;whether they relapsed during withdrawal (69.1%[123/178] and 88.8% [95/107] for patients who&#160;<br/>relapsed and who did not relapse during the withdrawal period, respectively). A similar safety profile was&#160;<br/>observed during retreatment as before withdrawal.</p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft285">Significant improvements at Week&#160;16 from baseline compared to placebo (Studies I and II) and MTX&#160;<br/>(Study II) were demonstrated in the DLQI (Dermatology Life Quality Index). In Study I, improvements in&#160;<br/>the physical and mental component summary scores of the SF-36 were also significant compared to&#160;<br/>placebo.</p>
<p style="position:absolute;top:352px;left:106px;white-space:nowrap" class="ft284">In an open-label extension study, for patients who dose escalated from 40&#160;mg&#160;every other week to&#160;40&#160;mg&#160;<br/>weekly due to a PASI response below 50%, 26.4%&#160;(92/349) and 37.8% (132/349)&#160;of patients achieved&#160;<br/>PASI 75 response&#160;at Week&#160;12 and 24, respectively.</p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft284">Psoriasis Study III (REACH)&#160;compared the efficacy and safety of Humira&#160;<i>versus&#160;</i>placebo in&#160;72&#160;patients&#160;<br/>with&#160;moderate to severe chronic plaque psoriasis and hand and/or foot psoriasis. Patients received an&#160;<br/>initial&#160;dose of 80&#160;mg Humira followed by 40&#160;mg every other week (starting one week after the initial dose)&#160;<br/>or placebo for 16&#160;weeks. At Week&#160;16, a statistically significantly greater proportion of patients who&#160;<br/>received Humira achieved PGA of 'clear' or 'almost clear' for the hands and/or feet compared to patients&#160;<br/>who received placebo (30.6% versus 4.3%, respectively [P = 0.014]).</p>
<p style="position:absolute;top:560px;left:106px;white-space:nowrap" class="ft285">Psoriasis Study IV compared&#160;efficacy and safety of Humira versus placebo in 217 adult patients with&#160;<br/>moderate to severe nail psoriasis. Patients received an initial dose of 80&#160;mg Humira followed by 40&#160;mg&#160;<br/>every other week (starting one week after the initial dose) or placebo for 26&#160;weeks followed by open-label&#160;<br/>Humira treatment for an additional 26&#160;weeks. Nail psoriasis&#160;assessments included&#160;the&#160;Modified Nail&#160;<br/>Psoriasis Severity Index (mNAPSI),&#160;the Physician’s Global Assessment of Fingernail Psoriasis (PGA-F)<br/>and the Nail Psoriasis Severity Index (NAPSI) (see Table&#160;13).&#160;Humira demonstrated a treatment benefit in&#160;<br/>nail psoriasis patients with different extents of skin involvement (BSA≥10%&#160;(60% of patients)&#160;and&#160;<br/>BSA&lt;10% and&#160;≥5%&#160;(40% of patients)).</p>
<p style="position:absolute;top:731px;left:428px;white-space:nowrap" class="ft281"><b>Table&#160;13</b></p>
<p style="position:absolute;top:750px;left:275px;white-space:nowrap" class="ft281"><b>Ps Study IV&#160;Efficacy Results at&#160;16,&#160;26&#160;and 52&#160;Weeks</b></p>
<p style="position:absolute;top:770px;left:133px;white-space:nowrap" class="ft282">Endpoint</p>
<p style="position:absolute;top:770px;left:328px;white-space:nowrap" class="ft282">Week 16</p>
<p style="position:absolute;top:789px;left:293px;white-space:nowrap" class="ft282">Placebo-Controlled</p>
<p style="position:absolute;top:770px;left:500px;white-space:nowrap" class="ft282">Week 26</p>
<p style="position:absolute;top:789px;left:466px;white-space:nowrap" class="ft282">Placebo-Controlled</p>
<p style="position:absolute;top:770px;left:670px;white-space:nowrap" class="ft282">Week 52</p>
<p style="position:absolute;top:789px;left:663px;white-space:nowrap" class="ft282">Open-label</p>
<p style="position:absolute;top:809px;left:284px;white-space:nowrap" class="ft282">Placebo</p>
<p style="position:absolute;top:827px;left:287px;white-space:nowrap" class="ft282">N=108</p>
<p style="position:absolute;top:809px;left:373px;white-space:nowrap" class="ft282">Humira</p>
<p style="position:absolute;top:827px;left:361px;white-space:nowrap" class="ft282">40&#160;mg&#160;eow&#160;</p>
<p style="position:absolute;top:846px;left:375px;white-space:nowrap" class="ft282">N=109</p>
<p style="position:absolute;top:809px;left:456px;white-space:nowrap" class="ft282">Placebo</p>
<p style="position:absolute;top:827px;left:459px;white-space:nowrap" class="ft282">N=108</p>
<p style="position:absolute;top:809px;left:541px;white-space:nowrap" class="ft282">Humira</p>
<p style="position:absolute;top:827px;left:530px;white-space:nowrap" class="ft282">40&#160;mg&#160;eow&#160;</p>
<p style="position:absolute;top:846px;left:544px;white-space:nowrap" class="ft282">N=109</p>
<p style="position:absolute;top:809px;left:674px;white-space:nowrap" class="ft282">Humira</p>
<p style="position:absolute;top:827px;left:663px;white-space:nowrap" class="ft282">40&#160;mg&#160;eow&#160;</p>
<p style="position:absolute;top:846px;left:680px;white-space:nowrap" class="ft282">N=80</p>
<p style="position:absolute;top:866px;left:133px;white-space:nowrap" class="ft282">≥ mNAPSI 75 (%)</p>
<p style="position:absolute;top:866px;left:300px;white-space:nowrap" class="ft282">2.9</p>
<p style="position:absolute;top:866px;left:381px;white-space:nowrap" class="ft282">26.0a</p>
<p style="position:absolute;top:866px;left:472px;white-space:nowrap" class="ft282">3.4</p>
<p style="position:absolute;top:866px;left:550px;white-space:nowrap" class="ft282">46.6a</p>
<p style="position:absolute;top:866px;left:685px;white-space:nowrap" class="ft282">65.0</p>
<p style="position:absolute;top:886px;left:133px;white-space:nowrap" class="ft284">PGA-F&#160;<br/>clear/minimal and&#160;<br/>≥2-grade&#160;<br/>improvement (%)</p>
<p style="position:absolute;top:886px;left:300px;white-space:nowrap" class="ft282">2.9</p>
<p style="position:absolute;top:886px;left:381px;white-space:nowrap" class="ft282">29.7a</p>
<p style="position:absolute;top:886px;left:472px;white-space:nowrap" class="ft282">6.9</p>
<p style="position:absolute;top:886px;left:550px;white-space:nowrap" class="ft282">48.9a</p>
<p style="position:absolute;top:886px;left:685px;white-space:nowrap" class="ft282">61.3</p>
<p style="position:absolute;top:963px;left:133px;white-space:nowrap" class="ft284">Percent Change in&#160;<br/>Total Fingernail&#160;<br/>NAPSI (%)</p>
<p style="position:absolute;top:963px;left:297px;white-space:nowrap" class="ft282">-7.8</p>
<p style="position:absolute;top:963px;left:377px;white-space:nowrap" class="ft282">-44.2&#160;a</p>
<p style="position:absolute;top:963px;left:465px;white-space:nowrap" class="ft282">-11.5</p>
<p style="position:absolute;top:963px;left:547px;white-space:nowrap" class="ft282">-56.2a</p>
<p style="position:absolute;top:963px;left:682px;white-space:nowrap" class="ft282">-72.2</p>
<p style="position:absolute;top:1019px;left:133px;white-space:nowrap" class="ft289">a&#160;p&lt;0.001, Humira&#160;<i>vs.&#160;</i>placebo&#160;</p>
<p style="position:absolute;top:1059px;left:106px;white-space:nowrap" class="ft284">Humira treated patients showed statistically significant improvements at&#160;Week&#160;26 compared with placebo&#160;<br/>in the DLQI.&#160;</p>
</div>
<!-- Page 29 -->
<a name="29"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft2916{font-size:17px;line-height:24px;font-family:HORGHZ+TimesNewRoman;color:#000000;}
-->
</style>
<div id="page29-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft290">29</p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft293"><i>Adult&#160;Crohn’s disease</i></p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft297">The safety and efficacy of Humira were assessed in over 1500 patients with moderately to severely active&#160;<br/>Crohn’s disease (Crohn’s Disease Activity Index (CDAI)&#160;</p>
<p style="position:absolute;top:180px;left:489px;white-space:nowrap" class="ft296">&#160;220 and&#160;&#160;450) in randomised, double-blind,&#160;</p>
<p style="position:absolute;top:201px;left:106px;white-space:nowrap" class="ft294">placebo-controlled studies. Concomitant stable doses of aminosalicylates, corticosteroids, and/or&#160;<br/>immunomodulatory agents were permitted and 80% of patients continued to receive at least one of these&#160;<br/>medications.&#160;</p>
<p style="position:absolute;top:277px;left:106px;white-space:nowrap" class="ft295">Induction of clinical&#160;remission (defined as CDAI &lt;&#160;150) was evaluated in two studies, CD Study I&#160;<br/>(CLASSIC I) and CD Study II (GAIN). In CD Study I, 299 TNF-antagonist naive patients were&#160;<br/>randomised to one of four treatment groups; placebo at Weeks&#160;0 and 2, 160&#160;mg Humira at Week&#160;0 and&#160;<br/>80&#160;mg at Week&#160;2, 80&#160;mg at Week&#160;0 and 40&#160;mg at Week&#160;2, and 40&#160;mg at Week&#160;0 and 20&#160;mg at Week&#160;2. In&#160;<br/>CD Study II, 325 patients who had lost response or were intolerant to infliximab were randomised to&#160;<br/>receive either 160&#160;mg Humira at Week&#160;0 and 80&#160;mg at&#160;Week&#160;2 or placebo at Weeks&#160;0 and 2. The primary&#160;<br/>non-responders were excluded from the studies and therefore these patients were not further evaluated.</p>
<p style="position:absolute;top:429px;left:106px;white-space:nowrap" class="ft294">Maintenance of clinical remission was evaluated in CD study III (CHARM). In CD Study III, 854 patients&#160;<br/>received open-label 80&#160;mg at Week&#160;0 and 40&#160;mg at Week&#160;2. At Week&#160;4 patients were randomised to&#160;<br/>40&#160;mg&#160;every other&#160;week, 40&#160;mg every&#160;week, or placebo with a total study duration of 56&#160;weeks. Patients in&#160;<br/>clinical response (decrease in CDAI&#160;≥&#160;70) at Week&#160;4 were stratified and analysed separately from those&#160;<br/>not in clinical response at Week&#160;4. Corticosteroid taper was permitted after Week&#160;8.&#160;</p>
<p style="position:absolute;top:543px;left:106px;white-space:nowrap" class="ft292">CD study I and CD study II induction of remission and response rates are presented in Table&#160;14.</p>
<p style="position:absolute;top:583px;left:422px;white-space:nowrap" class="ft291"><b>Table&#160;14</b></p>
<p style="position:absolute;top:603px;left:291px;white-space:nowrap" class="ft291"><b>Induction of&#160;Clinical Remission and Response</b></p>
<p style="position:absolute;top:625px;left:380px;white-space:nowrap" class="ft291"><b>(Percent of Patients)</b></p>
<p style="position:absolute;top:649px;left:287px;white-space:nowrap" class="ft2915"><b>CD&#160;Study I: Infliximab Naive&#160;<br/>Patients</b></p>
<p style="position:absolute;top:649px;left:558px;white-space:nowrap" class="ft2915"><b>CD Study II: Infliximab&#160;<br/>Experienced Patients</b></p>
<p style="position:absolute;top:692px;left:296px;white-space:nowrap" class="ft291"><b>Placebo</b></p>
<p style="position:absolute;top:713px;left:305px;white-space:nowrap" class="ft291"><b>N=74</b></p>
<p style="position:absolute;top:692px;left:387px;white-space:nowrap" class="ft291"><b>Humira</b></p>
<p style="position:absolute;top:713px;left:383px;white-space:nowrap" class="ft291"><b>80/40&#160;mg</b></p>
<p style="position:absolute;top:734px;left:392px;white-space:nowrap" class="ft291"><b>N = 75</b></p>
<p style="position:absolute;top:692px;left:478px;white-space:nowrap" class="ft291"><b>Humira&#160;</b></p>
<p style="position:absolute;top:713px;left:470px;white-space:nowrap" class="ft291"><b>160/80&#160;mg&#160;</b></p>
<p style="position:absolute;top:731px;left:487px;white-space:nowrap" class="ft291"><b>N=76</b></p>
<p style="position:absolute;top:692px;left:579px;white-space:nowrap" class="ft291"><b>Placebo</b></p>
<p style="position:absolute;top:713px;left:583px;white-space:nowrap" class="ft291"><b>N=166</b></p>
<p style="position:absolute;top:692px;left:703px;white-space:nowrap" class="ft291"><b>Humira&#160;</b></p>
<p style="position:absolute;top:713px;left:694px;white-space:nowrap" class="ft291"><b>160/80&#160;mg</b></p>
<p style="position:absolute;top:734px;left:707px;white-space:nowrap" class="ft291"><b>N=159</b></p>
<p style="position:absolute;top:759px;left:114px;white-space:nowrap" class="ft2916">Week&#160;4<br/>Clinical remission</p>
<p style="position:absolute;top:784px;left:309px;white-space:nowrap" class="ft292">12%</p>
<p style="position:absolute;top:784px;left:400px;white-space:nowrap" class="ft292">24%</p>
<p style="position:absolute;top:784px;left:488px;white-space:nowrap" class="ft292">36%*</p>
<p style="position:absolute;top:784px;left:595px;white-space:nowrap" class="ft292">7%</p>
<p style="position:absolute;top:784px;left:713px;white-space:nowrap" class="ft292">21%*</p>
<p style="position:absolute;top:808px;left:114px;white-space:nowrap" class="ft292">Clinical response (CR-</p>
<p style="position:absolute;top:826px;left:114px;white-space:nowrap" class="ft292">100)</p>
<p style="position:absolute;top:809px;left:309px;white-space:nowrap" class="ft292">24%</p>
<p style="position:absolute;top:809px;left:400px;white-space:nowrap" class="ft292">37%</p>
<p style="position:absolute;top:809px;left:486px;white-space:nowrap" class="ft292">49%**</p>
<p style="position:absolute;top:809px;left:591px;white-space:nowrap" class="ft292">25%</p>
<p style="position:absolute;top:809px;left:710px;white-space:nowrap" class="ft292">38%**</p>
<p style="position:absolute;top:851px;left:114px;white-space:nowrap" class="ft294">All p-values are pairwise comparisons of proportions for Humira&#160;<i>versus&#160;</i>placebo<br/>*</p>
<p style="position:absolute;top:872px;left:141px;white-space:nowrap" class="ft292">p&#160;&lt;&#160;0.001</p>
<p style="position:absolute;top:892px;left:114px;white-space:nowrap" class="ft299">**</p>
<p style="position:absolute;top:893px;left:141px;white-space:nowrap" class="ft292">p&#160;&lt;&#160;0.01</p>
<p style="position:absolute;top:934px;left:106px;white-space:nowrap" class="ft294">Similar remission rates were observed for the 160/80&#160;mg&#160;and 80/40&#160;mg&#160;induction regimens by Week&#160;8 and&#160;<br/>adverse events were more frequently noted in the 160/80&#160;mg group.</p>
<p style="position:absolute;top:991px;left:106px;white-space:nowrap" class="ft294">In CD Study III, at Week&#160;4, 58% (499/854) of patients were in clinical response and were assessed in the&#160;<br/>primary analysis. Of those in clinical&#160;response at Week&#160;4, 48% had been previously exposed to other TNF-<br/>antagonists. Maintenance of remission and response rates are presented in Table&#160;15.&#160;Clinical remission&#160;<br/>results remained relatively constant irrespective of previous TNF-antagonist exposure.</p>
</div>
<!-- Page 30 -->
<a name="30"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page30-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft300">30</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft305">Disease-related hospitalisations and surgeries were statistically significantly reduced with adalimumab&#160;<br/>compared with placebo at Week&#160;56.</p>
<p style="position:absolute;top:145px;left:422px;white-space:nowrap" class="ft301"><b>Table&#160;15</b></p>
<p style="position:absolute;top:166px;left:279px;white-space:nowrap" class="ft301"><b>Maintenance of Clinical Remission and Response</b></p>
<p style="position:absolute;top:187px;left:380px;white-space:nowrap" class="ft301"><b>(Percent of Patients)</b></p>
<p style="position:absolute;top:212px;left:425px;white-space:nowrap" class="ft301"><b>Placebo</b></p>
<p style="position:absolute;top:212px;left:539px;white-space:nowrap" class="ft301"><b>40&#160;mg&#160;Humira</b></p>
<p style="position:absolute;top:230px;left:531px;white-space:nowrap" class="ft301"><b>every other&#160;week</b></p>
<p style="position:absolute;top:212px;left:675px;white-space:nowrap" class="ft301"><b>40&#160;mg&#160;Humira</b></p>
<p style="position:absolute;top:230px;left:687px;white-space:nowrap" class="ft301"><b>every week</b></p>
<p style="position:absolute;top:255px;left:122px;white-space:nowrap" class="ft301"><b>Week&#160;26</b></p>
<p style="position:absolute;top:255px;left:429px;white-space:nowrap" class="ft301"><b>N=170</b></p>
<p style="position:absolute;top:255px;left:567px;white-space:nowrap" class="ft301"><b>N=172</b></p>
<p style="position:absolute;top:255px;left:703px;white-space:nowrap" class="ft301"><b>N=157</b></p>
<p style="position:absolute;top:279px;left:122px;white-space:nowrap" class="ft302">Clinical remission</p>
<p style="position:absolute;top:279px;left:437px;white-space:nowrap" class="ft302">17%</p>
<p style="position:absolute;top:279px;left:571px;white-space:nowrap" class="ft302">40%*</p>
<p style="position:absolute;top:279px;left:707px;white-space:nowrap" class="ft302">47%*</p>
<p style="position:absolute;top:304px;left:122px;white-space:nowrap" class="ft302">Clinical response (CR-100)</p>
<p style="position:absolute;top:304px;left:437px;white-space:nowrap" class="ft302">27%</p>
<p style="position:absolute;top:304px;left:571px;white-space:nowrap" class="ft302">52%*</p>
<p style="position:absolute;top:304px;left:707px;white-space:nowrap" class="ft302">52%*</p>
<p style="position:absolute;top:329px;left:149px;white-space:nowrap" class="ft302">Patients in steroid-free remission&#160;</p>
<p style="position:absolute;top:347px;left:149px;white-space:nowrap" class="ft302">for &gt;=90 daysa</p>
<p style="position:absolute;top:329px;left:419px;white-space:nowrap" class="ft302">3% (2/66)</p>
<p style="position:absolute;top:329px;left:541px;white-space:nowrap" class="ft302">19% (11/58)**</p>
<p style="position:absolute;top:329px;left:677px;white-space:nowrap" class="ft302">15% (11/74)**</p>
<p style="position:absolute;top:372px;left:122px;white-space:nowrap" class="ft301"><b>Week&#160;56</b></p>
<p style="position:absolute;top:372px;left:429px;white-space:nowrap" class="ft301"><b>N=170</b></p>
<p style="position:absolute;top:372px;left:567px;white-space:nowrap" class="ft301"><b>N=172</b></p>
<p style="position:absolute;top:372px;left:703px;white-space:nowrap" class="ft301"><b>N=157</b></p>
<p style="position:absolute;top:396px;left:122px;white-space:nowrap" class="ft302">Clinical remission</p>
<p style="position:absolute;top:396px;left:437px;white-space:nowrap" class="ft302">12%</p>
<p style="position:absolute;top:396px;left:571px;white-space:nowrap" class="ft302">36%*</p>
<p style="position:absolute;top:396px;left:707px;white-space:nowrap" class="ft302">41%*</p>
<p style="position:absolute;top:421px;left:122px;white-space:nowrap" class="ft302">Clinical response (CR-100)</p>
<p style="position:absolute;top:421px;left:437px;white-space:nowrap" class="ft302">17%</p>
<p style="position:absolute;top:421px;left:571px;white-space:nowrap" class="ft302">41%*</p>
<p style="position:absolute;top:421px;left:707px;white-space:nowrap" class="ft302">48%*</p>
<p style="position:absolute;top:446px;left:149px;white-space:nowrap" class="ft302">Patients in steroid-free remission&#160;</p>
<p style="position:absolute;top:464px;left:149px;white-space:nowrap" class="ft302">for&#160;&gt;&#160;=&#160;90&#160;daysa</p>
<p style="position:absolute;top:446px;left:419px;white-space:nowrap" class="ft302">5% (3/66)</p>
<p style="position:absolute;top:446px;left:545px;white-space:nowrap" class="ft302">29% (17/58)*</p>
<p style="position:absolute;top:446px;left:677px;white-space:nowrap" class="ft302">20% (15/74)**</p>
<p style="position:absolute;top:489px;left:122px;white-space:nowrap" class="ft302">*</p>
<p style="position:absolute;top:489px;left:149px;white-space:nowrap" class="ft302">p&#160;&lt;&#160;0.001 for Humira&#160;<i>versus&#160;</i>placebo pairwise comparisons of proportions</p>
<p style="position:absolute;top:509px;left:122px;white-space:nowrap" class="ft304">**&#160;p&#160;&lt;&#160;0.02 for Humira&#160;<i>versus&#160;</i>placebo pairwise comparisons of proportions<br/>a</p>
<p style="position:absolute;top:530px;left:149px;white-space:nowrap" class="ft302">Of those receiving corticosteroids at baseline</p>
<p style="position:absolute;top:571px;left:106px;white-space:nowrap" class="ft305">Among patients who were not in response at Week&#160;4, 43% of Humira maintenance patients responded by&#160;<br/>Week&#160;12 compared to 30% of placebo&#160;maintenance patients. These results suggest that some patients who&#160;<br/>have not responded by Week&#160;4 benefit from continued maintenance therapy through Week&#160;12. Therapy&#160;<br/>continued beyond 12&#160;weeks did not result in significantly more responses&#160;(see section 4.2).</p>
<p style="position:absolute;top:666px;left:106px;white-space:nowrap" class="ft304">117/276 patients from CD study I and 272/777 patients from CD studies II and III were followed through&#160;<br/>at least 3&#160;years of open-label adalimumab therapy. 88 and 189 patients, respectively, continued to be in&#160;<br/>clinical remission. Clinical response&#160;(CR-100) was maintained in 102 and 233 patients, respectively.</p>
<p style="position:absolute;top:742px;left:106px;white-space:nowrap" class="ft303"><i>Quality of life</i></p>
<p style="position:absolute;top:780px;left:106px;white-space:nowrap" class="ft304">In CD Study I and CD Study II, statistically significant improvement in the disease-specific inflammatory&#160;<br/>bowel disease questionnaire (IBDQ) total score was achieved at Week&#160;4&#160;in patients randomised to Humira&#160;<br/>80/40&#160;mg and 160/80&#160;mg compared to placebo and was seen at Weeks&#160;26 and 56 in CD Study III as well&#160;<br/>among the adalimumab treatment groups compared to the placebo group.</p>
<p style="position:absolute;top:875px;left:106px;white-space:nowrap" class="ft303"><i>Adult&#160;Uveitis</i></p>
<p style="position:absolute;top:913px;left:106px;white-space:nowrap" class="ft304">The safety and efficacy of Humira were assessed in adult patients with non-infectious intermediate,&#160;<br/>posterior, and panuveitis, excluding patients with isolated anterior uveitis, in two randomised, double-<br/>masked, placebo-controlled studies (UV I and II). Patients received placebo or&#160;Humira at an initial dose of&#160;<br/>80&#160;mg followed by 40&#160;mg&#160;every other week starting one week after the initial dose.&#160;Concomitant stable&#160;<br/>doses of one&#160;non-biologic immunosuppressant were permitted.&#160;</p>
<p style="position:absolute;top:1027px;left:106px;white-space:nowrap" class="ft304">Study UV I evaluated 217 patients with active uveitis despite treatment with corticosteroids (oral&#160;<br/>prednisone at a dose of 10&#160;to&#160;60&#160;mg/day). All patients received a 2-week&#160;standardised dose of prednisone&#160;<br/>60&#160;mg/day at study entry followed by a mandatory taper schedule, with complete corticosteroid&#160;<br/>discontinuation by Week 15.&#160;</p>
</div>
<!-- Page 31 -->
<a name="31"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft3117{font-size:17px;font-family:HORGHZ+TimesNewRoman,BoldItalic;color:#000000;}
	.ft3118{font-size:8px;font-family:HORGHZ+TimesNewRoman;color:#000000;}
	.ft3119{font-size:17px;line-height:19px;font-family:HORGHZ+TimesNewRoman,Bold;color:#000000;}
-->
</style>
<div id="page31-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft310">31</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft314">Study UV II evaluated 226 patients with inactive uveitis requiring chronic corticosteroid treatment (oral&#160;<br/>prednisone 10&#160;to&#160;35&#160;mg/day) at baseline to control their disease. Patients subsequently underwent a&#160;<br/>mandatory taper schedule, with complete corticosteroid discontinuation by Week 19.&#160;</p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft315">The primary efficacy endpoint in both studies was ´time to treatment failure´. Treatment failure was&#160;<br/>defined by a multi-component outcome based on inflammatory chorioretinal and/or inflammatory retinal&#160;<br/>vascular lesions, anterior chamber (AC) cell grade, vitreous haze (VH) grade and best corrected visual&#160;<br/>acuity (BCVA).&#160;</p>
<p style="position:absolute;top:276px;left:106px;white-space:nowrap" class="ft315">Patients who completed Studies UV I and UV&#160;II were&#160;eligible to enroll in&#160;an uncontrolled long-term&#160;<br/>extension study with an originally planned duration of 78 weeks. Patients were allowed to continue on&#160;<br/>study medication beyond Week 78 until they had access to Humira.</p>
<p style="position:absolute;top:352px;left:106px;white-space:nowrap" class="ft313"><i>Clinical Response</i></p>
<p style="position:absolute;top:390px;left:106px;white-space:nowrap" class="ft315">Results from both studies demonstrated statistically significant reduction of the risk of treatment failure in&#160;<br/>patients treated with Humira versus patients receiving placebo (See Table&#160;16).&#160;Both studies demonstrated&#160;<br/>an early and sustained effect of Humira on the treatment failure rate versus placebo (see Figure&#160;1).</p>
<p style="position:absolute;top:465px;left:428px;white-space:nowrap" class="ft311"><b>Table&#160;16</b></p>
<p style="position:absolute;top:485px;left:270px;white-space:nowrap" class="ft311"><b>Time to Treatment Failure in Studies UV I and UV II</b></p>
<p style="position:absolute;top:523px;left:114px;white-space:nowrap" class="ft311"><b>Analysis</b></p>
<p style="position:absolute;top:542px;left:156px;white-space:nowrap" class="ft311"><b>Treatment</b></p>
<p style="position:absolute;top:523px;left:284px;white-space:nowrap" class="ft311"><b>N</b></p>
<p style="position:absolute;top:523px;left:338px;white-space:nowrap" class="ft3119"><b>Failure<br/>N (%)</b></p>
<p style="position:absolute;top:523px;left:426px;white-space:nowrap" class="ft3119"><b>Median Time to&#160;<br/>Failure (months)</b></p>
<p style="position:absolute;top:523px;left:567px;white-space:nowrap" class="ft311"><b>HRa</b></p>
<p style="position:absolute;top:523px;left:621px;white-space:nowrap" class="ft3119"><b>CI 95%&#160;<br/>for HRa</b></p>
<p style="position:absolute;top:523px;left:709px;white-space:nowrap" class="ft3117"><i><b>P&#160;</b></i><b>Value&#160;</b>b</p>
<p style="position:absolute;top:562px;left:114px;white-space:nowrap" class="ft3115"><b>Time to Treatment Failure At or After Week 6 in Study UV I &#160;<br/></b>Primary analysis (ITT)</p>
<p style="position:absolute;top:600px;left:156px;white-space:nowrap" class="ft312">Placebo</p>
<p style="position:absolute;top:600px;left:284px;white-space:nowrap" class="ft312">107</p>
<p style="position:absolute;top:600px;left:338px;white-space:nowrap" class="ft312">84 (78.5)</p>
<p style="position:absolute;top:600px;left:426px;white-space:nowrap" class="ft312">3.0</p>
<p style="position:absolute;top:600px;left:567px;white-space:nowrap" class="ft312">--</p>
<p style="position:absolute;top:600px;left:621px;white-space:nowrap" class="ft312">--</p>
<p style="position:absolute;top:600px;left:709px;white-space:nowrap" class="ft312">--</p>
<p style="position:absolute;top:619px;left:156px;white-space:nowrap" class="ft312">Adalimumab</p>
<p style="position:absolute;top:619px;left:284px;white-space:nowrap" class="ft312">110</p>
<p style="position:absolute;top:619px;left:338px;white-space:nowrap" class="ft312">60 (54.5)</p>
<p style="position:absolute;top:619px;left:426px;white-space:nowrap" class="ft312">5.6</p>
<p style="position:absolute;top:619px;left:567px;white-space:nowrap" class="ft312">0.50</p>
<p style="position:absolute;top:619px;left:621px;white-space:nowrap" class="ft312">0.36, 0.70</p>
<p style="position:absolute;top:619px;left:709px;white-space:nowrap" class="ft312">&lt; 0.001</p>
<p style="position:absolute;top:638px;left:114px;white-space:nowrap" class="ft3119"><b>Time to Treatment Failure At or After Week 2 in Study UV II<br/></b>Primary&#160;analysis (ITT)</p>
<p style="position:absolute;top:676px;left:156px;white-space:nowrap" class="ft312">Placebo</p>
<p style="position:absolute;top:676px;left:284px;white-space:nowrap" class="ft312">111</p>
<p style="position:absolute;top:676px;left:338px;white-space:nowrap" class="ft312">61 (55.0)</p>
<p style="position:absolute;top:676px;left:426px;white-space:nowrap" class="ft312">8.3</p>
<p style="position:absolute;top:676px;left:567px;white-space:nowrap" class="ft312">--</p>
<p style="position:absolute;top:676px;left:621px;white-space:nowrap" class="ft312">--</p>
<p style="position:absolute;top:676px;left:709px;white-space:nowrap" class="ft312">--</p>
<p style="position:absolute;top:696px;left:156px;white-space:nowrap" class="ft312">Adalimumab</p>
<p style="position:absolute;top:696px;left:284px;white-space:nowrap" class="ft312">115</p>
<p style="position:absolute;top:696px;left:338px;white-space:nowrap" class="ft312">45 (39.1)</p>
<p style="position:absolute;top:696px;left:426px;white-space:nowrap" class="ft312">NEc</p>
<p style="position:absolute;top:696px;left:567px;white-space:nowrap" class="ft312">0.57</p>
<p style="position:absolute;top:696px;left:621px;white-space:nowrap" class="ft312">0.39, 0.84</p>
<p style="position:absolute;top:696px;left:709px;white-space:nowrap" class="ft312">0.004</p>
<p style="position:absolute;top:715px;left:106px;white-space:nowrap" class="ft318">Note: Treatment failure at or after Week 6 (Study UV I), or at or after Week 2 (Study UV II), was counted&#160;<br/>as event. Drop outs due to reasons&#160;other than treatment failure were censored at the time of dropping out.<br/>a</p>
<p style="position:absolute;top:753px;left:133px;white-space:nowrap" class="ft312">HR of adalimumab vs placebo from proportional hazards regression with treatment as factor.</p>
<p style="position:absolute;top:776px;left:106px;white-space:nowrap" class="ft3118">b</p>
<p style="position:absolute;top:772px;left:133px;white-space:nowrap" class="ft312">2-sided&#160;<i>P&#160;</i>value from log rank test.</p>
<p style="position:absolute;top:795px;left:106px;white-space:nowrap" class="ft3118">c</p>
<p style="position:absolute;top:791px;left:133px;white-space:nowrap" class="ft312">NE = not estimable. Fewer than half of at-risk subjects had an event.&#160;</p>
</div>
<!-- Page 32 -->
<a name="32"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft3220{font-size:17px;font-family:HORGHZ+TimesNewRoman,Bold;color:#000000;-moz-transform: matrix(         0,         -1,          1,          0, 0, 0);-webkit-transform: matrix(         0,         -1,          1,          0, 0, 0);-o-transform: matrix(         0,         -1,          1,          0, 0, 0);-ms-transform: matrix(         0,         -1,          1,          0, 0, 0);-moz-transform-origin: left 75%;-webkit-transform-origin: left 75%;-o-transform-origin: left 75%;-ms-transform-origin: left 75%;}
-->
</style>
<div id="page32-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft320">32</p>
<p style="position:absolute;top:86px;left:108px;white-space:nowrap" class="ft321"><b>Figure&#160;1: Kaplan-Meier Curves Summarizing Time to Treatment Failure on or after Week 6 (Study&#160;</b></p>
<p style="position:absolute;top:105px;left:350px;white-space:nowrap" class="ft321"><b>UV I) or Week 2 (Study UV II)&#160;</b></p>
<p style="position:absolute;top:404px;left:130px;white-space:nowrap" class="ft3220"><b>T</b></p>
<p style="position:absolute;top:392px;left:130px;white-space:nowrap" class="ft3220"><b>R</b></p>
<p style="position:absolute;top:381px;left:130px;white-space:nowrap" class="ft3220"><b>E</b></p>
<p style="position:absolute;top:369px;left:130px;white-space:nowrap" class="ft3220"><b>A</b></p>
<p style="position:absolute;top:357px;left:130px;white-space:nowrap" class="ft3220"><b>T</b></p>
<p style="position:absolute;top:346px;left:130px;white-space:nowrap" class="ft3220"><b>M</b></p>
<p style="position:absolute;top:331px;left:130px;white-space:nowrap" class="ft3220"><b>E</b></p>
<p style="position:absolute;top:320px;left:130px;white-space:nowrap" class="ft3220"><b>N</b></p>
<p style="position:absolute;top:308px;left:130px;white-space:nowrap" class="ft3220"><b>T</b></p>
<p style="position:absolute;top:297px;left:130px;white-space:nowrap" class="ft3220"><b>&#160;F</b></p>
<p style="position:absolute;top:283px;left:130px;white-space:nowrap" class="ft3220"><b>A</b></p>
<p style="position:absolute;top:271px;left:130px;white-space:nowrap" class="ft3220"><b>IL</b></p>
<p style="position:absolute;top:253px;left:130px;white-space:nowrap" class="ft3220"><b>U</b></p>
<p style="position:absolute;top:242px;left:130px;white-space:nowrap" class="ft3220"><b>R</b></p>
<p style="position:absolute;top:230px;left:130px;white-space:nowrap" class="ft3220"><b>E</b></p>
<p style="position:absolute;top:219px;left:130px;white-space:nowrap" class="ft3220"><b>&#160;R</b></p>
<p style="position:absolute;top:202px;left:130px;white-space:nowrap" class="ft3220"><b>A</b></p>
<p style="position:absolute;top:191px;left:130px;white-space:nowrap" class="ft3220"><b>T</b></p>
<p style="position:absolute;top:180px;left:130px;white-space:nowrap" class="ft3220"><b>E</b></p>
<p style="position:absolute;top:169px;left:130px;white-space:nowrap" class="ft3220"><b>&#160;(</b></p>
<p style="position:absolute;top:159px;left:130px;white-space:nowrap" class="ft3220"><b>%</b></p>
<p style="position:absolute;top:143px;left:130px;white-space:nowrap" class="ft3220"><b>)</b></p>
<p style="position:absolute;top:428px;left:410px;white-space:nowrap" class="ft322">TIME (MONTHS)</p>
<p style="position:absolute;top:447px;left:150px;white-space:nowrap" class="ft322">Study UV I &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;Treatment</p>
<p style="position:absolute;top:447px;left:500px;white-space:nowrap" class="ft322">Placebo</p>
<p style="position:absolute;top:447px;left:669px;white-space:nowrap" class="ft322">Adalimumab</p>
<p style="position:absolute;top:733px;left:130px;white-space:nowrap" class="ft3220"><b>T</b></p>
<p style="position:absolute;top:721px;left:130px;white-space:nowrap" class="ft3220"><b>R</b></p>
<p style="position:absolute;top:710px;left:130px;white-space:nowrap" class="ft3220"><b>E</b></p>
<p style="position:absolute;top:698px;left:130px;white-space:nowrap" class="ft3220"><b>A</b></p>
<p style="position:absolute;top:687px;left:130px;white-space:nowrap" class="ft3220"><b>T</b></p>
<p style="position:absolute;top:675px;left:130px;white-space:nowrap" class="ft3220"><b>M</b></p>
<p style="position:absolute;top:660px;left:130px;white-space:nowrap" class="ft3220"><b>E</b></p>
<p style="position:absolute;top:649px;left:130px;white-space:nowrap" class="ft3220"><b>N</b></p>
<p style="position:absolute;top:637px;left:130px;white-space:nowrap" class="ft3220"><b>T</b></p>
<p style="position:absolute;top:626px;left:130px;white-space:nowrap" class="ft3220"><b>&#160;F</b></p>
<p style="position:absolute;top:612px;left:130px;white-space:nowrap" class="ft3220"><b>A</b></p>
<p style="position:absolute;top:600px;left:130px;white-space:nowrap" class="ft3220"><b>IL</b></p>
<p style="position:absolute;top:582px;left:130px;white-space:nowrap" class="ft3220"><b>U</b></p>
<p style="position:absolute;top:571px;left:130px;white-space:nowrap" class="ft3220"><b>R</b></p>
<p style="position:absolute;top:559px;left:130px;white-space:nowrap" class="ft3220"><b>E</b></p>
<p style="position:absolute;top:548px;left:130px;white-space:nowrap" class="ft3220"><b>&#160;R</b></p>
<p style="position:absolute;top:531px;left:130px;white-space:nowrap" class="ft3220"><b>A</b></p>
<p style="position:absolute;top:520px;left:130px;white-space:nowrap" class="ft3220"><b>T</b></p>
<p style="position:absolute;top:509px;left:130px;white-space:nowrap" class="ft3220"><b>E</b></p>
<p style="position:absolute;top:498px;left:130px;white-space:nowrap" class="ft3220"><b>&#160;(</b></p>
<p style="position:absolute;top:488px;left:130px;white-space:nowrap" class="ft3220"><b>%</b></p>
<p style="position:absolute;top:472px;left:130px;white-space:nowrap" class="ft3220"><b>)</b></p>
<p style="position:absolute;top:760px;left:410px;white-space:nowrap" class="ft322">TIME (MONTHS)</p>
<p style="position:absolute;top:779px;left:150px;white-space:nowrap" class="ft322">Study UV II &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; Treatment</p>
<p style="position:absolute;top:779px;left:500px;white-space:nowrap" class="ft322">Placebo</p>
<p style="position:absolute;top:779px;left:669px;white-space:nowrap" class="ft322">Adalimumab</p>
<p style="position:absolute;top:811px;left:114px;white-space:nowrap" class="ft324">Note: P# = Placebo (Number of Events/Number at Risk); A# = HUMIRA (Number of<br/>Events/Number at Risk).</p>
<p style="position:absolute;top:873px;left:106px;white-space:nowrap" class="ft324">In Study UV I statistically&#160;significant differences in favour of adalimumab versus placebo were observed&#160;<br/>for each component of treatment failure.&#160;In Study UV II, statistically significant differences were observed&#160;<br/>for visual acuity only, but the other components were numerically in favour of adalimumab.</p>
<p style="position:absolute;top:949px;left:106px;white-space:nowrap" class="ft324">Of the&#160;424&#160;subjects included&#160;in&#160;the&#160;uncontrolled long-term&#160;extension of Studies UV I and UV II,&#160;60<br/>subjects were regarded ineligible (e.g.&#160;due to deviations or due to&#160;complications secondary to diabetic&#160;<br/>retinopathy, due to cataract surgery or vitrectomy) and were excluded from the primary analysis&#160;of&#160;<br/>efficacy. Of the&#160;364&#160;remaining patients,&#160;269&#160;evaluable patients&#160;(74%)&#160;reached 78 weeks of open-label&#160;<br/>adalimumab treatment. Based on the observed data approach,&#160;216&#160;(80.3%) were in quiescence (no active&#160;<br/>inflammatory lesions, AC cell grade &#160;≤&#160;0.5+, VH grade&#160;≤ 0.5+) with a concomitant steroid dose ≤ 7.5 mg&#160;<br/>per day, and&#160;178&#160;(66.2%) were in steroid-free quiescence. BCVA was either improved or maintained (&lt; 5&#160;<br/>letters deterioration) in 88.6% of the&#160;eyes at week 78.&#160;Data beyond Week 78 were generally consistent&#160;</p>
</div>
<!-- Page 33 -->
<a name="33"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page33-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft330">33</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft334">with these results but the number of enrolled subjects declined after this time. Overall, among the patients&#160;<br/>who discontinued the study,&#160;18% discontinued due to adverse events, and&#160;8% due to&#160;insufficient response&#160;<br/>to adalimumab treatment.</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft333"><i>Quality of Life</i></p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft334">Patient reported outcomes regarding vision-related functioning were measured in both clinical studies,&#160;<br/>using the NEI VFQ-25. Humira was numerically favoured for the majority of subscores with&#160;statistically&#160;<br/>significant mean differences for general vision, ocular pain, near vision, mental health, and total score in&#160;<br/>Study UV I, and for general vision and mental health in Study UV II. Vision related effects were not&#160;<br/>numerically in favour of Humira&#160;for colour vision in Study UVI and for colour vision, peripheral vision&#160;<br/>and near vision in Study UV II.</p>
<p style="position:absolute;top:333px;left:106px;white-space:nowrap" class="ft332">Immunogenicity</p>
<p style="position:absolute;top:370px;left:106px;white-space:nowrap" class="ft334">Formation of anti-adalimumab antibodies is associated with increased clearance and reduced efficacy of&#160;<br/>adalimumab. There is no apparent correlation between the presence of anti-adalimumab antibodies and the&#160;<br/>occurrence of adverse events.</p>
<p style="position:absolute;top:446px;left:106px;white-space:nowrap" class="ft334">In patients with polyarticular juvenile idiopathic arthritis who were 4 to 17&#160;years, anti-adalimumab&#160;<br/>antibodies were identified in 15.8% (27/171) of patients treated with adalimumab. In patients not given&#160;<br/>concomitant methotrexate, the incidence was 25.6% (22/86) compared to 5.9% (5/85) when adalimumab&#160;<br/>was used as add-on to methotrexate.&#160;In patients with polyarticular juvenile idiopathic arthritis who were<br/>2&#160;to&#160;&lt;&#160;4&#160;years old or aged 4 and above weighing &lt;15&#160;kg, anti-adalimumab antibodies were identified in&#160;<br/>7% (1/15) of patients, and the one patient was receiving concomitant methotrexate.</p>
<p style="position:absolute;top:579px;left:106px;white-space:nowrap" class="ft335">In patients with enthesitis-related arthritis, anti-adalimumab antibodies were identified in 10.9% (5/46) of&#160;<br/>patients treated with adalimumab. In patients not given concomitant methotrexate, the incidence was&#160;<br/>13.6% (3/22), compared to 8.3% (2/24) when adalimumab was used as add-on to methotrexate.</p>
<p style="position:absolute;top:655px;left:106px;white-space:nowrap" class="ft334">Patients in rheumatoid arthritis studies I, II and III were tested at multiple time points for anti-adalimumab&#160;<br/>antibodies during the 6 to 12&#160;month period. In the pivotal trials, anti-adalimumab antibodies were&#160;<br/>identified in 5.5% (58/1053) of patients treated with adalimumab, compared to 0.5% (2/370) on placebo.&#160;<br/>In patients not given concomitant methotrexate, the incidence was 12.4%, compared to 0.6% when&#160;<br/>adalimumab was used as add-on to methotrexate. &#160;</p>
<p style="position:absolute;top:769px;left:106px;white-space:nowrap" class="ft334">In patients with paediatric psoriasis, anti-adalimumab antibodies were&#160;identified in 5/38 subjects (13%)&#160;<br/>treated with 0.8&#160;mg/kg adalimumab monotherapy.</p>
<p style="position:absolute;top:826px;left:106px;white-space:nowrap" class="ft334">In adult patients with psoriasis, anti-adalimumab antibodies were identified in 77/920 subjects (8.4%)&#160;<br/>treated with adalimumab monotherapy.</p>
<p style="position:absolute;top:883px;left:106px;white-space:nowrap" class="ft334">In adult plaque psoriasis patients on long term adalimumab monotherapy who participated in a withdrawal&#160;<br/>and retreatment study, the rate of antibodies to adalimumab after retreatment (11 of 482 subjects, 2.3%)&#160;<br/>was similar to the rate observed prior to withdrawal (11 of 590 subjects, 1.9%).</p>
<p style="position:absolute;top:959px;left:106px;white-space:nowrap" class="ft334">In patients with moderately to&#160;severely active paediatric Crohn’s disease, the rate of anti-adalimumab&#160;<br/>antibody development in patients receiving adalimumab was 3.3%.&#160;</p>
<p style="position:absolute;top:1016px;left:106px;white-space:nowrap" class="ft332">In patients with Crohn’s disease, anti-adalimumab antibodies were identified in 7/269&#160;subjects (2.6%).</p>
<p style="position:absolute;top:1054px;left:106px;white-space:nowrap" class="ft335">In&#160;adult&#160;patients with non-infectious uveitis, anti-adalimumab antibodies were identified in 4.8% (12/249)&#160;<br/>of patients treated with adalimumab.</p>
</div>
<!-- Page 34 -->
<a name="34"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page34-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft340">34</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft344">Because immunogenicity analyses are product-specific, comparison of antibody rates with those from&#160;<br/>other products is not appropriate.</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft342">Paediatric population</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft343"><i>Juvenile idiopathic arthritis (JIA)</i></p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft343"><i>Polyarticular juvenile&#160;idiopathic&#160;arthritis (pJIA)</i></p>
<p style="position:absolute;top:276px;left:106px;white-space:nowrap" class="ft345">The safety and efficacy of Humira was assessed in two studies (pJIA I and II) in children with active<br/>polyarticular or polyarticular course juvenile idiopathic arthritis, who had a variety of JIA onset types&#160;<br/>(most frequently rheumatoid-factor negative or positive polyarthritis and extended oligoarthritis).</p>
<p style="position:absolute;top:352px;left:106px;white-space:nowrap" class="ft342">pJIA I</p>
<p style="position:absolute;top:384px;left:106px;white-space:nowrap" class="ft347">The safety and efficacy of Humira were assessed in a multicentre, randomised, double-blind,&#160;<br/>parallel&#160;−&#160;group study in 171&#160;children (4-17&#160;years&#160;old) with polyarticular JIA. In the open-label lead in&#160;<br/>phase (OL LI) patients were stratified into two groups, MTX (methotrexate)-treated or non-MTX-treated.&#160;<br/>Patients who were in the non-MTX stratum were either naïve to or had been withdrawn from MTX at&#160;<br/>least two weeks prior to study drug administration. Patients remained on stable doses of&#160;non-steroidal&#160;<br/>anti-inflammatory drugs&#160;(NSAIDs)&#160;and or prednisone (</p>
<p style="position:absolute;top:478px;left:471px;white-space:nowrap" class="ft346">&#160;0.2&#160;mg/kg/day or 10&#160;mg/day maximum). In the&#160;</p>
<p style="position:absolute;top:499px;left:106px;white-space:nowrap" class="ft344">OL LI phase all patients received 24&#160;mg/m2&#160;up to a maximum of 40&#160;mg Humira every other week for&#160;<br/>16&#160;weeks. The distribution of patients by age and minimum, median and maximum dose received during&#160;<br/>the OL LI phase&#160;is presented in Table&#160;17.</p>
<p style="position:absolute;top:575px;left:431px;white-space:nowrap" class="ft341"><b>Table&#160;17</b></p>
<p style="position:absolute;top:594px;left:157px;white-space:nowrap" class="ft341"><b>Distribution of patients by age and adalimumab dose received during the OL LI phase</b></p>
<p style="position:absolute;top:633px;left:122px;white-space:nowrap" class="ft342">Age Group</p>
<p style="position:absolute;top:633px;left:304px;white-space:nowrap" class="ft344">Number of patients at Baseline&#160;<br/>n&#160;(%)</p>
<p style="position:absolute;top:633px;left:568px;white-space:nowrap" class="ft344">Minimum, median and maximum&#160;<br/>dose</p>
<p style="position:absolute;top:672px;left:122px;white-space:nowrap" class="ft342">4 to 7&#160;years</p>
<p style="position:absolute;top:672px;left:304px;white-space:nowrap" class="ft342">31 (18.1)</p>
<p style="position:absolute;top:672px;left:568px;white-space:nowrap" class="ft342">10, 20 and 25&#160;mg</p>
<p style="position:absolute;top:700px;left:122px;white-space:nowrap" class="ft342">8 to&#160;12&#160;years</p>
<p style="position:absolute;top:700px;left:304px;white-space:nowrap" class="ft342">71 (41.5)</p>
<p style="position:absolute;top:700px;left:568px;white-space:nowrap" class="ft342">20, 25 and 40&#160;mg</p>
<p style="position:absolute;top:720px;left:122px;white-space:nowrap" class="ft342">13 to 17&#160;years</p>
<p style="position:absolute;top:720px;left:304px;white-space:nowrap" class="ft342">69 (40.4)</p>
<p style="position:absolute;top:720px;left:568px;white-space:nowrap" class="ft342">25, 40 and 40&#160;mg</p>
<p style="position:absolute;top:759px;left:106px;white-space:nowrap" class="ft347">Patients demonstrating a Paediatric ACR 30 response at Week&#160;16 were eligible to be randomised into the&#160;<br/>double blind (DB) phase and received either Humira 24&#160;mg/m2&#160;up to a maximum of 40&#160;mg, or placebo&#160;<br/>every other week for an additional 32&#160;weeks or until disease flare. Disease flare criteria were defined as a&#160;<br/>worsening of&#160;</p>
<p style="position:absolute;top:815px;left:197px;white-space:nowrap" class="ft346">&#160;30% from baseline in&#160;&#160;3 of 6 Paediatric ACR core criteria,&#160;&#160;2 active joints, and&#160;</p>
<p style="position:absolute;top:837px;left:106px;white-space:nowrap" class="ft342">improvement of&#160;</p>
<p style="position:absolute;top:835px;left:216px;white-space:nowrap" class="ft346">&#160;30% in no more than 1 of the 6 criteria. After 32&#160;weeks or at disease flare, patients&#160;</p>
<p style="position:absolute;top:856px;left:106px;white-space:nowrap" class="ft342">were&#160;eligible to&#160;enrol&#160;into the open label extension phase.&#160;</p>
</div>
<!-- Page 35 -->
<a name="35"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page35-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft350">35</p>
<p style="position:absolute;top:86px;left:431px;white-space:nowrap" class="ft351"><b>Table&#160;18</b></p>
<p style="position:absolute;top:105px;left:321px;white-space:nowrap" class="ft351"><b>Ped ACR 30 Responses in the JIA study</b></p>
<p style="position:absolute;top:144px;left:122px;white-space:nowrap" class="ft351"><b>Stratum</b></p>
<p style="position:absolute;top:144px;left:406px;white-space:nowrap" class="ft351"><b>MTX</b></p>
<p style="position:absolute;top:144px;left:629px;white-space:nowrap" class="ft351"><b>Without&#160;MTX</b></p>
<p style="position:absolute;top:163px;left:122px;white-space:nowrap" class="ft3519"><b>Phase<br/></b>OL-LI 16 weeks</p>
<p style="position:absolute;top:203px;left:165px;white-space:nowrap" class="ft354">Ped ACR 30&#160;<br/>response (n/N)</p>
<p style="position:absolute;top:203px;left:378px;white-space:nowrap" class="ft352">94.1% (80/85)</p>
<p style="position:absolute;top:203px;left:631px;white-space:nowrap" class="ft352">74.4% (64/86)</p>
<p style="position:absolute;top:242px;left:122px;white-space:nowrap" class="ft354">&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;Efficacy Outcomes<br/>Double Blind 32&#160;weeks</p>
<p style="position:absolute;top:261px;left:304px;white-space:nowrap" class="ft355">Humira /MTX<br/>(N = 38)</p>
<p style="position:absolute;top:261px;left:436px;white-space:nowrap" class="ft355">Placebo / MTX<br/>(N = 37)</p>
<p style="position:absolute;top:261px;left:568px;white-space:nowrap" class="ft355">Humira&#160;<br/>(N = 30)</p>
<p style="position:absolute;top:261px;left:692px;white-space:nowrap" class="ft355">Placebo<br/>(N = 28)</p>
<p style="position:absolute;top:319px;left:165px;white-space:nowrap" class="ft355">Disease flares at&#160;<br/>the end of&#160;<br/>32&#160;weeksa&#160;(n/N)</p>
<p style="position:absolute;top:319px;left:304px;white-space:nowrap" class="ft352">36.8% (14/38)</p>
<p style="position:absolute;top:319px;left:436px;white-space:nowrap" class="ft352">64.9% (24/37)b</p>
<p style="position:absolute;top:319px;left:568px;white-space:nowrap" class="ft352">43.3% (13/30)</p>
<p style="position:absolute;top:319px;left:692px;white-space:nowrap" class="ft354">71.4%&#160;<br/>(20/28)c</p>
<p style="position:absolute;top:377px;left:165px;white-space:nowrap" class="ft354">Median time to&#160;<br/>disease flare</p>
<p style="position:absolute;top:377px;left:304px;white-space:nowrap" class="ft352">&gt;32&#160;weeks</p>
<p style="position:absolute;top:377px;left:436px;white-space:nowrap" class="ft352">20&#160;weeks</p>
<p style="position:absolute;top:377px;left:568px;white-space:nowrap" class="ft352">&gt;32&#160;weeks</p>
<p style="position:absolute;top:377px;left:692px;white-space:nowrap" class="ft352">14&#160;weeks</p>
<p style="position:absolute;top:435px;left:114px;white-space:nowrap" class="ft359">a&#160;Ped ACR 30/50/70 responses Week&#160;48 significantly greater than those of placebo treated patients&#160;</p>
<p style="position:absolute;top:454px;left:114px;white-space:nowrap" class="ft359">b&#160;p = 0.015</p>
<p style="position:absolute;top:472px;left:114px;white-space:nowrap" class="ft359">c&#160;p = 0.031</p>
<p style="position:absolute;top:512px;left:106px;white-space:nowrap" class="ft354">Amongst those who responded at Week&#160;16 (n=144), the Paediatric ACR 30/50/70/90 responses were&#160;<br/>maintained for up to six years in the&#160;OLE phase in patients who received Humira throughout the study.<br/>Over all 19&#160;subjects, of which 11 of the baseline age group 4 to 12 and 8 of the baseline age group 13 to&#160;<br/>17&#160;years were treated 6&#160;years or longer.</p>
<p style="position:absolute;top:607px;left:106px;white-space:nowrap" class="ft355">Overall responses were generally better and,&#160;fewer patients developed antibodies when treated with the&#160;<br/>combination of Humira and MTX compared to Humira alone. Taking these results into consideration,&#160;<br/>Humira is recommended for use in combination with MTX and for use as monotherapy in patients for&#160;<br/>whom&#160;MTX use is not appropriate (see section 4.2).</p>
<p style="position:absolute;top:702px;left:106px;white-space:nowrap" class="ft352">pJIA II</p>
<p style="position:absolute;top:739px;left:106px;white-space:nowrap" class="ft354">The safety and efficacy of Humira was assessed in an open-label,&#160;multicentre&#160;study in 32&#160;children&#160;<br/>(2&#160;-&#160;&lt;&#160;4&#160;years&#160;old or&#160;aged 4 and above weighing &lt;&#160;15&#160;kg) with moderately to severely active polyarticular&#160;<br/>JIA. The patients&#160;received 24&#160;mg/m2&#160;body surface area (BSA) of Humira up to a maximum of 20&#160;mg&#160;<br/>every other week as a single dose via SC injection for at least 24&#160;weeks. During the study, most subjects&#160;<br/>used concomitant MTX, with fewer reporting use of&#160;corticosteroids or NSAIDs.</p>
<p style="position:absolute;top:853px;left:106px;white-space:nowrap" class="ft354">At Week&#160;12 and Week&#160;24, PedACR30 response was 93.5% and 90.0%, respectively, using the observed&#160;<br/>data approach. The proportions of subjects with PedACR50/70/90 at Week&#160;12 and Week&#160;24 were&#160;<br/>90.3%/61.3%/38.7% and 83.3%/73.3%/36.7%,&#160;respectively. Amongst those who responded (Paediatric&#160;<br/>ACR 30) at Week&#160;24 (n=27 out of 30 patients), the Paediatric ACR 30 responses were maintained for up&#160;<br/>to 60&#160;weeks in the OLE phase in patients who received Humira throughout this time period. Overall,&#160;<br/>20&#160;subjects were treated for 60&#160;weeks or longer.</p>
<p style="position:absolute;top:986px;left:106px;white-space:nowrap" class="ft353"><i>Enthesitis-related arthritis</i></p>
<p style="position:absolute;top:1024px;left:106px;white-space:nowrap" class="ft354">The safety and efficacy of Humira were assessed in a&#160;multicentre, randomised, double-blind study in 46&#160;<br/>paediatric patients (6 to 17&#160;years&#160;old)&#160;with&#160;moderate enthesitis-related arthritis. Patients were randomised&#160;<br/>to receive either 24&#160;mg/m2&#160;body surface area (BSA) of Humira up to a maximum of 40&#160;mg, or placebo&#160;<br/>every other week for 12&#160;weeks. The double-blind period is followed by an open-label (OL) period during&#160;</p>
</div>
<!-- Page 36 -->
<a name="36"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page36-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft360">36</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft364">which patients received&#160;24&#160;mg/m2&#160;BSA of Humira up to a maximum of 40&#160;mg&#160;every other week&#160;<br/>subcutaneously for up to an additional 192&#160;weeks. The primary endpoint was the percent&#160;change from&#160;<br/>Baseline to Week&#160;12 in the number of active joints with arthritis (swelling not due to deformity or joints&#160;<br/>with loss of motion plus pain and/or tenderness), which was achieved with mean percent decrease of&#160;-<br/>62.6% (median percent change&#160;-88.9%) in patients in the Humira group compared to&#160;-11.6% (median&#160;<br/>percent change&#160;-50.0%) in patients in the&#160;placebo group. Improvement in number of active joints with&#160;<br/>arthritis was maintained during the OL period through Week&#160;156&#160;for the 26 of 31 (84%) patients in the&#160;<br/>Humira group who remained in&#160;the study. Although not statistically significant, the majority of patients&#160;<br/>demonstrated clinical improvement in secondary endpoints such as number of sites of enthesitis, tender&#160;<br/>joint count (TJC), swollen joint count (SJC), Paediatric ACR 50 response, and Paediatric ACR 70&#160;<br/>response.</p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft363"><i>Paediatric plaque psoriasis&#160;</i></p>
<p style="position:absolute;top:361px;left:106px;white-space:nowrap" class="ft364">The&#160;efficacy of Humira was assessed in a randomised, double-blind, controlled study of 114 paediatric&#160;<br/>patients from 4&#160;years of age with severe chronic plaque psoriasis (as defined by a&#160;Physician’s Global&#160;<br/>Assessment (PGA)&#160;≥&#160;4&#160;or&#160;&gt;&#160;20% BSA involvement or &gt;&#160;10% BSA involvement with very thick lesions or&#160;<br/>Psoriasis Area and Severity Index&#160;(PASI)&#160;≥&#160;20 or&#160;≥&#160;10 with clinically relevant facial, genital, or hand/ foot&#160;<br/>involvement) who were inadequately controlled with topical therapy and heliotherapy or phototherapy.&#160;</p>
<p style="position:absolute;top:475px;left:106px;white-space:nowrap" class="ft364">Patients received Humira 0.8&#160;mg/kg&#160;eow (up to 40&#160;mg), 0.4&#160;mg/kg&#160;eow (up to 20&#160;mg), or methotrexate&#160;<br/>0.1-0.4&#160;mg/kg&#160;weekly (up to 25&#160;mg). At&#160;Week&#160;16, more patients randomised to Humira 0.8&#160;mg/kg&#160;had&#160;<br/>positive efficacy responses (e.g., PASI 75) than those randomised to 0.4&#160;mg/kg eow or MTX. &#160;</p>
<p style="position:absolute;top:552px;left:221px;white-space:nowrap" class="ft361"><b>Table&#160;19:&#160;&#160;Paediatric Plaque Psoriasis Efficacy Results at 16&#160;Weeks</b></p>
<p style="position:absolute;top:593px;left:451px;white-space:nowrap" class="ft362">MTXa</p>
<p style="position:absolute;top:612px;left:453px;white-space:nowrap" class="ft362">N=37&#160;</p>
<p style="position:absolute;top:593px;left:578px;white-space:nowrap" class="ft362">Humira 0.8&#160;mg/kg&#160;eow</p>
<p style="position:absolute;top:612px;left:635px;white-space:nowrap" class="ft362">N=38&#160;</p>
<p style="position:absolute;top:635px;left:162px;white-space:nowrap" class="ft362">PASI 75b</p>
<p style="position:absolute;top:635px;left:435px;white-space:nowrap" class="ft362">12 (32.4%)</p>
<p style="position:absolute;top:635px;left:617px;white-space:nowrap" class="ft362">22 (57.9%)</p>
<p style="position:absolute;top:657px;left:162px;white-space:nowrap" class="ft362">PGA: Clear/minimalc</p>
<p style="position:absolute;top:657px;left:435px;white-space:nowrap" class="ft362">15 (40.5%)</p>
<p style="position:absolute;top:657px;left:617px;white-space:nowrap" class="ft362">23 (60.5%)</p>
<p style="position:absolute;top:678px;left:145px;white-space:nowrap" class="ft369">a&#160;MTX = methotrexate</p>
<p style="position:absolute;top:697px;left:145px;white-space:nowrap" class="ft369">b&#160;P=0.027, Humira 0.8&#160;mg/kg versus MTX</p>
<p style="position:absolute;top:716px;left:145px;white-space:nowrap" class="ft369">c&#160;P=0.083, Humira 0.8&#160;mg/kg versus MTX</p>
<p style="position:absolute;top:757px;left:106px;white-space:nowrap" class="ft364">Patients who achieved PASI 75 and PGA clear or minimal were withdrawn from treatment for up to&#160;<br/>36&#160;weeks and monitored for loss of disease control (i.e. a worsening of PGA by at&#160;least 2 grades). Patients&#160;<br/>were then re-treated with adalimumab 0.8&#160;mg/kg eow for an additional 16&#160;weeks and response rates&#160;<br/>observed during retreatment were similar to the previous double-blind period: PASI 75 response of 78.9%&#160;<br/>(15 of 19 subjects) and PGA clear or minimal of 52.6% (10 of 19 subjects).</p>
<p style="position:absolute;top:871px;left:106px;white-space:nowrap" class="ft364">In the open label period of the study, PASI 75 and PGA clear or minimal responses were maintained for&#160;<br/>up to an additional 52&#160;weeks with no&#160;new safety findings.</p>
<p style="position:absolute;top:928px;left:106px;white-space:nowrap" class="ft363"><i>Paediatric Crohn’s disease&#160;</i></p>
<p style="position:absolute;top:961px;left:106px;white-space:nowrap" class="ft364">Humira was assessed in a&#160;multicentre, randomised, double-blind clinical trial designed to evaluate the&#160;<br/>efficacy and safety of induction and maintenance treatment with doses dependent on body weight (&lt;&#160;40&#160;kg&#160;<br/>or&#160;≥&#160;40&#160;kg) in 192 paediatric subjects between the ages of 6 and 17 (inclusive) years, with moderate to&#160;<br/>severe Crohn´s disease (CD) defined as Paediatric Crohn's Disease Activity Index (PCDAI) score &gt;&#160;30.&#160;<br/>Subjects had to have failed conventional therapy (including a corticosteroid and/or an immunomodulator)&#160;<br/>for CD. Subjects may also have previously lost response or been intolerant to infliximab.&#160;</p>
</div>
<!-- Page 37 -->
<a name="37"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft3721{font-size:17px;line-height:20px;font-family:HORGHZ+TimesNewRoman,Bold;color:#000000;}
-->
</style>
<div id="page37-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft370">37</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft374">All subjects received open-label induction therapy at a dose based on their Baseline body weight: 160&#160;mg&#160;<br/>at Week&#160;0 and 80&#160;mg at Week&#160;2 for subjects&#160;≥&#160;40&#160;kg, and&#160;80&#160;mg and 40&#160;mg, respectively, for subjects&#160;<br/>&lt;&#160;40&#160;kg.</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft375">At Week&#160;4, subjects were randomised 1:1 based on their body weight at the time to either the Low Dose or&#160;<br/>Standard Dose maintenance regimens as shown in Table&#160;20.</p>
<p style="position:absolute;top:219px;left:428px;white-space:nowrap" class="ft371"><b>Table&#160;20</b></p>
<p style="position:absolute;top:238px;left:382px;white-space:nowrap" class="ft371"><b>Maintenance regimen</b></p>
<p style="position:absolute;top:257px;left:339px;white-space:nowrap" class="ft3719"><b>Patient&#160;<br/>Weight</b></p>
<p style="position:absolute;top:257px;left:413px;white-space:nowrap" class="ft371"><b>Low dose</b></p>
<p style="position:absolute;top:257px;left:504px;white-space:nowrap" class="ft3719"><b>Standard&#160;<br/>dose</b></p>
<p style="position:absolute;top:296px;left:339px;white-space:nowrap" class="ft372">&lt;&#160;40 kg</p>
<p style="position:absolute;top:296px;left:413px;white-space:nowrap" class="ft372">10&#160;mg&#160;eow&#160;20&#160;mg&#160;eow</p>
<p style="position:absolute;top:316px;left:339px;white-space:nowrap" class="ft372">≥&#160;40 kg</p>
<p style="position:absolute;top:316px;left:413px;white-space:nowrap" class="ft372">20&#160;mg&#160;eow&#160;40&#160;mg&#160;eow</p>
<p style="position:absolute;top:355px;left:106px;white-space:nowrap" class="ft373"><i>Efficacy results</i></p>
<p style="position:absolute;top:394px;left:106px;white-space:nowrap" class="ft372">The primary endpoint of the study was clinical remission at Week&#160;26, defined as PCDAI score&#160;</p>
<p style="position:absolute;top:392px;left:734px;white-space:nowrap" class="ft376">&#160;10.</p>
<p style="position:absolute;top:432px;left:106px;white-space:nowrap" class="ft374">Clinical remission and clinical response (defined as reduction in PCDAI score of at least 15 points from&#160;<br/>Baseline) rates are presented in Table&#160;21. Rates of discontinuation of corticosteroids or&#160;<br/>immunomodulators are presented in Table&#160;22.</p>
<p style="position:absolute;top:510px;left:429px;white-space:nowrap" class="ft371"><b>Table&#160;21</b></p>
<p style="position:absolute;top:530px;left:386px;white-space:nowrap" class="ft371"><b>Paediatric CD Study</b></p>
<p style="position:absolute;top:548px;left:315px;white-space:nowrap" class="ft371"><b>PCDAI Clinical Remission and Response</b></p>
<p style="position:absolute;top:568px;left:392px;white-space:nowrap" class="ft371"><b>Standard Dose</b></p>
<p style="position:absolute;top:588px;left:396px;white-space:nowrap" class="ft371"><b>40/20 mg eow&#160;</b></p>
<p style="position:absolute;top:607px;left:421px;white-space:nowrap" class="ft371"><b>N = 93</b></p>
<p style="position:absolute;top:568px;left:529px;white-space:nowrap" class="ft371"><b>Low Dose</b></p>
<p style="position:absolute;top:588px;left:516px;white-space:nowrap" class="ft371"><b>20/10 mg eow&#160;</b></p>
<p style="position:absolute;top:607px;left:541px;white-space:nowrap" class="ft371"><b>N = 95</b></p>
<p style="position:absolute;top:568px;left:637px;white-space:nowrap" class="ft371"><b>P value</b>*</p>
<p style="position:absolute;top:626px;left:210px;white-space:nowrap" class="ft3721"><b>Week&#160;26<br/></b>&#160; &#160;Clinical remission</p>
<p style="position:absolute;top:647px;left:423px;white-space:nowrap" class="ft372">38.7%</p>
<p style="position:absolute;top:647px;left:543px;white-space:nowrap" class="ft372">28.4%</p>
<p style="position:absolute;top:647px;left:648px;white-space:nowrap" class="ft372">0.075</p>
<p style="position:absolute;top:667px;left:210px;white-space:nowrap" class="ft372">&#160; &#160;Clinical response&#160;</p>
<p style="position:absolute;top:667px;left:423px;white-space:nowrap" class="ft372">59.1%</p>
<p style="position:absolute;top:667px;left:543px;white-space:nowrap" class="ft372">48.4%</p>
<p style="position:absolute;top:667px;left:648px;white-space:nowrap" class="ft372">0.073</p>
<p style="position:absolute;top:687px;left:210px;white-space:nowrap" class="ft3721"><b>Week&#160;52<br/></b>&#160; &#160;Clinical remission</p>
<p style="position:absolute;top:707px;left:423px;white-space:nowrap" class="ft372">33.3%</p>
<p style="position:absolute;top:707px;left:543px;white-space:nowrap" class="ft372">23.2%</p>
<p style="position:absolute;top:707px;left:648px;white-space:nowrap" class="ft372">0.100</p>
<p style="position:absolute;top:727px;left:210px;white-space:nowrap" class="ft372">&#160; &#160;Clinical response</p>
<p style="position:absolute;top:727px;left:423px;white-space:nowrap" class="ft372">41.9%</p>
<p style="position:absolute;top:727px;left:543px;white-space:nowrap" class="ft372">28.4%</p>
<p style="position:absolute;top:727px;left:648px;white-space:nowrap" class="ft372">0.038</p>
<p style="position:absolute;top:747px;left:210px;white-space:nowrap" class="ft372">*&#160;p value for Standard Dose&#160;<i>versus&#160;</i>Low Dose comparison.</p>
<p style="position:absolute;top:787px;left:428px;white-space:nowrap" class="ft371"><b>Table&#160;22</b></p>
<p style="position:absolute;top:806px;left:386px;white-space:nowrap" class="ft371"><b>Paediatric CD Study</b></p>
<p style="position:absolute;top:825px;left:175px;white-space:nowrap" class="ft371"><b>Discontinuation of Corticosteroids or Immunomodulators and Fistula Remission</b></p>
<p style="position:absolute;top:845px;left:455px;white-space:nowrap" class="ft371"><b>Standard Dose</b></p>
<p style="position:absolute;top:864px;left:459px;white-space:nowrap" class="ft371"><b>40/20&#160;mg&#160;eow&#160;</b></p>
<p style="position:absolute;top:845px;left:595px;white-space:nowrap" class="ft371"><b>Low&#160;Dose</b></p>
<p style="position:absolute;top:864px;left:582px;white-space:nowrap" class="ft371"><b>20/10&#160;mg&#160;eow&#160;</b></p>
<p style="position:absolute;top:845px;left:705px;white-space:nowrap" class="ft371"><b>P value1</b></p>
<p style="position:absolute;top:885px;left:143px;white-space:nowrap" class="ft371"><b>Discontinued corticosteroids</b></p>
<p style="position:absolute;top:885px;left:486px;white-space:nowrap" class="ft371"><b>N= 33</b></p>
<p style="position:absolute;top:885px;left:611px;white-space:nowrap" class="ft371"><b>N=38</b></p>
<p style="position:absolute;top:905px;left:143px;white-space:nowrap" class="ft372">Week&#160;26</p>
<p style="position:absolute;top:905px;left:486px;white-space:nowrap" class="ft372">84.8%</p>
<p style="position:absolute;top:905px;left:608px;white-space:nowrap" class="ft372">65.8%</p>
<p style="position:absolute;top:905px;left:715px;white-space:nowrap" class="ft372">0.066</p>
<p style="position:absolute;top:924px;left:143px;white-space:nowrap" class="ft372">Week&#160;52</p>
<p style="position:absolute;top:924px;left:486px;white-space:nowrap" class="ft372">69.7%</p>
<p style="position:absolute;top:924px;left:608px;white-space:nowrap" class="ft372">60.5%</p>
<p style="position:absolute;top:924px;left:715px;white-space:nowrap" class="ft372">0.420</p>
<p style="position:absolute;top:945px;left:143px;white-space:nowrap" class="ft371"><b>Discontinuation of Immunomodulators2</b></p>
<p style="position:absolute;top:945px;left:488px;white-space:nowrap" class="ft371"><b>N=60</b></p>
<p style="position:absolute;top:945px;left:611px;white-space:nowrap" class="ft371"><b>N=57</b></p>
<p style="position:absolute;top:965px;left:143px;white-space:nowrap" class="ft372">Week&#160;52</p>
<p style="position:absolute;top:965px;left:486px;white-space:nowrap" class="ft372">30.0%</p>
<p style="position:absolute;top:965px;left:608px;white-space:nowrap" class="ft372">29.8%</p>
<p style="position:absolute;top:965px;left:715px;white-space:nowrap" class="ft372">0.983</p>
<p style="position:absolute;top:985px;left:143px;white-space:nowrap" class="ft371"><b>Fistula remission3</b></p>
<p style="position:absolute;top:985px;left:488px;white-space:nowrap" class="ft371"><b>N=15</b></p>
<p style="position:absolute;top:985px;left:611px;white-space:nowrap" class="ft371"><b>N=21</b></p>
<p style="position:absolute;top:1005px;left:143px;white-space:nowrap" class="ft372">Week&#160;26</p>
<p style="position:absolute;top:1005px;left:486px;white-space:nowrap" class="ft372">46.7%</p>
<p style="position:absolute;top:1005px;left:608px;white-space:nowrap" class="ft372">38.1%</p>
<p style="position:absolute;top:1005px;left:715px;white-space:nowrap" class="ft372">0.608</p>
<p style="position:absolute;top:1025px;left:143px;white-space:nowrap" class="ft372">Week&#160;52</p>
<p style="position:absolute;top:1025px;left:486px;white-space:nowrap" class="ft372">40.0%</p>
<p style="position:absolute;top:1025px;left:608px;white-space:nowrap" class="ft372">23.8%</p>
<p style="position:absolute;top:1025px;left:715px;white-space:nowrap" class="ft372">0.303</p>
<p style="position:absolute;top:1043px;left:143px;white-space:nowrap" class="ft379">1&#160;&#160;p value for Standard Dose&#160;<i>versus&#160;</i>Low Dose comparison.</p>
<p style="position:absolute;top:1062px;left:143px;white-space:nowrap" class="ft377">2&#160;&#160;Immunosuppressant therapy could only be discontinued at or after Week&#160;26 at the&#160;<br/>investigator's discretion if the subject met the clinical response criterion&#160;</p>
</div>
<!-- Page 38 -->
<a name="38"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page38-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft380">38</p>
<p style="position:absolute;top:85px;left:143px;white-space:nowrap" class="ft387">3&#160;defined as a closure of all fistulas that were draining at Baseline for at least 2 consecutive&#160;<br/>post-Baseline visits</p>
<p style="position:absolute;top:144px;left:106px;white-space:nowrap" class="ft384">Statistically significant&#160;increases (improvement) from Baseline to Week&#160;26 and 52 in Body Mass Index&#160;<br/>and height velocity were observed for both treatment groups.</p>
<p style="position:absolute;top:201px;left:106px;white-space:nowrap" class="ft384">Statistically and clinically significant improvements from Baseline were also observed in both treatment&#160;<br/>groups for quality of life parameters (including IMPACT III).</p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft385">One&#160;hundred patients (n=100) from the Paediatric CD Study&#160;continued in an open-label long-term&#160;<br/>extension study. After 5 years of adalimumab therapy, 74.0% (37/50) of the 50 patients remaining in the&#160;<br/>study continued to be in clinical remission, and 92.0% (46/50) of patients continued to be in clinical&#160;<br/>response per&#160;PCDAI.</p>
<p style="position:absolute;top:352px;left:106px;white-space:nowrap" class="ft383"><i>Paediatric Uveitis&#160;</i></p>
<p style="position:absolute;top:390px;left:106px;white-space:nowrap" class="ft384">The safety and efficacy of Humira was assessed in a randomized, double-masked, controlled study of 90&#160;<br/>paediatric patients from 2&#160;to&#160;&lt;&#160;18 years of age with active JIA-associated noninfectious anterior uveitis&#160;<br/>who were&#160;refractory to at least 12&#160;weeks of methotrexate treatment. Patients received either placebo or&#160;<br/>20&#160;mg adalimumab (if&#160;&lt;&#160;30&#160;kg) or 40&#160;mg adalimumab (if&#160;≥&#160;30&#160;kg)&#160;every other week in combination with&#160;<br/>their baseline dose of methotrexate.&#160;</p>
<p style="position:absolute;top:504px;left:106px;white-space:nowrap" class="ft385">The primary endpoint&#160;was ‘time to treatment failure’.&#160;The criteria determining treatment failure were&#160;<br/>worsening or sustained non-improvement in ocular inflammation,&#160;partial improvement&#160;with development&#160;<br/>of sustained ocular co-morbidities or worsening of ocular co-morbidities, non-permitted use of&#160;<br/>concomitant medications, and suspension of treatment for an extended period of time.</p>
<p style="position:absolute;top:599px;left:106px;white-space:nowrap" class="ft383"><i>Clinical Response</i></p>
<p style="position:absolute;top:639px;left:106px;white-space:nowrap" class="ft384">Adalimumab significantly delayed the time to treatment failure, as compared to placebo (See Figure&#160;2,&#160;<br/>P&#160;&lt;&#160;0.0001 from log rank test).The median time to treatment failure was&#160;24.1&#160;weeks for subjects treated&#160;<br/>with placebo, whereas the median time to treatment failure was not estimable for subjects treated with&#160;<br/>adalimumab because less than one-half of these subjects experienced treatment failure. Adalimumab<br/>significantly decreased the risk of treatment failure by 75% relative to placebo, as shown by the hazard&#160;<br/>ratio (HR = 0.25 [95% CI: 0.12, 0.49]).</p>
</div>
<!-- Page 39 -->
<a name="39"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page39-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft390">39</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft3919"><b>Figure&#160;2: Kaplan-Meier Curves Summarizing Time to Treatment Failure in the Paediatric&#160;Uveitis&#160;<br/>Study</b></p>
<p style="position:absolute;top:584px;left:129px;white-space:nowrap" class="ft3920"><b>P</b></p>
<p style="position:absolute;top:574px;left:129px;white-space:nowrap" class="ft3920"><b>R</b></p>
<p style="position:absolute;top:562px;left:129px;white-space:nowrap" class="ft3920"><b>O</b></p>
<p style="position:absolute;top:549px;left:129px;white-space:nowrap" class="ft3920"><b>B</b></p>
<p style="position:absolute;top:538px;left:129px;white-space:nowrap" class="ft3920"><b>A</b></p>
<p style="position:absolute;top:526px;left:129px;white-space:nowrap" class="ft3920"><b>B</b></p>
<p style="position:absolute;top:515px;left:129px;white-space:nowrap" class="ft3920"><b>IL</b></p>
<p style="position:absolute;top:498px;left:129px;white-space:nowrap" class="ft3920"><b>IT</b></p>
<p style="position:absolute;top:480px;left:129px;white-space:nowrap" class="ft3920"><b>Y</b></p>
<p style="position:absolute;top:469px;left:129px;white-space:nowrap" class="ft3920"><b>&#160;O</b></p>
<p style="position:absolute;top:451px;left:129px;white-space:nowrap" class="ft3920"><b>F</b></p>
<p style="position:absolute;top:442px;left:129px;white-space:nowrap" class="ft3920"><b>&#160;F</b></p>
<p style="position:absolute;top:427px;left:129px;white-space:nowrap" class="ft3920"><b>A</b></p>
<p style="position:absolute;top:415px;left:129px;white-space:nowrap" class="ft3920"><b>IL</b></p>
<p style="position:absolute;top:398px;left:129px;white-space:nowrap" class="ft3920"><b>IN</b></p>
<p style="position:absolute;top:380px;left:129px;white-space:nowrap" class="ft3920"><b>G</b></p>
<p style="position:absolute;top:367px;left:129px;white-space:nowrap" class="ft3920"><b>&#160;T</b></p>
<p style="position:absolute;top:352px;left:129px;white-space:nowrap" class="ft3920"><b>R</b></p>
<p style="position:absolute;top:340px;left:129px;white-space:nowrap" class="ft3920"><b>E</b></p>
<p style="position:absolute;top:329px;left:129px;white-space:nowrap" class="ft3920"><b>A</b></p>
<p style="position:absolute;top:317px;left:129px;white-space:nowrap" class="ft3920"><b>T</b></p>
<p style="position:absolute;top:306px;left:129px;white-space:nowrap" class="ft3920"><b>M</b></p>
<p style="position:absolute;top:290px;left:129px;white-space:nowrap" class="ft3920"><b>E</b></p>
<p style="position:absolute;top:279px;left:129px;white-space:nowrap" class="ft3920"><b>N</b></p>
<p style="position:absolute;top:267px;left:129px;white-space:nowrap" class="ft3920"><b>T</b></p>
<p style="position:absolute;top:705px;left:412px;white-space:nowrap" class="ft391"><b>TIME (WEEKS)</b></p>
<p style="position:absolute;top:724px;left:149px;white-space:nowrap" class="ft392">Treatment</p>
<p style="position:absolute;top:724px;left:500px;white-space:nowrap" class="ft392">Placebo</p>
<p style="position:absolute;top:724px;left:669px;white-space:nowrap" class="ft392">Adalimumab</p>
<p style="position:absolute;top:743px;left:149px;white-space:nowrap" class="ft392">Note:&#160;P = Placebo (Number at Risk); H&#160;= HUMIRA (Number at Risk).</p>
<p style="position:absolute;top:800px;left:106px;white-space:nowrap" class="ft391"><b>5.2</b></p>
<p style="position:absolute;top:800px;left:148px;white-space:nowrap" class="ft391"><b>Pharmacokinetic properties</b></p>
<p style="position:absolute;top:837px;left:106px;white-space:nowrap" class="ft392">Absorption and distribution</p>
<p style="position:absolute;top:876px;left:106px;white-space:nowrap" class="ft394">Following the&#160;administration of 24&#160;mg/m2&#160;(maximum of 40&#160;mg) subcutaneously every other week to&#160;<br/>patients with&#160;polyarticular juvenile idiopathic arthritis (JIA) who were 4 to 17&#160;years the mean trough&#160;<br/>steady-state (values measured from Week&#160;20 to 48) serum adalimumab concentration was 5.6 ± 5.6&#160;µg/ml&#160;<br/>(102% CV) for adalimumab without concomitant methotrexate&#160;and 10.9&#160;± 5.2&#160;µg/ml (47.7% CV) with&#160;<br/>concomitant methotrexate.</p>
<p style="position:absolute;top:989px;left:106px;white-space:nowrap" class="ft395">In patients with&#160;polyarticular&#160;JIA who were 2 to&#160;&lt;&#160;4&#160;years old or aged 4 and above weighing &lt;&#160;15&#160;kg&#160;<br/>dosed&#160;with adalimumab 24&#160;mg/m2&#160;, the mean trough steady-state serum adalimumab concentrations was&#160;<br/>6.0&#160;±&#160;6.1&#160;µg/ml (101% CV) for adalimumab without concomitant methotrexate and 7.9 ±&#160;5.6&#160;µg/ml&#160;<br/>(71.2% CV) with concomitant methotrexate.</p>
</div>
<!-- Page 40 -->
<a name="40"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page40-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft400">40</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft404">Following the administration of 24&#160;mg/m2&#160;(maximum of 40&#160;mg) subcutaneously every other week to&#160;<br/>patients with enthesitis-related arthritis who were 6 to 17&#160;years, the mean trough steady-state (values&#160;<br/>measured at Week&#160;24) serum adalimumab concentrations were 8.8&#160;±&#160;6.6&#160;μg/ml for adalimumab without&#160;<br/>concomitant methotrexate and 11.8&#160;±&#160;4.3&#160;μg/ml with concomitant methotrexate.</p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft404">Following the administration of 0.8&#160;mg/kg (maximum of 40&#160;mg) subcutaneously every other week to&#160;<br/>paediatric patients with chronic plaque psoriasis, the mean ± SD steady-state adalimumab trough&#160;<br/>concentration was approximately 7.4&#160;±&#160;5.8&#160;µg/ml&#160;(79% CV).</p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft407">In paediatric patients with moderate to severe CD, the open-label adalimumab induction dose was&#160;<br/>160/80&#160;mg&#160;or 80/40&#160;mg at Weeks&#160;0 and 2, respectively, dependent on a body&#160;weight cut-off&#160;of 40&#160;kg.&#160;At&#160;<br/>Week&#160;4, patients were&#160;randomised 1:1 to either the Standard Dose (40/20&#160;mg&#160;eow)&#160;or Low Dose&#160;<br/>(20/10&#160;mg eow)&#160;maintenance treatment groups based on their body weight.&#160;The&#160;mean (±SD)&#160;serum&#160;<br/>adalimumab trough concentrations achieved&#160;at Week&#160;4 were 15.7&#160;±&#160;6.6</p>
<p style="position:absolute;top:332px;left:580px;white-space:nowrap" class="ft406">g/ml for patients&#160;≥&#160;40&#160;kg&#160;</p>
<p style="position:absolute;top:354px;left:106px;white-space:nowrap" class="ft402">(160/80&#160;mg) and&#160;10.6&#160;±&#160;6.1</p>
<p style="position:absolute;top:352px;left:291px;white-space:nowrap" class="ft406">g/ml for patients &lt;&#160;40&#160;kg (80/40&#160;mg).&#160;</p>
<p style="position:absolute;top:392px;left:106px;white-space:nowrap" class="ft407">For patients who stayed on their randomised therapy, the mean&#160;(±SD)&#160;adalimumab trough concentrations&#160;<br/>at Week&#160;52 were&#160;9.5&#160;±&#160;5.6</p>
<p style="position:absolute;top:410px;left:284px;white-space:nowrap" class="ft406">g/ml for the Standard Dose group and&#160;3.5&#160;±&#160;2.2&#160;g/ml for the Low Dose&#160;</p>
<p style="position:absolute;top:431px;left:106px;white-space:nowrap" class="ft404">group.&#160;The&#160;mean trough concentrations were maintained in patients who continued to receive adalimumab&#160;<br/>treatment eow for 52&#160;weeks.&#160;For patients who dose escalated from eow to weekly regimen, the&#160;mean&#160;<br/>(±SD)&#160;serum concentrations of adalimumab at Week&#160;52 were 15.3&#160;±&#160;11.4&#160;μg/ml (40/20&#160;mg, weekly) and&#160;<br/>6.7&#160;±&#160;3.5&#160;μg/ml (20/10&#160;mg, weekly).</p>
<p style="position:absolute;top:526px;left:106px;white-space:nowrap" class="ft404">Adalimumab exposure in paediatric uveitis patients was predicted using population pharmacokinetic&#160;<br/>modelling and simulation based on cross-indication pharmacokinetics in other paediatric patients&#160;<br/>(paediatric psoriasis, juvenile idiopathic arthritis, paediatric Crohn’s disease, and enthesitis-related&#160;<br/>arthritis). No clinical exposure data&#160;are&#160;available on the use of a loading dose in children &lt;&#160;6&#160;years. The&#160;<br/>predicted exposures indicate that in the absence of methotrexate, a loading dose may lead to an initial&#160;<br/>increase in systemic exposure.</p>
<p style="position:absolute;top:659px;left:106px;white-space:nowrap" class="ft404">Exposure-response relationship in paediatric population<br/>On the basis of clinical trial data in patients with JIA (pJIA and ERA), an exposure-response relationship&#160;<br/>was established between plasma concentrations and PedACR 50 response.&#160;The&#160;apparent adalimumab&#160;<br/>plasma concentration&#160;that produces half the maximum&#160;probability of&#160;PedACR 50 response (EC50) was&#160;<br/>3&#160;μg/ml (95% CI: 1-6&#160;μg/ml).</p>
<p style="position:absolute;top:773px;left:106px;white-space:nowrap" class="ft405">Exposure-response relationships between adalimumab concentration and efficacy in paediatric patients&#160;<br/>with severe chronic plaque psoriasis were established for PASI 75 and PGA clear&#160;or minimal,&#160;<br/>respectively.&#160;PASI 75 and PGA&#160;clear or minimal&#160;increased with increasing adalimumab concentrations,&#160;<br/>both with a similar&#160;apparent EC50 of approximately 4.5&#160;μg/ml&#160;(95% CI 0.4-47.6 and 1.9-10.5,&#160;<br/>respectively).</p>
<p style="position:absolute;top:887px;left:106px;white-space:nowrap" class="ft402">Adults</p>
<p style="position:absolute;top:924px;left:106px;white-space:nowrap" class="ft404">After subcutaneous&#160;administration of a single 40&#160;mg dose, absorption and distribution of adalimumab was&#160;<br/>slow, with peak serum concentrations being reached about 5 days after administration. The average&#160;<br/>absolute bioavailability of adalimumab estimated from three studies following a single 40&#160;mg&#160;<br/>subcutaneous dose was 64%. After single intravenous doses ranging from 0.25 to 10&#160;mg/kg,&#160;<br/>concentrations were dose proportional. After doses of 0.5&#160;mg/kg (~40&#160;mg), clearances ranged from 11 to&#160;<br/>15&#160;ml/hour, the distribution volume (Vss) ranged from 5 to 6&#160;litres and the mean terminal phase half-life&#160;<br/>was approximately two weeks. Adalimumab concentrations in the synovial fluid from several rheumatoid&#160;<br/>arthritis patients ranged from 31-96% of those in serum.</p>
</div>
<!-- Page 41 -->
<a name="41"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page41-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft410">41</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft417">Following subcutaneous administration of 40&#160;mg of adalimumab every other week in adult rheumatoid&#160;<br/>arthritis (RA) patients the mean steady-state trough concentrations were approximately 5</p>
<p style="position:absolute;top:104px;left:697px;white-space:nowrap" class="ft416">g/ml (without&#160;</p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft412">concomitant methotrexate) and 8 to 9</p>
<p style="position:absolute;top:124px;left:357px;white-space:nowrap" class="ft416">g/ml (with concomitant methotrexate), respectively.&#160;The serum&#160;</p>
<p style="position:absolute;top:145px;left:106px;white-space:nowrap" class="ft415">adalimumab trough levels at steady-state increased roughly proportionally with dose following 20, 40 and&#160;<br/>80&#160;mg subcutaneous dosing every other week and every week.</p>
<p style="position:absolute;top:203px;left:106px;white-space:nowrap" class="ft412">In adult patients with psoriasis, the mean steady-state trough concentration was&#160;5</p>
<p style="position:absolute;top:202px;left:645px;white-space:nowrap" class="ft416">g/ml&#160;during&#160;</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft412">adalimumab 40&#160;mg&#160;every other week&#160;monotherapy treatment.</p>
<p style="position:absolute;top:260px;left:106px;white-space:nowrap" class="ft417">In patients with Crohn’s disease, the loading dose of 80&#160;mg Humira on Week&#160;0 followed by 40&#160;mg Humira&#160;<br/>on Week&#160;2 achieves serum adalimumab trough concentrations of approximately 5.5</p>
<p style="position:absolute;top:279px;left:662px;white-space:nowrap" class="ft416">g/ml during the&#160;</p>
<p style="position:absolute;top:300px;left:106px;white-space:nowrap" class="ft417">induction period. A loading dose of 160&#160;mg Humira on Week&#160;0 followed by 80&#160;mg Humira on Week&#160;2&#160;<br/>achieves serum adalimumab trough concentrations of approximately 12</p>
<p style="position:absolute;top:318px;left:582px;white-space:nowrap" class="ft416">g/ml&#160;during the induction period.&#160;</p>
<p style="position:absolute;top:340px;left:106px;white-space:nowrap" class="ft412">Mean steady-state trough levels of approximately 7</p>
<p style="position:absolute;top:338px;left:449px;white-space:nowrap" class="ft416">g/ml&#160;were observed in Crohn’s disease patients who&#160;</p>
<p style="position:absolute;top:359px;left:106px;white-space:nowrap" class="ft412">received a maintenance dose of 40&#160;mg Humira every other week.</p>
<p style="position:absolute;top:397px;left:106px;white-space:nowrap" class="ft417">In&#160;adult&#160;patients with uveitis, a loading dose of 80&#160;mg adalimumab on Week 0 followed by 40&#160;mg&#160;<br/>adalimumab every other week starting&#160;at Week 1, resulted in mean steady-state concentrations of&#160;<br/>approximately 8 to 10</p>
<p style="position:absolute;top:434px;left:256px;white-space:nowrap" class="ft416">g/ml.</p>
<p style="position:absolute;top:474px;left:106px;white-space:nowrap" class="ft414">Population pharmacokinetic and pharmacokinetic/pharmacodynamic modelling and simulation predicted&#160;<br/>comparable adalimumab exposure and efficacy in patients treated with&#160;80&#160;mg&#160;every other week when&#160;<br/>compared with 40&#160;mg&#160;every week (including adult patients with RA, HS, UC, CD or&#160;Ps,&#160;patients with&#160;<br/>adolescent HS, and paediatric&#160;patients&#160;≥&#160;40&#160;kg&#160;with CD).</p>
<p style="position:absolute;top:569px;left:106px;white-space:nowrap" class="ft412">Elimination</p>
<p style="position:absolute;top:607px;left:106px;white-space:nowrap" class="ft414">Population pharmacokinetic analyses with data from over 1,300 RA patients revealed a trend toward&#160;<br/>higher apparent clearance of adalimumab with increasing body weight. After adjustment for weight&#160;<br/>differences, gender and age appeared to have a minimal effect on adalimumab clearance. The serum levels&#160;<br/>of free adalimumab (not bound to anti-adalimumab antibodies, AAA) were observed to be lower in&#160;<br/>patients with measurable AAA.</p>
<p style="position:absolute;top:721px;left:106px;white-space:nowrap" class="ft412">Hepatic or renal impairment</p>
<p style="position:absolute;top:759px;left:106px;white-space:nowrap" class="ft412">Humira has not been studied in patients with hepatic or renal impairment.</p>
<p style="position:absolute;top:797px;left:106px;white-space:nowrap" class="ft411"><b>5.3</b></p>
<p style="position:absolute;top:797px;left:148px;white-space:nowrap" class="ft411"><b>Preclinical safety data&#160;</b></p>
<p style="position:absolute;top:834px;left:106px;white-space:nowrap" class="ft414">Non-clinical data reveal no special hazard for humans based on studies of single dose toxicity, repeated&#160;<br/>dose toxicity, and genotoxicity. &#160;</p>
<p style="position:absolute;top:891px;left:106px;white-space:nowrap" class="ft414">An&#160;embryo-foetal developmental toxicity/perinatal developmental study has been performed in&#160;<br/>cynomolgus monkeys at 0, 30 and 100&#160;mg/kg (9-17 monkeys/group) and has revealed no evidence of harm&#160;<br/>to the foetuses due to adalimumab. Neither carcinogenicity studies, nor a standard assessment of fertility&#160;<br/>and postnatal toxicity, were performed with adalimumab due to the lack of appropriate models for an&#160;<br/>antibody with limited cross-reactivity to rodent TNF and to the development of neutralising antibodies in&#160;<br/>rodents.&#160;</p>
</div>
<!-- Page 42 -->
<a name="42"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page42-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft420">42</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft421"><b>6.</b></p>
<p style="position:absolute;top:86px;left:148px;white-space:nowrap" class="ft421"><b>PHARMACEUTICAL PARTICULARS</b></p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft421"><b>6.1</b></p>
<p style="position:absolute;top:124px;left:148px;white-space:nowrap" class="ft421"><b>List of excipients&#160;</b></p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft424">Mannitol<br/>Polysorbate 80<br/>Water for injections</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft421"><b>6.2</b></p>
<p style="position:absolute;top:238px;left:148px;white-space:nowrap" class="ft421"><b>Incompatibilities&#160;</b></p>
<p style="position:absolute;top:276px;left:106px;white-space:nowrap" class="ft424">In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal&#160;<br/>products.</p>
<p style="position:absolute;top:333px;left:106px;white-space:nowrap" class="ft421"><b>6.3</b></p>
<p style="position:absolute;top:333px;left:148px;white-space:nowrap" class="ft421"><b>Shelf life&#160;</b></p>
<p style="position:absolute;top:370px;left:106px;white-space:nowrap" class="ft422">2&#160;years</p>
<p style="position:absolute;top:409px;left:106px;white-space:nowrap" class="ft421"><b>6.4</b></p>
<p style="position:absolute;top:409px;left:148px;white-space:nowrap" class="ft421"><b>Special precautions for storage&#160;</b></p>
<p style="position:absolute;top:447px;left:106px;white-space:nowrap" class="ft422">Store in a refrigerator (2</p>
<p style="position:absolute;top:446px;left:266px;white-space:nowrap" class="ft426">C&#160;–&#160;8C). Do not freeze. Keep the&#160;pre-filled syringe&#160;in&#160;its&#160;outer carton in order to&#160;</p>
<p style="position:absolute;top:467px;left:106px;white-space:nowrap" class="ft422">protect from light. &#160;</p>
<p style="position:absolute;top:505px;left:106px;white-space:nowrap" class="ft424">A single Humira pre-filled syringe may be stored at temperatures up to a maximum of 25°C for a period of&#160;<br/>up to 14&#160;days. The syringe&#160;must be protected from light, and discarded if not&#160;used within the 14-day&#160;<br/>period.</p>
<p style="position:absolute;top:581px;left:106px;white-space:nowrap" class="ft421"><b>6.5</b></p>
<p style="position:absolute;top:581px;left:148px;white-space:nowrap" class="ft421"><b>Nature and contents of container &#160;</b></p>
<p style="position:absolute;top:618px;left:106px;white-space:nowrap" class="ft424">Humira&#160;20&#160;mg solution for injection in single-use pre-filled syringe (type I glass) with a plunger stopper&#160;<br/>(bromobutyl rubber) and a needle with a needle shield (thermoplastic elastomer).&#160;</p>
<p style="position:absolute;top:675px;left:106px;white-space:nowrap" class="ft422">Packs of:</p>
<p style="position:absolute;top:694px;left:106px;white-space:nowrap" class="ft426"></p>
<p style="position:absolute;top:696px;left:148px;white-space:nowrap" class="ft422">2 pre-filled syringes (0.2&#160;ml sterile solution), each with 1 alcohol pad, in a blister.&#160;</p>
<p style="position:absolute;top:733px;left:106px;white-space:nowrap" class="ft421"><b>6.6</b></p>
<p style="position:absolute;top:733px;left:148px;white-space:nowrap" class="ft421"><b>Special precautions for disposal</b></p>
<p style="position:absolute;top:771px;left:106px;white-space:nowrap" class="ft424">Any unused medicinal product or waste material should be disposed of in accordance with local&#160;<br/>requirements.</p>
<p style="position:absolute;top:847px;left:106px;white-space:nowrap" class="ft421"><b>7.</b></p>
<p style="position:absolute;top:847px;left:148px;white-space:nowrap" class="ft421"><b>MARKETING AUTHORISATION HOLDER&#160;</b></p>
<p style="position:absolute;top:885px;left:106px;white-space:nowrap" class="ft424">AbbVie Deutschland GmbH &amp; Co. KG<br/>Knollstrasse<br/>67061 Ludwigshafen<br/>Germany</p>
<p style="position:absolute;top:999px;left:106px;white-space:nowrap" class="ft421"><b>8.</b></p>
<p style="position:absolute;top:999px;left:148px;white-space:nowrap" class="ft421"><b>MARKETING AUTHORISATION NUMBERS&#160;</b></p>
<p style="position:absolute;top:1037px;left:106px;white-space:nowrap" class="ft422">EU/1/03/256/022</p>
</div>
<!-- Page 43 -->
<a name="43"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page43-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft430">43</p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft431"><b>9.</b></p>
<p style="position:absolute;top:124px;left:148px;white-space:nowrap" class="ft431"><b>DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</b></p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft435">Date of first authorisation:&#160;08 September 2003<br/>Date of latest renewal: 08 September 2008&#160;</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft431"><b>10.</b></p>
<p style="position:absolute;top:238px;left:148px;white-space:nowrap" class="ft431"><b>DATE OF REVISION&#160;OF THE TEXT</b></p>
<p style="position:absolute;top:276px;left:106px;white-space:nowrap" class="ft434">Detailed information on this medicinal product is available on the website of the European Medicines&#160;<br/><a href="http://www.ema.europa.eu/">Agency&#160;http://www.ema.europa.eu</a></p>
</div>
<!-- Page 44 -->
<a name="44"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page44-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft440">44</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft441"><b>1.</b></p>
<p style="position:absolute;top:86px;left:148px;white-space:nowrap" class="ft441"><b>NAME OF THE MEDICINAL PRODUCT&#160;</b></p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft442">Humira 40&#160;mg/0.8&#160;ml solution for injection</p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft441"><b>2.</b></p>
<p style="position:absolute;top:181px;left:148px;white-space:nowrap" class="ft441"><b>QUALITATIVE AND QUANTITATIVE COMPOSITION&#160;</b></p>
<p style="position:absolute;top:219px;left:106px;white-space:nowrap" class="ft442">Each 0.8&#160;ml single dose vial contains 40&#160;mg&#160;of adalimumab.&#160;</p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft442">Adalimumab is a recombinant human monoclonal antibody&#160;produced&#160;in Chinese Hamster Ovary cells.</p>
<p style="position:absolute;top:295px;left:106px;white-space:nowrap" class="ft442">For the full list of excipients, see section 6.1.&#160;</p>
<p style="position:absolute;top:352px;left:106px;white-space:nowrap" class="ft441"><b>3.</b></p>
<p style="position:absolute;top:352px;left:148px;white-space:nowrap" class="ft441"><b>PHARMACEUTICAL&#160;FORM&#160;</b></p>
<p style="position:absolute;top:390px;left:106px;white-space:nowrap" class="ft442">Solution for injection.&#160;(injection)</p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft442">Clear, colourless solution.</p>
<p style="position:absolute;top:485px;left:106px;white-space:nowrap" class="ft441"><b>4.</b></p>
<p style="position:absolute;top:485px;left:148px;white-space:nowrap" class="ft441"><b>CLINICAL PARTICULARS</b></p>
<p style="position:absolute;top:522px;left:106px;white-space:nowrap" class="ft441"><b>4.1</b></p>
<p style="position:absolute;top:522px;left:148px;white-space:nowrap" class="ft441"><b>Therapeutic indications&#160;</b></p>
<p style="position:absolute;top:560px;left:106px;white-space:nowrap" class="ft442">Juvenile idiopathic arthritis</p>
<p style="position:absolute;top:598px;left:106px;white-space:nowrap" class="ft443"><i>Polyarticular juvenile idiopathic arthritis</i></p>
<p style="position:absolute;top:636px;left:106px;white-space:nowrap" class="ft444">Humira in combination with methotrexate is indicated for the treatment of active polyarticular juvenile&#160;<br/>idiopathic arthritis, in patients from the age of 2&#160;years who have had an inadequate response to one or&#160;<br/>more&#160;disease-modifying anti-rheumatic drugs (DMARDs). Humira can be given as monotherapy in case&#160;<br/>of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the&#160;<br/>efficacy in monotherapy see&#160;section 5.1). Humira has not been studied in patients aged less than 2&#160;years.&#160;</p>
<p style="position:absolute;top:750px;left:106px;white-space:nowrap" class="ft443"><i>Enthesitis-related arthritis</i></p>
<p style="position:absolute;top:788px;left:106px;white-space:nowrap" class="ft445">Humira is indicated for the treatment of active enthesitis-related arthritis in patients, 6&#160;years of age and&#160;<br/>older, who have&#160;had an inadequate&#160;response to, or who are intolerant of, conventional therapy (see section&#160;<br/>5.1).</p>
<p style="position:absolute;top:864px;left:106px;white-space:nowrap" class="ft442">Paediatric plaque psoriasis</p>
<p style="position:absolute;top:902px;left:106px;white-space:nowrap" class="ft445">Humira is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from&#160;<br/>4&#160;years of age who have had an inadequate&#160;response to or are inappropriate candidates for topical therapy&#160;<br/>and phototherapies.</p>
</div>
<!-- Page 45 -->
<a name="45"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page45-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft450">45</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft452">Adolescent hidradenitis suppurativa</p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft454">Humira is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa)&#160;<br/>in&#160;adolescents&#160;from 12 years of age with an inadequate response to conventional systemic HS therapy (see&#160;<br/>sections 5.1 and 5.2).</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft452">Paediatric Crohn's disease&#160;</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft454">Humira is indicated for the treatment of moderately to severely active Crohn's disease in paediatric&#160;<br/>patients (from&#160;6&#160;years of age) who have had an inadequate response to conventional therapy including&#160;<br/>primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or&#160;<br/>have contraindications for such therapies.</p>
<p style="position:absolute;top:333px;left:106px;white-space:nowrap" class="ft452">Paediatric ulcerative colitis</p>
<p style="position:absolute;top:370px;left:106px;white-space:nowrap" class="ft455">Humira is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric&#160;<br/>patients (from 6&#160;years of age) who have had an inadequate response to conventional therapy including&#160;<br/>corticosteroids and/or 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant&#160;to or have&#160;<br/>medical contraindications for such therapies.</p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft452">Paediatric Uveitis</p>
<p style="position:absolute;top:503px;left:106px;white-space:nowrap" class="ft454">Humira is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from&#160;<br/>2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in&#160;<br/>whom conventional therapy is inappropriate.</p>
<p style="position:absolute;top:579px;left:106px;white-space:nowrap" class="ft451"><b>4.2</b></p>
<p style="position:absolute;top:579px;left:148px;white-space:nowrap" class="ft451"><b>Posology and method of administration &#160;</b></p>
<p style="position:absolute;top:617px;left:106px;white-space:nowrap" class="ft454">Humira treatment should be initiated and supervised by specialist physicians experienced in the diagnosis&#160;<br/>and treatment of conditions for which Humira is indicated. Ophthalmologists are advised to consult with&#160;<br/>an appropriate specialist before initiation of treatment with Humira (see section 4.4). Patients treated with&#160;<br/>Humira should be given the&#160;Patient Reminder Card.</p>
<p style="position:absolute;top:712px;left:106px;white-space:nowrap" class="ft454">After proper training in injection technique, patients may self-inject with Humira if their physician&#160;<br/>determines that it is appropriate and with medical follow-up as necessary.&#160;</p>
<p style="position:absolute;top:769px;left:106px;white-space:nowrap" class="ft454">During treatment with Humira, other concomitant therapies (e.g., corticosteroids and/or&#160;<br/>immunomodulatory agents) should be optimised.</p>
<p style="position:absolute;top:826px;left:106px;white-space:nowrap" class="ft452">Posology</p>
<p style="position:absolute;top:864px;left:106px;white-space:nowrap" class="ft452">Paediatric population</p>
<p style="position:absolute;top:902px;left:106px;white-space:nowrap" class="ft453"><i>Juvenile idiopathic arthritis</i></p>
<p style="position:absolute;top:940px;left:106px;white-space:nowrap" class="ft453"><i>Polyarticular juvenile idiopathic arthritis from 2 years of age</i></p>
<p style="position:absolute;top:978px;left:106px;white-space:nowrap" class="ft455">The recommended dose of Humira for patients with polyarticular juvenile idiopathic arthritis&#160;from&#160;2&#160;years<br/>of age is based on body weight (Table 1). Humira is&#160;administered every other week via subcutaneous&#160;<br/>injection.</p>
<p style="position:absolute;top:1054px;left:169px;white-space:nowrap" class="ft451"><b>Table 1. Humira&#160;Dose for Patients with Polyarticular Juvenile Idiopathic Arthritis&#160;</b></p>
</div>
<!-- Page 46 -->
<a name="46"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page46-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft460">46</p>
<p style="position:absolute;top:89px;left:279px;white-space:nowrap" class="ft461"><b>Patient Weight</b></p>
<p style="position:absolute;top:89px;left:529px;white-space:nowrap" class="ft461"><b>Dosing Regimen</b></p>
<p style="position:absolute;top:114px;left:278px;white-space:nowrap" class="ft462">10 kg to &lt; 30 kg</p>
<p style="position:absolute;top:114px;left:507px;white-space:nowrap" class="ft462">20 mg every other week</p>
<p style="position:absolute;top:139px;left:307px;white-space:nowrap" class="ft462">≥ 30 kg</p>
<p style="position:absolute;top:139px;left:507px;white-space:nowrap" class="ft462">40 mg every other week</p>
<p style="position:absolute;top:180px;left:106px;white-space:nowrap" class="ft464">Available&#160;data suggest that clinical response is usually achieved within 12&#160;weeks of treatment. Continued&#160;<br/>therapy should be carefully reconsidered in a patient not responding within this time period.</p>
<p style="position:absolute;top:237px;left:106px;white-space:nowrap" class="ft462">There is no relevant use of Humira in patients aged less than 2&#160;years for this indication.</p>
<p style="position:absolute;top:275px;left:106px;white-space:nowrap" class="ft464">Humira may be available in other strengths and/or presentations depending on the individual treatment&#160;<br/>needs.</p>
<p style="position:absolute;top:332px;left:106px;white-space:nowrap" class="ft463"><i>Enthesitis-related arthritis</i></p>
<p style="position:absolute;top:370px;left:106px;white-space:nowrap" class="ft464">The recommended dose of Humira for patients with enthesitis-related arthritis from&#160;6&#160;years of age&#160;is based&#160;<br/>on body weight (Table 2). &#160;Humira is administered every other week via subcutaneous injection.</p>
<p style="position:absolute;top:427px;left:221px;white-space:nowrap" class="ft461"><b>Table&#160;2. Humira Dose for Patients with Enthesitis-Related Arthritis&#160;</b></p>
<p style="position:absolute;top:468px;left:279px;white-space:nowrap" class="ft461"><b>Patient Weight</b></p>
<p style="position:absolute;top:468px;left:529px;white-space:nowrap" class="ft461"><b>Dosing Regimen</b></p>
<p style="position:absolute;top:492px;left:278px;white-space:nowrap" class="ft462">15&#160;kg to &lt; 30 kg</p>
<p style="position:absolute;top:492px;left:507px;white-space:nowrap" class="ft462">20 mg every other&#160;week</p>
<p style="position:absolute;top:517px;left:307px;white-space:nowrap" class="ft462">≥ 30 kg</p>
<p style="position:absolute;top:517px;left:507px;white-space:nowrap" class="ft462">40 mg every other week</p>
<p style="position:absolute;top:558px;left:106px;white-space:nowrap" class="ft462">Humira has not been studied in patients with enthesitis-related arthritis aged less than 6&#160;years.</p>
<p style="position:absolute;top:597px;left:106px;white-space:nowrap" class="ft464">Humira may be available in other strengths and/or presentations depending on the individual treatment&#160;<br/>needs.</p>
<p style="position:absolute;top:653px;left:106px;white-space:nowrap" class="ft463"><i>Paediatric plaque psoriasis</i></p>
<p style="position:absolute;top:691px;left:106px;white-space:nowrap" class="ft464">The recommended Humira dose&#160;for patients with plaque psoriasis from 4 to 17&#160;years of age is based on&#160;<br/>body weight (Table 3).&#160;Humira is administered via subcutaneous injection.</p>
<p style="position:absolute;top:748px;left:223px;white-space:nowrap" class="ft461"><b>Table 3. Humira Dose&#160;for&#160;Paediatric Patients with Plaque Psoriasis&#160;</b></p>
<p style="position:absolute;top:789px;left:279px;white-space:nowrap" class="ft461"><b>Patient Weight</b></p>
<p style="position:absolute;top:789px;left:529px;white-space:nowrap" class="ft461"><b>Dosing Regimen</b></p>
<p style="position:absolute;top:814px;left:278px;white-space:nowrap" class="ft462">15&#160;kg to &lt; 30 kg</p>
<p style="position:absolute;top:814px;left:474px;white-space:nowrap" class="ft462">Initial dose of 20 mg, followed by&#160;</p>
<p style="position:absolute;top:832px;left:486px;white-space:nowrap" class="ft462">20 mg given every other week&#160;</p>
<p style="position:absolute;top:850px;left:478px;white-space:nowrap" class="ft462">starting one week after the initial&#160;</p>
<p style="position:absolute;top:868px;left:571px;white-space:nowrap" class="ft462">dose</p>
<p style="position:absolute;top:893px;left:307px;white-space:nowrap" class="ft462">≥ 30 kg</p>
<p style="position:absolute;top:890px;left:474px;white-space:nowrap" class="ft462">Initial dose of 40 mg, followed by&#160;</p>
<p style="position:absolute;top:909px;left:486px;white-space:nowrap" class="ft462">40 mg given every&#160;other week&#160;</p>
<p style="position:absolute;top:928px;left:478px;white-space:nowrap" class="ft462">starting one week after the initial&#160;</p>
<p style="position:absolute;top:948px;left:571px;white-space:nowrap" class="ft462">dose</p>
<p style="position:absolute;top:986px;left:106px;white-space:nowrap" class="ft464">Continued therapy beyond 16&#160;weeks should be carefully considered in a patient not responding within this&#160;<br/>time period.</p>
<p style="position:absolute;top:1043px;left:106px;white-space:nowrap" class="ft464">If retreatment with Humira is indicated, the above guidance on dose and treatment&#160;duration should be&#160;<br/>followed.</p>
</div>
<!-- Page 47 -->
<a name="47"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page47-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft470">47</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft475">The safety of Humira in paediatric patients with plaque psoriasis has been assessed for a mean of&#160;<br/>13&#160;months.</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft472">There is no relevant use of Humira in children aged less than 4 years for this indication.</p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft474">Humira may be available&#160;in other strengths and/or presentations depending on the individual treatment&#160;<br/>needs.</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft473"><i>Adolescent hidradenitis suppurativa (from 12 years of age, weighing at least 30 kg)</i></p>
<p style="position:absolute;top:276px;left:106px;white-space:nowrap" class="ft472">There are no clinical trials with Humira in adolescent patients with HS. &#160;</p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft474">The posology of Humira in these patients has been determined from pharmacokinetic modelling and&#160;<br/>simulation (see section 5.2).</p>
<p style="position:absolute;top:370px;left:106px;white-space:nowrap" class="ft474">The recommended Humira dose is 80&#160;mg at Week&#160;0 followed by 40&#160;mg every other week starting at&#160;<br/>Week&#160;1 via subcutaneous injection.&#160;</p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft474">In adolescent patients with inadequate response to Humira 40&#160;mg every other week, an increase in dosage<br/>to 40&#160;mg&#160;every week&#160;or 80&#160;mg&#160;every other week&#160;may be considered.</p>
<p style="position:absolute;top:485px;left:106px;white-space:nowrap" class="ft474">Antibiotics may be continued during treatment with Humira if necessary. It is recommended that the&#160;<br/>patient should use a topical antiseptic wash on their HS lesions on a daily basis during treatment with&#160;<br/>Humira.&#160;</p>
<p style="position:absolute;top:560px;left:106px;white-space:nowrap" class="ft474">Continued therapy beyond 12&#160;weeks should be&#160;carefully reconsidered in a patient with no improvement&#160;<br/>within this time period. &#160;</p>
<p style="position:absolute;top:617px;left:106px;white-space:nowrap" class="ft472">Should treatment be interrupted, Humira may be re-introduced as appropriate.</p>
<p style="position:absolute;top:655px;left:106px;white-space:nowrap" class="ft474">The benefit and risk of continued long-term&#160;treatment should be periodically evaluated (see adult data in&#160;<br/>section 5.1).</p>
<p style="position:absolute;top:712px;left:106px;white-space:nowrap" class="ft472">There is no relevant use of Humira in children aged less than 12&#160;years in this indication.</p>
<p style="position:absolute;top:750px;left:106px;white-space:nowrap" class="ft474">Humira may be available in other strengths and/or presentations depending on the individual treatment&#160;<br/>needs.</p>
<p style="position:absolute;top:807px;left:106px;white-space:nowrap" class="ft473"><i>Paediatric Crohn's disease</i></p>
<p style="position:absolute;top:845px;left:106px;white-space:nowrap" class="ft474">The recommended dose of Humira for patients with&#160;Crohn’s disease from 6&#160;to 17&#160;years&#160;of age&#160;is based on&#160;<br/>body&#160;weight&#160;(Table 4).&#160;Humira is&#160;administered via subcutaneous injection.</p>
<p style="position:absolute;top:902px;left:225px;white-space:nowrap" class="ft471"><b>Table&#160;4. Humira Dose&#160;for&#160;Paediatric Patients with Crohn’s disease</b></p>
<p style="position:absolute;top:942px;left:118px;white-space:nowrap" class="ft471"><b>Patient&#160;</b></p>
<p style="position:absolute;top:961px;left:117px;white-space:nowrap" class="ft471"><b>Weight</b></p>
<p style="position:absolute;top:942px;left:383px;white-space:nowrap" class="ft471"><b>Induction Dose</b></p>
<p style="position:absolute;top:942px;left:707px;white-space:nowrap" class="ft471"><b>Maintenance&#160;</b></p>
<p style="position:absolute;top:961px;left:735px;white-space:nowrap" class="ft471"><b>Dose</b></p>
<p style="position:absolute;top:980px;left:715px;white-space:nowrap" class="ft471"><b>Starting at&#160;</b></p>
<p style="position:absolute;top:999px;left:726px;white-space:nowrap" class="ft471"><b>Week 4</b></p>
<p style="position:absolute;top:1021px;left:118px;white-space:nowrap" class="ft472">&lt; 40 kg</p>
<p style="position:absolute;top:1021px;left:190px;white-space:nowrap" class="ft476">&#160;40 mg at week 0 and 20 mg at week 2</p>
<p style="position:absolute;top:1021px;left:712px;white-space:nowrap" class="ft472">20 mg every&#160;</p>
<p style="position:absolute;top:1040px;left:716px;white-space:nowrap" class="ft472">other week</p>
</div>
<!-- Page 48 -->
<a name="48"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page48-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft480">48</p>
<p style="position:absolute;top:88px;left:118px;white-space:nowrap" class="ft481"><b>Patient&#160;</b></p>
<p style="position:absolute;top:107px;left:117px;white-space:nowrap" class="ft481"><b>Weight</b></p>
<p style="position:absolute;top:88px;left:383px;white-space:nowrap" class="ft481"><b>Induction Dose</b></p>
<p style="position:absolute;top:88px;left:707px;white-space:nowrap" class="ft481"><b>Maintenance&#160;</b></p>
<p style="position:absolute;top:107px;left:735px;white-space:nowrap" class="ft481"><b>Dose</b></p>
<p style="position:absolute;top:126px;left:715px;white-space:nowrap" class="ft481"><b>Starting at&#160;</b></p>
<p style="position:absolute;top:145px;left:726px;white-space:nowrap" class="ft481"><b>Week 4</b></p>
<p style="position:absolute;top:167px;left:192px;white-space:nowrap" class="ft484">In case there is a need for a more rapid response to therapy&#160;with the&#160;<br/>awareness that the risk for adverse events may be higher with use of the&#160;<br/>higher&#160;induction dose, the following dose may be used:</p>
<p style="position:absolute;top:224px;left:190px;white-space:nowrap" class="ft486">&#160;80 mg at week 0 and 40 mg at week 2</p>
<p style="position:absolute;top:248px;left:118px;white-space:nowrap" class="ft482">≥ 40 kg</p>
<p style="position:absolute;top:247px;left:190px;white-space:nowrap" class="ft486">&#160;80 mg at week 0 and 40 mg at week 2</p>
<p style="position:absolute;top:287px;left:192px;white-space:nowrap" class="ft484">In case there is a need for a more rapid response to therapy&#160;with the&#160;<br/>awareness that the risk for&#160;adverse events may be higher with use of the&#160;<br/>higher induction dose, the following dose may be used:</p>
<p style="position:absolute;top:343px;left:190px;white-space:nowrap" class="ft486">&#160;160 mg at week 0 and 80 mg at week 2</p>
<p style="position:absolute;top:248px;left:712px;white-space:nowrap" class="ft482">40 mg every&#160;</p>
<p style="position:absolute;top:267px;left:716px;white-space:nowrap" class="ft482">other week</p>
<p style="position:absolute;top:385px;left:106px;white-space:nowrap" class="ft482">Patients&#160;who&#160;experience insufficient response may benefit from&#160;an increase in&#160;dosage:</p>
<p style="position:absolute;top:403px;left:106px;white-space:nowrap" class="ft486"></p>
<p style="position:absolute;top:405px;left:147px;white-space:nowrap" class="ft482">&lt; 40&#160;kg:&#160;20&#160;mg&#160;every week</p>
<p style="position:absolute;top:424px;left:106px;white-space:nowrap" class="ft486"></p>
<p style="position:absolute;top:426px;left:147px;white-space:nowrap" class="ft482">≥ 40&#160;kg: 40&#160;mg&#160;every&#160;week&#160;or 80&#160;mg&#160;every other week</p>
<p style="position:absolute;top:464px;left:106px;white-space:nowrap" class="ft482">Continued therapy should be carefully considered in a subject not responding by&#160;week&#160;12.</p>
<p style="position:absolute;top:501px;left:106px;white-space:nowrap" class="ft482">There is no relevant use of Humira in children aged less than 6&#160;years for this indication.</p>
<p style="position:absolute;top:540px;left:106px;white-space:nowrap" class="ft485">Humira may be available in other strengths and/or presentations depending on the individual treatment&#160;<br/>needs.</p>
<p style="position:absolute;top:597px;left:106px;white-space:nowrap" class="ft483"><i>Paediatric ulcerative colitis</i></p>
<p style="position:absolute;top:634px;left:106px;white-space:nowrap" class="ft484">The recommended dose of Humira for patients from&#160;6&#160;to 17 years of age with ulcerative colitis is based on&#160;<br/>body weight (Table 5). Humira is administered via subcutaneous injection.&#160;</p>
<p style="position:absolute;top:691px;left:220px;white-space:nowrap" class="ft481"><b>Table&#160;5. Humira Dose for Paediatric Patients with Ulcerative Colitis&#160;</b></p>
<p style="position:absolute;top:722px;left:154px;white-space:nowrap" class="ft481"><b>Patient Weight</b></p>
<p style="position:absolute;top:722px;left:352px;white-space:nowrap" class="ft481"><b>Induction Dose</b></p>
<p style="position:absolute;top:712px;left:594px;white-space:nowrap" class="ft481"><b>Maintenance Dose</b></p>
<p style="position:absolute;top:732px;left:588px;white-space:nowrap" class="ft481"><b>Starting at Week 4*</b></p>
<p style="position:absolute;top:754px;left:181px;white-space:nowrap" class="ft482">&lt; 40 kg</p>
<p style="position:absolute;top:754px;left:289px;white-space:nowrap" class="ft482">•&#160;80 mg at Week 0&#160;(given as two 40&#160;</p>
<p style="position:absolute;top:773px;left:305px;white-space:nowrap" class="ft482">mg&#160;injections in one day)&#160;and</p>
<p style="position:absolute;top:792px;left:289px;white-space:nowrap" class="ft482">•&#160;40 mg at Week 2&#160;(given as one 40&#160;</p>
<p style="position:absolute;top:811px;left:305px;white-space:nowrap" class="ft482">mg&#160;injection)</p>
<p style="position:absolute;top:754px;left:548px;white-space:nowrap" class="ft482">•&#160;40 mg every other week</p>
<p style="position:absolute;top:833px;left:181px;white-space:nowrap" class="ft482">≥&#160;40 kg</p>
<p style="position:absolute;top:833px;left:289px;white-space:nowrap" class="ft482">•&#160;160 mg at Week 0&#160;(given as four&#160;</p>
<p style="position:absolute;top:852px;left:305px;white-space:nowrap" class="ft485">40 mg injections in one day or&#160;<br/>two 40 mg injections per day for&#160;<br/>two consecutive days)&#160;and</p>
<p style="position:absolute;top:909px;left:289px;white-space:nowrap" class="ft482">•&#160;80 mg at Week 2&#160;(given as two 40&#160;</p>
<p style="position:absolute;top:928px;left:305px;white-space:nowrap" class="ft482">mg&#160;injections in one day)</p>
<p style="position:absolute;top:833px;left:548px;white-space:nowrap" class="ft482">•&#160;80 mg every other week</p>
<p style="position:absolute;top:949px;left:138px;white-space:nowrap" class="ft487">*&#160;Paediatric patients who turn 18 years of age while on Humira&#160;should continue their prescribed&#160;<br/>maintenance dose.</p>
<p style="position:absolute;top:1029px;left:106px;white-space:nowrap" class="ft484">Continued therapy beyond 8 weeks should be carefully considered in patients not showing signs of&#160;<br/>response&#160;within this time period.</p>
</div>
<!-- Page 49 -->
<a name="49"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page49-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft490">49</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft492">There is no relevant use of Humira in children aged less than&#160;6&#160;years in this indication.</p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft494">Humira may be available in different strengths and/or presentations depending on the individual treatment&#160;<br/>needs.</p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft493"><i>Paediatric Uveitis</i></p>
<p style="position:absolute;top:219px;left:106px;white-space:nowrap" class="ft495">The recommended dose of Humira for&#160;paediatric&#160;patients with&#160;uveitis&#160;from 2&#160;years&#160;of age&#160;is based on&#160;<br/>body&#160;weight&#160;(Table&#160;6).&#160;Humira is&#160;administered via subcutaneous injection.</p>
<p style="position:absolute;top:276px;left:106px;white-space:nowrap" class="ft494">In paediatric uveitis, there is no experience in the treatment with Humira without concomitant treatment&#160;<br/>with methotrexate.</p>
<p style="position:absolute;top:333px;left:256px;white-space:nowrap" class="ft491"><b>Table&#160;6. Humira Dose for&#160;Paediatric&#160;Patients with&#160;Uveitis</b></p>
<p style="position:absolute;top:374px;left:279px;white-space:nowrap" class="ft491"><b>Patient Weight</b></p>
<p style="position:absolute;top:374px;left:529px;white-space:nowrap" class="ft491"><b>Dosing Regimen</b></p>
<p style="position:absolute;top:398px;left:307px;white-space:nowrap" class="ft492">&lt; 30 kg</p>
<p style="position:absolute;top:398px;left:498px;white-space:nowrap" class="ft492">20 mg every other week in&#160;</p>
<p style="position:absolute;top:416px;left:483px;white-space:nowrap" class="ft492">combination with methotrexate</p>
<p style="position:absolute;top:441px;left:307px;white-space:nowrap" class="ft492">≥ 30 kg</p>
<p style="position:absolute;top:441px;left:498px;white-space:nowrap" class="ft492">40 mg every other week in&#160;</p>
<p style="position:absolute;top:459px;left:483px;white-space:nowrap" class="ft492">combination with methotrexate</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft494">When Humira therapy is initiated, a loading dose of 40&#160;mg&#160;for patients &lt; 30 kg or 80 mg for patients&#160;≥ 30&#160;<br/>kg&#160;may be administered one week prior to the start of maintenance therapy. No clinical data are available&#160;<br/>on the use of a Humira loading dose in children &lt;&#160;6 years of age (see section 5.2).</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft492">There is no&#160;relevant use of Humira in children aged less than 2&#160;years in this indication.&#160;</p>
<p style="position:absolute;top:615px;left:106px;white-space:nowrap" class="ft495">It is recommended that the benefit and risk of continued long-term&#160;treatment should be evaluated on a&#160;<br/>yearly basis (see section 5.1).</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft495">Humira may be available in other strengths and/or presentations depending on the individual treatment&#160;<br/>needs.</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft493"><i>Renal and/or hepatic impairment</i></p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft492">Humira has not been studied in these patient populations. No dose recommendations can be made.</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft493"><i>Method of administration</i></p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft494">Humira is administered by&#160;subcutaneous injection. Full instructions for use are provided in the package&#160;<br/>leaflet.</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft492">Humira is available in other strengths and presentations.</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft491"><b>4.3</b></p>
<p style="position:absolute;top:937px;left:148px;white-space:nowrap" class="ft491"><b>Contraindications&#160;</b></p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft492">Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft492">Active tuberculosis or other severe infections such as sepsis, and opportunistic infections (see section 4.4).</p>
<p style="position:absolute;top:1049px;left:106px;white-space:nowrap" class="ft492">Moderate to severe heart failure (NYHA class III/IV) (see section 4.4).</p>
</div>
<!-- Page 50 -->
<a name="50"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page50-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft500">50</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft501"><b>4.4</b></p>
<p style="position:absolute;top:86px;left:148px;white-space:nowrap" class="ft501"><b>Special warnings and precautions for use &#160;</b></p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft502">Traceability</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft505">In&#160;order to improve traceability of biological medicinal products, the&#160;name&#160;and the batch number of the&#160;<br/>administered product should be clearly recorded.</p>
<p style="position:absolute;top:219px;left:106px;white-space:nowrap" class="ft502">Infections</p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft505">Patients taking TNF-antagonists are more susceptible to serious infections. Impaired lung&#160;function may&#160;<br/>increase the risk for developing infections. Patients must therefore be monitored closely for infections,&#160;<br/>including tuberculosis, before, during and after treatment with Humira. Because the elimination of&#160;<br/>adalimumab may take up to four months,&#160;monitoring should be continued throughout this period.</p>
<p style="position:absolute;top:352px;left:106px;white-space:nowrap" class="ft505">Treatment with Humira should not be initiated in patients with active infections including chronic or&#160;<br/>localised infections until infections are controlled. In patients who have been exposed to tuberculosis and&#160;<br/>patients who have travelled in areas of high risk of tuberculosis or endemic mycoses, such as&#160;<br/>histoplasmosis, coccidioidomycosis, or blastomycosis, the risk and benefits of treatment with Humira&#160;<br/>should be considered prior to initiating therapy (see&#160;<i>Other&#160;opportunistic infections</i>).</p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft505">Patients who develop a new infection while undergoing treatment with Humira should be monitored&#160;<br/>closely and undergo a complete diagnostic evaluation. Administration of Humira should be discontinued if&#160;<br/>a patient develops a new serious infection or sepsis, and appropriate antimicrobial or antifungal therapy&#160;<br/>should be initiated until the infection is controlled. Physicians should exercise caution when considering&#160;<br/>the use of Humira in patients with a history of recurring infection or with underlying conditions which&#160;<br/>may predispose patients to infections, including the use of concomitant immunosuppressive medications.</p>
<p style="position:absolute;top:598px;left:106px;white-space:nowrap" class="ft503"><i>Serious infections</i></p>
<p style="position:absolute;top:636px;left:106px;white-space:nowrap" class="ft504">Serious infections,&#160;including sepsis,&#160;due to bacterial, mycobacterial, invasive fungal,&#160;parasitic, viral, or&#160;<br/>other opportunistic infections&#160;such as listeriosis, legionellosis and pneumocystis&#160;have been reported in&#160;<br/>patients receiving Humira. &#160;</p>
<p style="position:absolute;top:712px;left:106px;white-space:nowrap" class="ft504">Other serious infections seen in clinical trials include pneumonia, pyelonephritis, septic arthritis&#160;and&#160;<br/>septicaemia. Hospitalisation or fatal outcomes associated with infections have been reported.&#160;</p>
<p style="position:absolute;top:769px;left:106px;white-space:nowrap" class="ft503"><i>Tuberculosis</i></p>
<p style="position:absolute;top:807px;left:106px;white-space:nowrap" class="ft505">Tuberculosis, including reactivation and new onset of tuberculosis, has been reported in patients receiving&#160;<br/>Humira. Reports included cases of&#160;pulmonary and extra-pulmonary (i.e. disseminated) tuberculosis.&#160;</p>
<p style="position:absolute;top:864px;left:106px;white-space:nowrap" class="ft504">Before initiation of therapy with Humira, all patients must be evaluated for both active or inactive&#160;<br/>(“latent”) tuberculosis infection. This evaluation should include a detailed medical assessment of patient&#160;<br/>history of tuberculosis or possible previous exposure to people with active tuberculosis and previous&#160;<br/>and/or current immunosuppressive therapy. Appropriate screening tests (i.e. tuberculin skin test and chest&#160;<br/>X-ray) should be performed in all patients (local recommendations may apply). It is recommended that the&#160;<br/>conduct and results of these tests are recorded in the&#160;Patient Reminder Card. Prescribers are reminded of&#160;<br/>the risk of false negative tuberculin skin test results, especially in patients who are severely ill or&#160;<br/>immunocompromised.&#160;</p>
<p style="position:absolute;top:1035px;left:106px;white-space:nowrap" class="ft502">If active tuberculosis is diagnosed, Humira therapy must not be initiated (see section 4.3).&#160;</p>
<p style="position:absolute;top:1072px;left:106px;white-space:nowrap" class="ft502">In all situations described below, the benefit/risk balance of therapy should be very carefully considered.</p>
</div>
<!-- Page 51 -->
<a name="51"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page51-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft510">51</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft514">If latent tuberculosis is suspected,&#160;a physician with expertise in the treatment of tuberculosis should be&#160;<br/>consulted.&#160;&#160;</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft515">If latent tuberculosis is diagnosed, appropriate treatment must be started with anti-tuberculosis prophylaxis&#160;<br/>treatment before the initiation of Humira, and in accordance with local recommendations.&#160;</p>
<p style="position:absolute;top:219px;left:106px;white-space:nowrap" class="ft514">Use&#160;of anti-tuberculosis prophylaxis treatment should also be considered before the initiation of Humira in&#160;<br/>patients with several or significant risk factors for tuberculosis despite a negative test for tuberculosis and&#160;<br/>in patients with a past history of latent or active tuberculosis in whom an adequate course&#160;of treatment&#160;<br/>cannot be confirmed. &#160;</p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft514">Despite prophylactic treatment for tuberculosis, cases of reactivated tuberculosis have occurred in patients&#160;<br/>treated with Humira. Some patients who have been successfully treated for active tuberculosis have&#160;<br/>redeveloped tuberculosis while being treated with Humira.</p>
<p style="position:absolute;top:390px;left:106px;white-space:nowrap" class="ft515">Patients should be instructed to seek medical advice if signs/symptoms suggestive of a tuberculosis&#160;<br/>infection (e.g., persistent cough, wasting/weight loss, low grade fever, listlessness) occur during or after&#160;<br/>therapy with Humira.&#160;</p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft513"><i>Other opportunistic infections</i></p>
<p style="position:absolute;top:503px;left:106px;white-space:nowrap" class="ft514">Opportunistic infections, including invasive fungal infections have been observed in patients receiving&#160;<br/>Humira. These infections have not consistently been recognised in patients taking TNF-antagonists and&#160;<br/>this has resulted in delays in appropriate treatment, sometimes resulting in fatal outcomes.&#160;</p>
<p style="position:absolute;top:579px;left:106px;white-space:nowrap" class="ft514">For patients who develop the signs and symptoms such as fever, malaise, weight loss, sweats, cough,&#160;<br/>dyspnoea, and/or pulmonary infiltrates or other serious systemic illness with or without concomitant shock&#160;<br/>an invasive fungal infection should be suspected and administration of Humira should be promptly&#160;<br/>discontinued. Diagnosis and administration of empiric antifungal therapy in these patients should be made&#160;<br/>in consultation with a physician with expertise in the care&#160;of patients with invasive fungal infections.</p>
<p style="position:absolute;top:693px;left:106px;white-space:nowrap" class="ft512">Hepatitis B reactivation</p>
<p style="position:absolute;top:731px;left:106px;white-space:nowrap" class="ft514">Reactivation of hepatitis B has occurred in patients receiving a TNF-antagonist including Humira, who are&#160;<br/>chronic carriers of this virus (i.e. surface antigen positive). Some cases&#160;have had a fatal outcome. Patients&#160;<br/>should be tested for HBV infection before initiating treatment with Humira. For patients who test positive&#160;<br/>for hepatitis B infection, consultation with a physician with expertise in the treatment of hepatitis B is&#160;<br/>recommended.</p>
<p style="position:absolute;top:845px;left:106px;white-space:nowrap" class="ft515">Carriers of HBV who require treatment with Humira should be closely monitored for signs and symptoms&#160;<br/>of active HBV infection throughout therapy and for several months following termination of therapy.&#160;<br/>Adequate data from treating patients who are carriers of HBV with anti-viral therapy in conjunction with&#160;<br/>TNF-antagonist therapy to prevent HBV reactivation are not available. In patients who develop HBV&#160;<br/>reactivation, Humira should be stopped and effective anti-viral therapy with appropriate supportive&#160;<br/>treatment should be initiated.&#160;</p>
<p style="position:absolute;top:978px;left:106px;white-space:nowrap" class="ft512">Neurological events&#160;</p>
<p style="position:absolute;top:1016px;left:106px;white-space:nowrap" class="ft515">TNF-antagonists including Humira have been associated in rare instances with new onset or exacerbation&#160;<br/>of clinical symptoms and/or radiographic evidence of central nervous system demyelinating disease&#160;<br/>including multiple sclerosis and optic neuritis, and peripheral demyelinating disease, including Guillain-<br/>Barré syndrome. Prescribers should exercise caution in considering the use of Humira in patients with pre-</p>
</div>
<!-- Page 52 -->
<a name="52"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page52-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft520">52</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft524">existing or recent-onset central or peripheral nervous system demyelinating disorders; discontinuation of&#160;<br/>Humira should be considered if any of these disorders develop. There is a known association between&#160;<br/>intermediate uveitis and central demyelinating disorders. Neurologic evaluation should be performed in&#160;<br/>patients with non-infectious intermediate uveitis prior to the initiation of Humira therapy and regularly&#160;<br/>during treatment to assess for pre-existing or developing central demyelinating disorders.&#160;</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft522">Allergic reactions</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft525">Serious allergic reactions&#160;associated with Humira were rare during clinical trials. Non-serious allergic&#160;<br/>reactions associated with Humira were uncommon during clinical trials. Reports of serious allergic&#160;<br/>reactions including anaphylaxis have been received following Humira administration. If an anaphylactic&#160;<br/>reaction or other serious allergic reaction occurs, administration of Humira should be discontinued&#160;<br/>immediately and&#160;appropriate therapy initiated.</p>
<p style="position:absolute;top:352px;left:106px;white-space:nowrap" class="ft522">Immunosuppression</p>
<p style="position:absolute;top:390px;left:106px;white-space:nowrap" class="ft525">In a study of 64 patients with rheumatoid arthritis that were treated with Humira, there was no evidence of&#160;<br/>depression of delayed-type hypersensitivity, depression of immunoglobulin levels, or change in&#160;<br/>enumeration of effector T-, B-, NK-cells, monocyte/macrophages, and neutrophils.</p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft522">Malignancies and lymphoproliferative&#160;disorders</p>
<p style="position:absolute;top:503px;left:106px;white-space:nowrap" class="ft524">In the controlled portions of clinical trials of TNF-antagonists, more cases of malignancies including&#160;<br/>lymphoma have been observed among patients receiving a TNF-antagonist compared with control&#160;<br/>patients. However, the occurrence was rare. In the post marketing setting, cases of leukaemia have been&#160;<br/>reported in patients treated with a TNF-antagonist. There is an increased background risk for lymphoma&#160;<br/>and leukaemia in rheumatoid arthritis patients with long-standing, highly active, inflammatory disease,&#160;<br/>which complicates the risk estimation. With the current knowledge, a possible risk for the development of&#160;<br/>lymphomas, leukaemia, and other malignancies in patients treated with a TNF-antagonist cannot be&#160;<br/>excluded.</p>
<p style="position:absolute;top:674px;left:106px;white-space:nowrap" class="ft524">Malignancies, some fatal, have been&#160;reported among children, adolescents and young adults (up to&#160;<br/>22&#160;years of age) treated with TNF-antagonists (initiation of therapy&#160;≤ 18&#160;years of age), including&#160;<br/>adalimumab in the post marketing setting. Approximately half the cases were lymphomas. The other&#160;cases&#160;<br/>represented a variety of different malignancies and included rare malignancies usually associated with&#160;<br/>immunosuppression. A risk for the development of malignancies in children and adolescents treated with&#160;<br/>TNF-antagonists cannot be excluded.&#160;</p>
<p style="position:absolute;top:807px;left:106px;white-space:nowrap" class="ft524">Rare&#160;postmarketing cases of hepatosplenic T-cell lymphoma have been identified in patients treated with&#160;<br/>adalimumab. This rare type of T-cell&#160;lymphoma has a very aggressive disease course and is usually fatal.&#160;<br/>Some of these hepatosplenic T-cell lymphomas with Humira have occurred in young adult patients on&#160;<br/>concomitant treatment with azathioprine or 6-mercaptopurine used for inflammatory bowel disease. The&#160;<br/>potential risk with the combination of azathioprine or 6-mercaptopurine and Humira should be carefully&#160;<br/>considered.&#160;A risk for the development of hepatosplenic T-cell lymphoma in patients treated with Humira&#160;<br/>cannot be excluded (see section 4.8).</p>
<p style="position:absolute;top:959px;left:106px;white-space:nowrap" class="ft524">No studies have been conducted that include patients with a history of malignancy or in whom treatment&#160;<br/>with Humira is continued following development of malignancy. Thus,&#160;additional caution should be&#160;<br/>exercised in considering Humira treatment of these patients (see section 4.8).</p>
<p style="position:absolute;top:1035px;left:106px;white-space:nowrap" class="ft525">All patients, and in particular patients with a medical history of extensive immunosuppressant&#160;therapy or&#160;<br/>psoriasis patients with a history of PUVA treatment should be examined for the presence of non-<br/>melanoma skin cancer prior to and during treatment with Humira. Melanoma and Merkel cell carcinoma&#160;</p>
</div>
<!-- Page 53 -->
<a name="53"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page53-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft530">53</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft532">have also been reported in patients treated with TNF-antagonists including adalimumab (see section 4.8).</p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft534">In an exploratory clinical trial evaluating the use of another TNF-antagonist, infliximab, in patients with&#160;<br/>moderate to severe chronic obstructive pulmonary disease (COPD), more malignancies, mostly in&#160;the lung&#160;<br/>or head and neck, were reported in infliximab-treated patients compared with control patients. All patients&#160;<br/>had a history of heavy smoking. Therefore, caution should be exercised when using any TNF-antagonist in&#160;<br/>COPD patients, as well as in patients with increased risk for malignancy due to heavy smoking.</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft534">With current data it is not known if adalimumab treatment influences the risk for developing dysplasia or&#160;<br/>colon cancer. All patients with ulcerative colitis who are at increased risk for dysplasia or colon carcinoma&#160;<br/>(for example, patients with long-standing ulcerative colitis or primary sclerosing cholangitis), or who had&#160;<br/>a prior history of dysplasia or colon carcinoma should be screened for dysplasia at regular intervals before&#160;<br/>therapy and throughout their disease course. This evaluation should include colonoscopy and biopsies per&#160;<br/>local recommendations.</p>
<p style="position:absolute;top:370px;left:106px;white-space:nowrap" class="ft532">Haematologic reactions</p>
<p style="position:absolute;top:409px;left:106px;white-space:nowrap" class="ft535">Rare reports of pancytopenia including aplastic anaemia have been reported with TNF-antagonists.&#160;<br/>Adverse events of the&#160;haematologic system, including medically significant cytopenia (e.g.&#160;<br/>thrombocytopenia, leukopenia) have been reported with Humira. All patients should be advised to seek&#160;<br/>immediate medical attention if they develop signs and symptoms suggestive of blood dyscrasias (e.g.&#160;<br/>persistent fever, bruising, bleeding, pallor) while on Humira. Discontinuation of Humira therapy should be&#160;<br/>considered in patients with confirmed significant haematologic abnormalities.</p>
<p style="position:absolute;top:541px;left:106px;white-space:nowrap" class="ft532">Vaccinations</p>
<p style="position:absolute;top:579px;left:106px;white-space:nowrap" class="ft534">Similar antibody responses to the standard&#160;23-valent pneumococcal vaccine and the influenza trivalent&#160;<br/>virus vaccination were observed in a study in 226 adult subjects with rheumatoid arthritis who were&#160;<br/>treated with adalimumab or placebo. No data are available on the secondary transmission of infection by&#160;<br/>live vaccines in patients receiving Humira. &#160;</p>
<p style="position:absolute;top:674px;left:106px;white-space:nowrap" class="ft535">It is recommended that paediatric patients, if possible, be brought up to date with all immunisations in&#160;<br/>agreement with current immunisation guidelines prior to initiating Humira therapy.</p>
<p style="position:absolute;top:731px;left:106px;white-space:nowrap" class="ft534">Patients on&#160;Humira may receive concurrent vaccinations, except for live vaccines. Administration of live&#160;<br/>vaccines&#160;(e.g., BCG vaccine)&#160;to&#160;infants exposed to adalimumab in utero is not recommended for 5&#160;months&#160;<br/>following the mother’s last adalimumab injection during pregnancy.</p>
<p style="position:absolute;top:807px;left:106px;white-space:nowrap" class="ft532">Congestive heart failure</p>
<p style="position:absolute;top:845px;left:106px;white-space:nowrap" class="ft535">In a clinical trial with another TNF-antagonist worsening congestive heart failure and increased mortality&#160;<br/>due to congestive heart failure have been observed. Cases of worsening congestive heart failure have also&#160;<br/>been reported in patients receiving Humira. Humira should be used with caution in patients with mild&#160;<br/>heart failure (NYHA class I/II). Humira is contraindicated in moderate to severe heart failure (see section&#160;<br/>4.3). Treatment with Humira must be discontinued in patients who develop new or worsening symptoms&#160;<br/>of congestive heart failure.</p>
<p style="position:absolute;top:978px;left:106px;white-space:nowrap" class="ft532">Autoimmune processes</p>
<p style="position:absolute;top:1016px;left:106px;white-space:nowrap" class="ft534">Treatment with Humira may result in the formation of autoimmune antibodies. The impact of long-term&#160;<br/>treatment with Humira on the development of autoimmune diseases is unknown.&#160;If a patient develops&#160;<br/>symptoms suggestive of a lupus-like syndrome following treatment with Humira and is positive for&#160;</p>
</div>
<!-- Page 54 -->
<a name="54"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page54-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft540">54</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft545">antibodies against double-stranded DNA, further treatment with Humira should not be given (see section&#160;<br/>4.8).</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft542">Concurrent administration of biologic DMARDS or TNF-antagonists</p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft544">Serious infections were seen in clinical studies with concurrent use of anakinra and another&#160;<br/>TNF-antagonist, etanercept, with no added clinical benefit compared to etanercept alone. Because of the&#160;<br/>nature&#160;of the adverse events seen with the combination of etanercept and anakinra therapy, similar&#160;<br/>toxicities may also result from the combination of anakinra and other TNF-antagonists. Therefore, the&#160;<br/>combination of adalimumab and anakinra is not recommended. (See section 4.5).</p>
<p style="position:absolute;top:295px;left:106px;white-space:nowrap" class="ft544">Concomitant administration of adalimumab with other biologic DMARDS (e.g, anakinra and abatacept) or&#160;<br/>other TNF-antagonists is not recommended based upon the possible increased risk for infections,&#160;<br/>including serious infections and other potential pharmacological interactions. (See section 4.5).</p>
<p style="position:absolute;top:370px;left:106px;white-space:nowrap" class="ft542">Surgery</p>
<p style="position:absolute;top:409px;left:106px;white-space:nowrap" class="ft544">There is limited safety experience of surgical procedures in patients treated with Humira. The long half-<br/>life of adalimumab should be taken into consideration if a surgical procedure is planned. A patient who&#160;<br/>requires surgery while on Humira should be closely monitored for infections, and appropriate actions&#160;<br/>should be taken. There is limited safety experience in patients undergoing arthroplasty while receiving&#160;<br/>Humira.&#160;</p>
<p style="position:absolute;top:522px;left:106px;white-space:nowrap" class="ft542">Small bowel obstruction</p>
<p style="position:absolute;top:560px;left:106px;white-space:nowrap" class="ft544">Failure to respond to treatment for Crohn’s disease may indicate the presence of fixed fibrotic stricture&#160;<br/>that may require surgical treatment. Available data suggest that Humira does not worsen or cause&#160;<br/>strictures.</p>
<p style="position:absolute;top:636px;left:106px;white-space:nowrap" class="ft542">Elderly</p>
<p style="position:absolute;top:674px;left:106px;white-space:nowrap" class="ft544">The frequency of serious infections among Humira treated subjects over 65&#160;years of age (3.7%)&#160;was&#160;<br/>higher than for those under 65&#160;years of age (1.5%). Some of those had a fatal outcome. Particular attention&#160;<br/>regarding the risk for infection should be paid when treating the elderly.</p>
<p style="position:absolute;top:750px;left:106px;white-space:nowrap" class="ft542">Paediatric population</p>
<p style="position:absolute;top:788px;left:106px;white-space:nowrap" class="ft542">See Vaccinations above.</p>
<p style="position:absolute;top:826px;left:106px;white-space:nowrap" class="ft542">Excipients&#160;with known effects</p>
<p style="position:absolute;top:864px;left:106px;white-space:nowrap" class="ft545">This medicinal product contains less than 1&#160;mmol&#160;of sodium (23&#160;mg) per 0.8&#160;ml dose, i.e. essentially&#160;<br/>‘sodium-free’.</p>
<p style="position:absolute;top:921px;left:106px;white-space:nowrap" class="ft541"><b>4.5</b></p>
<p style="position:absolute;top:921px;left:160px;white-space:nowrap" class="ft541"><b>Interaction with other medicinal products and other forms of interaction&#160;</b></p>
<p style="position:absolute;top:959px;left:106px;white-space:nowrap" class="ft544">Humira has been studied in rheumatoid arthritis,&#160;polyarticular juvenile idiopathic arthritis and psoriatic&#160;<br/>arthritis patients taking Humira as monotherapy and those taking concomitant methotrexate. Antibody&#160;<br/>formation was lower when Humira was given together with methotrexate in comparison with use as&#160;<br/>monotherapy. Administration of Humira without methotrexate resulted in increased formation of&#160;<br/>antibodies, increased clearance and reduced efficacy of adalimumab (see section 5.1).&#160;</p>
</div>
<!-- Page 55 -->
<a name="55"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page55-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft550">55</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft555">The combination of Humira and anakinra is not recommended (see section 4.4 “Concurrent administration&#160;<br/>of biologic DMARDS or TNF-antagonists”).&#160;</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft554">The combination of Humira and abatacept is not recommended (see section 4.4 “Concurrent&#160;<br/>administration of biologic DMARDS or TNF-antagonists”).</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft551"><b>4.6</b></p>
<p style="position:absolute;top:200px;left:148px;white-space:nowrap" class="ft551"><b>Fertility, pregnancy and lactation</b></p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft552">Women of childbearing potential</p>
<p style="position:absolute;top:276px;left:106px;white-space:nowrap" class="ft554">Women of childbearing potential&#160;should consider the&#160;use&#160;of&#160;adequate contraception to prevent pregnancy&#160;<br/>and continue its use for at least five months&#160;after the last Humira treatment.</p>
<p style="position:absolute;top:333px;left:106px;white-space:nowrap" class="ft552">Pregnancy</p>
<p style="position:absolute;top:370px;left:106px;white-space:nowrap" class="ft554">A large number (approximately 2100) of prospectively collected pregnancies exposed to adalimumab&#160;<br/>resulting in live birth with known outcomes, including more than 1500 exposed during the first trimester,&#160;<br/>does not&#160;indicate an increase in the rate of malformation in the newborn.</p>
<p style="position:absolute;top:446px;left:106px;white-space:nowrap" class="ft554">In a prospective cohort registry, 257 women with&#160;rheumatoid arthritis (RA) or Crohn’s disease (CD)<br/>treated with adalimumab at least during the first trimester and 120 women with RA or CD not treated with&#160;<br/>adalimumab were enrolled. &#160;The primary endpoint was the birth prevalence of major birth defects. The&#160;<br/>rate of&#160;pregnancies ending with at least one live born infant with a major birth defect&#160;was 6/69 (8.7%)&#160;in&#160;<br/>the adalimumab-treated women with&#160;RA&#160;and 5/74 (6.8%) in the untreated women with RA&#160;(unadjusted&#160;<br/>OR 1.31, 95% CI 0.38-4.52) and&#160;16/152 (10.5%) in the adalimumab-treated women with&#160;CD&#160;and 3/32&#160;<br/>(9.4%) in the untreated women with CD&#160;(unadjusted OR 1.14, 95% CI 0.31-4.16). The adjusted OR&#160;<br/>(accounting for baseline differences) was&#160;1.10&#160;(95% CI 0.45-2.73)&#160;with RA and CD combined.&#160;There&#160;were&#160;<br/>no distinct differences between&#160;adalimumab-treated and untreated women&#160;for the secondary&#160;endpoints&#160;<br/>spontaneous abortions, minor birth defects, preterm&#160;delivery, birth size and serious or opportunistic&#160;<br/>infections&#160;and no stillbirths or malignancies were reported.&#160;The interpretation of data&#160;may be impacted due&#160;<br/>to methodological limitations of the&#160;study, including small sample size and non-randomized design.</p>
<p style="position:absolute;top:693px;left:106px;white-space:nowrap" class="ft554">In a&#160;developmental toxicity study conducted in monkeys, there was no indication of maternal toxicity,&#160;<br/>embryotoxicity or teratogenicity. Preclinical data on postnatal toxicity of adalimumab are not available&#160;<br/>(see section 5.3).</p>
<p style="position:absolute;top:770px;left:106px;white-space:nowrap" class="ft552">Due to its inhibition of TNF</p>
<p style="position:absolute;top:768px;left:292px;white-space:nowrap" class="ft556">, adalimumab administered during pregnancy could affect normal immune&#160;</p>
<p style="position:absolute;top:789px;left:106px;white-space:nowrap" class="ft552">responses in the newborn.&#160;&#160;Adalimumab should only be used during&#160;pregnancy if clearly needed.</p>
<p style="position:absolute;top:827px;left:106px;white-space:nowrap" class="ft554">Adalimumab may cross the placenta into the serum of infants born to women treated with adalimumab&#160;<br/>during pregnancy. Consequently, these infants may be at increased risk for infection. Administration of&#160;<br/>live vaccines&#160;(e.g., BCG vaccine)&#160;to infants exposed to adalimumab in utero is not recommended for&#160;<br/>5&#160;months following the mother’s last adalimumab injection during pregnancy.</p>
<p style="position:absolute;top:922px;left:106px;white-space:nowrap" class="ft552">Breast-feeding</p>
<p style="position:absolute;top:960px;left:106px;white-space:nowrap" class="ft555">Limited information from the published literature indicates that adalimumab is excreted in breast milk at&#160;<br/>very low concentrations with the presence of adalimumab in human milk at concentrations of 0.1% to 1%&#160;<br/>of the maternal serum level. Given orally, immunoglobulin G proteins undergo intestinal proteolysis and&#160;<br/>have poor bioavailability. No effects on the breastfed newborns/infants are anticipated. Consequently,&#160;<br/>Humira can be used during breastfeeding.</p>
<p style="position:absolute;top:1074px;left:106px;white-space:nowrap" class="ft552">Fertility</p>
</div>
<!-- Page 56 -->
<a name="56"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page56-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft560">56</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft562">Preclinical data on fertility effects of adalimumab are not available.</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft561"><b>4.7</b></p>
<p style="position:absolute;top:143px;left:148px;white-space:nowrap" class="ft561"><b>Effects on ability to drive and use machines&#160;</b></p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft564">Humira may have a minor influence on the ability to drive and use machines. Vertigo and visual&#160;<br/>impairment may occur following administration of Humira (see section 4.8).</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft561"><b>4.8</b></p>
<p style="position:absolute;top:238px;left:148px;white-space:nowrap" class="ft561"><b>Undesirable effects</b></p>
<p style="position:absolute;top:276px;left:106px;white-space:nowrap" class="ft562">Summary of the safety profile</p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft565">Humira was studied in 9,506 patients in pivotal controlled and open label trials for up to 60&#160;months or&#160;<br/>more. These trials included rheumatoid arthritis&#160;patients with short term and long standing disease,&#160;<br/>juvenile idiopathic arthritis (polyarticular juvenile idiopathic arthritis and enthesitis-related arthritis) as&#160;<br/>well as axial spondyloarthritis (ankylosing spondylitis and axial spondyloarthritis without&#160;radiographic&#160;<br/>evidence of AS), psoriatic arthritis, Crohn’s disease, ulcerative colitis, psoriasis, hidradenitis suppurativa&#160;<br/>and uveitis patients. The pivotal controlled studies involved 6,089 patients receiving Humira and 3,801&#160;<br/>patients receiving placebo or active comparator during the controlled period.</p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft565">The proportion of patients who discontinued treatment due to adverse events during the double-blind,&#160;<br/>controlled portion of pivotal studies was 5.9% for patients taking Humira and 5.4% for control treated&#160;<br/>patients.</p>
<p style="position:absolute;top:541px;left:106px;white-space:nowrap" class="ft564">The&#160;most commonly reported adverse reactions are infections (such as nasopharyngitis, upper respiratory&#160;<br/>tract infection and sinusitis), injection site reactions (erythema, itching, haemorrhage, pain or swelling),&#160;<br/>headache and musculoskeletal pain.</p>
<p style="position:absolute;top:617px;left:106px;white-space:nowrap" class="ft565">Serious adverse reactions have been reported for Humira. TNF-antagonists, such as Humira affect the&#160;<br/>immune system and their use may affect the body’s defence against infection and cancer.<br/>Fatal and life-threatening infections (including sepsis,&#160;opportunistic infections and TB), HBV reactivation&#160;<br/>and various malignancies (including leukaemia, lymphoma and HSTCL) have also been reported with use&#160;<br/>of Humira.</p>
<p style="position:absolute;top:731px;left:106px;white-space:nowrap" class="ft564">Serious haematological, neurological and autoimmune reactions have also been reported. These&#160;include&#160;<br/>rare reports of pancytopenia, aplastic anaemia, central and peripheral demyelinating events and reports of&#160;<br/>lupus, lupus-related conditions and Stevens-Johnson syndrome.</p>
<p style="position:absolute;top:807px;left:106px;white-space:nowrap" class="ft562">Paediatric population</p>
<p style="position:absolute;top:845px;left:106px;white-space:nowrap" class="ft564">In&#160;general, the adverse events in paediatric patients were similar in frequency and type to those seen in&#160;<br/>adult patients.</p>
<p style="position:absolute;top:902px;left:106px;white-space:nowrap" class="ft562">Tabulated list of adverse reactions</p>
<p style="position:absolute;top:940px;left:106px;white-space:nowrap" class="ft567">The following list of adverse reactions is based on experience from clinical trials and on postmarketing&#160;<br/>experience and are displayed by system organ class and frequency in Table&#160;7&#160;below: very common&#160;<br/>(</p>
<p style="position:absolute;top:977px;left:111px;white-space:nowrap" class="ft566">&#160;1/10); common (&#160;1/100&#160;to &lt;&#160;1/10); uncommon (&#160;1/1,000&#160;to&lt;&#160;1/100); rare (&#160;1/10,000 to &lt;&#160;1/1,000);&#160;</p>
<p style="position:absolute;top:998px;left:106px;white-space:nowrap" class="ft564">and&#160;not&#160;known (cannot be estimated from the available data). Within each frequency grouping,&#160;<br/>undesirable&#160;effects are presented in order of decreasing seriousness. The highest frequency seen among the&#160;<br/>various indications has been included. An asterisk (*) appears in the SOC column if further information is&#160;<br/>found elsewhere in sections 4.3, 4.4 and 4.8.</p>
</div>
<!-- Page 57 -->
<a name="57"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page57-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft570">57</p>
<p style="position:absolute;top:86px;left:433px;white-space:nowrap" class="ft571"><b>Table&#160;7</b></p>
<p style="position:absolute;top:105px;left:390px;white-space:nowrap" class="ft571"><b>Undesirable Effects</b></p>
<p style="position:absolute;top:153px;left:132px;white-space:nowrap" class="ft571"><b>System&#160;Organ Class</b></p>
<p style="position:absolute;top:153px;left:341px;white-space:nowrap" class="ft571"><b>Frequency</b></p>
<p style="position:absolute;top:153px;left:566px;white-space:nowrap" class="ft571"><b>Adverse Reaction</b></p>
<p style="position:absolute;top:186px;left:114px;white-space:nowrap" class="ft574">Infections and&#160;<br/>infestations*</p>
<p style="position:absolute;top:186px;left:309px;white-space:nowrap" class="ft572">Very common</p>
<p style="position:absolute;top:186px;left:465px;white-space:nowrap" class="ft575">Respiratory tract infections (including lower and&#160;<br/>upper respiratory tract infection, pneumonia,&#160;<br/>sinusitis, pharyngitis, nasopharyngitis and&#160;<br/>pneumonia herpes viral)</p>
<p style="position:absolute;top:291px;left:309px;white-space:nowrap" class="ft572">Common</p>
<p style="position:absolute;top:286px;left:465px;white-space:nowrap" class="ft578">Systemic infections&#160;(including sepsis, candidiasis&#160;<br/>and influenza),<br/>intestinal infections&#160;(including gastroenteritis&#160;<br/>viral),<br/>skin and soft tissue infections (including&#160;<br/>paronychia, cellulitis, impetigo, necrotising&#160;<br/>fasciitis and herpes zoster),<br/>ear infections,<br/>oral infections&#160;(including herpes simplex, oral&#160;<br/>herpes and tooth infections),&#160;<br/>reproductive tract infections&#160;(including&#160;<br/>vulvovaginal mycotic infection),&#160;<br/>urinary tract infections (including&#160;<br/>pyelonephritis),<br/>fungal infections,<br/>joint infections</p>
<p style="position:absolute;top:627px;left:309px;white-space:nowrap" class="ft572">Uncommon</p>
<p style="position:absolute;top:627px;left:465px;white-space:nowrap" class="ft575">Neurological infections (including viral&#160;<br/>meningitis),<br/>opportunistic infections and tuberculosis&#160;<br/>(including coccidioidomycosis, histoplasmosis&#160;<br/>and mycobacterium avium complex infection),&#160;<br/>bacterial infections,<br/>eye&#160;infections,<br/>diverticulitis1)</p>
<p style="position:absolute;top:803px;left:114px;white-space:nowrap" class="ft575">Neoplasms benign,&#160;<br/>malignant and unspecified&#160;<br/>(including cysts and&#160;<br/>polyps)*</p>
<p style="position:absolute;top:803px;left:309px;white-space:nowrap" class="ft572">Common</p>
<p style="position:absolute;top:803px;left:465px;white-space:nowrap" class="ft578">Skin cancer excluding melanoma (including&#160;<br/>basal cell carcinoma and squamous cell&#160;<br/>carcinoma),<br/>benign neoplasm</p>
<p style="position:absolute;top:908px;left:309px;white-space:nowrap" class="ft572">Uncommon</p>
<p style="position:absolute;top:908px;left:465px;white-space:nowrap" class="ft574">Lymphoma**,&#160;<br/>solid organ neoplasm (including breast cancer,&#160;<br/>lung neoplasm and thyroid neoplasm),<br/>melanoma**</p>
<p style="position:absolute;top:1008px;left:309px;white-space:nowrap" class="ft572">Rare</p>
<p style="position:absolute;top:1008px;left:465px;white-space:nowrap" class="ft572">Leukaemia1)</p>
</div>
<!-- Page 58 -->
<a name="58"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page58-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft580">58</p>
<p style="position:absolute;top:96px;left:132px;white-space:nowrap" class="ft581"><b>System&#160;Organ Class</b></p>
<p style="position:absolute;top:96px;left:341px;white-space:nowrap" class="ft581"><b>Frequency</b></p>
<p style="position:absolute;top:96px;left:566px;white-space:nowrap" class="ft581"><b>Adverse Reaction</b></p>
<p style="position:absolute;top:129px;left:309px;white-space:nowrap" class="ft582">Not known</p>
<p style="position:absolute;top:129px;left:465px;white-space:nowrap" class="ft588">Hepatosplenic T-cell lymphoma1),<br/>Merkel cell carcinoma (neuroendocrine&#160;<br/>carcinoma of the skin)1),<br/>Kaposi’s sarcoma</p>
<p style="position:absolute;top:243px;left:114px;white-space:nowrap" class="ft585">Blood and&#160;the lymphatic&#160;<br/>system disorders*</p>
<p style="position:absolute;top:243px;left:309px;white-space:nowrap" class="ft582">Very common</p>
<p style="position:absolute;top:243px;left:465px;white-space:nowrap" class="ft588">Leukopenia (including neutropenia and&#160;<br/>agranulocytosis),&#160;<br/>anaemia&#160;</p>
<p style="position:absolute;top:328px;left:309px;white-space:nowrap" class="ft582">Common</p>
<p style="position:absolute;top:328px;left:465px;white-space:nowrap" class="ft585">Leucocytosis,<br/>thrombocytopenia</p>
<p style="position:absolute;top:386px;left:309px;white-space:nowrap" class="ft582">Uncommon</p>
<p style="position:absolute;top:386px;left:465px;white-space:nowrap" class="ft582">Idiopathic thrombocytopenic purpura</p>
<p style="position:absolute;top:424px;left:309px;white-space:nowrap" class="ft582">Rare</p>
<p style="position:absolute;top:424px;left:465px;white-space:nowrap" class="ft582">Pancytopenia</p>
<p style="position:absolute;top:468px;left:114px;white-space:nowrap" class="ft582">Immune system disorders*&#160;Common</p>
<p style="position:absolute;top:468px;left:465px;white-space:nowrap" class="ft588">Hypersensitivity,<br/>allergies (including seasonal allergy)</p>
<p style="position:absolute;top:539px;left:309px;white-space:nowrap" class="ft582">Uncommon</p>
<p style="position:absolute;top:539px;left:465px;white-space:nowrap" class="ft588">Sarcoidosis1),<br/>vasculitis</p>
<p style="position:absolute;top:610px;left:309px;white-space:nowrap" class="ft582">Rare</p>
<p style="position:absolute;top:610px;left:465px;white-space:nowrap" class="ft582">Anaphylaxis1)</p>
<p style="position:absolute;top:658px;left:114px;white-space:nowrap" class="ft584">Metabolism and nutrition&#160;<br/>disorders</p>
<p style="position:absolute;top:658px;left:309px;white-space:nowrap" class="ft582">Very common</p>
<p style="position:absolute;top:658px;left:465px;white-space:nowrap" class="ft582">Lipids increased</p>
<p style="position:absolute;top:706px;left:309px;white-space:nowrap" class="ft582">Common</p>
<p style="position:absolute;top:706px;left:465px;white-space:nowrap" class="ft588">Hypokalaemia,&#160;<br/>uric acid increased,&#160;<br/>blood sodium abnormal,<br/>hypocalcaemia,<br/>hyperglycaemia,<br/>hypophosphatemia,<br/>dehydration</p>
<p style="position:absolute;top:900px;left:114px;white-space:nowrap" class="ft582">Psychiatric disorders</p>
<p style="position:absolute;top:900px;left:309px;white-space:nowrap" class="ft582">Common</p>
<p style="position:absolute;top:900px;left:465px;white-space:nowrap" class="ft588">Mood alterations (including depression),&#160;<br/>anxiety,<br/>insomnia</p>
<p style="position:absolute;top:995px;left:114px;white-space:nowrap" class="ft582">Nervous system disorders*&#160;Very common</p>
<p style="position:absolute;top:995px;left:465px;white-space:nowrap" class="ft582">Headache</p>
</div>
<!-- Page 59 -->
<a name="59"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page59-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft590">59</p>
<p style="position:absolute;top:96px;left:132px;white-space:nowrap" class="ft591"><b>System&#160;Organ Class</b></p>
<p style="position:absolute;top:96px;left:341px;white-space:nowrap" class="ft591"><b>Frequency</b></p>
<p style="position:absolute;top:96px;left:566px;white-space:nowrap" class="ft591"><b>Adverse Reaction</b></p>
<p style="position:absolute;top:129px;left:309px;white-space:nowrap" class="ft592">Common</p>
<p style="position:absolute;top:129px;left:465px;white-space:nowrap" class="ft598">Paraesthesias (including hypoesthesia),<br/>migraine,<br/>nerve root compression</p>
<p style="position:absolute;top:219px;left:309px;white-space:nowrap" class="ft592">Uncommon</p>
<p style="position:absolute;top:219px;left:465px;white-space:nowrap" class="ft594">Cerebrovascular accident1),<br/>tremor,<br/>neuropathy&#160;</p>
<p style="position:absolute;top:296px;left:309px;white-space:nowrap" class="ft592">Rare</p>
<p style="position:absolute;top:296px;left:465px;white-space:nowrap" class="ft594">Multiple sclerosis,<br/>demyelinating disorders (e.g. optic neuritis,&#160;<br/>Guillain-Barré syndrome)&#160;1)</p>
<p style="position:absolute;top:386px;left:114px;white-space:nowrap" class="ft592">Eye&#160;disorders</p>
<p style="position:absolute;top:386px;left:309px;white-space:nowrap" class="ft592">Common</p>
<p style="position:absolute;top:386px;left:465px;white-space:nowrap" class="ft598">Visual impairment,<br/>conjunctivitis,<br/>blepharitis,<br/>eye swelling</p>
<p style="position:absolute;top:499px;left:309px;white-space:nowrap" class="ft592">Uncommon</p>
<p style="position:absolute;top:499px;left:465px;white-space:nowrap" class="ft592">Diplopia</p>
<p style="position:absolute;top:543px;left:114px;white-space:nowrap" class="ft594">Ear and labyrinth&#160;<br/>disorders&#160;</p>
<p style="position:absolute;top:543px;left:309px;white-space:nowrap" class="ft592">Common</p>
<p style="position:absolute;top:543px;left:465px;white-space:nowrap" class="ft592">Vertigo</p>
<p style="position:absolute;top:586px;left:309px;white-space:nowrap" class="ft592">Uncommon</p>
<p style="position:absolute;top:586px;left:465px;white-space:nowrap" class="ft594">Deafness,&#160;<br/>tinnitus</p>
<p style="position:absolute;top:648px;left:114px;white-space:nowrap" class="ft592">Cardiac disorders*&#160;</p>
<p style="position:absolute;top:648px;left:309px;white-space:nowrap" class="ft592">Common</p>
<p style="position:absolute;top:648px;left:465px;white-space:nowrap" class="ft592">Tachycardia</p>
<p style="position:absolute;top:691px;left:309px;white-space:nowrap" class="ft592">Uncommon</p>
<p style="position:absolute;top:687px;left:465px;white-space:nowrap" class="ft598">Myocardial infarction1),<br/>arrhythmia,<br/>congestive heart failure</p>
<p style="position:absolute;top:777px;left:309px;white-space:nowrap" class="ft592">Rare</p>
<p style="position:absolute;top:777px;left:465px;white-space:nowrap" class="ft592">Cardiac arrest</p>
<p style="position:absolute;top:820px;left:114px;white-space:nowrap" class="ft592">Vascular disorders</p>
<p style="position:absolute;top:820px;left:309px;white-space:nowrap" class="ft592">Common</p>
<p style="position:absolute;top:820px;left:465px;white-space:nowrap" class="ft598">Hypertension,&#160;<br/>flushing,&#160;<br/>haematoma</p>
<p style="position:absolute;top:910px;left:309px;white-space:nowrap" class="ft592">Uncommon</p>
<p style="position:absolute;top:910px;left:465px;white-space:nowrap" class="ft594">Aortic aneurysm,<br/>vascular arterial occlusion,<br/>thrombophlebitis&#160;</p>
<p style="position:absolute;top:991px;left:114px;white-space:nowrap" class="ft594">Respiratory, thoracic and&#160;<br/>mediastinal disorders*</p>
<p style="position:absolute;top:991px;left:309px;white-space:nowrap" class="ft592">Common</p>
<p style="position:absolute;top:991px;left:465px;white-space:nowrap" class="ft598">Asthma,<br/>dyspnoea,<br/>cough</p>
</div>
<!-- Page 60 -->
<a name="60"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page60-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft600">60</p>
<p style="position:absolute;top:96px;left:132px;white-space:nowrap" class="ft601"><b>System&#160;Organ Class</b></p>
<p style="position:absolute;top:96px;left:341px;white-space:nowrap" class="ft601"><b>Frequency</b></p>
<p style="position:absolute;top:96px;left:566px;white-space:nowrap" class="ft601"><b>Adverse Reaction</b></p>
<p style="position:absolute;top:125px;left:309px;white-space:nowrap" class="ft602">Uncommon</p>
<p style="position:absolute;top:129px;left:465px;white-space:nowrap" class="ft604">Pulmonary embolism1),<br/>interstitial lung disease,&#160;<br/>chronic obstructive pulmonary disease,<br/>pneumonitis,<br/>pleural effusion1)</p>
<p style="position:absolute;top:248px;left:309px;white-space:nowrap" class="ft602">Rare</p>
<p style="position:absolute;top:248px;left:465px;white-space:nowrap" class="ft602">Pulmonary fibrosis1)</p>
<p style="position:absolute;top:296px;left:114px;white-space:nowrap" class="ft602">Gastrointestinal disorders</p>
<p style="position:absolute;top:296px;left:309px;white-space:nowrap" class="ft602">Very common</p>
<p style="position:absolute;top:296px;left:465px;white-space:nowrap" class="ft608">Abdominal pain,&#160;<br/>nausea and vomiting</p>
<p style="position:absolute;top:363px;left:309px;white-space:nowrap" class="ft602">Common</p>
<p style="position:absolute;top:363px;left:465px;white-space:nowrap" class="ft604">GI haemorrhage,&#160;<br/>dyspepsia,<br/>gastroesophageal reflux disease,<br/>sicca syndrome</p>
<p style="position:absolute;top:458px;left:309px;white-space:nowrap" class="ft602">Uncommon</p>
<p style="position:absolute;top:458px;left:465px;white-space:nowrap" class="ft604">Pancreatitis,&#160;<br/>dysphagia,<br/>face oedema</p>
<p style="position:absolute;top:539px;left:309px;white-space:nowrap" class="ft602">Rare</p>
<p style="position:absolute;top:539px;left:465px;white-space:nowrap" class="ft602">Intestinal perforation1)</p>
<p style="position:absolute;top:587px;left:114px;white-space:nowrap" class="ft602">Hepato-biliary disorders*</p>
<p style="position:absolute;top:587px;left:309px;white-space:nowrap" class="ft602">Very Common</p>
<p style="position:absolute;top:587px;left:465px;white-space:nowrap" class="ft602">Elevated liver enzymes</p>
<p style="position:absolute;top:630px;left:309px;white-space:nowrap" class="ft602">Uncommon</p>
<p style="position:absolute;top:630px;left:465px;white-space:nowrap" class="ft604">Cholecystitis and cholelithiasis,<br/>hepatic steatosis,&#160;<br/>bilirubin increased</p>
<p style="position:absolute;top:711px;left:309px;white-space:nowrap" class="ft602">Rare</p>
<p style="position:absolute;top:711px;left:465px;white-space:nowrap" class="ft6010">Hepatitis<br/>reactivation of hepatitis B1)&#160;<br/>autoimmune hepatitis1)</p>
<p style="position:absolute;top:801px;left:309px;white-space:nowrap" class="ft602">Not known</p>
<p style="position:absolute;top:801px;left:465px;white-space:nowrap" class="ft602">Liver failure1)</p>
<p style="position:absolute;top:849px;left:114px;white-space:nowrap" class="ft604">Skin and subcutaneous&#160;<br/>tissue disorders</p>
<p style="position:absolute;top:849px;left:309px;white-space:nowrap" class="ft602">Very Common</p>
<p style="position:absolute;top:849px;left:465px;white-space:nowrap" class="ft602">Rash (including exfoliative rash)</p>
<p style="position:absolute;top:892px;left:309px;white-space:nowrap" class="ft602">Common</p>
<p style="position:absolute;top:892px;left:465px;white-space:nowrap" class="ft604">Worsening or&#160;new&#160;onset of psoriasis (including&#160;<br/>palmoplantar pustular psoriasis)1),<br/>urticaria,<br/>bruising (including purpura),&#160;<br/>dermatitis (including eczema),<br/>onychoclasis,&#160;<br/>hyperhidrosis,<br/>alopecia1),<br/>pruritus</p>
</div>
<!-- Page 61 -->
<a name="61"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page61-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft610">61</p>
<p style="position:absolute;top:96px;left:132px;white-space:nowrap" class="ft611"><b>System&#160;Organ Class</b></p>
<p style="position:absolute;top:96px;left:341px;white-space:nowrap" class="ft611"><b>Frequency</b></p>
<p style="position:absolute;top:96px;left:566px;white-space:nowrap" class="ft611"><b>Adverse Reaction</b></p>
<p style="position:absolute;top:125px;left:309px;white-space:nowrap" class="ft612">Uncommon</p>
<p style="position:absolute;top:125px;left:465px;white-space:nowrap" class="ft615">Night sweats,<br/>scar</p>
<p style="position:absolute;top:186px;left:309px;white-space:nowrap" class="ft612">Rare</p>
<p style="position:absolute;top:186px;left:465px;white-space:nowrap" class="ft6110">Erythema multiforme1),<br/>Stevens-Johnson syndrome1),<br/>angioedema1),<br/>cutaneous vasculitis1)<br/>lichenoid skin reaction1)</p>
<p style="position:absolute;top:328px;left:309px;white-space:nowrap" class="ft612">Not known</p>
<p style="position:absolute;top:328px;left:465px;white-space:nowrap" class="ft612">Worsening of symptoms of dermatomyositis1)</p>
<p style="position:absolute;top:376px;left:114px;white-space:nowrap" class="ft614">Musculoskeletal and&#160;<br/>connective tissue disorders</p>
<p style="position:absolute;top:376px;left:309px;white-space:nowrap" class="ft612">Very common</p>
<p style="position:absolute;top:376px;left:465px;white-space:nowrap" class="ft612">Musculoskeletal pain</p>
<p style="position:absolute;top:423px;left:309px;white-space:nowrap" class="ft612">Common</p>
<p style="position:absolute;top:423px;left:465px;white-space:nowrap" class="ft614">Muscle spasms&#160;(including blood creatine&#160;<br/>phosphokinase increased)</p>
<p style="position:absolute;top:486px;left:309px;white-space:nowrap" class="ft612">Uncommon</p>
<p style="position:absolute;top:486px;left:465px;white-space:nowrap" class="ft614">Rhabdomyolysis,<br/>systemic lupus erythematosus</p>
<p style="position:absolute;top:544px;left:309px;white-space:nowrap" class="ft612">Rare</p>
<p style="position:absolute;top:544px;left:465px;white-space:nowrap" class="ft612">Lupus-like syndrome1)</p>
<p style="position:absolute;top:586px;left:114px;white-space:nowrap" class="ft614">Renal and urinary&#160;<br/>disorders&#160;</p>
<p style="position:absolute;top:586px;left:309px;white-space:nowrap" class="ft612">Common</p>
<p style="position:absolute;top:586px;left:465px;white-space:nowrap" class="ft618">Renal impairment,<br/>haematuria</p>
<p style="position:absolute;top:653px;left:309px;white-space:nowrap" class="ft612">Uncommon</p>
<p style="position:absolute;top:653px;left:465px;white-space:nowrap" class="ft612">Nocturia</p>
<p style="position:absolute;top:697px;left:114px;white-space:nowrap" class="ft615">Reproductive system and&#160;<br/>breast disorders</p>
<p style="position:absolute;top:697px;left:309px;white-space:nowrap" class="ft612">Uncommon</p>
<p style="position:absolute;top:697px;left:465px;white-space:nowrap" class="ft612">Erectile dysfunction</p>
<p style="position:absolute;top:744px;left:114px;white-space:nowrap" class="ft614">General disorders and&#160;<br/>administration site&#160;<br/>conditions*</p>
<p style="position:absolute;top:744px;left:309px;white-space:nowrap" class="ft612">Very Common</p>
<p style="position:absolute;top:744px;left:465px;white-space:nowrap" class="ft614">Injection site reaction (including injection site&#160;<br/>erythema)</p>
<p style="position:absolute;top:806px;left:309px;white-space:nowrap" class="ft612">Common</p>
<p style="position:absolute;top:806px;left:465px;white-space:nowrap" class="ft615">Chest pain,&#160;<br/>oedema,<br/>pyrexia1)</p>
<p style="position:absolute;top:883px;left:309px;white-space:nowrap" class="ft612">Uncommon</p>
<p style="position:absolute;top:883px;left:465px;white-space:nowrap" class="ft612">Inflammation</p>
<p style="position:absolute;top:926px;left:114px;white-space:nowrap" class="ft612">Investigations*</p>
<p style="position:absolute;top:926px;left:309px;white-space:nowrap" class="ft612">Common</p>
<p style="position:absolute;top:926px;left:465px;white-space:nowrap" class="ft618">Coagulation and bleeding disorders (including&#160;<br/>activated partial thromboplastin time prolonged),&#160;<br/>autoantibody test positive (including double&#160;<br/>stranded DNA antibody),&#160;<br/>blood lactate dehydrogenase increased</p>
<p style="position:absolute;top:1059px;left:309px;white-space:nowrap" class="ft612">Not known</p>
<p style="position:absolute;top:1059px;left:465px;white-space:nowrap" class="ft612">Weight&#160;increased2)</p>
</div>
<!-- Page 62 -->
<a name="62"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page62-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft620">62</p>
<p style="position:absolute;top:96px;left:132px;white-space:nowrap" class="ft621"><b>System&#160;Organ Class</b></p>
<p style="position:absolute;top:96px;left:341px;white-space:nowrap" class="ft621"><b>Frequency</b></p>
<p style="position:absolute;top:96px;left:566px;white-space:nowrap" class="ft621"><b>Adverse Reaction</b></p>
<p style="position:absolute;top:129px;left:114px;white-space:nowrap" class="ft624">Injury, poisoning and&#160;<br/>procedural complications</p>
<p style="position:absolute;top:129px;left:309px;white-space:nowrap" class="ft622">Common</p>
<p style="position:absolute;top:129px;left:465px;white-space:nowrap" class="ft622">Impaired healing</p>
<p style="position:absolute;top:189px;left:106px;white-space:nowrap" class="ft624">*&#160;further information is found elsewhere in sections 4.3, 4.4 and 4.8<br/>**&#160;including open label extension studies</p>
<p style="position:absolute;top:226px;left:106px;white-space:nowrap" class="ft629">1)&#160;including spontaneous reporting data</p>
<p style="position:absolute;top:245px;left:106px;white-space:nowrap" class="ft624">2)&#160;The mean&#160;weight change from baseline for adalimumab ranged from 0.3&#160;kg to 1.0&#160;kg across adult&#160;<br/>indications compared to (minus)&#160;-0.4&#160;kg to 0.4&#160;kg for placebo over a treatment period of 4-6 months.&#160;<br/>Weight increase of 5-6&#160;kg has also been observed&#160;in long-term&#160;extension studies with mean exposures of&#160;<br/>approximately 1-2 years without control group,&#160;particularly in patients with Crohn’s disease and&#160;<br/>Ulcerative colitis. The mechanism behind this effect is unclear but could be associated with the&#160;<br/>anti-inflammatory effect of adalimumab.</p>
<p style="position:absolute;top:379px;left:106px;white-space:nowrap" class="ft622">Hidradenitis suppurativa</p>
<p style="position:absolute;top:417px;left:106px;white-space:nowrap" class="ft625">The safety profile for patients with HS treated with Humira weekly was consistent with the known safety&#160;<br/>profile of Humira.</p>
<p style="position:absolute;top:474px;left:106px;white-space:nowrap" class="ft622">Uveitis</p>
<p style="position:absolute;top:512px;left:106px;white-space:nowrap" class="ft624">The safety profile for patients with uveitis treated with Humira every other week was consistent with the&#160;<br/>known safety profile of Humira.</p>
<p style="position:absolute;top:569px;left:106px;white-space:nowrap" class="ft622">Description of selected adverse reactions</p>
<p style="position:absolute;top:607px;left:106px;white-space:nowrap" class="ft623"><i>Injection site reactions</i></p>
<p style="position:absolute;top:645px;left:106px;white-space:nowrap" class="ft624">In the pivotal controlled trials in adults and children, 12.9% of patients treated with Humira developed&#160;<br/>injection site reactions (erythema and/or itching, haemorrhage, pain or swelling), compared to 7.2% of&#160;<br/>patients receiving placebo or active control. Injection site reactions generally did not necessitate&#160;<br/>discontinuation of the medicinal product.&#160;</p>
<p style="position:absolute;top:739px;left:106px;white-space:nowrap" class="ft623"><i>Infections</i></p>
<p style="position:absolute;top:778px;left:106px;white-space:nowrap" class="ft624">In the pivotal controlled trials in adults and children, the rate of infection was 1.51&#160;per patient year in the&#160;<br/>Humira treated patients and 1.46&#160;per&#160;patient year in the placebo and active control-treated patients. The&#160;<br/>infections consisted primarily of nasopharyngitis, upper respiratory tract infection, and sinusitis. Most&#160;<br/>patients continued on Humira after the infection resolved. &#160;</p>
<p style="position:absolute;top:872px;left:106px;white-space:nowrap" class="ft624">The incidence of&#160;serious infections was 0.04&#160;per patient year in Humira treated patients and 0.03&#160;per&#160;<br/>patient year in placebo and active control&#160;−&#160;treated patients. &#160;</p>
<p style="position:absolute;top:930px;left:106px;white-space:nowrap" class="ft624">In controlled and open label adult and paediatric studies with Humira, serious infections (including fatal&#160;<br/>infections, which occurred rarely) have been reported, which include reports of tuberculosis (including&#160;<br/>miliary and extra-pulmonary locations) and invasive opportunistic infections (e.g. disseminated&#160;or&#160;<br/>extrapulmonary&#160;histoplasmosis,&#160;blastomycosis,&#160;coccidioidomycosis, pneumocystis,&#160;candidiasis,&#160;<br/>aspergillosis and listeriosis). Most of the cases of tuberculosis occurred within the first eight months after&#160;<br/>initiation of therapy and may reflect recrudescence of latent disease.</p>
<p style="position:absolute;top:1062px;left:106px;white-space:nowrap" class="ft623"><i>Malignancies and lymphoproliferative disorders</i></p>
</div>
<!-- Page 63 -->
<a name="63"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page63-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft630">63</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft635">No&#160;malignancies were observed in 249 paediatric patients with an exposure of 655.6&#160;patient years during&#160;<br/>Humira trials in patients with juvenile idiopathic arthritis (polyarticular juvenile idiopathic arthritis and&#160;<br/>enthesitis-related arthritis).&#160;In addition, no malignancies were observed in 192 paediatric patients with an&#160;<br/>exposure of 498.1&#160;patient years during Humira trials in paediatric patients with Crohn’s disease. No&#160;<br/>malignancies were observed in 77 paediatric patients with an exposure of 80.0&#160;patient years during a&#160;<br/>Humira trial in paediatric patients with chronic plaque psoriasis.&#160;No malignancies were observed in 93&#160;<br/>paediatric patients with an exposure of 65.3 patient years during a Humira trial in paediatric patients with&#160;<br/>ulcerative colitis.&#160;No&#160;malignancies were observed in 60 paediatric patients with an exposure of 58.4&#160;<br/>patient years during a Humira trial in paediatric patients with uveitis.</p>
<p style="position:absolute;top:276px;left:106px;white-space:nowrap" class="ft634">During the controlled portions of pivotal Humira trials in adults of at least 12&#160;weeks in&#160;duration in patients&#160;<br/>with moderately to severely active rheumatoid arthritis, ankylosing spondylitis, axial spondyloarthritis&#160;<br/>without radiographic evidence of AS, psoriatic arthritis, psoriasis, hidradenitis suppurativa, Crohn’s&#160;<br/>disease, ulcerative colitis&#160;and uveitis, malignancies, other than lymphoma and non-melanoma skin cancer,&#160;<br/>were observed at a rate (95% confidence interval) of 6.8 (4.4, 10.5) &#160;per 1,000 patient-years among 5,291&#160;<br/>Humira treated patients&#160;<i>versus&#160;</i>a rate of 6.3 (3.4, 11.8) per 1,000 patient-years among 3,444 control&#160;<br/>patients (median duration of treatment was 4.0&#160;months for Humira and 3.8&#160;months for control-treated&#160;<br/>patients). The rate (95% confidence interval) of non-melanoma skin cancers was 8.8 (6.0, 13.0) per 1,000&#160;<br/>patient-years among Humira-treated patients and 3.2 (1.3, 7.6) per 1,000 patient-years among control&#160;<br/>patients. Of these skin cancers, squamous cell carcinomas occurred at rates (95% confidence interval) of&#160;<br/>2.7 (1.4, 5.4) per 1,000 patient-years among Humira-treated patients and&#160;0.6 (0.1, 4.5) per 1,000 patient-<br/>years among control patients. The rate (95% confidence interval) of lymphomas was 0.7 (0.2, 2.7) per&#160;<br/>1,000 patient-years among Humira-treated patients and 0.6 (0.1, 4.5) per 1,000 patient-years among&#160;<br/>control patients.</p>
<p style="position:absolute;top:560px;left:106px;white-space:nowrap" class="ft634">When combining controlled portions of these trials and ongoing and completed open label extension&#160;<br/>studies with a median duration of approximately 3.3&#160;years including 6,427 patients and over 26,439&#160;<br/>patient-years of therapy, the observed rate of malignancies, other than lymphoma and non-melanoma skin&#160;<br/>cancers is approximately 8.5 per 1,000 patient years. The observed rate of non-melanoma skin cancers is&#160;<br/>approximately 9.6 per 1,000 patient years, and the observed rate of lymphomas is approximately 1.3 per&#160;<br/>1,000 patient years.</p>
<p style="position:absolute;top:693px;left:106px;white-space:nowrap" class="ft635">In post-marketing experience from January 2003 to December 2010, predominantly in patients with&#160;<br/>rheumatoid arthritis, the reported rate of malignancies is approximately 2.7 per 1,000 patient treatment&#160;<br/>years. The reported rates for non-melanoma skin cancers and lymphomas are approximately 0.2 and 0.3&#160;<br/>per 1,000 patient treatment years, respectively (see section 4.4).</p>
<p style="position:absolute;top:788px;left:106px;white-space:nowrap" class="ft634">Rare post-marketing cases of hepatosplenic T-cell&#160;lymphoma have been reported in patients treated with&#160;<br/>adalimumab (see section 4.4).</p>
<p style="position:absolute;top:845px;left:106px;white-space:nowrap" class="ft633"><i>Autoantibodies</i></p>
<p style="position:absolute;top:883px;left:106px;white-space:nowrap" class="ft634">Patients had serum samples tested for autoantibodies at multiple time points in rheumatoid arthritis studies&#160;<br/>I&#160;−&#160;V. In these trials, 11.9% of patients treated with Humira and 8.1% of placebo and active&#160;<br/>control&#160;−&#160;treated patients that&#160;had negative baseline anti-nuclear antibody titres reported positive titres at&#160;<br/>Week&#160;24. Two patients out of 3,441 treated with Humira in all rheumatoid arthritis and psoriatic arthritis&#160;<br/>studies developed clinical signs suggestive of new-onset lupus-like syndrome. The patients improved&#160;<br/>following discontinuation of therapy. No patients developed lupus nephritis or central nervous system&#160;<br/>symptoms.</p>
</div>
<!-- Page 64 -->
<a name="64"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page64-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft640">64</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft643"><i>Hepato-biliary events</i></p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft644">In controlled Phase 3 trials of Humira in patients with rheumatoid arthritis and psoriatic&#160;arthritis with a&#160;<br/>control period duration ranging from 4 to 104&#160;weeks, ALT elevations&#160;≥ 3 x ULN occurred in 3.7% of&#160;<br/>Humira-treated patients and 1.6% of control-treated patients.&#160;</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft644">In controlled Phase 3 trials of Humira in patients with polyarticular juvenile idiopathic arthritis who were&#160;<br/>4 to 17&#160;years and enthesitis-related arthritis who were 6 to 17&#160;years, ALT elevations&#160;≥ 3 x ULN occurred&#160;<br/>in 6.1% of Humira-treated patients and 1.3% of control-treated patients. Most ALT elevations occurred&#160;<br/>with concomitant&#160;methotrexate use. No ALT elevations&#160;≥ 3 x ULN occurred in the Phase 3 trial of Humira&#160;<br/>in patients with polyarticular juvenile idiopathic arthritis who were 2 to &lt;4&#160;years.</p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft644">In controlled Phase 3 trials of Humira in patients with&#160;Crohn’s disease and&#160;ulcerative colitis with a control&#160;<br/>period ranging from 4 to 52&#160;weeks. ALT elevations&#160;≥&#160;3&#160;x&#160;ULN occurred in 0.9% of Humira-treated&#160;<br/>patients and 0.9% of controlled-treated patients.</p>
<p style="position:absolute;top:390px;left:106px;white-space:nowrap" class="ft644">In the Phase 3 trial of Humira in patients with paediatric Crohn’s disease&#160;which evaluated efficacy and&#160;<br/>safety of two body weight adjusted maintenance dose regimens following body weight adjusted induction&#160;<br/>therapy up to 52&#160;weeks of treatment, ALT elevations&#160;≥&#160;3&#160;x&#160;ULN occurred in 2.6% (5/192) of patients of&#160;<br/>whom 4 were receiving concomitant immunosuppressants at baseline.</p>
<p style="position:absolute;top:485px;left:106px;white-space:nowrap" class="ft644">In controlled Phase 3 trials of Humira in patients with plaque&#160;psoriasis&#160;with a control period duration&#160;<br/>ranging from 12 to 24&#160;weeks, ALT elevations&#160;≥&#160;3&#160;x&#160;ULN occurred in 1.8% of Humira-treated patients and&#160;<br/>1.8% of control-treated patients.&#160;</p>
<p style="position:absolute;top:560px;left:106px;white-space:nowrap" class="ft644">No&#160;ALT elevations&#160;≥&#160;3&#160;X&#160;ULN occurred&#160;in the Phase 3 trial of Humira in paediatric patients with plaque&#160;<br/>psoriasis.</p>
<p style="position:absolute;top:617px;left:106px;white-space:nowrap" class="ft644">In controlled trials of Humira (initial doses of 160&#160;mg at Week&#160;0 and 80&#160;mg at Week&#160;2, followed by 40&#160;mg&#160;<br/>every&#160;week starting at Week&#160;4), in patients with hidradenitis suppurativa with a control period duration&#160;<br/>ranging from 12 to 16&#160;weeks, ALT elevations&#160;≥&#160;3&#160;x&#160;ULN occurred in 0.3% of Humira-treated patients and&#160;<br/>0.6% of control-treated patients.</p>
<p style="position:absolute;top:712px;left:106px;white-space:nowrap" class="ft644">In controlled trials&#160;of Humira (initial doses of 80&#160;mg at Week 0 followed by 40&#160;mg&#160;every other week&#160;<br/>starting at Week 1) in&#160;adult patients with uveitis up to 80&#160;weeks with a median exposure of 166.5 days and&#160;<br/>105.0 days in Humira-treated and control-treated patients, respectively, ALT elevations&#160;≥&#160;3&#160;x&#160;ULN&#160;<br/>occurred in 2.4% of Humira-treated patients and 2.4% of control-treated patients.&#160;<br/>In the controlled Phase 3 trial of Humira in patients with paediatric ulcerative colitis (N=93) which&#160;<br/>evaluated efficacy and safety of a maintenance dose&#160;of 0.6 mg/kg (maximum of 40 mg) every other week&#160;<br/>(N=31) and a maintenance dose of 0.6 mg/kg (maximum of 40 mg) every Week&#160;(N=32),&#160;following body&#160;<br/>weight adjusted induction dosing&#160;of 2.4 mg/kg (maximum&#160;of 160 mg) at Week 0 and Week 1, and 1.2&#160;<br/>mg/kg&#160;(maximum&#160;of 80 mg) at Week 2&#160;(N=63),&#160;or an induction dose of 2.4 mg/kg (maximum&#160;of 160 mg)&#160;<br/>at Week 0, placebo at Week 1, and 1.2 mg/kg (maximum of 80 mg) at Week 2&#160;(N=30),&#160;ALT elevations&#160;≥&#160;<br/>3 X ULN occurred in 1.1% (1/93) of patients.</p>
<p style="position:absolute;top:940px;left:106px;white-space:nowrap" class="ft644">Across all indications in clinical trials patients with raised ALT were asymptomatic and in most cases&#160;<br/>elevations were transient and resolved on continued treatment. However, there have also been post-<br/>marketing reports of liver failure as well as less severe liver disorders that may precede liver failure, such&#160;<br/>as hepatitis including autoimmune hepatitis in patients receiving adalimumab.</p>
<p style="position:absolute;top:1035px;left:106px;white-space:nowrap" class="ft642">Concurrent treatment with azathioprine/6-mercaptopurine</p>
</div>
<!-- Page 65 -->
<a name="65"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page65-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft650">65</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft654">In adult Crohn’s disease studies, higher incidences of malignant and serious&#160;infection-related adverse&#160;<br/>events were seen with the combination of Humira and azathioprine/6-mercaptopurine compared with&#160;<br/>Humira alone.</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft652">Reporting of suspected adverse reactions</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft655">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows&#160;<br/>continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are&#160;<br/>asked to report any suspected adverse reactions via&#160;<a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">the national reporting system listed in&#160;Appendix V.</a></p>
<p style="position:absolute;top:276px;left:106px;white-space:nowrap" class="ft651"><b>4.9</b></p>
<p style="position:absolute;top:276px;left:148px;white-space:nowrap" class="ft651"><b>Overdose&#160;</b></p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft654">No dose-limiting toxicity was observed during clinical trials. The highest dose level evaluated has been&#160;<br/>multiple intravenous doses of 10&#160;mg/kg, which is approximately 15 times the recommended dose. &#160;</p>
<p style="position:absolute;top:390px;left:106px;white-space:nowrap" class="ft651"><b>5.</b></p>
<p style="position:absolute;top:390px;left:148px;white-space:nowrap" class="ft651"><b>PHARMACOLOGICAL PROPERTIES</b></p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft651"><b>5.1</b></p>
<p style="position:absolute;top:427px;left:148px;white-space:nowrap" class="ft651"><b>Pharmacodynamic properties</b></p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft654">Pharmacotherapeutic group: Immunosuppressants, Tumour Necrosis Factor alpha (TNF-α) inhibitors.&#160;<br/>ATC code: L04AB04</p>
<p style="position:absolute;top:522px;left:106px;white-space:nowrap" class="ft652">Mechanism&#160;of action</p>
<p style="position:absolute;top:560px;left:106px;white-space:nowrap" class="ft654">Adalimumab binds specifically to TNF and neutralises the biological function of TNF by blocking its&#160;<br/>interaction with the p55 and p75 cell surface TNF receptors. &#160;</p>
<p style="position:absolute;top:617px;left:106px;white-space:nowrap" class="ft654">Adalimumab also modulates biological responses that are induced or regulated by TNF, including changes&#160;<br/>in the levels of adhesion molecules responsible for leukocyte migration (ELAM-1, VCAM-1, and ICAM-1&#160;<br/>with an IC50&#160;of&#160;0.1-0.2 nM).&#160;</p>
<p style="position:absolute;top:693px;left:106px;white-space:nowrap" class="ft652">Pharmacodynamic effects&#160;</p>
<p style="position:absolute;top:731px;left:106px;white-space:nowrap" class="ft655">After treatment with Humira, a rapid decrease in levels of acute phase reactants of&#160;inflammation&#160;<br/>(C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)) and serum cytokines (IL-6) was&#160;<br/>observed, compared to baseline in patients with rheumatoid arthritis. Serum levels of matrix&#160;<br/>metalloproteinases (MMP-1 and MMP-3) that produce tissue remodelling responsible for cartilage&#160;<br/>destruction were also decreased after Humira administration. Patients treated with Humira usually&#160;<br/>experienced improvement in haematological signs of chronic inflammation.</p>
<p style="position:absolute;top:864px;left:106px;white-space:nowrap" class="ft655">A rapid decrease in CRP levels was also&#160;observed in patients with polyarticular juvenile idiopathic&#160;<br/>arthritis, Crohn's disease, ulcerative colitis and hidradenitis suppurativa after treatment with Humira. In&#160;<br/>patients with Crohn’s disease, a reduction of the number of cells expressing inflammatory&#160;markers in the&#160;<br/>colon including a significant reduction of expression of TNFα was seen. Endoscopic studies in intestinal&#160;<br/>mucosa have shown evidence of mucosal healing in adalimumab treated patients.</p>
<p style="position:absolute;top:978px;left:106px;white-space:nowrap" class="ft652">Clinical efficacy and safety</p>
<p style="position:absolute;top:1016px;left:106px;white-space:nowrap" class="ft653"><i>Adults with rheumatoid arthritis</i></p>
</div>
<!-- Page 66 -->
<a name="66"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page66-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft660">66</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft664">Humira was evaluated in over 3,000 patients in all rheumatoid arthritis clinical trials. The efficacy and&#160;<br/>safety of Humira were assessed in five randomised, double-blind and well-controlled studies. Some&#160;<br/>patients were treated for up to 120&#160;months&#160;duration.&#160;</p>
<p style="position:absolute;top:163px;left:106px;white-space:nowrap" class="ft662">RA study I evaluated 271 patients with moderately to severely active rheumatoid arthritis who were&#160;</p>
<p style="position:absolute;top:161px;left:769px;white-space:nowrap" class="ft666">&#160;18&#160;</p>
<p style="position:absolute;top:182px;left:106px;white-space:nowrap" class="ft664">years old, had failed therapy with at least one disease-modifying, anti&#160;rheumatic drug and had insufficient&#160;<br/>efficacy with methotrexate at doses of 12.5 to 25&#160;mg (10&#160;mg if methotrexate-intolerant) every week and&#160;<br/>whose methotrexate dose remained constant at 10 to 25&#160;mg&#160;every week. Doses of 20, 40 or 80&#160;mg of&#160;<br/>Humira or placebo were given every other week for 24&#160;weeks.&#160;</p>
<p style="position:absolute;top:278px;left:106px;white-space:nowrap" class="ft662">RA study II evaluated 544&#160;patients with moderately to severely active rheumatoid arthritis who were&#160;</p>
<p style="position:absolute;top:276px;left:774px;white-space:nowrap" class="ft666">&#160;18&#160;</p>
<p style="position:absolute;top:297px;left:106px;white-space:nowrap" class="ft664">years old and had failed therapy with at least one disease-modifying, anti-rheumatic drugs. Doses of 20 or&#160;<br/>40&#160;mg of Humira were given by subcutaneous injection every other week&#160;with placebo on alternative&#160;<br/>weeks or every week for 26&#160;weeks; placebo was given every week for the same duration. No other&#160;<br/>disease-modifying anti-rheumatic drugs were allowed.</p>
<p style="position:absolute;top:393px;left:106px;white-space:nowrap" class="ft662">RA study III evaluated 619 patients with moderately to severely active rheumatoid arthritis who were&#160;</p>
<p style="position:absolute;top:391px;left:780px;white-space:nowrap" class="ft666">&#160;18&#160;</p>
<p style="position:absolute;top:412px;left:106px;white-space:nowrap" class="ft664">years old, and who had an ineffective response to methotrexate at doses of 12.5 to 25&#160;mg or have been&#160;<br/>intolerant to 10&#160;mg of methotrexate every week. There were three groups in this study. The first received&#160;<br/>placebo injections every&#160;week for 52&#160;weeks. The second received 20&#160;mg of Humira every week for&#160;<br/>52&#160;weeks. The third group received 40&#160;mg&#160;of Humira every other week with placebo injections on&#160;<br/>alternate weeks. Upon completion of the first 52&#160;weeks, 457 patients enrolled in an open-label extension&#160;<br/>phase in which 40&#160;mg&#160;of Humira/MTX was administered every other week up to 10&#160;years.</p>
<p style="position:absolute;top:545px;left:106px;white-space:nowrap" class="ft667">RA study IV primarily assessed safety in 636 patients with moderately to severely active rheumatoid&#160;<br/>arthritis who were&#160;</p>
<p style="position:absolute;top:563px;left:230px;white-space:nowrap" class="ft666">&#160;18 years old. Patients were permitted to be either disease-modifying, anti-rheumatic&#160;</p>
<p style="position:absolute;top:584px;left:106px;white-space:nowrap" class="ft664">drug-naïve or to remain on their pre-existing rheumatologic therapy provided that therapy was stable for a&#160;<br/>minimum of 28&#160;days. These therapies include methotrexate, leflunomide, hydroxychloroquine,&#160;<br/>sulfasalazine and/or gold salts. Patients were randomised to 40&#160;mg&#160;of Humira or placebo every other week&#160;<br/>for 24&#160;weeks. &#160;</p>
<p style="position:absolute;top:679px;left:106px;white-space:nowrap" class="ft664">RA study V evaluated 799 methotrexate-naïve, adult patients with moderate to severely active early&#160;<br/>rheumatoid arthritis (mean disease&#160;duration less than 9 months). This study evaluated the efficacy of&#160;<br/>Humira 40&#160;mg&#160;every other week/methotrexate combination therapy, Humira&#160;40&#160;mg&#160;every other week&#160;<br/>monotherapy and methotrexate monotherapy in reducing the signs and symptoms and rate of progression&#160;<br/>of joint damage in rheumatoid arthritis for 104&#160;weeks. Upon completion of the first 104 weeks, 497&#160;<br/>patients enrolled in an open-label extension phase in which 40 mg of Humira was administered every&#160;<br/>other week up to 10 years.</p>
<p style="position:absolute;top:831px;left:106px;white-space:nowrap" class="ft664">The primary end point in&#160;RA studies I, II and III and the secondary endpoint in RA study IV was the&#160;<br/>percent of patients who achieved an ACR 20 response at Week&#160;24 or 26. The primary endpoint in RA&#160;<br/>study V was the percent of patients who achieved an ACR 50 response at Week&#160;52. RA studies III and V&#160;<br/>had an additional primary endpoint at 52&#160;weeks of retardation of disease progression (as detected by X-ray&#160;<br/>results). RA study III also had a primary endpoint of changes in quality of life.&#160;</p>
<p style="position:absolute;top:945px;left:106px;white-space:nowrap" class="ft663"><i>ACR response</i></p>
<p style="position:absolute;top:983px;left:106px;white-space:nowrap" class="ft665">The percent of Humira-treated patients achieving ACR 20, 50 and 70 responses was consistent across RA&#160;<br/>studies I, II and III. The results for the 40&#160;mg&#160;every other week dose are summarised in Table&#160;8.&#160;</p>
</div>
<!-- Page 67 -->
<a name="67"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft6722{font-size:10px;line-height:19px;font-family:HORGHZ+TimesNewRoman;color:#000000;}
-->
</style>
<div id="page67-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft670">67</p>
<p style="position:absolute;top:105px;left:268px;white-space:nowrap" class="ft671"><b>Table&#160;8&#160;ACR Responses in Placebo-Controlled Trials</b></p>
<p style="position:absolute;top:124px;left:383px;white-space:nowrap" class="ft671"><b>(Percent of Patients)</b></p>
<p style="position:absolute;top:163px;left:113px;white-space:nowrap" class="ft672">Response</p>
<p style="position:absolute;top:163px;left:255px;white-space:nowrap" class="ft672">RA&#160;Study Ia**</p>
<p style="position:absolute;top:163px;left:448px;white-space:nowrap" class="ft672">RA Study IIa**</p>
<p style="position:absolute;top:163px;left:643px;white-space:nowrap" class="ft672">RA Study IIIa**</p>
<p style="position:absolute;top:202px;left:217px;white-space:nowrap" class="ft672">Placebo/&#160;</p>
<p style="position:absolute;top:221px;left:224px;white-space:nowrap" class="ft672">MTXc</p>
<p style="position:absolute;top:240px;left:228px;white-space:nowrap" class="ft672">n=60</p>
<p style="position:absolute;top:202px;left:292px;white-space:nowrap" class="ft672">Humirab/ MTXc</p>
<p style="position:absolute;top:221px;left:328px;white-space:nowrap" class="ft672">n=63</p>
<p style="position:absolute;top:202px;left:426px;white-space:nowrap" class="ft672">Placebo</p>
<p style="position:absolute;top:221px;left:431px;white-space:nowrap" class="ft672">n=110</p>
<p style="position:absolute;top:202px;left:519px;white-space:nowrap" class="ft672">Humirab</p>
<p style="position:absolute;top:221px;left:526px;white-space:nowrap" class="ft672">n=113</p>
<p style="position:absolute;top:202px;left:615px;white-space:nowrap" class="ft672">Placebo/&#160;</p>
<p style="position:absolute;top:221px;left:623px;white-space:nowrap" class="ft6722">MTXc<br/>n=200</p>
<p style="position:absolute;top:202px;left:691px;white-space:nowrap" class="ft672">Humirab/ MTXc</p>
<p style="position:absolute;top:221px;left:723px;white-space:nowrap" class="ft672">n=207</p>
<p style="position:absolute;top:260px;left:113px;white-space:nowrap" class="ft672">ACR 20</p>
<p style="position:absolute;top:279px;left:124px;white-space:nowrap" class="ft672">6&#160;months</p>
<p style="position:absolute;top:279px;left:224px;white-space:nowrap" class="ft672">13.3%</p>
<p style="position:absolute;top:279px;left:324px;white-space:nowrap" class="ft672">65.1%</p>
<p style="position:absolute;top:279px;left:431px;white-space:nowrap" class="ft672">19.1%</p>
<p style="position:absolute;top:279px;left:526px;white-space:nowrap" class="ft672">46.0%</p>
<p style="position:absolute;top:279px;left:622px;white-space:nowrap" class="ft672">29.5%</p>
<p style="position:absolute;top:279px;left:724px;white-space:nowrap" class="ft672">63.3%</p>
<p style="position:absolute;top:298px;left:124px;white-space:nowrap" class="ft672">12&#160;months</p>
<p style="position:absolute;top:298px;left:233px;white-space:nowrap" class="ft672">NA</p>
<p style="position:absolute;top:298px;left:333px;white-space:nowrap" class="ft672">NA</p>
<p style="position:absolute;top:298px;left:440px;white-space:nowrap" class="ft672">NA</p>
<p style="position:absolute;top:298px;left:535px;white-space:nowrap" class="ft672">NA</p>
<p style="position:absolute;top:298px;left:622px;white-space:nowrap" class="ft672">24.0%</p>
<p style="position:absolute;top:298px;left:724px;white-space:nowrap" class="ft672">58.9%</p>
<p style="position:absolute;top:317px;left:113px;white-space:nowrap" class="ft672">ACR 50</p>
<p style="position:absolute;top:336px;left:124px;white-space:nowrap" class="ft672">6&#160;months</p>
<p style="position:absolute;top:336px;left:228px;white-space:nowrap" class="ft672">6.7%</p>
<p style="position:absolute;top:336px;left:324px;white-space:nowrap" class="ft672">52.4%</p>
<p style="position:absolute;top:336px;left:436px;white-space:nowrap" class="ft672">8.2%</p>
<p style="position:absolute;top:336px;left:526px;white-space:nowrap" class="ft672">22.1%</p>
<p style="position:absolute;top:336px;left:630px;white-space:nowrap" class="ft672">9.5%</p>
<p style="position:absolute;top:336px;left:724px;white-space:nowrap" class="ft672">39.1%</p>
<p style="position:absolute;top:355px;left:124px;white-space:nowrap" class="ft672">12&#160;months</p>
<p style="position:absolute;top:355px;left:233px;white-space:nowrap" class="ft672">NA</p>
<p style="position:absolute;top:355px;left:333px;white-space:nowrap" class="ft672">NA</p>
<p style="position:absolute;top:355px;left:440px;white-space:nowrap" class="ft672">NA</p>
<p style="position:absolute;top:355px;left:535px;white-space:nowrap" class="ft672">NA</p>
<p style="position:absolute;top:355px;left:630px;white-space:nowrap" class="ft672">9.5%</p>
<p style="position:absolute;top:355px;left:724px;white-space:nowrap" class="ft672">41.5%</p>
<p style="position:absolute;top:374px;left:113px;white-space:nowrap" class="ft672">ACR 70</p>
<p style="position:absolute;top:393px;left:124px;white-space:nowrap" class="ft672">6&#160;months</p>
<p style="position:absolute;top:393px;left:228px;white-space:nowrap" class="ft672">3.3%</p>
<p style="position:absolute;top:393px;left:324px;white-space:nowrap" class="ft672">23.8%</p>
<p style="position:absolute;top:393px;left:436px;white-space:nowrap" class="ft672">1.8%</p>
<p style="position:absolute;top:393px;left:526px;white-space:nowrap" class="ft672">12.4%</p>
<p style="position:absolute;top:393px;left:630px;white-space:nowrap" class="ft672">2.5%</p>
<p style="position:absolute;top:393px;left:724px;white-space:nowrap" class="ft672">20.8%</p>
<p style="position:absolute;top:412px;left:124px;white-space:nowrap" class="ft672">12&#160;months</p>
<p style="position:absolute;top:412px;left:233px;white-space:nowrap" class="ft672">NA</p>
<p style="position:absolute;top:412px;left:333px;white-space:nowrap" class="ft672">NA</p>
<p style="position:absolute;top:412px;left:440px;white-space:nowrap" class="ft672">NA</p>
<p style="position:absolute;top:412px;left:535px;white-space:nowrap" class="ft672">NA</p>
<p style="position:absolute;top:412px;left:630px;white-space:nowrap" class="ft672">4.5%</p>
<p style="position:absolute;top:412px;left:724px;white-space:nowrap" class="ft672">23.2%</p>
<p style="position:absolute;top:431px;left:113px;white-space:nowrap" class="ft679">a&#160;RA &#160;study I at 24&#160;weeks, RA study II at 26&#160;weeks , and RA study III at&#160;24 and 52&#160;weeks</p>
<p style="position:absolute;top:450px;left:113px;white-space:nowrap" class="ft679">b&#160;40&#160;mg Humira administered every other week</p>
<p style="position:absolute;top:468px;left:113px;white-space:nowrap" class="ft677">c&#160;MTX = methotrexate<br/>**p&#160;&lt;&#160;0.01, Humira&#160;<i>versus&#160;</i>placebo</p>
<p style="position:absolute;top:527px;left:106px;white-space:nowrap" class="ft674">In RA studies I-IV, all individual components of the ACR response criteria (number of tender and swollen&#160;<br/>joints, physician and patient assessment of disease activity and pain, disability index (HAQ) scores and&#160;<br/>CRP (mg/dl) values) improved at 24 or 26&#160;weeks compared to placebo. In RA study III, these&#160;<br/>improvements were maintained throughout 52&#160;weeks.&#160;</p>
<p style="position:absolute;top:622px;left:106px;white-space:nowrap" class="ft675">In the open-label extension for RA study&#160;III, most patients who were ACR responders maintained&#160;<br/>response when followed for up to 10&#160;years. Of 207 patients&#160;who were randomised to Humira 40&#160;mg&#160;every&#160;<br/>other week, 114 patients continued on Humira 40&#160;mg&#160;every other week for 5&#160;years. Among those, 86&#160;<br/>patients (75.4%) had ACR 20 responses; 72 patients (63.2%) had ACR 50 responses; and 41 patients&#160;<br/>(36%) had ACR 70 responses. Of 207 patients, 81 patients continued on Humira 40&#160;mg every other week&#160;<br/>for 10&#160;years. Among those, 64 patients (79.0%) had ACR 20 responses; 56 patients (69.1%) had ACR 50&#160;<br/>responses; and 43 patients (53.1%) had ACR 70 responses.</p>
<p style="position:absolute;top:774px;left:106px;white-space:nowrap" class="ft675">In RA study IV, the ACR 20 response of patients treated with Humira plus standard of care was&#160;<br/>statistically significantly better than patients treated with placebo plus standard of care (p&#160;&lt;&#160;0.001). &#160;</p>
<p style="position:absolute;top:831px;left:106px;white-space:nowrap" class="ft675">In RA studies I-IV, Humira-treated patients achieved statistically significant ACR 20 and 50 responses&#160;<br/>compared to placebo as early as one to two weeks after initiation of treatment.</p>
<p style="position:absolute;top:887px;left:106px;white-space:nowrap" class="ft674">In RA study V with early rheumatoid arthritis patients who were methotrexate naïve, combination therapy&#160;<br/>with Humira and methotrexate led to faster and significantly greater ACR responses than methotrexate&#160;<br/>monotherapy and Humira monotherapy at Week&#160;52 and responses were sustained at Week&#160;104&#160;(see Table&#160;<br/>9).</p>
</div>
<!-- Page 68 -->
<a name="68"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page68-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft680">68</p>
<p style="position:absolute;top:105px;left:321px;white-space:nowrap" class="ft681"><b>Table&#160;9&#160;ACR Responses in RA Study V</b></p>
<p style="position:absolute;top:124px;left:388px;white-space:nowrap" class="ft681"><b>(percent of patients)</b></p>
<p style="position:absolute;top:172px;left:113px;white-space:nowrap" class="ft681"><b>Response</b></p>
<p style="position:absolute;top:163px;left:265px;white-space:nowrap" class="ft681"><b>MTX</b></p>
<p style="position:absolute;top:181px;left:262px;white-space:nowrap" class="ft681"><b>n=257</b></p>
<p style="position:absolute;top:163px;left:355px;white-space:nowrap" class="ft681"><b>Humira</b></p>
<p style="position:absolute;top:181px;left:361px;white-space:nowrap" class="ft681"><b>n=274</b></p>
<p style="position:absolute;top:163px;left:442px;white-space:nowrap" class="ft681"><b>Humira/MTX</b></p>
<p style="position:absolute;top:181px;left:470px;white-space:nowrap" class="ft681"><b>n=268</b></p>
<p style="position:absolute;top:172px;left:563px;white-space:nowrap" class="ft681"><b>p-valuea</b></p>
<p style="position:absolute;top:172px;left:648px;white-space:nowrap" class="ft681"><b>p-valueb</b></p>
<p style="position:absolute;top:172px;left:738px;white-space:nowrap" class="ft681"><b>p-valuec</b></p>
<p style="position:absolute;top:201px;left:113px;white-space:nowrap" class="ft682">ACR 20</p>
<p style="position:absolute;top:221px;left:156px;white-space:nowrap" class="ft682">Week&#160;52</p>
<p style="position:absolute;top:221px;left:263px;white-space:nowrap" class="ft682">62.6%</p>
<p style="position:absolute;top:221px;left:362px;white-space:nowrap" class="ft682">54.4%</p>
<p style="position:absolute;top:221px;left:470px;white-space:nowrap" class="ft682">72.8%</p>
<p style="position:absolute;top:221px;left:573px;white-space:nowrap" class="ft682">0.013</p>
<p style="position:absolute;top:221px;left:652px;white-space:nowrap" class="ft682">&lt;&#160;0.001</p>
<p style="position:absolute;top:221px;left:748px;white-space:nowrap" class="ft682">0.043</p>
<p style="position:absolute;top:241px;left:156px;white-space:nowrap" class="ft682">Week&#160;104</p>
<p style="position:absolute;top:241px;left:263px;white-space:nowrap" class="ft682">56.0%</p>
<p style="position:absolute;top:241px;left:362px;white-space:nowrap" class="ft682">49.3%</p>
<p style="position:absolute;top:241px;left:470px;white-space:nowrap" class="ft682">69.4%</p>
<p style="position:absolute;top:241px;left:573px;white-space:nowrap" class="ft682">0.002</p>
<p style="position:absolute;top:241px;left:652px;white-space:nowrap" class="ft682">&lt;&#160;0.001</p>
<p style="position:absolute;top:241px;left:748px;white-space:nowrap" class="ft682">0.140</p>
<p style="position:absolute;top:261px;left:113px;white-space:nowrap" class="ft682">ACR 50</p>
<p style="position:absolute;top:280px;left:156px;white-space:nowrap" class="ft682">Week&#160;52</p>
<p style="position:absolute;top:280px;left:263px;white-space:nowrap" class="ft682">45.9%</p>
<p style="position:absolute;top:280px;left:362px;white-space:nowrap" class="ft682">41.2%</p>
<p style="position:absolute;top:280px;left:470px;white-space:nowrap" class="ft682">61.6%</p>
<p style="position:absolute;top:280px;left:567px;white-space:nowrap" class="ft682">&lt;&#160;0.001</p>
<p style="position:absolute;top:280px;left:652px;white-space:nowrap" class="ft682">&lt;&#160;0.001</p>
<p style="position:absolute;top:280px;left:748px;white-space:nowrap" class="ft682">0.317</p>
<p style="position:absolute;top:300px;left:156px;white-space:nowrap" class="ft682">Week&#160;104</p>
<p style="position:absolute;top:300px;left:263px;white-space:nowrap" class="ft682">42.8%</p>
<p style="position:absolute;top:300px;left:362px;white-space:nowrap" class="ft682">36.9%</p>
<p style="position:absolute;top:300px;left:470px;white-space:nowrap" class="ft682">59.0%</p>
<p style="position:absolute;top:300px;left:567px;white-space:nowrap" class="ft682">&lt;&#160;0.001</p>
<p style="position:absolute;top:300px;left:652px;white-space:nowrap" class="ft682">&lt;&#160;0.001</p>
<p style="position:absolute;top:300px;left:748px;white-space:nowrap" class="ft682">0.162</p>
<p style="position:absolute;top:320px;left:113px;white-space:nowrap" class="ft682">ACR 70</p>
<p style="position:absolute;top:339px;left:156px;white-space:nowrap" class="ft682">Week&#160;52</p>
<p style="position:absolute;top:339px;left:263px;white-space:nowrap" class="ft682">27.2%</p>
<p style="position:absolute;top:339px;left:362px;white-space:nowrap" class="ft682">25.9%</p>
<p style="position:absolute;top:339px;left:470px;white-space:nowrap" class="ft682">45.5%</p>
<p style="position:absolute;top:339px;left:567px;white-space:nowrap" class="ft682">&lt;&#160;0.001</p>
<p style="position:absolute;top:339px;left:652px;white-space:nowrap" class="ft682">&lt;&#160;0.001</p>
<p style="position:absolute;top:339px;left:748px;white-space:nowrap" class="ft682">0.656</p>
<p style="position:absolute;top:359px;left:156px;white-space:nowrap" class="ft682">Week&#160;104</p>
<p style="position:absolute;top:359px;left:263px;white-space:nowrap" class="ft682">28.4%</p>
<p style="position:absolute;top:359px;left:362px;white-space:nowrap" class="ft682">28.1%</p>
<p style="position:absolute;top:359px;left:470px;white-space:nowrap" class="ft682">46.6%</p>
<p style="position:absolute;top:359px;left:567px;white-space:nowrap" class="ft682">&lt;&#160;0.001</p>
<p style="position:absolute;top:359px;left:652px;white-space:nowrap" class="ft682">&lt;&#160;0.001</p>
<p style="position:absolute;top:359px;left:748px;white-space:nowrap" class="ft682">0.864</p>
<p style="position:absolute;top:377px;left:114px;white-space:nowrap" class="ft689">a&#160;p-value&#160;is from the pairwise comparison of methotrexate monotherapy and Humira/methotrexate&#160;</p>
<p style="position:absolute;top:398px;left:141px;white-space:nowrap" class="ft682">combination therapy using the Mann-Whitney U test.</p>
<p style="position:absolute;top:415px;left:114px;white-space:nowrap" class="ft689">b&#160;p-value is from the pairwise comparison of Humira monotherapy and Humira/methotrexate&#160;</p>
<p style="position:absolute;top:436px;left:139px;white-space:nowrap" class="ft682">combination therapy using the Mann-Whitney U test</p>
<p style="position:absolute;top:453px;left:114px;white-space:nowrap" class="ft689">c&#160;p-value is from the pairwise comparison of Humira monotherapy and methotrexate monotherapy using&#160;</p>
<p style="position:absolute;top:474px;left:139px;white-space:nowrap" class="ft682">the Mann-Whitney U test</p>
<p style="position:absolute;top:512px;left:106px;white-space:nowrap" class="ft684">In the open-label extension for RA study V, ACR response rates were maintained when followed for up to&#160;<br/>10 years.&#160;Of 542 patients who were randomised to Humira 40 mg every other week, 170 patients&#160;<br/>continued on Humira 40 mg every other week for 10 years. Among those, 154 patients (90.6%) had ACR&#160;<br/>20 responses; 127 patients (74.7%) had ACR 50 responses; and 102 patients&#160;(60.0%) had ACR 70&#160;<br/>responses.</p>
<p style="position:absolute;top:626px;left:106px;white-space:nowrap" class="ft684">At Week&#160;52, 42.9% of patients who received Humira/methotrexate combination therapy achieved clinical&#160;<br/>remission (DAS28 (CRP)&#160;&lt;&#160;2.6) compared to 20.6% of patients receiving methotrexate monotherapy and&#160;<br/>23.4% of patients receiving Humira monotherapy. Humira/methotrexate combination therapy was&#160;<br/>clinically and statistically superior to methotrexate (p&#160;&lt;&#160;0.001) and Humira monotherapy (p&#160;&lt;&#160;0.001) in&#160;<br/>achieving a low disease state in patients with recently diagnosed moderate to severe&#160;rheumatoid arthritis.<br/>The response for the two monotherapy arms was similar (p&#160;=&#160;0.447). Of 342 subjects originally&#160;<br/>randomized to Humira monotherapy or Humira/methotrexate combination therapy who entered the open-<br/>label extension study, 171 subjects completed 10 years of Humira treatment. Among those, 109 subjects&#160;<br/>(63.7%) were reported to be in remission at 10 years.</p>
<p style="position:absolute;top:816px;left:106px;white-space:nowrap" class="ft683"><i>Radiographic response</i></p>
<p style="position:absolute;top:854px;left:106px;white-space:nowrap" class="ft684">In RA study III, where Humira treated patients had a mean duration of rheumatoid arthritis of&#160;<br/>approximately 11 years, structural joint damage was assessed radiographically and expressed as change in&#160;<br/>modified Total Sharp Score (TSS) and its components, the erosion score and joint space narrowing score.&#160;<br/>Humira/methotrexate patients demonstrated significantly less radiographic progression than patients&#160;<br/>receiving methotrexate alone at 6 and 12&#160;months (see Table&#160;10).&#160;</p>
<p style="position:absolute;top:968px;left:106px;white-space:nowrap" class="ft685">In the open-label extension of RA Study III, the reduction in rate of progression of structural damage is&#160;<br/>maintained for 8 and 10 years in a subset of patients. At 8&#160;years, 81 of 207 patients originally treated with&#160;<br/>40&#160;mg Humira every other week were evaluated radiographically. Among those, 48 patients showed no&#160;<br/>progression of structural damage defined by a change from baseline in the mTSS of 0.5 or less. At&#160;<br/>10&#160;years, 79 of 207 patients originally treated with 40&#160;mg Humira every other week were evaluated&#160;<br/>radiographically. Among those, 40 patients showed no progression of structural damage defined by a&#160;<br/>change from baseline in the mTSS of 0.5 or less.</p>
</div>
<!-- Page 69 -->
<a name="69"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page69-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft690">69</p>
<p style="position:absolute;top:105px;left:186px;white-space:nowrap" class="ft691"><b>Table&#160;10&#160;Radiographic Mean Changes Over 12&#160;Months in RA Study III</b></p>
<p style="position:absolute;top:144px;left:270px;white-space:nowrap" class="ft694">Placebo/<br/>MTXa</p>
<p style="position:absolute;top:144px;left:391px;white-space:nowrap" class="ft692">Humira/MTX</p>
<p style="position:absolute;top:163px;left:396px;white-space:nowrap" class="ft692">40&#160;mg&#160;every&#160;</p>
<p style="position:absolute;top:181px;left:400px;white-space:nowrap" class="ft692">other week</p>
<p style="position:absolute;top:144px;left:529px;white-space:nowrap" class="ft692">Placebo/MTX-</p>
<p style="position:absolute;top:163px;left:513px;white-space:nowrap" class="ft692">Humira/MTX (95%&#160;</p>
<p style="position:absolute;top:181px;left:541px;white-space:nowrap" class="ft692">Confidence&#160;</p>
<p style="position:absolute;top:201px;left:548px;white-space:nowrap" class="ft692">Intervalb)</p>
<p style="position:absolute;top:144px;left:687px;white-space:nowrap" class="ft692">p-value</p>
<p style="position:absolute;top:220px;left:124px;white-space:nowrap" class="ft692">Total Sharp Score</p>
<p style="position:absolute;top:220px;left:306px;white-space:nowrap" class="ft692">2.7</p>
<p style="position:absolute;top:220px;left:426px;white-space:nowrap" class="ft692">0.1</p>
<p style="position:absolute;top:220px;left:536px;white-space:nowrap" class="ft692">2.6 (1.4, 3.8)&#160;</p>
<p style="position:absolute;top:220px;left:684px;white-space:nowrap" class="ft692">&lt;&#160;0.001c</p>
<p style="position:absolute;top:240px;left:139px;white-space:nowrap" class="ft692">Erosion score</p>
<p style="position:absolute;top:240px;left:306px;white-space:nowrap" class="ft692">1.6</p>
<p style="position:absolute;top:240px;left:426px;white-space:nowrap" class="ft692">0.0</p>
<p style="position:absolute;top:240px;left:536px;white-space:nowrap" class="ft692">1.6 (0.9, 2.2)</p>
<p style="position:absolute;top:240px;left:687px;white-space:nowrap" class="ft692">&lt;&#160;0.001</p>
<p style="position:absolute;top:260px;left:148px;white-space:nowrap" class="ft692">JSNd&#160;score</p>
<p style="position:absolute;top:260px;left:306px;white-space:nowrap" class="ft692">1.0</p>
<p style="position:absolute;top:260px;left:426px;white-space:nowrap" class="ft692">0.1</p>
<p style="position:absolute;top:260px;left:536px;white-space:nowrap" class="ft692">0.9 (0.3, 1.4)</p>
<p style="position:absolute;top:260px;left:689px;white-space:nowrap" class="ft692">&#160;&#160;0.002</p>
<p style="position:absolute;top:277px;left:106px;white-space:nowrap" class="ft6913"><b>a</b>methotrexate</p>
<p style="position:absolute;top:297px;left:106px;white-space:nowrap" class="ft699">b95% confidence intervals for the differences in change scores between methotrexate and Humira.&#160;</p>
<p style="position:absolute;top:316px;left:106px;white-space:nowrap" class="ft699">cBased on rank analysis&#160;</p>
<p style="position:absolute;top:335px;left:106px;white-space:nowrap" class="ft699">dJoint Space Narrowing</p>
<p style="position:absolute;top:374px;left:106px;white-space:nowrap" class="ft695">In RA study V, structural joint damage was assessed radiographically and expressed as change in modified&#160;<br/>Total Sharp Score (see Table&#160;11).</p>
<p style="position:absolute;top:431px;left:217px;white-space:nowrap" class="ft691"><b>Table&#160;11&#160;Radiographic Mean Changes at Week&#160;52 in RA Study V</b></p>
<p style="position:absolute;top:470px;left:261px;white-space:nowrap" class="ft692">MTX</p>
<p style="position:absolute;top:489px;left:258px;white-space:nowrap" class="ft692">n=257</p>
<p style="position:absolute;top:508px;left:261px;white-space:nowrap" class="ft692">(95%&#160;</p>
<p style="position:absolute;top:527px;left:243px;white-space:nowrap" class="ft692">confidence&#160;</p>
<p style="position:absolute;top:546px;left:251px;white-space:nowrap" class="ft692">interval)</p>
<p style="position:absolute;top:470px;left:367px;white-space:nowrap" class="ft692">Humira</p>
<p style="position:absolute;top:489px;left:371px;white-space:nowrap" class="ft692">n=274</p>
<p style="position:absolute;top:508px;left:374px;white-space:nowrap" class="ft692">(95%</p>
<p style="position:absolute;top:527px;left:356px;white-space:nowrap" class="ft692">confidence&#160;</p>
<p style="position:absolute;top:546px;left:364px;white-space:nowrap" class="ft692">interval)</p>
<p style="position:absolute;top:470px;left:458px;white-space:nowrap" class="ft692">Humira/MTX</p>
<p style="position:absolute;top:489px;left:482px;white-space:nowrap" class="ft692">n=268</p>
<p style="position:absolute;top:508px;left:486px;white-space:nowrap" class="ft692">(95%&#160;</p>
<p style="position:absolute;top:527px;left:467px;white-space:nowrap" class="ft692">confidence&#160;</p>
<p style="position:absolute;top:546px;left:476px;white-space:nowrap" class="ft692">interval)</p>
<p style="position:absolute;top:508px;left:569px;white-space:nowrap" class="ft692">p-valuea</p>
<p style="position:absolute;top:508px;left:643px;white-space:nowrap" class="ft692">p-valueb</p>
<p style="position:absolute;top:508px;left:718px;white-space:nowrap" class="ft692">p-valuec</p>
<p style="position:absolute;top:566px;left:129px;white-space:nowrap" class="ft692">Total Sharp&#160;</p>
<p style="position:absolute;top:585px;left:149px;white-space:nowrap" class="ft692">Score</p>
<p style="position:absolute;top:566px;left:238px;white-space:nowrap" class="ft692">5.7 (4.2-7.3)</p>
<p style="position:absolute;top:566px;left:351px;white-space:nowrap" class="ft692">3.0 (1.7-4.3)</p>
<p style="position:absolute;top:566px;left:462px;white-space:nowrap" class="ft692">1.3 (0.5-2.1)</p>
<p style="position:absolute;top:566px;left:571px;white-space:nowrap" class="ft692">&lt;&#160;0.001</p>
<p style="position:absolute;top:566px;left:648px;white-space:nowrap" class="ft692">0.0020</p>
<p style="position:absolute;top:566px;left:720px;white-space:nowrap" class="ft692">&lt;&#160;0.001</p>
<p style="position:absolute;top:604px;left:122px;white-space:nowrap" class="ft692">Erosion score</p>
<p style="position:absolute;top:604px;left:238px;white-space:nowrap" class="ft692">3.7 (2.7-4.7)</p>
<p style="position:absolute;top:604px;left:351px;white-space:nowrap" class="ft692">1.7 (1.0-2.4)</p>
<p style="position:absolute;top:604px;left:462px;white-space:nowrap" class="ft692">0.8 (0.4-1.2)</p>
<p style="position:absolute;top:604px;left:571px;white-space:nowrap" class="ft692">&lt;&#160;0.001</p>
<p style="position:absolute;top:604px;left:648px;white-space:nowrap" class="ft692">0.0082</p>
<p style="position:absolute;top:604px;left:720px;white-space:nowrap" class="ft692">&lt;&#160;0.001</p>
<p style="position:absolute;top:624px;left:134px;white-space:nowrap" class="ft692">JSN score</p>
<p style="position:absolute;top:624px;left:238px;white-space:nowrap" class="ft692">2.0 (1.2-2.8)</p>
<p style="position:absolute;top:624px;left:351px;white-space:nowrap" class="ft692">1.3 (0.5-2.1)</p>
<p style="position:absolute;top:624px;left:468px;white-space:nowrap" class="ft692">0.5 (0-1.0)</p>
<p style="position:absolute;top:624px;left:571px;white-space:nowrap" class="ft692">&lt;&#160;0.001</p>
<p style="position:absolute;top:624px;left:648px;white-space:nowrap" class="ft692">0.0037</p>
<p style="position:absolute;top:624px;left:726px;white-space:nowrap" class="ft692">0.151</p>
<p style="position:absolute;top:642px;left:122px;white-space:nowrap" class="ft699">a&#160;p-value is from the pairwise comparison of methotrexate monotherapy and Humira/methotrexate&#160;</p>
<p style="position:absolute;top:663px;left:147px;white-space:nowrap" class="ft692">combination therapy using the Mann-Whitney U test.</p>
<p style="position:absolute;top:680px;left:122px;white-space:nowrap" class="ft699">b&#160;p-value is from the pairwise comparison of Humira monotherapy and Humira/methotrexate&#160;</p>
<p style="position:absolute;top:701px;left:149px;white-space:nowrap" class="ft692">combination therapy using the Mann-Whitney U test&#160;</p>
<p style="position:absolute;top:718px;left:122px;white-space:nowrap" class="ft699">c&#160;p-value is from the pairwise comparison of Humira monotherapy and methotrexate monotherapy&#160;</p>
<p style="position:absolute;top:739px;left:149px;white-space:nowrap" class="ft692">using the Mann-Whitney U test</p>
<p style="position:absolute;top:777px;left:106px;white-space:nowrap" class="ft697">Following 52&#160;weeks and 104&#160;weeks of treatment, the percentage of patients without progression (change&#160;<br/>from baseline in modified Total Sharp Score&#160;</p>
<p style="position:absolute;top:796px;left:404px;white-space:nowrap" class="ft696">&#160;0.5) was significantly higher with Humira/methotrexate&#160;</p>
<p style="position:absolute;top:816px;left:106px;white-space:nowrap" class="ft695">combination therapy (63.8% and 61.2% respectively) compared to methotrexate monotherapy (37.4% and&#160;<br/>33.5% respectively, p&#160;&lt;&#160;0.001) and Humira monotherapy (50.7%, p&#160;&lt;&#160;0.002 and 44.5%, p&#160;&lt;&#160;0.001&#160;<br/>respectively).</p>
<p style="position:absolute;top:892px;left:106px;white-space:nowrap" class="ft694">In the open-label extension of RA study V, the mean change from baseline at Year 10 in the modified&#160;<br/>Total Sharp Score was 10.8, 9.2 and 3.9 in patients originally randomized to methotrexate monotherapy,&#160;<br/>Humira monotherapy and Humira/methotrexate combination therapy, respectively.&#160;The corresponding&#160;<br/>proportions of patients with no radiographic progression were 31.3%, 23.7% and 36.7% respectively.</p>
<p style="position:absolute;top:987px;left:106px;white-space:nowrap" class="ft693"><i>Quality of life and physical function</i></p>
<p style="position:absolute;top:1025px;left:106px;white-space:nowrap" class="ft694">Health-related quality of life and physical function were assessed using the disability index of the Health&#160;<br/>Assessment Questionnaire (HAQ) in the four original adequate and well-controlled trials, which was a&#160;<br/>pre-specified primary endpoint at Week&#160;52 in RA&#160;study III. All doses/schedules of Humira in all four&#160;<br/>studies showed statistically significantly greater improvement in the disability index of the HAQ from&#160;</p>
</div>
<!-- Page 70 -->
<a name="70"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page70-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft700">70</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft705">baseline to Month&#160;6 compared to placebo and in RA study III the same was seen at Week&#160;52. Results from&#160;<br/>the Short Form Health Survey (SF 36) for all doses/schedules of Humira in all four studies support these&#160;<br/>findings, with statistically significant physical component summary (PCS) scores, as well as statistically&#160;<br/>significant pain and vitality domain scores for the 40&#160;mg&#160;every other week dose. A statistically significant&#160;<br/>decrease in fatigue as measured by functional assessment of chronic illness therapy (FACIT) scores was&#160;<br/>seen in all three studies in which it was assessed (RA studies I, III, IV).</p>
<p style="position:absolute;top:219px;left:106px;white-space:nowrap" class="ft704">In RA study III, most subjects who achieved improvement in physical function and continued treatment&#160;<br/>maintained improvement through Week&#160;520 (120&#160;months) of open-label treatment. Improvement in&#160;<br/>quality of life was measured up to Week&#160;156 (36&#160;months) and improvement was maintained through that&#160;<br/>time.</p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft704">In RA study V, the improvement in the HAQ disability index and the physical component of the SF 36&#160;<br/>showed greater improvement (p&#160;&lt;&#160;0.001) for Humira/methotrexate combination therapy&#160;<i>versus<br/></i>methotrexate monotherapy and&#160;Humira monotherapy at Week&#160;52, which was maintained through&#160;<br/>Week&#160;104.&#160;Among the 250 subjects who completed the open-label extension study, improvements in&#160;<br/>physical function were maintained through 10 years of treatment.</p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft703"><i>Adult plaque psoriasis</i></p>
<p style="position:absolute;top:467px;left:106px;white-space:nowrap" class="ft702">The safety&#160;and efficacy of Humira were studied in adult patients with chronic plaque psoriasis (</p>
<p style="position:absolute;top:465px;left:737px;white-space:nowrap" class="ft706">&#160;10%&#160;</p>
<p style="position:absolute;top:487px;left:106px;white-space:nowrap" class="ft702">BSA involvement and PASI&#160;</p>
<p style="position:absolute;top:485px;left:296px;white-space:nowrap" class="ft706">&#160;12 or&#160;&#160;10) who were candidates for systemic therapy or phototherapy in&#160;</p>
<p style="position:absolute;top:506px;left:106px;white-space:nowrap" class="ft705">randomised, double-blind studies. 73% of patients enrolled in Psoriasis Studies I and II had received prior&#160;<br/>systemic therapy or phototherapy. The safety and efficacy of Humira were also studied in adult patients&#160;<br/>with moderate to severe&#160;chronic plaque psoriasis with concomitant hand and/or foot psoriasis who were&#160;<br/>candidates for systemic therapy in a randomised double-blind study (Psoriasis Study III). &#160;</p>
<p style="position:absolute;top:599px;left:106px;white-space:nowrap" class="ft707">Psoriasis Study I (REVEAL) evaluated 1,212 patients within three treatment periods. In period A, patients&#160;<br/>received placebo or Humira at an initial dose of 80&#160;mg&#160;followed by 40&#160;mg&#160;every other week starting one&#160;<br/>week after the initial dose. After 16weeks of therapy, patients who achieved at least a PASI 75 response&#160;<br/>(PASI score improvement of at least 75% relative to baseline), entered period B and received open-label&#160;<br/>40&#160;mg Humira every other week. Patients who maintained&#160;</p>
<p style="position:absolute;top:674px;left:494px;white-space:nowrap" class="ft706">PASI 75 response at Week&#160;33 and were&#160;</p>
<p style="position:absolute;top:695px;left:106px;white-space:nowrap" class="ft704">originally randomised to active therapy in Period A, were re-randomised in period C to receive 40&#160;mg&#160;<br/>Humira every other week or placebo for an additional 19&#160;weeks. Across all treatment groups, the mean&#160;<br/>baseline PASI score was 18.9 and the baseline PGA score ranged from “moderate” (53% of subjects&#160;<br/>included) to “severe” (41%) to “very severe” (6%).</p>
<p style="position:absolute;top:790px;left:106px;white-space:nowrap" class="ft704">Psoriasis Study II (CHAMPION) compared the efficacy and safety of Humira&#160;<i>versus&#160;</i>methotrexate and&#160;<br/>placebo in 271 patients.&#160;Patients received placebo, an initial dose of MTX 7.5&#160;mg and thereafter dose&#160;<br/>increases up to Week&#160;12, with a maximum dose of 25&#160;mg&#160;or an initial dose of 80&#160;mg Humira followed by&#160;<br/>40&#160;mg&#160;every other week (starting one&#160;week after the initial dose) for 16&#160;weeks. There are no data available&#160;<br/>comparing Humira and MTX beyond 16&#160;weeks of therapy. Patients receiving MTX who achieved a&#160;</p>
<p style="position:absolute;top:884px;left:106px;white-space:nowrap" class="ft704">PASI 50 response at Week&#160;8 and/or 12 did not receive further dose increases. Across all treatment&#160;<br/>groups, the mean baseline&#160;PASI&#160;score was 19.7 and the baseline PGA score ranged from “mild” (&lt;1%) to&#160;<br/>“moderate” (48%) to “severe” (46%) to “very severe” (6%).</p>
<p style="position:absolute;top:962px;left:106px;white-space:nowrap" class="ft704">Patients participating in all Phase 2 and Phase 3 psoriasis studies were eligible to enrol&#160;into an open-label&#160;<br/>extension trial, where Humira was given for at least an additional 108&#160;weeks.</p>
<p style="position:absolute;top:1019px;left:106px;white-space:nowrap" class="ft704">In Psoriasis Studies I and II, a primary endpoint was the proportion of patients who achieved a PASI 75&#160;<br/>response from baseline at Week&#160;16&#160;(see Tables&#160;12&#160;and&#160;13).</p>
</div>
<!-- Page 71 -->
<a name="71"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page71-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft710">71</p>
<p style="position:absolute;top:105px;left:429px;white-space:nowrap" class="ft711"><b>Table&#160;12</b></p>
<p style="position:absolute;top:124px;left:271px;white-space:nowrap" class="ft711"><b>Ps Study I (REVEAL) &#160;-&#160;Efficacy Results at 16&#160;Weeks</b></p>
<p style="position:absolute;top:144px;left:455px;white-space:nowrap" class="ft711"><b>Placebo</b></p>
<p style="position:absolute;top:163px;left:459px;white-space:nowrap" class="ft711"><b>N=398</b></p>
<p style="position:absolute;top:181px;left:462px;white-space:nowrap" class="ft711"><b>n&#160;(%)</b></p>
<p style="position:absolute;top:144px;left:564px;white-space:nowrap" class="ft711"><b>Humira 40&#160;mg&#160;eow</b></p>
<p style="position:absolute;top:163px;left:608px;white-space:nowrap" class="ft711"><b>N=814</b></p>
<p style="position:absolute;top:181px;left:611px;white-space:nowrap" class="ft711"><b>n&#160;(%)</b></p>
<p style="position:absolute;top:202px;left:207px;white-space:nowrap" class="ft711"><b>&#160; &#160;&#160;</b></p>
<p style="position:absolute;top:200px;left:223px;white-space:nowrap" class="ft716"><b>PASI 75a</b></p>
<p style="position:absolute;top:201px;left:456px;white-space:nowrap" class="ft712">26 (6.5)</p>
<p style="position:absolute;top:201px;left:594px;white-space:nowrap" class="ft712">578 (70.9)b</p>
<p style="position:absolute;top:222px;left:207px;white-space:nowrap" class="ft711"><b>&#160; &#160;&#160;PASI 100</b></p>
<p style="position:absolute;top:222px;left:460px;white-space:nowrap" class="ft712">3 (0.8)</p>
<p style="position:absolute;top:222px;left:594px;white-space:nowrap" class="ft712">163 (20.0)b</p>
<p style="position:absolute;top:242px;left:207px;white-space:nowrap" class="ft711"><b>&#160; &#160;&#160;PGA: Clear/minimal</b></p>
<p style="position:absolute;top:242px;left:456px;white-space:nowrap" class="ft712">17 (4.3)</p>
<p style="position:absolute;top:242px;left:594px;white-space:nowrap" class="ft712">506 (62.2)b</p>
<p style="position:absolute;top:260px;left:207px;white-space:nowrap" class="ft717">a&#160;Percent of patients achieving PASI75 response was calculated as centre-<br/>adjusted rate</p>
<p style="position:absolute;top:298px;left:207px;white-space:nowrap" class="ft719">b&#160;p&lt;0.001, Humira vs. placebo</p>
<p style="position:absolute;top:333px;left:429px;white-space:nowrap" class="ft711"><b>Table&#160;13</b></p>
<p style="position:absolute;top:352px;left:264px;white-space:nowrap" class="ft711"><b>Ps Study II (CHAMPION) Efficacy Results at 16&#160;Weeks</b></p>
<p style="position:absolute;top:391px;left:353px;white-space:nowrap" class="ft711"><b>Placebo</b></p>
<p style="position:absolute;top:410px;left:361px;white-space:nowrap" class="ft711"><b>N=53</b></p>
<p style="position:absolute;top:429px;left:360px;white-space:nowrap" class="ft711"><b>n&#160;(%)</b></p>
<p style="position:absolute;top:391px;left:474px;white-space:nowrap" class="ft711"><b>MTX</b></p>
<p style="position:absolute;top:410px;left:470px;white-space:nowrap" class="ft711"><b>N=110</b></p>
<p style="position:absolute;top:429px;left:473px;white-space:nowrap" class="ft711"><b>n&#160;(%)</b></p>
<p style="position:absolute;top:391px;left:566px;white-space:nowrap" class="ft711"><b>Humira 40&#160;mg&#160;eow</b></p>
<p style="position:absolute;top:410px;left:610px;white-space:nowrap" class="ft711"><b>N=108</b></p>
<p style="position:absolute;top:429px;left:613px;white-space:nowrap" class="ft711"><b>n&#160;(%)</b></p>
<p style="position:absolute;top:450px;left:203px;white-space:nowrap" class="ft711"><b>&#160; &#160;&#160;</b></p>
<p style="position:absolute;top:448px;left:220px;white-space:nowrap" class="ft716"><b>PASI 75</b></p>
<p style="position:absolute;top:449px;left:350px;white-space:nowrap" class="ft712">10 (18.9)</p>
<p style="position:absolute;top:449px;left:463px;white-space:nowrap" class="ft712">39 (35.5)</p>
<p style="position:absolute;top:449px;left:594px;white-space:nowrap" class="ft712">86 (79.6)&#160;a, b</p>
<p style="position:absolute;top:469px;left:203px;white-space:nowrap" class="ft711"><b>&#160; &#160;&#160;PASI 100</b></p>
<p style="position:absolute;top:469px;left:358px;white-space:nowrap" class="ft712">1 (1.9)</p>
<p style="position:absolute;top:469px;left:471px;white-space:nowrap" class="ft712">8 (7.3)</p>
<p style="position:absolute;top:469px;left:594px;white-space:nowrap" class="ft712">18 (16.7)&#160;c, d</p>
<p style="position:absolute;top:489px;left:203px;white-space:nowrap" class="ft7119"><b>&#160; &#160;&#160;PGA:&#160;<br/>Clear/minimal</b></p>
<p style="position:absolute;top:489px;left:354px;white-space:nowrap" class="ft712">6 (11.3)</p>
<p style="position:absolute;top:489px;left:463px;white-space:nowrap" class="ft712">33 (30.0)</p>
<p style="position:absolute;top:489px;left:594px;white-space:nowrap" class="ft712">79 (73.1)&#160;a, b</p>
<p style="position:absolute;top:526px;left:203px;white-space:nowrap" class="ft719">a&#160;p&lt;0.001 Humira vs. placebo</p>
<p style="position:absolute;top:545px;left:203px;white-space:nowrap" class="ft719">b&#160;p&lt;0.001 Humira vs. methotrexate</p>
<p style="position:absolute;top:565px;left:203px;white-space:nowrap" class="ft719">c&#160;p&lt;0.01 Humira vs. placebo</p>
<p style="position:absolute;top:584px;left:203px;white-space:nowrap" class="ft719">d&#160;p&lt;0.05 Humira vs. methotrexate</p>
<p style="position:absolute;top:624px;left:106px;white-space:nowrap" class="ft715">In&#160;Psoriasis&#160;Study I, 28% of patients who were PASI 75 responders and were re-randomised to placebo at&#160;<br/>Week&#160;33 compared to 5% continuing on Humira, p&lt;0.001, experienced “loss of adequate response”&#160;(PASI&#160;<br/>score after Week&#160;33&#160;and on or before Week&#160;52 that resulted in a &lt;PASI 50 response relative to baseline&#160;<br/>with a minimum of a 6-point increase in PASI score relative to Week&#160;33). Of the patients who lost&#160;<br/>adequate response after re-randomisation to placebo who then enrolled into&#160;the open-label extension trial,&#160;<br/>38% (25/66) and 55% (36/66) regained PASI 75 response after 12 and 24&#160;weeks of re-treatment,&#160;<br/>respectively.</p>
<p style="position:absolute;top:775px;left:106px;white-space:nowrap" class="ft714">A total of 233 PASI 75 responders at Week&#160;16 and Week&#160;33 received continuous Humira therapy for&#160;<br/>52&#160;weeks in Psoriasis Study I, and continued Humira in the open-label extension trial. PASI 75 and PGA&#160;<br/>of clear or minimal response rates in these patients were 74.7% and 59.0%, respectively, after an&#160;<br/>additional 108&#160;weeks of open-label therapy (total of 160&#160;weeks). In an analysis in which all patients who&#160;<br/>dropped out of the study for adverse events or lack of efficacy, or who dose-escalated, were considered&#160;<br/>non-responders, PASI 75 and PGA of clear or minimal response rates in these patients were 69.6% and&#160;<br/>55.7%, respectively,&#160;after an additional 108&#160;weeks of open-label therapy (total of 160&#160;weeks).</p>
<p style="position:absolute;top:927px;left:106px;white-space:nowrap" class="ft714">A total of 347 stable responders participated in a withdrawal and retreatment evaluation in an open-label&#160;<br/>extension study. During the withdrawal period, symptoms of psoriasis returned over time with a median&#160;<br/>time to relapse (decline to PGA “moderate” or worse) of approximately 5&#160;months. None of these patients&#160;<br/>experienced rebound during the withdrawal period. A total of 76.5% (218/285) of patients who entered the&#160;<br/>retreatment period had a response of PGA “clear” or “minimal” after 16&#160;weeks of retreatment, irrespective&#160;<br/>of&#160;whether they relapsed during withdrawal (69.1%[123/178] and 88.8% [95/107] for patients who&#160;<br/>relapsed and who did not relapse during the withdrawal period, respectively). A similar safety profile was&#160;<br/>observed during retreatment as before withdrawal.</p>
</div>
<!-- Page 72 -->
<a name="72"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page72-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft720">72</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft724">Significant improvements at Week&#160;16 from baseline compared to placebo (Studies I and II) and MTX&#160;<br/>(Study II) were demonstrated in the DLQI (Dermatology Life Quality Index). In Study I, improvements in&#160;<br/>the physical and mental component summary scores of the SF-36 were also significant compared to&#160;<br/>placebo.</p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft724">In an open-label extension study, for patients who dose escalated from 40&#160;mg&#160;every other week to 40&#160;mg&#160;<br/>weekly due to a PASI&#160;response below 50%, 26.4% (92/349) and 37.8% (132/349) of patients achieved&#160;<br/>PASI 75 response at Week&#160;12 and 24, respectively.</p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft724">Psoriasis Study III (REACH)&#160;compared the efficacy and safety of Humira&#160;<i>versus&#160;</i>placebo in 72 patients&#160;<br/>with moderate to severe chronic plaque psoriasis and hand and/or foot psoriasis. Patients received an&#160;<br/>initial&#160;dose of 80&#160;mg Humira followed by 40&#160;mg every other week (starting one week after the initial dose)&#160;<br/>or placebo for 16&#160;weeks. At Week&#160;16, a statistically significantly greater&#160;proportion of patients who&#160;<br/>received Humira achieved PGA of 'clear' or 'almost clear' for the hands and/or feet compared to patients&#160;<br/>who received placebo (30.6% versus 4.3%, respectively [P = 0.014]).</p>
<p style="position:absolute;top:390px;left:106px;white-space:nowrap" class="ft724">Psoriasis Study IV compared efficacy and safety of Humira versus placebo in 217 adult patients with&#160;<br/>moderate to severe nail psoriasis. Patients received an initial dose of 80 mg Humira followed by 40&#160;mg&#160;<br/>every other week (starting one week after the initial&#160;dose) or placebo for 26&#160;weeks followed by open-label&#160;<br/>Humira treatment for an additional 26&#160;weeks. Nail psoriasis assessments included the Modified Nail&#160;<br/>Psoriasis Severity Index (mNAPSI), the Physician’s Global Assessment of Fingernail Psoriasis (PGA-F)&#160;<br/>and the Nail Psoriasis Severity Index (NAPSI) (see Table&#160;14). Humira demonstrated a treatment benefit in&#160;<br/>nail psoriasis patients with different extents of skin involvement (BSA≥10% (60% of patients) and&#160;<br/>BSA&lt;10% and&#160;≥5% (40% of patients)). &#160; &#160;</p>
<p style="position:absolute;top:560px;left:428px;white-space:nowrap" class="ft721"><b>Table&#160;14</b></p>
<p style="position:absolute;top:579px;left:275px;white-space:nowrap" class="ft721"><b>Ps&#160;Study IV Efficacy Results at 16, 26 and 52&#160;Weeks</b></p>
<p style="position:absolute;top:599px;left:114px;white-space:nowrap" class="ft722">Endpoint</p>
<p style="position:absolute;top:599px;left:368px;white-space:nowrap" class="ft722">Week 16</p>
<p style="position:absolute;top:618px;left:334px;white-space:nowrap" class="ft722">Placebo-Controlled</p>
<p style="position:absolute;top:599px;left:540px;white-space:nowrap" class="ft722">Week 26</p>
<p style="position:absolute;top:618px;left:506px;white-space:nowrap" class="ft722">Placebo-Controlled</p>
<p style="position:absolute;top:599px;left:710px;white-space:nowrap" class="ft722">Week 52</p>
<p style="position:absolute;top:618px;left:703px;white-space:nowrap" class="ft722">Open-label</p>
<p style="position:absolute;top:638px;left:324px;white-space:nowrap" class="ft722">Placebo</p>
<p style="position:absolute;top:657px;left:328px;white-space:nowrap" class="ft722">N=108</p>
<p style="position:absolute;top:638px;left:413px;white-space:nowrap" class="ft722">Humira</p>
<p style="position:absolute;top:657px;left:402px;white-space:nowrap" class="ft722">40&#160;mg&#160;eow&#160;</p>
<p style="position:absolute;top:676px;left:415px;white-space:nowrap" class="ft722">N=109</p>
<p style="position:absolute;top:638px;left:496px;white-space:nowrap" class="ft722">Placebo</p>
<p style="position:absolute;top:657px;left:499px;white-space:nowrap" class="ft722">N=108</p>
<p style="position:absolute;top:638px;left:581px;white-space:nowrap" class="ft722">Humira</p>
<p style="position:absolute;top:657px;left:570px;white-space:nowrap" class="ft722">40&#160;mg&#160;eow&#160;</p>
<p style="position:absolute;top:676px;left:584px;white-space:nowrap" class="ft722">N=109</p>
<p style="position:absolute;top:638px;left:714px;white-space:nowrap" class="ft722">Humira</p>
<p style="position:absolute;top:657px;left:703px;white-space:nowrap" class="ft722">40&#160;mg&#160;eow&#160;</p>
<p style="position:absolute;top:676px;left:720px;white-space:nowrap" class="ft722">N=80</p>
<p style="position:absolute;top:696px;left:114px;white-space:nowrap" class="ft722">≥ mNAPSI 75 (%)</p>
<p style="position:absolute;top:696px;left:340px;white-space:nowrap" class="ft722">2.9</p>
<p style="position:absolute;top:696px;left:422px;white-space:nowrap" class="ft722">26.0a</p>
<p style="position:absolute;top:696px;left:512px;white-space:nowrap" class="ft722">3.4</p>
<p style="position:absolute;top:696px;left:590px;white-space:nowrap" class="ft722">46.6a</p>
<p style="position:absolute;top:696px;left:725px;white-space:nowrap" class="ft722">65.0</p>
<p style="position:absolute;top:715px;left:114px;white-space:nowrap" class="ft724">PGA-F clear/minimal and&#160;<br/>≥2-grade improvement (%)</p>
<p style="position:absolute;top:715px;left:340px;white-space:nowrap" class="ft722">2.9</p>
<p style="position:absolute;top:715px;left:422px;white-space:nowrap" class="ft722">29.7a</p>
<p style="position:absolute;top:715px;left:512px;white-space:nowrap" class="ft722">6.9</p>
<p style="position:absolute;top:715px;left:590px;white-space:nowrap" class="ft722">48.9a</p>
<p style="position:absolute;top:715px;left:725px;white-space:nowrap" class="ft722">61.3</p>
<p style="position:absolute;top:754px;left:114px;white-space:nowrap" class="ft724">Percent Change in Total&#160;<br/>Fingernail NAPSI (%)</p>
<p style="position:absolute;top:754px;left:337px;white-space:nowrap" class="ft722">-7.8</p>
<p style="position:absolute;top:754px;left:417px;white-space:nowrap" class="ft722">-44.2&#160;a</p>
<p style="position:absolute;top:754px;left:505px;white-space:nowrap" class="ft722">-11.5</p>
<p style="position:absolute;top:754px;left:587px;white-space:nowrap" class="ft722">-56.2a</p>
<p style="position:absolute;top:754px;left:722px;white-space:nowrap" class="ft722">-72.2</p>
<p style="position:absolute;top:791px;left:114px;white-space:nowrap" class="ft729">a&#160;p&lt;0.001, Humira&#160;<i>vs.&#160;</i>placebo&#160;</p>
<p style="position:absolute;top:831px;left:106px;white-space:nowrap" class="ft724">Humira treated patients showed statistically significant improvements at Week&#160;26 compared with placebo&#160;<br/>in the DLQI.&#160;</p>
<p style="position:absolute;top:888px;left:106px;white-space:nowrap" class="ft723"><i>Adult hidradenitis suppurativa</i></p>
<p style="position:absolute;top:926px;left:106px;white-space:nowrap" class="ft724">The safety and efficacy of Humira were assessed in randomised, double-blind, placebo-controlled studies&#160;<br/>and an open-label extension study in adult patients with moderate to severe hidradenitis suppurativa (HS)&#160;<br/>who were&#160;intolerant, had a contraindication or an inadequate response to at least a 3-month trial of&#160;<br/>systemic antibiotic therapy. The patients in HS-I and HS-II had Hurley Stage II or III disease with at least&#160;<br/>3 abscesses or inflammatory nodules.</p>
<p style="position:absolute;top:1040px;left:106px;white-space:nowrap" class="ft724">Study HS-I (PIONEER I) evaluated 307 patients with 2 treatment periods. In Period A, patients received&#160;<br/>placebo or Humira at an initial dose of 160 mg at Week 0,&#160;80 mg at Week 2, and 40 mg every week&#160;<br/>starting at Week 4 to Week 11. Concomitant antibiotic use was not allowed during the study. After&#160;</p>
</div>
<!-- Page 73 -->
<a name="73"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page73-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft730">73</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft734">12&#160;weeks of therapy, patients who had received Humira in Period A were re-randomised in Period B to 1&#160;<br/>of 3 treatment groups (Humira 40 mg every week, Humira 40 mg every other week, or placebo from Week&#160;<br/>12 to Week 35). Patients who had been randomised to placebo in Period A were assigned to receive&#160;<br/>Humira 40 mg every week in Period B.</p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft734">Study HS-II (PIONEER II) evaluated 326&#160;patients with 2 treatment periods. In Period A, patients received&#160;<br/>placebo or Humira at an initial dose of 160 mg at Week 0 and 80 mg at Week 2 and 40 mg every week&#160;<br/>starting at Week 4 to Week 11. 19.3% of patients had continued baseline oral antibiotic therapy during the&#160;<br/>study. &#160;After 12&#160;weeks of therapy, patients who had received Humira in Period A were re-randomised in&#160;<br/>Period B to 1 of 3 treatment groups (Humira 40 mg every week, Humira 40 mg every other week, or&#160;<br/>placebo from Week 12 to Week 35). Patients&#160;who had been randomised to placebo in Period A were&#160;<br/>assigned to receive placebo in Period B.</p>
<p style="position:absolute;top:333px;left:106px;white-space:nowrap" class="ft735">Patients participating in Studies HS-I and HS-II were&#160;eligible to enrol into an open-label extension study&#160;<br/>in which Humira 40mg was administered every week.&#160;Mean&#160;exposure in all adalimumab population was&#160;<br/>762 days.&#160;Throughout all 3 studies patients used topical antiseptic wash daily.</p>
<p style="position:absolute;top:409px;left:106px;white-space:nowrap" class="ft733"><i>Clinical Response</i></p>
<p style="position:absolute;top:446px;left:106px;white-space:nowrap" class="ft734">Reduction of inflammatory lesions and prevention of worsening of abscesses and draining fistulas was&#160;<br/>assessed using Hidradenitis Suppurativa Clinical Response (HiSCR; at least a 50% reduction in total&#160;<br/>abscess and inflammatory nodule count with no increase&#160;in abscess count and no increase in draining&#160;<br/>fistula count relative to Baseline). Reduction in HS-related skin pain was assessed using a Numeric Rating&#160;<br/>Scale in patients who entered the study with an initial baseline score of 3 or greater on a 11 point scale.&#160;</p>
<p style="position:absolute;top:560px;left:106px;white-space:nowrap" class="ft735">At Week 12, a significantly higher proportion of patients treated with Humira versus placebo achieved&#160;<br/>HiSCR. &#160; At Week 12, a significantly higher proportion of patients in Study HS-II experienced a clinically&#160;<br/>relevant decrease in HS-related skin pain&#160;(see Table&#160;15). Patients treated with Humira had significantly&#160;<br/>reduced risk of disease flare during the initial 12 weeks of treatment.</p>
<p style="position:absolute;top:659px;left:262px;white-space:nowrap" class="ft731"><b>Table&#160;15: &#160;Efficacy Results at 12 Weeks, HS Studies I and II</b></p>
<p style="position:absolute;top:699px;left:404px;white-space:nowrap" class="ft731"><b>HS Study I</b></p>
<p style="position:absolute;top:699px;left:643px;white-space:nowrap" class="ft731"><b>HS Study II</b></p>
<p style="position:absolute;top:738px;left:350px;white-space:nowrap" class="ft731"><b>Placebo</b></p>
<p style="position:absolute;top:719px;left:446px;white-space:nowrap" class="ft731"><b>Humira 40 mg&#160;</b></p>
<p style="position:absolute;top:738px;left:471px;white-space:nowrap" class="ft731"><b>Weekly</b></p>
<p style="position:absolute;top:738px;left:588px;white-space:nowrap" class="ft731"><b>Placebo&#160;</b></p>
<p style="position:absolute;top:719px;left:687px;white-space:nowrap" class="ft731"><b>Humira 40 mg&#160;</b></p>
<p style="position:absolute;top:738px;left:711px;white-space:nowrap" class="ft731"><b>Weekly</b></p>
<p style="position:absolute;top:767px;left:119px;white-space:nowrap" class="ft735">Hidradenitis Suppurativa&#160;<br/>Clinical Response (HiSCR)a</p>
<p style="position:absolute;top:757px;left:351px;white-space:nowrap" class="ft732">N = 154</p>
<p style="position:absolute;top:776px;left:341px;white-space:nowrap" class="ft732">40 (26.0%)</p>
<p style="position:absolute;top:757px;left:470px;white-space:nowrap" class="ft732">N = 153</p>
<p style="position:absolute;top:776px;left:456px;white-space:nowrap" class="ft732">64 (41.8%)&#160;*</p>
<p style="position:absolute;top:757px;left:593px;white-space:nowrap" class="ft732">N=163</p>
<p style="position:absolute;top:776px;left:579px;white-space:nowrap" class="ft732">45 (27.6%)</p>
<p style="position:absolute;top:757px;left:715px;white-space:nowrap" class="ft732">N=163</p>
<p style="position:absolute;top:776px;left:691px;white-space:nowrap" class="ft732">96 (58.9%)&#160;***</p>
<p style="position:absolute;top:815px;left:119px;white-space:nowrap" class="ft734">≥30% Reduction in Skin&#160;<br/>Painb</p>
<p style="position:absolute;top:815px;left:351px;white-space:nowrap" class="ft732">N = 109</p>
<p style="position:absolute;top:834px;left:341px;white-space:nowrap" class="ft732">27 (24.8%)</p>
<p style="position:absolute;top:815px;left:470px;white-space:nowrap" class="ft732">N = 122</p>
<p style="position:absolute;top:834px;left:460px;white-space:nowrap" class="ft732">34 (27.9%)</p>
<p style="position:absolute;top:815px;left:593px;white-space:nowrap" class="ft732">N=111</p>
<p style="position:absolute;top:834px;left:579px;white-space:nowrap" class="ft732">23 (20.7%)</p>
<p style="position:absolute;top:815px;left:715px;white-space:nowrap" class="ft732">N=105</p>
<p style="position:absolute;top:834px;left:691px;white-space:nowrap" class="ft732">48 (45.7%)&#160;***</p>
<p style="position:absolute;top:854px;left:146px;white-space:nowrap" class="ft732">*&#160;<i>P&#160;</i>&lt; 0.05, ***<i>P&#160;</i>&lt; 0.001, Humira versus placebo&#160;</p>
<p style="position:absolute;top:876px;left:119px;white-space:nowrap" class="ft7318">a</p>
<p style="position:absolute;top:872px;left:146px;white-space:nowrap" class="ft732">Among all randomised patients.</p>
<p style="position:absolute;top:894px;left:119px;white-space:nowrap" class="ft7318">b</p>
<p style="position:absolute;top:890px;left:146px;white-space:nowrap" class="ft732">Among patients with baseline HS-related skin pain assessment&#160;≥ 3, based on Numeric Rating&#160;</p>
<p style="position:absolute;top:908px;left:146px;white-space:nowrap" class="ft732">Scale 0&#160;–&#160;10; 0&#160;=&#160;no skin pain, 10 = skin pain as bad as you can&#160;imagine.</p>
<p style="position:absolute;top:946px;left:106px;white-space:nowrap" class="ft734">Treatment with Humira 40 mg every week significantly reduced the risk of worsening of abscesses and&#160;<br/>draining fistulas. Approximately twice the proportion of patients in the placebo group in the first 12 weeks&#160;<br/>of Studies HS-I and HS-II, compared&#160;with those in the Humira group experienced worsening of abscesses&#160;<br/>(23.0% vs 11.4%, respectively) and draining fistulas (30.0% vs 13.9%, respectively).</p>
<p style="position:absolute;top:1041px;left:106px;white-space:nowrap" class="ft734">Greater improvements at Week 12 from baseline compared to placebo were demonstrated in skin-specific&#160;<br/>health-related quality of life, as measured by the Dermatology Life Quality Index (DLQI; Studies HS-I&#160;<br/>and HS-II), patient global satisfaction with medication treatment as measured by the Treatment&#160;</p>
</div>
<!-- Page 74 -->
<a name="74"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page74-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft740">74</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft745">Satisfaction Questionnaire&#160;-&#160;medication (TSQM; Studies HS-I and&#160;HS-II), and physical health as&#160;<br/>measured by the physical component summary score of the SF-36&#160;(Study HS-I).</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft745">In patients with at least a partial response to Humira 40 mg weekly at Week 12, the HiSCR rate at Week&#160;<br/>36 was higher in patients who continued weekly Humira than in patients in whom dosing frequency was&#160;<br/>reduced to every other week, or in whom treatment was withdrawn (see Table&#160;16). &#160;</p>
<p style="position:absolute;top:219px;left:164px;white-space:nowrap" class="ft741"><b>Table&#160;16:</b></p>
<p style="position:absolute;top:219px;left:276px;white-space:nowrap" class="ft741"><b>Proportion of Patientsa&#160;Achieving HiSCRb&#160;at Weeks 24 and 36 After&#160;</b></p>
<p style="position:absolute;top:238px;left:272px;white-space:nowrap" class="ft741"><b>Treatment Reassignment from&#160;Weekly&#160;Humira at Week 12</b></p>
<p style="position:absolute;top:275px;left:341px;white-space:nowrap" class="ft741"><b>Placebo</b></p>
<p style="position:absolute;top:293px;left:331px;white-space:nowrap" class="ft741"><b>(treatment&#160;</b></p>
<p style="position:absolute;top:311px;left:326px;white-space:nowrap" class="ft741"><b>withdrawal)</b></p>
<p style="position:absolute;top:329px;left:346px;white-space:nowrap" class="ft741"><b>N = 73</b></p>
<p style="position:absolute;top:293px;left:466px;white-space:nowrap" class="ft741"><b>Humira 40 mg</b></p>
<p style="position:absolute;top:311px;left:458px;white-space:nowrap" class="ft741"><b>every other week</b></p>
<p style="position:absolute;top:329px;left:494px;white-space:nowrap" class="ft741"><b>N = 70</b></p>
<p style="position:absolute;top:293px;left:610px;white-space:nowrap" class="ft741"><b>Humira 40 mg</b></p>
<p style="position:absolute;top:311px;left:637px;white-space:nowrap" class="ft741"><b>weekly</b></p>
<p style="position:absolute;top:329px;left:638px;white-space:nowrap" class="ft741"><b>N = 70</b></p>
<p style="position:absolute;top:348px;left:195px;white-space:nowrap" class="ft742">Week 24</p>
<p style="position:absolute;top:348px;left:332px;white-space:nowrap" class="ft742">24 (32.9%)</p>
<p style="position:absolute;top:348px;left:480px;white-space:nowrap" class="ft742">36 (51.4%)</p>
<p style="position:absolute;top:348px;left:624px;white-space:nowrap" class="ft742">40 (57.1%)</p>
<p style="position:absolute;top:367px;left:195px;white-space:nowrap" class="ft742">Week 36</p>
<p style="position:absolute;top:367px;left:332px;white-space:nowrap" class="ft742">22 (30.1%)</p>
<p style="position:absolute;top:367px;left:480px;white-space:nowrap" class="ft742">28 (40.0%)</p>
<p style="position:absolute;top:367px;left:624px;white-space:nowrap" class="ft742">39 (55.7%)</p>
<p style="position:absolute;top:390px;left:200px;white-space:nowrap" class="ft7418">a</p>
<p style="position:absolute;top:386px;left:220px;white-space:nowrap" class="ft742">Patients with at least a partial response to&#160;Humira 40 mg weekly after 12&#160;</p>
<p style="position:absolute;top:404px;left:220px;white-space:nowrap" class="ft742">weeks of treatment.</p>
<p style="position:absolute;top:426px;left:200px;white-space:nowrap" class="ft7418">b</p>
<p style="position:absolute;top:422px;left:220px;white-space:nowrap" class="ft742">Patients meeting protocol-specified criteria for loss of response or no&#160;</p>
<p style="position:absolute;top:440px;left:220px;white-space:nowrap" class="ft742">improvement were required to discontinue from the studies and were&#160;</p>
<p style="position:absolute;top:458px;left:220px;white-space:nowrap" class="ft742">counted as nonresponders.</p>
<p style="position:absolute;top:495px;left:106px;white-space:nowrap" class="ft744">Among patients who were at least&#160;partial responders at Week 12, and who received continuous weekly&#160;<br/>Humira therapy, the HiSCR rate at Week 48 was 68.3% and at Week 96 was 65.1%. Longer term&#160;<br/>treatment with Humira 40 mg weekly for 96 weeks identified no new safety findings.</p>
<p style="position:absolute;top:571px;left:106px;white-space:nowrap" class="ft745">Among patients&#160;whose Humira treatment was withdrawn at Week 12 in Studies HS-I and HS-II, the&#160;<br/>HiSCR rate 12 weeks after re-introduction of Humira 40 mg weekly returned to levels similar to that&#160;<br/>observed before withdrawal (56.0 %).</p>
<p style="position:absolute;top:647px;left:106px;white-space:nowrap" class="ft743"><i>Adult Crohn’s disease</i></p>
<p style="position:absolute;top:685px;left:106px;white-space:nowrap" class="ft747">The safety and efficacy of Humira were assessed in over 1500 patients with moderately to severely active&#160;<br/>Crohn’s disease (Crohn’s Disease Activity Index (CDAI)&#160;</p>
<p style="position:absolute;top:703px;left:489px;white-space:nowrap" class="ft746">&#160;220 and&#160;&#160;450) in randomised, double-blind,&#160;</p>
<p style="position:absolute;top:724px;left:106px;white-space:nowrap" class="ft744">placebo-controlled studies. Concomitant stable doses of aminosalicylates, corticosteroids, and/or&#160;<br/>immunomodulatory agents were permitted and 80% of patients continued to receive at least one of these&#160;<br/>medications.&#160;</p>
<p style="position:absolute;top:800px;left:106px;white-space:nowrap" class="ft744">Induction of clinical remission (defined as CDAI &lt;&#160;150) was evaluated in two studies, CD Study I&#160;<br/>(CLASSIC I) and CD Study II (GAIN). In CD Study I, 299 TNF-antagonist naive patients were&#160;<br/>randomised to one of four treatment groups; placebo at Weeks&#160;0 and 2, 160&#160;mg Humira at Week&#160;0 and&#160;<br/>80&#160;mg at Week&#160;2, 80&#160;mg at Week&#160;0 and 40&#160;mg at Week&#160;2, and 40&#160;mg at Week&#160;0 and&#160;20&#160;mg at Week&#160;2. In&#160;<br/>CD Study II, 325 patients who had lost response or were intolerant to infliximab were randomised to&#160;<br/>receive either 160&#160;mg Humira at Week&#160;0 and 80&#160;mg at Week&#160;2 or placebo at Weeks&#160;0 and 2. The primary&#160;<br/>non-responders were excluded from the studies and therefore these patients were not further evaluated.</p>
<p style="position:absolute;top:952px;left:106px;white-space:nowrap" class="ft745">Maintenance of clinical remission was evaluated in CD study III (CHARM). In CD Study III, 854 patients&#160;<br/>received open-label 80&#160;mg at Week&#160;0 and 40&#160;mg at Week&#160;2. At Week&#160;4 patients were randomised to&#160;<br/>40&#160;mg&#160;every other week, 40&#160;mg every week, or placebo with a total study duration of 56&#160;weeks. Patients in&#160;<br/>clinical response (decrease in CDAI&#160;≥ 70) at Week&#160;4 were stratified and analysed separately from those&#160;<br/>not in clinical response at Week&#160;4. Corticosteroid taper was permitted after Week&#160;8.&#160;</p>
<p style="position:absolute;top:1066px;left:106px;white-space:nowrap" class="ft742">CD study I and CD study II induction of remission and response rates are presented in Table&#160;17.</p>
</div>
<!-- Page 75 -->
<a name="75"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page75-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft750">75</p>
<p style="position:absolute;top:107px;left:422px;white-space:nowrap" class="ft751"><b>Table&#160;17</b></p>
<p style="position:absolute;top:128px;left:291px;white-space:nowrap" class="ft751"><b>Induction of Clinical Remission and Response</b></p>
<p style="position:absolute;top:149px;left:380px;white-space:nowrap" class="ft751"><b>(Percent of Patients)</b></p>
<p style="position:absolute;top:174px;left:287px;white-space:nowrap" class="ft7515"><b>CD Study I: Infliximab Naive&#160;<br/>Patients</b></p>
<p style="position:absolute;top:174px;left:558px;white-space:nowrap" class="ft7515"><b>CD Study II: Infliximab&#160;<br/>Experienced Patients</b></p>
<p style="position:absolute;top:217px;left:296px;white-space:nowrap" class="ft751"><b>Placebo</b></p>
<p style="position:absolute;top:238px;left:305px;white-space:nowrap" class="ft751"><b>N=74</b></p>
<p style="position:absolute;top:217px;left:387px;white-space:nowrap" class="ft751"><b>Humira</b></p>
<p style="position:absolute;top:238px;left:383px;white-space:nowrap" class="ft751"><b>80/40&#160;mg</b></p>
<p style="position:absolute;top:258px;left:392px;white-space:nowrap" class="ft751"><b>N = 75</b></p>
<p style="position:absolute;top:217px;left:478px;white-space:nowrap" class="ft751"><b>Humira&#160;</b></p>
<p style="position:absolute;top:238px;left:470px;white-space:nowrap" class="ft751"><b>160/80&#160;mg&#160;</b></p>
<p style="position:absolute;top:256px;left:487px;white-space:nowrap" class="ft751"><b>N=76</b></p>
<p style="position:absolute;top:217px;left:579px;white-space:nowrap" class="ft751"><b>Placebo</b></p>
<p style="position:absolute;top:238px;left:583px;white-space:nowrap" class="ft751"><b>N=166</b></p>
<p style="position:absolute;top:217px;left:703px;white-space:nowrap" class="ft751"><b>Humira&#160;</b></p>
<p style="position:absolute;top:238px;left:694px;white-space:nowrap" class="ft751"><b>160/80&#160;mg</b></p>
<p style="position:absolute;top:258px;left:707px;white-space:nowrap" class="ft751"><b>N=159</b></p>
<p style="position:absolute;top:283px;left:114px;white-space:nowrap" class="ft7516">Week&#160;4<br/>Clinical remission</p>
<p style="position:absolute;top:308px;left:309px;white-space:nowrap" class="ft752">12%</p>
<p style="position:absolute;top:308px;left:400px;white-space:nowrap" class="ft752">24%</p>
<p style="position:absolute;top:308px;left:488px;white-space:nowrap" class="ft752">36%*</p>
<p style="position:absolute;top:308px;left:595px;white-space:nowrap" class="ft752">7%</p>
<p style="position:absolute;top:308px;left:713px;white-space:nowrap" class="ft752">21%*</p>
<p style="position:absolute;top:333px;left:114px;white-space:nowrap" class="ft752">Clinical response (CR-</p>
<p style="position:absolute;top:351px;left:114px;white-space:nowrap" class="ft752">100)</p>
<p style="position:absolute;top:333px;left:309px;white-space:nowrap" class="ft752">24%</p>
<p style="position:absolute;top:333px;left:400px;white-space:nowrap" class="ft752">37%</p>
<p style="position:absolute;top:333px;left:486px;white-space:nowrap" class="ft752">49%**</p>
<p style="position:absolute;top:333px;left:591px;white-space:nowrap" class="ft752">25%</p>
<p style="position:absolute;top:333px;left:710px;white-space:nowrap" class="ft752">38%**</p>
<p style="position:absolute;top:376px;left:114px;white-space:nowrap" class="ft754">All p-values are pairwise comparisons of proportions for Humira&#160;<i>versus&#160;</i>placebo<br/>*</p>
<p style="position:absolute;top:396px;left:141px;white-space:nowrap" class="ft752">p&#160;&lt;&#160;0.001</p>
<p style="position:absolute;top:416px;left:114px;white-space:nowrap" class="ft759">**</p>
<p style="position:absolute;top:418px;left:141px;white-space:nowrap" class="ft752">p&#160;&lt;&#160;0.01</p>
<p style="position:absolute;top:458px;left:106px;white-space:nowrap" class="ft754">Similar remission rates were observed for the 160/80&#160;mg and 80/40&#160;mg&#160;induction regimens by Week&#160;8 and&#160;<br/>adverse events were more frequently noted in&#160;the 160/80&#160;mg group.</p>
<p style="position:absolute;top:515px;left:106px;white-space:nowrap" class="ft754">In CD Study III, at Week&#160;4, 58% (499/854) of patients were in clinical response and were assessed in the&#160;<br/>primary analysis. Of those in clinical response at Week 4, 48% had been previously exposed to other TNF-<br/>antagonists. Maintenance&#160;of remission and response rates are presented in Table&#160;18.&#160;Clinical remission&#160;<br/>results remained relatively constant irrespective of previous TNF-antagonist exposure.</p>
<p style="position:absolute;top:610px;left:106px;white-space:nowrap" class="ft754">Disease-related hospitalisations and surgeries were statistically significantly reduced with adalimumab&#160;<br/>compared with placebo at Week&#160;56.</p>
<p style="position:absolute;top:669px;left:422px;white-space:nowrap" class="ft751"><b>Table&#160;18</b></p>
<p style="position:absolute;top:690px;left:279px;white-space:nowrap" class="ft751"><b>Maintenance of Clinical Remission and Response</b></p>
<p style="position:absolute;top:711px;left:380px;white-space:nowrap" class="ft751"><b>(Percent of Patients)</b></p>
<p style="position:absolute;top:736px;left:425px;white-space:nowrap" class="ft751"><b>Placebo</b></p>
<p style="position:absolute;top:736px;left:539px;white-space:nowrap" class="ft751"><b>40&#160;mg&#160;Humira</b></p>
<p style="position:absolute;top:754px;left:531px;white-space:nowrap" class="ft751"><b>every other week</b></p>
<p style="position:absolute;top:736px;left:675px;white-space:nowrap" class="ft751"><b>40&#160;mg&#160;Humira</b></p>
<p style="position:absolute;top:754px;left:687px;white-space:nowrap" class="ft751"><b>every week</b></p>
<p style="position:absolute;top:779px;left:122px;white-space:nowrap" class="ft751"><b>Week&#160;26</b></p>
<p style="position:absolute;top:779px;left:429px;white-space:nowrap" class="ft751"><b>N=170</b></p>
<p style="position:absolute;top:779px;left:567px;white-space:nowrap" class="ft751"><b>N=172</b></p>
<p style="position:absolute;top:779px;left:703px;white-space:nowrap" class="ft751"><b>N=157</b></p>
<p style="position:absolute;top:804px;left:122px;white-space:nowrap" class="ft752">Clinical remission</p>
<p style="position:absolute;top:804px;left:437px;white-space:nowrap" class="ft752">17%</p>
<p style="position:absolute;top:804px;left:571px;white-space:nowrap" class="ft752">40%*</p>
<p style="position:absolute;top:804px;left:707px;white-space:nowrap" class="ft752">47%*</p>
<p style="position:absolute;top:828px;left:122px;white-space:nowrap" class="ft752">Clinical response (CR-100)</p>
<p style="position:absolute;top:828px;left:437px;white-space:nowrap" class="ft752">27%</p>
<p style="position:absolute;top:828px;left:571px;white-space:nowrap" class="ft752">52%*</p>
<p style="position:absolute;top:828px;left:707px;white-space:nowrap" class="ft752">52%*</p>
<p style="position:absolute;top:853px;left:149px;white-space:nowrap" class="ft752">Patients in steroid-free remission&#160;</p>
<p style="position:absolute;top:871px;left:149px;white-space:nowrap" class="ft752">for &gt;=90&#160;daysa</p>
<p style="position:absolute;top:853px;left:419px;white-space:nowrap" class="ft752">3% (2/66)</p>
<p style="position:absolute;top:853px;left:541px;white-space:nowrap" class="ft752">19% (11/58)**</p>
<p style="position:absolute;top:853px;left:677px;white-space:nowrap" class="ft752">15% (11/74)**</p>
<p style="position:absolute;top:896px;left:122px;white-space:nowrap" class="ft751"><b>Week&#160;56</b></p>
<p style="position:absolute;top:896px;left:429px;white-space:nowrap" class="ft751"><b>N=170</b></p>
<p style="position:absolute;top:896px;left:567px;white-space:nowrap" class="ft751"><b>N=172</b></p>
<p style="position:absolute;top:896px;left:703px;white-space:nowrap" class="ft751"><b>N=157</b></p>
<p style="position:absolute;top:921px;left:122px;white-space:nowrap" class="ft752">Clinical remission</p>
<p style="position:absolute;top:921px;left:437px;white-space:nowrap" class="ft752">12%</p>
<p style="position:absolute;top:921px;left:571px;white-space:nowrap" class="ft752">36%*</p>
<p style="position:absolute;top:921px;left:707px;white-space:nowrap" class="ft752">41%*</p>
<p style="position:absolute;top:945px;left:122px;white-space:nowrap" class="ft752">Clinical response (CR-100)</p>
<p style="position:absolute;top:945px;left:437px;white-space:nowrap" class="ft752">17%</p>
<p style="position:absolute;top:945px;left:571px;white-space:nowrap" class="ft752">41%*</p>
<p style="position:absolute;top:945px;left:707px;white-space:nowrap" class="ft752">48%*</p>
<p style="position:absolute;top:970px;left:149px;white-space:nowrap" class="ft752">Patients in steroid-free remission&#160;</p>
<p style="position:absolute;top:988px;left:149px;white-space:nowrap" class="ft752">for &gt;=90&#160;daysa</p>
<p style="position:absolute;top:970px;left:419px;white-space:nowrap" class="ft752">5% (3/66)</p>
<p style="position:absolute;top:970px;left:545px;white-space:nowrap" class="ft752">29% (17/58)*</p>
<p style="position:absolute;top:970px;left:677px;white-space:nowrap" class="ft752">20% (15/74)**</p>
<p style="position:absolute;top:1013px;left:122px;white-space:nowrap" class="ft752">*</p>
<p style="position:absolute;top:1013px;left:149px;white-space:nowrap" class="ft752">p&#160;&lt;&#160;0.001 for Humira&#160;<i>versus&#160;</i>placebo pairwise comparisons of proportions</p>
<p style="position:absolute;top:1034px;left:122px;white-space:nowrap" class="ft754">**&#160;p&#160;&lt;&#160;0.02 for Humira&#160;<i>versus&#160;</i>placebo pairwise comparisons of proportions<br/>a</p>
<p style="position:absolute;top:1055px;left:149px;white-space:nowrap" class="ft752">Of those receiving corticosteroids at baseline</p>
</div>
<!-- Page 76 -->
<a name="76"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page76-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft760">76</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft764">Among patients who were not in response at Week&#160;4, 43% of Humira maintenance patients responded by&#160;<br/>Week&#160;12 compared to 30% of placebo maintenance patients. These results suggest that some patients who&#160;<br/>have not responded by&#160;Week&#160;4 benefit from continued maintenance therapy through Week&#160;12. Therapy&#160;<br/>continued beyond 12&#160;weeks did not result in significantly more responses&#160;(see section 4.2).&#160;&#160;</p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft764">117/276 patients from CD study I and 272/777 patients from CD studies II and III were&#160;followed through&#160;<br/>at least 3&#160;years of open-label adalimumab therapy. 88 and 189 patients, respectively, continued to be in&#160;<br/>clinical remission. Clinical response (CR-100) was maintained in 102 and 233 patients, respectively.</p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft763"><i>Quality of life</i></p>
<p style="position:absolute;top:295px;left:106px;white-space:nowrap" class="ft764">In CD Study I and CD Study II, statistically significant improvement in the disease-specific inflammatory&#160;<br/>bowel disease questionnaire (IBDQ) total score was achieved at Week&#160;4 in patients randomised to Humira&#160;<br/>80/40&#160;mg and 160/80&#160;mg compared to placebo and was seen at Weeks 26 and 56 in CD Study III as well&#160;<br/>among the adalimumab treatment groups compared to the placebo group.</p>
<p style="position:absolute;top:390px;left:106px;white-space:nowrap" class="ft763"><i>Adult Uveitis</i></p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft765">The safety and efficacy of Humira were assessed in adult patients with non-infectious intermediate,&#160;<br/>posterior, and panuveitis, excluding patients with isolated anterior uveitis, in two randomised, double-<br/>masked, placebo-controlled studies (UV I and II). Patients received placebo or Humira at an initial dose of&#160;<br/>80&#160;mg followed by 40&#160;mg&#160;every other week starting one week after the initial dose. Concomitant stable&#160;<br/>doses of one&#160;non-biologic immunosuppressant were permitted.&#160;</p>
<p style="position:absolute;top:541px;left:106px;white-space:nowrap" class="ft764">Study UV I evaluated 217 patients with active uveitis despite treatment with corticosteroids (oral&#160;<br/>prednisone at a dose of 10&#160;to&#160;60&#160;mg/day). All patients received a 2-week&#160;standardised dose of prednisone&#160;<br/>60&#160;mg/day at study entry followed by a mandatory taper schedule, with complete corticosteroid&#160;<br/>discontinuation by Week 15.&#160;</p>
<p style="position:absolute;top:636px;left:106px;white-space:nowrap" class="ft764">Study UV II evaluated 226 patients with inactive uveitis requiring chronic corticosteroid treatment (oral&#160;<br/>prednisone 10&#160;to&#160;35&#160;mg/day) at baseline to control their disease. Patients subsequently underwent a&#160;<br/>mandatory taper schedule, with complete corticosteroid discontinuation by Week 19.&#160;</p>
<p style="position:absolute;top:712px;left:106px;white-space:nowrap" class="ft764">The primary efficacy endpoint in both studies was ´time to treatment failure´. Treatment failure was&#160;<br/>defined by a multi-component outcome based on inflammatory chorioretinal and/or inflammatory retinal&#160;<br/>vascular lesions, anterior chamber (AC) cell grade, vitreous haze (VH) grade and best corrected visual&#160;<br/>acuity (BCVA).</p>
<p style="position:absolute;top:807px;left:106px;white-space:nowrap" class="ft764">Patients who completed Studies UV I and UV&#160;II were&#160;eligible to enroll in&#160;an uncontrolled long-term&#160;<br/>extension study with an originally planned duration of 78 weeks. Patients were allowed to continue on&#160;<br/>study medication beyond Week 78 until they had access to Humira.</p>
<p style="position:absolute;top:883px;left:106px;white-space:nowrap" class="ft763"><i>Clinical Response</i></p>
<p style="position:absolute;top:921px;left:106px;white-space:nowrap" class="ft764">Results from both studies demonstrated statistically significant reduction of the risk of treatment failure in&#160;<br/>patients treated with Humira versus patients receiving placebo (See Table&#160;19). Both studies demonstrated&#160;<br/>an early and sustained effect of Humira&#160;on the treatment failure rate versus placebo (see Figure&#160;1).&#160;</p>
</div>
<!-- Page 77 -->
<a name="77"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page77-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft770">77</p>
<p style="position:absolute;top:86px;left:428px;white-space:nowrap" class="ft771"><b>Table&#160;19</b></p>
<p style="position:absolute;top:105px;left:270px;white-space:nowrap" class="ft771"><b>Time to Treatment Failure in Studies UV I and UV II</b></p>
<p style="position:absolute;top:144px;left:114px;white-space:nowrap" class="ft771"><b>Analysis</b></p>
<p style="position:absolute;top:163px;left:156px;white-space:nowrap" class="ft771"><b>Treatment</b></p>
<p style="position:absolute;top:144px;left:284px;white-space:nowrap" class="ft771"><b>N</b></p>
<p style="position:absolute;top:144px;left:338px;white-space:nowrap" class="ft7719"><b>Failure<br/>N (%)</b></p>
<p style="position:absolute;top:144px;left:426px;white-space:nowrap" class="ft7719"><b>Median Time to&#160;<br/>Failure (months)</b></p>
<p style="position:absolute;top:144px;left:567px;white-space:nowrap" class="ft771"><b>HRa</b></p>
<p style="position:absolute;top:144px;left:621px;white-space:nowrap" class="ft7719"><b>CI 95%&#160;<br/>for HRa</b></p>
<p style="position:absolute;top:144px;left:709px;white-space:nowrap" class="ft7717"><i><b>P&#160;</b></i><b>Value&#160;</b>b</p>
<p style="position:absolute;top:182px;left:114px;white-space:nowrap" class="ft7719"><b>Time to Treatment Failure At or After Week 6 in Study UV I &#160;<br/></b>Primary analysis (ITT)</p>
<p style="position:absolute;top:220px;left:156px;white-space:nowrap" class="ft772">Placebo</p>
<p style="position:absolute;top:220px;left:284px;white-space:nowrap" class="ft772">107</p>
<p style="position:absolute;top:220px;left:338px;white-space:nowrap" class="ft772">84 (78.5)</p>
<p style="position:absolute;top:220px;left:426px;white-space:nowrap" class="ft772">3.0</p>
<p style="position:absolute;top:220px;left:567px;white-space:nowrap" class="ft772">--</p>
<p style="position:absolute;top:220px;left:621px;white-space:nowrap" class="ft772">--</p>
<p style="position:absolute;top:220px;left:709px;white-space:nowrap" class="ft772">--</p>
<p style="position:absolute;top:239px;left:156px;white-space:nowrap" class="ft772">Adalimumab</p>
<p style="position:absolute;top:239px;left:284px;white-space:nowrap" class="ft772">110</p>
<p style="position:absolute;top:239px;left:338px;white-space:nowrap" class="ft772">60 (54.5)</p>
<p style="position:absolute;top:239px;left:426px;white-space:nowrap" class="ft772">5.6</p>
<p style="position:absolute;top:239px;left:567px;white-space:nowrap" class="ft772">0.50</p>
<p style="position:absolute;top:239px;left:621px;white-space:nowrap" class="ft772">0.36, 0.70</p>
<p style="position:absolute;top:239px;left:709px;white-space:nowrap" class="ft772">&lt; 0.001</p>
<p style="position:absolute;top:259px;left:114px;white-space:nowrap" class="ft7719"><b>Time to Treatment Failure At or After Week 2 in Study UV II<br/></b>Primary&#160;analysis (ITT)</p>
<p style="position:absolute;top:297px;left:156px;white-space:nowrap" class="ft772">Placebo</p>
<p style="position:absolute;top:297px;left:284px;white-space:nowrap" class="ft772">111</p>
<p style="position:absolute;top:297px;left:338px;white-space:nowrap" class="ft772">61 (55.0)</p>
<p style="position:absolute;top:297px;left:426px;white-space:nowrap" class="ft772">8.3</p>
<p style="position:absolute;top:297px;left:567px;white-space:nowrap" class="ft772">--</p>
<p style="position:absolute;top:297px;left:621px;white-space:nowrap" class="ft772">--</p>
<p style="position:absolute;top:297px;left:709px;white-space:nowrap" class="ft772">--</p>
<p style="position:absolute;top:316px;left:156px;white-space:nowrap" class="ft772">Adalimumab</p>
<p style="position:absolute;top:316px;left:284px;white-space:nowrap" class="ft772">115</p>
<p style="position:absolute;top:316px;left:338px;white-space:nowrap" class="ft772">45 (39.1)</p>
<p style="position:absolute;top:316px;left:426px;white-space:nowrap" class="ft772">NEc</p>
<p style="position:absolute;top:316px;left:567px;white-space:nowrap" class="ft772">0.57</p>
<p style="position:absolute;top:316px;left:621px;white-space:nowrap" class="ft772">0.39, 0.84</p>
<p style="position:absolute;top:316px;left:709px;white-space:nowrap" class="ft772">0.004</p>
<p style="position:absolute;top:336px;left:106px;white-space:nowrap" class="ft778">Note: Treatment failure at or after Week 6 (Study UV I), or at or after Week 2 (Study UV II), was counted&#160;<br/>as event. Drop outs due to reasons&#160;other than treatment failure were censored at the time of dropping out.<br/>a</p>
<p style="position:absolute;top:374px;left:133px;white-space:nowrap" class="ft772">HR of adalimumab vs placebo from proportional hazards regression with treatment as factor.</p>
<p style="position:absolute;top:397px;left:106px;white-space:nowrap" class="ft7718">b</p>
<p style="position:absolute;top:392px;left:133px;white-space:nowrap" class="ft772">2-sided&#160;<i>P&#160;</i>value from log rank test.</p>
<p style="position:absolute;top:416px;left:106px;white-space:nowrap" class="ft7718">c</p>
<p style="position:absolute;top:411px;left:133px;white-space:nowrap" class="ft772">NE = not estimable. Fewer than half of at-risk subjects had an event.&#160;</p>
<p style="position:absolute;top:449px;left:108px;white-space:nowrap" class="ft771"><b>Figure&#160;1: Kaplan-Meier Curves Summarizing Time to Treatment Failure on or after Week 6 (Study&#160;</b></p>
<p style="position:absolute;top:468px;left:350px;white-space:nowrap" class="ft771"><b>UV I) or Week 2 (Study UV II)</b></p>
<p style="position:absolute;top:767px;left:130px;white-space:nowrap" class="ft7720"><b>T</b></p>
<p style="position:absolute;top:756px;left:130px;white-space:nowrap" class="ft7720"><b>R</b></p>
<p style="position:absolute;top:744px;left:130px;white-space:nowrap" class="ft7720"><b>E</b></p>
<p style="position:absolute;top:733px;left:130px;white-space:nowrap" class="ft7720"><b>A</b></p>
<p style="position:absolute;top:721px;left:130px;white-space:nowrap" class="ft7720"><b>T</b></p>
<p style="position:absolute;top:710px;left:130px;white-space:nowrap" class="ft7720"><b>M</b></p>
<p style="position:absolute;top:694px;left:130px;white-space:nowrap" class="ft7720"><b>E</b></p>
<p style="position:absolute;top:683px;left:130px;white-space:nowrap" class="ft7720"><b>N</b></p>
<p style="position:absolute;top:672px;left:130px;white-space:nowrap" class="ft7720"><b>T</b></p>
<p style="position:absolute;top:661px;left:130px;white-space:nowrap" class="ft7720"><b>&#160;F</b></p>
<p style="position:absolute;top:646px;left:130px;white-space:nowrap" class="ft7720"><b>A</b></p>
<p style="position:absolute;top:634px;left:130px;white-space:nowrap" class="ft7720"><b>IL</b></p>
<p style="position:absolute;top:617px;left:130px;white-space:nowrap" class="ft7720"><b>U</b></p>
<p style="position:absolute;top:605px;left:130px;white-space:nowrap" class="ft7720"><b>R</b></p>
<p style="position:absolute;top:593px;left:130px;white-space:nowrap" class="ft7720"><b>E</b></p>
<p style="position:absolute;top:582px;left:130px;white-space:nowrap" class="ft7720"><b>&#160;R</b></p>
<p style="position:absolute;top:566px;left:130px;white-space:nowrap" class="ft7720"><b>A</b></p>
<p style="position:absolute;top:554px;left:130px;white-space:nowrap" class="ft7720"><b>T</b></p>
<p style="position:absolute;top:543px;left:130px;white-space:nowrap" class="ft7720"><b>E</b></p>
<p style="position:absolute;top:532px;left:130px;white-space:nowrap" class="ft7720"><b>&#160;(</b></p>
<p style="position:absolute;top:523px;left:130px;white-space:nowrap" class="ft7720"><b>%</b></p>
<p style="position:absolute;top:506px;left:130px;white-space:nowrap" class="ft7720"><b>)</b></p>
<p style="position:absolute;top:792px;left:410px;white-space:nowrap" class="ft772">TIME (MONTHS)</p>
<p style="position:absolute;top:811px;left:150px;white-space:nowrap" class="ft772">Study UV I &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;Treatment</p>
<p style="position:absolute;top:811px;left:500px;white-space:nowrap" class="ft772">Placebo</p>
<p style="position:absolute;top:811px;left:669px;white-space:nowrap" class="ft772">Adalimumab</p>
</div>
<!-- Page 78 -->
<a name="78"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page78-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft780">78</p>
<p style="position:absolute;top:349px;left:130px;white-space:nowrap" class="ft7820"><b>T</b></p>
<p style="position:absolute;top:338px;left:130px;white-space:nowrap" class="ft7820"><b>R</b></p>
<p style="position:absolute;top:326px;left:130px;white-space:nowrap" class="ft7820"><b>E</b></p>
<p style="position:absolute;top:315px;left:130px;white-space:nowrap" class="ft7820"><b>A</b></p>
<p style="position:absolute;top:303px;left:130px;white-space:nowrap" class="ft7820"><b>T</b></p>
<p style="position:absolute;top:292px;left:130px;white-space:nowrap" class="ft7820"><b>M</b></p>
<p style="position:absolute;top:276px;left:130px;white-space:nowrap" class="ft7820"><b>E</b></p>
<p style="position:absolute;top:265px;left:130px;white-space:nowrap" class="ft7820"><b>N</b></p>
<p style="position:absolute;top:253px;left:130px;white-space:nowrap" class="ft7820"><b>T</b></p>
<p style="position:absolute;top:242px;left:130px;white-space:nowrap" class="ft7820"><b>&#160;F</b></p>
<p style="position:absolute;top:228px;left:130px;white-space:nowrap" class="ft7820"><b>A</b></p>
<p style="position:absolute;top:216px;left:130px;white-space:nowrap" class="ft7820"><b>IL</b></p>
<p style="position:absolute;top:199px;left:130px;white-space:nowrap" class="ft7820"><b>U</b></p>
<p style="position:absolute;top:187px;left:130px;white-space:nowrap" class="ft7820"><b>R</b></p>
<p style="position:absolute;top:175px;left:130px;white-space:nowrap" class="ft7820"><b>E</b></p>
<p style="position:absolute;top:164px;left:130px;white-space:nowrap" class="ft7820"><b>&#160;R</b></p>
<p style="position:absolute;top:148px;left:130px;white-space:nowrap" class="ft7820"><b>A</b></p>
<p style="position:absolute;top:136px;left:130px;white-space:nowrap" class="ft7820"><b>T</b></p>
<p style="position:absolute;top:125px;left:130px;white-space:nowrap" class="ft7820"><b>E</b></p>
<p style="position:absolute;top:114px;left:130px;white-space:nowrap" class="ft7820"><b>&#160;(</b></p>
<p style="position:absolute;top:104px;left:130px;white-space:nowrap" class="ft7820"><b>%</b></p>
<p style="position:absolute;top:88px;left:130px;white-space:nowrap" class="ft7820"><b>)</b></p>
<p style="position:absolute;top:376px;left:410px;white-space:nowrap" class="ft782">TIME (MONTHS)</p>
<p style="position:absolute;top:395px;left:150px;white-space:nowrap" class="ft782">Study UV II &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; Treatment</p>
<p style="position:absolute;top:395px;left:500px;white-space:nowrap" class="ft782">Placebo</p>
<p style="position:absolute;top:395px;left:669px;white-space:nowrap" class="ft782">Adalimumab</p>
<p style="position:absolute;top:427px;left:114px;white-space:nowrap" class="ft784">Note: P# = Placebo (Number of Events/Number at Risk); A# = HUMIRA (Number of<br/>Events/Number at Risk).</p>
<p style="position:absolute;top:489px;left:106px;white-space:nowrap" class="ft784">In Study UV I statistically&#160;significant differences in favour of adalimumab versus placebo were observed&#160;<br/>for each component of treatment failure. In Study UV II, statistically significant differences were observed&#160;<br/>for visual acuity only, but the other components were numerically in favour of adalimumab.</p>
<p style="position:absolute;top:565px;left:106px;white-space:nowrap" class="ft784">Of the&#160;424&#160;subjects included&#160;in&#160;the&#160;uncontrolled long-term&#160;extension of Studies UV I and UV II,&#160;60<br/>subjects were regarded ineligible (e.g.&#160;due to deviations or due to&#160;complications secondary to diabetic&#160;<br/>retinopathy, due to cataract&#160;surgery or vitrectomy) and were excluded from the primary analysis&#160;of&#160;<br/>efficacy. Of the&#160;364&#160;remaining patients,&#160;269&#160;evaluable patients&#160;(74%)&#160;reached 78 weeks of open-label&#160;<br/>adalimumab treatment. Based on the observed data approach,&#160;216&#160;(80.3%) were in quiescence&#160;(no active&#160;<br/>inflammatory lesions, AC cell grade &#160;≤ 0.5+, VH grade ≤ 0.5+) with a concomitant steroid dose ≤ 7.5 mg&#160;<br/>per day, and&#160;178&#160;(66.2%) were in steroid-free quiescence. BCVA was either improved or maintained (&lt; 5&#160;<br/>letters deterioration) in 88.6% of&#160;the eyes at week 78.&#160;Data beyond Week 78 were generally consistent&#160;<br/>with these results but the number of enrolled subjects declined after this time. Overall, among the patients&#160;<br/>who discontinued the study,&#160;18% discontinued due to adverse events, and&#160;8% due to&#160;insufficient response&#160;<br/>to adalimumab treatment.</p>
<p style="position:absolute;top:792px;left:106px;white-space:nowrap" class="ft783"><i>Quality of Life</i></p>
<p style="position:absolute;top:831px;left:106px;white-space:nowrap" class="ft785">Patient reported outcomes regarding vision-related functioning were measured in both clinical studies,&#160;<br/>using the NEI VFQ-25. Humira was numerically favoured for the majority of subscores&#160;with statistically&#160;<br/>significant mean differences for general vision, ocular pain, near vision, mental health, and total score in&#160;<br/>Study UV I, and for general vision and mental health in Study UV II. Vision related effects were not&#160;<br/>numerically in favour of Humira for colour vision in Study UVI and for colour vision, peripheral vision&#160;<br/>and near vision in Study UV II.</p>
<p style="position:absolute;top:963px;left:106px;white-space:nowrap" class="ft782">Immunogenicity</p>
<p style="position:absolute;top:1001px;left:106px;white-space:nowrap" class="ft784">Formation of anti-adalimumab antibodies is associated with increased clearance and reduced efficacy of&#160;<br/>adalimumab. There is no apparent correlation between the presence of anti-adalimumab antibodies and the&#160;<br/>occurrence of adverse events.</p>
</div>
<!-- Page 79 -->
<a name="79"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page79-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft790">79</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft795">In patients with polyarticular juvenile idiopathic arthritis who were 4 to 17&#160;years, anti-&#160;adalimumab&#160;<br/>antibodies were identified in 15.8% (27/171) of patients treated with adalimumab. In patients not given&#160;<br/>concomitant methotrexate, the incidence was 25.6% (22/86) compared to 5.9% (5/85) when adalimumab&#160;<br/>was used as add-on to methotrexate.&#160;In patients with polyarticular juvenile idiopathic arthritis who&#160;were&#160;<br/>2&#160;to&#160;&lt;&#160;4 years old or aged 4 and above weighing &lt;15&#160;kg, anti-adalimumab antibodies were identified in&#160;<br/>7% (1/15) of patients, and the one patient was receiving concomitant methotrexate.</p>
<p style="position:absolute;top:219px;left:106px;white-space:nowrap" class="ft794">In patients with enthesitis-related arthritis, anti-adalimumab antibodies were identified in 10.9% (5/46) of&#160;<br/>patients treated with adalimumab. In patients not given concomitant methotrexate, the incidence was&#160;<br/>13.6% (3/22), compared to 8.3% (2/24) when adalimumab was used as add-on to methotrexate.</p>
<p style="position:absolute;top:295px;left:106px;white-space:nowrap" class="ft795">Patients in rheumatoid arthritis studies I, II and III were tested at multiple time points for anti-adalimumab&#160;<br/>antibodies during the 6 to 12&#160;month period. In the pivotal trials, anti-adalimumab antibodies were&#160;<br/>identified in 5.5% (58/1053) of patients treated with adalimumab,&#160;compared to 0.5% (2/370) on placebo.&#160;<br/>In patients not given concomitant methotrexate, the incidence was 12.4%, compared to 0.6% when&#160;<br/>adalimumab was used as add-on to methotrexate. &#160;</p>
<p style="position:absolute;top:409px;left:106px;white-space:nowrap" class="ft795">In patients with paediatric psoriasis, anti-adalimumab antibodies were identified in 5/38 subjects (13%)&#160;<br/>treated with 0.8&#160;mg/kg adalimumab monotherapy.</p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft794">In adult patients with psoriasis, anti-adalimumab antibodies were identified in 77/920 subjects (8.4%)&#160;<br/>treated with adalimumab monotherapy.</p>
<p style="position:absolute;top:522px;left:106px;white-space:nowrap" class="ft795">In adult plaque psoriasis patients&#160;on long term adalimumab monotherapy who participated in a withdrawal&#160;<br/>and retreatment study, the rate of antibodies to adalimumab after retreatment (11 of 482 subjects, 2.3%)&#160;<br/>was similar to the rate observed prior to withdrawal (11 of 590 subjects, 1.9%).</p>
<p style="position:absolute;top:598px;left:106px;white-space:nowrap" class="ft795">In patients with moderately to severely active paediatric Crohn’s disease, the rate of anti-adalimumab&#160;<br/>antibody development in patients receiving adalimumab was 3.3%.&#160;</p>
<p style="position:absolute;top:655px;left:106px;white-space:nowrap" class="ft794">In&#160;adult&#160;patients with Crohn’s disease, anti-adalimumab antibodies were identified in 7/269 subjects&#160;<br/>(2.6%).</p>
<p style="position:absolute;top:712px;left:106px;white-space:nowrap" class="ft794">In&#160;adult&#160;patients with non-infectious uveitis, anti-adalimumab antibodies were identified in 4.8% (12/249)&#160;<br/>of patients treated with adalimumab.</p>
<p style="position:absolute;top:769px;left:106px;white-space:nowrap" class="ft794">In patients with moderately to severely active paediatric ulcerative colitis, the rate of anti-adalimumab&#160;<br/>antibody development in patients receiving adalimumab was&#160;3%.</p>
<p style="position:absolute;top:826px;left:106px;white-space:nowrap" class="ft794">Because immunogenicity analyses are product-specific, comparison of antibody rates with&#160;those from&#160;<br/>other products is not appropriate.</p>
<p style="position:absolute;top:883px;left:106px;white-space:nowrap" class="ft792">Paediatric population</p>
<p style="position:absolute;top:921px;left:106px;white-space:nowrap" class="ft793"><i>Juvenile idiopathic arthritis (JIA)</i></p>
<p style="position:absolute;top:959px;left:106px;white-space:nowrap" class="ft793"><i>Polyarticular juvenile&#160;idiopathic&#160;arthritis (pJIA)</i></p>
<p style="position:absolute;top:997px;left:106px;white-space:nowrap" class="ft794">The safety and efficacy of Humira was assessed in two studies (pJIA I and II) in children with&#160;active&#160;<br/>polyarticular or polyarticular course juvenile idiopathic arthritis, who had a variety of JIA onset types&#160;<br/>(most frequently rheumatoid-factor negative or positive polyarthritis and extended oligoarthritis).</p>
<p style="position:absolute;top:1072px;left:106px;white-space:nowrap" class="ft792">pJIA I</p>
</div>
<!-- Page 80 -->
<a name="80"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page80-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft800">80</p>
<p style="position:absolute;top:100px;left:106px;white-space:nowrap" class="ft807">The safety and efficacy of Humira&#160;were assessed in a multicentre, randomised, double-blind,&#160;<br/>parallel&#160;−&#160;group study in 171 children (4-17&#160;years old) with polyarticular JIA. In the open-label lead in&#160;<br/>phase (OL LI) patients were stratified into two groups, MTX (methotrexate)-treated or non-&#160;MTX-treated.&#160;<br/>Patients who were in the non-MTX stratum were either naïve to or had been withdrawn from MTX at&#160;<br/>least two weeks prior to study drug administration. Patients remained on stable doses of&#160;non-steroidal&#160;<br/>anti-inflammatory drugs&#160;(NSAIDs)&#160;and or prednisone (</p>
<p style="position:absolute;top:194px;left:471px;white-space:nowrap" class="ft806">&#160;0.2&#160;mg /kg/day or 10&#160;mg/day&#160;maximum). In the&#160;</p>
<p style="position:absolute;top:215px;left:106px;white-space:nowrap" class="ft804">OL LI phase all patients received 24&#160;mg/m2&#160;up to a maximum of 40&#160;mg Humira every other week for&#160;<br/>16&#160;weeks. The distribution of patients by age and minimum, median and maximum dose received during&#160;<br/>the OL&#160;LI phase is presented in Table&#160;20.</p>
<p style="position:absolute;top:291px;left:431px;white-space:nowrap" class="ft801"><b>Table&#160;20</b></p>
<p style="position:absolute;top:310px;left:157px;white-space:nowrap" class="ft801"><b>Distribution of patients by age and adalimumab dose received during the OL LI phase</b></p>
<p style="position:absolute;top:350px;left:122px;white-space:nowrap" class="ft801"><b>Age Group</b></p>
<p style="position:absolute;top:350px;left:304px;white-space:nowrap" class="ft8015"><b>Number of patients at Baseline&#160;<br/>n&#160;(%)</b></p>
<p style="position:absolute;top:350px;left:568px;white-space:nowrap" class="ft8015"><b>Minimum, median and&#160;<br/>maximum dose</b></p>
<p style="position:absolute;top:389px;left:122px;white-space:nowrap" class="ft802">4 to 7&#160;years</p>
<p style="position:absolute;top:389px;left:304px;white-space:nowrap" class="ft802">31 (18.1)</p>
<p style="position:absolute;top:389px;left:568px;white-space:nowrap" class="ft802">10, 20 and 25&#160;mg</p>
<p style="position:absolute;top:409px;left:122px;white-space:nowrap" class="ft802">8 to&#160;12&#160;years</p>
<p style="position:absolute;top:409px;left:304px;white-space:nowrap" class="ft802">71 (41.5)</p>
<p style="position:absolute;top:409px;left:568px;white-space:nowrap" class="ft802">20, 25 and 40&#160;mg</p>
<p style="position:absolute;top:428px;left:122px;white-space:nowrap" class="ft802">13 to 17&#160;years</p>
<p style="position:absolute;top:428px;left:304px;white-space:nowrap" class="ft802">69 (40.4)</p>
<p style="position:absolute;top:428px;left:568px;white-space:nowrap" class="ft802">25, 40 and 40&#160;mg</p>
<p style="position:absolute;top:467px;left:106px;white-space:nowrap" class="ft807">Patients demonstrating a Paediatric ACR 30 response at Week&#160;16 were eligible to be randomised into the&#160;<br/>double blind (DB) phase and received either Humira 24&#160;mg/m2&#160;up to a maximum of 40&#160;mg, or placebo&#160;<br/>every other week for an additional 32&#160;weeks or until disease flare. Disease flare criteria were defined as a&#160;<br/>worsening of&#160;</p>
<p style="position:absolute;top:523px;left:197px;white-space:nowrap" class="ft806">&#160;30% from baseline in&#160;&#160;3 of 6 Paediatric ACR core criteria,&#160;&#160;2 active joints, and&#160;</p>
<p style="position:absolute;top:545px;left:106px;white-space:nowrap" class="ft802">improvement&#160;of&#160;</p>
<p style="position:absolute;top:544px;left:216px;white-space:nowrap" class="ft806">&#160;30% in no more than 1 of the 6 criteria. After 32&#160;weeks or at disease flare, patients&#160;</p>
<p style="position:absolute;top:564px;left:106px;white-space:nowrap" class="ft802">were&#160;eligible to enrol into the open label extension phase.&#160;</p>
<p style="position:absolute;top:602px;left:431px;white-space:nowrap" class="ft801"><b>Table&#160;21</b></p>
<p style="position:absolute;top:621px;left:321px;white-space:nowrap" class="ft801"><b>Ped ACR 30 Responses in the JIA study</b></p>
<p style="position:absolute;top:662px;left:122px;white-space:nowrap" class="ft801"><b>Stratum</b></p>
<p style="position:absolute;top:662px;left:406px;white-space:nowrap" class="ft801"><b>MTX</b></p>
<p style="position:absolute;top:662px;left:629px;white-space:nowrap" class="ft801"><b>Without MTX</b></p>
<p style="position:absolute;top:681px;left:122px;white-space:nowrap" class="ft8019"><b>Phase<br/></b>OL-LI 16&#160;weeks</p>
<p style="position:absolute;top:721px;left:165px;white-space:nowrap" class="ft804">Ped&#160;ACR 30&#160;<br/>response (n/N)</p>
<p style="position:absolute;top:721px;left:378px;white-space:nowrap" class="ft802">94.1% (80/85)</p>
<p style="position:absolute;top:721px;left:631px;white-space:nowrap" class="ft802">74.4% (64/86)</p>
<p style="position:absolute;top:760px;left:122px;white-space:nowrap" class="ft804">&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160;Efficacy Outcomes<br/>Double Blind 32&#160;weeks</p>
<p style="position:absolute;top:779px;left:304px;white-space:nowrap" class="ft805">Humira / MTX<br/>(N = 38)</p>
<p style="position:absolute;top:779px;left:436px;white-space:nowrap" class="ft805">Placebo / MTX<br/>(N = 37)</p>
<p style="position:absolute;top:779px;left:568px;white-space:nowrap" class="ft805">Humira&#160;<br/>(N = 30)</p>
<p style="position:absolute;top:779px;left:692px;white-space:nowrap" class="ft805">Placebo<br/>(N = 28)</p>
<p style="position:absolute;top:837px;left:165px;white-space:nowrap" class="ft804">Disease flares at&#160;<br/>the&#160;end of&#160;<br/>32weeksa&#160;(n/N)</p>
<p style="position:absolute;top:837px;left:304px;white-space:nowrap" class="ft802">36.8% (14/38)</p>
<p style="position:absolute;top:837px;left:436px;white-space:nowrap" class="ft802">64.9% (24/37)b</p>
<p style="position:absolute;top:837px;left:568px;white-space:nowrap" class="ft802">43.3% (13/30)</p>
<p style="position:absolute;top:837px;left:692px;white-space:nowrap" class="ft805">71.4%&#160;<br/>(20/28)c</p>
<p style="position:absolute;top:895px;left:165px;white-space:nowrap" class="ft804">Median time to&#160;<br/>disease flare</p>
<p style="position:absolute;top:895px;left:304px;white-space:nowrap" class="ft802">&gt;32&#160;weeks</p>
<p style="position:absolute;top:895px;left:436px;white-space:nowrap" class="ft802">20&#160;weeks</p>
<p style="position:absolute;top:895px;left:568px;white-space:nowrap" class="ft802">&gt;32&#160;weeks</p>
<p style="position:absolute;top:895px;left:692px;white-space:nowrap" class="ft802">14&#160;weeks</p>
<p style="position:absolute;top:953px;left:114px;white-space:nowrap" class="ft809">a&#160;Ped ACR 30/50/70 responses Week&#160;48 significantly greater than those of placebo treated patients&#160;</p>
<p style="position:absolute;top:972px;left:114px;white-space:nowrap" class="ft809">b&#160;p = 0.015</p>
<p style="position:absolute;top:990px;left:114px;white-space:nowrap" class="ft809">c&#160;p = 0.031</p>
<p style="position:absolute;top:1030px;left:106px;white-space:nowrap" class="ft805">Amongst those who responded at Week&#160;16&#160;(n=144), the Paediatric ACR 30/50/70/90 responses were&#160;<br/>maintained for up to six years in the OLE phase in patients who received Humira throughout the study.</p>
</div>
<!-- Page 81 -->
<a name="81"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page81-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft810">81</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft815">Over all 19 subjects, of which 11 of&#160;the baseline age group 4 to 12 and 8 of the baseline age group 13 to&#160;<br/>17&#160;years were treated 6&#160;years or longer.</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft814">Overall responses were generally better and, fewer patients developed antibodies when treated with the&#160;<br/>combination of Humira and MTX compared to&#160;Humira alone. Taking these results into consideration,&#160;<br/>Humira is recommended for use in combination with MTX and for use as monotherapy in patients for&#160;<br/>whom MTX use is not appropriate (see section 4.2).&#160;</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft812">pJIA II</p>
<p style="position:absolute;top:276px;left:106px;white-space:nowrap" class="ft814">The safety and efficacy of Humira was&#160;assessed in an open-label, multicentre study in 32 children (2&#160;-<br/>&lt;4&#160;years old or&#160;aged 4 and above weighing &lt; 15&#160;kg) with moderately to severely active polyarticular JIA.&#160;<br/>The patients&#160;received 24&#160;mg/m2&#160;body surface area (BSA) of Humira up to a maximum of 20&#160;mg&#160;every&#160;<br/>other week as a single dose via SC injection for at least 24&#160;weeks. During the study, most subjects used&#160;<br/>concomitant MTX, with fewer reporting use of corticosteroids or NSAIDs.</p>
<p style="position:absolute;top:390px;left:106px;white-space:nowrap" class="ft814">At Week 12&#160;and Week&#160;24, PedACR30 response was 93.5% and 90.0%, respectively, using the observed&#160;<br/>data approach. The proportions of subjects with PedACR50/70/90 at Week&#160;12 and Week&#160;24 were&#160;<br/>90.3%/61.3%/38.7% and 83.3%/73.3%/36.7%, respectively. Amongst those who responded (Paediatric&#160;<br/>ACR 30) at Week&#160;24 (n=27 out of 30 patients), the Paediatric ACR 30 responses were maintained for up&#160;<br/>to 60&#160;weeks in the OLE phase in patients who received Humira throughout this time period. Overall, 20&#160;<br/>subjects were treated for 60&#160;weeks&#160;or longer.</p>
<p style="position:absolute;top:522px;left:106px;white-space:nowrap" class="ft813"><i>Enthesitis-related arthritis</i></p>
<p style="position:absolute;top:560px;left:106px;white-space:nowrap" class="ft815">The safety and efficacy of Humira were assessed in a&#160;multicentre, randomised, double-blind study in 46&#160;<br/>paediatric patients (6 to 17&#160;years old) with moderate enthesitis-related arthritis. Patients were randomised&#160;<br/>to receive either 24&#160;mg/m2&#160;body surface area&#160;(BSA) of Humira up to a maximum of 40&#160;mg, or placebo&#160;<br/>every other week for 12&#160;weeks. The double-blind period is followed by an open-label (OL) period during&#160;<br/>which patients received&#160;24&#160;mg/m2&#160;BSA of Humira up to a maximum of 40&#160;mg&#160;every other week&#160;<br/>subcutaneously for up to an additional 192&#160;weeks. The primary endpoint was the percent change from&#160;<br/>Baseline to Week&#160;12 in the number of active joints with arthritis (swelling not due to deformity or joints&#160;<br/>with loss of motion plus pain and/or tenderness), which was&#160;achieved with mean percent decrease of&#160;-<br/>62.6% (median percent change&#160;-88.9%) in patients in the Humira group compared to&#160;-11.6% (median&#160;<br/>percent change&#160;-50.0%) in patients in the placebo group. Improvement in number of active joints with&#160;<br/>arthritis was maintained during the OL period through Week&#160;156 for the 26 of 31 (84%) patients in the&#160;<br/>Humira group who remained in&#160;the study. Although not statistically significant, the majority of patients&#160;<br/>demonstrated clinical improvement in secondary endpoints such as number of sites of enthesitis, tender&#160;<br/>joint count (TJC), swollen joint count (SJC), Paediatric ACR 50 response, and Paediatric ACR 70&#160;<br/>response.</p>
<p style="position:absolute;top:864px;left:106px;white-space:nowrap" class="ft813"><i>Paediatric plaque psoriasis</i></p>
<p style="position:absolute;top:911px;left:106px;white-space:nowrap" class="ft815">The&#160;efficacy of Humira was assessed in a randomised, double-blind, controlled study of 114 paediatric&#160;<br/>patients from 4&#160;years of age with severe chronic plaque psoriasis (as defined by a&#160;Physician’s Global&#160;<br/>Assessment&#160;(PGA)&#160;≥&#160;4 or &gt;&#160;20% BSA involvement or &gt;&#160;10% BSA involvement with very thick lesions or&#160;<br/>Psoriasis Area and Severity Index (PASI)&#160;≥&#160;20 or&#160;≥&#160;10 with clinically relevant facial, genital, or hand/ foot&#160;<br/>involvement) who were inadequately controlled with topical therapy and heliotherapy or phototherapy.&#160;</p>
<p style="position:absolute;top:1025px;left:106px;white-space:nowrap" class="ft814">Patients received Humira 0.8&#160;mg/kg&#160;eow (up to 40&#160;mg), 0.4&#160;mg/kg&#160;eow (up to 20&#160;mg),&#160;or methotrexate 0.1&#160;<br/>–&#160;0.4&#160;mg/kg&#160;weekly (up to 25&#160;mg). At week&#160;16, more patients randomised to Humira 0.8&#160;mg/kg had&#160;<br/>positive efficacy responses (e.g., PASI 75) than those randomised to 0.4&#160;mg/kg&#160;eow or MTX. &#160;</p>
</div>
<!-- Page 82 -->
<a name="82"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page82-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft820">82</p>
<p style="position:absolute;top:106px;left:224px;white-space:nowrap" class="ft821"><b>Table&#160;22:&#160;Paediatric Plaque Psoriasis Efficacy&#160;Results at 16&#160;Weeks</b></p>
<p style="position:absolute;top:147px;left:451px;white-space:nowrap" class="ft822">MTXa</p>
<p style="position:absolute;top:166px;left:453px;white-space:nowrap" class="ft822">N=37&#160;</p>
<p style="position:absolute;top:147px;left:578px;white-space:nowrap" class="ft822">Humira 0.8&#160;mg/kg&#160;eow</p>
<p style="position:absolute;top:166px;left:635px;white-space:nowrap" class="ft822">N=38&#160;</p>
<p style="position:absolute;top:189px;left:162px;white-space:nowrap" class="ft822">PASI 75b</p>
<p style="position:absolute;top:189px;left:435px;white-space:nowrap" class="ft822">12 (32.4%)</p>
<p style="position:absolute;top:189px;left:617px;white-space:nowrap" class="ft822">22 (57.9%)</p>
<p style="position:absolute;top:211px;left:162px;white-space:nowrap" class="ft822">PGA: Clear/minimalc</p>
<p style="position:absolute;top:211px;left:435px;white-space:nowrap" class="ft822">15 (40.5%)</p>
<p style="position:absolute;top:211px;left:617px;white-space:nowrap" class="ft822">23 (60.5%)</p>
<p style="position:absolute;top:232px;left:145px;white-space:nowrap" class="ft829">a&#160;MTX = methotrexate</p>
<p style="position:absolute;top:251px;left:145px;white-space:nowrap" class="ft829">b&#160;P=0.027, Humira 0.8&#160;mg/kg versus MTX</p>
<p style="position:absolute;top:270px;left:145px;white-space:nowrap" class="ft829">c&#160;P=0.083, Humira 0.8&#160;mg/kg versus MTX</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft825">Patients who&#160;achieved PASI 75 and PGA clear or minimal were withdrawn from treatment for up to&#160;<br/>36&#160;weeks and monitored for loss of disease control (i.e. a worsening of PGA by at least 2 grades). Patients&#160;<br/>were then re-treated with adalimumab 0.8 mg/kg eow for an additional 16&#160;weeks and response rates&#160;<br/>observed during retreatment were similar to the previous double-blind period: &#160;PASI 75 response of 78.9%&#160;<br/>(15 of 19 subjects) and PGA clear or minimal of 52.6% (10 of 19 subjects).</p>
<p style="position:absolute;top:426px;left:106px;white-space:nowrap" class="ft825">In the open label period of the study, PASI&#160;75 and PGA clear or minimal responses were maintained for&#160;<br/>up to an additional 52&#160;weeks with no&#160;new safety findings.</p>
<p style="position:absolute;top:482px;left:106px;white-space:nowrap" class="ft823"><i>Adolescent hidradenitis suppurativa</i></p>
<p style="position:absolute;top:520px;left:106px;white-space:nowrap" class="ft825">There are no clinical trials with Humira in adolescent patients with HS. Efficacy of adalimumab for the&#160;<br/>treatment of adolescent patients with HS is predicted based on the demonstrated efficacy and exposure-<br/>response relationship in adult HS patients and the likelihood that the disease course, pathophysiology, and&#160;<br/>drug effects are&#160;substantially similar to that of adults at the same exposure levels. Safety of the&#160;<br/>recommended adalimumab dose in the adolescent HS population is based on cross-indication safety&#160;<br/>profile of adalimumab in both adults and paediatric patients at similar or more frequent doses&#160;(see section&#160;<br/>5.2).</p>
<p style="position:absolute;top:672px;left:106px;white-space:nowrap" class="ft823"><i>Paediatric Crohn’s disease</i></p>
<p style="position:absolute;top:710px;left:106px;white-space:nowrap" class="ft825">Humira was assessed in a multicentre, randomised, double-blind clinical trial designed to evaluate the&#160;<br/>efficacy and safety of induction and maintenance treatment with doses dependent on body&#160;weight&#160;<br/>(&lt;&#160;40&#160;kg&#160;or&#160;≥&#160;40&#160;kg) in 192 paediatric subjects between the ages of 6 and 17 (inclusive) years, with&#160;<br/>moderate to severe Crohn´s disease (CD) defined as Paediatric Crohn's Disease Activity Index (PCDAI)&#160;<br/>score &gt;&#160;30. Subjects had to have failed conventional therapy (including a corticosteroid and/or an&#160;<br/>immunomodulator) for CD. Subjects may also have previously lost response or been intolerant to&#160;<br/>infliximab.&#160;</p>
<p style="position:absolute;top:862px;left:106px;white-space:nowrap" class="ft825">All subjects received open-label induction therapy at a dose based on their Baseline body weight: 160&#160;mg&#160;<br/>at Week&#160;0 and 80&#160;mg at Week&#160;2 for subjects&#160;≥&#160;40&#160;kg, and 80&#160;mg and 40&#160;mg, respectively, for subjects&#160;<br/>&lt;&#160;40&#160;kg.</p>
<p style="position:absolute;top:938px;left:106px;white-space:nowrap" class="ft825">At Week&#160;4, subjects were randomised 1:1 based on their body weight at the time to either the Low Dose or&#160;<br/>Standard Dose maintenance regimens as shown in Table&#160;23.</p>
</div>
<!-- Page 83 -->
<a name="83"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page83-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft830">83</p>
<p style="position:absolute;top:105px;left:428px;white-space:nowrap" class="ft831"><b>Table&#160;23</b></p>
<p style="position:absolute;top:124px;left:382px;white-space:nowrap" class="ft831"><b>Maintenance regimen</b></p>
<p style="position:absolute;top:144px;left:339px;white-space:nowrap" class="ft8319"><b>Patient&#160;<br/>Weight</b></p>
<p style="position:absolute;top:144px;left:413px;white-space:nowrap" class="ft831"><b>Low dose</b></p>
<p style="position:absolute;top:144px;left:504px;white-space:nowrap" class="ft8319"><b>Standard&#160;<br/>dose</b></p>
<p style="position:absolute;top:182px;left:339px;white-space:nowrap" class="ft832">&lt;&#160;40&#160;kg</p>
<p style="position:absolute;top:182px;left:413px;white-space:nowrap" class="ft832">10&#160;mg&#160;eow&#160;20&#160;mg&#160;eow</p>
<p style="position:absolute;top:202px;left:339px;white-space:nowrap" class="ft832">≥&#160;40&#160;kg</p>
<p style="position:absolute;top:202px;left:413px;white-space:nowrap" class="ft832">20&#160;mg&#160;eow&#160;40&#160;mg&#160;eow</p>
<p style="position:absolute;top:241px;left:106px;white-space:nowrap" class="ft833"><i>Efficacy results</i></p>
<p style="position:absolute;top:280px;left:106px;white-space:nowrap" class="ft832">The primary endpoint of the study was clinical remission at Week&#160;26, defined as PCDAI score&#160;</p>
<p style="position:absolute;top:278px;left:734px;white-space:nowrap" class="ft836">&#160;10.</p>
<p style="position:absolute;top:318px;left:106px;white-space:nowrap" class="ft835">Clinical remission and clinical response (defined as reduction in PCDAI score of at least 15 points from&#160;<br/>Baseline) rates are presented in Table&#160;24. Rates of&#160;discontinuation of corticosteroids or&#160;<br/>immunomodulators are presented in Table&#160;25.</p>
<p style="position:absolute;top:397px;left:429px;white-space:nowrap" class="ft831"><b>Table&#160;24</b></p>
<p style="position:absolute;top:415px;left:386px;white-space:nowrap" class="ft831"><b>Paediatric CD Study</b></p>
<p style="position:absolute;top:435px;left:315px;white-space:nowrap" class="ft831"><b>PCDAI Clinical Remission and Response</b></p>
<p style="position:absolute;top:455px;left:392px;white-space:nowrap" class="ft831"><b>Standard Dose</b></p>
<p style="position:absolute;top:474px;left:396px;white-space:nowrap" class="ft831"><b>40/20&#160;mg&#160;eow&#160;</b></p>
<p style="position:absolute;top:492px;left:421px;white-space:nowrap" class="ft831"><b>N = 93</b></p>
<p style="position:absolute;top:455px;left:529px;white-space:nowrap" class="ft831"><b>Low Dose</b></p>
<p style="position:absolute;top:474px;left:516px;white-space:nowrap" class="ft831"><b>20/10&#160;mg&#160;eow&#160;</b></p>
<p style="position:absolute;top:492px;left:541px;white-space:nowrap" class="ft831"><b>N = 95</b></p>
<p style="position:absolute;top:455px;left:637px;white-space:nowrap" class="ft831"><b>P value</b>*</p>
<p style="position:absolute;top:513px;left:210px;white-space:nowrap" class="ft8321"><b>Week&#160;26<br/></b>&#160; &#160;Clinical remission</p>
<p style="position:absolute;top:533px;left:423px;white-space:nowrap" class="ft832">38.7%</p>
<p style="position:absolute;top:533px;left:543px;white-space:nowrap" class="ft832">28.4%</p>
<p style="position:absolute;top:533px;left:648px;white-space:nowrap" class="ft832">0.075</p>
<p style="position:absolute;top:553px;left:210px;white-space:nowrap" class="ft832">&#160; &#160;Clinical response&#160;</p>
<p style="position:absolute;top:553px;left:423px;white-space:nowrap" class="ft832">59.1%</p>
<p style="position:absolute;top:553px;left:543px;white-space:nowrap" class="ft832">48.4%</p>
<p style="position:absolute;top:553px;left:648px;white-space:nowrap" class="ft832">0.073</p>
<p style="position:absolute;top:573px;left:210px;white-space:nowrap" class="ft8321"><b>Week&#160;52<br/></b>&#160; &#160;Clinical remission</p>
<p style="position:absolute;top:593px;left:423px;white-space:nowrap" class="ft832">33.3%</p>
<p style="position:absolute;top:593px;left:543px;white-space:nowrap" class="ft832">23.2%</p>
<p style="position:absolute;top:593px;left:648px;white-space:nowrap" class="ft832">0.100</p>
<p style="position:absolute;top:613px;left:210px;white-space:nowrap" class="ft832">&#160; &#160;Clinical response</p>
<p style="position:absolute;top:613px;left:423px;white-space:nowrap" class="ft832">41.9%</p>
<p style="position:absolute;top:613px;left:543px;white-space:nowrap" class="ft832">28.4%</p>
<p style="position:absolute;top:613px;left:648px;white-space:nowrap" class="ft832">0.038</p>
<p style="position:absolute;top:633px;left:210px;white-space:nowrap" class="ft832">*&#160;p value for Standard Dose&#160;<i>versus&#160;</i>Low Dose comparison.</p>
<p style="position:absolute;top:674px;left:428px;white-space:nowrap" class="ft831"><b>Table&#160;25</b></p>
<p style="position:absolute;top:693px;left:386px;white-space:nowrap" class="ft831"><b>Paediatric CD&#160;Study</b></p>
<p style="position:absolute;top:711px;left:175px;white-space:nowrap" class="ft831"><b>Discontinuation of Corticosteroids or Immunomodulators and Fistula Remission</b></p>
<p style="position:absolute;top:732px;left:455px;white-space:nowrap" class="ft831"><b>Standard Dose</b></p>
<p style="position:absolute;top:751px;left:459px;white-space:nowrap" class="ft831"><b>40/20&#160;mg&#160;eow&#160;</b></p>
<p style="position:absolute;top:732px;left:595px;white-space:nowrap" class="ft831"><b>Low Dose</b></p>
<p style="position:absolute;top:751px;left:582px;white-space:nowrap" class="ft831"><b>20/10&#160;mg&#160;eow&#160;</b></p>
<p style="position:absolute;top:732px;left:705px;white-space:nowrap" class="ft831"><b>P value1</b></p>
<p style="position:absolute;top:771px;left:143px;white-space:nowrap" class="ft831"><b>Discontinued corticosteroids</b></p>
<p style="position:absolute;top:771px;left:486px;white-space:nowrap" class="ft831"><b>N= 33</b></p>
<p style="position:absolute;top:771px;left:611px;white-space:nowrap" class="ft831"><b>N=38</b></p>
<p style="position:absolute;top:791px;left:143px;white-space:nowrap" class="ft832">Week&#160;26</p>
<p style="position:absolute;top:791px;left:486px;white-space:nowrap" class="ft832">84.8%</p>
<p style="position:absolute;top:791px;left:608px;white-space:nowrap" class="ft832">65.8%</p>
<p style="position:absolute;top:791px;left:715px;white-space:nowrap" class="ft832">0.066</p>
<p style="position:absolute;top:811px;left:143px;white-space:nowrap" class="ft832">Week&#160;52</p>
<p style="position:absolute;top:811px;left:486px;white-space:nowrap" class="ft832">69.7%</p>
<p style="position:absolute;top:811px;left:608px;white-space:nowrap" class="ft832">60.5%</p>
<p style="position:absolute;top:811px;left:715px;white-space:nowrap" class="ft832">0.420</p>
<p style="position:absolute;top:831px;left:143px;white-space:nowrap" class="ft831"><b>Discontinuation of Immunomodulators2</b></p>
<p style="position:absolute;top:831px;left:488px;white-space:nowrap" class="ft831"><b>N=60</b></p>
<p style="position:absolute;top:831px;left:611px;white-space:nowrap" class="ft831"><b>N=57</b></p>
<p style="position:absolute;top:851px;left:143px;white-space:nowrap" class="ft832">Week&#160;52</p>
<p style="position:absolute;top:851px;left:486px;white-space:nowrap" class="ft832">30.0%</p>
<p style="position:absolute;top:851px;left:608px;white-space:nowrap" class="ft832">29.8%</p>
<p style="position:absolute;top:851px;left:715px;white-space:nowrap" class="ft832">0.983</p>
<p style="position:absolute;top:871px;left:143px;white-space:nowrap" class="ft831"><b>Fistula remission3</b></p>
<p style="position:absolute;top:871px;left:488px;white-space:nowrap" class="ft831"><b>N=15</b></p>
<p style="position:absolute;top:871px;left:611px;white-space:nowrap" class="ft831"><b>N=21</b></p>
<p style="position:absolute;top:891px;left:143px;white-space:nowrap" class="ft832">Week&#160;26</p>
<p style="position:absolute;top:891px;left:486px;white-space:nowrap" class="ft832">46.7%</p>
<p style="position:absolute;top:891px;left:608px;white-space:nowrap" class="ft832">38.1%</p>
<p style="position:absolute;top:891px;left:715px;white-space:nowrap" class="ft832">0.608</p>
<p style="position:absolute;top:911px;left:143px;white-space:nowrap" class="ft832">Week&#160;52,</p>
<p style="position:absolute;top:911px;left:486px;white-space:nowrap" class="ft832">40.0%</p>
<p style="position:absolute;top:911px;left:608px;white-space:nowrap" class="ft832">23.8%</p>
<p style="position:absolute;top:911px;left:715px;white-space:nowrap" class="ft832">0.303</p>
<p style="position:absolute;top:930px;left:143px;white-space:nowrap" class="ft839">1&#160;&#160;p value for Standard Dose&#160;<i>versus&#160;</i>Low Dose comparison.</p>
<p style="position:absolute;top:949px;left:145px;white-space:nowrap" class="ft839">2&#160;&#160;Immunosuppressant therapy could only be discontinued at or after Week&#160;26 at the&#160;</p>
<p style="position:absolute;top:969px;left:143px;white-space:nowrap" class="ft832">investigator's discretion if the subject met the clinical response criterion&#160;</p>
<p style="position:absolute;top:986px;left:143px;white-space:nowrap" class="ft837">3&#160;&#160;defined as a closure of all fistulas that were draining at Baseline for at least 2 consecutive&#160;<br/>post-Baseline visits</p>
<p style="position:absolute;top:1045px;left:106px;white-space:nowrap" class="ft834">Statistically significant increases (improvement) from Baseline to Week&#160;26 and 52 in Body Mass Index&#160;<br/>and height velocity were observed for both treatment groups.</p>
</div>
<!-- Page 84 -->
<a name="84"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page84-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft840">84</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft845">Statistically and clinically significant improvements from Baseline&#160;were also observed in both treatment&#160;<br/>groups for quality of life parameters (including IMPACT III).</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft844">One&#160;hundred patients (n=100) from the Paediatric CD Study continued in an open-label long-term&#160;<br/>extension study. After&#160;5 years of adalimumab therapy, 74.0% (37/50) of the 50 patients remaining in the&#160;<br/>study continued to be in clinical remission, and 92.0% (46/50) of patients continued to be in clinical&#160;<br/>response per PCDAI.</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft843"><i>Paediatric ulcerative colitis</i></p>
<p style="position:absolute;top:276px;left:106px;white-space:nowrap" class="ft845">The safety and efficacy of Humira was assessed in a multicenter, randomized, double-blind, trial in 93&#160;<br/>paediatric patients from 5 to 17 years of age with moderate to severe ulcerative colitis (Mayo score 6 to 12&#160;<br/>with endoscopy subscore of 2 to 3 points, confirmed by centrally read endoscopy) who had an inadequate<br/>response or intolerance to conventional therapy. Approximately 16% of patients in the study had failed&#160;<br/>prior anti-TNF treatment. Patients who received corticosteroids at enrollment were allowed to taper their&#160;<br/>corticosteroid therapy after Week 4.</p>
<p style="position:absolute;top:409px;left:106px;white-space:nowrap" class="ft844">In the induction period of the study,&#160;77&#160;patients were randomized 3:2 to receive double-blind treatment&#160;<br/>with&#160;Humira at&#160;an&#160;induction dose of 2.4 mg/kg (maximum of 160 mg) at Week 0 and Week 1, and 1.2&#160;<br/>mg/kg (maximum of 80 mg) at Week 2; or an&#160;induction dose of 2.4&#160;mg/kg (maximum of 160 mg) at Week&#160;<br/>0, placebo at Week 1, and 1.2 mg/kg (maximum of 80 mg) at Week 2.&#160;Both groups received 0.6 mg/kg&#160;<br/>(maximum of 40 mg) at Week 4 and Week 6.&#160;Following an amendment to the study design, the remaining&#160;<br/>16 patients who enrolled in the induction period received open-label treatment with&#160;Humira&#160;at the&#160;<br/>induction dose&#160;of 2.4 mg/kg (maximum of 160 mg) at Week 0 and Week 1, and 1.2 mg/kg (maximum of&#160;<br/>80 mg) at Week 2.</p>
<p style="position:absolute;top:579px;left:106px;white-space:nowrap" class="ft844">At Week 8, 62 patients who demonstrated&#160;clinical response&#160;per&#160;Partial Mayo Score (PMS;&#160;defined as a&#160;<br/>decrease in PMS&#160;≥ 2 points and ≥ 30% from Baseline)&#160;were randomized equally to receive double-blind&#160;<br/>maintenance treatment&#160;with Humira&#160;at a dose&#160;of 0.6 mg/kg (maximum of 40 mg) every week&#160;(ew),&#160;or&#160;a&#160;<br/>maintenance dose&#160;of 0.6 mg/kg (maximum of 40 mg) every other&#160;week (eow).&#160;Prior to an amendment to&#160;<br/>the study design, 12 additional patients who demonstrated clinical response per PMS were randomized to&#160;<br/>receive&#160;placebo&#160;but were not included in&#160;the confirmatory&#160;analysis of efficacy.</p>
<p style="position:absolute;top:712px;left:106px;white-space:nowrap" class="ft845">Disease flare was defined as an increase in&#160;PMS&#160;of&#160;at least&#160;3 points (for patients with PMS of 0 to 2 at&#160;<br/>Week 8),&#160;at least&#160;2 points (for patients with PMS of 3 to 4 at Week 8), or&#160;at least&#160;1&#160;point (for patients with&#160;<br/>PMS of 5 to 6 at Week 8).</p>
<p style="position:absolute;top:788px;left:106px;white-space:nowrap" class="ft845">Patients who met criteria for disease flare&#160;at or after Week 12&#160;were randomized to receive a re-induction&#160;<br/>dose of 2.4 mg/kg (maximum of 160 mg) or a dose of 0.6 mg/kg (maximum of 40 mg) and continued to&#160;<br/>receive their respective maintenance dose regimen afterwards.</p>
<p style="position:absolute;top:869px;left:106px;white-space:nowrap" class="ft843"><i>Efficacy Results</i></p>
<p style="position:absolute;top:916px;left:106px;white-space:nowrap" class="ft844">The co-primary endpoints of the study were clinical remission per PMS (defined as PMS&#160;≤ 2 and no&#160;<br/>individual subscore &gt; 1) at Week 8, and clinical remission per FMS (Full Mayo Score) (defined as a Mayo&#160;<br/>Score&#160;≤ 2 and no individual&#160;subscore &gt; 1) at Week 52 in patients who achieved clinical response per PMS&#160;<br/>at Week 8.</p>
<p style="position:absolute;top:1011px;left:106px;white-space:nowrap" class="ft844">Clinical remission rates per PMS at Week 8 for&#160;patients&#160;in&#160;each&#160;of the&#160;Humira&#160;double-<br/>blind&#160;induction&#160;groups&#160;are&#160;presented in&#160;Table 26.</p>
</div>
<!-- Page 85 -->
<a name="85"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft8523{font-size:17px;line-height:21px;font-family:HORGHZ+TimesNewRoman;color:#000000;}
-->
</style>
<div id="page85-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft850">85</p>
<p style="position:absolute;top:86px;left:284px;white-space:nowrap" class="ft851"><b>Table 26: Clinical Remission per PMS at 8 Weeks&#160;</b></p>
<p style="position:absolute;top:130px;left:387px;white-space:nowrap" class="ft851"><b>Humiraa</b></p>
<p style="position:absolute;top:152px;left:315px;white-space:nowrap" class="ft851"><b>Maximum&#160;of&#160;160 mg&#160;at Week&#160;</b></p>
<p style="position:absolute;top:174px;left:342px;white-space:nowrap" class="ft851"><b>0&#160;/&#160;Placebo&#160;at Week 1</b></p>
<p style="position:absolute;top:195px;left:400px;white-space:nowrap" class="ft852">N=30</p>
<p style="position:absolute;top:130px;left:607px;white-space:nowrap" class="ft851"><b>Humirab, c</b></p>
<p style="position:absolute;top:152px;left:540px;white-space:nowrap" class="ft851"><b>Maximum of 160 mg&#160;at Week&#160;</b></p>
<p style="position:absolute;top:174px;left:594px;white-space:nowrap" class="ft851"><b>0&#160;and&#160;Week 1</b></p>
<p style="position:absolute;top:195px;left:626px;white-space:nowrap" class="ft852">N=47</p>
<p style="position:absolute;top:221px;left:161px;white-space:nowrap" class="ft852">Clinical remission</p>
<p style="position:absolute;top:221px;left:372px;white-space:nowrap" class="ft852">13/30 (43.3%)</p>
<p style="position:absolute;top:221px;left:597px;white-space:nowrap" class="ft852">28/47 (59.6%)</p>
<p style="position:absolute;top:244px;left:161px;white-space:nowrap" class="ft8523">a&#160;Humira&#160;2.4 mg/kg&#160;(maximum of 160&#160;mg)&#160;at Week 0, placebo at Week 1,&#160;and&#160;1.2&#160;<br/>mg/kg&#160;(maximum of 80 mg)&#160;at Week 2<br/>b&#160;Humira&#160;2.4 mg/kg&#160;(maximum&#160;of 160 mg)&#160;at Week 0 and Week 1,&#160;and&#160;1.2&#160;<br/>mg/kg&#160;(maximum of 80 mg)&#160;at Week 2<br/>c&#160;Not including open-label Induction dose of&#160;Humira&#160;2.4 mg/kg&#160;(maximum&#160;of&#160;160 mg)&#160;at&#160;<br/>Week 0 and Week 1, and 1.2 mg/kg&#160;(maximum of 80 mg)&#160;at Week 2<br/>Note 1: Both induction groups received 0.6 mg/kg (maximum of 40 mg) at Week 4 and&#160;<br/>Week 6<br/>Note 2: Patients with missing values at Week 8 were considered as not having met the&#160;<br/>endpoint</p>
<p style="position:absolute;top:485px;left:106px;white-space:nowrap" class="ft855">At Week 52, clinical remission per FMS in Week 8 responders, clinical response per FMS (defined as a&#160;<br/>decrease in Mayo Score&#160;≥ 3 points and ≥ 30% from Baseline) in Week 8 responders, mucosal healing&#160;<br/>(defined as Mayo endoscopy&#160;subscore&#160;≤ 1) in Week 8&#160;responders, clinical remission per FMS in Week 8&#160;<br/>remitters, and the proportion of subjects in corticosteroid-free remission per FMS in Week 8 responders&#160;<br/>were assessed in patients who received Humira at the double-blind&#160;maximum 40 mg&#160;eow&#160;(0.6 mg/kg) and&#160;<br/>maximum 40 mg&#160;ew&#160;(0.6 mg/kg) maintenance doses (Table&#160;27).</p>
<p style="position:absolute;top:618px;left:320px;white-space:nowrap" class="ft851"><b>Table&#160;27: Efficacy Results at 52 Weeks</b></p>
<p style="position:absolute;top:663px;left:420px;white-space:nowrap" class="ft851"><b>Humiraa</b></p>
<p style="position:absolute;top:682px;left:368px;white-space:nowrap" class="ft851"><b>Maximum&#160;of&#160;40 mg&#160;eow</b></p>
<p style="position:absolute;top:701px;left:436px;white-space:nowrap" class="ft852">N=31</p>
<p style="position:absolute;top:663px;left:608px;white-space:nowrap" class="ft851"><b>Humirab</b></p>
<p style="position:absolute;top:682px;left:561px;white-space:nowrap" class="ft851"><b>Maximum&#160;of&#160;40 mg&#160;ew</b></p>
<p style="position:absolute;top:701px;left:625px;white-space:nowrap" class="ft852">N=31</p>
<p style="position:absolute;top:729px;left:176px;white-space:nowrap" class="ft854">Clinical remission in Week&#160;<br/>8 PMS responders</p>
<p style="position:absolute;top:738px;left:409px;white-space:nowrap" class="ft852">9/31 (29.0%)</p>
<p style="position:absolute;top:738px;left:596px;white-space:nowrap" class="ft852">14/31 (45.2%)</p>
<p style="position:absolute;top:772px;left:176px;white-space:nowrap" class="ft854">Clinical&#160;response in Week 8&#160;<br/>PMS responders</p>
<p style="position:absolute;top:782px;left:405px;white-space:nowrap" class="ft852">19/31 (61.3%)</p>
<p style="position:absolute;top:782px;left:594px;white-space:nowrap" class="ft852">21/31 (67.7%)</p>
<p style="position:absolute;top:813px;left:176px;white-space:nowrap" class="ft854">Mucosal healing in&#160;<br/>Week&#160;8&#160;PMS responders</p>
<p style="position:absolute;top:823px;left:405px;white-space:nowrap" class="ft852">12/31 (38.7%)</p>
<p style="position:absolute;top:823px;left:594px;white-space:nowrap" class="ft852">16/31 (51.6%)</p>
<p style="position:absolute;top:852px;left:176px;white-space:nowrap" class="ft855">Clinical remission in Week&#160;<br/>8 PMS remitters</p>
<p style="position:absolute;top:862px;left:409px;white-space:nowrap" class="ft852">9/21 (42.9%)</p>
<p style="position:absolute;top:862px;left:594px;white-space:nowrap" class="ft852">10/22 (45.5%)</p>
<p style="position:absolute;top:891px;left:176px;white-space:nowrap" class="ft855">Corticosteroid-free&#160;<br/>remission in Week 8&#160;<br/>PMS&#160;respondersc</p>
<p style="position:absolute;top:910px;left:409px;white-space:nowrap" class="ft852">4/13 (30.8%)</p>
<p style="position:absolute;top:910px;left:598px;white-space:nowrap" class="ft852">5/16 (31.3%)</p>
<p style="position:absolute;top:948px;left:176px;white-space:nowrap" class="ft859">a&#160;Humira 0.6 mg/kg&#160;(maximum of&#160;40 mg)&#160;every other week</p>
<p style="position:absolute;top:967px;left:176px;white-space:nowrap" class="ft859">b&#160;Humira 0.6 mg/kg&#160;(maximum&#160;of&#160;40 mg) every week</p>
<p style="position:absolute;top:986px;left:176px;white-space:nowrap" class="ft854">c&#160;In&#160;patients receiving concomitant corticosteroids at baseline<br/>Note: Patients with missing values at&#160;Week 52 or who were randomized to receive&#160;<br/>re-induction or maintenance treatment were considered non-responders for Week 52&#160;<br/>endpoints</p>
</div>
<!-- Page 86 -->
<a name="86"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft8624{font-size:17px;line-height:22px;font-family:HORGHZ+TimesNewRoman;color:#000000;}
-->
</style>
<div id="page86-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft860">86</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft864">Additional exploratory efficacy endpoints included clinical response per the Paediatric Ulcerative Colitis&#160;<br/>Activity Index (PUCAI) (defined as a decrease in PUCAI&#160;≥ 20 points from Baseline) and clinical&#160;<br/>remission per PUCAI (defined as PUCAI &lt; 10) at Week 8&#160;and Week 52&#160;(Table 28).&#160;</p>
<p style="position:absolute;top:162px;left:273px;white-space:nowrap" class="ft861"><b>Table 28: Exploratory Endpoints Results per PUCAI</b></p>
<p style="position:absolute;top:185px;left:543px;white-space:nowrap" class="ft861"><b>Week 8</b></p>
<p style="position:absolute;top:208px;left:447px;white-space:nowrap" class="ft861"><b>Humiraa</b></p>
<p style="position:absolute;top:230px;left:396px;white-space:nowrap" class="ft861"><b>Maximum of 160 mg at&#160;</b></p>
<p style="position:absolute;top:252px;left:380px;white-space:nowrap" class="ft861"><b>Week&#160;0 / Placebo at Week 1</b></p>
<p style="position:absolute;top:273px;left:459px;white-space:nowrap" class="ft862">N=30</p>
<p style="position:absolute;top:208px;left:643px;white-space:nowrap" class="ft861"><b>Humirab,c</b></p>
<p style="position:absolute;top:230px;left:596px;white-space:nowrap" class="ft861"><b>Maximum of 160 mg at&#160;</b></p>
<p style="position:absolute;top:252px;left:607px;white-space:nowrap" class="ft861"><b>Week 0 and Week 1</b></p>
<p style="position:absolute;top:273px;left:659px;white-space:nowrap" class="ft862">N=47</p>
<p style="position:absolute;top:297px;left:157px;white-space:nowrap" class="ft862">Clinical remission per PUCAI</p>
<p style="position:absolute;top:297px;left:430px;white-space:nowrap" class="ft862">10/30 (33.3%)</p>
<p style="position:absolute;top:297px;left:630px;white-space:nowrap" class="ft862">22/47 (46.8%)</p>
<p style="position:absolute;top:320px;left:157px;white-space:nowrap" class="ft862">Clinical response per PUCAI</p>
<p style="position:absolute;top:320px;left:430px;white-space:nowrap" class="ft862">15/30 (50.0%)</p>
<p style="position:absolute;top:320px;left:630px;white-space:nowrap" class="ft862">32/47 (68.1%)</p>
<p style="position:absolute;top:342px;left:539px;white-space:nowrap" class="ft861"><b>Week 52</b></p>
<p style="position:absolute;top:365px;left:447px;white-space:nowrap" class="ft861"><b>Humirad</b></p>
<p style="position:absolute;top:387px;left:393px;white-space:nowrap" class="ft861"><b>Maximum of 40 mg eow</b></p>
<p style="position:absolute;top:409px;left:459px;white-space:nowrap" class="ft862">N=31</p>
<p style="position:absolute;top:365px;left:647px;white-space:nowrap" class="ft861"><b>Humirae</b></p>
<p style="position:absolute;top:387px;left:597px;white-space:nowrap" class="ft861"><b>Maximum of 40 mg ew</b></p>
<p style="position:absolute;top:409px;left:659px;white-space:nowrap" class="ft862">N=31</p>
<p style="position:absolute;top:431px;left:157px;white-space:nowrap" class="ft8623">Clinical remission per PUCAI&#160;<br/>in Week 8 PMS responders</p>
<p style="position:absolute;top:431px;left:430px;white-space:nowrap" class="ft862">14/31 (45.2%)</p>
<p style="position:absolute;top:431px;left:630px;white-space:nowrap" class="ft862">18/31 (58.1%)</p>
<p style="position:absolute;top:476px;left:157px;white-space:nowrap" class="ft8623">Clinical response per PUCAI&#160;<br/>in Week 8 PMS responders</p>
<p style="position:absolute;top:476px;left:430px;white-space:nowrap" class="ft862">18/31 (58.1%)</p>
<p style="position:absolute;top:476px;left:630px;white-space:nowrap" class="ft862">16/31 (51.6%)</p>
<p style="position:absolute;top:519px;left:157px;white-space:nowrap" class="ft8623">a&#160;Humira&#160;2.4 mg/kg&#160;(maximum of 160 mg)&#160;at Week 0, placebo at Week&#160;1,&#160;and&#160;1.2&#160;<br/>mg/kg&#160;(maximum of 80 mg)&#160;at Week 2<br/>b&#160;&#160;Humira&#160;2.4 mg/kg&#160;(maximum&#160;of 160 mg)&#160;at Week 0 and Week 1,&#160;and&#160;1.2&#160;<br/>mg/kg&#160;(maximum of 80 mg)&#160;at Week 2<br/>c&#160;Not including open-label Induction dose of&#160;Humira&#160;2.4 mg/kg&#160;(maximum&#160;of 160 mg)&#160;at&#160;<br/>Week 0 and Week&#160;1, and 1.2 mg/kg&#160;(maximum of 80 mg)&#160;at Week 2<br/>d&#160;Humira 0.6 mg/kg&#160;(maximum&#160;of&#160;40 mg)&#160;every other week<br/>e&#160;Humira 0.6 mg/kg&#160;(maximum of&#160;40 mg) every week<br/>Note 1: Both induction groups received 0.6 mg/kg (maximum of 40 mg) at Week 4 and&#160;<br/>Week 6<br/>Note 2: Patients&#160;with missing values at Week 8 were considered as not having met the&#160;<br/>endpoints<br/>Note 3:&#160;Patients with missing values at Week 52 or who were randomized to receive re-<br/>induction or maintenance treatment were considered non-responders for Week 52&#160;<br/>endpoints</p>
<p style="position:absolute;top:886px;left:106px;white-space:nowrap" class="ft864">Of the Humira-treated patients who received re-induction treatment during the maintenance period, 2/6&#160;<br/>(33%) achieved clinical response per FMS at Week 52.</p>
<p style="position:absolute;top:943px;left:106px;white-space:nowrap" class="ft863"><i>Quality of life</i></p>
<p style="position:absolute;top:981px;left:106px;white-space:nowrap" class="ft865">Clinically meaningful improvements from Baseline were observed in IMPACT III and the caregiver Work&#160;<br/>Productivity and Activity Impairment (WPAI) scores for the groups treated with&#160;Humira.</p>
<p style="position:absolute;top:1038px;left:106px;white-space:nowrap" class="ft865">Clinically meaningful increases (improvement) from Baseline in height&#160;velocity were observed for the&#160;<br/>groups treated with adalimumab, and clinically meaningful increases (improvement) from Baseline in&#160;</p>
</div>
<!-- Page 87 -->
<a name="87"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page87-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft870">87</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft875">Body Mass Index were observed for subjects on the high maintenance dose of maximum&#160;40 mg (0.6&#160;<br/>mg/kg) ew.&#160;</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft873"><i>Paediatric Uveitis</i></p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft874">The safety and efficacy of Humira was assessed in a randomized, double-masked, controlled study of 90&#160;<br/>paediatric patients from 2&#160;to&#160;&lt;&#160;18 years of age with active JIA-associated noninfectious anterior uveitis&#160;<br/>who were refractory to at least 12&#160;weeks of methotrexate treatment. Patients received either placebo or&#160;<br/>20&#160;mg adalimumab (if&#160;&lt;&#160;30&#160;kg) or 40&#160;mg adalimumab (if&#160;≥&#160;30&#160;kg)&#160;every other week in combination with&#160;<br/>their baseline dose of methotrexate.&#160;</p>
<p style="position:absolute;top:295px;left:106px;white-space:nowrap" class="ft874">The primary endpoint was ‘time to treatment failure’. The criteria determining treatment failure were&#160;<br/>worsening or sustained non-improvement in ocular inflammation, partial improvement with development&#160;<br/>of sustained ocular co-morbidities or worsening of ocular co-morbidities, non-permitted use of&#160;<br/>concomitant medications, and suspension of treatment for an extended period of time.</p>
<p style="position:absolute;top:390px;left:106px;white-space:nowrap" class="ft873"><i>Clinical Response</i></p>
<p style="position:absolute;top:429px;left:106px;white-space:nowrap" class="ft875">Adalimumab significantly delayed the time to treatment failure, as compared to placebo (See Figure&#160;2,&#160;<br/>P&#160;&lt;&#160;0.0001 from log rank test).The median time to treatment failure was 24.1&#160;weeks for subjects treated&#160;<br/>with placebo, whereas the median time to treatment failure was not estimable for subjects treated with&#160;<br/>adalimumab because less than one-half of these subjects experienced treatment failure. &#160;Adalimumab&#160;</p>
</div>
<!-- Page 88 -->
<a name="88"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page88-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft880">88</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft885">significantly decreased the risk of treatment failure by 75% relative to placebo, as shown&#160;by the hazard&#160;<br/>ratio (HR = 0.25 [95% CI: 0.12, 0.49]).</p>
<p style="position:absolute;top:143px;left:114px;white-space:nowrap" class="ft881"><b>Figure&#160;2: Kaplan-Meier Curves Summarizing Time to Treatment Failure in the Paediatric Uveitis&#160;</b></p>
<p style="position:absolute;top:167px;left:438px;white-space:nowrap" class="ft881"><b>Study</b></p>
<p style="position:absolute;top:632px;left:129px;white-space:nowrap" class="ft8820"><b>P</b></p>
<p style="position:absolute;top:622px;left:129px;white-space:nowrap" class="ft8820"><b>R</b></p>
<p style="position:absolute;top:610px;left:129px;white-space:nowrap" class="ft8820"><b>O</b></p>
<p style="position:absolute;top:597px;left:129px;white-space:nowrap" class="ft8820"><b>B</b></p>
<p style="position:absolute;top:586px;left:129px;white-space:nowrap" class="ft8820"><b>A</b></p>
<p style="position:absolute;top:574px;left:129px;white-space:nowrap" class="ft8820"><b>B</b></p>
<p style="position:absolute;top:563px;left:129px;white-space:nowrap" class="ft8820"><b>IL</b></p>
<p style="position:absolute;top:545px;left:129px;white-space:nowrap" class="ft8820"><b>IT</b></p>
<p style="position:absolute;top:528px;left:129px;white-space:nowrap" class="ft8820"><b>Y</b></p>
<p style="position:absolute;top:516px;left:129px;white-space:nowrap" class="ft8820"><b>&#160;O</b></p>
<p style="position:absolute;top:499px;left:129px;white-space:nowrap" class="ft8820"><b>F</b></p>
<p style="position:absolute;top:489px;left:129px;white-space:nowrap" class="ft8820"><b>&#160;F</b></p>
<p style="position:absolute;top:475px;left:129px;white-space:nowrap" class="ft8820"><b>A</b></p>
<p style="position:absolute;top:463px;left:129px;white-space:nowrap" class="ft8820"><b>IL</b></p>
<p style="position:absolute;top:445px;left:129px;white-space:nowrap" class="ft8820"><b>IN</b></p>
<p style="position:absolute;top:427px;left:129px;white-space:nowrap" class="ft8820"><b>G</b></p>
<p style="position:absolute;top:414px;left:129px;white-space:nowrap" class="ft8820"><b>&#160;T</b></p>
<p style="position:absolute;top:399px;left:129px;white-space:nowrap" class="ft8820"><b>R</b></p>
<p style="position:absolute;top:387px;left:129px;white-space:nowrap" class="ft8820"><b>E</b></p>
<p style="position:absolute;top:376px;left:129px;white-space:nowrap" class="ft8820"><b>A</b></p>
<p style="position:absolute;top:364px;left:129px;white-space:nowrap" class="ft8820"><b>T</b></p>
<p style="position:absolute;top:353px;left:129px;white-space:nowrap" class="ft8820"><b>M</b></p>
<p style="position:absolute;top:338px;left:129px;white-space:nowrap" class="ft8820"><b>E</b></p>
<p style="position:absolute;top:327px;left:129px;white-space:nowrap" class="ft8820"><b>N</b></p>
<p style="position:absolute;top:315px;left:129px;white-space:nowrap" class="ft8820"><b>T</b></p>
<p style="position:absolute;top:752px;left:412px;white-space:nowrap" class="ft881"><b>TIME (WEEKS)</b></p>
<p style="position:absolute;top:771px;left:149px;white-space:nowrap" class="ft882">Treatment</p>
<p style="position:absolute;top:771px;left:500px;white-space:nowrap" class="ft882">Placebo</p>
<p style="position:absolute;top:771px;left:669px;white-space:nowrap" class="ft882">Adalimumab</p>
<p style="position:absolute;top:790px;left:149px;white-space:nowrap" class="ft882">Note: P =&#160;Placebo (Number at Risk); H = HUMIRA (Number at Risk).</p>
<p style="position:absolute;top:847px;left:106px;white-space:nowrap" class="ft881"><b>5.2</b></p>
<p style="position:absolute;top:847px;left:148px;white-space:nowrap" class="ft881"><b>Pharmacokinetic properties</b></p>
<p style="position:absolute;top:885px;left:106px;white-space:nowrap" class="ft882">Absorption and distribution</p>
<p style="position:absolute;top:923px;left:106px;white-space:nowrap" class="ft885">Following the administration of 24&#160;mg/m2&#160;(maximum of 40&#160;mg) subcutaneously every other week to&#160;<br/>patients with polyarticular juvenile idiopathic arthritis (JIA) who were 4 to 17&#160;years the mean trough&#160;<br/>steady-state (values measured from Week&#160;20 to 48) serum adalimumab concentration was 5.6&#160;±&#160;5.6&#160;µg/ml&#160;<br/>(102% CV) for adalimumab without concomitant methotrexate and 10.9&#160;±&#160;5.2 µg/ml (47.7% CV) with&#160;<br/>concomitant methotrexate.</p>
<p style="position:absolute;top:1037px;left:106px;white-space:nowrap" class="ft884">In patients with polyarticular JIA who were 2 to &lt;4 years old or aged 4 and above weighing &lt;15 kg dosed&#160;<br/>with adalimumab 24&#160;mg/m2, the&#160;mean trough steady-state serum adalimumab concentrations was&#160;</p>
</div>
<!-- Page 89 -->
<a name="89"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page89-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft890">89</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft895">6.0&#160;±&#160;6.1&#160;µg/ml (101% CV) for adalimumab without concomitant methotrexate and 7.9&#160;±&#160;5.6&#160;µg/ml&#160;<br/>(71.2% CV) with concomitant methotrexate.</p>
<p style="position:absolute;top:144px;left:106px;white-space:nowrap" class="ft897">Following the administration of 24&#160;mg/m2&#160;(maximum of 40&#160;mg) subcutaneously every other week to&#160;<br/>patients with enthesitis-related arthritis who were 6 to 17&#160;years, the mean trough steady-state (values&#160;<br/>measured at Week&#160;24) serum adalimumab concentrations were 8.8&#160;±&#160;6.6&#160;μg/ml for adalimumab without&#160;<br/>concomitant methotrexate and 11.8&#160;±&#160;4.3&#160;μg/ml with concomitant methotrexate.</p>
<p style="position:absolute;top:245px;left:106px;white-space:nowrap" class="ft894">Following the administration of 0.8&#160;mg/kg (maximum of 40&#160;mg) subcutaneously every other week to&#160;<br/>paediatric patients with chronic plaque psoriasis, the mean&#160;±&#160;SD steady-state adalimumab trough&#160;<br/>concentration was approximately 7.4&#160;±&#160;5.8&#160;µg/ml&#160;(79% CV).</p>
<p style="position:absolute;top:320px;left:106px;white-space:nowrap" class="ft894">Adalimumab exposure in adolescent HS patients was predicted using population pharmacokinetic&#160;<br/>modelling and simulation based on cross-indication pharmacokinetics in other paediatric patients&#160;<br/>(paediatric psoriasis, juvenile idiopathic&#160;arthritis, paediatric Crohn’s disease, and&#160;enthesitis-related&#160;<br/>arthritis).&#160;The recommended adolescent HS dosing schedule is 40&#160;mg every other week. Since exposure to&#160;<br/>adalimumab can be affected by body size, adolescents with&#160;higher body weight and inadequate response&#160;<br/>may benefit from receiving the recommended adult dose of 40&#160;mg&#160;every week.</p>
<p style="position:absolute;top:453px;left:106px;white-space:nowrap" class="ft897">In paediatric patients with moderate to severe CD, the open-label adalimumab induction dose was&#160;<br/>160/80&#160;mg&#160;or 80/40&#160;mg at Weeks&#160;0 and 2,&#160;respectively, dependent on a body weight cut-off&#160;of 40&#160;kg. At&#160;<br/>Week&#160;4, patients were&#160;randomised 1:1 to either the Standard Dose (40/20&#160;mg&#160;eow)&#160;or Low Dose (20/10&#160;<br/>mg&#160;eow)&#160;maintenance treatment groups based on their body weight.&#160;The&#160;mean (±SD)&#160;serum&#160;adalimumab&#160;<br/>trough concentrations achieved at Week&#160;4 were 15.7&#160;±&#160;6.6</p>
<p style="position:absolute;top:528px;left:495px;white-space:nowrap" class="ft896">g/ml for patients&#160;&#160;40&#160;kg (160/80&#160;mg) and&#160;</p>
<p style="position:absolute;top:551px;left:106px;white-space:nowrap" class="ft892">10.6&#160;±&#160;6.1</p>
<p style="position:absolute;top:549px;left:177px;white-space:nowrap" class="ft896">g/ml for patients &lt;&#160;40&#160;kg (80/40&#160;mg).</p>
<p style="position:absolute;top:589px;left:106px;white-space:nowrap" class="ft897">For patients who stayed on their randomised therapy, the mean&#160;(±SD)&#160;adalimumab trough concentrations&#160;<br/>at Week&#160;52 were&#160;9.5&#160;±&#160;5.6</p>
<p style="position:absolute;top:607px;left:284px;white-space:nowrap" class="ft896">g/ml for the Standard Dose group and&#160;3.5&#160;±&#160;2.2&#160;g/ml for the Low Dose&#160;</p>
<p style="position:absolute;top:628px;left:106px;white-space:nowrap" class="ft894">group.&#160;The&#160;mean trough concentrations were maintained in patients who continued to receive adalimumab&#160;<br/>treatment eow for 52&#160;weeks.&#160;For patients who dose&#160;escalated from eow to weekly regimen, the mean&#160;<br/>(±SD)&#160;serum concentrations of adalimumab at Week&#160;52 were 15.3&#160;±&#160;11.4&#160;μg/ml (40/20&#160;mg, weekly) and&#160;<br/>6.7&#160;±&#160;3.5&#160;μg/ml (20/10&#160;mg, weekly).</p>
<p style="position:absolute;top:723px;left:106px;white-space:nowrap" class="ft894">Adalimumab exposure in paediatric uveitis patients was predicted using population pharmacokinetic&#160;<br/>modelling and simulation based on cross-indication pharmacokinetics in other paediatric patients&#160;<br/>(paediatric psoriasis, juvenile idiopathic arthritis, paediatric Crohn’s disease, and enthesitis-related&#160;<br/>arthritis). No clinical exposure&#160;data are available on the use of a loading dose in children &lt; 6 years. The&#160;<br/>predicted exposures indicate that in the absence of methotrexate, a loading dose may lead to an initial&#160;<br/>increase in systemic exposure.</p>
<p style="position:absolute;top:855px;left:106px;white-space:nowrap" class="ft895">Exposure-response relationship in paediatric population<br/>On the basis of clinical trial data in patients with JIA (pJIA and ERA), an exposure-response relationship&#160;<br/>was established between plasma concentrations and PedACR 50 response. The apparent adalimumab&#160;<br/>plasma concentration that produces half&#160;the&#160;maximum probability of PedACR 50 response (EC50) was&#160;<br/>3&#160;μg/ml (95% CI: 1-6&#160;μg/ml).&#160;</p>
<p style="position:absolute;top:969px;left:106px;white-space:nowrap" class="ft895">Exposure-response relationships between adalimumab concentration and efficacy in paediatric patients&#160;<br/>with severe chronic plaque psoriasis were established for PASI 75 and PGA&#160;clear or minimal,&#160;<br/>respectively. PASI 75 and PGA clear or minimal increased with increasing adalimumab concentrations,&#160;<br/>both with a similar apparent EC50 of approximately 4.5&#160;μg/ml&#160;(95% CI 0.4-47.6 and 1.9-10.5,&#160;<br/>respectively).</p>
<p style="position:absolute;top:1083px;left:106px;white-space:nowrap" class="ft892">Adults</p>
</div>
<!-- Page 90 -->
<a name="90"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page90-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft900">90</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft905">After&#160;subcutaneous administration of a single 40&#160;mg dose, absorption and distribution of adalimumab was&#160;<br/>slow, with peak serum concentrations being reached about 5&#160;days after administration. The average&#160;<br/>absolute bioavailability of adalimumab estimated from three&#160;studies following a single 40&#160;mg&#160;<br/>subcutaneous dose was 64%. After single intravenous doses ranging from 0.25 to 10&#160;mg/kg,&#160;<br/>concentrations were dose proportional. After doses of 0.5&#160;mg/kg (~40&#160;mg), clearances ranged from 11 to&#160;<br/>15&#160;ml/hour, the distribution volume (Vss) ranged from 5 to 6&#160;litres and the mean terminal phase half-life&#160;<br/>was approximately two weeks. Adalimumab concentrations in the synovial fluid from several rheumatoid&#160;<br/>arthritis patients ranged from 31-96% of those in serum.</p>
<p style="position:absolute;top:276px;left:106px;white-space:nowrap" class="ft907">Following subcutaneous&#160;administration of 40&#160;mg of adalimumab every other week in adult rheumatoid&#160;<br/>arthritis (RA) patients the mean steady-state trough concentrations were approximately 5</p>
<p style="position:absolute;top:294px;left:697px;white-space:nowrap" class="ft906">g/ml (without&#160;</p>
<p style="position:absolute;top:316px;left:106px;white-space:nowrap" class="ft902">concomitant methotrexate) and 8 to 9</p>
<p style="position:absolute;top:314px;left:357px;white-space:nowrap" class="ft906">g/ml (with concomitant methotrexate),&#160;respectively. The serum&#160;</p>
<p style="position:absolute;top:335px;left:106px;white-space:nowrap" class="ft904">adalimumab trough levels at steady-state increased roughly proportionally with dose following 20, 40 and&#160;<br/>80&#160;mg subcutaneous dosing every other week and every week.</p>
<p style="position:absolute;top:392px;left:106px;white-space:nowrap" class="ft904">In adult patients with psoriasis, the mean steady-state trough concentration was 5&#160;μg/ml during<br/>adalimumab 40&#160;mg&#160;every other week monotherapy treatment.</p>
<p style="position:absolute;top:449px;left:106px;white-space:nowrap" class="ft904">In&#160;adult&#160;patients with hidradenitis suppurativa, a dose of 160&#160;mg Humira on Week 0 followed by 80&#160;mg on&#160;<br/>Week 2 achieved serum adalimumab trough concentrations of approximately 7 to 8&#160;μg/ml&#160;at Week 2 and&#160;<br/>Week 4. &#160;The mean steady-state trough concentration at Week 12 through Week 36 were approximately 8&#160;<br/>to 10&#160;μg/ml&#160;during adalimumab 40&#160;mg&#160;every week treatment. &#160;</p>
<p style="position:absolute;top:544px;left:106px;white-space:nowrap" class="ft907">In patients with Crohn’s disease, the loading dose of 80&#160;mg&#160;Humira on Week&#160;0 followed by 40&#160;mg Humira&#160;<br/>on Week&#160;2 achieves serum adalimumab trough concentrations of approximately 5.5</p>
<p style="position:absolute;top:562px;left:662px;white-space:nowrap" class="ft906">g/ml during the&#160;</p>
<p style="position:absolute;top:583px;left:106px;white-space:nowrap" class="ft907">induction period. A loading dose of 160&#160;mg Humira on Week&#160;0 followed by 80&#160;mg Humira on Week&#160;2&#160;<br/>achieves serum adalimumab trough concentrations of approximately 12</p>
<p style="position:absolute;top:601px;left:582px;white-space:nowrap" class="ft906">g/ml&#160;during the induction period.&#160;</p>
<p style="position:absolute;top:624px;left:106px;white-space:nowrap" class="ft902">Mean steady-state trough levels of approximately 7</p>
<p style="position:absolute;top:622px;left:449px;white-space:nowrap" class="ft906">g/ml&#160;were observed in Crohn’s disease patients who&#160;</p>
<p style="position:absolute;top:642px;left:106px;white-space:nowrap" class="ft902">received a maintenance dose of 40&#160;mg Humira every other week.</p>
<p style="position:absolute;top:680px;left:106px;white-space:nowrap" class="ft904">Following&#160;the&#160;subcutaneous administration of body weight-based dosing of 0.6&#160;mg/kg (maximum of&#160;<br/>40&#160;mg)&#160;every other week to paediatric patients with ulcerative colitis, the mean trough steady-state serum&#160;<br/>adalimumab concentration was&#160;5.01±3.28&#160;µg/ml&#160;at Week&#160;52.&#160;For patients who received 0.6&#160;mg/kg&#160;<br/>(maximum of 40&#160;mg)&#160;every week, the mean (±SD) trough steady-state serum adalimumab concentration&#160;<br/>was&#160;15.7±5.60&#160;μg/ml&#160;at Week&#160;52.</p>
<p style="position:absolute;top:794px;left:106px;white-space:nowrap" class="ft907">In&#160;adult&#160;patients with uveitis, a loading dose of 80&#160;mg adalimumab on Week 0 followed by 40&#160;mg&#160;<br/>adalimumab every other week starting at Week 1, resulted in mean steady-state concentrations of&#160;<br/>approximately 8 to 10</p>
<p style="position:absolute;top:832px;left:256px;white-space:nowrap" class="ft906">g/ml.</p>
<p style="position:absolute;top:871px;left:106px;white-space:nowrap" class="ft905">Population pharmacokinetic and pharmacokinetic/pharmacodynamic modelling and simulation predicted&#160;<br/>comparable adalimumab exposure and&#160;efficacy in patients treated with 80&#160;mg&#160;every other week when&#160;<br/>compared with 40&#160;mg&#160;every week (including adult patients with RA, HS, UC, CD or&#160;Ps, patients with&#160;<br/>adolescent HS, and paediatric patients&#160;≥&#160;40&#160;kg with CD&#160;and UC).</p>
<p style="position:absolute;top:966px;left:106px;white-space:nowrap" class="ft902">Elimination</p>
<p style="position:absolute;top:1004px;left:106px;white-space:nowrap" class="ft904">Population pharmacokinetic analyses with data from over 1,300 RA patients revealed a trend toward&#160;<br/>higher apparent clearance of adalimumab with increasing body weight. After adjustment for weight&#160;<br/>differences, gender and age appeared to have a minimal effect on adalimumab clearance. The serum levels&#160;<br/>of free adalimumab (not bound to anti-adalimumab antibodies, AAA) were observed to be lower in&#160;<br/>patients with measurable AAA.&#160;</p>
</div>
<!-- Page 91 -->
<a name="91"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page91-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft910">91</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft912">Hepatic or renal impairment</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft912">Humira has not been studied in patients with hepatic or renal impairment.</p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft911"><b>5.3</b></p>
<p style="position:absolute;top:181px;left:148px;white-space:nowrap" class="ft911"><b>Preclinical safety data&#160;</b></p>
<p style="position:absolute;top:219px;left:106px;white-space:nowrap" class="ft915">Non-clinical data reveal no special hazard for humans based on studies of single dose toxicity, repeated&#160;<br/>dose toxicity, and genotoxicity. &#160;</p>
<p style="position:absolute;top:276px;left:106px;white-space:nowrap" class="ft915">An&#160;embryo-foetal developmental toxicity/perinatal developmental study has been performed in&#160;<br/>cynomolgus monkeys at 0, 30 and 100&#160;mg/kg (9-17 monkeys/group) and has revealed no evidence of harm&#160;<br/>to the foetuses due to adalimumab. Neither carcinogenicity studies, nor a standard assessment of fertility&#160;<br/>and postnatal toxicity, were performed with&#160;adalimumab due to the lack of appropriate models for an&#160;<br/>antibody with limited cross-reactivity to rodent TNF and to the development of neutralising antibodies in&#160;<br/>rodents.</p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft911"><b>6.</b></p>
<p style="position:absolute;top:427px;left:148px;white-space:nowrap" class="ft911"><b>PHARMACEUTICAL&#160;PARTICULARS</b></p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft911"><b>6.1</b></p>
<p style="position:absolute;top:465px;left:148px;white-space:nowrap" class="ft911"><b>List of excipients&#160;</b></p>
<p style="position:absolute;top:503px;left:106px;white-space:nowrap" class="ft914">Mannitol<br/>Citric acid monohydrate<br/>Sodium citrate<br/>Sodium dihydrogen phosphate dihydrate<br/>Disodium phosphate dihydrate<br/>Sodium chloride<br/>Polysorbate 80<br/>Sodium hydroxide<br/>Water for injections.</p>
<p style="position:absolute;top:693px;left:106px;white-space:nowrap" class="ft911"><b>6.2</b></p>
<p style="position:absolute;top:693px;left:148px;white-space:nowrap" class="ft911"><b>Incompatibilities&#160;</b></p>
<p style="position:absolute;top:731px;left:106px;white-space:nowrap" class="ft915">In the absence of compatibility studies, this medicinal product must&#160;not be mixed with other medicinal&#160;<br/>products.</p>
<p style="position:absolute;top:788px;left:106px;white-space:nowrap" class="ft911"><b>6.3</b></p>
<p style="position:absolute;top:788px;left:148px;white-space:nowrap" class="ft911"><b>Shelf life&#160;</b></p>
<p style="position:absolute;top:826px;left:106px;white-space:nowrap" class="ft912">2 years&#160;</p>
<p style="position:absolute;top:864px;left:106px;white-space:nowrap" class="ft911"><b>6.4</b></p>
<p style="position:absolute;top:864px;left:148px;white-space:nowrap" class="ft911"><b>Special precautions for storage&#160;</b></p>
<p style="position:absolute;top:903px;left:106px;white-space:nowrap" class="ft912">Store in a refrigerator (2</p>
<p style="position:absolute;top:901px;left:266px;white-space:nowrap" class="ft916">C&#160;–&#160;8C). Do not freeze. Keep the vial in the outer carton in order to protect from&#160;</p>
<p style="position:absolute;top:922px;left:106px;white-space:nowrap" class="ft912">light. &#160;</p>
<p style="position:absolute;top:960px;left:106px;white-space:nowrap" class="ft911"><b>6.5</b></p>
<p style="position:absolute;top:960px;left:148px;white-space:nowrap" class="ft911"><b>Nature and contents of container &#160;</b></p>
<p style="position:absolute;top:998px;left:106px;white-space:nowrap" class="ft914">Humira 40&#160;mg solution for injection in single-use vial (type I glass), fitted with rubber stoppers,&#160;<br/>aluminium crimps and flip-off seals.&#160;</p>
<p style="position:absolute;top:1055px;left:106px;white-space:nowrap" class="ft912">1 Pack of 2 boxes each containing:</p>
</div>
<!-- Page 92 -->
<a name="92"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page92-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft920">92</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft925">1 vial (0.8&#160;ml sterile solution), 1 empty sterile injection syringe, 1 needle, 1 vial adapter and 2 alcohol&#160;<br/>pads.</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft921"><b>6.6</b></p>
<p style="position:absolute;top:143px;left:148px;white-space:nowrap" class="ft921"><b>Special precautions for disposal</b></p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft924">Any unused medicinal product or waste material should be disposed of in accordance with local&#160;<br/>requirements.</p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft921"><b>7.</b></p>
<p style="position:absolute;top:257px;left:148px;white-space:nowrap" class="ft921"><b>MARKETING AUTHORISATION HOLDER&#160;</b></p>
<p style="position:absolute;top:295px;left:106px;white-space:nowrap" class="ft924">AbbVie Deutschland GmbH&#160;&amp; Co. KG<br/>Knollstrasse<br/>67061 Ludwigshafen<br/>Germany</p>
<p style="position:absolute;top:409px;left:106px;white-space:nowrap" class="ft921"><b>8.</b></p>
<p style="position:absolute;top:409px;left:148px;white-space:nowrap" class="ft921"><b>MARKETING AUTHORISATION NUMBER&#160;</b></p>
<p style="position:absolute;top:446px;left:106px;white-space:nowrap" class="ft922">EU/1/03/256/001</p>
<p style="position:absolute;top:503px;left:106px;white-space:nowrap" class="ft921"><b>9.</b></p>
<p style="position:absolute;top:503px;left:148px;white-space:nowrap" class="ft921"><b>DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</b></p>
<p style="position:absolute;top:541px;left:106px;white-space:nowrap" class="ft925">Date of first authorisation: &#160;8 September 2003<br/>Date of latest renewal: 8 September 2008</p>
<p style="position:absolute;top:617px;left:106px;white-space:nowrap" class="ft921"><b>10.</b></p>
<p style="position:absolute;top:617px;left:148px;white-space:nowrap" class="ft921"><b>DATE OF REVISION&#160;OF THE TEXT</b></p>
<p style="position:absolute;top:655px;left:106px;white-space:nowrap" class="ft924">Detailed information on this medicinal product is available on the website of the European Medicines&#160;<br/><a href="http://www.ema.europa.eu/">Agency&#160;http://www.ema.europa.eu</a></p>
</div>
<!-- Page 93 -->
<a name="93"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft9325{font-size:17px;font-family:HORGHZ+Wingdings;color:#000000;}
-->
</style>
<div id="page93-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft930">93</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft931"><b>1.</b></p>
<p style="position:absolute;top:86px;left:148px;white-space:nowrap" class="ft931"><b>NAME OF THE MEDICINAL PRODUCT&#160;</b></p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft934">Humira&#160;40&#160;mg solution for injection in pre-filled syringe<br/>Humira 40&#160;mg solution for injection in pre-filled pen</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft931"><b>2.</b></p>
<p style="position:absolute;top:200px;left:148px;white-space:nowrap" class="ft931"><b>QUALITATIVE AND QUANTITATIVE COMPOSITION&#160;</b></p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft934">Humira 40&#160;mg solution for injection in pre-filled syringe&#160;<br/>Each 0.8&#160;ml single dose pre-filled syringe contains 40&#160;mg&#160;of adalimumab.&#160;</p>
<p style="position:absolute;top:295px;left:106px;white-space:nowrap" class="ft935">Humira 40&#160;mg solution for injection in pre-filled pen<br/>Each 0.8&#160;ml single dose pre-filled pen contains 40&#160;mg of adalimumab.&#160;</p>
<p style="position:absolute;top:352px;left:106px;white-space:nowrap" class="ft932">Adalimumab is a recombinant human monoclonal antibody&#160;produced&#160;in Chinese Hamster Ovary cells.</p>
<p style="position:absolute;top:390px;left:106px;white-space:nowrap" class="ft932">For the full list of excipients, see section 6.1.&#160;</p>
<p style="position:absolute;top:446px;left:106px;white-space:nowrap" class="ft931"><b>3.</b></p>
<p style="position:absolute;top:446px;left:148px;white-space:nowrap" class="ft931"><b>PHARMACEUTICAL&#160;FORM&#160;</b></p>
<p style="position:absolute;top:485px;left:106px;white-space:nowrap" class="ft932">Solution for injection.&#160;(injection)</p>
<p style="position:absolute;top:522px;left:106px;white-space:nowrap" class="ft932">Clear, colourless solution.&#160;</p>
<p style="position:absolute;top:579px;left:106px;white-space:nowrap" class="ft931"><b>4.</b></p>
<p style="position:absolute;top:579px;left:148px;white-space:nowrap" class="ft931"><b>CLINICAL PARTICULARS</b></p>
<p style="position:absolute;top:617px;left:106px;white-space:nowrap" class="ft931"><b>4.1</b></p>
<p style="position:absolute;top:617px;left:148px;white-space:nowrap" class="ft931"><b>Therapeutic indications&#160;</b></p>
<p style="position:absolute;top:655px;left:106px;white-space:nowrap" class="ft932">Rheumatoid&#160;arthritis</p>
<p style="position:absolute;top:693px;left:106px;white-space:nowrap" class="ft932">Humira in combination with methotrexate, is indicated for:</p>
<p style="position:absolute;top:731px;left:106px;white-space:nowrap" class="ft9325"></p>
<p style="position:absolute;top:731px;left:147px;white-space:nowrap" class="ft935">the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response&#160;<br/>to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate.</p>
<p style="position:absolute;top:769px;left:106px;white-space:nowrap" class="ft9325"></p>
<p style="position:absolute;top:769px;left:147px;white-space:nowrap" class="ft934">the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated&#160;<br/>with methotrexate.</p>
<p style="position:absolute;top:826px;left:106px;white-space:nowrap" class="ft934">Humira can be given as monotherapy in case of intolerance to methotrexate or when continued treatment&#160;<br/>with methotrexate is inappropriate.</p>
<p style="position:absolute;top:883px;left:106px;white-space:nowrap" class="ft934">Humira has been shown to reduce the rate of progression of joint damage as measured by X-ray and to&#160;<br/>improve physical function, when given in combination with methotrexate.</p>
<p style="position:absolute;top:940px;left:106px;white-space:nowrap" class="ft932">Juvenile idiopathic arthritis</p>
<p style="position:absolute;top:978px;left:106px;white-space:nowrap" class="ft933"><i>Polyarticular juvenile idiopathic arthritis</i></p>
<p style="position:absolute;top:1016px;left:106px;white-space:nowrap" class="ft934">Humira in combination with methotrexate is indicated for the treatment of active polyarticular juvenile&#160;<br/>idiopathic arthritis, in patients from the age of&#160;2 years who have had an inadequate response to one or&#160;<br/>more&#160;disease-modifying anti-rheumatic drugs (DMARDs). Humira can be given as monotherapy in case&#160;</p>
</div>
<!-- Page 94 -->
<a name="94"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page94-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft940">94</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft945">of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the&#160;<br/>efficacy in monotherapy see section 5.1). Humira has not been studied in patients aged less than 2&#160;years.</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft943"><i>Enthesitis-related arthritis</i></p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft944">Humira is indicated for the treatment of active enthesitis-related arthritis in patients, 6&#160;years of age and&#160;<br/>older, who have&#160;had an inadequate response to, or who are intolerant of, conventional therapy (see section&#160;<br/>5.1).</p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft942">Axial spondyloarthritis&#160;</p>
<p style="position:absolute;top:295px;left:106px;white-space:nowrap" class="ft943"><i>Ankylosing spondylitis (AS)</i></p>
<p style="position:absolute;top:333px;left:106px;white-space:nowrap" class="ft944">Humira is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an&#160;<br/>inadequate response to conventional therapy.</p>
<p style="position:absolute;top:390px;left:106px;white-space:nowrap" class="ft943"><i>Axial spondyloarthritis without radiographic evidence of AS</i></p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft944">Humira is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic&#160;<br/>evidence of AS but with objective signs of inflammation by elevated CRP and / or MRI, who have had an&#160;<br/>inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs&#160;(NSAIDs).</p>
<p style="position:absolute;top:503px;left:106px;white-space:nowrap" class="ft942">Psoriatic arthritis</p>
<p style="position:absolute;top:541px;left:106px;white-space:nowrap" class="ft944">Humira is indicated for the treatment of active and progressive psoriatic arthritis in adults when the&#160;<br/>response to previous disease-modifying anti-rheumatic drug therapy has been&#160;inadequate. Humira has&#160;<br/>been shown to reduce the rate of progression of&#160;peripheral&#160;joint damage as measured by X-ray&#160;in patients&#160;<br/>with polyarticular symmetrical subtypes of the disease (see Section 5.1)&#160;and to improve physical function.</p>
<p style="position:absolute;top:636px;left:106px;white-space:nowrap" class="ft942">Psoriasis</p>
<p style="position:absolute;top:674px;left:106px;white-space:nowrap" class="ft945">Humira is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who&#160;<br/>are&#160;candidates for systemic therapy.</p>
<p style="position:absolute;top:731px;left:106px;white-space:nowrap" class="ft942">Paediatric plaque psoriasis</p>
<p style="position:absolute;top:769px;left:106px;white-space:nowrap" class="ft944">Humira is indicated for the treatment of severe chronic plaque psoriasis in children and&#160;adolescents from&#160;<br/>4&#160;years of age who have had an inadequate response to or are inappropriate candidates for topical therapy&#160;<br/>and phototherapies.</p>
<p style="position:absolute;top:845px;left:106px;white-space:nowrap" class="ft942">Hidradenitis suppurativa (HS)</p>
<p style="position:absolute;top:883px;left:106px;white-space:nowrap" class="ft944">Humira is indicated for the treatment of active moderate to severe hidradenitis&#160;suppurativa (acne inversa)&#160;<br/>in adults and adolescents from 12 years of age with an inadequate response to conventional systemic HS&#160;<br/>therapy (see sections 5.1 and 5.2).</p>
<p style="position:absolute;top:959px;left:106px;white-space:nowrap" class="ft942">Crohn’s disease</p>
<p style="position:absolute;top:997px;left:106px;white-space:nowrap" class="ft944">Humira is indicated for treatment of moderately to severely active Crohn’s disease, in adult patients who&#160;<br/>have not responded despite a full and adequate course of therapy with a corticosteroid and/or an&#160;<br/>immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.&#160;</p>
</div>
<!-- Page 95 -->
<a name="95"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page95-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft950">95</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft952">Paediatric Crohn's disease&#160;</p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft954">Humira is indicated for the treatment of moderately to severely active Crohn's disease in paediatric&#160;<br/>patients (from 6&#160;years of age) who have had an inadequate response to conventional therapy including&#160;<br/>primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or&#160;<br/>have contraindications for such therapies.</p>
<p style="position:absolute;top:221px;left:106px;white-space:nowrap" class="ft952">Ulcerative colitis</p>
<p style="position:absolute;top:258px;left:106px;white-space:nowrap" class="ft954">Humira is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who&#160;<br/>have had an inadequate response&#160;to&#160;conventional therapy including corticosteroids and 6-mercaptopurine&#160;<br/>(6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such&#160;<br/>therapies.&#160;</p>
<p style="position:absolute;top:353px;left:106px;white-space:nowrap" class="ft952">Paediatric ulcerative colitis</p>
<p style="position:absolute;top:391px;left:106px;white-space:nowrap" class="ft954">Humira is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric&#160;<br/>patients (from 6&#160;years of age) who have had an inadequate response to conventional therapy including&#160;<br/>corticosteroids and/or 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant&#160;to&#160;or have&#160;<br/>medical contraindications for such therapies.</p>
<p style="position:absolute;top:486px;left:106px;white-space:nowrap" class="ft952">Uveitis</p>
<p style="position:absolute;top:524px;left:106px;white-space:nowrap" class="ft954">Humira is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult&#160;<br/>patients who have had an inadequate response to corticosteroids, in patients in need of&#160;corticosteroid-<br/>sparing, or in whom corticosteroid treatment is inappropriate.</p>
<p style="position:absolute;top:600px;left:106px;white-space:nowrap" class="ft952">Paediatric Uveitis</p>
<p style="position:absolute;top:638px;left:106px;white-space:nowrap" class="ft955">Humira is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from&#160;<br/>2 years of age who have had an inadequate&#160;response to or are intolerant to conventional therapy, or in&#160;<br/>whom conventional therapy is inappropriate.</p>
<p style="position:absolute;top:714px;left:106px;white-space:nowrap" class="ft951"><b>4.2</b></p>
<p style="position:absolute;top:714px;left:148px;white-space:nowrap" class="ft951"><b>Posology and method of administration &#160;</b></p>
<p style="position:absolute;top:752px;left:106px;white-space:nowrap" class="ft955">Humira treatment should be initiated and supervised by specialist physicians experienced in the diagnosis<br/>and treatment of conditions for which Humira is indicated. Ophthalmologists are advised to consult with&#160;<br/>an appropriate specialist before initiation of treatment with Humira (see section 4.4). Patients treated with&#160;<br/>Humira should be given the&#160;Patient Reminder&#160;Card.</p>
<p style="position:absolute;top:847px;left:106px;white-space:nowrap" class="ft955">After proper training in injection technique, patients may self-inject with Humira if their physician&#160;<br/>determines that it is appropriate and with medical follow-up as necessary.&#160;</p>
<p style="position:absolute;top:904px;left:106px;white-space:nowrap" class="ft954">During treatment with Humira, other concomitant therapies (e.g., corticosteroids and/or&#160;<br/>immunomodulatory agents) should be optimised.</p>
<p style="position:absolute;top:960px;left:106px;white-space:nowrap" class="ft952">Posology</p>
<p style="position:absolute;top:998px;left:106px;white-space:nowrap" class="ft953"><i>Rheumatoid arthritis</i></p>
<p style="position:absolute;top:1036px;left:106px;white-space:nowrap" class="ft954">The recommended dose of Humira for adult patients with rheumatoid arthritis is 40&#160;mg adalimumab&#160;<br/>administered every other week as a single dose via subcutaneous injection. Methotrexate should be&#160;<br/>continued during treatment with Humira.</p>
</div>
<!-- Page 96 -->
<a name="96"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page96-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft960">96</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft964">Glucocorticoids, salicylates, non-steroidal anti-inflammatory drugs, or analgesics can be continued during&#160;<br/>treatment with Humira. Regarding combination with disease modifying anti-rheumatic drugs other than&#160;<br/>methotrexate see sections 4.4 and 5.1.</p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft964">In&#160;monotherapy, some patients who experience a decrease in their response&#160;to Humira 40&#160;mg every other&#160;<br/>week&#160;may benefit from an increase in dosage to 40&#160;mg adalimumab every week&#160;or 80&#160;mg&#160;every other&#160;<br/>week.&#160;</p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft964">Available data suggest that the clinical response is usually achieved within 12&#160;weeks of treatment.&#160;<br/>Continued therapy should be reconsidered in a patient not responding within this time period.</p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft964">Humira may be available in other strengths and/or presentations depending on the individual treatment&#160;<br/>needs.</p>
<p style="position:absolute;top:370px;left:106px;white-space:nowrap" class="ft963"><i>Dose interruption</i></p>
<p style="position:absolute;top:409px;left:106px;white-space:nowrap" class="ft962">There&#160;may be a need for dose interruption, for instance before surgery or if a serious infection occurs.</p>
<p style="position:absolute;top:446px;left:106px;white-space:nowrap" class="ft964">Available data suggest that re-introduction of Humira after&#160;discontinuation for 70&#160;days or longer resulted&#160;<br/>in the same magnitudes of clinical response and similar safety profile as before dose interruption.</p>
<p style="position:absolute;top:503px;left:106px;white-space:nowrap" class="ft963"><i>Ankylosing spondylitis, axial spondyloarthritis without radiographic evidence of AS and psoriatic arthritis</i></p>
<p style="position:absolute;top:541px;left:106px;white-space:nowrap" class="ft964">The recommended dose of Humira for patients with ankylosing spondylitis, axial spondyloarthritis without&#160;<br/>radiographic evidence of AS and for patients with psoriatic arthritis is 40&#160;mg adalimumab administered&#160;<br/>every other week as a single dose via subcutaneous injection.</p>
<p style="position:absolute;top:617px;left:106px;white-space:nowrap" class="ft964">Available data suggest that the clinical response is usually achieved within 12&#160;weeks of treatment.&#160;<br/>Continued therapy should be reconsidered in a patient not responding within this time period.</p>
<p style="position:absolute;top:674px;left:106px;white-space:nowrap" class="ft963"><i>Psoriasis</i></p>
<p style="position:absolute;top:712px;left:106px;white-space:nowrap" class="ft965">The recommended dose of Humira for&#160;adult patients is an initial dose of 80&#160;mg administered&#160;<br/>subcutaneously, followed by 40&#160;mg subcutaneously given every other week starting one week after the&#160;<br/>initial dose.</p>
<p style="position:absolute;top:788px;left:106px;white-space:nowrap" class="ft964">Continued therapy beyond 16&#160;weeks should be carefully reconsidered in a patient not&#160;responding within&#160;<br/>this time period.</p>
<p style="position:absolute;top:845px;left:106px;white-space:nowrap" class="ft965">Beyond 16 weeks, patients with inadequate response&#160;to Humira 40&#160;mg&#160;every other week&#160;may benefit from&#160;<br/>an increase in dosage&#160;to&#160;40 mg every week&#160;or 80&#160;mg&#160;every other week. The benefits and risks of continued<br/>40&#160;mg&#160;weekly&#160;or 80&#160;mg every other week&#160;therapy should be carefully reconsidered in a patient with an&#160;<br/>inadequate response after the increase in dosage&#160;(see section 5.1).&#160;If adequate response is achieved with&#160;<br/>40&#160;mg&#160;every week or 80&#160;mg&#160;every other week,&#160;the dosage&#160;may subsequently be reduced to 40&#160;mg&#160;every&#160;<br/>other week.</p>
<p style="position:absolute;top:978px;left:106px;white-space:nowrap" class="ft964">Humira may be available in other strengths and/or presentations depending on the individual treatment&#160;<br/>needs.</p>
<p style="position:absolute;top:1035px;left:106px;white-space:nowrap" class="ft963"><i>Hidradenitis suppurativa</i></p>
</div>
<!-- Page 97 -->
<a name="97"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page97-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft970">97</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft974">The recommended Humira dose regimen for adult patients with hidradenitis suppurativa (HS) is 160&#160;mg&#160;<br/>initially at Day&#160;1 (given as four 40&#160;mg injections in one day or as two 40&#160;mg&#160;injections per day for two&#160;<br/>consecutive days), followed by 80&#160;mg two weeks later at Day&#160;15 (given as two 40&#160;mg injections in one&#160;<br/>day). Two weeks later&#160;(Day 29) continue with a dose of 40&#160;mg&#160;every week&#160;or 80&#160;mg every other week&#160;<br/>(given as two 40&#160;mg injections in one day). Antibiotics may be continued during treatment with Humira if&#160;<br/>necessary. It is recommended that the patient should use a topical antiseptic wash on their HS lesions on a&#160;<br/>daily basis during treatment with Humira.</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft974">Continued therapy beyond 12&#160;weeks should be carefully reconsidered in a patient with no improvement&#160;<br/>within this time period. &#160;</p>
<p style="position:absolute;top:295px;left:106px;white-space:nowrap" class="ft975">Should treatment be interrupted, Humira 40&#160;mg&#160;every week&#160;or 80&#160;mg every other week&#160;may be re-<br/>introduced (see section 5.1).&#160;</p>
<p style="position:absolute;top:352px;left:106px;white-space:nowrap" class="ft972">The benefit and risk of continued long-term&#160;treatment should be periodically evaluated (see section 5.1).</p>
<p style="position:absolute;top:390px;left:106px;white-space:nowrap" class="ft974">Humira may be available&#160;in other strengths and/or presentations depending on the individual treatment&#160;<br/>needs.</p>
<p style="position:absolute;top:446px;left:106px;white-space:nowrap" class="ft973"><i>Crohn’s disease</i></p>
<p style="position:absolute;top:485px;left:106px;white-space:nowrap" class="ft974">The recommended Humira induction dose regimen for adult patients with moderately to severely active&#160;<br/>Crohn’s disease is 80&#160;mg at Week&#160;0 followed by 40&#160;mg&#160;at Week&#160;2. In case there is a need for a more rapid&#160;<br/>response to therapy, the regimen 160&#160;mg at Week&#160;0 (given&#160;as four&#160;40&#160;mg&#160;injections in one day or as two&#160;<br/>40&#160;mg&#160;injections per day for two consecutive days),&#160;followed by&#160;80&#160;mg at Week&#160;2&#160;(given as two 40&#160;mg&#160;<br/>injections in one day), can be used with the awareness that the risk for adverse events is higher during&#160;<br/>induction.</p>
<p style="position:absolute;top:617px;left:106px;white-space:nowrap" class="ft974">After induction treatment, the recommended dose is 40&#160;mg&#160;every other week via subcutaneous injection.&#160;<br/>Alternatively, if a patient has stopped Humira and signs and symptoms of disease recur, Humira may be&#160;<br/>re-administered. There is little experience from re-administration after more than 8&#160;weeks since the&#160;<br/>previous dose.</p>
<p style="position:absolute;top:712px;left:106px;white-space:nowrap" class="ft974">During maintenance treatment, corticosteroids may be tapered in accordance&#160;with clinical practice&#160;<br/>guidelines.</p>
<p style="position:absolute;top:769px;left:106px;white-space:nowrap" class="ft974">Some patients who experience decrease in their response&#160;to Humira 40&#160;mg&#160;every other week&#160;may benefit&#160;<br/>from an increase in dosage&#160;to 40&#160;mg Humira every week&#160;or 80&#160;mg&#160;every other week.</p>
<p style="position:absolute;top:826px;left:106px;white-space:nowrap" class="ft974">Some patients who have not responded&#160;by Week&#160;4 may benefit from continued maintenance therapy&#160;<br/>through Week&#160;12. Continued therapy should be carefully reconsidered in a patient not responding within&#160;<br/>this time period.</p>
<p style="position:absolute;top:902px;left:106px;white-space:nowrap" class="ft974">Humira may be available in other strengths and/or presentations depending on&#160;the individual treatment&#160;<br/>needs.</p>
<p style="position:absolute;top:959px;left:106px;white-space:nowrap" class="ft973"><i>Ulcerative colitis</i></p>
<p style="position:absolute;top:997px;left:106px;white-space:nowrap" class="ft975">The recommended Humira induction dose regimen for adult patients with moderate to severe ulcerative&#160;<br/>colitis is 160&#160;mg at Week 0 (given&#160;as four&#160;40&#160;mg&#160;injections in one day or as two&#160;40&#160;mg&#160;injections per day&#160;</p>
</div>
<!-- Page 98 -->
<a name="98"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page98-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft980">98</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft985">for two consecutive days) and 80&#160;mg at Week&#160;2&#160;(given as two 40&#160;mg injections in one day). After&#160;<br/>induction treatment, the recommended dose is 40&#160;mg&#160;every other week via subcutaneous injection.&#160;</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft984">During maintenance treatment, corticosteroids may be tapered in accordance with clinical practice&#160;<br/>guidelines.&#160;</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft984">Some patients who experience decrease in their response&#160;to Humira 40&#160;mg&#160;every other week&#160;may benefit&#160;<br/>from an increase in dosage&#160;to 40&#160;mg Humira&#160;every week&#160;or 80&#160;mg&#160;every other week.</p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft984">Available data suggest that clinical response is usually achieved within 2-8&#160;weeks of treatment. Humira&#160;<br/>therapy should not be continued in patients failing to respond within this time period.</p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft984">Humira may be available&#160;in other strengths and/or presentations depending on the individual treatment&#160;<br/>needs.</p>
<p style="position:absolute;top:370px;left:106px;white-space:nowrap" class="ft983"><i>Uveitis</i></p>
<p style="position:absolute;top:409px;left:106px;white-space:nowrap" class="ft985">The recommended dose of Humira for adult patients with uveitis is an initial dose of 80&#160;mg, followed by&#160;<br/>40&#160;mg given every other week starting one week after the initial dose. There is limited experience in the&#160;<br/>initiation of treatment with Humira alone. Treatment with Humira can be initiated in combination with&#160;<br/>corticosteroids and/or with other non-biologic immunomodulatory agents. Concomitant corticosteroids&#160;<br/>may be tapered in accordance with clinical practice starting two weeks after initiating treatment with&#160;<br/>Humira. &#160;&#160;</p>
<p style="position:absolute;top:541px;left:106px;white-space:nowrap" class="ft985">It is recommended that the benefit and risk of continued long-term&#160;treatment should be evaluated on a&#160;<br/>yearly basis (see section 5.1). &#160;</p>
<p style="position:absolute;top:598px;left:106px;white-space:nowrap" class="ft985">Humira may be available in other strengths and/or presentations depending on the individual treatment&#160;<br/>needs.</p>
<p style="position:absolute;top:655px;left:106px;white-space:nowrap" class="ft982">Special populations</p>
<p style="position:absolute;top:693px;left:106px;white-space:nowrap" class="ft982">Elderly</p>
<p style="position:absolute;top:731px;left:106px;white-space:nowrap" class="ft982">No dose adjustment is required.</p>
<p style="position:absolute;top:769px;left:106px;white-space:nowrap" class="ft982">Renal&#160;and/or hepatic impairment</p>
<p style="position:absolute;top:807px;left:106px;white-space:nowrap" class="ft982">Humira has not been studied in these patient populations. No dose recommendations can be made.</p>
<p style="position:absolute;top:845px;left:106px;white-space:nowrap" class="ft982">Paediatric population</p>
<p style="position:absolute;top:883px;left:106px;white-space:nowrap" class="ft983"><i>Juvenile idiopathic arthritis</i></p>
<p style="position:absolute;top:921px;left:106px;white-space:nowrap" class="ft983"><i>Polyarticular juvenile idiopathic arthritis from 2 years of age</i></p>
<p style="position:absolute;top:959px;left:106px;white-space:nowrap" class="ft984">The recommended dose of Humira for patients with polyarticular juvenile idiopathic arthritis&#160;from&#160;2 years<br/>of age is based on body weight (Table 1). Humira is&#160;administered every other week via subcutaneous&#160;<br/>injection.</p>
<p style="position:absolute;top:1035px;left:169px;white-space:nowrap" class="ft981"><b>Table 1. Humira&#160;Dose for Patients with Polyarticular Juvenile Idiopathic Arthritis&#160;</b></p>
</div>
<!-- Page 99 -->
<a name="99"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page99-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:449px;white-space:nowrap" class="ft990">99</p>
<p style="position:absolute;top:89px;left:279px;white-space:nowrap" class="ft991"><b>Patient Weight</b></p>
<p style="position:absolute;top:89px;left:529px;white-space:nowrap" class="ft991"><b>Dosing Regimen</b></p>
<p style="position:absolute;top:114px;left:278px;white-space:nowrap" class="ft992">10 kg to &lt; 30 kg</p>
<p style="position:absolute;top:114px;left:507px;white-space:nowrap" class="ft992">20 mg every other week</p>
<p style="position:absolute;top:139px;left:307px;white-space:nowrap" class="ft992">≥ 30 kg</p>
<p style="position:absolute;top:139px;left:507px;white-space:nowrap" class="ft992">40 mg every other week</p>
<p style="position:absolute;top:180px;left:106px;white-space:nowrap" class="ft994">Available data suggest that clinical response is usually achieved within 12&#160;weeks of treatment. Continued&#160;<br/>therapy should be carefully reconsidered in a patient not responding within this time period.</p>
<p style="position:absolute;top:237px;left:106px;white-space:nowrap" class="ft992">There is no relevant use of Humira in patients aged&#160;less than&#160;2&#160;years for this indication.</p>
<p style="position:absolute;top:275px;left:106px;white-space:nowrap" class="ft994">Humira may be available in other strengths and/or presentations depending on the individual treatment&#160;<br/>needs.</p>
<p style="position:absolute;top:332px;left:106px;white-space:nowrap" class="ft993"><i>Enthesitis-related arthritis</i></p>
<p style="position:absolute;top:370px;left:106px;white-space:nowrap" class="ft994">The recommended dose of Humira for patients with enthesitis-related arthritis&#160;from&#160;6&#160;years of age&#160;is based&#160;<br/>on body weight (Table 2).&#160;Humira is&#160;administered every other week via subcutaneous injection.</p>
<p style="position:absolute;top:427px;left:221px;white-space:nowrap" class="ft991"><b>Table&#160;2. Humira Dose for Patients with Enthesitis-Related Arthritis</b></p>
<p style="position:absolute;top:468px;left:279px;white-space:nowrap" class="ft991"><b>Patient Weight</b></p>
<p style="position:absolute;top:468px;left:529px;white-space:nowrap" class="ft991"><b>Dosing Regimen</b></p>
<p style="position:absolute;top:492px;left:278px;white-space:nowrap" class="ft992">15&#160;kg to &lt; 30 kg</p>
<p style="position:absolute;top:492px;left:507px;white-space:nowrap" class="ft992">20 mg every&#160;other week</p>
<p style="position:absolute;top:517px;left:307px;white-space:nowrap" class="ft992">≥ 30 kg</p>
<p style="position:absolute;top:517px;left:507px;white-space:nowrap" class="ft992">40 mg every other week</p>
<p style="position:absolute;top:560px;left:106px;white-space:nowrap" class="ft992">Humira has not been studied in patients with enthesitis-related arthritis aged less than 6&#160;years.</p>
<p style="position:absolute;top:598px;left:106px;white-space:nowrap" class="ft995">Humira may be available in other strengths and/or presentations depending on the individual treatment&#160;<br/>needs.</p>
<p style="position:absolute;top:655px;left:106px;white-space:nowrap" class="ft993"><i>Psoriatic arthritis and axial spondyloarthritis including ankylosing spondyliti</i>s</p>
<p style="position:absolute;top:693px;left:106px;white-space:nowrap" class="ft994">There is no relevant use of Humira in the paediatric population for the indications of ankylosing&#160;<br/>spondylitis and psoriatic arthritis.</p>
<p style="position:absolute;top:750px;left:106px;white-space:nowrap" class="ft993"><i>Paediatric plaque psoriasis</i></p>
<p style="position:absolute;top:788px;left:106px;white-space:nowrap" class="ft995">The recommended Humira dose for patients with plaque psoriasis from 4 to 17&#160;years of age is based on&#160;<br/>body weight (Table 3).&#160;Humira is administered&#160;via subcutaneous injection.</p>
<p style="position:absolute;top:845px;left:223px;white-space:nowrap" class="ft991"><b>Table 3. Humira Dose&#160;for&#160;Paediatric&#160;Patients with Plaque Psoriasis</b></p>
<p style="position:absolute;top:886px;left:279px;white-space:nowrap" class="ft991"><b>Patient Weight</b></p>
<p style="position:absolute;top:886px;left:529px;white-space:nowrap" class="ft991"><b>Dosing Regimen</b></p>
<p style="position:absolute;top:910px;left:278px;white-space:nowrap" class="ft992">15&#160;kg to &lt; 30 kg</p>
<p style="position:absolute;top:910px;left:474px;white-space:nowrap" class="ft992">Initial dose of 20 mg, followed by&#160;</p>
<p style="position:absolute;top:928px;left:486px;white-space:nowrap" class="ft992">20 mg given every other week&#160;</p>
<p style="position:absolute;top:946px;left:478px;white-space:nowrap" class="ft992">starting one week after the initial&#160;</p>
<p style="position:absolute;top:964px;left:571px;white-space:nowrap" class="ft992">dose</p>
<p style="position:absolute;top:989px;left:307px;white-space:nowrap" class="ft992">≥ 30 kg</p>
<p style="position:absolute;top:989px;left:474px;white-space:nowrap" class="ft992">Initial dose of 40 mg, followed by&#160;</p>
<p style="position:absolute;top:1007px;left:486px;white-space:nowrap" class="ft992">40 mg given every other week&#160;</p>
<p style="position:absolute;top:1025px;left:478px;white-space:nowrap" class="ft992">starting one week after the initial&#160;</p>
<p style="position:absolute;top:1043px;left:571px;white-space:nowrap" class="ft992">dose</p>
</div>
<!-- Page 100 -->
<a name="100"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page100-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1000">100</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft1005">Continued therapy beyond 16&#160;weeks should be carefully considered in a patient not responding within this&#160;<br/>time period.</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft1004">If retreatment with Humira is indicated, the above guidance on dose and treatment duration should be&#160;<br/>followed.</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft1004">The safety of Humira in paediatric patients with plaque psoriasis has been assessed for a mean of&#160;<br/>13&#160;months.</p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft1002">There is no relevant use of Humira in children aged less than 4&#160;years for this indication.</p>
<p style="position:absolute;top:295px;left:106px;white-space:nowrap" class="ft1005">Humira may be available in other strengths and/or presentations depending on the&#160;individual treatment&#160;<br/>needs.</p>
<p style="position:absolute;top:352px;left:106px;white-space:nowrap" class="ft1003"><i>Adolescent hidradenitis suppurativa (from 12 years of age, weighing at least 30 kg)</i></p>
<p style="position:absolute;top:390px;left:106px;white-space:nowrap" class="ft1004">There are no clinical trials with Humira in adolescent patients with HS. &#160;The posology of Humira in these&#160;<br/>patients has been determined from&#160;pharmacokinetic modelling and simulation (see section 5.2).</p>
<p style="position:absolute;top:446px;left:106px;white-space:nowrap" class="ft1004">The recommended Humira dose is 80&#160;mg at Week&#160;0 followed by 40&#160;mg every other week starting at&#160;<br/>Week&#160;1 via subcutaneous injection.&#160;</p>
<p style="position:absolute;top:503px;left:106px;white-space:nowrap" class="ft1004">In adolescent patients with inadequate response to Humira 40&#160;mg&#160;every other week, an increase in dosage<br/>to 40&#160;mg&#160;every week&#160;or 80&#160;mg&#160;every other week&#160;may be considered.</p>
<p style="position:absolute;top:560px;left:106px;white-space:nowrap" class="ft1004">Antibiotics may be continued during treatment with Humira if necessary. &#160;It is recommended that the&#160;<br/>patient should use a topical antiseptic wash on their HS lesions on a daily basis during treatment with&#160;<br/>Humira.&#160;</p>
<p style="position:absolute;top:636px;left:106px;white-space:nowrap" class="ft1004">Continued therapy beyond 12&#160;weeks should be carefully reconsidered in a patient with no improvement&#160;<br/>within this time period. &#160;</p>
<p style="position:absolute;top:693px;left:106px;white-space:nowrap" class="ft1002">Should treatment be interrupted, Humira may be re-introduced as appropriate.</p>
<p style="position:absolute;top:731px;left:106px;white-space:nowrap" class="ft1005">The benefit and risk of continued long-term&#160;treatment should be periodically evaluated (see&#160;adult data in&#160;<br/>section 5.1)</p>
<p style="position:absolute;top:788px;left:106px;white-space:nowrap" class="ft1002">There is no relevant use of Humira in children aged less than 12 years in this indication.</p>
<p style="position:absolute;top:826px;left:106px;white-space:nowrap" class="ft1004">Humira may be available in other strengths and/or presentations depending on the individual treatment&#160;<br/>needs.</p>
<p style="position:absolute;top:883px;left:106px;white-space:nowrap" class="ft1003"><i>Paediatric Crohn's disease</i></p>
<p style="position:absolute;top:921px;left:106px;white-space:nowrap" class="ft1005">The recommended dose of Humira for patients with&#160;Crohn’s disease from 6&#160;to 17&#160;years&#160;of age&#160;is based on&#160;<br/>body&#160;weight&#160;(Table 4).&#160;Humira is&#160;administered via subcutaneous injection.</p>
</div>
<!-- Page 101 -->
<a name="101"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page101-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1010">101</p>
<p style="position:absolute;top:86px;left:225px;white-space:nowrap" class="ft1011"><b>Table&#160;4. Humira Dose&#160;for&#160;Paediatric Patients with Crohn’s disease</b></p>
<p style="position:absolute;top:126px;left:118px;white-space:nowrap" class="ft1011"><b>Patient&#160;</b></p>
<p style="position:absolute;top:145px;left:117px;white-space:nowrap" class="ft1011"><b>Weight</b></p>
<p style="position:absolute;top:126px;left:383px;white-space:nowrap" class="ft1011"><b>Induction Dose</b></p>
<p style="position:absolute;top:126px;left:706px;white-space:nowrap" class="ft1011"><b>Maintenance&#160;</b></p>
<p style="position:absolute;top:145px;left:735px;white-space:nowrap" class="ft1011"><b>Dose</b></p>
<p style="position:absolute;top:164px;left:715px;white-space:nowrap" class="ft1011"><b>Starting at&#160;</b></p>
<p style="position:absolute;top:183px;left:726px;white-space:nowrap" class="ft1011"><b>Week 4</b></p>
<p style="position:absolute;top:206px;left:118px;white-space:nowrap" class="ft1012">&lt; 40 kg</p>
<p style="position:absolute;top:205px;left:190px;white-space:nowrap" class="ft1016">&#160;40 mg at Week 0 and 20 mg at week 2</p>
<p style="position:absolute;top:244px;left:192px;white-space:nowrap" class="ft1014">In case there is a need for a more rapid response to therapy&#160;with the&#160;<br/>awareness that the risk for adverse events may be higher with use of the&#160;<br/>higher induction dose, the following dose may be used:</p>
<p style="position:absolute;top:301px;left:190px;white-space:nowrap" class="ft1016">&#160;80 mg at week 0 and 40 mg at week 2</p>
<p style="position:absolute;top:206px;left:712px;white-space:nowrap" class="ft1012">20 mg every&#160;</p>
<p style="position:absolute;top:224px;left:717px;white-space:nowrap" class="ft1012">other week</p>
<p style="position:absolute;top:325px;left:118px;white-space:nowrap" class="ft1012">≥ 40 kg</p>
<p style="position:absolute;top:324px;left:190px;white-space:nowrap" class="ft1016">&#160;80 mg at week 0 and 40 mg at week 2</p>
<p style="position:absolute;top:364px;left:192px;white-space:nowrap" class="ft1014">In case there is a need for a more rapid response to therapy&#160;with the&#160;<br/>awareness that the risk&#160;for adverse events may be higher with use of the&#160;<br/>higher induction dose, the following dose may be used:</p>
<p style="position:absolute;top:420px;left:190px;white-space:nowrap" class="ft1016">&#160;160 mg at week 0 and 80 mg at week 2</p>
<p style="position:absolute;top:325px;left:712px;white-space:nowrap" class="ft1012">40 mg every&#160;</p>
<p style="position:absolute;top:344px;left:717px;white-space:nowrap" class="ft1012">other week</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft1012">Patients&#160;who&#160;experience insufficient response may benefit from&#160;an increase in&#160;dosage:</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft1016"></p>
<p style="position:absolute;top:483px;left:147px;white-space:nowrap" class="ft1012">&lt;&#160;40&#160;kg: 20&#160;mg&#160;every week</p>
<p style="position:absolute;top:501px;left:106px;white-space:nowrap" class="ft1016"></p>
<p style="position:absolute;top:503px;left:147px;white-space:nowrap" class="ft1012">≥ 40&#160;kg: 40&#160;mg&#160;every&#160;week&#160;or 80&#160;mg&#160;every other week</p>
<p style="position:absolute;top:541px;left:106px;white-space:nowrap" class="ft1012">Continued therapy should be carefully considered in a subject not responding by&#160;week&#160;12.</p>
<p style="position:absolute;top:579px;left:106px;white-space:nowrap" class="ft1012">There is no relevant use of Humira in children aged&#160;less than&#160;6&#160;years for this indication.</p>
<p style="position:absolute;top:617px;left:106px;white-space:nowrap" class="ft1015">Humira may be available in other strengths and/or presentations depending on the individual treatment&#160;<br/>needs.</p>
<p style="position:absolute;top:674px;left:106px;white-space:nowrap" class="ft1013"><i>Paediatric ulcerative colitis</i></p>
<p style="position:absolute;top:711px;left:106px;white-space:nowrap" class="ft1014">The recommended dose of Humira for patients from&#160;6&#160;to 17 years of age with ulcerative colitis is based on&#160;<br/>body weight (Table&#160;5). Humira is administered via subcutaneous injection.</p>
<p style="position:absolute;top:768px;left:220px;white-space:nowrap" class="ft1011"><b>Table&#160;5. Humira Dose for Paediatric Patients with Ulcerative Colitis&#160;</b></p>
<p style="position:absolute;top:799px;left:154px;white-space:nowrap" class="ft1011"><b>Patient Weight</b></p>
<p style="position:absolute;top:799px;left:352px;white-space:nowrap" class="ft1011"><b>Induction Dose</b></p>
<p style="position:absolute;top:789px;left:594px;white-space:nowrap" class="ft1011"><b>Maintenance Dose</b></p>
<p style="position:absolute;top:809px;left:588px;white-space:nowrap" class="ft1011"><b>Starting at Week 4*</b></p>
<p style="position:absolute;top:831px;left:181px;white-space:nowrap" class="ft1012">&lt; 40 kg</p>
<p style="position:absolute;top:831px;left:289px;white-space:nowrap" class="ft1012">•&#160;80 mg at Week 0&#160;(given as two 40&#160;</p>
<p style="position:absolute;top:850px;left:305px;white-space:nowrap" class="ft1012">mg&#160;injections in one day)&#160;and</p>
<p style="position:absolute;top:869px;left:289px;white-space:nowrap" class="ft1012">•&#160;40 mg at Week 2&#160;(given as one 40&#160;</p>
<p style="position:absolute;top:888px;left:305px;white-space:nowrap" class="ft1012">mg&#160;injection)</p>
<p style="position:absolute;top:831px;left:548px;white-space:nowrap" class="ft1012">•&#160;40 mg every other week</p>
<p style="position:absolute;top:910px;left:181px;white-space:nowrap" class="ft1012">≥&#160;40 kg</p>
<p style="position:absolute;top:910px;left:289px;white-space:nowrap" class="ft1012">•&#160;160 mg at Week 0&#160;(given as four&#160;</p>
<p style="position:absolute;top:929px;left:305px;white-space:nowrap" class="ft1015">40 mg injections in one day or&#160;<br/>two 40 mg injections per day for&#160;<br/>two consecutive days)&#160;and</p>
<p style="position:absolute;top:986px;left:289px;white-space:nowrap" class="ft1012">•&#160;80 mg at Week 2&#160;(given as two 40&#160;</p>
<p style="position:absolute;top:1005px;left:305px;white-space:nowrap" class="ft1012">mg&#160;injections in one day)</p>
<p style="position:absolute;top:910px;left:548px;white-space:nowrap" class="ft1012">•&#160;80 mg every other week</p>
<p style="position:absolute;top:1026px;left:138px;white-space:nowrap" class="ft1017">*&#160;Paediatric patients who turn 18 years of age while on Humira&#160;should continue their prescribed&#160;<br/>maintenance dose.</p>
</div>
<!-- Page 102 -->
<a name="102"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page102-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1020">102</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft1025">Continued therapy beyond 8 weeks should be carefully considered in&#160;patients not showing signs of&#160;<br/>response&#160;within this time period.</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft1022">There is no relevant use of Humira in children aged less than&#160;6&#160;years in this indication.</p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft1024">Humira may be available in different strengths and/or presentations&#160;depending on the individual treatment&#160;<br/>needs.</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft1023"><i>Paediatric Uveitis</i></p>
<p style="position:absolute;top:276px;left:106px;white-space:nowrap" class="ft1024">The recommended dose of Humira for&#160;paediatric&#160;patients with&#160;uveitis&#160;from 2&#160;years&#160;of age&#160;is based on&#160;<br/>body&#160;weight&#160;(Table&#160;6).&#160;Humira is&#160;administered via subcutaneous injection.</p>
<p style="position:absolute;top:333px;left:106px;white-space:nowrap" class="ft1024">In paediatric uveitis, there is no experience in the treatment with Humira without concomitant treatment&#160;<br/>with methotrexate.</p>
<p style="position:absolute;top:390px;left:256px;white-space:nowrap" class="ft1021"><b>Table&#160;6. Humira Dose for&#160;Paediatric&#160;Patients with&#160;Uveitis</b></p>
<p style="position:absolute;top:431px;left:279px;white-space:nowrap" class="ft1021"><b>Patient Weight</b></p>
<p style="position:absolute;top:431px;left:529px;white-space:nowrap" class="ft1021"><b>Dosing Regimen</b></p>
<p style="position:absolute;top:455px;left:307px;white-space:nowrap" class="ft1022">&lt; 30 kg</p>
<p style="position:absolute;top:455px;left:498px;white-space:nowrap" class="ft1022">20 mg every other week in&#160;</p>
<p style="position:absolute;top:473px;left:483px;white-space:nowrap" class="ft1022">combination with methotrexate</p>
<p style="position:absolute;top:498px;left:307px;white-space:nowrap" class="ft1022">≥ 30 kg</p>
<p style="position:absolute;top:498px;left:498px;white-space:nowrap" class="ft1022">40 mg every other week in&#160;</p>
<p style="position:absolute;top:516px;left:483px;white-space:nowrap" class="ft1022">combination with methotrexate</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft1024">When Humira therapy is initiated, a loading dose of 40&#160;mg&#160;for patients &lt; 30 kg or 80&#160;mg for patients&#160;≥ 30&#160;<br/>kg&#160;may be administered one week prior to the start of maintenance therapy. No clinical data are available&#160;<br/>on the use of a Humira loading dose in children &lt;&#160;6 years of age (see section 5.2).</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft1022">There is no relevant use of Humira in children aged less than 2&#160;years in this indication.</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft1025">It is recommended that the benefit and risk of continued long-term&#160;treatment should be evaluated on a&#160;<br/>yearly basis (see section 5.1).</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft1024">Humira may be available in other strengths and/or presentations depending&#160;on the individual treatment&#160;<br/>needs.</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft1022">Method of administration</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft1024">Humira is administered by subcutaneous injection. Full instructions for use are provided in the package&#160;<br/>leaflet.</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft1022">Humira is available in other strengths and presentations.</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft1021"><b>4.3</b></p>
<p style="position:absolute;top:918px;left:148px;white-space:nowrap" class="ft1021"><b>Contraindications&#160;</b></p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft1022">Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft1022">Active tuberculosis or other severe infections such as sepsis, and opportunistic infections (see section 4.4).</p>
<p style="position:absolute;top:1030px;left:106px;white-space:nowrap" class="ft1022">Moderate to severe heart failure&#160;(NYHA class III/IV) (see section 4.4).</p>
</div>
<!-- Page 103 -->
<a name="103"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page103-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1030">103</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft1031"><b>4.4</b></p>
<p style="position:absolute;top:86px;left:148px;white-space:nowrap" class="ft1031"><b>Special warnings and precautions for use &#160;</b></p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft1032">Traceability&#160;</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft1035">In&#160;order to improve traceability of biological medicinal products, the&#160;name&#160;and the batch number of the&#160;<br/>administered product should be clearly recorded.</p>
<p style="position:absolute;top:219px;left:106px;white-space:nowrap" class="ft1032">Infections</p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft1035">Patients taking TNF-antagonists are more susceptible to serious infections. Impaired lung function may&#160;<br/>increase the risk for developing infections. Patients must therefore be monitored closely for infections,&#160;<br/>including tuberculosis, before,&#160;during and after treatment with Humira. Because the elimination of&#160;<br/>adalimumab may take up to four months, monitoring should be continued throughout this period.</p>
<p style="position:absolute;top:352px;left:106px;white-space:nowrap" class="ft1035">Treatment with Humira should not be initiated in patients with active infections including chronic or&#160;<br/>localised infections until infections are controlled. In patients who have been exposed to tuberculosis and&#160;<br/>patients who have travelled in areas of high risk of tuberculosis or endemic mycoses, such as&#160;<br/>histoplasmosis, coccidioidomycosis, or blastomycosis, the risk and benefits of treatment with Humira&#160;<br/>should be considered prior to initiating therapy (see&#160;<i>Other opportunistic infections</i>).</p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft1035">Patients who develop a new infection while undergoing treatment with Humira should be monitored&#160;<br/>closely and&#160;undergo a complete diagnostic evaluation. Administration of Humira should be discontinued if&#160;<br/>a patient develops a new serious infection or sepsis, and appropriate antimicrobial or antifungal therapy&#160;<br/>should be initiated until the infection is controlled. Physicians should exercise caution when considering&#160;<br/>the use of Humira in patients with a history of recurring infection or with underlying conditions which&#160;<br/>may predispose patients to infections, including the use of concomitant immunosuppressive medications.</p>
<p style="position:absolute;top:598px;left:106px;white-space:nowrap" class="ft1033"><i>Serious infections</i></p>
<p style="position:absolute;top:636px;left:106px;white-space:nowrap" class="ft1034">Serious infections,&#160;including sepsis,&#160;due to bacterial, mycobacterial, invasive fungal, parasitic, viral, or&#160;<br/>other opportunistic infections&#160;such as listeriosis, legionellosis and pneumocystis&#160;have been reported in&#160;<br/>patients receiving Humira. &#160;</p>
<p style="position:absolute;top:712px;left:106px;white-space:nowrap" class="ft1034">Other serious infections seen in clinical trials include pneumonia, pyelonephritis, septic arthritis and&#160;<br/>septicaemia. Hospitalisation or fatal outcomes associated with infections have been reported.&#160;</p>
<p style="position:absolute;top:769px;left:106px;white-space:nowrap" class="ft1033"><i>Tuberculosis</i></p>
<p style="position:absolute;top:807px;left:106px;white-space:nowrap" class="ft1035">Tuberculosis, including reactivation and new onset of tuberculosis, has been reported in patients receiving&#160;<br/>Humira. &#160;Reports included cases of pulmonary and extra-pulmonary (i.e. disseminated) tuberculosis.&#160;</p>
<p style="position:absolute;top:864px;left:106px;white-space:nowrap" class="ft1034">Before initiation of therapy with Humira, all patients must be evaluated for both active or inactive&#160;<br/>(“latent”) tuberculosis infection. &#160;This evaluation should include a detailed medical assessment of patient&#160;<br/>history of tuberculosis or possible previous exposure to people with active tuberculosis and previous&#160;<br/>and/or current immunosuppressive therapy. &#160;Appropriate screening tests (i.e. tuberculin skin test and chest&#160;<br/>X-ray) should be performed in all patients (local recommendations may apply). &#160;It is recommended that&#160;<br/>the conduct and results of these tests are recorded in the&#160;Patient Reminder Card. &#160;Prescribers are reminded&#160;<br/>of the risk of false negative tuberculin skin test results, especially in patients who are severely ill or&#160;<br/>immunocompromised.&#160;</p>
<p style="position:absolute;top:1035px;left:106px;white-space:nowrap" class="ft1032">If active tuberculosis is diagnosed, Humira therapy must not be initiated (see section 4.3).&#160;</p>
<p style="position:absolute;top:1072px;left:106px;white-space:nowrap" class="ft1032">In all situations described below, the benefit/risk balance of therapy should be very carefully considered.</p>
</div>
<!-- Page 104 -->
<a name="104"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page104-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1040">104</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft1044">If latent tuberculosis is suspected,&#160;a physician with expertise in the treatment of tuberculosis should be&#160;<br/>consulted.&#160;&#160;</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft1045">If latent tuberculosis is diagnosed, appropriate treatment must be started with anti-tuberculosis prophylaxis&#160;<br/>treatment before the initiation of Humira, and in accordance with local recommendations.&#160;</p>
<p style="position:absolute;top:219px;left:106px;white-space:nowrap" class="ft1044">Use&#160;of anti-tuberculosis prophylaxis treatment should also be considered before the initiation of Humira in&#160;<br/>patients with several or significant risk factors for tuberculosis despite a negative test for tuberculosis and&#160;<br/>in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment&#160;<br/>cannot&#160;be&#160;confirmed. &#160;</p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft1044">Despite prophylactic treatment for tuberculosis, cases of reactivated tuberculosis have occurred in patients&#160;<br/>treated with Humira. Some patients who have been successfully treated for active tuberculosis have&#160;<br/>redeveloped tuberculosis while&#160;being treated with Humira.</p>
<p style="position:absolute;top:390px;left:106px;white-space:nowrap" class="ft1045">Patients should be instructed to seek medical advice if signs/symptoms suggestive of a tuberculosis&#160;<br/>infection (e.g., persistent cough, wasting/weight loss, low grade fever, listlessness) occur during or after&#160;<br/>therapy with Humira.&#160;</p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft1043"><i>Other opportunistic infections</i></p>
<p style="position:absolute;top:503px;left:106px;white-space:nowrap" class="ft1044">Opportunistic infections, including invasive fungal infections have been observed in patients receiving&#160;<br/>Humira. These infections have not consistently been recognised in patients taking TNF-antagonists and&#160;<br/>this has resulted in delays in appropriate treatment, sometimes resulting in fatal outcomes.&#160;</p>
<p style="position:absolute;top:579px;left:106px;white-space:nowrap" class="ft1044">For patients who develop the signs and symptoms such as fever, malaise, weight loss, sweats, cough,&#160;<br/>dyspnoea, and/or pulmonary infiltrates or other serious systemic illness with or without concomitant shock&#160;<br/>an invasive fungal infection should be suspected and administration of Humira should be promptly&#160;<br/>discontinued. &#160;Diagnosis and administration of empiric antifungal therapy in these patients should be made&#160;<br/>in consultation with a physician with expertise in the care of patients with invasive fungal infections.&#160;</p>
<p style="position:absolute;top:693px;left:106px;white-space:nowrap" class="ft1042">Hepatitis B reactivation</p>
<p style="position:absolute;top:731px;left:106px;white-space:nowrap" class="ft1044">Reactivation of hepatitis B has occurred in patients receiving a TNF-antagonist including Humira, who are&#160;<br/>chronic carriers of this virus (i.e.&#160;surface antigen positive). &#160;Some cases have had a fatal outcome. Patients&#160;<br/>should be tested for HBV infection before initiating treatment with Humira. For patients who test positive&#160;<br/>for hepatitis B infection, consultation with a physician with expertise in&#160;the&#160;treatment of hepatitis B is&#160;<br/>recommended.</p>
<p style="position:absolute;top:845px;left:106px;white-space:nowrap" class="ft1045">Carriers of HBV who require treatment with Humira should be closely monitored for signs and symptoms&#160;<br/>of active HBV infection throughout therapy and for several months following termination of therapy.&#160;<br/>Adequate&#160;data from treating patients who are carriers of HBV with anti-viral therapy in conjunction with&#160;<br/>TNF-antagonist therapy to prevent HBV reactivation are not available. In patients who develop HBV&#160;<br/>reactivation, Humira should be stopped and effective anti-viral therapy with appropriate supportive&#160;<br/>treatment should be initiated.&#160;</p>
<p style="position:absolute;top:978px;left:106px;white-space:nowrap" class="ft1042">Neurological events&#160;</p>
<p style="position:absolute;top:1016px;left:106px;white-space:nowrap" class="ft1045">TNF-antagonists including Humira have been associated in rare instances with new onset or exacerbation&#160;<br/>of clinical symptoms and/or radiographic evidence of&#160;central nervous system demyelinating disease&#160;<br/>including multiple sclerosis and optic neuritis, and peripheral demyelinating disease, including Guillain-<br/>Barré syndrome. Prescribers should exercise caution in considering the use of Humira in patients with pre-</p>
</div>
<!-- Page 105 -->
<a name="105"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page105-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1050">105</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft1054">existing or recent-onset central or peripheral nervous system demyelinating disorders; discontinuation of&#160;<br/>Humira should be considered if any of these disorders develop. There is a known association between&#160;<br/>intermediate uveitis and central demyelinating disorders. Neurologic evaluation should be performed in&#160;<br/>patients with non-infectious intermediate uveitis prior to the initiation of Humira therapy and regularly&#160;<br/>during treatment to assess for pre-existing or developing central demyelinating disorders.&#160;</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft1052">Allergic reactions</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft1055">Serious allergic reactions associated with Humira were rare during clinical trials. Non-serious allergic&#160;<br/>reactions associated with Humira were uncommon during clinical trials. Reports of serious allergic&#160;<br/>reactions including anaphylaxis have been received following Humira administration. If an anaphylactic&#160;<br/>reaction or other serious allergic reaction occurs, administration of Humira should be discontinued&#160;<br/>immediately and appropriate therapy initiated.&#160;</p>
<p style="position:absolute;top:352px;left:106px;white-space:nowrap" class="ft1052">Immunosuppression</p>
<p style="position:absolute;top:390px;left:106px;white-space:nowrap" class="ft1055">In a study of 64 patients with rheumatoid arthritis that were treated with Humira, there was no evidence of&#160;<br/>depression of delayed-type hypersensitivity, depression of immunoglobulin levels, or change in&#160;<br/>enumeration of effector T-, B-, NK-cells, monocyte/macrophages, and neutrophils.</p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft1052">Malignancies and lymphoproliferative disorders</p>
<p style="position:absolute;top:503px;left:106px;white-space:nowrap" class="ft1054">In the controlled portions of clinical trials of TNF-antagonists, more cases of malignancies including&#160;<br/>lymphoma have been observed among patients receiving a TNF-antagonist compared with control&#160;<br/>patients. However, the occurrence was rare. In the post marketing setting, cases of leukaemia have been&#160;<br/>reported in patients treated with a TNF-antagonist. There is an increased background risk for lymphoma&#160;<br/>and leukaemia in rheumatoid arthritis patients with long-standing, highly active, inflammatory disease,&#160;<br/>which complicates the risk estimation. With the current knowledge, a possible risk for the development of&#160;<br/>lymphomas, leukaemia, and other malignancies in patients treated with a TNF-antagonist cannot be&#160;<br/>excluded.</p>
<p style="position:absolute;top:674px;left:106px;white-space:nowrap" class="ft1054">Malignancies, some fatal, have been reported among children, adolescents and young adults (up to 22&#160;<br/>years of age) treated with TNF-antagonists (initiation of therapy&#160;≤&#160;18&#160;years of age), including adalimumab&#160;<br/>in the post marketing setting. Approximately half the cases were lymphomas. The other cases represented&#160;<br/>a variety of different malignancies and included rare malignancies usually associated with&#160;<br/>immunosuppression. A risk for the development of malignancies in children and adolescents treated with&#160;<br/>TNF-antagonists cannot be excluded.&#160;</p>
<p style="position:absolute;top:807px;left:106px;white-space:nowrap" class="ft1054">Rare postmarketing cases of hepatosplenic T-cell lymphoma have been identified in patients treated with&#160;<br/>adalimumab. This rare type of T-cell&#160;lymphoma has a very aggressive disease course and is usually fatal.&#160;<br/>Some of&#160;these hepatosplenic T-cell lymphomas with Humira have occurred in young adult patients on&#160;<br/>concomitant treatment with azathioprine or 6-mercaptopurine used for inflammatory bowel disease. The&#160;<br/>potential risk with the combination of azathioprine or 6-mercaptopurine and Humira should be carefully&#160;<br/>considered. A risk for the development of hepatosplenic T-cell lymphoma in patients treated with Humira&#160;<br/>cannot be excluded (see section 4.8).</p>
<p style="position:absolute;top:959px;left:106px;white-space:nowrap" class="ft1054">No studies have been conducted that include patients with a history of malignancy or in whom treatment&#160;<br/>with Humira is continued following development of malignancy. &#160;Thus,&#160;additional caution should be&#160;<br/>exercised in considering Humira treatment of these patients (see section 4.8).</p>
<p style="position:absolute;top:1035px;left:106px;white-space:nowrap" class="ft1054">All patients, and in particular patients with a medical history of extensive immunosuppressant therapy or&#160;<br/>psoriasis patients with a history of PUVA treatment should be examined for the presence of non-</p>
</div>
<!-- Page 106 -->
<a name="106"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page106-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1060">106</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft1065">melanoma skin cancer prior to and during treatment with Humira. &#160;Melanoma and Merkel cell carcinoma&#160;<br/>have&#160;also been reported in patients treated with TNF-antagonists including adalimumab (see section 4.8).</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft1064">In an exploratory clinical trial evaluating the use of another TNF-antagonist, infliximab, in patients with&#160;<br/>moderate to severe chronic obstructive pulmonary disease (COPD), more malignancies, mostly in the lung&#160;<br/>or head and neck, were reported in infliximab-treated patients compared with control patients. All patients&#160;<br/>had a history of heavy smoking. Therefore, caution should be exercised when using any TNF-antagonist in&#160;<br/>COPD patients, as well as in patients with increased risk for malignancy due to heavy smoking.</p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft1064">With current data it is not known if adalimumab treatment influences the risk for developing dysplasia or&#160;<br/>colon cancer. &#160;All patients with&#160;ulcerative colitis who are at increased risk for dysplasia or colon&#160;<br/>carcinoma (for example, patients with long-standing ulcerative colitis or primary sclerosing cholangitis),&#160;<br/>or who had a prior history of dysplasia or colon carcinoma should be screened for&#160;dysplasia at regular&#160;<br/>intervals before therapy and throughout their disease course. This evaluation should include colonoscopy&#160;<br/>and biopsies per local recommendations.</p>
<p style="position:absolute;top:390px;left:106px;white-space:nowrap" class="ft1062">Haematologic reactions</p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft1064">Rare reports of pancytopenia including aplastic anaemia have been reported with TNF-antagonists. &#160;<br/>Adverse events of the haematologic system, including medically significant cytopenia (e.g.&#160;<br/>thrombocytopenia, leukopenia) have been reported with Humira. All patients should be advised to seek&#160;<br/>immediate medical attention if&#160;they develop signs and symptoms suggestive of blood dyscrasias (e.g.&#160;<br/>persistent fever, bruising, bleeding, pallor) while on Humira. Discontinuation of Humira therapy should be&#160;<br/>considered in patients with confirmed significant haematologic abnormalities.</p>
<p style="position:absolute;top:560px;left:106px;white-space:nowrap" class="ft1062">Vaccinations&#160;</p>
<p style="position:absolute;top:598px;left:106px;white-space:nowrap" class="ft1064">Similar antibody responses to the standard 23-valent pneumococcal vaccine and the influenza trivalent&#160;<br/>virus vaccination were observed in a study in 226 adult subjects with rheumatoid arthritis who were&#160;<br/>treated with adalimumab or placebo. No data are available on the secondary transmission of infection by&#160;<br/>live vaccines in patients receiving Humira. &#160;</p>
<p style="position:absolute;top:693px;left:106px;white-space:nowrap" class="ft1064">It is recommended that paediatric patients, if possible, be brought up to date with all immunisations in&#160;<br/>agreement with current immunisation guidelines prior to initiating Humira therapy.</p>
<p style="position:absolute;top:750px;left:106px;white-space:nowrap" class="ft1064">Patients on Humira may receive concurrent vaccinations, except for live vaccines. Administration of live&#160;<br/>vaccines&#160;(e.g., BCG vaccine)&#160;to&#160;infants exposed to adalimumab in utero is not recommended for 5&#160;months&#160;<br/>following the mother’s last adalimumab injection during pregnancy.</p>
<p style="position:absolute;top:826px;left:106px;white-space:nowrap" class="ft1062">Congestive heart failure</p>
<p style="position:absolute;top:864px;left:106px;white-space:nowrap" class="ft1064">In a clinical trial with another TNF-antagonist worsening congestive heart failure and increased mortality&#160;<br/>due to congestive heart failure have been observed. Cases of worsening congestive heart failure have also&#160;<br/>been reported in patients receiving Humira. Humira should be used with caution in patients with mild&#160;<br/>heart failure (NYHA class I/II). Humira is contraindicated in moderate to severe heart failure (see section&#160;<br/>4.3). Treatment with Humira must be discontinued in patients who develop new or worsening symptoms&#160;<br/>of congestive heart failure.</p>
<p style="position:absolute;top:997px;left:106px;white-space:nowrap" class="ft1062">Autoimmune processes</p>
<p style="position:absolute;top:1035px;left:106px;white-space:nowrap" class="ft1065">Treatment with Humira may result in the formation of autoimmune antibodies.&#160;The impact of long-term&#160;<br/>treatment with Humira on the development of autoimmune diseases is unknown.&#160;If a patient develops&#160;<br/>symptoms suggestive of a lupus-like syndrome following treatment with Humira and is positive for&#160;</p>
</div>
<!-- Page 107 -->
<a name="107"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page107-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1070">107</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft1075">antibodies against double-stranded DNA, further treatment with Humira should not&#160;be&#160;given (see section&#160;<br/>4.8).</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft1072">Concurrent administration of biologic DMARDS or TNF-antagonists</p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft1074">Serious infections were seen in clinical studies with concurrent use of anakinra and another&#160;<br/>TNF-antagonist, etanercept, with no added clinical benefit compared&#160;to etanercept alone. Because of the&#160;<br/>nature of the adverse events seen with the combination of etanercept and anakinra therapy, similar&#160;<br/>toxicities may also result from the combination of anakinra and other TNF-antagonists. Therefore, the&#160;<br/>combination of adalimumab and anakinra is not recommended. (See section 4.5).</p>
<p style="position:absolute;top:295px;left:106px;white-space:nowrap" class="ft1074">Concomitant administration of adalimumab with other biologic DMARDS (e.g, anakinra and abatacept) or&#160;<br/>other TNF-antagonists is not recommended based upon the possible increased risk for infections,<br/>including serious infections and other potential pharmacological interactions. (See section 4.5).</p>
<p style="position:absolute;top:370px;left:106px;white-space:nowrap" class="ft1072">Surgery</p>
<p style="position:absolute;top:409px;left:106px;white-space:nowrap" class="ft1074">There is limited safety experience of surgical procedures in patients treated with Humira. The long half-<br/>life of adalimumab should be taken into consideration if a surgical procedure is planned. &#160;A patient who&#160;<br/>requires surgery while on Humira should be closely monitored for infections, and appropriate actions&#160;<br/>should be taken. There is limited safety experience in patients undergoing arthroplasty while receiving&#160;<br/>Humira.&#160;</p>
<p style="position:absolute;top:522px;left:106px;white-space:nowrap" class="ft1072">Small bowel obstruction</p>
<p style="position:absolute;top:560px;left:106px;white-space:nowrap" class="ft1074">Failure to respond to treatment for Crohn’s disease may indicate the presence of fixed fibrotic stricture&#160;<br/>that may require surgical treatment. Available data suggest that Humira does not worsen or cause&#160;<br/>strictures.</p>
<p style="position:absolute;top:636px;left:106px;white-space:nowrap" class="ft1072">Elderly</p>
<p style="position:absolute;top:674px;left:106px;white-space:nowrap" class="ft1074">The frequency of serious infections among Humira treated subjects over 65&#160;years of age (3.7%) was&#160;<br/>higher than for those under 65&#160;years of age (1.5%). Some of those had a fatal outcome. Particular attention&#160;<br/>regarding the risk for infection should be paid when treating the elderly.</p>
<p style="position:absolute;top:750px;left:106px;white-space:nowrap" class="ft1072">Paediatric population</p>
<p style="position:absolute;top:788px;left:106px;white-space:nowrap" class="ft1072">See Vaccinations above.</p>
<p style="position:absolute;top:826px;left:106px;white-space:nowrap" class="ft1072">Excipients&#160;with known effects</p>
<p style="position:absolute;top:864px;left:106px;white-space:nowrap" class="ft1075">This medicinal product contains less than 1&#160;mmol&#160;of sodium (23&#160;mg) per 0.8&#160;ml dose, i.e. essentially&#160;<br/>‘sodium-free’.</p>
<p style="position:absolute;top:921px;left:106px;white-space:nowrap" class="ft1071"><b>4.5</b></p>
<p style="position:absolute;top:921px;left:148px;white-space:nowrap" class="ft1071"><b>Interaction with other medicinal products and other forms of interaction&#160;</b></p>
<p style="position:absolute;top:959px;left:106px;white-space:nowrap" class="ft1074">Humira has been studied in rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and psoriatic&#160;<br/>arthritis patients taking Humira as monotherapy and those taking concomitant methotrexate. &#160;Antibody&#160;<br/>formation was lower when Humira was given together&#160;with methotrexate in comparison with use as&#160;<br/>monotherapy. Administration of Humira without methotrexate resulted in increased formation of&#160;<br/>antibodies, increased clearance and reduced efficacy of adalimumab (see section 5.1).&#160;</p>
</div>
<!-- Page 108 -->
<a name="108"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page108-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1080">108</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft1085">The combination of Humira and anakinra is not recommended (see section 4.4 “Concurrent administration&#160;<br/>of biologic DMARDS or TNF-antagonists”).&#160;</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft1084">The combination of Humira and abatacept is not recommended (see section 4.4 “Concurrent&#160;<br/>administration of biologic DMARDS or TNF-antagonists”).</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft1081"><b>4.6</b></p>
<p style="position:absolute;top:200px;left:148px;white-space:nowrap" class="ft1081"><b>Fertility, pregnancy and lactation</b></p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft1082">Women of childbearing potential</p>
<p style="position:absolute;top:276px;left:106px;white-space:nowrap" class="ft1084">Women of childbearing potential&#160;should consider the&#160;use&#160;of&#160;adequate contraception to prevent pregnancy&#160;<br/>and continue its use for at least five months after the last Humira treatment.</p>
<p style="position:absolute;top:333px;left:106px;white-space:nowrap" class="ft1082">Pregnancy</p>
<p style="position:absolute;top:370px;left:106px;white-space:nowrap" class="ft1084">A large number (approximately 2100) of prospectively collected pregnancies exposed to adalimumab&#160;<br/>resulting in live birth with known outcomes, including more than 1500 exposed during the first trimester,&#160;<br/>does not indicate an increase in the rate of malformation in the newborn.</p>
<p style="position:absolute;top:446px;left:106px;white-space:nowrap" class="ft1084">In a prospective cohort registry, 257 women with rheumatoid arthritis (RA) or Crohn’s disease (CD)&#160;<br/>treated with adalimumab at least during the first trimester and 120 women with RA or CD not treated with&#160;<br/>adalimumab were enrolled. &#160;The primary endpoint was&#160;the birth prevalence of major birth defects. The&#160;<br/>rate of&#160;pregnancies ending with at least one live born infant with a major birth defect was 6/69 (8.7%)&#160;in&#160;<br/>the adalimumab-treated women with RA and 5/74 (6.8%) in the untreated women with RA (unadjusted&#160;<br/>OR 1.31, 95% CI 0.38-4.52) and 16/152 (10.5%) in the adalimumab-treated women with CD and 3/32&#160;<br/>(9.4%) in the untreated women with CD (unadjusted OR 1.14, 95% CI 0.31-4.16). The adjusted OR&#160;<br/>(accounting for baseline differences) was&#160;1.10&#160;(95% CI 0.45-2.73) with&#160;RA and CD combined. There were&#160;<br/>no distinct differences between&#160;adalimumab-treated and untreated women&#160;for the secondary&#160;endpoints&#160;<br/>spontaneous abortions, minor birth defects, preterm&#160;delivery, birth size and serious or opportunistic&#160;<br/>infections&#160;and no stillbirths or malignancies were reported.&#160;The interpretation of data&#160;may be impacted due&#160;<br/>to methodological limitations of the study, including small sample size and non-randomized design.</p>
<p style="position:absolute;top:693px;left:106px;white-space:nowrap" class="ft1084">In a developmental toxicity study conducted in monkeys, there was no indication of maternal toxicity,&#160;<br/>embryotoxicity or teratogenicity. Preclinical data on postnatal toxicity of adalimumab are not available&#160;<br/>(see section 5.3).</p>
<p style="position:absolute;top:770px;left:106px;white-space:nowrap" class="ft1082">Due to its inhibition of TNF</p>
<p style="position:absolute;top:768px;left:292px;white-space:nowrap" class="ft1086">, adalimumab administered during pregnancy could affect normal immune&#160;</p>
<p style="position:absolute;top:789px;left:106px;white-space:nowrap" class="ft1082">responses in the newborn.&#160;Adalimumab should only be used during pregnancy if clearly needed.&#160;&#160;</p>
<p style="position:absolute;top:827px;left:106px;white-space:nowrap" class="ft1084">Adalimumab may cross the placenta into the serum of infants born to women treated with adalimumab&#160;<br/>during pregnancy. Consequently, these infants may be at increased risk for infection. Administration of&#160;<br/>live vaccines&#160;(e.g., BCG vaccine)&#160;to infants exposed to adalimumab in utero is not recommended for&#160;<br/>5&#160;months following the mother’s last adalimumab injection during pregnancy.</p>
<p style="position:absolute;top:922px;left:106px;white-space:nowrap" class="ft1082">Breast-feeding</p>
<p style="position:absolute;top:960px;left:106px;white-space:nowrap" class="ft1085">Limited information from&#160;the&#160;published literature indicates that adalimumab is excreted in breast milk at&#160;<br/>very low concentrations with the presence of adalimumab in human milk at concentrations of 0.1% to 1%&#160;<br/>of the maternal serum level. Given orally, immunoglobulin G proteins undergo intestinal proteolysis and&#160;<br/>have poor bioavailability. No effects on the breastfed newborns/infants are anticipated. Consequently,&#160;<br/>Humira can be used during breastfeeding.</p>
<p style="position:absolute;top:1074px;left:106px;white-space:nowrap" class="ft1082">Fertility</p>
</div>
<!-- Page 109 -->
<a name="109"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page109-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1090">109</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft1092">Preclinical data on fertility effects of adalimumab are not available.</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft1091"><b>4.7</b></p>
<p style="position:absolute;top:143px;left:148px;white-space:nowrap" class="ft1091"><b>Effects on ability to drive and use machines&#160;</b></p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft1094">Humira may have a minor influence on the ability to drive and use machines. Vertigo and visual&#160;<br/>impairment may occur following administration of Humira (see section 4.8).</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft1091"><b>4.8</b></p>
<p style="position:absolute;top:238px;left:148px;white-space:nowrap" class="ft1091"><b>Undesirable effects</b></p>
<p style="position:absolute;top:276px;left:106px;white-space:nowrap" class="ft1092">Summary of the safety profile</p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft1095">Humira was studied in 9,506 patients in pivotal controlled and open label trials for up to 60&#160;months or&#160;<br/>more. These trials included rheumatoid arthritis patients with short term and long standing disease,&#160;<br/>juvenile idiopathic arthritis (polyarticular juvenile idiopathic arthritis and enthesitis-related arthritis) as&#160;<br/>well as axial spondyloarthritis (ankylosing spondylitis and axial spondyloarthritis without radiographic&#160;<br/>evidence of AS), psoriatic arthritis, Crohn’s disease, ulcerative colitis, psoriasis, hidradenitis suppurativa&#160;<br/>and uveitis patients. The pivotal controlled studies involved 6,089 patients receiving Humira and&#160;<br/>3,801&#160;patients receiving placebo or active comparator during the controlled period.</p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft1095">The proportion of patients who discontinued treatment due to adverse events during the double-blind,&#160;<br/>controlled portion of pivotal studies was 5.9% for patients taking Humira and 5.4% for control treated&#160;<br/>patients.</p>
<p style="position:absolute;top:541px;left:106px;white-space:nowrap" class="ft1094">The&#160;most commonly reported adverse reactions are infections (such&#160;as nasopharyngitis, upper respiratory&#160;<br/>tract infection and sinusitis), injection site reactions (erythema, itching, haemorrhage, pain or swelling),&#160;<br/>headache and musculoskeletal pain.</p>
<p style="position:absolute;top:617px;left:106px;white-space:nowrap" class="ft1095">Serious adverse reactions have been reported for Humira. TNF-antagonists,&#160;such as Humira affect the&#160;<br/>immune system and their use may affect the body’s defence against infection and cancer.<br/>Fatal and life-threatening infections (including sepsis, opportunistic infections and TB), HBV reactivation&#160;<br/>and various malignancies (including leukaemia, lymphoma and HSTCL) have also been reported with use&#160;<br/>of Humira.</p>
<p style="position:absolute;top:731px;left:106px;white-space:nowrap" class="ft1094">Serious haematological, neurological and autoimmune reactions have also been reported. These include&#160;<br/>rare reports of pancytopenia, aplastic anaemia, central and peripheral demyelinating events and reports of&#160;<br/>lupus, lupus-related conditions and Stevens-Johnson syndrome.</p>
<p style="position:absolute;top:807px;left:106px;white-space:nowrap" class="ft1092">Paediatric population</p>
<p style="position:absolute;top:845px;left:106px;white-space:nowrap" class="ft1094">In&#160;general, the adverse events in paediatric patients were similar in frequency and type to those seen in&#160;<br/>adult patients.</p>
<p style="position:absolute;top:902px;left:106px;white-space:nowrap" class="ft1092">Tabulated list of adverse reactions</p>
<p style="position:absolute;top:940px;left:106px;white-space:nowrap" class="ft1097">The following list of adverse reactions is based on experience from clinical trials and on postmarketing&#160;<br/>experience and are displayed by system organ class and frequency in Table&#160;7&#160;below: very common&#160;<br/>(</p>
<p style="position:absolute;top:977px;left:111px;white-space:nowrap" class="ft1096">&#160;1/10); common (&#160;1/100&#160;to&#160;&lt;&#160;1/10); uncommon (&#160;1/1,000&#160;to&#160;&lt;&#160;1/100); rare (&#160;1/10,000&#160;to&#160;&lt;&#160;1/1,000);&#160;</p>
<p style="position:absolute;top:998px;left:106px;white-space:nowrap" class="ft1094">and not known (cannot be estimated from the available data). Within each frequency grouping,&#160;<br/>undesirable effects are presented in order of decreasing seriousness. The highest frequency seen among the&#160;<br/>various indications has been included. An asterisk (*) appears in the SOC column if further information is&#160;<br/>found elsewhere in sections 4.3, 4.4 and 4.8.</p>
</div>
<!-- Page 110 -->
<a name="110"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page110-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1100">110</p>
<p style="position:absolute;top:86px;left:433px;white-space:nowrap" class="ft1101"><b>Table&#160;7</b></p>
<p style="position:absolute;top:105px;left:390px;white-space:nowrap" class="ft1101"><b>Undesirable Effects</b></p>
<p style="position:absolute;top:153px;left:132px;white-space:nowrap" class="ft1101"><b>System&#160;Organ Class</b></p>
<p style="position:absolute;top:153px;left:341px;white-space:nowrap" class="ft1101"><b>Frequency</b></p>
<p style="position:absolute;top:153px;left:566px;white-space:nowrap" class="ft1101"><b>Adverse Reaction</b></p>
<p style="position:absolute;top:186px;left:114px;white-space:nowrap" class="ft1104">Infections and<br/>infestations*</p>
<p style="position:absolute;top:186px;left:309px;white-space:nowrap" class="ft1102">Very common</p>
<p style="position:absolute;top:186px;left:465px;white-space:nowrap" class="ft1105">Respiratory tract infections (including lower and&#160;<br/>upper respiratory tract infection, pneumonia,&#160;<br/>sinusitis, pharyngitis, nasopharyngitis and&#160;<br/>pneumonia herpes viral)</p>
<p style="position:absolute;top:291px;left:309px;white-space:nowrap" class="ft1102">Common</p>
<p style="position:absolute;top:286px;left:465px;white-space:nowrap" class="ft1108">Systemic infections&#160;(including sepsis, candidiasis&#160;<br/>and influenza),<br/>intestinal infections&#160;(including gastroenteritis&#160;<br/>viral),<br/>skin and soft tissue infections (including&#160;<br/>paronychia, cellulitis, impetigo, necrotising&#160;<br/>fasciitis and herpes zoster),<br/>ear infections,<br/>oral infections&#160;(including herpes simplex, oral&#160;<br/>herpes and tooth infections),&#160;<br/>reproductive tract infections&#160;(including&#160;<br/>vulvovaginal mycotic infection),&#160;<br/>urinary tract infections (including&#160;<br/>pyelonephritis),<br/>fungal infections,<br/>joint infections</p>
<p style="position:absolute;top:627px;left:309px;white-space:nowrap" class="ft1102">Uncommon</p>
<p style="position:absolute;top:627px;left:465px;white-space:nowrap" class="ft1105">Neurological infections (including viral&#160;<br/>meningitis),<br/>opportunistic infections and tuberculosis&#160;<br/>(including coccidioidomycosis, histoplasmosis&#160;<br/>and mycobacterium avium complex infection),&#160;<br/>bacterial infections,<br/>eye&#160;infections,<br/>diverticulitis1)</p>
<p style="position:absolute;top:803px;left:114px;white-space:nowrap" class="ft1105">Neoplasms benign,&#160;<br/>malignant and unspecified&#160;<br/>(including cysts and&#160;<br/>polyps)*</p>
<p style="position:absolute;top:803px;left:309px;white-space:nowrap" class="ft1102">Common</p>
<p style="position:absolute;top:803px;left:465px;white-space:nowrap" class="ft1104">Skin cancer excluding melanoma (including&#160;<br/>basal cell carcinoma and squamous cell&#160;<br/>carcinoma),</p>
<p style="position:absolute;top:884px;left:465px;white-space:nowrap" class="ft1102">benign neoplasm</p>
<p style="position:absolute;top:927px;left:309px;white-space:nowrap" class="ft1102">Uncommon</p>
<p style="position:absolute;top:927px;left:465px;white-space:nowrap" class="ft1104">Lymphoma**,&#160;<br/>solid organ neoplasm (including breast cancer,&#160;<br/>lung neoplasm and thyroid neoplasm),&#160;<br/>melanoma**</p>
<p style="position:absolute;top:1027px;left:309px;white-space:nowrap" class="ft1102">Rare</p>
<p style="position:absolute;top:1027px;left:465px;white-space:nowrap" class="ft1102">Leukaemia1)</p>
<p style="position:absolute;top:1075px;left:309px;white-space:nowrap" class="ft1102">Not known</p>
<p style="position:absolute;top:1075px;left:465px;white-space:nowrap" class="ft1102">Hepatosplenic T-cell lymphoma1),</p>
</div>
<!-- Page 111 -->
<a name="111"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page111-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1110">111</p>
<p style="position:absolute;top:96px;left:132px;white-space:nowrap" class="ft1111"><b>System&#160;Organ Class</b></p>
<p style="position:absolute;top:96px;left:341px;white-space:nowrap" class="ft1111"><b>Frequency</b></p>
<p style="position:absolute;top:96px;left:566px;white-space:nowrap" class="ft1111"><b>Adverse Reaction</b></p>
<p style="position:absolute;top:129px;left:465px;white-space:nowrap" class="ft1118">Merkel cell carcinoma (neuroendocrine&#160;<br/>carcinoma of the skin)1),<br/>Kaposi’s sarcoma</p>
<p style="position:absolute;top:219px;left:114px;white-space:nowrap" class="ft1114">Blood and&#160;the lymphatic&#160;<br/>system disorders*</p>
<p style="position:absolute;top:219px;left:309px;white-space:nowrap" class="ft1112">Very common</p>
<p style="position:absolute;top:219px;left:465px;white-space:nowrap" class="ft1118">Leukopenia (including neutropenia and&#160;<br/>agranulocytosis),&#160;<br/>anaemia</p>
<p style="position:absolute;top:305px;left:309px;white-space:nowrap" class="ft1112">Common</p>
<p style="position:absolute;top:305px;left:465px;white-space:nowrap" class="ft1114">Leucocytosis,<br/>thrombocytopenia</p>
<p style="position:absolute;top:343px;left:309px;white-space:nowrap" class="ft1112">Uncommon</p>
<p style="position:absolute;top:343px;left:465px;white-space:nowrap" class="ft1112">Idiopathic thrombocytopenic purpura</p>
<p style="position:absolute;top:382px;left:309px;white-space:nowrap" class="ft1112">Rare</p>
<p style="position:absolute;top:382px;left:465px;white-space:nowrap" class="ft1112">Pancytopenia</p>
<p style="position:absolute;top:425px;left:114px;white-space:nowrap" class="ft1112">Immune system disorders*&#160;Common</p>
<p style="position:absolute;top:425px;left:465px;white-space:nowrap" class="ft1118">Hypersensitivity,<br/>allergies (including seasonal allergy)</p>
<p style="position:absolute;top:496px;left:309px;white-space:nowrap" class="ft1112">Uncommon</p>
<p style="position:absolute;top:496px;left:465px;white-space:nowrap" class="ft1118">Sarcoidosis1),<br/>vasculitis</p>
<p style="position:absolute;top:568px;left:309px;white-space:nowrap" class="ft1112">Rare</p>
<p style="position:absolute;top:568px;left:465px;white-space:nowrap" class="ft1112">Anaphylaxis1)</p>
<p style="position:absolute;top:615px;left:114px;white-space:nowrap" class="ft1114">Metabolism and nutrition&#160;<br/>disorders</p>
<p style="position:absolute;top:615px;left:309px;white-space:nowrap" class="ft1112">Very common</p>
<p style="position:absolute;top:615px;left:465px;white-space:nowrap" class="ft1112">Lipids increased</p>
<p style="position:absolute;top:663px;left:309px;white-space:nowrap" class="ft1112">Common</p>
<p style="position:absolute;top:663px;left:465px;white-space:nowrap" class="ft1118">Hypokalaemia,&#160;<br/>uric acid increased,&#160;<br/>blood sodium abnormal,<br/>hypocalcaemia,<br/>hyperglycaemia,<br/>hypophosphatemia,<br/>dehydration</p>
<p style="position:absolute;top:865px;left:114px;white-space:nowrap" class="ft1112">Psychiatric disorders</p>
<p style="position:absolute;top:865px;left:309px;white-space:nowrap" class="ft1112">Common</p>
<p style="position:absolute;top:865px;left:465px;white-space:nowrap" class="ft1118">Mood alterations (including depression),&#160;<br/>anxiety,<br/>insomnia</p>
<p style="position:absolute;top:960px;left:114px;white-space:nowrap" class="ft1112">Nervous system disorders*&#160;Very common</p>
<p style="position:absolute;top:960px;left:465px;white-space:nowrap" class="ft1112">Headache</p>
<p style="position:absolute;top:1008px;left:309px;white-space:nowrap" class="ft1112">Common</p>
<p style="position:absolute;top:1008px;left:465px;white-space:nowrap" class="ft1118">Paraesthesias (including hypoesthesia),<br/>migraine,<br/>nerve root compression</p>
</div>
<!-- Page 112 -->
<a name="112"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page112-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1120">112</p>
<p style="position:absolute;top:96px;left:132px;white-space:nowrap" class="ft1121"><b>System&#160;Organ Class</b></p>
<p style="position:absolute;top:96px;left:341px;white-space:nowrap" class="ft1121"><b>Frequency</b></p>
<p style="position:absolute;top:96px;left:566px;white-space:nowrap" class="ft1121"><b>Adverse Reaction</b></p>
<p style="position:absolute;top:125px;left:309px;white-space:nowrap" class="ft1122">Uncommon</p>
<p style="position:absolute;top:125px;left:465px;white-space:nowrap" class="ft1124">Cerebrovascular accident1),<br/>tremor,<br/>neuropathy &#160;</p>
<p style="position:absolute;top:201px;left:309px;white-space:nowrap" class="ft1122">Rare</p>
<p style="position:absolute;top:201px;left:465px;white-space:nowrap" class="ft1125">Multiple sclerosis,<br/>demyelinating disorders (e.g. optic neuritis,&#160;<br/>Guillain-Barré syndrome)&#160;1)</p>
<p style="position:absolute;top:291px;left:114px;white-space:nowrap" class="ft1122">Eye&#160;disorders</p>
<p style="position:absolute;top:291px;left:309px;white-space:nowrap" class="ft1122">Common</p>
<p style="position:absolute;top:291px;left:465px;white-space:nowrap" class="ft1128">Visual impairment,<br/>conjunctivitis,<br/>blepharitis,<br/>eye swelling</p>
<p style="position:absolute;top:405px;left:309px;white-space:nowrap" class="ft1122">Uncommon</p>
<p style="position:absolute;top:405px;left:465px;white-space:nowrap" class="ft1122">Diplopia</p>
<p style="position:absolute;top:448px;left:114px;white-space:nowrap" class="ft1124">Ear and labyrinth&#160;<br/>disorders&#160;</p>
<p style="position:absolute;top:448px;left:309px;white-space:nowrap" class="ft1122">Common</p>
<p style="position:absolute;top:448px;left:465px;white-space:nowrap" class="ft1122">Vertigo</p>
<p style="position:absolute;top:491px;left:309px;white-space:nowrap" class="ft1122">Uncommon</p>
<p style="position:absolute;top:491px;left:465px;white-space:nowrap" class="ft1125">Deafness,&#160;<br/>tinnitus</p>
<p style="position:absolute;top:553px;left:114px;white-space:nowrap" class="ft1122">Cardiac disorders*&#160;</p>
<p style="position:absolute;top:553px;left:309px;white-space:nowrap" class="ft1122">Common</p>
<p style="position:absolute;top:553px;left:465px;white-space:nowrap" class="ft1122">Tachycardia</p>
<p style="position:absolute;top:601px;left:309px;white-space:nowrap" class="ft1122">Uncommon</p>
<p style="position:absolute;top:601px;left:465px;white-space:nowrap" class="ft1128">Myocardial infarction1),<br/>arrhythmia,<br/>congestive heart failure</p>
<p style="position:absolute;top:691px;left:309px;white-space:nowrap" class="ft1122">Rare</p>
<p style="position:absolute;top:691px;left:465px;white-space:nowrap" class="ft1122">Cardiac arrest</p>
<p style="position:absolute;top:734px;left:114px;white-space:nowrap" class="ft1122">Vascular disorders</p>
<p style="position:absolute;top:734px;left:309px;white-space:nowrap" class="ft1122">Common</p>
<p style="position:absolute;top:734px;left:465px;white-space:nowrap" class="ft1128">Hypertension,&#160;<br/>flushing,&#160;<br/>haematoma</p>
<p style="position:absolute;top:825px;left:309px;white-space:nowrap" class="ft1122">Uncommon</p>
<p style="position:absolute;top:825px;left:465px;white-space:nowrap" class="ft1124">Aortic aneurysm,<br/>vascular arterial occlusion,<br/>thrombophlebitis &#160;&#160;</p>
<p style="position:absolute;top:906px;left:114px;white-space:nowrap" class="ft1124">Respiratory, thoracic and&#160;<br/>mediastinal disorders*</p>
<p style="position:absolute;top:906px;left:309px;white-space:nowrap" class="ft1122">Common</p>
<p style="position:absolute;top:906px;left:465px;white-space:nowrap" class="ft1128">Asthma,<br/>dyspnoea,<br/>cough</p>
<p style="position:absolute;top:996px;left:309px;white-space:nowrap" class="ft1122">Uncommon</p>
<p style="position:absolute;top:996px;left:465px;white-space:nowrap" class="ft1125">Pulmonary embolism1),<br/>interstitial lung disease,&#160;<br/>chronic obstructive pulmonary disease,<br/>pneumonitis,</p>
</div>
<!-- Page 113 -->
<a name="113"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page113-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1130">113</p>
<p style="position:absolute;top:96px;left:132px;white-space:nowrap" class="ft1131"><b>System&#160;Organ Class</b></p>
<p style="position:absolute;top:96px;left:341px;white-space:nowrap" class="ft1131"><b>Frequency</b></p>
<p style="position:absolute;top:96px;left:566px;white-space:nowrap" class="ft1131"><b>Adverse Reaction</b></p>
<p style="position:absolute;top:125px;left:465px;white-space:nowrap" class="ft1132">pleural effusion1)</p>
<p style="position:absolute;top:167px;left:309px;white-space:nowrap" class="ft1132">Rare</p>
<p style="position:absolute;top:163px;left:465px;white-space:nowrap" class="ft1132">Pulmonary fibrosis1)</p>
<p style="position:absolute;top:206px;left:114px;white-space:nowrap" class="ft1132">Gastrointestinal disorders</p>
<p style="position:absolute;top:206px;left:309px;white-space:nowrap" class="ft1132">Very common</p>
<p style="position:absolute;top:206px;left:465px;white-space:nowrap" class="ft1138">Abdominal pain,&#160;<br/>nausea and vomiting</p>
<p style="position:absolute;top:273px;left:309px;white-space:nowrap" class="ft1132">Common</p>
<p style="position:absolute;top:273px;left:465px;white-space:nowrap" class="ft1135">GI haemorrhage,&#160;<br/>dyspepsia,<br/>gastroesophageal reflux disease,<br/>sicca syndrome</p>
<p style="position:absolute;top:369px;left:309px;white-space:nowrap" class="ft1132">Uncommon</p>
<p style="position:absolute;top:369px;left:465px;white-space:nowrap" class="ft1135">Pancreatitis,&#160;<br/>dysphagia,<br/>face oedema</p>
<p style="position:absolute;top:450px;left:309px;white-space:nowrap" class="ft1132">Rare</p>
<p style="position:absolute;top:450px;left:465px;white-space:nowrap" class="ft1132">Intestinal perforation1)</p>
<p style="position:absolute;top:498px;left:114px;white-space:nowrap" class="ft1132">Hepato-biliary disorders*</p>
<p style="position:absolute;top:498px;left:309px;white-space:nowrap" class="ft1132">Very Common</p>
<p style="position:absolute;top:498px;left:465px;white-space:nowrap" class="ft1132">Elevated liver enzymes</p>
<p style="position:absolute;top:541px;left:309px;white-space:nowrap" class="ft1132">Uncommon</p>
<p style="position:absolute;top:541px;left:465px;white-space:nowrap" class="ft1135">Cholecystitis and cholelithiasis,<br/>hepatic steatosis,<br/>bilirubin increased</p>
<p style="position:absolute;top:622px;left:309px;white-space:nowrap" class="ft1132">Rare</p>
<p style="position:absolute;top:622px;left:465px;white-space:nowrap" class="ft11310">Hepatitis<br/>reactivation of hepatitis B1)&#160;<br/>autoimmune hepatitis1)</p>
<p style="position:absolute;top:716px;left:309px;white-space:nowrap" class="ft1132">Not known</p>
<p style="position:absolute;top:716px;left:465px;white-space:nowrap" class="ft1132">Liver failure1)</p>
<p style="position:absolute;top:764px;left:114px;white-space:nowrap" class="ft1134">Skin and subcutaneous&#160;<br/>tissue disorders</p>
<p style="position:absolute;top:764px;left:309px;white-space:nowrap" class="ft1132">Very Common</p>
<p style="position:absolute;top:764px;left:465px;white-space:nowrap" class="ft1132">Rash (including exfoliative rash)</p>
<p style="position:absolute;top:807px;left:309px;white-space:nowrap" class="ft1132">Common</p>
<p style="position:absolute;top:807px;left:465px;white-space:nowrap" class="ft1135">Worsening or new&#160;onset of psoriasis(including&#160;<br/>palmoplantar pustular psoriasis)1),<br/>urticaria,<br/>bruising (including purpura),&#160;<br/>dermatitis (including eczema),<br/>onychoclasis,&#160;<br/>hyperhidrosis,<br/>alopecia1),<br/>pruritus&#160;</p>
<p style="position:absolute;top:998px;left:309px;white-space:nowrap" class="ft1132">Uncommon</p>
<p style="position:absolute;top:998px;left:465px;white-space:nowrap" class="ft1135">Night sweats,<br/>scar</p>
</div>
<!-- Page 114 -->
<a name="114"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page114-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1140">114</p>
<p style="position:absolute;top:96px;left:132px;white-space:nowrap" class="ft1141"><b>System&#160;Organ Class</b></p>
<p style="position:absolute;top:96px;left:341px;white-space:nowrap" class="ft1141"><b>Frequency</b></p>
<p style="position:absolute;top:96px;left:566px;white-space:nowrap" class="ft1141"><b>Adverse Reaction</b></p>
<p style="position:absolute;top:129px;left:309px;white-space:nowrap" class="ft1142">Rare</p>
<p style="position:absolute;top:129px;left:465px;white-space:nowrap" class="ft11410">Erythema multiforme1),<br/>Stevens-Johnson syndrome1),<br/>angioedema1),<br/>cutaneous vasculitis1)<br/>lichenoid skin reaction1)</p>
<p style="position:absolute;top:270px;left:309px;white-space:nowrap" class="ft1142">Not known</p>
<p style="position:absolute;top:270px;left:465px;white-space:nowrap" class="ft1142">Worsening of symptoms of dermatomyositis1)</p>
<p style="position:absolute;top:318px;left:114px;white-space:nowrap" class="ft1144">Musculoskeletal and&#160;<br/>connective tissue disorders</p>
<p style="position:absolute;top:318px;left:309px;white-space:nowrap" class="ft1142">Very common</p>
<p style="position:absolute;top:318px;left:465px;white-space:nowrap" class="ft1142">Musculoskeletal pain</p>
<p style="position:absolute;top:366px;left:309px;white-space:nowrap" class="ft1142">Common</p>
<p style="position:absolute;top:366px;left:465px;white-space:nowrap" class="ft1144">Muscle spasms&#160;(including blood creatine&#160;<br/>phosphokinase increased)</p>
<p style="position:absolute;top:428px;left:309px;white-space:nowrap" class="ft1142">Uncommon</p>
<p style="position:absolute;top:428px;left:465px;white-space:nowrap" class="ft1144">Rhabdomyolysis,<br/>systemic lupus erythematosus</p>
<p style="position:absolute;top:486px;left:309px;white-space:nowrap" class="ft1142">Rare</p>
<p style="position:absolute;top:486px;left:465px;white-space:nowrap" class="ft1142">Lupus-like syndrome1)</p>
<p style="position:absolute;top:529px;left:114px;white-space:nowrap" class="ft1144">Renal and urinary&#160;<br/>disorders&#160;</p>
<p style="position:absolute;top:529px;left:309px;white-space:nowrap" class="ft1142">Common</p>
<p style="position:absolute;top:529px;left:465px;white-space:nowrap" class="ft1148">Renal impairment,<br/>haematuria</p>
<p style="position:absolute;top:596px;left:309px;white-space:nowrap" class="ft1142">Uncommon</p>
<p style="position:absolute;top:596px;left:465px;white-space:nowrap" class="ft1142">Nocturia</p>
<p style="position:absolute;top:639px;left:114px;white-space:nowrap" class="ft1144">Reproductive system and&#160;<br/>breast disorders</p>
<p style="position:absolute;top:639px;left:309px;white-space:nowrap" class="ft1142">Uncommon</p>
<p style="position:absolute;top:639px;left:465px;white-space:nowrap" class="ft1142">Erectile dysfunction</p>
<p style="position:absolute;top:687px;left:114px;white-space:nowrap" class="ft1145">General disorders and&#160;<br/>administration site&#160;<br/>conditions*</p>
<p style="position:absolute;top:687px;left:309px;white-space:nowrap" class="ft1142">Very Common</p>
<p style="position:absolute;top:687px;left:465px;white-space:nowrap" class="ft1144">Injection site reaction (including injection site&#160;<br/>erythema)</p>
<p style="position:absolute;top:749px;left:309px;white-space:nowrap" class="ft1142">Common</p>
<p style="position:absolute;top:749px;left:465px;white-space:nowrap" class="ft1144">Chest pain,&#160;<br/>oedema,<br/>pyrexia1)</p>
<p style="position:absolute;top:825px;left:309px;white-space:nowrap" class="ft1142">Uncommon</p>
<p style="position:absolute;top:825px;left:465px;white-space:nowrap" class="ft1142">Inflammation</p>
<p style="position:absolute;top:868px;left:114px;white-space:nowrap" class="ft1142">Investigations*</p>
<p style="position:absolute;top:868px;left:309px;white-space:nowrap" class="ft1142">Common</p>
<p style="position:absolute;top:868px;left:465px;white-space:nowrap" class="ft1148">Coagulation and bleeding disorders (including&#160;<br/>activated partial thromboplastin time prolonged),&#160;<br/>autoantibody test positive (including double&#160;<br/>stranded DNA antibody),&#160;<br/>blood lactate dehydrogenase increased</p>
<p style="position:absolute;top:1001px;left:309px;white-space:nowrap" class="ft1142">Not known</p>
<p style="position:absolute;top:1001px;left:465px;white-space:nowrap" class="ft1142">Weight&#160;increased2)</p>
<p style="position:absolute;top:1025px;left:114px;white-space:nowrap" class="ft1144">Injury, poisoning and&#160;<br/>procedural complications</p>
<p style="position:absolute;top:1025px;left:309px;white-space:nowrap" class="ft1142">Common</p>
<p style="position:absolute;top:1025px;left:465px;white-space:nowrap" class="ft1142">Impaired healing</p>
</div>
<!-- Page 115 -->
<a name="115"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page115-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1150">115</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft1155">*&#160;further information is found elsewhere in sections 4.3, 4.4 and 4.8<br/>**&#160;including open label extension studies</p>
<p style="position:absolute;top:122px;left:106px;white-space:nowrap" class="ft1159">1)&#160;including spontaneous reporting data</p>
<p style="position:absolute;top:142px;left:106px;white-space:nowrap" class="ft1155">2)&#160;The mean&#160;weight change from baseline for adalimumab ranged from 0.3&#160;kg to 1.0&#160;kg across adult&#160;<br/>indications compared to (minus)&#160;-0.4&#160;kg to 0.4&#160;kg for placebo over a treatment period of 4-6 months.&#160;<br/>Weight increase of 5-6&#160;kg has also been observed&#160;in long-term&#160;extension studies with mean exposures of&#160;<br/>approximately 1-2 years without control group,&#160;particularly in patients with Crohn’s disease and&#160;<br/>Ulcerative colitis. The mechanism behind this effect is unclear but could be associated with the&#160;<br/>anti-inflammatory effect of adalimumab.</p>
<p style="position:absolute;top:276px;left:106px;white-space:nowrap" class="ft1152">Hidradenitis suppurativa</p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft1154">The safety profile for patients with HS treated with Humira weekly was consistent with the known safety&#160;<br/>profile of Humira.</p>
<p style="position:absolute;top:370px;left:106px;white-space:nowrap" class="ft1152">Uveitis</p>
<p style="position:absolute;top:409px;left:106px;white-space:nowrap" class="ft1155">The safety profile for patients with uveitis treated with Humira every other week was&#160;consistent with the&#160;<br/>known safety profile of Humira.</p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft1152">Description of selected adverse reactions</p>
<p style="position:absolute;top:503px;left:106px;white-space:nowrap" class="ft1153"><i>Injection site reactions</i>&#160;&#160;</p>
<p style="position:absolute;top:541px;left:106px;white-space:nowrap" class="ft1154">In the pivotal controlled trials in adults and children, 12.9% of patients treated with Humira developed&#160;<br/>injection site reactions (erythema and/or itching, haemorrhage, pain or swelling), compared to 7.2% of&#160;<br/>patients receiving placebo or active control. Injection site reactions generally did not necessitate&#160;<br/>discontinuation of the medicinal product.&#160;</p>
<p style="position:absolute;top:636px;left:106px;white-space:nowrap" class="ft1153"><i>Infections</i></p>
<p style="position:absolute;top:674px;left:106px;white-space:nowrap" class="ft1154">In the pivotal controlled trials in adults and children, the rate of infection was 1.51&#160;per patient year in the&#160;<br/>Humira treated patients and 1.46&#160;per&#160;patient year in the placebo and active control-treated patients. The&#160;<br/>infections consisted primarily of nasopharyngitis, upper respiratory tract infection, and sinusitis. Most&#160;<br/>patients continued on Humira after the infection resolved. &#160;</p>
<p style="position:absolute;top:769px;left:106px;white-space:nowrap" class="ft1154">The incidence of&#160;serious infections was 0.04&#160;per patient year in Humira treated patients and 0.03&#160;per&#160;<br/>patient year in placebo and active control&#160;−&#160;treated patients. &#160;</p>
<p style="position:absolute;top:826px;left:106px;white-space:nowrap" class="ft1154">In controlled and open label adult and paediatric studies with Humira, serious infections (including fatal&#160;<br/>infections, which occurred rarely) have been reported, which include reports of tuberculosis (including&#160;<br/>miliary and extra-pulmonary locations) and invasive opportunistic infections (e.g. disseminated&#160;or&#160;<br/>extrapulmonary&#160;&#160;histoplasmosis, &#160;blastomycosis, coccidioidomycosis, pneumocystis,&#160;&#160;candidiasis,&#160;<br/>aspergillosis and listeriosis). Most of the cases of tuberculosis occurred within the first eight months after&#160;<br/>initiation of therapy and may reflect recrudescence of latent disease.</p>
<p style="position:absolute;top:959px;left:106px;white-space:nowrap" class="ft1153"><i>Malignancies and lymphoproliferative disorders</i></p>
<p style="position:absolute;top:997px;left:106px;white-space:nowrap" class="ft1155">No&#160;malignancies were observed in 249 paediatric patients with an exposure of 655.6&#160;patient years during&#160;<br/>Humira trials in patients with juvenile idiopathic arthritis (polyarticular juvenile idiopathic arthritis and&#160;<br/>enthesitis-related arthritis).&#160;In addition, no malignancies were observed in 192&#160;paediatric patients with an&#160;<br/>exposure of 498.1&#160;patient years during Humira trials in paediatric patients with Crohn’s disease. No&#160;<br/>malignancies were observed in 77 paediatric patients with an exposure of 80.0&#160;patient years during a&#160;</p>
</div>
<!-- Page 116 -->
<a name="116"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page116-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1160">116</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft1164">Humira trial in paediatric patients with chronic plaque psoriasis.&#160;No malignancies were observed in 93&#160;<br/>paediatric patients with an exposure of 65.3 patient years during a Humira trial in paediatric patients with&#160;<br/>ulcerative colitis.&#160;No&#160;malignancies were observed in 60 paediatric patients with an exposure of 58.4&#160;<br/>patient years during a Humira trial in paediatric patients with uveitis.</p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft1165">During the controlled portions of pivotal Humira trials in adults of at least 12&#160;weeks in duration in patients&#160;<br/>with&#160;moderately to severely active rheumatoid arthritis, ankylosing spondylitis, axial spondyloarthritis&#160;<br/>without radiographic evidence of AS, &#160;psoriatic arthritis, psoriasis, hidradenitis suppurativa, Crohn’s&#160;<br/>disease, ulcerative colitis and uveitis, malignancies, other than lymphoma and non-melanoma skin cancer,&#160;<br/>were observed at a rate (95% confidence interval) of 6.8 (4.4, 10.5)&#160;&#160;per 1,000 patient-years among 5,291&#160;<br/>Humira treated patients&#160;<i>versus&#160;</i>a rate of 6.3 (3.4, 11.8)&#160;&#160;per 1,000 patient-years among 3,444&#160;control&#160;<br/>patients (median duration of treatment was 4.0&#160;months for Humira and 3.8&#160;months for control-treated&#160;<br/>patients). The rate (95% confidence interval) of non-melanoma skin cancers was 8.8 (6.0, 13.0) per 1,000&#160;<br/>patient-years among Humira-treated patients and 3.2 (1.3, 7.6)&#160;&#160;per 1,000 patient-years among control&#160;<br/>patients. Of these skin cancers, squamous cell carcinomas occurred at rates (95% confidence interval) of&#160;<br/>2.7 (1.4, 5.4) per 1,000 patient-years among Humira-treated patients and 0.6 (0.1, 4.5) per&#160;1,000 patient-<br/>years among control patients. The rate (95% confidence interval) of lymphomas was 0.7 (0.2, 2.7) per&#160;<br/>1,000 patient-years among Humira-treated patients and 0.6 (0.1, 4.5)&#160;&#160;per 1,000 patient-years among&#160;<br/>control patients.</p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft1165">When combining controlled portions of these trials and ongoing and completed open label extension&#160;<br/>studies with a median duration of approximately 3.3&#160;years including 6,427 patients and over&#160;<br/>26,439&#160;patient-years of therapy, the observed rate of malignancies, other than lymphoma&#160;and non-<br/>melanoma skin cancers is approximately 8.5&#160;per 1,000 patient years. The observed rate of non-melanoma&#160;<br/>skin cancers is approximately 9.6&#160;per 1,000 patient years, and the observed rate of lymphomas is&#160;<br/>approximately 1.3&#160;per 1,000 patient years.</p>
<p style="position:absolute;top:598px;left:106px;white-space:nowrap" class="ft1164">In post-marketing experience from January 2003 to December 2010, predominantly in patients with&#160;<br/>rheumatoid arthritis, the reported rate of malignancies is approximately 2.7&#160;per 1,000 patient treatment&#160;<br/>years. The reported rates for non-melanoma skin cancers and&#160;lymphomas are approximately 0.2 and&#160;<br/>0.3&#160;per 1,000 patient treatment years, respectively (see section 4.4).</p>
<p style="position:absolute;top:693px;left:106px;white-space:nowrap" class="ft1164">Rare post-marketing cases of hepatosplenic T-cell&#160;lymphoma have been reported in patients treated with&#160;<br/>adalimumab (see section 4.4).</p>
<p style="position:absolute;top:750px;left:106px;white-space:nowrap" class="ft1163"><i>Autoantibodies</i></p>
<p style="position:absolute;top:788px;left:106px;white-space:nowrap" class="ft1164">Patients had serum samples tested for autoantibodies at multiple time points in rheumatoid arthritis studies&#160;<br/>I&#160;−&#160;V. In these trials, 11.9% of patients treated with Humira and 8.1% of placebo and active&#160;<br/>control&#160;−&#160;treated patients that had negative&#160;baseline anti-nuclear antibody titres reported positive titres at&#160;<br/>Week&#160;24. Two patients out of 3,441 treated with Humira in all rheumatoid arthritis and psoriatic arthritis&#160;<br/>studies developed clinical signs suggestive of new-onset lupus-like syndrome. The patients improved&#160;<br/>following discontinuation of therapy. No patients developed lupus nephritis or central nervous system&#160;<br/>symptoms.</p>
<p style="position:absolute;top:940px;left:106px;white-space:nowrap" class="ft1163"><i>Hepato-biliary events</i></p>
<p style="position:absolute;top:978px;left:106px;white-space:nowrap" class="ft1165">In controlled Phase 3 trials of Humira in patients with rheumatoid arthritis and psoriatic arthritis with a&#160;<br/>control period duration ranging from 4 to 104&#160;weeks, ALT elevations&#160;≥ 3 x ULN occurred in 3.7%&#160;of&#160;<br/>Humira-treated patients and 1.6% of control-treated patients.&#160;</p>
<p style="position:absolute;top:1054px;left:106px;white-space:nowrap" class="ft1165">In controlled Phase 3 trials of Humira in patients with polyarticular juvenile idiopathic&#160;arthritis who were&#160;<br/>4 to 17&#160;years and enthesitis-related arthritis who were 6 to 17&#160;years, ALT elevations&#160;≥ 3 x ULN occurred&#160;</p>
</div>
<!-- Page 117 -->
<a name="117"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page117-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1170">117</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft1174">in 6.1% of Humira-treated patients and 1.3% of control-treated patients. Most ALT elevations occurred&#160;<br/>with concomitant methotrexate&#160;use. No ALT elevations&#160;≥ 3 x ULN occurred in the Phase 3 trial of Humira&#160;<br/>in patients with polyarticular juvenile idiopathic arthritis who were 2 to &lt;4&#160;years.</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft1174">In controlled Phase 3 trials of Humira in patients with&#160;Crohn’s disease and ulcerative colitis with a control&#160;<br/>period ranging from 4 to 52&#160;weeks. ALT elevations&#160;≥ 3 x ULN occurred in 0.9% of Humira-treated&#160;<br/>patients and 0.9% of controlled-treated patients.</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft1174">In the Phase 3 trial of Humira in patients with paediatric Crohn’s disease which evaluated efficacy and&#160;<br/>safety of two body weight adjusted maintenance dose regimens following body weight adjusted induction&#160;<br/>therapy up to 52&#160;weeks of treatment, ALT elevations&#160;≥ 3 x ULN occurred in 2.6% (5/192) of patients of&#160;<br/>whom 4 were receiving concomitant immunosuppressants at baseline.</p>
<p style="position:absolute;top:333px;left:106px;white-space:nowrap" class="ft1175">In controlled Phase 3 trials of Humira in patients with plaque Psoriasis&#160;with a control period duration&#160;<br/>ranging from 12 to 24&#160;weeks, ALT elevations&#160;≥ 3 x ULN occurred in 1.8% of Humira-treated patients and&#160;<br/>1.8% of control-treated patients.&#160;</p>
<p style="position:absolute;top:409px;left:106px;white-space:nowrap" class="ft1175">No&#160;ALT elevations&#160;≥3 X ULN occurred in the Phase 3 trial of Humira in paediatric patients with plaque&#160;<br/>psoriasis.</p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft1174">In controlled trials of Humira (initial doses of 160&#160;mg at Week&#160;0 and 80&#160;mg at Week&#160;2, followed by 40&#160;mg&#160;<br/>every week starting at&#160;Week&#160;4), in patients with hidradenitis suppurativa with a control period duration&#160;<br/>ranging from 12 to 16&#160;weeks, ALT elevations&#160;≥ 3 x ULN occurred in 0.3% of Humira-treated patients and&#160;<br/>0.6% of control-treated patients.</p>
<p style="position:absolute;top:560px;left:106px;white-space:nowrap" class="ft1175">In controlled trials of Humira (initial doses of 80&#160;mg at Week 0 followed by 40&#160;mg&#160;every other week&#160;<br/>starting at Week 1) in&#160;adult&#160;patients with uveitis up to 80 weeks with a median exposure of 166.5 days and&#160;<br/>105.0 days in Humira-treated and control-treated patients, respectively, ALT elevations&#160;≥ 3 x ULN&#160;<br/>occurred in 2.4% of Humira-treated patients and 2.4% of control-treated patients.&#160;</p>
<p style="position:absolute;top:655px;left:106px;white-space:nowrap" class="ft1174">In the controlled Phase 3 trial of Humira in patients with paediatric ulcerative colitis (N=93) which&#160;<br/>evaluated efficacy and safety of a maintenance dose&#160;of 0.6&#160;mg/kg (maximum of 40 mg) every other week&#160;<br/>(N=31) and a maintenance dose of 0.6 mg/kg (maximum of 40 mg) every Week&#160;(N=32),&#160;following body&#160;<br/>weight adjusted induction dosing&#160;of 2.4 mg/kg (maximum&#160;of 160 mg) at Week 0 and Week 1, and 1.2&#160;<br/>mg/kg (maximum&#160;of 80&#160;mg) at Week 2&#160;(N=63),&#160;or an induction dose of 2.4 mg/kg (maximum&#160;of 160 mg)&#160;<br/>at Week 0, placebo at Week 1, and 1.2 mg/kg (maximum of 80 mg) at Week 2&#160;(N=30),&#160;ALT elevations&#160;≥&#160;<br/>3 X ULN occurred in 1.1% (1/93) of patients.</p>
<p style="position:absolute;top:807px;left:106px;white-space:nowrap" class="ft1174">Across all indications in clinical trials patients with raised ALT were asymptomatic and in most cases&#160;<br/>elevations were transient and resolved on continued treatment. &#160;However, there have also been post-<br/>marketing reports of liver failure as well as less severe liver disorders that may precede&#160;liver failure, such&#160;<br/>as hepatitis including autoimmune hepatitis in patients receiving adalimumab.</p>
<p style="position:absolute;top:902px;left:106px;white-space:nowrap" class="ft1172">Concurrent treatment with azathioprine/6-mercaptopurine</p>
<p style="position:absolute;top:940px;left:106px;white-space:nowrap" class="ft1174">In adult Crohn’s disease studies, higher incidences of malignant and serious infection-related adverse&#160;<br/>events were seen with the combination of Humira and azathioprine/6-mercaptopurine compared with&#160;<br/>Humira alone.</p>
<p style="position:absolute;top:1016px;left:106px;white-space:nowrap" class="ft1172">Reporting of suspected adverse reactions</p>
</div>
<!-- Page 118 -->
<a name="118"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page118-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1180">118</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft1184">Reporting suspected adverse reactions after authorisation of the medicinal product is important. &#160;It allows&#160;<br/>continued monitoring of the benefit/risk balance of the medicinal product. &#160;Healthcare professionals are&#160;<br/>asked to report any suspected adverse reactions via&#160;<a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">the national reporting system listed in&#160;Appendix V.</a></p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft1181"><b>4.9</b></p>
<p style="position:absolute;top:162px;left:160px;white-space:nowrap" class="ft1181"><b>Overdose</b></p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft1184">No dose-limiting toxicity was observed during clinical trials. The highest dose level evaluated has been&#160;<br/>multiple intravenous doses of 10&#160;mg/kg, which is approximately&#160;15 times the recommended dose. &#160; &#160;</p>
<p style="position:absolute;top:276px;left:106px;white-space:nowrap" class="ft1181"><b>5.</b></p>
<p style="position:absolute;top:276px;left:148px;white-space:nowrap" class="ft1181"><b>PHARMACOLOGICAL PROPERTIES</b></p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft1181"><b>5.1</b></p>
<p style="position:absolute;top:314px;left:148px;white-space:nowrap" class="ft1181"><b>Pharmacodynamic properties</b></p>
<p style="position:absolute;top:352px;left:106px;white-space:nowrap" class="ft1185">Pharmacotherapeutic group: Immunosuppressants, Tumour Necrosis Factor alpha (TNF-α) inhibitors.&#160;<br/>ATC code: L04AB04</p>
<p style="position:absolute;top:409px;left:106px;white-space:nowrap" class="ft1182">Mechanism&#160;of action</p>
<p style="position:absolute;top:446px;left:106px;white-space:nowrap" class="ft1184">Adalimumab binds specifically to TNF and neutralises the biological function of TNF by blocking its&#160;<br/>interaction with the p55 and p75 cell surface TNF receptors. &#160;</p>
<p style="position:absolute;top:503px;left:106px;white-space:nowrap" class="ft1184">Adalimumab also modulates biological responses that are induced or regulated by TNF, including changes&#160;<br/>in the levels of adhesion molecules responsible for leukocyte migration (ELAM-1, VCAM-1, and ICAM-1&#160;<br/>with an IC50&#160;of&#160;0.1-0.2 nM).&#160;</p>
<p style="position:absolute;top:579px;left:106px;white-space:nowrap" class="ft1182">Pharmacodynamic effects&#160;</p>
<p style="position:absolute;top:617px;left:106px;white-space:nowrap" class="ft1184">After treatment with Humira, a rapid decrease in levels of acute phase reactants of inflammation&#160;<br/>(C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)) and serum cytokines (IL-6) was&#160;<br/>observed, compared to baseline in patients with rheumatoid arthritis. Serum levels of matrix&#160;<br/>metalloproteinases (MMP-1 and MMP-3) that produce tissue remodelling responsible for cartilage&#160;<br/>destruction were also decreased after Humira administration. Patients treated with Humira usually&#160;<br/>experienced improvement in haematological signs of chronic inflammation.</p>
<p style="position:absolute;top:750px;left:106px;white-space:nowrap" class="ft1185">A rapid decrease in CRP levels was also observed in patients with polyarticular juvenile idiopathic&#160;<br/>arthritis, Crohn’s disease, ulcerative colitis and hidradenitis suppurativa after treatment with Humira. In&#160;<br/>patients with Crohn’s disease, a reduction of the number of cells expressing inflammatory markers in the&#160;<br/>colon including a significant reduction of expression of TNFα was seen. Endoscopic studies in intestinal&#160;<br/>mucosa have shown evidence of mucosal healing in adalimumab treated patients.</p>
<p style="position:absolute;top:864px;left:106px;white-space:nowrap" class="ft1182">Clinical efficacy and safety</p>
<p style="position:absolute;top:902px;left:106px;white-space:nowrap" class="ft1183"><i>Rheumatoid arthritis</i></p>
<p style="position:absolute;top:940px;left:106px;white-space:nowrap" class="ft1184">Humira&#160;was evaluated in over 3,000 patients in all rheumatoid arthritis clinical trials. The efficacy and&#160;<br/>safety of Humira were assessed in five randomised, double-blind and well-controlled studies. Some&#160;<br/>patients were treated for up to 120&#160;months duration.&#160;</p>
<p style="position:absolute;top:1017px;left:106px;white-space:nowrap" class="ft1182">RA study I evaluated 271 patients with moderately to severely active rheumatoid arthritis who were&#160;</p>
<p style="position:absolute;top:1015px;left:769px;white-space:nowrap" class="ft1186">&#160;18&#160;</p>
<p style="position:absolute;top:1036px;left:106px;white-space:nowrap" class="ft1184">years old, had failed therapy with at least one disease-modifying, anti&#160;rheumatic drug and had insufficient&#160;<br/>efficacy with methotrexate at doses of 12.5&#160;to 25&#160;mg (10&#160;mg if methotrexate-intolerant) every week and&#160;</p>
</div>
<!-- Page 119 -->
<a name="119"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page119-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1190">119</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft1195">whose methotrexate dose remained constant at 10 to 25&#160;mg&#160;every week. Doses of 20, 40 or 80&#160;mg of&#160;<br/>Humira or placebo were given every other week for 24&#160;weeks.&#160;</p>
<p style="position:absolute;top:144px;left:106px;white-space:nowrap" class="ft1192">RA study II evaluated 544 patients with&#160;moderately to severely active rheumatoid arthritis who were&#160;</p>
<p style="position:absolute;top:142px;left:774px;white-space:nowrap" class="ft1196">&#160;18&#160;</p>
<p style="position:absolute;top:163px;left:106px;white-space:nowrap" class="ft1194">years old and had failed therapy with at least one disease-modifying, anti-rheumatic drugs. &#160;Doses of 20 or&#160;<br/>40&#160;mg of Humira were given by subcutaneous injection every other week with placebo on alternative&#160;<br/>weeks or every week for 26&#160;weeks; placebo was given every week for the same duration. &#160;No other&#160;<br/>disease-modifying anti-rheumatic drugs were allowed.</p>
<p style="position:absolute;top:259px;left:106px;white-space:nowrap" class="ft1192">RA study III evaluated 619 patients with moderately to severely active rheumatoid arthritis who were&#160;</p>
<p style="position:absolute;top:257px;left:780px;white-space:nowrap" class="ft1196">&#160;18&#160;</p>
<p style="position:absolute;top:278px;left:106px;white-space:nowrap" class="ft1195">years old, and who had an ineffective response to methotrexate at doses of 12.5 to 25&#160;mg or have been&#160;<br/>intolerant to 10&#160;mg of methotrexate every week. There were three groups in this study. &#160;The first received&#160;<br/>placebo injections every week&#160;for 52&#160;weeks. The second received 20&#160;mg of Humira every week for&#160;<br/>52&#160;weeks. The third group received 40&#160;mg&#160;of Humira every other week with placebo injections on&#160;<br/>alternate weeks. Upon completion of the first 52&#160;weeks, 457 patients enrolled in an open-label extension&#160;<br/>phase in which 40&#160;mg&#160;of Humira/MTX was administered every other week up to 10&#160;years.</p>
<p style="position:absolute;top:411px;left:106px;white-space:nowrap" class="ft1197">RA study IV primarily assessed safety in 636 patients with moderately to severely active rheumatoid&#160;<br/>arthritis who were&#160;</p>
<p style="position:absolute;top:429px;left:230px;white-space:nowrap" class="ft1196">&#160;18 years old. Patients were permitted to&#160;be&#160;either disease-modifying, anti-rheumatic&#160;</p>
<p style="position:absolute;top:450px;left:106px;white-space:nowrap" class="ft1194">drug-naïve or to remain on their pre-existing rheumatologic therapy provided that therapy was stable for a&#160;<br/>minimum of 28&#160;days. These therapies include methotrexate, leflunomide, hydroxychloroquine,&#160;<br/>sulfasalazine&#160;and/or gold salts. Patients were randomised to 40&#160;mg&#160;of Humira or placebo every other week&#160;<br/>for 24&#160;weeks. &#160;</p>
<p style="position:absolute;top:545px;left:106px;white-space:nowrap" class="ft1195">RA study V evaluated 799 methotrexate-naïve, adult patients with moderate to severely active early&#160;<br/>rheumatoid arthritis (mean disease duration less&#160;than 9&#160;months). This study evaluated the efficacy of&#160;<br/>Humira 40&#160;mg&#160;every other week/methotrexate combination therapy, Humira&#160;40&#160;mg&#160;every other week&#160;<br/>monotherapy and methotrexate monotherapy in reducing the signs and symptoms and rate of progression&#160;<br/>of joint&#160;damage&#160;in rheumatoid arthritis for 104&#160;weeks. Upon completion of the first 104 weeks, 497&#160;<br/>patients enrolled in an open-label extension phase in which 40&#160;mg&#160;of Humira was administered every&#160;<br/>other week up to 10 years.</p>
<p style="position:absolute;top:697px;left:106px;white-space:nowrap" class="ft1195">The primary end point in RA studies I,&#160;II and III and the secondary endpoint in RA study IV was the&#160;<br/>percent of patients who achieved an ACR 20 response at Week&#160;24 or 26. The primary endpoint in RA&#160;<br/>study V was the percent of patients who achieved an ACR 50 response at Week&#160;52. RA studies III and V&#160;<br/>had an additional primary endpoint at 52&#160;weeks of retardation of disease progression (as detected by X-ray&#160;<br/>results). RA study III also had a primary endpoint of changes in quality of life.</p>
<p style="position:absolute;top:811px;left:106px;white-space:nowrap" class="ft1193"><i>ACR response</i></p>
<p style="position:absolute;top:849px;left:106px;white-space:nowrap" class="ft1194">The percent of Humira-treated patients achieving ACR 20, 50 and 70 responses was consistent across RA&#160;<br/>studies I, II and III. The results for the 40&#160;mg&#160;every other week dose are summarised in Table&#160;8.&#160;</p>
</div>
<!-- Page 120 -->
<a name="120"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page120-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1200">120</p>
<p style="position:absolute;top:86px;left:429px;white-space:nowrap" class="ft1201"><b>Table&#160;8</b></p>
<p style="position:absolute;top:105px;left:297px;white-space:nowrap" class="ft1201"><b>ACR Responses in Placebo-Controlled Trials</b></p>
<p style="position:absolute;top:124px;left:383px;white-space:nowrap" class="ft1201"><b>(Percent of Patients)</b></p>
<p style="position:absolute;top:163px;left:113px;white-space:nowrap" class="ft1202">Response</p>
<p style="position:absolute;top:163px;left:255px;white-space:nowrap" class="ft1202">RA Study Ia**</p>
<p style="position:absolute;top:163px;left:448px;white-space:nowrap" class="ft1202">RA Study IIa**</p>
<p style="position:absolute;top:163px;left:643px;white-space:nowrap" class="ft1202">RA Study IIIa**</p>
<p style="position:absolute;top:202px;left:217px;white-space:nowrap" class="ft1202">Placebo/&#160;</p>
<p style="position:absolute;top:221px;left:224px;white-space:nowrap" class="ft1202">MTXc</p>
<p style="position:absolute;top:240px;left:228px;white-space:nowrap" class="ft1202">n=60</p>
<p style="position:absolute;top:202px;left:292px;white-space:nowrap" class="ft1202">Humirab/ MTXc</p>
<p style="position:absolute;top:221px;left:328px;white-space:nowrap" class="ft1202">n=63</p>
<p style="position:absolute;top:202px;left:426px;white-space:nowrap" class="ft1202">Placebo</p>
<p style="position:absolute;top:221px;left:431px;white-space:nowrap" class="ft1202">n=110</p>
<p style="position:absolute;top:202px;left:519px;white-space:nowrap" class="ft1202">Humirab</p>
<p style="position:absolute;top:221px;left:526px;white-space:nowrap" class="ft1202">n=113</p>
<p style="position:absolute;top:202px;left:615px;white-space:nowrap" class="ft1202">Placebo/&#160;</p>
<p style="position:absolute;top:221px;left:623px;white-space:nowrap" class="ft12022">MTXc<br/>n=200</p>
<p style="position:absolute;top:202px;left:691px;white-space:nowrap" class="ft1202">Humirab/ MTXc</p>
<p style="position:absolute;top:221px;left:723px;white-space:nowrap" class="ft1202">n=207</p>
<p style="position:absolute;top:260px;left:113px;white-space:nowrap" class="ft1202">ACR 20</p>
<p style="position:absolute;top:279px;left:124px;white-space:nowrap" class="ft1202">6&#160;months</p>
<p style="position:absolute;top:279px;left:224px;white-space:nowrap" class="ft1202">13.3%</p>
<p style="position:absolute;top:279px;left:324px;white-space:nowrap" class="ft1202">65.1%</p>
<p style="position:absolute;top:279px;left:431px;white-space:nowrap" class="ft1202">19.1%</p>
<p style="position:absolute;top:279px;left:526px;white-space:nowrap" class="ft1202">46.0%</p>
<p style="position:absolute;top:279px;left:622px;white-space:nowrap" class="ft1202">29.5%</p>
<p style="position:absolute;top:279px;left:724px;white-space:nowrap" class="ft1202">63.3%</p>
<p style="position:absolute;top:298px;left:124px;white-space:nowrap" class="ft1202">12&#160;months</p>
<p style="position:absolute;top:298px;left:233px;white-space:nowrap" class="ft1202">NA</p>
<p style="position:absolute;top:298px;left:333px;white-space:nowrap" class="ft1202">NA</p>
<p style="position:absolute;top:298px;left:440px;white-space:nowrap" class="ft1202">NA</p>
<p style="position:absolute;top:298px;left:535px;white-space:nowrap" class="ft1202">NA</p>
<p style="position:absolute;top:298px;left:622px;white-space:nowrap" class="ft1202">24.0%</p>
<p style="position:absolute;top:298px;left:724px;white-space:nowrap" class="ft1202">58.9%</p>
<p style="position:absolute;top:317px;left:113px;white-space:nowrap" class="ft1202">ACR 50</p>
<p style="position:absolute;top:336px;left:124px;white-space:nowrap" class="ft1202">6&#160;months</p>
<p style="position:absolute;top:336px;left:228px;white-space:nowrap" class="ft1202">6.7%</p>
<p style="position:absolute;top:336px;left:324px;white-space:nowrap" class="ft1202">52.4%</p>
<p style="position:absolute;top:336px;left:436px;white-space:nowrap" class="ft1202">8.2%</p>
<p style="position:absolute;top:336px;left:526px;white-space:nowrap" class="ft1202">22.1%</p>
<p style="position:absolute;top:336px;left:630px;white-space:nowrap" class="ft1202">9.5%</p>
<p style="position:absolute;top:336px;left:724px;white-space:nowrap" class="ft1202">39.1%</p>
<p style="position:absolute;top:355px;left:124px;white-space:nowrap" class="ft1202">12&#160;months</p>
<p style="position:absolute;top:355px;left:233px;white-space:nowrap" class="ft1202">NA</p>
<p style="position:absolute;top:355px;left:333px;white-space:nowrap" class="ft1202">NA</p>
<p style="position:absolute;top:355px;left:440px;white-space:nowrap" class="ft1202">NA</p>
<p style="position:absolute;top:355px;left:535px;white-space:nowrap" class="ft1202">NA</p>
<p style="position:absolute;top:355px;left:630px;white-space:nowrap" class="ft1202">9.5%</p>
<p style="position:absolute;top:355px;left:724px;white-space:nowrap" class="ft1202">41.5%</p>
<p style="position:absolute;top:374px;left:113px;white-space:nowrap" class="ft1202">ACR 70</p>
<p style="position:absolute;top:393px;left:124px;white-space:nowrap" class="ft1202">6&#160;months</p>
<p style="position:absolute;top:393px;left:228px;white-space:nowrap" class="ft1202">3.3%</p>
<p style="position:absolute;top:393px;left:324px;white-space:nowrap" class="ft1202">23.8%</p>
<p style="position:absolute;top:393px;left:436px;white-space:nowrap" class="ft1202">1.8%</p>
<p style="position:absolute;top:393px;left:526px;white-space:nowrap" class="ft1202">12.4%</p>
<p style="position:absolute;top:393px;left:630px;white-space:nowrap" class="ft1202">2.5%</p>
<p style="position:absolute;top:393px;left:724px;white-space:nowrap" class="ft1202">20.8%</p>
<p style="position:absolute;top:412px;left:124px;white-space:nowrap" class="ft1202">12&#160;months</p>
<p style="position:absolute;top:412px;left:233px;white-space:nowrap" class="ft1202">NA</p>
<p style="position:absolute;top:412px;left:333px;white-space:nowrap" class="ft1202">NA</p>
<p style="position:absolute;top:412px;left:440px;white-space:nowrap" class="ft1202">NA</p>
<p style="position:absolute;top:412px;left:535px;white-space:nowrap" class="ft1202">NA</p>
<p style="position:absolute;top:412px;left:630px;white-space:nowrap" class="ft1202">4.5%</p>
<p style="position:absolute;top:412px;left:724px;white-space:nowrap" class="ft1202">23.2%</p>
<p style="position:absolute;top:431px;left:113px;white-space:nowrap" class="ft1209">a&#160;RA study I at 24&#160;weeks, RA study&#160;II at 26&#160;weeks , and RA study III at 24 and 52&#160;weeks</p>
<p style="position:absolute;top:450px;left:113px;white-space:nowrap" class="ft1209">b&#160;40&#160;mg Humira administered every other week</p>
<p style="position:absolute;top:468px;left:113px;white-space:nowrap" class="ft1207">c&#160;MTX = methotrexate<br/>**p&#160;&lt;&#160;0.01, Humira&#160;<i>versus&#160;</i>placebo</p>
<p style="position:absolute;top:527px;left:106px;white-space:nowrap" class="ft1204">In RA studies I-IV, all individual components of the ACR response criteria (number of tender and swollen&#160;<br/>joints, physician and patient assessment of disease activity and pain, disability index (HAQ) scores and&#160;<br/>CRP (mg/dl) values) improved at 24 or 26&#160;weeks compared to placebo. In RA study III, these&#160;<br/>improvements were maintained throughout 52&#160;weeks.&#160;</p>
<p style="position:absolute;top:622px;left:106px;white-space:nowrap" class="ft1205">In&#160;the open-label extension for RA study III, most patients who were ACR responders maintained&#160;<br/>response when followed for up to 10&#160;years. Of 207 patients who were randomised to Humira 40&#160;mg&#160;every&#160;<br/>other week, 114 patients continued on Humira 40&#160;mg&#160;every other&#160;week for 5&#160;years. Among those, 86&#160;<br/>patients (75.4%) had ACR 20 responses; 72 patients (63.2%) had ACR 50 responses; and 41 patients&#160;<br/>(36%) had ACR 70 responses. Of 207 patients, 81 patients continued on Humira 40&#160;mg every other week&#160;<br/>for 10&#160;years. Among those, 64 patients (79.0%) had ACR 20 responses; 56 patients (69.1%) had ACR 50&#160;<br/>responses; and 43 patients (53.1%) had ACR 70 responses.</p>
<p style="position:absolute;top:774px;left:106px;white-space:nowrap" class="ft1205">In RA study IV, the ACR 20 response of patients treated with Humira plus standard of care was&#160;<br/>statistically significantly better than patients treated with placebo plus standard of care (p&#160;&lt;&#160;0.001). &#160;</p>
<p style="position:absolute;top:831px;left:106px;white-space:nowrap" class="ft1205">In RA studies I-IV, Humira-treated patients achieved statistically significant ACR 20 and 50 responses&#160;<br/>compared to placebo as early as one to two weeks after initiation of treatment.</p>
<p style="position:absolute;top:887px;left:106px;white-space:nowrap" class="ft1204">In RA study V with early rheumatoid arthritis patients who were methotrexate naïve, combination therapy&#160;<br/>with Humira and methotrexate led to faster and significantly greater ACR responses than methotrexate&#160;<br/>monotherapy and Humira monotherapy at Week 52 and responses were sustained at Week&#160;104 (see Table&#160;<br/>9).</p>
</div>
<!-- Page 121 -->
<a name="121"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page121-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1210">121</p>
<p style="position:absolute;top:86px;left:433px;white-space:nowrap" class="ft1211"><b>Table&#160;9</b></p>
<p style="position:absolute;top:105px;left:350px;white-space:nowrap" class="ft1211"><b>ACR Responses in RA Study V</b></p>
<p style="position:absolute;top:124px;left:388px;white-space:nowrap" class="ft1211"><b>(percent of patients)</b></p>
<p style="position:absolute;top:172px;left:120px;white-space:nowrap" class="ft1211"><b>Response</b></p>
<p style="position:absolute;top:163px;left:258px;white-space:nowrap" class="ft1211"><b>MTX</b></p>
<p style="position:absolute;top:181px;left:256px;white-space:nowrap" class="ft1211"><b>n=257</b></p>
<p style="position:absolute;top:163px;left:348px;white-space:nowrap" class="ft1211"><b>Humira</b></p>
<p style="position:absolute;top:181px;left:355px;white-space:nowrap" class="ft1211"><b>n=274</b></p>
<p style="position:absolute;top:163px;left:436px;white-space:nowrap" class="ft1211"><b>Humira/MTX</b></p>
<p style="position:absolute;top:181px;left:463px;white-space:nowrap" class="ft1211"><b>n=268</b></p>
<p style="position:absolute;top:172px;left:557px;white-space:nowrap" class="ft1211"><b>p-valuea</b></p>
<p style="position:absolute;top:172px;left:642px;white-space:nowrap" class="ft1211"><b>p-valueb</b></p>
<p style="position:absolute;top:172px;left:731px;white-space:nowrap" class="ft1211"><b>p-valuec</b></p>
<p style="position:absolute;top:201px;left:120px;white-space:nowrap" class="ft1212">ACR 20</p>
<p style="position:absolute;top:221px;left:162px;white-space:nowrap" class="ft1212">Week&#160;</p>
<p style="position:absolute;top:240px;left:120px;white-space:nowrap" class="ft1212">52</p>
<p style="position:absolute;top:221px;left:256px;white-space:nowrap" class="ft1212">62.6%</p>
<p style="position:absolute;top:221px;left:355px;white-space:nowrap" class="ft1212">54.4%</p>
<p style="position:absolute;top:221px;left:464px;white-space:nowrap" class="ft1212">72.8%</p>
<p style="position:absolute;top:221px;left:567px;white-space:nowrap" class="ft1212">0.013</p>
<p style="position:absolute;top:221px;left:645px;white-space:nowrap" class="ft1212">&lt;&#160;0.001</p>
<p style="position:absolute;top:221px;left:741px;white-space:nowrap" class="ft1212">0.043</p>
<p style="position:absolute;top:260px;left:162px;white-space:nowrap" class="ft1212">Week&#160;</p>
<p style="position:absolute;top:279px;left:120px;white-space:nowrap" class="ft1212">104</p>
<p style="position:absolute;top:260px;left:256px;white-space:nowrap" class="ft1212">56.0%</p>
<p style="position:absolute;top:260px;left:355px;white-space:nowrap" class="ft1212">49.3%</p>
<p style="position:absolute;top:260px;left:464px;white-space:nowrap" class="ft1212">69.4%</p>
<p style="position:absolute;top:260px;left:567px;white-space:nowrap" class="ft1212">0.002</p>
<p style="position:absolute;top:260px;left:645px;white-space:nowrap" class="ft1212">&lt;&#160;0.001</p>
<p style="position:absolute;top:260px;left:741px;white-space:nowrap" class="ft1212">0.140</p>
<p style="position:absolute;top:298px;left:120px;white-space:nowrap" class="ft1212">ACR 50</p>
<p style="position:absolute;top:318px;left:162px;white-space:nowrap" class="ft1212">Week&#160;</p>
<p style="position:absolute;top:337px;left:120px;white-space:nowrap" class="ft1212">52</p>
<p style="position:absolute;top:318px;left:256px;white-space:nowrap" class="ft1212">45.9%</p>
<p style="position:absolute;top:318px;left:355px;white-space:nowrap" class="ft1212">41.2%</p>
<p style="position:absolute;top:318px;left:464px;white-space:nowrap" class="ft1212">61.6%</p>
<p style="position:absolute;top:318px;left:560px;white-space:nowrap" class="ft1212">&lt;&#160;0.001</p>
<p style="position:absolute;top:318px;left:645px;white-space:nowrap" class="ft1212">&lt;&#160;0.001</p>
<p style="position:absolute;top:318px;left:741px;white-space:nowrap" class="ft1212">0.317</p>
<p style="position:absolute;top:357px;left:162px;white-space:nowrap" class="ft1212">Week&#160;</p>
<p style="position:absolute;top:376px;left:120px;white-space:nowrap" class="ft1212">104</p>
<p style="position:absolute;top:357px;left:256px;white-space:nowrap" class="ft1212">42.8%</p>
<p style="position:absolute;top:357px;left:355px;white-space:nowrap" class="ft1212">36.9%</p>
<p style="position:absolute;top:357px;left:464px;white-space:nowrap" class="ft1212">59.0%</p>
<p style="position:absolute;top:357px;left:560px;white-space:nowrap" class="ft1212">&lt;&#160;0.001</p>
<p style="position:absolute;top:357px;left:645px;white-space:nowrap" class="ft1212">&lt;&#160;0.001</p>
<p style="position:absolute;top:357px;left:741px;white-space:nowrap" class="ft1212">0.162</p>
<p style="position:absolute;top:396px;left:120px;white-space:nowrap" class="ft1212">ACR 70</p>
<p style="position:absolute;top:415px;left:162px;white-space:nowrap" class="ft1212">Week&#160;</p>
<p style="position:absolute;top:434px;left:120px;white-space:nowrap" class="ft1212">52</p>
<p style="position:absolute;top:415px;left:256px;white-space:nowrap" class="ft1212">27.2%</p>
<p style="position:absolute;top:415px;left:355px;white-space:nowrap" class="ft1212">25.9%</p>
<p style="position:absolute;top:415px;left:464px;white-space:nowrap" class="ft1212">45.5%</p>
<p style="position:absolute;top:415px;left:560px;white-space:nowrap" class="ft1212">&lt;&#160;0.001</p>
<p style="position:absolute;top:415px;left:645px;white-space:nowrap" class="ft1212">&lt;&#160;0.001</p>
<p style="position:absolute;top:415px;left:741px;white-space:nowrap" class="ft1212">0.656</p>
<p style="position:absolute;top:454px;left:162px;white-space:nowrap" class="ft1212">Week&#160;</p>
<p style="position:absolute;top:473px;left:120px;white-space:nowrap" class="ft1212">104</p>
<p style="position:absolute;top:454px;left:256px;white-space:nowrap" class="ft1212">28.4%</p>
<p style="position:absolute;top:454px;left:355px;white-space:nowrap" class="ft1212">28.1%</p>
<p style="position:absolute;top:454px;left:464px;white-space:nowrap" class="ft1212">46.6%</p>
<p style="position:absolute;top:454px;left:560px;white-space:nowrap" class="ft1212">&lt;&#160;0.001</p>
<p style="position:absolute;top:454px;left:645px;white-space:nowrap" class="ft1212">&lt;&#160;0.001</p>
<p style="position:absolute;top:454px;left:741px;white-space:nowrap" class="ft1212">0.864</p>
<p style="position:absolute;top:492px;left:121px;white-space:nowrap" class="ft1212">a.&#160;p-value is from the pairwise comparison of methotrexate monotherapy and Humira/methotrexate&#160;</p>
<p style="position:absolute;top:512px;left:148px;white-space:nowrap" class="ft1212">combination&#160;therapy using the Mann-Whitney U test.</p>
<p style="position:absolute;top:531px;left:121px;white-space:nowrap" class="ft1212">b.&#160;p-value is from the pairwise comparison of Humira monotherapy and Humira/methotrexate&#160;</p>
<p style="position:absolute;top:550px;left:145px;white-space:nowrap" class="ft1212">combination therapy using the Mann-Whitney U test</p>
<p style="position:absolute;top:568px;left:121px;white-space:nowrap" class="ft1212">c. &#160; p-value is from the pairwise comparison of Humira monotherapy and methotrexate monotherapy&#160;</p>
<p style="position:absolute;top:588px;left:145px;white-space:nowrap" class="ft1212">using the Mann-Whitney U test</p>
<p style="position:absolute;top:626px;left:106px;white-space:nowrap" class="ft1215">In the open-label extension for RA study V, ACR response rates were maintained when followed for up to&#160;<br/>10 years. Of 542 patients who were randomised to Humira 40 mg every other week, 170 patients&#160;<br/>continued&#160;on Humira 40 mg every other week for 10 years. Among those, 154 patients (90.6%) had ACR&#160;<br/>20 responses; 127 patients (74.7%) had ACR 50 responses; and 102 patients (60.0%) had ACR 70&#160;<br/>responses.</p>
<p style="position:absolute;top:740px;left:106px;white-space:nowrap" class="ft1215">At Week&#160;52, 42.9% of patients who received Humira/methotrexate combination therapy achieved clinical&#160;<br/>remission (DAS28 (CRP)&#160;&lt;&#160;2.6) compared to 20.6% of patients receiving methotrexate monotherapy and&#160;<br/>23.4% of patients receiving Humira monotherapy. Humira/methotrexate combination therapy was&#160;<br/>clinically and statistically superior to methotrexate (p&#160;&lt;&#160;0.001) and Humira monotherapy (p&#160;&lt;&#160;0.001) in&#160;<br/>achieving a low disease state in patients with recently diagnosed moderate to severe rheumatoid arthritis.&#160;<br/>The response for the two monotherapy arms was similar (p&#160;=&#160;0.447). &#160;Of&#160;342 subjects originally&#160;<br/>randomized to Humira monotherapy or Humira/methotrexate combination therapy who entered the open-<br/>label extension study, 171 subjects completed 10 years of Humira treatment. Among those, 109 subjects&#160;<br/>(63.7%) were reported to be in remission at 10 years.</p>
<p style="position:absolute;top:930px;left:106px;white-space:nowrap" class="ft1213"><i>Radiographic response</i></p>
<p style="position:absolute;top:968px;left:106px;white-space:nowrap" class="ft1214">In RA study III, where Humira treated patients had a mean duration of rheumatoid arthritis of&#160;<br/>approximately 11&#160;years, structural joint damage was assessed radiographically and expressed as change in&#160;<br/>modified Total Sharp Score (TSS) and its components, the erosion score and joint space narrowing score. &#160;<br/>Humira/methotrexate patients demonstrated significantly less radiographic progression than patients&#160;<br/>receiving methotrexate alone at 6 and 12&#160;months (see Table&#160;10). &#160;</p>
</div>
<!-- Page 122 -->
<a name="122"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page122-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1220">122</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft1224">In the open-label extension of RA Study III, the reduction in rate of progression of structural damage is&#160;<br/>maintained for 8 and 10&#160;years in a subset of patients. At 8&#160;years, 81 of 207 patients originally treated with&#160;<br/>40&#160;mg Humira every other week were&#160;evaluated radiographically. Among those, 48 patients showed no&#160;<br/>progression of structural damage defined by a change from baseline in the mTSS of 0.5 or less. At&#160;<br/>10&#160;years, 79 of 207 patients originally treated with 40&#160;mg Humira every other week were evaluated&#160;<br/>radiographically. Among those, 40 patients showed no progression of structural damage defined by a&#160;<br/>change from baseline in the mTSS of 0.5 or less.</p>
<p style="position:absolute;top:238px;left:407px;white-space:nowrap" class="ft1221"><b>Table&#160;10</b></p>
<p style="position:absolute;top:257px;left:221px;white-space:nowrap" class="ft1221"><b>Radiographic Mean Changes Over 12&#160;Months in RA Study III</b></p>
<p style="position:absolute;top:296px;left:270px;white-space:nowrap" class="ft1225">Placebo/<br/>MTXa</p>
<p style="position:absolute;top:296px;left:391px;white-space:nowrap" class="ft1222">Humira/MTX</p>
<p style="position:absolute;top:314px;left:396px;white-space:nowrap" class="ft1222">40&#160;mg&#160;every&#160;</p>
<p style="position:absolute;top:333px;left:400px;white-space:nowrap" class="ft1222">other week</p>
<p style="position:absolute;top:296px;left:529px;white-space:nowrap" class="ft1222">Placebo/MTX-</p>
<p style="position:absolute;top:314px;left:513px;white-space:nowrap" class="ft1222">Humira/MTX (95%&#160;</p>
<p style="position:absolute;top:333px;left:541px;white-space:nowrap" class="ft1222">Confidence&#160;</p>
<p style="position:absolute;top:352px;left:548px;white-space:nowrap" class="ft1222">Intervalb)</p>
<p style="position:absolute;top:296px;left:687px;white-space:nowrap" class="ft1222">p-value</p>
<p style="position:absolute;top:372px;left:124px;white-space:nowrap" class="ft1222">Total Sharp Score</p>
<p style="position:absolute;top:372px;left:306px;white-space:nowrap" class="ft1222">2.7</p>
<p style="position:absolute;top:372px;left:426px;white-space:nowrap" class="ft1222">0.1</p>
<p style="position:absolute;top:372px;left:536px;white-space:nowrap" class="ft1222">2.6 (1.4, 3.8)&#160;</p>
<p style="position:absolute;top:372px;left:684px;white-space:nowrap" class="ft1222">&lt;&#160;0.001c</p>
<p style="position:absolute;top:392px;left:139px;white-space:nowrap" class="ft1222">Erosion score</p>
<p style="position:absolute;top:392px;left:306px;white-space:nowrap" class="ft1222">1.6</p>
<p style="position:absolute;top:392px;left:426px;white-space:nowrap" class="ft1222">0.0</p>
<p style="position:absolute;top:392px;left:536px;white-space:nowrap" class="ft1222">1.6 (0.9, 2.2)</p>
<p style="position:absolute;top:392px;left:687px;white-space:nowrap" class="ft1222">&lt;&#160;0.001</p>
<p style="position:absolute;top:411px;left:148px;white-space:nowrap" class="ft1222">JSNd&#160;score</p>
<p style="position:absolute;top:411px;left:306px;white-space:nowrap" class="ft1222">1.0</p>
<p style="position:absolute;top:411px;left:426px;white-space:nowrap" class="ft1222">0.1</p>
<p style="position:absolute;top:411px;left:536px;white-space:nowrap" class="ft1222">0.9 (0.3, 1.4)</p>
<p style="position:absolute;top:411px;left:689px;white-space:nowrap" class="ft1222">&#160;&#160;0.002</p>
<p style="position:absolute;top:429px;left:106px;white-space:nowrap" class="ft12213"><b>a</b>methotrexate</p>
<p style="position:absolute;top:449px;left:106px;white-space:nowrap" class="ft1229">b95% confidence intervals for the differences in change scores between methotrexate and Humira.&#160;</p>
<p style="position:absolute;top:468px;left:106px;white-space:nowrap" class="ft1229">cBased on rank analysis&#160;</p>
<p style="position:absolute;top:487px;left:106px;white-space:nowrap" class="ft1229">dJoint Space Narrowing</p>
<p style="position:absolute;top:526px;left:106px;white-space:nowrap" class="ft1224">In RA study V, structural joint damage was assessed radiographically and expressed as change in modified&#160;<br/>Total&#160;Sharp Score (see Table&#160;11).</p>
<p style="position:absolute;top:583px;left:418px;white-space:nowrap" class="ft1221"><b>Table&#160;11</b></p>
<p style="position:absolute;top:606px;left:246px;white-space:nowrap" class="ft1221"><b>&#160;&#160;Radiographic Mean Changes at Week&#160;52 in RA Study V</b></p>
<p style="position:absolute;top:645px;left:261px;white-space:nowrap" class="ft1222">MTX</p>
<p style="position:absolute;top:665px;left:258px;white-space:nowrap" class="ft1222">n=257</p>
<p style="position:absolute;top:684px;left:261px;white-space:nowrap" class="ft1222">(95%&#160;</p>
<p style="position:absolute;top:702px;left:243px;white-space:nowrap" class="ft1222">confidence&#160;</p>
<p style="position:absolute;top:721px;left:251px;white-space:nowrap" class="ft1222">interval)</p>
<p style="position:absolute;top:645px;left:367px;white-space:nowrap" class="ft1222">Humira</p>
<p style="position:absolute;top:665px;left:371px;white-space:nowrap" class="ft1222">n=274</p>
<p style="position:absolute;top:684px;left:374px;white-space:nowrap" class="ft1222">(95%&#160;</p>
<p style="position:absolute;top:702px;left:356px;white-space:nowrap" class="ft1222">confidence&#160;</p>
<p style="position:absolute;top:721px;left:364px;white-space:nowrap" class="ft1222">interval)</p>
<p style="position:absolute;top:645px;left:458px;white-space:nowrap" class="ft1222">Humira/MTX</p>
<p style="position:absolute;top:665px;left:482px;white-space:nowrap" class="ft1222">n=268</p>
<p style="position:absolute;top:684px;left:486px;white-space:nowrap" class="ft1222">(95%&#160;</p>
<p style="position:absolute;top:702px;left:467px;white-space:nowrap" class="ft1222">confidence&#160;</p>
<p style="position:absolute;top:721px;left:476px;white-space:nowrap" class="ft1222">interval)</p>
<p style="position:absolute;top:684px;left:569px;white-space:nowrap" class="ft1222">p-valuea</p>
<p style="position:absolute;top:684px;left:643px;white-space:nowrap" class="ft1222">p-valueb</p>
<p style="position:absolute;top:684px;left:718px;white-space:nowrap" class="ft1222">p-valuec</p>
<p style="position:absolute;top:741px;left:129px;white-space:nowrap" class="ft1222">Total Sharp&#160;</p>
<p style="position:absolute;top:760px;left:149px;white-space:nowrap" class="ft1222">Score</p>
<p style="position:absolute;top:741px;left:238px;white-space:nowrap" class="ft1222">5.7 (4.2-7.3)</p>
<p style="position:absolute;top:741px;left:351px;white-space:nowrap" class="ft1222">3.0 (1.7-4.3)</p>
<p style="position:absolute;top:741px;left:462px;white-space:nowrap" class="ft1222">1.3 (0.5-2.1)</p>
<p style="position:absolute;top:741px;left:571px;white-space:nowrap" class="ft1222">&lt;&#160;0.001</p>
<p style="position:absolute;top:741px;left:648px;white-space:nowrap" class="ft1222">0.0020</p>
<p style="position:absolute;top:741px;left:720px;white-space:nowrap" class="ft1222">&lt;&#160;0.001</p>
<p style="position:absolute;top:780px;left:122px;white-space:nowrap" class="ft1222">Erosion score</p>
<p style="position:absolute;top:780px;left:238px;white-space:nowrap" class="ft1222">3.7 (2.7-4.7)</p>
<p style="position:absolute;top:780px;left:351px;white-space:nowrap" class="ft1222">1.7 (1.0-2.4)</p>
<p style="position:absolute;top:780px;left:462px;white-space:nowrap" class="ft1222">0.8 (0.4-1.2)</p>
<p style="position:absolute;top:780px;left:571px;white-space:nowrap" class="ft1222">&lt;&#160;0.001</p>
<p style="position:absolute;top:780px;left:648px;white-space:nowrap" class="ft1222">0.0082</p>
<p style="position:absolute;top:780px;left:720px;white-space:nowrap" class="ft1222">&lt;&#160;0.001</p>
<p style="position:absolute;top:800px;left:134px;white-space:nowrap" class="ft1222">JSN score</p>
<p style="position:absolute;top:800px;left:238px;white-space:nowrap" class="ft1222">2.0 (1.2-2.8)</p>
<p style="position:absolute;top:800px;left:351px;white-space:nowrap" class="ft1222">1.3 (0.5-2.1)</p>
<p style="position:absolute;top:800px;left:468px;white-space:nowrap" class="ft1222">0.5 (0-1.0)</p>
<p style="position:absolute;top:800px;left:571px;white-space:nowrap" class="ft1222">&lt;&#160;0.001</p>
<p style="position:absolute;top:800px;left:648px;white-space:nowrap" class="ft1222">0.0037</p>
<p style="position:absolute;top:800px;left:726px;white-space:nowrap" class="ft1222">0.151</p>
<p style="position:absolute;top:818px;left:122px;white-space:nowrap" class="ft1229">a&#160;p-value is from the pairwise&#160;comparison of methotrexate monotherapy and Humira/methotrexate&#160;</p>
<p style="position:absolute;top:838px;left:147px;white-space:nowrap" class="ft1222">combination therapy using the Mann-Whitney U test.</p>
<p style="position:absolute;top:856px;left:122px;white-space:nowrap" class="ft1229">b&#160;p-value is from the pairwise comparison of Humira monotherapy and Humira/methotrexate&#160;</p>
<p style="position:absolute;top:876px;left:149px;white-space:nowrap" class="ft1222">combination therapy using the Mann-Whitney U test&#160;</p>
<p style="position:absolute;top:894px;left:122px;white-space:nowrap" class="ft1229">c&#160;p-value is from the pairwise comparison of Humira monotherapy and methotrexate monotherapy&#160;</p>
<p style="position:absolute;top:914px;left:149px;white-space:nowrap" class="ft1222">using the Mann-Whitney U test</p>
<p style="position:absolute;top:952px;left:106px;white-space:nowrap" class="ft1227">Following 52&#160;weeks and 104&#160;weeks of treatment, the percentage of patients without progression (change&#160;<br/>from baseline in modified Total Sharp Score&#160;</p>
<p style="position:absolute;top:970px;left:404px;white-space:nowrap" class="ft1226">&#160;0.5) was significantly higher with Humira/methotrexate&#160;</p>
<p style="position:absolute;top:991px;left:106px;white-space:nowrap" class="ft1224">combination therapy (63.8% and 61.2% respectively) compared to methotrexate monotherapy (37.4% and&#160;<br/>33.5% respectively, p&#160;&lt;&#160;0.001) and Humira monotherapy (50.7%, p&#160;&lt;&#160;0.002 and 44.5%, p&#160;&lt;&#160;0.001&#160;<br/>respectively).&#160;</p>
</div>
<!-- Page 123 -->
<a name="123"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft12326{font-size:17px;line-height:18px;font-family:HORGHZ+TimesNewRoman,Italic;color:#000000;}
-->
</style>
<div id="page123-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1230">123</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft1234">In the open-label extension of RA study V, the mean change from baseline at Year 10 in the modified&#160;<br/>Total Sharp Score was 10.8, 9.2 and 3.9 in patients originally randomized to methotrexate monotherapy,&#160;<br/>Humira monotherapy and Humira/methotrexate combination therapy, respectively.&#160;The corresponding&#160;<br/>proportions of patients with no radiographic progression were 31.3%, 23.7% and 36.7% respectively.</p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft1233"><i>Quality of life and physical function</i></p>
<p style="position:absolute;top:219px;left:106px;white-space:nowrap" class="ft1234">Health-related quality of life and physical function were assessed using the disability index of the Health&#160;<br/>Assessment Questionnaire (HAQ) in the four original adequate and well-controlled trials, which was a&#160;<br/>pre-specified primary endpoint at Week&#160;52 in RA study III. All doses/schedules of Humira in all&#160;four&#160;<br/>studies showed statistically significantly greater improvement in the disability index of the HAQ from&#160;<br/>baseline to Month 6 compared to placebo and in RA study III the same was seen at Week&#160;52. Results from&#160;<br/>the Short Form Health Survey (SF 36) for all&#160;doses/schedules of Humira in all four studies support these&#160;<br/>findings, with statistically significant physical component summary (PCS) scores, as well as statistically&#160;<br/>significant pain and vitality domain scores for the 40&#160;mg&#160;every other week dose. A statistically significant&#160;<br/>decrease in fatigue as measured by functional assessment of chronic illness therapy (FACIT) scores was&#160;<br/>seen in all three studies in which it was assessed (RA studies I, III, IV).</p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft1234">In RA study III, most subjects who achieved improvement&#160;in physical function and continued treatment&#160;<br/>maintained improvement through Week&#160;520 (120&#160;months) of open-label treatment. Improvement in&#160;<br/>quality of life was measured up to Week&#160;156 (36&#160;months) and improvement was maintained through that&#160;<br/>time.</p>
<p style="position:absolute;top:522px;left:106px;white-space:nowrap" class="ft1234">In RA study V, the improvement in the HAQ disability index and the physical component of the SF 36&#160;<br/>showed greater improvement (p&#160;&lt;&#160;0.001) for Humira/methotrexate combination therapy&#160;<i>versus<br/></i>methotrexate monotherapy and Humira monotherapy at Week&#160;52, which was maintained through&#160;<br/>Week&#160;104. &#160;Among the 250 subjects who completed the open-label extension study, improvements in&#160;<br/>physical function were maintained through 10 years of treatment.</p>
<p style="position:absolute;top:636px;left:106px;white-space:nowrap" class="ft1233"><i>Axial spondyloarthritis</i></p>
<p style="position:absolute;top:674px;left:106px;white-space:nowrap" class="ft1233"><i>Ankylosing spondylitis (AS)</i></p>
<p style="position:absolute;top:712px;left:106px;white-space:nowrap" class="ft1235">Humira&#160;40&#160;mg&#160;every other week was assessed in 393&#160;patients in two randomised, 24&#160;week double&#160;−&#160;blind,&#160;<br/>placebo&#160;−&#160;controlled studies in patients with active ankylosing spondylitis (mean baseline score of disease&#160;<br/>activity [Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)] was 6.3 in all groups) who have&#160;<br/>had an inadequate response to conventional therapy. Seventy-nine (20.1%) patients were treated&#160;<br/>concomitantly with disease modifying anti&#160;− rheumatic drugs, and 37 (9.4%) patients with&#160;<br/>glucocorticoids. The blinded&#160;period was followed by an open&#160;−&#160;label period during which patients&#160;<br/>received Humira 40&#160;mg&#160;every other week subcutaneously for up to an additional 28&#160;weeks. Subjects&#160;<br/>(n=215, 54.7%) who failed to achieve ASAS 20 at Weeks&#160;12, or 16 or 20 received early escape open-label&#160;<br/>adalimumab 40&#160;mg&#160;every other week subcutaneously and were subsequently treated as non-responders in&#160;<br/>the double-blind statistical analyses.</p>
<p style="position:absolute;top:921px;left:106px;white-space:nowrap" class="ft1234">In the larger AS study I with 315&#160;patients, results showed statistically significant improvement of the&#160;signs&#160;<br/>and symptoms of ankylosing spondylitis in patients treated with Humira compared to placebo. &#160;Significant&#160;<br/>response was first observed at Week&#160;2 and maintained through 24&#160;weeks (Table&#160;12).&#160;</p>
</div>
<!-- Page 124 -->
<a name="124"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page124-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1240">124</p>
<p style="position:absolute;top:86px;left:428px;white-space:nowrap" class="ft1241"><b>Table&#160;12</b></p>
<p style="position:absolute;top:105px;left:245px;white-space:nowrap" class="ft1241"><b>Efficacy Responses in Placebo-Controlled AS Study&#160;–&#160;Study I</b></p>
<p style="position:absolute;top:124px;left:338px;white-space:nowrap" class="ft1241"><b>Reduction of Signs and Symptoms</b></p>
<p style="position:absolute;top:163px;left:191px;white-space:nowrap" class="ft1241"><b>Response</b></p>
<p style="position:absolute;top:163px;left:442px;white-space:nowrap" class="ft1241"><b>Placebo</b></p>
<p style="position:absolute;top:181px;left:447px;white-space:nowrap" class="ft1241"><b>N=107</b></p>
<p style="position:absolute;top:163px;left:607px;white-space:nowrap" class="ft1241"><b>Humira</b></p>
<p style="position:absolute;top:181px;left:612px;white-space:nowrap" class="ft1241"><b>N=208</b></p>
<p style="position:absolute;top:201px;left:191px;white-space:nowrap" class="ft1244">ASASa&#160;20<br/>&#160; &#160; &#160; &#160; &#160; &#160; &#160;Week&#160;2</p>
<p style="position:absolute;top:221px;left:455px;white-space:nowrap" class="ft1242">16%</p>
<p style="position:absolute;top:221px;left:608px;white-space:nowrap" class="ft1242">42%***</p>
<p style="position:absolute;top:241px;left:245px;white-space:nowrap" class="ft1242">Week&#160;12</p>
<p style="position:absolute;top:241px;left:455px;white-space:nowrap" class="ft1242">21%</p>
<p style="position:absolute;top:241px;left:608px;white-space:nowrap" class="ft1242">58%***</p>
<p style="position:absolute;top:261px;left:245px;white-space:nowrap" class="ft1242">Week&#160;24</p>
<p style="position:absolute;top:261px;left:455px;white-space:nowrap" class="ft1242">19%</p>
<p style="position:absolute;top:261px;left:608px;white-space:nowrap" class="ft1242">51%***</p>
<p style="position:absolute;top:280px;left:191px;white-space:nowrap" class="ft1244">ASAS 50<br/>&#160; &#160; &#160; &#160; &#160; &#160; &#160;Week&#160;2</p>
<p style="position:absolute;top:300px;left:459px;white-space:nowrap" class="ft1242">3%</p>
<p style="position:absolute;top:300px;left:608px;white-space:nowrap" class="ft1242">16%***</p>
<p style="position:absolute;top:320px;left:245px;white-space:nowrap" class="ft1242">Week&#160;12</p>
<p style="position:absolute;top:320px;left:455px;white-space:nowrap" class="ft1242">10%</p>
<p style="position:absolute;top:320px;left:608px;white-space:nowrap" class="ft1242">38%***</p>
<p style="position:absolute;top:339px;left:245px;white-space:nowrap" class="ft1242">Week&#160;24</p>
<p style="position:absolute;top:339px;left:455px;white-space:nowrap" class="ft1242">11%</p>
<p style="position:absolute;top:339px;left:608px;white-space:nowrap" class="ft1242">35%***</p>
<p style="position:absolute;top:359px;left:191px;white-space:nowrap" class="ft1244">ASAS 70<br/>&#160; &#160; &#160; &#160; &#160; &#160; &#160;Week&#160;2</p>
<p style="position:absolute;top:379px;left:459px;white-space:nowrap" class="ft1242">0%</p>
<p style="position:absolute;top:379px;left:616px;white-space:nowrap" class="ft1242">7%**</p>
<p style="position:absolute;top:399px;left:245px;white-space:nowrap" class="ft1242">Week&#160;12</p>
<p style="position:absolute;top:399px;left:459px;white-space:nowrap" class="ft1242">5%</p>
<p style="position:absolute;top:399px;left:608px;white-space:nowrap" class="ft1242">23%***</p>
<p style="position:absolute;top:418px;left:245px;white-space:nowrap" class="ft1242">Week&#160;24</p>
<p style="position:absolute;top:418px;left:459px;white-space:nowrap" class="ft1242">8%</p>
<p style="position:absolute;top:418px;left:608px;white-space:nowrap" class="ft1242">24%***</p>
<p style="position:absolute;top:458px;left:191px;white-space:nowrap" class="ft1244">BASDAIb&#160;50&#160;<br/>&#160; &#160; &#160; &#160; &#160; &#160; &#160;Week&#160;2</p>
<p style="position:absolute;top:477px;left:459px;white-space:nowrap" class="ft1242">4%</p>
<p style="position:absolute;top:477px;left:608px;white-space:nowrap" class="ft1242">20%***</p>
<p style="position:absolute;top:497px;left:245px;white-space:nowrap" class="ft1242">Week&#160;12&#160;</p>
<p style="position:absolute;top:497px;left:455px;white-space:nowrap" class="ft1242">16%</p>
<p style="position:absolute;top:497px;left:608px;white-space:nowrap" class="ft1242">45%***</p>
<p style="position:absolute;top:517px;left:245px;white-space:nowrap" class="ft1242">Week&#160;24&#160;</p>
<p style="position:absolute;top:517px;left:455px;white-space:nowrap" class="ft1242">15%</p>
<p style="position:absolute;top:517px;left:608px;white-space:nowrap" class="ft1242">42%***</p>
<p style="position:absolute;top:537px;left:180px;white-space:nowrap" class="ft1245">***,** Statistically significant at p&#160;&lt;&#160;0.001, &lt;&#160;0.01 for all comparisons between Humira and&#160;<br/>placebo at Weeks&#160;2, 12 and &#160;24</p>
<p style="position:absolute;top:573px;left:180px;white-space:nowrap" class="ft1249">a&#160;Assessments in Ankylosing Spondylitis</p>
<p style="position:absolute;top:592px;left:180px;white-space:nowrap" class="ft1249">b&#160;Bath Ankylosing Spondylitis Disease Activity Index</p>
<p style="position:absolute;top:631px;left:106px;white-space:nowrap" class="ft1244">Humira treated patients had significantly greater improvement at Week&#160;12 which was maintained through&#160;<br/>Week&#160;24 in both the SF36 and&#160;Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL).</p>
<p style="position:absolute;top:688px;left:106px;white-space:nowrap" class="ft1244">Similar trends (not all statistically significant) were seen in the smaller randomised, double&#160;−&#160;blind,&#160;<br/>placebo controlled AS study II of 82&#160;adult patients with active ankylosing spondylitis.</p>
<p style="position:absolute;top:746px;left:106px;white-space:nowrap" class="ft1243"><i>Axial spondyloarthritis without radiographic evidence of AS</i></p>
<p style="position:absolute;top:783px;left:106px;white-space:nowrap" class="ft1244">The safety and efficacy of&#160;Humira were assessed in two randomized, double-blind placebo-controlled&#160;<br/>studies in patients with non-radiographic axial spondyloarthritis (nr-axSpA). Study nr-axSpA I evaluated&#160;<br/>patients with active&#160;nr-axSpA. Study nr-axSpA II was a treatment withdrawal study in active&#160;nr-axSpA<br/>patients who achieved remission during open-label treatment with Humira.</p>
<p style="position:absolute;top:878px;left:106px;white-space:nowrap" class="ft1242">Study nr-axSpA I</p>
<p style="position:absolute;top:916px;left:106px;white-space:nowrap" class="ft1247">In Study nr-axSpA I,&#160;Humira 40&#160;mg&#160;every other week was assessed in 185 patients in&#160;a&#160;randomised,&#160;<br/>12&#160;week double&#160;-&#160;blind, placebo&#160;-&#160;controlled&#160;study in patients with active&#160;nr-axSpA&#160;(mean baseline score&#160;<br/>of&#160;disease activity [Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)] was 6.4 for patients&#160;<br/>treated with Humira and 6.5 for those on placebo) who have had an inadequate response to or intolerance&#160;<br/>to&#160;</p>
<p style="position:absolute;top:991px;left:123px;white-space:nowrap" class="ft1246">&#160;1 NSAIDs, or a contraindication for NSAIDs.</p>
<p style="position:absolute;top:1031px;left:106px;white-space:nowrap" class="ft1244">Thirty-three (18%)&#160;patients were treated concomitantly with disease modifying anti-rheumatic drugs, and&#160;<br/>146 (79%) patients with NSAIDs at baseline. The double-blind period was followed by an open-label&#160;<br/>period during which patients receive Humira 40&#160;mg&#160;every other week subcutaneously for up to an&#160;</p>
</div>
<!-- Page 125 -->
<a name="125"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft12527{font-size:15px;font-family:HORGHZ+TimesNewRoman,Bold;color:#000000;}
	.ft12528{font-size:17px;font-family:HORGHZ+TimesNewRoman;color:#221e1f;}
	.ft12529{font-size:17px;line-height:19px;font-family:HORGHZ+TimesNewRoman;color:#221e1f;}
	.ft12530{font-size:17px;line-height:18px;font-family:HORGHZ+TimesNewRoman;color:#221e1f;}
-->
</style>
<div id="page125-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1250">125</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft1255">additional 144&#160;weeks. Week&#160;12 results showed statistically significant improvement of the signs and&#160;<br/>symptoms of active&#160;nr-axSpA&#160;in patients treated with Humira compared to placebo (Table&#160;13).</p>
<p style="position:absolute;top:143px;left:428px;white-space:nowrap" class="ft1251"><b>Table&#160;13</b></p>
<p style="position:absolute;top:162px;left:251px;white-space:nowrap" class="ft1251"><b>Efficacy Response in Placebo-Controlled&#160;Study&#160;nr-axSpA I</b></p>
<p style="position:absolute;top:201px;left:112px;white-space:nowrap" class="ft12519"><b>Double-Blind<br/>Response at Week&#160;12</b></p>
<p style="position:absolute;top:200px;left:572px;white-space:nowrap" class="ft12527"><b>Placebo</b></p>
<p style="position:absolute;top:218px;left:580px;white-space:nowrap" class="ft12527"><b>N=94</b></p>
<p style="position:absolute;top:200px;left:712px;white-space:nowrap" class="ft12527"><b>Humira</b></p>
<p style="position:absolute;top:218px;left:720px;white-space:nowrap" class="ft12527"><b>N=91</b></p>
<p style="position:absolute;top:239px;left:112px;white-space:nowrap" class="ft1252">ASASa&#160;40</p>
<p style="position:absolute;top:239px;left:582px;white-space:nowrap" class="ft1252">15%</p>
<p style="position:absolute;top:239px;left:710px;white-space:nowrap" class="ft1252">36%***</p>
<p style="position:absolute;top:259px;left:112px;white-space:nowrap" class="ft1252">ASAS 20</p>
<p style="position:absolute;top:259px;left:582px;white-space:nowrap" class="ft1252">31%</p>
<p style="position:absolute;top:259px;left:714px;white-space:nowrap" class="ft1252">52%**</p>
<p style="position:absolute;top:279px;left:112px;white-space:nowrap" class="ft1252">ASAS 5/6</p>
<p style="position:absolute;top:279px;left:586px;white-space:nowrap" class="ft1252">6%</p>
<p style="position:absolute;top:279px;left:710px;white-space:nowrap" class="ft1252">31%***</p>
<p style="position:absolute;top:298px;left:112px;white-space:nowrap" class="ft1252">ASAS Partial Remission</p>
<p style="position:absolute;top:298px;left:586px;white-space:nowrap" class="ft1252">5%</p>
<p style="position:absolute;top:298px;left:714px;white-space:nowrap" class="ft1252">&#160;&#160;16%*</p>
<p style="position:absolute;top:318px;left:112px;white-space:nowrap" class="ft1252">BASDAIb&#160;50</p>
<p style="position:absolute;top:318px;left:582px;white-space:nowrap" class="ft1252">15%</p>
<p style="position:absolute;top:318px;left:708px;white-space:nowrap" class="ft1252">&#160; &#160;35%**</p>
<p style="position:absolute;top:338px;left:112px;white-space:nowrap" class="ft1252">ASDASc,d,e</p>
<p style="position:absolute;top:338px;left:584px;white-space:nowrap" class="ft1252">-0.3</p>
<p style="position:absolute;top:338px;left:712px;white-space:nowrap" class="ft1252">-1.0***</p>
<p style="position:absolute;top:357px;left:112px;white-space:nowrap" class="ft1252">ASDAS Inactive Disease</p>
<p style="position:absolute;top:357px;left:586px;white-space:nowrap" class="ft1252">4%</p>
<p style="position:absolute;top:357px;left:710px;white-space:nowrap" class="ft1252">24%***</p>
<p style="position:absolute;top:377px;left:112px;white-space:nowrap" class="ft1252">hs-CRPd,f,g</p>
<p style="position:absolute;top:377px;left:584px;white-space:nowrap" class="ft1252">-0.3</p>
<p style="position:absolute;top:377px;left:712px;white-space:nowrap" class="ft1252">-4.7***</p>
<p style="position:absolute;top:397px;left:112px;white-space:nowrap" class="ft1252">SPARCCh&#160;MRI Sacroiliac Jointsd,i</p>
<p style="position:absolute;top:397px;left:584px;white-space:nowrap" class="ft1252">-0.6</p>
<p style="position:absolute;top:397px;left:716px;white-space:nowrap" class="ft1252">-3.2**</p>
<p style="position:absolute;top:417px;left:112px;white-space:nowrap" class="ft1252">SPARCC MRI Spined,j</p>
<p style="position:absolute;top:417px;left:584px;white-space:nowrap" class="ft1252">-0.2</p>
<p style="position:absolute;top:417px;left:716px;white-space:nowrap" class="ft1252">-1.8**</p>
<p style="position:absolute;top:435px;left:112px;white-space:nowrap" class="ft1259">a&#160;Assessment of SpondyloArthritis international Society</p>
<p style="position:absolute;top:454px;left:113px;white-space:nowrap" class="ft1259">b&#160;Bath Ankylosing Spondylitis Disease Activity Index</p>
<p style="position:absolute;top:473px;left:113px;white-space:nowrap" class="ft1259">c&#160;Ankylosing Spondylitis Disease Activity Score</p>
<p style="position:absolute;top:492px;left:113px;white-space:nowrap" class="ft1259">d&#160;mean change from baseline</p>
<p style="position:absolute;top:511px;left:113px;white-space:nowrap" class="ft1259">e&#160;n=91 placebo and n=87 Humira</p>
<p style="position:absolute;top:530px;left:113px;white-space:nowrap" class="ft1259">f&#160;high sensitivity C-Reactive Protein (mg/L)</p>
<p style="position:absolute;top:549px;left:113px;white-space:nowrap" class="ft1259">g&#160;n=73 placebo and n=70 Humira</p>
<p style="position:absolute;top:568px;left:113px;white-space:nowrap" class="ft1259">h&#160;Spondyloarthritis Research Consortium of Canada</p>
<p style="position:absolute;top:587px;left:113px;white-space:nowrap" class="ft1259">i&#160;n=84 placebo and Humira</p>
<p style="position:absolute;top:606px;left:113px;white-space:nowrap" class="ft1254">j&#160;n=82 placebo and n=85 Humira<br/>***, **, * Statistically significant at p &lt;&#160;0.001, &lt;&#160;0.01, and&#160;&lt;&#160;0.05, respectively, for all comparisons&#160;<br/>between Humira and placebo.</p>
<p style="position:absolute;top:683px;left:112px;white-space:nowrap" class="ft1255">In the open-label&#160;extension, improvement in the signs and symptoms was maintained with Humira&#160;<br/>therapy through Week&#160;156.</p>
<p style="position:absolute;top:740px;left:112px;white-space:nowrap" class="ft1252">Inhibition of inflammation</p>
<p style="position:absolute;top:780px;left:112px;white-space:nowrap" class="ft12530">Significant improvement of signs of inflammation as measured by hs-CRP and MRI of both Sacroiliac&#160;<br/>Joints and the Spine was&#160;maintained in Humira-treated patients through Week&#160;156 and Week&#160;104,&#160;<br/>respectively.</p>
<p style="position:absolute;top:856px;left:112px;white-space:nowrap" class="ft1252">Quality of life and physical function</p>
<p style="position:absolute;top:894px;left:106px;white-space:nowrap" class="ft1254">Health-related quality of life and physical function were assessed using the HAQ-S and the SF-36&#160;<br/>questionnaires. Humira showed statistically significantly greater improvement in the HAQ-S total score&#160;<br/>and the SF-36 Physical Component Score (PCS) from baseline to Week&#160;12 compared to placebo.&#160;<br/>Improvement in health-related quality of life and physical function was maintained during the open-label&#160;<br/>extension through Week&#160;156.</p>
<p style="position:absolute;top:1008px;left:106px;white-space:nowrap" class="ft1252">Study nr-axSpA&#160;II</p>
<p style="position:absolute;top:1046px;left:106px;white-space:nowrap" class="ft1257">673 patients with active nr-axSpA (mean baseline disease activity [BASDAI] was 7.0) who had an&#160;<br/>inadequate response to&#160;</p>
<p style="position:absolute;top:1064px;left:260px;white-space:nowrap" class="ft1256">&#160;2 NSAIDs, or an intolerance to or a contraindication for NSAIDs&#160;enrolled into&#160;</p>
</div>
<!-- Page 126 -->
<a name="126"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft12631{font-size:15px;font-family:HORGHZ+TimesNewRoman,Bold;color:#000000;-moz-transform: matrix(         0,         -1,          1,          0, 0, 0);-webkit-transform: matrix(         0,         -1,          1,          0, 0, 0);-o-transform: matrix(         0,         -1,          1,          0, 0, 0);-ms-transform: matrix(         0,         -1,          1,          0, 0, 0);-moz-transform-origin: left 75%;-webkit-transform-origin: left 75%;-o-transform-origin: left 75%;-ms-transform-origin: left 75%;}
	.ft12632{font-size:15px;font-family:HORGHZ+TimesNewRoman;color:#000000;}
-->
</style>
<div id="page126-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1260">126</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft1264">the open-label period of Study nr-axSpA&#160;II during which they received&#160;Humira&#160;40&#160;mg eow for 28 weeks.&#160;<br/>These patients also had objective evidence of inflammation in the sacroiliac joints or spine on MRI or&#160;<br/>elevated hs-CRP.&#160;Patients who achieved sustained&#160;remission for at least 12 weeks (N=305)&#160;(ASDAS &lt;&#160;1.3&#160;<br/>at Weeks 16, 20, 24, and 28) during the open-label period were then randomized to receive either&#160;<br/>continued treatment with Humira 40&#160;mg&#160;eow&#160;(N=152)&#160;or placebo&#160;(N=153)&#160;for an additional 40 weeks in a&#160;<br/>double-blind, placebo-controlled period (total study duration 68 weeks).&#160;Subjects who flared during the&#160;<br/>double-blind period were allowed&#160;Humira 40&#160;mg&#160;eow&#160;rescue therapy&#160;for at least 12 weeks.</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft1264">The primary efficacy endpoint was the proportion of patients with no flare&#160;by Week 68&#160;of the&#160;study.&#160;Flare&#160;<br/>was defined as ASDAS&#160;≥&#160;2.1 at two consecutive visits four weeks apart. A greater proportion of patients&#160;<br/>on Humira had no disease flare during the double-blind period, when compared with those on placebo&#160;<br/>(70.4%&#160;vs. 47.1%,&#160;p&lt;0.001)&#160;(Figure&#160;1).&#160;</p>
<p style="position:absolute;top:333px;left:239px;white-space:nowrap" class="ft1261"><b>Figure&#160;1: Kaplan-Meier Curves Summarizing Time to Flare in&#160;</b></p>
<p style="position:absolute;top:352px;left:393px;white-space:nowrap" class="ft1261"><b>Study nr-axSpA&#160;II</b></p>
<p style="position:absolute;top:675px;left:128px;white-space:nowrap" class="ft12631"><b>&#160;&#160;&#160;</b></p>
<p style="position:absolute;top:663px;left:128px;white-space:nowrap" class="ft12631"><b>&#160;&#160;&#160;</b></p>
<p style="position:absolute;top:652px;left:128px;white-space:nowrap" class="ft12631"><b>&#160;&#160;&#160;</b></p>
<p style="position:absolute;top:641px;left:128px;white-space:nowrap" class="ft12631"><b>&#160;&#160;&#160;</b></p>
<p style="position:absolute;top:630px;left:128px;white-space:nowrap" class="ft12631"><b>&#160;&#160;&#160;</b></p>
<p style="position:absolute;top:618px;left:128px;white-space:nowrap" class="ft12631"><b>&#160;&#160;&#160;</b></p>
<p style="position:absolute;top:607px;left:128px;white-space:nowrap" class="ft12631"><b>&#160;P</b></p>
<p style="position:absolute;top:594px;left:128px;white-space:nowrap" class="ft12631"><b>R</b></p>
<p style="position:absolute;top:583px;left:128px;white-space:nowrap" class="ft12631"><b>O</b></p>
<p style="position:absolute;top:572px;left:128px;white-space:nowrap" class="ft12631"><b>B</b></p>
<p style="position:absolute;top:561px;left:128px;white-space:nowrap" class="ft12631"><b>A</b></p>
<p style="position:absolute;top:551px;left:128px;white-space:nowrap" class="ft12631"><b>B</b></p>
<p style="position:absolute;top:541px;left:128px;white-space:nowrap" class="ft12631"><b>IL</b></p>
<p style="position:absolute;top:525px;left:128px;white-space:nowrap" class="ft12631"><b>IT</b></p>
<p style="position:absolute;top:509px;left:128px;white-space:nowrap" class="ft12631"><b>Y</b></p>
<p style="position:absolute;top:498px;left:128px;white-space:nowrap" class="ft12631"><b>&#160;O</b></p>
<p style="position:absolute;top:483px;left:128px;white-space:nowrap" class="ft12631"><b>F</b></p>
<p style="position:absolute;top:474px;left:128px;white-space:nowrap" class="ft12631"><b>&#160;N</b></p>
<p style="position:absolute;top:459px;left:128px;white-space:nowrap" class="ft12631"><b>O</b></p>
<p style="position:absolute;top:448px;left:128px;white-space:nowrap" class="ft12631"><b>&#160;F</b></p>
<p style="position:absolute;top:435px;left:128px;white-space:nowrap" class="ft12631"><b>L</b></p>
<p style="position:absolute;top:425px;left:128px;white-space:nowrap" class="ft12631"><b>A</b></p>
<p style="position:absolute;top:414px;left:128px;white-space:nowrap" class="ft12631"><b>R</b></p>
<p style="position:absolute;top:403px;left:128px;white-space:nowrap" class="ft12631"><b>E</b></p>
<p style="position:absolute;top:726px;left:422px;white-space:nowrap" class="ft12627"><b>TIME (WEEKS)</b></p>
<p style="position:absolute;top:743px;left:114px;white-space:nowrap" class="ft12632">&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160;Treatment &#160; &#160; &#160;</p>
<p style="position:absolute;top:743px;left:378px;white-space:nowrap" class="ft12632">Placebo &#160; &#160;&#160;</p>
<p style="position:absolute;top:743px;left:498px;white-space:nowrap" class="ft12632">Humira &#160; &#160;&#160;∆ Censored</p>
<p style="position:absolute;top:779px;left:106px;white-space:nowrap" class="ft1262">Note: P = Placebo (Number at Risk (flared)); A = HUMIRA (Number at Risk (flared)).</p>
<p style="position:absolute;top:818px;left:106px;white-space:nowrap" class="ft1264">Among the 68 patients who flared in the group allocated to treatment withdrawal, 65 completed 12 weeks&#160;<br/>of rescue therapy with Humira, out of which 37&#160;(56.9%)&#160;had&#160;regained remission (ASDAS &lt;&#160;1.3) after&#160;<br/>12&#160;weeks of restarting the open-label treatment.</p>
<p style="position:absolute;top:894px;left:106px;white-space:nowrap" class="ft1264">By&#160;Week&#160;68,&#160;patients receiving continuous Humira treatment&#160;showed statistically significant&#160;greater<br/>improvement of the signs and symptoms of active nr-axSpA&#160;as&#160;compared to patients allocated to treatment&#160;<br/>withdrawal during the double-blind period of the study (Table&#160;14).</p>
</div>
<!-- Page 127 -->
<a name="127"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page127-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1270">127</p>
<p style="position:absolute;top:86px;left:455px;white-space:nowrap" class="ft1271"><b>Table 14</b></p>
<p style="position:absolute;top:105px;left:160px;white-space:nowrap" class="ft1271"><b>Efficacy Response in Placebo-Controlled&#160;Period for Study nr-axSpA II</b></p>
<p style="position:absolute;top:144px;left:112px;white-space:nowrap" class="ft12719"><b>Double-Blind<br/>Response at Week&#160;68</b></p>
<p style="position:absolute;top:143px;left:580px;white-space:nowrap" class="ft12727"><b>Placebo</b></p>
<p style="position:absolute;top:161px;left:584px;white-space:nowrap" class="ft12727"><b>N=153</b></p>
<p style="position:absolute;top:143px;left:716px;white-space:nowrap" class="ft12727"><b>Humira</b></p>
<p style="position:absolute;top:161px;left:720px;white-space:nowrap" class="ft12727"><b>N=152</b></p>
<p style="position:absolute;top:182px;left:112px;white-space:nowrap" class="ft1272">ASASa,b&#160;20</p>
<p style="position:absolute;top:182px;left:583px;white-space:nowrap" class="ft1272">47.1%</p>
<p style="position:absolute;top:182px;left:707px;white-space:nowrap" class="ft1272">70.4%***</p>
<p style="position:absolute;top:202px;left:112px;white-space:nowrap" class="ft1272">ASASa,b&#160;40</p>
<p style="position:absolute;top:202px;left:583px;white-space:nowrap" class="ft1272">45.8%</p>
<p style="position:absolute;top:202px;left:707px;white-space:nowrap" class="ft1272">65.8%***</p>
<p style="position:absolute;top:222px;left:112px;white-space:nowrap" class="ft1272">ASASa&#160;Partial Remission</p>
<p style="position:absolute;top:222px;left:583px;white-space:nowrap" class="ft1272">26.8%</p>
<p style="position:absolute;top:222px;left:711px;white-space:nowrap" class="ft1272">42.1%**</p>
<p style="position:absolute;top:242px;left:112px;white-space:nowrap" class="ft1272">ASDASc&#160;Inactive Disease</p>
<p style="position:absolute;top:242px;left:583px;white-space:nowrap" class="ft1272">33.3%</p>
<p style="position:absolute;top:242px;left:707px;white-space:nowrap" class="ft1272">57.2%***</p>
<p style="position:absolute;top:261px;left:112px;white-space:nowrap" class="ft1272">Partial Flared</p>
<p style="position:absolute;top:261px;left:583px;white-space:nowrap" class="ft1272">64.1%</p>
<p style="position:absolute;top:261px;left:707px;white-space:nowrap" class="ft1272">40.8%***</p>
<p style="position:absolute;top:279px;left:112px;white-space:nowrap" class="ft1279">a&#160;Assessment of SpondyloArthritis international Society</p>
<p style="position:absolute;top:298px;left:113px;white-space:nowrap" class="ft1279">b&#160;Baseline is defined as open label baseline when patients have active disease.</p>
<p style="position:absolute;top:318px;left:113px;white-space:nowrap" class="ft1279">c&#160;Ankylosing Spondylitis Disease Activity Score</p>
<p style="position:absolute;top:337px;left:112px;white-space:nowrap" class="ft1279">d&#160;Partial flare is defined as&#160;ASDAS&#160;≥ 1.3 but &lt; 2.1&#160;at 2 consecutive visits.</p>
<p style="position:absolute;top:357px;left:113px;white-space:nowrap" class="ft1274">***, **&#160;Statistically significant at p &lt;&#160;0.001&#160;and&#160;&lt;&#160;0.01, respectively, for all comparisons between&#160;<br/>Humira and placebo.</p>
<p style="position:absolute;top:414px;left:106px;white-space:nowrap" class="ft1273"><i>Psoriatic arthritis</i></p>
<p style="position:absolute;top:452px;left:106px;white-space:nowrap" class="ft1274">Humira, 40&#160;mg&#160;every other week, was studied in patients with moderately to severely active psoriatic&#160;<br/>arthritis in two placebo-controlled studies, PsA studies I and&#160;II. &#160;PsA study I with 24&#160;week&#160;duration,&#160;<br/>treated 313 adult patients who had an inadequate response to non-steroidal anti-inflammatory drug therapy&#160;<br/>and of these, approximately 50% were taking methotrexate. PsA study II with 12-week&#160;duration, treated&#160;<br/>100 patients who had an inadequate response to DMARD therapy. Upon completion of both studies, 383&#160;<br/>patients enrolled in an open-label extension study, in which 40&#160;mg Humira was administered every other&#160;<br/>week.</p>
<p style="position:absolute;top:603px;left:106px;white-space:nowrap" class="ft1274">There is insufficient evidence of the efficacy of Humira in patients with ankylosing spondylitis-like&#160;<br/>psoriatic arthropathy due to the small number of patients studied.&#160;</p>
<p style="position:absolute;top:660px;left:429px;white-space:nowrap" class="ft1271"><b>Table&#160;15</b></p>
<p style="position:absolute;top:679px;left:233px;white-space:nowrap" class="ft1271"><b>ACR Response in Placebo-Controlled Psoriatic Arthritis Studies</b></p>
<p style="position:absolute;top:698px;left:387px;white-space:nowrap" class="ft1271"><b>(Percent of Patients)</b></p>
<p style="position:absolute;top:737px;left:385px;white-space:nowrap" class="ft1272">PsA Study I</p>
<p style="position:absolute;top:737px;left:581px;white-space:nowrap" class="ft1272">PsA Study II</p>
<p style="position:absolute;top:766px;left:198px;white-space:nowrap" class="ft1272">Response</p>
<p style="position:absolute;top:757px;left:350px;white-space:nowrap" class="ft1272">Placebo</p>
<p style="position:absolute;top:776px;left:353px;white-space:nowrap" class="ft1272">N=162</p>
<p style="position:absolute;top:757px;left:450px;white-space:nowrap" class="ft1272">Humira</p>
<p style="position:absolute;top:776px;left:452px;white-space:nowrap" class="ft1272">N=151</p>
<p style="position:absolute;top:757px;left:549px;white-space:nowrap" class="ft1272">Placebo&#160;</p>
<p style="position:absolute;top:776px;left:556px;white-space:nowrap" class="ft1272">N=49</p>
<p style="position:absolute;top:757px;left:649px;white-space:nowrap" class="ft1272">Humira</p>
<p style="position:absolute;top:776px;left:656px;white-space:nowrap" class="ft1272">N=51</p>
<p style="position:absolute;top:796px;left:198px;white-space:nowrap" class="ft1272">ACR 20&#160;</p>
<p style="position:absolute;top:814px;left:240px;white-space:nowrap" class="ft1272">Week&#160;12</p>
<p style="position:absolute;top:814px;left:361px;white-space:nowrap" class="ft1272">14%</p>
<p style="position:absolute;top:814px;left:452px;white-space:nowrap" class="ft1272">58%***</p>
<p style="position:absolute;top:814px;left:559px;white-space:nowrap" class="ft1272">16%</p>
<p style="position:absolute;top:814px;left:657px;white-space:nowrap" class="ft1272">39%*</p>
<p style="position:absolute;top:833px;left:240px;white-space:nowrap" class="ft1272">Week&#160;24</p>
<p style="position:absolute;top:833px;left:361px;white-space:nowrap" class="ft1272">15%</p>
<p style="position:absolute;top:833px;left:452px;white-space:nowrap" class="ft1272">57%***</p>
<p style="position:absolute;top:833px;left:561px;white-space:nowrap" class="ft1272">N/A</p>
<p style="position:absolute;top:833px;left:660px;white-space:nowrap" class="ft1272">N/A</p>
<p style="position:absolute;top:852px;left:198px;white-space:nowrap" class="ft1272">ACR 50&#160;</p>
<p style="position:absolute;top:871px;left:240px;white-space:nowrap" class="ft1272">Week&#160;12</p>
<p style="position:absolute;top:871px;left:365px;white-space:nowrap" class="ft1272">4%</p>
<p style="position:absolute;top:871px;left:452px;white-space:nowrap" class="ft1272">36%***</p>
<p style="position:absolute;top:871px;left:564px;white-space:nowrap" class="ft1272">2%</p>
<p style="position:absolute;top:871px;left:651px;white-space:nowrap" class="ft1272">25%***</p>
<p style="position:absolute;top:890px;left:240px;white-space:nowrap" class="ft1272">Week&#160;24</p>
<p style="position:absolute;top:890px;left:365px;white-space:nowrap" class="ft1272">6%</p>
<p style="position:absolute;top:890px;left:452px;white-space:nowrap" class="ft1272">39%***</p>
<p style="position:absolute;top:890px;left:561px;white-space:nowrap" class="ft1272">N/A</p>
<p style="position:absolute;top:890px;left:660px;white-space:nowrap" class="ft1272">N/A</p>
<p style="position:absolute;top:909px;left:198px;white-space:nowrap" class="ft1272">ACR 70&#160;</p>
<p style="position:absolute;top:928px;left:240px;white-space:nowrap" class="ft1272">Week&#160;12</p>
<p style="position:absolute;top:928px;left:365px;white-space:nowrap" class="ft1272">1%</p>
<p style="position:absolute;top:928px;left:452px;white-space:nowrap" class="ft1272">20%***</p>
<p style="position:absolute;top:928px;left:564px;white-space:nowrap" class="ft1272">0%</p>
<p style="position:absolute;top:928px;left:655px;white-space:nowrap" class="ft1272">14%&#160;*</p>
<p style="position:absolute;top:947px;left:240px;white-space:nowrap" class="ft1272">Week&#160;24</p>
<p style="position:absolute;top:947px;left:365px;white-space:nowrap" class="ft1272">1%</p>
<p style="position:absolute;top:947px;left:452px;white-space:nowrap" class="ft1272">23%***</p>
<p style="position:absolute;top:947px;left:561px;white-space:nowrap" class="ft1272">N/A</p>
<p style="position:absolute;top:947px;left:660px;white-space:nowrap" class="ft1272">N/A</p>
<p style="position:absolute;top:967px;left:198px;white-space:nowrap" class="ft1274">***&#160;p&#160;&lt;&#160;0.001 for all comparisons between Humira and placebo<br/>*</p>
<p style="position:absolute;top:986px;left:240px;white-space:nowrap" class="ft1272">p&#160;&lt;&#160;0.05 for all comparisons between Humira and placebo &#160;</p>
<p style="position:absolute;top:1005px;left:198px;white-space:nowrap" class="ft1272">N/A &#160;not applicable</p>
<p style="position:absolute;top:1043px;left:106px;white-space:nowrap" class="ft1274">ACR responses in PsA study I were similar with and without concomitant methotrexate therapy.<br/>ACR responses&#160;were&#160;maintained in the open-label extension study for up to 136&#160;weeks.</p>
</div>
<!-- Page 128 -->
<a name="128"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page128-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1280">128</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft1284">Radiographic changes were assessed in the psoriatic arthritis studies. Radiographs of hands, wrists, and&#160;<br/>feet were obtained at baseline and Week&#160;24 during the double-blind period when&#160;patients were on Humira&#160;<br/>or placebo and at Week&#160;48 when all patients were on open-label Humira. A modified Total Sharp Score&#160;<br/>(mTSS), which included distal interphalangeal joints (i.e. not identical to the TSS used for rheumatoid&#160;<br/>arthritis), was used.</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft1285">Humira treatment reduced the rate of progression of peripheral joint damage compared with placebo&#160;<br/>treatment as measured by change from baseline in mTSS &#160;(mean ± SD) 0.8 ± 2.5 in the placebo group (at&#160;<br/>Week&#160;24) compared with 0.0&#160;±&#160;1.9; (p&lt;&#160;0.001) in the Humira group (at Week&#160;48).</p>
<p style="position:absolute;top:276px;left:106px;white-space:nowrap" class="ft1284">In subjects treated with Humira with no radiographic progression from baseline to Week&#160;48 (n=102), 84%&#160;<br/>continued to show no radiographic progression through 144&#160;weeks&#160;of treatment.<br/>Humira treated patients demonstrated statistically significant improvement in physical function as assessed&#160;<br/>by HAQ and Short Form Health Survey (SF 36) compared to placebo at Week&#160;24. Improved&#160;physical&#160;<br/>function continued during the open label extension up to Week&#160;136.</p>
<p style="position:absolute;top:390px;left:106px;white-space:nowrap" class="ft1283"><i>Psoriasis</i></p>
<p style="position:absolute;top:429px;left:106px;white-space:nowrap" class="ft1282">The safety and efficacy of&#160;Humira were studied in adult patients with chronic plaque psoriasis (</p>
<p style="position:absolute;top:427px;left:737px;white-space:nowrap" class="ft1286">&#160;10%&#160;</p>
<p style="position:absolute;top:449px;left:106px;white-space:nowrap" class="ft1282">BSA involvement and Psoriasis Area and Severity Index (PASI)&#160;</p>
<p style="position:absolute;top:447px;left:535px;white-space:nowrap" class="ft1286">&#160;12 or&#160;&#160;10) who were candidates for&#160;</p>
<p style="position:absolute;top:468px;left:106px;white-space:nowrap" class="ft1284">systemic therapy or phototherapy in randomised, double-blind studies. 73% of patients enrolled in&#160;<br/>Psoriasis Studies I and II had received prior systemic therapy or phototherapy. The safety and efficacy of&#160;<br/>Humira were also studied in adult patients with moderate to severe&#160;chronic plaque psoriasis with&#160;<br/>concomitant hand and/or foot psoriasis who were candidates for systemic therapy in a randomised double-<br/>blind study (Psoriasis Study III). &#160;</p>
<p style="position:absolute;top:580px;left:106px;white-space:nowrap" class="ft1287">Psoriasis Study I (REVEAL) evaluated 1,212 patients within three treatment periods. In period A, patients&#160;<br/>received placebo or Humira at an initial dose&#160;of 80&#160;mg&#160;followed by 40&#160;mg&#160;every other week starting one&#160;<br/>week after the initial dose. After 16&#160;weeks&#160;of therapy, patients who achieved at least a PASI 75 response&#160;<br/>(PASI score improvement of at least 75% relative to baseline), entered period B and received&#160;open-label&#160;<br/>40&#160;mg Humira every other week. Patients who maintained&#160;</p>
<p style="position:absolute;top:655px;left:494px;white-space:nowrap" class="ft1286">PASI 75 response at Week&#160;33 and were&#160;</p>
<p style="position:absolute;top:676px;left:106px;white-space:nowrap" class="ft1285">originally randomised to active therapy in Period A, were re-randomised in period C to receive 40 mg&#160;<br/>Humira every other week or placebo for an additional 19&#160;weeks. Across all treatment groups, the mean&#160;<br/>baseline PASI score was 18.9 and the baseline Physician’s Global Assessment (PGA) score ranged from&#160;<br/>“moderate” (53% of subjects included) to “severe” (41%) to “very severe” (6%).</p>
<p style="position:absolute;top:771px;left:106px;white-space:nowrap" class="ft1285">Psoriasis Study II (CHAMPION) compared the efficacy and safety of Humira&#160;<i>versus&#160;</i>methotrexate and&#160;<br/>placebo in 271 patients.&#160;Patients received placebo, an initial dose of MTX 7.5&#160;mg and thereafter dose&#160;<br/>increases up to Week&#160;12, with a maximum dose of 25&#160;mg&#160;or an initial dose of 80&#160;mg&#160;Humira followed by&#160;<br/>40&#160;mg&#160;every other week (starting one week after the initial dose) for 16&#160;weeks. There are no data available&#160;<br/>comparing Humira and MTX beyond 16&#160;weeks of therapy. Patients receiving MTX who achieved a&#160;</p>
<p style="position:absolute;top:865px;left:106px;white-space:nowrap" class="ft1284">PASI 50 response at Week&#160;8 and/or 12&#160;did not receive further dose increases. Across all treatment&#160;<br/>groups, the mean baseline&#160;PASI&#160;score was 19.7 and the baseline PGA score ranged from “mild” (&lt;1%) to&#160;<br/>“moderate” (48%) to “severe” (46%) to “very severe” (6%).</p>
<p style="position:absolute;top:943px;left:106px;white-space:nowrap" class="ft1284">Patients participating in all Phase&#160;2 and Phase 3 psoriasis studies were eligible to enrol into an open-label&#160;<br/>extension trial, where Humira was given for at least an additional 108&#160;weeks.</p>
<p style="position:absolute;top:1000px;left:106px;white-space:nowrap" class="ft1285">In Psoriasis Studies I and II, a primary endpoint was the proportion of patients who achieved a PASI 75&#160;<br/>response from baseline at Week&#160;16&#160;(see Tables&#160;16&#160;and&#160;17).</p>
</div>
<!-- Page 129 -->
<a name="129"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page129-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1290">129</p>
<p style="position:absolute;top:86px;left:429px;white-space:nowrap" class="ft1291"><b>Table&#160;16</b></p>
<p style="position:absolute;top:105px;left:271px;white-space:nowrap" class="ft1291"><b>Ps Study I (REVEAL) &#160;-&#160;Efficacy Results at 16&#160;Weeks</b></p>
<p style="position:absolute;top:125px;left:455px;white-space:nowrap" class="ft1291"><b>Placebo</b></p>
<p style="position:absolute;top:144px;left:459px;white-space:nowrap" class="ft1291"><b>N=398</b></p>
<p style="position:absolute;top:163px;left:462px;white-space:nowrap" class="ft1291"><b>n&#160;(%)</b></p>
<p style="position:absolute;top:125px;left:564px;white-space:nowrap" class="ft1291"><b>Humira 40 mg eow</b></p>
<p style="position:absolute;top:144px;left:608px;white-space:nowrap" class="ft1291"><b>N=814</b></p>
<p style="position:absolute;top:163px;left:611px;white-space:nowrap" class="ft1291"><b>n&#160;(%)</b></p>
<p style="position:absolute;top:184px;left:207px;white-space:nowrap" class="ft1291"><b>&#160; &#160;&#160;</b></p>
<p style="position:absolute;top:182px;left:223px;white-space:nowrap" class="ft1296"><b>PASI 75a</b></p>
<p style="position:absolute;top:183px;left:456px;white-space:nowrap" class="ft1292">26 (6.5)</p>
<p style="position:absolute;top:183px;left:594px;white-space:nowrap" class="ft1292">578 (70.9)b</p>
<p style="position:absolute;top:203px;left:207px;white-space:nowrap" class="ft1291"><b>&#160; &#160;&#160;PASI 100</b></p>
<p style="position:absolute;top:203px;left:460px;white-space:nowrap" class="ft1292">3 (0.8)</p>
<p style="position:absolute;top:203px;left:594px;white-space:nowrap" class="ft1292">163 (20.0)b</p>
<p style="position:absolute;top:223px;left:207px;white-space:nowrap" class="ft1291"><b>&#160; &#160;&#160;PGA:&#160;Clear/minimal</b></p>
<p style="position:absolute;top:223px;left:456px;white-space:nowrap" class="ft1292">17 (4.3)</p>
<p style="position:absolute;top:223px;left:594px;white-space:nowrap" class="ft1292">506 (62.2)b</p>
<p style="position:absolute;top:241px;left:207px;white-space:nowrap" class="ft1297">a&#160;Percent of patients achieving PASI75 response was calculated as centre-<br/>adjusted rate</p>
<p style="position:absolute;top:279px;left:207px;white-space:nowrap" class="ft1299">b&#160;p&lt;0.001, Humira vs.&#160;Placebo</p>
<p style="position:absolute;top:314px;left:429px;white-space:nowrap" class="ft1291"><b>Table&#160;17</b></p>
<p style="position:absolute;top:333px;left:264px;white-space:nowrap" class="ft1291"><b>Ps Study II (CHAMPION) Efficacy Results at 16&#160;Weeks</b></p>
<p style="position:absolute;top:372px;left:353px;white-space:nowrap" class="ft1291"><b>Placebo</b></p>
<p style="position:absolute;top:391px;left:361px;white-space:nowrap" class="ft1291"><b>N=53</b></p>
<p style="position:absolute;top:410px;left:360px;white-space:nowrap" class="ft1291"><b>n&#160;(%)</b></p>
<p style="position:absolute;top:372px;left:474px;white-space:nowrap" class="ft1291"><b>MTX</b></p>
<p style="position:absolute;top:391px;left:470px;white-space:nowrap" class="ft1291"><b>N=110</b></p>
<p style="position:absolute;top:410px;left:473px;white-space:nowrap" class="ft1291"><b>n&#160;(%)</b></p>
<p style="position:absolute;top:372px;left:566px;white-space:nowrap" class="ft1291"><b>Humira 40 mg eow</b></p>
<p style="position:absolute;top:391px;left:610px;white-space:nowrap" class="ft1291"><b>N=108</b></p>
<p style="position:absolute;top:410px;left:613px;white-space:nowrap" class="ft1291"><b>n&#160;(%)</b></p>
<p style="position:absolute;top:431px;left:203px;white-space:nowrap" class="ft1291"><b>&#160; &#160;&#160;</b></p>
<p style="position:absolute;top:429px;left:220px;white-space:nowrap" class="ft1296"><b>PASI 75</b></p>
<p style="position:absolute;top:430px;left:350px;white-space:nowrap" class="ft1292">10 (18.9)</p>
<p style="position:absolute;top:430px;left:463px;white-space:nowrap" class="ft1292">39 (35.5)</p>
<p style="position:absolute;top:430px;left:594px;white-space:nowrap" class="ft1292">86 (79.6)&#160;a, b</p>
<p style="position:absolute;top:451px;left:203px;white-space:nowrap" class="ft1291"><b>&#160; &#160;&#160;PASI 100</b></p>
<p style="position:absolute;top:451px;left:358px;white-space:nowrap" class="ft1292">1 (1.9)</p>
<p style="position:absolute;top:451px;left:471px;white-space:nowrap" class="ft1292">8 (7.3)</p>
<p style="position:absolute;top:451px;left:594px;white-space:nowrap" class="ft1292">18 (16.7)&#160;c, d</p>
<p style="position:absolute;top:471px;left:203px;white-space:nowrap" class="ft12915"><b>&#160; &#160;&#160;PGA:&#160;<br/>Clear/minimal</b></p>
<p style="position:absolute;top:471px;left:354px;white-space:nowrap" class="ft1292">6 (11.3)</p>
<p style="position:absolute;top:471px;left:463px;white-space:nowrap" class="ft1292">33 (30.0)</p>
<p style="position:absolute;top:471px;left:594px;white-space:nowrap" class="ft1292">79 (73.1)&#160;a, b</p>
<p style="position:absolute;top:508px;left:203px;white-space:nowrap" class="ft1299">a&#160;p&lt;0.001 Humira vs. placebo</p>
<p style="position:absolute;top:527px;left:203px;white-space:nowrap" class="ft1299">b&#160;p&lt;0.001 Humira vs. methotrexate</p>
<p style="position:absolute;top:546px;left:203px;white-space:nowrap" class="ft1299">c&#160;p&lt;0.01 Humira vs. placebo</p>
<p style="position:absolute;top:565px;left:203px;white-space:nowrap" class="ft1299">d&#160;p&lt;0.05 Humira vs. methotrexate</p>
<p style="position:absolute;top:605px;left:106px;white-space:nowrap" class="ft1294">In&#160;Psoriasis&#160;Study I, 28% of patients who were PASI 75 responders and were re-randomised to placebo at&#160;<br/>Week&#160;33 compared to 5% continuing on Humira, p&lt;0.001, experienced “loss of adequate&#160;response”&#160;(PASI&#160;<br/>score after Week&#160;33 and on or before Week&#160;52 that resulted in a &lt;PASI 50 response relative to baseline&#160;<br/>with a minimum of a 6-point increase in PASI score relative to Week&#160;33). Of the patients who lost&#160;<br/>adequate response after re-randomisation to placebo who then enrolled into the open-label extension trial,&#160;<br/>38% (25/66) and 55% (36/66) regained PASI 75 response after 12 and 24&#160;weeks of re-treatment,&#160;<br/>respectively.</p>
<p style="position:absolute;top:756px;left:106px;white-space:nowrap" class="ft1294">A total of 233 PASI 75 responders at Week&#160;16 and Week&#160;33 received continuous Humira therapy for&#160;<br/>52&#160;weeks in Psoriasis Study I, and continued Humira in the open-label extension trial. &#160;PASI 75 and PGA&#160;<br/>of clear or minimal response rates in these patients were 74.7% and 59.0%, respectively, after an&#160;<br/>additional 108&#160;weeks of open-label therapy (total of 160&#160;weeks). In an analysis in which all patients who&#160;<br/>dropped out of the study for adverse events or lack of efficacy, or who dose-escalated, were considered&#160;<br/>non-responders, PASI 75 and PGA of clear or minimal response rates in these patients&#160;were 69.6% and&#160;<br/>55.7%, respectively, after an additional 108&#160;weeks of open-label therapy (total of 160&#160;weeks).</p>
<p style="position:absolute;top:908px;left:106px;white-space:nowrap" class="ft1294">A total of 347 stable responders participated in a withdrawal and retreatment evaluation in an open-label&#160;<br/>extension study. During the withdrawal&#160;period, symptoms of psoriasis returned over time with a median&#160;<br/>time to relapse (decline to PGA “moderate” or worse) of approximately 5&#160;months. None of these patients&#160;<br/>experienced rebound during the withdrawal period. A total of 76.5% (218/285) of patients&#160;who&#160;entered the&#160;<br/>retreatment period had a response of PGA “clear” or “minimal” after 16&#160;weeks of retreatment, irrespective&#160;<br/>of&#160;whether they relapsed during withdrawal (69.1%[123/178] and 88.8% [95/107] for patients who&#160;<br/>relapsed and who did not relapse during&#160;the withdrawal period, respectively). &#160;A similar safety profile was&#160;<br/>observed during retreatment as before withdrawal.</p>
</div>
<!-- Page 130 -->
<a name="130"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page130-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1300">130</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft1304">Significant improvements at Week&#160;16 from baseline compared to placebo (Studies I and II) and MTX&#160;<br/>(Study II) were demonstrated in the DLQI (Dermatology Life Quality Index). In Study I, improvements in&#160;<br/>the physical and mental component summary scores of the SF-36 were also significant compared to&#160;<br/>placebo.</p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft1304">In an open-label extension study, for patients who dose escalated from 40&#160;mg&#160;every other&#160;week to 40&#160;mg&#160;<br/>weekly due to a PASI response below 50%, 26.4% (92/349) and 37.8% (132/349) of patients achieved&#160;<br/>PASI 75 response at Week&#160;12 and 24, respectively.</p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft1304">Psoriasis Study III (REACH)&#160;compared the efficacy and safety of Humira&#160;<i>versus&#160;</i>placebo in 72 patients&#160;<br/>with moderate to severe chronic plaque psoriasis and hand and/or foot psoriasis. Patients received an&#160;<br/>initial&#160;dose of 80&#160;mg Humira followed by 40&#160;mg every other week (starting one week after the initial dose)&#160;<br/>or placebo for 16&#160;weeks. At Week&#160;16, a statistically significantly greater proportion of patients who&#160;<br/>received Humira achieved PGA of 'clear' or 'almost clear' for the hands and/or feet compared to patients&#160;<br/>who received placebo (30.6% versus 4.3%, respectively [P&#160;=&#160;0.014]).</p>
<p style="position:absolute;top:390px;left:106px;white-space:nowrap" class="ft1304">Psoriasis Study IV compared efficacy and safety of Humira versus placebo in 217 adult patients with&#160;<br/>moderate to severe nail psoriasis. Patients received an initial dose of 80 mg Humira followed by 40&#160;mg&#160;<br/>every other week (starting one week after the initial&#160;dose) or placebo for 26&#160;weeks followed by open-label&#160;<br/>Humira treatment for an additional 26&#160;weeks. Nail psoriasis assessments included the Modified Nail&#160;<br/>Psoriasis Severity Index (mNAPSI), the Physician’s Global Assessment of Fingernail Psoriasis (PGA-F)&#160;<br/>and the Nail Psoriasis Severity Index (NAPSI) (see Table&#160;18). Humira demonstrated a treatment benefit in&#160;<br/>nail psoriasis patients with different extents of skin involvement (BSA≥10% (60% of patients) and&#160;<br/>BSA&lt;10% and&#160;≥5% (40% of patients)). &#160; &#160;</p>
<p style="position:absolute;top:560px;left:428px;white-space:nowrap" class="ft1301"><b>Table&#160;18</b></p>
<p style="position:absolute;top:579px;left:275px;white-space:nowrap" class="ft1301"><b>Ps Study IV Efficacy Results at 16, 26 and 52&#160;Weeks</b></p>
<p style="position:absolute;top:599px;left:114px;white-space:nowrap" class="ft1302">Endpoint</p>
<p style="position:absolute;top:599px;left:368px;white-space:nowrap" class="ft1302">Week 16</p>
<p style="position:absolute;top:618px;left:334px;white-space:nowrap" class="ft1302">Placebo-Controlled</p>
<p style="position:absolute;top:599px;left:540px;white-space:nowrap" class="ft1302">Week 26</p>
<p style="position:absolute;top:618px;left:506px;white-space:nowrap" class="ft1302">Placebo-Controlled</p>
<p style="position:absolute;top:599px;left:710px;white-space:nowrap" class="ft1302">Week 52</p>
<p style="position:absolute;top:618px;left:703px;white-space:nowrap" class="ft1302">Open-label</p>
<p style="position:absolute;top:638px;left:324px;white-space:nowrap" class="ft1302">Placebo</p>
<p style="position:absolute;top:657px;left:328px;white-space:nowrap" class="ft1302">N=108</p>
<p style="position:absolute;top:638px;left:413px;white-space:nowrap" class="ft1302">Humira</p>
<p style="position:absolute;top:657px;left:402px;white-space:nowrap" class="ft1302">40&#160;mg&#160;eow&#160;</p>
<p style="position:absolute;top:676px;left:415px;white-space:nowrap" class="ft1302">N=109</p>
<p style="position:absolute;top:638px;left:496px;white-space:nowrap" class="ft1302">Placebo</p>
<p style="position:absolute;top:657px;left:499px;white-space:nowrap" class="ft1302">N=108</p>
<p style="position:absolute;top:638px;left:581px;white-space:nowrap" class="ft1302">Humira</p>
<p style="position:absolute;top:657px;left:570px;white-space:nowrap" class="ft1302">40&#160;mg&#160;eow&#160;</p>
<p style="position:absolute;top:676px;left:584px;white-space:nowrap" class="ft1302">N=109</p>
<p style="position:absolute;top:638px;left:714px;white-space:nowrap" class="ft1302">Humira</p>
<p style="position:absolute;top:657px;left:703px;white-space:nowrap" class="ft1302">40&#160;mg&#160;eow&#160;</p>
<p style="position:absolute;top:676px;left:720px;white-space:nowrap" class="ft1302">N=80</p>
<p style="position:absolute;top:696px;left:114px;white-space:nowrap" class="ft1302">≥ mNAPSI 75 (%)</p>
<p style="position:absolute;top:696px;left:340px;white-space:nowrap" class="ft1302">2.9</p>
<p style="position:absolute;top:696px;left:422px;white-space:nowrap" class="ft1302">26.0a</p>
<p style="position:absolute;top:696px;left:512px;white-space:nowrap" class="ft1302">3.4</p>
<p style="position:absolute;top:696px;left:590px;white-space:nowrap" class="ft1302">46.6a</p>
<p style="position:absolute;top:696px;left:725px;white-space:nowrap" class="ft1302">65.0</p>
<p style="position:absolute;top:715px;left:114px;white-space:nowrap" class="ft1304">PGA-F clear/minimal and&#160;<br/>≥2-grade improvement (%)</p>
<p style="position:absolute;top:715px;left:340px;white-space:nowrap" class="ft1302">2.9</p>
<p style="position:absolute;top:715px;left:422px;white-space:nowrap" class="ft1302">29.7a</p>
<p style="position:absolute;top:715px;left:512px;white-space:nowrap" class="ft1302">6.9</p>
<p style="position:absolute;top:715px;left:590px;white-space:nowrap" class="ft1302">48.9a</p>
<p style="position:absolute;top:715px;left:725px;white-space:nowrap" class="ft1302">61.3</p>
<p style="position:absolute;top:754px;left:114px;white-space:nowrap" class="ft1304">Percent Change in Total&#160;<br/>Fingernail NAPSI (%)</p>
<p style="position:absolute;top:754px;left:337px;white-space:nowrap" class="ft1302">-7.8</p>
<p style="position:absolute;top:754px;left:417px;white-space:nowrap" class="ft1302">-44.2&#160;a</p>
<p style="position:absolute;top:754px;left:505px;white-space:nowrap" class="ft1302">-11.5</p>
<p style="position:absolute;top:754px;left:587px;white-space:nowrap" class="ft1302">-56.2a</p>
<p style="position:absolute;top:754px;left:722px;white-space:nowrap" class="ft1302">-72.2</p>
<p style="position:absolute;top:791px;left:114px;white-space:nowrap" class="ft1309">a&#160;p&lt;0.001, Humira&#160;<i>vs.&#160;</i>placebo&#160;</p>
<p style="position:absolute;top:831px;left:106px;white-space:nowrap" class="ft1304">Humira treated patients showed statistically significant improvements at Week&#160;26 compared with placebo&#160;<br/>in the DLQI.&#160;</p>
<p style="position:absolute;top:907px;left:106px;white-space:nowrap" class="ft1303"><i>Hidradenitis suppurativa</i></p>
<p style="position:absolute;top:945px;left:106px;white-space:nowrap" class="ft1304">The safety and efficacy of Humira were assessed in randomised, double-blind, placebo-controlled studies&#160;<br/>and an&#160;open-label extension study in adult patients with moderate to severe hidradenitis suppurativa (HS)&#160;<br/>who were&#160;intolerant, had a contraindication or an inadequate response to at least a 3-month trial of&#160;<br/>systemic antibiotic therapy. The patients in HS-I and HS-II had Hurley Stage II or III disease with at least&#160;<br/>3 abscesses or inflammatory nodules.</p>
<p style="position:absolute;top:1059px;left:106px;white-space:nowrap" class="ft1304">Study HS-I (PIONEER I) evaluated 307 patients with 2 treatment periods. In Period A, patients received&#160;<br/>placebo or Humira at an initial dose of 160&#160;mg at Week 0, 80&#160;mg at Week&#160;2, and 40&#160;mg every week&#160;</p>
</div>
<!-- Page 131 -->
<a name="131"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page131-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1310">131</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft1314">starting at Week&#160;4 to Week&#160;11. Concomitant antibiotic use was not allowed during the study. &#160;After&#160;<br/>12&#160;weeks of therapy, patients who had received Humira in Period A were re-randomised in Period B to 1&#160;<br/>of 3 treatment groups&#160;(Humira 40&#160;mg&#160;every week, Humira 40&#160;mg every other week, or placebo from&#160;<br/>Week&#160;12 to Week&#160;35). Patients who had been randomised to placebo in Period A were assigned to receive&#160;<br/>Humira 40&#160;mg&#160;every week in Period B.</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft1315">Study HS-II (PIONEER II) evaluated 326 patients with 2 treatment periods. In Period A, patients received&#160;<br/>placebo or Humira at an initial dose of 160&#160;mg at Week&#160;0 and 80&#160;mg at Week&#160;2 and 40&#160;mg&#160;every week&#160;<br/>starting at Week&#160;4 to Week&#160;11. 19.3% of patients had continued baseline oral antibiotic therapy&#160;during the&#160;<br/>study. After 12&#160;weeks&#160;of therapy, patients who had received Humira in Period A were re-randomised in&#160;<br/>Period B to 1 of 3 treatment groups (Humira 40&#160;mg&#160;every week, Humira 40&#160;mg every other week, or&#160;<br/>placebo from Week&#160;12 to Week&#160;35). Patients who&#160;had been randomised to placebo in Period A were&#160;<br/>assigned to receive placebo in Period B.</p>
<p style="position:absolute;top:352px;left:106px;white-space:nowrap" class="ft1314">Patients participating in Studies HS-I and HS-II were&#160;eligible to enrol into an open-label extension study&#160;<br/>in which Humira 40mg was administered every week.&#160;Mean exposure in all adalimumab population was&#160;<br/>762 days.&#160;Throughout all 3 studies patients used topical antiseptic wash daily.</p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft1313"><i>Clinical Response</i></p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft1314">Reduction of inflammatory lesions and prevention of worsening of abscesses and draining fistulas was&#160;<br/>assessed using Hidradenitis Suppurativa Clinical Response (HiSCR; at least a 50% reduction in total&#160;<br/>abscess and inflammatory nodule count with no increase in abscess count and no increase in draining&#160;<br/>fistula count relative to Baseline). Reduction in HS-related skin pain was assessed using a Numeric Rating&#160;<br/>Scale in patients who entered the study with an initial baseline score of 3 or greater on a 11 point scale.&#160;</p>
<p style="position:absolute;top:579px;left:106px;white-space:nowrap" class="ft1314">At Week&#160;12, a significantly higher proportion of patients treated with Humira versus placebo achieved&#160;<br/>HiSCR. &#160;&#160;At Week&#160;12, a significantly higher proportion of patients in Study HS-II experienced a clinically&#160;<br/>relevant decrease in HS-related skin pain (see Table&#160;19). Patients treated with Humira had significantly&#160;<br/>reduced risk of disease flare during the initial 12&#160;weeks of treatment.</p>
<p style="position:absolute;top:678px;left:262px;white-space:nowrap" class="ft1311"><b>Table&#160;19: &#160;Efficacy Results at 12&#160;Weeks, HS Studies I and II</b></p>
<p style="position:absolute;top:699px;left:404px;white-space:nowrap" class="ft1311"><b>HS Study I</b></p>
<p style="position:absolute;top:699px;left:643px;white-space:nowrap" class="ft1311"><b>HS Study II</b></p>
<p style="position:absolute;top:738px;left:350px;white-space:nowrap" class="ft1311"><b>Placebo</b></p>
<p style="position:absolute;top:719px;left:446px;white-space:nowrap" class="ft1311"><b>Humira 40 mg&#160;</b></p>
<p style="position:absolute;top:738px;left:471px;white-space:nowrap" class="ft1311"><b>Weekly</b></p>
<p style="position:absolute;top:738px;left:588px;white-space:nowrap" class="ft1311"><b>Placebo&#160;</b></p>
<p style="position:absolute;top:719px;left:687px;white-space:nowrap" class="ft1311"><b>Humira 40 mg&#160;</b></p>
<p style="position:absolute;top:738px;left:711px;white-space:nowrap" class="ft1311"><b>Weekly</b></p>
<p style="position:absolute;top:767px;left:119px;white-space:nowrap" class="ft1315">Hidradenitis Suppurativa&#160;<br/>Clinical Response (HiSCR)a</p>
<p style="position:absolute;top:757px;left:351px;white-space:nowrap" class="ft1312">N = 154</p>
<p style="position:absolute;top:776px;left:341px;white-space:nowrap" class="ft1312">40 (26.0%)</p>
<p style="position:absolute;top:757px;left:470px;white-space:nowrap" class="ft1312">N = 153</p>
<p style="position:absolute;top:776px;left:456px;white-space:nowrap" class="ft1312">64 (41.8%)&#160;*</p>
<p style="position:absolute;top:757px;left:593px;white-space:nowrap" class="ft1312">N=163</p>
<p style="position:absolute;top:776px;left:579px;white-space:nowrap" class="ft1312">45 (27.6%)</p>
<p style="position:absolute;top:757px;left:715px;white-space:nowrap" class="ft1312">N=163</p>
<p style="position:absolute;top:776px;left:691px;white-space:nowrap" class="ft1312">96 (58.9%)&#160;***</p>
<p style="position:absolute;top:815px;left:119px;white-space:nowrap" class="ft1314">≥30% Reduction in Skin&#160;<br/>Painb</p>
<p style="position:absolute;top:815px;left:351px;white-space:nowrap" class="ft1312">N = 109</p>
<p style="position:absolute;top:834px;left:341px;white-space:nowrap" class="ft1312">27 (24.8%)</p>
<p style="position:absolute;top:815px;left:470px;white-space:nowrap" class="ft1312">N = 122</p>
<p style="position:absolute;top:834px;left:460px;white-space:nowrap" class="ft1312">34 (27.9%)</p>
<p style="position:absolute;top:815px;left:593px;white-space:nowrap" class="ft1312">N=111</p>
<p style="position:absolute;top:834px;left:579px;white-space:nowrap" class="ft1312">23 (20.7%)</p>
<p style="position:absolute;top:815px;left:715px;white-space:nowrap" class="ft1312">N=105</p>
<p style="position:absolute;top:834px;left:691px;white-space:nowrap" class="ft1312">48 (45.7%)&#160;***</p>
<p style="position:absolute;top:854px;left:146px;white-space:nowrap" class="ft1312">*&#160;<i>P&#160;</i>&lt; 0.05, ***<i>P&#160;</i>&lt;&#160;0.001, Humira versus placebo&#160;</p>
<p style="position:absolute;top:879px;left:119px;white-space:nowrap" class="ft13118">a</p>
<p style="position:absolute;top:874px;left:146px;white-space:nowrap" class="ft1312">Among all randomised patients.</p>
<p style="position:absolute;top:900px;left:119px;white-space:nowrap" class="ft13118">b</p>
<p style="position:absolute;top:895px;left:146px;white-space:nowrap" class="ft1312">Among patients&#160;with baseline HS-related skin pain assessment&#160;≥ 3, based on Numeric Rating&#160;</p>
<p style="position:absolute;top:913px;left:146px;white-space:nowrap" class="ft1312">Scale 0&#160;–&#160;10; 0&#160;=&#160;no skin pain, 10 = skin pain as bad as you can imagine.</p>
<p style="position:absolute;top:952px;left:106px;white-space:nowrap" class="ft1314">Treatment with Humira 40&#160;mg&#160;every week significantly reduced the risk of worsening of abscesses and&#160;<br/>draining fistulas. Approximately twice the proportion of patients in the placebo group in the first 12&#160;weeks&#160;<br/>of Studies HS-I and HS-II, compared with those in the Humira group experienced worsening of abscesses&#160;<br/>(23.0% vs 11.4%, respectively) and draining fistulas (30.0% vs 13.9%, respectively).</p>
<p style="position:absolute;top:1047px;left:106px;white-space:nowrap" class="ft1314">Greater improvements at Week&#160;12 from baseline compared to placebo were demonstrated in skin-specific&#160;<br/>health-related quality of life, as measured by the Dermatology Life Quality Index (DLQI; Studies HS-I&#160;</p>
</div>
<!-- Page 132 -->
<a name="132"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page132-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1320">132</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft1324">and HS-II),&#160;patient global satisfaction with medication treatment as measured by the Treatment&#160;<br/>Satisfaction Questionnaire&#160;-&#160;medication (TSQM; Studies HS-I and&#160;HS-II), and physical health as&#160;<br/>measured by the physical component summary score of the SF-36&#160;(Study HS-I).</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft1324">In patients with at least a partial response to Humira 40&#160;mg&#160;weekly at Week&#160;12, the HiSCR rate at&#160;<br/>Week&#160;36 was higher in patients who continued weekly Humira than in patients in whom dosing frequency&#160;<br/>was reduced to every other week, or in whom treatment was&#160;withdrawn (see Table&#160;20). &#160;</p>
<p style="position:absolute;top:239px;left:164px;white-space:nowrap" class="ft1321"><b>Table&#160;20:</b></p>
<p style="position:absolute;top:239px;left:276px;white-space:nowrap" class="ft1321"><b>Proportion of Patientsa&#160;Achieving HiSCRb&#160;at Weeks&#160;24 and 36 After&#160;</b></p>
<p style="position:absolute;top:258px;left:272px;white-space:nowrap" class="ft1321"><b>Treatment Reassignment from&#160;Weekly Humira at Week 12</b></p>
<p style="position:absolute;top:280px;left:341px;white-space:nowrap" class="ft1321"><b>Placebo</b></p>
<p style="position:absolute;top:298px;left:331px;white-space:nowrap" class="ft1321"><b>(treatment&#160;</b></p>
<p style="position:absolute;top:316px;left:326px;white-space:nowrap" class="ft1321"><b>withdrawal)</b></p>
<p style="position:absolute;top:334px;left:346px;white-space:nowrap" class="ft1321"><b>N = 73</b></p>
<p style="position:absolute;top:298px;left:466px;white-space:nowrap" class="ft1321"><b>Humira 40 mg</b></p>
<p style="position:absolute;top:316px;left:458px;white-space:nowrap" class="ft1321"><b>every other week</b></p>
<p style="position:absolute;top:334px;left:494px;white-space:nowrap" class="ft1321"><b>N = 70</b></p>
<p style="position:absolute;top:298px;left:610px;white-space:nowrap" class="ft1321"><b>Humira 40 mg</b></p>
<p style="position:absolute;top:316px;left:637px;white-space:nowrap" class="ft1321"><b>weekly</b></p>
<p style="position:absolute;top:334px;left:638px;white-space:nowrap" class="ft1321"><b>N = 70</b></p>
<p style="position:absolute;top:359px;left:195px;white-space:nowrap" class="ft1322">Week&#160;24</p>
<p style="position:absolute;top:359px;left:332px;white-space:nowrap" class="ft1322">24 (32.9%)</p>
<p style="position:absolute;top:359px;left:480px;white-space:nowrap" class="ft1322">36 (51.4%)</p>
<p style="position:absolute;top:359px;left:624px;white-space:nowrap" class="ft1322">40 (57.1%)</p>
<p style="position:absolute;top:384px;left:195px;white-space:nowrap" class="ft1322">Week&#160;36</p>
<p style="position:absolute;top:384px;left:332px;white-space:nowrap" class="ft1322">22 (30.1%)</p>
<p style="position:absolute;top:384px;left:480px;white-space:nowrap" class="ft1322">28 (40.0%)</p>
<p style="position:absolute;top:384px;left:624px;white-space:nowrap" class="ft1322">39 (55.7%)</p>
<p style="position:absolute;top:413px;left:195px;white-space:nowrap" class="ft13218">a</p>
<p style="position:absolute;top:408px;left:214px;white-space:nowrap" class="ft1325">Patients with at least a partial response to Humira 40&#160;mg weekly after&#160;<br/>12&#160;weeks of treatment.</p>
<p style="position:absolute;top:452px;left:195px;white-space:nowrap" class="ft13218">b</p>
<p style="position:absolute;top:447px;left:215px;white-space:nowrap" class="ft1322">Patients meeting protocol-specified criteria for loss of response or&#160;no&#160;</p>
<p style="position:absolute;top:465px;left:215px;white-space:nowrap" class="ft1322">improvement were required to discontinue from the studies and were&#160;</p>
<p style="position:absolute;top:483px;left:215px;white-space:nowrap" class="ft1322">counted as nonresponders.</p>
<p style="position:absolute;top:521px;left:106px;white-space:nowrap" class="ft1324">Among patients who were at least partial responders at Week&#160;12, and who received continuous weekly&#160;<br/>Humira therapy, the HiSCR rate at Week&#160;48 was 68.3% and&#160;at Week 96 was 65.1%. Longer term&#160;<br/>treatment with Humira 40 mg weekly for 96 weeks identified no new safety findings.</p>
<p style="position:absolute;top:597px;left:106px;white-space:nowrap" class="ft1324">Among patients whose Humira treatment was withdrawn at Week&#160;12 in Studies HS-I and HS-II, the&#160;<br/>HiSCR rate 12&#160;weeks after re-introduction of&#160;Humira 40&#160;mg weekly returned to levels similar to that&#160;<br/>observed before withdrawal (56.0 %).</p>
<p style="position:absolute;top:673px;left:106px;white-space:nowrap" class="ft1323"><i>Crohn’s disease</i></p>
<p style="position:absolute;top:711px;left:106px;white-space:nowrap" class="ft1327">The safety and efficacy of Humira were assessed in over 1500 patients with moderately to severely active&#160;<br/>Crohn’s disease (Crohn’s Disease Activity Index (CDAI)&#160;</p>
<p style="position:absolute;top:729px;left:489px;white-space:nowrap" class="ft1326">&#160;220 and&#160;&#160;450) in randomised, double-blind,&#160;</p>
<p style="position:absolute;top:750px;left:106px;white-space:nowrap" class="ft1324">placebo-controlled studies. Concomitant stable doses of aminosalicylates, corticosteroids, and/or&#160;<br/>immunomodulatory agents were permitted and 80% of patients continued to receive at least one of these&#160;<br/>medications.&#160;</p>
<p style="position:absolute;top:826px;left:106px;white-space:nowrap" class="ft1324">Induction of clinical remission (defined as CDAI &lt;&#160;150) was evaluated in two studies, CD Study I&#160;<br/>(CLASSIC I) and CD Study II (GAIN). In CD Study I, 299 TNF-antagonist naive patients were&#160;<br/>randomised to one of four treatment groups; placebo at Weeks&#160;0 and 2, 160&#160;mg Humira at Week&#160;0 and&#160;<br/>80&#160;mg at Week&#160;2, 80&#160;mg at Week&#160;0 and 40&#160;mg at Week&#160;2, and 40&#160;mg at Week&#160;0 and 20&#160;mg at Week&#160;2. In&#160;<br/>CD Study II, 325 patients who had lost response or were intolerant to infliximab were randomised to&#160;<br/>receive either 160&#160;mg Humira at Week&#160;0 and 80&#160;mg at Week&#160;2 or placebo at Weeks&#160;0 and 2. The primary&#160;<br/>non-responders were excluded from the studies and therefore these patients were not further evaluated.</p>
<p style="position:absolute;top:978px;left:106px;white-space:nowrap" class="ft1324">Maintenance of clinical remission was evaluated in CD study III (CHARM). &#160;In CD Study III, 854 patients&#160;<br/>received open-label 80&#160;mg at Week&#160;0 and 40&#160;mg at Week&#160;2. At Week&#160;4 patients were randomised to&#160;<br/>40&#160;mg&#160;every other week, 40&#160;mg every week, or placebo with a total study duration of 56&#160;weeks. Patients in&#160;<br/>clinical response (decrease in CDAI&#160;≥ 70) at Week&#160;4 were stratified and analysed separately from those&#160;<br/>not in clinical response at Week&#160;4. Corticosteroid taper was permitted after Week&#160;8.&#160;</p>
</div>
<!-- Page 133 -->
<a name="133"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page133-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1330">133</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft1332">CD study I and CD study II induction of remission and response rates are presented in Table&#160;21.</p>
<p style="position:absolute;top:126px;left:422px;white-space:nowrap" class="ft1331"><b>Table&#160;21</b></p>
<p style="position:absolute;top:147px;left:291px;white-space:nowrap" class="ft1331"><b>Induction of Clinical Remission and Response</b></p>
<p style="position:absolute;top:168px;left:380px;white-space:nowrap" class="ft1331"><b>(Percent of Patients)</b></p>
<p style="position:absolute;top:193px;left:287px;white-space:nowrap" class="ft1331"><b>CD Study I: Infliximab Naive&#160;</b></p>
<p style="position:absolute;top:211px;left:287px;white-space:nowrap" class="ft1331"><b>Patients</b></p>
<p style="position:absolute;top:193px;left:558px;white-space:nowrap" class="ft1331"><b>CD Study II: Infliximab&#160;</b></p>
<p style="position:absolute;top:211px;left:558px;white-space:nowrap" class="ft1331"><b>Experienced&#160;Patients</b></p>
<p style="position:absolute;top:236px;left:296px;white-space:nowrap" class="ft1331"><b>Placebo</b></p>
<p style="position:absolute;top:256px;left:305px;white-space:nowrap" class="ft1331"><b>N=74</b></p>
<p style="position:absolute;top:236px;left:387px;white-space:nowrap" class="ft1331"><b>Humira</b></p>
<p style="position:absolute;top:256px;left:383px;white-space:nowrap" class="ft1331"><b>80/40&#160;mg</b></p>
<p style="position:absolute;top:278px;left:392px;white-space:nowrap" class="ft1331"><b>N = 75</b></p>
<p style="position:absolute;top:236px;left:478px;white-space:nowrap" class="ft1331"><b>Humira&#160;</b></p>
<p style="position:absolute;top:256px;left:470px;white-space:nowrap" class="ft1331"><b>160/80&#160;mg&#160;</b></p>
<p style="position:absolute;top:274px;left:487px;white-space:nowrap" class="ft1331"><b>N=76</b></p>
<p style="position:absolute;top:236px;left:579px;white-space:nowrap" class="ft1331"><b>Placebo</b></p>
<p style="position:absolute;top:256px;left:583px;white-space:nowrap" class="ft1331"><b>N=166</b></p>
<p style="position:absolute;top:236px;left:703px;white-space:nowrap" class="ft1331"><b>Humira&#160;</b></p>
<p style="position:absolute;top:256px;left:694px;white-space:nowrap" class="ft1331"><b>160/80&#160;mg</b></p>
<p style="position:absolute;top:278px;left:707px;white-space:nowrap" class="ft1331"><b>N=159</b></p>
<p style="position:absolute;top:302px;left:114px;white-space:nowrap" class="ft13316">Week&#160;4<br/>Clinical remission</p>
<p style="position:absolute;top:327px;left:309px;white-space:nowrap" class="ft1332">12%</p>
<p style="position:absolute;top:327px;left:400px;white-space:nowrap" class="ft1332">24%</p>
<p style="position:absolute;top:327px;left:488px;white-space:nowrap" class="ft1332">36%*</p>
<p style="position:absolute;top:327px;left:595px;white-space:nowrap" class="ft1332">7%</p>
<p style="position:absolute;top:327px;left:713px;white-space:nowrap" class="ft1332">21%*</p>
<p style="position:absolute;top:352px;left:114px;white-space:nowrap" class="ft1332">Clinical response (CR-</p>
<p style="position:absolute;top:370px;left:114px;white-space:nowrap" class="ft1332">100)</p>
<p style="position:absolute;top:352px;left:309px;white-space:nowrap" class="ft1332">24%</p>
<p style="position:absolute;top:352px;left:400px;white-space:nowrap" class="ft1332">37%</p>
<p style="position:absolute;top:352px;left:486px;white-space:nowrap" class="ft1332">49%**</p>
<p style="position:absolute;top:352px;left:591px;white-space:nowrap" class="ft1332">25%</p>
<p style="position:absolute;top:352px;left:710px;white-space:nowrap" class="ft1332">38%**</p>
<p style="position:absolute;top:395px;left:114px;white-space:nowrap" class="ft1334">All p-values are pairwise comparisons of proportions for Humira&#160;<i>versus&#160;</i>placebo<br/>*</p>
<p style="position:absolute;top:415px;left:141px;white-space:nowrap" class="ft1332">p&#160;&lt;&#160;0.001</p>
<p style="position:absolute;top:435px;left:114px;white-space:nowrap" class="ft1339">**</p>
<p style="position:absolute;top:436px;left:141px;white-space:nowrap" class="ft1332">p&#160;&lt;&#160;0.01</p>
<p style="position:absolute;top:477px;left:106px;white-space:nowrap" class="ft1334">Similar remission rates were observed for the 160/80&#160;mg and 80/40&#160;mg&#160;induction regimens by Week&#160;8 and&#160;<br/>adverse events were more frequently noted in the&#160;160/80&#160;mg group.</p>
<p style="position:absolute;top:534px;left:106px;white-space:nowrap" class="ft1335">In CD Study III, at Week&#160;4, 58% (499/854) of patients were in clinical response and were assessed in the&#160;<br/>primary analysis. Of those in clinical response at Week&#160;4, 48% had been previously exposed to other TNF-<br/>antagonists. Maintenance of remission and response rates are presented in Table&#160;22. &#160;Clinical remission&#160;<br/>results remained relatively constant irrespective of previous TNF-antagonist exposure.</p>
<p style="position:absolute;top:629px;left:106px;white-space:nowrap" class="ft1335">Disease-related hospitalisations and surgeries were statistically significantly reduced with&#160;adalimumab&#160;<br/>compared with placebo at Week&#160;56.</p>
</div>
<!-- Page 134 -->
<a name="134"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page134-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1340">134</p>
<p style="position:absolute;top:88px;left:422px;white-space:nowrap" class="ft1341"><b>Table&#160;22</b></p>
<p style="position:absolute;top:109px;left:279px;white-space:nowrap" class="ft1341"><b>Maintenance of Clinical Remission and Response</b></p>
<p style="position:absolute;top:130px;left:380px;white-space:nowrap" class="ft1341"><b>(Percent of Patients)</b></p>
<p style="position:absolute;top:155px;left:425px;white-space:nowrap" class="ft1341"><b>Placebo</b></p>
<p style="position:absolute;top:154px;left:539px;white-space:nowrap" class="ft1341"><b>40&#160;mg&#160;Humira</b></p>
<p style="position:absolute;top:173px;left:531px;white-space:nowrap" class="ft1341"><b>every other week</b></p>
<p style="position:absolute;top:154px;left:675px;white-space:nowrap" class="ft1341"><b>40&#160;mg&#160;Humira</b></p>
<p style="position:absolute;top:173px;left:687px;white-space:nowrap" class="ft1341"><b>every week</b></p>
<p style="position:absolute;top:198px;left:122px;white-space:nowrap" class="ft1341"><b>Week&#160;26</b></p>
<p style="position:absolute;top:198px;left:429px;white-space:nowrap" class="ft1341"><b>N=170</b></p>
<p style="position:absolute;top:198px;left:567px;white-space:nowrap" class="ft1341"><b>N=172</b></p>
<p style="position:absolute;top:198px;left:703px;white-space:nowrap" class="ft1341"><b>N=157</b></p>
<p style="position:absolute;top:222px;left:122px;white-space:nowrap" class="ft1342">Clinical remission</p>
<p style="position:absolute;top:222px;left:437px;white-space:nowrap" class="ft1342">17%</p>
<p style="position:absolute;top:222px;left:571px;white-space:nowrap" class="ft1342">40%*</p>
<p style="position:absolute;top:222px;left:707px;white-space:nowrap" class="ft1342">47%*</p>
<p style="position:absolute;top:247px;left:122px;white-space:nowrap" class="ft1342">Clinical response (CR-100)</p>
<p style="position:absolute;top:247px;left:437px;white-space:nowrap" class="ft1342">27%</p>
<p style="position:absolute;top:247px;left:571px;white-space:nowrap" class="ft1342">52%*</p>
<p style="position:absolute;top:247px;left:707px;white-space:nowrap" class="ft1342">52%*</p>
<p style="position:absolute;top:271px;left:149px;white-space:nowrap" class="ft1345">Patients in steroid-free remission&#160;<br/>for &gt;=90&#160;daysa</p>
<p style="position:absolute;top:272px;left:419px;white-space:nowrap" class="ft1342">3% (2/66)</p>
<p style="position:absolute;top:272px;left:541px;white-space:nowrap" class="ft1342">19% (11/58)**</p>
<p style="position:absolute;top:272px;left:677px;white-space:nowrap" class="ft1342">15% (11/74)**</p>
<p style="position:absolute;top:315px;left:122px;white-space:nowrap" class="ft1341"><b>Week 56</b></p>
<p style="position:absolute;top:315px;left:429px;white-space:nowrap" class="ft1341"><b>N=170</b></p>
<p style="position:absolute;top:315px;left:567px;white-space:nowrap" class="ft1341"><b>N=172</b></p>
<p style="position:absolute;top:315px;left:703px;white-space:nowrap" class="ft1341"><b>N=157</b></p>
<p style="position:absolute;top:339px;left:122px;white-space:nowrap" class="ft1342">Clinical remission</p>
<p style="position:absolute;top:339px;left:437px;white-space:nowrap" class="ft1342">12%</p>
<p style="position:absolute;top:339px;left:571px;white-space:nowrap" class="ft1342">36%*</p>
<p style="position:absolute;top:339px;left:707px;white-space:nowrap" class="ft1342">41%*</p>
<p style="position:absolute;top:364px;left:122px;white-space:nowrap" class="ft1342">Clinical response (CR-100)</p>
<p style="position:absolute;top:364px;left:437px;white-space:nowrap" class="ft1342">17%</p>
<p style="position:absolute;top:364px;left:571px;white-space:nowrap" class="ft1342">41%*</p>
<p style="position:absolute;top:364px;left:707px;white-space:nowrap" class="ft1342">48%*</p>
<p style="position:absolute;top:388px;left:149px;white-space:nowrap" class="ft1345">Patients in steroid-free remission&#160;<br/>for &gt;=90&#160;daysa</p>
<p style="position:absolute;top:389px;left:419px;white-space:nowrap" class="ft1342">5% (3/66)</p>
<p style="position:absolute;top:389px;left:545px;white-space:nowrap" class="ft1342">29% (17/58)*</p>
<p style="position:absolute;top:389px;left:677px;white-space:nowrap" class="ft1342">20% (15/74)**</p>
<p style="position:absolute;top:432px;left:122px;white-space:nowrap" class="ft1342">*</p>
<p style="position:absolute;top:432px;left:149px;white-space:nowrap" class="ft1342">p&#160;&lt;&#160;0.001 for Humira&#160;<i>versus&#160;</i>placebo pairwise comparisons &#160; of proportions</p>
<p style="position:absolute;top:453px;left:122px;white-space:nowrap" class="ft1344">**&#160;p&#160;&lt;&#160;0.02 for Humira&#160;<i>versus&#160;</i>placebo pairwise comparisons of proportions<br/>a</p>
<p style="position:absolute;top:473px;left:149px;white-space:nowrap" class="ft1342">Of those&#160;receiving corticosteroids at baseline</p>
<p style="position:absolute;top:514px;left:106px;white-space:nowrap" class="ft1344">Among patients who were not in response at Week&#160;4, 43% of Humira maintenance patients responded by&#160;<br/>Week&#160;12 compared to 30% of placebo maintenance patients. These results suggest that some patients who&#160;<br/>have not&#160;responded by Week&#160;4 benefit from continued maintenance therapy through Week&#160;12. Therapy&#160;<br/>continued beyond 12&#160;weeks did not result in significantly more responses&#160;(see section 4.2).&#160;&#160;</p>
<p style="position:absolute;top:609px;left:106px;white-space:nowrap" class="ft1344">117/276 patients from CD study I and 272/777 patients from CD studies II&#160;and III were followed through&#160;<br/>at least 3 years of open-label adalimumab therapy. 88 and 189 patients, respectively, continued to be in&#160;<br/>clinical remission. Clinical response (CR-100) was maintained in 102 and 233 patients, respectively.</p>
<p style="position:absolute;top:685px;left:106px;white-space:nowrap" class="ft1343"><i>Quality of life</i></p>
<p style="position:absolute;top:723px;left:106px;white-space:nowrap" class="ft1344">In&#160;CD Study I and CD Study II, statistically significant improvement in the disease-specific inflammatory&#160;<br/>bowel disease questionnaire (IBDQ) total score was achieved at Week&#160;4 in patients randomised to Humira&#160;<br/>80/40&#160;mg and 160/80&#160;mg compared to placebo and was seen at Weeks&#160;26 and 56 in CD Study III as well&#160;<br/>among the adalimumab treatment groups compared to the placebo group.</p>
<p style="position:absolute;top:818px;left:106px;white-space:nowrap" class="ft1343"><i>Ulcerative colitis</i></p>
<p style="position:absolute;top:856px;left:106px;white-space:nowrap" class="ft1344">The safety and efficacy of multiple doses of Humira were assessed in adult patients with moderately to&#160;<br/>severely active ulcerative colitis (Mayo score 6 to 12 with endoscopy subscore of 2 to 3) in randomised,&#160;<br/>double-blind, placebo-controlled studies.&#160;</p>
<p style="position:absolute;top:932px;left:106px;white-space:nowrap" class="ft1344">In study UC-I, 390 TNF-antagonist naïve patients were randomised to receive either placebo at Weeks&#160;0&#160;<br/>and 2, 160&#160;mg&#160;Humira at Week&#160;0 &#160;followed by 80&#160;mg at Week&#160;2, &#160;or 80&#160;mg Humira at Week&#160;0 &#160;followed&#160;<br/>by 40&#160;mg at Week&#160;2. After Week&#160;2, patients in both adalimumab arms received 40&#160;mg&#160;eow. Clinical&#160;<br/>remission (defined as Mayo score&#160;≤&#160;2 with no subscore &gt; 1)&#160;was assessed at Week&#160;8.&#160;</p>
<p style="position:absolute;top:1027px;left:106px;white-space:nowrap" class="ft1345">In study UC-II, 248 patients received 160&#160;mg&#160;of Humira at Week&#160;0, 80&#160;mg at Week&#160;2 and 40&#160;mg&#160;eow&#160;<br/>thereafter, and 246 patients received placebo. Clinical results were assessed for induction of remission at&#160;<br/>Week&#160;8 and for maintenance of remission at&#160;Week&#160;52.&#160;</p>
</div>
<!-- Page 135 -->
<a name="135"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft13533{font-size:12px;font-family:HORGHZ+TimesNewRoman;color:#000000;}
-->
</style>
<div id="page135-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1350">135</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft1354">Patients induced with 160/80&#160;mg Humira achieved clinical remission versus placebo at Week&#160;8 in&#160;<br/>statistically significantly greater percentages in study UC-I (18% vs. 9% respectively, p=0.031) and study&#160;<br/>UC-II (17% vs. 9% respectively, p=0.019).&#160;In study UC-II, among those treated with Humira who were in&#160;<br/>remission at Week&#160;8, 21/41 (51%) were in remission at Week&#160;52.</p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft1352">Results from the overall UC-II study population are shown in Table&#160;23.</p>
<p style="position:absolute;top:230px;left:428px;white-space:nowrap" class="ft1351"><b>Table&#160;23</b></p>
<p style="position:absolute;top:259px;left:254px;white-space:nowrap" class="ft1351"><b>Response, Remission and Mucosal Healing in Study&#160;UC-II</b></p>
<p style="position:absolute;top:289px;left:387px;white-space:nowrap" class="ft1351"><b>(Percent of Patients)</b></p>
<p style="position:absolute;top:310px;left:477px;white-space:nowrap" class="ft1351"><b>Placebo</b></p>
<p style="position:absolute;top:310px;left:576px;white-space:nowrap" class="ft1351"><b>Humira 40&#160;mg</b></p>
<p style="position:absolute;top:329px;left:616px;white-space:nowrap" class="ft1351"><b>eow</b></p>
<p style="position:absolute;top:371px;left:108px;white-space:nowrap" class="ft1352">Week&#160;52</p>
<p style="position:absolute;top:371px;left:481px;white-space:nowrap" class="ft1351"><b>N=246</b></p>
<p style="position:absolute;top:371px;left:607px;white-space:nowrap" class="ft1351"><b>N=248</b></p>
<p style="position:absolute;top:392px;left:108px;white-space:nowrap" class="ft1352">&#160;&#160;Clinical Response&#160;</p>
<p style="position:absolute;top:392px;left:489px;white-space:nowrap" class="ft1352">18%&#160;</p>
<p style="position:absolute;top:392px;left:605px;white-space:nowrap" class="ft1352">&#160; &#160;30%*</p>
<p style="position:absolute;top:413px;left:108px;white-space:nowrap" class="ft1352">&#160;&#160;Clinical Remission</p>
<p style="position:absolute;top:413px;left:494px;white-space:nowrap" class="ft1352">9%</p>
<p style="position:absolute;top:413px;left:604px;white-space:nowrap" class="ft1352">&#160; &#160;17%*</p>
<p style="position:absolute;top:434px;left:108px;white-space:nowrap" class="ft1352">&#160;&#160;Mucosal Healing&#160;</p>
<p style="position:absolute;top:434px;left:489px;white-space:nowrap" class="ft1352">15%</p>
<p style="position:absolute;top:434px;left:604px;white-space:nowrap" class="ft1352">&#160; &#160;25%*</p>
<p style="position:absolute;top:455px;left:108px;white-space:nowrap" class="ft1352">&#160;&#160;Steroid-free remission for&#160;≥ 90 days&#160;a</p>
<p style="position:absolute;top:455px;left:494px;white-space:nowrap" class="ft1352">6%&#160;</p>
<p style="position:absolute;top:474px;left:476px;white-space:nowrap" class="ft1352">(N=140)</p>
<p style="position:absolute;top:455px;left:598px;white-space:nowrap" class="ft1352">&#160; &#160; &#160;13% *</p>
<p style="position:absolute;top:474px;left:601px;white-space:nowrap" class="ft1352">(N=150)</p>
<p style="position:absolute;top:515px;left:108px;white-space:nowrap" class="ft13523">Week&#160;8 and 52<br/>&#160;&#160;Sustained Response&#160;</p>
<p style="position:absolute;top:536px;left:489px;white-space:nowrap" class="ft1352">12%</p>
<p style="position:absolute;top:536px;left:600px;white-space:nowrap" class="ft1352">&#160; &#160;24%**</p>
<p style="position:absolute;top:557px;left:108px;white-space:nowrap" class="ft1352">&#160;&#160;Sustained Remission&#160;</p>
<p style="position:absolute;top:557px;left:494px;white-space:nowrap" class="ft1352">4%</p>
<p style="position:absolute;top:557px;left:608px;white-space:nowrap" class="ft1352">&#160; &#160;8%*</p>
<p style="position:absolute;top:579px;left:108px;white-space:nowrap" class="ft1352">&#160;&#160;Sustained Mucosal Healing&#160;</p>
<p style="position:absolute;top:579px;left:489px;white-space:nowrap" class="ft1352">11%</p>
<p style="position:absolute;top:579px;left:606px;white-space:nowrap" class="ft1352">&#160;&#160;19%*</p>
<p style="position:absolute;top:600px;left:108px;white-space:nowrap" class="ft1354">Clinical remission is Mayo score&#160;≤&#160;2 with no subscore &gt;&#160;1;<br/>Clinical response is decrease from baseline in Mayo score&#160;≥3 points&#160;and&#160;≥30% plus a&#160;<br/>decrease in the rectal bleeding subscore [RBS]&#160;≥1 or an absolute RBS of 0 or 1;</p>
<p style="position:absolute;top:658px;left:108px;white-space:nowrap" class="ft13516">*p&lt;0.05 for Humira&#160;<i>vs.&#160;</i>placebo pairwise comparison of proportions&#160;<br/>**</p>
<p style="position:absolute;top:680px;left:123px;white-space:nowrap" class="ft1352">p&lt;0.001 for Humira&#160;<i>vs.&#160;</i>placebo pairwise comparison of proportions</p>
<p style="position:absolute;top:699px;left:108px;white-space:nowrap" class="ft1359">a&#160;&#160;&#160;Of those receiving corticosteroids at baseline</p>
<p style="position:absolute;top:739px;left:106px;white-space:nowrap" class="ft1354">Of those patients who had a response at Week&#160;8, 47% were in response, 29% were in remission, 41% had&#160;<br/>mucosal healing, and 20% were in steroid-free remission for&#160;≥&#160;90 days at Week&#160;52.</p>
<p style="position:absolute;top:796px;left:106px;white-space:nowrap" class="ft1354">Approximately 40% of patients in study UC-II&#160;had failed prior anti-TNF treatment with infliximab. The&#160;<br/>efficacy of adalimumab in those patients was reduced compared to that in anti-TNF naïve patients. &#160;<br/>Among patients who had failed prior anti-TNF treatment, Week&#160;52 remission was achieved by 3% on&#160;<br/>placebo and 10% on adalimumab.</p>
<p style="position:absolute;top:891px;left:106px;white-space:nowrap" class="ft1354">Patients from studies UC-I and UC-II had the option to roll over into an open-label long-term&#160;extension&#160;<br/>study (UC III). Following 3&#160;years of adalimumab therapy, 75% (301/402) continued to be in clinical&#160;<br/>remission per partial Mayo score.&#160;</p>
<p style="position:absolute;top:967px;left:106px;white-space:nowrap" class="ft1353"><i>Hospitalisation rates</i></p>
<p style="position:absolute;top:1005px;left:106px;white-space:nowrap" class="ft1354">During 52&#160;weeks of studies UC-I and UC-II, lower rates of all-cause hospitalisations and UC-related&#160;<br/>hospitalisations were observed for the adalimumab-treated arm compared to the placebo arm.&#160;The&#160;number&#160;<br/>of all cause hospitalisations in the adalimumab treatment group was 0.18 per patient year&#160;<i>vs</i>. 0.26 per&#160;</p>
</div>
<!-- Page 136 -->
<a name="136"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page136-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1360">136</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft1365">patient year in the placebo group and the corresponding figures for UC-related hospitalisations were 0.12&#160;<br/>per patient year&#160;<i>vs.&#160;</i>0.22 per patient year.</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft1363"><i>Quality of life</i></p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft1364">In study UC-II, treatment with adalimumab resulted in improvements in the Inflammatory Bowel Disease&#160;<br/>Questionnaire (IBDQ) score. &#160;&#160;</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft1363"><i>Uveitis</i></p>
<p style="position:absolute;top:276px;left:106px;white-space:nowrap" class="ft1364">The safety and efficacy&#160;of Humira were assessed in adult patients with non-infectious intermediate,&#160;<br/>posterior, and panuveitis, excluding patients with isolated anterior uveitis, in two randomised, double-<br/>masked, placebo-controlled studies (UV I and II). Patients received placebo&#160;or Humira at an initial dose of&#160;<br/>80&#160;mg followed by 40&#160;mg&#160;every other week starting one week after the initial dose. Concomitant stable&#160;<br/>doses of one&#160;non-biologic immunosuppressant were permitted.&#160;</p>
<p style="position:absolute;top:390px;left:106px;white-space:nowrap" class="ft1364">Study UV I evaluated 217 patients with active uveitis despite&#160;treatment with corticosteroids (oral&#160;<br/>prednisone at a dose of 10 to 60&#160;mg/day). All patients received a 2-week&#160;standardised dose of prednisone&#160;<br/>60&#160;mg/day at study entry followed by a mandatory taper schedule, with complete corticosteroid&#160;<br/>discontinuation by Week 15.&#160;</p>
<p style="position:absolute;top:485px;left:106px;white-space:nowrap" class="ft1364">Study UV II evaluated 226 patients with inactive uveitis requiring chronic corticosteroid treatment (oral&#160;<br/>prednisone 10 to 35&#160;mg/day) at baseline to control their disease. Patients subsequently underwent a&#160;<br/>mandatory taper schedule, with complete&#160;corticosteroid discontinuation by Week 19.&#160;</p>
<p style="position:absolute;top:560px;left:106px;white-space:nowrap" class="ft1365">The primary efficacy endpoint in both studies was ´time to treatment failure´. Treatment failure was&#160;<br/>defined by a multi-component outcome based on inflammatory chorioretinal and/or inflammatory retinal&#160;<br/>vascular lesions, anterior chamber (AC) cell grade, vitreous haze (VH) grade and best corrected visual&#160;<br/>acuity (BCVA).&#160;</p>
<p style="position:absolute;top:655px;left:106px;white-space:nowrap" class="ft1365">Patients&#160;who completed Studies&#160;UV&#160;I and UV&#160;II were&#160;eligible to enroll in&#160;an uncontrolled long-term<br/>extension study with an originally planned&#160;duration of 78 weeks. Patients were allowed to continue on&#160;<br/>study medication beyond Week 78 until they had access to Humira.</p>
<p style="position:absolute;top:731px;left:106px;white-space:nowrap" class="ft1363"><i>Clinical Response</i></p>
<p style="position:absolute;top:769px;left:106px;white-space:nowrap" class="ft1364">Results from both studies demonstrated statistically significant reduction of the risk of treatment failure in&#160;<br/>patients treated with Humira versus patients receiving placebo (See Table&#160;24). Both studies demonstrated&#160;<br/>an early and sustained effect of Humira&#160;on the treatment failure rate versus placebo (see Figure&#160;2).&#160;</p>
</div>
<!-- Page 137 -->
<a name="137"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page137-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1370">137</p>
<p style="position:absolute;top:86px;left:428px;white-space:nowrap" class="ft1371"><b>Table&#160;24</b></p>
<p style="position:absolute;top:105px;left:270px;white-space:nowrap" class="ft1371"><b>Time to Treatment Failure in Studies UV I and UV II</b></p>
<p style="position:absolute;top:144px;left:114px;white-space:nowrap" class="ft1371"><b>Analysis</b></p>
<p style="position:absolute;top:163px;left:156px;white-space:nowrap" class="ft1371"><b>Treatment</b></p>
<p style="position:absolute;top:144px;left:284px;white-space:nowrap" class="ft1371"><b>N</b></p>
<p style="position:absolute;top:144px;left:338px;white-space:nowrap" class="ft13719"><b>Failure<br/>N (%)</b></p>
<p style="position:absolute;top:144px;left:426px;white-space:nowrap" class="ft13719"><b>Median Time to&#160;<br/>Failure (months)</b></p>
<p style="position:absolute;top:144px;left:567px;white-space:nowrap" class="ft1371"><b>HRa</b></p>
<p style="position:absolute;top:144px;left:621px;white-space:nowrap" class="ft13719"><b>CI 95%&#160;<br/>for HRa</b></p>
<p style="position:absolute;top:144px;left:709px;white-space:nowrap" class="ft13717"><i><b>P&#160;</b></i><b>Value&#160;</b>b</p>
<p style="position:absolute;top:182px;left:114px;white-space:nowrap" class="ft13719"><b>Time to Treatment Failure At or After Week 6 in Study UV I &#160;<br/></b>Primary analysis (ITT)</p>
<p style="position:absolute;top:220px;left:156px;white-space:nowrap" class="ft1372">Placebo</p>
<p style="position:absolute;top:220px;left:284px;white-space:nowrap" class="ft1372">107</p>
<p style="position:absolute;top:220px;left:338px;white-space:nowrap" class="ft1372">84 (78.5)</p>
<p style="position:absolute;top:220px;left:426px;white-space:nowrap" class="ft1372">3.0</p>
<p style="position:absolute;top:220px;left:567px;white-space:nowrap" class="ft1372">--</p>
<p style="position:absolute;top:220px;left:621px;white-space:nowrap" class="ft1372">--</p>
<p style="position:absolute;top:220px;left:709px;white-space:nowrap" class="ft1372">--</p>
<p style="position:absolute;top:239px;left:156px;white-space:nowrap" class="ft1372">Adalimumab</p>
<p style="position:absolute;top:239px;left:284px;white-space:nowrap" class="ft1372">110</p>
<p style="position:absolute;top:239px;left:338px;white-space:nowrap" class="ft1372">60 (54.5)</p>
<p style="position:absolute;top:239px;left:426px;white-space:nowrap" class="ft1372">5.6</p>
<p style="position:absolute;top:239px;left:567px;white-space:nowrap" class="ft1372">0.50</p>
<p style="position:absolute;top:239px;left:621px;white-space:nowrap" class="ft1372">0.36, 0.70</p>
<p style="position:absolute;top:239px;left:709px;white-space:nowrap" class="ft1372">&lt; 0.001</p>
<p style="position:absolute;top:259px;left:114px;white-space:nowrap" class="ft13719"><b>Time to Treatment Failure At or After Week 2 in Study UV II<br/></b>Primary&#160;analysis (ITT)</p>
<p style="position:absolute;top:297px;left:156px;white-space:nowrap" class="ft1372">Placebo</p>
<p style="position:absolute;top:297px;left:284px;white-space:nowrap" class="ft1372">111</p>
<p style="position:absolute;top:297px;left:338px;white-space:nowrap" class="ft1372">61 (55.0)</p>
<p style="position:absolute;top:297px;left:426px;white-space:nowrap" class="ft1372">8.3</p>
<p style="position:absolute;top:297px;left:567px;white-space:nowrap" class="ft1372">--</p>
<p style="position:absolute;top:297px;left:621px;white-space:nowrap" class="ft1372">--</p>
<p style="position:absolute;top:297px;left:709px;white-space:nowrap" class="ft1372">--</p>
<p style="position:absolute;top:316px;left:156px;white-space:nowrap" class="ft1372">Adalimumab</p>
<p style="position:absolute;top:316px;left:284px;white-space:nowrap" class="ft1372">115</p>
<p style="position:absolute;top:316px;left:338px;white-space:nowrap" class="ft1372">45 (39.1)</p>
<p style="position:absolute;top:316px;left:426px;white-space:nowrap" class="ft1372">NEc</p>
<p style="position:absolute;top:316px;left:567px;white-space:nowrap" class="ft1372">0.57</p>
<p style="position:absolute;top:316px;left:621px;white-space:nowrap" class="ft1372">0.39, 0.84</p>
<p style="position:absolute;top:316px;left:709px;white-space:nowrap" class="ft1372">0.004</p>
<p style="position:absolute;top:336px;left:106px;white-space:nowrap" class="ft1378">Note: &#160;Treatment failure at or after Week 6 (Study UV I), or at or after Week 2 (Study UV II), was&#160;<br/>counted as event. Drop outs due to reasons&#160;other than treatment failure were censored at the time of&#160;<br/>dropping out.<br/>a</p>
<p style="position:absolute;top:392px;left:133px;white-space:nowrap" class="ft1372">HR of adalimumab vs placebo from proportional hazards regression with treatment as factor.</p>
<p style="position:absolute;top:416px;left:106px;white-space:nowrap" class="ft13718">b</p>
<p style="position:absolute;top:411px;left:133px;white-space:nowrap" class="ft1372">2-sided&#160;<i>P&#160;</i>value from log rank test.</p>
<p style="position:absolute;top:435px;left:106px;white-space:nowrap" class="ft13718">c</p>
<p style="position:absolute;top:431px;left:133px;white-space:nowrap" class="ft1372">NE = not estimable. Fewer than half of at-risk subjects had an event.&#160;</p>
<p style="position:absolute;top:468px;left:108px;white-space:nowrap" class="ft1371"><b>Figure&#160;2: Kaplan-Meier Curves Summarizing Time to Treatment Failure on or after Week 6 (Study&#160;</b></p>
<p style="position:absolute;top:487px;left:350px;white-space:nowrap" class="ft1371"><b>UV I) or Week 2 (Study UV II)</b></p>
<p style="position:absolute;top:786px;left:130px;white-space:nowrap" class="ft13720"><b>T</b></p>
<p style="position:absolute;top:775px;left:130px;white-space:nowrap" class="ft13720"><b>R</b></p>
<p style="position:absolute;top:763px;left:130px;white-space:nowrap" class="ft13720"><b>E</b></p>
<p style="position:absolute;top:752px;left:130px;white-space:nowrap" class="ft13720"><b>A</b></p>
<p style="position:absolute;top:740px;left:130px;white-space:nowrap" class="ft13720"><b>T</b></p>
<p style="position:absolute;top:729px;left:130px;white-space:nowrap" class="ft13720"><b>M</b></p>
<p style="position:absolute;top:714px;left:130px;white-space:nowrap" class="ft13720"><b>E</b></p>
<p style="position:absolute;top:702px;left:130px;white-space:nowrap" class="ft13720"><b>N</b></p>
<p style="position:absolute;top:691px;left:130px;white-space:nowrap" class="ft13720"><b>T</b></p>
<p style="position:absolute;top:680px;left:130px;white-space:nowrap" class="ft13720"><b>&#160;F</b></p>
<p style="position:absolute;top:665px;left:130px;white-space:nowrap" class="ft13720"><b>A</b></p>
<p style="position:absolute;top:653px;left:130px;white-space:nowrap" class="ft13720"><b>IL</b></p>
<p style="position:absolute;top:636px;left:130px;white-space:nowrap" class="ft13720"><b>U</b></p>
<p style="position:absolute;top:624px;left:130px;white-space:nowrap" class="ft13720"><b>R</b></p>
<p style="position:absolute;top:612px;left:130px;white-space:nowrap" class="ft13720"><b>E</b></p>
<p style="position:absolute;top:601px;left:130px;white-space:nowrap" class="ft13720"><b>&#160;R</b></p>
<p style="position:absolute;top:585px;left:130px;white-space:nowrap" class="ft13720"><b>A</b></p>
<p style="position:absolute;top:573px;left:130px;white-space:nowrap" class="ft13720"><b>T</b></p>
<p style="position:absolute;top:562px;left:130px;white-space:nowrap" class="ft13720"><b>E</b></p>
<p style="position:absolute;top:552px;left:130px;white-space:nowrap" class="ft13720"><b>&#160;(</b></p>
<p style="position:absolute;top:542px;left:130px;white-space:nowrap" class="ft13720"><b>%</b></p>
<p style="position:absolute;top:525px;left:130px;white-space:nowrap" class="ft13720"><b>)</b></p>
<p style="position:absolute;top:811px;left:406px;white-space:nowrap" class="ft1371"><b>TIME (MONTHS)</b></p>
<p style="position:absolute;top:830px;left:150px;white-space:nowrap" class="ft1372">Study UV I &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;Treatment</p>
<p style="position:absolute;top:830px;left:500px;white-space:nowrap" class="ft1372">Placebo</p>
<p style="position:absolute;top:830px;left:669px;white-space:nowrap" class="ft1372">Adalimumab</p>
</div>
<!-- Page 138 -->
<a name="138"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page138-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1380">138</p>
<p style="position:absolute;top:349px;left:130px;white-space:nowrap" class="ft13820"><b>T</b></p>
<p style="position:absolute;top:338px;left:130px;white-space:nowrap" class="ft13820"><b>R</b></p>
<p style="position:absolute;top:326px;left:130px;white-space:nowrap" class="ft13820"><b>E</b></p>
<p style="position:absolute;top:315px;left:130px;white-space:nowrap" class="ft13820"><b>A</b></p>
<p style="position:absolute;top:303px;left:130px;white-space:nowrap" class="ft13820"><b>T</b></p>
<p style="position:absolute;top:292px;left:130px;white-space:nowrap" class="ft13820"><b>M</b></p>
<p style="position:absolute;top:276px;left:130px;white-space:nowrap" class="ft13820"><b>E</b></p>
<p style="position:absolute;top:265px;left:130px;white-space:nowrap" class="ft13820"><b>N</b></p>
<p style="position:absolute;top:253px;left:130px;white-space:nowrap" class="ft13820"><b>T</b></p>
<p style="position:absolute;top:242px;left:130px;white-space:nowrap" class="ft13820"><b>&#160;F</b></p>
<p style="position:absolute;top:228px;left:130px;white-space:nowrap" class="ft13820"><b>A</b></p>
<p style="position:absolute;top:216px;left:130px;white-space:nowrap" class="ft13820"><b>IL</b></p>
<p style="position:absolute;top:199px;left:130px;white-space:nowrap" class="ft13820"><b>U</b></p>
<p style="position:absolute;top:187px;left:130px;white-space:nowrap" class="ft13820"><b>R</b></p>
<p style="position:absolute;top:175px;left:130px;white-space:nowrap" class="ft13820"><b>E</b></p>
<p style="position:absolute;top:164px;left:130px;white-space:nowrap" class="ft13820"><b>&#160;R</b></p>
<p style="position:absolute;top:148px;left:130px;white-space:nowrap" class="ft13820"><b>A</b></p>
<p style="position:absolute;top:136px;left:130px;white-space:nowrap" class="ft13820"><b>T</b></p>
<p style="position:absolute;top:125px;left:130px;white-space:nowrap" class="ft13820"><b>E</b></p>
<p style="position:absolute;top:114px;left:130px;white-space:nowrap" class="ft13820"><b>&#160;(</b></p>
<p style="position:absolute;top:104px;left:130px;white-space:nowrap" class="ft13820"><b>%</b></p>
<p style="position:absolute;top:88px;left:130px;white-space:nowrap" class="ft13820"><b>)</b></p>
<p style="position:absolute;top:376px;left:406px;white-space:nowrap" class="ft1381"><b>TIME (MONTHS)</b></p>
<p style="position:absolute;top:395px;left:150px;white-space:nowrap" class="ft1382">Study UV II &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; Treatment</p>
<p style="position:absolute;top:395px;left:500px;white-space:nowrap" class="ft1382">Placebo</p>
<p style="position:absolute;top:395px;left:669px;white-space:nowrap" class="ft1382">Adalimumab</p>
<p style="position:absolute;top:427px;left:114px;white-space:nowrap" class="ft1384">Note: P# = Placebo (Number of Events/Number at Risk); A# = HUMIRA (Number of<br/>Events/Number at Risk).</p>
<p style="position:absolute;top:489px;left:106px;white-space:nowrap" class="ft1384">In Study UV I statistically&#160;significant differences in favour of adalimumab versus placebo were observed&#160;<br/>for each component of treatment failure. &#160;In Study UV II, statistically significant differences were&#160;<br/>observed for visual acuity only, but the other components were numerically in&#160;favour of adalimumab.</p>
<p style="position:absolute;top:565px;left:106px;white-space:nowrap" class="ft1384">Of the&#160;424&#160;subjects included&#160;in&#160;the&#160;uncontrolled long-term&#160;extension of Studies UV I and UV II,&#160;60<br/>subjects were regarded ineligible (e.g.&#160;due to deviations or due to&#160;complications secondary to diabetic&#160;<br/>retinopathy, due to cataract&#160;surgery or vitrectomy) and were excluded from the primary analysis&#160;of&#160;<br/>efficacy. Of the&#160;364&#160;remaining patients,&#160;269&#160;evaluable patients&#160;(74%)&#160;reached 78 weeks of open-label&#160;<br/>adalimumab treatment. Based on the observed data approach,&#160;216&#160;(80.3%) were in quiescence&#160;(no active&#160;<br/>inflammatory lesions, AC cell grade&#160;≤ 0.5+, VH grade ≤ 0.5+) with a concomitant steroid dose ≤ 7.5 mg&#160;<br/>per day, and&#160;178&#160;(66.2%) were in steroid-free quiescence. BCVA was either improved or maintained (&lt; 5&#160;<br/>letters deterioration) in 88.6% of the&#160;eyes at week 78.&#160;Data beyond Week 78 were generally consistent&#160;<br/>with these results but the number of enrolled subjects declined after this time. Overall, among the patients&#160;<br/>who discontinued the study,&#160;18% discontinued due to adverse events, and&#160;8% due to&#160;insufficient response&#160;<br/>to adalimumab treatment.</p>
<p style="position:absolute;top:792px;left:106px;white-space:nowrap" class="ft1383"><i>Quality of Life</i></p>
<p style="position:absolute;top:831px;left:106px;white-space:nowrap" class="ft1385">Patient reported outcomes regarding vision-related functioning were measured in both clinical studies,&#160;<br/>using the NEI VFQ-25. Humira was numerically favoured for the majority of subscores&#160;with statistically&#160;<br/>significant mean differences for general vision, ocular pain, near vision, mental health, and total score in&#160;<br/>Study UV I, and for general vision and mental health in Study UV II. Vision related effects were not&#160;<br/>numerically in favour of Humira for colour vision in Study UVI and for colour vision, peripheral vision&#160;<br/>and near vision in Study UV II.</p>
<p style="position:absolute;top:963px;left:106px;white-space:nowrap" class="ft1382">Immunogenicity &#160;</p>
<p style="position:absolute;top:1001px;left:106px;white-space:nowrap" class="ft1384">Formation of anti-adalimumab antibodies is associated with increased clearance and reduced efficacy of&#160;<br/>adalimumab. There is no apparent correlation between the presence of anti-adalimumab antibodies and the&#160;<br/>occurrence of adverse events.</p>
</div>
<!-- Page 139 -->
<a name="139"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page139-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1390">139</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft1394">Patients in rheumatoid arthritis studies I, II and III were tested at multiple time points for anti-adalimumab&#160;<br/>antibodies during the 6 to 12 month&#160;period. In the pivotal trials, anti-adalimumab antibodies were&#160;<br/>identified in 5.5% (58/1053) of patients treated with adalimumab, compared to 0.5% (2/370) on placebo. &#160;<br/>In patients not given concomitant methotrexate, the incidence was 12.4%, compared to 0.6% when&#160;<br/>adalimumab was used as add-on to methotrexate. &#160;</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft1394">In patients with polyarticular juvenile idiopathic arthritis who were 4 to 17&#160;years, anti-adalimumab&#160;<br/>antibodies were identified in 15.8% (27/171) of patients treated with adalimumab. In patients not&#160;given&#160;<br/>concomitant methotrexate, the incidence was 25.6% (22/86) compared to 5.9% (5/85) when adalimumab&#160;<br/>was used as add-on to methotrexate.&#160;In patients with polyarticular juvenile idiopathic arthritis who were&#160;<br/>2&#160;to&#160;&lt;4&#160;years old or aged 4 and above weighing&#160;&lt;15&#160;kg,&#160;anti-adalimumab antibodies were identified in 7%&#160;<br/>(1/15) of patients, and the one patient was receiving concomitant methotrexate.</p>
<p style="position:absolute;top:333px;left:106px;white-space:nowrap" class="ft1395">In patients with enthesitis-related arthritis, anti-adalimumab antibodies were identified in 10.9% (5/46) of&#160;<br/>patients&#160;treated with adalimumab. In patients not given concomitant methotrexate, the incidence was&#160;<br/>13.6% (3/22), compared to 8.3% (2/24) when adalimumab was used as add-on to methotrexate.</p>
<p style="position:absolute;top:409px;left:106px;white-space:nowrap" class="ft1394">In patients with psoriatic arthritis, anti-adalimumab antibodies were identified in 38/376 subjects (10%)&#160;<br/>treated with adalimumab. In patients not given concomitant methotrexate, the incidence was 13.5%&#160;<br/>(24/178 subjects), compared to 7% (14 of 198 subjects) when adalimumab was used as add-on to&#160;<br/>methotrexate.</p>
<p style="position:absolute;top:503px;left:106px;white-space:nowrap" class="ft1394">In patients with ankylosing spondylitis anti-adalimumab antibodies were identified in 17/204 subjects&#160;<br/>(8.3%) treated with adalimumab. In patients not given concomitant methotrexate, the incidence was&#160;<br/>16/185 (8.6%), compared to 1/19 (5.3%) when adalimumab was used as add-on&#160;to&#160;methotrexate.</p>
<p style="position:absolute;top:579px;left:106px;white-space:nowrap" class="ft1394">In patients with non-radiographic axial spondyloarthritis, anti-adalimumab antibodies were identified in&#160;<br/>8/152 subjects (5.3%) who were treated continuously with adalimumab.</p>
<p style="position:absolute;top:636px;left:106px;white-space:nowrap" class="ft1394">In patients with Crohn’s disease, anti-adalimumab antibodies were&#160;identified in 7/269 subjects (2.6%) and&#160;<br/>in 19/487 subjects (3.9%) with ulcerative colitis.</p>
<p style="position:absolute;top:693px;left:106px;white-space:nowrap" class="ft1394">In adult patients with psoriasis, anti-adalimumab antibodies were identified in 77/920 subjects (8.4%)&#160;<br/>treated with adalimumab monotherapy.</p>
<p style="position:absolute;top:750px;left:106px;white-space:nowrap" class="ft1394">In adult plaque&#160;psoriasis patients on long term adalimumab monotherapy who participated in a withdrawal&#160;<br/>and retreatment study, the rate of antibodies to adalimumab after retreatment (11 of 482 subjects, 2.3%)&#160;<br/>was similar to the rate observed prior to withdrawal (11 of 590&#160;subjects, 1.9%).</p>
<p style="position:absolute;top:826px;left:106px;white-space:nowrap" class="ft1394">In patients with paediatric psoriasis, anti-adalimumab antibodies were identified in 5/38 subjects (13%)&#160;<br/>treated with 0.8&#160;mg/kg adalimumab monotherapy.</p>
<p style="position:absolute;top:883px;left:106px;white-space:nowrap" class="ft1394">In patients with moderate to severe hidradenitis suppurativa, anti-adalimumab antibodies were identified&#160;<br/>in 10/99 subjects (10.1%) treated with adalimumab.</p>
<p style="position:absolute;top:940px;left:106px;white-space:nowrap" class="ft1394">In patients with moderately to severely active paediatric Crohn’s disease, the rate of anti-adalimumab&#160;<br/>antibody development in patients receiving adalimumab was 3.3%.&#160;</p>
<p style="position:absolute;top:997px;left:106px;white-space:nowrap" class="ft1395">In&#160;adult&#160;patients with non-infectious uveitis, anti-adalimumab antibodies were identified in 4.8% (12/249)&#160;<br/>of patients treated with adalimumab.</p>
<p style="position:absolute;top:1054px;left:106px;white-space:nowrap" class="ft1395">In patients with moderately to severely active paediatric ulcerative colitis, the rate of anti-adalimumab&#160;<br/>antibody development in patients receiving adalimumab was&#160;3%.</p>
</div>
<!-- Page 140 -->
<a name="140"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page140-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1400">140</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft1404">Because immunogenicity analyses are product-specific, comparison of antibody rates with those from&#160;<br/>other products is not appropriate.</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft1402">Paediatric population</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft1403"><i>Juvenile idiopathic arthritis (JIA)</i></p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft1403"><i>Polyarticular&#160;juvenile&#160;idiopathic&#160;arthritis (pJIA)</i></p>
<p style="position:absolute;top:276px;left:106px;white-space:nowrap" class="ft1405">The safety and efficacy of Humira was assessed in two studies (pJIA I and II) in children with active&#160;<br/>polyarticular or polyarticular course juvenile idiopathic arthritis, who had a variety of JIA onset types&#160;<br/>(most frequently rheumatoid-factor negative or positive polyarthritis and extended oligoarthritis).</p>
<p style="position:absolute;top:352px;left:106px;white-space:nowrap" class="ft1402">pJIA I</p>
<p style="position:absolute;top:384px;left:106px;white-space:nowrap" class="ft1407">The safety and efficacy of Humira were assessed in a multicentre, randomised, double-blind,&#160;<br/>parallel&#160;−&#160;group study in 171 children (4-17&#160;years old) with&#160;polyarticular JIA. In the open-label lead in&#160;<br/>phase (OL LI) patients were stratified into two groups, MTX (methotrexate)-treated or non-MTX-treated.&#160;<br/>Patients who were in the non-MTX stratum were either naïve to or had been withdrawn from MTX at&#160;<br/>least two weeks prior to study drug administration. Patients remained on stable doses of NSAIDs and or&#160;<br/>prednisone (</p>
<p style="position:absolute;top:478px;left:188px;white-space:nowrap" class="ft1406">&#160;0.2&#160;mg&#160;/kg/day or 10&#160;mg/day maximum). In the OL LI phase all patients received 24&#160;mg/m2&#160;</p>
<p style="position:absolute;top:499px;left:106px;white-space:nowrap" class="ft1404">up to a maximum of 40&#160;mg Humira every other week for 16&#160;weeks.&#160;&#160;The distribution of patients by age&#160;<br/>and minimum, median and maximum dose received during the OL LI phase is presented in Table&#160;25.</p>
<p style="position:absolute;top:556px;left:431px;white-space:nowrap" class="ft1401"><b>Table&#160;25</b></p>
<p style="position:absolute;top:575px;left:157px;white-space:nowrap" class="ft1401"><b>Distribution of patients by age and adalimumab dose received during the OL LI phase</b></p>
<p style="position:absolute;top:614px;left:122px;white-space:nowrap" class="ft1402">Age Group</p>
<p style="position:absolute;top:614px;left:304px;white-space:nowrap" class="ft1405">Number of patients&#160;at Baseline&#160;<br/>n&#160;(%)</p>
<p style="position:absolute;top:614px;left:568px;white-space:nowrap" class="ft1405">Minimum, median and maximum&#160;<br/>dose</p>
<p style="position:absolute;top:654px;left:122px;white-space:nowrap" class="ft1402">4 to 7&#160;years</p>
<p style="position:absolute;top:653px;left:304px;white-space:nowrap" class="ft1402">31 (18.1)</p>
<p style="position:absolute;top:654px;left:568px;white-space:nowrap" class="ft1402">10, 20 and 25&#160;mg</p>
<p style="position:absolute;top:675px;left:122px;white-space:nowrap" class="ft1402">8 to 12&#160;years</p>
<p style="position:absolute;top:674px;left:304px;white-space:nowrap" class="ft1402">71 (41.5)</p>
<p style="position:absolute;top:675px;left:568px;white-space:nowrap" class="ft1402">20, 25 and 40&#160;mg</p>
<p style="position:absolute;top:697px;left:122px;white-space:nowrap" class="ft1402">13 to 17&#160;years</p>
<p style="position:absolute;top:696px;left:304px;white-space:nowrap" class="ft1402">69 (40.4)</p>
<p style="position:absolute;top:697px;left:568px;white-space:nowrap" class="ft1402">25, 40 and 40&#160;mg</p>
<p style="position:absolute;top:736px;left:106px;white-space:nowrap" class="ft1407">Patients demonstrating a Paediatric ACR 30 response at Week&#160;16 were eligible&#160;to&#160;be&#160;randomised into the&#160;<br/>double blind (DB) phase and received either Humira 24&#160;mg/m2&#160;up to a maximum of 40&#160;mg, or placebo&#160;<br/>every other week for an additional 32&#160;weeks or until disease flare. Disease flare criteria were defined as a&#160;<br/>worsening of&#160;</p>
<p style="position:absolute;top:792px;left:197px;white-space:nowrap" class="ft1406">&#160;30% from&#160;baseline in&#160;&#160;3 of 6 Paediatric ACR core criteria,&#160;&#160;2 active joints, and&#160;</p>
<p style="position:absolute;top:814px;left:106px;white-space:nowrap" class="ft1402">improvement of&#160;</p>
<p style="position:absolute;top:812px;left:216px;white-space:nowrap" class="ft1406">&#160;30% in no more than 1 of the 6 criteria. &#160;After 32&#160;weeks&#160;or at disease flare, patients&#160;</p>
<p style="position:absolute;top:833px;left:106px;white-space:nowrap" class="ft1402">were&#160;eligible to enrol into&#160;the open label extension phase.</p>
</div>
<!-- Page 141 -->
<a name="141"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page141-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1410">141</p>
<p style="position:absolute;top:86px;left:431px;white-space:nowrap" class="ft1411"><b>Table&#160;26</b></p>
<p style="position:absolute;top:105px;left:321px;white-space:nowrap" class="ft1411"><b>Ped ACR&#160;30 Responses in the JIA study</b></p>
<p style="position:absolute;top:145px;left:122px;white-space:nowrap" class="ft1411"><b>Stratum</b></p>
<p style="position:absolute;top:145px;left:406px;white-space:nowrap" class="ft1411"><b>MTX</b></p>
<p style="position:absolute;top:145px;left:629px;white-space:nowrap" class="ft1411"><b>Without MTX</b></p>
<p style="position:absolute;top:165px;left:122px;white-space:nowrap" class="ft14119"><b>Phase<br/></b>OL-LI 16 weeks</p>
<p style="position:absolute;top:204px;left:165px;white-space:nowrap" class="ft1414">Ped ACR 30&#160;<br/>response (n/N)</p>
<p style="position:absolute;top:204px;left:378px;white-space:nowrap" class="ft1412">94.1% (80/85)</p>
<p style="position:absolute;top:204px;left:631px;white-space:nowrap" class="ft1412">74.4% (64/86)</p>
<p style="position:absolute;top:243px;left:122px;white-space:nowrap" class="ft1417">&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;Efficacy Outcomes<br/>Double Blind 32&#160;weeks</p>
<p style="position:absolute;top:263px;left:304px;white-space:nowrap" class="ft1414">Humira /MTX<br/>(N =&#160;38)</p>
<p style="position:absolute;top:263px;left:436px;white-space:nowrap" class="ft1414">Placebo / MTX<br/>(N = 37)</p>
<p style="position:absolute;top:263px;left:568px;white-space:nowrap" class="ft1414">Humira&#160;<br/>(N = 30)</p>
<p style="position:absolute;top:263px;left:692px;white-space:nowrap" class="ft1414">Placebo<br/>(N = 28)</p>
<p style="position:absolute;top:321px;left:165px;white-space:nowrap" class="ft1417">Disease flares at&#160;<br/>the end of&#160;<br/>32&#160;weeksa&#160;(n/N)</p>
<p style="position:absolute;top:321px;left:304px;white-space:nowrap" class="ft1412">36.8% (14/38)</p>
<p style="position:absolute;top:321px;left:436px;white-space:nowrap" class="ft1412">64.9% (24/37)b</p>
<p style="position:absolute;top:321px;left:568px;white-space:nowrap" class="ft1412">43.3% (13/30)</p>
<p style="position:absolute;top:321px;left:692px;white-space:nowrap" class="ft1415">71.4%&#160;<br/>(20/28)c</p>
<p style="position:absolute;top:380px;left:165px;white-space:nowrap" class="ft1415">Median time to&#160;<br/>disease flare</p>
<p style="position:absolute;top:381px;left:304px;white-space:nowrap" class="ft1412">&gt;32&#160;weeks</p>
<p style="position:absolute;top:381px;left:436px;white-space:nowrap" class="ft1412">20&#160;weeks</p>
<p style="position:absolute;top:381px;left:568px;white-space:nowrap" class="ft1412">&gt;32&#160;weeks</p>
<p style="position:absolute;top:381px;left:692px;white-space:nowrap" class="ft1412">14&#160;weeks</p>
<p style="position:absolute;top:438px;left:114px;white-space:nowrap" class="ft1417">a&#160;Ped ACR 30/50/70 responses Week 48 significantly greater than those of placebo treated patients&#160;<br/>b&#160;p =&#160;0.015<br/>c&#160;p =&#160;0.031</p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft1414">Amongst those who responded at Week&#160;16 (n=144), the Paediatric ACR 30/50/70/90 responses were&#160;<br/>maintained for up to six years in the&#160;OLE phase in patients who received Humira throughout the study.<br/>Over all 19 subjects, of which 11 of the baseline age group 4 to 12 and 8 of the baseline age group 13 to&#160;<br/>17&#160;years were treated 6&#160;years or longer.</p>
<p style="position:absolute;top:613px;left:106px;white-space:nowrap" class="ft1414">Overall responses were generally better and,&#160;fewer patients developed antibodies when treated with the&#160;<br/>combination of Humira and MTX compared to Humira alone. Taking these results into consideration,&#160;<br/>Humira is recommended for use in combination with MTX and for use as monotherapy in patients for&#160;<br/>whom&#160;MTX use is not appropriate (see section 4.2).</p>
<p style="position:absolute;top:708px;left:106px;white-space:nowrap" class="ft1412">pJIA II</p>
<p style="position:absolute;top:746px;left:106px;white-space:nowrap" class="ft1415">The safety and efficacy of Humira was assessed in an open-label,&#160;multicentre&#160;study in 32 children (2&#160;-<br/>&lt;4&#160;years old or&#160;aged 4 and above weighing &lt;&#160;15&#160;kg) with moderately to severely active polyarticular JIA.&#160;<br/>The patients&#160;received 24&#160;mg/m2&#160;body surface area (BSA) of Humira up to a maximum of 20&#160;mg&#160;every&#160;<br/>other week as a single dose via SC injection for at least 24&#160;weeks. During the study, most subjects used&#160;<br/>concomitant MTX, with fewer reporting use of&#160;corticosteroids or NSAIDs.</p>
<p style="position:absolute;top:860px;left:106px;white-space:nowrap" class="ft1414">At Week&#160;12 and Week&#160;24, PedACR30 response was 93.5% and 90.0%, respectively, using the observed&#160;<br/>data approach. The proportions of subjects with PedACR50/70/90 at Week&#160;12 and Week&#160;24 were&#160;<br/>90.3%/61.3%/38.7% and 83.3%/73.3%/36.7%,&#160;respectively. Amongst those who responded (Paediatric&#160;<br/>ACR 30) at Week&#160;24 (n=27 out of 30 patients), the Paediatric ACR 30 responses were maintained for up&#160;<br/>to 60&#160;weeks in the OLE phase in patients who received Humira throughout this time period. Overall, 20<br/>subjects were treated for 60&#160;weeks&#160;or longer.</p>
<p style="position:absolute;top:993px;left:106px;white-space:nowrap" class="ft1413"><i>Enthesitis-related arthritis</i></p>
<p style="position:absolute;top:1031px;left:106px;white-space:nowrap" class="ft1415">The safety and efficacy of Humira were assessed in a multicentre, randomised, double-blind study in 46&#160;<br/>paediatric patients (6 to 17&#160;years old) with moderate enthesitis-related arthritis. Patients were randomised&#160;<br/>to receive either 24&#160;mg/m2&#160;body surface area (BSA) of Humira up to a maximum of 40&#160;mg, or placebo&#160;</p>
</div>
<!-- Page 142 -->
<a name="142"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page142-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1420">142</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft1424">every other week for 12&#160;weeks. The double-blind period is followed by an open-label (OL) period during&#160;<br/>which patients received&#160;24 mg/m2&#160;BSA of Humira up to a maximum of 40&#160;mg&#160;every other week&#160;<br/>subcutaneously for up to an additional 192&#160;weeks. The primary endpoint was the percent change from&#160;<br/>Baseline to Week&#160;12 in the number of active joints with arthritis (swelling not due to deformity or joints&#160;<br/>with loss of motion plus pain and/or tenderness), which was achieved with mean percent decrease of&#160;-<br/>62.6% (median percent change&#160;-88.9%) in patients in the Humira group compared to&#160;-11.6% (median&#160;<br/>percent change&#160;-50.0%) in patients in the&#160;placebo group. Improvement in number of active joints with&#160;<br/>arthritis was maintained during the OL period through Week&#160;156 for the 26 of 31 (84%) patients in the&#160;<br/>Humira group who remained in the study. Although not statistically significant, the majority of&#160;patients&#160;<br/>demonstrated clinical improvement in secondary endpoints such as number of sites of enthesitis, tender&#160;<br/>joint count (TJC), swollen joint count (SJC), Paediatric ACR 50 response, and Paediatric ACR 70&#160;<br/>response.</p>
<p style="position:absolute;top:333px;left:106px;white-space:nowrap" class="ft1423"><i>Paediatric plaque psoriasis</i></p>
<p style="position:absolute;top:375px;left:106px;white-space:nowrap" class="ft1425">The&#160;efficacy of Humira was assessed in a randomised, double-blind, controlled study of 114 paediatric&#160;<br/>patients from 4&#160;years of age with severe chronic plaque psoriasis (as defined by a PGA&#160;≥&#160;4 or&#160;&gt;&#160;20% BSA&#160;<br/>involvement or &gt;&#160;10% BSA involvement with very thick&#160;lesions or PASI&#160;≥&#160;20&#160;or&#160;≥&#160;10 with clinically&#160;<br/>relevant facial, genital, or hand/ foot involvement) who were inadequately controlled with topical therapy&#160;<br/>and heliotherapy or phototherapy.&#160;</p>
<p style="position:absolute;top:489px;left:106px;white-space:nowrap" class="ft1424">Patients received Humira 0.8&#160;mg/kg&#160;eow (up to 40&#160;mg), 0.4&#160;mg/kg&#160;eow&#160;(up to 20&#160;mg), or methotrexate 0.1&#160;<br/>–&#160;0.4&#160;mg/kg&#160;weekly (up to 25&#160;mg). &#160; At Week&#160;16, more patients randomised to Humira 0.8&#160;mg/kg had&#160;<br/>positive efficacy responses (e.g., PASI 75) than those randomised to 0.4&#160;mg/kg&#160;eow or MTX. &#160;</p>
<p style="position:absolute;top:566px;left:224px;white-space:nowrap" class="ft1421"><b>Table&#160;27:&#160;Paediatric Plaque&#160;Psoriasis Efficacy Results at 16&#160;Weeks</b></p>
<p style="position:absolute;top:607px;left:451px;white-space:nowrap" class="ft1422">MTXa</p>
<p style="position:absolute;top:626px;left:453px;white-space:nowrap" class="ft1422">N=37&#160;</p>
<p style="position:absolute;top:607px;left:578px;white-space:nowrap" class="ft1422">Humira 0.8&#160;mg/kg&#160;eow</p>
<p style="position:absolute;top:626px;left:635px;white-space:nowrap" class="ft1422">N=38&#160;</p>
<p style="position:absolute;top:649px;left:162px;white-space:nowrap" class="ft1422">PASI 75b</p>
<p style="position:absolute;top:649px;left:435px;white-space:nowrap" class="ft1422">12 (32.4%)</p>
<p style="position:absolute;top:649px;left:617px;white-space:nowrap" class="ft1422">22 (57.9%)</p>
<p style="position:absolute;top:671px;left:162px;white-space:nowrap" class="ft1422">PGA: Clear/minimalc</p>
<p style="position:absolute;top:671px;left:435px;white-space:nowrap" class="ft1422">15 (40.5%)</p>
<p style="position:absolute;top:671px;left:617px;white-space:nowrap" class="ft1422">23 (60.5%)</p>
<p style="position:absolute;top:692px;left:145px;white-space:nowrap" class="ft1429">a&#160;MTX = methotrexate</p>
<p style="position:absolute;top:711px;left:145px;white-space:nowrap" class="ft1429">b&#160;P=0.027, Humira 0.8&#160;mg/kg versus MTX</p>
<p style="position:absolute;top:730px;left:145px;white-space:nowrap" class="ft1429">c&#160;P=0.083, Humira 0.8&#160;mg/kg versus MTX</p>
<p style="position:absolute;top:771px;left:106px;white-space:nowrap" class="ft1425">Patients who achieved PASI 75 and PGA clear or minimal were withdrawn from treatment for up to&#160;<br/>36&#160;weeks and monitored for loss of disease control (i.e. a worsening of PGA by at least 2 grades). &#160;Patients&#160;<br/>were then re-treated with adalimumab 0.8&#160;mg/kg&#160;eow for an additional 16&#160;weeks and response rates&#160;<br/>observed during retreatment were similar to the previous double-blind period: &#160;PASI 75 response of 78.9%&#160;<br/>(15 of 19 subjects) and PGA clear or minimal of 52.6% (10 of 19 subjects).</p>
<p style="position:absolute;top:886px;left:106px;white-space:nowrap" class="ft1425">In the open label period&#160;of the study, PASI 75 and PGA clear or minimal responses were maintained for&#160;<br/>up to an additional 52&#160;weeks with no&#160;new safety findings.</p>
<p style="position:absolute;top:942px;left:106px;white-space:nowrap" class="ft1423"><i>Adolescent hidradenitis suppurativa</i></p>
<p style="position:absolute;top:980px;left:106px;white-space:nowrap" class="ft1424">There are no clinical trials with Humira in adolescent patients with HS. Efficacy of adalimumab for the&#160;<br/>treatment of adolescent patients with HS is predicted based on the demonstrated efficacy and exposure-<br/>response relationship in adult HS patients and the likelihood that the disease course, pathophysiology, and&#160;<br/>drug effects are&#160;substantially similar to that of adults at the same exposure levels. Safety of the&#160;<br/>recommended adalimumab dose in the adolescent HS population is based on cross-indication safety&#160;</p>
</div>
<!-- Page 143 -->
<a name="143"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page143-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1430">143</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft1435">profile of adalimumab in both adults and paediatric patients at similar or more frequent doses&#160;(see section&#160;<br/>5.2).</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft1433"><i>Paediatric Crohn’s disease</i></p>
<p style="position:absolute;top:176px;left:106px;white-space:nowrap" class="ft1434">Humira was assessed in a multicentre, randomised, double-blind clinical trial designed to evaluate the&#160;<br/>efficacy and safety of induction and maintenance treatment with doses dependent on body weight&#160;<br/>(&lt;&#160;40&#160;kg&#160;or&#160;≥&#160;40 kg) in 192 paediatric subjects between the ages of 6 and 17 (inclusive) years, with&#160;<br/>moderate to severe Crohn´s disease (CD) defined as Paediatric Crohn's Disease Activity Index (PCDAI)&#160;<br/>score &gt;&#160;30. Subjects had to have failed conventional therapy (including a corticosteroid and/or an&#160;<br/>immunomodulator) for CD. Subjects may also have previously lost response or been intolerant to&#160;<br/>infliximab.&#160;</p>
<p style="position:absolute;top:328px;left:106px;white-space:nowrap" class="ft1434">All subjects received open-label induction therapy at a dose based on their Baseline body weight: 160&#160;mg&#160;<br/>at Week&#160;0 and 80&#160;mg at Week&#160;2 for subjects&#160;≥&#160;40&#160;kg, and 80&#160;mg and 40&#160;mg, respectively, for subjects&#160;<br/>&lt;&#160;40&#160;kg.</p>
<p style="position:absolute;top:403px;left:106px;white-space:nowrap" class="ft1434">At Week&#160;4, subjects were randomised 1:1 based on their body weight at the time to either the Low Dose or&#160;<br/>Standard Dose maintenance regimens as shown in Table&#160;28.</p>
<p style="position:absolute;top:460px;left:428px;white-space:nowrap" class="ft1431"><b>Table&#160;28</b></p>
<p style="position:absolute;top:479px;left:382px;white-space:nowrap" class="ft1431"><b>Maintenance regimen</b></p>
<p style="position:absolute;top:499px;left:339px;white-space:nowrap" class="ft14319"><b>Patient&#160;<br/>Weight</b></p>
<p style="position:absolute;top:499px;left:413px;white-space:nowrap" class="ft1431"><b>Low dose</b></p>
<p style="position:absolute;top:499px;left:504px;white-space:nowrap" class="ft14319"><b>Standard&#160;<br/>dose</b></p>
<p style="position:absolute;top:537px;left:339px;white-space:nowrap" class="ft1432">&lt; 40&#160;kg</p>
<p style="position:absolute;top:537px;left:413px;white-space:nowrap" class="ft1432">10&#160;mg&#160;eow&#160;20&#160;mg&#160;eow</p>
<p style="position:absolute;top:557px;left:339px;white-space:nowrap" class="ft1432">≥ 40&#160;kg</p>
<p style="position:absolute;top:557px;left:413px;white-space:nowrap" class="ft1432">20&#160;mg&#160;eow&#160;40&#160;mg&#160;eow</p>
<p style="position:absolute;top:596px;left:106px;white-space:nowrap" class="ft1433"><i>Efficacy results</i></p>
<p style="position:absolute;top:635px;left:106px;white-space:nowrap" class="ft1432">The primary endpoint of the study was clinical remission at Week&#160;26, defined as PCDAI score&#160;</p>
<p style="position:absolute;top:633px;left:734px;white-space:nowrap" class="ft1436">&#160;10.</p>
<p style="position:absolute;top:673px;left:106px;white-space:nowrap" class="ft1435">Clinical remission and clinical response (defined as reduction in PCDAI score of at least 15 points from&#160;<br/>Baseline) rates are presented in Table&#160;29. Rates of&#160;discontinuation of corticosteroids or&#160;<br/>immunomodulators are presented in Table&#160;30.</p>
</div>
<!-- Page 144 -->
<a name="144"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page144-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1440">144</p>
<p style="position:absolute;top:87px;left:429px;white-space:nowrap" class="ft1441"><b>Table&#160;29</b></p>
<p style="position:absolute;top:106px;left:386px;white-space:nowrap" class="ft1441"><b>Paediatric CD Study</b></p>
<p style="position:absolute;top:125px;left:315px;white-space:nowrap" class="ft1441"><b>PCDAI Clinical Remission and Response</b></p>
<p style="position:absolute;top:145px;left:392px;white-space:nowrap" class="ft1441"><b>Standard Dose</b></p>
<p style="position:absolute;top:164px;left:396px;white-space:nowrap" class="ft1441"><b>40/20&#160;mg&#160;eow&#160;</b></p>
<p style="position:absolute;top:183px;left:421px;white-space:nowrap" class="ft1441"><b>N = 93</b></p>
<p style="position:absolute;top:145px;left:529px;white-space:nowrap" class="ft1441"><b>Low Dose</b></p>
<p style="position:absolute;top:164px;left:516px;white-space:nowrap" class="ft1441"><b>20/10&#160;mg&#160;eow&#160;</b></p>
<p style="position:absolute;top:183px;left:541px;white-space:nowrap" class="ft1441"><b>N = 95</b></p>
<p style="position:absolute;top:145px;left:637px;white-space:nowrap" class="ft1441"><b>P value</b>*</p>
<p style="position:absolute;top:203px;left:210px;white-space:nowrap" class="ft14421"><b>Week&#160;26<br/></b>&#160; &#160;Clinical remission</p>
<p style="position:absolute;top:223px;left:423px;white-space:nowrap" class="ft1442">38.7%</p>
<p style="position:absolute;top:223px;left:543px;white-space:nowrap" class="ft1442">28.4%</p>
<p style="position:absolute;top:223px;left:648px;white-space:nowrap" class="ft1442">0.075</p>
<p style="position:absolute;top:243px;left:210px;white-space:nowrap" class="ft1442">&#160; &#160;Clinical response&#160;</p>
<p style="position:absolute;top:243px;left:423px;white-space:nowrap" class="ft1442">59.1%</p>
<p style="position:absolute;top:243px;left:543px;white-space:nowrap" class="ft1442">48.4%</p>
<p style="position:absolute;top:243px;left:648px;white-space:nowrap" class="ft1442">0.073</p>
<p style="position:absolute;top:264px;left:210px;white-space:nowrap" class="ft14421"><b>Week&#160;52<br/></b>&#160; &#160;Clinical remission</p>
<p style="position:absolute;top:284px;left:423px;white-space:nowrap" class="ft1442">33.3%</p>
<p style="position:absolute;top:284px;left:543px;white-space:nowrap" class="ft1442">23.2%</p>
<p style="position:absolute;top:284px;left:648px;white-space:nowrap" class="ft1442">0.100</p>
<p style="position:absolute;top:304px;left:210px;white-space:nowrap" class="ft1442">&#160; &#160;Clinical response</p>
<p style="position:absolute;top:304px;left:423px;white-space:nowrap" class="ft1442">41.9%</p>
<p style="position:absolute;top:304px;left:543px;white-space:nowrap" class="ft1442">28.4%</p>
<p style="position:absolute;top:304px;left:648px;white-space:nowrap" class="ft1442">0.038</p>
<p style="position:absolute;top:324px;left:210px;white-space:nowrap" class="ft1442">*&#160;p value for Standard Dose&#160;<i>versus&#160;</i>Low Dose comparison.</p>
<p style="position:absolute;top:364px;left:428px;white-space:nowrap" class="ft1441"><b>Table&#160;30</b></p>
<p style="position:absolute;top:383px;left:386px;white-space:nowrap" class="ft1441"><b>Paediatric CD&#160;Study</b></p>
<p style="position:absolute;top:402px;left:175px;white-space:nowrap" class="ft1441"><b>Discontinuation of Corticosteroids or Immunomodulators and Fistula Remission</b></p>
<p style="position:absolute;top:422px;left:455px;white-space:nowrap" class="ft1441"><b>Standard Dose</b></p>
<p style="position:absolute;top:441px;left:459px;white-space:nowrap" class="ft1441"><b>40/20&#160;mg&#160;eow&#160;</b></p>
<p style="position:absolute;top:422px;left:595px;white-space:nowrap" class="ft1441"><b>Low Dose</b></p>
<p style="position:absolute;top:441px;left:582px;white-space:nowrap" class="ft1441"><b>20/10&#160;mg&#160;eow&#160;</b></p>
<p style="position:absolute;top:422px;left:705px;white-space:nowrap" class="ft1441"><b>P value1</b></p>
<p style="position:absolute;top:461px;left:143px;white-space:nowrap" class="ft1441"><b>Discontinued corticosteroids</b></p>
<p style="position:absolute;top:461px;left:486px;white-space:nowrap" class="ft1441"><b>N= 33</b></p>
<p style="position:absolute;top:461px;left:611px;white-space:nowrap" class="ft1441"><b>N=38</b></p>
<p style="position:absolute;top:481px;left:143px;white-space:nowrap" class="ft1442">Week&#160;26</p>
<p style="position:absolute;top:481px;left:486px;white-space:nowrap" class="ft1442">84.8%</p>
<p style="position:absolute;top:481px;left:608px;white-space:nowrap" class="ft1442">65.8%</p>
<p style="position:absolute;top:481px;left:715px;white-space:nowrap" class="ft1442">0.066</p>
<p style="position:absolute;top:501px;left:143px;white-space:nowrap" class="ft1442">Week&#160;52</p>
<p style="position:absolute;top:501px;left:486px;white-space:nowrap" class="ft1442">69.7%</p>
<p style="position:absolute;top:501px;left:608px;white-space:nowrap" class="ft1442">60.5%</p>
<p style="position:absolute;top:501px;left:715px;white-space:nowrap" class="ft1442">0.420</p>
<p style="position:absolute;top:521px;left:143px;white-space:nowrap" class="ft1441"><b>Discontinuation of Immunomodulators2</b></p>
<p style="position:absolute;top:521px;left:488px;white-space:nowrap" class="ft1441"><b>N=60</b></p>
<p style="position:absolute;top:521px;left:611px;white-space:nowrap" class="ft1441"><b>N=57</b></p>
<p style="position:absolute;top:541px;left:143px;white-space:nowrap" class="ft1442">Week&#160;52</p>
<p style="position:absolute;top:541px;left:486px;white-space:nowrap" class="ft1442">30.0%</p>
<p style="position:absolute;top:541px;left:608px;white-space:nowrap" class="ft1442">29.8%</p>
<p style="position:absolute;top:541px;left:715px;white-space:nowrap" class="ft1442">0.983</p>
<p style="position:absolute;top:562px;left:143px;white-space:nowrap" class="ft1441"><b>Fistula remission3</b></p>
<p style="position:absolute;top:562px;left:488px;white-space:nowrap" class="ft1441"><b>N=15</b></p>
<p style="position:absolute;top:562px;left:611px;white-space:nowrap" class="ft1441"><b>N=21</b></p>
<p style="position:absolute;top:582px;left:143px;white-space:nowrap" class="ft1442">Week&#160;26</p>
<p style="position:absolute;top:582px;left:486px;white-space:nowrap" class="ft1442">46.7%</p>
<p style="position:absolute;top:582px;left:608px;white-space:nowrap" class="ft1442">38.1%</p>
<p style="position:absolute;top:582px;left:715px;white-space:nowrap" class="ft1442">0.608</p>
<p style="position:absolute;top:602px;left:143px;white-space:nowrap" class="ft1442">Week&#160;52</p>
<p style="position:absolute;top:602px;left:486px;white-space:nowrap" class="ft1442">40.0%</p>
<p style="position:absolute;top:602px;left:608px;white-space:nowrap" class="ft1442">23.8%</p>
<p style="position:absolute;top:602px;left:715px;white-space:nowrap" class="ft1442">0.303</p>
<p style="position:absolute;top:620px;left:143px;white-space:nowrap" class="ft1449">1&#160;&#160;p value for Standard Dose&#160;<i>versus&#160;</i>Low Dose comparison.</p>
<p style="position:absolute;top:639px;left:143px;white-space:nowrap" class="ft1447">2&#160;&#160;Immunosuppressant therapy could only be discontinued at or after Week&#160;26 at the&#160;<br/>investigator's discretion if the subject met the clinical response criterion&#160;</p>
<p style="position:absolute;top:677px;left:143px;white-space:nowrap" class="ft1447">3&#160;defined as a closure of all fistulas that were draining at Baseline for at least 2 consecutive&#160;<br/>post-Baseline visits</p>
<p style="position:absolute;top:735px;left:106px;white-space:nowrap" class="ft1445">Statistically significant&#160;increases (improvement) from Baseline to Week&#160;26 and 52 in Body Mass Index&#160;<br/>and height velocity were observed for both treatment groups.</p>
<p style="position:absolute;top:792px;left:106px;white-space:nowrap" class="ft1445">Statistically and clinically significant improvements from Baseline were also observed in both treatment&#160;<br/>groups for quality of life parameters (including IMPACT III).</p>
<p style="position:absolute;top:849px;left:106px;white-space:nowrap" class="ft1444">One&#160;hundred patients (n=100) from the Paediatric CD Study&#160;continued in an open-label long-term&#160;<br/>extension study. &#160;After 5 years of adalimumab therapy, 74.0% (37/50) of the 50 patients remaining in the&#160;<br/>study continued to be in clinical remission, and 92.0% (46/50) of patients continued to be in clinical&#160;<br/>response per PCDAI.</p>
<p style="position:absolute;top:944px;left:106px;white-space:nowrap" class="ft1443"><i>Paediatric ulcerative colitis</i></p>
<p style="position:absolute;top:982px;left:106px;white-space:nowrap" class="ft1445">The safety and efficacy of Humira was assessed in a multicenter, randomized, double-blind, trial in 93&#160;<br/>paediatric patients from 5 to 17 years of age with moderate to severe ulcerative colitis (Mayo score 6 to 12&#160;<br/>with&#160;endoscopy subscore of 2 to 3 points, confirmed by centrally read endoscopy) who had an inadequate&#160;<br/>response or intolerance to conventional therapy. Approximately 16% of patients in the study had failed&#160;<br/>prior anti-TNF treatment. Patients who received corticosteroids at enrollment were allowed to taper their&#160;<br/>corticosteroid therapy after Week 4.</p>
</div>
<!-- Page 145 -->
<a name="145"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page145-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1450">145</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft1455">In the induction period of the study,&#160;77&#160;patients were randomized 3:2 to receive double-blind treatment&#160;<br/>with&#160;Humira at&#160;an&#160;induction dose of 2.4 mg/kg (maximum of 160&#160;mg) at Week 0 and Week 1, and 1.2&#160;<br/>mg/kg (maximum of 80 mg) at Week 2; or an&#160;induction dose of 2.4 mg/kg (maximum of 160 mg) at Week&#160;<br/>0, placebo at Week 1, and 1.2 mg/kg (maximum of 80 mg) at Week 2.&#160;Both groups received 0.6 mg/kg&#160;<br/>(maximum of 40 mg) at Week&#160;4 and Week 6.&#160;Following an amendment to the study design, the remaining&#160;<br/>16 patients who enrolled in the induction period received open-label treatment with&#160;Humira&#160;at the&#160;<br/>induction dose&#160;of 2.4 mg/kg (maximum of 160 mg) at Week 0 and Week 1, and 1.2 mg/kg (maximum of&#160;<br/>80 mg) at Week 2.</p>
<p style="position:absolute;top:276px;left:106px;white-space:nowrap" class="ft1455">At Week 8, 62 patients who demonstrated&#160;clinical response per&#160;Partial Mayo Score (PMS;&#160;defined as a&#160;<br/>decrease in PMS&#160;≥ 2 points and ≥ 30% from Baseline)&#160;were randomized equally to receive double-blind&#160;<br/>maintenance treatment&#160;with Humira&#160;at a dose&#160;of 0.6 mg/kg (maximum of 40 mg) every week&#160;(ew),&#160;or&#160;a&#160;<br/>maintenance dose of 0.6 mg/kg (maximum of 40 mg) every other&#160;week (eow).&#160;Prior to an amendment to&#160;<br/>the study design, 12 additional patients who demonstrated clinical response per PMS were randomized to&#160;<br/>receive&#160;placebo&#160;but were not included in&#160;the confirmatory&#160;analysis of efficacy.</p>
<p style="position:absolute;top:409px;left:106px;white-space:nowrap" class="ft1454">Disease flare was defined as an increase in&#160;PMS&#160;of at least 3 points (for patients with PMS of 0 to 2 at&#160;<br/>Week 8), at least 2 points (for patients with PMS of&#160;3 to 4 at Week 8), or at least 1 point (for patients with&#160;<br/>PMS of 5 to 6 at Week 8).</p>
<p style="position:absolute;top:485px;left:106px;white-space:nowrap" class="ft1454">Patients who met criteria for disease flare&#160;at or after Week 12&#160;were randomized to receive a re-induction&#160;<br/>dose of 2.4 mg/kg (maximum of 160 mg) or a dose of 0.6 mg/kg (maximum of 40 mg) and continued to&#160;<br/>receive their respective maintenance dose regimen afterwards.</p>
<p style="position:absolute;top:565px;left:106px;white-space:nowrap" class="ft1453"><i>Efficacy Results</i></p>
<p style="position:absolute;top:612px;left:106px;white-space:nowrap" class="ft1455">The co-primary endpoints of the study were clinical remission per PMS (defined as PMS&#160;≤ 2 and no&#160;<br/>individual subscore &gt; 1) at Week 8, and&#160;clinical remission per FMS (Full Mayo Score) (defined as a Mayo&#160;<br/>Score&#160;≤ 2 and no individual subscore &gt; 1) at Week 52 in patients who achieved clinical response per PMS&#160;<br/>at Week 8.</p>
<p style="position:absolute;top:707px;left:106px;white-space:nowrap" class="ft1454">Clinical remission rates per PMS at Week 8 for&#160;patients&#160;in&#160;each&#160;of the&#160;Humira&#160;double-<br/>blind&#160;induction&#160;groups&#160;are&#160;presented in&#160;Table 31.</p>
<p style="position:absolute;top:764px;left:284px;white-space:nowrap" class="ft1451"><b>Table 31: Clinical Remission per PMS at 8 Weeks</b></p>
<p style="position:absolute;top:807px;left:404px;white-space:nowrap" class="ft1451"><b>Humiraa</b></p>
<p style="position:absolute;top:826px;left:333px;white-space:nowrap" class="ft1451"><b>Maximum&#160;of&#160;160 mg&#160;at Week&#160;</b></p>
<p style="position:absolute;top:848px;left:359px;white-space:nowrap" class="ft1451"><b>0&#160;/&#160;Placebo&#160;at Week 1</b></p>
<p style="position:absolute;top:870px;left:418px;white-space:nowrap" class="ft1452">N=30</p>
<p style="position:absolute;top:807px;left:624px;white-space:nowrap" class="ft1451"><b>Humirab, c</b></p>
<p style="position:absolute;top:826px;left:558px;white-space:nowrap" class="ft1451"><b>Maximum of 160 mg&#160;at Week&#160;</b></p>
<p style="position:absolute;top:848px;left:612px;white-space:nowrap" class="ft1451"><b>0&#160;and&#160;Week 1</b></p>
<p style="position:absolute;top:870px;left:643px;white-space:nowrap" class="ft1452">N=47</p>
<p style="position:absolute;top:895px;left:178px;white-space:nowrap" class="ft1452">Clinical remission</p>
<p style="position:absolute;top:895px;left:389px;white-space:nowrap" class="ft1452">13/30&#160;(43.3%)</p>
<p style="position:absolute;top:895px;left:614px;white-space:nowrap" class="ft1452">28/47 (59.6%)</p>
</div>
<!-- Page 146 -->
<a name="146"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page146-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1460">146</p>
<p style="position:absolute;top:87px;left:178px;white-space:nowrap" class="ft1467">a&#160;Humira&#160;2.4 mg/kg&#160;(maximum of 160 mg)&#160;at Week 0, placebo at Week 1,&#160;and&#160;1.2&#160;<br/>mg/kg&#160;(maximum of 80 mg)&#160;at Week 2</p>
<p style="position:absolute;top:125px;left:178px;white-space:nowrap" class="ft1467">b&#160;Humira&#160;2.4 mg/kg&#160;(maximum&#160;of 160 mg)&#160;at Week 0 and Week 1,&#160;and&#160;1.2&#160;<br/>mg/kg&#160;(maximum of 80 mg)&#160;at Week 2</p>
<p style="position:absolute;top:163px;left:178px;white-space:nowrap" class="ft1465">c&#160;Not including&#160;open-label Induction dose of&#160;Humira&#160;2.4 mg/kg&#160;(maximum&#160;of 160 mg)&#160;at&#160;<br/>Week 0 and Week 1, and 1.2 mg/kg&#160;(maximum of 80 mg)&#160;at Week 2<br/>Note 1: Both induction groups received 0.6 mg/kg (maximum of 40 mg) at Week 4 and&#160;<br/>Week 6<br/>Note 2: Patients with missing values at Week 8 were considered as not having met the&#160;<br/>endpoint</p>
<p style="position:absolute;top:299px;left:106px;white-space:nowrap" class="ft1464">At Week 52, clinical remission per FMS in Week 8 responders, clinical response per FMS (defined as a&#160;<br/>decrease in Mayo Score&#160;≥ 3 points and ≥ 30% from Baseline) in Week 8 responders, mucosal healing&#160;<br/>(defined as Mayo endoscopy&#160;subscore&#160;≤ 1) in Week 8 responders, clinical remission per FMS in Week 8&#160;<br/>remitters, and the proportion of subjects in corticosteroid-free remission per FMS in Week 8 responders&#160;<br/>were assessed in patients who received Humira at the double-blind&#160;maximum 40 mg&#160;eow&#160;(0.6 mg/kg) and&#160;<br/>maximum&#160;40 mg&#160;ew&#160;(0.6 mg/kg) maintenance doses (Table&#160;32).</p>
<p style="position:absolute;top:432px;left:320px;white-space:nowrap" class="ft1461"><b>Table&#160;32: Efficacy Results at 52 Weeks</b></p>
<p style="position:absolute;top:458px;left:420px;white-space:nowrap" class="ft1461"><b>Humiraa</b></p>
<p style="position:absolute;top:477px;left:368px;white-space:nowrap" class="ft1461"><b>Maximum&#160;of&#160;40 mg&#160;eow</b></p>
<p style="position:absolute;top:496px;left:436px;white-space:nowrap" class="ft1462">N=31</p>
<p style="position:absolute;top:458px;left:608px;white-space:nowrap" class="ft1461"><b>Humirab</b></p>
<p style="position:absolute;top:477px;left:561px;white-space:nowrap" class="ft1461"><b>Maximum&#160;of&#160;40 mg&#160;ew</b></p>
<p style="position:absolute;top:496px;left:625px;white-space:nowrap" class="ft1462">N=31</p>
<p style="position:absolute;top:524px;left:176px;white-space:nowrap" class="ft1465">Clinical remission in Week&#160;<br/>8 PMS responders</p>
<p style="position:absolute;top:534px;left:409px;white-space:nowrap" class="ft1462">9/31 (29.0%)</p>
<p style="position:absolute;top:534px;left:596px;white-space:nowrap" class="ft1462">14/31 (45.2%)</p>
<p style="position:absolute;top:567px;left:176px;white-space:nowrap" class="ft1464">Clinical response in Week 8&#160;<br/>PMS responders</p>
<p style="position:absolute;top:577px;left:405px;white-space:nowrap" class="ft1462">19/31 (61.3%)</p>
<p style="position:absolute;top:577px;left:594px;white-space:nowrap" class="ft1462">21/31 (67.7%)</p>
<p style="position:absolute;top:608px;left:176px;white-space:nowrap" class="ft1465">Mucosal healing in&#160;<br/>Week&#160;8&#160;PMS responders</p>
<p style="position:absolute;top:618px;left:405px;white-space:nowrap" class="ft1462">12/31 (38.7%)</p>
<p style="position:absolute;top:618px;left:594px;white-space:nowrap" class="ft1462">16/31 (51.6%)</p>
<p style="position:absolute;top:647px;left:176px;white-space:nowrap" class="ft1464">Clinical remission in Week&#160;<br/>8 PMS remitters</p>
<p style="position:absolute;top:657px;left:409px;white-space:nowrap" class="ft1462">9/21 (42.9%)</p>
<p style="position:absolute;top:657px;left:594px;white-space:nowrap" class="ft1462">10/22 (45.5%)</p>
<p style="position:absolute;top:687px;left:176px;white-space:nowrap" class="ft1464">Corticosteroid-free&#160;<br/>remission in Week 8&#160;<br/>PMS&#160;respondersc</p>
<p style="position:absolute;top:705px;left:409px;white-space:nowrap" class="ft1462">4/13 (30.8%)</p>
<p style="position:absolute;top:705px;left:598px;white-space:nowrap" class="ft1462">5/16 (31.3%)</p>
<p style="position:absolute;top:743px;left:176px;white-space:nowrap" class="ft1469">a&#160;Humira 0.6 mg/kg&#160;(maximum of&#160;40 mg)&#160;every other week</p>
<p style="position:absolute;top:762px;left:176px;white-space:nowrap" class="ft1469">b&#160;Humira 0.6 mg/kg&#160;(maximum&#160;of&#160;40 mg) every week</p>
<p style="position:absolute;top:781px;left:176px;white-space:nowrap" class="ft1465">c&#160;In&#160;patients receiving concomitant&#160;corticosteroids at baseline<br/>Note: Patients with missing values at Week 52 or who were randomized to receive&#160;<br/>re-induction or maintenance treatment were considered non-responders for Week 52&#160;<br/>endpoints</p>
<p style="position:absolute;top:878px;left:106px;white-space:nowrap" class="ft1465">Additional exploratory efficacy endpoints included clinical response per the Paediatric Ulcerative Colitis&#160;<br/>Activity Index (PUCAI) (defined as a decrease in PUCAI&#160;≥ 20 points from Baseline) and clinical&#160;<br/>remission per PUCAI (defined as PUCAI &lt; 10) at Week 8 and Week 52 (Table 33).&#160;</p>
</div>
<!-- Page 147 -->
<a name="147"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page147-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1470">147</p>
<p style="position:absolute;top:86px;left:229px;white-space:nowrap" class="ft1471"><b>Table&#160;33:&#160;Exploratory Endpoints Results per PUCAI</b></p>
<p style="position:absolute;top:106px;left:499px;white-space:nowrap" class="ft1471"><b>Week 8</b></p>
<p style="position:absolute;top:127px;left:404px;white-space:nowrap" class="ft1471"><b>Humiraa</b></p>
<p style="position:absolute;top:146px;left:353px;white-space:nowrap" class="ft1471"><b>Maximum of 160 mg at&#160;</b></p>
<p style="position:absolute;top:165px;left:337px;white-space:nowrap" class="ft1471"><b>Week 0 / Placebo at Week 1</b></p>
<p style="position:absolute;top:184px;left:416px;white-space:nowrap" class="ft1472">N=30</p>
<p style="position:absolute;top:127px;left:599px;white-space:nowrap" class="ft1471"><b>Humirab,c</b></p>
<p style="position:absolute;top:146px;left:552px;white-space:nowrap" class="ft1471"><b>Maximum of 160 mg at&#160;</b></p>
<p style="position:absolute;top:165px;left:564px;white-space:nowrap" class="ft1471"><b>Week 0 and Week 1</b></p>
<p style="position:absolute;top:184px;left:615px;white-space:nowrap" class="ft1472">N=47</p>
<p style="position:absolute;top:207px;left:114px;white-space:nowrap" class="ft1472">Clinical remission per PUCAI</p>
<p style="position:absolute;top:207px;left:387px;white-space:nowrap" class="ft1472">10/30 (33.3%)</p>
<p style="position:absolute;top:207px;left:586px;white-space:nowrap" class="ft1472">22/47 (46.8%)</p>
<p style="position:absolute;top:227px;left:114px;white-space:nowrap" class="ft1472">Clinical response per PUCAI</p>
<p style="position:absolute;top:227px;left:387px;white-space:nowrap" class="ft1472">15/30 (50.0%)</p>
<p style="position:absolute;top:227px;left:586px;white-space:nowrap" class="ft1472">32/47&#160;(68.1%)</p>
<p style="position:absolute;top:247px;left:495px;white-space:nowrap" class="ft1471"><b>Week 52</b></p>
<p style="position:absolute;top:267px;left:404px;white-space:nowrap" class="ft1471"><b>Humirad</b></p>
<p style="position:absolute;top:285px;left:350px;white-space:nowrap" class="ft1471"><b>Maximum of 40 mg eow</b></p>
<p style="position:absolute;top:305px;left:416px;white-space:nowrap" class="ft1472">N=31</p>
<p style="position:absolute;top:267px;left:604px;white-space:nowrap" class="ft1471"><b>Humirae</b></p>
<p style="position:absolute;top:285px;left:553px;white-space:nowrap" class="ft1471"><b>Maximum of 40 mg ew</b></p>
<p style="position:absolute;top:305px;left:615px;white-space:nowrap" class="ft1472">N=31</p>
<p style="position:absolute;top:324px;left:114px;white-space:nowrap" class="ft1474">Clinical remission per PUCAI&#160;<br/>in Week 8 PMS responders</p>
<p style="position:absolute;top:324px;left:387px;white-space:nowrap" class="ft1472">14/31 (45.2%)</p>
<p style="position:absolute;top:324px;left:586px;white-space:nowrap" class="ft1472">18/31 (58.1%)</p>
<p style="position:absolute;top:363px;left:114px;white-space:nowrap" class="ft1474">Clinical response per PUCAI&#160;<br/>in Week 8 PMS responders</p>
<p style="position:absolute;top:363px;left:387px;white-space:nowrap" class="ft1472">18/31 (58.1%)</p>
<p style="position:absolute;top:363px;left:586px;white-space:nowrap" class="ft1472">16/31 (51.6%)</p>
<p style="position:absolute;top:400px;left:114px;white-space:nowrap" class="ft1477">a&#160;Humira&#160;2.4 mg/kg&#160;(maximum of 160 mg)&#160;at Week 0, placebo at Week 1,&#160;and&#160;1.2&#160;<br/>mg/kg&#160;(maximum of 80 mg)&#160;at Week 2</p>
<p style="position:absolute;top:438px;left:114px;white-space:nowrap" class="ft1477">b&#160;&#160;Humira&#160;2.4 mg/kg&#160;(maximum&#160;of 160 mg)&#160;at Week 0 and Week 1,&#160;and&#160;1.2&#160;<br/>mg/kg&#160;(maximum of 80 mg)&#160;at Week 2</p>
<p style="position:absolute;top:476px;left:114px;white-space:nowrap" class="ft1477">c&#160;Not including open-label Induction dose&#160;of&#160;Humira&#160;2.4 mg/kg&#160;(maximum&#160;of 160 mg)&#160;at&#160;<br/>Week 0 and Week 1, and 1.2 mg/kg&#160;(maximum of 80 mg)&#160;at Week 2</p>
<p style="position:absolute;top:514px;left:114px;white-space:nowrap" class="ft1479">d&#160;Humira 0.6 mg/kg&#160;(maximum&#160;of&#160;40 mg)&#160;every other week</p>
<p style="position:absolute;top:533px;left:114px;white-space:nowrap" class="ft1474">e&#160;Humira 0.6 mg/kg&#160;(maximum of&#160;40 mg) every week<br/>Note 1: Both induction groups received 0.6&#160;mg/kg (maximum of 40 mg) at Week 4 and&#160;<br/>Week 6<br/>Note 2: Patients with missing values at Week 8 were considered as not having met the&#160;<br/>endpoints<br/>Note 3:&#160;Patients with missing values at Week 52 or who were randomized to receive re-<br/>induction or maintenance&#160;treatment were considered non-responders for Week 52&#160;<br/>endpoints</p>
<p style="position:absolute;top:706px;left:106px;white-space:nowrap" class="ft1474">Of the Humira-treated patients who received re-induction treatment during the maintenance period, 2/6&#160;<br/>(33%) achieved clinical response per FMS at Week 52.</p>
<p style="position:absolute;top:763px;left:106px;white-space:nowrap" class="ft1473"><i>Quality of life</i></p>
<p style="position:absolute;top:801px;left:106px;white-space:nowrap" class="ft1475">Clinically meaningful improvements from Baseline were observed in IMPACT III and the caregiver Work&#160;<br/>Productivity and Activity Impairment (WPAI) scores for the groups treated with&#160;Humira.&#160;</p>
<p style="position:absolute;top:858px;left:106px;white-space:nowrap" class="ft1474">Clinically meaningful increases (improvement) from Baseline in height&#160;velocity were observed for the&#160;<br/>groups treated with adalimumab, and clinically meaningful increases (improvement) from Baseline in&#160;<br/>Body Mass Index were observed for subjects on the high maintenance dose of maximum&#160;40 mg (0.6&#160;<br/>mg/kg) ew.&#160;</p>
<p style="position:absolute;top:953px;left:106px;white-space:nowrap" class="ft1473"><i>Paediatric Uveitis</i></p>
<p style="position:absolute;top:991px;left:106px;white-space:nowrap" class="ft1474">The safety&#160;and efficacy of Humira was assessed in a randomized, double-masked, controlled study of 90&#160;<br/>paediatric patients from 2&#160;to&#160;&lt;&#160;18 years of age with active JIA-associated noninfectious anterior uveitis&#160;<br/>who were refractory to at least 12&#160;weeks of methotrexate treatment. &#160;Patients received either placebo or&#160;<br/>20&#160;mg adalimumab (if&#160;&lt;&#160;30&#160;kg) or 40&#160;mg adalimumab (if&#160;≥&#160;30&#160;kg)&#160;every other week in combination with&#160;<br/>their baseline dose of methotrexate.&#160;</p>
</div>
<!-- Page 148 -->
<a name="148"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page148-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1480">148</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft1484">The primary endpoint was ‘time to treatment failure’. The criteria determining treatment failure were&#160;<br/>worsening or sustained non-improvement in ocular inflammation, partial improvement with development&#160;<br/>of sustained ocular co-morbidities or worsening of ocular co-morbidities, non-permitted use of&#160;<br/>concomitant medications, and suspension of treatment for an extended period of time.</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft1483"><i>Clinical Response</i></p>
<p style="position:absolute;top:239px;left:106px;white-space:nowrap" class="ft1484">Adalimumab significantly delayed the time to treatment failure, as compared to placebo (See Figure&#160;3,&#160;<br/>P&#160;&lt;&#160;0.0001 from log rank test).The median time to treatment failure was 24.1&#160;weeks for subjects treated&#160;<br/>with placebo, whereas the median time to treatment failure was not estimable for subjects treated with&#160;<br/>adalimumab because less than one-half of these subjects experienced treatment failure. &#160;Adalimumab&#160;<br/>significantly decreased the risk of treatment failure by 75% relative to placebo, as shown by the hazard&#160;<br/>ratio (HR = 0.25 [95% CI: &#160;0.12, 0.49]).</p>
<p style="position:absolute;top:372px;left:114px;white-space:nowrap" class="ft1481"><b>Figure&#160;3: Kaplan-Meier Curves Summarizing Time to Treatment Failure in the Paediatric Uveitis&#160;</b></p>
<p style="position:absolute;top:396px;left:438px;white-space:nowrap" class="ft1481"><b>Study</b></p>
<p style="position:absolute;top:861px;left:129px;white-space:nowrap" class="ft14820"><b>P</b></p>
<p style="position:absolute;top:851px;left:129px;white-space:nowrap" class="ft14820"><b>R</b></p>
<p style="position:absolute;top:839px;left:129px;white-space:nowrap" class="ft14820"><b>O</b></p>
<p style="position:absolute;top:826px;left:129px;white-space:nowrap" class="ft14820"><b>B</b></p>
<p style="position:absolute;top:815px;left:129px;white-space:nowrap" class="ft14820"><b>A</b></p>
<p style="position:absolute;top:803px;left:129px;white-space:nowrap" class="ft14820"><b>B</b></p>
<p style="position:absolute;top:792px;left:129px;white-space:nowrap" class="ft14820"><b>IL</b></p>
<p style="position:absolute;top:775px;left:129px;white-space:nowrap" class="ft14820"><b>IT</b></p>
<p style="position:absolute;top:757px;left:129px;white-space:nowrap" class="ft14820"><b>Y</b></p>
<p style="position:absolute;top:746px;left:129px;white-space:nowrap" class="ft14820"><b>&#160;O</b></p>
<p style="position:absolute;top:728px;left:129px;white-space:nowrap" class="ft14820"><b>F</b></p>
<p style="position:absolute;top:719px;left:129px;white-space:nowrap" class="ft14820"><b>&#160;F</b></p>
<p style="position:absolute;top:704px;left:129px;white-space:nowrap" class="ft14820"><b>A</b></p>
<p style="position:absolute;top:692px;left:129px;white-space:nowrap" class="ft14820"><b>IL</b></p>
<p style="position:absolute;top:675px;left:129px;white-space:nowrap" class="ft14820"><b>IN</b></p>
<p style="position:absolute;top:657px;left:129px;white-space:nowrap" class="ft14820"><b>G</b></p>
<p style="position:absolute;top:644px;left:129px;white-space:nowrap" class="ft14820"><b>&#160;T</b></p>
<p style="position:absolute;top:629px;left:129px;white-space:nowrap" class="ft14820"><b>R</b></p>
<p style="position:absolute;top:617px;left:129px;white-space:nowrap" class="ft14820"><b>E</b></p>
<p style="position:absolute;top:606px;left:129px;white-space:nowrap" class="ft14820"><b>A</b></p>
<p style="position:absolute;top:594px;left:129px;white-space:nowrap" class="ft14820"><b>T</b></p>
<p style="position:absolute;top:582px;left:129px;white-space:nowrap" class="ft14820"><b>M</b></p>
<p style="position:absolute;top:567px;left:129px;white-space:nowrap" class="ft14820"><b>E</b></p>
<p style="position:absolute;top:556px;left:129px;white-space:nowrap" class="ft14820"><b>N</b></p>
<p style="position:absolute;top:544px;left:129px;white-space:nowrap" class="ft14820"><b>T</b></p>
<p style="position:absolute;top:982px;left:412px;white-space:nowrap" class="ft1481"><b>TIME (WEEKS)</b></p>
<p style="position:absolute;top:1000px;left:149px;white-space:nowrap" class="ft1482">Treatment</p>
<p style="position:absolute;top:1000px;left:500px;white-space:nowrap" class="ft1482">Placebo</p>
<p style="position:absolute;top:1000px;left:669px;white-space:nowrap" class="ft1482">Adalimumab</p>
<p style="position:absolute;top:1020px;left:149px;white-space:nowrap" class="ft1482">Note: P = Placebo (Number at Risk); H = HUMIRA (Number at Risk).</p>
<p style="position:absolute;top:1076px;left:106px;white-space:nowrap" class="ft1481"><b>5.2</b></p>
<p style="position:absolute;top:1076px;left:148px;white-space:nowrap" class="ft1481"><b>Pharmacokinetic properties</b></p>
</div>
<!-- Page 149 -->
<a name="149"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page149-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1490">149</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft1492">Absorption and distribution</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft1494">After subcutaneous administration of a single 40&#160;mg dose, absorption and&#160;distribution of adalimumab was&#160;<br/>slow, with peak serum concentrations being reached about 5&#160;days after administration. The average&#160;<br/>absolute bioavailability of adalimumab estimated from three studies following a single 40&#160;mg&#160;<br/>subcutaneous dose was 64%. After single intravenous doses ranging from 0.25 to 10&#160;mg/kg,&#160;<br/>concentrations were dose proportional. After doses of 0.5&#160;mg/kg (~40&#160;mg), clearances ranged from 11 to&#160;<br/>15&#160;ml/hour, the distribution volume (Vss) ranged from 5 to 6&#160;litres and the mean terminal phase half-life&#160;<br/>was approximately two weeks. Adalimumab concentrations in the synovial fluid from several rheumatoid&#160;<br/>arthritis patients ranged from 31-96% of those in serum.</p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft1497">Following subcutaneous administration of 40&#160;mg of adalimumab every other week in adult rheumatoid&#160;<br/>arthritis (RA) patients the mean steady-state trough concentrations were approximately 5</p>
<p style="position:absolute;top:332px;left:697px;white-space:nowrap" class="ft1496">g/ml (without&#160;</p>
<p style="position:absolute;top:354px;left:106px;white-space:nowrap" class="ft1492">concomitant methotrexate) and 8 to 9</p>
<p style="position:absolute;top:352px;left:357px;white-space:nowrap" class="ft1496">g/ml (with concomitant methotrexate), respectively. &#160;The serum&#160;</p>
<p style="position:absolute;top:373px;left:106px;white-space:nowrap" class="ft1494">adalimumab trough levels at steady-state increased roughly proportionally with dose following 20, 40 and&#160;<br/>80&#160;mg subcutaneous dosing every other week and every week.</p>
<p style="position:absolute;top:430px;left:106px;white-space:nowrap" class="ft1494">Following the administration of 24&#160;mg/m2&#160;(maximum of 40&#160;mg) subcutaneously every other week to&#160;<br/>patients with polyarticular juvenile idiopathic arthritis (JIA) who were 4 to 17&#160;years the mean trough&#160;<br/>steady-state (values measured from Week&#160;20 to 48) serum adalimumab concentration was 5.6&#160;±&#160;5.6&#160;µg/ml&#160;<br/>(102% CV) for adalimumab without concomitant methotrexate and 10.9&#160;±&#160;5.2&#160;µg/ml (47.7% CV)&#160;with&#160;<br/>concomitant methotrexate.</p>
<p style="position:absolute;top:544px;left:106px;white-space:nowrap" class="ft1494">In patients with&#160;polyarticular&#160;JIA who were 2&#160;to&#160;&lt;4&#160;years old or aged 4 and above weighing &lt;15&#160;kg dosed&#160;<br/>with adalimumab 24&#160;mg/m2&#160;, the mean trough steady-state serum adalimumab concentrations was&#160;<br/>6.0&#160;±&#160;6.1&#160;µg/ml&#160;(101% CV) for adalimumab without concomitant methotrexate and 7.9&#160;±&#160;5.6&#160;µg/ml&#160;<br/>(71.2% CV) with concomitant methotrexate.</p>
<p style="position:absolute;top:640px;left:106px;white-space:nowrap" class="ft1497">Following the administration of 24&#160;mg/m2&#160;(maximum of 40&#160;mg) subcutaneously every other week to&#160;<br/>patients with enthesitis-related arthritis who were&#160;6 to 17&#160;years, the mean trough steady-state (values&#160;<br/>measured at Week&#160;24) serum adalimumab concentrations were 8.8&#160;±&#160;6.6&#160;μg/ml for adalimumab without&#160;<br/>concomitant methotrexate and 11.8&#160;±&#160;4.3&#160;μg/ml with concomitant methotrexate.</p>
<p style="position:absolute;top:741px;left:106px;white-space:nowrap" class="ft1497">Following subcutaneous administration of 40&#160;mg of adalimumab every other week in adult non-<br/>radiographic axial spondyloarthritis patients, the mean (±SD) trough steady-state concentration at Week&#160;<br/>68 was 8.0&#160;± 4.6</p>
<p style="position:absolute;top:778px;left:219px;white-space:nowrap" class="ft1496">g/ml.</p>
<p style="position:absolute;top:819px;left:106px;white-space:nowrap" class="ft1492">In adult patients with psoriasis, the mean steady-state trough concentration was 5</p>
<p style="position:absolute;top:817px;left:645px;white-space:nowrap" class="ft1496">g/ml&#160;during&#160;</p>
<p style="position:absolute;top:838px;left:106px;white-space:nowrap" class="ft1492">adalimumab 40&#160;mg&#160;every other week&#160;monotherapy treatment.</p>
<p style="position:absolute;top:876px;left:106px;white-space:nowrap" class="ft1494">Following the administration of 0.8&#160;mg/kg (maximum of 40&#160;mg) subcutaneously every other week to&#160;<br/>paediatric patients with chronic plaque psoriasis, the mean&#160;±&#160;SD steady-state adalimumab trough&#160;<br/>concentration was approximately 7.4&#160;±&#160;5.8&#160;µg/ml (79% CV).</p>
<p style="position:absolute;top:951px;left:106px;white-space:nowrap" class="ft1494">In adult patients with hidradenitis suppurativa, a dose of 160&#160;mg Humira on Week&#160;0 followed by 80&#160;mg on&#160;<br/>Week&#160;2 achieved serum adalimumab trough concentrations of approximately 7 to 8&#160;μg/ml at Week&#160;2 and&#160;<br/>Week&#160;4. &#160;The mean steady-state trough concentration at Week&#160;12 through Week&#160;36 were approximately 8&#160;<br/>to 10&#160;μg/ml during adalimumab 40&#160;mg&#160;every week treatment. &#160;</p>
<p style="position:absolute;top:1047px;left:106px;white-space:nowrap" class="ft1494">Adalimumab exposure in adolescent HS patients was predicted using population pharmacokinetic&#160;<br/>modelling and simulation based on cross-indication pharmacokinetics in other paediatric patients&#160;</p>
</div>
<!-- Page 150 -->
<a name="150"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page150-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1500">150</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft1504">(paediatric psoriasis, juvenile idiopathic arthritis, paediatric Crohn’s disease, and enthesitis-related&#160;<br/>arthritis).&#160;The recommended adolescent HS dosing schedule is 40&#160;mg every other week. Since exposure to&#160;<br/>adalimumab can be affected by body size, adolescents with higher body weight and inadequate response&#160;<br/>may benefit from receiving the recommended adult dose of 40&#160;mg&#160;every week.</p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft1507">In patients with Crohn’s disease, the loading dose of 80&#160;mg Humira on Week&#160;0 followed by 40&#160;mg Humira&#160;<br/>on Week&#160;2 achieves serum adalimumab trough concentrations of approximately 5.5</p>
<p style="position:absolute;top:199px;left:662px;white-space:nowrap" class="ft1506">g/ml during the&#160;</p>
<p style="position:absolute;top:220px;left:106px;white-space:nowrap" class="ft1507">induction period. A loading dose of 160&#160;mg Humira on Week&#160;0&#160;followed by 80&#160;mg Humira on Week&#160;2&#160;<br/>achieves serum adalimumab trough concentrations of approximately 12</p>
<p style="position:absolute;top:238px;left:582px;white-space:nowrap" class="ft1506">g/ml&#160;during the induction period.&#160;</p>
<p style="position:absolute;top:260px;left:106px;white-space:nowrap" class="ft1502">Mean steady-state trough levels of approximately 7</p>
<p style="position:absolute;top:258px;left:449px;white-space:nowrap" class="ft1506">g/ml&#160;were observed in Crohn’s disease patients who&#160;</p>
<p style="position:absolute;top:279px;left:106px;white-space:nowrap" class="ft1502">received a maintenance dose of 40&#160;mg Humira every other week.</p>
<p style="position:absolute;top:318px;left:106px;white-space:nowrap" class="ft1507">In paediatric patients with moderate to severe CD, the open-label adalimumab induction dose was&#160;<br/>160/80&#160;mg&#160;or 80/40&#160;mg at Weeks&#160;0 and 2, respectively, dependent on a body weight cut-off&#160;of 40&#160;kg. &#160;At&#160;<br/>Week&#160;4, patients were&#160;randomised 1:1 to either the Standard Dose (40/20&#160;mg&#160;eow)&#160;or Low Dose&#160;<br/>(20/10&#160;mg eow)&#160;maintenance treatment groups based on their body weight.&#160;The&#160;mean (±SD)&#160;serum&#160;<br/>adalimumab trough concentrations achieved at Week&#160;4 were 15.7±6.6</p>
<p style="position:absolute;top:393px;left:572px;white-space:nowrap" class="ft1506">g/ml for&#160;patients&#160;≥&#160;40&#160;kg&#160;</p>
<p style="position:absolute;top:415px;left:106px;white-space:nowrap" class="ft1502">(160/80&#160;mg) and&#160;10.6±6.1</p>
<p style="position:absolute;top:413px;left:283px;white-space:nowrap" class="ft1506">g/ml for patients &lt;&#160;40&#160;kg (80/40&#160;mg).&#160;</p>
<p style="position:absolute;top:453px;left:106px;white-space:nowrap" class="ft1507">For patients who stayed on their randomised therapy, the mean&#160;(±SD)&#160;adalimumab trough concentrations&#160;<br/>at Week&#160;52 were&#160;9.5±5.6</p>
<p style="position:absolute;top:471px;left:272px;white-space:nowrap" class="ft1506">g/ml for the Standard Dose group and&#160;3.5±2.2&#160;g/ml for the Low Dose group. &#160;</p>
<p style="position:absolute;top:492px;left:106px;white-space:nowrap" class="ft1505">The&#160;mean trough concentrations were maintained in patients who continued to receive adalimumab&#160;<br/>treatment eow for 52&#160;weeks.&#160;For patients who dose escalated from eow to weekly regimen, the mean&#160;<br/>(±SD)&#160;serum concentrations of adalimumab at Week&#160;52 were 15.3±11.4&#160;μg/ml (40/20&#160;mg, weekly) and&#160;<br/>6.7±3.5&#160;μg/ml (20/10&#160;mg, weekly).</p>
<p style="position:absolute;top:587px;left:106px;white-space:nowrap" class="ft1507">In patients with ulcerative colitis, a loading dose of 160&#160;mg Humira on Week&#160;0 followed by 80&#160;mg Humira&#160;<br/>on Week&#160;2 achieves serum adalimumab trough concentrations of approximately 12</p>
<p style="position:absolute;top:605px;left:658px;white-space:nowrap" class="ft1506">g/ml during the&#160;</p>
<p style="position:absolute;top:627px;left:106px;white-space:nowrap" class="ft1502">induction period. &#160;Mean steady-state trough levels of approximately 8</p>
<p style="position:absolute;top:625px;left:570px;white-space:nowrap" class="ft1506">g/ml were&#160;observed in ulcerative&#160;</p>
<p style="position:absolute;top:646px;left:106px;white-space:nowrap" class="ft1502">colitis patients who received a maintenance dose of 40&#160;mg Humira every other week.&#160;</p>
<p style="position:absolute;top:684px;left:106px;white-space:nowrap" class="ft1504">Following the subcutaneous&#160;administration of body weight-based dosing of 0.6&#160;mg/kg (maximum of&#160;<br/>40&#160;mg)&#160;every other week to paediatric patients with ulcerative colitis, the mean trough steady-state serum&#160;<br/>adalimumab concentration was 5.01±3.28&#160;µg/ml&#160;at Week&#160;52. For patients who received 0.6&#160;mg/kg&#160;<br/>(maximum of 40&#160;mg)&#160;every week, the mean (±SD) trough steady-state serum adalimumab concentration&#160;<br/>was 15.7±5.60&#160;μg/ml at Week&#160;52.</p>
<p style="position:absolute;top:798px;left:106px;white-space:nowrap" class="ft1507">In&#160;adult&#160;patients with uveitis, a loading dose of 80&#160;mg adalimumab on Week 0 followed by 40&#160;mg&#160;<br/>adalimumab every other week starting at Week 1, resulted in mean steady-state concentrations of&#160;<br/>approximately 8 to 10</p>
<p style="position:absolute;top:835px;left:256px;white-space:nowrap" class="ft1506">g/ml.</p>
<p style="position:absolute;top:875px;left:106px;white-space:nowrap" class="ft1504">Adalimumab exposure in paediatric uveitis patients was predicted using population pharmacokinetic&#160;<br/>modelling and simulation based on cross-indication&#160;pharmacokinetics in other paediatric patients&#160;<br/>(paediatric psoriasis, juvenile idiopathic arthritis, paediatric Crohn’s disease, and enthesitis-related&#160;<br/>arthritis). No clinical exposure data are available on the use of a loading dose in children &lt; 6 years. The&#160;<br/>predicted exposures indicate that in the absence of methotrexate, a loading dose may lead to an initial&#160;<br/>increase in systemic exposure.</p>
<p style="position:absolute;top:1008px;left:106px;white-space:nowrap" class="ft1504">Population pharmacokinetic and pharmacokinetic/pharmacodynamic modelling and simulation predicted&#160;<br/>comparable adalimumab exposure and efficacy in patients treated with 80&#160;mg&#160;every other week when&#160;<br/>compared with 40&#160;mg&#160;every week (including adult patients with RA, HS,&#160;UC, CD or&#160;Ps, patients with&#160;<br/>adolescent HS, and paediatric patients&#160;≥&#160;40&#160;kg with CD&#160;and UC).</p>
</div>
<!-- Page 151 -->
<a name="151"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page151-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1510">151</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft1512">Exposure-response&#160;relationship in paediatric population</p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft1515">On the basis of clinical trial data in patients with JIA (pJIA and ERA), an exposure-response relationship&#160;<br/>was established between plasma concentrations and PedACR 50 response. The apparent adalimumab&#160;<br/>plasma&#160;concentration that produces half the maximum probability of PedACR 50 response (EC50) was&#160;<br/>3&#160;μg/ml (95% CI: 1-6&#160;μg/ml).&#160;</p>
<p style="position:absolute;top:219px;left:106px;white-space:nowrap" class="ft1514">Exposure-response relationships between adalimumab concentration and efficacy in paediatric patients&#160;<br/>with severe chronic plaque psoriasis were&#160;established for PASI 75 and PGA clear or minimal,&#160;<br/>respectively. PASI 75 and PGA clear or minimal increased with increasing adalimumab concentrations,&#160;<br/>both with a similar apparent EC50 of approximately 4.5&#160;μg/ml&#160;(95% CI 0.4-47.6 and 1.9-10.5,&#160;<br/>respectively). &#160;</p>
<p style="position:absolute;top:333px;left:106px;white-space:nowrap" class="ft1512">Elimination</p>
<p style="position:absolute;top:370px;left:106px;white-space:nowrap" class="ft1514">Population pharmacokinetic analyses with data from over 1,300 RA patients revealed a trend toward&#160;<br/>higher apparent clearance of adalimumab with increasing body weight. After adjustment for weight&#160;<br/>differences, gender and age appeared to have a minimal effect&#160;on adalimumab clearance. &#160;The serum&#160;<br/>levels of free adalimumab (not bound to anti-adalimumab antibodies, AAA) were observed to be lower in&#160;<br/>patients with measurable AAA. &#160;</p>
<p style="position:absolute;top:485px;left:106px;white-space:nowrap" class="ft1512">Hepatic or renal impairment</p>
<p style="position:absolute;top:522px;left:106px;white-space:nowrap" class="ft1512">Humira has not been studied in patients with hepatic or&#160;renal impairment.</p>
<p style="position:absolute;top:560px;left:106px;white-space:nowrap" class="ft1511"><b>5.3</b></p>
<p style="position:absolute;top:560px;left:148px;white-space:nowrap" class="ft1511"><b>Preclinical safety data&#160;</b></p>
<p style="position:absolute;top:598px;left:106px;white-space:nowrap" class="ft1515">Non-clinical data reveal no special hazard for humans based on studies of single dose toxicity, repeated&#160;<br/>dose toxicity, and genotoxicity. &#160;</p>
<p style="position:absolute;top:655px;left:106px;white-space:nowrap" class="ft1515">An&#160;embryo-foetal developmental toxicity/perinatal developmental study has been performed in&#160;<br/>cynomolgus monkeys at 0, 30 and 100&#160;mg/kg (9-17 monkeys/group) and has revealed no evidence of harm&#160;<br/>to the foetuses due to adalimumab. Neither carcinogenicity studies, nor a standard assessment of fertility&#160;<br/>and postnatal toxicity, were performed with adalimumab due to the lack of appropriate models for an&#160;<br/>antibody with limited cross-reactivity to rodent TNF and to the development of neutralising antibodies in&#160;<br/>rodents.&#160;</p>
<p style="position:absolute;top:807px;left:106px;white-space:nowrap" class="ft1511"><b>6.</b></p>
<p style="position:absolute;top:807px;left:148px;white-space:nowrap" class="ft1511"><b>PHARMACEUTICAL PARTICULARS</b></p>
<p style="position:absolute;top:845px;left:106px;white-space:nowrap" class="ft1511"><b>6.1</b></p>
<p style="position:absolute;top:845px;left:148px;white-space:nowrap" class="ft1511"><b>List of excipients&#160;</b></p>
<p style="position:absolute;top:883px;left:106px;white-space:nowrap" class="ft1514">Mannitol<br/>Citric acid monohydrate<br/>Sodium citrate<br/>Sodium dihydrogen phosphate dihydrate<br/>Disodium phosphate dihydrate<br/>Sodium chloride<br/>Polysorbate 80<br/>Sodium hydroxide<br/>Water for injections</p>
<p style="position:absolute;top:1072px;left:106px;white-space:nowrap" class="ft1511"><b>6.2</b></p>
<p style="position:absolute;top:1072px;left:148px;white-space:nowrap" class="ft1511"><b>Incompatibilities&#160;</b></p>
</div>
<!-- Page 152 -->
<a name="152"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page152-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1520">152</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft1524">In the absence of compatibility studies, this&#160;medicinal product must not be mixed with other medicinal&#160;<br/>products.</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft1521"><b>6.3</b></p>
<p style="position:absolute;top:162px;left:148px;white-space:nowrap" class="ft1521"><b>Shelf life&#160;</b></p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft1522">2 years</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft1521"><b>6.4</b></p>
<p style="position:absolute;top:238px;left:148px;white-space:nowrap" class="ft1521"><b>Special precautions for storage&#160;</b></p>
<p style="position:absolute;top:277px;left:106px;white-space:nowrap" class="ft1522">Store in a refrigerator (2</p>
<p style="position:absolute;top:275px;left:266px;white-space:nowrap" class="ft1526">C&#160;–&#160;8C). Do not freeze. Keep the pre-filled syringe or pre-filled pen in its outer&#160;</p>
<p style="position:absolute;top:296px;left:106px;white-space:nowrap" class="ft1522">carton in order&#160;to protect from light. &#160;</p>
<p style="position:absolute;top:334px;left:106px;white-space:nowrap" class="ft1524">A single Humira pre-filled syringe or pre-filled pen may be stored at temperatures up to a maximum of&#160;<br/>25°C for a period of up to 14&#160;days. The syringe or pen must be protected from light, and discarded if not&#160;<br/>used within the 14-day period.</p>
<p style="position:absolute;top:410px;left:106px;white-space:nowrap" class="ft1521"><b>6.5</b></p>
<p style="position:absolute;top:410px;left:148px;white-space:nowrap" class="ft1521"><b>Nature and contents of container &#160;</b></p>
<p style="position:absolute;top:448px;left:106px;white-space:nowrap" class="ft1524">Humira 40&#160;mg solution for injection in pre-filled syringe&#160;<br/>Humira 40&#160;mg solution for injection in single-use pre-filled syringe (type I glass) with a plunger stopper&#160;<br/>(bromobutyl rubber) and a needle with&#160;a needle shield (thermoplastic elastomer).</p>
<p style="position:absolute;top:523px;left:106px;white-space:nowrap" class="ft1522">Packs of:</p>
<p style="position:absolute;top:542px;left:106px;white-space:nowrap" class="ft1526"></p>
<p style="position:absolute;top:544px;left:148px;white-space:nowrap" class="ft1522">1 pre-filled syringe (0.8&#160;ml sterile solution) with 1 alcohol pad in a blister.&#160;</p>
<p style="position:absolute;top:562px;left:106px;white-space:nowrap" class="ft1526"></p>
<p style="position:absolute;top:564px;left:148px;white-space:nowrap" class="ft1522">2 pre-filled syringes (0.8&#160;ml sterile solution), each with 1 alcohol pad, in a blister.&#160;</p>
<p style="position:absolute;top:582px;left:106px;white-space:nowrap" class="ft1526"></p>
<p style="position:absolute;top:584px;left:148px;white-space:nowrap" class="ft1522">4 pre-filled syringes (0.8&#160;ml sterile solution), each with 1 alcohol pad, in a blister.&#160;</p>
<p style="position:absolute;top:602px;left:106px;white-space:nowrap" class="ft1526"></p>
<p style="position:absolute;top:604px;left:148px;white-space:nowrap" class="ft1522">6 pre-filled syringes (0.8&#160;ml sterile solution), each with 1 alcohol pad, in a blister.</p>
<p style="position:absolute;top:640px;left:106px;white-space:nowrap" class="ft1524">Humira 40&#160;mg solution for injection in pre-filled syringe with needle&#160;guard&#160;<br/>Humira 40&#160;mg solution for injection in single-use pre-filled syringe (type I glass) with needle&#160;guard for&#160;<br/>hospital and caregiver use. The syringe is made from type 1 glass with a plunger stopper (bromobutyl&#160;<br/>rubber) and a needle with a needle shield (thermoplastic elastomer).</p>
<p style="position:absolute;top:735px;left:106px;white-space:nowrap" class="ft1525">Packs of:<br/>1 pre-filled syringe with needle&#160;guard (0.8&#160;ml sterile solution) in a blister, and 1 alcohol pad.</p>
<p style="position:absolute;top:792px;left:106px;white-space:nowrap" class="ft1524">Humira 40&#160;mg solution for injection in pre-filled pen<br/>Humira 40&#160;mg solution for injection in single-use pre-filled pen for&#160;patient use containing a pre-filled&#160;<br/>syringe. The syringe inside the pen is made from type 1 glass with a plunger stopper (bromobutyl rubber)&#160;<br/>and a needle with a needle shield (thermoplastic elastomer).</p>
<p style="position:absolute;top:887px;left:106px;white-space:nowrap" class="ft1522">Packs of:</p>
<p style="position:absolute;top:905px;left:133px;white-space:nowrap" class="ft1526">&#160;1 pre-filled pen (0.8 ml sterile solution),&#160;with 2 alcohol pads in a blister.&#160;</p>
<p style="position:absolute;top:925px;left:133px;white-space:nowrap" class="ft1526">&#160;2 pre-filled pens (0.8 ml sterile solution), each with 1 alcohol pad, in a blister.&#160;</p>
<p style="position:absolute;top:946px;left:133px;white-space:nowrap" class="ft1526">&#160;4 pre-filled pens (0.8 ml sterile solution), each with 1 alcohol pad, in a blister.&#160;</p>
<p style="position:absolute;top:966px;left:133px;white-space:nowrap" class="ft1526">&#160;6 pre-filled pens (0.8 ml sterile solution), each&#160;with 1 alcohol pad, in a blister.</p>
<p style="position:absolute;top:1006px;left:106px;white-space:nowrap" class="ft1522">Not all presentations or pack sizes may be marketed.</p>
<p style="position:absolute;top:1044px;left:106px;white-space:nowrap" class="ft1521"><b>6.6</b></p>
<p style="position:absolute;top:1044px;left:148px;white-space:nowrap" class="ft1521"><b>Special precautions for disposal</b></p>
</div>
<!-- Page 153 -->
<a name="153"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page153-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1530">153</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft1535">Any unused medicinal product or waste material should be disposed of in accordance with local&#160;<br/>requirements.</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft1531"><b>7.</b></p>
<p style="position:absolute;top:162px;left:148px;white-space:nowrap" class="ft1531"><b>MARKETING AUTHORISATION HOLDER&#160;</b></p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft1534">AbbVie Deutschland GmbH &amp; Co. KG<br/>Knollstrasse<br/>67061 Ludwigshafen<br/>Germany</p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft1531"><b>8.</b></p>
<p style="position:absolute;top:314px;left:148px;white-space:nowrap" class="ft1531"><b>MARKETING AUTHORISATION NUMBERS&#160;</b></p>
<p style="position:absolute;top:352px;left:106px;white-space:nowrap" class="ft1535">Humira 40&#160;mg solution for injection in pre-filled syringe&#160;<br/>EU/1/03/256/002<br/>EU/1/03/256/003<br/>EU/1/03/256/004<br/>EU/1/03/256/005</p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft1534">Humira 40&#160;mg solution for injection in pre-filled syringe with needle&#160;guard&#160;<br/>EU/1/03/256/006</p>
<p style="position:absolute;top:522px;left:106px;white-space:nowrap" class="ft1534">Humira 40&#160;mg solution for injection in pre-filled pen<br/>EU/1/03/256/007<br/>EU/1/03/256/008<br/>EU/1/03/256/009<br/>EU/1/03/256/010</p>
<p style="position:absolute;top:655px;left:106px;white-space:nowrap" class="ft1531"><b>9.</b></p>
<p style="position:absolute;top:655px;left:148px;white-space:nowrap" class="ft1531"><b>DATE OF FIRST&#160;AUTHORISATION/RENEWAL OF THE AUTHORISATION</b></p>
<p style="position:absolute;top:693px;left:106px;white-space:nowrap" class="ft1534">Date of first authorisation: &#160;08 September 2003<br/>Date of latest renewal: 08 September 2008&#160;</p>
<p style="position:absolute;top:769px;left:106px;white-space:nowrap" class="ft1531"><b>10.</b></p>
<p style="position:absolute;top:769px;left:148px;white-space:nowrap" class="ft1531"><b>DATE OF REVISION&#160;OF THE TEXT</b></p>
<p style="position:absolute;top:807px;left:106px;white-space:nowrap" class="ft1535">Detailed information on this medicinal product is available on the website of the European Medicines&#160;<br/><a href="http://www.ema.europa.eu/">Agency&#160;http://www.ema.europa.eu</a></p>
</div>
<!-- Page 154 -->
<a name="154"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page154-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1540">154</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft1541"><b>1.</b></p>
<p style="position:absolute;top:86px;left:148px;white-space:nowrap" class="ft1541"><b>NAME OF THE MEDICINAL PRODUCT</b></p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft1544">Humira 40&#160;mg solution for injection in pre-filled syringe<br/>Humira 40&#160;mg solution for injection in pre-filled pen</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft1541"><b>2.</b></p>
<p style="position:absolute;top:200px;left:148px;white-space:nowrap" class="ft1541"><b>QUALITATIVE&#160;AND QUANTITATIVE COMPOSITION</b></p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft1544">Humira 40&#160;mg solution for injection in pre-filled syringe&#160;<br/>Each 0.4&#160;ml single dose pre-filled syringe&#160;contains 40&#160;mg&#160;of adalimumab.</p>
<p style="position:absolute;top:295px;left:106px;white-space:nowrap" class="ft1545">Humira 40&#160;mg solution for injection in pre-filled pen<br/>Each 0.4&#160;ml single dose pre-filled pen&#160;contains 40&#160;mg of adalimumab.</p>
<p style="position:absolute;top:352px;left:106px;white-space:nowrap" class="ft1542">Adalimumab is a recombinant human monoclonal antibody&#160;produced&#160;in Chinese Hamster Ovary cells.</p>
<p style="position:absolute;top:390px;left:106px;white-space:nowrap" class="ft1542">For the full list&#160;of&#160;excipients, see section 6.1.</p>
<p style="position:absolute;top:446px;left:106px;white-space:nowrap" class="ft1541"><b>3.</b></p>
<p style="position:absolute;top:446px;left:148px;white-space:nowrap" class="ft1541"><b>PHARMACEUTICAL&#160;FORM&#160;</b></p>
<p style="position:absolute;top:485px;left:106px;white-space:nowrap" class="ft1542">Solution for injection.&#160;(injection)</p>
<p style="position:absolute;top:522px;left:106px;white-space:nowrap" class="ft1542">Clear, colourless solution.&#160;</p>
<p style="position:absolute;top:579px;left:106px;white-space:nowrap" class="ft1541"><b>4.</b></p>
<p style="position:absolute;top:579px;left:148px;white-space:nowrap" class="ft1541"><b>CLINICAL PARTICULARS</b></p>
<p style="position:absolute;top:617px;left:106px;white-space:nowrap" class="ft1541"><b>4.1</b></p>
<p style="position:absolute;top:617px;left:148px;white-space:nowrap" class="ft1541"><b>Therapeutic indications&#160;</b></p>
<p style="position:absolute;top:655px;left:106px;white-space:nowrap" class="ft1542">Rheumatoid arthritis</p>
<p style="position:absolute;top:693px;left:106px;white-space:nowrap" class="ft1542">Humira in combination with methotrexate, is indicated for:</p>
<p style="position:absolute;top:731px;left:106px;white-space:nowrap" class="ft15425"></p>
<p style="position:absolute;top:731px;left:147px;white-space:nowrap" class="ft1545">the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response&#160;<br/>to&#160;disease-modifying anti-rheumatic drugs including methotrexate has been inadequate.</p>
<p style="position:absolute;top:769px;left:106px;white-space:nowrap" class="ft15425"></p>
<p style="position:absolute;top:769px;left:147px;white-space:nowrap" class="ft1544">the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated&#160;<br/>with methotrexate.</p>
<p style="position:absolute;top:826px;left:106px;white-space:nowrap" class="ft1544">Humira can be given as monotherapy in case of intolerance to methotrexate or when continued treatment&#160;<br/>with methotrexate is inappropriate.</p>
<p style="position:absolute;top:883px;left:106px;white-space:nowrap" class="ft1544">Humira has been shown to reduce the rate of progression of joint damage as measured by X-ray and to&#160;<br/>improve physical function, when given in combination with methotrexate.</p>
<p style="position:absolute;top:940px;left:106px;white-space:nowrap" class="ft1542">Juvenile idiopathic arthritis</p>
<p style="position:absolute;top:978px;left:106px;white-space:nowrap" class="ft1543"><i>Polyarticular juvenile idiopathic arthritis</i></p>
<p style="position:absolute;top:1016px;left:106px;white-space:nowrap" class="ft1544">Humira in combination with methotrexate is indicated for the treatment of active polyarticular juvenile&#160;<br/>idiopathic arthritis, in patients from the age of 2&#160;years who have had&#160;an inadequate response to one or&#160;<br/>more&#160;disease-modifying anti-rheumatic drugs (DMARDs). Humira can be given as monotherapy in case&#160;</p>
</div>
<!-- Page 155 -->
<a name="155"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page155-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1550">155</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft1555">of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the&#160;<br/>efficacy in monotherapy see section 5.1). Humira has not been studied in patients aged less than 2&#160;years.</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft1553"><i>Enthesitis-related arthritis</i></p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft1554">Humira is indicated for the treatment of active enthesitis-related arthritis in patients, 6&#160;years of age and&#160;<br/>older, who have&#160;had an&#160;inadequate response to, or who are intolerant of, conventional therapy (see section&#160;<br/>5.1).</p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft1552">Axial spondyloarthritis&#160;</p>
<p style="position:absolute;top:295px;left:106px;white-space:nowrap" class="ft1553"><i>Ankylosing spondylitis (AS)</i></p>
<p style="position:absolute;top:333px;left:106px;white-space:nowrap" class="ft1554">Humira is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an&#160;<br/>inadequate response to conventional therapy.</p>
<p style="position:absolute;top:390px;left:106px;white-space:nowrap" class="ft1553"><i>Axial spondyloarthritis without radiographic evidence of AS</i></p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft1554">Humira is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic&#160;<br/>evidence of AS but with objective signs of inflammation by elevated CRP and / or MRI, who have had an&#160;<br/>inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs&#160;(NSAIDs).</p>
<p style="position:absolute;top:503px;left:106px;white-space:nowrap" class="ft1552">Psoriatic arthritis</p>
<p style="position:absolute;top:541px;left:106px;white-space:nowrap" class="ft1554">Humira is indicated for the treatment of active and progressive psoriatic arthritis in&#160;adults when the&#160;<br/>response to previous disease-modifying anti-rheumatic drug therapy has been inadequate. Humira has&#160;<br/>been shown to reduce the rate of progression of&#160;peripheral&#160;joint damage as measured by X-ray&#160;in patients&#160;<br/>with polyarticular symmetrical subtypes of the disease (see Section 5.1)&#160;and to improve physical function.</p>
<p style="position:absolute;top:636px;left:106px;white-space:nowrap" class="ft1552">Psoriasis</p>
<p style="position:absolute;top:674px;left:106px;white-space:nowrap" class="ft1555">Humira is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who&#160;<br/>are&#160;candidates for systemic therapy.</p>
<p style="position:absolute;top:731px;left:106px;white-space:nowrap" class="ft1552">Paediatric plaque psoriasis</p>
<p style="position:absolute;top:769px;left:106px;white-space:nowrap" class="ft1554">Humira is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from&#160;<br/>4&#160;years of age who have had an inadequate response to or are inappropriate candidates for topical therapy&#160;<br/>and phototherapies.</p>
<p style="position:absolute;top:845px;left:106px;white-space:nowrap" class="ft1552">Hidradenitis&#160;suppurativa (HS)</p>
<p style="position:absolute;top:883px;left:106px;white-space:nowrap" class="ft1554">Humira is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa)&#160;<br/>in adults and adolescents from 12 years of age with an inadequate response to conventional systemic HS&#160;<br/>therapy (see sections 5.1 and 5.2).</p>
<p style="position:absolute;top:959px;left:106px;white-space:nowrap" class="ft1552">Crohn’s disease</p>
<p style="position:absolute;top:997px;left:106px;white-space:nowrap" class="ft1554">Humira is indicated for treatment of moderately to severely active Crohn’s disease, in adult patients who&#160;<br/>have not responded despite a full and adequate course of therapy with a corticosteroid and/or an&#160;<br/>immunosuppressant; or who are&#160;intolerant to or have medical contraindications for such therapies.&#160;</p>
</div>
<!-- Page 156 -->
<a name="156"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page156-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1560">156</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft1562">Paediatric Crohn's disease&#160;</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft1564">Humira is indicated for the treatment of moderately to severely active Crohn's disease in paediatric&#160;<br/>patients (from 6&#160;years of age) who have had an inadequate&#160;response to conventional therapy including&#160;<br/>primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or&#160;<br/>have contraindications for such therapies.</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft1562">Ulcerative colitis</p>
<p style="position:absolute;top:276px;left:106px;white-space:nowrap" class="ft1564">Humira is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who&#160;<br/>have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine&#160;<br/>(6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such&#160;<br/>therapies.&#160;</p>
<p style="position:absolute;top:370px;left:106px;white-space:nowrap" class="ft1562">Paediatric ulcerative colitis</p>
<p style="position:absolute;top:409px;left:106px;white-space:nowrap" class="ft1564">Humira is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric&#160;<br/>patients (from 6&#160;years of age) who have had an inadequate response to conventional therapy including&#160;<br/>corticosteroids and/or 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant&#160;to or have&#160;<br/>medical contraindications for such therapies.</p>
<p style="position:absolute;top:503px;left:106px;white-space:nowrap" class="ft1562">Uveitis</p>
<p style="position:absolute;top:541px;left:106px;white-space:nowrap" class="ft1564">Humira is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult&#160;<br/>patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-<br/>sparing, or in whom corticosteroid treatment is inappropriate.</p>
<p style="position:absolute;top:617px;left:106px;white-space:nowrap" class="ft1562">Paediatric Uveitis</p>
<p style="position:absolute;top:655px;left:106px;white-space:nowrap" class="ft1565">Humira is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from&#160;<br/>2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in&#160;<br/>whom conventional&#160;therapy is inappropriate.</p>
<p style="position:absolute;top:731px;left:106px;white-space:nowrap" class="ft1561"><b>4.2</b></p>
<p style="position:absolute;top:731px;left:148px;white-space:nowrap" class="ft1561"><b>Posology and method of administration &#160;</b></p>
<p style="position:absolute;top:769px;left:106px;white-space:nowrap" class="ft1565">Humira treatment should be initiated and supervised by specialist physicians experienced in the diagnosis&#160;<br/>and treatment of conditions for which Humira is indicated. Ophthalmologists are advised to consult with&#160;<br/>an appropriate specialist before initiation of treatment with Humira (see section 4.4). Patients treated with&#160;<br/>Humira should be given the&#160;Patient Reminder Card.</p>
<p style="position:absolute;top:864px;left:106px;white-space:nowrap" class="ft1565">After proper training in injection technique, patients may self-inject with Humira if their physician&#160;<br/>determines that it is appropriate and with medical follow-up as necessary.&#160;</p>
<p style="position:absolute;top:921px;left:106px;white-space:nowrap" class="ft1565">During treatment with Humira, other concomitant therapies (e.g., corticosteroids and/or&#160;<br/>immunomodulatory agents) should be optimised.</p>
<p style="position:absolute;top:978px;left:106px;white-space:nowrap" class="ft1562">Posology</p>
<p style="position:absolute;top:1016px;left:106px;white-space:nowrap" class="ft1563"><i>Rheumatoid arthritis</i></p>
</div>
<!-- Page 157 -->
<a name="157"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page157-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1570">157</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft1574">The recommended dose of Humira for adult patients with rheumatoid arthritis is 40&#160;mg adalimumab&#160;<br/>administered every other week as a single dose via subcutaneous injection. Methotrexate should be&#160;<br/>continued during treatment with Humira.</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft1574">Glucocorticoids, salicylates, non-steroidal anti-inflammatory drugs, or analgesics can be continued during&#160;<br/>treatment with Humira. &#160;Regarding combination with disease modifying anti-rheumatic drugs other than&#160;<br/>methotrexate see sections 4.4 and 5.1.</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft1574">In&#160;monotherapy, some patients who experience a decrease in their response&#160;to Humira 40&#160;mg every other&#160;<br/>week&#160;may benefit from an increase in dosage to 40&#160;mg adalimumab every week&#160;or 80&#160;mg&#160;every other&#160;<br/>week.&#160;</p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft1574">Available data suggest that the clinical response is usually achieved within 12 weeks of treatment. &#160;<br/>Continued therapy should be reconsidered in a patient not responding within this time period.</p>
<p style="position:absolute;top:370px;left:106px;white-space:nowrap" class="ft1574">Humira may be available in other strengths and/or presentations depending on the individual treatment&#160;<br/>needs.</p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft1573"><i>Dose&#160;interruption</i></p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft1572">There&#160;may be a need for dose interruption, for instance before surgery or if a serious infection occurs.</p>
<p style="position:absolute;top:503px;left:106px;white-space:nowrap" class="ft1574">Available data suggest that re-introduction of Humira after discontinuation for 70&#160;days or longer resulted&#160;<br/>in the same magnitudes of clinical response and similar safety profile as before dose interruption.</p>
<p style="position:absolute;top:560px;left:106px;white-space:nowrap" class="ft1573"><i>Ankylosing spondylitis, axial spondyloarthritis without radiographic evidence of AS and psoriatic arthritis</i></p>
<p style="position:absolute;top:598px;left:106px;white-space:nowrap" class="ft1574">The recommended dose of Humira for patients with ankylosing spondylitis, axial spondyloarthritis without&#160;<br/>radiographic evidence of AS and for patients with psoriatic arthritis is 40&#160;mg adalimumab administered&#160;<br/>every other week as a single dose via subcutaneous injection.</p>
<p style="position:absolute;top:674px;left:106px;white-space:nowrap" class="ft1575">Available data suggest that the clinical response is usually&#160;achieved within 12&#160;weeks of treatment. &#160;<br/>Continued therapy should be reconsidered in a patient not responding within this time period.</p>
<p style="position:absolute;top:731px;left:106px;white-space:nowrap" class="ft1573"><i>Psoriasis</i></p>
<p style="position:absolute;top:769px;left:106px;white-space:nowrap" class="ft1574">The recommended dose of Humira for adult patients is an initial dose of 80&#160;mg administered&#160;<br/>subcutaneously, followed by 40&#160;mg subcutaneously given every other week starting one week after the&#160;<br/>initial dose.</p>
<p style="position:absolute;top:845px;left:106px;white-space:nowrap" class="ft1574">Continued therapy beyond 16&#160;weeks should be carefully reconsidered in a patient not responding within&#160;<br/>this time period.</p>
<p style="position:absolute;top:902px;left:106px;white-space:nowrap" class="ft1574">Beyond 16 weeks, patients with inadequate response&#160;to Humira 40&#160;mg&#160;every other week&#160;may benefit from&#160;<br/>an increase in dosage&#160;to&#160;40&#160;mg&#160;every week&#160;or 80&#160;mg&#160;every other week. The benefits and risks of continued&#160;<br/>40&#160;mg&#160;weekly&#160;or 80&#160;mg every other week&#160;therapy should be carefully reconsidered in a patient with an&#160;<br/>inadequate response after the increase in dosage&#160;(see section 5.1).&#160;&#160;If adequate response is achieved with&#160;<br/>40&#160;mg&#160;every week or 80&#160;mg&#160;every other week,&#160;the dosage&#160;may subsequently be reduced to 40&#160;mg&#160;every&#160;<br/>other week.</p>
<p style="position:absolute;top:1035px;left:106px;white-space:nowrap" class="ft1574">Humira may be available in other strengths and/or presentations depending on the individual treatment&#160;<br/>needs.</p>
</div>
<!-- Page 158 -->
<a name="158"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page158-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1580">158</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft1583"><i>Hidradenitis suppurativa</i></p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft1585">The recommended Humira dose regimen for adult patients with hidradenitis suppurativa (HS) is 160&#160;mg&#160;<br/>initially at Day 1 (given as four 40&#160;mg injections in one day or as two 40&#160;mg&#160;injections per day for two&#160;<br/>consecutive days),&#160;followed by 80&#160;mg two weeks later at Day 15 (given as two 40&#160;mg injections in one&#160;<br/>day). Two weeks later (Day&#160;29) continue with a dose of&#160;40&#160;mg&#160;every week&#160;or 80&#160;mg every other week&#160;<br/>(given as two 40&#160;mg injections in one day). Antibiotics may be continued during treatment with Humira if&#160;<br/>necessary. It is recommended that the patient should use a topical antiseptic wash on their HS lesions on a&#160;<br/>daily basis during treatment with Humira.</p>
<p style="position:absolute;top:276px;left:106px;white-space:nowrap" class="ft1584">Continued therapy beyond 12 weeks should be carefully reconsidered in a patient with no improvement&#160;<br/>within this time period. &#160;</p>
<p style="position:absolute;top:333px;left:106px;white-space:nowrap" class="ft1584">Should treatment be interrupted, Humira 40&#160;mg&#160;every week&#160;or 80&#160;mg every other week&#160;may be re-<br/>introduced (see section 5.1).&#160;</p>
<p style="position:absolute;top:390px;left:106px;white-space:nowrap" class="ft1582">The benefit and risk of continued long-term&#160;treatment should be periodically evaluated (see section 5.1).</p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft1584">Humira may be available in other strengths and/or presentations depending on the individual treatment&#160;<br/>needs.</p>
<p style="position:absolute;top:485px;left:106px;white-space:nowrap" class="ft1583"><i>Crohn’s disease</i></p>
<p style="position:absolute;top:522px;left:106px;white-space:nowrap" class="ft1585">The recommended Humira induction dose regimen for adult patients with moderately to severely active&#160;<br/>Crohn’s disease is 80&#160;mg at Week&#160;0 followed by 40&#160;mg at Week&#160;2. In case there is a need for a more rapid&#160;<br/>response to therapy, the regimen 160&#160;mg at Week&#160;0 (given&#160;as four&#160;40&#160;mg&#160;injections in one day or as two&#160;<br/>40&#160;mg&#160;injections per day for two consecutive days),&#160;followed by&#160;80&#160;mg at Week&#160;2&#160;(given as two 40&#160;mg&#160;<br/>injections in one day), can be used with the awareness that the risk for adverse events is higher during&#160;<br/>induction.</p>
<p style="position:absolute;top:655px;left:106px;white-space:nowrap" class="ft1584">After induction treatment, the recommended dose is 40&#160;mg&#160;every other week via subcutaneous injection.&#160;<br/>Alternatively, if a patient has stopped Humira and signs and symptoms of disease recur, Humira may be&#160;<br/>re-administered.&#160;There is little experience from re-administration after more than 8&#160;weeks since the&#160;<br/>previous dose.</p>
<p style="position:absolute;top:750px;left:106px;white-space:nowrap" class="ft1584">During maintenance treatment, corticosteroids may be tapered in accordance with clinical practice&#160;<br/>guidelines.</p>
<p style="position:absolute;top:807px;left:106px;white-space:nowrap" class="ft1585">Some patients who experience decrease in their response&#160;to Humira 40&#160;mg&#160;every other week&#160;may benefit&#160;<br/>from an increase in dosage&#160;to 40&#160;mg Humira every week&#160;or 80&#160;mg&#160;every other week.</p>
<p style="position:absolute;top:864px;left:106px;white-space:nowrap" class="ft1584">Some patients who have not responded by Week&#160;4 may benefit from continued maintenance therapy&#160;<br/>through Week&#160;12. Continued therapy should be carefully reconsidered in a patient not responding within&#160;<br/>this time period.</p>
<p style="position:absolute;top:940px;left:106px;white-space:nowrap" class="ft1584">Humira may be available in other strengths and/or presentations depending on the individual treatment&#160;<br/>needs.</p>
<p style="position:absolute;top:997px;left:106px;white-space:nowrap" class="ft1583"><i>Ulcerative colitis</i></p>
<p style="position:absolute;top:1035px;left:106px;white-space:nowrap" class="ft1584">The recommended Humira induction dose regimen for adult patients with moderate to severe ulcerative&#160;<br/>colitis is 160&#160;mg at Week&#160;0 (given&#160;as four&#160;40&#160;mg&#160;injections in one day or as two&#160;40&#160;mg&#160;injections per day&#160;</p>
</div>
<!-- Page 159 -->
<a name="159"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page159-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1590">159</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft1595">for two consecutive days) and 80&#160;mg at Week&#160;2&#160;(given as two 40&#160;mg injections in&#160;one day). After&#160;<br/>induction treatment, the recommended dose is 40&#160;mg&#160;every other week via subcutaneous injection.&#160;</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft1594">During maintenance treatment, corticosteroids may be tapered in accordance with clinical practice&#160;<br/>guidelines.&#160;</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft1594">Some patients who experience decrease in their response&#160;to 40&#160;mg&#160;every other week&#160;may benefit from an&#160;<br/>increase in dosage&#160;to 40&#160;mg Humira every week&#160;or 80&#160;mg&#160;every other week.</p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft1594">Available data suggest that clinical response is usually achieved within 2-8&#160;weeks of treatment. &#160;Humira&#160;<br/>therapy should not be continued in patients failing to respond within this time period.</p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft1594">Humira may be available in other strengths and/or presentations depending on the individual treatment&#160;<br/>needs.</p>
<p style="position:absolute;top:370px;left:106px;white-space:nowrap" class="ft1593"><i>Uveitis</i></p>
<p style="position:absolute;top:409px;left:106px;white-space:nowrap" class="ft1595">The recommended dose of Humira for adult patients with uveitis is an initial dose of 80 mg, followed by&#160;<br/>40 mg given every other week starting one week after the initial dose. There is limited experience in the&#160;<br/>initiation of treatment with Humira alone. Treatment with Humira can be initiated in combination with&#160;<br/>corticosteroids and/or with other non-biologic immunomodulatory agents. Concomitant corticosteroids&#160;<br/>may be tapered in accordance with clinical practice starting two weeks after initiating treatment with&#160;<br/>Humira. &#160;&#160;</p>
<p style="position:absolute;top:541px;left:106px;white-space:nowrap" class="ft1595">It is recommended that the benefit and risk of continued long-term&#160;treatment should be evaluated on a&#160;<br/>yearly basis (see section 5.1). &#160;</p>
<p style="position:absolute;top:598px;left:106px;white-space:nowrap" class="ft1595">Humira may be available in other strengths and/or presentations depending on the individual treatment&#160;<br/>needs.</p>
<p style="position:absolute;top:655px;left:106px;white-space:nowrap" class="ft1592">Special populations</p>
<p style="position:absolute;top:693px;left:106px;white-space:nowrap" class="ft1592">Elderly</p>
<p style="position:absolute;top:731px;left:106px;white-space:nowrap" class="ft1592">No dose adjustment is required.</p>
<p style="position:absolute;top:769px;left:106px;white-space:nowrap" class="ft1592">Renal and/or hepatic impairment</p>
<p style="position:absolute;top:807px;left:106px;white-space:nowrap" class="ft1592">Humira has not been studied in these patient populations. No dose recommendations can be made.</p>
<p style="position:absolute;top:845px;left:106px;white-space:nowrap" class="ft1592">Paediatric population</p>
<p style="position:absolute;top:883px;left:106px;white-space:nowrap" class="ft1593"><i>Juvenile idiopathic arthritis</i></p>
<p style="position:absolute;top:921px;left:106px;white-space:nowrap" class="ft1593"><i>Polyarticular juvenile idiopathic arthritis from 2 years of age</i></p>
<p style="position:absolute;top:959px;left:106px;white-space:nowrap" class="ft1594">The recommended dose of Humira for patients with polyarticular juvenile idiopathic arthritis&#160;from 2&#160;years&#160;<br/>of age is based on body weight (Table 1).&#160;Humira is&#160;administered every other week via&#160;subcutaneous&#160;<br/>injection.</p>
<p style="position:absolute;top:1035px;left:169px;white-space:nowrap" class="ft1591"><b>Table 1. Humira&#160;Dose for Patients with Polyarticular Juvenile Idiopathic Arthritis&#160;</b></p>
</div>
<!-- Page 160 -->
<a name="160"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page160-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1600">160</p>
<p style="position:absolute;top:89px;left:279px;white-space:nowrap" class="ft1601"><b>Patient Weight</b></p>
<p style="position:absolute;top:89px;left:529px;white-space:nowrap" class="ft1601"><b>Dosing Regimen</b></p>
<p style="position:absolute;top:114px;left:278px;white-space:nowrap" class="ft1602">10 kg to &lt; 30 kg</p>
<p style="position:absolute;top:114px;left:507px;white-space:nowrap" class="ft1602">20 mg every other week</p>
<p style="position:absolute;top:139px;left:307px;white-space:nowrap" class="ft1602">≥ 30 kg</p>
<p style="position:absolute;top:139px;left:507px;white-space:nowrap" class="ft1602">40 mg every other week</p>
<p style="position:absolute;top:180px;left:106px;white-space:nowrap" class="ft1604">Available data suggest that clinical&#160;response is usually achieved within 12&#160;weeks of treatment. Continued&#160;<br/>therapy should be carefully reconsidered in a patient not responding within this time period.</p>
<p style="position:absolute;top:237px;left:106px;white-space:nowrap" class="ft1602">There is no relevant use of Humira in patients aged&#160;less than&#160;2&#160;years for this indication.</p>
<p style="position:absolute;top:275px;left:106px;white-space:nowrap" class="ft1604">Humira may be available in other strengths and/or presentations depending on the individual treatment&#160;<br/>needs.</p>
<p style="position:absolute;top:332px;left:106px;white-space:nowrap" class="ft1603"><i>Enthesitis-related arthritis</i></p>
<p style="position:absolute;top:370px;left:106px;white-space:nowrap" class="ft1604">The recommended dose of Humira for patients with enthesitis-related arthritis&#160;from&#160;6&#160;years of age&#160;is based&#160;<br/>on body weight (Table 2).&#160;Humira is&#160;administered every other week via subcutaneous injection.</p>
<p style="position:absolute;top:427px;left:221px;white-space:nowrap" class="ft1601"><b>Table&#160;2. Humira Dose for Patients with Enthesitis-Related Arthritis&#160;</b></p>
<p style="position:absolute;top:468px;left:279px;white-space:nowrap" class="ft1601"><b>Patient Weight</b></p>
<p style="position:absolute;top:468px;left:529px;white-space:nowrap" class="ft1601"><b>Dosing Regimen</b></p>
<p style="position:absolute;top:492px;left:278px;white-space:nowrap" class="ft1602">15&#160;kg to &lt; 30 kg</p>
<p style="position:absolute;top:492px;left:507px;white-space:nowrap" class="ft1602">20 mg every other week</p>
<p style="position:absolute;top:517px;left:307px;white-space:nowrap" class="ft1602">≥ 30 kg</p>
<p style="position:absolute;top:517px;left:507px;white-space:nowrap" class="ft1602">40 mg every other&#160;week</p>
<p style="position:absolute;top:558px;left:106px;white-space:nowrap" class="ft1602">Humira has not been studied in patients with enthesitis-related arthritis aged less than 6&#160;years.</p>
<p style="position:absolute;top:597px;left:106px;white-space:nowrap" class="ft1604">Humira may be available in other strengths and/or presentations depending on the individual treatment&#160;<br/>needs.</p>
<p style="position:absolute;top:653px;left:106px;white-space:nowrap" class="ft1603"><i>Psoriatic arthritis and axial&#160;spondyloarthritis including ankylosing spondyliti</i>s</p>
<p style="position:absolute;top:691px;left:106px;white-space:nowrap" class="ft1604">There is no relevant use of Humira in the paediatric population for the indications of ankylosing&#160;<br/>spondylitis and psoriatic arthritis.</p>
<p style="position:absolute;top:748px;left:106px;white-space:nowrap" class="ft1603"><i>Paediatric plaque psoriasis</i></p>
<p style="position:absolute;top:786px;left:106px;white-space:nowrap" class="ft1604">The recommended Humira dose&#160;for patients with plaque psoriasis from 4 to 17&#160;years of age is based on&#160;<br/>body weight (Table 3).&#160;Humira is administered via subcutaneous injection.</p>
</div>
<!-- Page 161 -->
<a name="161"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page161-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1610">161</p>
<p style="position:absolute;top:86px;left:223px;white-space:nowrap" class="ft1611"><b>Table 3. Humira Dose&#160;for&#160;Paediatric Patients with Plaque Psoriasis&#160;</b></p>
<p style="position:absolute;top:127px;left:279px;white-space:nowrap" class="ft1611"><b>Patient Weight</b></p>
<p style="position:absolute;top:127px;left:529px;white-space:nowrap" class="ft1611"><b>Dosing Regimen</b></p>
<p style="position:absolute;top:152px;left:278px;white-space:nowrap" class="ft1612">15&#160;kg to &lt; 30 kg</p>
<p style="position:absolute;top:151px;left:474px;white-space:nowrap" class="ft1612">Initial dose of 20 mg, followed by&#160;</p>
<p style="position:absolute;top:170px;left:486px;white-space:nowrap" class="ft1612">20 mg given every other week&#160;</p>
<p style="position:absolute;top:188px;left:478px;white-space:nowrap" class="ft1612">starting one week after the initial&#160;</p>
<p style="position:absolute;top:206px;left:571px;white-space:nowrap" class="ft1612">dose&#160;</p>
<p style="position:absolute;top:230px;left:307px;white-space:nowrap" class="ft1612">≥ 30 kg</p>
<p style="position:absolute;top:230px;left:474px;white-space:nowrap" class="ft1612">Initial dose of 40 mg, followed by&#160;</p>
<p style="position:absolute;top:248px;left:486px;white-space:nowrap" class="ft1612">40 mg given every other week&#160;</p>
<p style="position:absolute;top:266px;left:478px;white-space:nowrap" class="ft1612">starting one week after the initial&#160;</p>
<p style="position:absolute;top:284px;left:571px;white-space:nowrap" class="ft1612">dose</p>
<p style="position:absolute;top:326px;left:106px;white-space:nowrap" class="ft1614">Continued therapy beyond 16&#160;weeks&#160;should be carefully considered in a patient not responding within this&#160;<br/>time period.</p>
<p style="position:absolute;top:383px;left:106px;white-space:nowrap" class="ft1614">If retreatment with Humira is indicated, the above guidance on dose and treatment duration should be&#160;<br/>followed.</p>
<p style="position:absolute;top:440px;left:106px;white-space:nowrap" class="ft1614">The safety of Humira in paediatric patients with plaque psoriasis has been assessed for a mean of&#160;<br/>13&#160;months.</p>
<p style="position:absolute;top:497px;left:106px;white-space:nowrap" class="ft1612">There is no relevant use of Humira in children aged less than 4&#160;years for this indication.</p>
<p style="position:absolute;top:535px;left:106px;white-space:nowrap" class="ft1614">Humira may be available in other strengths and/or presentations depending on the individual treatment&#160;<br/>needs.</p>
<p style="position:absolute;top:591px;left:106px;white-space:nowrap" class="ft1613"><i>Adolescent hidradenitis suppurativa (from 12 years of age, weighing at least 30 kg)</i></p>
<p style="position:absolute;top:629px;left:106px;white-space:nowrap" class="ft1614">There are no clinical trials with Humira in adolescent patients with HS. &#160;The posology of Humira in these&#160;<br/>patients has been determined from pharmacokinetic modelling and&#160;simulation (see section 5.2).</p>
<p style="position:absolute;top:687px;left:106px;white-space:nowrap" class="ft1615">The recommended Humira dose is 80&#160;mg at Week 0 followed by 40&#160;mg every other week starting at Week&#160;<br/>1 via subcutaneous injection.&#160;</p>
<p style="position:absolute;top:743px;left:106px;white-space:nowrap" class="ft1615">In adolescent patients with inadequate response to Humira 40&#160;mg every other week, an increase&#160;in&#160;dosage<br/>to 40&#160;mg&#160;every week&#160;or 80&#160;mg&#160;every other week&#160;may be considered.</p>
<p style="position:absolute;top:800px;left:106px;white-space:nowrap" class="ft1615">Antibiotics may be continued during treatment with Humira if necessary. &#160;It is recommended that the&#160;<br/>patient should use a topical antiseptic wash on their HS lesions on a daily basis during treatment with&#160;<br/>Humira.&#160;</p>
<p style="position:absolute;top:876px;left:106px;white-space:nowrap" class="ft1615">Continued therapy beyond 12 weeks should be carefully reconsidered in a patient with no improvement&#160;<br/>within this time period. &#160;</p>
<p style="position:absolute;top:933px;left:106px;white-space:nowrap" class="ft1612">Should treatment be interrupted, Humira may be re-introduced as appropriate.</p>
<p style="position:absolute;top:971px;left:106px;white-space:nowrap" class="ft1614">The benefit and&#160;risk of continued long-term&#160;treatment should be periodically evaluated (see adult data in&#160;<br/>section 5.1)</p>
<p style="position:absolute;top:1028px;left:106px;white-space:nowrap" class="ft1612">There is no relevant use of Humira in children aged less than 12 years in this indication.</p>
</div>
<!-- Page 162 -->
<a name="162"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page162-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1620">162</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft1624">Humira may be available in other strengths and/or presentations depending on the individual treatment&#160;<br/>needs.</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft1623"><i>Paediatric Crohn's disease</i></p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft1624">The recommended dose of Humira for patients with&#160;Crohn’s disease from 6&#160;to 17&#160;years&#160;of age is&#160;based on&#160;<br/>body&#160;weight&#160;(Table 4).&#160;Humira is&#160;administered via subcutaneous injection.</p>
<p style="position:absolute;top:257px;left:225px;white-space:nowrap" class="ft1621"><b>Table&#160;4. Humira Dose&#160;for&#160;Paediatric Patients with Crohn’s disease</b></p>
<p style="position:absolute;top:297px;left:118px;white-space:nowrap" class="ft1621"><b>Patient&#160;</b></p>
<p style="position:absolute;top:316px;left:117px;white-space:nowrap" class="ft1621"><b>Weight</b></p>
<p style="position:absolute;top:297px;left:383px;white-space:nowrap" class="ft1621"><b>Induction Dose</b></p>
<p style="position:absolute;top:297px;left:707px;white-space:nowrap" class="ft1621"><b>Maintenance&#160;</b></p>
<p style="position:absolute;top:316px;left:735px;white-space:nowrap" class="ft1621"><b>Dose</b></p>
<p style="position:absolute;top:335px;left:715px;white-space:nowrap" class="ft1621"><b>Starting at&#160;</b></p>
<p style="position:absolute;top:354px;left:726px;white-space:nowrap" class="ft1621"><b>Week 4</b></p>
<p style="position:absolute;top:376px;left:118px;white-space:nowrap" class="ft1622">&lt; 40 kg</p>
<p style="position:absolute;top:375px;left:190px;white-space:nowrap" class="ft1626">&#160;40 mg at&#160;week 0 and 20 mg at&#160;week 2</p>
<p style="position:absolute;top:415px;left:192px;white-space:nowrap" class="ft1624">In case there is a need for a more rapid response to therapy&#160;with the&#160;<br/>awareness that the risk for adverse events may be higher with use of the&#160;<br/>higher induction dose, the following dose may be used:</p>
<p style="position:absolute;top:472px;left:190px;white-space:nowrap" class="ft1626">&#160;80 mg at week 0 and 40 mg at&#160;week 2</p>
<p style="position:absolute;top:376px;left:712px;white-space:nowrap" class="ft1622">20 mg every&#160;</p>
<p style="position:absolute;top:395px;left:716px;white-space:nowrap" class="ft1622">other week</p>
<p style="position:absolute;top:496px;left:118px;white-space:nowrap" class="ft1622">≥ 40 kg</p>
<p style="position:absolute;top:495px;left:190px;white-space:nowrap" class="ft1626">&#160;80 mg at week 0 and 40 mg at week 2</p>
<p style="position:absolute;top:535px;left:192px;white-space:nowrap" class="ft1625">In case there is a need for a more rapid response to therapy&#160;with the&#160;<br/>awareness that the risk for adverse events may be higher with use of the&#160;<br/>higher induction dose, the following dose may be used:</p>
<p style="position:absolute;top:591px;left:190px;white-space:nowrap" class="ft1626">&#160;160 mg at week 0 and 80 mg at week 2</p>
<p style="position:absolute;top:496px;left:712px;white-space:nowrap" class="ft1622">40 mg every&#160;</p>
<p style="position:absolute;top:515px;left:716px;white-space:nowrap" class="ft1622">other week</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft1622">Patients&#160;who&#160;experience insufficient response may benefit from&#160;an increase in&#160;dosage:</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft1626"></p>
<p style="position:absolute;top:653px;left:147px;white-space:nowrap" class="ft1622">&lt; 40&#160;kg: 20&#160;mg&#160;every week</p>
<p style="position:absolute;top:672px;left:106px;white-space:nowrap" class="ft1626"></p>
<p style="position:absolute;top:674px;left:147px;white-space:nowrap" class="ft1622">≥ 40&#160;kg: 40&#160;mg&#160;every&#160;week&#160;or 80&#160;mg&#160;every other week</p>
<p style="position:absolute;top:711px;left:106px;white-space:nowrap" class="ft1622">Continued therapy should be carefully considered in a subject not responding by&#160;week&#160;12.</p>
<p style="position:absolute;top:750px;left:106px;white-space:nowrap" class="ft1622">There is no relevant use of Humira in children aged&#160;less than&#160;6&#160;years for this indication.</p>
<p style="position:absolute;top:787px;left:106px;white-space:nowrap" class="ft1624">Humira may be available in other strengths and/or presentations depending on the individual treatment&#160;<br/>needs.</p>
<p style="position:absolute;top:844px;left:106px;white-space:nowrap" class="ft1623"><i>Paediatric ulcerative colitis</i></p>
<p style="position:absolute;top:882px;left:106px;white-space:nowrap" class="ft1625">The recommended dose of Humira for patients from&#160;6&#160;to 17 years of age with ulcerative colitis is based on&#160;<br/>body weight (Table&#160;5).&#160;Humira is administered via subcutaneous injection.</p>
<p style="position:absolute;top:939px;left:220px;white-space:nowrap" class="ft1621"><b>Table 5. Humira Dose for Paediatric Patients with Ulcerative Colitis&#160;</b></p>
<p style="position:absolute;top:970px;left:154px;white-space:nowrap" class="ft1621"><b>Patient Weight</b></p>
<p style="position:absolute;top:970px;left:352px;white-space:nowrap" class="ft1621"><b>Induction Dose</b></p>
<p style="position:absolute;top:960px;left:594px;white-space:nowrap" class="ft1621"><b>Maintenance Dose</b></p>
<p style="position:absolute;top:979px;left:588px;white-space:nowrap" class="ft1621"><b>Starting at Week 4*</b></p>
<p style="position:absolute;top:1002px;left:181px;white-space:nowrap" class="ft1622">&lt; 40 kg</p>
<p style="position:absolute;top:1002px;left:289px;white-space:nowrap" class="ft1622">•&#160;80 mg at Week 0&#160;(given as two 40&#160;</p>
<p style="position:absolute;top:1021px;left:305px;white-space:nowrap" class="ft1622">mg&#160;injections in one day)&#160;and</p>
<p style="position:absolute;top:1040px;left:289px;white-space:nowrap" class="ft1622">•&#160;40 mg at Week 2&#160;(given as one 40&#160;</p>
<p style="position:absolute;top:1059px;left:305px;white-space:nowrap" class="ft1622">mg&#160;injection)</p>
<p style="position:absolute;top:1002px;left:548px;white-space:nowrap" class="ft1622">•&#160;40 mg every other week</p>
</div>
<!-- Page 163 -->
<a name="163"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page163-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1630">163</p>
<p style="position:absolute;top:88px;left:181px;white-space:nowrap" class="ft1632">≥ 40 kg</p>
<p style="position:absolute;top:88px;left:289px;white-space:nowrap" class="ft1632">•&#160;160 mg at Week 0&#160;(given as four&#160;</p>
<p style="position:absolute;top:107px;left:305px;white-space:nowrap" class="ft1634">40 mg injections in one day or&#160;<br/>two 40 mg injections per day for&#160;<br/>two consecutive days)&#160;and</p>
<p style="position:absolute;top:164px;left:289px;white-space:nowrap" class="ft1632">•&#160;80 mg at Week 2&#160;(given as two 40&#160;</p>
<p style="position:absolute;top:183px;left:305px;white-space:nowrap" class="ft1632">mg&#160;injections in one day)</p>
<p style="position:absolute;top:88px;left:548px;white-space:nowrap" class="ft1632">•&#160;80 mg every other week</p>
<p style="position:absolute;top:204px;left:138px;white-space:nowrap" class="ft1637">*&#160;Paediatric patients who turn 18 years of age while on Humira&#160;should continue their prescribed&#160;<br/>maintenance dose.</p>
<p style="position:absolute;top:267px;left:106px;white-space:nowrap" class="ft1634">Continued therapy beyond 8 weeks should be carefully considered in&#160;patients not showing signs of&#160;<br/>response&#160;within this time period.</p>
<p style="position:absolute;top:324px;left:106px;white-space:nowrap" class="ft1632">There is no relevant use of Humira in children aged less than&#160;6&#160;years in this indication.</p>
<p style="position:absolute;top:362px;left:106px;white-space:nowrap" class="ft1635">Humira may be available in different strengths and/or presentations&#160;depending on the individual treatment&#160;<br/>needs.</p>
<p style="position:absolute;top:419px;left:106px;white-space:nowrap" class="ft1633"><i>Paediatric Uveitis</i></p>
<p style="position:absolute;top:456px;left:106px;white-space:nowrap" class="ft1634">The recommended dose of Humira for paediatric patients with uveitis&#160;from 2&#160;years of age is based on&#160;<br/>body weight (Table&#160;6). Humira is administered via subcutaneous injection.</p>
<p style="position:absolute;top:513px;left:106px;white-space:nowrap" class="ft1634">In paediatric uveitis, there is no experience in the treatment with Humira without concomitant treatment&#160;<br/>with methotrexate.</p>
<p style="position:absolute;top:571px;left:256px;white-space:nowrap" class="ft1631"><b>Table&#160;6.&#160;Humira Dose for Paediatric Patients with Uveitis</b></p>
<p style="position:absolute;top:611px;left:279px;white-space:nowrap" class="ft1631"><b>Patient Weight</b></p>
<p style="position:absolute;top:611px;left:529px;white-space:nowrap" class="ft1631"><b>Dosing Regimen</b></p>
<p style="position:absolute;top:636px;left:307px;white-space:nowrap" class="ft1632">&lt; 30 kg</p>
<p style="position:absolute;top:636px;left:498px;white-space:nowrap" class="ft1632">20 mg every other week in&#160;</p>
<p style="position:absolute;top:654px;left:483px;white-space:nowrap" class="ft1632">combination with methotrexate</p>
<p style="position:absolute;top:679px;left:307px;white-space:nowrap" class="ft1632">≥ 30 kg</p>
<p style="position:absolute;top:679px;left:498px;white-space:nowrap" class="ft1632">40 mg every other week in&#160;</p>
<p style="position:absolute;top:697px;left:483px;white-space:nowrap" class="ft1632">combination with methotrexate</p>
<p style="position:absolute;top:738px;left:106px;white-space:nowrap" class="ft1635">When Humira therapy is initiated, a loading dose of 40&#160;mg&#160;for patients &lt;&#160;30&#160;kg&#160;or 80&#160;mg for patients&#160;<br/>≥&#160;30&#160;kg&#160;may be administered one week prior to the start of maintenance therapy. No clinical data are&#160;<br/>available on the use of a Humira loading dose in children &lt;&#160;6 years of age (see section 5.2).</p>
<p style="position:absolute;top:814px;left:106px;white-space:nowrap" class="ft1632">There is no relevant use of Humira in children aged less than 2&#160;years in this indication.</p>
<p style="position:absolute;top:852px;left:106px;white-space:nowrap" class="ft1634">It is recommended that the benefit and risk of continued long-term&#160;treatment should be evaluated on a&#160;<br/>yearly basis (see section 5.1).</p>
<p style="position:absolute;top:909px;left:106px;white-space:nowrap" class="ft1634">Humira may be available in other strengths and/or presentations depending on the individual treatment&#160;<br/>needs.</p>
<p style="position:absolute;top:966px;left:106px;white-space:nowrap" class="ft1632">Method of administration</p>
<p style="position:absolute;top:1004px;left:106px;white-space:nowrap" class="ft1634">Humira is administered by subcutaneous injection. Full instructions for use are provided in the package&#160;<br/>leaflet.</p>
<p style="position:absolute;top:1061px;left:106px;white-space:nowrap" class="ft1632">Humira is available in other strengths and presentations.</p>
</div>
<!-- Page 164 -->
<a name="164"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page164-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1640">164</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft1641"><b>4.3</b></p>
<p style="position:absolute;top:86px;left:148px;white-space:nowrap" class="ft1641"><b>Contraindications&#160;</b></p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft1642">Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.&#160;</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft1642">Active tuberculosis or other severe infections such as sepsis, and&#160;opportunistic infections (see section 4.4).</p>
<p style="position:absolute;top:198px;left:106px;white-space:nowrap" class="ft1642">Moderate to severe heart failure (NYHA class III/IV) (see section 4.4).</p>
<p style="position:absolute;top:236px;left:106px;white-space:nowrap" class="ft1641"><b>4.4</b></p>
<p style="position:absolute;top:236px;left:148px;white-space:nowrap" class="ft1641"><b>Special warnings and precautions for use</b></p>
<p style="position:absolute;top:274px;left:106px;white-space:nowrap" class="ft1642">Traceability&#160;</p>
<p style="position:absolute;top:312px;left:106px;white-space:nowrap" class="ft1644">In&#160;order to improve traceability of biological medicinal products, the&#160;name&#160;and the batch number of the&#160;<br/>administered product should be clearly recorded.</p>
<p style="position:absolute;top:369px;left:106px;white-space:nowrap" class="ft1642">Infections</p>
<p style="position:absolute;top:407px;left:106px;white-space:nowrap" class="ft1644">Patients taking TNF-antagonists are more susceptible to serious infections. Impaired lung function may&#160;<br/>increase the risk for developing infections. Patients must&#160;therefore be monitored closely for infections,&#160;<br/>including tuberculosis, before, during and after treatment with Humira. &#160;Because the elimination of&#160;<br/>adalimumab may take up to four months, monitoring should be continued throughout this period.</p>
<p style="position:absolute;top:501px;left:106px;white-space:nowrap" class="ft1645">Treatment with&#160;Humira should not be initiated in patients with active infections including chronic or&#160;<br/>localised infections until infections are controlled. In patients who have been exposed to tuberculosis and&#160;<br/>patients who have travelled in areas of high risk of tuberculosis or endemic mycoses, such as&#160;<br/>histoplasmosis, coccidioidomycosis, or blastomycosis, the risk and benefits of treatment with Humira&#160;<br/>should be considered prior to initiating therapy (see&#160;<i>Other opportunistic infections</i>).</p>
<p style="position:absolute;top:616px;left:106px;white-space:nowrap" class="ft1645">Patients who develop a new&#160;infection while undergoing treatment with Humira should be monitored&#160;<br/>closely and undergo a complete diagnostic evaluation. Administration of Humira should be discontinued if&#160;<br/>a patient develops a new serious infection or sepsis, and appropriate antimicrobial or antifungal therapy&#160;<br/>should be initiated until the infection is controlled. &#160;Physicians should exercise caution when considering&#160;<br/>the use of Humira in patients with a history of recurring infection or with underlying conditions which&#160;<br/>may predispose patients to infections, including the use of concomitant immunosuppressive medications.</p>
<p style="position:absolute;top:748px;left:106px;white-space:nowrap" class="ft1643"><i>Serious infections</i></p>
<p style="position:absolute;top:786px;left:106px;white-space:nowrap" class="ft1645">Serious infections,&#160;including sepsis,&#160;due to bacterial, mycobacterial, invasive fungal, parasitic, viral, or&#160;<br/>other opportunistic infections&#160;such as listeriosis, legionellosis and pneumocystis&#160;have been reported in&#160;<br/>patients receiving Humira. &#160;</p>
<p style="position:absolute;top:862px;left:106px;white-space:nowrap" class="ft1644">Other serious infections seen in clinical trials include pneumonia, pyelonephritis, septic arthritis and&#160;<br/>septicaemia. Hospitalisation or fatal outcomes associated with infections have been reported.&#160;</p>
<p style="position:absolute;top:919px;left:106px;white-space:nowrap" class="ft1643"><i>Tuberculosis</i></p>
<p style="position:absolute;top:957px;left:106px;white-space:nowrap" class="ft1644">Tuberculosis, including reactivation and new onset of tuberculosis, has been reported in patients receiving&#160;<br/>Humira. &#160;Reports included cases of pulmonary and extra-pulmonary (i.e. disseminated) tuberculosis.&#160;</p>
<p style="position:absolute;top:1014px;left:106px;white-space:nowrap" class="ft1644">Before initiation of therapy with Humira, all patients must be evaluated for both active or inactive&#160;<br/>(“latent”) tuberculosis infection. &#160;This evaluation should include a detailed medical assessment of patient&#160;<br/>history of tuberculosis or possible previous exposure to people with active tuberculosis and previous&#160;<br/>and/or current immunosuppressive therapy. &#160;Appropriate screening tests (i.e. tuberculin skin test and chest&#160;</p>
</div>
<!-- Page 165 -->
<a name="165"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page165-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1650">165</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft1654">X-ray) should be performed in all patients (local recommendations may apply). &#160;It is recommended that&#160;<br/>the conduct and results of these tests are recorded in the&#160;Patient Reminder Card. &#160;Prescribers are reminded&#160;<br/>of the risk of false negative tuberculin skin test results, especially in patients who are severely ill or&#160;<br/>immunocompromised.&#160;</p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft1652">If active tuberculosis is diagnosed, Humira therapy must not be initiated (see section 4.3).&#160;</p>
<p style="position:absolute;top:219px;left:106px;white-space:nowrap" class="ft1652">In all situations described below, the benefit/risk balance of therapy should be very carefully considered.</p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft1654">If latent tuberculosis is suspected,&#160;a physician with expertise in the treatment of tuberculosis should be&#160;<br/>consulted.&#160;&#160;</p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft1654">If latent tuberculosis is diagnosed, appropriate treatment must be started with anti-tuberculosis prophylaxis&#160;<br/>treatment before the initiation of Humira, and in accordance with local recommendations.&#160;</p>
<p style="position:absolute;top:370px;left:106px;white-space:nowrap" class="ft1655">Use&#160;of anti-tuberculosis prophylaxis treatment should also be considered before the initiation of Humira in&#160;<br/>patients with several or significant risk factors for tuberculosis despite a negative test for tuberculosis and&#160;<br/>in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment&#160;<br/>cannot be confirmed. &#160;</p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft1655">Despite prophylactic treatment for tuberculosis, cases of reactivated tuberculosis have occurred in patients&#160;<br/>treated with Humira. Some patients who have been successfully treated for active tuberculosis have&#160;<br/>redeveloped tuberculosis while being treated with Humira.</p>
<p style="position:absolute;top:541px;left:106px;white-space:nowrap" class="ft1654">Patients should be instructed to seek medical advice if signs/symptoms suggestive of a tuberculosis&#160;<br/>infection (e.g., persistent cough, wasting/weight loss, low grade fever, listlessness) occur during or after&#160;<br/>therapy with Humira.&#160;</p>
<p style="position:absolute;top:617px;left:106px;white-space:nowrap" class="ft1653"><i>Other opportunistic infections</i></p>
<p style="position:absolute;top:655px;left:106px;white-space:nowrap" class="ft1655">Opportunistic infections, including invasive fungal infections have been observed in patients receiving&#160;<br/>Humira. These infections have not consistently been recognised in patients taking TNF-antagonists and&#160;<br/>this has resulted in delays in appropriate&#160;treatment, sometimes resulting in fatal outcomes.&#160;</p>
<p style="position:absolute;top:731px;left:106px;white-space:nowrap" class="ft1654">For patients who develop the signs and symptoms such as fever, malaise, weight loss, sweats, cough,&#160;<br/>dyspnoea, and/or pulmonary infiltrates or other serious systemic illness with or without concomitant shock&#160;<br/>an invasive fungal infection should be suspected and administration of Humira should be promptly&#160;<br/>discontinued. &#160;Diagnosis and administration of empiric antifungal therapy in these patients should be made&#160;<br/>in consultation with a physician with expertise&#160;in the care of patients with invasive fungal infections.&#160;</p>
<p style="position:absolute;top:845px;left:106px;white-space:nowrap" class="ft1652">Hepatitis B reactivation</p>
<p style="position:absolute;top:883px;left:106px;white-space:nowrap" class="ft1654">Reactivation of hepatitis B has occurred in patients receiving a TNF-antagonist including Humira, who are&#160;<br/>chronic carriers of this virus (i.e. surface antigen positive). &#160;Some cases have had a fatal outcome. Patients&#160;<br/>should be tested for HBV infection before initiating treatment with Humira. For patients who test positive&#160;<br/>for hepatitis B infection, consultation with a physician with expertise in the treatment of hepatitis B&#160;is&#160;<br/>recommended.</p>
<p style="position:absolute;top:997px;left:106px;white-space:nowrap" class="ft1654">Carriers of HBV who require treatment with Humira should be closely monitored for signs and symptoms&#160;<br/>of active HBV infection throughout therapy and for several months following termination of therapy.&#160;<br/>Adequate data from treating patients&#160;who are carriers of HBV with anti-viral therapy in conjunction with&#160;<br/>TNF-antagonist therapy to prevent HBV reactivation are not available. In patients who develop HBV&#160;</p>
</div>
<!-- Page 166 -->
<a name="166"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page166-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1660">166</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft1665">reactivation, Humira should be stopped and effective anti-viral therapy with appropriate supportive&#160;<br/>treatment should be initiated.&#160;</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft1662">Neurological events&#160;</p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft1664">TNF-antagonists including Humira have been associated in rare instances with new onset or exacerbation&#160;<br/>of clinical symptoms and/or radiographic evidence of central nervous system demyelinating&#160;disease&#160;<br/>including multiple sclerosis and optic neuritis, and peripheral demyelinating disease, including Guillain-<br/>Barré syndrome. Prescribers should exercise caution in considering the use of Humira in patients with pre-<br/>existing or recent-onset central or peripheral nervous system demyelinating disorders; discontinuation of&#160;<br/>Humira should be considered if any of these disorders develop. There is a known association between&#160;<br/>intermediate uveitis and central demyelinating disorders. Neurologic evaluation should be performed in&#160;<br/>patients with non-infectious intermediate uveitis prior to the initiation of Humira therapy and regularly&#160;<br/>during treatment to assess for pre-existing or developing central demyelinating disorders.&#160;</p>
<p style="position:absolute;top:370px;left:106px;white-space:nowrap" class="ft1662">Allergic reactions</p>
<p style="position:absolute;top:409px;left:106px;white-space:nowrap" class="ft1664">Serious allergic reactions associated with Humira were rare during clinical trials. Non-serious allergic&#160;<br/>reactions associated with Humira were uncommon during clinical trials. Reports of serious allergic&#160;<br/>reactions including anaphylaxis have been received following Humira administration. If an anaphylactic&#160;<br/>reaction or other serious allergic reaction occurs, administration of Humira should be discontinued&#160;<br/>immediately and appropriate therapy initiated.&#160;</p>
<p style="position:absolute;top:522px;left:106px;white-space:nowrap" class="ft1662">Immunosuppression</p>
<p style="position:absolute;top:560px;left:106px;white-space:nowrap" class="ft1664">In a study of 64&#160;patients with rheumatoid arthritis&#160;that were treated with Humira, there was no evidence of&#160;<br/>depression of delayed-type hypersensitivity, depression of immunoglobulin levels, or change in&#160;<br/>enumeration of effector T-, B-, NK-cells, monocyte/macrophages, and neutrophils.</p>
<p style="position:absolute;top:636px;left:106px;white-space:nowrap" class="ft1662">Malignancies and lymphoproliferative disorders</p>
<p style="position:absolute;top:674px;left:106px;white-space:nowrap" class="ft1664">In the controlled portions of clinical trials of TNF-antagonists, more cases of malignancies including&#160;<br/>lymphoma have been observed among patients receiving a TNF-antagonist compared with control&#160;<br/>patients. However, the occurrence was rare. In the post marketing setting, cases of leukaemia have been&#160;<br/>reported in patients treated with a TNF-antagonist. There is an increased background risk for lymphoma&#160;<br/>and leukaemia in rheumatoid arthritis patients with long-standing, highly active, inflammatory disease,&#160;<br/>which complicates the risk estimation. With the current knowledge, a possible risk for the development of&#160;<br/>lymphomas, leukaemia, and other malignancies in patients treated with a TNF-antagonist cannot be&#160;<br/>excluded.</p>
<p style="position:absolute;top:845px;left:106px;white-space:nowrap" class="ft1665">Malignancies, some fatal, have been reported among children, adolescents and young adults (up to&#160;<br/>22&#160;years of age) treated with TNF-antagonists (initiation of therapy&#160;≤&#160;18&#160;years of age), including&#160;<br/>adalimumab in the post marketing setting. Approximately half the cases were lymphomas. The other cases&#160;<br/>represented a variety of different malignancies and included rare malignancies usually associated with&#160;<br/>immunosuppression. A risk for the development of malignancies in children and adolescents treated with&#160;<br/>TNF-antagonists cannot be excluded.&#160;</p>
<p style="position:absolute;top:978px;left:106px;white-space:nowrap" class="ft1664">Rare postmarketing cases of hepatosplenic T-cell lymphoma have been identified in patients treated with&#160;<br/>adalimumab. This rare type of T-cell&#160;lymphoma has a very aggressive disease course and is usually fatal.&#160;<br/>Some of these hepatosplenic T-cell lymphomas with Humira have occurred in young adult patients on&#160;<br/>concomitant treatment with azathioprine or 6-mercaptopurine used for inflammatory bowel disease. The&#160;<br/>potential risk with the combination of azathioprine or 6-mercaptopurine and Humira should be carefully&#160;</p>
</div>
<!-- Page 167 -->
<a name="167"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page167-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1670">167</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft1675">considered. A risk for the development of hepatosplenic T-cell lymphoma in patients treated with Humira&#160;<br/>cannot be excluded (see section 4.8).</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft1675">No studies have been conducted that include patients with a history of malignancy or in whom treatment&#160;<br/>with Humira is continued following development of malignancy. &#160;Thus,&#160;additional caution should be&#160;<br/>exercised in considering Humira treatment of these patients (see section 4.8).</p>
<p style="position:absolute;top:219px;left:106px;white-space:nowrap" class="ft1674">All patients, and in particular patients with a medical history of extensive immunosuppressant therapy or&#160;<br/>psoriasis patients with a history of PUVA treatment should be examined for the presence of non-<br/>melanoma skin cancer prior to and during treatment with Humira. &#160;Melanoma and Merkel cell carcinoma&#160;<br/>have also been reported in patients&#160;treated with TNF-antagonists including adalimumab (see section 4.8).</p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft1674">In an exploratory clinical trial evaluating the use of another TNF-antagonist, infliximab, in patients with&#160;<br/>moderate to severe chronic obstructive pulmonary disease (COPD), more malignancies, mostly in the lung&#160;<br/>or head and neck, were reported in infliximab-treated patients compared with control patients. All patients&#160;<br/>had a history of heavy smoking. Therefore, caution should be exercised when using any TNF-antagonist in&#160;<br/>COPD patients, as well as in patients with increased risk for malignancy due to heavy smoking.</p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft1674">With current data it is not known if adalimumab treatment influences the risk for developing dysplasia or&#160;<br/>colon cancer. &#160;All patients with ulcerative colitis who are at increased&#160;risk for dysplasia or colon&#160;<br/>carcinoma (for example, patients with long-standing ulcerative colitis or primary sclerosing cholangitis),&#160;<br/>or who had a prior history of dysplasia or colon carcinoma should be screened for dysplasia at regular&#160;<br/>intervals before therapy and throughout their disease course. This evaluation should include colonoscopy&#160;<br/>and biopsies per local recommendations.</p>
<p style="position:absolute;top:560px;left:106px;white-space:nowrap" class="ft1672">Haematologic reactions</p>
<p style="position:absolute;top:598px;left:106px;white-space:nowrap" class="ft1675">Rare reports of pancytopenia including aplastic anaemia have been reported with TNF-antagonists. &#160;<br/>Adverse events of the haematologic system, including medically significant cytopenia (e.g.&#160;<br/>thrombocytopenia, leukopenia) have been reported with Humira. All patients should be advised to seek&#160;<br/>immediate medical attention if they develop signs and symptoms suggestive of blood dyscrasias (e.g.&#160;<br/>persistent fever, bruising, bleeding, pallor) while on Humira. Discontinuation of Humira therapy should be&#160;<br/>considered in patients with confirmed significant haematologic abnormalities.</p>
<p style="position:absolute;top:731px;left:106px;white-space:nowrap" class="ft1672">Vaccinations&#160;</p>
<p style="position:absolute;top:769px;left:106px;white-space:nowrap" class="ft1675">Similar antibody responses to the standard 23-valent pneumococcal vaccine and the influenza trivalent&#160;<br/>virus vaccination were observed in a study in 226&#160;adult subjects with rheumatoid arthritis who were&#160;<br/>treated with adalimumab or placebo. No data are available on the secondary transmission of infection by&#160;<br/>live vaccines in patients receiving Humira. &#160;</p>
<p style="position:absolute;top:864px;left:106px;white-space:nowrap" class="ft1675">It is recommended that paediatric patients, if possible, be brought up to date with all immunisations in&#160;<br/>agreement with current immunisation guidelines prior to initiating Humira&#160;therapy.</p>
<p style="position:absolute;top:921px;left:106px;white-space:nowrap" class="ft1674">Patients on Humira may receive concurrent vaccinations, except for live vaccines. Administration of live&#160;<br/>vaccines&#160;(e.g., BCG vaccine)&#160;to&#160;infants exposed to adalimumab in utero is not recommended for 5&#160;months&#160;<br/>following the mother’s last adalimumab injection during pregnancy.</p>
<p style="position:absolute;top:997px;left:106px;white-space:nowrap" class="ft1672">Congestive heart failure</p>
<p style="position:absolute;top:1035px;left:106px;white-space:nowrap" class="ft1675">In a clinical trial with another TNF-antagonist worsening congestive heart failure and increased mortality&#160;<br/>due to congestive heart failure have been observed. Cases of worsening congestive heart failure have also&#160;<br/>been reported in patients receiving Humira. Humira should be used with caution in patients with mild&#160;</p>
</div>
<!-- Page 168 -->
<a name="168"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page168-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1680">168</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft1684">heart failure (NYHA class I/II). Humira is contraindicated in moderate to severe heart failure (see section&#160;<br/>4.3). Treatment with Humira must&#160;be discontinued in patients who develop new or worsening symptoms&#160;<br/>of congestive heart failure.</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft1682">Autoimmune processes</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft1684">Treatment with Humira may result in the formation of autoimmune antibodies.&#160;The impact of long-term&#160;<br/>treatment with Humira on the development of autoimmune diseases is unknown.&#160;If a patient develops&#160;<br/>symptoms suggestive of a lupus-like syndrome following treatment with Humira and is positive for&#160;<br/>antibodies against double-stranded DNA, further treatment with Humira should not be given (see section&#160;<br/>4.8).</p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft1682">Concurrent administration of biologic DMARDS or TNF-antagonists</p>
<p style="position:absolute;top:352px;left:106px;white-space:nowrap" class="ft1685">Serious infections were seen in clinical studies with concurrent use of anakinra and another&#160;<br/>TNF-antagonist, etanercept, with no added clinical benefit compared to etanercept alone. Because of the&#160;<br/>nature of the adverse events seen with the combination of etanercept and anakinra therapy, similar&#160;<br/>toxicities may also result from the combination of anakinra and other TNF-antagonists. Therefore, the&#160;<br/>combination of adalimumab and anakinra&#160;is not recommended. (See section 4.5).</p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft1685">Concomitant administration of adalimumab with other biologic DMARDS (e.g, anakinra and abatacept) or&#160;<br/>other TNF-antagonists is not recommended based upon the possible increased risk for infections,&#160;<br/>including serious&#160;infections and other potential pharmacological interactions. (See section 4.5).</p>
<p style="position:absolute;top:541px;left:106px;white-space:nowrap" class="ft1682">Surgery</p>
<p style="position:absolute;top:579px;left:106px;white-space:nowrap" class="ft1684">There is limited safety experience of surgical procedures in patients treated with Humira. The long half-<br/>life of adalimumab should be taken into consideration if a surgical procedure is planned. &#160;A patient who&#160;<br/>requires surgery while on Humira should be closely monitored for infections, and appropriate actions&#160;<br/>should be taken. There is limited safety experience in patients undergoing arthroplasty while receiving&#160;<br/>Humira.</p>
<p style="position:absolute;top:693px;left:106px;white-space:nowrap" class="ft1682">Small bowel obstruction</p>
<p style="position:absolute;top:731px;left:106px;white-space:nowrap" class="ft1684">Failure to respond to treatment for Crohn’s disease may indicate the presence of fixed fibrotic stricture&#160;<br/>that may require surgical treatment. Available data suggest that Humira does not worsen or cause&#160;<br/>strictures.</p>
<p style="position:absolute;top:807px;left:106px;white-space:nowrap" class="ft1682">Elderly</p>
<p style="position:absolute;top:845px;left:106px;white-space:nowrap" class="ft1685">The&#160;frequency of serious infections among Humira treated subjects over 65&#160;years of age (3.7%) was&#160;<br/>higher than for those under 65&#160;years of age (1.5%). Some of those had a fatal outcome. Particular attention&#160;<br/>regarding the risk for infection should be paid when&#160;treating the elderly.</p>
<p style="position:absolute;top:921px;left:106px;white-space:nowrap" class="ft1682">Paediatric population</p>
<p style="position:absolute;top:959px;left:106px;white-space:nowrap" class="ft1682">See Vaccinations above.</p>
<p style="position:absolute;top:997px;left:106px;white-space:nowrap" class="ft1681"><b>4.5</b></p>
<p style="position:absolute;top:997px;left:148px;white-space:nowrap" class="ft1681"><b>Interaction with other medicinal products and other forms of interaction&#160;</b></p>
<p style="position:absolute;top:1035px;left:106px;white-space:nowrap" class="ft1685">Humira has been studied in rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and psoriatic&#160;<br/>arthritis patients taking Humira as monotherapy and those taking concomitant methotrexate. &#160;Antibody&#160;<br/>formation was lower when Humira was given together&#160;with methotrexate in comparison with use as&#160;</p>
</div>
<!-- Page 169 -->
<a name="169"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page169-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1690">169</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft1695">monotherapy. Administration of Humira without methotrexate resulted in increased formation of&#160;<br/>antibodies, increased clearance and reduced efficacy of adalimumab (see section 5.1).&#160;</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft1694">The combination of Humira and anakinra is not recommended (see section 4.4 “Concurrent administration&#160;<br/>of biologic DMARDS or TNF-antagonists”).&#160;</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft1694">The combination of Humira and abatacept is not recommended (see section 4.4 “Concurrent&#160;<br/>administration of biologic DMARDS or TNF-antagonists”).</p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft1691"><b>4.6</b></p>
<p style="position:absolute;top:257px;left:148px;white-space:nowrap" class="ft1691"><b>Fertility, pregnancy and lactation</b></p>
<p style="position:absolute;top:295px;left:106px;white-space:nowrap" class="ft1692">Women of childbearing potential</p>
<p style="position:absolute;top:333px;left:106px;white-space:nowrap" class="ft1694">Women of childbearing potential&#160;should consider the&#160;use&#160;of&#160;adequate contraception to prevent pregnancy&#160;<br/>and continue its use for at least five months after the last Humira treatment.</p>
<p style="position:absolute;top:390px;left:106px;white-space:nowrap" class="ft1692">Pregnancy</p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft1694">A large number (approximately 2100) of prospectively collected pregnancies exposed to adalimumab&#160;<br/>resulting in live birth with known outcomes, including more than 1500 exposed during the first trimester,&#160;<br/>does not indicate an increase in&#160;the rate of malformation in the newborn.</p>
<p style="position:absolute;top:503px;left:106px;white-space:nowrap" class="ft1694">In a prospective cohort registry, 257 women with rheumatoid arthritis (RA) or Crohn’s disease (CD)&#160;<br/>treated with adalimumab at least during the first trimester and 120 women with RA or CD not treated with&#160;<br/>adalimumab&#160;were&#160;enrolled. &#160;The primary endpoint was the birth prevalence of major birth defects. The&#160;<br/>rate of&#160;pregnancies ending with at least one live born infant with a major birth defect was 6/69 (8.7%)&#160;in&#160;<br/>the adalimumab-treated women with RA and 5/74 (6.8%) in the untreated women with RA (unadjusted&#160;<br/>OR 1.31, 95% CI 0.38-4.52) and 16/152 (10.5%) in the adalimumab-treated women with CD and 3/32&#160;<br/>(9.4%) in the untreated women with CD (unadjusted OR 1.14, 95% CI 0.31-4.16). The adjusted OR&#160;<br/>(accounting for baseline differences) was&#160;1.10&#160;(95% CI 0.45-2.73) with RA and CD combined. There were&#160;<br/>no distinct differences between&#160;adalimumab-treated and untreated women&#160;for the secondary&#160;endpoints&#160;<br/>spontaneous abortions, minor birth defects, preterm&#160;delivery, birth size and serious&#160;or opportunistic&#160;<br/>infections&#160;and no stillbirths or malignancies were reported.&#160;The interpretation of data&#160;may be impacted due&#160;<br/>to methodological limitations of the study, including small sample size and non-randomized design.</p>
<p style="position:absolute;top:750px;left:106px;white-space:nowrap" class="ft1694">In a developmental toxicity&#160;study conducted in monkeys, there was no indication of maternal toxicity,&#160;<br/>embryotoxicity or teratogenicity. Preclinical data on postnatal toxicity of adalimumab are not available&#160;<br/>(see section 5.3).</p>
<p style="position:absolute;top:827px;left:106px;white-space:nowrap" class="ft1692">Due to its inhibition of TNF</p>
<p style="position:absolute;top:825px;left:292px;white-space:nowrap" class="ft1696">, adalimumab administered during pregnancy could affect normal immune&#160;</p>
<p style="position:absolute;top:846px;left:106px;white-space:nowrap" class="ft1692">responses in the newborn.&#160;Adalimumab should only be used during pregnancy if clearly needed.&#160;&#160;</p>
<p style="position:absolute;top:884px;left:106px;white-space:nowrap" class="ft1694">Adalimumab may cross the placenta into the serum of infants born to women treated with adalimumab&#160;<br/>during pregnancy. Consequently, these infants may be at increased risk for infection. Administration of&#160;<br/>live vaccines&#160;(e.g., BCG vaccine)&#160;to infants exposed to adalimumab in utero is not recommended for&#160;<br/>5&#160;months following the mother’s last adalimumab injection during pregnancy.</p>
<p style="position:absolute;top:979px;left:106px;white-space:nowrap" class="ft1692">Breast-feeding</p>
<p style="position:absolute;top:1017px;left:106px;white-space:nowrap" class="ft1694">Limited information from the published literature indicates that adalimumab is excreted in breast milk at&#160;<br/>very low concentrations with the presence of adalimumab in human milk at concentrations of 0.1% to 1%&#160;<br/>of the maternal serum level.&#160;Given orally, immunoglobulin G proteins undergo intestinal proteolysis and&#160;</p>
</div>
<!-- Page 170 -->
<a name="170"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page170-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1700">170</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft1705">have poor bioavailability. No effects on the breastfed newborns/infants are anticipated. Consequently,&#160;<br/>Humira can be used during breastfeeding.</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft1702">Fertility</p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft1702">Preclinical data on fertility effects of adalimumab are not available.</p>
<p style="position:absolute;top:219px;left:106px;white-space:nowrap" class="ft1701"><b>4.7</b></p>
<p style="position:absolute;top:219px;left:148px;white-space:nowrap" class="ft1701"><b>Effects on ability to drive and use machines&#160;</b></p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft1704">Humira may have a minor influence on the ability to drive and use machines. Vertigo and visual&#160;<br/>impairment may occur following administration of Humira (see section 4.8).</p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft1701"><b>4.8</b></p>
<p style="position:absolute;top:314px;left:148px;white-space:nowrap" class="ft1701"><b>Undesirable effects</b></p>
<p style="position:absolute;top:352px;left:106px;white-space:nowrap" class="ft1702">Summary of the safety profile</p>
<p style="position:absolute;top:390px;left:106px;white-space:nowrap" class="ft1705">Humira was studied in 9,506 patients in pivotal controlled and open label trials for up to 60 months or&#160;<br/>more. &#160;These trials included rheumatoid arthritis patients with short term and&#160;long standing disease,&#160;<br/>juvenile idiopathic arthritis (polyarticular juvenile idiopathic arthritis and enthesitis-related arthritis) as&#160;<br/>well as axial spondyloarthritis (ankylosing spondylitis and axial spondyloarthritis without radiographic&#160;<br/>evidence of AS),&#160;psoriatic arthritis, Crohn’s disease, ulcerative colitis, psoriasis, hidradenitis suppurativa&#160;<br/>and uveitis patients. The pivotal controlled studies involved 6,089 patients receiving Humira and 3,801&#160;<br/>patients receiving placebo or active comparator during the controlled period.</p>
<p style="position:absolute;top:541px;left:106px;white-space:nowrap" class="ft1704">The proportion of patients who discontinued treatment due to adverse events during the double-blind,&#160;<br/>controlled portion of pivotal studies&#160;was 5.9% for patients taking Humira and 5.4% for control treated&#160;<br/>patients.</p>
<p style="position:absolute;top:617px;left:106px;white-space:nowrap" class="ft1704">The&#160;most commonly&#160;reported adverse reactions are infections (such as nasopharyngitis, upper respiratory&#160;<br/>tract infection and sinusitis), injection site reactions (erythema, itching, haemorrhage, pain or swelling),&#160;<br/>headache and musculoskeletal pain.</p>
<p style="position:absolute;top:693px;left:106px;white-space:nowrap" class="ft1704">Serious adverse reactions&#160;have been reported for Humira. TNF-antagonists, such as Humira affect the&#160;<br/>immune system and their use may affect the body’s defence against infection and cancer.<br/>Fatal and life-threatening infections (including sepsis, opportunistic infections and TB), HBV reactivation&#160;<br/>and various malignancies (including leukaemia, lymphoma and HSTCL) have also been reported with use&#160;<br/>of Humira.</p>
<p style="position:absolute;top:807px;left:106px;white-space:nowrap" class="ft1704">Serious haematological, neurological and autoimmune reactions have also been reported. These include&#160;<br/>rare reports of pancytopenia, aplastic anaemia, central and peripheral demyelinating events and reports of&#160;<br/>lupus, lupus-related conditions and Stevens-Johnson syndrome.</p>
<p style="position:absolute;top:883px;left:106px;white-space:nowrap" class="ft1702">Paediatric population</p>
<p style="position:absolute;top:921px;left:106px;white-space:nowrap" class="ft1705">In&#160;general, the adverse events in paediatric patients were similar in frequency and type to&#160;those seen in&#160;<br/>adult patients.</p>
<p style="position:absolute;top:978px;left:106px;white-space:nowrap" class="ft1702">Tabulated list of adverse reactions</p>
<p style="position:absolute;top:1016px;left:106px;white-space:nowrap" class="ft1707">The following list of adverse reactions is based on experience from clinical trials and on postmarketing&#160;<br/>experience and are displayed by system organ class and frequency in Table&#160;7&#160;below:&#160;very common&#160;<br/>(</p>
<p style="position:absolute;top:1053px;left:111px;white-space:nowrap" class="ft1706">&#160;1/10); common (&#160;1/100&#160;to&#160;&lt;&#160;1/10); uncommon (&#160;1/1,000&#160;to&#160;&lt;&#160;1/100); rare (&#160;1/10,000 to&#160;&lt;&#160;1/1,000);&#160;</p>
<p style="position:absolute;top:1074px;left:106px;white-space:nowrap" class="ft1702">and not known (cannot be estimated from the available data). Within each frequency grouping,&#160;</p>
</div>
<!-- Page 171 -->
<a name="171"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page171-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1710">171</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft1714">undesirable effects are presented in order of decreasing seriousness. The highest frequency seen among the&#160;<br/>various indications has been included. An asterisk (*) appears in the SOC column if further information is&#160;<br/>found elsewhere in sections 4.3, 4.4 and 4.8.</p>
<p style="position:absolute;top:162px;left:433px;white-space:nowrap" class="ft1711"><b>Table&#160;7</b></p>
<p style="position:absolute;top:181px;left:390px;white-space:nowrap" class="ft1711"><b>Undesirable Effects</b></p>
<p style="position:absolute;top:229px;left:132px;white-space:nowrap" class="ft1711"><b>System&#160;Organ&#160;Class</b></p>
<p style="position:absolute;top:229px;left:341px;white-space:nowrap" class="ft1711"><b>Frequency</b></p>
<p style="position:absolute;top:229px;left:566px;white-space:nowrap" class="ft1711"><b>Adverse Reaction</b></p>
<p style="position:absolute;top:262px;left:114px;white-space:nowrap" class="ft1714">Infections and&#160;<br/>infestations*</p>
<p style="position:absolute;top:262px;left:309px;white-space:nowrap" class="ft1712">Very common</p>
<p style="position:absolute;top:262px;left:465px;white-space:nowrap" class="ft1714">Respiratory tract infections (including lower and&#160;<br/>upper respiratory tract infection, pneumonia,&#160;<br/>sinusitis, pharyngitis, nasopharyngitis and&#160;<br/>pneumonia herpes viral)</p>
<p style="position:absolute;top:366px;left:309px;white-space:nowrap" class="ft1712">Common</p>
<p style="position:absolute;top:362px;left:465px;white-space:nowrap" class="ft1718">Systemic infections&#160;(including sepsis, candidiasis&#160;<br/>and influenza),<br/>intestinal infections&#160;(including gastroenteritis&#160;<br/>viral),<br/>skin and soft tissue infections (including&#160;<br/>paronychia, cellulitis, impetigo, necrotising&#160;<br/>fasciitis and herpes zoster),<br/>ear infections,<br/>oral infections&#160;(including herpes simplex, oral&#160;<br/>herpes and tooth infections),&#160;<br/>reproductive tract infections&#160;(including&#160;<br/>vulvovaginal mycotic infection),&#160;<br/>urinary tract infections (including&#160;<br/>pyelonephritis),<br/>fungal infections,<br/>joint infections</p>
<p style="position:absolute;top:703px;left:309px;white-space:nowrap" class="ft1712">Uncommon</p>
<p style="position:absolute;top:703px;left:465px;white-space:nowrap" class="ft1714">Neurological infections (including viral&#160;<br/>meningitis),<br/>opportunistic infections and tuberculosis&#160;<br/>(including coccidioidomycosis, histoplasmosis&#160;<br/>and mycobacterium avium complex infection),&#160;<br/>bacterial infections,<br/>eye&#160;infections,<br/>diverticulitis1)</p>
<p style="position:absolute;top:879px;left:114px;white-space:nowrap" class="ft1715">Neoplasms&#160;benign,&#160;<br/>malignant and unspecified&#160;<br/>(including cysts and&#160;<br/>polyps)*</p>
<p style="position:absolute;top:879px;left:309px;white-space:nowrap" class="ft1712">Common</p>
<p style="position:absolute;top:879px;left:465px;white-space:nowrap" class="ft1718">Skin cancer excluding melanoma (including&#160;<br/>basal cell carcinoma and squamous cell&#160;<br/>carcinoma),<br/>benign neoplasm</p>
<p style="position:absolute;top:984px;left:309px;white-space:nowrap" class="ft1712">Uncommon</p>
<p style="position:absolute;top:984px;left:465px;white-space:nowrap" class="ft1714">Lymphoma**,&#160;<br/>solid organ neoplasm (including breast cancer,&#160;<br/>lung neoplasm and thyroid neoplasm),&#160;<br/>melanoma**</p>
</div>
<!-- Page 172 -->
<a name="172"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page172-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1720">172</p>
<p style="position:absolute;top:96px;left:132px;white-space:nowrap" class="ft1721"><b>System&#160;Organ&#160;Class</b></p>
<p style="position:absolute;top:96px;left:341px;white-space:nowrap" class="ft1721"><b>Frequency</b></p>
<p style="position:absolute;top:96px;left:566px;white-space:nowrap" class="ft1721"><b>Adverse Reaction</b></p>
<p style="position:absolute;top:129px;left:309px;white-space:nowrap" class="ft1722">Rare</p>
<p style="position:absolute;top:129px;left:465px;white-space:nowrap" class="ft1722">Leukaemia1)</p>
<p style="position:absolute;top:176px;left:309px;white-space:nowrap" class="ft1722">Not known</p>
<p style="position:absolute;top:176px;left:465px;white-space:nowrap" class="ft1728">Hepatosplenic T-cell lymphoma1)<br/>Merkel cell carcinoma (neuroendocrine&#160;<br/>carcinoma of the skin)1),<br/>Kaposi’s sarcoma</p>
<p style="position:absolute;top:290px;left:114px;white-space:nowrap" class="ft1724">Blood and&#160;the lymphatic&#160;<br/>system disorders*</p>
<p style="position:absolute;top:290px;left:309px;white-space:nowrap" class="ft1722">Very common</p>
<p style="position:absolute;top:290px;left:465px;white-space:nowrap" class="ft1728">Leukopenia (including neutropenia and&#160;<br/>agranulocytosis),&#160;<br/>anaemia</p>
<p style="position:absolute;top:376px;left:309px;white-space:nowrap" class="ft1722">Common</p>
<p style="position:absolute;top:376px;left:465px;white-space:nowrap" class="ft1724">Leucocytosis,<br/>thrombocytopenia</p>
<p style="position:absolute;top:433px;left:309px;white-space:nowrap" class="ft1722">Uncommon</p>
<p style="position:absolute;top:433px;left:465px;white-space:nowrap" class="ft1722">Idiopathic thrombocytopenic purpura</p>
<p style="position:absolute;top:472px;left:309px;white-space:nowrap" class="ft1722">Rare</p>
<p style="position:absolute;top:472px;left:465px;white-space:nowrap" class="ft1722">Pancytopenia</p>
<p style="position:absolute;top:516px;left:114px;white-space:nowrap" class="ft1722">Immune system disorders*&#160;Common</p>
<p style="position:absolute;top:516px;left:465px;white-space:nowrap" class="ft1728">Hypersensitivity,<br/>allergies (including seasonal allergy)</p>
<p style="position:absolute;top:586px;left:309px;white-space:nowrap" class="ft1722">Uncommon</p>
<p style="position:absolute;top:586px;left:465px;white-space:nowrap" class="ft1728">Sarcoidosis1),<br/>vasculitis</p>
<p style="position:absolute;top:658px;left:309px;white-space:nowrap" class="ft1722">Rare</p>
<p style="position:absolute;top:658px;left:465px;white-space:nowrap" class="ft1722">Anaphylaxis1)</p>
<p style="position:absolute;top:706px;left:114px;white-space:nowrap" class="ft1725">Metabolism and nutrition&#160;<br/>disorders</p>
<p style="position:absolute;top:706px;left:309px;white-space:nowrap" class="ft1722">Very common</p>
<p style="position:absolute;top:706px;left:465px;white-space:nowrap" class="ft1722">Lipids increased</p>
<p style="position:absolute;top:753px;left:309px;white-space:nowrap" class="ft1722">Common</p>
<p style="position:absolute;top:753px;left:465px;white-space:nowrap" class="ft1728">Hypokalaemia,&#160;<br/>uric acid increased,&#160;<br/>blood sodium abnormal,<br/>hypocalcaemia,<br/>hyperglycaemia,<br/>hypophosphatemia,<br/>dehydration</p>
<p style="position:absolute;top:955px;left:114px;white-space:nowrap" class="ft1722">Psychiatric disorders</p>
<p style="position:absolute;top:955px;left:309px;white-space:nowrap" class="ft1722">Common</p>
<p style="position:absolute;top:955px;left:465px;white-space:nowrap" class="ft1728">Mood alterations (including depression),&#160;<br/>anxiety,<br/>insomnia</p>
<p style="position:absolute;top:1050px;left:114px;white-space:nowrap" class="ft1722">Nervous system disorders*&#160;Very common</p>
<p style="position:absolute;top:1050px;left:465px;white-space:nowrap" class="ft1722">Headache</p>
</div>
<!-- Page 173 -->
<a name="173"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page173-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1730">173</p>
<p style="position:absolute;top:96px;left:132px;white-space:nowrap" class="ft1731"><b>System&#160;Organ&#160;Class</b></p>
<p style="position:absolute;top:96px;left:341px;white-space:nowrap" class="ft1731"><b>Frequency</b></p>
<p style="position:absolute;top:96px;left:566px;white-space:nowrap" class="ft1731"><b>Adverse Reaction</b></p>
<p style="position:absolute;top:129px;left:309px;white-space:nowrap" class="ft1732">Common</p>
<p style="position:absolute;top:129px;left:465px;white-space:nowrap" class="ft1738">Paraesthesias (including hypoesthesia),<br/>migraine,<br/>nerve root compression</p>
<p style="position:absolute;top:219px;left:309px;white-space:nowrap" class="ft1732">Uncommon</p>
<p style="position:absolute;top:219px;left:465px;white-space:nowrap" class="ft1734">Cerebrovascular accident1),<br/>tremor,<br/>neuropathy &#160;</p>
<p style="position:absolute;top:296px;left:309px;white-space:nowrap" class="ft1732">Rare</p>
<p style="position:absolute;top:296px;left:465px;white-space:nowrap" class="ft1734">Multiple sclerosis,<br/>demyelinating disorders (e.g. optic neuritis,&#160;<br/>Guillain-Barré syndrome)&#160;1)</p>
<p style="position:absolute;top:386px;left:114px;white-space:nowrap" class="ft1732">Eye&#160;disorders</p>
<p style="position:absolute;top:386px;left:309px;white-space:nowrap" class="ft1732">Common</p>
<p style="position:absolute;top:386px;left:465px;white-space:nowrap" class="ft1738">Visual impairment,<br/>conjunctivitis,<br/>blepharitis,<br/>eye swelling</p>
<p style="position:absolute;top:499px;left:309px;white-space:nowrap" class="ft1732">Uncommon</p>
<p style="position:absolute;top:499px;left:465px;white-space:nowrap" class="ft1732">Diplopia</p>
<p style="position:absolute;top:543px;left:114px;white-space:nowrap" class="ft1734">Ear and labyrinth&#160;<br/>disorders&#160;</p>
<p style="position:absolute;top:543px;left:309px;white-space:nowrap" class="ft1732">Common</p>
<p style="position:absolute;top:543px;left:465px;white-space:nowrap" class="ft1732">Vertigo</p>
<p style="position:absolute;top:586px;left:309px;white-space:nowrap" class="ft1732">Uncommon</p>
<p style="position:absolute;top:586px;left:465px;white-space:nowrap" class="ft1734">Deafness,&#160;<br/>tinnitus</p>
<p style="position:absolute;top:648px;left:114px;white-space:nowrap" class="ft1732">Cardiac disorders*&#160;</p>
<p style="position:absolute;top:648px;left:309px;white-space:nowrap" class="ft1732">Common</p>
<p style="position:absolute;top:648px;left:465px;white-space:nowrap" class="ft1732">Tachycardia</p>
<p style="position:absolute;top:696px;left:309px;white-space:nowrap" class="ft1732">Uncommon</p>
<p style="position:absolute;top:696px;left:465px;white-space:nowrap" class="ft1738">Myocardial infarction1),<br/>arrhythmia,<br/>congestive heart failure</p>
<p style="position:absolute;top:786px;left:309px;white-space:nowrap" class="ft1732">Rare</p>
<p style="position:absolute;top:786px;left:465px;white-space:nowrap" class="ft1732">Cardiac arrest</p>
<p style="position:absolute;top:829px;left:114px;white-space:nowrap" class="ft1732">Vascular disorders</p>
<p style="position:absolute;top:829px;left:309px;white-space:nowrap" class="ft1732">Common</p>
<p style="position:absolute;top:829px;left:465px;white-space:nowrap" class="ft1738">Hypertension,&#160;<br/>flushing,&#160;<br/>haematoma</p>
<p style="position:absolute;top:919px;left:309px;white-space:nowrap" class="ft1732">Uncommon</p>
<p style="position:absolute;top:919px;left:465px;white-space:nowrap" class="ft1734">Aortic aneurysm,<br/>vascular arterial occlusion,<br/>thrombophlebitis &#160;&#160;</p>
<p style="position:absolute;top:1000px;left:114px;white-space:nowrap" class="ft1734">Respiratory, thoracic and&#160;<br/>mediastinal disorders*</p>
<p style="position:absolute;top:1000px;left:309px;white-space:nowrap" class="ft1732">Common</p>
<p style="position:absolute;top:1000px;left:465px;white-space:nowrap" class="ft1738">Asthma,<br/>dyspnoea,<br/>cough</p>
</div>
<!-- Page 174 -->
<a name="174"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page174-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1740">174</p>
<p style="position:absolute;top:96px;left:132px;white-space:nowrap" class="ft1741"><b>System&#160;Organ&#160;Class</b></p>
<p style="position:absolute;top:96px;left:341px;white-space:nowrap" class="ft1741"><b>Frequency</b></p>
<p style="position:absolute;top:96px;left:566px;white-space:nowrap" class="ft1741"><b>Adverse Reaction</b></p>
<p style="position:absolute;top:125px;left:309px;white-space:nowrap" class="ft1742">Uncommon</p>
<p style="position:absolute;top:125px;left:465px;white-space:nowrap" class="ft1745">Pulmonary embolism1),<br/>interstitial lung disease,&#160;<br/>chronic obstructive pulmonary disease,<br/>pneumonitis,<br/>pleural effusion1)</p>
<p style="position:absolute;top:243px;left:309px;white-space:nowrap" class="ft1742">Rare</p>
<p style="position:absolute;top:239px;left:465px;white-space:nowrap" class="ft1742">Pulmonary fibrosis1)</p>
<p style="position:absolute;top:282px;left:114px;white-space:nowrap" class="ft1742">Gastrointestinal disorders</p>
<p style="position:absolute;top:282px;left:309px;white-space:nowrap" class="ft1742">Very common</p>
<p style="position:absolute;top:282px;left:465px;white-space:nowrap" class="ft1748">Abdominal pain,&#160;<br/>nausea and vomiting</p>
<p style="position:absolute;top:349px;left:309px;white-space:nowrap" class="ft1742">Common</p>
<p style="position:absolute;top:349px;left:465px;white-space:nowrap" class="ft1745">GI haemorrhage,&#160;<br/>dyspepsia,<br/>gastroesophageal reflux disease,<br/>sicca syndrome</p>
<p style="position:absolute;top:445px;left:309px;white-space:nowrap" class="ft1742">Uncommon</p>
<p style="position:absolute;top:445px;left:465px;white-space:nowrap" class="ft1744">Pancreatitis,&#160;<br/>dysphagia,<br/>face oedema</p>
<p style="position:absolute;top:526px;left:309px;white-space:nowrap" class="ft1742">Rare</p>
<p style="position:absolute;top:526px;left:465px;white-space:nowrap" class="ft1742">Intestinal perforation1)</p>
<p style="position:absolute;top:573px;left:114px;white-space:nowrap" class="ft1742">Hepato-biliary disorders*</p>
<p style="position:absolute;top:573px;left:309px;white-space:nowrap" class="ft1742">Very Common</p>
<p style="position:absolute;top:573px;left:465px;white-space:nowrap" class="ft1742">Elevated liver enzymes</p>
<p style="position:absolute;top:617px;left:309px;white-space:nowrap" class="ft1742">Uncommon</p>
<p style="position:absolute;top:617px;left:465px;white-space:nowrap" class="ft1744">Cholecystitis and cholelithiasis,<br/>hepatic steatosis,<br/>bilirubin increased</p>
<p style="position:absolute;top:698px;left:309px;white-space:nowrap" class="ft1742">Rare</p>
<p style="position:absolute;top:698px;left:465px;white-space:nowrap" class="ft17410">Hepatitis<br/>reactivation of hepatitis B1)&#160;<br/>autoimmune hepatitis1)</p>
<p style="position:absolute;top:788px;left:309px;white-space:nowrap" class="ft1742">Not known</p>
<p style="position:absolute;top:788px;left:465px;white-space:nowrap" class="ft1742">Liver failure1)</p>
<p style="position:absolute;top:836px;left:114px;white-space:nowrap" class="ft1744">Skin and subcutaneous&#160;<br/>tissue disorders</p>
<p style="position:absolute;top:836px;left:309px;white-space:nowrap" class="ft1742">Very Common</p>
<p style="position:absolute;top:836px;left:465px;white-space:nowrap" class="ft1742">Rash (including exfoliative rash)</p>
<p style="position:absolute;top:879px;left:309px;white-space:nowrap" class="ft1742">Common</p>
<p style="position:absolute;top:879px;left:465px;white-space:nowrap" class="ft1744">Worsening or new&#160;onset of psoriasis(including&#160;<br/>palmoplantar pustular psoriasis)1),<br/>urticaria,<br/>bruising (including purpura),&#160;<br/>dermatitis (including eczema),<br/>onychoclasis,&#160;<br/>hyperhidrosis,<br/>alopecia1),<br/>pruritus&#160;</p>
<p style="position:absolute;top:1069px;left:309px;white-space:nowrap" class="ft1742">Uncommon</p>
<p style="position:absolute;top:1069px;left:465px;white-space:nowrap" class="ft1742">Night sweats,</p>
</div>
<!-- Page 175 -->
<a name="175"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page175-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1750">175</p>
<p style="position:absolute;top:96px;left:132px;white-space:nowrap" class="ft1751"><b>System&#160;Organ&#160;Class</b></p>
<p style="position:absolute;top:96px;left:341px;white-space:nowrap" class="ft1751"><b>Frequency</b></p>
<p style="position:absolute;top:96px;left:566px;white-space:nowrap" class="ft1751"><b>Adverse Reaction</b></p>
<p style="position:absolute;top:125px;left:465px;white-space:nowrap" class="ft1752">scar</p>
<p style="position:absolute;top:167px;left:309px;white-space:nowrap" class="ft1752">Rare</p>
<p style="position:absolute;top:167px;left:465px;white-space:nowrap" class="ft17510">Erythema multiforme1),<br/>Stevens-Johnson syndrome1),<br/>angioedema1),<br/>cutaneous vasculitis1)<br/>lichenoid skin reaction1)</p>
<p style="position:absolute;top:309px;left:309px;white-space:nowrap" class="ft1752">Not known</p>
<p style="position:absolute;top:309px;left:465px;white-space:nowrap" class="ft1752">Worsening of symptoms of dermatomyositis1)</p>
<p style="position:absolute;top:357px;left:114px;white-space:nowrap" class="ft1754">Musculoskeletal and&#160;<br/>connective tissue disorders</p>
<p style="position:absolute;top:357px;left:309px;white-space:nowrap" class="ft1752">Very common</p>
<p style="position:absolute;top:357px;left:465px;white-space:nowrap" class="ft1752">Musculoskeletal pain</p>
<p style="position:absolute;top:405px;left:309px;white-space:nowrap" class="ft1752">Common</p>
<p style="position:absolute;top:405px;left:465px;white-space:nowrap" class="ft1754">Muscle spasms&#160;(including blood creatine&#160;<br/>phosphokinase increased)</p>
<p style="position:absolute;top:467px;left:309px;white-space:nowrap" class="ft1752">Uncommon</p>
<p style="position:absolute;top:467px;left:465px;white-space:nowrap" class="ft1755">Rhabdomyolysis,<br/>systemic lupus erythematosus</p>
<p style="position:absolute;top:525px;left:309px;white-space:nowrap" class="ft1752">Rare</p>
<p style="position:absolute;top:525px;left:465px;white-space:nowrap" class="ft1752">Lupus-like syndrome1)</p>
<p style="position:absolute;top:568px;left:114px;white-space:nowrap" class="ft1754">Renal and urinary&#160;<br/>disorders&#160;</p>
<p style="position:absolute;top:568px;left:309px;white-space:nowrap" class="ft1752">Common</p>
<p style="position:absolute;top:568px;left:465px;white-space:nowrap" class="ft1758">Renal impairment,<br/>haematuria</p>
<p style="position:absolute;top:634px;left:309px;white-space:nowrap" class="ft1752">Uncommon</p>
<p style="position:absolute;top:634px;left:465px;white-space:nowrap" class="ft1752">Nocturia</p>
<p style="position:absolute;top:678px;left:114px;white-space:nowrap" class="ft1754">Reproductive system and&#160;<br/>breast disorders</p>
<p style="position:absolute;top:678px;left:309px;white-space:nowrap" class="ft1752">Uncommon</p>
<p style="position:absolute;top:678px;left:465px;white-space:nowrap" class="ft1752">Erectile dysfunction</p>
<p style="position:absolute;top:725px;left:114px;white-space:nowrap" class="ft1754">General disorders and&#160;<br/>administration site&#160;<br/>conditions*</p>
<p style="position:absolute;top:725px;left:309px;white-space:nowrap" class="ft1752">Very Common</p>
<p style="position:absolute;top:725px;left:465px;white-space:nowrap" class="ft1754">Injection site reaction (including injection site&#160;<br/>erythema)</p>
<p style="position:absolute;top:787px;left:309px;white-space:nowrap" class="ft1752">Common</p>
<p style="position:absolute;top:787px;left:465px;white-space:nowrap" class="ft1754">Chest pain,&#160;<br/>oedema,<br/>pyrexia1)</p>
<p style="position:absolute;top:864px;left:309px;white-space:nowrap" class="ft1752">Uncommon</p>
<p style="position:absolute;top:864px;left:465px;white-space:nowrap" class="ft1752">Inflammation</p>
<p style="position:absolute;top:907px;left:114px;white-space:nowrap" class="ft1752">Investigations*</p>
<p style="position:absolute;top:907px;left:309px;white-space:nowrap" class="ft1752">Common</p>
<p style="position:absolute;top:907px;left:465px;white-space:nowrap" class="ft1758">Coagulation and bleeding disorders (including&#160;<br/>activated partial thromboplastin time prolonged),&#160;<br/>autoantibody test positive (including double&#160;<br/>stranded DNA antibody),&#160;<br/>blood lactate dehydrogenase increased</p>
<p style="position:absolute;top:1040px;left:309px;white-space:nowrap" class="ft1752">Not known</p>
<p style="position:absolute;top:1040px;left:465px;white-space:nowrap" class="ft1752">Weight&#160;increased2)</p>
<p style="position:absolute;top:1064px;left:114px;white-space:nowrap" class="ft1754">Injury, poisoning and&#160;<br/>procedural complications</p>
<p style="position:absolute;top:1064px;left:309px;white-space:nowrap" class="ft1752">Common</p>
<p style="position:absolute;top:1064px;left:465px;white-space:nowrap" class="ft1752">Impaired healing</p>
</div>
<!-- Page 176 -->
<a name="176"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page176-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1760">176</p>
<p style="position:absolute;top:103px;left:106px;white-space:nowrap" class="ft1765">*&#160;further information is found elsewhere in sections 4.3, 4.4 and 4.8<br/>**&#160;including open label extension studies</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft1769">1)&#160;including spontaneous reporting data</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft1765">2)&#160;The mean weight&#160;change from baseline for adalimumab ranged from 0.3&#160;kg to 1.0&#160;kg across adult&#160;<br/>indications compared to (minus)&#160;-0.4&#160;kg to 0.4&#160;kg for placebo over a treatment period of 4-6 months.&#160;<br/>Weight increase of 5-6&#160;kg has also been observed&#160;in long-term&#160;extension studies with mean exposures of&#160;<br/>approximately 1-2 years without control group,&#160;particularly in patients with Crohn’s disease and&#160;<br/>Ulcerative colitis. The mechanism behind this effect is unclear but could be associated with the&#160;<br/>anti-inflammatory effect of&#160;adalimumab.</p>
<p style="position:absolute;top:293px;left:106px;white-space:nowrap" class="ft1762">Hidradenitis suppurativa</p>
<p style="position:absolute;top:331px;left:106px;white-space:nowrap" class="ft1764">The safety profile for patients with HS treated with Humira weekly was consistent with the known safety&#160;<br/>profile of Humira.</p>
<p style="position:absolute;top:388px;left:106px;white-space:nowrap" class="ft1762">Uveitis</p>
<p style="position:absolute;top:426px;left:106px;white-space:nowrap" class="ft1765">The safety profile for patients with uveitis treated with Humira every other week was consistent with the&#160;<br/>known safety profile of Humira.</p>
<p style="position:absolute;top:483px;left:106px;white-space:nowrap" class="ft1762">Description of selected adverse reactions</p>
<p style="position:absolute;top:521px;left:106px;white-space:nowrap" class="ft1763"><i>Injection site reactions</i></p>
<p style="position:absolute;top:559px;left:106px;white-space:nowrap" class="ft1764">In the pivotal controlled trials in adults and children, 12.9% of patients treated with Humira developed&#160;<br/>injection site reactions (erythema and/or itching, haemorrhage, pain or swelling), compared to 7.2% of&#160;<br/>patients receiving placebo or active control. Injection site reactions generally did not necessitate&#160;<br/>discontinuation of the medicinal product.</p>
<p style="position:absolute;top:653px;left:106px;white-space:nowrap" class="ft1763"><i>Infections&#160;</i></p>
<p style="position:absolute;top:692px;left:106px;white-space:nowrap" class="ft1764">In the pivotal controlled trials in adults and children, the rate of infection was 1.51 per patient year in the&#160;<br/>Humira treated patients and 1.46 per patient year in the placebo and active control-treated patients. The&#160;<br/>infections consisted primarily of&#160;nasopharyngitis, upper respiratory tract infection, and sinusitis.&#160;Most&#160;<br/>patients continued on Humira after the infection resolved. &#160;</p>
<p style="position:absolute;top:786px;left:106px;white-space:nowrap" class="ft1764">The incidence of serious infections was 0.04&#160;per patient year in Humira treated patients and 0.03&#160;per&#160;<br/>patient year in placebo and active control&#160;−&#160;treated patients. &#160;</p>
<p style="position:absolute;top:843px;left:106px;white-space:nowrap" class="ft1764">In controlled and open label adult and paediatric studies with Humira, serious infections (including fatal&#160;<br/>infections, which occurred rarely) have been reported, which include reports of tuberculosis (including&#160;<br/>miliary and extra-pulmonary locations) and invasive opportunistic infections (e.g. disseminated&#160;or&#160;<br/>extrapulmonary&#160;histoplasmosis,&#160;blastomycosis, coccidioidomycosis, pneumocystis,&#160;candidiasis,&#160;<br/>aspergillosis and listeriosis). Most of the cases of tuberculosis occurred within the first eight months after&#160;<br/>initiation of therapy and may reflect recrudescence of latent disease.</p>
<p style="position:absolute;top:976px;left:106px;white-space:nowrap" class="ft1763"><i>Malignancies and lymphoproliferative disorders</i></p>
<p style="position:absolute;top:1014px;left:106px;white-space:nowrap" class="ft1764">No&#160;malignancies were observed in 249 paediatric patients with an exposure of 655.6 patient years during&#160;<br/>Humira trials in patients with juvenile idiopathic arthritis (polyarticular juvenile idiopathic arthritis and&#160;<br/>enthesitis-related arthritis).&#160;In addition, no malignancies were observed in 192 paediatric patients with an&#160;<br/>exposure of 498.1 patient years during Humira trials in paediatric patients with Crohn’s disease. No&#160;</p>
</div>
<!-- Page 177 -->
<a name="177"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page177-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1770">177</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft1774">malignancies were observed in 77 paediatric patients with an exposure of 80.0 patient years during a&#160;<br/>Humira trial in paediatric patients with chronic plaque psoriasis.&#160;No malignancies were observed in 93<br/>paediatric patients with an exposure of 65.3 patient years during a Humira trial in paediatric patients with&#160;<br/>ulcerative colitis.&#160;No&#160;malignancies were observed in 60 paediatric patients with an exposure of 58.4&#160;<br/>patient years during a Humira trial in&#160;paediatric patients with uveitis.</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft1774">During the controlled portions of pivotal Humira trials in adults of at least 12 weeks in duration in patients&#160;<br/>with moderately to severely active rheumatoid arthritis, ankylosing spondylitis, axial spondyloarthritis&#160;<br/>without radiographic evidence of AS, &#160;psoriatic arthritis, psoriasis, hidradenitis suppurativa, Crohn’s&#160;<br/>disease, ulcerative colitis and uveitis, malignancies, other than lymphoma and non-melanoma skin cancer,&#160;<br/>were observed at a rate (95% confidence interval) of 6.8 (4.4, 10.5) &#160;per 1,000 patient-years among 5,291&#160;<br/>Humira treated patients&#160;<i>versus&#160;</i>a rate of 6.3 (3.4, 11.8) per 1,000 patient-years among 3,444 control&#160;<br/>patients (median duration of treatment was 4.0 months for Humira and 3.8 months for control-treated&#160;<br/>patients). The rate (95% confidence&#160;interval) of non-melanoma skin cancers was 8.8 (6.0, 13.0) per 1,000&#160;<br/>patient-years among Humira-treated patients and 3.2 (1.3, 7.6) per 1,000 patient-years among control&#160;<br/>patients. Of these skin cancers, squamous cell carcinomas occurred at rates (95% confidence interval) of&#160;<br/>2.7 (1.4, 5.4) per 1,000 patient-years among Humira-treated patients and 0.6 (0.1, 4.5) per 1,000 patient-<br/>years among control patients. The rate (95% confidence interval) of lymphomas was 0.7 (0.2, 2.7) per&#160;<br/>1,000 patient-years among Humira-treated patients and 0.6 (0.1, 4.5) per 1,000 patient-years among&#160;<br/>control patients.</p>
<p style="position:absolute;top:485px;left:106px;white-space:nowrap" class="ft1774">When combining controlled portions of these trials and ongoing and completed open label extension&#160;<br/>studies with a median duration of approximately 3.3 years including 6,427 patients and over 26,439&#160;<br/>patient-years of therapy, the observed rate of malignancies, other than lymphoma and non-melanoma skin&#160;<br/>cancers is approximately 8.5 per 1,000 patient years. The observed rate of non-melanoma skin cancers is&#160;<br/>approximately 9.6 per 1,000 patient years, and the observed rate of lymphomas is approximately 1.3 per&#160;<br/>1,000 patient years.</p>
<p style="position:absolute;top:617px;left:106px;white-space:nowrap" class="ft1774">In post-marketing experience from January 2003 to December 2010, predominantly in patients with&#160;<br/>rheumatoid arthritis, the reported rate of malignancies&#160;is approximately 2.7 per 1,000 patient treatment&#160;<br/>years. The reported rates for non-melanoma skin cancers and lymphomas are approximately 0.2 and 0.3&#160;<br/>per 1,000 patient treatment years, respectively (see section 4.4).</p>
<p style="position:absolute;top:712px;left:106px;white-space:nowrap" class="ft1774">Rare post-marketing cases of hepatosplenic T-cell&#160;lymphoma have been reported in patients treated with&#160;<br/>adalimumab (see section 4.4).</p>
<p style="position:absolute;top:769px;left:106px;white-space:nowrap" class="ft1773"><i>Autoantibodies&#160;</i></p>
<p style="position:absolute;top:807px;left:106px;white-space:nowrap" class="ft1774">Patients had serum samples tested for autoantibodies at multiple time points in rheumatoid arthritis studies&#160;<br/>I&#160;−&#160;V. In these trials, 11.9% of patients treated with Humira and 8.1% of placebo and active&#160;<br/>control&#160;−&#160;treated patients that had negative baseline anti-nuclear antibody titres reported positive titres at&#160;<br/>Week&#160;24. Two patients out of 3,441 treated with Humira in all rheumatoid arthritis and&#160;psoriatic arthritis&#160;<br/>studies developed clinical signs suggestive of new-onset lupus-like syndrome. The patients improved&#160;<br/>following discontinuation of therapy. No patients developed lupus nephritis or central nervous system&#160;<br/>symptoms.</p>
</div>
<!-- Page 178 -->
<a name="178"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page178-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1780">178</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft1783"><i>Hepato-biliary events</i></p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft1784">In controlled Phase 3 trials of Humira in patients with rheumatoid arthritis and psoriatic arthritis with a&#160;<br/>control period duration ranging from 4 to 104&#160;weeks, ALT elevations&#160;≥&#160;3 x ULN occurred in 3.7% of&#160;<br/>Humira-treated patients and 1.6% of control-treated patients.&#160;</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft1784">In controlled Phase 3 trials of Humira in patients with polyarticular juvenile idiopathic arthritis who were&#160;<br/>4 to 17&#160;years and enthesitis-related arthritis who were 6 to 17&#160;years, ALT elevations&#160;≥&#160;3 x ULN occurred&#160;<br/>in 6.1% of Humira-treated patients and 1.3% of control-treated patients. Most ALT elevations occurred&#160;<br/>with concomitant methotrexate use. No ALT elevations&#160;≥&#160;3 x ULN occurred in the Phase 3 trial of Humira&#160;<br/>in patients with polyarticular juvenile idiopathic arthritis who were 2 to &lt;&#160;4&#160;years.</p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft1784">In controlled Phase 3 trials of Humira in patients with&#160;Crohn’s disease and ulcerative colitis with a control&#160;<br/>period ranging from 4 to 52&#160;weeks. ALT elevations&#160;≥&#160;3 x ULN occurred in 0.9% of Humira-treated&#160;<br/>patients and 0.9% of controlled-treated patients.</p>
<p style="position:absolute;top:390px;left:106px;white-space:nowrap" class="ft1784">In the Phase 3 trial of Humira in patients with paediatric Crohn’s disease which evaluated efficacy and&#160;<br/>safety of two body weight adjusted maintenance dose regimens following body weight adjusted induction&#160;<br/>therapy up to 52&#160;weeks of treatment, ALT&#160;elevations&#160;≥&#160;3 x ULN occurred in 2.6%&#160;&#160;(5/192)&#160;of patients of&#160;<br/>whom 4 were receiving concomitant immunosuppressants at baseline.</p>
<p style="position:absolute;top:485px;left:106px;white-space:nowrap" class="ft1784">In controlled Phase 3 trials of Humira in patients with plaque&#160;psoriasis&#160;with a control period duration&#160;<br/>ranging from 12 to 24&#160;weeks, ALT elevations&#160;≥&#160;3 x ULN occurred in 1.8% of Humira-treated patients and&#160;<br/>1.8% of control-treated patients.&#160;</p>
<p style="position:absolute;top:560px;left:106px;white-space:nowrap" class="ft1784">No&#160;ALT elevations&#160;≥&#160;3 X ULN occurred in the Phase 3 trial of Humira in paediatric patients with plaque&#160;<br/>psoriasis.</p>
<p style="position:absolute;top:617px;left:106px;white-space:nowrap" class="ft1784">In controlled trials of&#160;Humira (initial doses of 160 mg at Week 0 and 80 mg at Week 2, followed by 40 mg&#160;<br/>every week starting at Week 4), in patients with hidradenitis suppurativa with a control period duration&#160;<br/>ranging from 12 to 16 weeks, ALT elevations&#160;≥ 3 x ULN occurred in 0.3%&#160;of Humira-treated patients and&#160;<br/>0.6% of control-treated patients.</p>
<p style="position:absolute;top:712px;left:106px;white-space:nowrap" class="ft1784">In controlled trials of Humira (initial doses of 80&#160;mg at Week 0 followed by 40&#160;mg&#160;every other week&#160;<br/>starting at Week 1) in&#160;adult&#160;patients with uveitis up to 80 weeks with a median exposure&#160;of 166.5 days and&#160;<br/>105.0 days in Humira-treated and control-treated patients, respectively, ALT elevations&#160;≥ 3 x ULN&#160;<br/>occurred in 2.4% of Humira-treated patients and 2.4% of control-treated patients.&#160;</p>
<p style="position:absolute;top:807px;left:106px;white-space:nowrap" class="ft1784">In the controlled Phase 3 trial of Humira in patients with&#160;paediatric ulcerative colitis (N=93) which&#160;<br/>evaluated efficacy and safety of a maintenance dose&#160;of 0.6 mg/kg (maximum of 40 mg) every other week&#160;<br/>(N=31) and a maintenance dose of 0.6 mg/kg (maximum of 40 mg) every Week&#160;(N=32),&#160;following body&#160;<br/>weight adjusted induction dosing&#160;of 2.4 mg/kg (maximum&#160;of 160 mg) at Week 0 and Week 1, and 1.2&#160;<br/>mg/kg (maximum&#160;of 80 mg) at Week 2&#160;(N=63),&#160;or an induction dose of 2.4 mg/kg (maximum&#160;of 160 mg)&#160;<br/>at Week 0, placebo at Week 1, and 1.2 mg/kg (maximum of 80 mg) at Week 2&#160;(N=30),&#160;ALT elevations&#160;≥&#160;<br/>3 X ULN occurred in 1.1% (1/93) of patients.</p>
<p style="position:absolute;top:959px;left:106px;white-space:nowrap" class="ft1785">Across all indications in clinical trials patients with raised ALT were asymptomatic and in most cases&#160;<br/>elevations were transient and resolved on continued treatment. &#160;However, there have also been post-<br/>marketing reports of liver failure as well as less severe liver disorders that may precede liver failure, such&#160;<br/>as hepatitis including autoimmune hepatitis in patients receiving adalimumab.</p>
</div>
<!-- Page 179 -->
<a name="179"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page179-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1790">179</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft1792">Concurrent treatment with azathioprine/6-mercaptopurine</p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft1794">In adult Crohn’s disease studies, higher incidences of malignant and serious infection-related adverse&#160;<br/>events were seen with the combination of Humira and azathioprine/6-mercaptopurine compared with&#160;<br/>Humira alone.</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft1792">Reporting of suspected adverse reactions</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft1794">Reporting suspected adverse reactions after authorisation of the medicinal product is important. &#160;It allows&#160;<br/>continued monitoring of the benefit/risk balance of the medicinal product. &#160;Healthcare professionals are&#160;<br/>asked to report any suspected adverse&#160;reactions via&#160;<a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">the national reporting system listed in&#160;Appendix V.</a></p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft1791"><b>4.9</b></p>
<p style="position:absolute;top:314px;left:160px;white-space:nowrap" class="ft1791"><b>Overdose</b></p>
<p style="position:absolute;top:352px;left:106px;white-space:nowrap" class="ft1795">No dose-limiting toxicity was observed during clinical trials. The highest dose level evaluated has been&#160;<br/>multiple intravenous doses of 10&#160;mg/kg, which is approximately 15&#160;times the recommended dose.&#160;</p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft1791"><b>5.</b></p>
<p style="position:absolute;top:427px;left:148px;white-space:nowrap" class="ft1791"><b>PHARMACOLOGICAL PROPERTIES</b></p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft1791"><b>5.1</b></p>
<p style="position:absolute;top:465px;left:148px;white-space:nowrap" class="ft1791"><b>Pharmacodynamic&#160;properties</b></p>
<p style="position:absolute;top:503px;left:106px;white-space:nowrap" class="ft1794">Pharmacotherapeutic group: Immunosuppressants, Tumour Necrosis Factor alpha (TNF-α) inhibitors.&#160;<br/>ATC code: L04AB04</p>
<p style="position:absolute;top:560px;left:106px;white-space:nowrap" class="ft1792">Mechanism&#160;of action</p>
<p style="position:absolute;top:598px;left:106px;white-space:nowrap" class="ft1795">Adalimumab binds specifically to TNF and neutralises the biological function of TNF by blocking its&#160;<br/>interaction with the p55 and p75 cell surface TNF receptors. &#160;</p>
<p style="position:absolute;top:655px;left:106px;white-space:nowrap" class="ft1795">Adalimumab also modulates biological responses that are induced or regulated by TNF, including changes&#160;<br/>in the levels of adhesion molecules responsible for leukocyte migration (ELAM-1, VCAM-1, and ICAM-1&#160;<br/>with an IC50&#160;of&#160;0.1-0.2 nM).&#160;</p>
<p style="position:absolute;top:731px;left:106px;white-space:nowrap" class="ft1792">Pharmacodynamic effects&#160;</p>
<p style="position:absolute;top:769px;left:106px;white-space:nowrap" class="ft1794">After treatment with Humira, a rapid decrease in levels of acute phase reactants of inflammation&#160;<br/>(C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)) and serum cytokines (IL-6) was&#160;<br/>observed, compared to baseline in patients with rheumatoid arthritis. Serum levels of matrix&#160;<br/>metalloproteinases (MMP-1 and MMP-3) that produce tissue remodelling responsible for cartilage&#160;<br/>destruction were also decreased after Humira administration. Patients treated with Humira usually&#160;<br/>experienced improvement in haematological signs of chronic inflammation.</p>
<p style="position:absolute;top:902px;left:106px;white-space:nowrap" class="ft1794">A rapid decrease in CRP levels was also observed in patients with polyarticular juvenile idiopathic&#160;<br/>arthritis, Crohn’s disease, ulcerative colitis and hidradenitis suppurativa after treatment with Humira. In&#160;<br/>patients with Crohn’s disease, a reduction of the number of cells expressing inflammatory markers in the&#160;<br/>colon including a significant reduction of expression of TNFα was seen. Endoscopic studies in intestinal&#160;<br/>mucosa have shown evidence of mucosal healing in adalimumab treated patients.</p>
</div>
<!-- Page 180 -->
<a name="180"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page180-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1800">180</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft1802">Clinical efficacy and safety</p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft1803"><i>Rheumatoid arthritis</i></p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft1804">Humira was evaluated in over 3,000 patients in all rheumatoid arthritis clinical trials. The efficacy and&#160;<br/>safety of&#160;Humira were assessed in five randomised, double-blind and well-controlled studies. Some&#160;<br/>patients were treated for up to 120&#160;months duration. Injection site pain of Humira 40&#160;mg/0.4&#160;ml was&#160;<br/>assessed in two randomised, active control, single-blind, two-period crossover studies.&#160;</p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft1802">RA study I evaluated 271 patients with moderately to severely active rheumatoid arthritis who were&#160;</p>
<p style="position:absolute;top:275px;left:106px;white-space:nowrap" class="ft1805">&#160;18&#160;years old, had failed therapy with at least one disease-modifying, anti&#160;rheumatic drug and had&#160;<br/>insufficient efficacy with methotrexate at doses of 12.5 to 25&#160;mg (10&#160;mg if methotrexate-intolerant) every&#160;<br/>week and whose methotrexate dose remained constant at 10 to 25&#160;mg&#160;every&#160;week. Doses of 20, 40 or&#160;<br/>80&#160;mg of Humira or placebo were given every other week for 24&#160;weeks.&#160;</p>
<p style="position:absolute;top:372px;left:106px;white-space:nowrap" class="ft1802">RA study II evaluated 544 patients with moderately to severely active rheumatoid arthritis who were&#160;</p>
<p style="position:absolute;top:390px;left:106px;white-space:nowrap" class="ft1804">&#160;18&#160;years old and had failed therapy with at least one disease-modifying, anti-rheumatic drugs. &#160;Doses of&#160;<br/>20 or 40&#160;mg of Humira were given by subcutaneous&#160;injection every other week with placebo on alternative&#160;<br/>weeks or every week for 26&#160;weeks; placebo was given every week for the same duration. &#160;No other&#160;<br/>disease-modifying anti-rheumatic drugs were allowed.</p>
<p style="position:absolute;top:487px;left:106px;white-space:nowrap" class="ft1802">RA study III evaluated 619 patients with moderately&#160;to severely active rheumatoid arthritis who were&#160;</p>
<p style="position:absolute;top:505px;left:106px;white-space:nowrap" class="ft1804">&#160;18&#160;years old, and who had an ineffective response to methotrexate at doses of 12.5 to 25&#160;mg or have&#160;<br/>been intolerant to 10&#160;mg of methotrexate every week. There were three groups in this study. &#160;The first&#160;<br/>received placebo injections every week for 52&#160;weeks. The second received 20&#160;mg of Humira every week&#160;<br/>for 52&#160;weeks. The third group received 40&#160;mg&#160;of Humira every other week with placebo injections on&#160;<br/>alternate weeks. Upon completion of the first 52&#160;weeks, 457 patients enrolled in an open-label extension&#160;<br/>phase in which 40&#160;mg&#160;of Humira/MTX was administered every other week up to 10&#160;years.</p>
<p style="position:absolute;top:640px;left:106px;white-space:nowrap" class="ft1807">RA study IV primarily assessed safety in 636 patients with moderately to severely active rheumatoid&#160;<br/>arthritis who were&#160;</p>
<p style="position:absolute;top:658px;left:230px;white-space:nowrap" class="ft1806">&#160;18&#160;years old. Patients were permitted to be either disease-modifying, anti-rheumatic&#160;</p>
<p style="position:absolute;top:679px;left:106px;white-space:nowrap" class="ft1804">drug-naïve or to remain on their pre-existing rheumatologic therapy provided that therapy was stable for a&#160;<br/>minimum of 28&#160;days. These therapies include methotrexate, leflunomide, hydroxychloroquine,&#160;<br/>sulfasalazine and/or gold salts. Patients were randomised to 40&#160;mg&#160;of Humira or placebo every other week&#160;<br/>for 24&#160;weeks. &#160;</p>
<p style="position:absolute;top:774px;left:106px;white-space:nowrap" class="ft1804">RA study V evaluated 799 methotrexate-naïve, adult patients with moderate to severely active early&#160;<br/>rheumatoid arthritis (mean disease duration less than 9&#160;months). This study evaluated the efficacy of&#160;<br/>Humira 40&#160;mg&#160;every other week/methotrexate combination therapy, Humira&#160;40&#160;mg&#160;every other week&#160;<br/>monotherapy and methotrexate monotherapy in reducing the signs and&#160;symptoms and rate of progression&#160;<br/>of joint damage in rheumatoid arthritis for 104&#160;weeks. Upon completion of the first 104 weeks, 497&#160;<br/>patients enrolled in an open-label extension phase in which 40 mg of Humira was administered every&#160;<br/>other week up to 10 years.</p>
<p style="position:absolute;top:926px;left:106px;white-space:nowrap" class="ft1804">RA studies VI and VII each evaluated 60 patients with moderately to severely active rheumatoid arthritis&#160;<br/>who were&#160;≥&#160;18&#160;years old. Enrolled patients were&#160;either current users of Humira 40&#160;mg/0.8&#160;ml and rated&#160;<br/>their average injection site pain as at least&#160;3&#160;cm (on a 0-10&#160;cm&#160;VAS) or were biologic-naïve subjects who&#160;<br/>were starting Humira 40&#160;mg/0.8&#160;ml. Patients were randomised to receive a single dose of Humira&#160;<br/>40&#160;mg/0.8&#160;ml or Humira 40&#160;mg/0.4&#160;ml, followed by a single injection of the opposite treatment at their&#160;<br/>next dose.&#160;</p>
<p style="position:absolute;top:1058px;left:106px;white-space:nowrap" class="ft1804">The primary end point in RA studies I, II and III and the secondary endpoint in RA study IV was the&#160;<br/>percent of patients who achieved an ACR 20 response at Week 24 or 26. The primary endpoint in RA&#160;</p>
</div>
<!-- Page 181 -->
<a name="181"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page181-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1810">181</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft1814">study V was the percent of patients who achieved an ACR 50 response at Week&#160;52. RA studies III and V&#160;<br/>had an additional primary endpoint at 52&#160;weeks of retardation of disease progression (as detected by X-ray&#160;<br/>results). RA study III also had a primary endpoint of changes in quality of life. The primary&#160;endpoint in&#160;<br/>RA studies VI and VII was injection site pain immediately after injection as measured by a 0-10&#160;cm VAS.</p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft1813"><i>ACR response</i></p>
<p style="position:absolute;top:219px;left:106px;white-space:nowrap" class="ft1815">The percent of Humira-treated patients achieving ACR 20, 50 and 70 responses was consistent across RA&#160;<br/>studies I, II and III. The results for the 40&#160;mg&#160;every other week dose are summarised in Table&#160;8.&#160;</p>
<p style="position:absolute;top:276px;left:429px;white-space:nowrap" class="ft1811"><b>Table&#160;8</b></p>
<p style="position:absolute;top:295px;left:297px;white-space:nowrap" class="ft1811"><b>ACR Responses in Placebo-Controlled Trials</b></p>
<p style="position:absolute;top:314px;left:383px;white-space:nowrap" class="ft1811"><b>(Percent of Patients)</b></p>
<p style="position:absolute;top:353px;left:113px;white-space:nowrap" class="ft1812">Response</p>
<p style="position:absolute;top:353px;left:255px;white-space:nowrap" class="ft1812">RA Study Ia**</p>
<p style="position:absolute;top:353px;left:448px;white-space:nowrap" class="ft1812">RA Study IIa**</p>
<p style="position:absolute;top:353px;left:643px;white-space:nowrap" class="ft1812">RA Study IIIa**</p>
<p style="position:absolute;top:392px;left:217px;white-space:nowrap" class="ft1812">Placebo/&#160;</p>
<p style="position:absolute;top:411px;left:224px;white-space:nowrap" class="ft1812">MTXc</p>
<p style="position:absolute;top:430px;left:228px;white-space:nowrap" class="ft1812">n=60</p>
<p style="position:absolute;top:392px;left:292px;white-space:nowrap" class="ft1812">Humirab/ MTXc</p>
<p style="position:absolute;top:411px;left:328px;white-space:nowrap" class="ft1812">n=63</p>
<p style="position:absolute;top:392px;left:426px;white-space:nowrap" class="ft1812">Placebo</p>
<p style="position:absolute;top:411px;left:431px;white-space:nowrap" class="ft1812">n=110</p>
<p style="position:absolute;top:392px;left:519px;white-space:nowrap" class="ft1812">Humirab</p>
<p style="position:absolute;top:411px;left:526px;white-space:nowrap" class="ft1812">n=113</p>
<p style="position:absolute;top:392px;left:615px;white-space:nowrap" class="ft1812">Placebo/&#160;</p>
<p style="position:absolute;top:411px;left:623px;white-space:nowrap" class="ft18122">MTXc<br/>n=200</p>
<p style="position:absolute;top:392px;left:691px;white-space:nowrap" class="ft1812">Humirab/ MTXc</p>
<p style="position:absolute;top:411px;left:723px;white-space:nowrap" class="ft1812">n=207</p>
<p style="position:absolute;top:450px;left:113px;white-space:nowrap" class="ft1812">ACR 20</p>
<p style="position:absolute;top:469px;left:124px;white-space:nowrap" class="ft1812">6&#160;months</p>
<p style="position:absolute;top:469px;left:224px;white-space:nowrap" class="ft1812">13.3%</p>
<p style="position:absolute;top:469px;left:324px;white-space:nowrap" class="ft1812">65.1%</p>
<p style="position:absolute;top:469px;left:431px;white-space:nowrap" class="ft1812">19.1%</p>
<p style="position:absolute;top:469px;left:526px;white-space:nowrap" class="ft1812">46.0%</p>
<p style="position:absolute;top:469px;left:622px;white-space:nowrap" class="ft1812">29.5%</p>
<p style="position:absolute;top:469px;left:724px;white-space:nowrap" class="ft1812">63.3%</p>
<p style="position:absolute;top:488px;left:124px;white-space:nowrap" class="ft1812">12&#160;months</p>
<p style="position:absolute;top:488px;left:233px;white-space:nowrap" class="ft1812">NA</p>
<p style="position:absolute;top:488px;left:333px;white-space:nowrap" class="ft1812">NA</p>
<p style="position:absolute;top:488px;left:440px;white-space:nowrap" class="ft1812">NA</p>
<p style="position:absolute;top:488px;left:535px;white-space:nowrap" class="ft1812">NA</p>
<p style="position:absolute;top:488px;left:622px;white-space:nowrap" class="ft1812">24.0%</p>
<p style="position:absolute;top:488px;left:724px;white-space:nowrap" class="ft1812">58.9%</p>
<p style="position:absolute;top:507px;left:113px;white-space:nowrap" class="ft1812">ACR 50</p>
<p style="position:absolute;top:526px;left:124px;white-space:nowrap" class="ft1812">6&#160;months</p>
<p style="position:absolute;top:526px;left:228px;white-space:nowrap" class="ft1812">6.7%</p>
<p style="position:absolute;top:526px;left:324px;white-space:nowrap" class="ft1812">52.4%</p>
<p style="position:absolute;top:526px;left:436px;white-space:nowrap" class="ft1812">8.2%</p>
<p style="position:absolute;top:526px;left:526px;white-space:nowrap" class="ft1812">22.1%</p>
<p style="position:absolute;top:526px;left:630px;white-space:nowrap" class="ft1812">9.5%</p>
<p style="position:absolute;top:526px;left:724px;white-space:nowrap" class="ft1812">39.1%</p>
<p style="position:absolute;top:545px;left:124px;white-space:nowrap" class="ft1812">12&#160;months</p>
<p style="position:absolute;top:545px;left:233px;white-space:nowrap" class="ft1812">NA</p>
<p style="position:absolute;top:545px;left:333px;white-space:nowrap" class="ft1812">NA</p>
<p style="position:absolute;top:545px;left:440px;white-space:nowrap" class="ft1812">NA</p>
<p style="position:absolute;top:545px;left:535px;white-space:nowrap" class="ft1812">NA</p>
<p style="position:absolute;top:545px;left:630px;white-space:nowrap" class="ft1812">9.5%</p>
<p style="position:absolute;top:545px;left:724px;white-space:nowrap" class="ft1812">41.5%</p>
<p style="position:absolute;top:564px;left:113px;white-space:nowrap" class="ft1812">ACR 70</p>
<p style="position:absolute;top:582px;left:124px;white-space:nowrap" class="ft1812">6&#160;months</p>
<p style="position:absolute;top:582px;left:228px;white-space:nowrap" class="ft1812">3.3%</p>
<p style="position:absolute;top:582px;left:324px;white-space:nowrap" class="ft1812">23.8%</p>
<p style="position:absolute;top:582px;left:436px;white-space:nowrap" class="ft1812">1.8%</p>
<p style="position:absolute;top:582px;left:526px;white-space:nowrap" class="ft1812">12.4%</p>
<p style="position:absolute;top:582px;left:630px;white-space:nowrap" class="ft1812">2.5%</p>
<p style="position:absolute;top:582px;left:724px;white-space:nowrap" class="ft1812">20.8%</p>
<p style="position:absolute;top:602px;left:124px;white-space:nowrap" class="ft1812">12&#160;months</p>
<p style="position:absolute;top:602px;left:233px;white-space:nowrap" class="ft1812">NA</p>
<p style="position:absolute;top:602px;left:333px;white-space:nowrap" class="ft1812">NA</p>
<p style="position:absolute;top:602px;left:440px;white-space:nowrap" class="ft1812">NA</p>
<p style="position:absolute;top:602px;left:535px;white-space:nowrap" class="ft1812">NA</p>
<p style="position:absolute;top:602px;left:630px;white-space:nowrap" class="ft1812">4.5%</p>
<p style="position:absolute;top:602px;left:724px;white-space:nowrap" class="ft1812">23.2%</p>
<p style="position:absolute;top:620px;left:113px;white-space:nowrap" class="ft1819">a&#160;RA study I at 24&#160;weeks, RA study II at 26&#160;weeks, and RA study III at 24&#160;and 52&#160;weeks</p>
<p style="position:absolute;top:639px;left:113px;white-space:nowrap" class="ft1819">b&#160;40&#160;mg Humira administered every other week</p>
<p style="position:absolute;top:658px;left:113px;white-space:nowrap" class="ft1817">c&#160;MTX = methotrexate<br/>**p&#160;&lt;&#160;0.01, Humira&#160;<i>versus&#160;</i>placebo</p>
<p style="position:absolute;top:717px;left:106px;white-space:nowrap" class="ft1814">In RA studies I-IV, all individual components of the ACR response criteria (number of tender and swollen&#160;<br/>joints, physician and patient assessment of disease activity and pain, disability index (HAQ) scores and&#160;<br/>CRP (mg/dl) values) improved at 24 or 26&#160;weeks&#160;compared to placebo. In RA study III, these&#160;<br/>improvements were maintained throughout 52&#160;weeks.&#160;</p>
<p style="position:absolute;top:811px;left:106px;white-space:nowrap" class="ft1815">In the open-label extension for RA study III, most patients who were ACR responders maintained&#160;<br/>response when followed for up to 10&#160;years. Of 207 patients who were randomised to Humira 40&#160;mg&#160;every&#160;<br/>other week, 114 patients continued on Humira 40&#160;mg&#160;every other week for 5&#160;years. Among those, 86&#160;<br/>patients (75.4%) had ACR 20 responses; 72 patients (63.2%) had ACR 50 responses; and 41 patients&#160;<br/>(36%) had ACR 70 responses. Of 207 patients, 81 patients continued on Humira 40&#160;mg every other week&#160;<br/>for 10&#160;years. Among those, 64 patients (79.0%) had ACR 20 responses; 56 patients (69.1%) had ACR 50&#160;<br/>responses; and 43 patients (53.1%) had ACR 70 responses.</p>
<p style="position:absolute;top:963px;left:106px;white-space:nowrap" class="ft1815">In RA study IV, the ACR&#160;20 response of patients treated with Humira plus standard of care was&#160;<br/>statistically significantly better than patients treated with placebo plus standard of care (p&#160;&lt;&#160;0.001). &#160;</p>
<p style="position:absolute;top:1020px;left:106px;white-space:nowrap" class="ft1815">In RA studies I-IV, Humira-treated patients achieved statistically significant ACR 20 and 50 responses&#160;<br/>compared to placebo as early as one to two weeks after initiation of treatment.</p>
</div>
<!-- Page 182 -->
<a name="182"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page182-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1820">182</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft1824">In RA study V with early rheumatoid arthritis patients who were methotrexate naïve, combination therapy&#160;<br/>with Humira and methotrexate led to faster and significantly greater ACR responses than methotrexate&#160;<br/>monotherapy and Humira monotherapy at Week&#160;52 and responses were sustained at Week&#160;104 (see Table&#160;<br/>9).</p>
<p style="position:absolute;top:181px;left:433px;white-space:nowrap" class="ft1821"><b>Table&#160;9</b></p>
<p style="position:absolute;top:200px;left:350px;white-space:nowrap" class="ft1821"><b>ACR Responses in RA Study V</b></p>
<p style="position:absolute;top:219px;left:388px;white-space:nowrap" class="ft1821"><b>(percent of patients)</b></p>
<p style="position:absolute;top:267px;left:120px;white-space:nowrap" class="ft1821"><b>Response</b></p>
<p style="position:absolute;top:257px;left:258px;white-space:nowrap" class="ft1821"><b>MTX</b></p>
<p style="position:absolute;top:276px;left:256px;white-space:nowrap" class="ft1821"><b>n=257</b></p>
<p style="position:absolute;top:257px;left:348px;white-space:nowrap" class="ft1821"><b>Humira</b></p>
<p style="position:absolute;top:276px;left:355px;white-space:nowrap" class="ft1821"><b>n=274</b></p>
<p style="position:absolute;top:257px;left:436px;white-space:nowrap" class="ft1821"><b>Humira/MTX</b></p>
<p style="position:absolute;top:276px;left:463px;white-space:nowrap" class="ft1821"><b>n=268</b></p>
<p style="position:absolute;top:267px;left:557px;white-space:nowrap" class="ft1821"><b>p-valuea</b></p>
<p style="position:absolute;top:267px;left:642px;white-space:nowrap" class="ft1821"><b>p-valueb</b></p>
<p style="position:absolute;top:267px;left:731px;white-space:nowrap" class="ft1821"><b>p-valuec</b></p>
<p style="position:absolute;top:296px;left:120px;white-space:nowrap" class="ft1822">ACR 20</p>
<p style="position:absolute;top:316px;left:162px;white-space:nowrap" class="ft1822">Week&#160;</p>
<p style="position:absolute;top:335px;left:120px;white-space:nowrap" class="ft1822">52</p>
<p style="position:absolute;top:316px;left:256px;white-space:nowrap" class="ft1822">62.6%</p>
<p style="position:absolute;top:316px;left:355px;white-space:nowrap" class="ft1822">54.4%</p>
<p style="position:absolute;top:316px;left:464px;white-space:nowrap" class="ft1822">72.8%</p>
<p style="position:absolute;top:316px;left:567px;white-space:nowrap" class="ft1822">0.013</p>
<p style="position:absolute;top:316px;left:645px;white-space:nowrap" class="ft1822">&lt;&#160;0.001</p>
<p style="position:absolute;top:316px;left:741px;white-space:nowrap" class="ft1822">0.043</p>
<p style="position:absolute;top:355px;left:162px;white-space:nowrap" class="ft1822">Week&#160;</p>
<p style="position:absolute;top:374px;left:120px;white-space:nowrap" class="ft1822">104</p>
<p style="position:absolute;top:355px;left:256px;white-space:nowrap" class="ft1822">56.0%</p>
<p style="position:absolute;top:355px;left:355px;white-space:nowrap" class="ft1822">49.3%</p>
<p style="position:absolute;top:355px;left:464px;white-space:nowrap" class="ft1822">69.4%</p>
<p style="position:absolute;top:355px;left:567px;white-space:nowrap" class="ft1822">0.002</p>
<p style="position:absolute;top:355px;left:645px;white-space:nowrap" class="ft1822">&lt;&#160;0.001</p>
<p style="position:absolute;top:355px;left:741px;white-space:nowrap" class="ft1822">0.140</p>
<p style="position:absolute;top:393px;left:120px;white-space:nowrap" class="ft1822">ACR 50</p>
<p style="position:absolute;top:413px;left:162px;white-space:nowrap" class="ft1822">Week&#160;</p>
<p style="position:absolute;top:432px;left:120px;white-space:nowrap" class="ft1822">52</p>
<p style="position:absolute;top:413px;left:256px;white-space:nowrap" class="ft1822">45.9%</p>
<p style="position:absolute;top:413px;left:355px;white-space:nowrap" class="ft1822">41.2%</p>
<p style="position:absolute;top:413px;left:464px;white-space:nowrap" class="ft1822">61.6%</p>
<p style="position:absolute;top:413px;left:560px;white-space:nowrap" class="ft1822">&lt;&#160;0.001</p>
<p style="position:absolute;top:413px;left:645px;white-space:nowrap" class="ft1822">&lt;&#160;0.001</p>
<p style="position:absolute;top:413px;left:741px;white-space:nowrap" class="ft1822">0.317</p>
<p style="position:absolute;top:452px;left:162px;white-space:nowrap" class="ft1822">Week&#160;</p>
<p style="position:absolute;top:471px;left:120px;white-space:nowrap" class="ft1822">104</p>
<p style="position:absolute;top:452px;left:256px;white-space:nowrap" class="ft1822">42.8%</p>
<p style="position:absolute;top:452px;left:355px;white-space:nowrap" class="ft1822">36.9%</p>
<p style="position:absolute;top:452px;left:464px;white-space:nowrap" class="ft1822">59.0%</p>
<p style="position:absolute;top:452px;left:560px;white-space:nowrap" class="ft1822">&lt;&#160;0.001</p>
<p style="position:absolute;top:452px;left:645px;white-space:nowrap" class="ft1822">&lt;&#160;0.001</p>
<p style="position:absolute;top:452px;left:741px;white-space:nowrap" class="ft1822">0.162</p>
<p style="position:absolute;top:490px;left:120px;white-space:nowrap" class="ft1822">ACR 70</p>
<p style="position:absolute;top:510px;left:162px;white-space:nowrap" class="ft1822">Week&#160;</p>
<p style="position:absolute;top:529px;left:120px;white-space:nowrap" class="ft1822">52</p>
<p style="position:absolute;top:510px;left:256px;white-space:nowrap" class="ft1822">27.2%</p>
<p style="position:absolute;top:510px;left:355px;white-space:nowrap" class="ft1822">25.9%</p>
<p style="position:absolute;top:510px;left:464px;white-space:nowrap" class="ft1822">45.5%</p>
<p style="position:absolute;top:510px;left:560px;white-space:nowrap" class="ft1822">&lt;&#160;0.001</p>
<p style="position:absolute;top:510px;left:645px;white-space:nowrap" class="ft1822">&lt;&#160;0.001</p>
<p style="position:absolute;top:510px;left:741px;white-space:nowrap" class="ft1822">0.656</p>
<p style="position:absolute;top:549px;left:162px;white-space:nowrap" class="ft1822">Week&#160;</p>
<p style="position:absolute;top:568px;left:120px;white-space:nowrap" class="ft1822">104</p>
<p style="position:absolute;top:549px;left:256px;white-space:nowrap" class="ft1822">28.4%</p>
<p style="position:absolute;top:549px;left:355px;white-space:nowrap" class="ft1822">28.1%</p>
<p style="position:absolute;top:549px;left:464px;white-space:nowrap" class="ft1822">46.6%</p>
<p style="position:absolute;top:549px;left:560px;white-space:nowrap" class="ft1822">&lt;&#160;0.001</p>
<p style="position:absolute;top:549px;left:645px;white-space:nowrap" class="ft1822">&lt;&#160;0.001</p>
<p style="position:absolute;top:549px;left:741px;white-space:nowrap" class="ft1822">0.864</p>
<p style="position:absolute;top:588px;left:121px;white-space:nowrap" class="ft1822">a.&#160;p-value is from the pairwise comparison of methotrexate monotherapy and Humira/methotrexate&#160;</p>
<p style="position:absolute;top:607px;left:148px;white-space:nowrap" class="ft1822">combination therapy using the&#160;Mann-Whitney U test.</p>
<p style="position:absolute;top:625px;left:121px;white-space:nowrap" class="ft1822">b.&#160;p-value is from the pairwise comparison of Humira monotherapy and Humira/methotrexate&#160;</p>
<p style="position:absolute;top:644px;left:145px;white-space:nowrap" class="ft1822">combination therapy using the Mann-Whitney U test</p>
<p style="position:absolute;top:663px;left:121px;white-space:nowrap" class="ft1822">c. &#160; p-value is from the pairwise comparison of Humira monotherapy and methotrexate monotherapy&#160;</p>
<p style="position:absolute;top:683px;left:145px;white-space:nowrap" class="ft1822">using the Mann-Whitney U test</p>
<p style="position:absolute;top:721px;left:106px;white-space:nowrap" class="ft1824">In the open-label extension for RA study V, ACR response rates were maintained when followed for up to&#160;<br/>10 years. Of 542 patients who were randomised to Humira 40 mg every other week, 170 patients&#160;<br/>continued on Humira 40 mg&#160;every other week for 10 years. Among those, 154 patients (90.6%) had ACR&#160;<br/>20 responses; 127 patients (74.7%) had ACR 50 responses; and 102 patients (60.0%) had ACR 70&#160;<br/>responses.</p>
<p style="position:absolute;top:835px;left:106px;white-space:nowrap" class="ft1824">At Week&#160;52, 42.9% of patients who received Humira/methotrexate combination therapy achieved clinical&#160;<br/>remission (DAS28 (CRP)&#160;&lt;&#160;2.6) compared to 20.6% of patients receiving methotrexate monotherapy and&#160;<br/>23.4% of patients receiving Humira monotherapy. Humira/methotrexate combination therapy was&#160;<br/>clinically and statistically superior to methotrexate (p&#160;&lt;&#160;0.001) and Humira monotherapy (p&#160;&lt;&#160;0.001) in&#160;<br/>achieving a low disease state in patients with recently diagnosed moderate to severe rheumatoid arthritis.&#160;<br/>The response for the two monotherapy arms was similar (p&#160;=&#160;0.447). &#160;Of 342 subjects originally&#160;<br/>randomized to Humira monotherapy or Humira/methotrexate combination therapy who entered the open-<br/>label extension study, 171 subjects completed 10 years of Humira treatment. Among those, 109 subjects&#160;<br/>(63.7%) were reported to be in remission at 10 years.</p>
<p style="position:absolute;top:1025px;left:106px;white-space:nowrap" class="ft1823"><i>Radiographic response</i></p>
<p style="position:absolute;top:1063px;left:106px;white-space:nowrap" class="ft1825">In RA study III, where Humira treated patients had a mean duration of rheumatoid arthritis of&#160;<br/>approximately 11&#160;years, structural joint damage was assessed radiographically and expressed as change in&#160;</p>
</div>
<!-- Page 183 -->
<a name="183"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page183-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1830">183</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft1834">modified Total Sharp Score (TSS) and its components, the erosion score and joint space narrowing score. &#160;<br/>Humira/methotrexate patients demonstrated significantly less radiographic progression than patients&#160;<br/>receiving methotrexate alone at 6 and 12&#160;months (see Table&#160;10). &#160;</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft1834">In the open-label extension of RA Study III, the reduction in rate of progression of structural damage is&#160;<br/>maintained for 8 and 10&#160;years in a subset of patients. At 8&#160;years, 81 of 207 patients originally treated with&#160;<br/>40&#160;mg Humira every other week were evaluated radiographically. Among those, 48 patients showed no&#160;<br/>progression of structural damage defined by a change from baseline in the mTSS of 0.5 or less. At&#160;<br/>10&#160;years, 79 of 207 patients originally treated with 40&#160;mg Humira every other week were evaluated&#160;<br/>radiographically. Among those, 40 patients showed no progression of structural damage defined by a&#160;<br/>change from baseline in the mTSS of 0.5 or less.</p>
<p style="position:absolute;top:314px;left:407px;white-space:nowrap" class="ft1831"><b>Table&#160;10</b></p>
<p style="position:absolute;top:333px;left:221px;white-space:nowrap" class="ft1831"><b>Radiographic Mean Changes Over 12&#160;Months in RA Study III</b></p>
<p style="position:absolute;top:371px;left:270px;white-space:nowrap" class="ft1834">Placebo/<br/>MTXa</p>
<p style="position:absolute;top:371px;left:391px;white-space:nowrap" class="ft1832">Humira/MTX</p>
<p style="position:absolute;top:390px;left:396px;white-space:nowrap" class="ft1832">40&#160;mg&#160;every&#160;</p>
<p style="position:absolute;top:409px;left:400px;white-space:nowrap" class="ft1832">other week</p>
<p style="position:absolute;top:371px;left:529px;white-space:nowrap" class="ft1832">Placebo/MTX-</p>
<p style="position:absolute;top:390px;left:513px;white-space:nowrap" class="ft1832">Humira/MTX (95%&#160;</p>
<p style="position:absolute;top:409px;left:541px;white-space:nowrap" class="ft1832">Confidence&#160;</p>
<p style="position:absolute;top:428px;left:548px;white-space:nowrap" class="ft1832">Intervalb)</p>
<p style="position:absolute;top:371px;left:687px;white-space:nowrap" class="ft1832">p-value</p>
<p style="position:absolute;top:448px;left:124px;white-space:nowrap" class="ft1832">Total Sharp Score</p>
<p style="position:absolute;top:448px;left:306px;white-space:nowrap" class="ft1832">2.7</p>
<p style="position:absolute;top:448px;left:426px;white-space:nowrap" class="ft1832">0.1</p>
<p style="position:absolute;top:448px;left:536px;white-space:nowrap" class="ft1832">2.6 (1.4, 3.8)&#160;</p>
<p style="position:absolute;top:448px;left:684px;white-space:nowrap" class="ft1832">&lt;&#160;0.001c</p>
<p style="position:absolute;top:468px;left:139px;white-space:nowrap" class="ft1832">Erosion score</p>
<p style="position:absolute;top:468px;left:306px;white-space:nowrap" class="ft1832">1.6</p>
<p style="position:absolute;top:468px;left:426px;white-space:nowrap" class="ft1832">0.0</p>
<p style="position:absolute;top:468px;left:536px;white-space:nowrap" class="ft1832">1.6 (0.9, 2.2)</p>
<p style="position:absolute;top:468px;left:687px;white-space:nowrap" class="ft1832">&lt;&#160;0.001</p>
<p style="position:absolute;top:487px;left:148px;white-space:nowrap" class="ft1832">JSNd&#160;score</p>
<p style="position:absolute;top:487px;left:306px;white-space:nowrap" class="ft1832">1.0</p>
<p style="position:absolute;top:487px;left:426px;white-space:nowrap" class="ft1832">0.1</p>
<p style="position:absolute;top:487px;left:536px;white-space:nowrap" class="ft1832">0.9 (0.3, 1.4)</p>
<p style="position:absolute;top:487px;left:689px;white-space:nowrap" class="ft1832">&#160;&#160;0.002</p>
<p style="position:absolute;top:505px;left:106px;white-space:nowrap" class="ft18313"><b>a</b>methotrexate</p>
<p style="position:absolute;top:525px;left:106px;white-space:nowrap" class="ft1839">b95% confidence intervals for the differences in change scores between methotrexate and Humira.&#160;</p>
<p style="position:absolute;top:544px;left:106px;white-space:nowrap" class="ft1839">cBased on rank analysis&#160;</p>
<p style="position:absolute;top:563px;left:106px;white-space:nowrap" class="ft1839">dJoint Space Narrowing</p>
<p style="position:absolute;top:602px;left:106px;white-space:nowrap" class="ft1834">In RA study V, structural joint damage was assessed radiographically and expressed as change in modified&#160;<br/>Total&#160;Sharp Score (see Table&#160;11).</p>
<p style="position:absolute;top:659px;left:418px;white-space:nowrap" class="ft1831"><b>Table&#160;11</b></p>
<p style="position:absolute;top:678px;left:246px;white-space:nowrap" class="ft1831"><b>&#160;&#160;Radiographic Mean Changes at Week&#160;52 in RA Study V</b></p>
<p style="position:absolute;top:717px;left:261px;white-space:nowrap" class="ft1832">MTX</p>
<p style="position:absolute;top:735px;left:258px;white-space:nowrap" class="ft1832">n=257</p>
<p style="position:absolute;top:755px;left:261px;white-space:nowrap" class="ft1832">(95%&#160;</p>
<p style="position:absolute;top:774px;left:243px;white-space:nowrap" class="ft1832">confidence&#160;</p>
<p style="position:absolute;top:792px;left:251px;white-space:nowrap" class="ft1832">interval)</p>
<p style="position:absolute;top:717px;left:367px;white-space:nowrap" class="ft1832">Humira</p>
<p style="position:absolute;top:735px;left:371px;white-space:nowrap" class="ft1832">n=274</p>
<p style="position:absolute;top:755px;left:374px;white-space:nowrap" class="ft1832">(95%&#160;</p>
<p style="position:absolute;top:774px;left:356px;white-space:nowrap" class="ft1832">confidence&#160;</p>
<p style="position:absolute;top:792px;left:364px;white-space:nowrap" class="ft1832">interval)</p>
<p style="position:absolute;top:717px;left:458px;white-space:nowrap" class="ft1832">Humira/MTX</p>
<p style="position:absolute;top:735px;left:482px;white-space:nowrap" class="ft1832">n=268</p>
<p style="position:absolute;top:755px;left:486px;white-space:nowrap" class="ft1832">(95%&#160;</p>
<p style="position:absolute;top:774px;left:467px;white-space:nowrap" class="ft1832">confidence&#160;</p>
<p style="position:absolute;top:792px;left:476px;white-space:nowrap" class="ft1832">interval)</p>
<p style="position:absolute;top:755px;left:569px;white-space:nowrap" class="ft1832">p-valuea</p>
<p style="position:absolute;top:755px;left:643px;white-space:nowrap" class="ft1832">p-valueb</p>
<p style="position:absolute;top:755px;left:718px;white-space:nowrap" class="ft1832">p-valuec</p>
<p style="position:absolute;top:812px;left:129px;white-space:nowrap" class="ft1832">Total Sharp&#160;</p>
<p style="position:absolute;top:831px;left:149px;white-space:nowrap" class="ft1832">Score</p>
<p style="position:absolute;top:812px;left:238px;white-space:nowrap" class="ft1832">5.7 (4.2-7.3)</p>
<p style="position:absolute;top:812px;left:351px;white-space:nowrap" class="ft1832">3.0 (1.7-4.3)</p>
<p style="position:absolute;top:812px;left:462px;white-space:nowrap" class="ft1832">1.3 (0.5-2.1)</p>
<p style="position:absolute;top:812px;left:571px;white-space:nowrap" class="ft1832">&lt;&#160;0.001</p>
<p style="position:absolute;top:812px;left:648px;white-space:nowrap" class="ft1832">0.0020</p>
<p style="position:absolute;top:812px;left:720px;white-space:nowrap" class="ft1832">&lt;&#160;0.001</p>
<p style="position:absolute;top:851px;left:122px;white-space:nowrap" class="ft1832">Erosion score</p>
<p style="position:absolute;top:851px;left:238px;white-space:nowrap" class="ft1832">3.7 (2.7-4.7)</p>
<p style="position:absolute;top:851px;left:351px;white-space:nowrap" class="ft1832">1.7 (1.0-2.4)</p>
<p style="position:absolute;top:851px;left:462px;white-space:nowrap" class="ft1832">0.8 (0.4-1.2)</p>
<p style="position:absolute;top:851px;left:571px;white-space:nowrap" class="ft1832">&lt;&#160;0.001</p>
<p style="position:absolute;top:851px;left:648px;white-space:nowrap" class="ft1832">0.0082</p>
<p style="position:absolute;top:851px;left:720px;white-space:nowrap" class="ft1832">&lt;&#160;0.001</p>
<p style="position:absolute;top:870px;left:134px;white-space:nowrap" class="ft1832">JSN score</p>
<p style="position:absolute;top:870px;left:238px;white-space:nowrap" class="ft1832">2.0 (1.2-2.8)</p>
<p style="position:absolute;top:870px;left:351px;white-space:nowrap" class="ft1832">1.3 (0.5-2.1)</p>
<p style="position:absolute;top:870px;left:468px;white-space:nowrap" class="ft1832">0.5 (0-1.0)</p>
<p style="position:absolute;top:870px;left:571px;white-space:nowrap" class="ft1832">&lt;&#160;0.001</p>
<p style="position:absolute;top:870px;left:648px;white-space:nowrap" class="ft1832">0.0037</p>
<p style="position:absolute;top:870px;left:726px;white-space:nowrap" class="ft1832">0.151</p>
<p style="position:absolute;top:889px;left:122px;white-space:nowrap" class="ft1839">a&#160;p-value is from the pairwise&#160;comparison of methotrexate monotherapy and Humira/methotrexate&#160;</p>
<p style="position:absolute;top:909px;left:147px;white-space:nowrap" class="ft1832">combination therapy using the Mann-Whitney U test.</p>
<p style="position:absolute;top:927px;left:122px;white-space:nowrap" class="ft1839">b&#160;p-value is from the pairwise comparison of Humira monotherapy and Humira/methotrexate&#160;</p>
<p style="position:absolute;top:947px;left:149px;white-space:nowrap" class="ft1832">combination therapy using the Mann-Whitney U test&#160;</p>
<p style="position:absolute;top:965px;left:122px;white-space:nowrap" class="ft1839">c&#160;p-value is from the pairwise comparison of Humira monotherapy and methotrexate monotherapy&#160;</p>
<p style="position:absolute;top:985px;left:149px;white-space:nowrap" class="ft1832">using the Mann-Whitney U test</p>
<p style="position:absolute;top:1023px;left:106px;white-space:nowrap" class="ft1837">Following 52&#160;weeks and 104&#160;weeks of treatment, the percentage of patients without progression (change&#160;<br/>from baseline in modified Total Sharp Score&#160;</p>
<p style="position:absolute;top:1041px;left:404px;white-space:nowrap" class="ft1836">&#160;0.5) was significantly higher with Humira/methotrexate&#160;</p>
<p style="position:absolute;top:1062px;left:106px;white-space:nowrap" class="ft1832">combination therapy (63.8% and 61.2% respectively) compared to methotrexate monotherapy (37.4% and&#160;</p>
</div>
<!-- Page 184 -->
<a name="184"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page184-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1840">184</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft1845">33.5% respectively, p&#160;&lt;&#160;0.001) and Humira monotherapy (50.7%, p&#160;&lt;&#160;0.002 and 44.5%, p&#160;&lt;&#160;0.001&#160;<br/>respectively).</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft1844">In the open-label extension of RA study V, the mean change from baseline at Year 10 in the modified&#160;<br/>Total Sharp Score was 10.8, 9.2 and 3.9 in patients originally randomized to methotrexate monotherapy,&#160;<br/>Humira monotherapy and Humira/methotrexate combination therapy, respectively.&#160;The corresponding&#160;<br/>proportions of patients with no radiographic progression were 31.3%, 23.7% and 36.7% respectively.</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft1843"><i>Quality of life and physical function&#160;</i></p>
<p style="position:absolute;top:276px;left:106px;white-space:nowrap" class="ft1844">Health-related quality of life and physical function were assessed using the disability index of the Health&#160;<br/>Assessment Questionnaire (HAQ) in the four original adequate and well-controlled trials, which was a&#160;<br/>pre-specified primary endpoint at Week&#160;52 in RA study III. All doses/schedules of Humira in all four&#160;<br/>studies showed statistically significantly greater improvement in the disability index of the HAQ from&#160;<br/>baseline to Month&#160;6 compared to placebo and in RA study III the same was seen at Week&#160;52. Results from&#160;<br/>the Short Form Health Survey (SF 36) for all doses/schedules of Humira in all four studies support these&#160;<br/>findings, with statistically significant physical component summary (PCS) scores, as well as statistically&#160;<br/>significant pain and vitality domain scores for the 40&#160;mg&#160;every other week dose. A statistically significant&#160;<br/>decrease in fatigue as measured by functional assessment of chronic illness therapy (FACIT) scores was&#160;<br/>seen in all three studies in which it was assessed (RA studies I, III, IV).</p>
<p style="position:absolute;top:485px;left:106px;white-space:nowrap" class="ft1844">In RA study III, most subjects who achieved improvement in physical function and continued treatment&#160;<br/>maintained improvement through Week&#160;520 (120&#160;months) of open-label treatment. Improvement in&#160;<br/>quality of life was measured up to Week&#160;156 (36&#160;months) and improvement was maintained through that&#160;<br/>time.</p>
<p style="position:absolute;top:579px;left:106px;white-space:nowrap" class="ft1844">In RA study&#160;V, the improvement in the HAQ disability index and the physical component of the SF 36&#160;<br/>showed greater improvement (p&#160;&lt;&#160;0.001) for Humira/methotrexate combination therapy&#160;<i>versus<br/></i>methotrexate monotherapy and Humira monotherapy at Week&#160;52, which was maintained through&#160;<br/>Week&#160;104.&#160;Among the 250 subjects who completed the open-label extension study, improvements in&#160;<br/>physical function were maintained through 10 years of treatment.</p>
<p style="position:absolute;top:693px;left:106px;white-space:nowrap" class="ft1843"><i>Injection site pain</i></p>
<p style="position:absolute;top:731px;left:106px;white-space:nowrap" class="ft1844">For the pooled crossover RA studies VI and VII, a statistically significant difference for injection site pain&#160;<br/>immediately after dosing was observed between Humira 40&#160;mg/0.8&#160;ml and Humira 40&#160;mg/0.4&#160;ml (mean&#160;<br/>VAS of 3.7&#160;cm&#160;versus 1.2&#160;cm, scale of 0-10&#160;cm, P&#160;&lt;&#160;0.001).&#160;This represented an 84% median reduction in&#160;<br/>injection site pain.</p>
<p style="position:absolute;top:826px;left:106px;white-space:nowrap" class="ft1843"><i>Axial spondyloarthritis&#160;</i></p>
<p style="position:absolute;top:864px;left:106px;white-space:nowrap" class="ft1843"><i>Ankylosing spondylitis (AS)</i></p>
<p style="position:absolute;top:902px;left:106px;white-space:nowrap" class="ft1845">Humira&#160;40&#160;mg&#160;every other week was assessed in 393&#160;patients in two randomised, 24&#160;week double&#160;−&#160;blind,&#160;<br/>placebo&#160;−&#160;controlled studies in patients with active ankylosing spondylitis (mean baseline score of disease&#160;<br/>activity [Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)] was 6.3 in all groups) who have&#160;<br/>had an inadequate response to conventional therapy. Seventy-nine (20.1%) patients were treated&#160;<br/>concomitantly with disease modifying anti&#160;− rheumatic drugs, and 37 (9.4%) patients with&#160;<br/>glucocorticoids. The blinded period was followed by an open&#160;−&#160;label period during which patients&#160;<br/>received Humira 40&#160;mg&#160;every other week subcutaneously for up to an additional 28&#160;weeks. Subjects&#160;<br/>(n=215, 54.7%) who failed to achieve ASAS 20 at Weeks&#160;12, or 16 or 20 received early escape open-label&#160;<br/>adalimumab 40&#160;mg&#160;every other week subcutaneously and were subsequently treated as non-responders in&#160;<br/>the double-blind statistical analyses.</p>
</div>
<!-- Page 185 -->
<a name="185"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page185-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1850">185</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft1854">In the larger AS study I with 315&#160;patients, results showed statistically significant improvement of the signs&#160;<br/>and symptoms of ankylosing spondylitis in patients treated with Humira compared to&#160;placebo. &#160;Significant&#160;<br/>response was first observed at Week&#160;2 and maintained through 24&#160;weeks (Table&#160;12).&#160;</p>
<p style="position:absolute;top:181px;left:428px;white-space:nowrap" class="ft1851"><b>Table&#160;12</b></p>
<p style="position:absolute;top:200px;left:245px;white-space:nowrap" class="ft1851"><b>Efficacy Responses in Placebo-Controlled AS Study&#160;–&#160;Study I</b></p>
<p style="position:absolute;top:219px;left:338px;white-space:nowrap" class="ft1851"><b>Reduction of Signs and Symptoms</b></p>
<p style="position:absolute;top:257px;left:191px;white-space:nowrap" class="ft1851"><b>Response</b></p>
<p style="position:absolute;top:257px;left:442px;white-space:nowrap" class="ft1851"><b>Placebo</b></p>
<p style="position:absolute;top:276px;left:447px;white-space:nowrap" class="ft1851"><b>N=107</b></p>
<p style="position:absolute;top:257px;left:607px;white-space:nowrap" class="ft1851"><b>Humira</b></p>
<p style="position:absolute;top:276px;left:612px;white-space:nowrap" class="ft1851"><b>N=208</b></p>
<p style="position:absolute;top:296px;left:191px;white-space:nowrap" class="ft1854">ASASa&#160;20<br/>&#160; &#160; &#160; &#160; &#160; &#160; &#160;Week&#160;2</p>
<p style="position:absolute;top:316px;left:455px;white-space:nowrap" class="ft1852">16%</p>
<p style="position:absolute;top:316px;left:608px;white-space:nowrap" class="ft1852">42%***</p>
<p style="position:absolute;top:336px;left:245px;white-space:nowrap" class="ft1852">Week&#160;12</p>
<p style="position:absolute;top:336px;left:455px;white-space:nowrap" class="ft1852">21%</p>
<p style="position:absolute;top:336px;left:608px;white-space:nowrap" class="ft1852">58%***</p>
<p style="position:absolute;top:355px;left:245px;white-space:nowrap" class="ft1852">Week&#160;24</p>
<p style="position:absolute;top:355px;left:455px;white-space:nowrap" class="ft1852">19%</p>
<p style="position:absolute;top:355px;left:608px;white-space:nowrap" class="ft1852">51%***</p>
<p style="position:absolute;top:375px;left:191px;white-space:nowrap" class="ft1854">ASAS 50<br/>&#160; &#160; &#160; &#160; &#160; &#160; &#160;Week&#160;2</p>
<p style="position:absolute;top:395px;left:459px;white-space:nowrap" class="ft1852">3%</p>
<p style="position:absolute;top:395px;left:608px;white-space:nowrap" class="ft1852">16%***</p>
<p style="position:absolute;top:414px;left:245px;white-space:nowrap" class="ft1852">Week&#160;12</p>
<p style="position:absolute;top:414px;left:455px;white-space:nowrap" class="ft1852">10%</p>
<p style="position:absolute;top:414px;left:608px;white-space:nowrap" class="ft1852">38%***</p>
<p style="position:absolute;top:434px;left:245px;white-space:nowrap" class="ft1852">Week&#160;24</p>
<p style="position:absolute;top:434px;left:455px;white-space:nowrap" class="ft1852">11%</p>
<p style="position:absolute;top:434px;left:608px;white-space:nowrap" class="ft1852">35%***</p>
<p style="position:absolute;top:454px;left:191px;white-space:nowrap" class="ft1854">ASAS 70<br/>&#160; &#160; &#160; &#160; &#160; &#160; &#160;Week&#160;2</p>
<p style="position:absolute;top:474px;left:459px;white-space:nowrap" class="ft1852">0%</p>
<p style="position:absolute;top:474px;left:616px;white-space:nowrap" class="ft1852">7%**</p>
<p style="position:absolute;top:494px;left:245px;white-space:nowrap" class="ft1852">Week&#160;12</p>
<p style="position:absolute;top:494px;left:459px;white-space:nowrap" class="ft1852">5%</p>
<p style="position:absolute;top:494px;left:608px;white-space:nowrap" class="ft1852">23%***</p>
<p style="position:absolute;top:513px;left:245px;white-space:nowrap" class="ft1852">Week&#160;24</p>
<p style="position:absolute;top:513px;left:459px;white-space:nowrap" class="ft1852">8%</p>
<p style="position:absolute;top:513px;left:608px;white-space:nowrap" class="ft1852">24%***</p>
<p style="position:absolute;top:553px;left:191px;white-space:nowrap" class="ft1854">BASDAIb&#160;50&#160;<br/>&#160; &#160; &#160; &#160; &#160; &#160; &#160;Week&#160;2</p>
<p style="position:absolute;top:572px;left:459px;white-space:nowrap" class="ft1852">4%</p>
<p style="position:absolute;top:572px;left:608px;white-space:nowrap" class="ft1852">20%***</p>
<p style="position:absolute;top:592px;left:245px;white-space:nowrap" class="ft1852">Week&#160;12&#160;</p>
<p style="position:absolute;top:592px;left:455px;white-space:nowrap" class="ft1852">16%</p>
<p style="position:absolute;top:592px;left:608px;white-space:nowrap" class="ft1852">45%***</p>
<p style="position:absolute;top:612px;left:245px;white-space:nowrap" class="ft1852">Week&#160;24&#160;</p>
<p style="position:absolute;top:612px;left:455px;white-space:nowrap" class="ft1852">15%</p>
<p style="position:absolute;top:612px;left:608px;white-space:nowrap" class="ft1852">42%***</p>
<p style="position:absolute;top:631px;left:180px;white-space:nowrap" class="ft1854">***,** Statistically significant at p&#160;&lt;&#160;0.001, &lt;&#160;0.01 for all comparisons between Humira and&#160;<br/>placebo at Weeks&#160;2, 12 and &#160;24</p>
<p style="position:absolute;top:668px;left:180px;white-space:nowrap" class="ft1859">a&#160;Assessments in Ankylosing Spondylitis</p>
<p style="position:absolute;top:687px;left:180px;white-space:nowrap" class="ft1859">b&#160;Bath Ankylosing Spondylitis Disease Activity Index</p>
<p style="position:absolute;top:726px;left:106px;white-space:nowrap" class="ft1855">Humira treated patients had significantly greater improvement at Week&#160;12 which was maintained through&#160;<br/>Week&#160;24 in both the SF36 and Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL).</p>
<p style="position:absolute;top:783px;left:106px;white-space:nowrap" class="ft1855">Similar trends (not all statistically significant) were seen in the smaller randomised, double&#160;−&#160;blind,&#160;<br/>placebo controlled AS study II of 82&#160;adult patients with active ankylosing spondylitis.</p>
<p style="position:absolute;top:840px;left:106px;white-space:nowrap" class="ft1853"><i>Axial spondyloarthritis without radiographic evidence of AS</i></p>
<p style="position:absolute;top:878px;left:106px;white-space:nowrap" class="ft1855">The safety&#160;and efficacy of&#160;Humira were assessed in two randomized, double-blind placebo controlled&#160;<br/>studies in patients with non-radiographic axial spondyloarthritis (nr-axSpA). Study nr-axSpA I evaluated&#160;<br/>patients with active&#160;nr-axSpA. Study nr-axSpA II was a treatment withdrawal study in&#160;active&#160;nr-axSpA<br/>patients who achieved remission during open-label treatment with Humira.</p>
<p style="position:absolute;top:973px;left:106px;white-space:nowrap" class="ft1852">Study nr-axSpA I</p>
<p style="position:absolute;top:1011px;left:106px;white-space:nowrap" class="ft1854">In Study nr-axSpA I,&#160;Humira 40&#160;mg&#160;every other week was assessed in 185 patients in&#160;a&#160;randomised,&#160;<br/>12&#160;week double&#160;-&#160;blind, placebo&#160;-&#160;controlled study in patients with active&#160;nr-axSpA&#160;(mean baseline score&#160;<br/>of&#160;disease activity [Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)] was 6.4 for patients&#160;</p>
</div>
<!-- Page 186 -->
<a name="186"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page186-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1860">186</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft1867">treated with Humira and 6.5 for those&#160;on placebo) who have had an inadequate response to or intolerance&#160;<br/>to&#160;</p>
<p style="position:absolute;top:104px;left:123px;white-space:nowrap" class="ft1866">&#160;1 NSAIDs, or a contraindication for NSAIDs.</p>
<p style="position:absolute;top:144px;left:106px;white-space:nowrap" class="ft1864">Thirty-three (18%) &#160;patients were treated concomitantly with disease modifying anti-rheumatic drugs, and&#160;<br/>146 (79%) patients with NSAIDs at baseline. The double-blind period was followed by an open-label&#160;<br/>period during which patients receive Humira 40&#160;mg&#160;every other week subcutaneously for up to an&#160;<br/>additional 144&#160;weeks. Week&#160;12 results showed statistically significant improvement of the signs&#160;and&#160;<br/>symptoms of active&#160;nr-axSpA&#160;in patients treated with Humira compared to placebo (Table&#160;13).</p>
<p style="position:absolute;top:258px;left:428px;white-space:nowrap" class="ft1861"><b>Table&#160;13</b></p>
<p style="position:absolute;top:277px;left:251px;white-space:nowrap" class="ft1861"><b>Efficacy Response in Placebo-Controlled Study&#160;nr-axSpA I</b></p>
<p style="position:absolute;top:316px;left:112px;white-space:nowrap" class="ft18615"><b>Double-Blind<br/>Response at Week 12</b></p>
<p style="position:absolute;top:316px;left:572px;white-space:nowrap" class="ft18627"><b>Placebo</b></p>
<p style="position:absolute;top:333px;left:580px;white-space:nowrap" class="ft18627"><b>N=94</b></p>
<p style="position:absolute;top:316px;left:712px;white-space:nowrap" class="ft18627"><b>Humira</b></p>
<p style="position:absolute;top:333px;left:720px;white-space:nowrap" class="ft18627"><b>N=91</b></p>
<p style="position:absolute;top:354px;left:112px;white-space:nowrap" class="ft1862">ASASa&#160;40</p>
<p style="position:absolute;top:354px;left:582px;white-space:nowrap" class="ft1862">15%</p>
<p style="position:absolute;top:354px;left:710px;white-space:nowrap" class="ft1862">36%***</p>
<p style="position:absolute;top:374px;left:112px;white-space:nowrap" class="ft1862">ASAS 20</p>
<p style="position:absolute;top:374px;left:582px;white-space:nowrap" class="ft1862">31%</p>
<p style="position:absolute;top:374px;left:714px;white-space:nowrap" class="ft1862">52%**</p>
<p style="position:absolute;top:394px;left:112px;white-space:nowrap" class="ft1862">ASAS 5/6</p>
<p style="position:absolute;top:394px;left:586px;white-space:nowrap" class="ft1862">6%</p>
<p style="position:absolute;top:394px;left:710px;white-space:nowrap" class="ft1862">31%***</p>
<p style="position:absolute;top:414px;left:112px;white-space:nowrap" class="ft1862">ASAS Partial Remission</p>
<p style="position:absolute;top:414px;left:586px;white-space:nowrap" class="ft1862">5%</p>
<p style="position:absolute;top:414px;left:714px;white-space:nowrap" class="ft1862">&#160;&#160;16%*</p>
<p style="position:absolute;top:433px;left:112px;white-space:nowrap" class="ft1862">BASDAIb&#160;50</p>
<p style="position:absolute;top:433px;left:582px;white-space:nowrap" class="ft1862">15%</p>
<p style="position:absolute;top:433px;left:708px;white-space:nowrap" class="ft1862">&#160; &#160;35%**</p>
<p style="position:absolute;top:453px;left:112px;white-space:nowrap" class="ft1862">ASDASc,d,e</p>
<p style="position:absolute;top:453px;left:584px;white-space:nowrap" class="ft1862">-0.3</p>
<p style="position:absolute;top:453px;left:712px;white-space:nowrap" class="ft1862">-1.0***</p>
<p style="position:absolute;top:473px;left:112px;white-space:nowrap" class="ft1862">ASDAS Inactive Disease</p>
<p style="position:absolute;top:473px;left:586px;white-space:nowrap" class="ft1862">4%</p>
<p style="position:absolute;top:473px;left:710px;white-space:nowrap" class="ft1862">24%***</p>
<p style="position:absolute;top:492px;left:112px;white-space:nowrap" class="ft1862">hs-CRPd,f,g</p>
<p style="position:absolute;top:492px;left:584px;white-space:nowrap" class="ft1862">-0.3</p>
<p style="position:absolute;top:492px;left:712px;white-space:nowrap" class="ft1862">-4.7***</p>
<p style="position:absolute;top:512px;left:112px;white-space:nowrap" class="ft1862">SPARCCh&#160;MRI Sacroiliac Jointsd,i</p>
<p style="position:absolute;top:512px;left:584px;white-space:nowrap" class="ft1862">-0.6</p>
<p style="position:absolute;top:512px;left:716px;white-space:nowrap" class="ft1862">-3.2**</p>
<p style="position:absolute;top:532px;left:112px;white-space:nowrap" class="ft1862">SPARCC MRI Spined,j</p>
<p style="position:absolute;top:532px;left:584px;white-space:nowrap" class="ft1862">-0.2</p>
<p style="position:absolute;top:532px;left:716px;white-space:nowrap" class="ft1862">-1.8**</p>
<p style="position:absolute;top:550px;left:112px;white-space:nowrap" class="ft1869">a&#160;Assessment of SpondyloArthritis international Society</p>
<p style="position:absolute;top:569px;left:113px;white-space:nowrap" class="ft1869">b&#160;Bath Ankylosing Spondylitis Disease Activity Index</p>
<p style="position:absolute;top:588px;left:113px;white-space:nowrap" class="ft1869">c&#160;Ankylosing Spondylitis Disease Activity Score</p>
<p style="position:absolute;top:607px;left:113px;white-space:nowrap" class="ft1869">d&#160;mean change from baseline</p>
<p style="position:absolute;top:626px;left:113px;white-space:nowrap" class="ft1869">e&#160;n=91 placebo and n=87 Humira</p>
<p style="position:absolute;top:645px;left:113px;white-space:nowrap" class="ft1869">f&#160;high sensitivity C-Reactive Protein (mg/L)</p>
<p style="position:absolute;top:664px;left:113px;white-space:nowrap" class="ft1869">g&#160;n=73 placebo and n=70 Humira</p>
<p style="position:absolute;top:683px;left:113px;white-space:nowrap" class="ft1869">h&#160;Spondyloarthritis Research Consortium of Canada</p>
<p style="position:absolute;top:702px;left:113px;white-space:nowrap" class="ft1869">i&#160;n=84 placebo and Humira</p>
<p style="position:absolute;top:721px;left:113px;white-space:nowrap" class="ft1864">j&#160;n=82 placebo and n=85 Humira<br/>***, **, * Statistically significant at p &lt; 0.001, &lt; 0.01, and&#160;&lt; 0.05, respectively, for all comparisons&#160;<br/>between Humira and placebo.</p>
<p style="position:absolute;top:798px;left:112px;white-space:nowrap" class="ft1864">In the open-label extension, improvement in the signs and symptoms was maintained with Humira&#160;<br/>therapy through Week 156.</p>
<p style="position:absolute;top:855px;left:112px;white-space:nowrap" class="ft1862">Inhibition of inflammation</p>
<p style="position:absolute;top:896px;left:112px;white-space:nowrap" class="ft18629">Significant improvement of signs of&#160;inflammation as measured by hs-CRP and MRI of both Sacroiliac&#160;<br/>Joints and the Spine was maintained in Humira-treated patients through Week 156 and Week 104,&#160;<br/>respectively.</p>
<p style="position:absolute;top:971px;left:112px;white-space:nowrap" class="ft1862">Quality of life and physical function</p>
<p style="position:absolute;top:1009px;left:106px;white-space:nowrap" class="ft1864">Health-related quality of life and physical function were assessed using the HAQ-S and the SF-36&#160;<br/>questionnaires. Humira showed statistically significantly greater improvement in the HAQ-S total score&#160;<br/>and the SF-36 Physical Component Score (PCS) from baseline to Week 12 compared to placebo.&#160;</p>
</div>
<!-- Page 187 -->
<a name="187"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page187-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1870">187</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft1875">Improvement in health-related quality of life and physical function was maintained during the open-label&#160;<br/>extension through Week 156.</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft1872">Study nr-axSpA&#160;II</p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft1877">673 patients with active nr-axSpA (mean baseline disease activity [BASDAI] was 7.0) who had an&#160;<br/>inadequate response to&#160;</p>
<p style="position:absolute;top:199px;left:260px;white-space:nowrap" class="ft1876">&#160;2 NSAIDs, or an intolerance to or a contraindication for NSAIDs&#160;enrolled into&#160;</p>
<p style="position:absolute;top:220px;left:106px;white-space:nowrap" class="ft1875">the open-label period of Study nr-axSpA&#160;II during which they received&#160;Humira&#160;40&#160;mg eow for 28 weeks.&#160;<br/>These patients also had objective evidence of inflammation in the sacroiliac joints or spine on MRI or&#160;<br/>elevated hs-CRP.&#160;Patients who achieved sustained remission&#160;for at least 12 weeks&#160;(N=305)&#160;(ASDAS &lt;&#160;1.3&#160;<br/>at Weeks&#160;16, 20, 24, and 28) during the open-label period were then randomized to receive either&#160;<br/>continued treatment with Humira 40&#160;mg&#160;eow&#160;(N=152)&#160;or placebo&#160;(N=153)&#160;for an additional 40 weeks in a&#160;<br/>double-blind, placebo-controlled period (total study duration 68 weeks).&#160;Subjects who flared during the&#160;<br/>double-blind period were allowed&#160;Humira 40&#160;mg&#160;eow&#160;rescue therapy&#160;for at least 12 weeks.</p>
<p style="position:absolute;top:372px;left:106px;white-space:nowrap" class="ft1874">The primary efficacy endpoint was the proportion of patients with no flare by Week 68&#160;of the&#160;study.&#160;Flare&#160;<br/>was defined as ASDAS&#160;≥&#160;2.1 at two consecutive visits four weeks apart. A greater proportion of patients&#160;<br/>on Humira had no disease flare during the double-blind period, when compared with those on placebo&#160;<br/>(70.4%&#160;vs. 47.1%, p&lt;0.001)&#160;(Figure&#160;1).</p>
<p style="position:absolute;top:467px;left:238px;white-space:nowrap" class="ft1871"><b>Figure&#160;1: Kaplan-Meier Curves Summarizing Time to Flare in</b></p>
<p style="position:absolute;top:486px;left:393px;white-space:nowrap" class="ft1871"><b>Study nr-axSpA&#160;II</b></p>
<p style="position:absolute;top:809px;left:128px;white-space:nowrap" class="ft18731"><b>&#160;&#160;&#160;</b></p>
<p style="position:absolute;top:798px;left:128px;white-space:nowrap" class="ft18731"><b>&#160;&#160;&#160;</b></p>
<p style="position:absolute;top:786px;left:128px;white-space:nowrap" class="ft18731"><b>&#160;&#160;&#160;</b></p>
<p style="position:absolute;top:775px;left:128px;white-space:nowrap" class="ft18731"><b>&#160;&#160;&#160;</b></p>
<p style="position:absolute;top:764px;left:128px;white-space:nowrap" class="ft18731"><b>&#160;&#160;&#160;</b></p>
<p style="position:absolute;top:753px;left:128px;white-space:nowrap" class="ft18731"><b>&#160;&#160;&#160;</b></p>
<p style="position:absolute;top:741px;left:128px;white-space:nowrap" class="ft18731"><b>&#160;P</b></p>
<p style="position:absolute;top:728px;left:128px;white-space:nowrap" class="ft18731"><b>R</b></p>
<p style="position:absolute;top:718px;left:128px;white-space:nowrap" class="ft18731"><b>O</b></p>
<p style="position:absolute;top:706px;left:128px;white-space:nowrap" class="ft18731"><b>B</b></p>
<p style="position:absolute;top:696px;left:128px;white-space:nowrap" class="ft18731"><b>A</b></p>
<p style="position:absolute;top:685px;left:128px;white-space:nowrap" class="ft18731"><b>B</b></p>
<p style="position:absolute;top:675px;left:128px;white-space:nowrap" class="ft18731"><b>IL</b></p>
<p style="position:absolute;top:659px;left:128px;white-space:nowrap" class="ft18731"><b>IT</b></p>
<p style="position:absolute;top:644px;left:128px;white-space:nowrap" class="ft18731"><b>Y</b></p>
<p style="position:absolute;top:633px;left:128px;white-space:nowrap" class="ft18731"><b>&#160;O</b></p>
<p style="position:absolute;top:617px;left:128px;white-space:nowrap" class="ft18731"><b>F</b></p>
<p style="position:absolute;top:608px;left:128px;white-space:nowrap" class="ft18731"><b>&#160;N</b></p>
<p style="position:absolute;top:593px;left:128px;white-space:nowrap" class="ft18731"><b>O</b></p>
<p style="position:absolute;top:582px;left:128px;white-space:nowrap" class="ft18731"><b>&#160;F</b></p>
<p style="position:absolute;top:569px;left:128px;white-space:nowrap" class="ft18731"><b>L</b></p>
<p style="position:absolute;top:559px;left:128px;white-space:nowrap" class="ft18731"><b>A</b></p>
<p style="position:absolute;top:548px;left:128px;white-space:nowrap" class="ft18731"><b>R</b></p>
<p style="position:absolute;top:537px;left:128px;white-space:nowrap" class="ft18731"><b>E</b></p>
<p style="position:absolute;top:860px;left:422px;white-space:nowrap" class="ft18727"><b>TIME (WEEKS)</b></p>
<p style="position:absolute;top:877px;left:114px;white-space:nowrap" class="ft18732">&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160;Treatment &#160; &#160; &#160;</p>
<p style="position:absolute;top:877px;left:378px;white-space:nowrap" class="ft18732">Placebo &#160; &#160;&#160;</p>
<p style="position:absolute;top:877px;left:498px;white-space:nowrap" class="ft18732">Humira &#160; &#160;&#160;∆ Censored</p>
<p style="position:absolute;top:914px;left:106px;white-space:nowrap" class="ft1872">Note: P = Placebo (Number at Risk (flared)); A = HUMIRA (Number&#160;at Risk (flared)).</p>
<p style="position:absolute;top:951px;left:106px;white-space:nowrap" class="ft1874">Among the 68 patients who flared in the group allocated to treatment withdrawal, 65 completed 12 weeks&#160;<br/>of rescue therapy with Humira, out of which 37 (56.9%)&#160;had&#160;regained remission (ASDAS &lt;&#160;1.3) after&#160;<br/>12&#160;weeks of restarting the open-label treatment.</p>
<p style="position:absolute;top:1027px;left:106px;white-space:nowrap" class="ft1875">By&#160;Week&#160;68,&#160;patients receiving continuous Humira treatment&#160;showed statistically significant&#160;greater<br/>improvement of the signs and symptoms of active nr-axSpA&#160;as&#160;compared to patients allocated to treatment&#160;<br/>withdrawal during the double-blind period of the study (Table&#160;14).</p>
</div>
<!-- Page 188 -->
<a name="188"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page188-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1880">188</p>
<p style="position:absolute;top:105px;left:455px;white-space:nowrap" class="ft1881"><b>Table 14</b></p>
<p style="position:absolute;top:124px;left:237px;white-space:nowrap" class="ft1881"><b>Efficacy Response in Placebo-Controlled&#160;Period for Study nr-axSpA II</b></p>
<p style="position:absolute;top:163px;left:112px;white-space:nowrap" class="ft18815"><b>Double-Blind<br/>Response at Week&#160;68</b></p>
<p style="position:absolute;top:163px;left:580px;white-space:nowrap" class="ft18827"><b>Placebo</b></p>
<p style="position:absolute;top:180px;left:584px;white-space:nowrap" class="ft18827"><b>N=153</b></p>
<p style="position:absolute;top:163px;left:716px;white-space:nowrap" class="ft18827"><b>Humira</b></p>
<p style="position:absolute;top:180px;left:720px;white-space:nowrap" class="ft18827"><b>N=152</b></p>
<p style="position:absolute;top:201px;left:112px;white-space:nowrap" class="ft1882">ASASa,b&#160;20</p>
<p style="position:absolute;top:201px;left:583px;white-space:nowrap" class="ft1882">47.1%</p>
<p style="position:absolute;top:201px;left:707px;white-space:nowrap" class="ft1882">70.4%***</p>
<p style="position:absolute;top:221px;left:112px;white-space:nowrap" class="ft1882">ASASa,b&#160;40</p>
<p style="position:absolute;top:221px;left:583px;white-space:nowrap" class="ft1882">45.8%</p>
<p style="position:absolute;top:221px;left:707px;white-space:nowrap" class="ft1882">65.8%***</p>
<p style="position:absolute;top:241px;left:112px;white-space:nowrap" class="ft1882">ASASa&#160;Partial Remission</p>
<p style="position:absolute;top:241px;left:583px;white-space:nowrap" class="ft1882">26.8%</p>
<p style="position:absolute;top:241px;left:711px;white-space:nowrap" class="ft1882">42.1%**</p>
<p style="position:absolute;top:261px;left:112px;white-space:nowrap" class="ft1882">ASDASc&#160;Inactive Disease</p>
<p style="position:absolute;top:261px;left:583px;white-space:nowrap" class="ft1882">33.3%</p>
<p style="position:absolute;top:261px;left:707px;white-space:nowrap" class="ft1882">57.2%***</p>
<p style="position:absolute;top:280px;left:112px;white-space:nowrap" class="ft1882">Partial Flared</p>
<p style="position:absolute;top:280px;left:583px;white-space:nowrap" class="ft1882">64.1%</p>
<p style="position:absolute;top:280px;left:707px;white-space:nowrap" class="ft1882">40.8%***</p>
<p style="position:absolute;top:298px;left:112px;white-space:nowrap" class="ft1889">a&#160;Assessment of SpondyloArthritis&#160;international Society</p>
<p style="position:absolute;top:318px;left:113px;white-space:nowrap" class="ft1889">b&#160;Baseline is defined as open label baseline when patients have active disease.</p>
<p style="position:absolute;top:337px;left:113px;white-space:nowrap" class="ft1889">c&#160;Ankylosing Spondylitis Disease&#160;Activity Score</p>
<p style="position:absolute;top:355px;left:113px;white-space:nowrap" class="ft1884">d&#160;Partial flare is defined as&#160;ASDAS&#160;≥ 1.3 but &lt; 2.1&#160;at 2 consecutive visits.<br/>***, **&#160;Statistically significant at p &lt;&#160;0.001 and&#160;&lt;&#160;0.01, respectively, for all comparisons between&#160;<br/>Humira and placebo.</p>
<p style="position:absolute;top:433px;left:106px;white-space:nowrap" class="ft1883"><i>Psoriatic arthritis</i></p>
<p style="position:absolute;top:471px;left:106px;white-space:nowrap" class="ft1884">Humira, 40&#160;mg&#160;every&#160;other week, was studied in patients with moderately to severely active psoriatic&#160;<br/>arthritis in two placebo-controlled studies, PsA studies I and II. &#160;PsA study I with 24&#160;week&#160;duration,&#160;<br/>treated 313 adult patients who had an inadequate response to non-steroidal anti-inflammatory drug therapy&#160;<br/>and of these, approximately 50% were taking methotrexate. PsA study II with 12-week&#160;duration, treated&#160;<br/>100 patients who had an inadequate response to DMARD therapy. Upon completion of both studies, 383&#160;<br/>patients enrolled in&#160;an open-label extension study, in which 40&#160;mg Humira was administered every other&#160;<br/>week.</p>
<p style="position:absolute;top:622px;left:106px;white-space:nowrap" class="ft1884">There is insufficient evidence of the efficacy of Humira in patients with ankylosing spondylitis-like&#160;<br/>psoriatic arthropathy due to the small number of patients studied.&#160;</p>
<p style="position:absolute;top:679px;left:429px;white-space:nowrap" class="ft1881"><b>Table&#160;15</b></p>
<p style="position:absolute;top:698px;left:233px;white-space:nowrap" class="ft1881"><b>ACR Response in Placebo-Controlled Psoriatic Arthritis Studies</b></p>
<p style="position:absolute;top:717px;left:387px;white-space:nowrap" class="ft1881"><b>(Percent of Patients)</b></p>
<p style="position:absolute;top:756px;left:385px;white-space:nowrap" class="ft1882">PsA Study I</p>
<p style="position:absolute;top:756px;left:581px;white-space:nowrap" class="ft1882">PsA Study II</p>
<p style="position:absolute;top:785px;left:198px;white-space:nowrap" class="ft1882">Response</p>
<p style="position:absolute;top:776px;left:350px;white-space:nowrap" class="ft1882">Placebo</p>
<p style="position:absolute;top:795px;left:353px;white-space:nowrap" class="ft1882">N=162</p>
<p style="position:absolute;top:776px;left:450px;white-space:nowrap" class="ft1882">Humira</p>
<p style="position:absolute;top:795px;left:452px;white-space:nowrap" class="ft1882">N=151</p>
<p style="position:absolute;top:776px;left:549px;white-space:nowrap" class="ft1882">Placebo&#160;</p>
<p style="position:absolute;top:795px;left:556px;white-space:nowrap" class="ft1882">N=49</p>
<p style="position:absolute;top:776px;left:649px;white-space:nowrap" class="ft1882">Humira</p>
<p style="position:absolute;top:795px;left:656px;white-space:nowrap" class="ft1882">N=51</p>
<p style="position:absolute;top:814px;left:198px;white-space:nowrap" class="ft1882">ACR 20&#160;</p>
<p style="position:absolute;top:833px;left:240px;white-space:nowrap" class="ft1882">Week&#160;12</p>
<p style="position:absolute;top:833px;left:361px;white-space:nowrap" class="ft1882">14%</p>
<p style="position:absolute;top:833px;left:452px;white-space:nowrap" class="ft1882">58%***</p>
<p style="position:absolute;top:833px;left:559px;white-space:nowrap" class="ft1882">16%</p>
<p style="position:absolute;top:833px;left:657px;white-space:nowrap" class="ft1882">39%*</p>
<p style="position:absolute;top:852px;left:240px;white-space:nowrap" class="ft1882">Week&#160;24</p>
<p style="position:absolute;top:852px;left:361px;white-space:nowrap" class="ft1882">15%</p>
<p style="position:absolute;top:852px;left:452px;white-space:nowrap" class="ft1882">57%***</p>
<p style="position:absolute;top:852px;left:561px;white-space:nowrap" class="ft1882">N/A</p>
<p style="position:absolute;top:852px;left:660px;white-space:nowrap" class="ft1882">N/A</p>
<p style="position:absolute;top:871px;left:198px;white-space:nowrap" class="ft1882">ACR 50&#160;</p>
<p style="position:absolute;top:890px;left:240px;white-space:nowrap" class="ft1882">Week&#160;12</p>
<p style="position:absolute;top:890px;left:365px;white-space:nowrap" class="ft1882">4%</p>
<p style="position:absolute;top:890px;left:452px;white-space:nowrap" class="ft1882">36%***</p>
<p style="position:absolute;top:890px;left:564px;white-space:nowrap" class="ft1882">2%</p>
<p style="position:absolute;top:890px;left:651px;white-space:nowrap" class="ft1882">25%***</p>
<p style="position:absolute;top:909px;left:240px;white-space:nowrap" class="ft1882">Week&#160;24</p>
<p style="position:absolute;top:909px;left:365px;white-space:nowrap" class="ft1882">6%</p>
<p style="position:absolute;top:909px;left:452px;white-space:nowrap" class="ft1882">39%***</p>
<p style="position:absolute;top:909px;left:561px;white-space:nowrap" class="ft1882">N/A</p>
<p style="position:absolute;top:909px;left:660px;white-space:nowrap" class="ft1882">N/A</p>
<p style="position:absolute;top:928px;left:198px;white-space:nowrap" class="ft1882">ACR 70&#160;</p>
<p style="position:absolute;top:947px;left:240px;white-space:nowrap" class="ft1882">Week&#160;12</p>
<p style="position:absolute;top:947px;left:365px;white-space:nowrap" class="ft1882">1%</p>
<p style="position:absolute;top:947px;left:452px;white-space:nowrap" class="ft1882">20%***</p>
<p style="position:absolute;top:947px;left:564px;white-space:nowrap" class="ft1882">0%</p>
<p style="position:absolute;top:947px;left:655px;white-space:nowrap" class="ft1882">14%&#160;*</p>
<p style="position:absolute;top:966px;left:240px;white-space:nowrap" class="ft1882">Week&#160;24</p>
<p style="position:absolute;top:966px;left:365px;white-space:nowrap" class="ft1882">1%</p>
<p style="position:absolute;top:966px;left:452px;white-space:nowrap" class="ft1882">23%***</p>
<p style="position:absolute;top:966px;left:561px;white-space:nowrap" class="ft1882">N/A</p>
<p style="position:absolute;top:966px;left:660px;white-space:nowrap" class="ft1882">N/A</p>
<p style="position:absolute;top:986px;left:198px;white-space:nowrap" class="ft1885">***&#160;p&#160;&lt;&#160;0.001 for all comparisons between Humira and placebo<br/>*</p>
<p style="position:absolute;top:1005px;left:240px;white-space:nowrap" class="ft1882">p&#160;&lt;&#160;0.05 for all comparisons between Humira&#160;and placebo</p>
<p style="position:absolute;top:1024px;left:198px;white-space:nowrap" class="ft1882">N/A &#160;not applicable</p>
<p style="position:absolute;top:1062px;left:106px;white-space:nowrap" class="ft1885">ACR responses in PsA study I were similar with and without concomitant methotrexate therapy.<br/>ACR responses were maintained in the open-label extension study for up to 136&#160;weeks.</p>
</div>
<!-- Page 189 -->
<a name="189"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page189-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1890">189</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft1895">Radiographic changes were assessed in the&#160;psoriatic arthritis studies. Radiographs of hands, wrists, and&#160;<br/>feet were obtained at baseline and Week&#160;24 during the double-blind period when patients were on Humira&#160;<br/>or placebo and at Week&#160;48 when all patients were on open-label Humira. A modified Total Sharp Score&#160;<br/>(mTSS), which included distal interphalangeal joints (i.e. not identical to the TSS used for rheumatoid&#160;<br/>arthritis), was used.</p>
<p style="position:absolute;top:219px;left:106px;white-space:nowrap" class="ft1894">Humira treatment reduced the rate of progression of peripheral joint damage compared with placebo&#160;<br/>treatment as measured&#160;by change from baseline in mTSS &#160;(mean ± SD) 0.8 ± 2.5 in the placebo group (at&#160;<br/>Week&#160;24) compared with 0.0 ± 1.9; (p&lt; 0.001) in the Humira group (at Week&#160;48).</p>
<p style="position:absolute;top:295px;left:106px;white-space:nowrap" class="ft1895">In subjects treated with Humira with no radiographic progression from baseline to Week&#160;48 (n=102), 84%&#160;<br/>continued to show no radiographic progression through 144&#160;weeks&#160;of treatment.<br/>Humira treated patients demonstrated statistically significant improvement in physical function as assessed&#160;<br/>by HAQ and Short Form Health Survey (SF 36) compared to placebo at Week&#160;24. Improved&#160;physical&#160;<br/>function continued during the open label extension up to Week&#160;136.</p>
<p style="position:absolute;top:409px;left:106px;white-space:nowrap" class="ft1893"><i>Psoriasis&#160;</i></p>
<p style="position:absolute;top:447px;left:106px;white-space:nowrap" class="ft1892">The safety and efficacy of Humira were studied in adult patients with chronic plaque psoriasis (</p>
<p style="position:absolute;top:446px;left:737px;white-space:nowrap" class="ft1896">&#160;10%&#160;</p>
<p style="position:absolute;top:468px;left:106px;white-space:nowrap" class="ft1892">BSA involvement and Psoriasis Area and Severity Index (PASI)&#160;</p>
<p style="position:absolute;top:466px;left:535px;white-space:nowrap" class="ft1896">&#160;12 or&#160;&#160;10) who were candidates for&#160;</p>
<p style="position:absolute;top:487px;left:106px;white-space:nowrap" class="ft1895">systemic therapy or phototherapy in randomised, double-blind studies. 73% of patients enrolled in&#160;<br/>Psoriasis Studies I and II had received prior systemic therapy or phototherapy. &#160;The safety and efficacy of&#160;<br/>Humira were also studied in adult patients with moderate to severe&#160;chronic plaque psoriasis with&#160;<br/>concomitant hand and/or foot psoriasis who were candidates for systemic therapy in a randomised double-<br/>blind study (Psoriasis Study III). &#160;</p>
<p style="position:absolute;top:599px;left:106px;white-space:nowrap" class="ft1897">Psoriasis Study I (REVEAL) evaluated 1,212 patients within three treatment periods. &#160;In period A, patients&#160;<br/>received placebo or Humira at an initial dose of 80&#160;mg&#160;followed by 40&#160;mg&#160;every other week starting one&#160;<br/>week after the initial dose. After 16&#160;weeks&#160;of therapy, patients who achieved at least a PASI 75 response&#160;<br/>(PASI score improvement of at least 75% relative to baseline), entered period B and received open-label&#160;<br/>40&#160;mg Humira every other week. Patients who maintained&#160;</p>
<p style="position:absolute;top:674px;left:494px;white-space:nowrap" class="ft1896">PASI 75 response at Week&#160;33 and were&#160;</p>
<p style="position:absolute;top:695px;left:106px;white-space:nowrap" class="ft1894">originally&#160;randomised to active therapy in Period A, were re-randomised in period C to receive 40&#160;mg&#160;<br/>Humira every other week or placebo for an additional 19&#160;weeks. Across all treatment groups, the mean&#160;<br/>baseline PASI score was 18.9 and the baseline Physician’s Global&#160;Assessment (PGA) score ranged from&#160;<br/>“moderate” (53% of subjects included) to “severe” (41%) to “very severe” (6%).</p>
<p style="position:absolute;top:790px;left:106px;white-space:nowrap" class="ft1894">Psoriasis Study II (CHAMPION) compared the efficacy and safety of Humira&#160;<i>versus&#160;</i>methotrexate and&#160;<br/>placebo in 271 patients.&#160;Patients received placebo, an initial dose of MTX 7.5&#160;mg and thereafter dose&#160;<br/>increases up to Week&#160;12, with a maximum dose of 25&#160;mg&#160;or an initial dose of 80&#160;mg Humira followed by&#160;<br/>40&#160;mg&#160;every other week (starting one week after the initial dose) for 16&#160;weeks. There are no data available&#160;<br/>comparing Humira and MTX beyond 16&#160;weeks of therapy. Patients receiving MTX who achieved a&#160;</p>
<p style="position:absolute;top:884px;left:106px;white-space:nowrap" class="ft1894">PASI 50 response at Week&#160;8 and/or 12 did not receive further dose increases. Across all treatment&#160;<br/>groups, the mean baseline&#160;PASI&#160;score&#160;was 19.7 and the baseline PGA score ranged from “mild” (&lt;1%) to&#160;<br/>“moderate” (48%) to “severe” (46%) to “very severe” (6%).</p>
<p style="position:absolute;top:962px;left:106px;white-space:nowrap" class="ft1894">Patients participating in all Phase 2 and Phase 3 psoriasis studies were eligible to enrol into an open-label&#160;<br/>extension trial, where&#160;Humira was given for at least an additional 108&#160;weeks.</p>
<p style="position:absolute;top:1019px;left:106px;white-space:nowrap" class="ft1894">In Psoriasis Studies I and II, a primary endpoint was the proportion of patients who achieved a PASI 75&#160;<br/>response from baseline at Week&#160;16&#160;(see Tables&#160;16&#160;and&#160;17).</p>
</div>
<!-- Page 190 -->
<a name="190"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page190-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1900">190</p>
<p style="position:absolute;top:105px;left:429px;white-space:nowrap" class="ft1901"><b>Table&#160;16</b></p>
<p style="position:absolute;top:124px;left:271px;white-space:nowrap" class="ft1901"><b>Ps Study I (REVEAL) &#160;-&#160;Efficacy Results at 16&#160;Weeks</b></p>
<p style="position:absolute;top:144px;left:455px;white-space:nowrap" class="ft1901"><b>Placebo</b></p>
<p style="position:absolute;top:163px;left:459px;white-space:nowrap" class="ft1901"><b>N=398</b></p>
<p style="position:absolute;top:181px;left:462px;white-space:nowrap" class="ft1901"><b>n&#160;(%)</b></p>
<p style="position:absolute;top:144px;left:564px;white-space:nowrap" class="ft1901"><b>Humira 40 mg eow</b></p>
<p style="position:absolute;top:163px;left:608px;white-space:nowrap" class="ft1901"><b>N=814</b></p>
<p style="position:absolute;top:181px;left:611px;white-space:nowrap" class="ft1901"><b>n&#160;(%)</b></p>
<p style="position:absolute;top:202px;left:207px;white-space:nowrap" class="ft1901"><b>&#160; &#160;&#160;</b></p>
<p style="position:absolute;top:200px;left:223px;white-space:nowrap" class="ft1906">&#160;<b>PASI 75a</b></p>
<p style="position:absolute;top:201px;left:456px;white-space:nowrap" class="ft1902">26 (6.5)</p>
<p style="position:absolute;top:201px;left:594px;white-space:nowrap" class="ft1902">578 (70.9)b</p>
<p style="position:absolute;top:222px;left:207px;white-space:nowrap" class="ft1901"><b>&#160; &#160;&#160;PASI 100</b></p>
<p style="position:absolute;top:222px;left:460px;white-space:nowrap" class="ft1902">3 (0.8)</p>
<p style="position:absolute;top:222px;left:594px;white-space:nowrap" class="ft1902">163 (20.0)b</p>
<p style="position:absolute;top:242px;left:207px;white-space:nowrap" class="ft1901"><b>&#160; &#160;&#160;PGA: Clear/minimal</b></p>
<p style="position:absolute;top:242px;left:456px;white-space:nowrap" class="ft1902">17 (4.3)</p>
<p style="position:absolute;top:242px;left:594px;white-space:nowrap" class="ft1902">506 (62.2)b</p>
<p style="position:absolute;top:260px;left:207px;white-space:nowrap" class="ft1907">a&#160;Percent of patients achieving PASI75 response was calculated as centre-<br/>adjusted rate</p>
<p style="position:absolute;top:298px;left:207px;white-space:nowrap" class="ft1909">b&#160;p&#160;&lt;&#160;0.001, Humira vs. placebo</p>
<p style="position:absolute;top:333px;left:429px;white-space:nowrap" class="ft1901"><b>Table&#160;17</b></p>
<p style="position:absolute;top:352px;left:264px;white-space:nowrap" class="ft1901"><b>Ps Study II (CHAMPION) Efficacy Results at 16&#160;Weeks</b></p>
<p style="position:absolute;top:372px;left:353px;white-space:nowrap" class="ft1901"><b>Placebo</b></p>
<p style="position:absolute;top:391px;left:361px;white-space:nowrap" class="ft1901"><b>N=53</b></p>
<p style="position:absolute;top:410px;left:360px;white-space:nowrap" class="ft1901"><b>n&#160;(%)</b></p>
<p style="position:absolute;top:372px;left:474px;white-space:nowrap" class="ft1901"><b>MTX</b></p>
<p style="position:absolute;top:391px;left:470px;white-space:nowrap" class="ft1901"><b>N=110</b></p>
<p style="position:absolute;top:410px;left:473px;white-space:nowrap" class="ft1901"><b>n&#160;(%)</b></p>
<p style="position:absolute;top:372px;left:566px;white-space:nowrap" class="ft1901"><b>Humira 40 mg eow</b></p>
<p style="position:absolute;top:391px;left:610px;white-space:nowrap" class="ft1901"><b>N=108</b></p>
<p style="position:absolute;top:410px;left:613px;white-space:nowrap" class="ft1901"><b>n&#160;(%)</b></p>
<p style="position:absolute;top:431px;left:203px;white-space:nowrap" class="ft1901"><b>&#160; &#160;&#160;</b></p>
<p style="position:absolute;top:429px;left:220px;white-space:nowrap" class="ft1906">&#160;<b>PASI 75</b></p>
<p style="position:absolute;top:429px;left:350px;white-space:nowrap" class="ft1902">10 (18.9)</p>
<p style="position:absolute;top:429px;left:463px;white-space:nowrap" class="ft1902">39 (35.5)</p>
<p style="position:absolute;top:429px;left:594px;white-space:nowrap" class="ft1902">86 (79.6)&#160;a, b</p>
<p style="position:absolute;top:450px;left:203px;white-space:nowrap" class="ft1901"><b>&#160; &#160;&#160;PASI 100</b></p>
<p style="position:absolute;top:450px;left:358px;white-space:nowrap" class="ft1902">1 (1.9)</p>
<p style="position:absolute;top:450px;left:471px;white-space:nowrap" class="ft1902">8 (7.3)</p>
<p style="position:absolute;top:450px;left:594px;white-space:nowrap" class="ft1902">18 (16.7)&#160;c, d</p>
<p style="position:absolute;top:470px;left:203px;white-space:nowrap" class="ft19019"><b>&#160; &#160;&#160;PGA:&#160;<br/>Clear/minimal</b></p>
<p style="position:absolute;top:470px;left:354px;white-space:nowrap" class="ft1902">6 (11.3)</p>
<p style="position:absolute;top:470px;left:463px;white-space:nowrap" class="ft1902">33 (30.0)</p>
<p style="position:absolute;top:470px;left:594px;white-space:nowrap" class="ft1902">79 (73.1)&#160;a, b</p>
<p style="position:absolute;top:508px;left:203px;white-space:nowrap" class="ft1909">a&#160;p&#160;&lt;&#160;0.001 Humira vs. placebo</p>
<p style="position:absolute;top:526px;left:203px;white-space:nowrap" class="ft1909">b&#160;p&#160;&lt;&#160;0.001 Humira vs. methotrexate</p>
<p style="position:absolute;top:545px;left:203px;white-space:nowrap" class="ft1909">c&#160;p&#160;&lt;&#160;0.01 Humira vs. placebo</p>
<p style="position:absolute;top:565px;left:203px;white-space:nowrap" class="ft1909">d&#160;p&#160;&lt;&#160;0.05 Humira vs. methotrexate</p>
<p style="position:absolute;top:604px;left:106px;white-space:nowrap" class="ft1904">In&#160;Psoriasis&#160;Study I, 28% of patients who were PASI 75 responders and were re-randomised to placebo at&#160;<br/>Week&#160;33 compared to 5% continuing on Humira, p&#160;&lt;&#160;0.001, experienced “loss of adequate response”<br/>(PASI score after Week&#160;33 and on or before Week&#160;52 that resulted in a &lt;PASI 50 response relative to&#160;<br/>baseline with a minimum of a 6-point increase in PASI score relative to Week&#160;33). Of the patients who&#160;<br/>lost adequate response after re-randomisation to placebo who then enrolled&#160;into the open-label extension&#160;<br/>trial, 38% (25/66) and 55% (36/66) regained PASI 75 response after 12 and 24&#160;weeks of re-treatment,&#160;<br/>respectively.</p>
<p style="position:absolute;top:756px;left:106px;white-space:nowrap" class="ft1904">A total of 233 PASI 75 responders at Week&#160;16 and Week&#160;33 received continuous Humira therapy for&#160;<br/>52&#160;weeks in Psoriasis Study I, and continued Humira in the open-label extension trial. &#160;PASI 75 and PGA&#160;<br/>of clear or minimal response rates in these patients were 74.7% and 59.0%, respectively, after an&#160;<br/>additional 108&#160;weeks of open-label therapy (total of 160&#160;weeks). In an analysis in which all patients who&#160;<br/>dropped out of the study for adverse events or lack of efficacy, or who dose-escalated, were considered&#160;<br/>non-responders, PASI 75 and PGA of clear or minimal response rates in these patients were 69.6% and&#160;<br/>55.7%, respectively, after an additional 108&#160;weeks of open-label therapy (total of 160&#160;weeks).</p>
<p style="position:absolute;top:908px;left:106px;white-space:nowrap" class="ft1905">A total of 347 stable responders participated in a withdrawal and retreatment evaluation in an open-label&#160;<br/>extension study. During the withdrawal period, symptoms of psoriasis&#160;returned over time with a median&#160;<br/>time to relapse (decline to PGA “moderate” or worse) of approximately 5&#160;months. None of these patients&#160;<br/>experienced rebound during the withdrawal period. A total of 76.5% (218/285) of patients who entered the&#160;<br/>retreatment period had a response of PGA “clear” or “minimal” after 16&#160;weeks of retreatment, irrespective&#160;<br/>of&#160;whether they relapsed during withdrawal (69.1%[123/178] and 88.8% [95/107] for patients who&#160;<br/>relapsed and who did not relapse during the withdrawal period, respectively). &#160;A similar safety profile was&#160;<br/>observed during retreatment as before withdrawal.</p>
</div>
<!-- Page 191 -->
<a name="191"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page191-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1910">191</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft1914">Significant improvements at Week&#160;16 from baseline compared to placebo (Studies I and II) and MTX&#160;<br/>(Study II) were demonstrated in the DLQI (Dermatology Life Quality Index). In Study I, improvements in&#160;<br/>the physical and mental component summary scores of the SF-36 were also significant compared to&#160;<br/>placebo.</p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft1914">In an open-label extension study, for patients who dose escalated from 40&#160;mg&#160;every other week to 40&#160;mg&#160;<br/>weekly due to&#160;a PASI response below 50%, 26.4% (92/349) and 37.8% (132/349) of patients achieved&#160;<br/>PASI 75 response at Week 12 and 24, respectively.</p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft1914">Psoriasis Study III (REACH)&#160;compared the efficacy and safety of Humira&#160;<i>versus&#160;</i>placebo in 72 patients&#160;<br/>with moderate to severe&#160;chronic plaque psoriasis and hand and/or foot psoriasis. Patients received an&#160;<br/>initial&#160;dose of 80&#160;mg Humira followed by 40&#160;mg every other week (starting one week after the initial dose)&#160;<br/>or placebo for 16&#160;weeks. At Week&#160;16, a statistically significantly greater proportion of patients who&#160;<br/>received Humira achieved PGA of 'clear' or 'almost clear' for the hands and/or feet compared to patients&#160;<br/>who received placebo (30.6% versus 4.3%, respectively [P = 0.014]).</p>
<p style="position:absolute;top:390px;left:106px;white-space:nowrap" class="ft1914">Psoriasis Study IV compared efficacy and safety of Humira versus placebo in 217 adult patients with&#160;<br/>moderate to severe nail psoriasis. Patients received an initial dose of 80 mg Humira followed by 40&#160;mg&#160;<br/>every other week (starting one week after the initial&#160;dose) or placebo for 26&#160;weeks followed by open-label&#160;<br/>Humira treatment for an additional 26&#160;weeks. Nail psoriasis assessments included the Modified Nail&#160;<br/>Psoriasis Severity Index (mNAPSI), the Physician’s Global Assessment of Fingernail Psoriasis (PGA-F)&#160;<br/>and the Nail Psoriasis Severity Index (NAPSI) (see Table&#160;18). Humira demonstrated a treatment benefit in&#160;<br/>nail psoriasis patients with different extents of skin involvement (BSA≥10% (60% of patients) and&#160;<br/>BSA&lt;10% and&#160;≥5% (40% of patients)).</p>
<p style="position:absolute;top:560px;left:240px;white-space:nowrap" class="ft1911"><b>Table&#160;18:&#160;Ps Study&#160;IV Efficacy Results at 16, 26 and 52&#160;Weeks</b></p>
<p style="position:absolute;top:580px;left:114px;white-space:nowrap" class="ft1912">Endpoint</p>
<p style="position:absolute;top:580px;left:368px;white-space:nowrap" class="ft1912">Week 16</p>
<p style="position:absolute;top:599px;left:334px;white-space:nowrap" class="ft1912">Placebo-Controlled</p>
<p style="position:absolute;top:580px;left:540px;white-space:nowrap" class="ft1912">Week 26</p>
<p style="position:absolute;top:599px;left:506px;white-space:nowrap" class="ft1912">Placebo-Controlled</p>
<p style="position:absolute;top:580px;left:710px;white-space:nowrap" class="ft1912">Week 52</p>
<p style="position:absolute;top:599px;left:703px;white-space:nowrap" class="ft1912">Open-label</p>
<p style="position:absolute;top:619px;left:324px;white-space:nowrap" class="ft1912">Placebo</p>
<p style="position:absolute;top:638px;left:328px;white-space:nowrap" class="ft1912">N=108</p>
<p style="position:absolute;top:619px;left:413px;white-space:nowrap" class="ft1912">Humira</p>
<p style="position:absolute;top:638px;left:402px;white-space:nowrap" class="ft1912">40&#160;mg&#160;eow&#160;</p>
<p style="position:absolute;top:657px;left:415px;white-space:nowrap" class="ft1912">N=109</p>
<p style="position:absolute;top:619px;left:496px;white-space:nowrap" class="ft1912">Placebo</p>
<p style="position:absolute;top:638px;left:499px;white-space:nowrap" class="ft1912">N=108</p>
<p style="position:absolute;top:619px;left:581px;white-space:nowrap" class="ft1912">Humira</p>
<p style="position:absolute;top:638px;left:570px;white-space:nowrap" class="ft1912">40&#160;mg&#160;eow&#160;</p>
<p style="position:absolute;top:657px;left:584px;white-space:nowrap" class="ft1912">N=109</p>
<p style="position:absolute;top:619px;left:714px;white-space:nowrap" class="ft1912">Humira</p>
<p style="position:absolute;top:638px;left:703px;white-space:nowrap" class="ft1912">40&#160;mg&#160;eow&#160;</p>
<p style="position:absolute;top:657px;left:720px;white-space:nowrap" class="ft1912">N=80</p>
<p style="position:absolute;top:676px;left:114px;white-space:nowrap" class="ft1912">≥ mNAPSI 75 (%)</p>
<p style="position:absolute;top:676px;left:340px;white-space:nowrap" class="ft1912">2.9</p>
<p style="position:absolute;top:676px;left:422px;white-space:nowrap" class="ft1912">26.0a</p>
<p style="position:absolute;top:676px;left:512px;white-space:nowrap" class="ft1912">3.4</p>
<p style="position:absolute;top:676px;left:590px;white-space:nowrap" class="ft1912">46.6a</p>
<p style="position:absolute;top:676px;left:725px;white-space:nowrap" class="ft1912">65.0</p>
<p style="position:absolute;top:696px;left:114px;white-space:nowrap" class="ft1915">PGA-F clear/minimal and&#160;<br/>≥2-grade improvement (%)</p>
<p style="position:absolute;top:696px;left:340px;white-space:nowrap" class="ft1912">2.9</p>
<p style="position:absolute;top:696px;left:422px;white-space:nowrap" class="ft1912">29.7a</p>
<p style="position:absolute;top:696px;left:512px;white-space:nowrap" class="ft1912">6.9</p>
<p style="position:absolute;top:696px;left:590px;white-space:nowrap" class="ft1912">48.9a</p>
<p style="position:absolute;top:696px;left:725px;white-space:nowrap" class="ft1912">61.3</p>
<p style="position:absolute;top:735px;left:114px;white-space:nowrap" class="ft1914">Percent Change in Total&#160;<br/>Fingernail NAPSI (%)</p>
<p style="position:absolute;top:735px;left:337px;white-space:nowrap" class="ft1912">-7.8</p>
<p style="position:absolute;top:735px;left:417px;white-space:nowrap" class="ft1912">-44.2&#160;a</p>
<p style="position:absolute;top:735px;left:505px;white-space:nowrap" class="ft1912">-11.5</p>
<p style="position:absolute;top:735px;left:587px;white-space:nowrap" class="ft1912">-56.2a</p>
<p style="position:absolute;top:735px;left:722px;white-space:nowrap" class="ft1912">-72.2</p>
<p style="position:absolute;top:772px;left:114px;white-space:nowrap" class="ft1919">a&#160;p&lt;0.001, Humira&#160;<i>vs.&#160;</i>placebo&#160;</p>
<p style="position:absolute;top:812px;left:106px;white-space:nowrap" class="ft1914">Humira treated patients showed statistically significant improvements at Week&#160;26 compared with placebo&#160;<br/>in the DLQI.&#160;</p>
<p style="position:absolute;top:888px;left:106px;white-space:nowrap" class="ft1913"><i>Hidradenitis suppurativa</i></p>
<p style="position:absolute;top:926px;left:106px;white-space:nowrap" class="ft1914">The safety and efficacy of Humira were assessed in randomised, double-blind, placebo-controlled studies&#160;<br/>and an&#160;open-label extension study in adult patients with moderate to severe hidradenitis suppurativa (HS)&#160;<br/>who were&#160;intolerant, had a contraindication or an inadequate response to at least a 3-month trial of&#160;<br/>systemic antibiotic therapy. &#160;The patients in HS-I and HS-II had Hurley Stage II or III disease with at least&#160;<br/>3 abscesses or inflammatory nodules.</p>
<p style="position:absolute;top:1040px;left:106px;white-space:nowrap" class="ft1914">Study HS-I (PIONEER I) evaluated 307 patients with 2 treatment periods. &#160;In Period A, patients received&#160;<br/>placebo or Humira at an initial dose of 160 mg at Week 0, 80&#160;mg at Week 2, and 40 mg every week&#160;<br/>starting at Week 4 to Week 11. &#160;Concomitant antibiotic use was not allowed during the study. &#160;After&#160;</p>
</div>
<!-- Page 192 -->
<a name="192"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page192-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1920">192</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft1924">12&#160;weeks of therapy, patients who had received Humira in Period A were re-randomised in Period B to 1&#160;<br/>of 3 treatment groups (Humira 40 mg every week, Humira 40 mg every other week, or placebo from Week&#160;<br/>12 to Week 35). &#160;Patients who had been randomised to placebo in Period A were assigned to receive&#160;<br/>Humira 40 mg every week in Period B.</p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft1924">Study HS-II (PIONEER II) evaluated 326&#160;patients with 2 treatment periods. &#160;In Period A, patients received&#160;<br/>placebo or Humira at an initial dose of 160 mg at Week 0 and 80 mg at Week 2 and 40 mg every week&#160;<br/>starting at Week 4 to Week 11. &#160;19.3% of patients had continued baseline oral antibiotic therapy during the&#160;<br/>study. &#160;After 12&#160;weeks of therapy, patients who had received Humira in Period A were re-randomised in&#160;<br/>Period B to 1 of 3 treatment groups (Humira 40 mg every week, Humira 40 mg every other week, or&#160;<br/>placebo from Week 12 to Week 35). &#160;Patients who had been randomised to placebo in Period A were&#160;<br/>assigned to receive placebo in Period B.</p>
<p style="position:absolute;top:333px;left:106px;white-space:nowrap" class="ft1925">Patients participating in Studies HS-I and HS-II were&#160;eligible to enrol into an open-label extension study&#160;<br/>in which Humira 40mg was administered every week.&#160;Mean&#160;exposure in all adalimumab population was&#160;<br/>762 days.&#160;&#160;Throughout all 3 studies patients used topical antiseptic wash daily.</p>
<p style="position:absolute;top:409px;left:106px;white-space:nowrap" class="ft1923"><i>Clinical Response</i></p>
<p style="position:absolute;top:446px;left:106px;white-space:nowrap" class="ft1924">Reduction of inflammatory lesions and prevention of worsening of abscesses and draining fistulas was&#160;<br/>assessed using Hidradenitis Suppurativa Clinical Response (HiSCR; at least a 50% reduction in total&#160;<br/>abscess and inflammatory nodule count with no increase&#160;in abscess count and no increase in draining&#160;<br/>fistula count relative to Baseline). &#160;Reduction in HS-related skin pain was assessed using a Numeric&#160;<br/>Rating Scale in patients who entered the study with an initial baseline score of 3 or greater on a 11 point&#160;<br/>scale.&#160;</p>
<p style="position:absolute;top:579px;left:106px;white-space:nowrap" class="ft1924">At Week 12, a significantly higher proportion of patients treated with Humira versus placebo achieved&#160;<br/>HiSCR. &#160; At Week 12, a significantly higher proportion of patients in Study HS-II experienced a clinically&#160;<br/>relevant decrease in HS-related skin pain (see&#160;Table&#160;19). &#160;Patients treated with Humira had significantly&#160;<br/>reduced risk of disease flare during the initial 12 weeks of treatment.</p>
<p style="position:absolute;top:678px;left:262px;white-space:nowrap" class="ft1921"><b>Table&#160;19: &#160;Efficacy Results at 12 Weeks, HS Studies I and II</b></p>
<p style="position:absolute;top:699px;left:404px;white-space:nowrap" class="ft1921"><b>HS Study I</b></p>
<p style="position:absolute;top:699px;left:643px;white-space:nowrap" class="ft1921"><b>HS Study II</b></p>
<p style="position:absolute;top:738px;left:350px;white-space:nowrap" class="ft1921"><b>Placebo</b></p>
<p style="position:absolute;top:719px;left:446px;white-space:nowrap" class="ft1921"><b>Humira 40 mg&#160;</b></p>
<p style="position:absolute;top:738px;left:471px;white-space:nowrap" class="ft1921"><b>Weekly</b></p>
<p style="position:absolute;top:738px;left:588px;white-space:nowrap" class="ft1921"><b>Placebo&#160;</b></p>
<p style="position:absolute;top:719px;left:687px;white-space:nowrap" class="ft1921"><b>Humira 40 mg&#160;</b></p>
<p style="position:absolute;top:738px;left:711px;white-space:nowrap" class="ft1921"><b>Weekly</b></p>
<p style="position:absolute;top:767px;left:119px;white-space:nowrap" class="ft1925">Hidradenitis Suppurativa&#160;<br/>Clinical Response (HiSCR)a</p>
<p style="position:absolute;top:757px;left:351px;white-space:nowrap" class="ft1922">N = 154</p>
<p style="position:absolute;top:776px;left:341px;white-space:nowrap" class="ft1922">40 (26.0%)</p>
<p style="position:absolute;top:757px;left:470px;white-space:nowrap" class="ft1922">N = 153</p>
<p style="position:absolute;top:776px;left:456px;white-space:nowrap" class="ft1922">64 (41.8%)&#160;*</p>
<p style="position:absolute;top:757px;left:593px;white-space:nowrap" class="ft1922">N=163</p>
<p style="position:absolute;top:776px;left:579px;white-space:nowrap" class="ft1922">45 (27.6%)</p>
<p style="position:absolute;top:757px;left:715px;white-space:nowrap" class="ft1922">N=163</p>
<p style="position:absolute;top:776px;left:691px;white-space:nowrap" class="ft1922">96 (58.9%)&#160;***</p>
<p style="position:absolute;top:815px;left:119px;white-space:nowrap" class="ft1924">≥30% Reduction in Skin&#160;<br/>Painb</p>
<p style="position:absolute;top:815px;left:351px;white-space:nowrap" class="ft1922">N = 109</p>
<p style="position:absolute;top:834px;left:341px;white-space:nowrap" class="ft1922">27 (24.8%)</p>
<p style="position:absolute;top:815px;left:470px;white-space:nowrap" class="ft1922">N = 122</p>
<p style="position:absolute;top:834px;left:460px;white-space:nowrap" class="ft1922">34 (27.9%)</p>
<p style="position:absolute;top:815px;left:593px;white-space:nowrap" class="ft1922">N=111</p>
<p style="position:absolute;top:834px;left:579px;white-space:nowrap" class="ft1922">23 (20.7%)</p>
<p style="position:absolute;top:815px;left:715px;white-space:nowrap" class="ft1922">N=105</p>
<p style="position:absolute;top:834px;left:691px;white-space:nowrap" class="ft1922">48 (45.7%)&#160;***</p>
<p style="position:absolute;top:854px;left:146px;white-space:nowrap" class="ft1922">*&#160;<i>P&#160;</i>&lt; 0.05, ***<i>P&#160;</i>&lt; 0.001, Humira versus placebo&#160;</p>
<p style="position:absolute;top:879px;left:119px;white-space:nowrap" class="ft19218">a</p>
<p style="position:absolute;top:874px;left:146px;white-space:nowrap" class="ft1922">Among all randomised patients.</p>
<p style="position:absolute;top:900px;left:119px;white-space:nowrap" class="ft19218">b</p>
<p style="position:absolute;top:895px;left:146px;white-space:nowrap" class="ft1922">Among patients with baseline HS-related skin pain assessment&#160;≥ 3, based on Numeric Rating&#160;</p>
<p style="position:absolute;top:913px;left:146px;white-space:nowrap" class="ft1922">Scale 0&#160;–&#160;10; 0&#160;=&#160;no skin pain, 10 = skin pain as bad as you can imagine.</p>
<p style="position:absolute;top:952px;left:106px;white-space:nowrap" class="ft1924">Treatment with Humira 40 mg every week significantly reduced the risk of worsening of abscesses and&#160;<br/>draining fistulas. &#160;Approximately twice the proportion of patients in the placebo group in the first 12&#160;<br/>weeks of Studies HS-I and HS-II, compared with those&#160;in the Humira group experienced worsening of&#160;<br/>abscesses (23.0% vs 11.4%, respectively) and draining fistulas (30.0% vs 13.9%, respectively).</p>
<p style="position:absolute;top:1047px;left:106px;white-space:nowrap" class="ft1924">Greater improvements at Week 12 from baseline compared to placebo were demonstrated in skin-specific&#160;<br/>health-related quality of life, as measured by the Dermatology Life Quality Index (DLQI; Studies HS-I&#160;</p>
</div>
<!-- Page 193 -->
<a name="193"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page193-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1930">193</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft1934">and HS-II), patient global satisfaction with medication treatment as measured by the Treatment&#160;<br/>Satisfaction Questionnaire&#160;-&#160;medication (TSQM; Studies HS-I and&#160;HS-II),&#160;and physical health as&#160;<br/>measured by the physical component summary score of the SF-36&#160;(Study HS-I).</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft1934">In patients with at least a partial response to Humira 40 mg weekly at Week 12, the HiSCR rate at Week&#160;<br/>36 was higher in patients who continued weekly Humira&#160;than in patients in whom dosing frequency was&#160;<br/>reduced to every other week, or in whom treatment was withdrawn (see Table&#160;20). &#160;</p>
<p style="position:absolute;top:238px;left:164px;white-space:nowrap" class="ft1931"><b>Table&#160;20:</b></p>
<p style="position:absolute;top:238px;left:276px;white-space:nowrap" class="ft1931"><b>Proportion of Patientsa&#160;Achieving HiSCRb&#160;at Weeks 24 and 36 After&#160;</b></p>
<p style="position:absolute;top:257px;left:272px;white-space:nowrap" class="ft1931"><b>Treatment Reassignment from&#160;Weekly Humira at&#160;Week 12</b></p>
<p style="position:absolute;top:278px;left:341px;white-space:nowrap" class="ft1931"><b>Placebo</b></p>
<p style="position:absolute;top:297px;left:331px;white-space:nowrap" class="ft1931"><b>(treatment&#160;</b></p>
<p style="position:absolute;top:315px;left:326px;white-space:nowrap" class="ft1931"><b>withdrawal)</b></p>
<p style="position:absolute;top:333px;left:346px;white-space:nowrap" class="ft1931"><b>N = 73</b></p>
<p style="position:absolute;top:296px;left:466px;white-space:nowrap" class="ft1931"><b>Humira 40 mg</b></p>
<p style="position:absolute;top:315px;left:458px;white-space:nowrap" class="ft1931"><b>every other week</b></p>
<p style="position:absolute;top:333px;left:494px;white-space:nowrap" class="ft1931"><b>N = 70</b></p>
<p style="position:absolute;top:296px;left:610px;white-space:nowrap" class="ft1931"><b>Humira 40 mg</b></p>
<p style="position:absolute;top:315px;left:637px;white-space:nowrap" class="ft1931"><b>weekly</b></p>
<p style="position:absolute;top:333px;left:638px;white-space:nowrap" class="ft1931"><b>N = 70</b></p>
<p style="position:absolute;top:357px;left:195px;white-space:nowrap" class="ft1932">Week 24</p>
<p style="position:absolute;top:357px;left:332px;white-space:nowrap" class="ft1932">24 (32.9%)</p>
<p style="position:absolute;top:357px;left:480px;white-space:nowrap" class="ft1932">36 (51.4%)</p>
<p style="position:absolute;top:357px;left:624px;white-space:nowrap" class="ft1932">40 (57.1%)</p>
<p style="position:absolute;top:382px;left:195px;white-space:nowrap" class="ft1932">Week 36</p>
<p style="position:absolute;top:382px;left:332px;white-space:nowrap" class="ft1932">22 (30.1%)</p>
<p style="position:absolute;top:382px;left:480px;white-space:nowrap" class="ft1932">28 (40.0%)</p>
<p style="position:absolute;top:382px;left:624px;white-space:nowrap" class="ft1932">39 (55.7%)</p>
<p style="position:absolute;top:405px;left:195px;white-space:nowrap" class="ft1939">a</p>
<p style="position:absolute;top:406px;left:213px;white-space:nowrap" class="ft1935">Patients with at least a partial response to Humira 40 mg&#160;weekly after 12&#160;<br/>weeks of treatment.</p>
<p style="position:absolute;top:444px;left:195px;white-space:nowrap" class="ft1939">b</p>
<p style="position:absolute;top:446px;left:213px;white-space:nowrap" class="ft1932">Patients meeting protocol-specified criteria for loss of response or no&#160;</p>
<p style="position:absolute;top:464px;left:213px;white-space:nowrap" class="ft1932">improvement were required to discontinue from the studies and were&#160;</p>
<p style="position:absolute;top:482px;left:213px;white-space:nowrap" class="ft1932">counted as nonresponders.</p>
<p style="position:absolute;top:521px;left:106px;white-space:nowrap" class="ft1934">Among patients who were at least partial responders&#160;at Week 12, and who received continuous weekly&#160;<br/>Humira therapy, the HiSCR rate at Week 48 was 68.3% and at Week 96 was 65.1%. Longer term&#160;<br/>treatment with Humira 40 mg weekly for 96 weeks identified no new safety findings.</p>
<p style="position:absolute;top:596px;left:106px;white-space:nowrap" class="ft1934">Among patients whose Humira treatment was withdrawn at Week 12 in Studies HS-I and HS-II, the&#160;<br/>HiSCR rate 12 weeks after re-introduction of Humira 40 mg weekly returned to levels similar to that&#160;<br/>observed before withdrawal (56.0 %).</p>
<p style="position:absolute;top:672px;left:106px;white-space:nowrap" class="ft1933"><i>Crohn’s disease</i></p>
<p style="position:absolute;top:710px;left:106px;white-space:nowrap" class="ft1937">The safety and efficacy of Humira were assessed in over 1500 patients with moderately to severely active&#160;<br/>Crohn’s disease (Crohn’s Disease Activity Index (CDAI)&#160;</p>
<p style="position:absolute;top:729px;left:489px;white-space:nowrap" class="ft1936">&#160;220 and&#160;&#160;450) in randomised, double-blind,&#160;</p>
<p style="position:absolute;top:750px;left:106px;white-space:nowrap" class="ft1934">placebo-controlled studies. Concomitant stable doses of aminosalicylates, corticosteroids, and/or&#160;<br/>immunomodulatory agents were permitted and 80% of patients continued to receive at least one of these&#160;<br/>medications.&#160;</p>
<p style="position:absolute;top:825px;left:106px;white-space:nowrap" class="ft1934">Induction of clinical remission (defined as CDAI &lt;&#160;150) was evaluated in two studies, CD Study I&#160;<br/>(CLASSIC I) and CD Study II (GAIN).&#160;In CD Study I, 299 TNF-antagonist naive patients were&#160;<br/>randomised to one of four treatment groups; placebo at Weeks&#160;0 and 2, 160&#160;mg Humira at Week&#160;0 and&#160;<br/>80&#160;mg at Week&#160;2, 80&#160;mg at Week&#160;0 and 40&#160;mg at Week&#160;2, and 40&#160;mg at Week&#160;0 and 20&#160;mg at Week&#160;2. In&#160;<br/>CD Study II, 325 patients who had lost response or were intolerant to infliximab were randomised to&#160;<br/>receive either 160&#160;mg Humira at Week&#160;0 and 80&#160;mg at Week&#160;2 or placebo at Weeks&#160;0 and 2. The primary&#160;<br/>non-responders were excluded from the studies and therefore these patients were not further evaluated.</p>
<p style="position:absolute;top:977px;left:106px;white-space:nowrap" class="ft1934">Maintenance of clinical remission was evaluated in CD study III (CHARM). &#160;In CD Study III, 854 patients&#160;<br/>received open-label 80&#160;mg at Week&#160;0 and 40&#160;mg at Week&#160;2. &#160;At Week&#160;4 patients were randomised to&#160;<br/>40&#160;mg&#160;every other week, 40&#160;mg every week, or placebo with a total study duration of 56&#160;weeks. Patients in&#160;<br/>clinical response (decrease in CDAI&#160;≥ 70) at Week&#160;4 were stratified and analysed separately from those&#160;<br/>not in clinical response at Week&#160;4. &#160;Corticosteroid taper was&#160;permitted after Week&#160;8.&#160;</p>
</div>
<!-- Page 194 -->
<a name="194"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page194-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1940">194</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft1942">CD study I and CD study II induction of remission and response rates are presented in Table&#160;21.</p>
<p style="position:absolute;top:126px;left:422px;white-space:nowrap" class="ft1941"><b>Table&#160;21</b></p>
<p style="position:absolute;top:147px;left:291px;white-space:nowrap" class="ft1941"><b>Induction of Clinical Remission and Response</b></p>
<p style="position:absolute;top:168px;left:380px;white-space:nowrap" class="ft1941"><b>(Percent of Patients)</b></p>
<p style="position:absolute;top:193px;left:287px;white-space:nowrap" class="ft1941"><b>CD Study I: Infliximab Naive&#160;</b></p>
<p style="position:absolute;top:211px;left:287px;white-space:nowrap" class="ft1941"><b>Patients</b></p>
<p style="position:absolute;top:193px;left:558px;white-space:nowrap" class="ft1941"><b>CD Study II:&#160;Infliximab&#160;</b></p>
<p style="position:absolute;top:211px;left:558px;white-space:nowrap" class="ft1941"><b>Experienced Patients</b></p>
<p style="position:absolute;top:236px;left:296px;white-space:nowrap" class="ft1941"><b>Placebo</b></p>
<p style="position:absolute;top:256px;left:305px;white-space:nowrap" class="ft1941"><b>N=74</b></p>
<p style="position:absolute;top:236px;left:387px;white-space:nowrap" class="ft1941"><b>Humira</b></p>
<p style="position:absolute;top:256px;left:383px;white-space:nowrap" class="ft1941"><b>80/40&#160;mg</b></p>
<p style="position:absolute;top:278px;left:392px;white-space:nowrap" class="ft1941"><b>N = 75</b></p>
<p style="position:absolute;top:236px;left:478px;white-space:nowrap" class="ft1941"><b>Humira&#160;</b></p>
<p style="position:absolute;top:256px;left:470px;white-space:nowrap" class="ft1941"><b>160/80&#160;mg&#160;</b></p>
<p style="position:absolute;top:274px;left:487px;white-space:nowrap" class="ft1941"><b>N=76</b></p>
<p style="position:absolute;top:236px;left:579px;white-space:nowrap" class="ft1941"><b>Placebo</b></p>
<p style="position:absolute;top:256px;left:583px;white-space:nowrap" class="ft1941"><b>N=166</b></p>
<p style="position:absolute;top:236px;left:703px;white-space:nowrap" class="ft1941"><b>Humira&#160;</b></p>
<p style="position:absolute;top:256px;left:694px;white-space:nowrap" class="ft1941"><b>160/80&#160;mg</b></p>
<p style="position:absolute;top:278px;left:707px;white-space:nowrap" class="ft1941"><b>N=159</b></p>
<p style="position:absolute;top:302px;left:114px;white-space:nowrap" class="ft19416">Week&#160;4<br/>Clinical remission</p>
<p style="position:absolute;top:327px;left:309px;white-space:nowrap" class="ft1942">12%</p>
<p style="position:absolute;top:327px;left:400px;white-space:nowrap" class="ft1942">24%</p>
<p style="position:absolute;top:327px;left:488px;white-space:nowrap" class="ft1942">36%*</p>
<p style="position:absolute;top:327px;left:595px;white-space:nowrap" class="ft1942">7%</p>
<p style="position:absolute;top:327px;left:713px;white-space:nowrap" class="ft1942">21%*</p>
<p style="position:absolute;top:352px;left:114px;white-space:nowrap" class="ft1942">Clinical response (CR-</p>
<p style="position:absolute;top:370px;left:114px;white-space:nowrap" class="ft1942">100)</p>
<p style="position:absolute;top:352px;left:309px;white-space:nowrap" class="ft1942">24%</p>
<p style="position:absolute;top:352px;left:400px;white-space:nowrap" class="ft1942">37%</p>
<p style="position:absolute;top:352px;left:486px;white-space:nowrap" class="ft1942">49%**</p>
<p style="position:absolute;top:352px;left:591px;white-space:nowrap" class="ft1942">25%</p>
<p style="position:absolute;top:352px;left:710px;white-space:nowrap" class="ft1942">38%**</p>
<p style="position:absolute;top:395px;left:114px;white-space:nowrap" class="ft1944">All p-values are pairwise comparisons of proportions for Humira&#160;<i>versus&#160;</i>placebo<br/>*</p>
<p style="position:absolute;top:415px;left:141px;white-space:nowrap" class="ft1942">p&#160;&lt;&#160;0.001</p>
<p style="position:absolute;top:435px;left:114px;white-space:nowrap" class="ft1949">**</p>
<p style="position:absolute;top:436px;left:141px;white-space:nowrap" class="ft1942">p&#160;&lt;&#160;0.01</p>
<p style="position:absolute;top:477px;left:106px;white-space:nowrap" class="ft1944">Similar remission rates were observed for the 160/80&#160;mg and 80/40&#160;mg&#160;induction regimens by Week&#160;8 and&#160;<br/>adverse events were more frequently noted in the&#160;160/80&#160;mg group.</p>
<p style="position:absolute;top:534px;left:106px;white-space:nowrap" class="ft1945">In CD Study III, at Week&#160;4, 58% (499/854) of patients were in clinical response and were assessed in the&#160;<br/>primary analysis. Of those in clinical response at Week&#160;4, 48% had been previously exposed to other TNF-<br/>antagonists. Maintenance of remission and response rates are presented in Table&#160;22. &#160;Clinical remission&#160;<br/>results remained relatively constant irrespective of previous TNF-antagonist exposure.</p>
<p style="position:absolute;top:629px;left:106px;white-space:nowrap" class="ft1945">Disease-related hospitalisations and surgeries were statistically significantly reduced with&#160;adalimumab&#160;<br/>compared with placebo at Week&#160;56.</p>
</div>
<!-- Page 195 -->
<a name="195"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page195-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1950">195</p>
<p style="position:absolute;top:107px;left:422px;white-space:nowrap" class="ft1951"><b>Table&#160;22</b></p>
<p style="position:absolute;top:128px;left:279px;white-space:nowrap" class="ft1951"><b>Maintenance of Clinical Remission and Response</b></p>
<p style="position:absolute;top:149px;left:380px;white-space:nowrap" class="ft1951"><b>(Percent of Patients)</b></p>
<p style="position:absolute;top:174px;left:425px;white-space:nowrap" class="ft1951"><b>Placebo</b></p>
<p style="position:absolute;top:174px;left:539px;white-space:nowrap" class="ft1951"><b>40&#160;mg&#160;Humira</b></p>
<p style="position:absolute;top:192px;left:531px;white-space:nowrap" class="ft1951"><b>every other week</b></p>
<p style="position:absolute;top:174px;left:675px;white-space:nowrap" class="ft1951"><b>40&#160;mg&#160;Humira</b></p>
<p style="position:absolute;top:192px;left:687px;white-space:nowrap" class="ft1951"><b>every week</b></p>
<p style="position:absolute;top:217px;left:122px;white-space:nowrap" class="ft1951"><b>Week&#160;26</b></p>
<p style="position:absolute;top:217px;left:429px;white-space:nowrap" class="ft1951"><b>N=170</b></p>
<p style="position:absolute;top:217px;left:567px;white-space:nowrap" class="ft1951"><b>N=172</b></p>
<p style="position:absolute;top:217px;left:703px;white-space:nowrap" class="ft1951"><b>N=157</b></p>
<p style="position:absolute;top:242px;left:122px;white-space:nowrap" class="ft1952">Clinical remission</p>
<p style="position:absolute;top:242px;left:437px;white-space:nowrap" class="ft1952">17%</p>
<p style="position:absolute;top:242px;left:571px;white-space:nowrap" class="ft1952">40%*</p>
<p style="position:absolute;top:242px;left:707px;white-space:nowrap" class="ft1952">47%*</p>
<p style="position:absolute;top:266px;left:122px;white-space:nowrap" class="ft1952">Clinical response (CR-100)</p>
<p style="position:absolute;top:266px;left:437px;white-space:nowrap" class="ft1952">27%</p>
<p style="position:absolute;top:266px;left:571px;white-space:nowrap" class="ft1952">52%*</p>
<p style="position:absolute;top:266px;left:707px;white-space:nowrap" class="ft1952">52%*</p>
<p style="position:absolute;top:291px;left:149px;white-space:nowrap" class="ft1955">Patients in steroid-free remission&#160;<br/>for &gt;=90 daysa</p>
<p style="position:absolute;top:291px;left:419px;white-space:nowrap" class="ft1952">3% (2/66)</p>
<p style="position:absolute;top:291px;left:541px;white-space:nowrap" class="ft1952">19% (11/58)**</p>
<p style="position:absolute;top:291px;left:677px;white-space:nowrap" class="ft1952">15% (11/74)**</p>
<p style="position:absolute;top:334px;left:122px;white-space:nowrap" class="ft1951"><b>Week&#160;56</b></p>
<p style="position:absolute;top:334px;left:429px;white-space:nowrap" class="ft1951"><b>N=170</b></p>
<p style="position:absolute;top:334px;left:567px;white-space:nowrap" class="ft1951"><b>N=172</b></p>
<p style="position:absolute;top:334px;left:703px;white-space:nowrap" class="ft1951"><b>N=157</b></p>
<p style="position:absolute;top:359px;left:122px;white-space:nowrap" class="ft1952">Clinical remission</p>
<p style="position:absolute;top:359px;left:437px;white-space:nowrap" class="ft1952">12%</p>
<p style="position:absolute;top:359px;left:571px;white-space:nowrap" class="ft1952">36%*</p>
<p style="position:absolute;top:359px;left:707px;white-space:nowrap" class="ft1952">41%*</p>
<p style="position:absolute;top:383px;left:122px;white-space:nowrap" class="ft1952">Clinical response (CR-100)</p>
<p style="position:absolute;top:383px;left:437px;white-space:nowrap" class="ft1952">17%</p>
<p style="position:absolute;top:383px;left:571px;white-space:nowrap" class="ft1952">41%*</p>
<p style="position:absolute;top:383px;left:707px;white-space:nowrap" class="ft1952">48%*</p>
<p style="position:absolute;top:408px;left:149px;white-space:nowrap" class="ft1955">Patients in steroid-free remission&#160;<br/>for&#160;&gt;&#160;=&#160;90&#160;daysa</p>
<p style="position:absolute;top:408px;left:419px;white-space:nowrap" class="ft1952">5% (3/66)</p>
<p style="position:absolute;top:408px;left:545px;white-space:nowrap" class="ft1952">29% (17/58)*</p>
<p style="position:absolute;top:408px;left:677px;white-space:nowrap" class="ft1952">20% (15/74)**</p>
<p style="position:absolute;top:451px;left:122px;white-space:nowrap" class="ft1952">*</p>
<p style="position:absolute;top:451px;left:149px;white-space:nowrap" class="ft1952">p&#160;&lt;&#160;0.001 for Humira&#160;<i>versus&#160;</i>placebo pairwise comparisons of proportions</p>
<p style="position:absolute;top:472px;left:122px;white-space:nowrap" class="ft1954">**&#160;p&#160;&lt;&#160;0.02 for Humira&#160;<i>versus&#160;</i>placebo pairwise comparisons of proportions<br/>a</p>
<p style="position:absolute;top:492px;left:149px;white-space:nowrap" class="ft1952">Of those&#160;receiving corticosteroids at baseline</p>
<p style="position:absolute;top:534px;left:106px;white-space:nowrap" class="ft1954">Among patients who were not in response at Week&#160;4, 43% of Humira maintenance patients responded by&#160;<br/>Week&#160;12 compared to 30% of placebo maintenance patients. These results suggest that some patients who&#160;<br/>have not responded by Week&#160;4 benefit from continued maintenance therapy through Week&#160;12. &#160;Therapy&#160;<br/>continued beyond 12&#160;weeks did not result in significantly more responses&#160;(see section 4.2).&#160;&#160;</p>
<p style="position:absolute;top:628px;left:106px;white-space:nowrap" class="ft1954">117/276 patients from CD study I and 272/777 patients from CD studies II and III were followed through&#160;<br/>at least&#160;3&#160;years of open-label adalimumab therapy. &#160;88 and 189 patients, respectively, continued to be in&#160;<br/>clinical remission. &#160;Clinical response (CR-100) was maintained in 102 and 233 patients, respectively.</p>
<p style="position:absolute;top:704px;left:106px;white-space:nowrap" class="ft1953"><i>Quality of life</i></p>
<p style="position:absolute;top:742px;left:106px;white-space:nowrap" class="ft1954">In CD Study I and CD Study II, statistically significant improvement in the disease-specific inflammatory&#160;<br/>bowel disease questionnaire (IBDQ) total score was achieved at Week&#160;4 in patients randomised to Humira&#160;<br/>80/40&#160;mg and 160/80&#160;mg compared to placebo and was seen at Weeks&#160;26 and 56 in CD Study&#160;III as well&#160;<br/>among the adalimumab treatment groups compared to the placebo group.</p>
<p style="position:absolute;top:837px;left:106px;white-space:nowrap" class="ft1953"><i>Ulcerative colitis</i></p>
<p style="position:absolute;top:875px;left:106px;white-space:nowrap" class="ft1954">The safety and efficacy of multiple doses of Humira were assessed in adult patients with moderately to&#160;<br/>severely active ulcerative colitis (Mayo score 6 to 12 with endoscopy subscore of 2 to 3) in randomised,&#160;<br/>double-blind, placebo-controlled studies.&#160;</p>
<p style="position:absolute;top:951px;left:106px;white-space:nowrap" class="ft1955">In study UC-I, 390 TNF-antagonist naïve patients were randomised to receive either placebo at Weeks 0&#160;<br/>and 2, 160&#160;mg Humira at Week&#160;0 followed by 80&#160;mg at Week&#160;2, or 80&#160;mg Humira at Week&#160;0 followed by&#160;<br/>40&#160;mg at Week&#160;2. &#160;After Week&#160;2, patients in both adalimumab arms received 40&#160;mg&#160;eow. &#160;Clinical&#160;<br/>remission (defined as Mayo score&#160;≤&#160;2 with no subscore &gt;&#160;1)&#160;was assessed at Week&#160;8.&#160;</p>
<p style="position:absolute;top:1046px;left:106px;white-space:nowrap" class="ft1954">In study UC-II, 248 patients received 160&#160;mg&#160;of Humira at Week&#160;0, 80&#160;mg at Week&#160;2 and 40&#160;mg&#160;eow&#160;<br/>thereafter, and 246 patients received placebo. Clinical results were assessed for induction of remission at&#160;<br/>Week&#160;8 and for maintenance of remission at Week&#160;52.&#160;</p>
</div>
<!-- Page 196 -->
<a name="196"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page196-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1960">196</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft1964">Patients induced with 160/80&#160;mg&#160;Humira achieved clinical remission versus placebo at Week&#160;8 in&#160;<br/>statistically significantly greater percentages in study UC-I (18% vs. 9% respectively, p=0.031) and study&#160;<br/>UC-II (17% vs. 9% respectively, p=0.019).&#160;In study UC-II, among those treated with Humira who were in&#160;<br/>remission at Week&#160;8, 21/41 (51%) were in remission at Week&#160;52.</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft1962">Results from the overall UC-II study population are shown in Table&#160;23.</p>
<p style="position:absolute;top:239px;left:428px;white-space:nowrap" class="ft1961"><b>Table&#160;23</b></p>
<p style="position:absolute;top:258px;left:254px;white-space:nowrap" class="ft1961"><b>Response, Remission and Mucosal Healing in Study UC-II</b></p>
<p style="position:absolute;top:278px;left:387px;white-space:nowrap" class="ft1961"><b>(Percent of Patients)</b></p>
<p style="position:absolute;top:299px;left:477px;white-space:nowrap" class="ft1961"><b>Placebo</b></p>
<p style="position:absolute;top:299px;left:579px;white-space:nowrap" class="ft1961"><b>Humira 40&#160;mg&#160;</b></p>
<p style="position:absolute;top:318px;left:616px;white-space:nowrap" class="ft1961"><b>eow</b></p>
<p style="position:absolute;top:359px;left:108px;white-space:nowrap" class="ft1962">Week&#160;52</p>
<p style="position:absolute;top:359px;left:481px;white-space:nowrap" class="ft1961"><b>N=246</b></p>
<p style="position:absolute;top:359px;left:607px;white-space:nowrap" class="ft1961"><b>N=248</b></p>
<p style="position:absolute;top:380px;left:108px;white-space:nowrap" class="ft1962">&#160;&#160;Clinical Response&#160;</p>
<p style="position:absolute;top:380px;left:489px;white-space:nowrap" class="ft1962">18%&#160;</p>
<p style="position:absolute;top:380px;left:605px;white-space:nowrap" class="ft1962">&#160; &#160;30%*</p>
<p style="position:absolute;top:401px;left:108px;white-space:nowrap" class="ft1962">&#160;&#160;Clinical Remission</p>
<p style="position:absolute;top:401px;left:494px;white-space:nowrap" class="ft1962">9%</p>
<p style="position:absolute;top:401px;left:604px;white-space:nowrap" class="ft1962">&#160; &#160;17%*</p>
<p style="position:absolute;top:423px;left:108px;white-space:nowrap" class="ft1962">&#160;&#160;Mucosal Healing&#160;</p>
<p style="position:absolute;top:423px;left:489px;white-space:nowrap" class="ft1962">15%</p>
<p style="position:absolute;top:423px;left:604px;white-space:nowrap" class="ft1962">&#160; &#160;25%*</p>
<p style="position:absolute;top:444px;left:108px;white-space:nowrap" class="ft1962">&#160;&#160;Steroid-free remission for&#160;≥&#160;90 days&#160;a</p>
<p style="position:absolute;top:444px;left:494px;white-space:nowrap" class="ft1962">6%&#160;</p>
<p style="position:absolute;top:463px;left:476px;white-space:nowrap" class="ft1962">(N=140)</p>
<p style="position:absolute;top:444px;left:598px;white-space:nowrap" class="ft1962">&#160; &#160; &#160;13% *</p>
<p style="position:absolute;top:463px;left:601px;white-space:nowrap" class="ft1962">(N=150)</p>
<p style="position:absolute;top:503px;left:108px;white-space:nowrap" class="ft19623">Week&#160;8 and 52<br/>&#160;&#160;Sustained Response&#160;</p>
<p style="position:absolute;top:524px;left:489px;white-space:nowrap" class="ft1962">12%</p>
<p style="position:absolute;top:524px;left:600px;white-space:nowrap" class="ft1962">&#160; &#160;24%**</p>
<p style="position:absolute;top:545px;left:108px;white-space:nowrap" class="ft1962">&#160;&#160;Sustained Remission&#160;</p>
<p style="position:absolute;top:545px;left:494px;white-space:nowrap" class="ft1962">4%</p>
<p style="position:absolute;top:545px;left:608px;white-space:nowrap" class="ft1962">&#160; &#160;8%*</p>
<p style="position:absolute;top:567px;left:108px;white-space:nowrap" class="ft1962">&#160;&#160;Sustained Mucosal Healing&#160;</p>
<p style="position:absolute;top:567px;left:489px;white-space:nowrap" class="ft1962">11%</p>
<p style="position:absolute;top:567px;left:606px;white-space:nowrap" class="ft1962">&#160;&#160;19%*</p>
<p style="position:absolute;top:589px;left:108px;white-space:nowrap" class="ft1964">Clinical remission is Mayo score&#160;&#160;≤&#160;2 with no subscore&#160;&gt;&#160;1;<br/>Clinical response is decrease from baseline in Mayo score&#160;≥&#160;3 points and&#160;≥&#160;30% plus a&#160;<br/>decrease in the&#160;rectal bleeding subscore [RBS]&#160;≥&#160;1 or an absolute RBS of 0 or 1;</p>
<p style="position:absolute;top:646px;left:108px;white-space:nowrap" class="ft19616">*p&#160;&lt;&#160;0.05 for Humira&#160;<i>vs.&#160;</i>placebo pairwise comparison of proportions&#160;<br/>**</p>
<p style="position:absolute;top:669px;left:123px;white-space:nowrap" class="ft1962">p&#160;&lt;&#160;0.001 for Humira&#160;<i>vs.&#160;</i>placebo pairwise comparison of proportions</p>
<p style="position:absolute;top:687px;left:108px;white-space:nowrap" class="ft1969">a&#160;&#160;&#160;Of those receiving corticosteroids at baseline</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft1964">Of those patients who had a response at Week&#160;8, 47% were in response, 29% were in remission, 41% had&#160;<br/>mucosal healing, and 20% were in steroid-free remission for&#160;≥&#160;90 days at Week&#160;52.</p>
<p style="position:absolute;top:784px;left:106px;white-space:nowrap" class="ft1964">Approximately 40% of patients in study UC-II had failed prior anti-TNF&#160;treatment with infliximab. The&#160;<br/>efficacy of adalimumab in those patients was reduced compared to that in anti-TNF naïve patients. &#160;<br/>Among patients who had failed prior anti-TNF treatment, Week&#160;52 remission was achieved by 3% on&#160;<br/>placebo and 10% on adalimumab.</p>
<p style="position:absolute;top:879px;left:106px;white-space:nowrap" class="ft1965">Patients from studies UC-I and UC-II had the option to roll over into an open-label long-term&#160;extension&#160;<br/>study (UC III). Following 3&#160;years of adalimumab therapy, 75% (301/402) continued to be in clinical&#160;<br/>remission per partial Mayo score.&#160;</p>
<p style="position:absolute;top:955px;left:106px;white-space:nowrap" class="ft1963"><i>Hospitalisation&#160;rates</i></p>
<p style="position:absolute;top:993px;left:106px;white-space:nowrap" class="ft1964">During 52&#160;weeks of studies UC-I and UC-II, lower rates of all-cause hospitalisations and UC-related&#160;<br/>hospitalisations were observed for the adalimumab-treated arm compared to the placebo arm.&#160;The&#160;number&#160;<br/>of all cause hospitalisations in the adalimumab treatment group was 0.18 per patient year&#160;<i>vs</i>. 0.26 per&#160;</p>
</div>
<!-- Page 197 -->
<a name="197"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page197-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1970">197</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft1975">patient year in the placebo group and the corresponding figures for UC-related hospitalisations were 0.12&#160;<br/>per patient year&#160;<i>vs.&#160;</i>0.22 per patient year.</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft1973"><i>Quality of life</i></p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft1974">In study UC-II, treatment with&#160;adalimumab resulted in improvements in the Inflammatory Bowel Disease&#160;<br/>Questionnaire (IBDQ) score.</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft1973"><i>Uveitis</i></p>
<p style="position:absolute;top:276px;left:106px;white-space:nowrap" class="ft1974">The safety and efficacy of Humira were assessed in adult patients with non-infectious intermediate,&#160;<br/>posterior, and panuveitis, excluding patients with&#160;isolated anterior uveitis, in two randomised, double-<br/>masked, placebo-controlled studies (UV I and II). Patients received placebo or Humira at an initial dose of&#160;<br/>80&#160;mg followed by 40&#160;mg&#160;every other week starting one week after the initial dose. Concomitant stable&#160;<br/>doses of one&#160;non-biologic immunosuppressant were permitted.&#160;</p>
<p style="position:absolute;top:390px;left:106px;white-space:nowrap" class="ft1974">Study UV I evaluated 217 patients with active uveitis despite treatment with corticosteroids (oral&#160;<br/>prednisone at a dose of 10 to 60&#160;mg/day). All patients received a 2-week&#160;standardised&#160;dose of prednisone&#160;<br/>60&#160;mg/day at study entry followed by a mandatory taper schedule, with complete corticosteroid&#160;<br/>discontinuation by Week 15.&#160;</p>
<p style="position:absolute;top:485px;left:106px;white-space:nowrap" class="ft1974">Study UV II evaluated 226 patients with inactive uveitis requiring chronic corticosteroid treatment (oral&#160;<br/>prednisone 10 to 35&#160;mg/day) at baseline to control their disease. Patients subsequently underwent a&#160;<br/>mandatory taper schedule, with complete corticosteroid discontinuation by Week 19.&#160;</p>
<p style="position:absolute;top:560px;left:106px;white-space:nowrap" class="ft1975">The primary efficacy endpoint in both studies was ´time to treatment failure´. Treatment failure was&#160;<br/>defined by a multi-component outcome based on inflammatory chorioretinal and/or inflammatory retinal&#160;<br/>vascular lesions, anterior chamber (AC) cell grade, vitreous haze (VH) grade and best corrected visual&#160;<br/>acuity (BCVA).&#160;</p>
<p style="position:absolute;top:655px;left:106px;white-space:nowrap" class="ft1975">Patients who completed Studies UV I and UV&#160;II were&#160;eligible to enroll in&#160;an uncontrolled long-term&#160;<br/>extension study with an originally planned duration of 78 weeks. Patients were allowed to continue on&#160;<br/>study medication beyond Week 78 until they had access to Humira.</p>
<p style="position:absolute;top:731px;left:106px;white-space:nowrap" class="ft1973"><i>Clinical Response</i></p>
<p style="position:absolute;top:769px;left:106px;white-space:nowrap" class="ft1974">Results from both studies demonstrated statistically significant reduction of the risk of treatment failure in&#160;<br/>patients treated with Humira versus patients receiving placebo (See Table&#160;24). Both studies demonstrated&#160;<br/>an early and sustained effect of Humira on the treatment failure rate versus placebo (see Figure&#160;2).&#160;</p>
</div>
<!-- Page 198 -->
<a name="198"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page198-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1980">198</p>
<p style="position:absolute;top:86px;left:428px;white-space:nowrap" class="ft1981"><b>Table&#160;24</b></p>
<p style="position:absolute;top:105px;left:270px;white-space:nowrap" class="ft1981"><b>Time to Treatment Failure in Studies UV I and UV II</b></p>
<p style="position:absolute;top:144px;left:114px;white-space:nowrap" class="ft1981"><b>Analysis</b></p>
<p style="position:absolute;top:163px;left:156px;white-space:nowrap" class="ft1981"><b>Treatment</b></p>
<p style="position:absolute;top:144px;left:284px;white-space:nowrap" class="ft1981"><b>N</b></p>
<p style="position:absolute;top:144px;left:338px;white-space:nowrap" class="ft19819"><b>Failure<br/>N (%)</b></p>
<p style="position:absolute;top:144px;left:426px;white-space:nowrap" class="ft19819"><b>Median Time to&#160;<br/>Failure&#160;(months)</b></p>
<p style="position:absolute;top:144px;left:567px;white-space:nowrap" class="ft1981"><b>HRa</b></p>
<p style="position:absolute;top:144px;left:621px;white-space:nowrap" class="ft19819"><b>CI 95%&#160;<br/>for HRa</b></p>
<p style="position:absolute;top:144px;left:709px;white-space:nowrap" class="ft19817"><i><b>P&#160;</b></i><b>Value&#160;</b>b</p>
<p style="position:absolute;top:182px;left:114px;white-space:nowrap" class="ft19819"><b>Time to Treatment Failure At or After Week 6 in Study UV I &#160;<br/></b>Primary analysis (ITT)</p>
<p style="position:absolute;top:220px;left:156px;white-space:nowrap" class="ft1982">Placebo</p>
<p style="position:absolute;top:220px;left:284px;white-space:nowrap" class="ft1982">107</p>
<p style="position:absolute;top:220px;left:338px;white-space:nowrap" class="ft1982">84 (78.5)</p>
<p style="position:absolute;top:220px;left:426px;white-space:nowrap" class="ft1982">3.0</p>
<p style="position:absolute;top:220px;left:567px;white-space:nowrap" class="ft1982">--</p>
<p style="position:absolute;top:220px;left:621px;white-space:nowrap" class="ft1982">--</p>
<p style="position:absolute;top:220px;left:709px;white-space:nowrap" class="ft1982">--</p>
<p style="position:absolute;top:239px;left:156px;white-space:nowrap" class="ft1982">Adalimumab</p>
<p style="position:absolute;top:239px;left:284px;white-space:nowrap" class="ft1982">110</p>
<p style="position:absolute;top:239px;left:338px;white-space:nowrap" class="ft1982">60 (54.5)</p>
<p style="position:absolute;top:239px;left:426px;white-space:nowrap" class="ft1982">5.6</p>
<p style="position:absolute;top:239px;left:567px;white-space:nowrap" class="ft1982">0.50</p>
<p style="position:absolute;top:239px;left:621px;white-space:nowrap" class="ft1982">0.36, 0.70</p>
<p style="position:absolute;top:239px;left:709px;white-space:nowrap" class="ft1982">&lt; 0.001</p>
<p style="position:absolute;top:259px;left:114px;white-space:nowrap" class="ft19819"><b>Time to Treatment Failure At or&#160;After Week 2 in Study UV II<br/></b>Primary analysis (ITT)</p>
<p style="position:absolute;top:297px;left:156px;white-space:nowrap" class="ft1982">Placebo</p>
<p style="position:absolute;top:297px;left:284px;white-space:nowrap" class="ft1982">111</p>
<p style="position:absolute;top:297px;left:338px;white-space:nowrap" class="ft1982">61 (55.0)</p>
<p style="position:absolute;top:297px;left:426px;white-space:nowrap" class="ft1982">8.3</p>
<p style="position:absolute;top:297px;left:567px;white-space:nowrap" class="ft1982">--</p>
<p style="position:absolute;top:297px;left:621px;white-space:nowrap" class="ft1982">--</p>
<p style="position:absolute;top:297px;left:709px;white-space:nowrap" class="ft1982">--</p>
<p style="position:absolute;top:316px;left:156px;white-space:nowrap" class="ft1982">Adalimumab</p>
<p style="position:absolute;top:316px;left:284px;white-space:nowrap" class="ft1982">115</p>
<p style="position:absolute;top:316px;left:338px;white-space:nowrap" class="ft1982">45 (39.1)</p>
<p style="position:absolute;top:316px;left:426px;white-space:nowrap" class="ft1982">NEc</p>
<p style="position:absolute;top:316px;left:567px;white-space:nowrap" class="ft1982">0.57</p>
<p style="position:absolute;top:316px;left:621px;white-space:nowrap" class="ft1982">0.39, 0.84</p>
<p style="position:absolute;top:316px;left:709px;white-space:nowrap" class="ft1982">0.004</p>
<p style="position:absolute;top:336px;left:106px;white-space:nowrap" class="ft1988">Note: &#160;Treatment failure at or after Week 6 (Study UV I), or at or after Week 2 (Study UV II), was&#160;<br/>counted&#160;as event. Drop outs due to reasons other than treatment failure were censored at the time of&#160;<br/>dropping out.<br/>a</p>
<p style="position:absolute;top:392px;left:133px;white-space:nowrap" class="ft1982">HR of adalimumab vs placebo from proportional hazards regression with treatment as factor.</p>
<p style="position:absolute;top:416px;left:106px;white-space:nowrap" class="ft19818">b</p>
<p style="position:absolute;top:411px;left:133px;white-space:nowrap" class="ft1982">2-sided&#160;<i>P&#160;</i>value from log rank test.</p>
<p style="position:absolute;top:435px;left:106px;white-space:nowrap" class="ft19818">c</p>
<p style="position:absolute;top:431px;left:133px;white-space:nowrap" class="ft1982">NE = not estimable. Fewer than half of at-risk subjects had an event.&#160;</p>
<p style="position:absolute;top:468px;left:108px;white-space:nowrap" class="ft1981"><b>Figure&#160;2: Kaplan-Meier Curves Summarizing Time to Treatment Failure on or after Week 6 (Study&#160;</b></p>
<p style="position:absolute;top:487px;left:350px;white-space:nowrap" class="ft1981"><b>UV I) or Week 2 (Study UV II)</b></p>
<p style="position:absolute;top:786px;left:130px;white-space:nowrap" class="ft19820"><b>T</b></p>
<p style="position:absolute;top:775px;left:130px;white-space:nowrap" class="ft19820"><b>R</b></p>
<p style="position:absolute;top:763px;left:130px;white-space:nowrap" class="ft19820"><b>E</b></p>
<p style="position:absolute;top:752px;left:130px;white-space:nowrap" class="ft19820"><b>A</b></p>
<p style="position:absolute;top:740px;left:130px;white-space:nowrap" class="ft19820"><b>T</b></p>
<p style="position:absolute;top:729px;left:130px;white-space:nowrap" class="ft19820"><b>M</b></p>
<p style="position:absolute;top:714px;left:130px;white-space:nowrap" class="ft19820"><b>E</b></p>
<p style="position:absolute;top:702px;left:130px;white-space:nowrap" class="ft19820"><b>N</b></p>
<p style="position:absolute;top:691px;left:130px;white-space:nowrap" class="ft19820"><b>T</b></p>
<p style="position:absolute;top:680px;left:130px;white-space:nowrap" class="ft19820"><b>&#160;F</b></p>
<p style="position:absolute;top:665px;left:130px;white-space:nowrap" class="ft19820"><b>A</b></p>
<p style="position:absolute;top:653px;left:130px;white-space:nowrap" class="ft19820"><b>IL</b></p>
<p style="position:absolute;top:636px;left:130px;white-space:nowrap" class="ft19820"><b>U</b></p>
<p style="position:absolute;top:624px;left:130px;white-space:nowrap" class="ft19820"><b>R</b></p>
<p style="position:absolute;top:612px;left:130px;white-space:nowrap" class="ft19820"><b>E</b></p>
<p style="position:absolute;top:601px;left:130px;white-space:nowrap" class="ft19820"><b>&#160;R</b></p>
<p style="position:absolute;top:585px;left:130px;white-space:nowrap" class="ft19820"><b>A</b></p>
<p style="position:absolute;top:573px;left:130px;white-space:nowrap" class="ft19820"><b>T</b></p>
<p style="position:absolute;top:562px;left:130px;white-space:nowrap" class="ft19820"><b>E</b></p>
<p style="position:absolute;top:552px;left:130px;white-space:nowrap" class="ft19820"><b>&#160;(</b></p>
<p style="position:absolute;top:542px;left:130px;white-space:nowrap" class="ft19820"><b>%</b></p>
<p style="position:absolute;top:525px;left:130px;white-space:nowrap" class="ft19820"><b>)</b></p>
<p style="position:absolute;top:811px;left:406px;white-space:nowrap" class="ft1981"><b>TIME (MONTHS)</b></p>
<p style="position:absolute;top:830px;left:150px;white-space:nowrap" class="ft1982">Study UV I &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;Treatment</p>
<p style="position:absolute;top:830px;left:500px;white-space:nowrap" class="ft1982">Placebo</p>
<p style="position:absolute;top:830px;left:669px;white-space:nowrap" class="ft1982">Adalimumab</p>
</div>
<!-- Page 199 -->
<a name="199"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page199-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft1990">199</p>
<p style="position:absolute;top:349px;left:130px;white-space:nowrap" class="ft19920"><b>T</b></p>
<p style="position:absolute;top:338px;left:130px;white-space:nowrap" class="ft19920"><b>R</b></p>
<p style="position:absolute;top:326px;left:130px;white-space:nowrap" class="ft19920"><b>E</b></p>
<p style="position:absolute;top:315px;left:130px;white-space:nowrap" class="ft19920"><b>A</b></p>
<p style="position:absolute;top:303px;left:130px;white-space:nowrap" class="ft19920"><b>T</b></p>
<p style="position:absolute;top:292px;left:130px;white-space:nowrap" class="ft19920"><b>M</b></p>
<p style="position:absolute;top:276px;left:130px;white-space:nowrap" class="ft19920"><b>E</b></p>
<p style="position:absolute;top:265px;left:130px;white-space:nowrap" class="ft19920"><b>N</b></p>
<p style="position:absolute;top:253px;left:130px;white-space:nowrap" class="ft19920"><b>T</b></p>
<p style="position:absolute;top:242px;left:130px;white-space:nowrap" class="ft19920"><b>&#160;F</b></p>
<p style="position:absolute;top:228px;left:130px;white-space:nowrap" class="ft19920"><b>A</b></p>
<p style="position:absolute;top:216px;left:130px;white-space:nowrap" class="ft19920"><b>IL</b></p>
<p style="position:absolute;top:199px;left:130px;white-space:nowrap" class="ft19920"><b>U</b></p>
<p style="position:absolute;top:187px;left:130px;white-space:nowrap" class="ft19920"><b>R</b></p>
<p style="position:absolute;top:175px;left:130px;white-space:nowrap" class="ft19920"><b>E</b></p>
<p style="position:absolute;top:164px;left:130px;white-space:nowrap" class="ft19920"><b>&#160;R</b></p>
<p style="position:absolute;top:148px;left:130px;white-space:nowrap" class="ft19920"><b>A</b></p>
<p style="position:absolute;top:136px;left:130px;white-space:nowrap" class="ft19920"><b>T</b></p>
<p style="position:absolute;top:125px;left:130px;white-space:nowrap" class="ft19920"><b>E</b></p>
<p style="position:absolute;top:114px;left:130px;white-space:nowrap" class="ft19920"><b>&#160;(</b></p>
<p style="position:absolute;top:104px;left:130px;white-space:nowrap" class="ft19920"><b>%</b></p>
<p style="position:absolute;top:88px;left:130px;white-space:nowrap" class="ft19920"><b>)</b></p>
<p style="position:absolute;top:376px;left:406px;white-space:nowrap" class="ft1991"><b>TIME (MONTHS)</b></p>
<p style="position:absolute;top:395px;left:150px;white-space:nowrap" class="ft1992">Study UV II &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; Treatment</p>
<p style="position:absolute;top:395px;left:500px;white-space:nowrap" class="ft1992">Placebo</p>
<p style="position:absolute;top:395px;left:669px;white-space:nowrap" class="ft1992">Adalimumab</p>
<p style="position:absolute;top:427px;left:114px;white-space:nowrap" class="ft1994">Note: P# = Placebo (Number of Events/Number at Risk); A# = HUMIRA (Number of<br/>Events/Number at Risk).</p>
<p style="position:absolute;top:489px;left:106px;white-space:nowrap" class="ft1994">In&#160;Study UV I statistically significant differences in favour of adalimumab versus placebo were observed&#160;<br/>for each component of treatment failure. &#160;In Study UV II, statistically significant differences were&#160;<br/>observed for visual acuity only, but the other components were numerically in favour of adalimumab.</p>
<p style="position:absolute;top:565px;left:106px;white-space:nowrap" class="ft1994">Of the&#160;424&#160;subjects included&#160;in&#160;the&#160;uncontrolled long-term&#160;extension of Studies UV I and UV II,&#160;60<br/>subjects were regarded ineligible (e.g.&#160;due to deviations or due to&#160;complications secondary to diabetic&#160;<br/>retinopathy, due to cataract surgery or vitrectomy) and were excluded from the primary analysis&#160;of&#160;<br/>efficacy. Of the&#160;364&#160;remaining patients,&#160;269&#160;evaluable patients&#160;(74%)&#160;reached 78 weeks of open-label&#160;<br/>adalimumab treatment. Based on the observed data approach,&#160;216&#160;(80.3%) were in quiescence (no active&#160;<br/>inflammatory lesions, AC cell grade &#160;≤ 0.5+, VH grade ≤ 0.5+) with a concomitant steroid dose ≤ 7.5 mg&#160;<br/>per day, and&#160;178&#160;(66.2%) were in steroid-free quiescence. BCVA was either improved or maintained (&lt; 5&#160;<br/>letters deterioration) in 88.6% of the eyes at week 78.&#160;Data beyond Week 78 were generally consistent&#160;<br/>with these results but the number of enrolled subjects declined after this time. Overall,&#160;among the patients&#160;<br/>who discontinued the study,&#160;18% discontinued due to&#160;adverse events, and&#160;8% due to insufficient response&#160;<br/>to adalimumab treatment.</p>
<p style="position:absolute;top:792px;left:106px;white-space:nowrap" class="ft1993"><i>Quality of Life</i></p>
<p style="position:absolute;top:831px;left:106px;white-space:nowrap" class="ft1995">Patient reported outcomes regarding vision-related functioning were measured in both clinical studies,&#160;<br/>using the NEI VFQ-25. Humira was numerically favoured for&#160;the majority of subscores with statistically&#160;<br/>significant mean differences for general vision, ocular pain, near vision, mental health, and total score in&#160;<br/>Study UV I, and for general vision and mental health in Study UV II. Vision related effects were not&#160;<br/>numerically in favour of Humira for colour vision in Study UVI and for colour vision, peripheral vision&#160;<br/>and near vision in Study UV II.</p>
<p style="position:absolute;top:963px;left:106px;white-space:nowrap" class="ft1992">Immunogenicity</p>
<p style="position:absolute;top:1001px;left:106px;white-space:nowrap" class="ft1994">Formation of anti-adalimumab antibodies is associated with increased clearance and reduced efficacy of&#160;<br/>adalimumab. There is no apparent correlation between the presence of anti-adalimumab antibodies and the&#160;<br/>occurrence of adverse events.</p>
</div>
<!-- Page 200 -->
<a name="200"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page200-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2000">200</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft2004">Patients in rheumatoid arthritis studies I, II and III were tested at multiple time points for anti-adalimumab&#160;<br/>antibodies&#160;during the 6 to 12&#160;month period. In the pivotal trials, anti-adalimumab antibodies were&#160;<br/>identified in 5.5% (58/1053) of patients treated with adalimumab, compared to 0.5% (2/370) on placebo. &#160;<br/>In patients not given concomitant methotrexate, the incidence was 12.4%, compared to 0.6% when&#160;<br/>adalimumab was used as add-on to methotrexate. &#160;</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft2004">In patients with polyarticular juvenile idiopathic arthritis who were 4 to 17&#160;years, anti-adalimumab&#160;<br/>antibodies were identified in 15.8% (27/171) of patients treated with adalimumab. In patients not given&#160;<br/>concomitant methotrexate, the incidence was 25.6% (22/86) compared to 5.9% (5/85) when adalimumab&#160;<br/>was used as add-on to methotrexate.&#160;In patients with polyarticular juvenile idiopathic arthritis who were&#160;<br/>2&#160;to&#160;&lt;4&#160;years old or&#160;aged 4 and above weighing &lt;15&#160;kg,&#160;anti-adalimumab antibodies were identified in 7%&#160;<br/>(1/15) of patients, and the one patient was receiving concomitant methotrexate.</p>
<p style="position:absolute;top:333px;left:106px;white-space:nowrap" class="ft2005">In patients with enthesitis-related arthritis, anti-adalimumab antibodies were identified in&#160;10.9% (5/46) of&#160;<br/>patients treated with adalimumab. In patients not given concomitant methotrexate, the incidence was&#160;<br/>13.6% (3/22), compared to 8.3% (2/24) when adalimumab was used as add-on to methotrexate.</p>
<p style="position:absolute;top:409px;left:106px;white-space:nowrap" class="ft2004">In patients with psoriatic arthritis, anti-adalimumab antibodies were identified in 38/376 subjects (10%)&#160;<br/>treated with adalimumab. In patients not given concomitant methotrexate, the incidence was 13.5%&#160;<br/>(24/178 subjects), compared to 7% (14 of 198 subjects) when adalimumab was used as add-on to&#160;<br/>methotrexate.</p>
<p style="position:absolute;top:503px;left:106px;white-space:nowrap" class="ft2004">In patients with ankylosing spondylitis anti-adalimumab antibodies were identified in 17/204 subjects&#160;<br/>(8.3%) treated with adalimumab. In patients not given concomitant methotrexate, the incidence was&#160;<br/>16/185 (8.6%), compared to 1/19 (5.3%) when adalimumab was used as add-on to methotrexate.</p>
<p style="position:absolute;top:579px;left:106px;white-space:nowrap" class="ft2004">In patients with non-radiographic axial spondyloarthritis, anti-adalimumab antibodies were identified in&#160;<br/>8/152 subjects (5.3%) who were treated continuously with adalimumab.</p>
<p style="position:absolute;top:636px;left:106px;white-space:nowrap" class="ft2004">In patients with Crohn’s disease, anti-adalimumab antibodies were identified in 7/269 subjects (2.6%) and&#160;<br/>in 19/487 subjects (3.9%) with ulcerative colitis.</p>
<p style="position:absolute;top:693px;left:106px;white-space:nowrap" class="ft2004">In adult patients with psoriasis, anti-adalimumab antibodies were identified in 77/920 subjects (8.4%)&#160;<br/>treated with adalimumab monotherapy.</p>
<p style="position:absolute;top:750px;left:106px;white-space:nowrap" class="ft2004">In adult plaque psoriasis patients on long term adalimumab monotherapy who participated in a withdrawal&#160;<br/>and retreatment study, the rate of antibodies to adalimumab after retreatment (11 of 482 subjects, 2.3%)&#160;<br/>was similar to the rate observed prior to&#160;withdrawal (11 of 590 subjects, 1.9%).</p>
<p style="position:absolute;top:826px;left:106px;white-space:nowrap" class="ft2004">In patients with paediatric psoriasis, anti-adalimumab antibodies were identified in 5/38 subjects (13%)&#160;<br/>treated with 0.8&#160;mg/kg adalimumab monotherapy.</p>
<p style="position:absolute;top:883px;left:106px;white-space:nowrap" class="ft2004">In patients with moderate to severe hidradenitis suppurativa, anti-adalimumab antibodies were identified&#160;<br/>in 10/99 subjects (10.1%) treated with adalimumab.</p>
<p style="position:absolute;top:940px;left:106px;white-space:nowrap" class="ft2004">In patients with moderately to severely active paediatric Crohn’s disease, the rate of anti-adalimumab&#160;<br/>antibody development in patients receiving adalimumab was 3.3%.&#160;</p>
<p style="position:absolute;top:997px;left:106px;white-space:nowrap" class="ft2005">In&#160;adult&#160;patients with non-infectious uveitis, anti-adalimumab antibodies were identified in 4.8% (12/249)&#160;<br/>of patients treated with adalimumab.</p>
<p style="position:absolute;top:1054px;left:106px;white-space:nowrap" class="ft2005">In patients with moderately to severely active paediatric ulcerative colitis, the rate of anti-adalimumab&#160;<br/>antibody development in patients receiving adalimumab was&#160;3%.</p>
</div>
<!-- Page 201 -->
<a name="201"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page201-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2010">201</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft2014">Because immunogenicity analyses are product-specific, comparison of antibody rates with those from&#160;<br/>other products is not appropriate.</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft2012">Paediatric population</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft2013"><i>Juvenile idiopathic arthritis&#160;(JIA)</i></p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft2013"><i>Polyarticular juvenile&#160;idiopathic&#160;arthritis (pJIA)</i></p>
<p style="position:absolute;top:276px;left:106px;white-space:nowrap" class="ft2015">The safety and efficacy of Humira was assessed in two studies (pJIA I and II) in children with active&#160;<br/>polyarticular or polyarticular course juvenile idiopathic arthritis, who had a variety of JIA onset types&#160;<br/>(most frequently rheumatoid-factor negative or positive polyarthritis and extended oligoarthritis).</p>
<p style="position:absolute;top:352px;left:106px;white-space:nowrap" class="ft2012">pJIA I</p>
<p style="position:absolute;top:384px;left:106px;white-space:nowrap" class="ft2017">The safety and efficacy of Humira were assessed in a multicentre, randomised, double-blind,&#160;<br/>parallel&#160;−&#160;group study in 171&#160;children&#160;(4-17&#160;years&#160;old) with polyarticular JIA. In the open-label lead in&#160;<br/>phase (OL LI) patients were stratified into two groups, MTX (methotrexate)-treated or non-MTX-treated.&#160;<br/>Patients who were in the non-MTX stratum were either naïve to or had been withdrawn from MTX at&#160;<br/>least two weeks prior to study drug administration. Patients remained on stable doses of NSAIDs and or&#160;<br/>prednisone (</p>
<p style="position:absolute;top:478px;left:188px;white-space:nowrap" class="ft2016">&#160;0.2&#160;mg/kg/day or 10&#160;mg/day maximum). In the OL LI phase all patients received 24&#160;mg/m2&#160;</p>
<p style="position:absolute;top:499px;left:106px;white-space:nowrap" class="ft2014">up to a maximum of 40&#160;mg Humira every other week for 16&#160;weeks. &#160;The distribution of patients by age&#160;<br/>and minimum, median and maximum dose received during the OL LI phase is presented in Table&#160;25.</p>
<p style="position:absolute;top:556px;left:431px;white-space:nowrap" class="ft2011"><b>Table&#160;25</b></p>
<p style="position:absolute;top:575px;left:157px;white-space:nowrap" class="ft2011"><b>Distribution of patients by age and adalimumab dose received during the OL LI phase</b></p>
<p style="position:absolute;top:616px;left:122px;white-space:nowrap" class="ft2012">Age&#160;Group</p>
<p style="position:absolute;top:616px;left:304px;white-space:nowrap" class="ft2014">Number of patients at Baseline&#160;<br/>n&#160;(%)</p>
<p style="position:absolute;top:616px;left:568px;white-space:nowrap" class="ft2014">Minimum, median and maximum&#160;<br/>dose</p>
<p style="position:absolute;top:654px;left:122px;white-space:nowrap" class="ft2012">4 to 7&#160;years</p>
<p style="position:absolute;top:654px;left:304px;white-space:nowrap" class="ft2012">31 (18.1)</p>
<p style="position:absolute;top:654px;left:568px;white-space:nowrap" class="ft2012">10, 20 and 25&#160;mg</p>
<p style="position:absolute;top:683px;left:122px;white-space:nowrap" class="ft2012">8 to 12&#160;years</p>
<p style="position:absolute;top:683px;left:304px;white-space:nowrap" class="ft2012">71 (41.5)</p>
<p style="position:absolute;top:683px;left:568px;white-space:nowrap" class="ft2012">20, 25 and 40&#160;mg</p>
<p style="position:absolute;top:702px;left:122px;white-space:nowrap" class="ft2012">13 to 17&#160;years</p>
<p style="position:absolute;top:702px;left:304px;white-space:nowrap" class="ft2012">69 (40.4)</p>
<p style="position:absolute;top:702px;left:568px;white-space:nowrap" class="ft2012">25, 40 and 40&#160;mg</p>
<p style="position:absolute;top:741px;left:106px;white-space:nowrap" class="ft2017">Patients demonstrating a Paediatric ACR 30 response&#160;at Week&#160;16 were eligible to be randomised into the&#160;<br/>double blind (DB) phase and received either Humira 24&#160;mg/m2&#160;up to a maximum of 40&#160;mg, or placebo&#160;<br/>every other week for an additional 32&#160;weeks or until disease flare. Disease flare criteria were defined as a<br/>worsening of&#160;</p>
<p style="position:absolute;top:797px;left:197px;white-space:nowrap" class="ft2016">&#160;30% from baseline in&#160;&#160;3 of 6 Paediatric ACR core criteria,&#160;&#160;2 active joints, and&#160;</p>
<p style="position:absolute;top:820px;left:106px;white-space:nowrap" class="ft2012">improvement of&#160;</p>
<p style="position:absolute;top:818px;left:216px;white-space:nowrap" class="ft2016">&#160;30% in no more than 1 of the 6 criteria. After 32&#160;weeks or at disease flare, patients&#160;</p>
<p style="position:absolute;top:838px;left:106px;white-space:nowrap" class="ft2012">were&#160;eligible to enrol into the open label extension phase.&#160;</p>
</div>
<!-- Page 202 -->
<a name="202"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page202-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2020">202</p>
<p style="position:absolute;top:86px;left:431px;white-space:nowrap" class="ft2021"><b>Table&#160;26</b></p>
<p style="position:absolute;top:105px;left:321px;white-space:nowrap" class="ft2021"><b>Ped ACR 30 Responses in the JIA study</b></p>
<p style="position:absolute;top:144px;left:122px;white-space:nowrap" class="ft2021"><b>Stratum</b></p>
<p style="position:absolute;top:144px;left:406px;white-space:nowrap" class="ft2021"><b>MTX</b></p>
<p style="position:absolute;top:144px;left:629px;white-space:nowrap" class="ft2021"><b>Without MTX</b></p>
<p style="position:absolute;top:163px;left:122px;white-space:nowrap" class="ft20219"><b>Phase<br/></b>OL-LI 16 weeks</p>
<p style="position:absolute;top:203px;left:165px;white-space:nowrap" class="ft2024">Ped ACR 30&#160;<br/>response (n/N)</p>
<p style="position:absolute;top:203px;left:378px;white-space:nowrap" class="ft2022">94.1% (80/85)</p>
<p style="position:absolute;top:203px;left:631px;white-space:nowrap" class="ft2022">74.4% (64/86)</p>
<p style="position:absolute;top:242px;left:122px;white-space:nowrap" class="ft2024">&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;Efficacy Outcomes<br/>Double Blind&#160;32&#160;weeks</p>
<p style="position:absolute;top:261px;left:304px;white-space:nowrap" class="ft2025">Humira /MTX<br/>(N = 38)</p>
<p style="position:absolute;top:261px;left:436px;white-space:nowrap" class="ft2025">Placebo / MTX<br/>(N = 37)</p>
<p style="position:absolute;top:261px;left:568px;white-space:nowrap" class="ft2025">Humira&#160;<br/>(N = 30)</p>
<p style="position:absolute;top:261px;left:692px;white-space:nowrap" class="ft2025">Placebo<br/>(N = 28)</p>
<p style="position:absolute;top:319px;left:165px;white-space:nowrap" class="ft2025">Disease flares at&#160;<br/>the end of&#160;<br/>32&#160;weeksa&#160;(n/N)</p>
<p style="position:absolute;top:319px;left:304px;white-space:nowrap" class="ft2022">36.8% (14/38)</p>
<p style="position:absolute;top:319px;left:436px;white-space:nowrap" class="ft2022">64.9% (24/37)b</p>
<p style="position:absolute;top:319px;left:568px;white-space:nowrap" class="ft2022">43.3% (13/30)</p>
<p style="position:absolute;top:319px;left:692px;white-space:nowrap" class="ft2024">71.4%&#160;<br/>(20/28)c</p>
<p style="position:absolute;top:377px;left:165px;white-space:nowrap" class="ft2024">Median time to&#160;<br/>disease flare</p>
<p style="position:absolute;top:377px;left:304px;white-space:nowrap" class="ft2022">&gt;32&#160;weeks</p>
<p style="position:absolute;top:377px;left:436px;white-space:nowrap" class="ft2022">20&#160;weeks</p>
<p style="position:absolute;top:377px;left:568px;white-space:nowrap" class="ft2022">&gt;32&#160;weeks</p>
<p style="position:absolute;top:377px;left:692px;white-space:nowrap" class="ft2022">14&#160;weeks</p>
<p style="position:absolute;top:435px;left:114px;white-space:nowrap" class="ft2029">a&#160;Ped ACR 30/50/70 responses Week&#160;48 significantly greater than those of placebo treated patients&#160;</p>
<p style="position:absolute;top:454px;left:114px;white-space:nowrap" class="ft2029">b&#160;p = 0.015</p>
<p style="position:absolute;top:472px;left:114px;white-space:nowrap" class="ft2029">c&#160;p = 0.031</p>
<p style="position:absolute;top:512px;left:106px;white-space:nowrap" class="ft2024">Amongst those who responded at Week&#160;16 (n=144), the Paediatric ACR 30/50/70/90 responses were&#160;<br/>maintained for up to six&#160;years in the OLE phase in patients who received Humira throughout the study.<br/>Over all 19&#160;subjects, of which 11 of the baseline age group 4 to 12 and 8 of the baseline age group 13 to&#160;<br/>17&#160;years were treated 6&#160;years or longer.</p>
<p style="position:absolute;top:607px;left:106px;white-space:nowrap" class="ft2025">Overall responses were generally better and, fewer patients developed antibodies when treated with the&#160;<br/>combination of Humira and MTX compared to Humira alone. Taking these results into consideration,&#160;<br/>Humira is recommended for use in combination with MTX and for use as monotherapy in patients for&#160;<br/>whom MTX use is not appropriate (see section 4.2).</p>
<p style="position:absolute;top:702px;left:106px;white-space:nowrap" class="ft2022">pJIA II</p>
<p style="position:absolute;top:739px;left:106px;white-space:nowrap" class="ft2024">The safety and efficacy of Humira was assessed in an open-label, multicentre study in 32&#160;children&#160;<br/>(2&#160;-&#160;&lt;&#160;4&#160;years&#160;old or&#160;aged 4 and above weighing &lt;&#160;15&#160;kg) with moderately to severely active polyarticular&#160;<br/>JIA. The patients&#160;received 24&#160;mg/m2&#160;body surface area (BSA) of Humira up to a maximum of 20&#160;mg&#160;<br/>every other week as a single dose via SC injection for at least 24&#160;weeks. During the study, most subjects&#160;<br/>used concomitant MTX, with fewer reporting use of corticosteroids or NSAIDs.</p>
<p style="position:absolute;top:853px;left:106px;white-space:nowrap" class="ft2024">At Week&#160;12 and Week&#160;24, PedACR30 response was 93.5% and 90.0%, respectively, using the observed&#160;<br/>data approach. The proportions of subjects with PedACR50/70/90 at Week&#160;12 and Week&#160;24 were&#160;<br/>90.3%/61.3%/38.7% and 83.3%/73.3%/36.7%, respectively. Amongst those who responded (Paediatric&#160;<br/>ACR 30) at Week&#160;24 (n=27 out of 30 patients), the Paediatric ACR 30 responses were maintained for up&#160;<br/>to 60&#160;weeks in the OLE phase in patients who received Humira throughout this time period. Overall,&#160;<br/>20&#160;subjects were treated for 60&#160;weeks or longer.</p>
<p style="position:absolute;top:986px;left:106px;white-space:nowrap" class="ft2023"><i>Enthesitis-related arthritis</i></p>
<p style="position:absolute;top:1024px;left:106px;white-space:nowrap" class="ft2024">The safety and efficacy of Humira were assessed in a&#160;multicentre, randomised, double-blind study in 46&#160;<br/>paediatric patients (6 to 17&#160;years&#160;old)&#160;with&#160;moderate&#160;enthesitis-related arthritis. Patients were randomised&#160;<br/>to receive either 24&#160;mg/m2&#160;body surface area (BSA) of Humira up to a maximum of 40&#160;mg, or placebo&#160;<br/>every other week for 12&#160;weeks. The double-blind period is followed by an open-label (OL) period during&#160;</p>
</div>
<!-- Page 203 -->
<a name="203"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page203-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2030">203</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft2034">which patients received&#160;24&#160;mg/m2&#160;BSA of Humira up to a maximum of 40&#160;mg&#160;every other week&#160;<br/>subcutaneously for up to an additional 192&#160;weeks. The primary endpoint was the percent change from&#160;<br/>Baseline to Week&#160;12 in the number of active joints with arthritis (swelling not due to deformity or joints&#160;<br/>with loss of motion plus pain and/or tenderness), which was achieved with mean percent decrease of&#160;-<br/>62.6% (median percent change&#160;-88.9%) in patients in the Humira group compared to&#160;-11.6% (median&#160;<br/>percent change&#160;-50.0%) in patients in the placebo group. Improvement in number of active joints with&#160;<br/>arthritis was maintained during the OL period through Week&#160;156 for the 26 of 31 (84%) patients in the&#160;<br/>Humira group who remained in the study. Although not statistically significant, the majority of patients&#160;<br/>demonstrated clinical improvement in secondary endpoints such as number of sites of enthesitis, tender&#160;<br/>joint count (TJC), swollen joint count (SJC), Paediatric ACR 50 response, and Paediatric ACR 70&#160;<br/>response.</p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft2033"><i>Paediatric&#160;plaque psoriasis</i></p>
<p style="position:absolute;top:352px;left:106px;white-space:nowrap" class="ft2035">The&#160;efficacy of Humira was assessed in a randomised, double-blind, controlled study of 114 paediatric&#160;<br/>patients from 4&#160;years of age with severe chronic plaque psoriasis (as defined by a PGA&#160;≥ 4 or &gt;&#160;20% BSA&#160;<br/>involvement or &gt;&#160;10% BSA involvement with very thick lesions or PASI&#160;≥&#160;20 or&#160;≥&#160;10 with clinically&#160;<br/>relevant facial, genital, or hand/ foot involvement) who were inadequately controlled with topical therapy&#160;<br/>and heliotherapy or phototherapy.&#160;</p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft2035">Patients received Humira 0.8&#160;mg/kg&#160;eow (up to&#160;40&#160;mg), 0.4&#160;mg/kg&#160;eow (up to 20&#160;mg), or methotrexate&#160;<br/>0.1-&#160;0.4&#160;mg/kg&#160;weekly (up to 25&#160;mg). &#160; At Week&#160;16, more patients randomised to Humira 0.8&#160;mg/kg had&#160;<br/>positive efficacy responses (e.g., PASI 75) than those randomised to 0.4&#160;mg/kg eow or MTX. &#160;</p>
<p style="position:absolute;top:543px;left:221px;white-space:nowrap" class="ft2031"><b>Table&#160;27:&#160;Paediatric Plaque Psoriasis Efficacy Results at 16&#160;Weeks</b></p>
<p style="position:absolute;top:565px;left:451px;white-space:nowrap" class="ft2032">MTXa</p>
<p style="position:absolute;top:584px;left:453px;white-space:nowrap" class="ft2032">N=37&#160;</p>
<p style="position:absolute;top:565px;left:578px;white-space:nowrap" class="ft2032">Humira 0.8&#160;mg/kg&#160;eow</p>
<p style="position:absolute;top:584px;left:635px;white-space:nowrap" class="ft2032">N=38&#160;</p>
<p style="position:absolute;top:606px;left:162px;white-space:nowrap" class="ft2032">PASI 75b</p>
<p style="position:absolute;top:606px;left:435px;white-space:nowrap" class="ft2032">12 (32.4%)</p>
<p style="position:absolute;top:606px;left:617px;white-space:nowrap" class="ft2032">22 (57.9%)</p>
<p style="position:absolute;top:629px;left:162px;white-space:nowrap" class="ft2032">PGA: Clear/minimalc</p>
<p style="position:absolute;top:629px;left:435px;white-space:nowrap" class="ft2032">15 (40.5%)</p>
<p style="position:absolute;top:629px;left:617px;white-space:nowrap" class="ft2032">23 (60.5%)</p>
<p style="position:absolute;top:649px;left:145px;white-space:nowrap" class="ft2039">a&#160;MTX = methotrexate</p>
<p style="position:absolute;top:669px;left:145px;white-space:nowrap" class="ft2039">b&#160;P=0.027, Humira 0.8&#160;mg/kg versus MTX</p>
<p style="position:absolute;top:687px;left:145px;white-space:nowrap" class="ft2039">c&#160;P=0.083, Humira 0.8&#160;mg/kg versus MTX</p>
<p style="position:absolute;top:729px;left:106px;white-space:nowrap" class="ft2034">Patients who achieved PASI 75 and PGA clear or minimal were withdrawn from treatment for up to&#160;<br/>36&#160;weeks and monitored for loss of disease control (i.e. a worsening of PGA by at least 2 grades). &#160;Patients&#160;<br/>were then&#160;re-treated with adalimumab 0.8&#160;mg/kg eow for an additional 16&#160;weeks and response rates&#160;<br/>observed during retreatment were similar to the previous double-blind period: &#160;PASI 75 response of 78.9%&#160;<br/>(15 of 19 subjects) and PGA clear or minimal of 52.6% (10 of 19&#160;subjects).</p>
<p style="position:absolute;top:843px;left:106px;white-space:nowrap" class="ft2034">In the open label period of the study, PASI 75 and PGA clear or minimal responses were maintained for&#160;<br/>up to an additional 52&#160;weeks with no&#160;new safety findings.</p>
<p style="position:absolute;top:900px;left:106px;white-space:nowrap" class="ft2033"><i>Adolescent hidradenitis suppurativa</i></p>
<p style="position:absolute;top:938px;left:106px;white-space:nowrap" class="ft2034">There are no clinical trials with Humira in&#160;adolescent patients with HS. &#160;Efficacy of adalimumab for the&#160;<br/>treatment of adolescent patients with HS is predicted based on the demonstrated efficacy and exposure-<br/>response relationship in adult HS patients and the likelihood that the disease course, pathophysiology, and&#160;<br/>drug effects are substantially similar to that of adults at the same exposure levels. Safety of the&#160;<br/>recommended adalimumab dose in the adolescent HS population is based on cross-indication safety&#160;<br/>profile of adalimumab in both adults and paediatric patients at similar or more frequent doses&#160;(see section&#160;<br/>5.2).</p>
</div>
<!-- Page 204 -->
<a name="204"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page204-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2040">204</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft2043"><i>Paediatric Crohn’s disease</i></p>
<p style="position:absolute;top:119px;left:106px;white-space:nowrap" class="ft2045">Humira was assessed in a multicentre, randomised, double-blind clinical trial designed to evaluate the&#160;<br/>efficacy and safety of induction and maintenance treatment with doses dependent on body weight (&lt;&#160;40&#160;kg&#160;<br/>or&#160;≥&#160;40&#160;kg) in 192 paediatric subjects between the ages of 6 and 17 (inclusive) years, with moderate to&#160;<br/>severe Crohn´s disease (CD) defined as Paediatric Crohn's Disease Activity Index (PCDAI) score &gt;&#160;30. &#160;<br/>Subjects had to have failed conventional therapy (including a corticosteroid and/or an immunomodulator)&#160;<br/>for CD. Subjects may also have previously lost response or been intolerant to infliximab.&#160;</p>
<p style="position:absolute;top:252px;left:106px;white-space:nowrap" class="ft2044">All subjects received open-label induction therapy at a dose&#160;based on their Baseline body weight: 160&#160;mg&#160;<br/>at Week&#160;0 and 80&#160;mg at Week&#160;2 for subjects&#160;≥&#160;40&#160;kg, and 80&#160;mg and 40&#160;mg, respectively, for subjects&#160;<br/>&lt;&#160;40&#160;kg.</p>
<p style="position:absolute;top:328px;left:106px;white-space:nowrap" class="ft2045">At Week&#160;4, subjects were randomised 1:1 based on their body weight at the time to either the Low Dose&#160;or&#160;<br/>Standard Dose maintenance regimens as shown in Table&#160;28.</p>
<p style="position:absolute;top:384px;left:428px;white-space:nowrap" class="ft2041"><b>Table&#160;28</b></p>
<p style="position:absolute;top:403px;left:382px;white-space:nowrap" class="ft2041"><b>Maintenance regimen</b></p>
<p style="position:absolute;top:423px;left:339px;white-space:nowrap" class="ft20419"><b>Patient&#160;<br/>Weight</b></p>
<p style="position:absolute;top:423px;left:413px;white-space:nowrap" class="ft2041"><b>Low dose</b></p>
<p style="position:absolute;top:423px;left:504px;white-space:nowrap" class="ft20419"><b>Standard&#160;<br/>dose</b></p>
<p style="position:absolute;top:462px;left:339px;white-space:nowrap" class="ft2042">&lt;&#160;40 kg</p>
<p style="position:absolute;top:462px;left:413px;white-space:nowrap" class="ft2042">10&#160;mg&#160;eow&#160;20&#160;mg&#160;eow</p>
<p style="position:absolute;top:481px;left:339px;white-space:nowrap" class="ft2042">≥&#160;40 kg</p>
<p style="position:absolute;top:481px;left:413px;white-space:nowrap" class="ft2042">20&#160;mg&#160;eow&#160;40&#160;mg&#160;eow</p>
<p style="position:absolute;top:520px;left:106px;white-space:nowrap" class="ft2043"><i>Efficacy results</i></p>
<p style="position:absolute;top:559px;left:106px;white-space:nowrap" class="ft2042">The primary endpoint of the study was clinical remission at Week&#160;26, defined as PCDAI score&#160;</p>
<p style="position:absolute;top:558px;left:734px;white-space:nowrap" class="ft2046">&#160;10.</p>
<p style="position:absolute;top:597px;left:106px;white-space:nowrap" class="ft2044">Clinical remission and clinical response (defined as reduction in PCDAI score of at least 15 points from&#160;<br/>Baseline) rates are presented in Table&#160;29. Rates of&#160;discontinuation of corticosteroids or&#160;<br/>immunomodulators are presented in Table&#160;30.</p>
<p style="position:absolute;top:676px;left:429px;white-space:nowrap" class="ft2041"><b>Table&#160;29</b></p>
<p style="position:absolute;top:695px;left:386px;white-space:nowrap" class="ft2041"><b>Paediatric CD Study</b></p>
<p style="position:absolute;top:714px;left:315px;white-space:nowrap" class="ft2041"><b>PCDAI Clinical Remission and Response</b></p>
<p style="position:absolute;top:734px;left:392px;white-space:nowrap" class="ft2041"><b>Standard Dose</b></p>
<p style="position:absolute;top:753px;left:396px;white-space:nowrap" class="ft2041"><b>40/20 mg eow&#160;</b></p>
<p style="position:absolute;top:772px;left:421px;white-space:nowrap" class="ft2041"><b>N = 93</b></p>
<p style="position:absolute;top:734px;left:529px;white-space:nowrap" class="ft2041"><b>Low Dose</b></p>
<p style="position:absolute;top:753px;left:516px;white-space:nowrap" class="ft2041"><b>20/10 mg eow&#160;</b></p>
<p style="position:absolute;top:772px;left:541px;white-space:nowrap" class="ft2041"><b>N = 95</b></p>
<p style="position:absolute;top:734px;left:637px;white-space:nowrap" class="ft2041"><b>P value</b>*</p>
<p style="position:absolute;top:792px;left:210px;white-space:nowrap" class="ft20421"><b>Week&#160;26<br/></b>&#160; &#160;Clinical remission</p>
<p style="position:absolute;top:812px;left:423px;white-space:nowrap" class="ft2042">38.7%</p>
<p style="position:absolute;top:812px;left:543px;white-space:nowrap" class="ft2042">28.4%</p>
<p style="position:absolute;top:812px;left:648px;white-space:nowrap" class="ft2042">0.075</p>
<p style="position:absolute;top:832px;left:210px;white-space:nowrap" class="ft2042">&#160; &#160;Clinical response&#160;</p>
<p style="position:absolute;top:832px;left:423px;white-space:nowrap" class="ft2042">59.1%</p>
<p style="position:absolute;top:832px;left:543px;white-space:nowrap" class="ft2042">48.4%</p>
<p style="position:absolute;top:832px;left:648px;white-space:nowrap" class="ft2042">0.073</p>
<p style="position:absolute;top:852px;left:210px;white-space:nowrap" class="ft20421"><b>Week&#160;52<br/></b>&#160; &#160;Clinical remission</p>
<p style="position:absolute;top:873px;left:423px;white-space:nowrap" class="ft2042">33.3%</p>
<p style="position:absolute;top:873px;left:543px;white-space:nowrap" class="ft2042">23.2%</p>
<p style="position:absolute;top:873px;left:648px;white-space:nowrap" class="ft2042">0.100</p>
<p style="position:absolute;top:893px;left:210px;white-space:nowrap" class="ft2042">&#160; &#160;Clinical response</p>
<p style="position:absolute;top:893px;left:423px;white-space:nowrap" class="ft2042">41.9%</p>
<p style="position:absolute;top:893px;left:543px;white-space:nowrap" class="ft2042">28.4%</p>
<p style="position:absolute;top:893px;left:648px;white-space:nowrap" class="ft2042">0.038</p>
<p style="position:absolute;top:913px;left:210px;white-space:nowrap" class="ft2042">*&#160;p value for Standard Dose&#160;<i>versus&#160;</i>Low Dose comparison.</p>
</div>
<!-- Page 205 -->
<a name="205"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page205-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2050">205</p>
<p style="position:absolute;top:87px;left:428px;white-space:nowrap" class="ft2051"><b>Table&#160;30</b></p>
<p style="position:absolute;top:106px;left:386px;white-space:nowrap" class="ft2051"><b>Paediatric CD&#160;Study</b></p>
<p style="position:absolute;top:125px;left:175px;white-space:nowrap" class="ft2051"><b>Discontinuation of Corticosteroids or Immunomodulators and Fistula Remission</b></p>
<p style="position:absolute;top:145px;left:455px;white-space:nowrap" class="ft2051"><b>Standard Dose</b></p>
<p style="position:absolute;top:164px;left:459px;white-space:nowrap" class="ft2051"><b>40/20&#160;mg&#160;eow&#160;</b></p>
<p style="position:absolute;top:145px;left:595px;white-space:nowrap" class="ft2051"><b>Low Dose</b></p>
<p style="position:absolute;top:164px;left:582px;white-space:nowrap" class="ft2051"><b>20/10&#160;mg&#160;eow&#160;</b></p>
<p style="position:absolute;top:145px;left:705px;white-space:nowrap" class="ft2051"><b>P value1</b></p>
<p style="position:absolute;top:184px;left:143px;white-space:nowrap" class="ft2051"><b>Discontinued corticosteroids</b></p>
<p style="position:absolute;top:184px;left:486px;white-space:nowrap" class="ft2051"><b>N= 33</b></p>
<p style="position:absolute;top:184px;left:611px;white-space:nowrap" class="ft2051"><b>N=38</b></p>
<p style="position:absolute;top:204px;left:143px;white-space:nowrap" class="ft2052">Week&#160;26</p>
<p style="position:absolute;top:204px;left:486px;white-space:nowrap" class="ft2052">84.8%</p>
<p style="position:absolute;top:204px;left:608px;white-space:nowrap" class="ft2052">65.8%</p>
<p style="position:absolute;top:204px;left:715px;white-space:nowrap" class="ft2052">0.066</p>
<p style="position:absolute;top:224px;left:143px;white-space:nowrap" class="ft2052">Week&#160;52</p>
<p style="position:absolute;top:224px;left:486px;white-space:nowrap" class="ft2052">69.7%</p>
<p style="position:absolute;top:224px;left:608px;white-space:nowrap" class="ft2052">60.5%</p>
<p style="position:absolute;top:224px;left:715px;white-space:nowrap" class="ft2052">0.420</p>
<p style="position:absolute;top:244px;left:143px;white-space:nowrap" class="ft2051"><b>Discontinuation of Immunomodulators2</b></p>
<p style="position:absolute;top:244px;left:488px;white-space:nowrap" class="ft2051"><b>N=60</b></p>
<p style="position:absolute;top:244px;left:611px;white-space:nowrap" class="ft2051"><b>N=57</b></p>
<p style="position:absolute;top:265px;left:143px;white-space:nowrap" class="ft2052">Week&#160;52</p>
<p style="position:absolute;top:265px;left:486px;white-space:nowrap" class="ft2052">30.0%</p>
<p style="position:absolute;top:265px;left:608px;white-space:nowrap" class="ft2052">29.8%</p>
<p style="position:absolute;top:265px;left:715px;white-space:nowrap" class="ft2052">0.983</p>
<p style="position:absolute;top:285px;left:143px;white-space:nowrap" class="ft2051"><b>Fistula remission3</b></p>
<p style="position:absolute;top:285px;left:488px;white-space:nowrap" class="ft2051"><b>N=15</b></p>
<p style="position:absolute;top:285px;left:611px;white-space:nowrap" class="ft2051"><b>N=21</b></p>
<p style="position:absolute;top:305px;left:143px;white-space:nowrap" class="ft2052">Week&#160;26</p>
<p style="position:absolute;top:305px;left:486px;white-space:nowrap" class="ft2052">46.7%</p>
<p style="position:absolute;top:305px;left:608px;white-space:nowrap" class="ft2052">38.1%</p>
<p style="position:absolute;top:305px;left:715px;white-space:nowrap" class="ft2052">0.608</p>
<p style="position:absolute;top:325px;left:143px;white-space:nowrap" class="ft2052">Week&#160;52</p>
<p style="position:absolute;top:325px;left:486px;white-space:nowrap" class="ft2052">40.0%</p>
<p style="position:absolute;top:325px;left:608px;white-space:nowrap" class="ft2052">23.8%</p>
<p style="position:absolute;top:325px;left:715px;white-space:nowrap" class="ft2052">0.303</p>
<p style="position:absolute;top:343px;left:143px;white-space:nowrap" class="ft2059">1&#160;&#160;p value for Standard Dose&#160;<i>versus&#160;</i>Low Dose comparison.</p>
<p style="position:absolute;top:362px;left:143px;white-space:nowrap" class="ft2057">2&#160;&#160;Immunosuppressant therapy could only be discontinued at or after Week&#160;26 at the&#160;<br/>investigator's discretion if the subject met the clinical response criterion&#160;</p>
<p style="position:absolute;top:400px;left:143px;white-space:nowrap" class="ft2057">3&#160;defined as a closure of all fistulas that were draining at Baseline for at least 2 consecutive<br/>post-Baseline visits</p>
<p style="position:absolute;top:458px;left:106px;white-space:nowrap" class="ft2054">Statistically significant&#160;increases (improvement) from Baseline to Week&#160;26 and 52 in Body Mass Index&#160;<br/>and height velocity were observed for both treatment groups.</p>
<p style="position:absolute;top:516px;left:106px;white-space:nowrap" class="ft2055">Statistically and clinically significant improvements from Baseline were also observed in both treatment&#160;<br/>groups for quality of life parameters (including IMPACT III).</p>
<p style="position:absolute;top:572px;left:106px;white-space:nowrap" class="ft2054">One&#160;hundred patients (n=100) from the Paediatric CD Study continued in an open-label long-term&#160;<br/>extension study. &#160;After 5 years of adalimumab therapy, 74.0%&#160;(37/50) of the 50 patients remaining in the&#160;<br/>study continued to be in clinical remission, and 92.0% (46/50) of patients continued to be in clinical&#160;<br/>response per PCDAI.</p>
<p style="position:absolute;top:667px;left:106px;white-space:nowrap" class="ft2053"><i>Paediatric ulcerative colitis</i></p>
<p style="position:absolute;top:705px;left:106px;white-space:nowrap" class="ft2054">The safety and efficacy of Humira was assessed in a multicenter, randomized, double-blind, trial in 93&#160;<br/>paediatric patients from 5 to 17 years of age with moderate to severe ulcerative colitis (Mayo score 6 to 12&#160;<br/>with endoscopy subscore of 2 to 3 points, confirmed by centrally read endoscopy) who had an inadequate&#160;<br/>response or intolerance to conventional therapy. Approximately 16% of patients in the study had failed&#160;<br/>prior anti-TNF treatment. Patients who received corticosteroids at enrollment were allowed to taper their&#160;<br/>corticosteroid therapy after Week 4.</p>
<p style="position:absolute;top:838px;left:106px;white-space:nowrap" class="ft2055">In the&#160;induction period of the study,&#160;77&#160;patients were randomized 3:2 to receive double-blind treatment&#160;<br/>with&#160;Humira at&#160;an&#160;induction dose of 2.4 mg/kg (maximum of 160 mg) at Week 0 and Week 1, and 1.2&#160;<br/>mg/kg (maximum of 80 mg) at Week 2; or an&#160;induction dose of 2.4&#160;mg/kg (maximum of 160 mg) at Week&#160;<br/>0, placebo at Week 1, and 1.2 mg/kg (maximum of 80 mg) at Week 2.&#160;Both groups received 0.6 mg/kg&#160;<br/>(maximum of 40 mg) at Week 4 and Week 6.&#160;Following an amendment to the study design, the remaining&#160;<br/>16 patients who enrolled&#160;in the induction period received open-label treatment with&#160;Humira&#160;at the&#160;<br/>induction dose&#160;of 2.4 mg/kg (maximum of 160 mg) at Week 0 and Week 1, and 1.2 mg/kg (maximum of&#160;<br/>80 mg) at Week 2.</p>
<p style="position:absolute;top:1009px;left:106px;white-space:nowrap" class="ft2054">At Week 8, 62 patients who demonstrated&#160;clinical response per&#160;Partial Mayo Score (PMS;&#160;defined as a&#160;<br/>decrease in PMS&#160;≥ 2 points and ≥ 30% from Baseline)&#160;were randomized equally to receive double-blind&#160;<br/>maintenance treatment&#160;with Humira&#160;at a dose&#160;of 0.6 mg/kg (maximum of 40 mg) every week&#160;(ew),&#160;or&#160;a&#160;<br/>maintenance dose of 0.6&#160;mg/kg (maximum of 40 mg) every other&#160;week (eow).&#160;Prior to an amendment to&#160;</p>
</div>
<!-- Page 206 -->
<a name="206"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page206-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2060">206</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft2065">the study design, 12 additional patients who demonstrated clinical response per PMS were randomized to&#160;<br/>receive&#160;placebo&#160;but were not included in&#160;the confirmatory&#160;analysis of efficacy.</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft2065">Disease flare was defined as an increase in&#160;PMS&#160;of&#160;at least&#160;3 points (for patients with PMS of 0 to 2 at&#160;<br/>Week 8),&#160;at least&#160;2 points (for patients with PMS of 3 to 4 at Week 8), or&#160;at least&#160;1 point (for patients with&#160;<br/>PMS of 5 to 6 at Week 8).</p>
<p style="position:absolute;top:219px;left:106px;white-space:nowrap" class="ft2064">Patients who&#160;met criteria for disease flare&#160;at or after Week 12&#160;were randomized to receive a re-induction&#160;<br/>dose of 2.4 mg/kg (maximum of 160 mg) or a dose of 0.6 mg/kg (maximum of 40 mg) and continued to&#160;<br/>receive their respective maintenance dose regimen afterwards.</p>
<p style="position:absolute;top:300px;left:106px;white-space:nowrap" class="ft2063"><i>Efficacy Results</i></p>
<p style="position:absolute;top:347px;left:106px;white-space:nowrap" class="ft2064">The co-primary endpoints of the study were clinical remission per PMS (defined as PMS&#160;≤ 2 and no&#160;<br/>individual subscore &gt; 1) at Week 8, and clinical remission per FMS (Full Mayo Score) (defined as a Mayo&#160;<br/>Score&#160;≤ 2 and no individual subscore&#160;&gt; 1) at Week 52 in patients who achieved clinical response per PMS&#160;<br/>at Week 8.</p>
<p style="position:absolute;top:442px;left:106px;white-space:nowrap" class="ft2064">Clinical remission rates per PMS at Week 8 for&#160;patients&#160;in&#160;each&#160;of the&#160;Humira&#160;double-<br/>blind&#160;induction&#160;groups&#160;are&#160;presented in&#160;Table&#160;31.</p>
<p style="position:absolute;top:498px;left:284px;white-space:nowrap" class="ft2061"><b>Table&#160;31: Clinical Remission per PMS at&#160;8 Weeks&#160;</b></p>
<p style="position:absolute;top:542px;left:387px;white-space:nowrap" class="ft2061"><b>Humiraa</b></p>
<p style="position:absolute;top:561px;left:315px;white-space:nowrap" class="ft2061"><b>Maximum&#160;of&#160;160 mg&#160;at Week&#160;</b></p>
<p style="position:absolute;top:582px;left:342px;white-space:nowrap" class="ft2061"><b>0&#160;/&#160;Placebo&#160;at Week 1</b></p>
<p style="position:absolute;top:604px;left:400px;white-space:nowrap" class="ft2062">N=30</p>
<p style="position:absolute;top:542px;left:607px;white-space:nowrap" class="ft2061"><b>Humirab, c</b></p>
<p style="position:absolute;top:561px;left:540px;white-space:nowrap" class="ft2061"><b>Maximum of 160 mg&#160;at Week&#160;</b></p>
<p style="position:absolute;top:582px;left:594px;white-space:nowrap" class="ft2061"><b>0&#160;and&#160;Week 1</b></p>
<p style="position:absolute;top:604px;left:626px;white-space:nowrap" class="ft2062">N=47</p>
<p style="position:absolute;top:630px;left:161px;white-space:nowrap" class="ft2062">Clinical remission</p>
<p style="position:absolute;top:630px;left:372px;white-space:nowrap" class="ft2062">13/30 (43.3%)</p>
<p style="position:absolute;top:630px;left:597px;white-space:nowrap" class="ft2062">28/47 (59.6%)</p>
<p style="position:absolute;top:653px;left:161px;white-space:nowrap" class="ft2067">a&#160;Humira&#160;2.4 mg/kg&#160;(maximum of 160 mg)&#160;at Week 0, placebo at Week 1,&#160;and&#160;1.2&#160;<br/>mg/kg&#160;(maximum of 80 mg)&#160;at Week 2</p>
<p style="position:absolute;top:691px;left:161px;white-space:nowrap" class="ft2067">b&#160;Humira&#160;2.4 mg/kg&#160;(maximum&#160;of 160 mg)&#160;at Week 0 and Week 1,&#160;and&#160;1.2&#160;<br/>mg/kg&#160;(maximum of 80 mg)&#160;at Week 2</p>
<p style="position:absolute;top:729px;left:161px;white-space:nowrap" class="ft2064">c&#160;Not including open-label Induction dose of&#160;Humira&#160;2.4 mg/kg&#160;(maximum&#160;of 160 mg)&#160;at&#160;<br/>Week 0 and Week 1, and 1.2 mg/kg&#160;(maximum of 80 mg)&#160;at Week 2<br/>Note 1: Both induction groups received 0.6 mg/kg (maximum of 40 mg) at Week 4 and&#160;<br/>Week 6<br/>Note 2: Patients with missing values at Week 8 were considered as not having met the&#160;<br/>endpoint</p>
<p style="position:absolute;top:865px;left:106px;white-space:nowrap" class="ft2064">At Week 52, clinical remission per FMS in Week 8 responders, clinical response per FMS (defined as a&#160;<br/>decrease in Mayo Score&#160;≥ 3 points and ≥ 30% from Baseline) in Week 8 responders, mucosal healing&#160;<br/>(defined as Mayo endoscopy&#160;subscore&#160;≤ 1) in Week 8 responders, clinical remission per FMS in Week 8&#160;<br/>remitters, and the proportion of subjects in corticosteroid-free remission per FMS in Week 8 responders&#160;<br/>were assessed in patients who received Humira at the double-blind&#160;maximum 40 mg&#160;eow&#160;(0.6 mg/kg) and&#160;<br/>maximum&#160;40 mg&#160;ew&#160;(0.6 mg/kg) maintenance doses&#160;(Table&#160;32).</p>
</div>
<!-- Page 207 -->
<a name="207"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page207-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2070">207</p>
<p style="position:absolute;top:86px;left:320px;white-space:nowrap" class="ft2071"><b>Table&#160;32: Efficacy Results at 52 Weeks</b></p>
<p style="position:absolute;top:112px;left:420px;white-space:nowrap" class="ft2071"><b>Humiraa</b></p>
<p style="position:absolute;top:131px;left:368px;white-space:nowrap" class="ft2071"><b>Maximum&#160;of&#160;40 mg&#160;eow</b></p>
<p style="position:absolute;top:150px;left:436px;white-space:nowrap" class="ft2072">N=31</p>
<p style="position:absolute;top:112px;left:608px;white-space:nowrap" class="ft2071"><b>Humirab</b></p>
<p style="position:absolute;top:131px;left:561px;white-space:nowrap" class="ft2071"><b>Maximum&#160;of&#160;40 mg&#160;ew</b></p>
<p style="position:absolute;top:150px;left:625px;white-space:nowrap" class="ft2072">N=31</p>
<p style="position:absolute;top:178px;left:176px;white-space:nowrap" class="ft2074">Clinical remission in Week&#160;<br/>8 PMS responders</p>
<p style="position:absolute;top:188px;left:409px;white-space:nowrap" class="ft2072">9/31 (29.0%)</p>
<p style="position:absolute;top:188px;left:596px;white-space:nowrap" class="ft2072">14/31 (45.2%)</p>
<p style="position:absolute;top:221px;left:176px;white-space:nowrap" class="ft2075">Clinical response in Week 8&#160;<br/>PMS responders</p>
<p style="position:absolute;top:231px;left:405px;white-space:nowrap" class="ft2072">19/31&#160;(61.3%)</p>
<p style="position:absolute;top:231px;left:594px;white-space:nowrap" class="ft2072">21/31 (67.7%)</p>
<p style="position:absolute;top:262px;left:176px;white-space:nowrap" class="ft2074">Mucosal healing in&#160;<br/>Week&#160;8&#160;PMS responders</p>
<p style="position:absolute;top:272px;left:405px;white-space:nowrap" class="ft2072">12/31 (38.7%)</p>
<p style="position:absolute;top:272px;left:594px;white-space:nowrap" class="ft2072">16/31 (51.6%)</p>
<p style="position:absolute;top:301px;left:176px;white-space:nowrap" class="ft2074">Clinical remission in Week&#160;<br/>8 PMS remitters</p>
<p style="position:absolute;top:311px;left:409px;white-space:nowrap" class="ft2072">9/21 (42.9%)</p>
<p style="position:absolute;top:311px;left:594px;white-space:nowrap" class="ft2072">10/22 (45.5%)</p>
<p style="position:absolute;top:340px;left:176px;white-space:nowrap" class="ft2074">Corticosteroid-free&#160;<br/>remission in Week 8&#160;<br/>PMS&#160;respondersc</p>
<p style="position:absolute;top:359px;left:409px;white-space:nowrap" class="ft2072">4/13 (30.8%)</p>
<p style="position:absolute;top:359px;left:598px;white-space:nowrap" class="ft2072">5/16 (31.3%)</p>
<p style="position:absolute;top:397px;left:176px;white-space:nowrap" class="ft2079">a&#160;Humira 0.6 mg/kg&#160;(maximum of&#160;40 mg)&#160;every other week</p>
<p style="position:absolute;top:416px;left:176px;white-space:nowrap" class="ft2079">b&#160;Humira 0.6 mg/kg&#160;(maximum&#160;of&#160;40 mg) every week</p>
<p style="position:absolute;top:435px;left:176px;white-space:nowrap" class="ft2074">c&#160;In&#160;patients receiving concomitant corticosteroids at baseline<br/>Note: Patients with missing values at Week 52 or who were randomized to receive&#160;<br/>re-induction or maintenance treatment were considered non-responders for Week 52&#160;<br/>endpoints</p>
<p style="position:absolute;top:532px;left:106px;white-space:nowrap" class="ft2074">Additional exploratory efficacy endpoints included clinical response per the Paediatric Ulcerative Colitis&#160;<br/>Activity Index (PUCAI) (defined as a decrease in PUCAI&#160;≥ 20 points from Baseline) and clinical&#160;<br/>remission per PUCAI (defined as PUCAI &lt; 10) at Week 8&#160;and Week 52 (Table 33).&#160;</p>
</div>
<!-- Page 208 -->
<a name="208"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page208-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2080">208</p>
<p style="position:absolute;top:86px;left:273px;white-space:nowrap" class="ft2081"><b>Table&#160;33:&#160;Exploratory Endpoints Results per PUCAI</b></p>
<p style="position:absolute;top:106px;left:543px;white-space:nowrap" class="ft2081"><b>Week 8</b></p>
<p style="position:absolute;top:127px;left:447px;white-space:nowrap" class="ft2081"><b>Humiraa</b></p>
<p style="position:absolute;top:146px;left:396px;white-space:nowrap" class="ft2081"><b>Maximum of 160 mg at&#160;</b></p>
<p style="position:absolute;top:165px;left:380px;white-space:nowrap" class="ft2081"><b>Week 0 / Placebo at Week 1</b></p>
<p style="position:absolute;top:184px;left:459px;white-space:nowrap" class="ft2082">N=30</p>
<p style="position:absolute;top:127px;left:643px;white-space:nowrap" class="ft2081"><b>Humirab,c</b></p>
<p style="position:absolute;top:146px;left:596px;white-space:nowrap" class="ft2081"><b>Maximum of 160 mg at&#160;</b></p>
<p style="position:absolute;top:165px;left:607px;white-space:nowrap" class="ft2081"><b>Week 0 and Week 1</b></p>
<p style="position:absolute;top:184px;left:659px;white-space:nowrap" class="ft2082">N=47</p>
<p style="position:absolute;top:207px;left:157px;white-space:nowrap" class="ft2082">Clinical remission per PUCAI</p>
<p style="position:absolute;top:207px;left:430px;white-space:nowrap" class="ft2082">10/30 (33.3%)</p>
<p style="position:absolute;top:207px;left:630px;white-space:nowrap" class="ft2082">22/47&#160;(46.8%)</p>
<p style="position:absolute;top:227px;left:157px;white-space:nowrap" class="ft2082">Clinical response per PUCAI</p>
<p style="position:absolute;top:227px;left:430px;white-space:nowrap" class="ft2082">15/30 (50.0%)</p>
<p style="position:absolute;top:227px;left:630px;white-space:nowrap" class="ft2082">32/47 (68.1%)</p>
<p style="position:absolute;top:247px;left:539px;white-space:nowrap" class="ft2081"><b>Week 52</b></p>
<p style="position:absolute;top:267px;left:447px;white-space:nowrap" class="ft2081"><b>Humirad</b></p>
<p style="position:absolute;top:285px;left:393px;white-space:nowrap" class="ft2081"><b>Maximum of 40 mg eow</b></p>
<p style="position:absolute;top:305px;left:459px;white-space:nowrap" class="ft2082">N=31</p>
<p style="position:absolute;top:267px;left:647px;white-space:nowrap" class="ft2081"><b>Humirae</b></p>
<p style="position:absolute;top:285px;left:597px;white-space:nowrap" class="ft2081"><b>Maximum of 40 mg ew</b></p>
<p style="position:absolute;top:305px;left:659px;white-space:nowrap" class="ft2082">N=31</p>
<p style="position:absolute;top:324px;left:157px;white-space:nowrap" class="ft2084">Clinical remission per PUCAI&#160;<br/>in Week 8 PMS responders</p>
<p style="position:absolute;top:324px;left:430px;white-space:nowrap" class="ft2082">14/31 (45.2%)</p>
<p style="position:absolute;top:324px;left:630px;white-space:nowrap" class="ft2082">18/31 (58.1%)</p>
<p style="position:absolute;top:363px;left:157px;white-space:nowrap" class="ft2084">Clinical response per PUCAI&#160;<br/>in Week 8 PMS responders</p>
<p style="position:absolute;top:363px;left:430px;white-space:nowrap" class="ft2082">18/31 (58.1%)</p>
<p style="position:absolute;top:363px;left:630px;white-space:nowrap" class="ft2082">16/31 (51.6%)</p>
<p style="position:absolute;top:400px;left:157px;white-space:nowrap" class="ft2087">a&#160;Humira&#160;2.4 mg/kg&#160;(maximum of 160 mg)&#160;at Week 0, placebo at Week 1,&#160;and&#160;1.2&#160;<br/>mg/kg&#160;(maximum of 80 mg)&#160;at Week 2</p>
<p style="position:absolute;top:438px;left:157px;white-space:nowrap" class="ft2087">b&#160;&#160;Humira&#160;2.4 mg/kg&#160;(maximum&#160;of 160 mg)&#160;at Week 0 and Week 1,&#160;and&#160;1.2&#160;<br/>mg/kg&#160;(maximum of 80 mg)&#160;at Week 2</p>
<p style="position:absolute;top:476px;left:157px;white-space:nowrap" class="ft2087">c&#160;Not including open-label Induction dose of&#160;Humira&#160;2.4 mg/kg&#160;(maximum&#160;of 160 mg)&#160;at&#160;<br/>Week 0 and Week 1, and 1.2 mg/kg&#160;(maximum of 80 mg)&#160;at Week 2</p>
<p style="position:absolute;top:514px;left:157px;white-space:nowrap" class="ft2089">d&#160;Humira 0.6 mg/kg&#160;(maximum&#160;of&#160;40 mg)&#160;every other week</p>
<p style="position:absolute;top:533px;left:157px;white-space:nowrap" class="ft2084">e&#160;Humira 0.6 mg/kg&#160;(maximum of&#160;40 mg) every week<br/>Note 1: Both induction groups received 0.6 mg/kg (maximum of 40 mg) at Week 4 and&#160;<br/>Week 6<br/>Note 2: Patients with missing values at Week 8 were considered as not having met the&#160;<br/>endpoints<br/>Note 3:&#160;Patients with&#160;missing values at Week 52 or who were randomized to receive re-<br/>induction or maintenance treatment were considered non-responders for Week 52&#160;<br/>endpoints</p>
<p style="position:absolute;top:706px;left:106px;white-space:nowrap" class="ft2084">Of the Humira-treated patients who received re-induction treatment during the maintenance period, 2/6&#160;<br/>(33%) achieved clinical response per FMS at Week 52.</p>
<p style="position:absolute;top:763px;left:106px;white-space:nowrap" class="ft2083"><i>Quality of life</i></p>
<p style="position:absolute;top:801px;left:106px;white-space:nowrap" class="ft2085">Clinically meaningful improvements from Baseline were observed in IMPACT III and the caregiver Work&#160;<br/>Productivity and Activity Impairment (WPAI) scores for the groups treated with Humira.</p>
<p style="position:absolute;top:858px;left:106px;white-space:nowrap" class="ft2084">Clinically meaningful increases (improvement) from Baseline in height velocity were observed for the&#160;<br/>groups treated with adalimumab, and clinically meaningful increases (improvement) from Baseline in&#160;<br/>Body Mass Index were observed for subjects on the high&#160;maintenance dose of maximum&#160;40 mg (0.6&#160;<br/>mg/kg) ew.&#160;</p>
<p style="position:absolute;top:953px;left:106px;white-space:nowrap" class="ft2083"><i>Paediatric Uveitis</i></p>
<p style="position:absolute;top:991px;left:106px;white-space:nowrap" class="ft2084">The safety and efficacy of Humira was assessed in a randomized, double-masked, controlled study of 90&#160;<br/>paediatric patients from 2&#160;to&#160;&lt;&#160;18 years of age with active JIA-associated noninfectious anterior uveitis&#160;<br/>who were refractory to at least 12&#160;weeks of methotrexate treatment. &#160;Patients received either placebo or&#160;<br/>20&#160;mg adalimumab (if&#160;&lt;&#160;30&#160;kg) or 40&#160;mg adalimumab (if&#160;≥&#160;30&#160;kg)&#160;every other week in combination with&#160;<br/>their baseline dose of methotrexate.&#160;</p>
</div>
<!-- Page 209 -->
<a name="209"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft20934{font-size:17px;line-height:23px;font-family:HORGHZ+TimesNewRoman,Bold;color:#000000;}
-->
</style>
<div id="page209-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2090">209</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft2094">The primary endpoint was ‘time to treatment failure’. The criteria determining treatment failure were&#160;<br/>worsening or sustained non-improvement in ocular inflammation, partial improvement with development&#160;<br/>of sustained ocular co-morbidities or worsening of ocular co-morbidities, non-permitted use of&#160;<br/>concomitant medications, and suspension of treatment for an extended period of time.</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft2093"><i>Clinical Response</i></p>
<p style="position:absolute;top:239px;left:106px;white-space:nowrap" class="ft2094">Adalimumab significantly delayed the time to treatment failure, as compared to placebo (See Figure&#160;3,&#160;<br/>P&#160;&lt;&#160;0.0001 from log rank test).The median time to treatment failure was 24.1&#160;weeks for subjects treated&#160;<br/>with placebo, whereas the median time to treatment failure was not estimable for subjects treated with&#160;<br/>adalimumab because less than one-half of these subjects experienced treatment failure. &#160;Adalimumab&#160;<br/>significantly decreased the risk of treatment failure by 75% relative to placebo, as shown by the hazard&#160;<br/>ratio (HR = 0.25 [95% CI: &#160;0.12, 0.49]).</p>
<p style="position:absolute;top:377px;left:106px;white-space:nowrap" class="ft20934"><b>Figure&#160;3: Kaplan-Meier Curves Summarizing Time to Treatment Failure in the Paediatric Uveitis&#160;<br/>Study</b></p>
<p style="position:absolute;top:861px;left:129px;white-space:nowrap" class="ft20920"><b>P</b></p>
<p style="position:absolute;top:851px;left:129px;white-space:nowrap" class="ft20920"><b>R</b></p>
<p style="position:absolute;top:839px;left:129px;white-space:nowrap" class="ft20920"><b>O</b></p>
<p style="position:absolute;top:826px;left:129px;white-space:nowrap" class="ft20920"><b>B</b></p>
<p style="position:absolute;top:815px;left:129px;white-space:nowrap" class="ft20920"><b>A</b></p>
<p style="position:absolute;top:803px;left:129px;white-space:nowrap" class="ft20920"><b>B</b></p>
<p style="position:absolute;top:792px;left:129px;white-space:nowrap" class="ft20920"><b>IL</b></p>
<p style="position:absolute;top:775px;left:129px;white-space:nowrap" class="ft20920"><b>IT</b></p>
<p style="position:absolute;top:757px;left:129px;white-space:nowrap" class="ft20920"><b>Y</b></p>
<p style="position:absolute;top:746px;left:129px;white-space:nowrap" class="ft20920"><b>&#160;O</b></p>
<p style="position:absolute;top:728px;left:129px;white-space:nowrap" class="ft20920"><b>F</b></p>
<p style="position:absolute;top:719px;left:129px;white-space:nowrap" class="ft20920"><b>&#160;F</b></p>
<p style="position:absolute;top:704px;left:129px;white-space:nowrap" class="ft20920"><b>A</b></p>
<p style="position:absolute;top:692px;left:129px;white-space:nowrap" class="ft20920"><b>IL</b></p>
<p style="position:absolute;top:675px;left:129px;white-space:nowrap" class="ft20920"><b>IN</b></p>
<p style="position:absolute;top:657px;left:129px;white-space:nowrap" class="ft20920"><b>G</b></p>
<p style="position:absolute;top:644px;left:129px;white-space:nowrap" class="ft20920"><b>&#160;T</b></p>
<p style="position:absolute;top:629px;left:129px;white-space:nowrap" class="ft20920"><b>R</b></p>
<p style="position:absolute;top:617px;left:129px;white-space:nowrap" class="ft20920"><b>E</b></p>
<p style="position:absolute;top:606px;left:129px;white-space:nowrap" class="ft20920"><b>A</b></p>
<p style="position:absolute;top:594px;left:129px;white-space:nowrap" class="ft20920"><b>T</b></p>
<p style="position:absolute;top:582px;left:129px;white-space:nowrap" class="ft20920"><b>M</b></p>
<p style="position:absolute;top:567px;left:129px;white-space:nowrap" class="ft20920"><b>E</b></p>
<p style="position:absolute;top:556px;left:129px;white-space:nowrap" class="ft20920"><b>N</b></p>
<p style="position:absolute;top:544px;left:129px;white-space:nowrap" class="ft20920"><b>T</b></p>
<p style="position:absolute;top:982px;left:412px;white-space:nowrap" class="ft2091"><b>TIME (WEEKS)</b></p>
<p style="position:absolute;top:1000px;left:149px;white-space:nowrap" class="ft2092">Treatment</p>
<p style="position:absolute;top:1000px;left:500px;white-space:nowrap" class="ft2092">Placebo</p>
<p style="position:absolute;top:1000px;left:669px;white-space:nowrap" class="ft2092">Adalimumab</p>
<p style="position:absolute;top:1020px;left:149px;white-space:nowrap" class="ft2092">Note: P =&#160;Placebo (Number at Risk); H = HUMIRA (Number at Risk).</p>
<p style="position:absolute;top:1076px;left:106px;white-space:nowrap" class="ft2091"><b>5.2</b></p>
<p style="position:absolute;top:1076px;left:148px;white-space:nowrap" class="ft2091"><b>Pharmacokinetic properties</b></p>
</div>
<!-- Page 210 -->
<a name="210"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page210-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2100">210</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft2102">Absorption and distribution</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft2104">After subcutaneous administration of a single 40&#160;mg dose, absorption and distribution of adalimumab was&#160;<br/>slow, with peak serum&#160;concentrations being reached about 5 days after administration. The average&#160;<br/>absolute bioavailability of adalimumab estimated from three studies following a single 40&#160;mg&#160;<br/>subcutaneous dose was 64%. After single intravenous doses ranging from 0.25 to 10&#160;mg/kg,&#160;<br/>concentrations were dose proportional. After doses of 0.5&#160;mg/kg (~40&#160;mg), clearances ranged from 11 to&#160;<br/>15&#160;ml/hour, the distribution volume (Vss) ranged from 5 to 6&#160;litres and the mean terminal phase half-life&#160;<br/>was approximately two weeks. Adalimumab concentrations in the synovial fluid from several rheumatoid&#160;<br/>arthritis patients ranged from 31-96% of those in serum.</p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft2107">Following subcutaneous administration of 40&#160;mg of adalimumab every other week in adult rheumatoid&#160;<br/>arthritis (RA) patients the mean steady-state trough concentrations were approximately 5</p>
<p style="position:absolute;top:332px;left:697px;white-space:nowrap" class="ft2106">g/ml (without&#160;</p>
<p style="position:absolute;top:354px;left:106px;white-space:nowrap" class="ft2102">concomitant methotrexate) and 8 to 9</p>
<p style="position:absolute;top:352px;left:357px;white-space:nowrap" class="ft2106">g/ml (with concomitant methotrexate), respectively. &#160;The serum&#160;</p>
<p style="position:absolute;top:373px;left:106px;white-space:nowrap" class="ft2104">adalimumab trough levels at steady-state increased roughly proportionally with dose following 20, 40 and&#160;<br/>80&#160;mg subcutaneous dosing every other week and every week.</p>
<p style="position:absolute;top:430px;left:106px;white-space:nowrap" class="ft2104">Following the administration of 24&#160;mg/m2&#160;(maximum of 40&#160;mg) subcutaneously every other week to&#160;<br/>patients with polyarticular juvenile idiopathic arthritis (JIA) who were 4 to 17&#160;years the&#160;mean trough&#160;<br/>steady-state (values measured from Week&#160;20 to 48) serum adalimumab concentration was 5.6 ± 5.6&#160;µg/ml&#160;<br/>(102% CV) for adalimumab without concomitant methotrexate and 10.9 ± 5.2&#160;µg/ml (47.7% CV) with&#160;<br/>concomitant methotrexate.</p>
<p style="position:absolute;top:544px;left:106px;white-space:nowrap" class="ft2104">In patients with&#160;polyarticular&#160;JIA who were 2 to&#160;&lt;&#160;4&#160;years old or aged 4 and above weighing &lt;&#160;15&#160;kg&#160;<br/>dosed with adalimumab 24&#160;mg/m2&#160;, the mean trough steady-state serum adalimumab concentrations was&#160;<br/>6.0&#160;±&#160;6.1&#160;µg/ml (101% CV) for adalimumab without concomitant methotrexate and&#160;7.9 ±&#160;5.6&#160;µg/ml&#160;<br/>(71.2% CV) with concomitant methotrexate.</p>
<p style="position:absolute;top:639px;left:106px;white-space:nowrap" class="ft2104">Following the administration of 24&#160;mg/m2&#160;(maximum of 40&#160;mg) subcutaneously every other week to&#160;<br/>patients with enthesitis-related arthritis who were 6 to 17&#160;years, the mean trough steady-state (values&#160;<br/>measured at Week&#160;24) serum adalimumab concentrations were 8.8&#160;±&#160;6.6&#160;μg/ml for adalimumab without&#160;<br/>concomitant methotrexate and 11.8&#160;±&#160;4.3&#160;μg/ml with concomitant methotrexate.</p>
<p style="position:absolute;top:734px;left:106px;white-space:nowrap" class="ft2107">Following subcutaneous administration of 40&#160;mg of adalimumab every other week in adult non-<br/>radiographic axial spondyloarthritis patients, the mean (±SD) trough steady-state concentration at&#160;<br/>Week&#160;68 was 8.0&#160;± 4.6</p>
<p style="position:absolute;top:771px;left:262px;white-space:nowrap" class="ft2106">g/ml.</p>
<p style="position:absolute;top:812px;left:106px;white-space:nowrap" class="ft2102">In adult patients with psoriasis, the mean steady-state trough concentration was 5</p>
<p style="position:absolute;top:810px;left:645px;white-space:nowrap" class="ft2106">g/ml&#160;during&#160;</p>
<p style="position:absolute;top:831px;left:106px;white-space:nowrap" class="ft2102">adalimumab 40&#160;mg&#160;every other week&#160;monotherapy treatment.</p>
<p style="position:absolute;top:869px;left:106px;white-space:nowrap" class="ft2104">Following the administration of 0.8&#160;mg/kg (maximum of 40&#160;mg)&#160;subcutaneously every other week to&#160;<br/>paediatric patients with chronic plaque psoriasis, the mean ± SD steady-state adalimumab trough&#160;<br/>concentration was approximately 7.4&#160;±&#160;5.8&#160;µg/ml (79% CV).</p>
<p style="position:absolute;top:945px;left:106px;white-space:nowrap" class="ft2105">In adult patients with hidradenitis suppurativa, a dose of 160 mg&#160;Humira on Week 0 followed by 80 mg on&#160;<br/>Week 2 achieved serum adalimumab trough concentrations of approximately 7 to 8 μg/ml at Week 2 and&#160;<br/>Week 4. &#160;The mean steady-state trough concentration at Week 12 through Week 36 were approximately 8&#160;<br/>to 10 μg/ml during&#160;adalimumab 40 mg every week treatment. &#160;</p>
<p style="position:absolute;top:1040px;left:106px;white-space:nowrap" class="ft2104">Adalimumab exposure in adolescent HS patients was predicted using population pharmacokinetic&#160;<br/>modelling and simulation based on cross-indication pharmacokinetics in other paediatric patients&#160;<br/>(paediatric psoriasis,&#160;juvenile idiopathic arthritis, paediatric Crohn’s disease, and enthesitis-related&#160;</p>
</div>
<!-- Page 211 -->
<a name="211"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page211-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2110">211</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft2114">arthritis).&#160;The recommended adolescent HS dosing schedule is 40 mg every other week. Since exposure to&#160;<br/>adalimumab can be affected by body size, adolescents with higher body weight and inadequate response&#160;<br/>may benefit from receiving the recommended adult dose of 40 mg every week.</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft2117">In patients with Crohn’s disease, the loading dose of 80&#160;mg Humira on Week&#160;0 followed by 40&#160;mg Humira&#160;<br/>on Week&#160;2 achieves serum adalimumab trough concentrations of approximately 5.5</p>
<p style="position:absolute;top:180px;left:662px;white-space:nowrap" class="ft2116">g/ml during the&#160;</p>
<p style="position:absolute;top:201px;left:106px;white-space:nowrap" class="ft2117">induction period. A loading dose of 160&#160;mg Humira on Week&#160;0 followed by 80&#160;mg Humira on Week&#160;2&#160;<br/>achieves serum adalimumab trough concentrations of approximately 12</p>
<p style="position:absolute;top:219px;left:582px;white-space:nowrap" class="ft2116">g/ml&#160;during the induction period.&#160;</p>
<p style="position:absolute;top:242px;left:106px;white-space:nowrap" class="ft2112">Mean steady-state trough levels of approximately 7</p>
<p style="position:absolute;top:240px;left:449px;white-space:nowrap" class="ft2116">g/ml&#160;were observed in Crohn’s disease patients who&#160;</p>
<p style="position:absolute;top:260px;left:106px;white-space:nowrap" class="ft2112">received a maintenance dose of 40&#160;mg Humira every other week.</p>
<p style="position:absolute;top:298px;left:106px;white-space:nowrap" class="ft2117">In paediatric patients with moderate to severe CD, the open-label adalimumab induction dose was&#160;<br/>160/80&#160;mg&#160;or 80/40&#160;mg at Weeks&#160;0 and 2, respectively, dependent on a body weight cut-off&#160;of 40&#160;kg. &#160;At&#160;<br/>Week&#160;4, patients were&#160;randomised 1:1 to either the Standard Dose (40/20&#160;mg&#160;eow)&#160;or Low Dose&#160;<br/>(20/10&#160;mg eow)&#160;maintenance treatment groups based on their body weight.&#160;The&#160;mean (±SD)&#160;serum&#160;<br/>adalimumab trough concentrations achieved at Week&#160;4 were 15.7&#160;±&#160;6.6</p>
<p style="position:absolute;top:374px;left:580px;white-space:nowrap" class="ft2116">g/ml for patients&#160;≥&#160;40&#160;kg&#160;</p>
<p style="position:absolute;top:396px;left:106px;white-space:nowrap" class="ft2112">(160/80&#160;mg) and&#160;10.6&#160;±&#160;6.1</p>
<p style="position:absolute;top:394px;left:291px;white-space:nowrap" class="ft2116">g/ml for patients &lt;&#160;40&#160;kg (80/40&#160;mg).&#160;</p>
<p style="position:absolute;top:434px;left:106px;white-space:nowrap" class="ft2117">For patients who stayed on their randomised therapy, the mean&#160;(±SD)&#160;adalimumab trough concentrations&#160;<br/>at Week&#160;52 were&#160;9.5&#160;±&#160;5.6</p>
<p style="position:absolute;top:452px;left:284px;white-space:nowrap" class="ft2116">g/ml for the Standard Dose group and&#160;3.5&#160;±&#160;2.2&#160;g/ml for the Low Dose&#160;</p>
<p style="position:absolute;top:473px;left:106px;white-space:nowrap" class="ft2114">group. &#160;The mean trough concentrations were maintained in patients who continued to receive adalimumab&#160;<br/>treatment eow for&#160;52&#160;weeks.&#160;For patients who dose escalated from eow to weekly regimen, the mean&#160;<br/>(±SD)&#160;serum concentrations of adalimumab at Week&#160;52 were 15.3&#160;±&#160;11.4&#160;μg/ml (40/20&#160;mg, weekly) and&#160;<br/>6.7&#160;±&#160;3.5&#160;μg/ml (20/10&#160;mg, weekly).</p>
<p style="position:absolute;top:568px;left:106px;white-space:nowrap" class="ft2117">In patients with ulcerative colitis, a loading dose of 160&#160;mg Humira on Week&#160;0 followed by 80&#160;mg Humira&#160;<br/>on Week&#160;2 achieves serum adalimumab trough concentrations of approximately 12</p>
<p style="position:absolute;top:586px;left:658px;white-space:nowrap" class="ft2116">g/ml during the&#160;</p>
<p style="position:absolute;top:608px;left:106px;white-space:nowrap" class="ft2112">induction period. &#160;Mean steady-state trough levels of approximately 8</p>
<p style="position:absolute;top:606px;left:570px;white-space:nowrap" class="ft2116">g/ml were&#160;observed in ulcerative&#160;</p>
<p style="position:absolute;top:627px;left:106px;white-space:nowrap" class="ft2112">colitis patients who received a maintenance dose of 40&#160;mg Humira every other week.&#160;</p>
<p style="position:absolute;top:665px;left:106px;white-space:nowrap" class="ft2115">Following the subcutaneous administration of body weight-based dosing of 0.6&#160;mg/kg (maximum of&#160;<br/>40&#160;mg)&#160;every other week to paediatric patients with ulcerative colitis,&#160;the mean trough steady-state serum&#160;<br/>adalimumab concentration was 5.01±3.28&#160;µg/ml&#160;at Week&#160;52. For patients who received 0.6&#160;mg/kg&#160;<br/>(maximum of 40&#160;mg)&#160;every week, the mean (±SD) trough steady-state serum adalimumab concentration&#160;<br/>was&#160;15.7±5.60&#160;μg/ml&#160;at Week&#160;52.&#160;</p>
<p style="position:absolute;top:779px;left:106px;white-space:nowrap" class="ft2117">In&#160;adult&#160;patients with uveitis, a loading dose of 80&#160;mg adalimumab on Week 0 followed by 40&#160;mg&#160;<br/>adalimumab every other week starting at Week 1, resulted in mean steady-state concentrations of&#160;<br/>approximately 8 to 10</p>
<p style="position:absolute;top:816px;left:256px;white-space:nowrap" class="ft2116">g/ml.</p>
<p style="position:absolute;top:856px;left:106px;white-space:nowrap" class="ft2115">Adalimumab exposure in paediatric uveitis patients was predicted using population pharmacokinetic&#160;<br/>modelling and simulation based on cross-indication pharmacokinetics in other paediatric patients&#160;<br/>(paediatric psoriasis, juvenile idiopathic arthritis, paediatric Crohn’s disease, and enthesitis-related&#160;<br/>arthritis). No clinical exposure data are available on the use of a loading dose in children &lt; 6 years. The&#160;<br/>predicted exposures indicate that in the absence of methotrexate, a loading dose may lead to an initial&#160;<br/>increase in systemic exposure.</p>
<p style="position:absolute;top:989px;left:106px;white-space:nowrap" class="ft2114">Population pharmacokinetic and pharmacokinetic/pharmacodynamic modelling and simulation predicted&#160;<br/>comparable adalimumab exposure and efficacy in patients treated with 80&#160;mg&#160;every other week when&#160;<br/>compared with 40&#160;mg&#160;every week (including adult patients with RA, HS, UC, CD or&#160;Ps, patients with&#160;<br/>adolescent HS, and paediatric patients&#160;≥&#160;40&#160;kg with CD&#160;and UC).</p>
<p style="position:absolute;top:1084px;left:106px;white-space:nowrap" class="ft2112">Exposure-response relationship in paediatric population</p>
</div>
<!-- Page 212 -->
<a name="212"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page212-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2120">212</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft2124">On the basis of clinical trial data in patients with JIA (pJIA and ERA), an exposure-response relationship&#160;<br/>was established between plasma concentrations and PedACR 50 response. The apparent adalimumab&#160;<br/>plasma concentration that produces half the maximum probability of PedACR 50 response (EC50) was&#160;<br/>3&#160;μg/ml (95% CI: 1-6&#160;μg/ml).&#160;</p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft2124">Exposure-response&#160;relationships between adalimumab concentration and efficacy in paediatric patients&#160;<br/>with severe chronic plaque psoriasis were established for PASI 75 and PGA clear or minimal,&#160;<br/>respectively. PASI 75 and PGA clear or minimal increased with increasing adalimumab concentrations,&#160;<br/>both with a similar apparent EC50 of approximately 4.5&#160;μg/ml&#160;(95% CI 0.4-47.6 and 1.9-10.5,&#160;<br/>respectively). &#160;</p>
<p style="position:absolute;top:295px;left:106px;white-space:nowrap" class="ft2122">Elimination</p>
<p style="position:absolute;top:333px;left:106px;white-space:nowrap" class="ft2124">Population pharmacokinetic analyses with data from over 1,300 RA patients revealed a trend toward&#160;<br/>higher apparent&#160;clearance of adalimumab with increasing body weight. After adjustment for weight&#160;<br/>differences, gender and age appeared to have a minimal effect on adalimumab clearance. &#160;The serum&#160;<br/>levels of free adalimumab (not bound to anti-adalimumab antibodies, AAA) were&#160;observed to be lower in&#160;<br/>patients with measurable AAA.</p>
<p style="position:absolute;top:446px;left:106px;white-space:nowrap" class="ft2122">Hepatic or renal impairment</p>
<p style="position:absolute;top:485px;left:106px;white-space:nowrap" class="ft2122">Humira has not been studied in patients with hepatic or renal impairment.</p>
<p style="position:absolute;top:522px;left:106px;white-space:nowrap" class="ft2121"><b>5.3</b></p>
<p style="position:absolute;top:522px;left:148px;white-space:nowrap" class="ft2121"><b>Preclinical safety data&#160;</b></p>
<p style="position:absolute;top:560px;left:106px;white-space:nowrap" class="ft2124">Non-clinical data reveal no special hazard for humans based on studies of single dose toxicity, repeated&#160;<br/>dose toxicity, and genotoxicity. &#160;</p>
<p style="position:absolute;top:617px;left:106px;white-space:nowrap" class="ft2124">An&#160;embryo-foetal developmental toxicity/perinatal developmental study has been performed in&#160;<br/>cynomolgus monkeys at 0, 30 and 100&#160;mg/kg (9-17 monkeys/group) and has revealed no evidence of harm&#160;<br/>to the foetuses due to adalimumab. Neither carcinogenicity studies, nor a standard assessment of fertility&#160;<br/>and postnatal toxicity, were performed with adalimumab due to the lack of appropriate models for an&#160;<br/>antibody with limited cross-reactivity to rodent TNF and to the development of neutralising antibodies in&#160;<br/>rodents.&#160;</p>
<p style="position:absolute;top:769px;left:106px;white-space:nowrap" class="ft2121"><b>6.</b></p>
<p style="position:absolute;top:769px;left:148px;white-space:nowrap" class="ft2121"><b>PHARMACEUTICAL PARTICULARS</b></p>
<p style="position:absolute;top:807px;left:106px;white-space:nowrap" class="ft2121"><b>6.1</b></p>
<p style="position:absolute;top:807px;left:148px;white-space:nowrap" class="ft2121"><b>List of excipients&#160;</b></p>
<p style="position:absolute;top:845px;left:106px;white-space:nowrap" class="ft2125">Mannitol<br/>Polysorbate 80<br/>Water for injections</p>
<p style="position:absolute;top:921px;left:106px;white-space:nowrap" class="ft2121"><b>6.2</b></p>
<p style="position:absolute;top:921px;left:148px;white-space:nowrap" class="ft2121"><b>Incompatibilities&#160;</b></p>
<p style="position:absolute;top:959px;left:106px;white-space:nowrap" class="ft2124">In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal&#160;<br/>products.</p>
<p style="position:absolute;top:1016px;left:106px;white-space:nowrap" class="ft2121"><b>6.3</b></p>
<p style="position:absolute;top:1016px;left:148px;white-space:nowrap" class="ft2121"><b>Shelf life&#160;</b></p>
<p style="position:absolute;top:1054px;left:106px;white-space:nowrap" class="ft2122">2&#160;years</p>
</div>
<!-- Page 213 -->
<a name="213"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page213-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2130">213</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft2131"><b>6.4</b></p>
<p style="position:absolute;top:86px;left:148px;white-space:nowrap" class="ft2131"><b>Special precautions for storage&#160;</b></p>
<p style="position:absolute;top:125px;left:106px;white-space:nowrap" class="ft2132">Store in a refrigerator (2</p>
<p style="position:absolute;top:123px;left:266px;white-space:nowrap" class="ft2136">C&#160;–&#160;8C). Do not freeze. Keep the pre-filled syringe or pre-filled pen in its outer&#160;</p>
<p style="position:absolute;top:144px;left:106px;white-space:nowrap" class="ft2132">carton in order to protect from light. &#160;</p>
<p style="position:absolute;top:182px;left:106px;white-space:nowrap" class="ft2134">A single Humira pre-filled syringe or pre-filled pen may be stored at temperatures up to a maximum of&#160;<br/>25°C for a period of up to 14&#160;days. The syringe or pen must be protected from light, and discarded if not&#160;<br/>used within the 14-day period.</p>
<p style="position:absolute;top:258px;left:106px;white-space:nowrap" class="ft2131"><b>6.5</b></p>
<p style="position:absolute;top:258px;left:148px;white-space:nowrap" class="ft2131"><b>Nature and contents of container</b></p>
<p style="position:absolute;top:296px;left:106px;white-space:nowrap" class="ft2135">Humira 40&#160;mg solution for injection in pre-filled syringe<br/>Humira 40&#160;mg solution for injection in single-use pre-filled syringe (type I glass) with a plunger stopper&#160;<br/>(bromobutyl rubber) and a needle with a needle shield (thermoplastic elastomer).&#160;</p>
<p style="position:absolute;top:372px;left:106px;white-space:nowrap" class="ft2132">Packs of:</p>
<p style="position:absolute;top:390px;left:106px;white-space:nowrap" class="ft2136"></p>
<p style="position:absolute;top:392px;left:148px;white-space:nowrap" class="ft2132">1 pre-filled syringe (0.4&#160;ml sterile solution) with 1 alcohol pad in a blister.</p>
<p style="position:absolute;top:410px;left:106px;white-space:nowrap" class="ft2136"></p>
<p style="position:absolute;top:412px;left:148px;white-space:nowrap" class="ft2132">2 pre-filled syringes (0.4&#160;ml sterile solution), each with 1 alcohol pad, in a blister.</p>
<p style="position:absolute;top:430px;left:106px;white-space:nowrap" class="ft2136"></p>
<p style="position:absolute;top:432px;left:148px;white-space:nowrap" class="ft2132">4 pre-filled syringes (0.4&#160;ml sterile solution), each with 1 alcohol pad, in a blister.</p>
<p style="position:absolute;top:451px;left:106px;white-space:nowrap" class="ft2136"></p>
<p style="position:absolute;top:453px;left:148px;white-space:nowrap" class="ft2132">6 pre-filled syringes (0.4&#160;ml sterile solution), each with 1 alcohol pad, in a blister.</p>
<p style="position:absolute;top:490px;left:106px;white-space:nowrap" class="ft2135">Humira 40&#160;mg solution&#160;for injection in pre-filled pen<br/>Humira 40&#160;mg solution for injection in single-use pre-filled pen for patient use containing a pre-filled&#160;<br/>syringe. The syringe inside the pen is made from type 1 glass with a plunger stopper (bromobutyl rubber)&#160;<br/>and a needle with a needle shield (thermoplastic elastomer).</p>
<p style="position:absolute;top:585px;left:106px;white-space:nowrap" class="ft2132">Packs of:</p>
<p style="position:absolute;top:604px;left:133px;white-space:nowrap" class="ft2136">&#160;1 pre-filled pen (0.4&#160;ml sterile solution), with&#160;2 alcohol pads in a blister.</p>
<p style="position:absolute;top:624px;left:133px;white-space:nowrap" class="ft2136">&#160;2 pre-filled pens (0.4&#160;ml sterile solution), each with&#160;1 alcohol pad, in a blister.</p>
<p style="position:absolute;top:644px;left:133px;white-space:nowrap" class="ft2136">&#160;4 pre-filled pens (0.4&#160;ml sterile solution), each with&#160;1 alcohol pad, in a blister.</p>
<p style="position:absolute;top:664px;left:133px;white-space:nowrap" class="ft2136">&#160;6 pre-filled pens (0.4&#160;ml sterile solution), each with 1 alcohol pad, in a blister.</p>
<p style="position:absolute;top:704px;left:106px;white-space:nowrap" class="ft2132">Not all presentations or pack sizes may be marketed.</p>
<p style="position:absolute;top:742px;left:106px;white-space:nowrap" class="ft2131"><b>6.6</b></p>
<p style="position:absolute;top:742px;left:148px;white-space:nowrap" class="ft2131"><b>Special precautions for disposal</b></p>
<p style="position:absolute;top:780px;left:106px;white-space:nowrap" class="ft2134">Any unused medicinal product or&#160;waste material should be disposed of in accordance with local&#160;<br/>requirements.</p>
<p style="position:absolute;top:856px;left:106px;white-space:nowrap" class="ft2131"><b>7.</b></p>
<p style="position:absolute;top:856px;left:148px;white-space:nowrap" class="ft2131"><b>MARKETING AUTHORISATION HOLDER&#160;</b></p>
<p style="position:absolute;top:894px;left:106px;white-space:nowrap" class="ft2135">AbbVie Deutschland GmbH &amp; Co. KG<br/>Knollstrasse<br/>67061 Ludwigshafen<br/>Germany</p>
</div>
<!-- Page 214 -->
<a name="214"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page214-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2140">214</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft2141"><b>8.</b></p>
<p style="position:absolute;top:86px;left:148px;white-space:nowrap" class="ft2141"><b>MARKETING AUTHORISATION NUMBERS&#160;</b></p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft2144">Humira 40&#160;mg solution for&#160;injection in pre-filled syringe<br/>EU/1/03/256/012<br/>EU/1/03/256/013<br/>EU/1/03/256/014<br/>EU/1/03/256/015</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft2145">Humira 40&#160;mg solution for injection in pre-filled pen<br/>EU/1/03/256/016<br/>EU/1/03/256/017<br/>EU/1/03/256/018<br/>EU/1/03/256/019</p>
<p style="position:absolute;top:370px;left:106px;white-space:nowrap" class="ft2141"><b>9.</b></p>
<p style="position:absolute;top:370px;left:148px;white-space:nowrap" class="ft2141"><b>DATE OF FIRST AUTHORISATION/RENEWAL&#160;OF THE AUTHORISATION</b></p>
<p style="position:absolute;top:409px;left:106px;white-space:nowrap" class="ft2145">Date of first authorisation: 08 September 2003<br/>Date of latest renewal: 08 September 2008&#160;</p>
<p style="position:absolute;top:485px;left:106px;white-space:nowrap" class="ft2141"><b>10.</b></p>
<p style="position:absolute;top:485px;left:148px;white-space:nowrap" class="ft2141"><b>DATE OF REVISION&#160;OF THE TEXT</b></p>
<p style="position:absolute;top:522px;left:106px;white-space:nowrap" class="ft2144">Detailed information on this medicinal product is available on the website of the European Medicines&#160;<br/><a href="http://www.ema.europa.eu/">Agency&#160;http://www.ema.europa.eu</a></p>
</div>
<!-- Page 215 -->
<a name="215"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page215-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2150">215</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft2151"><b>Error! Hyperlink reference not valid.1.</b></p>
<p style="position:absolute;top:86px;left:430px;white-space:nowrap" class="ft2151"><b>NAME OF THE MEDICINAL PRODUCT&#160;</b></p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft2154">Humira 80&#160;mg solution for injection in pre-filled syringe<br/>Humira 80&#160;mg solution for injection in&#160;pre-filled pen</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft2151"><b>2.</b></p>
<p style="position:absolute;top:200px;left:148px;white-space:nowrap" class="ft2151"><b>QUALITATIVE AND QUANTITATIVE COMPOSITION&#160;</b></p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft2154">Humira 80&#160;mg solution for injection in pre-filled syringe&#160;<br/>Each 0.8&#160;ml single dose pre-filled syringe contains 80&#160;mg&#160;of adalimumab.&#160;</p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft2154">Humira 80&#160;mg solution for injection in pre-filled pen<br/>Each 0.8&#160;ml single dose pre-filled pen contains 80&#160;mg of adalimumab.&#160;</p>
<p style="position:absolute;top:370px;left:106px;white-space:nowrap" class="ft2152">Adalimumab is a recombinant human monoclonal antibody&#160;produced&#160;in Chinese Hamster Ovary cells.</p>
<p style="position:absolute;top:409px;left:106px;white-space:nowrap" class="ft2152">For the full list of excipients, see section 6.1.&#160;</p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft2151"><b>3.</b></p>
<p style="position:absolute;top:465px;left:148px;white-space:nowrap" class="ft2151"><b>PHARMACEUTICAL&#160;FORM&#160;</b></p>
<p style="position:absolute;top:503px;left:106px;white-space:nowrap" class="ft2154">Solution for injection.&#160;(injection)<br/>Clear, colourless solution.&#160;</p>
<p style="position:absolute;top:579px;left:106px;white-space:nowrap" class="ft2151"><b>4.</b></p>
<p style="position:absolute;top:579px;left:148px;white-space:nowrap" class="ft2151"><b>CLINICAL PARTICULARS</b></p>
<p style="position:absolute;top:617px;left:106px;white-space:nowrap" class="ft2151"><b>4.1</b></p>
<p style="position:absolute;top:617px;left:148px;white-space:nowrap" class="ft2151"><b>Therapeutic indications&#160;</b></p>
<p style="position:absolute;top:655px;left:106px;white-space:nowrap" class="ft2152">Rheumatoid arthritis</p>
<p style="position:absolute;top:693px;left:106px;white-space:nowrap" class="ft2152">Humira in combination with methotrexate, is indicated for:</p>
<p style="position:absolute;top:731px;left:106px;white-space:nowrap" class="ft21525"></p>
<p style="position:absolute;top:731px;left:147px;white-space:nowrap" class="ft2155">the treatment of moderate to severe, active rheumatoid&#160;arthritis in adult patients when the response&#160;<br/>to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate.</p>
<p style="position:absolute;top:769px;left:106px;white-space:nowrap" class="ft21525"></p>
<p style="position:absolute;top:769px;left:147px;white-space:nowrap" class="ft2154">the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated&#160;<br/>with methotrexate.</p>
<p style="position:absolute;top:826px;left:106px;white-space:nowrap" class="ft2154">Humira can be given as monotherapy in case of intolerance to methotrexate or when continued treatment&#160;<br/>with methotrexate is inappropriate.</p>
<p style="position:absolute;top:883px;left:106px;white-space:nowrap" class="ft2154">Humira has been shown to reduce the rate of progression of joint damage as measured by X-ray and to&#160;<br/>improve physical&#160;function, when given in combination with methotrexate.</p>
<p style="position:absolute;top:940px;left:106px;white-space:nowrap" class="ft2152">Psoriasis</p>
<p style="position:absolute;top:978px;left:106px;white-space:nowrap" class="ft2154">Humira is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who&#160;<br/>are&#160;candidates for systemic therapy.</p>
</div>
<!-- Page 216 -->
<a name="216"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page216-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2160">216</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft2162">Hidradenitis suppurativa (HS)</p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft2164">Humira is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa)&#160;<br/>in adults and adolescents from 12 years of age with an inadequate response to conventional systemic HS&#160;<br/>therapy (see sections 5.1 and 5.2).</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft2162">Crohn’s disease</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft2164">Humira is indicated for treatment of moderately to severely active Crohn’s disease, in adult patients who&#160;<br/>have not responded despite a full and adequate course of therapy with a corticosteroid and/or an&#160;<br/>immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.&#160;</p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft2162">Paediatric Crohn's disease&#160;</p>
<p style="position:absolute;top:352px;left:106px;white-space:nowrap" class="ft2164">Humira is indicated for the treatment of moderately to severely active Crohn's disease in paediatric&#160;<br/>patients (from 6&#160;years of age) who have had an inadequate response to conventional&#160;therapy including&#160;<br/>primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or&#160;<br/>have contraindications for such therapies.</p>
<p style="position:absolute;top:446px;left:106px;white-space:nowrap" class="ft2162">Ulcerative colitis</p>
<p style="position:absolute;top:485px;left:106px;white-space:nowrap" class="ft2164">Humira is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who&#160;<br/>have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine&#160;<br/>(6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such&#160;<br/>therapies.&#160;</p>
<p style="position:absolute;top:579px;left:106px;white-space:nowrap" class="ft2162">Paediatric ulcerative colitis</p>
<p style="position:absolute;top:617px;left:106px;white-space:nowrap" class="ft2164">Humira is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric&#160;<br/>patients (from 6&#160;years of age) who have had an inadequate response to conventional therapy including&#160;<br/>corticosteroids and/or 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant&#160;to or have&#160;<br/>medical contraindications for such therapies.</p>
<p style="position:absolute;top:712px;left:106px;white-space:nowrap" class="ft2162">Uveitis</p>
<p style="position:absolute;top:750px;left:106px;white-space:nowrap" class="ft2164">Humira is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult&#160;<br/>patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-<br/>sparing, or in whom corticosteroid treatment is inappropriate.</p>
<p style="position:absolute;top:826px;left:106px;white-space:nowrap" class="ft2162">Paediatric Uveitis</p>
<p style="position:absolute;top:864px;left:106px;white-space:nowrap" class="ft2164">Humira is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from&#160;<br/>2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in&#160;<br/>whom conventional therapy is inappropriate.</p>
<p style="position:absolute;top:940px;left:106px;white-space:nowrap" class="ft2161"><b>4.2</b></p>
<p style="position:absolute;top:940px;left:148px;white-space:nowrap" class="ft2161"><b>Posology and method of administration &#160;</b></p>
<p style="position:absolute;top:978px;left:106px;white-space:nowrap" class="ft2164">Humira treatment should be initiated and supervised by specialist physicians experienced in the diagnosis&#160;<br/>and treatment of conditions for which Humira is indicated. Ophthalmologists are advised to consult with&#160;<br/>an appropriate specialist before initiation of treatment with Humira (see section 4.4). Patients treated with&#160;<br/>Humira should be given the&#160;Patient Reminder Card.</p>
</div>
<!-- Page 217 -->
<a name="217"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page217-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2170">217</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft2175">After proper training in injection technique, patients may self-inject with Humira if their physician&#160;<br/>determines that it is appropriate and with medical follow-up as necessary.&#160;</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft2174">During treatment with Humira, other concomitant therapies (e.g., corticosteroids and/or&#160;<br/>immunomodulatory agents) should be optimised.</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft2172">Posology</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft2173"><i>Rheumatoid arthritis</i></p>
<p style="position:absolute;top:276px;left:106px;white-space:nowrap" class="ft2175">The recommended dose of Humira for adult patients with rheumatoid arthritis is 40&#160;mg adalimumab&#160;<br/>administered every other week as a single dose via subcutaneous injection. Methotrexate should be&#160;<br/>continued during treatment with Humira.</p>
<p style="position:absolute;top:352px;left:106px;white-space:nowrap" class="ft2174">Glucocorticoids, salicylates, non-steroidal anti-inflammatory drugs&#160;(NSAIDs), or analgesics can be&#160;<br/>continued during treatment with Humira. &#160;Regarding combination with disease modifying anti-rheumatic&#160;<br/>drugs other than methotrexate see sections 4.4 and 5.1.</p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft2174">In&#160;monotherapy, some patients who experience a decrease in their response&#160;to Humira 40&#160;mg every other&#160;<br/>week&#160;may benefit from an increase in dosage to 40&#160;mg adalimumab every week&#160;or 80&#160;mg&#160;every other&#160;<br/>week.&#160;</p>
<p style="position:absolute;top:503px;left:106px;white-space:nowrap" class="ft2174">Available data suggest that the clinical response&#160;is usually achieved within 12&#160;weeks of treatment. &#160;<br/>Continued therapy should be reconsidered in a patient not responding within this time period.</p>
<p style="position:absolute;top:560px;left:106px;white-space:nowrap" class="ft2174">Humira may be available in other strengths and/or presentations depending on the individual treatment&#160;<br/>needs.</p>
<p style="position:absolute;top:617px;left:106px;white-space:nowrap" class="ft2173"><i>Psoriasis</i></p>
<p style="position:absolute;top:655px;left:106px;white-space:nowrap" class="ft2174">The recommended dose of Humira for adult patients is an initial dose of 80&#160;mg administered&#160;<br/>subcutaneously, followed by 40&#160;mg subcutaneously given every other week starting one week after the&#160;<br/>initial dose. Humira 40&#160;mg solution for injection in&#160;pre-filled syringe and/or pre-filled pen is available for&#160;<br/>the maintenance dose.</p>
<p style="position:absolute;top:750px;left:106px;white-space:nowrap" class="ft2174">Continued therapy beyond 16&#160;weeks should be carefully reconsidered in a patient not responding within&#160;<br/>this time period.</p>
<p style="position:absolute;top:807px;left:106px;white-space:nowrap" class="ft2174">Beyond 16&#160;weeks, patients with inadequate response&#160;to&#160;Humira 40&#160;mg&#160;every other week&#160;may benefit from&#160;<br/>an increase in dosage&#160;to&#160;40&#160;mg&#160;every week&#160;or 80&#160;mg&#160;every other week. The benefits and risks of continued&#160;<br/>40&#160;mg&#160;weekly&#160;or 80&#160;mg every other week&#160;therapy should be carefully reconsidered in a patient with an&#160;<br/>inadequate response after the increase in dosage&#160;(see section 5.1).&#160;If adequate response is achieved with&#160;<br/>40&#160;mg&#160;every week or 80&#160;mg&#160;every other week, the dosage&#160;may subsequently be reduced to&#160;40&#160;mg&#160;every&#160;<br/>other week.</p>
<p style="position:absolute;top:940px;left:106px;white-space:nowrap" class="ft2174">Humira may be available in other strengths and/or presentations depending on the individual treatment&#160;<br/>needs.</p>
<p style="position:absolute;top:997px;left:106px;white-space:nowrap" class="ft2173"><i>Hidradenitis suppurativa</i></p>
<p style="position:absolute;top:1035px;left:106px;white-space:nowrap" class="ft2175">The recommended Humira dose regimen for adult patients with hidradenitis suppurativa (HS) is 160&#160;mg&#160;<br/>initially at Day 1 (given as two 80&#160;mg injections in one day&#160;or as one 80&#160;mg&#160;injection per day for two&#160;<br/>consecutive days), followed by 80&#160;mg two weeks later at Day 15. Two weeks later (Day&#160;29) continue with&#160;</p>
</div>
<!-- Page 218 -->
<a name="218"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page218-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2180">218</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft2184">a dose of 40&#160;mg&#160;every week&#160;or 80&#160;mg&#160;every other week. Antibiotics may be continued during treatment&#160;<br/>with Humira if necessary. It is recommended that the patient should use a topical antiseptic wash on their&#160;<br/>HS lesions on a daily basis during treatment with Humira.&#160;</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft2185">Continued therapy beyond 12 weeks should&#160;be&#160;carefully reconsidered in a patient with no improvement&#160;<br/>within this time period. &#160;</p>
<p style="position:absolute;top:219px;left:106px;white-space:nowrap" class="ft2185">Should treatment be interrupted, Humira 40 mg every week&#160;or 80&#160;mg every other week&#160;may be re-<br/>introduced (see section 5.1).&#160;</p>
<p style="position:absolute;top:276px;left:106px;white-space:nowrap" class="ft2182">The benefit and risk of continued long-term&#160;treatment should be periodically evaluated (see section 5.1).</p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft2184">Humira may be available in other strengths and/or presentations depending on the individual treatment&#160;<br/>needs.</p>
<p style="position:absolute;top:370px;left:106px;white-space:nowrap" class="ft2183"><i>Crohn’s disease</i></p>
<p style="position:absolute;top:409px;left:106px;white-space:nowrap" class="ft2184">The recommended Humira induction dose regimen for adult patients with moderately to severely active&#160;<br/>Crohn’s disease is 80&#160;mg at Week&#160;0 followed by 40&#160;mg at Week&#160;2. In case there is a need for a more rapid&#160;<br/>response to therapy, the regimen 160&#160;mg at Week&#160;0 (given as two 80 mg injections in one day or as one&#160;<br/>80&#160;mg injection&#160;per day for two consecutive days),&#160;followed by&#160;80&#160;mg at Week&#160;2, can be used with the&#160;<br/>awareness that the risk for adverse events is higher during induction.</p>
<p style="position:absolute;top:522px;left:106px;white-space:nowrap" class="ft2184">After induction treatment, the recommended dose is 40&#160;mg&#160;every other week via subcutaneous injection.&#160;<br/>Alternatively, if a patient has stopped Humira and signs and symptoms of disease recur, Humira may be&#160;<br/>re-administered. There is little experience from re-administration after more than 8&#160;weeks since the&#160;<br/>previous dose.&#160;</p>
<p style="position:absolute;top:617px;left:106px;white-space:nowrap" class="ft2184">During maintenance treatment, corticosteroids may be tapered in accordance with clinical practice&#160;<br/>guidelines.</p>
<p style="position:absolute;top:674px;left:106px;white-space:nowrap" class="ft2185">Some patients who experience decrease in their response&#160;to Humira 40&#160;mg&#160;every other week&#160;may benefit&#160;<br/>from an increase in dosage&#160;to 40&#160;mg Humira every week&#160;or 80&#160;mg&#160;every other week.</p>
<p style="position:absolute;top:731px;left:106px;white-space:nowrap" class="ft2184">Some patients who have not responded by Week&#160;4 may benefit from continued maintenance therapy&#160;<br/>through Week&#160;12. Continued therapy should be carefully reconsidered in a patient not responding within&#160;<br/>this time period.</p>
<p style="position:absolute;top:807px;left:106px;white-space:nowrap" class="ft2185">Humira may be available in other&#160;strengths and/or presentations depending on the individual treatment&#160;<br/>needs.</p>
<p style="position:absolute;top:864px;left:106px;white-space:nowrap" class="ft2183"><i>Ulcerative colitis</i></p>
<p style="position:absolute;top:902px;left:106px;white-space:nowrap" class="ft2184">The recommended Humira induction dose regimen for adult patients with moderate to severe ulcerative&#160;<br/>colitis is 160&#160;mg at Week&#160;0 (given as two 80 mg injections&#160;in one day or as one 80 mg injection per day&#160;<br/>for two consecutive days) and 80&#160;mg at Week&#160;2. After induction treatment, the recommended dose is&#160;<br/>40&#160;mg&#160;every other week via subcutaneous injection.&#160;</p>
<p style="position:absolute;top:997px;left:106px;white-space:nowrap" class="ft2185">During maintenance treatment, corticosteroids may be tapered in accordance with clinical practice&#160;<br/>guidelines.&#160;</p>
<p style="position:absolute;top:1054px;left:106px;white-space:nowrap" class="ft2185">Some patients who experience decrease in their response&#160;to 40&#160;mg&#160;every other week&#160;may benefit from an&#160;<br/>increase in dosage&#160;to 40&#160;mg Humira every week&#160;or 80&#160;mg&#160;every other week.</p>
</div>
<!-- Page 219 -->
<a name="219"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page219-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2190">219</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft2194">Available data suggest that clinical response is usually achieved within 2-8&#160;weeks of treatment. &#160;Humira&#160;<br/>therapy should not be continued in patients failing to respond within this time period.</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft2195">Humira may be available in other&#160;strengths and/or presentations depending on the individual treatment&#160;<br/>needs.</p>
<p style="position:absolute;top:219px;left:106px;white-space:nowrap" class="ft2193"><i>Uveitis</i></p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft2195">The recommended dose of Humira for adult patients with uveitis is an initial dose of 80 mg, followed by&#160;<br/>40 mg given every other week starting one week after the initial dose.&#160;Humira 40&#160;mg solution for injection&#160;<br/>in pre-filled syringe and/or pre-filled pen is available for the maintenance dose.&#160;There is limited&#160;<br/>experience in the initiation of treatment with Humira alone. Treatment with Humira can be initiated in&#160;<br/>combination with corticosteroids and/or with other non-biologic immunomodulatory agents. Concomitant&#160;<br/>corticosteroids may be tapered in accordance with clinical practice starting two weeks after initiating&#160;<br/>treatment with Humira.</p>
<p style="position:absolute;top:409px;left:106px;white-space:nowrap" class="ft2195">It is recommended that the benefit and risk of continued long-term&#160;treatment should be evaluated on a&#160;<br/>yearly basis (see section 5.1). &#160;</p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft2194">Humira may be available in other strengths and/or presentations depending on the individual treatment&#160;<br/>needs.</p>
<p style="position:absolute;top:522px;left:106px;white-space:nowrap" class="ft2192">Special populations</p>
<p style="position:absolute;top:560px;left:106px;white-space:nowrap" class="ft2192">Elderly</p>
<p style="position:absolute;top:598px;left:106px;white-space:nowrap" class="ft2192">No dose&#160;adjustment is required.</p>
<p style="position:absolute;top:636px;left:106px;white-space:nowrap" class="ft2192">Renal and/or hepatic impairment</p>
<p style="position:absolute;top:674px;left:106px;white-space:nowrap" class="ft2192">Humira has not been studied in these patient populations. No dose recommendations can be made.</p>
<p style="position:absolute;top:712px;left:106px;white-space:nowrap" class="ft2192">Paediatric population</p>
<p style="position:absolute;top:750px;left:106px;white-space:nowrap" class="ft2193"><i>Paediatric plaque psoriasis</i></p>
<p style="position:absolute;top:788px;left:106px;white-space:nowrap" class="ft2194">The safety and efficacy of Humira in children aged 4-17&#160;years have been established for plaque psoriasis.&#160;<br/>The recommended Humira dose is up to a maximum of 40&#160;mg per dose. &#160;</p>
<p style="position:absolute;top:845px;left:106px;white-space:nowrap" class="ft2193"><i>Adolescent hidradenitis suppurativa (from 12 years of age, weighing at least 30 kg)</i></p>
<p style="position:absolute;top:883px;left:106px;white-space:nowrap" class="ft2194">There are no clinical trials with Humira in adolescent patients with HS. &#160;The posology of Humira in these&#160;<br/>patients has been determined from pharmacokinetic modelling and simulation (see section 5.2).</p>
<p style="position:absolute;top:940px;left:106px;white-space:nowrap" class="ft2194">The recommended Humira dose is 80&#160;mg at Week 0 followed by 40&#160;mg every other week starting at&#160;<br/>Week&#160;1 via subcutaneous injection.&#160;</p>
<p style="position:absolute;top:997px;left:106px;white-space:nowrap" class="ft2195">In adolescent patients with inadequate response to Humira 40&#160;mg every other week, an increase in dosage<br/>to 40&#160;mg&#160;every week&#160;or 80&#160;mg&#160;every other week&#160;may be considered.&#160;</p>
</div>
<!-- Page 220 -->
<a name="220"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page220-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2200">220</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft2204">Antibiotics may be continued during treatment with Humira if necessary. It is recommended that the&#160;<br/>patient should use a topical antiseptic wash on their HS lesions on a daily basis during treatment with&#160;<br/>Humira.&#160;</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft2205">Continued therapy beyond 12 weeks should be carefully reconsidered in a patient with no improvement&#160;<br/>within this time period. &#160;</p>
<p style="position:absolute;top:219px;left:106px;white-space:nowrap" class="ft2202">Should treatment be interrupted, Humira may be re-introduced as appropriate.</p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft2204">The benefit and risk of continued long-term&#160;treatment should be periodically evaluated (see adult&#160;data in&#160;<br/>section 5.1)</p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft2202">There is no relevant use of Humira in children aged less than 12 years in this indication.</p>
<p style="position:absolute;top:352px;left:106px;white-space:nowrap" class="ft2205">Humira may be available in other strengths and/or presentations depending on the individual treatment&#160;<br/>needs.</p>
<p style="position:absolute;top:409px;left:106px;white-space:nowrap" class="ft2203"><i>Paediatric Crohn's disease</i></p>
<p style="position:absolute;top:446px;left:106px;white-space:nowrap" class="ft2204">The recommended dose of Humira for patients with Crohn’s disease from 6 to 17&#160;years of age is based on&#160;<br/>body weight (Table 1). Humira is administered via subcutaneous injection.&#160;</p>
<p style="position:absolute;top:503px;left:225px;white-space:nowrap" class="ft2201"><b>Table 1. Humira Dose for Paediatric Patients with Crohn’s disease</b></p>
<p style="position:absolute;top:544px;left:118px;white-space:nowrap" class="ft2201"><b>Patient&#160;</b></p>
<p style="position:absolute;top:563px;left:117px;white-space:nowrap" class="ft2201"><b>Weight</b></p>
<p style="position:absolute;top:544px;left:383px;white-space:nowrap" class="ft2201"><b>Induction Dose</b></p>
<p style="position:absolute;top:544px;left:707px;white-space:nowrap" class="ft2201"><b>Maintenance&#160;</b></p>
<p style="position:absolute;top:563px;left:735px;white-space:nowrap" class="ft2201"><b>Dose</b></p>
<p style="position:absolute;top:581px;left:715px;white-space:nowrap" class="ft2201"><b>Starting at&#160;</b></p>
<p style="position:absolute;top:600px;left:726px;white-space:nowrap" class="ft2201"><b>Week 4</b></p>
<p style="position:absolute;top:623px;left:118px;white-space:nowrap" class="ft2202">&lt; 40 kg</p>
<p style="position:absolute;top:622px;left:190px;white-space:nowrap" class="ft2206">&#160;40 mg at Week 0 and 20 mg at Week 2</p>
<p style="position:absolute;top:662px;left:192px;white-space:nowrap" class="ft2205">In case there is a need for a more rapid response to therapy&#160;with the&#160;<br/>awareness that the risk for adverse events may be higher with use of the&#160;<br/>higher&#160;induction dose, the following dose may be used:</p>
<p style="position:absolute;top:718px;left:190px;white-space:nowrap" class="ft2206">&#160;80 mg at Week 0 and 40 mg at Week 2</p>
<p style="position:absolute;top:623px;left:711px;white-space:nowrap" class="ft2202">20 mg every&#160;</p>
<p style="position:absolute;top:642px;left:716px;white-space:nowrap" class="ft2202">other week</p>
<p style="position:absolute;top:742px;left:118px;white-space:nowrap" class="ft2202">≥ 40 kg</p>
<p style="position:absolute;top:742px;left:190px;white-space:nowrap" class="ft2206">&#160;80 mg at Week 0 and 40 mg at Week 2</p>
<p style="position:absolute;top:782px;left:192px;white-space:nowrap" class="ft2205">In case there is a need for a more rapid response to therapy&#160;with the&#160;<br/>awareness that the risk for&#160;adverse events may be higher with use of the&#160;<br/>higher induction dose, the following dose may be used:</p>
<p style="position:absolute;top:838px;left:190px;white-space:nowrap" class="ft2206">&#160;160 mg at Week 0 and 80 mg at Week 2</p>
<p style="position:absolute;top:742px;left:711px;white-space:nowrap" class="ft2202">40 mg every&#160;</p>
<p style="position:absolute;top:761px;left:716px;white-space:nowrap" class="ft2202">other week</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft2202">Patients who experience insufficient response may benefit from an increase in&#160;dosage:</p>
<p style="position:absolute;top:898px;left:106px;white-space:nowrap" class="ft2206"></p>
<p style="position:absolute;top:900px;left:147px;white-space:nowrap" class="ft2202">&lt; 40&#160;kg:&#160;20&#160;mg&#160;every week</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft2206"></p>
<p style="position:absolute;top:920px;left:147px;white-space:nowrap" class="ft2202">≥ 40&#160;kg: 40&#160;mg&#160;every&#160;week&#160;or 80&#160;mg&#160;every other week</p>
<p style="position:absolute;top:958px;left:106px;white-space:nowrap" class="ft2202">Continued therapy should be carefully considered in a subject not responding by Week&#160;12.</p>
<p style="position:absolute;top:996px;left:106px;white-space:nowrap" class="ft2204">Humira may be available in other strengths and/or presentations depending on the individual treatment&#160;<br/>needs.</p>
<p style="position:absolute;top:1053px;left:106px;white-space:nowrap" class="ft2202">There is no relevant use of Humira in children aged&#160;less than&#160;6&#160;years for this indication.</p>
</div>
<!-- Page 221 -->
<a name="221"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page221-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2210">221</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft2213"><i>Paediatric ulcerative colitis</i></p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft2214">The recommended dose of Humira for patients from&#160;6&#160;to 17 years of age with ulcerative colitis is based on&#160;<br/>body weight (Table&#160;2). Humira is administered via subcutaneous injection.&#160;</p>
<p style="position:absolute;top:181px;left:220px;white-space:nowrap" class="ft2211"><b>Table&#160;2. Humira Dose for Paediatric Patients with Ulcerative Colitis&#160;</b></p>
<p style="position:absolute;top:212px;left:154px;white-space:nowrap" class="ft2211"><b>Patient Weight</b></p>
<p style="position:absolute;top:212px;left:352px;white-space:nowrap" class="ft2211"><b>Induction Dose</b></p>
<p style="position:absolute;top:202px;left:594px;white-space:nowrap" class="ft2211"><b>Maintenance Dose</b></p>
<p style="position:absolute;top:221px;left:588px;white-space:nowrap" class="ft2211"><b>Starting at Week 4*</b></p>
<p style="position:absolute;top:243px;left:181px;white-space:nowrap" class="ft2212">&lt; 40 kg</p>
<p style="position:absolute;top:243px;left:289px;white-space:nowrap" class="ft2212">•&#160;80 mg at Week 0&#160;(given as one 80&#160;</p>
<p style="position:absolute;top:262px;left:305px;white-space:nowrap" class="ft2212">mg&#160;injection)&#160;and</p>
<p style="position:absolute;top:281px;left:289px;white-space:nowrap" class="ft2212">•&#160;40 mg at Week 2&#160;(given as one 40&#160;</p>
<p style="position:absolute;top:300px;left:305px;white-space:nowrap" class="ft2212">mg&#160;injection)</p>
<p style="position:absolute;top:243px;left:548px;white-space:nowrap" class="ft2212">•&#160;40 mg every other week</p>
<p style="position:absolute;top:323px;left:181px;white-space:nowrap" class="ft2212">≥ 40 kg</p>
<p style="position:absolute;top:323px;left:289px;white-space:nowrap" class="ft2212">•&#160;160 mg at Week 0&#160;(given as two&#160;</p>
<p style="position:absolute;top:342px;left:305px;white-space:nowrap" class="ft2215">80 mg injections in one day or one&#160;<br/>80 mg injection per day for two&#160;<br/>consecutive days)&#160;and</p>
<p style="position:absolute;top:399px;left:289px;white-space:nowrap" class="ft2212">•&#160;80 mg at Week 2&#160;(given as one 80&#160;</p>
<p style="position:absolute;top:418px;left:305px;white-space:nowrap" class="ft2212">mg&#160;injection)</p>
<p style="position:absolute;top:323px;left:548px;white-space:nowrap" class="ft2212">•&#160;80 mg every other week</p>
<p style="position:absolute;top:438px;left:138px;white-space:nowrap" class="ft2217">*&#160;Paediatric patients who turn 18 years of age while on Humira should continue&#160;their prescribed&#160;<br/>maintenance dose.</p>
<p style="position:absolute;top:501px;left:106px;white-space:nowrap" class="ft2214">Continued therapy beyond 8 weeks should be carefully considered in&#160;patients not showing signs of&#160;<br/>response&#160;within this time period.</p>
<p style="position:absolute;top:558px;left:106px;white-space:nowrap" class="ft2212">There is no relevant use of Humira in children aged less than&#160;6&#160;years in this indication.</p>
<p style="position:absolute;top:596px;left:106px;white-space:nowrap" class="ft2214">Humira may be available in different strengths and/or presentations&#160;depending on the individual treatment&#160;<br/>needs.</p>
<p style="position:absolute;top:653px;left:106px;white-space:nowrap" class="ft2213"><i>Paediatric Uveitis&#160;</i></p>
<p style="position:absolute;top:691px;left:106px;white-space:nowrap" class="ft2214">The recommended dose of Humira for paediatric patients with uveitis&#160;from 2&#160;years of age is based on&#160;<br/>body weight (Table&#160;3). Humira is administered via subcutaneous injection.</p>
<p style="position:absolute;top:748px;left:106px;white-space:nowrap" class="ft2215">In paediatric uveitis, there is no experience in the treatment with Humira without concomitant treatment&#160;<br/>with methotrexate.</p>
<p style="position:absolute;top:805px;left:256px;white-space:nowrap" class="ft2211"><b>Table&#160;3. Humira Dose for Paediatric Patients&#160;with Uveitis</b></p>
<p style="position:absolute;top:846px;left:279px;white-space:nowrap" class="ft2211"><b>Patient Weight</b></p>
<p style="position:absolute;top:846px;left:529px;white-space:nowrap" class="ft2211"><b>Dosing Regimen</b></p>
<p style="position:absolute;top:870px;left:307px;white-space:nowrap" class="ft2212">&lt; 30 kg</p>
<p style="position:absolute;top:870px;left:498px;white-space:nowrap" class="ft2212">20 mg every other week in&#160;</p>
<p style="position:absolute;top:888px;left:483px;white-space:nowrap" class="ft2212">combination with methotrexate</p>
<p style="position:absolute;top:913px;left:307px;white-space:nowrap" class="ft2212">≥ 30 kg</p>
<p style="position:absolute;top:913px;left:498px;white-space:nowrap" class="ft2212">40 mg every other week in&#160;</p>
<p style="position:absolute;top:931px;left:483px;white-space:nowrap" class="ft2212">combination with methotrexate</p>
<p style="position:absolute;top:973px;left:106px;white-space:nowrap" class="ft2214">When Humira therapy is initiated, a loading dose of 40&#160;mg&#160;for patients &lt;&#160;30&#160;kg&#160;or 80&#160;mg for patients&#160;<br/>≥&#160;30&#160;kg&#160;may be administered one week prior to the start of maintenance therapy. No clinical data are&#160;<br/>available on the use of a Humira loading dose in children &lt;&#160;6 years of age (see section 5.2).</p>
<p style="position:absolute;top:1049px;left:106px;white-space:nowrap" class="ft2212">There is no relevant use of Humira in&#160;children aged less than 2&#160;years in this indication.</p>
</div>
<!-- Page 222 -->
<a name="222"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page222-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2220">222</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft2225">It is recommended that the benefit and risk of continued long-term&#160;treatment should be evaluated on a&#160;<br/>yearly basis (see section 5.1).</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft2224">Humira may be available in other strengths and/or presentations depending on the individual treatment&#160;<br/>needs.</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft2222">Method of administration</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft2224">Humira is administered by subcutaneous injection. Full instructions for use are provided in the package&#160;<br/>leaflet.</p>
<p style="position:absolute;top:295px;left:106px;white-space:nowrap" class="ft2222">Humira is available in other strengths and presentations.</p>
<p style="position:absolute;top:333px;left:106px;white-space:nowrap" class="ft2221"><b>4.3</b></p>
<p style="position:absolute;top:333px;left:148px;white-space:nowrap" class="ft2221"><b>Contraindications&#160;</b></p>
<p style="position:absolute;top:370px;left:106px;white-space:nowrap" class="ft2222">Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.&#160;</p>
<p style="position:absolute;top:409px;left:106px;white-space:nowrap" class="ft2222">Active tuberculosis or other severe infections such as sepsis, and opportunistic infections (see section 4.4).</p>
<p style="position:absolute;top:445px;left:106px;white-space:nowrap" class="ft2222">Moderate to severe heart&#160;failure (NYHA class III/IV) (see section 4.4).</p>
<p style="position:absolute;top:483px;left:106px;white-space:nowrap" class="ft2221"><b>4.4</b></p>
<p style="position:absolute;top:483px;left:148px;white-space:nowrap" class="ft2221"><b>Special warnings and precautions for use</b></p>
<p style="position:absolute;top:521px;left:106px;white-space:nowrap" class="ft2222">Traceability&#160;</p>
<p style="position:absolute;top:559px;left:106px;white-space:nowrap" class="ft2225">In&#160;order to improve traceability of biological medicinal products, the&#160;name&#160;and the batch number of the&#160;<br/>administered product should be clearly recorded.</p>
<p style="position:absolute;top:616px;left:106px;white-space:nowrap" class="ft2222">Infections</p>
<p style="position:absolute;top:653px;left:106px;white-space:nowrap" class="ft2225">Patients taking TNF-antagonists are more susceptible to serious infections. Impaired lung function may&#160;<br/>increase the risk for developing infections. Patients must therefore be monitored closely for infections,&#160;<br/>including tuberculosis, before, during and after treatment with Humira. &#160;Because the elimination of&#160;<br/>adalimumab may take up to four months, monitoring should be continued throughout this period.</p>
<p style="position:absolute;top:748px;left:106px;white-space:nowrap" class="ft2225">Treatment with Humira should not be initiated in patients with active infections including chronic or&#160;<br/>localised infections until infections are controlled. In patients who have been exposed to tuberculosis and&#160;<br/>patients who have travelled in areas of high risk of tuberculosis or endemic mycoses, such as&#160;<br/>histoplasmosis, coccidioidomycosis, or blastomycosis, the risk and benefits of treatment with Humira&#160;<br/>should be considered prior to initiating therapy (see&#160;<i>Other opportunistic infections</i>).</p>
<p style="position:absolute;top:862px;left:106px;white-space:nowrap" class="ft2225">Patients who develop a new infection while undergoing treatment with Humira should be monitored&#160;<br/>closely and&#160;undergo a complete diagnostic evaluation. Administration of Humira should be discontinued if&#160;<br/>a patient develops a new serious infection or sepsis, and appropriate antimicrobial or antifungal therapy&#160;<br/>should be initiated until the infection is controlled. &#160;Physicians should exercise caution when considering&#160;<br/>the use of Humira in patients with a history of recurring infection or with underlying conditions which&#160;<br/>may predispose patients to infections, including the use of concomitant immunosuppressive medications.</p>
</div>
<!-- Page 223 -->
<a name="223"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page223-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2230">223</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft2233"><i>Serious infections</i></p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft2234">Serious infections,&#160;including sepsis,&#160;due to bacterial, mycobacterial, invasive fungal, parasitic, viral, or&#160;<br/>other opportunistic infections&#160;such as listeriosis, legionellosis and pneumocystis&#160;have been reported in&#160;<br/>patients receiving&#160;Humira. &#160;</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft2234">Other serious infections seen in clinical trials include pneumonia, pyelonephritis, septic arthritis and&#160;<br/>septicaemia. Hospitalisation or fatal outcomes associated with infections have been reported.&#160;</p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft2233"><i>Tuberculosis</i></p>
<p style="position:absolute;top:295px;left:106px;white-space:nowrap" class="ft2235">Tuberculosis, including reactivation and new onset of tuberculosis, has been reported in patients receiving&#160;<br/>Humira. &#160;Reports included cases of pulmonary and extra-pulmonary (i.e. disseminated) tuberculosis.&#160;</p>
<p style="position:absolute;top:352px;left:106px;white-space:nowrap" class="ft2234">Before initiation of therapy with Humira, all patients must be evaluated for both active or inactive&#160;<br/>(“latent”) tuberculosis infection. &#160;This evaluation should include a detailed medical assessment of patient&#160;<br/>history of tuberculosis or possible previous exposure to people with active tuberculosis and previous&#160;<br/>and/or current immunosuppressive therapy. &#160;Appropriate screening tests (i.e. tuberculin skin test and chest&#160;<br/>X-ray) should be performed in all patients (local recommendations may apply). &#160;It is recommended that&#160;<br/>the conduct and results of these tests&#160;are recorded in the&#160;Patient Reminder Card. &#160;Prescribers are reminded&#160;<br/>of the risk of false negative tuberculin skin test results, especially in patients who are severely ill or&#160;<br/>immunocompromised.&#160;</p>
<p style="position:absolute;top:522px;left:106px;white-space:nowrap" class="ft2232">If active tuberculosis is diagnosed, Humira therapy must not be initiated (see section 4.3).&#160;</p>
<p style="position:absolute;top:560px;left:106px;white-space:nowrap" class="ft2232">In all situations described below, the benefit/risk balance of therapy should be very carefully considered.</p>
<p style="position:absolute;top:598px;left:106px;white-space:nowrap" class="ft2235">If latent tuberculosis is suspected,&#160;a physician with expertise in the treatment of tuberculosis should be&#160;<br/>consulted.&#160;&#160;</p>
<p style="position:absolute;top:655px;left:106px;white-space:nowrap" class="ft2234">If latent tuberculosis is diagnosed, appropriate treatment must be started with anti-tuberculosis prophylaxis&#160;<br/>treatment before the initiation of Humira, and in accordance with local recommendations.&#160;</p>
<p style="position:absolute;top:712px;left:106px;white-space:nowrap" class="ft2234">Use&#160;of anti-tuberculosis prophylaxis treatment should also be considered before the initiation of Humira in&#160;<br/>patients with several or significant risk factors for tuberculosis despite a negative test for tuberculosis and&#160;<br/>in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment&#160;<br/>cannot be confirmed. &#160;</p>
<p style="position:absolute;top:807px;left:106px;white-space:nowrap" class="ft2234">Despite prophylactic treatment for tuberculosis, cases of reactivated tuberculosis have occurred in patients&#160;<br/>treated with Humira. Some patients who have been successfully treated for active tuberculosis have<br/>redeveloped tuberculosis while being treated with Humira.</p>
<p style="position:absolute;top:883px;left:106px;white-space:nowrap" class="ft2234">Patients should be instructed to seek medical advice if signs/symptoms suggestive of a tuberculosis&#160;<br/>infection (e.g., persistent cough, wasting/weight loss, low grade fever, listlessness) occur during or after&#160;<br/>therapy with Humira.&#160;</p>
<p style="position:absolute;top:959px;left:106px;white-space:nowrap" class="ft2233"><i>Other opportunistic infections</i></p>
<p style="position:absolute;top:997px;left:106px;white-space:nowrap" class="ft2234">Opportunistic infections, including invasive fungal infections have been observed in patients receiving&#160;<br/>Humira. These infections have not consistently been recognised in patients taking TNF-antagonists and&#160;<br/>this has resulted in delays in appropriate&#160;treatment, sometimes resulting in fatal outcomes.&#160;</p>
</div>
<!-- Page 224 -->
<a name="224"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page224-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2240">224</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft2244">For patients who develop the signs and symptoms such as fever, malaise, weight loss, sweats, cough,&#160;<br/>dyspnoea, and/or pulmonary infiltrates or other serious systemic illness with or without concomitant shock&#160;<br/>an invasive fungal infection should be suspected and administration of Humira should be promptly&#160;<br/>discontinued. &#160;Diagnosis and administration of empiric antifungal therapy in these patients should be made&#160;<br/>in consultation with a physician with expertise&#160;in the care of patients with invasive fungal infections.&#160;</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft2242">Hepatitis B reactivation</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft2245">Reactivation of hepatitis B has occurred in patients receiving a TNF-antagonist including Humira, who are&#160;<br/>chronic carriers of this virus (i.e. surface antigen positive). &#160;Some cases have had a fatal outcome. Patients&#160;<br/>should be tested for HBV infection before initiating treatment with Humira. For patients who test positive&#160;<br/>for hepatitis B infection, consultation with a physician with expertise in the treatment of hepatitis B&#160;is&#160;<br/>recommended.</p>
<p style="position:absolute;top:352px;left:106px;white-space:nowrap" class="ft2244">Carriers of HBV who require treatment with Humira should be closely monitored for signs and symptoms&#160;<br/>of active HBV infection throughout therapy and for several months following termination of therapy.&#160;<br/>Adequate data from treating patients&#160;who are carriers of HBV with anti-viral therapy in conjunction with&#160;<br/>TNF-antagonist therapy to prevent HBV reactivation are not available. In patients who develop HBV&#160;<br/>reactivation, Humira should be stopped and effective anti-viral therapy with appropriate supportive&#160;<br/>treatment should be initiated.&#160;</p>
<p style="position:absolute;top:485px;left:106px;white-space:nowrap" class="ft2242">Neurological events&#160;</p>
<p style="position:absolute;top:522px;left:106px;white-space:nowrap" class="ft2244">TNF-antagonists including Humira have been associated in rare instances with new onset or exacerbation&#160;<br/>of clinical symptoms and/or radiographic evidence of central nervous system demyelinating&#160;disease&#160;<br/>including multiple sclerosis and optic neuritis, and peripheral demyelinating disease, including Guillain-<br/>Barré syndrome. Prescribers should exercise caution in considering the use of Humira in patients with pre-<br/>existing or recent-onset central or peripheral nervous system demyelinating disorders; discontinuation of&#160;<br/>Humira should be considered if any of these disorders develop. There is a known association between&#160;<br/>intermediate uveitis and central demyelinating disorders. Neurologic evaluation should be performed in&#160;<br/>patients with non-infectious intermediate uveitis prior to the initiation of Humira therapy and regularly&#160;<br/>during treatment to assess for pre-existing or developing central demyelinating disorders.&#160;</p>
<p style="position:absolute;top:712px;left:106px;white-space:nowrap" class="ft2242">Allergic reactions</p>
<p style="position:absolute;top:750px;left:106px;white-space:nowrap" class="ft2245">Serious allergic reactions associated with Humira were rare during clinical trials. Non-serious allergic&#160;<br/>reactions associated with Humira were uncommon during clinical trials. Reports of serious allergic&#160;<br/>reactions including anaphylaxis have been received following Humira administration. If an anaphylactic&#160;<br/>reaction or other serious allergic reaction occurs, administration of Humira should be discontinued&#160;<br/>immediately and appropriate therapy initiated.&#160;</p>
<p style="position:absolute;top:864px;left:106px;white-space:nowrap" class="ft2242">Immunosuppression</p>
<p style="position:absolute;top:902px;left:106px;white-space:nowrap" class="ft2245">In a study of 64&#160;patients with rheumatoid arthritis that were treated with Humira, there was no evidence of&#160;<br/>depression of delayed-type hypersensitivity, depression of immunoglobulin levels, or change in&#160;<br/>enumeration of effector T-, B-, NK-cells, monocyte/macrophages, and neutrophils.</p>
<p style="position:absolute;top:978px;left:106px;white-space:nowrap" class="ft2242">Malignancies and lymphoproliferative disorders</p>
<p style="position:absolute;top:1016px;left:106px;white-space:nowrap" class="ft2245">In the controlled portions of clinical trials of TNF-antagonists, more cases of malignancies including&#160;<br/>lymphoma have been observed among patients receiving a TNF-antagonist compared with control&#160;<br/>patients. However, the&#160;occurrence was rare. In the post marketing setting, cases of leukaemia have been&#160;<br/>reported in patients treated with a TNF-antagonist. There is an increased background risk for lymphoma&#160;</p>
</div>
<!-- Page 225 -->
<a name="225"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page225-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2250">225</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft2254">and leukaemia in rheumatoid arthritis patients with long-standing, highly active, inflammatory disease,&#160;<br/>which complicates the risk estimation. With the current knowledge, a possible risk for the development of&#160;<br/>lymphomas, leukaemia, and other malignancies in patients treated with a TNF-antagonist cannot be&#160;<br/>excluded.</p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft2254">Malignancies, some fatal, have been reported among children, adolescents and young adults (up to&#160;<br/>22&#160;years of age) treated with TNF-antagonists (initiation of therapy&#160;≤&#160;18&#160;years of age), including&#160;<br/>adalimumab in the post marketing setting. Approximately half the cases&#160;were lymphomas. The other cases&#160;<br/>represented a variety of different malignancies and included rare malignancies usually associated with&#160;<br/>immunosuppression. A risk for the development of malignancies in children and adolescents treated with&#160;<br/>TNF-antagonists&#160;cannot be excluded.&#160;</p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft2255">Rare postmarketing cases of hepatosplenic T-cell lymphoma have been identified in patients treated with&#160;<br/>adalimumab. This rare type of T-cell&#160;lymphoma has a very aggressive disease course and is usually fatal.&#160;<br/>Some of these hepatosplenic T-cell lymphomas with Humira have occurred in young adult patients on&#160;<br/>concomitant treatment with azathioprine or 6-mercaptopurine used for inflammatory bowel disease. The&#160;<br/>potential risk with the combination of azathioprine or 6-mercaptopurine and Humira should be carefully&#160;<br/>considered. A risk for the development of hepatosplenic T-cell lymphoma in patients treated with Humira&#160;<br/>cannot be excluded (see section 4.8).</p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft2255">No studies have been conducted that include patients with a history of malignancy or in whom&#160;treatment&#160;<br/>with Humira is continued following development of malignancy. &#160;Thus,&#160;additional caution should be&#160;<br/>exercised in considering Humira treatment of these patients (see section 4.8).</p>
<p style="position:absolute;top:541px;left:106px;white-space:nowrap" class="ft2254">All patients, and in particular patients with a medical history of&#160;extensive immunosuppressant therapy or&#160;<br/>psoriasis patients with a history of PUVA treatment should be examined for the presence of non-<br/>melanoma skin cancer prior to and during treatment with Humira. &#160;Melanoma and Merkel cell carcinoma&#160;<br/>have also been reported in patients treated with TNF-antagonists including adalimumab (see section 4.8).</p>
<p style="position:absolute;top:636px;left:106px;white-space:nowrap" class="ft2254">In an exploratory clinical trial evaluating the use of another TNF-antagonist, infliximab, in patients with&#160;<br/>moderate to severe chronic obstructive pulmonary disease (COPD), more&#160;malignancies, mostly in the lung&#160;<br/>or head and neck, were reported in infliximab-treated patients compared with control patients. All patients&#160;<br/>had a history of heavy smoking. Therefore, caution should be exercised when using any TNF-antagonist in&#160;<br/>COPD&#160;patients, as well as in patients with increased risk for malignancy due to heavy smoking.</p>
<p style="position:absolute;top:750px;left:106px;white-space:nowrap" class="ft2254">With current data it is not known if adalimumab treatment influences the risk for developing dysplasia or&#160;<br/>colon cancer. &#160;All patients with ulcerative colitis who are at increased risk for dysplasia or colon&#160;<br/>carcinoma (for example, patients with long-standing ulcerative colitis or primary sclerosing cholangitis),&#160;<br/>or who had a prior history of dysplasia or colon carcinoma should be screened for dysplasia at regular&#160;<br/>intervals before therapy and throughout their disease course. This evaluation should include colonoscopy&#160;<br/>and biopsies per local recommendations.</p>
<p style="position:absolute;top:883px;left:106px;white-space:nowrap" class="ft2252">Haematologic reactions</p>
<p style="position:absolute;top:921px;left:106px;white-space:nowrap" class="ft2255">Rare reports of pancytopenia including aplastic anaemia have been reported with&#160;TNF-antagonists. &#160;<br/>Adverse events of the haematologic system, including medically significant cytopenia (e.g.&#160;<br/>thrombocytopenia, leukopenia) have been reported with Humira. All patients should be advised to seek&#160;<br/>immediate medical attention if they develop signs and symptoms suggestive of blood dyscrasias (e.g.&#160;<br/>persistent fever, bruising, bleeding, pallor) while on Humira. Discontinuation of Humira therapy should be&#160;<br/>considered in patients with confirmed significant haematologic abnormalities.</p>
<p style="position:absolute;top:1054px;left:106px;white-space:nowrap" class="ft2252">Vaccinations&#160;</p>
</div>
<!-- Page 226 -->
<a name="226"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page226-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2260">226</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft2264">Similar antibody responses to the standard 23-valent pneumococcal vaccine and the influenza trivalent&#160;<br/>virus vaccination were observed in a study in 226&#160;adult subjects with rheumatoid arthritis who were&#160;<br/>treated with adalimumab or placebo. No data are available on the secondary transmission of infection by&#160;<br/>live vaccines in patients receiving Humira. &#160;</p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft2264">It is recommended that paediatric patients, if possible, be brought up to date with all immunisations in&#160;<br/>agreement with current immunisation guidelines prior to&#160;initiating Humira therapy.</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft2264">Patients on Humira may receive concurrent vaccinations, except for live vaccines. Administration of live&#160;<br/>vaccines&#160;(e.g., BCG vaccine)&#160;to&#160;infants exposed to adalimumab in utero is not recommended for 5&#160;months&#160;<br/>following the mother’s last adalimumab injection during pregnancy.</p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft2262">Congestive heart failure</p>
<p style="position:absolute;top:352px;left:106px;white-space:nowrap" class="ft2264">In a clinical trial with another TNF-antagonist worsening congestive heart failure and increased mortality&#160;<br/>due to congestive heart failure have been observed. Cases of worsening&#160;congestive heart failure have also&#160;<br/>been reported in patients receiving Humira. Humira should be used with caution in patients with mild&#160;<br/>heart failure (NYHA class I/II). Humira is contraindicated in moderate to severe heart failure (see section&#160;<br/>4.3). Treatment with Humira must be discontinued in patients who develop new or worsening symptoms&#160;<br/>of congestive heart failure.</p>
<p style="position:absolute;top:485px;left:106px;white-space:nowrap" class="ft2262">Autoimmune processes</p>
<p style="position:absolute;top:522px;left:106px;white-space:nowrap" class="ft2264">Treatment with Humira may result in the formation of autoimmune antibodies.&#160;The impact of long-term&#160;<br/>treatment with Humira on the development of autoimmune diseases is unknown.&#160;If a patient develops&#160;<br/>symptoms suggestive of a lupus-like syndrome following treatment with Humira and is positive for&#160;<br/>antibodies against double-stranded DNA, further treatment with Humira should not be given (see section&#160;<br/>4.8).</p>
<p style="position:absolute;top:636px;left:106px;white-space:nowrap" class="ft2262">Concurrent administration of biologic DMARDS or TNF-antagonists</p>
<p style="position:absolute;top:674px;left:106px;white-space:nowrap" class="ft2265">Serious infections were seen in clinical studies with concurrent use of anakinra and another&#160;<br/>TNF-antagonist, etanercept, with no added clinical benefit compared to etanercept alone. Because of the&#160;<br/>nature of the adverse events seen with the combination of etanercept and anakinra therapy, similar&#160;<br/>toxicities may also result from the combination of anakinra and other TNF-antagonists. Therefore, the&#160;<br/>combination of adalimumab and anakinra is not recommended. (See section 4.5).</p>
<p style="position:absolute;top:788px;left:106px;white-space:nowrap" class="ft2265">Concomitant administration of adalimumab with other biologic DMARDS (e.g, anakinra and abatacept) or&#160;<br/>other TNF-antagonists is not recommended based upon the possible increased risk for infections,&#160;<br/>including serious infections and other potential pharmacological interactions. (See section 4.5).</p>
<p style="position:absolute;top:864px;left:106px;white-space:nowrap" class="ft2262">Surgery</p>
<p style="position:absolute;top:902px;left:106px;white-space:nowrap" class="ft2264">There is limited safety experience of surgical procedures in patients treated with Humira. The long half-<br/>life of adalimumab should be taken into consideration if a surgical procedure is planned. &#160;A patient who&#160;<br/>requires surgery while on Humira should be closely monitored for infections, and appropriate actions&#160;<br/>should be taken. There is limited safety experience in patients undergoing arthroplasty while receiving&#160;<br/>Humira.&#160;</p>
</div>
<!-- Page 227 -->
<a name="227"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page227-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2270">227</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft2272">Small bowel obstruction</p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft2274">Failure to respond to treatment for Crohn’s disease may indicate the presence of fixed fibrotic stricture&#160;<br/>that may require surgical treatment. Available data suggest that Humira does not worsen or cause&#160;<br/>strictures.</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft2272">Elderly</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft2274">The frequency of serious infections among Humira treated subjects over 65&#160;years of age (3.7%)&#160;was&#160;<br/>higher than for those under 65&#160;years of age (1.5%). Some of those had a fatal outcome. Particular attention&#160;<br/>regarding the risk for infection should be paid when treating the elderly.</p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft2272">Paediatric population</p>
<p style="position:absolute;top:352px;left:106px;white-space:nowrap" class="ft2272">See Vaccinations above.</p>
<p style="position:absolute;top:390px;left:106px;white-space:nowrap" class="ft2271"><b>4.5</b></p>
<p style="position:absolute;top:390px;left:148px;white-space:nowrap" class="ft2271"><b>Interaction with&#160;other medicinal products and other forms of interaction&#160;</b></p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft2275">Humira has been studied in rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and psoriatic&#160;<br/>arthritis patients taking Humira as monotherapy and those taking concomitant methotrexate. &#160;Antibody&#160;<br/>formation was lower when Humira was given together with methotrexate in comparison with use as&#160;<br/>monotherapy. Administration of Humira without methotrexate resulted in increased formation of&#160;<br/>antibodies, increased clearance and reduced efficacy of&#160;adalimumab (see section 5.1).&#160;</p>
<p style="position:absolute;top:541px;left:106px;white-space:nowrap" class="ft2275">The combination of Humira and anakinra is not recommended (see section 4.4 “Concurrent administration&#160;<br/>of biologic DMARDS or TNF-antagonists”).&#160;</p>
<p style="position:absolute;top:598px;left:106px;white-space:nowrap" class="ft2275">The combination of Humira and abatacept is not recommended (see section 4.4 “Concurrent&#160;<br/>administration of biologic DMARDS or TNF-antagonists”).</p>
<p style="position:absolute;top:655px;left:106px;white-space:nowrap" class="ft2271"><b>4.6</b></p>
<p style="position:absolute;top:655px;left:148px;white-space:nowrap" class="ft2271"><b>Fertility, pregnancy and lactation</b></p>
<p style="position:absolute;top:693px;left:106px;white-space:nowrap" class="ft2272">Women of childbearing potential</p>
<p style="position:absolute;top:731px;left:106px;white-space:nowrap" class="ft2275">Women of childbearing potential&#160;should consider the&#160;use&#160;of&#160;adequate contraception to prevent pregnancy&#160;<br/>and continue&#160;its use for at least five months after the last Humira treatment.</p>
<p style="position:absolute;top:788px;left:106px;white-space:nowrap" class="ft2272">Pregnancy</p>
<p style="position:absolute;top:826px;left:106px;white-space:nowrap" class="ft2274">A large number (approximately 2100) of prospectively collected pregnancies exposed to adalimumab&#160;<br/>resulting in live birth with known outcomes, including more than 1500 exposed during the first trimester,&#160;<br/>does not indicate an increase in the rate of malformation in the newborn.</p>
<p style="position:absolute;top:902px;left:106px;white-space:nowrap" class="ft2275">In a prospective cohort registry, 257 women with rheumatoid arthritis (RA) or Crohn’s disease (CD)&#160;<br/>treated with adalimumab at least during the first trimester&#160;and 120 women with RA or CD not treated with&#160;<br/>adalimumab were enrolled. &#160;The primary endpoint was the birth prevalence of major birth defects. The&#160;<br/>rate of&#160;pregnancies ending with at least one live born infant with a major birth defect was 6/69 (8.7%)&#160;in&#160;<br/>the adalimumab-treated women with RA and 5/74 (6.8%) in the untreated women with RA (unadjusted&#160;<br/>OR 1.31, 95% CI 0.38-4.52) and 16/152 (10.5%) in the adalimumab-treated women with CD and 3/32&#160;<br/>(9.4%) in the untreated women with CD (unadjusted OR 1.14, 95% CI&#160;0.31-4.16). The adjusted OR&#160;<br/>(accounting for baseline differences) was&#160;1.10&#160;(95% CI 0.45-2.73) with RA and CD combined. There were&#160;<br/>no distinct differences between&#160;adalimumab-treated and untreated women&#160;for the secondary&#160;endpoints&#160;<br/>spontaneous abortions, minor birth defects, preterm&#160;delivery, birth size and serious or opportunistic&#160;</p>
</div>
<!-- Page 228 -->
<a name="228"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page228-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2280">228</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft2285">infections&#160;and no stillbirths or malignancies were reported.&#160;The interpretation of data&#160;may be impacted due&#160;<br/>to methodological limitations of the study, including small sample size&#160;and non-randomized design.</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft2285">In a developmental toxicity study conducted in monkeys, there was no indication of maternal toxicity,&#160;<br/>embryotoxicity or teratogenicity. Preclinical data on postnatal toxicity of adalimumab are not available&#160;<br/>(see section 5.3).</p>
<p style="position:absolute;top:220px;left:106px;white-space:nowrap" class="ft2282">Due to its inhibition of TNF</p>
<p style="position:absolute;top:218px;left:292px;white-space:nowrap" class="ft2286">, adalimumab administered during pregnancy could affect normal immune&#160;</p>
<p style="position:absolute;top:239px;left:106px;white-space:nowrap" class="ft2282">responses in the newborn.&#160;&#160;Adalimumab should only be used during pregnancy if clearly needed.</p>
<p style="position:absolute;top:277px;left:106px;white-space:nowrap" class="ft2285">Adalimumab may cross the placenta into the serum of infants born to women treated with adalimumab&#160;<br/>during pregnancy. Consequently, these infants may be at increased risk for infection. Administration of&#160;<br/>live vaccines&#160;(e.g., BCG vaccine)&#160;to infants exposed to&#160;adalimumab in utero is not recommended for&#160;<br/>5&#160;months following the mother’s last adalimumab injection during pregnancy.</p>
<p style="position:absolute;top:372px;left:106px;white-space:nowrap" class="ft2282">Breast-feeding</p>
<p style="position:absolute;top:410px;left:106px;white-space:nowrap" class="ft2284">Limited information from the published literature indicates that adalimumab is excreted in breast milk at&#160;<br/>very low concentrations with the presence of adalimumab in human milk at concentrations of 0.1% to 1%&#160;<br/>of the maternal serum level. Given orally, immunoglobulin G proteins undergo intestinal proteolysis and&#160;<br/>have poor bioavailability. No effects on the breastfed newborns/infants are anticipated. Consequently,&#160;<br/>Humira can be used during breastfeeding.</p>
<p style="position:absolute;top:523px;left:106px;white-space:nowrap" class="ft2282">Fertility</p>
<p style="position:absolute;top:562px;left:106px;white-space:nowrap" class="ft2282">Preclinical data on fertility effects of adalimumab are not available.</p>
<p style="position:absolute;top:599px;left:106px;white-space:nowrap" class="ft2281"><b>4.7</b></p>
<p style="position:absolute;top:599px;left:148px;white-space:nowrap" class="ft2281"><b>Effects on ability to drive and use machines&#160;</b></p>
<p style="position:absolute;top:638px;left:106px;white-space:nowrap" class="ft2285">Humira may have a minor influence on the&#160;ability to drive and use machines. Vertigo and visual&#160;<br/>impairment may occur following administration of Humira (see section 4.8).</p>
<p style="position:absolute;top:694px;left:106px;white-space:nowrap" class="ft2281"><b>4.8</b></p>
<p style="position:absolute;top:694px;left:148px;white-space:nowrap" class="ft2281"><b>Undesirable effects</b></p>
<p style="position:absolute;top:732px;left:106px;white-space:nowrap" class="ft2282">Summary of the safety profile</p>
<p style="position:absolute;top:770px;left:106px;white-space:nowrap" class="ft2284">Humira was studied in 9,506 patients in pivotal controlled and open label trials for up to 60 months or&#160;<br/>more. &#160;These trials included rheumatoid arthritis patients with short term and long standing disease,&#160;<br/>juvenile idiopathic arthritis (polyarticular juvenile idiopathic arthritis and enthesitis-related arthritis) as&#160;<br/>well as&#160;axial spondyloarthritis (ankylosing spondylitis and axial spondyloarthritis without radiographic&#160;<br/>evidence of AS), psoriatic arthritis, Crohn’s disease, ulcerative colitis, psoriasis, hidradenitis suppurativa&#160;<br/>and uveitis patients. The pivotal controlled studies involved 6,089 patients receiving Humira and 3,801&#160;<br/>patients receiving placebo or active comparator during the controlled period.</p>
<p style="position:absolute;top:922px;left:106px;white-space:nowrap" class="ft2284">The proportion of patients who discontinued treatment due to adverse events during the double-blind,&#160;<br/>controlled portion&#160;of pivotal studies&#160;was 5.9% for patients taking Humira and 5.4% for control treated&#160;<br/>patients.</p>
<p style="position:absolute;top:998px;left:106px;white-space:nowrap" class="ft2285">The&#160;most commonly reported adverse reactions are infections (such as nasopharyngitis, upper respiratory&#160;<br/>tract infection and sinusitis), injection site reactions&#160;(erythema, itching, haemorrhage, pain or swelling),&#160;<br/>headache and musculoskeletal pain.</p>
</div>
<!-- Page 229 -->
<a name="229"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page229-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2290">229</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft2294">Serious adverse reactions have been reported for Humira. TNF-antagonists, such as Humira affect the&#160;<br/>immune system and their use may affect the body’s defence against infection and cancer.<br/>Fatal and life-threatening infections (including sepsis, opportunistic infections and TB), HBV reactivation&#160;<br/>and various malignancies (including leukaemia, lymphoma and HSTCL) have also been reported with use&#160;<br/>of Humira.</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft2295">Serious haematological, neurological and autoimmune reactions have also been reported. These include&#160;<br/>rare reports of pancytopenia, aplastic anaemia, central and peripheral demyelinating events and reports of&#160;<br/>lupus, lupus-related conditions and Stevens-Johnson syndrome.</p>
<p style="position:absolute;top:276px;left:106px;white-space:nowrap" class="ft2292">Paediatric population</p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft2294">In&#160;general, the adverse events in paediatric patients were similar in frequency and type to those seen in&#160;<br/>adult patients.</p>
<p style="position:absolute;top:370px;left:106px;white-space:nowrap" class="ft2292">Tabulated list of adverse reactions</p>
<p style="position:absolute;top:409px;left:106px;white-space:nowrap" class="ft2297">The following list of adverse reactions is based on experience from clinical trials and on postmarketing&#160;<br/>experience and are displayed by system organ class and frequency in Table&#160;4&#160;below: very common&#160;<br/>(</p>
<p style="position:absolute;top:446px;left:111px;white-space:nowrap" class="ft2296">&#160;1/10); common (&#160;1/100&#160;to&#160;&lt;&#160;1/10); uncommon (&#160;1/1,000&#160;to&#160;&lt;&#160;1/100); rare (&#160;1/10,000 to&#160;&lt;&#160;1/1,000);&#160;</p>
<p style="position:absolute;top:467px;left:106px;white-space:nowrap" class="ft2295">and not known (cannot be estimated from the available data). Within each frequency grouping,&#160;<br/>undesirable effects are presented in order of decreasing seriousness. The highest frequency seen among the&#160;<br/>various indications has been included. An asterisk (*) appears in the SOC column if further information is&#160;<br/>found elsewhere in sections 4.3, 4.4 and 4.8.</p>
<p style="position:absolute;top:562px;left:433px;white-space:nowrap" class="ft2291"><b>Table&#160;4</b></p>
<p style="position:absolute;top:581px;left:390px;white-space:nowrap" class="ft2291"><b>Undesirable Effects</b></p>
<p style="position:absolute;top:628px;left:132px;white-space:nowrap" class="ft2291"><b>System&#160;Organ Class</b></p>
<p style="position:absolute;top:628px;left:341px;white-space:nowrap" class="ft2291"><b>Frequency</b></p>
<p style="position:absolute;top:628px;left:566px;white-space:nowrap" class="ft2291"><b>Adverse Reaction</b></p>
<p style="position:absolute;top:661px;left:114px;white-space:nowrap" class="ft2294">Infections and&#160;<br/>infestations*</p>
<p style="position:absolute;top:661px;left:309px;white-space:nowrap" class="ft2292">Very&#160;common</p>
<p style="position:absolute;top:661px;left:465px;white-space:nowrap" class="ft2295">Respiratory tract infections (including lower and&#160;<br/>upper respiratory tract infection, pneumonia,&#160;<br/>sinusitis, pharyngitis, nasopharyngitis and&#160;<br/>pneumonia herpes viral)</p>
<p style="position:absolute;top:766px;left:309px;white-space:nowrap" class="ft2292">Common</p>
<p style="position:absolute;top:761px;left:465px;white-space:nowrap" class="ft2298">Systemic infections&#160;(including sepsis, candidiasis&#160;<br/>and influenza),<br/>intestinal infections&#160;(including gastroenteritis&#160;<br/>viral),<br/>skin and soft tissue infections (including&#160;<br/>paronychia, cellulitis, impetigo, necrotising&#160;<br/>fasciitis and herpes zoster),<br/>ear infections,<br/>oral infections&#160;(including herpes simplex, oral&#160;<br/>herpes and tooth&#160;infections),&#160;<br/>reproductive tract infections&#160;(including&#160;<br/>vulvovaginal mycotic infection),&#160;<br/>urinary tract infections (including&#160;<br/>pyelonephritis),<br/>fungal infections,<br/>joint infections</p>
</div>
<!-- Page 230 -->
<a name="230"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page230-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2300">230</p>
<p style="position:absolute;top:96px;left:132px;white-space:nowrap" class="ft2301"><b>System&#160;Organ Class</b></p>
<p style="position:absolute;top:96px;left:341px;white-space:nowrap" class="ft2301"><b>Frequency</b></p>
<p style="position:absolute;top:96px;left:566px;white-space:nowrap" class="ft2301"><b>Adverse Reaction</b></p>
<p style="position:absolute;top:125px;left:309px;white-space:nowrap" class="ft2302">Uncommon</p>
<p style="position:absolute;top:125px;left:465px;white-space:nowrap" class="ft2304">Neurological infections (including viral&#160;<br/>meningitis),<br/>opportunistic infections and tuberculosis&#160;<br/>(including coccidioidomycosis, histoplasmosis&#160;<br/>and mycobacterium avium complex infection),&#160;<br/>bacterial infections,<br/>eye&#160;infections,<br/>diverticulitis1)</p>
<p style="position:absolute;top:300px;left:114px;white-space:nowrap" class="ft2304">Neoplasms benign,&#160;<br/>malignant and unspecified&#160;<br/>(including cysts and&#160;<br/>polyps)*</p>
<p style="position:absolute;top:300px;left:309px;white-space:nowrap" class="ft2302">Common</p>
<p style="position:absolute;top:300px;left:465px;white-space:nowrap" class="ft2308">Skin cancer excluding melanoma (including&#160;<br/>basal cell carcinoma and squamous cell&#160;<br/>carcinoma),<br/>benign neoplasm</p>
<p style="position:absolute;top:405px;left:309px;white-space:nowrap" class="ft2302">Uncommon</p>
<p style="position:absolute;top:405px;left:465px;white-space:nowrap" class="ft2305">Lymphoma**,&#160;<br/>solid organ neoplasm (including breast cancer,&#160;<br/>lung neoplasm and thyroid neoplasm),&#160;<br/>melanoma**</p>
<p style="position:absolute;top:505px;left:309px;white-space:nowrap" class="ft2302">Rare</p>
<p style="position:absolute;top:505px;left:465px;white-space:nowrap" class="ft2302">Leukaemia1)</p>
<p style="position:absolute;top:553px;left:309px;white-space:nowrap" class="ft2302">Not known</p>
<p style="position:absolute;top:553px;left:465px;white-space:nowrap" class="ft2308">Hepatosplenic T-cell lymphoma1)<br/>Merkel cell carcinoma (neuroendocrine&#160;<br/>carcinoma of the skin)1),<br/>Kaposi’s sarcoma</p>
<p style="position:absolute;top:666px;left:114px;white-space:nowrap" class="ft2304">Blood and the lymphatic&#160;<br/>system disorders*</p>
<p style="position:absolute;top:666px;left:309px;white-space:nowrap" class="ft2302">Very common</p>
<p style="position:absolute;top:666px;left:465px;white-space:nowrap" class="ft2308">Leukopenia (including neutropenia and&#160;<br/>agranulocytosis),&#160;<br/>anaemia</p>
<p style="position:absolute;top:752px;left:309px;white-space:nowrap" class="ft2302">Common</p>
<p style="position:absolute;top:752px;left:465px;white-space:nowrap" class="ft2304">Leucocytosis,<br/>thrombocytopenia</p>
<p style="position:absolute;top:810px;left:309px;white-space:nowrap" class="ft2302">Uncommon</p>
<p style="position:absolute;top:810px;left:465px;white-space:nowrap" class="ft2302">Idiopathic thrombocytopenic purpura</p>
<p style="position:absolute;top:849px;left:309px;white-space:nowrap" class="ft2302">Rare</p>
<p style="position:absolute;top:849px;left:465px;white-space:nowrap" class="ft2302">Pancytopenia</p>
<p style="position:absolute;top:892px;left:114px;white-space:nowrap" class="ft2302">Immune system disorders*&#160;Common</p>
<p style="position:absolute;top:892px;left:465px;white-space:nowrap" class="ft2308">Hypersensitivity,<br/>allergies (including seasonal allergy)</p>
<p style="position:absolute;top:963px;left:309px;white-space:nowrap" class="ft2302">Uncommon</p>
<p style="position:absolute;top:963px;left:465px;white-space:nowrap" class="ft2308">Sarcoidosis1),<br/>vasculitis</p>
<p style="position:absolute;top:1034px;left:309px;white-space:nowrap" class="ft2302">Rare</p>
<p style="position:absolute;top:1034px;left:465px;white-space:nowrap" class="ft2302">Anaphylaxis1)</p>
<p style="position:absolute;top:1082px;left:114px;white-space:nowrap" class="ft2302">Metabolism and nutrition&#160;</p>
<p style="position:absolute;top:1082px;left:309px;white-space:nowrap" class="ft2302">Very common</p>
<p style="position:absolute;top:1082px;left:465px;white-space:nowrap" class="ft2302">Lipids increased</p>
</div>
<!-- Page 231 -->
<a name="231"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page231-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2310">231</p>
<p style="position:absolute;top:96px;left:132px;white-space:nowrap" class="ft2311"><b>System&#160;Organ Class</b></p>
<p style="position:absolute;top:96px;left:341px;white-space:nowrap" class="ft2311"><b>Frequency</b></p>
<p style="position:absolute;top:96px;left:566px;white-space:nowrap" class="ft2311"><b>Adverse Reaction</b></p>
<p style="position:absolute;top:125px;left:114px;white-space:nowrap" class="ft2312">disorders</p>
<p style="position:absolute;top:153px;left:309px;white-space:nowrap" class="ft2312">Common</p>
<p style="position:absolute;top:153px;left:465px;white-space:nowrap" class="ft2318">Hypokalaemia,&#160;<br/>uric acid increased,&#160;<br/>blood sodium abnormal,<br/>hypocalcaemia,<br/>hyperglycaemia,<br/>hypophosphatemia,<br/>dehydration</p>
<p style="position:absolute;top:355px;left:114px;white-space:nowrap" class="ft2312">Psychiatric disorders</p>
<p style="position:absolute;top:355px;left:309px;white-space:nowrap" class="ft2312">Common</p>
<p style="position:absolute;top:355px;left:465px;white-space:nowrap" class="ft2318">Mood alterations (including depression),&#160;<br/>anxiety,<br/>insomnia</p>
<p style="position:absolute;top:450px;left:114px;white-space:nowrap" class="ft2312">Nervous system disorders*&#160;Very common</p>
<p style="position:absolute;top:450px;left:465px;white-space:nowrap" class="ft2312">Headache</p>
<p style="position:absolute;top:498px;left:309px;white-space:nowrap" class="ft2312">Common</p>
<p style="position:absolute;top:498px;left:465px;white-space:nowrap" class="ft2318">Paraesthesias (including hypoesthesia),<br/>migraine,<br/>nerve root compression</p>
<p style="position:absolute;top:588px;left:309px;white-space:nowrap" class="ft2312">Uncommon</p>
<p style="position:absolute;top:588px;left:465px;white-space:nowrap" class="ft2314">Cerebrovascular accident1),<br/>tremor,<br/>neuropathy &#160;</p>
<p style="position:absolute;top:665px;left:309px;white-space:nowrap" class="ft2312">Rare</p>
<p style="position:absolute;top:665px;left:465px;white-space:nowrap" class="ft2314">Multiple sclerosis,<br/>demyelinating disorders (e.g. optic neuritis,&#160;<br/>Guillain-Barré syndrome)&#160;1)</p>
<p style="position:absolute;top:755px;left:114px;white-space:nowrap" class="ft2312">Eye&#160;disorders</p>
<p style="position:absolute;top:755px;left:309px;white-space:nowrap" class="ft2312">Common</p>
<p style="position:absolute;top:755px;left:465px;white-space:nowrap" class="ft2318">Visual impairment,<br/>conjunctivitis,<br/>blepharitis,<br/>eye swelling</p>
<p style="position:absolute;top:868px;left:309px;white-space:nowrap" class="ft2312">Uncommon</p>
<p style="position:absolute;top:868px;left:465px;white-space:nowrap" class="ft2312">Diplopia</p>
<p style="position:absolute;top:912px;left:114px;white-space:nowrap" class="ft2314">Ear and labyrinth&#160;<br/>disorders&#160;</p>
<p style="position:absolute;top:912px;left:309px;white-space:nowrap" class="ft2312">Common</p>
<p style="position:absolute;top:912px;left:465px;white-space:nowrap" class="ft2312">Vertigo</p>
<p style="position:absolute;top:955px;left:309px;white-space:nowrap" class="ft2312">Uncommon</p>
<p style="position:absolute;top:955px;left:465px;white-space:nowrap" class="ft2314">Deafness,&#160;<br/>tinnitus</p>
<p style="position:absolute;top:1017px;left:114px;white-space:nowrap" class="ft2312">Cardiac disorders*&#160;</p>
<p style="position:absolute;top:1017px;left:309px;white-space:nowrap" class="ft2312">Common</p>
<p style="position:absolute;top:1017px;left:465px;white-space:nowrap" class="ft2312">Tachycardia</p>
<p style="position:absolute;top:1065px;left:309px;white-space:nowrap" class="ft2312">Uncommon</p>
<p style="position:absolute;top:1065px;left:465px;white-space:nowrap" class="ft2312">Myocardial infarction1),</p>
</div>
<!-- Page 232 -->
<a name="232"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page232-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2320">232</p>
<p style="position:absolute;top:96px;left:132px;white-space:nowrap" class="ft2321"><b>System&#160;Organ Class</b></p>
<p style="position:absolute;top:96px;left:341px;white-space:nowrap" class="ft2321"><b>Frequency</b></p>
<p style="position:absolute;top:96px;left:566px;white-space:nowrap" class="ft2321"><b>Adverse Reaction</b></p>
<p style="position:absolute;top:129px;left:465px;white-space:nowrap" class="ft2328">arrhythmia,<br/>congestive heart failure</p>
<p style="position:absolute;top:195px;left:309px;white-space:nowrap" class="ft2322">Rare</p>
<p style="position:absolute;top:195px;left:465px;white-space:nowrap" class="ft2322">Cardiac arrest</p>
<p style="position:absolute;top:239px;left:114px;white-space:nowrap" class="ft2322">Vascular disorders</p>
<p style="position:absolute;top:239px;left:309px;white-space:nowrap" class="ft2322">Common</p>
<p style="position:absolute;top:239px;left:465px;white-space:nowrap" class="ft2328">Hypertension,&#160;<br/>flushing,&#160;<br/>haematoma</p>
<p style="position:absolute;top:329px;left:309px;white-space:nowrap" class="ft2322">Uncommon</p>
<p style="position:absolute;top:329px;left:465px;white-space:nowrap" class="ft2324">Aortic&#160;aneurysm,<br/>vascular arterial occlusion,<br/>thrombophlebitis &#160;&#160;</p>
<p style="position:absolute;top:410px;left:114px;white-space:nowrap" class="ft2324">Respiratory, thoracic and&#160;<br/>mediastinal disorders*</p>
<p style="position:absolute;top:410px;left:309px;white-space:nowrap" class="ft2322">Common</p>
<p style="position:absolute;top:410px;left:465px;white-space:nowrap" class="ft2328">Asthma,<br/>dyspnoea,<br/>cough</p>
<p style="position:absolute;top:500px;left:309px;white-space:nowrap" class="ft2322">Uncommon</p>
<p style="position:absolute;top:500px;left:465px;white-space:nowrap" class="ft2325">Pulmonary embolism1),<br/>interstitial lung disease,&#160;<br/>chronic obstructive pulmonary disease,<br/>pneumonitis,<br/>pleural effusion1)</p>
<p style="position:absolute;top:619px;left:309px;white-space:nowrap" class="ft2322">Rare</p>
<p style="position:absolute;top:615px;left:465px;white-space:nowrap" class="ft2322">Pulmonary fibrosis1)</p>
<p style="position:absolute;top:658px;left:114px;white-space:nowrap" class="ft2322">Gastrointestinal disorders</p>
<p style="position:absolute;top:658px;left:309px;white-space:nowrap" class="ft2322">Very common</p>
<p style="position:absolute;top:658px;left:465px;white-space:nowrap" class="ft2328">Abdominal pain,&#160;<br/>nausea and vomiting</p>
<p style="position:absolute;top:725px;left:309px;white-space:nowrap" class="ft2322">Common</p>
<p style="position:absolute;top:725px;left:465px;white-space:nowrap" class="ft2324">GI haemorrhage,&#160;<br/>dyspepsia,<br/>gastroesophageal reflux disease,<br/>sicca syndrome</p>
<p style="position:absolute;top:820px;left:309px;white-space:nowrap" class="ft2322">Uncommon</p>
<p style="position:absolute;top:820px;left:465px;white-space:nowrap" class="ft2324">Pancreatitis,&#160;<br/>dysphagia,<br/>face oedema</p>
<p style="position:absolute;top:901px;left:309px;white-space:nowrap" class="ft2322">Rare</p>
<p style="position:absolute;top:901px;left:465px;white-space:nowrap" class="ft2322">Intestinal perforation1)</p>
<p style="position:absolute;top:949px;left:114px;white-space:nowrap" class="ft2322">Hepato-biliary disorders*</p>
<p style="position:absolute;top:949px;left:309px;white-space:nowrap" class="ft2322">Very Common</p>
<p style="position:absolute;top:949px;left:465px;white-space:nowrap" class="ft2322">Elevated liver enzymes</p>
<p style="position:absolute;top:993px;left:309px;white-space:nowrap" class="ft2322">Uncommon</p>
<p style="position:absolute;top:993px;left:465px;white-space:nowrap" class="ft2324">Cholecystitis and cholelithiasis,<br/>hepatic steatosis,<br/>bilirubin increased</p>
<p style="position:absolute;top:1074px;left:309px;white-space:nowrap" class="ft2322">Rare</p>
<p style="position:absolute;top:1074px;left:465px;white-space:nowrap" class="ft2322">Hepatitis</p>
</div>
<!-- Page 233 -->
<a name="233"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page233-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2330">233</p>
<p style="position:absolute;top:96px;left:132px;white-space:nowrap" class="ft2331"><b>System&#160;Organ Class</b></p>
<p style="position:absolute;top:96px;left:341px;white-space:nowrap" class="ft2331"><b>Frequency</b></p>
<p style="position:absolute;top:96px;left:566px;white-space:nowrap" class="ft2331"><b>Adverse Reaction</b></p>
<p style="position:absolute;top:129px;left:465px;white-space:nowrap" class="ft23310">reactivation of hepatitis B1)&#160;<br/>autoimmune&#160;hepatitis1)</p>
<p style="position:absolute;top:195px;left:309px;white-space:nowrap" class="ft2332">Not known</p>
<p style="position:absolute;top:195px;left:465px;white-space:nowrap" class="ft2332">Liver failure1)</p>
<p style="position:absolute;top:243px;left:114px;white-space:nowrap" class="ft2334">Skin and subcutaneous&#160;<br/>tissue disorders</p>
<p style="position:absolute;top:243px;left:309px;white-space:nowrap" class="ft2332">Very Common</p>
<p style="position:absolute;top:243px;left:465px;white-space:nowrap" class="ft2332">Rash (including exfoliative rash)</p>
<p style="position:absolute;top:287px;left:309px;white-space:nowrap" class="ft2332">Common</p>
<p style="position:absolute;top:287px;left:465px;white-space:nowrap" class="ft2335">Worsening or new onset of psoriasis (including&#160;<br/>palmoplantar pustular psoriasis)1),<br/>urticaria,<br/>bruising (including purpura),&#160;<br/>dermatitis (including eczema),<br/>onychoclasis,&#160;<br/>hyperhidrosis,<br/>alopecia1),<br/>pruritus&#160;</p>
<p style="position:absolute;top:477px;left:309px;white-space:nowrap" class="ft2332">Uncommon</p>
<p style="position:absolute;top:477px;left:465px;white-space:nowrap" class="ft2334">Night sweats,<br/>scar</p>
<p style="position:absolute;top:539px;left:309px;white-space:nowrap" class="ft2332">Rare</p>
<p style="position:absolute;top:539px;left:465px;white-space:nowrap" class="ft23310">Erythema multiforme1),<br/>Stevens-Johnson syndrome1),<br/>angioedema1),<br/>cutaneous vasculitis1)<br/>lichenoid skin&#160;reaction1)</p>
<p style="position:absolute;top:681px;left:309px;white-space:nowrap" class="ft2332">Not known</p>
<p style="position:absolute;top:681px;left:465px;white-space:nowrap" class="ft2332">Worsening of symptoms of dermatomyositis1)</p>
<p style="position:absolute;top:728px;left:114px;white-space:nowrap" class="ft2334">Musculoskeletal and&#160;<br/>connective tissue disorders</p>
<p style="position:absolute;top:728px;left:309px;white-space:nowrap" class="ft2332">Very common</p>
<p style="position:absolute;top:728px;left:465px;white-space:nowrap" class="ft2332">Musculoskeletal pain</p>
<p style="position:absolute;top:776px;left:309px;white-space:nowrap" class="ft2332">Common</p>
<p style="position:absolute;top:776px;left:465px;white-space:nowrap" class="ft2334">Muscle spasms (including blood creatine&#160;<br/>phosphokinase increased)</p>
<p style="position:absolute;top:838px;left:309px;white-space:nowrap" class="ft2332">Uncommon</p>
<p style="position:absolute;top:838px;left:465px;white-space:nowrap" class="ft2335">Rhabdomyolysis,<br/>systemic lupus erythematosus</p>
<p style="position:absolute;top:896px;left:309px;white-space:nowrap" class="ft2332">Rare</p>
<p style="position:absolute;top:896px;left:465px;white-space:nowrap" class="ft2332">Lupus-like syndrome1)</p>
<p style="position:absolute;top:939px;left:114px;white-space:nowrap" class="ft2334">Renal and urinary&#160;<br/>disorders&#160;</p>
<p style="position:absolute;top:939px;left:309px;white-space:nowrap" class="ft2332">Common</p>
<p style="position:absolute;top:939px;left:465px;white-space:nowrap" class="ft2338">Renal impairment,<br/>haematuria</p>
<p style="position:absolute;top:1006px;left:309px;white-space:nowrap" class="ft2332">Uncommon</p>
<p style="position:absolute;top:1006px;left:465px;white-space:nowrap" class="ft2332">Nocturia</p>
<p style="position:absolute;top:1049px;left:114px;white-space:nowrap" class="ft2334">Reproductive system and&#160;<br/>breast disorders</p>
<p style="position:absolute;top:1049px;left:309px;white-space:nowrap" class="ft2332">Uncommon</p>
<p style="position:absolute;top:1049px;left:465px;white-space:nowrap" class="ft2332">Erectile dysfunction</p>
</div>
<!-- Page 234 -->
<a name="234"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page234-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2340">234</p>
<p style="position:absolute;top:96px;left:132px;white-space:nowrap" class="ft2341"><b>System&#160;Organ Class</b></p>
<p style="position:absolute;top:96px;left:341px;white-space:nowrap" class="ft2341"><b>Frequency</b></p>
<p style="position:absolute;top:96px;left:566px;white-space:nowrap" class="ft2341"><b>Adverse Reaction</b></p>
<p style="position:absolute;top:129px;left:114px;white-space:nowrap" class="ft2344">General disorders and&#160;<br/>administration site&#160;<br/>conditions*</p>
<p style="position:absolute;top:129px;left:309px;white-space:nowrap" class="ft2342">Very Common</p>
<p style="position:absolute;top:129px;left:465px;white-space:nowrap" class="ft2344">Injection site reaction (including injection site&#160;<br/>erythema)</p>
<p style="position:absolute;top:191px;left:309px;white-space:nowrap" class="ft2342">Common</p>
<p style="position:absolute;top:191px;left:465px;white-space:nowrap" class="ft2345">Chest pain,&#160;<br/>oedema,<br/>pyrexia1)</p>
<p style="position:absolute;top:268px;left:309px;white-space:nowrap" class="ft2342">Uncommon</p>
<p style="position:absolute;top:268px;left:465px;white-space:nowrap" class="ft2342">Inflammation</p>
<p style="position:absolute;top:311px;left:114px;white-space:nowrap" class="ft2342">Investigations*</p>
<p style="position:absolute;top:311px;left:309px;white-space:nowrap" class="ft2342">Common</p>
<p style="position:absolute;top:311px;left:465px;white-space:nowrap" class="ft2348">Coagulation and bleeding disorders (including&#160;<br/>activated partial thromboplastin time prolonged),&#160;<br/>autoantibody test positive (including double&#160;<br/>stranded DNA antibody),&#160;<br/>blood lactate dehydrogenase increased</p>
<p style="position:absolute;top:444px;left:309px;white-space:nowrap" class="ft2342">Not known</p>
<p style="position:absolute;top:444px;left:465px;white-space:nowrap" class="ft2342">Weight increased2)</p>
<p style="position:absolute;top:468px;left:114px;white-space:nowrap" class="ft2344">Injury, poisoning&#160;and&#160;<br/>procedural complications</p>
<p style="position:absolute;top:468px;left:309px;white-space:nowrap" class="ft2342">Common</p>
<p style="position:absolute;top:468px;left:465px;white-space:nowrap" class="ft2342">Impaired healing</p>
<p style="position:absolute;top:528px;left:106px;white-space:nowrap" class="ft2344">*&#160;further information is found elsewhere in sections 4.3, 4.4 and 4.8<br/>**&#160;including open label extension studies</p>
<p style="position:absolute;top:565px;left:106px;white-space:nowrap" class="ft2349">1)&#160;including spontaneous reporting data</p>
<p style="position:absolute;top:584px;left:106px;white-space:nowrap" class="ft2344">2)&#160;The mean weight change from baseline for&#160;adalimumab ranged from 0.3&#160;kg to 1.0&#160;kg across adult&#160;<br/>indications compared to (minus)&#160;-0.4&#160;kg to 0.4&#160;kg for placebo over a treatment period of 4-6 months.&#160;<br/>Weight increase of 5-6&#160;kg has also been observed&#160;in long-term&#160;extension studies with mean exposures of<br/>approximately 1-2 years without control group,&#160;particularly in patients with Crohn’s disease and&#160;<br/>Ulcerative colitis. The mechanism behind this effect is unclear but could be associated with the&#160;<br/>anti-inflammatory effect of adalimumab.</p>
<p style="position:absolute;top:718px;left:106px;white-space:nowrap" class="ft2342">Hidradenitis&#160;suppurativa</p>
<p style="position:absolute;top:756px;left:106px;white-space:nowrap" class="ft2345">The safety profile for patients with HS treated with Humira weekly was consistent with the known safety&#160;<br/>profile of Humira.</p>
<p style="position:absolute;top:813px;left:106px;white-space:nowrap" class="ft2342">Uveitis</p>
<p style="position:absolute;top:851px;left:106px;white-space:nowrap" class="ft2344">The safety profile for patients with uveitis treated with Humira every other week was consistent with the&#160;<br/>known safety profile of Humira.</p>
<p style="position:absolute;top:908px;left:106px;white-space:nowrap" class="ft2342">Description of selected adverse reactions</p>
<p style="position:absolute;top:946px;left:106px;white-space:nowrap" class="ft2343"><i>Injection site reactions</i></p>
<p style="position:absolute;top:984px;left:106px;white-space:nowrap" class="ft2345">In the pivotal controlled trials in adults and children, 12.9% of patients treated with Humira developed&#160;<br/>injection site reactions (erythema and/or itching, haemorrhage, pain or swelling), compared to 7.2% of&#160;<br/>patients receiving placebo or active control. Injection site reactions generally did not necessitate&#160;<br/>discontinuation of the medicinal product.</p>
</div>
<!-- Page 235 -->
<a name="235"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page235-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2350">235</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft2353"><i>Infections&#160;</i></p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft2355">In the pivotal controlled trials in adults and children, the rate of infection was 1.51 per patient year in the&#160;<br/>Humira treated patients and 1.46 per patient year in the placebo and active control-treated patients. The&#160;<br/>infections consisted primarily of&#160;nasopharyngitis, upper respiratory tract infection, and sinusitis.&#160;Most&#160;<br/>patients continued on Humira after the infection resolved.</p>
<p style="position:absolute;top:219px;left:106px;white-space:nowrap" class="ft2355">The incidence of serious infections was 0.04&#160;per patient year in Humira treated patients and 0.03&#160;per&#160;<br/>patient year in placebo and active control&#160;−&#160;treated patients.</p>
<p style="position:absolute;top:276px;left:106px;white-space:nowrap" class="ft2355">In controlled and open label adult and paediatric studies with Humira, serious infections (including fatal&#160;<br/>infections, which occurred rarely) have been reported, which include reports of tuberculosis (including&#160;<br/>miliary and extra-pulmonary locations) and invasive opportunistic infections (e.g. disseminated&#160;or&#160;<br/>extrapulmonary&#160;histoplasmosis,&#160;blastomycosis, coccidioidomycosis, pneumocystis,&#160;candidiasis,&#160;<br/>aspergillosis and listeriosis). Most of the cases of tuberculosis occurred within the first eight months after&#160;<br/>initiation&#160;of therapy and may reflect recrudescence of latent disease.</p>
<p style="position:absolute;top:409px;left:106px;white-space:nowrap" class="ft2353"><i>Malignancies and lymphoproliferative disorders</i></p>
<p style="position:absolute;top:446px;left:106px;white-space:nowrap" class="ft2354">No&#160;malignancies were observed in 249 paediatric patients with an exposure of 655.6 patient years during&#160;<br/>Humira trials in patients with juvenile idiopathic arthritis (polyarticular juvenile idiopathic arthritis and&#160;<br/>enthesitis-related arthritis).&#160;In addition, no malignancies were observed in 192 paediatric patients with an&#160;<br/>exposure of 498.1 patient years during Humira trials in paediatric patients with Crohn’s disease. No&#160;<br/>malignancies were observed in 77 paediatric patients with an exposure of 80.0 patient years during a&#160;<br/>Humira trial in paediatric patients with chronic plaque psoriasis.&#160;No malignancies were observed in 93&#160;<br/>paediatric patients with an exposure of 65.3 patient years during a Humira trial in paediatric patients with&#160;<br/>ulcerative colitis.&#160;No&#160;malignancies were observed in 60 paediatric patients with an exposure of 58.4&#160;<br/>patient years during a Humira trial in paediatric patients with uveitis.</p>
<p style="position:absolute;top:636px;left:106px;white-space:nowrap" class="ft2355">During the controlled portions of pivotal Humira trials in adults of at least 12 weeks in duration in patients&#160;<br/>with moderately to severely active rheumatoid arthritis, ankylosing spondylitis, axial spondyloarthritis&#160;<br/>without radiographic evidence of AS, &#160;psoriatic arthritis, psoriasis, hidradenitis suppurativa, Crohn’s&#160;<br/>disease, ulcerative colitis and uveitis,&#160;malignancies, other than lymphoma and non-melanoma skin cancer,&#160;<br/>were observed at a rate (95% confidence interval) of 6.8 (4.4, 10.5) &#160;per 1,000 patient-years among 5,291&#160;<br/>Humira treated patients&#160;<i>versus&#160;</i>a rate of 6.3 (3.4, 11.8) per 1,000 patient-years among 3,444 control&#160;<br/>patients (median duration of treatment was 4.0 months for Humira and 3.8 months for control-treated&#160;<br/>patients). The rate (95% confidence interval) of non-melanoma skin cancers was 8.8 (6.0, 13.0) per 1,000&#160;<br/>patient-years among Humira-treated&#160;patients and 3.2 (1.3, 7.6) per 1,000 patient-years among control&#160;<br/>patients. Of these skin cancers, squamous cell carcinomas occurred at rates (95% confidence interval) of&#160;<br/>2.7 (1.4, 5.4) per 1,000 patient-years among Humira-treated patients and 0.6 (0.1, 4.5) per 1,000 patient-<br/>years among control patients. The rate (95% confidence interval) of lymphomas was 0.7 (0.2, 2.7) per&#160;<br/>1,000 patient-years among Humira-treated patients and 0.6 (0.1, 4.5) per 1,000 patient-years among&#160;<br/>control patients.</p>
<p style="position:absolute;top:921px;left:106px;white-space:nowrap" class="ft2355">When combining controlled portions of these trials and ongoing and completed open label extension&#160;<br/>studies with a median duration of approximately 3.3 years including 6,427 patients and over 26,439&#160;<br/>patient-years of therapy, the observed rate of malignancies, other than lymphoma and non-melanoma skin&#160;<br/>cancers is approximately 8.5 per 1,000 patient years. The observed rate of non-melanoma skin cancers is&#160;<br/>approximately 9.6 per 1,000 patient years, and the observed rate of lymphomas is approximately 1.3 per&#160;<br/>1,000 patient years.</p>
<p style="position:absolute;top:1054px;left:106px;white-space:nowrap" class="ft2355">In post-marketing experience from January 2003 to December 2010, predominantly in patients with&#160;<br/>rheumatoid arthritis, the reported rate of malignancies is approximately 2.7 per 1,000 patient treatment&#160;</p>
</div>
<!-- Page 236 -->
<a name="236"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page236-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2360">236</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft2365">years. The reported rates for non-melanoma skin cancers and lymphomas are approximately 0.2 and 0.3&#160;<br/>per 1,000 patient treatment years, respectively (see section 4.4).</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft2364">Rare post-marketing cases of hepatosplenic T-cell&#160;lymphoma have been reported in patients treated with&#160;<br/>adalimumab (see section 4.4).</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft2363"><i>Autoantibodies&#160;</i></p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft2364">Patients had serum samples tested for autoantibodies at multiple time points in rheumatoid arthritis studies&#160;<br/>I&#160;−&#160;V. In these trials, 11.9% of patients treated with Humira and 8.1% of placebo and active&#160;<br/>control&#160;−&#160;treated patients that had negative&#160;baseline anti-nuclear antibody titres reported positive titres at&#160;<br/>Week&#160;24. Two patients out of 3,441 treated with Humira in all rheumatoid arthritis and psoriatic arthritis&#160;<br/>studies developed clinical signs suggestive of new-onset lupus-like syndrome. The patients improved&#160;<br/>following discontinuation of therapy. No patients developed lupus nephritis or central nervous system&#160;<br/>symptoms.</p>
<p style="position:absolute;top:390px;left:106px;white-space:nowrap" class="ft2363"><i>Hepato-biliary events</i></p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft2364">In controlled Phase 3 trials of Humira in patients with rheumatoid arthritis and psoriatic arthritis with a&#160;<br/>control period duration ranging from 4 to 104&#160;weeks, ALT elevations&#160;≥&#160;3 x ULN occurred in 3.7% of&#160;<br/>Humira-treated patients and 1.6% of control-treated patients.&#160;</p>
<p style="position:absolute;top:503px;left:106px;white-space:nowrap" class="ft2364">In controlled Phase 3 trials of Humira in patients with polyarticular juvenile idiopathic&#160;arthritis who were&#160;<br/>4 to 17&#160;years and enthesitis-related arthritis who were 6 to 17&#160;years, ALT elevations&#160;≥&#160;3 x ULN occurred&#160;<br/>in 6.1% of Humira-treated patients and 1.3% of control-treated patients. Most ALT elevations occurred&#160;<br/>with concomitant methotrexate&#160;use. No ALT elevations&#160;≥&#160;3 x ULN occurred in the Phase 3 trial of Humira&#160;<br/>in patients with polyarticular juvenile idiopathic arthritis who were 2 to &lt;&#160;4&#160;years.</p>
<p style="position:absolute;top:617px;left:106px;white-space:nowrap" class="ft2364">In controlled Phase 3 trials of Humira in patients with&#160;Crohn’s disease and ulcerative colitis&#160;with a control&#160;<br/>period ranging from 4 to 52&#160;weeks. ALT elevations&#160;≥&#160;3 x ULN occurred in 0.9% of Humira-treated&#160;<br/>patients and 0.9% of controlled-treated patients.</p>
<p style="position:absolute;top:693px;left:106px;white-space:nowrap" class="ft2365">In the Phase 3 trial of Humira in patients with paediatric Crohn’s disease which evaluated efficacy and&#160;<br/>safety of two body weight adjusted maintenance dose regimens following body weight adjusted induction&#160;<br/>therapy up to 52&#160;weeks of treatment, ALT elevations&#160;≥&#160;3 x ULN occurred in 2.6%&#160;&#160;(5/192)&#160;of patients of&#160;<br/>whom 4 were receiving concomitant immunosuppressants at baseline.</p>
<p style="position:absolute;top:788px;left:106px;white-space:nowrap" class="ft2365">In controlled Phase 3 trials of Humira in patients with plaque&#160;psoriasis&#160;with a control period duration&#160;<br/>ranging from 12 to 24&#160;weeks, ALT elevations&#160;≥&#160;3 x ULN occurred in 1.8% of Humira-treated patients and&#160;<br/>1.8% of control-treated&#160;patients.&#160;</p>
<p style="position:absolute;top:864px;left:106px;white-space:nowrap" class="ft2365">No&#160;ALT elevations&#160;≥&#160;3 X ULN occurred in the Phase 3 trial of Humira in paediatric patients with plaque&#160;<br/>psoriasis.</p>
<p style="position:absolute;top:921px;left:106px;white-space:nowrap" class="ft2364">In controlled trials of Humira (initial doses of 160 mg at Week 0 and 80 mg at Week 2, followed by 40 mg&#160;<br/>every week starting at&#160;Week 4), in patients with hidradenitis suppurativa with a control period duration&#160;<br/>ranging from 12 to 16 weeks, ALT elevations&#160;≥ 3 x ULN occurred in 0.3% of Humira-treated patients and&#160;<br/>0.6% of control-treated patients.</p>
<p style="position:absolute;top:1016px;left:106px;white-space:nowrap" class="ft2365">In controlled trials of Humira (initial doses of 80&#160;mg at Week 0 followed by 40&#160;mg&#160;every other week&#160;<br/>starting at Week 1) in&#160;adult&#160;patients with uveitis up to 80 weeks with a median exposure of 166.5 days and&#160;<br/>105.0 days in Humira-treated and control-treated patients, respectively, ALT elevations&#160;≥ 3 x ULN&#160;<br/>occurred in 2.4% of Humira-treated patients and 2.4% of control-treated patients.&#160;</p>
</div>
<!-- Page 237 -->
<a name="237"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page237-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2370">237</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft2374">In the controlled Phase 3 trial of Humira in patients with paediatric ulcerative colitis (N=93) which&#160;<br/>evaluated efficacy and safety of a maintenance dose&#160;of 0.6&#160;mg/kg (maximum of 40 mg) every other week&#160;<br/>(N=31) and a maintenance dose of 0.6 mg/kg (maximum of 40 mg) every Week&#160;(N=32),&#160;following body&#160;<br/>weight adjusted induction dosing&#160;of 2.4 mg/kg (maximum of 160 mg) at Week 0 and Week 1, and 1.2&#160;<br/>mg/kg (maximum of 80&#160;mg) at Week 2&#160;(N=63),&#160;or an induction dose of 2.4 mg/kg (maximum of 160 mg)&#160;<br/>at Week 0, placebo at Week 1, and 1.2 mg/kg (maximum of 80 mg) at Week 2&#160;(N=30),&#160;ALT elevations&#160;≥&#160;<br/>3 X ULN occurred in 1.1% (1/93) of patients.</p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft2375">Across all indications in clinical trials patients with raised ALT were asymptomatic and in most cases&#160;<br/>elevations were transient and resolved on continued treatment. &#160;However, there have also been post-<br/>marketing reports of liver failure as well as less severe liver disorders that may precede&#160;liver failure, such&#160;<br/>as hepatitis including autoimmune hepatitis in patients receiving adalimumab.</p>
<p style="position:absolute;top:352px;left:106px;white-space:nowrap" class="ft2372">Concurrent treatment with azathioprine/6-mercaptopurine</p>
<p style="position:absolute;top:390px;left:106px;white-space:nowrap" class="ft2375">In adult Crohn’s disease studies, higher incidences of malignant and serious infection-related adverse&#160;<br/>events were seen with the combination of Humira and azathioprine/6-mercaptopurine compared with&#160;<br/>Humira alone.</p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft2372">Reporting of suspected adverse reactions</p>
<p style="position:absolute;top:503px;left:106px;white-space:nowrap" class="ft2374">Reporting suspected adverse reactions after authorisation of the medicinal product is important. &#160;It allows&#160;<br/>continued monitoring of the benefit/risk balance of the medicinal product. &#160;Healthcare professionals are&#160;<br/>asked to report any suspected adverse reactions via&#160;<a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">the national reporting system listed in&#160;Appendix V.</a></p>
<p style="position:absolute;top:579px;left:106px;white-space:nowrap" class="ft2371"><b>4.9</b></p>
<p style="position:absolute;top:579px;left:160px;white-space:nowrap" class="ft2371"><b>Overdose</b></p>
<p style="position:absolute;top:617px;left:106px;white-space:nowrap" class="ft2374">No dose-limiting toxicity was observed during clinical trials. The highest dose level evaluated has been&#160;<br/>multiple intravenous doses of 10&#160;mg/kg, which is approximately 15&#160;times the recommended dose.&#160;</p>
<p style="position:absolute;top:693px;left:106px;white-space:nowrap" class="ft2371"><b>5.</b></p>
<p style="position:absolute;top:693px;left:148px;white-space:nowrap" class="ft2371"><b>PHARMACOLOGICAL PROPERTIES</b></p>
<p style="position:absolute;top:731px;left:106px;white-space:nowrap" class="ft2371"><b>5.1</b></p>
<p style="position:absolute;top:731px;left:148px;white-space:nowrap" class="ft2371"><b>Pharmacodynamic&#160;properties</b></p>
<p style="position:absolute;top:769px;left:106px;white-space:nowrap" class="ft2374">Pharmacotherapeutic group: Immunosuppressants, Tumour Necrosis Factor alpha (TNF-α) inhibitors.&#160;<br/>ATC code: L04AB04</p>
<p style="position:absolute;top:826px;left:106px;white-space:nowrap" class="ft2372">Mechanism&#160;of action</p>
<p style="position:absolute;top:864px;left:106px;white-space:nowrap" class="ft2375">Adalimumab binds specifically to TNF and neutralises the biological function of TNF by blocking its&#160;<br/>interaction with the p55 and p75 cell surface TNF receptors. &#160;</p>
<p style="position:absolute;top:921px;left:106px;white-space:nowrap" class="ft2374">Adalimumab also modulates biological responses that are induced or regulated by TNF, including changes&#160;<br/>in the levels of adhesion molecules responsible for leukocyte migration (ELAM-1, VCAM-1, and ICAM-1&#160;<br/>with an IC50&#160;of&#160;0.1-0.2 nM).&#160;</p>
<p style="position:absolute;top:997px;left:106px;white-space:nowrap" class="ft2372">Pharmacodynamic effects&#160;</p>
<p style="position:absolute;top:1035px;left:106px;white-space:nowrap" class="ft2375">After treatment with Humira, a rapid decrease in levels of acute phase reactants of inflammation&#160;<br/>(C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)) and serum cytokines (IL-6) was&#160;<br/>observed, compared to baseline in patients with rheumatoid arthritis. Serum levels of matrix&#160;</p>
</div>
<!-- Page 238 -->
<a name="238"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page238-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2380">238</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft2384">metalloproteinases (MMP-1 and MMP-3) that produce tissue remodelling responsible for cartilage&#160;<br/>destruction were also decreased after Humira administration. Patients treated with Humira usually&#160;<br/>experienced improvement in haematological signs of chronic inflammation.</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft2385">A rapid decrease in CRP levels was also observed in patients with polyarticular juvenile idiopathic&#160;<br/>arthritis, Crohn’s disease, ulcerative colitis and hidradenitis suppurativa after treatment with Humira. In&#160;<br/>patients with Crohn’s disease, a reduction of the number of cells expressing inflammatory markers in the&#160;<br/>colon including a significant reduction of expression of TNFα was seen. Endoscopic studies in intestinal&#160;<br/>mucosa have shown evidence of mucosal healing in adalimumab treated patients.</p>
<p style="position:absolute;top:276px;left:106px;white-space:nowrap" class="ft2382">Clinical efficacy and safety</p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft2383"><i>Rheumatoid arthritis</i></p>
<p style="position:absolute;top:352px;left:106px;white-space:nowrap" class="ft2384">Humira was evaluated in over 3,000 patients in all rheumatoid arthritis clinical trials. The efficacy and&#160;<br/>safety of&#160;Humira were assessed in five randomised, double-blind and well-controlled studies. Some&#160;<br/>patients were treated for up to 120&#160;months duration. Injection site pain of Humira 40&#160;mg/0.4&#160;ml was&#160;<br/>assessed in two randomised, active control, single-blind, two-period crossover studies.&#160;</p>
<p style="position:absolute;top:446px;left:106px;white-space:nowrap" class="ft2382">RA study I evaluated 271 patients with moderately to severely active rheumatoid arthritis who were&#160;</p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft2385">&#160;18&#160;years old, had failed therapy with at least one disease-modifying, anti&#160;rheumatic drug and had&#160;<br/>insufficient efficacy with methotrexate at doses of 12.5 to 25&#160;mg (10&#160;mg if methotrexate-intolerant) every&#160;<br/>week and whose methotrexate dose remained constant at 10 to 25&#160;mg&#160;every&#160;week. Doses of 20, 40 or&#160;<br/>80&#160;mg of Humira or placebo were given every other week for 24&#160;weeks.&#160;</p>
<p style="position:absolute;top:562px;left:106px;white-space:nowrap" class="ft2382">RA study II evaluated 544 patients with moderately to severely active rheumatoid arthritis who were&#160;</p>
<p style="position:absolute;top:580px;left:106px;white-space:nowrap" class="ft2384">&#160;18&#160;years old and had failed therapy with at least one disease-modifying, anti-rheumatic drugs. &#160;Doses of&#160;<br/>20 or 40&#160;mg of Humira were given by subcutaneous injection every&#160;other week with placebo on alternative&#160;<br/>weeks or every week for 26&#160;weeks; placebo was given every week for the same duration. &#160;No other&#160;<br/>disease-modifying anti-rheumatic drugs were allowed.</p>
<p style="position:absolute;top:676px;left:106px;white-space:nowrap" class="ft2382">RA study III evaluated 619 patients with moderately to severely active rheumatoid arthritis who were&#160;</p>
<p style="position:absolute;top:695px;left:106px;white-space:nowrap" class="ft2384">&#160;18&#160;years old, and who had an ineffective response to methotrexate at doses of 12.5 to 25&#160;mg or have&#160;<br/>been intolerant to 10&#160;mg of methotrexate every week.&#160;There were three groups in this study. &#160;The first&#160;<br/>received placebo injections every week for 52&#160;weeks. The second received 20&#160;mg of Humira every week&#160;<br/>for 52&#160;weeks. The third group received 40&#160;mg&#160;of Humira every other week with placebo injections on&#160;<br/>alternate&#160;weeks. Upon completion of the first 52&#160;weeks, 457 patients enrolled in an open-label extension&#160;<br/>phase in which 40&#160;mg&#160;of Humira/MTX was administered every other week up to 10&#160;years.</p>
<p style="position:absolute;top:830px;left:106px;white-space:nowrap" class="ft2387">RA study IV primarily assessed safety in 636 patients with moderately to&#160;severely active rheumatoid&#160;<br/>arthritis who were&#160;</p>
<p style="position:absolute;top:848px;left:230px;white-space:nowrap" class="ft2386">&#160;18&#160;years old. Patients were permitted to be either disease-modifying, anti-rheumatic&#160;</p>
<p style="position:absolute;top:869px;left:106px;white-space:nowrap" class="ft2384">drug-naïve or to remain on their pre-existing rheumatologic therapy provided that therapy was stable for a&#160;<br/>minimum of 28&#160;days. These therapies include methotrexate, leflunomide, hydroxychloroquine,&#160;<br/>sulfasalazine and/or gold salts. Patients were randomised to 40&#160;mg&#160;of Humira or placebo every other week&#160;<br/>for 24&#160;weeks. &#160;</p>
<p style="position:absolute;top:964px;left:106px;white-space:nowrap" class="ft2384">RA study V evaluated 799 methotrexate-naïve, adult patients with moderate to severely active early&#160;<br/>rheumatoid arthritis (mean disease duration less than 9&#160;months). This study evaluated the efficacy of&#160;<br/>Humira 40&#160;mg&#160;every other week/methotrexate combination therapy, Humira&#160;40&#160;mg&#160;every other week&#160;<br/>monotherapy and methotrexate monotherapy in reducing the signs and symptoms and rate of progression&#160;<br/>of joint damage in rheumatoid arthritis for 104&#160;weeks. Upon completion of the first 104 weeks, 497&#160;<br/>patients enrolled in an open-label extension phase in which 40 mg of Humira&#160;was administered every&#160;<br/>other week up to 10 years.</p>
</div>
<!-- Page 239 -->
<a name="239"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page239-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2390">239</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft2394">RA studies VI and VII each evaluated 60 patients with moderately to severely active rheumatoid arthritis&#160;<br/>who were&#160;≥&#160;18&#160;years old. Enrolled patients were&#160;either current users of Humira 40&#160;mg/0.8&#160;ml and rated&#160;<br/>their average injection site pain as at least 3&#160;cm (on a 0-10&#160;cm&#160;VAS) or were biologic-naïve subjects who&#160;<br/>were starting Humira 40&#160;mg/0.8&#160;ml. Patients were randomised to receive a single dose of Humira&#160;<br/>40&#160;mg/0.8&#160;ml or Humira 40&#160;mg/0.4&#160;ml, followed by a single injection of the opposite treatment at their&#160;<br/>next dose.&#160;</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft2394">The primary end point in RA studies I, II and III and the secondary endpoint in RA study IV was the&#160;<br/>percent of patients who achieved an ACR 20 response at Week 24 or 26. The primary endpoint in&#160;RA&#160;<br/>study V was the percent of patients who achieved an ACR 50 response at Week&#160;52. RA studies III and V&#160;<br/>had an additional primary endpoint at 52&#160;weeks of retardation of disease progression (as detected by X-ray&#160;<br/>results). RA study III also had a primary endpoint of changes in quality of life. The primary endpoint in&#160;<br/>RA studies VI and VII was injection site pain immediately after injection as measured by a 0-10&#160;cm VAS.</p>
<p style="position:absolute;top:370px;left:106px;white-space:nowrap" class="ft2393"><i>ACR response</i></p>
<p style="position:absolute;top:409px;left:106px;white-space:nowrap" class="ft2395">The percent of Humira-treated patients achieving ACR 20, 50 and 70 responses was consistent across RA&#160;<br/>studies I, II and III. The results for the 40&#160;mg&#160;every other week dose are summarised in Table&#160;5.&#160;</p>
<p style="position:absolute;top:465px;left:429px;white-space:nowrap" class="ft2391"><b>Table&#160;5</b></p>
<p style="position:absolute;top:485px;left:297px;white-space:nowrap" class="ft2391"><b>ACR Responses in Placebo-Controlled Trials</b></p>
<p style="position:absolute;top:503px;left:383px;white-space:nowrap" class="ft2391"><b>(Percent of Patients)</b></p>
<p style="position:absolute;top:543px;left:113px;white-space:nowrap" class="ft2392">Response</p>
<p style="position:absolute;top:543px;left:255px;white-space:nowrap" class="ft2392">RA Study Ia**</p>
<p style="position:absolute;top:543px;left:448px;white-space:nowrap" class="ft2392">RA Study IIa**</p>
<p style="position:absolute;top:543px;left:643px;white-space:nowrap" class="ft2392">RA Study IIIa**</p>
<p style="position:absolute;top:581px;left:217px;white-space:nowrap" class="ft2392">Placebo/&#160;</p>
<p style="position:absolute;top:600px;left:224px;white-space:nowrap" class="ft2392">MTXc</p>
<p style="position:absolute;top:620px;left:228px;white-space:nowrap" class="ft2392">n=60</p>
<p style="position:absolute;top:581px;left:292px;white-space:nowrap" class="ft2392">Humirab/ MTXc</p>
<p style="position:absolute;top:600px;left:328px;white-space:nowrap" class="ft2392">n=63</p>
<p style="position:absolute;top:581px;left:426px;white-space:nowrap" class="ft2392">Placebo</p>
<p style="position:absolute;top:600px;left:431px;white-space:nowrap" class="ft2392">n=110</p>
<p style="position:absolute;top:581px;left:519px;white-space:nowrap" class="ft2392">Humirab</p>
<p style="position:absolute;top:600px;left:526px;white-space:nowrap" class="ft2392">n=113</p>
<p style="position:absolute;top:581px;left:615px;white-space:nowrap" class="ft2392">Placebo/&#160;</p>
<p style="position:absolute;top:600px;left:623px;white-space:nowrap" class="ft23922">MTXc<br/>n=200</p>
<p style="position:absolute;top:581px;left:691px;white-space:nowrap" class="ft2392">Humirab/ MTXc</p>
<p style="position:absolute;top:600px;left:723px;white-space:nowrap" class="ft2392">n=207</p>
<p style="position:absolute;top:640px;left:113px;white-space:nowrap" class="ft2392">ACR 20</p>
<p style="position:absolute;top:658px;left:124px;white-space:nowrap" class="ft2392">6&#160;months</p>
<p style="position:absolute;top:658px;left:224px;white-space:nowrap" class="ft2392">13.3%</p>
<p style="position:absolute;top:658px;left:324px;white-space:nowrap" class="ft2392">65.1%</p>
<p style="position:absolute;top:658px;left:431px;white-space:nowrap" class="ft2392">19.1%</p>
<p style="position:absolute;top:658px;left:526px;white-space:nowrap" class="ft2392">46.0%</p>
<p style="position:absolute;top:658px;left:622px;white-space:nowrap" class="ft2392">29.5%</p>
<p style="position:absolute;top:658px;left:724px;white-space:nowrap" class="ft2392">63.3%</p>
<p style="position:absolute;top:678px;left:124px;white-space:nowrap" class="ft2392">12&#160;months</p>
<p style="position:absolute;top:678px;left:233px;white-space:nowrap" class="ft2392">NA</p>
<p style="position:absolute;top:678px;left:333px;white-space:nowrap" class="ft2392">NA</p>
<p style="position:absolute;top:678px;left:440px;white-space:nowrap" class="ft2392">NA</p>
<p style="position:absolute;top:678px;left:535px;white-space:nowrap" class="ft2392">NA</p>
<p style="position:absolute;top:678px;left:622px;white-space:nowrap" class="ft2392">24.0%</p>
<p style="position:absolute;top:678px;left:724px;white-space:nowrap" class="ft2392">58.9%</p>
<p style="position:absolute;top:697px;left:113px;white-space:nowrap" class="ft2392">ACR 50</p>
<p style="position:absolute;top:715px;left:124px;white-space:nowrap" class="ft2392">6&#160;months</p>
<p style="position:absolute;top:715px;left:228px;white-space:nowrap" class="ft2392">6.7%</p>
<p style="position:absolute;top:715px;left:324px;white-space:nowrap" class="ft2392">52.4%</p>
<p style="position:absolute;top:715px;left:436px;white-space:nowrap" class="ft2392">8.2%</p>
<p style="position:absolute;top:715px;left:526px;white-space:nowrap" class="ft2392">22.1%</p>
<p style="position:absolute;top:715px;left:630px;white-space:nowrap" class="ft2392">9.5%</p>
<p style="position:absolute;top:715px;left:724px;white-space:nowrap" class="ft2392">39.1%</p>
<p style="position:absolute;top:734px;left:124px;white-space:nowrap" class="ft2392">12&#160;months</p>
<p style="position:absolute;top:734px;left:233px;white-space:nowrap" class="ft2392">NA</p>
<p style="position:absolute;top:734px;left:333px;white-space:nowrap" class="ft2392">NA</p>
<p style="position:absolute;top:734px;left:440px;white-space:nowrap" class="ft2392">NA</p>
<p style="position:absolute;top:734px;left:535px;white-space:nowrap" class="ft2392">NA</p>
<p style="position:absolute;top:734px;left:630px;white-space:nowrap" class="ft2392">9.5%</p>
<p style="position:absolute;top:734px;left:724px;white-space:nowrap" class="ft2392">41.5%</p>
<p style="position:absolute;top:753px;left:113px;white-space:nowrap" class="ft2392">ACR 70</p>
<p style="position:absolute;top:773px;left:124px;white-space:nowrap" class="ft2392">6&#160;months</p>
<p style="position:absolute;top:773px;left:228px;white-space:nowrap" class="ft2392">3.3%</p>
<p style="position:absolute;top:773px;left:324px;white-space:nowrap" class="ft2392">23.8%</p>
<p style="position:absolute;top:773px;left:436px;white-space:nowrap" class="ft2392">1.8%</p>
<p style="position:absolute;top:773px;left:526px;white-space:nowrap" class="ft2392">12.4%</p>
<p style="position:absolute;top:773px;left:630px;white-space:nowrap" class="ft2392">2.5%</p>
<p style="position:absolute;top:773px;left:724px;white-space:nowrap" class="ft2392">20.8%</p>
<p style="position:absolute;top:791px;left:124px;white-space:nowrap" class="ft2392">12&#160;months</p>
<p style="position:absolute;top:791px;left:233px;white-space:nowrap" class="ft2392">NA</p>
<p style="position:absolute;top:791px;left:333px;white-space:nowrap" class="ft2392">NA</p>
<p style="position:absolute;top:791px;left:440px;white-space:nowrap" class="ft2392">NA</p>
<p style="position:absolute;top:791px;left:535px;white-space:nowrap" class="ft2392">NA</p>
<p style="position:absolute;top:791px;left:630px;white-space:nowrap" class="ft2392">4.5%</p>
<p style="position:absolute;top:791px;left:724px;white-space:nowrap" class="ft2392">23.2%</p>
<p style="position:absolute;top:810px;left:113px;white-space:nowrap" class="ft2399">a&#160;RA study I at 24&#160;weeks, RA study II at 26&#160;weeks , and RA study III at 24&#160;and 52&#160;weeks</p>
<p style="position:absolute;top:829px;left:113px;white-space:nowrap" class="ft2399">b&#160;40&#160;mg Humira&#160;administered every other week</p>
<p style="position:absolute;top:848px;left:113px;white-space:nowrap" class="ft2397">c&#160;MTX = methotrexate<br/>**p&#160;&lt;&#160;0.01, Humira&#160;<i>versus&#160;</i>placebo</p>
<p style="position:absolute;top:906px;left:106px;white-space:nowrap" class="ft2394">In RA studies I-IV, all individual components of the ACR response criteria (number of tender and swollen&#160;<br/>joints, physician and patient assessment of disease activity and pain, disability index (HAQ) scores and&#160;<br/>CRP (mg/dl) values) improved at 24 or 26&#160;weeks&#160;compared to placebo. In RA study III, these&#160;<br/>improvements were maintained throughout 52&#160;weeks.&#160;</p>
<p style="position:absolute;top:1001px;left:106px;white-space:nowrap" class="ft2394">In the open-label extension for RA study III, most patients who were ACR responders maintained&#160;<br/>response when followed for up to 10&#160;years. Of 207 patients who were randomised to Humira 40&#160;mg&#160;every&#160;<br/>other week, 114 patients continued on Humira 40&#160;mg&#160;every other week for 5&#160;years. Among those, 86&#160;<br/>patients (75.4%) had ACR 20 responses; 72 patients (63.2%) had ACR 50 responses; and 41 patients&#160;<br/>(36%) had ACR 70 responses. Of 207 patients, 81 patients continued on Humira 40&#160;mg every other week&#160;</p>
</div>
<!-- Page 240 -->
<a name="240"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page240-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2400">240</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft2405">for 10&#160;years. Among those, 64 patients (79.0%) had ACR 20 responses; 56 patients (69.1%) had ACR 50&#160;<br/>responses; and 43 patients (53.1%) had ACR 70 responses.</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft2404">In RA study IV, the ACR&#160;20 response of patients treated with Humira plus standard of care was&#160;<br/>statistically significantly better than patients treated with placebo plus standard of care (p&#160;&lt;&#160;0.001). &#160;</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft2404">In RA studies I-IV, Humira-treated patients achieved statistically significant ACR 20 and 50 responses&#160;<br/>compared to placebo as early as one to two weeks after initiation of treatment.</p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft2405">In RA study V with early rheumatoid arthritis patients who were methotrexate naïve, combination therapy&#160;<br/>with Humira and methotrexate led to faster and significantly greater ACR responses than methotrexate&#160;<br/>monotherapy and Humira monotherapy at Week&#160;52 and responses were sustained at Week&#160;104 (see Table&#160;<br/>6).</p>
<p style="position:absolute;top:352px;left:433px;white-space:nowrap" class="ft2401"><b>Table&#160;6</b></p>
<p style="position:absolute;top:370px;left:350px;white-space:nowrap" class="ft2401"><b>ACR Responses in RA Study V</b></p>
<p style="position:absolute;top:390px;left:388px;white-space:nowrap" class="ft2401"><b>(percent of patients)</b></p>
<p style="position:absolute;top:438px;left:120px;white-space:nowrap" class="ft2401"><b>Response</b></p>
<p style="position:absolute;top:428px;left:258px;white-space:nowrap" class="ft2401"><b>MTX</b></p>
<p style="position:absolute;top:447px;left:256px;white-space:nowrap" class="ft2401"><b>n=257</b></p>
<p style="position:absolute;top:428px;left:348px;white-space:nowrap" class="ft2401"><b>Humira</b></p>
<p style="position:absolute;top:447px;left:355px;white-space:nowrap" class="ft2401"><b>n=274</b></p>
<p style="position:absolute;top:428px;left:436px;white-space:nowrap" class="ft2401"><b>Humira/MTX</b></p>
<p style="position:absolute;top:447px;left:463px;white-space:nowrap" class="ft2401"><b>n=268</b></p>
<p style="position:absolute;top:438px;left:557px;white-space:nowrap" class="ft2401"><b>p-valuea</b></p>
<p style="position:absolute;top:438px;left:642px;white-space:nowrap" class="ft2401"><b>p-valueb</b></p>
<p style="position:absolute;top:438px;left:731px;white-space:nowrap" class="ft2401"><b>p-valuec</b></p>
<p style="position:absolute;top:467px;left:120px;white-space:nowrap" class="ft2402">ACR 20</p>
<p style="position:absolute;top:487px;left:162px;white-space:nowrap" class="ft2402">Week&#160;</p>
<p style="position:absolute;top:506px;left:120px;white-space:nowrap" class="ft2402">52</p>
<p style="position:absolute;top:487px;left:256px;white-space:nowrap" class="ft2402">62.6%</p>
<p style="position:absolute;top:487px;left:355px;white-space:nowrap" class="ft2402">54.4%</p>
<p style="position:absolute;top:487px;left:464px;white-space:nowrap" class="ft2402">72.8%</p>
<p style="position:absolute;top:487px;left:567px;white-space:nowrap" class="ft2402">0.013</p>
<p style="position:absolute;top:487px;left:645px;white-space:nowrap" class="ft2402">&lt;&#160;0.001</p>
<p style="position:absolute;top:487px;left:741px;white-space:nowrap" class="ft2402">0.043</p>
<p style="position:absolute;top:525px;left:162px;white-space:nowrap" class="ft2402">Week&#160;</p>
<p style="position:absolute;top:544px;left:120px;white-space:nowrap" class="ft2402">104</p>
<p style="position:absolute;top:525px;left:256px;white-space:nowrap" class="ft2402">56.0%</p>
<p style="position:absolute;top:525px;left:355px;white-space:nowrap" class="ft2402">49.3%</p>
<p style="position:absolute;top:525px;left:464px;white-space:nowrap" class="ft2402">69.4%</p>
<p style="position:absolute;top:525px;left:567px;white-space:nowrap" class="ft2402">0.002</p>
<p style="position:absolute;top:525px;left:645px;white-space:nowrap" class="ft2402">&lt;&#160;0.001</p>
<p style="position:absolute;top:525px;left:741px;white-space:nowrap" class="ft2402">0.140</p>
<p style="position:absolute;top:564px;left:120px;white-space:nowrap" class="ft2402">ACR 50</p>
<p style="position:absolute;top:584px;left:162px;white-space:nowrap" class="ft2402">Week&#160;</p>
<p style="position:absolute;top:603px;left:120px;white-space:nowrap" class="ft2402">52</p>
<p style="position:absolute;top:584px;left:256px;white-space:nowrap" class="ft2402">45.9%</p>
<p style="position:absolute;top:584px;left:355px;white-space:nowrap" class="ft2402">41.2%</p>
<p style="position:absolute;top:584px;left:464px;white-space:nowrap" class="ft2402">61.6%</p>
<p style="position:absolute;top:584px;left:560px;white-space:nowrap" class="ft2402">&lt;&#160;0.001</p>
<p style="position:absolute;top:584px;left:645px;white-space:nowrap" class="ft2402">&lt;&#160;0.001</p>
<p style="position:absolute;top:584px;left:741px;white-space:nowrap" class="ft2402">0.317</p>
<p style="position:absolute;top:622px;left:162px;white-space:nowrap" class="ft2402">Week&#160;</p>
<p style="position:absolute;top:642px;left:120px;white-space:nowrap" class="ft2402">104</p>
<p style="position:absolute;top:622px;left:256px;white-space:nowrap" class="ft2402">42.8%</p>
<p style="position:absolute;top:622px;left:355px;white-space:nowrap" class="ft2402">36.9%</p>
<p style="position:absolute;top:622px;left:464px;white-space:nowrap" class="ft2402">59.0%</p>
<p style="position:absolute;top:622px;left:560px;white-space:nowrap" class="ft2402">&lt;&#160;0.001</p>
<p style="position:absolute;top:622px;left:645px;white-space:nowrap" class="ft2402">&lt;&#160;0.001</p>
<p style="position:absolute;top:622px;left:741px;white-space:nowrap" class="ft2402">0.162</p>
<p style="position:absolute;top:661px;left:120px;white-space:nowrap" class="ft2402">ACR 70</p>
<p style="position:absolute;top:681px;left:162px;white-space:nowrap" class="ft2402">Week&#160;</p>
<p style="position:absolute;top:700px;left:120px;white-space:nowrap" class="ft2402">52</p>
<p style="position:absolute;top:681px;left:256px;white-space:nowrap" class="ft2402">27.2%</p>
<p style="position:absolute;top:681px;left:355px;white-space:nowrap" class="ft2402">25.9%</p>
<p style="position:absolute;top:681px;left:464px;white-space:nowrap" class="ft2402">45.5%</p>
<p style="position:absolute;top:681px;left:560px;white-space:nowrap" class="ft2402">&lt;&#160;0.001</p>
<p style="position:absolute;top:681px;left:645px;white-space:nowrap" class="ft2402">&lt;&#160;0.001</p>
<p style="position:absolute;top:681px;left:741px;white-space:nowrap" class="ft2402">0.656</p>
<p style="position:absolute;top:720px;left:162px;white-space:nowrap" class="ft2402">Week&#160;</p>
<p style="position:absolute;top:739px;left:120px;white-space:nowrap" class="ft2402">104</p>
<p style="position:absolute;top:720px;left:256px;white-space:nowrap" class="ft2402">28.4%</p>
<p style="position:absolute;top:720px;left:355px;white-space:nowrap" class="ft2402">28.1%</p>
<p style="position:absolute;top:720px;left:464px;white-space:nowrap" class="ft2402">46.6%</p>
<p style="position:absolute;top:720px;left:560px;white-space:nowrap" class="ft2402">&lt;&#160;0.001</p>
<p style="position:absolute;top:720px;left:645px;white-space:nowrap" class="ft2402">&lt;&#160;0.001</p>
<p style="position:absolute;top:720px;left:741px;white-space:nowrap" class="ft2402">0.864</p>
<p style="position:absolute;top:758px;left:121px;white-space:nowrap" class="ft2402">a.&#160;p-value is from the pairwise comparison of methotrexate monotherapy and Humira/methotrexate&#160;</p>
<p style="position:absolute;top:777px;left:148px;white-space:nowrap" class="ft2402">combination therapy using the&#160;Mann-Whitney U test.</p>
<p style="position:absolute;top:796px;left:121px;white-space:nowrap" class="ft2402">b.&#160;p-value is from the pairwise comparison of Humira monotherapy and Humira/methotrexate&#160;</p>
<p style="position:absolute;top:815px;left:145px;white-space:nowrap" class="ft2402">combination therapy using the Mann-Whitney U test</p>
<p style="position:absolute;top:834px;left:121px;white-space:nowrap" class="ft2402">c. &#160; p-value is from the pairwise comparison of Humira monotherapy and methotrexate monotherapy&#160;</p>
<p style="position:absolute;top:853px;left:145px;white-space:nowrap" class="ft2402">using the Mann-Whitney U test</p>
<p style="position:absolute;top:892px;left:106px;white-space:nowrap" class="ft2404">In the open-label extension for RA study V, ACR response rates were maintained when followed for up to&#160;<br/>10 years. Of 542 patients who were randomised to Humira 40 mg every other week, 170 patients&#160;<br/>continued on Humira 40 mg&#160;every other week for 10 years. Among those, 154 patients (90.6%) had ACR&#160;<br/>20 responses; 127 patients (74.7%) had ACR 50 responses; and 102 patients (60.0%) had ACR 70&#160;<br/>responses.</p>
<p style="position:absolute;top:1006px;left:106px;white-space:nowrap" class="ft2405">At Week&#160;52, 42.9% of patients who received Humira/methotrexate combination therapy achieved clinical&#160;<br/>remission (DAS28 (CRP)&#160;&lt;&#160;2.6) compared to 20.6% of patients receiving methotrexate monotherapy and&#160;<br/>23.4% of patients receiving Humira monotherapy. Humira/methotrexate combination therapy was&#160;<br/>clinically and statistically superior to methotrexate (p&#160;&lt;&#160;0.001) and Humira monotherapy (p&#160;&lt;&#160;0.001) in&#160;<br/>achieving a low disease state in patients with recently diagnosed moderate to severe rheumatoid arthritis.&#160;</p>
</div>
<!-- Page 241 -->
<a name="241"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page241-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2410">241</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft2414">The response for the two monotherapy arms was similar (p&#160;=&#160;0.447). &#160;Of 342 subjects originally&#160;<br/>randomized to Humira monotherapy or Humira/methotrexate combination therapy who entered the open-<br/>label extension study, 171 subjects completed 10 years of Humira treatment. Among those, 109 subjects&#160;<br/>(63.7%) were reported to be in remission at 10 years.</p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft2413"><i>Radiographic response</i></p>
<p style="position:absolute;top:219px;left:106px;white-space:nowrap" class="ft2414">In RA study III, where Humira treated patients had a mean duration of rheumatoid arthritis of&#160;<br/>approximately 11&#160;years, structural joint damage was assessed radiographically and expressed as change in&#160;<br/>modified Total Sharp Score (TSS) and its components, the erosion score and joint space narrowing score. &#160;<br/>Humira/methotrexate patients demonstrated significantly less radiographic progression than patients&#160;<br/>receiving methotrexate alone at 6 and 12&#160;months (see Table&#160;7).</p>
<p style="position:absolute;top:333px;left:106px;white-space:nowrap" class="ft2414">In the open-label&#160;extension of RA Study III, the reduction in rate of progression of structural damage is&#160;<br/>maintained for 8 and 10&#160;years in a subset of patients. At 8&#160;years, 81 of 207 patients originally treated with&#160;<br/>40&#160;mg Humira every other week were evaluated radiographically. Among those, 48 patients showed no&#160;<br/>progression of structural damage defined by a change from baseline in the mTSS of 0.5 or less. At&#160;<br/>10&#160;years, 79 of 207 patients originally treated with 40&#160;mg Humira every other week were evaluated&#160;<br/>radiographically.&#160;Among those, 40 patients showed no progression of structural damage defined by a&#160;<br/>change from baseline in the mTSS of 0.5 or less.</p>
<p style="position:absolute;top:485px;left:411px;white-space:nowrap" class="ft2411"><b>Table&#160;7</b></p>
<p style="position:absolute;top:503px;left:221px;white-space:nowrap" class="ft2411"><b>Radiographic Mean Changes Over 12&#160;Months in RA Study III</b></p>
<p style="position:absolute;top:542px;left:270px;white-space:nowrap" class="ft2415">Placebo/<br/>MTXa</p>
<p style="position:absolute;top:542px;left:391px;white-space:nowrap" class="ft2412">Humira/MTX</p>
<p style="position:absolute;top:561px;left:396px;white-space:nowrap" class="ft2412">40&#160;mg&#160;every&#160;</p>
<p style="position:absolute;top:580px;left:400px;white-space:nowrap" class="ft2412">other week</p>
<p style="position:absolute;top:542px;left:529px;white-space:nowrap" class="ft2412">Placebo/MTX-</p>
<p style="position:absolute;top:561px;left:513px;white-space:nowrap" class="ft2412">Humira/MTX (95%&#160;</p>
<p style="position:absolute;top:580px;left:541px;white-space:nowrap" class="ft2412">Confidence&#160;</p>
<p style="position:absolute;top:599px;left:548px;white-space:nowrap" class="ft2412">Intervalb)</p>
<p style="position:absolute;top:542px;left:687px;white-space:nowrap" class="ft2412">p-value</p>
<p style="position:absolute;top:619px;left:124px;white-space:nowrap" class="ft2412">Total Sharp Score</p>
<p style="position:absolute;top:619px;left:306px;white-space:nowrap" class="ft2412">2.7</p>
<p style="position:absolute;top:619px;left:426px;white-space:nowrap" class="ft2412">0.1</p>
<p style="position:absolute;top:619px;left:536px;white-space:nowrap" class="ft2412">2.6 (1.4, 3.8)&#160;</p>
<p style="position:absolute;top:619px;left:684px;white-space:nowrap" class="ft2412">&lt;&#160;0.001c</p>
<p style="position:absolute;top:638px;left:139px;white-space:nowrap" class="ft2412">Erosion score</p>
<p style="position:absolute;top:638px;left:306px;white-space:nowrap" class="ft2412">1.6</p>
<p style="position:absolute;top:638px;left:426px;white-space:nowrap" class="ft2412">0.0</p>
<p style="position:absolute;top:638px;left:536px;white-space:nowrap" class="ft2412">1.6 (0.9, 2.2)</p>
<p style="position:absolute;top:638px;left:687px;white-space:nowrap" class="ft2412">&lt;&#160;0.001</p>
<p style="position:absolute;top:658px;left:148px;white-space:nowrap" class="ft2412">JSNd&#160;score</p>
<p style="position:absolute;top:658px;left:306px;white-space:nowrap" class="ft2412">1.0</p>
<p style="position:absolute;top:658px;left:426px;white-space:nowrap" class="ft2412">0.1</p>
<p style="position:absolute;top:658px;left:536px;white-space:nowrap" class="ft2412">0.9 (0.3, 1.4)</p>
<p style="position:absolute;top:658px;left:689px;white-space:nowrap" class="ft2412">&#160;&#160;0.002</p>
<p style="position:absolute;top:676px;left:106px;white-space:nowrap" class="ft24113"><b>a</b>methotrexate</p>
<p style="position:absolute;top:696px;left:106px;white-space:nowrap" class="ft2419">b95% confidence intervals for the differences in change scores between methotrexate and Humira.&#160;</p>
<p style="position:absolute;top:714px;left:106px;white-space:nowrap" class="ft2419">cBased on rank analysis&#160;</p>
<p style="position:absolute;top:733px;left:106px;white-space:nowrap" class="ft2419">dJoint Space Narrowing</p>
<p style="position:absolute;top:773px;left:106px;white-space:nowrap" class="ft2415">In RA study V, structural joint damage was assessed radiographically and expressed as change in modified&#160;<br/>Total Sharp Score (see Table&#160;8).</p>
<p style="position:absolute;top:830px;left:422px;white-space:nowrap" class="ft2411"><b>Table&#160;8</b></p>
<p style="position:absolute;top:849px;left:246px;white-space:nowrap" class="ft2411"><b>&#160;&#160;Radiographic Mean Changes at Week&#160;52 in RA Study V</b></p>
<p style="position:absolute;top:887px;left:261px;white-space:nowrap" class="ft2412">MTX</p>
<p style="position:absolute;top:906px;left:258px;white-space:nowrap" class="ft2412">n=257</p>
<p style="position:absolute;top:925px;left:261px;white-space:nowrap" class="ft2412">(95%&#160;</p>
<p style="position:absolute;top:944px;left:243px;white-space:nowrap" class="ft2412">confidence&#160;</p>
<p style="position:absolute;top:963px;left:251px;white-space:nowrap" class="ft2412">interval)</p>
<p style="position:absolute;top:887px;left:367px;white-space:nowrap" class="ft2412">Humira</p>
<p style="position:absolute;top:906px;left:371px;white-space:nowrap" class="ft2412">n=274</p>
<p style="position:absolute;top:925px;left:374px;white-space:nowrap" class="ft2412">(95%</p>
<p style="position:absolute;top:944px;left:356px;white-space:nowrap" class="ft2412">confidence&#160;</p>
<p style="position:absolute;top:963px;left:364px;white-space:nowrap" class="ft2412">interval)</p>
<p style="position:absolute;top:887px;left:458px;white-space:nowrap" class="ft2412">Humira/MTX</p>
<p style="position:absolute;top:906px;left:482px;white-space:nowrap" class="ft2412">n=268</p>
<p style="position:absolute;top:925px;left:486px;white-space:nowrap" class="ft2412">(95%&#160;</p>
<p style="position:absolute;top:944px;left:467px;white-space:nowrap" class="ft2412">confidence&#160;</p>
<p style="position:absolute;top:963px;left:476px;white-space:nowrap" class="ft2412">interval)</p>
<p style="position:absolute;top:925px;left:569px;white-space:nowrap" class="ft2412">p-valuea</p>
<p style="position:absolute;top:925px;left:643px;white-space:nowrap" class="ft2412">p-valueb</p>
<p style="position:absolute;top:925px;left:718px;white-space:nowrap" class="ft2412">p-valuec</p>
<p style="position:absolute;top:983px;left:129px;white-space:nowrap" class="ft2412">Total Sharp&#160;</p>
<p style="position:absolute;top:1002px;left:149px;white-space:nowrap" class="ft2412">Score</p>
<p style="position:absolute;top:983px;left:238px;white-space:nowrap" class="ft2412">5.7 (4.2-7.3)</p>
<p style="position:absolute;top:983px;left:351px;white-space:nowrap" class="ft2412">3.0 (1.7-4.3)</p>
<p style="position:absolute;top:983px;left:462px;white-space:nowrap" class="ft2412">1.3 (0.5-2.1)</p>
<p style="position:absolute;top:983px;left:571px;white-space:nowrap" class="ft2412">&lt;&#160;0.001</p>
<p style="position:absolute;top:983px;left:648px;white-space:nowrap" class="ft2412">0.0020</p>
<p style="position:absolute;top:983px;left:720px;white-space:nowrap" class="ft2412">&lt;&#160;0.001</p>
<p style="position:absolute;top:1022px;left:122px;white-space:nowrap" class="ft2412">Erosion score</p>
<p style="position:absolute;top:1022px;left:238px;white-space:nowrap" class="ft2412">3.7 (2.7-4.7)</p>
<p style="position:absolute;top:1022px;left:351px;white-space:nowrap" class="ft2412">1.7 (1.0-2.4)</p>
<p style="position:absolute;top:1022px;left:462px;white-space:nowrap" class="ft2412">0.8 (0.4-1.2)</p>
<p style="position:absolute;top:1022px;left:571px;white-space:nowrap" class="ft2412">&lt;&#160;0.001</p>
<p style="position:absolute;top:1022px;left:648px;white-space:nowrap" class="ft2412">0.0082</p>
<p style="position:absolute;top:1022px;left:720px;white-space:nowrap" class="ft2412">&lt;&#160;0.001</p>
<p style="position:absolute;top:1041px;left:134px;white-space:nowrap" class="ft2412">JSN score</p>
<p style="position:absolute;top:1041px;left:238px;white-space:nowrap" class="ft2412">2.0 (1.2-2.8)</p>
<p style="position:absolute;top:1041px;left:351px;white-space:nowrap" class="ft2412">1.3 (0.5-2.1)</p>
<p style="position:absolute;top:1041px;left:468px;white-space:nowrap" class="ft2412">0.5 (0-1.0)</p>
<p style="position:absolute;top:1041px;left:571px;white-space:nowrap" class="ft2412">&lt;&#160;0.001</p>
<p style="position:absolute;top:1041px;left:648px;white-space:nowrap" class="ft2412">0.0037</p>
<p style="position:absolute;top:1041px;left:726px;white-space:nowrap" class="ft2412">0.151</p>
</div>
<!-- Page 242 -->
<a name="242"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page242-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2420">242</p>
<p style="position:absolute;top:85px;left:122px;white-space:nowrap" class="ft2429">a&#160;p-value is from the pairwise comparison of methotrexate monotherapy and Humira/methotrexate&#160;</p>
<p style="position:absolute;top:106px;left:147px;white-space:nowrap" class="ft2422">combination therapy using the Mann-Whitney U test.</p>
<p style="position:absolute;top:123px;left:122px;white-space:nowrap" class="ft2429">b&#160;p-value is from the pairwise comparison of Humira monotherapy and Humira/methotrexate&#160;</p>
<p style="position:absolute;top:144px;left:149px;white-space:nowrap" class="ft2422">combination therapy using the Mann-Whitney U test&#160;</p>
<p style="position:absolute;top:161px;left:122px;white-space:nowrap" class="ft2429">c&#160;p-value is from the pairwise comparison of Humira monotherapy and methotrexate monotherapy&#160;</p>
<p style="position:absolute;top:181px;left:149px;white-space:nowrap" class="ft2422">using the Mann-Whitney U&#160;test</p>
<p style="position:absolute;top:220px;left:106px;white-space:nowrap" class="ft2427">Following 52&#160;weeks and 104&#160;weeks of treatment, the percentage of patients without progression (change&#160;<br/>from baseline in modified Total Sharp Score&#160;</p>
<p style="position:absolute;top:238px;left:404px;white-space:nowrap" class="ft2426">&#160;0.5) was significantly higher with Humira/methotrexate&#160;</p>
<p style="position:absolute;top:259px;left:106px;white-space:nowrap" class="ft2424">combination therapy (63.8% and 61.2% respectively) compared to methotrexate monotherapy (37.4% and&#160;<br/>33.5% respectively, p&#160;&lt;&#160;0.001) and Humira monotherapy (50.7%, p&#160;&lt;&#160;0.002 and 44.5%, p&#160;&lt;&#160;0.001&#160;<br/>respectively).</p>
<p style="position:absolute;top:334px;left:106px;white-space:nowrap" class="ft2424">In the open-label extension of RA study V, the mean change from baseline at Year 10 in the modified&#160;<br/>Total Sharp Score was 10.8, 9.2 and 3.9 in patients originally randomized to methotrexate monotherapy,&#160;<br/>Humira monotherapy and Humira/methotrexate combination therapy, respectively.&#160;The corresponding&#160;<br/>proportions of patients with no radiographic progression were 31.3%, 23.7% and 36.7% respectively.</p>
<p style="position:absolute;top:429px;left:106px;white-space:nowrap" class="ft2423"><i>Quality of life and physical function&#160;</i></p>
<p style="position:absolute;top:467px;left:106px;white-space:nowrap" class="ft2424">Health-related quality of life and physical function were assessed using the disability index of the Health&#160;<br/>Assessment Questionnaire (HAQ) in the four original adequate and well-controlled trials, which was a&#160;<br/>pre-specified primary endpoint at Week&#160;52 in RA study III. All doses/schedules of Humira in all four&#160;<br/>studies showed statistically significantly greater improvement in the disability index of the HAQ from&#160;<br/>baseline to Month&#160;6 compared to placebo and in RA study III the same was seen at Week&#160;52. Results from&#160;<br/>the Short Form Health Survey (SF 36) for all doses/schedules of Humira in all four studies support these&#160;<br/>findings, with statistically significant physical component summary (PCS) scores, as well as statistically&#160;<br/>significant pain and vitality domain scores for the 40&#160;mg&#160;every other week dose. A statistically significant&#160;<br/>decrease in fatigue as measured by functional assessment of chronic illness therapy (FACIT) scores&#160;was&#160;<br/>seen in all three studies in which it was assessed (RA studies I, III, IV).</p>
<p style="position:absolute;top:676px;left:106px;white-space:nowrap" class="ft2425">In RA study III, most subjects who achieved improvement in physical function and continued treatment&#160;<br/>maintained improvement through Week&#160;520 (120&#160;months) of open-label treatment. Improvement in&#160;<br/>quality of life was measured up to Week&#160;156 (36&#160;months) and improvement was maintained through that&#160;<br/>time.</p>
<p style="position:absolute;top:771px;left:106px;white-space:nowrap" class="ft2425">In RA study V, the improvement in the HAQ disability index and the physical component of the SF 36&#160;<br/>showed greater improvement (p&#160;&lt;&#160;0.001) for Humira/methotrexate combination therapy&#160;<i>versus<br/></i>methotrexate monotherapy and Humira monotherapy at Week&#160;52, which was maintained through&#160;<br/>Week&#160;104.&#160;Among the 250 subjects who completed the open-label extension study, improvements in&#160;<br/>physical&#160;function were maintained through 10 years of treatment.</p>
<p style="position:absolute;top:885px;left:106px;white-space:nowrap" class="ft2423"><i>Injection site pain</i></p>
<p style="position:absolute;top:923px;left:106px;white-space:nowrap" class="ft2425">For the pooled crossover RA studies VI and VII, a statistically significant difference for injection site pain&#160;<br/>immediately after dosing was observed between Humira 40&#160;mg/0.8&#160;ml and Humira 40&#160;mg/0.4&#160;ml (mean&#160;<br/>VAS of 3.7&#160;cm&#160;versus 1.2&#160;cm, scale of 0-10&#160;cm, P&#160;&lt;&#160;0.001).&#160;This represented an 84% median reduction in&#160;<br/>injection site pain.</p>
<p style="position:absolute;top:1018px;left:106px;white-space:nowrap" class="ft2423"><i>Psoriasis&#160;</i></p>
<p style="position:absolute;top:1057px;left:106px;white-space:nowrap" class="ft2422">The safety and efficacy of Humira were studied in adult patients with chronic plaque&#160;psoriasis (</p>
<p style="position:absolute;top:1055px;left:737px;white-space:nowrap" class="ft2426">&#160;10%&#160;</p>
<p style="position:absolute;top:1077px;left:106px;white-space:nowrap" class="ft2422">BSA involvement and Psoriasis Area and Severity Index (PASI)&#160;</p>
<p style="position:absolute;top:1075px;left:535px;white-space:nowrap" class="ft2426">&#160;12 or&#160;&#160;10) who were candidates for&#160;</p>
</div>
<!-- Page 243 -->
<a name="243"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page243-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2430">243</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft2434">systemic therapy or phototherapy in randomised, double-blind studies. 73% of patients enrolled in&#160;<br/>Psoriasis Studies I and II had received prior systemic therapy or phototherapy. &#160;The safety and efficacy of&#160;<br/>Humira were also studied in adult patients with moderate to severe&#160;chronic plaque psoriasis with&#160;<br/>concomitant hand and/or foot psoriasis who were candidates for systemic therapy in a randomised double-<br/>blind study (Psoriasis Study III). &#160;</p>
<p style="position:absolute;top:198px;left:106px;white-space:nowrap" class="ft2437">Psoriasis Study I (REVEAL) evaluated 1,212 patients within three treatment periods. &#160;In period A, patients&#160;<br/>received placebo or Humira at an initial dose of 80&#160;mg&#160;followed by 40&#160;mg&#160;every other week starting one&#160;<br/>week after the initial dose. After 16&#160;weeks&#160;of therapy, patients who achieved at least a PASI 75 response&#160;<br/>(PASI score improvement of at least 75% relative to baseline), entered period B and received open-label&#160;<br/>40&#160;mg Humira every other week. Patients who&#160;maintained&#160;</p>
<p style="position:absolute;top:273px;left:494px;white-space:nowrap" class="ft2436">PASI 75 response at Week&#160;33 and were&#160;</p>
<p style="position:absolute;top:294px;left:106px;white-space:nowrap" class="ft2435">originally randomised to active therapy in Period A, were re-randomised in period C to receive 40&#160;mg&#160;<br/>Humira every other week or placebo for an additional 19&#160;weeks. Across all treatment groups, the mean&#160;<br/>baseline PASI score was 18.9 and the baseline Physician’s Global Assessment (PGA) score ranged from&#160;<br/>“moderate” (53% of subjects included) to “severe” (41%) to “very severe” (6%).</p>
<p style="position:absolute;top:389px;left:106px;white-space:nowrap" class="ft2434">Psoriasis Study II (CHAMPION) compared the efficacy and safety of Humira&#160;<i>versus&#160;</i>methotrexate and&#160;<br/>placebo in 271 patients.&#160;Patients received placebo, an initial dose of MTX 7.5&#160;mg and thereafter dose&#160;<br/>increases up to Week&#160;12, with a maximum dose of 25&#160;mg&#160;or an initial dose of 80&#160;mg Humira followed by&#160;<br/>40&#160;mg&#160;every other week (starting one&#160;week after the initial dose) for 16&#160;weeks. There are no data available&#160;<br/>comparing Humira and MTX beyond 16&#160;weeks of therapy. Patients receiving MTX who achieved a&#160;</p>
<p style="position:absolute;top:483px;left:106px;white-space:nowrap" class="ft2434">PASI 50 response at Week&#160;8 and/or 12 did not receive further dose increases. Across all treatment&#160;<br/>groups, the mean baseline&#160;PASI&#160;score was 19.7 and the baseline PGA score ranged from “mild” (&lt;1%) to&#160;<br/>“moderate” (48%) to “severe” (46%) to “very severe” (6%).</p>
<p style="position:absolute;top:561px;left:106px;white-space:nowrap" class="ft2434">Patients participating in all Phase 2 and Phase 3 psoriasis studies were eligible to enrol&#160;into an open-label&#160;<br/>extension trial, where Humira was given for at least an additional 108&#160;weeks.</p>
<p style="position:absolute;top:618px;left:106px;white-space:nowrap" class="ft2435">In Psoriasis Studies I and II, a primary endpoint was the proportion of patients who achieved a PASI 75&#160;<br/>response from baseline at Week&#160;16&#160;(see Tables&#160;9&#160;and&#160;10).</p>
<p style="position:absolute;top:675px;left:433px;white-space:nowrap" class="ft2431"><b>Table&#160;9</b></p>
<p style="position:absolute;top:694px;left:271px;white-space:nowrap" class="ft2431"><b>Ps Study I (REVEAL) &#160;-&#160;Efficacy Results at 16&#160;Weeks</b></p>
<p style="position:absolute;top:714px;left:455px;white-space:nowrap" class="ft2431"><b>Placebo</b></p>
<p style="position:absolute;top:733px;left:459px;white-space:nowrap" class="ft2431"><b>N=398</b></p>
<p style="position:absolute;top:752px;left:462px;white-space:nowrap" class="ft2431"><b>n&#160;(%)</b></p>
<p style="position:absolute;top:714px;left:564px;white-space:nowrap" class="ft2431"><b>Humira 40 mg eow</b></p>
<p style="position:absolute;top:733px;left:608px;white-space:nowrap" class="ft2431"><b>N=814</b></p>
<p style="position:absolute;top:752px;left:611px;white-space:nowrap" class="ft2431"><b>n&#160;(%)</b></p>
<p style="position:absolute;top:773px;left:207px;white-space:nowrap" class="ft2431"><b>&#160; &#160;&#160;</b></p>
<p style="position:absolute;top:771px;left:223px;white-space:nowrap" class="ft2436">&#160;<b>PASI 75a</b></p>
<p style="position:absolute;top:771px;left:456px;white-space:nowrap" class="ft2432">26 (6.5)</p>
<p style="position:absolute;top:771px;left:594px;white-space:nowrap" class="ft2432">578 (70.9)b</p>
<p style="position:absolute;top:792px;left:207px;white-space:nowrap" class="ft2431"><b>&#160; &#160;&#160;PASI 100</b></p>
<p style="position:absolute;top:792px;left:460px;white-space:nowrap" class="ft2432">3 (0.8)</p>
<p style="position:absolute;top:792px;left:594px;white-space:nowrap" class="ft2432">163 (20.0)b</p>
<p style="position:absolute;top:812px;left:207px;white-space:nowrap" class="ft2431"><b>&#160; &#160;&#160;PGA: Clear/minimal</b></p>
<p style="position:absolute;top:812px;left:456px;white-space:nowrap" class="ft2432">17 (4.3)</p>
<p style="position:absolute;top:812px;left:594px;white-space:nowrap" class="ft2432">506 (62.2)b</p>
<p style="position:absolute;top:830px;left:207px;white-space:nowrap" class="ft2437">a&#160;Percent of patients achieving PASI75 response was calculated as centre-<br/>adjusted rate</p>
<p style="position:absolute;top:868px;left:207px;white-space:nowrap" class="ft2439">b&#160;p&#160;&lt;&#160;0.001, Humira vs.&#160;Placebo</p>
<p style="position:absolute;top:908px;left:429px;white-space:nowrap" class="ft2431"><b>Table&#160;10</b></p>
<p style="position:absolute;top:927px;left:264px;white-space:nowrap" class="ft2431"><b>Ps Study II (CHAMPION) Efficacy Results at 16&#160;Weeks</b></p>
<p style="position:absolute;top:966px;left:353px;white-space:nowrap" class="ft2431"><b>Placebo</b></p>
<p style="position:absolute;top:985px;left:361px;white-space:nowrap" class="ft2431"><b>N=53</b></p>
<p style="position:absolute;top:1004px;left:360px;white-space:nowrap" class="ft2431"><b>n&#160;(%)</b></p>
<p style="position:absolute;top:966px;left:474px;white-space:nowrap" class="ft2431"><b>MTX</b></p>
<p style="position:absolute;top:985px;left:470px;white-space:nowrap" class="ft2431"><b>N=110</b></p>
<p style="position:absolute;top:1004px;left:473px;white-space:nowrap" class="ft2431"><b>n&#160;(%)</b></p>
<p style="position:absolute;top:966px;left:566px;white-space:nowrap" class="ft2431"><b>Humira 40 mg eow</b></p>
<p style="position:absolute;top:985px;left:610px;white-space:nowrap" class="ft2431"><b>N=108</b></p>
<p style="position:absolute;top:1004px;left:613px;white-space:nowrap" class="ft2431"><b>n&#160;(%)</b></p>
<p style="position:absolute;top:1025px;left:203px;white-space:nowrap" class="ft2431"><b>&#160; &#160;&#160;</b></p>
<p style="position:absolute;top:1023px;left:220px;white-space:nowrap" class="ft2436">&#160;<b>PASI 75</b></p>
<p style="position:absolute;top:1023px;left:350px;white-space:nowrap" class="ft2432">10 (18.9)</p>
<p style="position:absolute;top:1023px;left:463px;white-space:nowrap" class="ft2432">39 (35.5)</p>
<p style="position:absolute;top:1023px;left:594px;white-space:nowrap" class="ft2432">86 (79.6)&#160;a, b</p>
<p style="position:absolute;top:1045px;left:203px;white-space:nowrap" class="ft2431"><b>&#160; &#160;&#160;PASI 100</b></p>
<p style="position:absolute;top:1045px;left:358px;white-space:nowrap" class="ft2432">1 (1.9)</p>
<p style="position:absolute;top:1045px;left:471px;white-space:nowrap" class="ft2432">8 (7.3)</p>
<p style="position:absolute;top:1045px;left:594px;white-space:nowrap" class="ft2432">18 (16.7)&#160;c, d</p>
<p style="position:absolute;top:1065px;left:203px;white-space:nowrap" class="ft24315"><b>&#160; &#160;&#160;PGA:&#160;<br/>Clear/minimal</b></p>
<p style="position:absolute;top:1065px;left:354px;white-space:nowrap" class="ft2432">6 (11.3)</p>
<p style="position:absolute;top:1065px;left:463px;white-space:nowrap" class="ft2432">33 (30.0)</p>
<p style="position:absolute;top:1065px;left:594px;white-space:nowrap" class="ft2432">79 (73.1)&#160;a, b</p>
</div>
<!-- Page 244 -->
<a name="244"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page244-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2440">244</p>
<p style="position:absolute;top:85px;left:203px;white-space:nowrap" class="ft2449">a&#160;p&#160;&lt;&#160;0.001 Humira vs. placebo</p>
<p style="position:absolute;top:104px;left:203px;white-space:nowrap" class="ft2449">b&#160;p&#160;&lt;&#160;0.001 Humira vs. methotrexate</p>
<p style="position:absolute;top:123px;left:203px;white-space:nowrap" class="ft2449">c&#160;p&#160;&lt;&#160;0.01 Humira vs. placebo</p>
<p style="position:absolute;top:142px;left:203px;white-space:nowrap" class="ft2449">d&#160;p&#160;&lt;&#160;0.05 Humira vs. methotrexate</p>
<p style="position:absolute;top:182px;left:106px;white-space:nowrap" class="ft2444">In&#160;Psoriasis&#160;Study I, 28% of patients who were PASI 75 responders and were re-randomised to placebo at&#160;<br/>Week&#160;33 compared to 5% continuing on Humira, p&#160;&lt;&#160;0.001, experienced “loss of adequate response”<br/>(PASI score after Week&#160;33 and on or before Week&#160;52 that resulted in a &lt;PASI 50 response relative to&#160;<br/>baseline with a minimum of a 6-point increase in PASI score relative to Week&#160;33). Of the patients who&#160;<br/>lost adequate response after re-randomisation to placebo who then enrolled&#160;into the open-label extension&#160;<br/>trial, 38% (25/66) and 55% (36/66) regained PASI 75 response after 12 and 24&#160;weeks of re-treatment,&#160;<br/>respectively.</p>
<p style="position:absolute;top:334px;left:106px;white-space:nowrap" class="ft2445">A total of 233 PASI 75 responders at Week&#160;16 and Week&#160;33 received continuous Humira therapy for&#160;<br/>52&#160;weeks in Psoriasis Study I, and continued Humira in the open-label extension trial. &#160;PASI 75 and PGA&#160;<br/>of clear or minimal response rates in these patients were 74.7% and 59.0%, respectively, after an&#160;<br/>additional 108&#160;weeks of open-label therapy (total of 160&#160;weeks). In an analysis in which all patients who&#160;<br/>dropped out of the study for adverse events or lack of efficacy, or who dose-escalated, were considered&#160;<br/>non-responders, PASI 75 and PGA of clear or minimal response rates in these patients were 69.6% and&#160;<br/>55.7%, respectively, after an additional 108&#160;weeks of open-label therapy (total of 160&#160;weeks).</p>
<p style="position:absolute;top:486px;left:106px;white-space:nowrap" class="ft2444">A total of 347 stable responders participated in a withdrawal and retreatment evaluation in an open-label&#160;<br/>extension study. During the withdrawal period, symptoms of psoriasis&#160;returned over time with a median&#160;<br/>time to relapse (decline to PGA “moderate” or worse) of approximately 5&#160;months. None of these patients&#160;<br/>experienced rebound during the withdrawal period. A total of 76.5% (218/285) of patients who entered the&#160;<br/>retreatment period had a response of PGA “clear” or “minimal” after 16&#160;weeks of retreatment, irrespective&#160;<br/>of&#160;whether they relapsed during withdrawal (69.1%[123/178] and 88.8% [95/107] for patients who&#160;<br/>relapsed and who did not relapse during the withdrawal period, respectively). &#160;A similar safety profile was&#160;<br/>observed during retreatment as before withdrawal.</p>
<p style="position:absolute;top:657px;left:106px;white-space:nowrap" class="ft2444">Significant improvements at Week&#160;16 from baseline compared to placebo (Studies I and II) and MTX&#160;<br/>(Study II) were demonstrated in the DLQI (Dermatology Life Quality Index). In Study I, improvements in&#160;<br/>the physical and mental component summary scores of the SF-36 were also significant compared to&#160;<br/>placebo.</p>
<p style="position:absolute;top:752px;left:106px;white-space:nowrap" class="ft2444">In an open-label extension study, for patients who dose escalated from 40&#160;mg&#160;every other week to 40&#160;mg&#160;<br/>weekly due to&#160;a PASI response below 50%, 26.4% (92/349) and 37.8% (132/349) of patients achieved&#160;<br/>PASI 75 response at Week 12 and 24, respectively.</p>
<p style="position:absolute;top:827px;left:106px;white-space:nowrap" class="ft2444">Psoriasis Study III (REACH)&#160;compared the efficacy and safety of Humira&#160;<i>versus&#160;</i>placebo in 72 patients&#160;<br/>with moderate to severe&#160;chronic plaque psoriasis and hand and/or foot psoriasis. Patients received an&#160;<br/>initial&#160;dose of 80&#160;mg Humira followed by 40&#160;mg every other week (starting one week after the initial dose)&#160;<br/>or placebo for 16&#160;weeks. At Week&#160;16, a statistically significantly greater proportion of patients who&#160;<br/>received Humira achieved PGA of 'clear' or 'almost clear' for the hands and/or feet compared to patients&#160;<br/>who received placebo (30.6% versus 4.3%, respectively [P = 0.014]).</p>
<p style="position:absolute;top:960px;left:106px;white-space:nowrap" class="ft2444">Psoriasis Study IV compared efficacy and safety of Humira versus placebo in 217 adult patients with&#160;<br/>moderate to severe nail psoriasis. Patients received an initial dose of 80 mg Humira followed by 40&#160;mg&#160;<br/>every other week (starting one week after the initial&#160;dose) or placebo for 26&#160;weeks followed by open-label&#160;<br/>Humira treatment for an additional 26&#160;weeks. Nail psoriasis assessments included the Modified Nail&#160;<br/>Psoriasis Severity Index (mNAPSI), the Physician’s Global Assessment of Fingernail Psoriasis (PGA-F)&#160;<br/>and the Nail Psoriasis Severity Index (NAPSI) (see Table&#160;11). Humira demonstrated a treatment benefit in&#160;</p>
</div>
<!-- Page 245 -->
<a name="245"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page245-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2450">245</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft2455">nail psoriasis patients with different extents of skin involvement (BSA≥10% (60% of patients) and&#160;<br/>BSA&lt;10% and&#160;≥5% (40% of patients)). &#160; &#160;</p>
<p style="position:absolute;top:143px;left:428px;white-space:nowrap" class="ft2451"><b>Table&#160;11</b></p>
<p style="position:absolute;top:162px;left:275px;white-space:nowrap" class="ft2451"><b>Ps Study IV Efficacy Results at 16, 26 and 52&#160;Weeks</b></p>
<p style="position:absolute;top:181px;left:114px;white-space:nowrap" class="ft2452">Endpoint</p>
<p style="position:absolute;top:181px;left:368px;white-space:nowrap" class="ft2452">Week 16</p>
<p style="position:absolute;top:201px;left:334px;white-space:nowrap" class="ft2452">Placebo-Controlled</p>
<p style="position:absolute;top:181px;left:540px;white-space:nowrap" class="ft2452">Week 26</p>
<p style="position:absolute;top:201px;left:506px;white-space:nowrap" class="ft2452">Placebo-Controlled</p>
<p style="position:absolute;top:181px;left:710px;white-space:nowrap" class="ft2452">Week 52</p>
<p style="position:absolute;top:201px;left:703px;white-space:nowrap" class="ft2452">Open-label</p>
<p style="position:absolute;top:220px;left:324px;white-space:nowrap" class="ft2452">Placebo</p>
<p style="position:absolute;top:239px;left:328px;white-space:nowrap" class="ft2452">N=108</p>
<p style="position:absolute;top:220px;left:413px;white-space:nowrap" class="ft2452">Humira</p>
<p style="position:absolute;top:239px;left:402px;white-space:nowrap" class="ft2452">40&#160;mg&#160;eow&#160;</p>
<p style="position:absolute;top:258px;left:415px;white-space:nowrap" class="ft2452">N=109</p>
<p style="position:absolute;top:220px;left:496px;white-space:nowrap" class="ft2452">Placebo</p>
<p style="position:absolute;top:239px;left:499px;white-space:nowrap" class="ft2452">N=108</p>
<p style="position:absolute;top:220px;left:581px;white-space:nowrap" class="ft2452">Humira</p>
<p style="position:absolute;top:239px;left:570px;white-space:nowrap" class="ft2452">40&#160;mg&#160;eow&#160;</p>
<p style="position:absolute;top:258px;left:584px;white-space:nowrap" class="ft2452">N=109</p>
<p style="position:absolute;top:220px;left:714px;white-space:nowrap" class="ft2452">Humira</p>
<p style="position:absolute;top:239px;left:703px;white-space:nowrap" class="ft2452">40&#160;mg&#160;eow&#160;</p>
<p style="position:absolute;top:258px;left:720px;white-space:nowrap" class="ft2452">N=80</p>
<p style="position:absolute;top:278px;left:114px;white-space:nowrap" class="ft2452">≥ mNAPSI 75 (%)</p>
<p style="position:absolute;top:278px;left:340px;white-space:nowrap" class="ft2452">2.9</p>
<p style="position:absolute;top:278px;left:422px;white-space:nowrap" class="ft2452">26.0a</p>
<p style="position:absolute;top:278px;left:512px;white-space:nowrap" class="ft2452">3.4</p>
<p style="position:absolute;top:278px;left:590px;white-space:nowrap" class="ft2452">46.6a</p>
<p style="position:absolute;top:278px;left:725px;white-space:nowrap" class="ft2452">65.0</p>
<p style="position:absolute;top:298px;left:114px;white-space:nowrap" class="ft2454">PGA-F clear/minimal and&#160;<br/>≥2-grade improvement (%)</p>
<p style="position:absolute;top:298px;left:340px;white-space:nowrap" class="ft2452">2.9</p>
<p style="position:absolute;top:298px;left:422px;white-space:nowrap" class="ft2452">29.7a</p>
<p style="position:absolute;top:298px;left:512px;white-space:nowrap" class="ft2452">6.9</p>
<p style="position:absolute;top:298px;left:590px;white-space:nowrap" class="ft2452">48.9a</p>
<p style="position:absolute;top:298px;left:725px;white-space:nowrap" class="ft2452">61.3</p>
<p style="position:absolute;top:336px;left:114px;white-space:nowrap" class="ft2454">Percent Change in Total&#160;<br/>Fingernail NAPSI (%)</p>
<p style="position:absolute;top:336px;left:337px;white-space:nowrap" class="ft2452">-7.8</p>
<p style="position:absolute;top:336px;left:417px;white-space:nowrap" class="ft2452">-44.2&#160;a</p>
<p style="position:absolute;top:336px;left:505px;white-space:nowrap" class="ft2452">-11.5</p>
<p style="position:absolute;top:336px;left:587px;white-space:nowrap" class="ft2452">-56.2a</p>
<p style="position:absolute;top:336px;left:722px;white-space:nowrap" class="ft2452">-72.2</p>
<p style="position:absolute;top:374px;left:114px;white-space:nowrap" class="ft2459">a&#160;p&lt;0.001, Humira&#160;<i>vs.&#160;</i>placebo&#160;</p>
<p style="position:absolute;top:414px;left:106px;white-space:nowrap" class="ft2454">Humira treated patients showed statistically significant improvements at Week&#160;26 compared with placebo&#160;<br/>in the DLQI.&#160;</p>
<p style="position:absolute;top:471px;left:106px;white-space:nowrap" class="ft2453"><i>Hidradenitis suppurativa</i></p>
<p style="position:absolute;top:509px;left:106px;white-space:nowrap" class="ft2454">The safety and efficacy of Humira were assessed in randomised, double-blind, placebo-controlled studies&#160;<br/>and an open-label extension study in adult patients with moderate to severe hidradenitis suppurativa (HS)&#160;<br/>who were&#160;intolerant, had a contraindication or an inadequate response to at least a 3-month trial of&#160;<br/>systemic antibiotic therapy. &#160;The patients in HS-I and HS-II had Hurley Stage II or III disease with at least&#160;<br/>3 abscesses or inflammatory nodules.</p>
<p style="position:absolute;top:622px;left:106px;white-space:nowrap" class="ft2455">Study HS-I (PIONEER I) evaluated 307 patients with 2 treatment periods. &#160;In Period A, patients received&#160;<br/>placebo or Humira at an initial dose of 160 mg at Week 0, 80&#160;mg at Week 2, and 40 mg every week&#160;<br/>starting at Week 4 to Week 11. &#160;Concomitant antibiotic use was not allowed during the study. &#160;After&#160;<br/>12&#160;weeks of therapy, patients who had received Humira in Period A were re-randomised in Period B to 1&#160;<br/>of 3 treatment groups (Humira 40 mg every week, Humira 40 mg every other week, or placebo from Week&#160;<br/>12 to Week 35). &#160;Patients who had been randomised to placebo in Period A were assigned to receive&#160;<br/>Humira 40 mg every week in Period B.</p>
<p style="position:absolute;top:774px;left:106px;white-space:nowrap" class="ft2454">Study HS-II (PIONEER II) evaluated 326&#160;patients with 2 treatment periods. &#160;In Period A, patients received&#160;<br/>placebo or Humira at an initial dose of 160 mg at Week 0 and 80 mg at Week 2 and 40 mg every week&#160;<br/>starting at Week 4 to Week 11. &#160;19.3% of patients had continued baseline oral antibiotic therapy during the&#160;<br/>study. &#160;After 12&#160;weeks of therapy, patients who had received Humira in Period A were re-randomised in&#160;<br/>Period B to 1 of 3 treatment groups (Humira 40 mg every week, Humira 40 mg every other week, or&#160;<br/>placebo from Week 12 to Week 35). &#160;Patients who had been randomised to placebo in Period A were&#160;<br/>assigned to receive placebo in Period B.</p>
<p style="position:absolute;top:926px;left:106px;white-space:nowrap" class="ft2454">Patients participating in Studies HS-I and HS-II were&#160;eligible to enrol into an open-label extension study&#160;<br/>in which Humira 40mg was administered every week.&#160;Mean exposure in all adalimumab population was&#160;<br/>762 days.&#160;&#160;Throughout all 3 studies patients used topical antiseptic wash daily.</p>
<p style="position:absolute;top:1002px;left:106px;white-space:nowrap" class="ft2453"><i>Clinical Response</i></p>
<p style="position:absolute;top:1040px;left:106px;white-space:nowrap" class="ft2454">Reduction of inflammatory lesions and prevention of worsening of abscesses and draining fistulas was&#160;<br/>assessed using Hidradenitis Suppurativa Clinical Response (HiSCR; at least a 50% reduction in total&#160;<br/>abscess and inflammatory nodule count with no increase&#160;in abscess count and no increase in draining&#160;</p>
</div>
<!-- Page 246 -->
<a name="246"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page246-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2460">246</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft2464">fistula count relative to Baseline). &#160;Reduction in HS-related skin pain was assessed using a Numeric&#160;<br/>Rating Scale in patients who entered the study with an initial baseline score of 3 or greater on a 11 point&#160;<br/>scale.&#160;</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft2464">At Week 12, a significantly higher proportion of patients treated with Humira versus placebo achieved&#160;<br/>HiSCR. &#160; At Week 12, a significantly higher proportion of patients in Study HS-II experienced a clinically&#160;<br/>relevant decrease in HS-related skin pain (see Table&#160;12). &#160;Patients treated with Humira had significantly&#160;<br/>reduced risk of disease flare during the initial 12 weeks of treatment.</p>
<p style="position:absolute;top:261px;left:262px;white-space:nowrap" class="ft2461"><b>Table&#160;12: &#160;Efficacy Results at 12 Weeks, HS Studies I and II</b></p>
<p style="position:absolute;top:306px;left:404px;white-space:nowrap" class="ft2461"><b>HS Study I</b></p>
<p style="position:absolute;top:306px;left:643px;white-space:nowrap" class="ft2461"><b>HS Study II</b></p>
<p style="position:absolute;top:344px;left:350px;white-space:nowrap" class="ft2461"><b>Placebo</b></p>
<p style="position:absolute;top:325px;left:446px;white-space:nowrap" class="ft2461"><b>Humira 40 mg&#160;</b></p>
<p style="position:absolute;top:344px;left:471px;white-space:nowrap" class="ft2461"><b>Weekly</b></p>
<p style="position:absolute;top:344px;left:588px;white-space:nowrap" class="ft2461"><b>Placebo&#160;</b></p>
<p style="position:absolute;top:325px;left:687px;white-space:nowrap" class="ft2461"><b>Humira 40 mg&#160;</b></p>
<p style="position:absolute;top:344px;left:711px;white-space:nowrap" class="ft2461"><b>Weekly</b></p>
<p style="position:absolute;top:373px;left:119px;white-space:nowrap" class="ft2465">Hidradenitis Suppurativa&#160;<br/>Clinical Response (HiSCR)a</p>
<p style="position:absolute;top:364px;left:351px;white-space:nowrap" class="ft2462">N = 154</p>
<p style="position:absolute;top:383px;left:341px;white-space:nowrap" class="ft2462">40 (26.0%)</p>
<p style="position:absolute;top:364px;left:470px;white-space:nowrap" class="ft2462">N = 153</p>
<p style="position:absolute;top:383px;left:456px;white-space:nowrap" class="ft2462">64 (41.8%)&#160;*</p>
<p style="position:absolute;top:364px;left:593px;white-space:nowrap" class="ft2462">N=163</p>
<p style="position:absolute;top:383px;left:579px;white-space:nowrap" class="ft2462">45 (27.6%)</p>
<p style="position:absolute;top:364px;left:715px;white-space:nowrap" class="ft2462">N=163</p>
<p style="position:absolute;top:383px;left:691px;white-space:nowrap" class="ft2462">96 (58.9%)&#160;***</p>
<p style="position:absolute;top:421px;left:119px;white-space:nowrap" class="ft2464">≥30% Reduction in Skin&#160;<br/>Painb</p>
<p style="position:absolute;top:421px;left:351px;white-space:nowrap" class="ft2462">N = 109</p>
<p style="position:absolute;top:440px;left:341px;white-space:nowrap" class="ft2462">27 (24.8%)</p>
<p style="position:absolute;top:421px;left:470px;white-space:nowrap" class="ft2462">N = 122</p>
<p style="position:absolute;top:440px;left:460px;white-space:nowrap" class="ft2462">34 (27.9%)</p>
<p style="position:absolute;top:421px;left:593px;white-space:nowrap" class="ft2462">N=111</p>
<p style="position:absolute;top:440px;left:579px;white-space:nowrap" class="ft2462">23 (20.7%)</p>
<p style="position:absolute;top:421px;left:715px;white-space:nowrap" class="ft2462">N=105</p>
<p style="position:absolute;top:440px;left:691px;white-space:nowrap" class="ft2462">48 (45.7%)&#160;***</p>
<p style="position:absolute;top:460px;left:146px;white-space:nowrap" class="ft2462">*&#160;<i>P&#160;</i>&lt; 0.05, ***<i>P&#160;</i>&lt; 0.001, Humira versus placebo&#160;</p>
<p style="position:absolute;top:485px;left:119px;white-space:nowrap" class="ft24618">a</p>
<p style="position:absolute;top:481px;left:146px;white-space:nowrap" class="ft2462">Among all randomised patients.</p>
<p style="position:absolute;top:506px;left:119px;white-space:nowrap" class="ft24618">b</p>
<p style="position:absolute;top:502px;left:146px;white-space:nowrap" class="ft2462">Among patients with baseline HS-related skin pain assessment&#160;≥ 3, based on Numeric Rating&#160;</p>
<p style="position:absolute;top:520px;left:146px;white-space:nowrap" class="ft2462">Scale 0&#160;–&#160;10; 0&#160;=&#160;no skin pain, 10 = skin pain as bad as you can&#160;imagine.</p>
<p style="position:absolute;top:559px;left:106px;white-space:nowrap" class="ft2464">Treatment with Humira 40 mg every week significantly reduced the risk of worsening of abscesses and&#160;<br/>draining fistulas. &#160;Approximately twice the proportion of patients in the placebo group in the first 12&#160;<br/>weeks of Studies HS-I and HS-II, compared&#160;with those in the Humira group experienced worsening of&#160;<br/>abscesses (23.0% vs 11.4%, respectively) and draining fistulas (30.0% vs 13.9%, respectively).</p>
<p style="position:absolute;top:653px;left:106px;white-space:nowrap" class="ft2464">Greater improvements at Week 12 from baseline compared to placebo were demonstrated in skin-specific&#160;<br/>health-related quality of life, as measured by the Dermatology Life Quality Index (DLQI; Studies HS-I&#160;<br/>and HS-II), patient global satisfaction with medication treatment as measured by the Treatment&#160;<br/>Satisfaction Questionnaire&#160;-&#160;medication (TSQM; Studies HS-I and&#160;HS-II), and physical health as&#160;<br/>measured by the physical component summary score of the SF-36&#160;(Study HS-I).</p>
<p style="position:absolute;top:768px;left:106px;white-space:nowrap" class="ft2464">In patients with at least a partial response to Humira 40 mg weekly at Week 12, the HiSCR rate at Week&#160;<br/>36 was higher in patients who continued weekly Humira than in patients in whom dosing frequency was&#160;<br/>reduced to every other week, or in whom treatment was withdrawn (see Table&#160;13).</p>
</div>
<!-- Page 247 -->
<a name="247"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page247-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2470">247</p>
<p style="position:absolute;top:86px;left:164px;white-space:nowrap" class="ft2471"><b>Table&#160;13:</b></p>
<p style="position:absolute;top:86px;left:276px;white-space:nowrap" class="ft2471"><b>Proportion of Patientsa&#160;Achieving HiSCRb&#160;at Weeks 24 and 36 After</b></p>
<p style="position:absolute;top:105px;left:272px;white-space:nowrap" class="ft2471"><b>Treatment Reassignment from&#160;Weekly&#160;Humira at Week 12</b></p>
<p style="position:absolute;top:127px;left:341px;white-space:nowrap" class="ft2471"><b>Placebo</b></p>
<p style="position:absolute;top:145px;left:331px;white-space:nowrap" class="ft2471"><b>(treatment&#160;</b></p>
<p style="position:absolute;top:163px;left:326px;white-space:nowrap" class="ft2471"><b>withdrawal)</b></p>
<p style="position:absolute;top:181px;left:346px;white-space:nowrap" class="ft2471"><b>N = 73</b></p>
<p style="position:absolute;top:145px;left:466px;white-space:nowrap" class="ft2471"><b>Humira 40 mg</b></p>
<p style="position:absolute;top:163px;left:458px;white-space:nowrap" class="ft2471"><b>every other week</b></p>
<p style="position:absolute;top:181px;left:494px;white-space:nowrap" class="ft2471"><b>N = 70</b></p>
<p style="position:absolute;top:145px;left:610px;white-space:nowrap" class="ft2471"><b>Humira 40 mg</b></p>
<p style="position:absolute;top:163px;left:637px;white-space:nowrap" class="ft2471"><b>weekly</b></p>
<p style="position:absolute;top:181px;left:638px;white-space:nowrap" class="ft2471"><b>N = 70</b></p>
<p style="position:absolute;top:206px;left:195px;white-space:nowrap" class="ft2472">Week 24</p>
<p style="position:absolute;top:206px;left:332px;white-space:nowrap" class="ft2472">24 (32.9%)</p>
<p style="position:absolute;top:206px;left:480px;white-space:nowrap" class="ft2472">36 (51.4%)</p>
<p style="position:absolute;top:206px;left:624px;white-space:nowrap" class="ft2472">40 (57.1%)</p>
<p style="position:absolute;top:230px;left:195px;white-space:nowrap" class="ft2472">Week 36</p>
<p style="position:absolute;top:230px;left:332px;white-space:nowrap" class="ft2472">22 (30.1%)</p>
<p style="position:absolute;top:230px;left:480px;white-space:nowrap" class="ft2472">28 (40.0%)</p>
<p style="position:absolute;top:230px;left:624px;white-space:nowrap" class="ft2472">39 (55.7%)</p>
<p style="position:absolute;top:253px;left:194px;white-space:nowrap" class="ft2479">a</p>
<p style="position:absolute;top:255px;left:221px;white-space:nowrap" class="ft2472">Patients with at least a partial response to&#160;Humira 40 mg weekly after 12&#160;</p>
<p style="position:absolute;top:273px;left:221px;white-space:nowrap" class="ft2472">weeks of treatment.</p>
<p style="position:absolute;top:292px;left:195px;white-space:nowrap" class="ft2479">b</p>
<p style="position:absolute;top:294px;left:213px;white-space:nowrap" class="ft2472">Patients meeting protocol-specified criteria for loss of response or no&#160;</p>
<p style="position:absolute;top:312px;left:213px;white-space:nowrap" class="ft2472">improvement were required to discontinue from the studies and were&#160;</p>
<p style="position:absolute;top:330px;left:213px;white-space:nowrap" class="ft2472">counted as nonresponders.</p>
<p style="position:absolute;top:369px;left:106px;white-space:nowrap" class="ft2475">Among patients who were at least partial&#160;responders at Week 12, and who received continuous weekly&#160;<br/>Humira therapy, the HiSCR rate at Week 48 was 68.3% and at Week 96 was 65.1%. Longer term&#160;<br/>treatment with Humira 40 mg weekly for 96 weeks identified no new safety findings.</p>
<p style="position:absolute;top:445px;left:106px;white-space:nowrap" class="ft2475">Among patients whose Humira treatment was withdrawn at Week 12 in Studies HS-I and HS-II, the&#160;<br/>HiSCR rate 12 weeks after re-introduction of Humira 40 mg weekly returned to levels similar to that&#160;<br/>observed before withdrawal (56.0 %).</p>
<p style="position:absolute;top:521px;left:106px;white-space:nowrap" class="ft2473"><i>Crohn’s disease</i></p>
<p style="position:absolute;top:558px;left:106px;white-space:nowrap" class="ft2477">The safety and efficacy of Humira were assessed in over 1500 patients with moderately to severely active&#160;<br/>Crohn’s disease (Crohn’s Disease Activity Index (CDAI)&#160;</p>
<p style="position:absolute;top:577px;left:489px;white-space:nowrap" class="ft2476">&#160;220 and&#160;&#160;450) in randomised, double-blind,&#160;</p>
<p style="position:absolute;top:598px;left:106px;white-space:nowrap" class="ft2475">placebo-controlled studies. Concomitant stable doses of aminosalicylates, corticosteroids, and/or&#160;<br/>immunomodulatory agents were permitted and 80% of patients continued to receive at least one of these&#160;<br/>medications.&#160;</p>
<p style="position:absolute;top:674px;left:106px;white-space:nowrap" class="ft2474">Induction of clinical remission (defined as CDAI &lt;&#160;150) was evaluated in two studies, CD Study I&#160;<br/>(CLASSIC I) and CD Study II (GAIN). In CD Study I, 299 TNF-antagonist naive patients were&#160;<br/>randomised to one of four treatment groups; placebo at Weeks&#160;0 and 2, 160&#160;mg Humira at Week&#160;0 and&#160;<br/>80&#160;mg at Week&#160;2, 80&#160;mg at Week&#160;0 and 40&#160;mg at Week&#160;2, and 40&#160;mg at Week&#160;0 and 20&#160;mg at Week&#160;2. In&#160;<br/>CD Study II, 325 patients who had lost response or were intolerant to infliximab were randomised to&#160;<br/>receive either 160&#160;mg Humira at Week&#160;0 and 80&#160;mg at Week&#160;2 or placebo at Weeks&#160;0 and 2. The primary&#160;<br/>non-responders were&#160;excluded from the studies and therefore these patients were not further evaluated.</p>
<p style="position:absolute;top:825px;left:106px;white-space:nowrap" class="ft2474">Maintenance of clinical remission was evaluated in CD study III (CHARM). &#160;In CD Study III, 854 patients&#160;<br/>received open-label 80&#160;mg at Week&#160;0 and 40&#160;mg at Week&#160;2. &#160;At Week&#160;4&#160;patients were randomised to&#160;<br/>40&#160;mg&#160;every other week, 40&#160;mg every week, or placebo with a total study duration of 56&#160;weeks. Patients in&#160;<br/>clinical response (decrease in CDAI&#160;≥ 70) at Week&#160;4 were stratified and analysed separately from those&#160;<br/>not in clinical response at Week&#160;4. &#160;Corticosteroid taper was permitted after Week&#160;8.&#160;</p>
<p style="position:absolute;top:939px;left:106px;white-space:nowrap" class="ft2472">CD study I and CD study II induction of remission and response rates are presented in Table&#160;14.</p>
</div>
<!-- Page 248 -->
<a name="248"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page248-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2480">248</p>
<p style="position:absolute;top:88px;left:422px;white-space:nowrap" class="ft2481"><b>Table&#160;14</b></p>
<p style="position:absolute;top:109px;left:291px;white-space:nowrap" class="ft2481"><b>Induction of Clinical Remission and Response</b></p>
<p style="position:absolute;top:130px;left:380px;white-space:nowrap" class="ft2481"><b>(Percent of Patients)</b></p>
<p style="position:absolute;top:154px;left:287px;white-space:nowrap" class="ft24815"><b>CD&#160;Study I:&#160;Infliximab Naive&#160;<br/>Patients</b></p>
<p style="position:absolute;top:154px;left:558px;white-space:nowrap" class="ft24815"><b>CD Study II: Infliximab&#160;<br/>Experienced Patients</b></p>
<p style="position:absolute;top:198px;left:296px;white-space:nowrap" class="ft2481"><b>Placebo</b></p>
<p style="position:absolute;top:219px;left:305px;white-space:nowrap" class="ft2481"><b>N=74</b></p>
<p style="position:absolute;top:198px;left:387px;white-space:nowrap" class="ft2481"><b>Humira</b></p>
<p style="position:absolute;top:219px;left:383px;white-space:nowrap" class="ft2481"><b>80/40&#160;mg</b></p>
<p style="position:absolute;top:239px;left:392px;white-space:nowrap" class="ft2481"><b>N = 75</b></p>
<p style="position:absolute;top:198px;left:478px;white-space:nowrap" class="ft2481"><b>Humira&#160;</b></p>
<p style="position:absolute;top:219px;left:470px;white-space:nowrap" class="ft2481"><b>160/80&#160;mg&#160;</b></p>
<p style="position:absolute;top:237px;left:487px;white-space:nowrap" class="ft2481"><b>N=76</b></p>
<p style="position:absolute;top:198px;left:579px;white-space:nowrap" class="ft2481"><b>Placebo</b></p>
<p style="position:absolute;top:219px;left:583px;white-space:nowrap" class="ft2481"><b>N=166</b></p>
<p style="position:absolute;top:198px;left:703px;white-space:nowrap" class="ft2481"><b>Humira&#160;</b></p>
<p style="position:absolute;top:219px;left:694px;white-space:nowrap" class="ft2481"><b>160/80&#160;mg</b></p>
<p style="position:absolute;top:239px;left:707px;white-space:nowrap" class="ft2481"><b>N=159</b></p>
<p style="position:absolute;top:265px;left:114px;white-space:nowrap" class="ft24816">Week&#160;4<br/>Clinical remission</p>
<p style="position:absolute;top:289px;left:309px;white-space:nowrap" class="ft2482">12%</p>
<p style="position:absolute;top:289px;left:400px;white-space:nowrap" class="ft2482">24%</p>
<p style="position:absolute;top:289px;left:488px;white-space:nowrap" class="ft2482">36%*</p>
<p style="position:absolute;top:289px;left:595px;white-space:nowrap" class="ft2482">7%</p>
<p style="position:absolute;top:289px;left:713px;white-space:nowrap" class="ft2482">21%*</p>
<p style="position:absolute;top:314px;left:114px;white-space:nowrap" class="ft2482">Clinical response (CR-</p>
<p style="position:absolute;top:332px;left:114px;white-space:nowrap" class="ft2482">100)</p>
<p style="position:absolute;top:314px;left:309px;white-space:nowrap" class="ft2482">24%</p>
<p style="position:absolute;top:314px;left:400px;white-space:nowrap" class="ft2482">37%</p>
<p style="position:absolute;top:314px;left:486px;white-space:nowrap" class="ft2482">49%**</p>
<p style="position:absolute;top:314px;left:591px;white-space:nowrap" class="ft2482">25%</p>
<p style="position:absolute;top:314px;left:710px;white-space:nowrap" class="ft2482">38%**</p>
<p style="position:absolute;top:357px;left:114px;white-space:nowrap" class="ft2484">All p-values are pairwise comparisons of proportions for Humira&#160;<i>versus&#160;</i>placebo<br/>*</p>
<p style="position:absolute;top:378px;left:141px;white-space:nowrap" class="ft2482">p&#160;&lt;&#160;0.001</p>
<p style="position:absolute;top:397px;left:114px;white-space:nowrap" class="ft2489">**</p>
<p style="position:absolute;top:399px;left:141px;white-space:nowrap" class="ft2482">p&#160;&lt;&#160;0.01</p>
<p style="position:absolute;top:440px;left:106px;white-space:nowrap" class="ft2485">Similar remission rates were observed for the 160/80&#160;mg and 80/40&#160;mg&#160;induction regimens by Week&#160;8 and&#160;<br/>adverse events were more&#160;frequently noted in the 160/80&#160;mg group.</p>
<p style="position:absolute;top:496px;left:106px;white-space:nowrap" class="ft2484">In CD Study III, at Week&#160;4, 58% (499/854) of patients were in clinical response and were assessed in the&#160;<br/>primary analysis. Of those in clinical response at Week&#160;4, 48% had been previously exposed to other TNF-<br/>antagonists. Maintenance of remission and response rates are presented in Table&#160;15. &#160;Clinical remission&#160;<br/>results remained relatively constant irrespective of previous TNF-antagonist exposure.</p>
<p style="position:absolute;top:591px;left:106px;white-space:nowrap" class="ft2484">Disease-related hospitalisations and surgeries were statistically significantly reduced with adalimumab&#160;<br/>compared with placebo at Week&#160;56.</p>
<p style="position:absolute;top:651px;left:422px;white-space:nowrap" class="ft2481"><b>Table&#160;15</b></p>
<p style="position:absolute;top:671px;left:279px;white-space:nowrap" class="ft2481"><b>Maintenance of Clinical Remission and Response</b></p>
<p style="position:absolute;top:692px;left:380px;white-space:nowrap" class="ft2481"><b>(Percent of Patients)</b></p>
<p style="position:absolute;top:717px;left:425px;white-space:nowrap" class="ft2481"><b>Placebo</b></p>
<p style="position:absolute;top:717px;left:539px;white-space:nowrap" class="ft2481"><b>40&#160;mg&#160;Humira</b></p>
<p style="position:absolute;top:735px;left:531px;white-space:nowrap" class="ft2481"><b>every other week</b></p>
<p style="position:absolute;top:717px;left:675px;white-space:nowrap" class="ft2481"><b>40&#160;mg&#160;Humira</b></p>
<p style="position:absolute;top:735px;left:687px;white-space:nowrap" class="ft2481"><b>every week</b></p>
<p style="position:absolute;top:760px;left:122px;white-space:nowrap" class="ft2481"><b>Week&#160;26</b></p>
<p style="position:absolute;top:760px;left:429px;white-space:nowrap" class="ft2481"><b>N=170</b></p>
<p style="position:absolute;top:760px;left:567px;white-space:nowrap" class="ft2481"><b>N=172</b></p>
<p style="position:absolute;top:760px;left:703px;white-space:nowrap" class="ft2481"><b>N=157</b></p>
<p style="position:absolute;top:785px;left:122px;white-space:nowrap" class="ft2482">Clinical&#160;remission</p>
<p style="position:absolute;top:785px;left:437px;white-space:nowrap" class="ft2482">17%</p>
<p style="position:absolute;top:785px;left:571px;white-space:nowrap" class="ft2482">40%*</p>
<p style="position:absolute;top:785px;left:707px;white-space:nowrap" class="ft2482">47%*</p>
<p style="position:absolute;top:809px;left:122px;white-space:nowrap" class="ft2482">Clinical response (CR-100)</p>
<p style="position:absolute;top:809px;left:437px;white-space:nowrap" class="ft2482">27%</p>
<p style="position:absolute;top:809px;left:571px;white-space:nowrap" class="ft2482">52%*</p>
<p style="position:absolute;top:809px;left:707px;white-space:nowrap" class="ft2482">52%*</p>
<p style="position:absolute;top:834px;left:149px;white-space:nowrap" class="ft2482">Patients in steroid-free remission&#160;</p>
<p style="position:absolute;top:852px;left:149px;white-space:nowrap" class="ft2482">for &gt;=90 daysa</p>
<p style="position:absolute;top:834px;left:419px;white-space:nowrap" class="ft2482">3% (2/66)</p>
<p style="position:absolute;top:834px;left:541px;white-space:nowrap" class="ft2482">19% (11/58)**</p>
<p style="position:absolute;top:834px;left:677px;white-space:nowrap" class="ft2482">15% (11/74)**</p>
<p style="position:absolute;top:877px;left:122px;white-space:nowrap" class="ft2481"><b>Week&#160;56</b></p>
<p style="position:absolute;top:877px;left:429px;white-space:nowrap" class="ft2481"><b>N=170</b></p>
<p style="position:absolute;top:877px;left:567px;white-space:nowrap" class="ft2481"><b>N=172</b></p>
<p style="position:absolute;top:877px;left:703px;white-space:nowrap" class="ft2481"><b>N=157</b></p>
<p style="position:absolute;top:902px;left:122px;white-space:nowrap" class="ft2482">Clinical remission</p>
<p style="position:absolute;top:902px;left:437px;white-space:nowrap" class="ft2482">12%</p>
<p style="position:absolute;top:902px;left:571px;white-space:nowrap" class="ft2482">36%*</p>
<p style="position:absolute;top:902px;left:707px;white-space:nowrap" class="ft2482">41%*</p>
<p style="position:absolute;top:926px;left:122px;white-space:nowrap" class="ft2482">Clinical response (CR-100)</p>
<p style="position:absolute;top:926px;left:437px;white-space:nowrap" class="ft2482">17%</p>
<p style="position:absolute;top:926px;left:571px;white-space:nowrap" class="ft2482">41%*</p>
<p style="position:absolute;top:926px;left:707px;white-space:nowrap" class="ft2482">48%*</p>
<p style="position:absolute;top:951px;left:149px;white-space:nowrap" class="ft2482">Patients in steroid-free remission&#160;</p>
<p style="position:absolute;top:969px;left:149px;white-space:nowrap" class="ft2482">for&#160;&gt;&#160;=&#160;90&#160;daysa</p>
<p style="position:absolute;top:951px;left:419px;white-space:nowrap" class="ft2482">5% (3/66)</p>
<p style="position:absolute;top:951px;left:545px;white-space:nowrap" class="ft2482">29% (17/58)*</p>
<p style="position:absolute;top:951px;left:677px;white-space:nowrap" class="ft2482">20% (15/74)**</p>
<p style="position:absolute;top:994px;left:122px;white-space:nowrap" class="ft2482">*</p>
<p style="position:absolute;top:994px;left:149px;white-space:nowrap" class="ft2482">p&#160;&lt;&#160;0.001 for Humira&#160;<i>versus&#160;</i>placebo pairwise comparisons of proportions</p>
<p style="position:absolute;top:1015px;left:122px;white-space:nowrap" class="ft2484">**&#160;p&#160;&lt;&#160;0.02 for Humira&#160;<i>versus&#160;</i>placebo pairwise comparisons of proportions<br/>a</p>
<p style="position:absolute;top:1036px;left:149px;white-space:nowrap" class="ft2482">Of those&#160;receiving corticosteroids at baseline</p>
</div>
<!-- Page 249 -->
<a name="249"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page249-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2490">249</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft2494">Among patients who were not in response at Week&#160;4, 43% of Humira maintenance patients responded by&#160;<br/>Week&#160;12 compared to 30% of placebo maintenance patients. These results suggest that some patients who&#160;<br/>have not responded by Week&#160;4 benefit from continued maintenance therapy through Week&#160;12. &#160;Therapy&#160;<br/>continued beyond 12&#160;weeks did not result in significantly more responses&#160;(see section 4.2).&#160;&#160;</p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft2494">117/276 patients from CD study I and 272/777 patients from CD studies II and III were followed through&#160;<br/>at least 3&#160;years of open-label adalimumab therapy. &#160;88 and 189 patients, respectively, continued to be in&#160;<br/>clinical remission. &#160;Clinical response (CR-100) was maintained in 102 and 233 patients, respectively.</p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft2493"><i>Quality of life</i></p>
<p style="position:absolute;top:295px;left:106px;white-space:nowrap" class="ft2494">In CD Study I and CD Study II, statistically&#160;significant improvement in the disease-specific inflammatory&#160;<br/>bowel disease questionnaire (IBDQ) total score was achieved at Week&#160;4 in patients randomised to Humira&#160;<br/>80/40&#160;mg and 160/80&#160;mg compared to placebo and was seen at Weeks&#160;26 and 56 in CD Study III as well&#160;<br/>among the adalimumab treatment groups compared to the placebo group.</p>
<p style="position:absolute;top:390px;left:106px;white-space:nowrap" class="ft2493"><i>Ulcerative colitis</i></p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft2494">The safety and efficacy of multiple doses of Humira were assessed in adult patients with moderately to&#160;<br/>severely active ulcerative colitis (Mayo score 6 to 12 with&#160;endoscopy subscore of 2 to 3) in randomised,&#160;<br/>double-blind, placebo-controlled studies.&#160;</p>
<p style="position:absolute;top:503px;left:106px;white-space:nowrap" class="ft2495">In study UC-I, 390 TNF-antagonist naïve patients were randomised to receive either placebo at Weeks 0&#160;<br/>and 2, 160&#160;mg Humira at Week&#160;0 followed by 80&#160;mg at Week&#160;2, or 80&#160;mg Humira at Week&#160;0 followed by&#160;<br/>40&#160;mg at Week&#160;2. &#160;After Week&#160;2, patients in both adalimumab arms received 40&#160;mg&#160;eow. &#160;Clinical&#160;<br/>remission (defined as Mayo score&#160;≤&#160;2 with no subscore &gt;&#160;1)&#160;was assessed at Week&#160;8.&#160;</p>
<p style="position:absolute;top:598px;left:106px;white-space:nowrap" class="ft2494">In study UC-II, 248 patients received 160&#160;mg&#160;of Humira at Week&#160;0, 80&#160;mg at Week&#160;2 and 40&#160;mg&#160;eow&#160;<br/>thereafter, and 246 patients received placebo. Clinical results were assessed for induction of remission at&#160;<br/>Week&#160;8 and for maintenance of remission at Week&#160;52.&#160;</p>
<p style="position:absolute;top:674px;left:106px;white-space:nowrap" class="ft2494">Patients induced with 160/80&#160;mg Humira achieved clinical remission versus placebo at Week&#160;8 in&#160;<br/>statistically significantly greater percentages in study UC-I (18% vs. 9% respectively, p=0.031) and study&#160;<br/>UC-II (17% vs. 9% respectively, p=0.019).&#160;In study UC-II, among those treated with Humira who were in&#160;<br/>remission at Week&#160;8, 21/41 (51%) were in remission at Week&#160;52.</p>
<p style="position:absolute;top:769px;left:106px;white-space:nowrap" class="ft2492">Results from the overall UC-II study population are shown in Table&#160;16.</p>
<p style="position:absolute;top:807px;left:428px;white-space:nowrap" class="ft2491"><b>Table&#160;16</b></p>
<p style="position:absolute;top:826px;left:254px;white-space:nowrap" class="ft2491"><b>Response, Remission and Mucosal Healing in Study UC-II</b></p>
<p style="position:absolute;top:845px;left:387px;white-space:nowrap" class="ft2491"><b>(Percent of Patients)</b></p>
<p style="position:absolute;top:866px;left:477px;white-space:nowrap" class="ft2491"><b>Placebo</b></p>
<p style="position:absolute;top:866px;left:579px;white-space:nowrap" class="ft2491"><b>Humira 40&#160;mg&#160;</b></p>
<p style="position:absolute;top:885px;left:616px;white-space:nowrap" class="ft2491"><b>eow</b></p>
<p style="position:absolute;top:926px;left:108px;white-space:nowrap" class="ft2492">Week&#160;52</p>
<p style="position:absolute;top:926px;left:481px;white-space:nowrap" class="ft2491"><b>N=246</b></p>
<p style="position:absolute;top:926px;left:607px;white-space:nowrap" class="ft2491"><b>N=248</b></p>
<p style="position:absolute;top:948px;left:108px;white-space:nowrap" class="ft2492">&#160;&#160;Clinical Response&#160;</p>
<p style="position:absolute;top:948px;left:489px;white-space:nowrap" class="ft2492">18%&#160;</p>
<p style="position:absolute;top:948px;left:605px;white-space:nowrap" class="ft2492">&#160; &#160;30%*</p>
<p style="position:absolute;top:969px;left:108px;white-space:nowrap" class="ft2492">&#160;&#160;Clinical Remission</p>
<p style="position:absolute;top:969px;left:494px;white-space:nowrap" class="ft2492">9%</p>
<p style="position:absolute;top:969px;left:604px;white-space:nowrap" class="ft2492">&#160; &#160;17%*</p>
<p style="position:absolute;top:990px;left:108px;white-space:nowrap" class="ft2492">&#160;&#160;Mucosal Healing&#160;</p>
<p style="position:absolute;top:990px;left:489px;white-space:nowrap" class="ft2492">15%</p>
<p style="position:absolute;top:990px;left:604px;white-space:nowrap" class="ft2492">&#160; &#160;25%*</p>
<p style="position:absolute;top:1011px;left:108px;white-space:nowrap" class="ft2492">&#160;&#160;Steroid-free remission for&#160;≥&#160;90 days&#160;a</p>
<p style="position:absolute;top:1011px;left:494px;white-space:nowrap" class="ft2492">6%&#160;</p>
<p style="position:absolute;top:1030px;left:476px;white-space:nowrap" class="ft2492">(N=140)</p>
<p style="position:absolute;top:1011px;left:598px;white-space:nowrap" class="ft2492">&#160; &#160; &#160;13% *</p>
<p style="position:absolute;top:1030px;left:601px;white-space:nowrap" class="ft2492">(N=150)</p>
<p style="position:absolute;top:1071px;left:108px;white-space:nowrap" class="ft2492">Week&#160;8 and 52</p>
</div>
<!-- Page 250 -->
<a name="250"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page250-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2500">250</p>
<p style="position:absolute;top:87px;left:108px;white-space:nowrap" class="ft2502">&#160;&#160;Sustained Response&#160;</p>
<p style="position:absolute;top:87px;left:489px;white-space:nowrap" class="ft2502">12%</p>
<p style="position:absolute;top:87px;left:600px;white-space:nowrap" class="ft2502">&#160; &#160;24%**</p>
<p style="position:absolute;top:108px;left:108px;white-space:nowrap" class="ft2502">&#160;&#160;Sustained Remission&#160;</p>
<p style="position:absolute;top:108px;left:494px;white-space:nowrap" class="ft2502">4%</p>
<p style="position:absolute;top:108px;left:608px;white-space:nowrap" class="ft2502">&#160; &#160;8%*</p>
<p style="position:absolute;top:130px;left:108px;white-space:nowrap" class="ft2502">&#160;&#160;Sustained Mucosal Healing&#160;</p>
<p style="position:absolute;top:130px;left:489px;white-space:nowrap" class="ft2502">11%</p>
<p style="position:absolute;top:130px;left:606px;white-space:nowrap" class="ft2502">&#160;&#160;19%*</p>
<p style="position:absolute;top:152px;left:108px;white-space:nowrap" class="ft2504">Clinical remission is Mayo score&#160;&#160;≤&#160;2 with no subscore&#160;&gt;&#160;1;<br/>Clinical response is decrease from baseline in Mayo score&#160;≥&#160;3 points and&#160;≥&#160;30% plus a&#160;<br/>decrease in the rectal bleeding&#160;subscore [RBS]&#160;≥&#160;1 or an absolute RBS of 0 or 1;</p>
<p style="position:absolute;top:209px;left:108px;white-space:nowrap" class="ft25016">*p&#160;&lt;&#160;0.05 for Humira&#160;<i>vs.&#160;</i>placebo pairwise comparison of proportions&#160;<br/>**</p>
<p style="position:absolute;top:232px;left:123px;white-space:nowrap" class="ft2502">p&#160;&lt;&#160;0.001 for Humira&#160;<i>vs.&#160;</i>placebo pairwise comparison of proportions</p>
<p style="position:absolute;top:250px;left:108px;white-space:nowrap" class="ft2509">a&#160;&#160;&#160;Of those receiving corticosteroids at baseline</p>
<p style="position:absolute;top:291px;left:106px;white-space:nowrap" class="ft2504">Of those patients who had a response at Week&#160;8, 47% were in response, 29% were in remission, 41% had&#160;<br/>mucosal healing, and 20% were in steroid-free remission for&#160;≥&#160;90 days at Week&#160;52.</p>
<p style="position:absolute;top:347px;left:106px;white-space:nowrap" class="ft2505">Approximately 40% of patients in study UC-II had failed prior anti-TNF treatment with infliximab. The&#160;<br/>efficacy of adalimumab in those patients was reduced compared to that in anti-TNF naïve patients. &#160;<br/>Among patients who had failed prior anti-TNF treatment, Week&#160;52 remission was achieved by 3% on&#160;<br/>placebo and 10% on adalimumab.</p>
<p style="position:absolute;top:442px;left:106px;white-space:nowrap" class="ft2504">Patients from studies UC-I and UC-II had the option to roll over into an open-label long-term&#160;extension&#160;<br/>study (UC III). Following 3&#160;years of adalimumab therapy, 75% (301/402) continued to be in clinical&#160;<br/>remission per partial Mayo score.&#160;</p>
<p style="position:absolute;top:518px;left:106px;white-space:nowrap" class="ft2503"><i>Hospitalisation rates</i></p>
<p style="position:absolute;top:556px;left:106px;white-space:nowrap" class="ft2504">During 52&#160;weeks of studies UC-I and UC-II, lower rates of all-cause hospitalisations and UC-related&#160;<br/>hospitalisations were observed for the adalimumab-treated arm compared to the placebo arm.&#160;The&#160;number&#160;<br/>of all cause hospitalisations in the adalimumab&#160;treatment group was 0.18 per patient year&#160;<i>vs</i>. 0.26 per&#160;<br/>patient year in the placebo group and the corresponding figures for UC-related hospitalisations were 0.12&#160;<br/>per patient year&#160;<i>vs.&#160;</i>0.22 per patient year.</p>
<p style="position:absolute;top:670px;left:106px;white-space:nowrap" class="ft2503"><i>Quality of life</i></p>
<p style="position:absolute;top:708px;left:106px;white-space:nowrap" class="ft2505">In study UC-II, treatment with&#160;adalimumab resulted in improvements in the Inflammatory Bowel Disease&#160;<br/>Questionnaire (IBDQ) score.</p>
<p style="position:absolute;top:765px;left:106px;white-space:nowrap" class="ft2503"><i>Uveitis</i></p>
<p style="position:absolute;top:803px;left:106px;white-space:nowrap" class="ft2504">The safety and efficacy of Humira were assessed in adult patients with non-infectious intermediate,&#160;<br/>posterior, and panuveitis, excluding patients with&#160;isolated anterior uveitis, in two randomised, double-<br/>masked, placebo-controlled studies (UV I and II). Patients received placebo or Humira at an initial dose of&#160;<br/>80&#160;mg followed by 40&#160;mg&#160;every other week starting one week after the initial dose. Concomitant stable&#160;<br/>doses of one&#160;non-biologic immunosuppressant were permitted.&#160;</p>
<p style="position:absolute;top:917px;left:106px;white-space:nowrap" class="ft2505">Study UV I evaluated 217 patients with active uveitis despite treatment with corticosteroids (oral&#160;<br/>prednisone at a dose of 10 to 60&#160;mg/day). All patients received a 2-week&#160;standardised&#160;dose of prednisone&#160;<br/>60&#160;mg/day at study entry followed by a mandatory taper schedule, with complete corticosteroid&#160;<br/>discontinuation by Week 15.&#160;</p>
<p style="position:absolute;top:1012px;left:106px;white-space:nowrap" class="ft2505">Study UV II evaluated 226 patients with inactive uveitis requiring chronic corticosteroid treatment (oral&#160;<br/>prednisone 10 to 35&#160;mg/day) at baseline to control their disease. Patients subsequently underwent a&#160;<br/>mandatory taper schedule, with complete corticosteroid discontinuation by Week 19.&#160;</p>
</div>
<!-- Page 251 -->
<a name="251"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page251-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2510">251</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft2514">The primary efficacy endpoint in both studies was ´time to treatment failure´. Treatment failure was&#160;<br/>defined by a multi-component outcome based on inflammatory chorioretinal and/or inflammatory retinal&#160;<br/>vascular lesions, anterior chamber (AC) cell grade, vitreous haze (VH) grade and best corrected visual&#160;<br/>acuity (BCVA).&#160;</p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft2514">Patients who completed Studies UV I and UV&#160;II were&#160;eligible to enroll in&#160;an uncontrolled long-term&#160;<br/>extension study with an originally planned duration of 78 weeks. Patients were allowed to continue on&#160;<br/>study medication beyond Week 78 until they had access to Humira.</p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft2513"><i>Clinical Response</i></p>
<p style="position:absolute;top:295px;left:106px;white-space:nowrap" class="ft2514">Results from both studies demonstrated statistically significant reduction of the risk of treatment failure in&#160;<br/>patients treated with Humira versus patients receiving placebo (See Table&#160;17). Both studies demonstrated&#160;<br/>an early and sustained effect of Humira on the treatment failure rate versus placebo (see Figure 1).&#160;</p>
<p style="position:absolute;top:370px;left:428px;white-space:nowrap" class="ft2511"><b>Table&#160;17</b></p>
<p style="position:absolute;top:390px;left:270px;white-space:nowrap" class="ft2511"><b>Time to Treatment Failure in Studies UV I and UV II</b></p>
<p style="position:absolute;top:428px;left:114px;white-space:nowrap" class="ft2511"><b>Analysis</b></p>
<p style="position:absolute;top:447px;left:156px;white-space:nowrap" class="ft2511"><b>Treatment</b></p>
<p style="position:absolute;top:428px;left:284px;white-space:nowrap" class="ft2511"><b>N</b></p>
<p style="position:absolute;top:428px;left:338px;white-space:nowrap" class="ft25115"><b>Failure<br/>N (%)</b></p>
<p style="position:absolute;top:428px;left:426px;white-space:nowrap" class="ft25115"><b>Median Time to&#160;<br/>Failure&#160;(months)</b></p>
<p style="position:absolute;top:428px;left:567px;white-space:nowrap" class="ft2511"><b>HRa</b></p>
<p style="position:absolute;top:428px;left:621px;white-space:nowrap" class="ft25115"><b>CI 95%&#160;<br/>for HRa</b></p>
<p style="position:absolute;top:428px;left:709px;white-space:nowrap" class="ft25117"><i><b>P&#160;</b></i><b>Value&#160;</b>b</p>
<p style="position:absolute;top:467px;left:114px;white-space:nowrap" class="ft25119"><b>Time to Treatment Failure At or After Week 6 in Study UV I &#160;<br/></b>Primary analysis (ITT)</p>
<p style="position:absolute;top:505px;left:156px;white-space:nowrap" class="ft2512">Placebo</p>
<p style="position:absolute;top:505px;left:284px;white-space:nowrap" class="ft2512">107</p>
<p style="position:absolute;top:505px;left:338px;white-space:nowrap" class="ft2512">84 (78.5)</p>
<p style="position:absolute;top:505px;left:426px;white-space:nowrap" class="ft2512">3.0</p>
<p style="position:absolute;top:505px;left:567px;white-space:nowrap" class="ft2512">--</p>
<p style="position:absolute;top:505px;left:621px;white-space:nowrap" class="ft2512">--</p>
<p style="position:absolute;top:505px;left:709px;white-space:nowrap" class="ft2512">--</p>
<p style="position:absolute;top:524px;left:156px;white-space:nowrap" class="ft2512">Adalimumab</p>
<p style="position:absolute;top:524px;left:284px;white-space:nowrap" class="ft2512">110</p>
<p style="position:absolute;top:524px;left:338px;white-space:nowrap" class="ft2512">60 (54.5)</p>
<p style="position:absolute;top:524px;left:426px;white-space:nowrap" class="ft2512">5.6</p>
<p style="position:absolute;top:524px;left:567px;white-space:nowrap" class="ft2512">0.50</p>
<p style="position:absolute;top:524px;left:621px;white-space:nowrap" class="ft2512">0.36, 0.70</p>
<p style="position:absolute;top:524px;left:709px;white-space:nowrap" class="ft2512">&lt; 0.001</p>
<p style="position:absolute;top:544px;left:114px;white-space:nowrap" class="ft25119"><b>Time to Treatment Failure At or&#160;After Week 2 in Study UV II<br/></b>Primary analysis (ITT)</p>
<p style="position:absolute;top:581px;left:156px;white-space:nowrap" class="ft2512">Placebo</p>
<p style="position:absolute;top:581px;left:284px;white-space:nowrap" class="ft2512">111</p>
<p style="position:absolute;top:581px;left:338px;white-space:nowrap" class="ft2512">61 (55.0)</p>
<p style="position:absolute;top:581px;left:426px;white-space:nowrap" class="ft2512">8.3</p>
<p style="position:absolute;top:581px;left:567px;white-space:nowrap" class="ft2512">--</p>
<p style="position:absolute;top:581px;left:621px;white-space:nowrap" class="ft2512">--</p>
<p style="position:absolute;top:581px;left:709px;white-space:nowrap" class="ft2512">--</p>
<p style="position:absolute;top:600px;left:156px;white-space:nowrap" class="ft2512">Adalimumab</p>
<p style="position:absolute;top:600px;left:284px;white-space:nowrap" class="ft2512">115</p>
<p style="position:absolute;top:600px;left:338px;white-space:nowrap" class="ft2512">45 (39.1)</p>
<p style="position:absolute;top:600px;left:426px;white-space:nowrap" class="ft2512">NEc</p>
<p style="position:absolute;top:600px;left:567px;white-space:nowrap" class="ft2512">0.57</p>
<p style="position:absolute;top:600px;left:621px;white-space:nowrap" class="ft2512">0.39, 0.84</p>
<p style="position:absolute;top:600px;left:709px;white-space:nowrap" class="ft2512">0.004</p>
<p style="position:absolute;top:620px;left:106px;white-space:nowrap" class="ft2518">Note: &#160;Treatment failure at or after Week 6 (Study UV I), or at or after Week 2 (Study UV II), was&#160;<br/>counted&#160;as event. Drop outs due to reasons other than treatment failure were censored at the time of&#160;<br/>dropping out.<br/>a</p>
<p style="position:absolute;top:677px;left:133px;white-space:nowrap" class="ft2512">HR of adalimumab vs placebo from proportional hazards regression with treatment as factor.</p>
<p style="position:absolute;top:701px;left:106px;white-space:nowrap" class="ft25118">b</p>
<p style="position:absolute;top:696px;left:133px;white-space:nowrap" class="ft2512">2-sided&#160;<i>P&#160;</i>value from log rank test.</p>
<p style="position:absolute;top:719px;left:106px;white-space:nowrap" class="ft25118">c</p>
<p style="position:absolute;top:715px;left:133px;white-space:nowrap" class="ft2512">NE = not estimable. Fewer than half of at-risk subjects had an event.&#160;</p>
</div>
<!-- Page 252 -->
<a name="252"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page252-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2520">252</p>
<p style="position:absolute;top:86px;left:108px;white-space:nowrap" class="ft2521"><b>Figure 1: Kaplan-Meier Curves Summarizing Time to Treatment Failure on or after Week 6 (Study&#160;</b></p>
<p style="position:absolute;top:105px;left:350px;white-space:nowrap" class="ft2521"><b>UV I) or Week 2 (Study UV II)</b></p>
<p style="position:absolute;top:404px;left:130px;white-space:nowrap" class="ft25220"><b>T</b></p>
<p style="position:absolute;top:392px;left:130px;white-space:nowrap" class="ft25220"><b>R</b></p>
<p style="position:absolute;top:381px;left:130px;white-space:nowrap" class="ft25220"><b>E</b></p>
<p style="position:absolute;top:369px;left:130px;white-space:nowrap" class="ft25220"><b>A</b></p>
<p style="position:absolute;top:357px;left:130px;white-space:nowrap" class="ft25220"><b>T</b></p>
<p style="position:absolute;top:346px;left:130px;white-space:nowrap" class="ft25220"><b>M</b></p>
<p style="position:absolute;top:331px;left:130px;white-space:nowrap" class="ft25220"><b>E</b></p>
<p style="position:absolute;top:320px;left:130px;white-space:nowrap" class="ft25220"><b>N</b></p>
<p style="position:absolute;top:308px;left:130px;white-space:nowrap" class="ft25220"><b>T</b></p>
<p style="position:absolute;top:297px;left:130px;white-space:nowrap" class="ft25220"><b>&#160;F</b></p>
<p style="position:absolute;top:283px;left:130px;white-space:nowrap" class="ft25220"><b>A</b></p>
<p style="position:absolute;top:271px;left:130px;white-space:nowrap" class="ft25220"><b>IL</b></p>
<p style="position:absolute;top:253px;left:130px;white-space:nowrap" class="ft25220"><b>U</b></p>
<p style="position:absolute;top:242px;left:130px;white-space:nowrap" class="ft25220"><b>R</b></p>
<p style="position:absolute;top:230px;left:130px;white-space:nowrap" class="ft25220"><b>E</b></p>
<p style="position:absolute;top:219px;left:130px;white-space:nowrap" class="ft25220"><b>&#160;R</b></p>
<p style="position:absolute;top:202px;left:130px;white-space:nowrap" class="ft25220"><b>A</b></p>
<p style="position:absolute;top:191px;left:130px;white-space:nowrap" class="ft25220"><b>T</b></p>
<p style="position:absolute;top:180px;left:130px;white-space:nowrap" class="ft25220"><b>E</b></p>
<p style="position:absolute;top:169px;left:130px;white-space:nowrap" class="ft25220"><b>&#160;(</b></p>
<p style="position:absolute;top:159px;left:130px;white-space:nowrap" class="ft25220"><b>%</b></p>
<p style="position:absolute;top:143px;left:130px;white-space:nowrap" class="ft25220"><b>)</b></p>
<p style="position:absolute;top:428px;left:406px;white-space:nowrap" class="ft2521"><b>TIME (MONTHS)</b></p>
<p style="position:absolute;top:447px;left:150px;white-space:nowrap" class="ft2522">Study UV I &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;Treatment</p>
<p style="position:absolute;top:447px;left:500px;white-space:nowrap" class="ft2522">Placebo</p>
<p style="position:absolute;top:447px;left:669px;white-space:nowrap" class="ft2522">Adalimumab</p>
<p style="position:absolute;top:733px;left:130px;white-space:nowrap" class="ft25220"><b>T</b></p>
<p style="position:absolute;top:721px;left:130px;white-space:nowrap" class="ft25220"><b>R</b></p>
<p style="position:absolute;top:710px;left:130px;white-space:nowrap" class="ft25220"><b>E</b></p>
<p style="position:absolute;top:698px;left:130px;white-space:nowrap" class="ft25220"><b>A</b></p>
<p style="position:absolute;top:687px;left:130px;white-space:nowrap" class="ft25220"><b>T</b></p>
<p style="position:absolute;top:675px;left:130px;white-space:nowrap" class="ft25220"><b>M</b></p>
<p style="position:absolute;top:660px;left:130px;white-space:nowrap" class="ft25220"><b>E</b></p>
<p style="position:absolute;top:649px;left:130px;white-space:nowrap" class="ft25220"><b>N</b></p>
<p style="position:absolute;top:637px;left:130px;white-space:nowrap" class="ft25220"><b>T</b></p>
<p style="position:absolute;top:626px;left:130px;white-space:nowrap" class="ft25220"><b>&#160;F</b></p>
<p style="position:absolute;top:612px;left:130px;white-space:nowrap" class="ft25220"><b>A</b></p>
<p style="position:absolute;top:600px;left:130px;white-space:nowrap" class="ft25220"><b>IL</b></p>
<p style="position:absolute;top:582px;left:130px;white-space:nowrap" class="ft25220"><b>U</b></p>
<p style="position:absolute;top:571px;left:130px;white-space:nowrap" class="ft25220"><b>R</b></p>
<p style="position:absolute;top:559px;left:130px;white-space:nowrap" class="ft25220"><b>E</b></p>
<p style="position:absolute;top:548px;left:130px;white-space:nowrap" class="ft25220"><b>&#160;R</b></p>
<p style="position:absolute;top:531px;left:130px;white-space:nowrap" class="ft25220"><b>A</b></p>
<p style="position:absolute;top:520px;left:130px;white-space:nowrap" class="ft25220"><b>T</b></p>
<p style="position:absolute;top:509px;left:130px;white-space:nowrap" class="ft25220"><b>E</b></p>
<p style="position:absolute;top:498px;left:130px;white-space:nowrap" class="ft25220"><b>&#160;(</b></p>
<p style="position:absolute;top:488px;left:130px;white-space:nowrap" class="ft25220"><b>%</b></p>
<p style="position:absolute;top:472px;left:130px;white-space:nowrap" class="ft25220"><b>)</b></p>
<p style="position:absolute;top:760px;left:406px;white-space:nowrap" class="ft2521"><b>TIME (MONTHS)</b></p>
<p style="position:absolute;top:779px;left:150px;white-space:nowrap" class="ft2522">Study UV II &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; Treatment</p>
<p style="position:absolute;top:779px;left:500px;white-space:nowrap" class="ft2522">Placebo</p>
<p style="position:absolute;top:779px;left:669px;white-space:nowrap" class="ft2522">Adalimumab</p>
<p style="position:absolute;top:811px;left:114px;white-space:nowrap" class="ft2524">Note: P# = Placebo (Number of Events/Number at Risk); A# = HUMIRA (Number of<br/>Events/Number at Risk).</p>
<p style="position:absolute;top:873px;left:106px;white-space:nowrap" class="ft2524">In&#160;Study UV I statistically significant differences in favour of adalimumab versus placebo were observed&#160;<br/>for each component of treatment failure. &#160;In Study UV II, statistically significant differences were&#160;<br/>observed for visual acuity only, but the other components were numerically in favour of adalimumab.</p>
<p style="position:absolute;top:949px;left:106px;white-space:nowrap" class="ft2524">Of the&#160;424&#160;subjects included&#160;in&#160;the&#160;uncontrolled long-term&#160;extension of Studies UV I and UV II,&#160;60<br/>subjects were regarded ineligible (e.g.&#160;due to deviations or due to&#160;complications secondary to diabetic&#160;<br/>retinopathy, due to cataract surgery or vitrectomy) and were excluded from the primary analysis&#160;of&#160;<br/>efficacy. Of the&#160;364&#160;remaining patients,&#160;269&#160;evaluable patients&#160;(74%)&#160;reached 78 weeks of open-label&#160;<br/>adalimumab treatment. Based on the observed data approach,&#160;216&#160;(80.3%) were in quiescence (no active&#160;<br/>inflammatory lesions, AC cell grade&#160;≤ 0.5+, VH grade ≤ 0.5+) with a concomitant steroid dose ≤ 7.5 mg&#160;<br/>per day, and&#160;178&#160;(66.2%) were in steroid-free quiescence. BCVA was either improved or maintained (&lt; 5&#160;<br/>letters&#160;deterioration) in 88.6% of the eyes at week 78.&#160;Data beyond Week 78 were generally consistent&#160;</p>
</div>
<!-- Page 253 -->
<a name="253"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page253-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2530">253</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft2534">with these results but the number of enrolled subjects declined after this time. Overall,&#160;among the patients&#160;<br/>who discontinued the study,&#160;18% discontinued due to&#160;adverse events, and&#160;8% due to insufficient response&#160;<br/>to adalimumab treatment.</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft2533"><i>Quality of Life</i></p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft2534">Patient reported outcomes regarding vision-related functioning were measured in both clinical studies,&#160;<br/>using the NEI VFQ-25. Humira was numerically favoured for&#160;the majority of subscores with statistically&#160;<br/>significant mean differences for general vision, ocular pain, near vision, mental health, and total score in&#160;<br/>Study UV I, and for general vision and mental health in Study UV II. Vision related effects were not&#160;<br/>numerically in favour of Humira for colour vision in Study UVI and for colour vision, peripheral vision&#160;<br/>and near vision in Study UV II.</p>
<p style="position:absolute;top:333px;left:106px;white-space:nowrap" class="ft2532">Immunogenicity</p>
<p style="position:absolute;top:370px;left:106px;white-space:nowrap" class="ft2534">Formation of anti-adalimumab antibodies is associated with increased clearance and reduced efficacy of&#160;<br/>adalimumab. There is no apparent correlation between the presence of anti-adalimumab antibodies and the&#160;<br/>occurrence of adverse events.</p>
<p style="position:absolute;top:446px;left:106px;white-space:nowrap" class="ft2534">Patients in rheumatoid arthritis studies I, II and III were tested at multiple time points for anti-adalimumab&#160;<br/>antibodies&#160;during the 6 to 12&#160;month period. In the pivotal trials, anti-adalimumab antibodies were&#160;<br/>identified in 5.5% (58/1053) of patients treated with adalimumab, compared to 0.5% (2/370) on placebo. &#160;<br/>In patients not given concomitant methotrexate, the incidence was 12.4%, compared to 0.6% when&#160;<br/>adalimumab was used as add-on to methotrexate. &#160;</p>
<p style="position:absolute;top:560px;left:106px;white-space:nowrap" class="ft2534">In patients with Crohn’s disease, anti-adalimumab antibodies were identified in 7/269 subjects (2.6%) and&#160;<br/>in 19/487 subjects (3.9%) with ulcerative colitis.</p>
<p style="position:absolute;top:617px;left:106px;white-space:nowrap" class="ft2534">In adult patients&#160;with psoriasis, anti-adalimumab antibodies were identified in 77/920 subjects (8.4%)&#160;<br/>treated with adalimumab monotherapy.</p>
<p style="position:absolute;top:674px;left:106px;white-space:nowrap" class="ft2534">In adult plaque psoriasis patients on long term adalimumab monotherapy who participated in a withdrawal&#160;<br/>and retreatment study, the rate of antibodies to adalimumab after retreatment (11 of 482 subjects, 2.3%)&#160;<br/>was similar to the rate observed prior to withdrawal (11 of 590 subjects, 1.9%).</p>
<p style="position:absolute;top:750px;left:106px;white-space:nowrap" class="ft2534">In patients with moderate to severe hidradenitis suppurativa, anti-adalimumab antibodies were identified&#160;<br/>in 10/99 subjects (10.1%) treated with adalimumab.</p>
<p style="position:absolute;top:807px;left:106px;white-space:nowrap" class="ft2535">In patients with moderately to severely active paediatric Crohn’s disease, the rate of anti-adalimumab&#160;<br/>antibody development in patients receiving adalimumab was 3.3%.&#160;</p>
<p style="position:absolute;top:864px;left:106px;white-space:nowrap" class="ft2535">In&#160;adult&#160;patients with&#160;non-infectious uveitis, anti-adalimumab antibodies were identified in 4.8% (12/249)&#160;<br/>of patients treated with adalimumab.</p>
<p style="position:absolute;top:921px;left:106px;white-space:nowrap" class="ft2535">In patients with moderately to severely active paediatric ulcerative colitis, the rate of anti-adalimumab&#160;<br/>antibody development in patients receiving adalimumab was&#160;3%.</p>
<p style="position:absolute;top:978px;left:106px;white-space:nowrap" class="ft2534">Because immunogenicity analyses are product-specific, comparison of antibody rates with those from&#160;<br/>other products is not appropriate.</p>
<p style="position:absolute;top:1035px;left:106px;white-space:nowrap" class="ft2532">Paediatric population</p>
<p style="position:absolute;top:1072px;left:106px;white-space:nowrap" class="ft2533"><i>Adolescent hidradenitis suppurativa</i></p>
</div>
<!-- Page 254 -->
<a name="254"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page254-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2540">254</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft2544">There are no clinical trials with Humira in adolescent patients with HS. &#160;Efficacy of adalimumab for the&#160;<br/>treatment of adolescent patients with HS is predicted based on the demonstrated efficacy and exposure-<br/>response relationship in adult HS patients and the likelihood that the disease&#160;course, pathophysiology, and&#160;<br/>drug effects are substantially similar to that of adults at the same exposure levels. Safety of the&#160;<br/>recommended adalimumab dose in the adolescent HS population is based on cross-indication safety&#160;<br/>profile of adalimumab in both&#160;adults and paediatric patients at similar or more frequent doses&#160;(see section&#160;<br/>5.2).</p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft2543"><i>Paediatric Crohn’s disease&#160;</i></p>
<p style="position:absolute;top:295px;left:106px;white-space:nowrap" class="ft2544">Humira was assessed in a multicentre, randomised, double-blind clinical trial designed to evaluate the&#160;<br/>efficacy and safety of induction and&#160;maintenance treatment with doses dependent on body weight (&lt;&#160;40&#160;kg&#160;<br/>or&#160;≥&#160;40&#160;kg) in 192 paediatric subjects between the ages of 6 and 17 (inclusive) years, with moderate to&#160;<br/>severe Crohn´s disease (CD) defined as Paediatric Crohn's Disease Activity Index (PCDAI) score &gt;&#160;30. &#160;<br/>Subjects had to have failed conventional therapy (including a corticosteroid and/or an immunomodulator)&#160;<br/>for CD. Subjects may also have previously lost response or been intolerant to infliximab.&#160;</p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft2544">All subjects received open-label induction&#160;therapy at a dose based on their Baseline body weight: 160&#160;mg&#160;<br/>at Week&#160;0 and 80&#160;mg at Week&#160;2 for subjects&#160;≥&#160;40&#160;kg, and 80&#160;mg and 40&#160;mg, respectively, for subjects&#160;<br/>&lt;&#160;40&#160;kg.</p>
<p style="position:absolute;top:503px;left:106px;white-space:nowrap" class="ft2544">At Week&#160;4, subjects were randomised 1:1 based on their body weight at the time to either the Low Dose or&#160;<br/>Standard Dose maintenance regimens as shown in Table&#160;18.</p>
<p style="position:absolute;top:560px;left:428px;white-space:nowrap" class="ft2541"><b>Table&#160;18</b></p>
<p style="position:absolute;top:579px;left:382px;white-space:nowrap" class="ft2541"><b>Maintenance regimen</b></p>
<p style="position:absolute;top:599px;left:339px;white-space:nowrap" class="ft25419"><b>Patient&#160;<br/>Weight</b></p>
<p style="position:absolute;top:599px;left:413px;white-space:nowrap" class="ft2541"><b>Low dose</b></p>
<p style="position:absolute;top:599px;left:504px;white-space:nowrap" class="ft25419"><b>Standard&#160;<br/>dose</b></p>
<p style="position:absolute;top:638px;left:339px;white-space:nowrap" class="ft2542">&lt;&#160;40 kg</p>
<p style="position:absolute;top:638px;left:413px;white-space:nowrap" class="ft2542">10&#160;mg&#160;eow&#160;20&#160;mg&#160;eow</p>
<p style="position:absolute;top:657px;left:339px;white-space:nowrap" class="ft2542">≥&#160;40 kg</p>
<p style="position:absolute;top:657px;left:413px;white-space:nowrap" class="ft2542">20&#160;mg&#160;eow&#160;40&#160;mg&#160;eow</p>
<p style="position:absolute;top:696px;left:106px;white-space:nowrap" class="ft2543"><i>Efficacy results</i></p>
<p style="position:absolute;top:735px;left:106px;white-space:nowrap" class="ft2542">The primary endpoint of the study was clinical remission at Week&#160;26, defined as PCDAI score&#160;</p>
<p style="position:absolute;top:733px;left:734px;white-space:nowrap" class="ft2546">&#160;10.</p>
<p style="position:absolute;top:773px;left:106px;white-space:nowrap" class="ft2545">Clinical remission and clinical response (defined as reduction in PCDAI score of at least 15 points from&#160;<br/>Baseline) rates are presented in Table&#160;19. Rates of&#160;discontinuation of corticosteroids or&#160;<br/>immunomodulators are presented in Table&#160;20.</p>
</div>
<!-- Page 255 -->
<a name="255"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page255-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2550">255</p>
<p style="position:absolute;top:87px;left:429px;white-space:nowrap" class="ft2551"><b>Table&#160;19</b></p>
<p style="position:absolute;top:106px;left:386px;white-space:nowrap" class="ft2551"><b>Paediatric CD Study</b></p>
<p style="position:absolute;top:125px;left:315px;white-space:nowrap" class="ft2551"><b>PCDAI Clinical Remission and Response</b></p>
<p style="position:absolute;top:145px;left:392px;white-space:nowrap" class="ft2551"><b>Standard Dose</b></p>
<p style="position:absolute;top:164px;left:396px;white-space:nowrap" class="ft2551"><b>40/20 mg eow&#160;</b></p>
<p style="position:absolute;top:183px;left:421px;white-space:nowrap" class="ft2551"><b>N = 93</b></p>
<p style="position:absolute;top:145px;left:529px;white-space:nowrap" class="ft2551"><b>Low Dose</b></p>
<p style="position:absolute;top:164px;left:516px;white-space:nowrap" class="ft2551"><b>20/10 mg eow&#160;</b></p>
<p style="position:absolute;top:183px;left:541px;white-space:nowrap" class="ft2551"><b>N = 95</b></p>
<p style="position:absolute;top:145px;left:637px;white-space:nowrap" class="ft2551"><b>P value</b>*</p>
<p style="position:absolute;top:203px;left:210px;white-space:nowrap" class="ft25521"><b>Week&#160;26<br/></b>&#160; &#160;Clinical remission</p>
<p style="position:absolute;top:223px;left:423px;white-space:nowrap" class="ft2552">38.7%</p>
<p style="position:absolute;top:223px;left:543px;white-space:nowrap" class="ft2552">28.4%</p>
<p style="position:absolute;top:223px;left:648px;white-space:nowrap" class="ft2552">0.075</p>
<p style="position:absolute;top:243px;left:210px;white-space:nowrap" class="ft2552">&#160; &#160;Clinical response&#160;</p>
<p style="position:absolute;top:243px;left:423px;white-space:nowrap" class="ft2552">59.1%</p>
<p style="position:absolute;top:243px;left:543px;white-space:nowrap" class="ft2552">48.4%</p>
<p style="position:absolute;top:243px;left:648px;white-space:nowrap" class="ft2552">0.073</p>
<p style="position:absolute;top:264px;left:210px;white-space:nowrap" class="ft25521"><b>Week&#160;52<br/></b>&#160; &#160;Clinical remission</p>
<p style="position:absolute;top:284px;left:423px;white-space:nowrap" class="ft2552">33.3%</p>
<p style="position:absolute;top:284px;left:543px;white-space:nowrap" class="ft2552">23.2%</p>
<p style="position:absolute;top:284px;left:648px;white-space:nowrap" class="ft2552">0.100</p>
<p style="position:absolute;top:304px;left:210px;white-space:nowrap" class="ft2552">&#160; &#160;Clinical response</p>
<p style="position:absolute;top:304px;left:423px;white-space:nowrap" class="ft2552">41.9%</p>
<p style="position:absolute;top:304px;left:543px;white-space:nowrap" class="ft2552">28.4%</p>
<p style="position:absolute;top:304px;left:648px;white-space:nowrap" class="ft2552">0.038</p>
<p style="position:absolute;top:324px;left:210px;white-space:nowrap" class="ft2552">*&#160;p value for Standard Dose&#160;<i>versus&#160;</i>Low Dose comparison.</p>
<p style="position:absolute;top:364px;left:428px;white-space:nowrap" class="ft2551"><b>Table&#160;20</b></p>
<p style="position:absolute;top:383px;left:386px;white-space:nowrap" class="ft2551"><b>Paediatric CD&#160;Study</b></p>
<p style="position:absolute;top:402px;left:175px;white-space:nowrap" class="ft2551"><b>Discontinuation of Corticosteroids or Immunomodulators and Fistula Remission</b></p>
<p style="position:absolute;top:422px;left:455px;white-space:nowrap" class="ft2551"><b>Standard Dose</b></p>
<p style="position:absolute;top:441px;left:459px;white-space:nowrap" class="ft2551"><b>40/20&#160;mg&#160;eow&#160;</b></p>
<p style="position:absolute;top:422px;left:595px;white-space:nowrap" class="ft2551"><b>Low Dose</b></p>
<p style="position:absolute;top:441px;left:582px;white-space:nowrap" class="ft2551"><b>20/10&#160;mg&#160;eow&#160;</b></p>
<p style="position:absolute;top:422px;left:705px;white-space:nowrap" class="ft2551"><b>P value1</b></p>
<p style="position:absolute;top:461px;left:143px;white-space:nowrap" class="ft2551"><b>Discontinued corticosteroids</b></p>
<p style="position:absolute;top:461px;left:486px;white-space:nowrap" class="ft2551"><b>N= 33</b></p>
<p style="position:absolute;top:461px;left:611px;white-space:nowrap" class="ft2551"><b>N=38</b></p>
<p style="position:absolute;top:481px;left:143px;white-space:nowrap" class="ft2552">Week&#160;26</p>
<p style="position:absolute;top:481px;left:486px;white-space:nowrap" class="ft2552">84.8%</p>
<p style="position:absolute;top:481px;left:608px;white-space:nowrap" class="ft2552">65.8%</p>
<p style="position:absolute;top:481px;left:715px;white-space:nowrap" class="ft2552">0.066</p>
<p style="position:absolute;top:501px;left:143px;white-space:nowrap" class="ft2552">Week&#160;52</p>
<p style="position:absolute;top:501px;left:486px;white-space:nowrap" class="ft2552">69.7%</p>
<p style="position:absolute;top:501px;left:608px;white-space:nowrap" class="ft2552">60.5%</p>
<p style="position:absolute;top:501px;left:715px;white-space:nowrap" class="ft2552">0.420</p>
<p style="position:absolute;top:521px;left:143px;white-space:nowrap" class="ft2551"><b>Discontinuation of Immunomodulators2</b></p>
<p style="position:absolute;top:521px;left:488px;white-space:nowrap" class="ft2551"><b>N=60</b></p>
<p style="position:absolute;top:521px;left:611px;white-space:nowrap" class="ft2551"><b>N=57</b></p>
<p style="position:absolute;top:541px;left:143px;white-space:nowrap" class="ft2552">Week&#160;52</p>
<p style="position:absolute;top:541px;left:486px;white-space:nowrap" class="ft2552">30.0%</p>
<p style="position:absolute;top:541px;left:608px;white-space:nowrap" class="ft2552">29.8%</p>
<p style="position:absolute;top:541px;left:715px;white-space:nowrap" class="ft2552">0.983</p>
<p style="position:absolute;top:562px;left:143px;white-space:nowrap" class="ft2551"><b>Fistula remission3</b></p>
<p style="position:absolute;top:562px;left:488px;white-space:nowrap" class="ft2551"><b>N=15</b></p>
<p style="position:absolute;top:562px;left:611px;white-space:nowrap" class="ft2551"><b>N=21</b></p>
<p style="position:absolute;top:582px;left:143px;white-space:nowrap" class="ft2552">Week&#160;26</p>
<p style="position:absolute;top:582px;left:486px;white-space:nowrap" class="ft2552">46.7%</p>
<p style="position:absolute;top:582px;left:608px;white-space:nowrap" class="ft2552">38.1%</p>
<p style="position:absolute;top:582px;left:715px;white-space:nowrap" class="ft2552">0.608</p>
<p style="position:absolute;top:602px;left:143px;white-space:nowrap" class="ft2552">Week&#160;52</p>
<p style="position:absolute;top:602px;left:486px;white-space:nowrap" class="ft2552">40.0%</p>
<p style="position:absolute;top:602px;left:608px;white-space:nowrap" class="ft2552">23.8%</p>
<p style="position:absolute;top:602px;left:715px;white-space:nowrap" class="ft2552">0.303</p>
<p style="position:absolute;top:620px;left:143px;white-space:nowrap" class="ft2559">1&#160;&#160;p value for Standard Dose&#160;<i>versus&#160;</i>Low Dose comparison.</p>
<p style="position:absolute;top:639px;left:143px;white-space:nowrap" class="ft2557">2&#160;&#160;Immunosuppressant therapy could only be discontinued at or after Week&#160;26 at the&#160;<br/>investigator's discretion if the subject met the clinical response criterion&#160;</p>
<p style="position:absolute;top:677px;left:143px;white-space:nowrap" class="ft2557">3&#160;defined as a closure of all fistulas that were draining at Baseline for at least 2 consecutive<br/>post-Baseline visits</p>
<p style="position:absolute;top:735px;left:106px;white-space:nowrap" class="ft2555">Statistically significant&#160;increases (improvement) from Baseline to Week&#160;26 and 52 in Body Mass Index&#160;<br/>and height velocity were observed for both treatment groups.</p>
<p style="position:absolute;top:792px;left:106px;white-space:nowrap" class="ft2555">Statistically and clinically significant improvements from Baseline were also observed in both treatment&#160;<br/>groups for quality of life parameters (including IMPACT III).</p>
<p style="position:absolute;top:849px;left:106px;white-space:nowrap" class="ft2554">One&#160;hundred patients (n=100) from the Paediatric CD Study continued in an open-label long-term&#160;<br/>extension study. &#160;After 5 years of adalimumab therapy, 74.0%&#160;(37/50) of the 50 patients remaining in the&#160;<br/>study continued to be in clinical remission, and 92.0% (46/50) of patients continued to be in clinical&#160;<br/>response per PCDAI.</p>
<p style="position:absolute;top:944px;left:106px;white-space:nowrap" class="ft2553"><i>Paediatric ulcerative colitis</i></p>
<p style="position:absolute;top:982px;left:106px;white-space:nowrap" class="ft2555">The safety and efficacy of Humira was assessed in a multicenter, randomized, double-blind, trial in 93&#160;<br/>paediatric patients from 5 to 17 years of age with moderate to severe ulcerative colitis (Mayo score 6 to 12&#160;<br/>with endoscopy subscore of 2 to 3 points, confirmed by centrally read endoscopy) who had an inadequate&#160;<br/>response or intolerance to conventional therapy. Approximately 16% of patients in the study had failed&#160;<br/>prior anti-TNF treatment. Patients who received corticosteroids at enrollment were allowed to taper their&#160;<br/>corticosteroid therapy after Week 4.</p>
</div>
<!-- Page 256 -->
<a name="256"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page256-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2560">256</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft2565">In the&#160;induction period of the study,&#160;77&#160;patients were randomized 3:2 to receive double-blind treatment&#160;<br/>with&#160;Humira at&#160;an&#160;induction dose of 2.4 mg/kg (maximum of 160 mg) at Week 0 and Week 1, and 1.2&#160;<br/>mg/kg (maximum of 80 mg) at Week 2; or an&#160;induction dose of 2.4&#160;mg/kg (maximum of 160 mg) at Week&#160;<br/>0, placebo at Week 1, and 1.2 mg/kg (maximum of 80 mg) at Week 2.&#160;Both groups received 0.6 mg/kg&#160;<br/>(maximum of 40 mg) at Week 4 and Week 6.&#160;Following an amendment to the study design, the remaining&#160;<br/>16 patients who enrolled&#160;in the induction period received open-label treatment with&#160;Humira&#160;at the&#160;<br/>induction dose&#160;of 2.4 mg/kg (maximum of 160 mg) at Week 0 and Week 1, and 1.2 mg/kg (maximum of&#160;<br/>80 mg) at Week 2.</p>
<p style="position:absolute;top:276px;left:106px;white-space:nowrap" class="ft2565">At Week 8, 62 patients who demonstrated&#160;clinical response per&#160;Partial Mayo Score (PMS;&#160;defined as a&#160;<br/>decrease in PMS&#160;≥ 2 points and ≥ 30% from Baseline)&#160;were randomized equally to receive double-blind&#160;<br/>maintenance treatment&#160;with Humira&#160;at a dose&#160;of 0.6 mg/kg (maximum of 40 mg) every week&#160;(ew),&#160;or&#160;a&#160;<br/>maintenance dose of 0.6 mg/kg (maximum of 40 mg) every other&#160;week (eow).&#160;Prior to an amendment to&#160;<br/>the study design, 12 additional patients who demonstrated clinical response per PMS were randomized to&#160;<br/>receive&#160;placebo&#160;but were not included in&#160;the confirmatory&#160;analysis of efficacy.</p>
<p style="position:absolute;top:409px;left:106px;white-space:nowrap" class="ft2564">Disease flare was defined as an increase in&#160;PMS&#160;of&#160;at least&#160;3 points (for patients with PMS of 0 to 2 at&#160;<br/>Week 8),&#160;at least&#160;2 points (for patients with PMS of 3 to 4 at Week 8), or&#160;at least&#160;1 point (for patients with&#160;<br/>PMS of 5 to 6 at Week 8).</p>
<p style="position:absolute;top:485px;left:106px;white-space:nowrap" class="ft2564">Patients who&#160;met criteria for disease flare&#160;at or after Week 12&#160;were randomized to receive a re-induction&#160;<br/>dose of 2.4 mg/kg (maximum of 160 mg) or a dose of 0.6 mg/kg (maximum of 40 mg) and continued to&#160;<br/>receive their respective maintenance dose regimen afterwards.</p>
<p style="position:absolute;top:565px;left:106px;white-space:nowrap" class="ft2563"><i>Efficacy Results</i></p>
<p style="position:absolute;top:612px;left:106px;white-space:nowrap" class="ft2565">The co-primary endpoints of the study were clinical remission per PMS (defined as PMS&#160;≤ 2 and no&#160;<br/>individual subscore &gt; 1) at Week 8, and clinical remission per FMS (Full Mayo Score) (defined as a Mayo&#160;<br/>Score&#160;≤ 2 and no individual subscore&#160;&gt; 1) at Week 52 in patients who achieved clinical response per PMS&#160;<br/>at Week 8.</p>
<p style="position:absolute;top:707px;left:106px;white-space:nowrap" class="ft2564">Clinical remission rates per PMS at Week 8 for&#160;patients&#160;in&#160;each&#160;of the&#160;Humira&#160;double-<br/>blind&#160;induction&#160;groups&#160;are&#160;presented in&#160;Table&#160;21.</p>
<p style="position:absolute;top:782px;left:284px;white-space:nowrap" class="ft2561"><b>Table&#160;21: Clinical Remission per PMS at&#160;8 Weeks&#160;</b></p>
<p style="position:absolute;top:826px;left:387px;white-space:nowrap" class="ft2561"><b>Humiraa</b></p>
<p style="position:absolute;top:845px;left:315px;white-space:nowrap" class="ft2561"><b>Maximum&#160;of&#160;160 mg&#160;at Week&#160;</b></p>
<p style="position:absolute;top:867px;left:342px;white-space:nowrap" class="ft2561"><b>0&#160;/&#160;Placebo&#160;at Week 1</b></p>
<p style="position:absolute;top:889px;left:400px;white-space:nowrap" class="ft2562">N=30</p>
<p style="position:absolute;top:826px;left:607px;white-space:nowrap" class="ft2561"><b>Humirab, c</b></p>
<p style="position:absolute;top:845px;left:540px;white-space:nowrap" class="ft2561"><b>Maximum of 160 mg&#160;at Week&#160;</b></p>
<p style="position:absolute;top:867px;left:594px;white-space:nowrap" class="ft2561"><b>0&#160;and&#160;Week 1</b></p>
<p style="position:absolute;top:889px;left:626px;white-space:nowrap" class="ft2562">N=47</p>
<p style="position:absolute;top:914px;left:161px;white-space:nowrap" class="ft2562">Clinical remission</p>
<p style="position:absolute;top:914px;left:372px;white-space:nowrap" class="ft2562">13/30 (43.3%)</p>
<p style="position:absolute;top:914px;left:597px;white-space:nowrap" class="ft2562">28/47 (59.6%)</p>
</div>
<!-- Page 257 -->
<a name="257"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page257-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2570">257</p>
<p style="position:absolute;top:87px;left:161px;white-space:nowrap" class="ft2577">a&#160;Humira&#160;2.4 mg/kg&#160;(maximum of 160 mg)&#160;at Week 0, placebo at Week 1,&#160;and&#160;1.2&#160;<br/>mg/kg&#160;(maximum of 80 mg)&#160;at Week 2</p>
<p style="position:absolute;top:125px;left:161px;white-space:nowrap" class="ft2577">b&#160;Humira&#160;2.4 mg/kg&#160;(maximum&#160;of 160 mg)&#160;at Week 0 and Week 1,&#160;and&#160;1.2&#160;<br/>mg/kg&#160;(maximum of 80 mg)&#160;at Week 2</p>
<p style="position:absolute;top:163px;left:161px;white-space:nowrap" class="ft2575">c&#160;Not including open-label Induction dose of&#160;Humira&#160;2.4 mg/kg&#160;(maximum&#160;of 160 mg)&#160;at&#160;<br/>Week 0 and Week 1, and 1.2 mg/kg&#160;(maximum of 80 mg)&#160;at Week 2<br/>Note 1: Both induction groups received 0.6 mg/kg (maximum of 40 mg) at Week 4 and&#160;<br/>Week 6<br/>Note 2: Patients with missing values at Week 8 were considered as not having met the&#160;<br/>endpoint</p>
<p style="position:absolute;top:299px;left:106px;white-space:nowrap" class="ft2574">At Week 52, clinical remission per FMS in Week 8 responders, clinical response per FMS (defined as a&#160;<br/>decrease in Mayo Score&#160;≥ 3 points and ≥ 30% from Baseline) in Week 8 responders, mucosal healing&#160;<br/>(defined as Mayo endoscopy&#160;subscore&#160;≤ 1) in Week 8 responders, clinical remission per FMS in Week 8&#160;<br/>remitters, and the proportion of subjects in corticosteroid-free remission per FMS in Week 8 responders&#160;<br/>were assessed in patients who received Humira at the double-blind&#160;maximum 40 mg&#160;eow&#160;(0.6 mg/kg) and&#160;<br/>maximum&#160;40&#160;mg&#160;ew&#160;(0.6 mg/kg) maintenance doses (Table 22).</p>
<p style="position:absolute;top:470px;left:320px;white-space:nowrap" class="ft2571"><b>Table&#160;22: Efficacy Results at 52 Weeks</b></p>
<p style="position:absolute;top:496px;left:420px;white-space:nowrap" class="ft2571"><b>Humiraa</b></p>
<p style="position:absolute;top:515px;left:368px;white-space:nowrap" class="ft2571"><b>Maximum&#160;of&#160;40 mg&#160;eow</b></p>
<p style="position:absolute;top:534px;left:436px;white-space:nowrap" class="ft2572">N=31</p>
<p style="position:absolute;top:496px;left:608px;white-space:nowrap" class="ft2571"><b>Humirab</b></p>
<p style="position:absolute;top:515px;left:561px;white-space:nowrap" class="ft2571"><b>Maximum&#160;of&#160;40 mg&#160;ew</b></p>
<p style="position:absolute;top:534px;left:625px;white-space:nowrap" class="ft2572">N=31</p>
<p style="position:absolute;top:562px;left:176px;white-space:nowrap" class="ft2574">Clinical remission in Week&#160;<br/>8 PMS responders</p>
<p style="position:absolute;top:571px;left:409px;white-space:nowrap" class="ft2572">9/31 (29.0%)</p>
<p style="position:absolute;top:571px;left:596px;white-space:nowrap" class="ft2572">14/31 (45.2%)</p>
<p style="position:absolute;top:605px;left:176px;white-space:nowrap" class="ft2574">Clinical&#160;response in Week 8&#160;<br/>PMS responders</p>
<p style="position:absolute;top:615px;left:405px;white-space:nowrap" class="ft2572">19/31 (61.3%)</p>
<p style="position:absolute;top:615px;left:594px;white-space:nowrap" class="ft2572">21/31 (67.7%)</p>
<p style="position:absolute;top:646px;left:176px;white-space:nowrap" class="ft2574">Mucosal healing in&#160;<br/>Week&#160;8&#160;PMS responders</p>
<p style="position:absolute;top:656px;left:405px;white-space:nowrap" class="ft2572">12/31 (38.7%)</p>
<p style="position:absolute;top:656px;left:594px;white-space:nowrap" class="ft2572">16/31 (51.6%)</p>
<p style="position:absolute;top:685px;left:176px;white-space:nowrap" class="ft2574">Clinical remission in Week&#160;<br/>8 PMS remitters</p>
<p style="position:absolute;top:695px;left:409px;white-space:nowrap" class="ft2572">9/21 (42.9%)</p>
<p style="position:absolute;top:695px;left:594px;white-space:nowrap" class="ft2572">10/22 (45.5%)</p>
<p style="position:absolute;top:724px;left:176px;white-space:nowrap" class="ft2575">Corticosteroid-free&#160;<br/>remission in Week 8&#160;<br/>PMS&#160;respondersc</p>
<p style="position:absolute;top:743px;left:409px;white-space:nowrap" class="ft2572">4/13 (30.8%)</p>
<p style="position:absolute;top:743px;left:598px;white-space:nowrap" class="ft2572">5/16 (31.3%)</p>
<p style="position:absolute;top:781px;left:176px;white-space:nowrap" class="ft2579">a&#160;Humira 0.6 mg/kg&#160;(maximum of&#160;40 mg)&#160;every other week</p>
<p style="position:absolute;top:800px;left:176px;white-space:nowrap" class="ft2579">b&#160;Humira 0.6 mg/kg&#160;(maximum&#160;of&#160;40 mg) every week</p>
<p style="position:absolute;top:819px;left:176px;white-space:nowrap" class="ft2574">c&#160;In&#160;patients receiving concomitant corticosteroids at baseline<br/>Note: Patients with missing values at&#160;Week 52 or who were randomized to receive&#160;<br/>re-induction or maintenance treatment were considered non-responders for Week 52&#160;<br/>endpoints</p>
<p style="position:absolute;top:916px;left:106px;white-space:nowrap" class="ft2574">Additional exploratory efficacy endpoints included clinical response per the Paediatric Ulcerative Colitis&#160;<br/>Activity&#160;Index (PUCAI) (defined as a decrease in PUCAI&#160;≥ 20 points from Baseline) and clinical&#160;<br/>remission per PUCAI (defined as PUCAI &lt; 10) at Week 8 and Week 52&#160;(Table 23).&#160;</p>
</div>
<!-- Page 258 -->
<a name="258"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page258-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2580">258</p>
<p style="position:absolute;top:86px;left:273px;white-space:nowrap" class="ft2581"><b>Table&#160;23:&#160;Exploratory Endpoints Results per PUCAI</b></p>
<p style="position:absolute;top:106px;left:543px;white-space:nowrap" class="ft2581"><b>Week 8</b></p>
<p style="position:absolute;top:127px;left:447px;white-space:nowrap" class="ft2581"><b>Humiraa</b></p>
<p style="position:absolute;top:146px;left:396px;white-space:nowrap" class="ft2581"><b>Maximum of 160 mg at&#160;</b></p>
<p style="position:absolute;top:165px;left:380px;white-space:nowrap" class="ft2581"><b>Week 0 / Placebo at Week 1</b></p>
<p style="position:absolute;top:184px;left:459px;white-space:nowrap" class="ft2582">N=30</p>
<p style="position:absolute;top:127px;left:643px;white-space:nowrap" class="ft2581"><b>Humirab,c</b></p>
<p style="position:absolute;top:146px;left:596px;white-space:nowrap" class="ft2581"><b>Maximum of 160 mg at&#160;</b></p>
<p style="position:absolute;top:165px;left:607px;white-space:nowrap" class="ft2581"><b>Week 0 and Week 1</b></p>
<p style="position:absolute;top:184px;left:659px;white-space:nowrap" class="ft2582">N=47</p>
<p style="position:absolute;top:207px;left:157px;white-space:nowrap" class="ft2582">Clinical remission per PUCAI</p>
<p style="position:absolute;top:207px;left:430px;white-space:nowrap" class="ft2582">10/30 (33.3%)</p>
<p style="position:absolute;top:207px;left:630px;white-space:nowrap" class="ft2582">22/47 (46.8%)</p>
<p style="position:absolute;top:227px;left:157px;white-space:nowrap" class="ft2582">Clinical response per PUCAI</p>
<p style="position:absolute;top:227px;left:430px;white-space:nowrap" class="ft2582">15/30 (50.0%)</p>
<p style="position:absolute;top:227px;left:630px;white-space:nowrap" class="ft2582">32/47 (68.1%)</p>
<p style="position:absolute;top:247px;left:539px;white-space:nowrap" class="ft2581"><b>Week 52</b></p>
<p style="position:absolute;top:267px;left:447px;white-space:nowrap" class="ft2581"><b>Humirad</b></p>
<p style="position:absolute;top:285px;left:393px;white-space:nowrap" class="ft2581"><b>Maximum of 40 mg eow</b></p>
<p style="position:absolute;top:305px;left:459px;white-space:nowrap" class="ft2582">N=31</p>
<p style="position:absolute;top:267px;left:647px;white-space:nowrap" class="ft2581"><b>Humirae</b></p>
<p style="position:absolute;top:285px;left:597px;white-space:nowrap" class="ft2581"><b>Maximum of 40 mg ew</b></p>
<p style="position:absolute;top:305px;left:659px;white-space:nowrap" class="ft2582">N=31</p>
<p style="position:absolute;top:324px;left:157px;white-space:nowrap" class="ft2584">Clinical remission per PUCAI&#160;<br/>in Week 8 PMS responders</p>
<p style="position:absolute;top:324px;left:430px;white-space:nowrap" class="ft2582">14/31 (45.2%)</p>
<p style="position:absolute;top:324px;left:630px;white-space:nowrap" class="ft2582">18/31 (58.1%)</p>
<p style="position:absolute;top:363px;left:157px;white-space:nowrap" class="ft2584">Clinical response per PUCAI&#160;<br/>in Week 8 PMS responders</p>
<p style="position:absolute;top:363px;left:430px;white-space:nowrap" class="ft2582">18/31 (58.1%)</p>
<p style="position:absolute;top:363px;left:630px;white-space:nowrap" class="ft2582">16/31 (51.6%)</p>
<p style="position:absolute;top:400px;left:157px;white-space:nowrap" class="ft2587">a&#160;Humira&#160;2.4 mg/kg&#160;(maximum of 160 mg)&#160;at Week 0, placebo at Week&#160;1,&#160;and&#160;1.2&#160;<br/>mg/kg&#160;(maximum of 80 mg)&#160;at Week 2</p>
<p style="position:absolute;top:438px;left:157px;white-space:nowrap" class="ft2587">b&#160;&#160;Humira&#160;2.4 mg/kg&#160;(maximum&#160;of 160 mg)&#160;at Week 0 and Week 1,&#160;and&#160;1.2&#160;<br/>mg/kg&#160;(maximum of 80 mg)&#160;at Week 2</p>
<p style="position:absolute;top:476px;left:157px;white-space:nowrap" class="ft2587">c&#160;Not including open-label Induction dose of&#160;Humira&#160;2.4 mg/kg&#160;(maximum&#160;of 160 mg)&#160;at&#160;<br/>Week 0 and Week&#160;1, and 1.2 mg/kg&#160;(maximum of 80 mg)&#160;at Week 2</p>
<p style="position:absolute;top:514px;left:157px;white-space:nowrap" class="ft2589">d&#160;Humira 0.6 mg/kg&#160;(maximum&#160;of&#160;40 mg)&#160;every other week</p>
<p style="position:absolute;top:533px;left:157px;white-space:nowrap" class="ft2584">e&#160;Humira 0.6 mg/kg&#160;(maximum of&#160;40 mg) every week<br/>Note 1: Both induction groups received 0.6 mg/kg (maximum of 40 mg) at Week 4 and&#160;<br/>Week 6<br/>Note 2: Patients&#160;with missing values at Week 8 were considered as not having met the&#160;<br/>endpoints<br/>Note 3:&#160;Patients with missing values at Week 52 or who were randomized to receive re-<br/>induction or maintenance treatment were considered non-responders for Week 52&#160;<br/>endpoints</p>
<p style="position:absolute;top:706px;left:106px;white-space:nowrap" class="ft2584">Of the Humira-treated patients who received re-induction treatment during the maintenance period, 2/6&#160;<br/>(33%) achieved clinical response per FMS at Week 52.</p>
<p style="position:absolute;top:763px;left:106px;white-space:nowrap" class="ft2583"><i>Quality of life</i></p>
<p style="position:absolute;top:801px;left:106px;white-space:nowrap" class="ft2585">Clinically meaningful improvements from Baseline were observed in IMPACT III and the caregiver Work&#160;<br/>Productivity and Activity Impairment (WPAI) scores for the groups treated with&#160;Humira.</p>
<p style="position:absolute;top:858px;left:106px;white-space:nowrap" class="ft2584">Clinically meaningful increases (improvement) from Baseline in height&#160;velocity were observed for the&#160;<br/>groups treated with adalimumab, and clinically meaningful increases (improvement) from Baseline in&#160;<br/>Body Mass Index were observed for subjects on the high maintenance dose of maximum&#160;40 mg (0.6&#160;<br/>mg/kg) ew.&#160;</p>
<p style="position:absolute;top:953px;left:106px;white-space:nowrap" class="ft2583"><i>Paediatric Uveitis&#160;</i></p>
<p style="position:absolute;top:991px;left:106px;white-space:nowrap" class="ft2584">The safety and efficacy of Humira was assessed in a randomized, double-masked, controlled study of 90&#160;<br/>paediatric patients from 2&#160;to&#160;&lt;&#160;18 years of age with active JIA-associated noninfectious anterior uveitis&#160;<br/>who were refractory to at least 12&#160;weeks of methotrexate treatment. &#160;Patients received either placebo or&#160;<br/>20&#160;mg adalimumab (if&#160;&lt;&#160;30&#160;kg) or 40&#160;mg adalimumab (if&#160;≥&#160;30&#160;kg)&#160;every other week in combination with&#160;<br/>their baseline dose of methotrexate.&#160;</p>
</div>
<!-- Page 259 -->
<a name="259"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page259-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2590">259</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft2594">The primary endpoint was ‘time to treatment failure’. The criteria determining treatment failure were&#160;<br/>worsening or sustained non-improvement in ocular inflammation, partial improvement with development&#160;<br/>of sustained ocular co-morbidities or worsening of ocular co-morbidities, non-permitted use of&#160;<br/>concomitant medications, and suspension of treatment for an extended period of time.</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft2593"><i>Clinical Response</i></p>
<p style="position:absolute;top:239px;left:106px;white-space:nowrap" class="ft2594">Adalimumab significantly delayed the time to treatment failure, as compared to placebo (See Figure 2,&#160;<br/>P&#160;&lt;&#160;0.0001 from log rank test).The median time to treatment failure was 24.1&#160;weeks for subjects treated&#160;<br/>with placebo, whereas the median time to treatment failure was not estimable for subjects treated with&#160;<br/>adalimumab because less than one-half of these subjects experienced treatment failure. &#160;Adalimumab&#160;<br/>significantly decreased the risk of treatment failure by 75% relative to placebo, as shown by the hazard&#160;<br/>ratio (HR = 0.25 [95% CI: &#160;0.12, 0.49]).</p>
<p style="position:absolute;top:372px;left:114px;white-space:nowrap" class="ft2591"><b>Figure 2: Kaplan-Meier Curves Summarizing Time to Treatment Failure in the Paediatric Uveitis&#160;</b></p>
<p style="position:absolute;top:396px;left:438px;white-space:nowrap" class="ft2591"><b>Study</b></p>
<p style="position:absolute;top:861px;left:129px;white-space:nowrap" class="ft25920"><b>P</b></p>
<p style="position:absolute;top:851px;left:129px;white-space:nowrap" class="ft25920"><b>R</b></p>
<p style="position:absolute;top:839px;left:129px;white-space:nowrap" class="ft25920"><b>O</b></p>
<p style="position:absolute;top:826px;left:129px;white-space:nowrap" class="ft25920"><b>B</b></p>
<p style="position:absolute;top:815px;left:129px;white-space:nowrap" class="ft25920"><b>A</b></p>
<p style="position:absolute;top:803px;left:129px;white-space:nowrap" class="ft25920"><b>B</b></p>
<p style="position:absolute;top:792px;left:129px;white-space:nowrap" class="ft25920"><b>IL</b></p>
<p style="position:absolute;top:775px;left:129px;white-space:nowrap" class="ft25920"><b>IT</b></p>
<p style="position:absolute;top:757px;left:129px;white-space:nowrap" class="ft25920"><b>Y</b></p>
<p style="position:absolute;top:746px;left:129px;white-space:nowrap" class="ft25920"><b>&#160;O</b></p>
<p style="position:absolute;top:728px;left:129px;white-space:nowrap" class="ft25920"><b>F</b></p>
<p style="position:absolute;top:719px;left:129px;white-space:nowrap" class="ft25920"><b>&#160;F</b></p>
<p style="position:absolute;top:704px;left:129px;white-space:nowrap" class="ft25920"><b>A</b></p>
<p style="position:absolute;top:692px;left:129px;white-space:nowrap" class="ft25920"><b>IL</b></p>
<p style="position:absolute;top:675px;left:129px;white-space:nowrap" class="ft25920"><b>IN</b></p>
<p style="position:absolute;top:657px;left:129px;white-space:nowrap" class="ft25920"><b>G</b></p>
<p style="position:absolute;top:644px;left:129px;white-space:nowrap" class="ft25920"><b>&#160;T</b></p>
<p style="position:absolute;top:629px;left:129px;white-space:nowrap" class="ft25920"><b>R</b></p>
<p style="position:absolute;top:617px;left:129px;white-space:nowrap" class="ft25920"><b>E</b></p>
<p style="position:absolute;top:606px;left:129px;white-space:nowrap" class="ft25920"><b>A</b></p>
<p style="position:absolute;top:594px;left:129px;white-space:nowrap" class="ft25920"><b>T</b></p>
<p style="position:absolute;top:582px;left:129px;white-space:nowrap" class="ft25920"><b>M</b></p>
<p style="position:absolute;top:567px;left:129px;white-space:nowrap" class="ft25920"><b>E</b></p>
<p style="position:absolute;top:556px;left:129px;white-space:nowrap" class="ft25920"><b>N</b></p>
<p style="position:absolute;top:544px;left:129px;white-space:nowrap" class="ft25920"><b>T</b></p>
<p style="position:absolute;top:982px;left:412px;white-space:nowrap" class="ft2591"><b>TIME (WEEKS)</b></p>
<p style="position:absolute;top:1000px;left:149px;white-space:nowrap" class="ft2592">Treatment</p>
<p style="position:absolute;top:1000px;left:500px;white-space:nowrap" class="ft2592">Placebo</p>
<p style="position:absolute;top:1000px;left:669px;white-space:nowrap" class="ft2592">Adalimumab</p>
<p style="position:absolute;top:1020px;left:149px;white-space:nowrap" class="ft2592">Note: P =&#160;Placebo (Number at Risk); H = HUMIRA (Number at Risk).</p>
</div>
<!-- Page 260 -->
<a name="260"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page260-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2600">260</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft2601"><b>5.2</b></p>
<p style="position:absolute;top:86px;left:148px;white-space:nowrap" class="ft2601"><b>Pharmacokinetic properties</b></p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft2602">Absorption and distribution</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft2604">After subcutaneous administration of a single 40&#160;mg dose, absorption and distribution of adalimumab was&#160;<br/>slow, with peak serum&#160;concentrations being reached about 5 days after administration. The average&#160;<br/>absolute bioavailability of adalimumab estimated from three studies following a single 40&#160;mg&#160;<br/>subcutaneous dose was 64%. After single intravenous doses ranging from 0.25 to 10&#160;mg/kg,&#160;<br/>concentrations were dose proportional. After doses of 0.5&#160;mg/kg (~40&#160;mg), clearances ranged from 11 to&#160;<br/>15&#160;ml/hour, the distribution volume (Vss) ranged from 5 to 6&#160;litres and the mean terminal phase half-life&#160;<br/>was approximately two weeks. Adalimumab concentrations in the synovial fluid from several rheumatoid&#160;<br/>arthritis patients ranged from 31-96% of those in serum.</p>
<p style="position:absolute;top:333px;left:106px;white-space:nowrap" class="ft2607">Following subcutaneous administration of 40&#160;mg of adalimumab every other week in adult rheumatoid&#160;<br/>arthritis (RA) patients the mean steady-state trough concentrations were approximately 5</p>
<p style="position:absolute;top:351px;left:697px;white-space:nowrap" class="ft2606">g/ml (without&#160;</p>
<p style="position:absolute;top:373px;left:106px;white-space:nowrap" class="ft2602">concomitant methotrexate) and 8 to 9</p>
<p style="position:absolute;top:371px;left:357px;white-space:nowrap" class="ft2606">g/ml (with concomitant methotrexate), respectively. &#160;The serum&#160;</p>
<p style="position:absolute;top:392px;left:106px;white-space:nowrap" class="ft2604">adalimumab trough levels at steady-state increased roughly proportionally with dose following 20, 40 and&#160;<br/>80&#160;mg subcutaneous dosing every other week and every week.</p>
<p style="position:absolute;top:450px;left:106px;white-space:nowrap" class="ft2602">In adult patients with psoriasis, the mean steady-state trough concentration was 5</p>
<p style="position:absolute;top:448px;left:645px;white-space:nowrap" class="ft2606">g/ml&#160;during&#160;</p>
<p style="position:absolute;top:469px;left:106px;white-space:nowrap" class="ft2602">adalimumab 40&#160;mg&#160;every other week&#160;monotherapy treatment.</p>
<p style="position:absolute;top:507px;left:106px;white-space:nowrap" class="ft2604">In adult patients with hidradenitis suppurativa, a dose of 160 mg Humira on Week 0 followed by 80 mg on&#160;<br/>Week 2 achieved serum adalimumab trough concentrations of approximately 7 to 8 μg/ml at Week 2 and&#160;<br/>Week 4. &#160;The mean steady-state trough concentration at Week 12 through Week 36 were approximately 8&#160;<br/>to 10 μg/ml during adalimumab 40 mg every week treatment. &#160;</p>
<p style="position:absolute;top:602px;left:106px;white-space:nowrap" class="ft2604">Adalimumab exposure in adolescent HS patients was predicted using population pharmacokinetic&#160;<br/>modelling and simulation based on cross-indication pharmacokinetics in other paediatric patients&#160;<br/>(paediatric psoriasis, juvenile idiopathic arthritis, paediatric Crohn’s disease, and enthesitis-related&#160;<br/>arthritis).&#160;The recommended adolescent HS dosing schedule is 40 mg every other week. Since exposure to&#160;<br/>adalimumab can be affected by body size, adolescents with higher body weight and inadequate response&#160;<br/>may benefit from receiving the recommended adult dose of 40 mg every week.</p>
<p style="position:absolute;top:735px;left:106px;white-space:nowrap" class="ft2607">In patients with Crohn’s disease, the loading dose of 80&#160;mg Humira on Week&#160;0 followed&#160;by 40&#160;mg Humira&#160;<br/>on Week&#160;2 achieves serum adalimumab trough concentrations of approximately 5.5</p>
<p style="position:absolute;top:753px;left:662px;white-space:nowrap" class="ft2606">g/ml during the&#160;</p>
<p style="position:absolute;top:774px;left:106px;white-space:nowrap" class="ft2607">induction period. A loading dose of 160&#160;mg Humira on Week&#160;0 followed by 80&#160;mg Humira on Week&#160;2&#160;<br/>achieves serum adalimumab trough concentrations&#160;of approximately 12</p>
<p style="position:absolute;top:792px;left:582px;white-space:nowrap" class="ft2606">g/ml&#160;during the induction period.&#160;</p>
<p style="position:absolute;top:814px;left:106px;white-space:nowrap" class="ft2602">Mean steady-state trough levels of approximately 7</p>
<p style="position:absolute;top:812px;left:449px;white-space:nowrap" class="ft2606">g/ml&#160;were observed in Crohn’s disease patients who&#160;</p>
<p style="position:absolute;top:833px;left:106px;white-space:nowrap" class="ft2602">received a maintenance dose of 40&#160;mg Humira every other week.</p>
<p style="position:absolute;top:871px;left:106px;white-space:nowrap" class="ft2607">In paediatric patients with moderate to severe CD, the open-label adalimumab induction dose was&#160;<br/>160/80&#160;mg&#160;or 80/40&#160;mg at Weeks&#160;0 and 2, respectively, dependent on a body weight cut-off&#160;of 40&#160;kg. &#160;At&#160;<br/>Week&#160;4, patients were&#160;randomised 1:1 to either the Standard Dose (40/20&#160;mg&#160;eow)&#160;or Low Dose&#160;<br/>(20/10&#160;mg eow)&#160;maintenance treatment groups based on their body weight.&#160;The&#160;mean (±SD)&#160;serum&#160;<br/>adalimumab trough concentrations achieved at Week&#160;4 were 15.7&#160;±&#160;6.6</p>
<p style="position:absolute;top:946px;left:580px;white-space:nowrap" class="ft2606">g/ml for patients&#160;≥&#160;40&#160;kg&#160;</p>
<p style="position:absolute;top:969px;left:106px;white-space:nowrap" class="ft2602">(160/80&#160;mg) and&#160;10.6&#160;±&#160;6.1</p>
<p style="position:absolute;top:967px;left:291px;white-space:nowrap" class="ft2606">g/ml for patients &lt;&#160;40&#160;kg (80/40&#160;mg).&#160;</p>
<p style="position:absolute;top:1007px;left:106px;white-space:nowrap" class="ft2607">For patients who stayed on their randomised therapy, the mean&#160;(±SD)&#160;adalimumab trough concentrations&#160;<br/>at Week&#160;52 were&#160;9.5&#160;±&#160;5.6</p>
<p style="position:absolute;top:1025px;left:284px;white-space:nowrap" class="ft2606">g/ml for the Standard Dose group and&#160;3.5&#160;±&#160;2.2&#160;g/ml for the Low Dose&#160;</p>
<p style="position:absolute;top:1046px;left:106px;white-space:nowrap" class="ft2604">group. &#160;The mean trough concentrations were maintained in patients who continued to receive adalimumab&#160;<br/>treatment eow for 52&#160;weeks.&#160;For patients who dose escalated from eow to weekly regimen, the mean&#160;</p>
</div>
<!-- Page 261 -->
<a name="261"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page261-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2610">261</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft2615">(±SD)&#160;serum concentrations of adalimumab at Week&#160;52 were 15.3&#160;±&#160;11.4&#160;μg/ml (40/20&#160;mg, weekly) and&#160;<br/>6.7&#160;±&#160;3.5&#160;μg/ml (20/10&#160;mg, weekly).</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft2617">In patients with ulcerative colitis, a loading dose of 160&#160;mg Humira on Week&#160;0 followed by 80&#160;mg Humira&#160;<br/>on Week&#160;2 achieves serum adalimumab trough concentrations of approximately 12</p>
<p style="position:absolute;top:161px;left:658px;white-space:nowrap" class="ft2616">g/ml during the&#160;</p>
<p style="position:absolute;top:183px;left:106px;white-space:nowrap" class="ft2612">induction period. &#160;Mean steady-state trough levels of approximately 8</p>
<p style="position:absolute;top:181px;left:570px;white-space:nowrap" class="ft2616">g/ml were&#160;observed in ulcerative&#160;</p>
<p style="position:absolute;top:202px;left:106px;white-space:nowrap" class="ft2612">colitis patients who received a maintenance dose of 40&#160;mg Humira every other week.&#160;</p>
<p style="position:absolute;top:240px;left:106px;white-space:nowrap" class="ft2614">Following the subcutaneous administration of body weight-based dosing of 0.6&#160;mg/kg (maximum of&#160;<br/>40&#160;mg)&#160;every other week to paediatric patients with ulcerative colitis, the mean trough steady-state serum&#160;<br/>adalimumab concentration was 5.01±3.28&#160;µg/ml&#160;at Week&#160;52. For patients who received 0.6&#160;mg/kg&#160;<br/>(maximum of 40&#160;mg)&#160;every week, the mean (±SD) trough steady-state serum adalimumab concentration&#160;<br/>was 15.7±5.60&#160;μg/ml at Week&#160;52.</p>
<p style="position:absolute;top:354px;left:106px;white-space:nowrap" class="ft2617">In&#160;adult&#160;patients with uveitis, a loading dose of 80&#160;mg adalimumab on Week 0 followed by 40&#160;mg&#160;<br/>adalimumab every other week starting at Week&#160;1, resulted in mean steady-state concentrations of&#160;<br/>approximately 8 to 10</p>
<p style="position:absolute;top:391px;left:256px;white-space:nowrap" class="ft2616">g/ml.</p>
<p style="position:absolute;top:431px;left:106px;white-space:nowrap" class="ft2615">Adalimumab exposure in paediatric uveitis patients was predicted using population pharmacokinetic&#160;<br/>modelling and simulation based on cross-indication pharmacokinetics in other&#160;paediatric patients&#160;<br/>(paediatric psoriasis, juvenile idiopathic arthritis, paediatric Crohn’s disease, and enthesitis-related&#160;<br/>arthritis). No clinical exposure data are available on the use of a loading dose in children &lt; 6 years. The&#160;<br/>predicted exposures indicate that in the absence of methotrexate, a loading dose may lead to an initial&#160;<br/>increase in systemic exposure.</p>
<p style="position:absolute;top:564px;left:106px;white-space:nowrap" class="ft2614">Population pharmacokinetic and pharmacokinetic/pharmacodynamic modelling and simulation predicted&#160;<br/>comparable adalimumab exposure and efficacy in patients treated with 80&#160;mg&#160;every other week when&#160;<br/>compared with 40&#160;mg&#160;every week (including adult patients with RA, HS, UC, CD or&#160;Ps, patients with&#160;<br/>adolescent HS, and paediatric patients&#160;≥&#160;40&#160;kg with CD&#160;and UC).</p>
<p style="position:absolute;top:659px;left:106px;white-space:nowrap" class="ft2614">Exposure-response relationship in&#160;paediatric population<br/>On the basis of clinical trial data in patients with JIA (pJIA and ERA), an exposure-response relationship&#160;<br/>was established between plasma concentrations and PedACR 50 response. The apparent adalimumab&#160;<br/>plasma concentration that produces half the maximum probability of PedACR 50 response (EC50) was&#160;<br/>3&#160;μg/ml (95% CI: 1-6&#160;μg/ml).&#160;</p>
<p style="position:absolute;top:773px;left:106px;white-space:nowrap" class="ft2615">Exposure-response relationships between adalimumab concentration and efficacy in paediatric patients&#160;<br/>with severe chronic plaque psoriasis were established for PASI 75 and PGA clear or minimal,&#160;<br/>respectively. PASI 75 and PGA clear or minimal increased with increasing adalimumab concentrations,&#160;<br/>both with a similar apparent EC50 of approximately 4.5&#160;μg/ml&#160;(95% CI 0.4-47.6 and 1.9-10.5,&#160;<br/>respectively). &#160;</p>
<p style="position:absolute;top:887px;left:106px;white-space:nowrap" class="ft2612">Elimination</p>
<p style="position:absolute;top:924px;left:106px;white-space:nowrap" class="ft2614">Population pharmacokinetic analyses with data from over 1,300 RA patients revealed a trend toward&#160;<br/>higher apparent clearance of adalimumab with increasing body weight. After adjustment for weight&#160;<br/>differences, gender and age appeared to have a minimal effect&#160;on adalimumab clearance. &#160;The serum&#160;<br/>levels of free adalimumab (not bound to anti-adalimumab antibodies, AAA) were observed to be lower in&#160;<br/>patients with measurable AAA.</p>
<p style="position:absolute;top:1038px;left:106px;white-space:nowrap" class="ft2612">Hepatic or renal impairment</p>
<p style="position:absolute;top:1076px;left:106px;white-space:nowrap" class="ft2612">Humira has not been studied in patients with hepatic or renal impairment.</p>
</div>
<!-- Page 262 -->
<a name="262"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page262-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2620">262</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft2621"><b>5.3</b></p>
<p style="position:absolute;top:105px;left:148px;white-space:nowrap" class="ft2621"><b>Preclinical safety data&#160;</b></p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft2624">Non-clinical data reveal no special hazard for humans based on studies of single dose toxicity, repeated&#160;<br/>dose toxicity, and genotoxicity. &#160;</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft2624">An&#160;embryo-foetal developmental toxicity/perinatal developmental study has been performed in&#160;<br/>cynomolgus monkeys at 0, 30 and 100&#160;mg/kg (9-17 monkeys/group) and has revealed no evidence of harm&#160;<br/>to the foetuses due to adalimumab. Neither carcinogenicity studies, nor a standard assessment of fertility&#160;<br/>and postnatal toxicity, were performed with adalimumab due to the lack of appropriate models for an&#160;<br/>antibody with limited cross-reactivity to rodent TNF and to the development of neutralising antibodies in&#160;<br/>rodents.&#160;</p>
<p style="position:absolute;top:352px;left:106px;white-space:nowrap" class="ft2621"><b>6.</b></p>
<p style="position:absolute;top:352px;left:148px;white-space:nowrap" class="ft2621"><b>PHARMACEUTICAL PARTICULARS</b></p>
<p style="position:absolute;top:390px;left:106px;white-space:nowrap" class="ft2621"><b>6.1</b></p>
<p style="position:absolute;top:390px;left:148px;white-space:nowrap" class="ft2621"><b>List of excipients&#160;</b></p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft2624">Mannitol<br/>Polysorbate 80<br/>Water for injections</p>
<p style="position:absolute;top:503px;left:106px;white-space:nowrap" class="ft2621"><b>6.2</b></p>
<p style="position:absolute;top:503px;left:148px;white-space:nowrap" class="ft2621"><b>Incompatibilities&#160;</b></p>
<p style="position:absolute;top:541px;left:106px;white-space:nowrap" class="ft2625">In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal&#160;<br/>products.</p>
<p style="position:absolute;top:598px;left:106px;white-space:nowrap" class="ft2621"><b>6.3</b></p>
<p style="position:absolute;top:598px;left:148px;white-space:nowrap" class="ft2621"><b>Shelf life&#160;</b></p>
<p style="position:absolute;top:636px;left:106px;white-space:nowrap" class="ft2622">2&#160;years</p>
<p style="position:absolute;top:674px;left:106px;white-space:nowrap" class="ft2621"><b>6.4</b></p>
<p style="position:absolute;top:674px;left:148px;white-space:nowrap" class="ft2621"><b>Special precautions for storage&#160;</b></p>
<p style="position:absolute;top:713px;left:106px;white-space:nowrap" class="ft2622">Store in a refrigerator (2</p>
<p style="position:absolute;top:711px;left:266px;white-space:nowrap" class="ft2626">C&#160;–&#160;8C). Do not freeze. Keep the pre-filled syringe or pre-filled pen in its outer&#160;</p>
<p style="position:absolute;top:732px;left:106px;white-space:nowrap" class="ft2622">carton in order to protect from light. &#160;</p>
<p style="position:absolute;top:770px;left:106px;white-space:nowrap" class="ft2624">A single Humira pre-filled syringe or&#160;pre-filled pen may be stored at temperatures up to a maximum of&#160;<br/>25°C for a period of up to 14&#160;days. The syringe or pen must be protected from light, and discarded if not&#160;<br/>used within the 14-day period.</p>
<p style="position:absolute;top:846px;left:106px;white-space:nowrap" class="ft2621"><b>6.5</b></p>
<p style="position:absolute;top:846px;left:148px;white-space:nowrap" class="ft2621"><b>Nature and contents of container</b></p>
<p style="position:absolute;top:884px;left:106px;white-space:nowrap" class="ft2624">Humira 80&#160;mg solution for injection in pre-filled syringe<br/>Humira 80&#160;mg solution for injection in single-use pre-filled syringe (type I glass) with a plunger stopper&#160;<br/>(bromobutyl rubber) and a needle with a needle shield (thermoplastic elastomer).&#160;</p>
<p style="position:absolute;top:960px;left:106px;white-space:nowrap" class="ft2622">Packs of:</p>
<p style="position:absolute;top:978px;left:106px;white-space:nowrap" class="ft2626"></p>
<p style="position:absolute;top:980px;left:148px;white-space:nowrap" class="ft2622">1 pre-filled syringe (0.8&#160;ml sterile solution) with 1 alcohol pad in a blister.</p>
<p style="position:absolute;top:1018px;left:106px;white-space:nowrap" class="ft2624">Humira 80&#160;mg solution for injection in pre-filled pen<br/>Humira 80&#160;mg solution for injection in single-use pre-filled pen for patient use containing a pre-filled&#160;<br/>syringe. The syringe inside the pen is made from type 1 glass with a plunger stopper (bromobutyl rubber)&#160;<br/>and a needle with a needle shield (thermoplastic elastomer).</p>
</div>
<!-- Page 263 -->
<a name="263"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page263-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2630">263</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft2632">Packs of:</p>
<p style="position:absolute;top:123px;left:133px;white-space:nowrap" class="ft2636">&#160;1 pre-filled pen (0.8&#160;ml sterile solution), with&#160;2 alcohol pads in a blister.</p>
<p style="position:absolute;top:143px;left:133px;white-space:nowrap" class="ft2636">&#160;3 pre-filled pens (0.8&#160;ml&#160;sterile solution), with 4 alcohol pads in a blister.</p>
<p style="position:absolute;top:202px;left:106px;white-space:nowrap" class="ft2632">Not all presentations&#160;or pack sizes may be marketed.</p>
<p style="position:absolute;top:240px;left:106px;white-space:nowrap" class="ft2631"><b>6.6</b></p>
<p style="position:absolute;top:240px;left:148px;white-space:nowrap" class="ft2631"><b>Special precautions for disposal</b></p>
<p style="position:absolute;top:278px;left:106px;white-space:nowrap" class="ft2634">Any unused medicinal product or waste material should be disposed of in accordance with local&#160;<br/>requirements.</p>
<p style="position:absolute;top:354px;left:106px;white-space:nowrap" class="ft2631"><b>7.</b></p>
<p style="position:absolute;top:354px;left:148px;white-space:nowrap" class="ft2631"><b>MARKETING AUTHORISATION HOLDER&#160;</b></p>
<p style="position:absolute;top:392px;left:106px;white-space:nowrap" class="ft2634">AbbVie Deutschland GmbH &amp; Co. KG<br/>Knollstrasse<br/>67061 Ludwigshafen<br/>Germany</p>
<p style="position:absolute;top:506px;left:106px;white-space:nowrap" class="ft2631"><b>8.</b></p>
<p style="position:absolute;top:506px;left:148px;white-space:nowrap" class="ft2631"><b>MARKETING AUTHORISATION NUMBERS&#160;</b></p>
<p style="position:absolute;top:544px;left:106px;white-space:nowrap" class="ft2634">Humira 80&#160;mg solution for injection in pre-filled syringe<br/>EU/1/03/256/020</p>
<p style="position:absolute;top:600px;left:106px;white-space:nowrap" class="ft2634">Humira 80&#160;mg solution for&#160;injection in pre-filled pen<br/>EU/1/03/256/021<br/>EU/1/03/256/027</p>
<p style="position:absolute;top:696px;left:106px;white-space:nowrap" class="ft2631"><b>9.</b></p>
<p style="position:absolute;top:696px;left:148px;white-space:nowrap" class="ft2631"><b>DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</b></p>
<p style="position:absolute;top:733px;left:106px;white-space:nowrap" class="ft2634">Date of first authorisation: 08 September 2003<br/>Date of latest renewal: 08 September 2008&#160;</p>
<p style="position:absolute;top:809px;left:106px;white-space:nowrap" class="ft2631"><b>10.</b></p>
<p style="position:absolute;top:809px;left:148px;white-space:nowrap" class="ft2631"><b>DATE OF REVISION&#160;OF THE TEXT</b></p>
<p style="position:absolute;top:847px;left:106px;white-space:nowrap" class="ft2635">Detailed information on this medicinal product is available on the website of the European Medicines&#160;<br/><a href="http://www.ema.europa.eu/">Agency&#160;http://www.ema.europa.eu</a></p>
</div>
<!-- Page 264 -->
<a name="264"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page264-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2640">264</p>
<p style="position:absolute;top:522px;left:421px;white-space:nowrap" class="ft2641"><b>ANNEX II</b></p>
<p style="position:absolute;top:560px;left:188px;white-space:nowrap" class="ft2641"><b>A.</b></p>
<p style="position:absolute;top:560px;left:233px;white-space:nowrap" class="ft26419"><b>MANUFACTURERS OF THE BIOLOGICAL ACTIVE&#160;<br/>SUBSTANCE AND MANUFACTURERS RESPONSIBLE FOR&#160;<br/>BATCH RELEASE</b></p>
<p style="position:absolute;top:636px;left:188px;white-space:nowrap" class="ft2641"><b>B.</b></p>
<p style="position:absolute;top:636px;left:233px;white-space:nowrap" class="ft26419"><b>CONDITIONS OR RESTRICTIONS REGARDING SUPPLY&#160;<br/>AND USE</b></p>
<p style="position:absolute;top:693px;left:188px;white-space:nowrap" class="ft2641"><b>C.</b></p>
<p style="position:absolute;top:693px;left:238px;white-space:nowrap" class="ft2641"><b>OTHER CONDITIONS AND REQUIREMENTS OF THE&#160;</b></p>
<p style="position:absolute;top:712px;left:233px;white-space:nowrap" class="ft2641"><b>MARKETING AUTHORISATION</b></p>
<p style="position:absolute;top:750px;left:188px;white-space:nowrap" class="ft2641"><b>D.</b></p>
<p style="position:absolute;top:750px;left:233px;white-space:nowrap" class="ft26419"><b>CONDITIONS OR RESTRICTIONS WITH REGARD TO THE&#160;<br/>SAFE AND EFFECTIVE USE OF&#160;THE MEDICINAL PRODUCT</b></p>
</div>
<!-- Page 265 -->
<a name="265"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page265-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2650">265</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft2651"><b>A.</b></p>
<p style="position:absolute;top:86px;left:147px;white-space:nowrap" class="ft26515"><b>MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCE AND&#160;<br/>MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE</b></p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft2652">Name and address of the manufacturers of the biological active substance</p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft2654">AbbVie Bioresearch Center<br/>100 Research Drive<br/>Worcester<br/>MA&#160;01605<br/>USA</p>
<p style="position:absolute;top:295px;left:106px;white-space:nowrap" class="ft2652">and</p>
<p style="position:absolute;top:333px;left:106px;white-space:nowrap" class="ft2654">AbbVie Biotechnology Ltd.<br/>Road No. 2, Km. 59.2<br/>Barceloneta<br/>Puerto Rico 00617</p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft2652">and</p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft2655">Lonza Biologics Tuas PTE Ltd<br/>35 Tuas South Ave 6<br/>Singapore 637377</p>
<p style="position:absolute;top:541px;left:106px;white-space:nowrap" class="ft2652">and</p>
<p style="position:absolute;top:579px;left:106px;white-space:nowrap" class="ft2655">AbbVie Operations Singapore PTE Ltd<br/>23 Tuas South Avenue 6<br/>Singapore 637022</p>
<p style="position:absolute;top:655px;left:106px;white-space:nowrap" class="ft2652">Name and&#160;address of the manufacturer responsible for batch release</p>
<p style="position:absolute;top:693px;left:106px;white-space:nowrap" class="ft2655">AbbVie Biotechnology GmbH<br/>Knollstrasse<br/>67061 Ludwigshafen<br/>Germany</p>
<p style="position:absolute;top:807px;left:106px;white-space:nowrap" class="ft2651"><b>B.</b></p>
<p style="position:absolute;top:807px;left:147px;white-space:nowrap" class="ft2651"><b>CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE&#160;</b></p>
<p style="position:absolute;top:845px;left:106px;white-space:nowrap" class="ft2654">Medicinal product subject to restricted medical prescription (see Annex&#160;I: Summary of Product&#160;<br/>Characteristics, section 4.2).</p>
<p style="position:absolute;top:921px;left:106px;white-space:nowrap" class="ft2651"><b>C.&#160;</b></p>
<p style="position:absolute;top:921px;left:147px;white-space:nowrap" class="ft26515"><b>OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING&#160;<br/>AUTHORISATION</b></p>
<p style="position:absolute;top:977px;left:133px;white-space:nowrap" class="ft2656">&#160;<b>Periodic&#160;safety&#160;update&#160;reports&#160;(PSURs)</b></p>
<p style="position:absolute;top:998px;left:106px;white-space:nowrap" class="ft2655">The requirements for submission of&#160;PSURs&#160;for this medicinal product are set out in the list&#160;of Union&#160;<br/>reference&#160;dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC&#160;and any&#160;<br/>subsequent updates published on the European medicines web-portal.</p>
</div>
<!-- Page 266 -->
<a name="266"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page266-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2660">266</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft2661"><b>D.</b></p>
<p style="position:absolute;top:86px;left:147px;white-space:nowrap" class="ft26615"><b>CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE&#160;<br/>USE OF THE MEDICINAL PRODUCT</b></p>
<p style="position:absolute;top:141px;left:106px;white-space:nowrap" class="ft2666"></p>
<p style="position:absolute;top:143px;left:147px;white-space:nowrap" class="ft2661"><b>Risk&#160;management&#160;plan (RMP)</b></p>
<p style="position:absolute;top:182px;left:106px;white-space:nowrap" class="ft2664">The&#160;marketing authorization holder (MAH)&#160;shall perform the required pharmacovigilance activities&#160;<br/>and interventions detailed in the agreed RMP presented in Module 1.8.2 of the&#160;marketing&#160;<br/>authorisation and any&#160;agreed subsequent updates of the RMP.</p>
<p style="position:absolute;top:258px;left:106px;white-space:nowrap" class="ft2662">An updated RMP should be submitted:</p>
<p style="position:absolute;top:275px;left:133px;white-space:nowrap" class="ft2666">&#160;At the request of the European Medicines Agency;&#160;</p>
<p style="position:absolute;top:294px;left:133px;white-space:nowrap" class="ft2666">&#160;Whenever&#160;the risk management system is modified, especially as the result of&#160;new&#160;information&#160;</p>
<p style="position:absolute;top:316px;left:148px;white-space:nowrap" class="ft2664">being received that may lead to a&#160;significant change to the benefit/risk profile or as the result&#160;of an&#160;<br/>important (pharmacovigilance or risk minimisation) milestone being reached.</p>
<p style="position:absolute;top:372px;left:106px;white-space:nowrap" class="ft2666"></p>
<p style="position:absolute;top:374px;left:147px;white-space:nowrap" class="ft26619"><b>Additional risk minimisation measures<br/>&#160;&#160;</b></p>
<p style="position:absolute;top:413px;left:106px;white-space:nowrap" class="ft2662">The&#160;Patient Reminder Cards (adult and paediatric) contain the following&#160;key elements</p>
<p style="position:absolute;top:451px;left:106px;white-space:nowrap" class="ft2662">-</p>
<p style="position:absolute;top:451px;left:148px;white-space:nowrap" class="ft2662">infections, including tuberculosis</p>
<p style="position:absolute;top:470px;left:106px;white-space:nowrap" class="ft2662">-</p>
<p style="position:absolute;top:470px;left:148px;white-space:nowrap" class="ft2662">cancer</p>
<p style="position:absolute;top:489px;left:106px;white-space:nowrap" class="ft2662">-</p>
<p style="position:absolute;top:489px;left:148px;white-space:nowrap" class="ft2662">nervous system problems</p>
<p style="position:absolute;top:508px;left:106px;white-space:nowrap" class="ft2662">-</p>
<p style="position:absolute;top:508px;left:148px;white-space:nowrap" class="ft2662">vaccinations</p>
</div>
<!-- Page 267 -->
<a name="267"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page267-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2670">267</p>
<p style="position:absolute;top:522px;left:418px;white-space:nowrap" class="ft2671"><b>ANNEX III</b></p>
<p style="position:absolute;top:560px;left:306px;white-space:nowrap" class="ft2671"><b>LABELLING AND PACKAGE LEAFLET</b></p>
</div>
<!-- Page 268 -->
<a name="268"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page268-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2680">268</p>
<p style="position:absolute;top:522px;left:400px;white-space:nowrap" class="ft2681"><b>A. LABELLING</b></p>
</div>
<!-- Page 269 -->
<a name="269"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page269-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2690">269</p>
<p style="position:absolute;top:88px;left:106px;white-space:nowrap" class="ft2691"><b>PARTICULARS TO APPEAR ON THE OUTER PACKAGING&#160;</b></p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft2691"><b>OUTER&#160;CARTON</b></p>
<p style="position:absolute;top:188px;left:106px;white-space:nowrap" class="ft2691"><b>1.</b></p>
<p style="position:absolute;top:188px;left:148px;white-space:nowrap" class="ft2691"><b>NAME OF THE MEDICINAL PRODUCT</b></p>
<p style="position:absolute;top:228px;left:106px;white-space:nowrap" class="ft2695">Humira 20&#160;mg solution for injection in pre-filled syringe<br/>adalimumab</p>
<p style="position:absolute;top:306px;left:106px;white-space:nowrap" class="ft2691"><b>2.</b></p>
<p style="position:absolute;top:306px;left:148px;white-space:nowrap" class="ft2691"><b>STATEMENT OF ACTIVE SUBSTANCE</b></p>
<p style="position:absolute;top:346px;left:106px;white-space:nowrap" class="ft2692">One 0.2&#160;ml pre-filled syringe contains 20&#160;mg adalimumab.</p>
<p style="position:absolute;top:405px;left:106px;white-space:nowrap" class="ft2691"><b>3.</b></p>
<p style="position:absolute;top:405px;left:148px;white-space:nowrap" class="ft2691"><b>LIST OF EXCIPIENTS</b></p>
<p style="position:absolute;top:445px;left:106px;white-space:nowrap" class="ft2692">Excipients: mannitol,&#160;polysorbate&#160;80, and water for injections. See leaflet for further information.</p>
<p style="position:absolute;top:505px;left:106px;white-space:nowrap" class="ft2691"><b>4.</b></p>
<p style="position:absolute;top:505px;left:148px;white-space:nowrap" class="ft2691"><b>PHARMACEUTICAL FORM AND CONTENTS</b></p>
<p style="position:absolute;top:545px;left:106px;white-space:nowrap" class="ft2694">Solution for injection<br/>2 pre-filled syringes<br/>2 alcohol pads&#160;</p>
<p style="position:absolute;top:642px;left:106px;white-space:nowrap" class="ft2691"><b>5.</b></p>
<p style="position:absolute;top:642px;left:148px;white-space:nowrap" class="ft2691"><b>METHOD AND ROUTE&#160;OF ADMINISTRATION</b></p>
<p style="position:absolute;top:682px;left:106px;white-space:nowrap" class="ft2692">Subcutaneous use</p>
<p style="position:absolute;top:720px;left:106px;white-space:nowrap" class="ft2692">Read the package&#160;leaflet before use.</p>
<p style="position:absolute;top:758px;left:106px;white-space:nowrap" class="ft2692">For single use only.</p>
<p style="position:absolute;top:796px;left:106px;white-space:nowrap" class="ft2692">For paediatric use</p>
<p style="position:absolute;top:855px;left:105px;white-space:nowrap" class="ft2691"><b>6.</b></p>
<p style="position:absolute;top:855px;left:147px;white-space:nowrap" class="ft26919"><b>SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED&#160;OUT OF&#160;<br/>THE SIGHT AND REACH&#160;OF CHILDREN</b></p>
<p style="position:absolute;top:914px;left:106px;white-space:nowrap" class="ft2692">Keep out of the sight and reach of children.</p>
<p style="position:absolute;top:973px;left:106px;white-space:nowrap" class="ft2691"><b>7.</b></p>
<p style="position:absolute;top:973px;left:148px;white-space:nowrap" class="ft2691"><b>OTHER SPECIAL WARNING, IF NECESSARY</b></p>
<p style="position:absolute;top:1035px;left:106px;white-space:nowrap" class="ft2691"><b>8.</b></p>
<p style="position:absolute;top:1035px;left:148px;white-space:nowrap" class="ft2691"><b>EXPIRY DATE</b></p>
<p style="position:absolute;top:1075px;left:106px;white-space:nowrap" class="ft2692">EXP</p>
</div>
<!-- Page 270 -->
<a name="270"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page270-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2700">270</p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft2701"><b>9.</b></p>
<p style="position:absolute;top:126px;left:148px;white-space:nowrap" class="ft2701"><b>SPECIAL STORAGE CONDITIONS</b></p>
<p style="position:absolute;top:166px;left:106px;white-space:nowrap" class="ft2704">Store in a refrigerator. Do not freeze.&#160;<br/>Refer to package leaflet for alternative storage details.</p>
<p style="position:absolute;top:223px;left:106px;white-space:nowrap" class="ft2702">Keep the syringe in the outer carton in order to protect from light.</p>
<p style="position:absolute;top:283px;left:106px;white-space:nowrap" class="ft2701"><b>10.</b></p>
<p style="position:absolute;top:283px;left:148px;white-space:nowrap" class="ft27019"><b>SPECIAL PRECAUTIONS FOR&#160;DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR<br/>WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF&#160;<br/>APPROPRIATE</b></p>
<p style="position:absolute;top:382px;left:106px;white-space:nowrap" class="ft2701"><b>11.</b></p>
<p style="position:absolute;top:382px;left:148px;white-space:nowrap" class="ft2701"><b>NAME AND ADDRESS&#160;OF THE MARKETING AUTHORISATION HOLDER</b></p>
<p style="position:absolute;top:422px;left:106px;white-space:nowrap" class="ft2705">AbbVie Deutschland GmbH &amp; Co. KG<br/>Knollstrasse<br/>67061 Ludwigshafen<br/>Germany</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft2701"><b>12.</b></p>
<p style="position:absolute;top:538px;left:148px;white-space:nowrap" class="ft2701"><b>MARKETING AUTHORISATION NUMBER</b></p>
<p style="position:absolute;top:578px;left:106px;white-space:nowrap" class="ft2702">EU/1/03/256/022</p>
<p style="position:absolute;top:638px;left:106px;white-space:nowrap" class="ft2701"><b>13.</b></p>
<p style="position:absolute;top:638px;left:148px;white-space:nowrap" class="ft2701"><b>BATCH NUMBER</b></p>
<p style="position:absolute;top:678px;left:106px;white-space:nowrap" class="ft2702">Lot</p>
<p style="position:absolute;top:737px;left:106px;white-space:nowrap" class="ft2701"><b>14.</b></p>
<p style="position:absolute;top:737px;left:148px;white-space:nowrap" class="ft2701"><b>GENERAL CLASSIFICATION FOR SUPPLY</b></p>
<p style="position:absolute;top:798px;left:104px;white-space:nowrap" class="ft2701"><b>15.</b></p>
<p style="position:absolute;top:798px;left:147px;white-space:nowrap" class="ft2701"><b>INSTRUCTIONS ON&#160;USE</b></p>
<p style="position:absolute;top:860px;left:106px;white-space:nowrap" class="ft2701"><b>16.</b></p>
<p style="position:absolute;top:860px;left:148px;white-space:nowrap" class="ft2701"><b>INFORMATION IN BRAILLE</b></p>
<p style="position:absolute;top:900px;left:106px;white-space:nowrap" class="ft2702">Humira 20&#160;mg</p>
<p style="position:absolute;top:959px;left:106px;white-space:nowrap" class="ft2701"><b>17.&#160;&#160;UNIQUE INDENTIFIER&#160;–&#160;2D BARCODE</b></p>
<p style="position:absolute;top:999px;left:106px;white-space:nowrap" class="ft2702">2D barcode carrying the unique&#160;identifier included.</p>
</div>
<!-- Page 271 -->
<a name="271"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page271-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2710">271</p>
<p style="position:absolute;top:88px;left:106px;white-space:nowrap" class="ft2711"><b>18.&#160;&#160;UNIQUE INDENTIFIER&#160;–&#160;HUMAN READABLE&#160;DATA</b></p>
<p style="position:absolute;top:129px;left:106px;white-space:nowrap" class="ft2714">PC<br/>SN<br/>NN</p>
</div>
<!-- Page 272 -->
<a name="272"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page272-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2720">272</p>
<p style="position:absolute;top:88px;left:106px;white-space:nowrap" class="ft2721"><b>MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</b></p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft2721"><b>TRAY BACKING TEXT</b></p>
<p style="position:absolute;top:188px;left:106px;white-space:nowrap" class="ft2721"><b>1.</b></p>
<p style="position:absolute;top:188px;left:148px;white-space:nowrap" class="ft2721"><b>NAME OF THE MEDICINAL PRODUCT</b></p>
<p style="position:absolute;top:228px;left:106px;white-space:nowrap" class="ft2725">Humira 20&#160;mg solution for injection in pre-filled syringe&#160;<br/>adalimumab</p>
<p style="position:absolute;top:306px;left:106px;white-space:nowrap" class="ft2721"><b>2.</b></p>
<p style="position:absolute;top:306px;left:148px;white-space:nowrap" class="ft2721"><b>NAME OF THE MARKETING AUTHORISATION HOLDER</b></p>
<p style="position:absolute;top:346px;left:106px;white-space:nowrap" class="ft2722">AbbVie&#160;(as logo)</p>
<p style="position:absolute;top:405px;left:106px;white-space:nowrap" class="ft2721"><b>3.</b></p>
<p style="position:absolute;top:405px;left:148px;white-space:nowrap" class="ft2721"><b>EXPIRY DATE</b></p>
<p style="position:absolute;top:445px;left:106px;white-space:nowrap" class="ft2722">EXP</p>
<p style="position:absolute;top:505px;left:106px;white-space:nowrap" class="ft2721"><b>4.</b></p>
<p style="position:absolute;top:505px;left:148px;white-space:nowrap" class="ft2721"><b>BATCH NUMBER</b></p>
<p style="position:absolute;top:545px;left:106px;white-space:nowrap" class="ft2722">Lot</p>
<p style="position:absolute;top:604px;left:104px;white-space:nowrap" class="ft2721"><b>5.</b></p>
<p style="position:absolute;top:604px;left:147px;white-space:nowrap" class="ft2721"><b>OTHER</b></p>
<p style="position:absolute;top:644px;left:106px;white-space:nowrap" class="ft2722">For storage information, see package leaflet.</p>
<p style="position:absolute;top:682px;left:106px;white-space:nowrap" class="ft2722">For single use only.</p>
<p style="position:absolute;top:720px;left:106px;white-space:nowrap" class="ft2722">For paediatric use</p>
</div>
<!-- Page 273 -->
<a name="273"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page273-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2730">273</p>
<p style="position:absolute;top:88px;left:106px;white-space:nowrap" class="ft2731"><b>MINIMUM PARTICULARS&#160;TO APPEAR&#160;ON SMALL IMMEDIATE PACKAGING UNITS</b></p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft2731"><b>SYRINGE LABEL</b></p>
<p style="position:absolute;top:188px;left:106px;white-space:nowrap" class="ft2731"><b>1.</b></p>
<p style="position:absolute;top:188px;left:148px;white-space:nowrap" class="ft2731"><b>NAME OF THE MEDICINAL PRODUCT AND ROUTE OF ADMINISTRATION</b></p>
<p style="position:absolute;top:228px;left:106px;white-space:nowrap" class="ft2734">Humira 20&#160;mg injection<br/>adalimumab<br/>SC</p>
<p style="position:absolute;top:325px;left:106px;white-space:nowrap" class="ft2731"><b>2.</b></p>
<p style="position:absolute;top:325px;left:148px;white-space:nowrap" class="ft2731"><b>METHOD OF ADMINISTRATION</b></p>
<p style="position:absolute;top:386px;left:106px;white-space:nowrap" class="ft2731"><b>3.</b></p>
<p style="position:absolute;top:386px;left:148px;white-space:nowrap" class="ft2731"><b>EXPIRY DATE</b></p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft2732">EXP</p>
<p style="position:absolute;top:486px;left:106px;white-space:nowrap" class="ft2731"><b>4.</b></p>
<p style="position:absolute;top:486px;left:148px;white-space:nowrap" class="ft2731"><b>BATCH NUMBER</b></p>
<p style="position:absolute;top:526px;left:106px;white-space:nowrap" class="ft2732">Lot</p>
<p style="position:absolute;top:585px;left:106px;white-space:nowrap" class="ft2731"><b>5.</b></p>
<p style="position:absolute;top:585px;left:148px;white-space:nowrap" class="ft2731"><b>CONTENTS BY WEIGHT, BY&#160;VOLUME OR BY UNIT</b></p>
<p style="position:absolute;top:625px;left:106px;white-space:nowrap" class="ft2732">20&#160;mg/0.2&#160;ml</p>
<p style="position:absolute;top:684px;left:106px;white-space:nowrap" class="ft2731"><b>6.</b></p>
<p style="position:absolute;top:684px;left:148px;white-space:nowrap" class="ft2731"><b>OTHER</b></p>
</div>
<!-- Page 274 -->
<a name="274"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page274-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2740">274</p>
<p style="position:absolute;top:88px;left:106px;white-space:nowrap" class="ft2741"><b>PARTICULARS TO APPEAR ON THE OUTER PACKAGING&#160;</b></p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft2741"><b>OUTER&#160;CARTON&#160;</b></p>
<p style="position:absolute;top:188px;left:106px;white-space:nowrap" class="ft2741"><b>1.</b></p>
<p style="position:absolute;top:188px;left:148px;white-space:nowrap" class="ft2741"><b>NAME OF THE MEDICINAL PRODUCT</b></p>
<p style="position:absolute;top:228px;left:106px;white-space:nowrap" class="ft2745">Humira 40&#160;mg/0.8&#160;ml solution for injection<br/>adalimumab</p>
<p style="position:absolute;top:306px;left:106px;white-space:nowrap" class="ft2741"><b>2.</b></p>
<p style="position:absolute;top:306px;left:148px;white-space:nowrap" class="ft2741"><b>STATEMENT OF ACTIVE SUBSTANCE</b></p>
<p style="position:absolute;top:346px;left:106px;white-space:nowrap" class="ft2742">One 0.8&#160;ml vial contains&#160;40&#160;mg adalimumab.</p>
<p style="position:absolute;top:405px;left:106px;white-space:nowrap" class="ft2741"><b>3.</b></p>
<p style="position:absolute;top:405px;left:148px;white-space:nowrap" class="ft2741"><b>LIST OF EXCIPIENTS</b></p>
<p style="position:absolute;top:445px;left:106px;white-space:nowrap" class="ft2744">Excipients: mannitol, citric acid monohydrate, sodium citrate, sodium dihydrogen phosphate dihydrate,&#160;<br/>disodium phosphate dihydrate, sodium chloride, polysorbate&#160;80, sodium hydroxide and water for&#160;<br/>injections. See&#160;leaflet for further information.</p>
<p style="position:absolute;top:543px;left:106px;white-space:nowrap" class="ft2741"><b>4.</b></p>
<p style="position:absolute;top:543px;left:148px;white-space:nowrap" class="ft2741"><b>PHARMACEUTICAL FORM AND CONTENTS</b></p>
<p style="position:absolute;top:583px;left:106px;white-space:nowrap" class="ft2744">Solution for injection<br/>Contains 2 cartons each for a single injection only<br/><b>Each carton contains</b>:<br/>1 vial&#160;<br/>1 sterile injection syringe&#160;<br/>1 sterile needle<br/>1 sterile vial adapter<br/>2 alcohol&#160;pads&#160;</p>
<p style="position:absolute;top:775px;left:106px;white-space:nowrap" class="ft2741"><b>5.</b></p>
<p style="position:absolute;top:775px;left:148px;white-space:nowrap" class="ft2741"><b>METHOD AND ROUTE&#160;OF ADMINISTRATION</b></p>
<p style="position:absolute;top:815px;left:106px;white-space:nowrap" class="ft2742">Subcutaneous use</p>
<p style="position:absolute;top:853px;left:106px;white-space:nowrap" class="ft2742">Read the package leaflet before use.</p>
<p style="position:absolute;top:891px;left:106px;white-space:nowrap" class="ft2742">For paediatric use</p>
<p style="position:absolute;top:950px;left:106px;white-space:nowrap" class="ft2741"><b>6.</b></p>
<p style="position:absolute;top:950px;left:148px;white-space:nowrap" class="ft27419"><b>SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED&#160;OUT OF&#160;<br/>THE SIGHT AND REACH&#160;OF CHILDREN</b></p>
<p style="position:absolute;top:1009px;left:106px;white-space:nowrap" class="ft2742">Keep out of the sight and reach&#160;of children.</p>
<p style="position:absolute;top:1068px;left:106px;white-space:nowrap" class="ft2741"><b>7.</b></p>
<p style="position:absolute;top:1068px;left:148px;white-space:nowrap" class="ft2741"><b>OTHER SPECIAL WARNING, IF NECESSARY</b></p>
</div>
<!-- Page 275 -->
<a name="275"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page275-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2750">275</p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft2751"><b>8.</b></p>
<p style="position:absolute;top:126px;left:148px;white-space:nowrap" class="ft2751"><b>EXPIRY DATE</b></p>
<p style="position:absolute;top:166px;left:106px;white-space:nowrap" class="ft2752">EXP</p>
<p style="position:absolute;top:226px;left:106px;white-space:nowrap" class="ft2751"><b>9.</b></p>
<p style="position:absolute;top:226px;left:148px;white-space:nowrap" class="ft2751"><b>SPECIAL STORAGE CONDITIONS</b></p>
<p style="position:absolute;top:266px;left:106px;white-space:nowrap" class="ft2754">Store in a refrigerator. Do not freeze.<br/>Keep the vial in the outer carton in order to protect from light.</p>
<p style="position:absolute;top:344px;left:106px;white-space:nowrap" class="ft2751"><b>10.</b></p>
<p style="position:absolute;top:344px;left:148px;white-space:nowrap" class="ft27519"><b>SPECIAL PRECAUTIONS FOR DISPOSAL&#160;OF UNUSED MEDICINAL&#160;PRODUCTS OR&#160;<br/>WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF&#160;<br/>APPROPRIATE</b></p>
<p style="position:absolute;top:443px;left:106px;white-space:nowrap" class="ft2751"><b>11.</b></p>
<p style="position:absolute;top:443px;left:148px;white-space:nowrap" class="ft2751"><b>NAME AND ADDRESS&#160;OF THE MARKETING AUTHORISATION HOLDER</b></p>
<p style="position:absolute;top:483px;left:106px;white-space:nowrap" class="ft2754">AbbVie Deutschland GmbH &amp; Co. KG<br/>Knollstrasse<br/>67061 Ludwigshafen<br/>Germany</p>
<p style="position:absolute;top:599px;left:106px;white-space:nowrap" class="ft2751"><b>12.</b></p>
<p style="position:absolute;top:599px;left:148px;white-space:nowrap" class="ft2751"><b>MARKETING&#160;AUTHORISATION NUMBER</b></p>
<p style="position:absolute;top:640px;left:106px;white-space:nowrap" class="ft2752">EU/1/03/256/001</p>
<p style="position:absolute;top:699px;left:106px;white-space:nowrap" class="ft2751"><b>13.</b></p>
<p style="position:absolute;top:699px;left:148px;white-space:nowrap" class="ft2751"><b>BATCH NUMBER</b></p>
<p style="position:absolute;top:739px;left:106px;white-space:nowrap" class="ft2752">Lot&#160;</p>
<p style="position:absolute;top:798px;left:106px;white-space:nowrap" class="ft2751"><b>14.</b></p>
<p style="position:absolute;top:798px;left:148px;white-space:nowrap" class="ft2751"><b>GENERAL CLASSIFICATION FOR SUPPLY</b></p>
<p style="position:absolute;top:860px;left:106px;white-space:nowrap" class="ft2751"><b>15.</b></p>
<p style="position:absolute;top:860px;left:148px;white-space:nowrap" class="ft2751"><b>INSTRUCTIONS ON&#160;USE</b></p>
<p style="position:absolute;top:921px;left:106px;white-space:nowrap" class="ft2751"><b>16.</b></p>
<p style="position:absolute;top:921px;left:148px;white-space:nowrap" class="ft2751"><b>INFORMATION IN BRAILLE</b></p>
<p style="position:absolute;top:961px;left:106px;white-space:nowrap" class="ft2752">Humira 40&#160;mg</p>
<p style="position:absolute;top:1021px;left:106px;white-space:nowrap" class="ft2751"><b>17.&#160;&#160;UNIQUE INDENTIFIER&#160;–&#160;2D BARCODE</b></p>
<p style="position:absolute;top:1061px;left:106px;white-space:nowrap" class="ft2752">2D barcode carrying the unique identifier&#160;included.</p>
</div>
<!-- Page 276 -->
<a name="276"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page276-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2760">276</p>
<p style="position:absolute;top:107px;left:106px;white-space:nowrap" class="ft2761"><b>18.&#160;&#160;UNIQUE INDENTIFIER&#160;–&#160;HUMAN READABLE&#160;DATA</b></p>
<p style="position:absolute;top:147px;left:106px;white-space:nowrap" class="ft2764">PC<br/>SN<br/>NN</p>
</div>
<!-- Page 277 -->
<a name="277"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page277-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2770">277</p>
<p style="position:absolute;top:88px;left:106px;white-space:nowrap" class="ft2771"><b>PARTICULARS TO APPEAR ON THE OUTER PACKAGING&#160;</b></p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft2771"><b>INNER&#160;CARTON</b></p>
<p style="position:absolute;top:188px;left:106px;white-space:nowrap" class="ft2771"><b>1.</b></p>
<p style="position:absolute;top:188px;left:148px;white-space:nowrap" class="ft2771"><b>NAME OF THE MEDICINAL PRODUCT</b></p>
<p style="position:absolute;top:228px;left:106px;white-space:nowrap" class="ft2775">Humira 40&#160;mg/0.8&#160;ml solution for injection<br/>adalimumab</p>
<p style="position:absolute;top:306px;left:106px;white-space:nowrap" class="ft2771"><b>2.</b></p>
<p style="position:absolute;top:306px;left:148px;white-space:nowrap" class="ft2771"><b>STATEMENT OF ACTIVE SUBSTANCE</b></p>
<p style="position:absolute;top:346px;left:106px;white-space:nowrap" class="ft2772">One 0.8&#160;ml vial contains 40&#160;mg adalimumab.</p>
<p style="position:absolute;top:405px;left:106px;white-space:nowrap" class="ft2771"><b>3.</b></p>
<p style="position:absolute;top:405px;left:148px;white-space:nowrap" class="ft2771"><b>LIST OF EXCIPIENTS</b></p>
<p style="position:absolute;top:445px;left:106px;white-space:nowrap" class="ft2774">Excipients: mannitol, citric acid monohydrate, sodium citrate, sodium dihydrogen phosphate dihydrate,&#160;<br/>disodium phosphate dihydrate, sodium chloride, polysorbate&#160;80, sodium hydroxide and water for&#160;<br/>injections. See leaflet for further information.</p>
<p style="position:absolute;top:543px;left:106px;white-space:nowrap" class="ft2771"><b>4.</b></p>
<p style="position:absolute;top:543px;left:148px;white-space:nowrap" class="ft2771"><b>PHARMACEUTICAL FORM AND CONTENTS</b></p>
<p style="position:absolute;top:583px;left:106px;white-space:nowrap" class="ft2775">Solution for injection<br/>1 vial&#160;<br/>1 sterile injection syringe&#160;<br/>1 sterile needle<br/>1 sterile vial adapter<br/>2 alcohol pads&#160;</p>
<p style="position:absolute;top:737px;left:106px;white-space:nowrap" class="ft2771"><b>5.</b></p>
<p style="position:absolute;top:737px;left:148px;white-space:nowrap" class="ft2771"><b>METHOD AND ROUTE&#160;OF ADMINISTRATION</b></p>
<p style="position:absolute;top:777px;left:106px;white-space:nowrap" class="ft2772">Subcutaneous use</p>
<p style="position:absolute;top:815px;left:106px;white-space:nowrap" class="ft2772">Read the package leaflet before use.</p>
<p style="position:absolute;top:853px;left:106px;white-space:nowrap" class="ft2772">For single use only.&#160;</p>
<p style="position:absolute;top:891px;left:106px;white-space:nowrap" class="ft2772">For paediatric use</p>
<p style="position:absolute;top:950px;left:106px;white-space:nowrap" class="ft2771"><b>6.</b></p>
<p style="position:absolute;top:950px;left:148px;white-space:nowrap" class="ft27719"><b>SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED&#160;OUT OF&#160;<br/>THE SIGHT AND REACH&#160;OF CHILDREN</b></p>
<p style="position:absolute;top:1009px;left:106px;white-space:nowrap" class="ft2772">Keep out of the sight and reach of children.</p>
<p style="position:absolute;top:1068px;left:106px;white-space:nowrap" class="ft2771"><b>7.</b></p>
<p style="position:absolute;top:1068px;left:148px;white-space:nowrap" class="ft2771"><b>OTHER&#160;SPECIAL WARNING, IF&#160;NECESSARY</b></p>
</div>
<!-- Page 278 -->
<a name="278"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page278-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2780">278</p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft2781"><b>8.</b></p>
<p style="position:absolute;top:126px;left:148px;white-space:nowrap" class="ft2781"><b>EXPIRY DATE</b></p>
<p style="position:absolute;top:166px;left:106px;white-space:nowrap" class="ft2782">EXP</p>
<p style="position:absolute;top:226px;left:106px;white-space:nowrap" class="ft2781"><b>9.</b></p>
<p style="position:absolute;top:226px;left:148px;white-space:nowrap" class="ft2781"><b>SPECIAL STORAGE CONDITIONS</b></p>
<p style="position:absolute;top:266px;left:106px;white-space:nowrap" class="ft2784">Store in a refrigerator. Do not freeze.<br/>Keep the vial in the outer carton in order to protect from light.</p>
<p style="position:absolute;top:344px;left:106px;white-space:nowrap" class="ft2781"><b>10.</b></p>
<p style="position:absolute;top:344px;left:148px;white-space:nowrap" class="ft27819"><b>SPECIAL PRECAUTIONS FOR DISPOSAL OF&#160;UNUSED MEDICINAL&#160;PRODUCTS OR&#160;<br/>WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF&#160;<br/>APPROPRIATE</b></p>
<p style="position:absolute;top:443px;left:106px;white-space:nowrap" class="ft2781"><b>11.</b></p>
<p style="position:absolute;top:443px;left:148px;white-space:nowrap" class="ft2781"><b>NAME AND ADDRESS&#160;OF THE MARKETING AUTHORISATION HOLDER</b></p>
<p style="position:absolute;top:483px;left:106px;white-space:nowrap" class="ft2784">AbbVie Deutschland GmbH &amp; Co. KG<br/>Knollstrasse<br/>67061 Ludwigshafen<br/>Germany</p>
<p style="position:absolute;top:599px;left:106px;white-space:nowrap" class="ft2781"><b>12.</b></p>
<p style="position:absolute;top:599px;left:148px;white-space:nowrap" class="ft2781"><b>MARKETING AUTHORISATION NUMBER</b></p>
<p style="position:absolute;top:640px;left:106px;white-space:nowrap" class="ft2782">EU/1/03/256/001</p>
<p style="position:absolute;top:699px;left:106px;white-space:nowrap" class="ft2781"><b>13.</b></p>
<p style="position:absolute;top:699px;left:148px;white-space:nowrap" class="ft2781"><b>BATCH NUMBER</b></p>
<p style="position:absolute;top:739px;left:106px;white-space:nowrap" class="ft2782">Lot&#160;</p>
<p style="position:absolute;top:798px;left:106px;white-space:nowrap" class="ft2781"><b>14.</b></p>
<p style="position:absolute;top:798px;left:148px;white-space:nowrap" class="ft2781"><b>GENERAL CLASSIFICATION FOR SUPPLY</b></p>
<p style="position:absolute;top:860px;left:106px;white-space:nowrap" class="ft2781"><b>15.</b></p>
<p style="position:absolute;top:860px;left:148px;white-space:nowrap" class="ft2781"><b>INSTRUCTIONS ON&#160;USE</b></p>
<p style="position:absolute;top:921px;left:106px;white-space:nowrap" class="ft2781"><b>16.</b></p>
<p style="position:absolute;top:921px;left:148px;white-space:nowrap" class="ft2781"><b>INFORMATION IN BRAILLE</b></p>
<p style="position:absolute;top:961px;left:106px;white-space:nowrap" class="ft2782">Humira 40&#160;mg</p>
<p style="position:absolute;top:1021px;left:106px;white-space:nowrap" class="ft2781"><b>17.&#160;&#160;UNIQUE INDENTIFIER&#160;–&#160;2D BARCODE</b></p>
</div>
<!-- Page 279 -->
<a name="279"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page279-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2790">279</p>
<p style="position:absolute;top:88px;left:106px;white-space:nowrap" class="ft2791"><b>18.&#160;&#160;UNIQUE INDENTIFIER&#160;–&#160;HUMAN READABLE&#160;DATA</b></p>
</div>
<!-- Page 280 -->
<a name="280"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page280-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2800">280</p>
<p style="position:absolute;top:88px;left:106px;white-space:nowrap" class="ft2801"><b>MINIMUM&#160;PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</b></p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft2801"><b>VIAL LABEL</b></p>
<p style="position:absolute;top:188px;left:106px;white-space:nowrap" class="ft2801"><b>1.</b></p>
<p style="position:absolute;top:188px;left:148px;white-space:nowrap" class="ft2801"><b>NAME OF THE MEDICINAL PRODUCT AND ROUTE OF ADMINISTRATION</b></p>
<p style="position:absolute;top:228px;left:106px;white-space:nowrap" class="ft2804">Humira 40&#160;mg/0.8&#160;ml injection<br/>adalimumab<br/>SC</p>
<p style="position:absolute;top:325px;left:106px;white-space:nowrap" class="ft2801"><b>2.</b></p>
<p style="position:absolute;top:325px;left:148px;white-space:nowrap" class="ft2801"><b>METHOD OF ADMINISTRATION</b></p>
<p style="position:absolute;top:386px;left:106px;white-space:nowrap" class="ft2801"><b>3.</b></p>
<p style="position:absolute;top:386px;left:148px;white-space:nowrap" class="ft2801"><b>EXPIRY DATE</b></p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft2802">EXP</p>
<p style="position:absolute;top:486px;left:106px;white-space:nowrap" class="ft2801"><b>4.</b></p>
<p style="position:absolute;top:486px;left:148px;white-space:nowrap" class="ft2801"><b>BATCH NUMBER</b></p>
<p style="position:absolute;top:526px;left:106px;white-space:nowrap" class="ft2802">Lot&#160;</p>
<p style="position:absolute;top:585px;left:106px;white-space:nowrap" class="ft2801"><b>5.</b></p>
<p style="position:absolute;top:585px;left:148px;white-space:nowrap" class="ft2801"><b>CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT</b></p>
<p style="position:absolute;top:625px;left:106px;white-space:nowrap" class="ft2802">40&#160;mg/0.8&#160;ml</p>
<p style="position:absolute;top:684px;left:122px;white-space:nowrap" class="ft2801"><b>6. OTHER</b></p>
<p style="position:absolute;top:725px;left:106px;white-space:nowrap" class="ft2802">For single use only</p>
</div>
<!-- Page 281 -->
<a name="281"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page281-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2810">281</p>
<p style="position:absolute;top:88px;left:106px;white-space:nowrap" class="ft2811"><b>PARTICULARS TO APPEAR ON THE OUTER PACKAGING&#160;</b></p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft2811"><b>OUTER CARTON</b></p>
<p style="position:absolute;top:188px;left:106px;white-space:nowrap" class="ft2811"><b>1.</b></p>
<p style="position:absolute;top:188px;left:148px;white-space:nowrap" class="ft2811"><b>NAME OF THE MEDICINAL PRODUCT</b></p>
<p style="position:absolute;top:228px;left:106px;white-space:nowrap" class="ft2815">Humira 40&#160;mg solution for injection in pre-filled syringe&#160;<br/>adalimumab</p>
<p style="position:absolute;top:306px;left:106px;white-space:nowrap" class="ft2811"><b>2.</b></p>
<p style="position:absolute;top:306px;left:148px;white-space:nowrap" class="ft2811"><b>STATEMENT OF ACTIVE SUBSTANCE</b></p>
<p style="position:absolute;top:346px;left:106px;white-space:nowrap" class="ft2812">One 0.8&#160;ml pre-filled syringe contains 40&#160;mg adalimumab.</p>
<p style="position:absolute;top:405px;left:106px;white-space:nowrap" class="ft2811"><b>3.</b></p>
<p style="position:absolute;top:405px;left:148px;white-space:nowrap" class="ft2811"><b>LIST OF EXCIPIENTS</b></p>
<p style="position:absolute;top:445px;left:106px;white-space:nowrap" class="ft2814">Excipients: &#160;mannitol, citric acid monohydrate, sodium citrate, sodium dihydrogen phosphate dihydrate,&#160;<br/>disodium phosphate dihydrate, sodium chloride, polysorbate&#160;80, sodium hydroxide and water for&#160;<br/>injections. See leaflet for further information.</p>
<p style="position:absolute;top:543px;left:106px;white-space:nowrap" class="ft2811"><b>4.</b></p>
<p style="position:absolute;top:543px;left:148px;white-space:nowrap" class="ft2811"><b>PHARMACEUTICAL FORM AND CONTENTS</b></p>
<p style="position:absolute;top:583px;left:106px;white-space:nowrap" class="ft2815">Solution for injection<br/>1 pre-filled syringe<br/>1 alcohol pad</p>
<p style="position:absolute;top:659px;left:106px;white-space:nowrap" class="ft2815">2 pre-filled syringes<br/>2 alcohol pads&#160;</p>
<p style="position:absolute;top:716px;left:106px;white-space:nowrap" class="ft2814">4 pre-filled syringes<br/>4 alcohol pads&#160;</p>
<p style="position:absolute;top:773px;left:106px;white-space:nowrap" class="ft2814">6 pre-filled syringes<br/>6 alcohol pads</p>
<p style="position:absolute;top:851px;left:106px;white-space:nowrap" class="ft2811"><b>5.</b></p>
<p style="position:absolute;top:851px;left:148px;white-space:nowrap" class="ft2811"><b>METHOD AND ROUTE&#160;OF ADMINISTRATION</b></p>
<p style="position:absolute;top:891px;left:106px;white-space:nowrap" class="ft2812">Subcutaneous use</p>
<p style="position:absolute;top:929px;left:106px;white-space:nowrap" class="ft2812">Read the package leaflet before use.</p>
<p style="position:absolute;top:967px;left:106px;white-space:nowrap" class="ft2812">For single use only.</p>
</div>
<!-- Page 282 -->
<a name="282"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page282-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2820">282</p>
<p style="position:absolute;top:88px;left:106px;white-space:nowrap" class="ft2821"><b>6.</b></p>
<p style="position:absolute;top:88px;left:147px;white-space:nowrap" class="ft28219"><b>SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE&#160;STORED OUT OF&#160;<br/>THE SIGHT AND REACH&#160;OF CHILDREN</b></p>
<p style="position:absolute;top:147px;left:106px;white-space:nowrap" class="ft2822">Keep out of the sight and reach of children.</p>
<p style="position:absolute;top:207px;left:106px;white-space:nowrap" class="ft2821"><b>7.</b></p>
<p style="position:absolute;top:207px;left:148px;white-space:nowrap" class="ft2821"><b>OTHER SPECIAL WARNING, IF NECESSARY</b></p>
<p style="position:absolute;top:268px;left:106px;white-space:nowrap" class="ft2821"><b>8.</b></p>
<p style="position:absolute;top:268px;left:148px;white-space:nowrap" class="ft2821"><b>EXPIRY DATE</b></p>
<p style="position:absolute;top:308px;left:106px;white-space:nowrap" class="ft2822">EXP</p>
<p style="position:absolute;top:367px;left:106px;white-space:nowrap" class="ft2821"><b>9.</b></p>
<p style="position:absolute;top:367px;left:148px;white-space:nowrap" class="ft2821"><b>SPECIAL STORAGE CONDITIONS</b></p>
<p style="position:absolute;top:408px;left:106px;white-space:nowrap" class="ft2824">Store in a refrigerator. Do not freeze.<br/>Refer to package leaflet for&#160;alternative storage details.</p>
<p style="position:absolute;top:464px;left:106px;white-space:nowrap" class="ft2822">Keep the syringe in the outer carton in order to protect from light.</p>
<p style="position:absolute;top:524px;left:106px;white-space:nowrap" class="ft2821"><b>10.</b></p>
<p style="position:absolute;top:524px;left:148px;white-space:nowrap" class="ft28219"><b>SPECIAL PRECAUTIONS FOR DISPOSAL OF&#160;UNUSED MEDICINAL PRODUCTS OR&#160;<br/>WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF&#160;<br/>APPROPRIATE</b></p>
<p style="position:absolute;top:623px;left:106px;white-space:nowrap" class="ft2821"><b>11.</b></p>
<p style="position:absolute;top:623px;left:148px;white-space:nowrap" class="ft2821"><b>NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</b></p>
<p style="position:absolute;top:663px;left:106px;white-space:nowrap" class="ft2825">AbbVie Deutschland GmbH &amp; Co. KG<br/>Knollstrasse<br/>67061 Ludwigshafen<br/>Germany&#160;</p>
<p style="position:absolute;top:779px;left:106px;white-space:nowrap" class="ft2821"><b>12.</b></p>
<p style="position:absolute;top:779px;left:148px;white-space:nowrap" class="ft2821"><b>MARKETING AUTHORISATION NUMBER</b></p>
<p style="position:absolute;top:819px;left:106px;white-space:nowrap" class="ft2825">EU/1/03/256/002<br/>EU/1/03/256/003<br/>EU/1/03/256/004<br/>EU/1/03/256/005</p>
<p style="position:absolute;top:936px;left:106px;white-space:nowrap" class="ft2821"><b>13.</b></p>
<p style="position:absolute;top:936px;left:148px;white-space:nowrap" class="ft2821"><b>BATCH NUMBER</b></p>
<p style="position:absolute;top:976px;left:106px;white-space:nowrap" class="ft2822">Lot&#160;</p>
<p style="position:absolute;top:1035px;left:106px;white-space:nowrap" class="ft2821"><b>14.</b></p>
<p style="position:absolute;top:1035px;left:148px;white-space:nowrap" class="ft2821"><b>GENERAL CLASSIFICATION FOR SUPPLY</b></p>
</div>
<!-- Page 283 -->
<a name="283"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page283-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2830">283</p>
<p style="position:absolute;top:88px;left:106px;white-space:nowrap" class="ft2831"><b>15.</b></p>
<p style="position:absolute;top:88px;left:148px;white-space:nowrap" class="ft2831"><b>INSTRUCTIONS ON&#160;USE</b></p>
<p style="position:absolute;top:150px;left:106px;white-space:nowrap" class="ft2831"><b>16.</b></p>
<p style="position:absolute;top:150px;left:148px;white-space:nowrap" class="ft2831"><b>INFORMATION IN BRAILLE</b></p>
<p style="position:absolute;top:190px;left:106px;white-space:nowrap" class="ft2832">Humira 40&#160;mg</p>
<p style="position:absolute;top:249px;left:106px;white-space:nowrap" class="ft2831"><b>17.&#160;&#160;UNIQUE INDENTIFIER&#160;–&#160;2D BARCODE</b></p>
<p style="position:absolute;top:289px;left:106px;white-space:nowrap" class="ft2832">2D barcode carrying the unique identifier included.</p>
<p style="position:absolute;top:348px;left:106px;white-space:nowrap" class="ft2831"><b>18.&#160;&#160;UNIQUE INDENTIFIER&#160;–&#160;HUMAN READABLE&#160;DATA</b></p>
<p style="position:absolute;top:388px;left:106px;white-space:nowrap" class="ft2834">PC<br/>SN<br/>NN</p>
</div>
<!-- Page 284 -->
<a name="284"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page284-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2840">284</p>
<p style="position:absolute;top:88px;left:106px;white-space:nowrap" class="ft2841"><b>MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</b></p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft2841"><b>TRAY BACKING TEXT</b></p>
<p style="position:absolute;top:188px;left:106px;white-space:nowrap" class="ft2841"><b>1.</b></p>
<p style="position:absolute;top:188px;left:148px;white-space:nowrap" class="ft2841"><b>NAME OF THE MEDICINAL PRODUCT</b></p>
<p style="position:absolute;top:228px;left:106px;white-space:nowrap" class="ft2845">Humira 40&#160;mg solution for injection in pre-filled syringe<br/>adalimumab</p>
<p style="position:absolute;top:306px;left:106px;white-space:nowrap" class="ft2841"><b>2.</b></p>
<p style="position:absolute;top:306px;left:148px;white-space:nowrap" class="ft2841"><b>NAME OF THE MARKETING AUTHORISATION HOLDER</b></p>
<p style="position:absolute;top:346px;left:106px;white-space:nowrap" class="ft2842">AbbVie&#160;(as logo)</p>
<p style="position:absolute;top:405px;left:106px;white-space:nowrap" class="ft2841"><b>3.</b></p>
<p style="position:absolute;top:405px;left:148px;white-space:nowrap" class="ft2841"><b>EXPIRY&#160;DATE</b></p>
<p style="position:absolute;top:445px;left:106px;white-space:nowrap" class="ft2842">EXP</p>
<p style="position:absolute;top:505px;left:106px;white-space:nowrap" class="ft2841"><b>4.</b></p>
<p style="position:absolute;top:505px;left:148px;white-space:nowrap" class="ft2841"><b>BATCH NUMBER</b></p>
<p style="position:absolute;top:545px;left:106px;white-space:nowrap" class="ft2842">Lot&#160;</p>
<p style="position:absolute;top:604px;left:106px;white-space:nowrap" class="ft2841"><b>5.</b></p>
<p style="position:absolute;top:604px;left:148px;white-space:nowrap" class="ft2841"><b>OTHER</b></p>
<p style="position:absolute;top:644px;left:106px;white-space:nowrap" class="ft2842">For storage information, see package leaflet.</p>
<p style="position:absolute;top:682px;left:106px;white-space:nowrap" class="ft2842">For single use only.</p>
</div>
<!-- Page 285 -->
<a name="285"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page285-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2850">285</p>
<p style="position:absolute;top:88px;left:106px;white-space:nowrap" class="ft2851"><b>MINIMUM PARTICULARS&#160;TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</b></p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft2851"><b>SYRINGE LABEL</b></p>
<p style="position:absolute;top:188px;left:106px;white-space:nowrap" class="ft2851"><b>1.</b></p>
<p style="position:absolute;top:188px;left:148px;white-space:nowrap" class="ft2851"><b>NAME OF THE MEDICINAL PRODUCT AND ROUTE OF&#160;ADMINISTRATION</b></p>
<p style="position:absolute;top:228px;left:106px;white-space:nowrap" class="ft2854">Humira 40&#160;mg injection<br/>adalimumab<br/>SC</p>
<p style="position:absolute;top:325px;left:106px;white-space:nowrap" class="ft2851"><b>2.</b></p>
<p style="position:absolute;top:325px;left:148px;white-space:nowrap" class="ft2851"><b>METHOD OF ADMINISTRATION</b></p>
<p style="position:absolute;top:386px;left:106px;white-space:nowrap" class="ft2851"><b>3.</b></p>
<p style="position:absolute;top:386px;left:148px;white-space:nowrap" class="ft2851"><b>EXPIRY DATE</b></p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft2852">EXP</p>
<p style="position:absolute;top:486px;left:106px;white-space:nowrap" class="ft2851"><b>4.</b></p>
<p style="position:absolute;top:486px;left:148px;white-space:nowrap" class="ft2851"><b>BATCH NUMBER</b></p>
<p style="position:absolute;top:526px;left:106px;white-space:nowrap" class="ft2852">Lot&#160;</p>
<p style="position:absolute;top:585px;left:106px;white-space:nowrap" class="ft2851"><b>5.</b></p>
<p style="position:absolute;top:585px;left:148px;white-space:nowrap" class="ft2851"><b>CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT</b></p>
<p style="position:absolute;top:625px;left:106px;white-space:nowrap" class="ft2852">40&#160;mg/0.8&#160;ml</p>
<p style="position:absolute;top:684px;left:106px;white-space:nowrap" class="ft2851"><b>6.</b></p>
<p style="position:absolute;top:684px;left:148px;white-space:nowrap" class="ft2851"><b>OTHER</b></p>
</div>
<!-- Page 286 -->
<a name="286"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page286-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2860">286</p>
<p style="position:absolute;top:88px;left:106px;white-space:nowrap" class="ft28619"><b>PARTICULARS TO APPEAR ON THE OUTER PACKAGING OR,&#160;WHERE THERE IS NO&#160;<br/>OUTER PACKAGING, ON&#160;THE IMMEDIATE PACKAGING</b></p>
<p style="position:absolute;top:145px;left:106px;white-space:nowrap" class="ft2861"><b>OUTER CARTON</b></p>
<p style="position:absolute;top:207px;left:106px;white-space:nowrap" class="ft2861"><b>1.</b></p>
<p style="position:absolute;top:207px;left:148px;white-space:nowrap" class="ft2861"><b>NAME OF THE MEDICINAL PRODUCT</b></p>
<p style="position:absolute;top:247px;left:106px;white-space:nowrap" class="ft2864">Humira 40&#160;mg solution for injection in pre-filled syringe<br/>adalimumab</p>
<p style="position:absolute;top:325px;left:106px;white-space:nowrap" class="ft2861"><b>2.</b></p>
<p style="position:absolute;top:325px;left:148px;white-space:nowrap" class="ft2861"><b>STATEMENT OF ACTIVE SUBSTANCE</b></p>
<p style="position:absolute;top:365px;left:106px;white-space:nowrap" class="ft2862">One 0.8&#160;ml pre-filled syringe with&#160;needle&#160;guard contains 40&#160;mg adalimumab.</p>
<p style="position:absolute;top:424px;left:106px;white-space:nowrap" class="ft2861"><b>3.</b></p>
<p style="position:absolute;top:424px;left:148px;white-space:nowrap" class="ft2861"><b>LIST OF EXCIPIENTS</b></p>
<p style="position:absolute;top:464px;left:106px;white-space:nowrap" class="ft2864">Excipients: mannitol, citric acid monohydrate, sodium citrate, sodium dihydrogen phosphate dihydrate,&#160;<br/>disodium phosphate dihydrate, sodium chloride, polysorbate&#160;80, sodium hydroxide and water&#160;for&#160;<br/>injections. See leaflet for further information.</p>
<p style="position:absolute;top:562px;left:106px;white-space:nowrap" class="ft2861"><b>4.</b></p>
<p style="position:absolute;top:562px;left:148px;white-space:nowrap" class="ft2861"><b>PHARMACEUTICAL FORM AND CONTENTS</b></p>
<p style="position:absolute;top:602px;left:106px;white-space:nowrap" class="ft2864">Solution for injection<br/>1 pre-filled syringe<br/>1 alcohol pad</p>
<p style="position:absolute;top:699px;left:106px;white-space:nowrap" class="ft2861"><b>5.</b></p>
<p style="position:absolute;top:699px;left:148px;white-space:nowrap" class="ft2861"><b>METHOD AND ROUTE&#160;OF ADMINISTRATION</b></p>
<p style="position:absolute;top:739px;left:106px;white-space:nowrap" class="ft2862">Subcutaneous use</p>
<p style="position:absolute;top:777px;left:106px;white-space:nowrap" class="ft2862">Read the package leaflet before use.</p>
<p style="position:absolute;top:815px;left:106px;white-space:nowrap" class="ft2862">For&#160;single use only.</p>
<p style="position:absolute;top:853px;left:106px;white-space:nowrap" class="ft2862">With needle&#160;guard.</p>
<p style="position:absolute;top:912px;left:106px;white-space:nowrap" class="ft2861"><b>6.</b></p>
<p style="position:absolute;top:912px;left:147px;white-space:nowrap" class="ft28619"><b>SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED&#160;OUT OF&#160;<br/>THE SIGHT AND REACH&#160;OF CHILDREN</b></p>
<p style="position:absolute;top:971px;left:106px;white-space:nowrap" class="ft2862">Keep out of the sight and reach of children.</p>
<p style="position:absolute;top:1030px;left:106px;white-space:nowrap" class="ft2861"><b>7.</b></p>
<p style="position:absolute;top:1030px;left:148px;white-space:nowrap" class="ft2861"><b>OTHER SPECIAL WARNING, IF NECESSARY</b></p>
</div>
<!-- Page 287 -->
<a name="287"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page287-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2870">287</p>
<p style="position:absolute;top:88px;left:106px;white-space:nowrap" class="ft2871"><b>8.</b></p>
<p style="position:absolute;top:88px;left:148px;white-space:nowrap" class="ft2871"><b>EXPIRY DATE</b></p>
<p style="position:absolute;top:129px;left:106px;white-space:nowrap" class="ft2872">EXP</p>
<p style="position:absolute;top:188px;left:106px;white-space:nowrap" class="ft2871"><b>9.</b></p>
<p style="position:absolute;top:188px;left:148px;white-space:nowrap" class="ft2871"><b>SPECIAL STORAGE CONDITIONS</b></p>
<p style="position:absolute;top:228px;left:106px;white-space:nowrap" class="ft2875">Store in a refrigerator. Do not freeze.&#160;<br/>Refer to package leaflet for alternative storage details.</p>
<p style="position:absolute;top:285px;left:106px;white-space:nowrap" class="ft2872">Keep the syringe in the outer carton in order to protect from light.</p>
<p style="position:absolute;top:344px;left:106px;white-space:nowrap" class="ft2871"><b>10.</b></p>
<p style="position:absolute;top:344px;left:148px;white-space:nowrap" class="ft28719"><b>SPECIAL PRECAUTIONS FOR DISPOSAL OF&#160;UNUSED MEDICINAL&#160;PRODUCTS OR&#160;<br/>WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF&#160;<br/>APPROPRIATE</b></p>
<p style="position:absolute;top:443px;left:106px;white-space:nowrap" class="ft2871"><b>11.</b></p>
<p style="position:absolute;top:443px;left:148px;white-space:nowrap" class="ft2871"><b>NAME AND ADDRESS&#160;OF THE MARKETING AUTHORISATION HOLDER</b></p>
<p style="position:absolute;top:483px;left:106px;white-space:nowrap" class="ft2874">AbbVie Deutschland GmbH &amp; Co. KG<br/>Knollstrasse<br/>67061 Ludwigshafen<br/>Germany</p>
<p style="position:absolute;top:599px;left:106px;white-space:nowrap" class="ft2871"><b>12.</b></p>
<p style="position:absolute;top:599px;left:148px;white-space:nowrap" class="ft2871"><b>MARKETING AUTHORISATION NUMBER</b></p>
<p style="position:absolute;top:640px;left:106px;white-space:nowrap" class="ft2872">EU/1/03/256/006</p>
<p style="position:absolute;top:699px;left:106px;white-space:nowrap" class="ft2871"><b>13.</b></p>
<p style="position:absolute;top:699px;left:148px;white-space:nowrap" class="ft2871"><b>BATCH NUMBER</b></p>
<p style="position:absolute;top:739px;left:106px;white-space:nowrap" class="ft2872">Lot&#160;</p>
<p style="position:absolute;top:798px;left:106px;white-space:nowrap" class="ft2871"><b>14.</b></p>
<p style="position:absolute;top:798px;left:148px;white-space:nowrap" class="ft2871"><b>GENERAL CLASSIFICATION FOR SUPPLY</b></p>
<p style="position:absolute;top:860px;left:106px;white-space:nowrap" class="ft2871"><b>15.</b></p>
<p style="position:absolute;top:860px;left:148px;white-space:nowrap" class="ft2871"><b>INSTRUCTIONS ON&#160;USE</b></p>
<p style="position:absolute;top:921px;left:106px;white-space:nowrap" class="ft2871"><b>16.</b></p>
<p style="position:absolute;top:921px;left:148px;white-space:nowrap" class="ft2871"><b>INFORMATION IN BRAILLE</b></p>
<p style="position:absolute;top:961px;left:106px;white-space:nowrap" class="ft2872">Humira 40&#160;mg</p>
<p style="position:absolute;top:1021px;left:106px;white-space:nowrap" class="ft2871"><b>17.&#160;&#160;UNIQUE INDENTIFIER&#160;–&#160;2D BARCODE</b></p>
<p style="position:absolute;top:1061px;left:106px;white-space:nowrap" class="ft2872">2D barcode carrying the unique identifier included.</p>
</div>
<!-- Page 288 -->
<a name="288"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page288-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2880">288</p>
<p style="position:absolute;top:107px;left:106px;white-space:nowrap" class="ft2881"><b>18.&#160;&#160;UNIQUE&#160;INDENTIFIER&#160;–&#160;HUMAN&#160;READABLE DATA</b></p>
<p style="position:absolute;top:147px;left:106px;white-space:nowrap" class="ft2884">PC<br/>SN<br/>NN</p>
</div>
<!-- Page 289 -->
<a name="289"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page289-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2890">289</p>
<p style="position:absolute;top:88px;left:106px;white-space:nowrap" class="ft2891"><b>MINIMUM PARTICULARS&#160;TO APPEAR ON BLISTERS OR STRIPS</b></p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft2891"><b>TRAY BACKING TEXT</b></p>
<p style="position:absolute;top:188px;left:106px;white-space:nowrap" class="ft2891"><b>1.</b></p>
<p style="position:absolute;top:188px;left:148px;white-space:nowrap" class="ft2891"><b>NAME OF THE MEDICINAL PRODUCT</b></p>
<p style="position:absolute;top:228px;left:106px;white-space:nowrap" class="ft2895">Humira 40&#160;mg solution for injection in pre-filled syringe<br/>adalimumab</p>
<p style="position:absolute;top:306px;left:106px;white-space:nowrap" class="ft2891"><b>2.</b></p>
<p style="position:absolute;top:306px;left:148px;white-space:nowrap" class="ft2891"><b>NAME OF THE MARKETING&#160;AUTHORISATION HOLDER</b></p>
<p style="position:absolute;top:346px;left:106px;white-space:nowrap" class="ft2892">AbbVie&#160;(as logo)</p>
<p style="position:absolute;top:405px;left:106px;white-space:nowrap" class="ft2891"><b>3.</b></p>
<p style="position:absolute;top:405px;left:148px;white-space:nowrap" class="ft2891"><b>EXPIRY DATE</b></p>
<p style="position:absolute;top:445px;left:106px;white-space:nowrap" class="ft2892">EXP</p>
<p style="position:absolute;top:505px;left:106px;white-space:nowrap" class="ft2891"><b>4.</b></p>
<p style="position:absolute;top:505px;left:148px;white-space:nowrap" class="ft2891"><b>BATCH NUMBER</b></p>
<p style="position:absolute;top:545px;left:106px;white-space:nowrap" class="ft2892">Lot&#160;</p>
<p style="position:absolute;top:604px;left:106px;white-space:nowrap" class="ft2891"><b>5.</b></p>
<p style="position:absolute;top:604px;left:148px;white-space:nowrap" class="ft2891"><b>OTHER</b></p>
<p style="position:absolute;top:644px;left:106px;white-space:nowrap" class="ft2892">For storage information, see package leaflet.</p>
<p style="position:absolute;top:682px;left:106px;white-space:nowrap" class="ft2892">For single use only.</p>
<p style="position:absolute;top:720px;left:106px;white-space:nowrap" class="ft2892">With needle&#160;guard.</p>
</div>
<!-- Page 290 -->
<a name="290"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page290-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2900">290</p>
<p style="position:absolute;top:88px;left:106px;white-space:nowrap" class="ft2901"><b>MINIMUM PARTICULARS&#160;TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</b></p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft2901"><b>SYRINGE LABEL</b></p>
<p style="position:absolute;top:188px;left:106px;white-space:nowrap" class="ft2901"><b>1.</b></p>
<p style="position:absolute;top:188px;left:148px;white-space:nowrap" class="ft2901"><b>NAME OF THE MEDICINAL PRODUCT AND ROUTE OF ADMINISTRATION</b></p>
<p style="position:absolute;top:228px;left:106px;white-space:nowrap" class="ft2904">Humira 40&#160;mg injection&#160;<br/>adalimumab<br/>SC</p>
<p style="position:absolute;top:325px;left:106px;white-space:nowrap" class="ft2901"><b>2.</b></p>
<p style="position:absolute;top:325px;left:148px;white-space:nowrap" class="ft2901"><b>METHOD OF ADMINISTRATION</b></p>
<p style="position:absolute;top:386px;left:106px;white-space:nowrap" class="ft2901"><b>3.</b></p>
<p style="position:absolute;top:386px;left:148px;white-space:nowrap" class="ft2901"><b>EXPIRY DATE</b></p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft2902">EXP</p>
<p style="position:absolute;top:486px;left:106px;white-space:nowrap" class="ft2901"><b>4.</b></p>
<p style="position:absolute;top:486px;left:148px;white-space:nowrap" class="ft2901"><b>BATCH NUMBER</b></p>
<p style="position:absolute;top:526px;left:106px;white-space:nowrap" class="ft2902">Lot&#160;</p>
<p style="position:absolute;top:585px;left:106px;white-space:nowrap" class="ft2901"><b>5.</b></p>
<p style="position:absolute;top:585px;left:148px;white-space:nowrap" class="ft2901"><b>CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT</b></p>
<p style="position:absolute;top:625px;left:106px;white-space:nowrap" class="ft2902">40&#160;mg/0.8&#160;ml</p>
<p style="position:absolute;top:684px;left:106px;white-space:nowrap" class="ft2901"><b>6.</b></p>
<p style="position:absolute;top:684px;left:148px;white-space:nowrap" class="ft2901"><b>OTHER</b></p>
</div>
<!-- Page 291 -->
<a name="291"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page291-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2910">291</p>
<p style="position:absolute;top:88px;left:106px;white-space:nowrap" class="ft2911"><b>PARTICULARS TO APPEAR ON THE OUTER PACKAGING&#160;</b></p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft2911"><b>OUTER CARTON</b></p>
<p style="position:absolute;top:188px;left:106px;white-space:nowrap" class="ft2911"><b>1.</b></p>
<p style="position:absolute;top:188px;left:148px;white-space:nowrap" class="ft2911"><b>NAME OF THE MEDICINAL PRODUCT</b></p>
<p style="position:absolute;top:228px;left:106px;white-space:nowrap" class="ft2915">Humira 40&#160;mg solution for injection in pre-filled pen<br/>adalimumab</p>
<p style="position:absolute;top:306px;left:106px;white-space:nowrap" class="ft2911"><b>2.</b></p>
<p style="position:absolute;top:306px;left:148px;white-space:nowrap" class="ft2911"><b>STATEMENT OF ACTIVE SUBSTANCE</b></p>
<p style="position:absolute;top:346px;left:106px;white-space:nowrap" class="ft2912">One 0.8&#160;ml pre-filled pen contains 40&#160;mg&#160;adalimumab.</p>
<p style="position:absolute;top:405px;left:106px;white-space:nowrap" class="ft2911"><b>3.</b></p>
<p style="position:absolute;top:405px;left:148px;white-space:nowrap" class="ft2911"><b>LIST OF EXCIPIENTS</b></p>
<p style="position:absolute;top:445px;left:106px;white-space:nowrap" class="ft2914">Excipients: mannitol, citric acid monohydrate, sodium citrate, sodium dihydrogen phosphate dihydrate,&#160;<br/>disodium phosphate dihydrate, sodium chloride, polysorbate&#160;80, sodium hydroxide and water for&#160;<br/>injections. See leaflet&#160;for further information.</p>
<p style="position:absolute;top:543px;left:106px;white-space:nowrap" class="ft2911"><b>4.</b></p>
<p style="position:absolute;top:543px;left:148px;white-space:nowrap" class="ft2911"><b>PHARMACEUTICAL FORM AND CONTENTS</b></p>
<p style="position:absolute;top:581px;left:106px;white-space:nowrap" class="ft2915">Solution for injection<br/>1 pre-filled pen<br/>2 alcohol pads&#160;</p>
<p style="position:absolute;top:657px;left:106px;white-space:nowrap" class="ft2914">2 pre-filled pens<br/>2 alcohol pads&#160;</p>
<p style="position:absolute;top:714px;left:106px;white-space:nowrap" class="ft2914">4 pre-filled pens<br/>4 alcohol pads&#160;</p>
<p style="position:absolute;top:771px;left:106px;white-space:nowrap" class="ft2914">6 pre-filled pens<br/>6 alcohol pads</p>
<p style="position:absolute;top:849px;left:106px;white-space:nowrap" class="ft2911"><b>5.</b></p>
<p style="position:absolute;top:849px;left:148px;white-space:nowrap" class="ft2911"><b>METHOD AND ROUTE&#160;OF&#160;ADMINISTRATION</b></p>
<p style="position:absolute;top:889px;left:106px;white-space:nowrap" class="ft2912">Subcutaneous use</p>
<p style="position:absolute;top:927px;left:106px;white-space:nowrap" class="ft2912">Read the package leaflet before use.</p>
<p style="position:absolute;top:965px;left:106px;white-space:nowrap" class="ft2912">For single use only.</p>
<p style="position:absolute;top:1024px;left:106px;white-space:nowrap" class="ft2911"><b>6.</b></p>
<p style="position:absolute;top:1024px;left:147px;white-space:nowrap" class="ft29119"><b>SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED&#160;OUT OF&#160;<br/>THE SIGHT AND REACH&#160;OF CHILDREN</b></p>
<p style="position:absolute;top:1083px;left:106px;white-space:nowrap" class="ft2912">Keep out of the sight and reach of children.</p>
</div>
<!-- Page 292 -->
<a name="292"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page292-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2920">292</p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft2921"><b>7.</b></p>
<p style="position:absolute;top:126px;left:148px;white-space:nowrap" class="ft2921"><b>OTHER&#160;SPECIAL WARNING, IF&#160;NECESSARY</b></p>
<p style="position:absolute;top:188px;left:106px;white-space:nowrap" class="ft2921"><b>8.</b></p>
<p style="position:absolute;top:188px;left:148px;white-space:nowrap" class="ft2921"><b>EXPIRY DATE</b></p>
<p style="position:absolute;top:228px;left:106px;white-space:nowrap" class="ft2922">EXP</p>
<p style="position:absolute;top:287px;left:106px;white-space:nowrap" class="ft2921"><b>9.</b></p>
<p style="position:absolute;top:287px;left:148px;white-space:nowrap" class="ft2921"><b>SPECIAL STORAGE CONDITIONS</b></p>
<p style="position:absolute;top:327px;left:106px;white-space:nowrap" class="ft2925">Store in a refrigerator. Do not freeze.&#160;<br/>Refer to package leaflet for alternative storage details.</p>
<p style="position:absolute;top:384px;left:106px;white-space:nowrap" class="ft2922">Keep the pre-filled pen in the outer carton in order to protect from&#160;light.</p>
<p style="position:absolute;top:443px;left:106px;white-space:nowrap" class="ft2921"><b>10.</b></p>
<p style="position:absolute;top:443px;left:148px;white-space:nowrap" class="ft29219"><b>SPECIAL PRECAUTIONS FOR DISPOSAL OF&#160;UNUSED MEDICINAL PRODUCTS OR&#160;<br/>WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF&#160;<br/>APPROPRIATE</b></p>
<p style="position:absolute;top:543px;left:106px;white-space:nowrap" class="ft2921"><b>11.</b></p>
<p style="position:absolute;top:543px;left:148px;white-space:nowrap" class="ft2921"><b>NAME AND ADDRESS&#160;OF THE MARKETING AUTHORISATION HOLDER</b></p>
<p style="position:absolute;top:583px;left:106px;white-space:nowrap" class="ft2924">AbbVie Deutschland GmbH &amp; Co. KG<br/>Knollstrasse<br/>67061 Ludwigshafen<br/>Germany&#160;</p>
<p style="position:absolute;top:699px;left:106px;white-space:nowrap" class="ft2921"><b>12.</b></p>
<p style="position:absolute;top:699px;left:148px;white-space:nowrap" class="ft2921"><b>MARKETING AUTHORISATION NUMBER</b></p>
<p style="position:absolute;top:739px;left:106px;white-space:nowrap" class="ft2924">EU/1/03/256/007<br/>EU/1/03/256/008<br/>EU/1/03/256/009<br/>EU/1/03/256/010</p>
<p style="position:absolute;top:855px;left:106px;white-space:nowrap" class="ft2921"><b>13.</b></p>
<p style="position:absolute;top:855px;left:148px;white-space:nowrap" class="ft2921"><b>BATCH NUMBER</b></p>
<p style="position:absolute;top:895px;left:106px;white-space:nowrap" class="ft2922">Lot&#160;</p>
<p style="position:absolute;top:955px;left:106px;white-space:nowrap" class="ft2921"><b>14.</b></p>
<p style="position:absolute;top:955px;left:148px;white-space:nowrap" class="ft2921"><b>GENERAL CLASSIFICATION FOR SUPPLY</b></p>
<p style="position:absolute;top:1016px;left:106px;white-space:nowrap" class="ft2921"><b>15.</b></p>
<p style="position:absolute;top:1016px;left:148px;white-space:nowrap" class="ft2921"><b>INSTRUCTIONS ON&#160;USE</b></p>
</div>
<!-- Page 293 -->
<a name="293"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page293-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2930">293</p>
<p style="position:absolute;top:88px;left:106px;white-space:nowrap" class="ft2931"><b>16.</b></p>
<p style="position:absolute;top:88px;left:148px;white-space:nowrap" class="ft2931"><b>INFORMATION IN BRAILLE</b></p>
<p style="position:absolute;top:129px;left:106px;white-space:nowrap" class="ft2932">Humira 40&#160;mg</p>
<p style="position:absolute;top:188px;left:106px;white-space:nowrap" class="ft2931"><b>17.&#160;&#160;UNIQUE INDENTIFIER&#160;–&#160;2D BARCODE</b></p>
<p style="position:absolute;top:228px;left:106px;white-space:nowrap" class="ft2932">2D barcode carrying the unique identifier included.</p>
<p style="position:absolute;top:287px;left:106px;white-space:nowrap" class="ft2931"><b>18.&#160;&#160;UNIQUE INDENTIFIER&#160;–&#160;HUMAN READABLE&#160;DATA</b></p>
<p style="position:absolute;top:327px;left:106px;white-space:nowrap" class="ft2934">PC<br/>SN<br/>NN</p>
</div>
<!-- Page 294 -->
<a name="294"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page294-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2940">294</p>
<p style="position:absolute;top:107px;left:106px;white-space:nowrap" class="ft2941"><b>MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</b></p>
<p style="position:absolute;top:145px;left:106px;white-space:nowrap" class="ft2941"><b>TRAY BACKING TEXT</b></p>
<p style="position:absolute;top:207px;left:106px;white-space:nowrap" class="ft2941"><b>1.</b></p>
<p style="position:absolute;top:207px;left:148px;white-space:nowrap" class="ft2941"><b>NAME OF THE&#160;MEDICINAL PRODUCT</b></p>
<p style="position:absolute;top:247px;left:106px;white-space:nowrap" class="ft2944">Humira 40&#160;mg solution for injection in pre-filled pen<br/>adalimumab</p>
<p style="position:absolute;top:325px;left:106px;white-space:nowrap" class="ft2941"><b>2.</b></p>
<p style="position:absolute;top:325px;left:148px;white-space:nowrap" class="ft2941"><b>NAME OF THE MARKETING AUTHORISATION HOLDER</b></p>
<p style="position:absolute;top:365px;left:106px;white-space:nowrap" class="ft2942">AbbVie&#160;(as logo)</p>
<p style="position:absolute;top:424px;left:106px;white-space:nowrap" class="ft2941"><b>3.</b></p>
<p style="position:absolute;top:424px;left:148px;white-space:nowrap" class="ft2941"><b>EXPIRY DATE</b></p>
<p style="position:absolute;top:464px;left:106px;white-space:nowrap" class="ft2942">EXP</p>
<p style="position:absolute;top:524px;left:106px;white-space:nowrap" class="ft2941"><b>4.</b></p>
<p style="position:absolute;top:524px;left:148px;white-space:nowrap" class="ft2941"><b>BATCH NUMBER</b></p>
<p style="position:absolute;top:564px;left:106px;white-space:nowrap" class="ft2942">Lot&#160;</p>
<p style="position:absolute;top:623px;left:106px;white-space:nowrap" class="ft2941"><b>5.</b></p>
<p style="position:absolute;top:623px;left:148px;white-space:nowrap" class="ft2941"><b>OTHER</b></p>
<p style="position:absolute;top:663px;left:106px;white-space:nowrap" class="ft2942">For storage information, see package leaflet.</p>
<p style="position:absolute;top:701px;left:106px;white-space:nowrap" class="ft2942">For single use only.</p>
</div>
<!-- Page 295 -->
<a name="295"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page295-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2950">295</p>
<p style="position:absolute;top:88px;left:106px;white-space:nowrap" class="ft2951"><b>MINIMUM PARTICULARS&#160;TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</b></p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft2951"><b>PEN LABEL</b></p>
<p style="position:absolute;top:188px;left:106px;white-space:nowrap" class="ft2951"><b>1.</b></p>
<p style="position:absolute;top:188px;left:148px;white-space:nowrap" class="ft2951"><b>NAME OF THE MEDICINAL PRODUCT AND ROUTE OF ADMINISTRATION</b></p>
<p style="position:absolute;top:228px;left:106px;white-space:nowrap" class="ft2954">Humira 40&#160;mg injection<br/>adalimumab<br/>SC</p>
<p style="position:absolute;top:325px;left:106px;white-space:nowrap" class="ft2951"><b>2.</b></p>
<p style="position:absolute;top:325px;left:148px;white-space:nowrap" class="ft2951"><b>METHOD OF ADMINISTRATION</b></p>
<p style="position:absolute;top:386px;left:106px;white-space:nowrap" class="ft2951"><b>3.</b></p>
<p style="position:absolute;top:386px;left:148px;white-space:nowrap" class="ft2951"><b>EXPIRY DATE</b></p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft2952">EXP</p>
<p style="position:absolute;top:486px;left:106px;white-space:nowrap" class="ft2951"><b>4.</b></p>
<p style="position:absolute;top:486px;left:148px;white-space:nowrap" class="ft2951"><b>BATCH NUMBER</b></p>
<p style="position:absolute;top:526px;left:106px;white-space:nowrap" class="ft2952">Lot&#160;</p>
<p style="position:absolute;top:585px;left:106px;white-space:nowrap" class="ft2951"><b>5.</b></p>
<p style="position:absolute;top:585px;left:148px;white-space:nowrap" class="ft2951"><b>CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT</b></p>
<p style="position:absolute;top:625px;left:106px;white-space:nowrap" class="ft2952">40&#160;mg/0.8&#160;ml</p>
<p style="position:absolute;top:684px;left:106px;white-space:nowrap" class="ft2951"><b>6.</b></p>
<p style="position:absolute;top:684px;left:148px;white-space:nowrap" class="ft2951"><b>OTHER</b></p>
</div>
<!-- Page 296 -->
<a name="296"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page296-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2960">296</p>
<p style="position:absolute;top:88px;left:106px;white-space:nowrap" class="ft2961"><b>PARTICULARS TO APPEAR ON THE OUTER PACKAGING&#160;</b></p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft2961"><b>OUTER CARTON</b></p>
<p style="position:absolute;top:188px;left:106px;white-space:nowrap" class="ft2961"><b>1.</b></p>
<p style="position:absolute;top:188px;left:148px;white-space:nowrap" class="ft2961"><b>NAME OF THE MEDICINAL PRODUCT</b></p>
<p style="position:absolute;top:228px;left:106px;white-space:nowrap" class="ft2965">Humira 40&#160;mg solution for injection in pre-filled syringe&#160;<br/>adalimumab</p>
<p style="position:absolute;top:306px;left:106px;white-space:nowrap" class="ft2961"><b>2.</b></p>
<p style="position:absolute;top:306px;left:148px;white-space:nowrap" class="ft2961"><b>STATEMENT OF ACTIVE SUBSTANCE</b></p>
<p style="position:absolute;top:346px;left:106px;white-space:nowrap" class="ft2962">One 0.4&#160;ml pre-filled syringe contains 40&#160;mg adalimumab.</p>
<p style="position:absolute;top:405px;left:106px;white-space:nowrap" class="ft2961"><b>3.</b></p>
<p style="position:absolute;top:405px;left:148px;white-space:nowrap" class="ft2961"><b>LIST OF&#160;EXCIPIENTS</b></p>
<p style="position:absolute;top:445px;left:106px;white-space:nowrap" class="ft2962">Excipients: mannitol, polysorbate&#160;80, and water for injections. See leaflet for further information.</p>
<p style="position:absolute;top:505px;left:106px;white-space:nowrap" class="ft2961"><b>4.</b></p>
<p style="position:absolute;top:505px;left:148px;white-space:nowrap" class="ft2961"><b>PHARMACEUTICAL FORM&#160;AND CONTENTS</b></p>
<p style="position:absolute;top:545px;left:106px;white-space:nowrap" class="ft2964">Solution for injection<br/>1 pre-filled syringe<br/>1 alcohol pad</p>
<p style="position:absolute;top:621px;left:106px;white-space:nowrap" class="ft2964">2 pre-filled syringes<br/>2 alcohol pads&#160;</p>
<p style="position:absolute;top:678px;left:106px;white-space:nowrap" class="ft2964">4 pre-filled syringes<br/>4 alcohol pads</p>
<p style="position:absolute;top:735px;left:106px;white-space:nowrap" class="ft2965">6 pre-filled syringes<br/>6 alcohol pads</p>
<p style="position:absolute;top:813px;left:106px;white-space:nowrap" class="ft2961"><b>5.</b></p>
<p style="position:absolute;top:813px;left:148px;white-space:nowrap" class="ft2961"><b>METHOD AND ROUTE&#160;OF ADMINISTRATION</b></p>
<p style="position:absolute;top:853px;left:106px;white-space:nowrap" class="ft2962">Subcutaneous use</p>
<p style="position:absolute;top:891px;left:106px;white-space:nowrap" class="ft2962">Read the&#160;package leaflet before use.</p>
<p style="position:absolute;top:929px;left:106px;white-space:nowrap" class="ft2962">For single use only.</p>
<p style="position:absolute;top:988px;left:106px;white-space:nowrap" class="ft2961"><b>6.</b></p>
<p style="position:absolute;top:988px;left:147px;white-space:nowrap" class="ft29619"><b>SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED&#160;OUT OF&#160;<br/>THE SIGHT AND REACH&#160;OF CHILDREN</b></p>
<p style="position:absolute;top:1047px;left:106px;white-space:nowrap" class="ft2962">Keep out of the sight and reach of children.</p>
</div>
<!-- Page 297 -->
<a name="297"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page297-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2970">297</p>
<p style="position:absolute;top:107px;left:106px;white-space:nowrap" class="ft2971"><b>7.</b></p>
<p style="position:absolute;top:107px;left:148px;white-space:nowrap" class="ft2971"><b>OTHER SPECIAL WARNING, IF NECESSARY</b></p>
<p style="position:absolute;top:168px;left:106px;white-space:nowrap" class="ft2971"><b>8.</b></p>
<p style="position:absolute;top:168px;left:148px;white-space:nowrap" class="ft2971"><b>EXPIRY DATE</b></p>
<p style="position:absolute;top:209px;left:106px;white-space:nowrap" class="ft2972">EXP</p>
<p style="position:absolute;top:268px;left:106px;white-space:nowrap" class="ft2971"><b>9.</b></p>
<p style="position:absolute;top:268px;left:148px;white-space:nowrap" class="ft2971"><b>SPECIAL STORAGE CONDITIONS</b></p>
<p style="position:absolute;top:308px;left:106px;white-space:nowrap" class="ft2974">Store in a refrigerator. Do not freeze.<br/>Refer to package leaflet for alternative storage details.</p>
<p style="position:absolute;top:365px;left:106px;white-space:nowrap" class="ft2972">Keep the syringe in the outer carton in order to protect from light.</p>
<p style="position:absolute;top:424px;left:106px;white-space:nowrap" class="ft2971"><b>10.</b></p>
<p style="position:absolute;top:424px;left:148px;white-space:nowrap" class="ft29719"><b>SPECIAL PRECAUTIONS FOR DISPOSAL OF&#160;UNUSED&#160;MEDICINAL PRODUCTS OR&#160;<br/>WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF&#160;<br/>APPROPRIATE</b></p>
<p style="position:absolute;top:524px;left:106px;white-space:nowrap" class="ft2971"><b>11.</b></p>
<p style="position:absolute;top:524px;left:148px;white-space:nowrap" class="ft2971"><b>NAME AND ADDRESS&#160;OF THE MARKETING AUTHORISATION HOLDER</b></p>
<p style="position:absolute;top:564px;left:106px;white-space:nowrap" class="ft2975">AbbVie Deutschland GmbH &amp; Co. KG<br/>Knollstrasse<br/>67061 Ludwigshafen<br/>Germany&#160;</p>
<p style="position:absolute;top:680px;left:106px;white-space:nowrap" class="ft2971"><b>12.</b></p>
<p style="position:absolute;top:680px;left:148px;white-space:nowrap" class="ft2971"><b>MARKETING AUTHORISATION&#160;NUMBER</b></p>
<p style="position:absolute;top:720px;left:106px;white-space:nowrap" class="ft2975">EU/1/03/256/012<br/>EU/1/03/256/013<br/>EU/1/03/256/014<br/>EU/1/03/256/015</p>
<p style="position:absolute;top:836px;left:106px;white-space:nowrap" class="ft2971"><b>13.</b></p>
<p style="position:absolute;top:836px;left:148px;white-space:nowrap" class="ft2971"><b>BATCH NUMBER</b></p>
<p style="position:absolute;top:876px;left:106px;white-space:nowrap" class="ft2972">Lot</p>
<p style="position:absolute;top:936px;left:106px;white-space:nowrap" class="ft2971"><b>14.</b></p>
<p style="position:absolute;top:936px;left:148px;white-space:nowrap" class="ft2971"><b>GENERAL CLASSIFICATION FOR SUPPLY</b></p>
<p style="position:absolute;top:997px;left:106px;white-space:nowrap" class="ft2971"><b>15.</b></p>
<p style="position:absolute;top:997px;left:148px;white-space:nowrap" class="ft2971"><b>INSTRUCTIONS ON&#160;USE</b></p>
</div>
<!-- Page 298 -->
<a name="298"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page298-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2980">298</p>
<p style="position:absolute;top:88px;left:106px;white-space:nowrap" class="ft2981"><b>16.</b></p>
<p style="position:absolute;top:88px;left:148px;white-space:nowrap" class="ft2981"><b>INFORMATION IN BRAILLE</b></p>
<p style="position:absolute;top:129px;left:106px;white-space:nowrap" class="ft2982">Humira 40 mg</p>
<p style="position:absolute;top:188px;left:106px;white-space:nowrap" class="ft2981"><b>17.&#160;&#160;UNIQUE INDENTIFIER&#160;–&#160;2D BARCODE</b></p>
<p style="position:absolute;top:228px;left:106px;white-space:nowrap" class="ft2982">2D barcode&#160;carrying the unique identifier included.</p>
<p style="position:absolute;top:287px;left:106px;white-space:nowrap" class="ft2981"><b>18.&#160;&#160;UNIQUE INDENTIFIER&#160;–&#160;HUMAN READABLE&#160;DATA</b></p>
<p style="position:absolute;top:327px;left:106px;white-space:nowrap" class="ft2984">PC<br/>SN<br/>NN</p>
</div>
<!-- Page 299 -->
<a name="299"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page299-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft2990">299</p>
<p style="position:absolute;top:107px;left:106px;white-space:nowrap" class="ft2991"><b>MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</b></p>
<p style="position:absolute;top:145px;left:106px;white-space:nowrap" class="ft2991"><b>TRAY BACKING TEXT</b></p>
<p style="position:absolute;top:207px;left:106px;white-space:nowrap" class="ft2991"><b>1.</b></p>
<p style="position:absolute;top:207px;left:148px;white-space:nowrap" class="ft2991"><b>NAME OF THE MEDICINAL PRODUCT</b></p>
<p style="position:absolute;top:247px;left:106px;white-space:nowrap" class="ft2994">Humira 40&#160;mg solution for injection in&#160;pre-filled syringe<br/>adalimumab</p>
<p style="position:absolute;top:325px;left:106px;white-space:nowrap" class="ft2991"><b>2.</b></p>
<p style="position:absolute;top:325px;left:148px;white-space:nowrap" class="ft2991"><b>NAME OF THE MARKETING AUTHORISATION HOLDER</b></p>
<p style="position:absolute;top:365px;left:106px;white-space:nowrap" class="ft2992">AbbVie&#160;(as logo)</p>
<p style="position:absolute;top:424px;left:106px;white-space:nowrap" class="ft2991"><b>3.</b></p>
<p style="position:absolute;top:424px;left:148px;white-space:nowrap" class="ft2991"><b>EXPIRY DATE</b></p>
<p style="position:absolute;top:464px;left:106px;white-space:nowrap" class="ft2992">EXP</p>
<p style="position:absolute;top:524px;left:106px;white-space:nowrap" class="ft2991"><b>4.</b></p>
<p style="position:absolute;top:524px;left:148px;white-space:nowrap" class="ft2991"><b>BATCH NUMBER</b></p>
<p style="position:absolute;top:564px;left:106px;white-space:nowrap" class="ft2992">Lot</p>
<p style="position:absolute;top:623px;left:106px;white-space:nowrap" class="ft2991"><b>5.</b></p>
<p style="position:absolute;top:623px;left:148px;white-space:nowrap" class="ft2991"><b>OTHER</b></p>
<p style="position:absolute;top:663px;left:106px;white-space:nowrap" class="ft2992">For storage information, see package leaflet.</p>
<p style="position:absolute;top:701px;left:106px;white-space:nowrap" class="ft2992">For single use only.</p>
<p style="position:absolute;top:739px;left:106px;white-space:nowrap" class="ft2992">40&#160;mg/0.4&#160;ml</p>
</div>
<!-- Page 300 -->
<a name="300"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page300-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3000">300</p>
<p style="position:absolute;top:88px;left:106px;white-space:nowrap" class="ft3001"><b>MINIMUM&#160;PARTICULARS TO APPEAR ON SMALL IMMEDIATE&#160;PACKAGING UNITS</b></p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft3001"><b>SYRINGE LABEL</b></p>
<p style="position:absolute;top:188px;left:106px;white-space:nowrap" class="ft3001"><b>1.</b></p>
<p style="position:absolute;top:188px;left:148px;white-space:nowrap" class="ft3001"><b>NAME OF THE MEDICINAL PRODUCT AND ROUTE OF ADMINISTRATION</b></p>
<p style="position:absolute;top:228px;left:106px;white-space:nowrap" class="ft3004">Humira 40&#160;mg injection<br/>adalimumab<br/>SC</p>
<p style="position:absolute;top:325px;left:106px;white-space:nowrap" class="ft3001"><b>2.</b></p>
<p style="position:absolute;top:325px;left:148px;white-space:nowrap" class="ft3001"><b>METHOD OF ADMINISTRATION</b></p>
<p style="position:absolute;top:386px;left:106px;white-space:nowrap" class="ft3001"><b>3.</b></p>
<p style="position:absolute;top:386px;left:148px;white-space:nowrap" class="ft3001"><b>EXPIRY DATE</b></p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft3002">EXP</p>
<p style="position:absolute;top:486px;left:106px;white-space:nowrap" class="ft3001"><b>4.</b></p>
<p style="position:absolute;top:486px;left:148px;white-space:nowrap" class="ft3001"><b>BATCH NUMBER</b></p>
<p style="position:absolute;top:526px;left:106px;white-space:nowrap" class="ft3002">Lot</p>
<p style="position:absolute;top:585px;left:106px;white-space:nowrap" class="ft3001"><b>5.</b></p>
<p style="position:absolute;top:585px;left:148px;white-space:nowrap" class="ft3001"><b>CONTENTS BY WEIGHT,&#160;BY VOLUME OR BY UNIT</b></p>
<p style="position:absolute;top:625px;left:106px;white-space:nowrap" class="ft3002">40&#160;mg/0.4&#160;ml</p>
<p style="position:absolute;top:684px;left:106px;white-space:nowrap" class="ft3001"><b>6.</b></p>
<p style="position:absolute;top:684px;left:148px;white-space:nowrap" class="ft3001"><b>OTHER</b></p>
</div>
<!-- Page 301 -->
<a name="301"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page301-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3010">301</p>
<p style="position:absolute;top:88px;left:110px;white-space:nowrap" class="ft3011"><b>PARTICULARS TO APPEAR ON THE OUTER PACKAGING&#160;</b></p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft3011"><b>OUTER CARTON</b></p>
<p style="position:absolute;top:188px;left:106px;white-space:nowrap" class="ft3011"><b>1.</b></p>
<p style="position:absolute;top:188px;left:148px;white-space:nowrap" class="ft3011"><b>NAME OF THE MEDICINAL PRODUCT</b></p>
<p style="position:absolute;top:228px;left:106px;white-space:nowrap" class="ft3015">Humira 40&#160;mg solution for injection in pre-filled pen<br/>adalimumab</p>
<p style="position:absolute;top:306px;left:106px;white-space:nowrap" class="ft3011"><b>2.</b></p>
<p style="position:absolute;top:306px;left:148px;white-space:nowrap" class="ft3011"><b>STATEMENT OF ACTIVE&#160;SUBSTANCE</b></p>
<p style="position:absolute;top:346px;left:106px;white-space:nowrap" class="ft3012">One 0.4&#160;ml pre-filled pen contains 40&#160;mg adalimumab.</p>
<p style="position:absolute;top:405px;left:106px;white-space:nowrap" class="ft3011"><b>3.</b></p>
<p style="position:absolute;top:405px;left:148px;white-space:nowrap" class="ft3011"><b>LIST OF EXCIPIENTS</b></p>
<p style="position:absolute;top:445px;left:106px;white-space:nowrap" class="ft3012">Excipients: mannitol, polysorbate&#160;80 and water for injections. See leaflet for further information.</p>
<p style="position:absolute;top:505px;left:106px;white-space:nowrap" class="ft3011"><b>4.</b></p>
<p style="position:absolute;top:505px;left:148px;white-space:nowrap" class="ft3011"><b>PHARMACEUTICAL FORM AND CONTENTS</b></p>
<p style="position:absolute;top:545px;left:106px;white-space:nowrap" class="ft3014">Solution for injection<br/>1 pre-filled pen<br/>2 alcohol pads</p>
<p style="position:absolute;top:621px;left:106px;white-space:nowrap" class="ft3014">2 pre-filled pens<br/>2 alcohol pads&#160;</p>
<p style="position:absolute;top:678px;left:106px;white-space:nowrap" class="ft3014">4 pre-filled pens<br/>4 alcohol pads&#160;</p>
<p style="position:absolute;top:735px;left:106px;white-space:nowrap" class="ft3015">6 pre-filled pens<br/>6 alcohol pads</p>
<p style="position:absolute;top:813px;left:106px;white-space:nowrap" class="ft3011"><b>5.</b></p>
<p style="position:absolute;top:813px;left:148px;white-space:nowrap" class="ft3011"><b>METHOD AND ROUTE&#160;OF ADMINISTRATION</b></p>
<p style="position:absolute;top:853px;left:106px;white-space:nowrap" class="ft3012">Subcutaneous use</p>
<p style="position:absolute;top:891px;left:106px;white-space:nowrap" class="ft3012">Read the package leaflet before use.</p>
<p style="position:absolute;top:929px;left:106px;white-space:nowrap" class="ft3012">For single use only.</p>
<p style="position:absolute;top:988px;left:106px;white-space:nowrap" class="ft3011"><b>6.</b></p>
<p style="position:absolute;top:988px;left:147px;white-space:nowrap" class="ft30119"><b>SPECIAL WARNING THAT&#160;THE MEDICINAL PRODUCT MUST BE STORED OUT OF&#160;<br/>THE SIGHT AND REACH&#160;OF CHILDREN</b></p>
<p style="position:absolute;top:1047px;left:106px;white-space:nowrap" class="ft3012">Keep out of the sight and reach of children.</p>
</div>
<!-- Page 302 -->
<a name="302"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page302-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3020">302</p>
<p style="position:absolute;top:107px;left:106px;white-space:nowrap" class="ft3021"><b>7.</b></p>
<p style="position:absolute;top:107px;left:148px;white-space:nowrap" class="ft3021"><b>OTHER SPECIAL WARNING, IF NECESSARY</b></p>
<p style="position:absolute;top:168px;left:106px;white-space:nowrap" class="ft3021"><b>8.</b></p>
<p style="position:absolute;top:168px;left:148px;white-space:nowrap" class="ft3021"><b>EXPIRY DATE</b></p>
<p style="position:absolute;top:209px;left:106px;white-space:nowrap" class="ft3022">EXP</p>
<p style="position:absolute;top:268px;left:106px;white-space:nowrap" class="ft3021"><b>9.</b></p>
<p style="position:absolute;top:268px;left:148px;white-space:nowrap" class="ft3021"><b>SPECIAL STORAGE CONDITIONS</b></p>
<p style="position:absolute;top:308px;left:106px;white-space:nowrap" class="ft3024">Store in a refrigerator. Do not freeze.&#160;<br/>Refer to package leaflet for alternative storage details.</p>
<p style="position:absolute;top:365px;left:106px;white-space:nowrap" class="ft3022">Keep the pre-filled pen in the outer carton in order to protect from light.</p>
<p style="position:absolute;top:424px;left:106px;white-space:nowrap" class="ft3021"><b>10.</b></p>
<p style="position:absolute;top:424px;left:148px;white-space:nowrap" class="ft30219"><b>SPECIAL PRECAUTIONS FOR DISPOSAL OF&#160;UNUSED MEDICINAL PRODUCTS OR&#160;<br/>WASTE MATERIALS DERIVED FROM&#160;SUCH MEDICINAL PRODUCTS, IF&#160;<br/>APPROPRIATE</b></p>
<p style="position:absolute;top:524px;left:106px;white-space:nowrap" class="ft3021"><b>11.</b></p>
<p style="position:absolute;top:524px;left:148px;white-space:nowrap" class="ft3021"><b>NAME AND ADDRESS&#160;OF THE MARKETING AUTHORISATION HOLDER</b></p>
<p style="position:absolute;top:564px;left:106px;white-space:nowrap" class="ft3025">AbbVie Deutschland GmbH &amp; Co. KG<br/>Knollstrasse<br/>67061 Ludwigshafen<br/>Germany</p>
<p style="position:absolute;top:680px;left:106px;white-space:nowrap" class="ft3021"><b>12.</b></p>
<p style="position:absolute;top:680px;left:148px;white-space:nowrap" class="ft3021"><b>MARKETING AUTHORISATION NUMBER</b></p>
<p style="position:absolute;top:720px;left:106px;white-space:nowrap" class="ft3025">EU/1/03/256/016<br/>EU/1/03/256/017<br/>EU/1/03/256/018<br/>EU/1/03/256/019</p>
<p style="position:absolute;top:836px;left:106px;white-space:nowrap" class="ft3021"><b>13.</b></p>
<p style="position:absolute;top:836px;left:148px;white-space:nowrap" class="ft3021"><b>BATCH NUMBER</b></p>
<p style="position:absolute;top:876px;left:106px;white-space:nowrap" class="ft3022">Lot&#160;</p>
<p style="position:absolute;top:936px;left:106px;white-space:nowrap" class="ft3021"><b>14.</b></p>
<p style="position:absolute;top:936px;left:148px;white-space:nowrap" class="ft3021"><b>GENERAL CLASSIFICATION FOR SUPPLY</b></p>
<p style="position:absolute;top:997px;left:106px;white-space:nowrap" class="ft3021"><b>15.</b></p>
<p style="position:absolute;top:997px;left:148px;white-space:nowrap" class="ft3021"><b>INSTRUCTIONS ON&#160;USE</b></p>
</div>
<!-- Page 303 -->
<a name="303"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page303-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3030">303</p>
<p style="position:absolute;top:88px;left:106px;white-space:nowrap" class="ft3031"><b>16.</b></p>
<p style="position:absolute;top:88px;left:148px;white-space:nowrap" class="ft3031"><b>INFORMATION IN BRAILLE</b></p>
<p style="position:absolute;top:129px;left:106px;white-space:nowrap" class="ft3032">Humira 40&#160;mg</p>
<p style="position:absolute;top:188px;left:106px;white-space:nowrap" class="ft3031"><b>17.&#160;&#160;UNIQUE INDENTIFIER&#160;–&#160;2D BARCODE</b></p>
<p style="position:absolute;top:228px;left:106px;white-space:nowrap" class="ft3032">2D barcode carrying the unique&#160;identifier included.</p>
<p style="position:absolute;top:287px;left:106px;white-space:nowrap" class="ft3031"><b>18.&#160;&#160;UNIQUE INDENTIFIER&#160;–&#160;HUMAN READABLE&#160;DATA</b></p>
<p style="position:absolute;top:327px;left:106px;white-space:nowrap" class="ft3034">PC<br/>SN<br/>NN</p>
</div>
<!-- Page 304 -->
<a name="304"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page304-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3040">304</p>
<p style="position:absolute;top:107px;left:106px;white-space:nowrap" class="ft3041"><b>MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</b></p>
<p style="position:absolute;top:145px;left:106px;white-space:nowrap" class="ft3041"><b>TRAY BACKING TEXT</b></p>
<p style="position:absolute;top:207px;left:106px;white-space:nowrap" class="ft3041"><b>1.</b></p>
<p style="position:absolute;top:207px;left:148px;white-space:nowrap" class="ft3041"><b>NAME OF THE MEDICINAL PRODUCT</b></p>
<p style="position:absolute;top:247px;left:106px;white-space:nowrap" class="ft3044">Humira 40&#160;mg solution for injection in pre-filled pen<br/>adalimumab</p>
<p style="position:absolute;top:325px;left:106px;white-space:nowrap" class="ft3041"><b>2.</b></p>
<p style="position:absolute;top:325px;left:148px;white-space:nowrap" class="ft3041"><b>NAME OF THE MARKETING AUTHORISATION HOLDER</b></p>
<p style="position:absolute;top:365px;left:106px;white-space:nowrap" class="ft3042">AbbVie&#160;(as logo)</p>
<p style="position:absolute;top:424px;left:106px;white-space:nowrap" class="ft3041"><b>3.</b></p>
<p style="position:absolute;top:424px;left:148px;white-space:nowrap" class="ft3041"><b>EXPIRY DATE</b></p>
<p style="position:absolute;top:464px;left:106px;white-space:nowrap" class="ft3042">EXP</p>
<p style="position:absolute;top:524px;left:106px;white-space:nowrap" class="ft3041"><b>4.</b></p>
<p style="position:absolute;top:524px;left:148px;white-space:nowrap" class="ft3041"><b>BATCH NUMBER</b></p>
<p style="position:absolute;top:564px;left:106px;white-space:nowrap" class="ft3042">Lot&#160;</p>
<p style="position:absolute;top:623px;left:106px;white-space:nowrap" class="ft3041"><b>5.</b></p>
<p style="position:absolute;top:623px;left:148px;white-space:nowrap" class="ft3041"><b>OTHER</b></p>
<p style="position:absolute;top:663px;left:106px;white-space:nowrap" class="ft3042">For storage information, see package leaflet.</p>
<p style="position:absolute;top:701px;left:106px;white-space:nowrap" class="ft3042">For single use only.</p>
<p style="position:absolute;top:739px;left:106px;white-space:nowrap" class="ft3042">40&#160;mg/0.4&#160;ml</p>
</div>
<!-- Page 305 -->
<a name="305"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page305-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3050">305</p>
<p style="position:absolute;top:88px;left:106px;white-space:nowrap" class="ft3051"><b>MINIMUM PARTICULARS&#160;TO APPEAR ON SMALL&#160;IMMEDIATE PACKAGING&#160;UNITS</b></p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft3051"><b>PEN LABEL</b></p>
<p style="position:absolute;top:188px;left:106px;white-space:nowrap" class="ft3051"><b>1.</b></p>
<p style="position:absolute;top:188px;left:148px;white-space:nowrap" class="ft3051"><b>NAME OF THE MEDICINAL PRODUCT AND ROUTE OF ADMINISTRATION</b></p>
<p style="position:absolute;top:228px;left:106px;white-space:nowrap" class="ft3054">Humira 40&#160;mg injection<br/>adalimumab<br/>SC</p>
<p style="position:absolute;top:325px;left:106px;white-space:nowrap" class="ft3051"><b>2.</b></p>
<p style="position:absolute;top:325px;left:148px;white-space:nowrap" class="ft3051"><b>METHOD OF ADMINISTRATION</b></p>
<p style="position:absolute;top:386px;left:106px;white-space:nowrap" class="ft3051"><b>3.</b></p>
<p style="position:absolute;top:386px;left:148px;white-space:nowrap" class="ft3051"><b>EXPIRY DATE</b></p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft3052">EXP</p>
<p style="position:absolute;top:486px;left:106px;white-space:nowrap" class="ft3051"><b>4.</b></p>
<p style="position:absolute;top:486px;left:148px;white-space:nowrap" class="ft3051"><b>BATCH NUMBER</b></p>
<p style="position:absolute;top:526px;left:106px;white-space:nowrap" class="ft3052">Lot&#160;</p>
<p style="position:absolute;top:585px;left:106px;white-space:nowrap" class="ft3051"><b>5.</b></p>
<p style="position:absolute;top:585px;left:148px;white-space:nowrap" class="ft3051"><b>CONTENTS BY WEIGHT, BY VOLUME OR BY&#160;UNIT</b></p>
<p style="position:absolute;top:625px;left:106px;white-space:nowrap" class="ft3052">40&#160;mg/0.4&#160;ml</p>
<p style="position:absolute;top:684px;left:106px;white-space:nowrap" class="ft3051"><b>6.</b></p>
<p style="position:absolute;top:684px;left:148px;white-space:nowrap" class="ft3051"><b>OTHER</b></p>
</div>
<!-- Page 306 -->
<a name="306"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page306-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3060">306</p>
<p style="position:absolute;top:88px;left:106px;white-space:nowrap" class="ft3061"><b>PARTICULARS TO APPEAR ON THE OUTER PACKAGING&#160;</b></p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft3061"><b>OUTER CARTON</b></p>
<p style="position:absolute;top:188px;left:106px;white-space:nowrap" class="ft3061"><b>1.</b></p>
<p style="position:absolute;top:188px;left:148px;white-space:nowrap" class="ft3061"><b>NAME OF THE MEDICINAL PRODUCT</b></p>
<p style="position:absolute;top:228px;left:106px;white-space:nowrap" class="ft3065">Humira 80&#160;mg solution for injection in pre-filled syringe&#160;<br/>adalimumab</p>
<p style="position:absolute;top:306px;left:106px;white-space:nowrap" class="ft3061"><b>2.</b></p>
<p style="position:absolute;top:306px;left:148px;white-space:nowrap" class="ft3061"><b>STATEMENT OF ACTIVE SUBSTANCE</b></p>
<p style="position:absolute;top:346px;left:106px;white-space:nowrap" class="ft3062">One 0.8&#160;ml&#160;pre-filled syringe contains 80&#160;mg adalimumab.</p>
<p style="position:absolute;top:405px;left:106px;white-space:nowrap" class="ft3061"><b>3.</b></p>
<p style="position:absolute;top:405px;left:148px;white-space:nowrap" class="ft3061"><b>LIST OF&#160;EXCIPIENTS</b></p>
<p style="position:absolute;top:445px;left:106px;white-space:nowrap" class="ft3062">Excipients: mannitol, polysorbate&#160;80, and water for injections. See leaflet for further information.</p>
<p style="position:absolute;top:505px;left:106px;white-space:nowrap" class="ft3061"><b>4.</b></p>
<p style="position:absolute;top:505px;left:148px;white-space:nowrap" class="ft3061"><b>PHARMACEUTICAL FORM AND CONTENTS</b></p>
<p style="position:absolute;top:545px;left:106px;white-space:nowrap" class="ft3064">Solution for injection<br/>1 pre-filled syringe<br/>1&#160;alcohol pad</p>
<p style="position:absolute;top:642px;left:106px;white-space:nowrap" class="ft3061"><b>5.</b></p>
<p style="position:absolute;top:642px;left:148px;white-space:nowrap" class="ft3061"><b>METHOD AND ROUTE&#160;OF ADMINISTRATION</b></p>
<p style="position:absolute;top:682px;left:106px;white-space:nowrap" class="ft3062">Subcutaneous use</p>
<p style="position:absolute;top:720px;left:106px;white-space:nowrap" class="ft3062">Read the package leaflet before use.</p>
<p style="position:absolute;top:758px;left:106px;white-space:nowrap" class="ft3062">For single use only.</p>
<p style="position:absolute;top:817px;left:106px;white-space:nowrap" class="ft3061"><b>6.</b></p>
<p style="position:absolute;top:817px;left:147px;white-space:nowrap" class="ft30619"><b>SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED&#160;OUT OF&#160;<br/>THE SIGHT AND REACH&#160;OF CHILDREN</b></p>
<p style="position:absolute;top:876px;left:106px;white-space:nowrap" class="ft3062">Keep out of the sight&#160;and reach of children.</p>
<p style="position:absolute;top:936px;left:106px;white-space:nowrap" class="ft3061"><b>7.</b></p>
<p style="position:absolute;top:936px;left:148px;white-space:nowrap" class="ft3061"><b>OTHER SPECIAL WARNING, IF NECESSARY</b></p>
<p style="position:absolute;top:997px;left:106px;white-space:nowrap" class="ft3061"><b>8.</b></p>
<p style="position:absolute;top:997px;left:148px;white-space:nowrap" class="ft3061"><b>EXPIRY DATE</b></p>
<p style="position:absolute;top:1037px;left:106px;white-space:nowrap" class="ft3062">EXP</p>
</div>
<!-- Page 307 -->
<a name="307"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page307-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3070">307</p>
<p style="position:absolute;top:88px;left:106px;white-space:nowrap" class="ft3071"><b>9.</b></p>
<p style="position:absolute;top:88px;left:148px;white-space:nowrap" class="ft3071"><b>SPECIAL STORAGE CONDITIONS</b></p>
<p style="position:absolute;top:129px;left:106px;white-space:nowrap" class="ft3075">Store in a refrigerator. Do not freeze.<br/>Refer to package leaflet for alternative storage details.</p>
<p style="position:absolute;top:185px;left:106px;white-space:nowrap" class="ft3072">Keep the syringe in the outer carton&#160;in order to protect from light.</p>
<p style="position:absolute;top:244px;left:106px;white-space:nowrap" class="ft3071"><b>10.</b></p>
<p style="position:absolute;top:244px;left:148px;white-space:nowrap" class="ft30719"><b>SPECIAL PRECAUTIONS FOR DISPOSAL OF&#160;UNUSED MEDICINAL PRODUCTS OR&#160;<br/>WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF&#160;<br/>APPROPRIATE</b></p>
<p style="position:absolute;top:344px;left:106px;white-space:nowrap" class="ft3071"><b>11.</b></p>
<p style="position:absolute;top:344px;left:148px;white-space:nowrap" class="ft3071"><b>NAME AND ADDRESS&#160;OF THE MARKETING AUTHORISATION HOLDER</b></p>
<p style="position:absolute;top:384px;left:106px;white-space:nowrap" class="ft3074">AbbVie Deutschland&#160;GmbH &amp; Co. KG<br/>Knollstrasse<br/>67061 Ludwigshafen<br/>Germany</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft3071"><b>12.</b></p>
<p style="position:absolute;top:500px;left:148px;white-space:nowrap" class="ft3071"><b>MARKETING AUTHORISATION NUMBER</b></p>
<p style="position:absolute;top:540px;left:106px;white-space:nowrap" class="ft3072">EU/1/03/256/020</p>
<p style="position:absolute;top:599px;left:106px;white-space:nowrap" class="ft3071"><b>13.</b></p>
<p style="position:absolute;top:599px;left:148px;white-space:nowrap" class="ft3071"><b>BATCH NUMBER</b></p>
<p style="position:absolute;top:640px;left:106px;white-space:nowrap" class="ft3072">Lot</p>
<p style="position:absolute;top:699px;left:106px;white-space:nowrap" class="ft3071"><b>14.</b></p>
<p style="position:absolute;top:699px;left:148px;white-space:nowrap" class="ft3071"><b>GENERAL CLASSIFICATION FOR SUPPLY</b></p>
<p style="position:absolute;top:760px;left:106px;white-space:nowrap" class="ft3071"><b>15.</b></p>
<p style="position:absolute;top:760px;left:148px;white-space:nowrap" class="ft3071"><b>INSTRUCTIONS ON&#160;USE</b></p>
<p style="position:absolute;top:822px;left:106px;white-space:nowrap" class="ft3071"><b>16.</b></p>
<p style="position:absolute;top:822px;left:148px;white-space:nowrap" class="ft3071"><b>INFORMATION IN BRAILLE</b></p>
<p style="position:absolute;top:862px;left:106px;white-space:nowrap" class="ft3072">Humira 80 mg</p>
<p style="position:absolute;top:921px;left:106px;white-space:nowrap" class="ft3071"><b>17.&#160;&#160;UNIQUE&#160;INDENTIFIER&#160;–&#160;2D BARCODE</b></p>
<p style="position:absolute;top:961px;left:106px;white-space:nowrap" class="ft3072">2D barcode carrying the unique identifier included.</p>
<p style="position:absolute;top:1021px;left:106px;white-space:nowrap" class="ft3071"><b>18.&#160;&#160;UNIQUE INDENTIFIER&#160;–&#160;HUMAN READABLE&#160;DATA</b></p>
<p style="position:absolute;top:1061px;left:106px;white-space:nowrap" class="ft3074">PC<br/>SN</p>
</div>
<!-- Page 308 -->
<a name="308"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page308-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3080">308</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft3082">NN</p>
</div>
<!-- Page 309 -->
<a name="309"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page309-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3090">309</p>
<p style="position:absolute;top:88px;left:106px;white-space:nowrap" class="ft3091"><b>MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</b></p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft3091"><b>TRAY BACKING TEXT</b></p>
<p style="position:absolute;top:188px;left:106px;white-space:nowrap" class="ft3091"><b>1.</b></p>
<p style="position:absolute;top:188px;left:148px;white-space:nowrap" class="ft3091"><b>NAME OF THE MEDICINAL PRODUCT</b></p>
<p style="position:absolute;top:228px;left:106px;white-space:nowrap" class="ft3095">Humira&#160;80&#160;mg solution for injection in pre-filled syringe<br/>adalimumab</p>
<p style="position:absolute;top:306px;left:106px;white-space:nowrap" class="ft3091"><b>2.</b></p>
<p style="position:absolute;top:306px;left:148px;white-space:nowrap" class="ft3091"><b>NAME OF THE MARKETING AUTHORISATION HOLDER</b></p>
<p style="position:absolute;top:346px;left:106px;white-space:nowrap" class="ft3092">AbbVie&#160;(as logo)</p>
<p style="position:absolute;top:405px;left:106px;white-space:nowrap" class="ft3091"><b>3.</b></p>
<p style="position:absolute;top:405px;left:148px;white-space:nowrap" class="ft3091"><b>EXPIRY DATE</b></p>
<p style="position:absolute;top:445px;left:106px;white-space:nowrap" class="ft3092">EXP</p>
<p style="position:absolute;top:505px;left:106px;white-space:nowrap" class="ft3091"><b>4.</b></p>
<p style="position:absolute;top:505px;left:148px;white-space:nowrap" class="ft3091"><b>BATCH NUMBER</b></p>
<p style="position:absolute;top:545px;left:106px;white-space:nowrap" class="ft3092">Lot</p>
<p style="position:absolute;top:604px;left:106px;white-space:nowrap" class="ft3091"><b>5.</b></p>
<p style="position:absolute;top:604px;left:148px;white-space:nowrap" class="ft3091"><b>OTHER</b></p>
<p style="position:absolute;top:644px;left:106px;white-space:nowrap" class="ft3092">For storage information, see package leaflet.</p>
<p style="position:absolute;top:682px;left:106px;white-space:nowrap" class="ft3092">For single use only.</p>
</div>
<!-- Page 310 -->
<a name="310"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page310-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3100">310</p>
<p style="position:absolute;top:88px;left:106px;white-space:nowrap" class="ft3101"><b>MINIMUM PARTICULARS&#160;TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</b></p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft3101"><b>SYRINGE LABEL</b></p>
<p style="position:absolute;top:188px;left:106px;white-space:nowrap" class="ft3101"><b>1.</b></p>
<p style="position:absolute;top:188px;left:148px;white-space:nowrap" class="ft3101"><b>NAME OF THE MEDICINAL PRODUCT AND ROUTE OF ADMINISTRATION</b></p>
<p style="position:absolute;top:228px;left:106px;white-space:nowrap" class="ft3104">Humira 80&#160;mg injection<br/>adalimumab<br/>SC</p>
<p style="position:absolute;top:325px;left:106px;white-space:nowrap" class="ft3101"><b>2.</b></p>
<p style="position:absolute;top:325px;left:148px;white-space:nowrap" class="ft3101"><b>METHOD OF ADMINISTRATION</b></p>
<p style="position:absolute;top:386px;left:106px;white-space:nowrap" class="ft3101"><b>3.</b></p>
<p style="position:absolute;top:386px;left:148px;white-space:nowrap" class="ft3101"><b>EXPIRY DATE</b></p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft3102">EXP</p>
<p style="position:absolute;top:486px;left:106px;white-space:nowrap" class="ft3101"><b>4.</b></p>
<p style="position:absolute;top:486px;left:148px;white-space:nowrap" class="ft3101"><b>BATCH NUMBER</b></p>
<p style="position:absolute;top:526px;left:106px;white-space:nowrap" class="ft3102">Lot</p>
<p style="position:absolute;top:585px;left:106px;white-space:nowrap" class="ft3101"><b>5.</b></p>
<p style="position:absolute;top:585px;left:148px;white-space:nowrap" class="ft3101"><b>CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT</b></p>
<p style="position:absolute;top:625px;left:106px;white-space:nowrap" class="ft3102">80&#160;mg/0.8&#160;ml</p>
<p style="position:absolute;top:684px;left:106px;white-space:nowrap" class="ft3101"><b>6.</b></p>
<p style="position:absolute;top:684px;left:148px;white-space:nowrap" class="ft3101"><b>OTHER</b></p>
</div>
<!-- Page 311 -->
<a name="311"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page311-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3110">311</p>
<p style="position:absolute;top:88px;left:110px;white-space:nowrap" class="ft3111"><b>PARTICULARS TO APPEAR ON THE OUTER PACKAGING&#160;</b></p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft3111"><b>OUTER CARTON</b></p>
<p style="position:absolute;top:188px;left:106px;white-space:nowrap" class="ft3111"><b>1.</b></p>
<p style="position:absolute;top:188px;left:148px;white-space:nowrap" class="ft3111"><b>NAME OF THE MEDICINAL PRODUCT</b></p>
<p style="position:absolute;top:228px;left:106px;white-space:nowrap" class="ft3115">Humira 80&#160;mg solution for injection in pre-filled pen<br/>adalimumab</p>
<p style="position:absolute;top:306px;left:106px;white-space:nowrap" class="ft3111"><b>2.</b></p>
<p style="position:absolute;top:306px;left:148px;white-space:nowrap" class="ft3111"><b>STATEMENT&#160;OF ACTIVE SUBSTANCE</b></p>
<p style="position:absolute;top:346px;left:106px;white-space:nowrap" class="ft3112">One 0.8&#160;ml pre-filled pen contains 80&#160;mg adalimumab.</p>
<p style="position:absolute;top:405px;left:106px;white-space:nowrap" class="ft3111"><b>3.</b></p>
<p style="position:absolute;top:405px;left:148px;white-space:nowrap" class="ft3111"><b>LIST OF EXCIPIENTS</b></p>
<p style="position:absolute;top:445px;left:106px;white-space:nowrap" class="ft3112">Excipients: mannitol, polysorbate&#160;80 and water for injections. See leaflet for further information.</p>
<p style="position:absolute;top:505px;left:106px;white-space:nowrap" class="ft3111"><b>4.</b></p>
<p style="position:absolute;top:505px;left:148px;white-space:nowrap" class="ft3111"><b>PHARMACEUTICAL FORM AND CONTENTS</b></p>
<p style="position:absolute;top:545px;left:106px;white-space:nowrap" class="ft3114">Solution for injection<br/>1 pre-filled pen<br/>2 alcohol pads</p>
<p style="position:absolute;top:621px;left:106px;white-space:nowrap" class="ft3114">3 pre-filled pens<br/>4&#160;alcohol pads</p>
<p style="position:absolute;top:699px;left:106px;white-space:nowrap" class="ft3111"><b>5.</b></p>
<p style="position:absolute;top:699px;left:148px;white-space:nowrap" class="ft3111"><b>METHOD AND ROUTE&#160;OF ADMINISTRATION</b></p>
<p style="position:absolute;top:739px;left:106px;white-space:nowrap" class="ft3112">Subcutaneous use</p>
<p style="position:absolute;top:777px;left:106px;white-space:nowrap" class="ft3112">Read the package leaflet before use.</p>
<p style="position:absolute;top:815px;left:106px;white-space:nowrap" class="ft3112">For single use only.</p>
<p style="position:absolute;top:874px;left:106px;white-space:nowrap" class="ft3111"><b>6.</b></p>
<p style="position:absolute;top:874px;left:147px;white-space:nowrap" class="ft31119"><b>SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED&#160;OUT&#160;OF&#160;<br/>THE SIGHT AND REACH&#160;OF CHILDREN</b></p>
<p style="position:absolute;top:933px;left:106px;white-space:nowrap" class="ft3112">Keep out of the sight and reach of children.</p>
<p style="position:absolute;top:993px;left:106px;white-space:nowrap" class="ft3111"><b>7.</b></p>
<p style="position:absolute;top:993px;left:148px;white-space:nowrap" class="ft3111"><b>OTHER SPECIAL WARNING, IF NECESSARY</b></p>
<p style="position:absolute;top:1054px;left:106px;white-space:nowrap" class="ft3111"><b>8.</b></p>
<p style="position:absolute;top:1054px;left:148px;white-space:nowrap" class="ft3111"><b>EXPIRY DATE</b></p>
</div>
<!-- Page 312 -->
<a name="312"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page312-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3120">312</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft3122">EXP</p>
<p style="position:absolute;top:145px;left:106px;white-space:nowrap" class="ft3121"><b>9.</b></p>
<p style="position:absolute;top:145px;left:148px;white-space:nowrap" class="ft3121"><b>SPECIAL STORAGE CONDITIONS</b></p>
<p style="position:absolute;top:185px;left:106px;white-space:nowrap" class="ft3124">Store in a refrigerator. Do not freeze.&#160;<br/>Refer to package leaflet for&#160;alternative storage details.</p>
<p style="position:absolute;top:242px;left:106px;white-space:nowrap" class="ft3122">Keep the pre-filled pen in the outer carton in order to protect from light.</p>
<p style="position:absolute;top:301px;left:106px;white-space:nowrap" class="ft3121"><b>10.</b></p>
<p style="position:absolute;top:301px;left:148px;white-space:nowrap" class="ft31219"><b>SPECIAL PRECAUTIONS FOR DISPOSAL OF&#160;UNUSED MEDICINAL PRODUCTS OR&#160;<br/>WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF&#160;<br/>APPROPRIATE</b></p>
<p style="position:absolute;top:401px;left:106px;white-space:nowrap" class="ft3121"><b>11.</b></p>
<p style="position:absolute;top:401px;left:148px;white-space:nowrap" class="ft3121"><b>NAME&#160;AND ADDRESS OF THE&#160;MARKETING AUTHORISATION HOLDER</b></p>
<p style="position:absolute;top:441px;left:106px;white-space:nowrap" class="ft3124">AbbVie Deutschland GmbH &amp; Co. KG<br/>Knollstrasse<br/>67061 Ludwigshafen<br/>Germany</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft3121"><b>12.</b></p>
<p style="position:absolute;top:557px;left:148px;white-space:nowrap" class="ft3121"><b>MARKETING AUTHORISATION NUMBER</b></p>
<p style="position:absolute;top:597px;left:106px;white-space:nowrap" class="ft3124">EU/1/03/256/021<br/>EU/1/03/256/027</p>
<p style="position:absolute;top:675px;left:106px;white-space:nowrap" class="ft3121"><b>13.</b></p>
<p style="position:absolute;top:675px;left:148px;white-space:nowrap" class="ft3121"><b>BATCH NUMBER</b></p>
<p style="position:absolute;top:716px;left:106px;white-space:nowrap" class="ft3122">Lot&#160;</p>
<p style="position:absolute;top:775px;left:106px;white-space:nowrap" class="ft3121"><b>14.</b></p>
<p style="position:absolute;top:775px;left:148px;white-space:nowrap" class="ft3121"><b>GENERAL CLASSIFICATION FOR&#160;SUPPLY</b></p>
<p style="position:absolute;top:836px;left:106px;white-space:nowrap" class="ft3121"><b>15.</b></p>
<p style="position:absolute;top:836px;left:148px;white-space:nowrap" class="ft3121"><b>INSTRUCTIONS ON&#160;USE</b></p>
<p style="position:absolute;top:897px;left:106px;white-space:nowrap" class="ft3121"><b>16.</b></p>
<p style="position:absolute;top:897px;left:148px;white-space:nowrap" class="ft3121"><b>INFORMATION IN BRAILLE</b></p>
<p style="position:absolute;top:938px;left:106px;white-space:nowrap" class="ft3122">Humira 80&#160;mg</p>
<p style="position:absolute;top:997px;left:106px;white-space:nowrap" class="ft3121"><b>17.&#160;&#160;UNIQUE INDENTIFIER&#160;–&#160;2D BARCODE</b></p>
<p style="position:absolute;top:1037px;left:106px;white-space:nowrap" class="ft3122">2D barcode carrying the unique identifier included.</p>
</div>
<!-- Page 313 -->
<a name="313"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page313-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3130">313</p>
<p style="position:absolute;top:88px;left:106px;white-space:nowrap" class="ft3131"><b>18.&#160;&#160;UNIQUE INDENTIFIER&#160;–&#160;HUMAN READABLE&#160;DATA</b></p>
<p style="position:absolute;top:129px;left:106px;white-space:nowrap" class="ft3134">PC<br/>SN<br/>NN</p>
</div>
<!-- Page 314 -->
<a name="314"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page314-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3140">314</p>
<p style="position:absolute;top:88px;left:106px;white-space:nowrap" class="ft3141"><b>MINIMUM PARTICULARS&#160;TO&#160;APPEAR ON BLISTERS OR STRIPS</b></p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft3141"><b>TRAY BACKING TEXT</b></p>
<p style="position:absolute;top:188px;left:106px;white-space:nowrap" class="ft3141"><b>1.</b></p>
<p style="position:absolute;top:188px;left:148px;white-space:nowrap" class="ft3141"><b>NAME OF THE MEDICINAL PRODUCT</b></p>
<p style="position:absolute;top:228px;left:106px;white-space:nowrap" class="ft3145">Humira 80&#160;mg solution for injection in pre-filled pen<br/>adalimumab</p>
<p style="position:absolute;top:306px;left:106px;white-space:nowrap" class="ft3141"><b>2.</b></p>
<p style="position:absolute;top:306px;left:148px;white-space:nowrap" class="ft3141"><b>NAME OF THE MARKETING AUTHORISATION HOLDER</b></p>
<p style="position:absolute;top:346px;left:106px;white-space:nowrap" class="ft3142">AbbVie&#160;(as logo)</p>
<p style="position:absolute;top:405px;left:106px;white-space:nowrap" class="ft3141"><b>3.</b></p>
<p style="position:absolute;top:405px;left:148px;white-space:nowrap" class="ft3141"><b>EXPIRY DATE</b></p>
<p style="position:absolute;top:445px;left:106px;white-space:nowrap" class="ft3142">EXP</p>
<p style="position:absolute;top:505px;left:106px;white-space:nowrap" class="ft3141"><b>4.</b></p>
<p style="position:absolute;top:505px;left:148px;white-space:nowrap" class="ft3141"><b>BATCH NUMBER</b></p>
<p style="position:absolute;top:545px;left:106px;white-space:nowrap" class="ft3142">Lot&#160;</p>
<p style="position:absolute;top:604px;left:106px;white-space:nowrap" class="ft3141"><b>5.</b></p>
<p style="position:absolute;top:604px;left:148px;white-space:nowrap" class="ft3141"><b>OTHER</b></p>
<p style="position:absolute;top:644px;left:106px;white-space:nowrap" class="ft3142">For storage information, see package leaflet.</p>
<p style="position:absolute;top:682px;left:106px;white-space:nowrap" class="ft3142">For single use only.</p>
</div>
<!-- Page 315 -->
<a name="315"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page315-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3150">315</p>
<p style="position:absolute;top:88px;left:106px;white-space:nowrap" class="ft3151"><b>MINIMUM PARTICULARS&#160;TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</b></p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft3151"><b>PEN LABEL</b></p>
<p style="position:absolute;top:188px;left:106px;white-space:nowrap" class="ft3151"><b>1.</b></p>
<p style="position:absolute;top:188px;left:148px;white-space:nowrap" class="ft3151"><b>NAME OF THE MEDICINAL PRODUCT AND ROUTE OF ADMINISTRATION</b></p>
<p style="position:absolute;top:228px;left:106px;white-space:nowrap" class="ft3154">Humira 80&#160;mg injection<br/>adalimumab<br/>SC</p>
<p style="position:absolute;top:325px;left:106px;white-space:nowrap" class="ft3151"><b>2.</b></p>
<p style="position:absolute;top:325px;left:148px;white-space:nowrap" class="ft3151"><b>METHOD OF ADMINISTRATION</b></p>
<p style="position:absolute;top:386px;left:106px;white-space:nowrap" class="ft3151"><b>3.</b></p>
<p style="position:absolute;top:386px;left:148px;white-space:nowrap" class="ft3151"><b>EXPIRY DATE</b></p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft3152">EXP</p>
<p style="position:absolute;top:486px;left:106px;white-space:nowrap" class="ft3151"><b>4.</b></p>
<p style="position:absolute;top:486px;left:148px;white-space:nowrap" class="ft3151"><b>BATCH NUMBER</b></p>
<p style="position:absolute;top:526px;left:106px;white-space:nowrap" class="ft3152">Lot&#160;</p>
<p style="position:absolute;top:585px;left:106px;white-space:nowrap" class="ft3151"><b>5.</b></p>
<p style="position:absolute;top:585px;left:148px;white-space:nowrap" class="ft3151"><b>CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT</b></p>
<p style="position:absolute;top:625px;left:106px;white-space:nowrap" class="ft3152">80&#160;mg/0.8 ml</p>
<p style="position:absolute;top:684px;left:106px;white-space:nowrap" class="ft3151"><b>6.</b></p>
<p style="position:absolute;top:684px;left:148px;white-space:nowrap" class="ft3151"><b>OTHER</b></p>
</div>
<!-- Page 316 -->
<a name="316"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page316-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3160">316</p>
<p style="position:absolute;top:88px;left:106px;white-space:nowrap" class="ft3161"><b>REMINDER STICKERS TEXT (included in pack)</b></p>
<p style="position:absolute;top:147px;left:106px;white-space:nowrap" class="ft3162">Humira&#160;</p>
<p style="position:absolute;top:185px;left:106px;white-space:nowrap" class="ft3162">Mark your calendar with the stickers&#160;provided to remind you of the date for your next dose.</p>
</div>
<!-- Page 317 -->
<a name="317"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page317-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3170">317</p>
<p style="position:absolute;top:522px;left:368px;white-space:nowrap" class="ft3171"><b>B. PACKAGE LEAFLET</b></p>
</div>
<!-- Page 318 -->
<a name="318"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page318-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3180">318</p>
<p style="position:absolute;top:105px;left:306px;white-space:nowrap" class="ft3181"><b>Package leaflet: Information for the patient</b></p>
<p style="position:absolute;top:143px;left:261px;white-space:nowrap" class="ft3181"><b>Humira&#160;20&#160;mg&#160;solution for injection in pre-filled syringe</b></p>
<p style="position:absolute;top:162px;left:418px;white-space:nowrap" class="ft3182">adalimumab</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft31819"><b>Read all of this leaflet carefully&#160;before your child starts using this medicine because it contains&#160;<br/>important information.</b></p>
<p style="position:absolute;top:237px;left:106px;white-space:nowrap" class="ft3186"></p>
<p style="position:absolute;top:239px;left:148px;white-space:nowrap" class="ft3182">Keep this leaflet. You may need to read it again.</p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft3186"></p>
<p style="position:absolute;top:259px;left:148px;white-space:nowrap" class="ft3184">Your doctor will also give you a&#160;<b>Patient Reminder Card</b>, which contains important safety&#160;<br/>information that you need to be aware of before your child begins using Humira and during&#160;<br/>treatment with Humira. Keep this&#160;<b>Patient Reminder Card&#160;</b>with you or your child.</p>
<p style="position:absolute;top:315px;left:106px;white-space:nowrap" class="ft3186"></p>
<p style="position:absolute;top:317px;left:148px;white-space:nowrap" class="ft3182">If you have any questions, ask your doctor or pharmacist.</p>
<p style="position:absolute;top:335px;left:106px;white-space:nowrap" class="ft3186"></p>
<p style="position:absolute;top:337px;left:148px;white-space:nowrap" class="ft3184">This medicine has been prescribed for your child only. Do not pass it on to others. It may harm&#160;<br/>them, even if their signs of illness are the same as your child.</p>
<p style="position:absolute;top:375px;left:106px;white-space:nowrap" class="ft3186"></p>
<p style="position:absolute;top:377px;left:148px;white-space:nowrap" class="ft3185">If your child gets any side effects, talk to your doctor or pharmacist. This includes any possible side&#160;<br/>effects not listed in this leaflet. See section 4.</p>
<p style="position:absolute;top:433px;left:106px;white-space:nowrap" class="ft31819"><b>What is in this leaflet<br/></b>1.</p>
<p style="position:absolute;top:453px;left:148px;white-space:nowrap" class="ft3182">What Humira is and what it is used for</p>
<p style="position:absolute;top:471px;left:106px;white-space:nowrap" class="ft3182">2.</p>
<p style="position:absolute;top:471px;left:148px;white-space:nowrap" class="ft3182">What you need to know before your child uses Humira</p>
<p style="position:absolute;top:490px;left:106px;white-space:nowrap" class="ft3182">3.</p>
<p style="position:absolute;top:490px;left:148px;white-space:nowrap" class="ft3182">How to use Humira</p>
<p style="position:absolute;top:509px;left:106px;white-space:nowrap" class="ft3182">4.</p>
<p style="position:absolute;top:509px;left:148px;white-space:nowrap" class="ft3182">Possible side effects</p>
<p style="position:absolute;top:528px;left:106px;white-space:nowrap" class="ft3182">5</p>
<p style="position:absolute;top:528px;left:148px;white-space:nowrap" class="ft3182">How to store Humira</p>
<p style="position:absolute;top:547px;left:106px;white-space:nowrap" class="ft3182">6.</p>
<p style="position:absolute;top:547px;left:148px;white-space:nowrap" class="ft3182">Contents of the pack and other information</p>
<p style="position:absolute;top:566px;left:106px;white-space:nowrap" class="ft3182">7.</p>
<p style="position:absolute;top:566px;left:148px;white-space:nowrap" class="ft3182">Injecting&#160;Humira</p>
<p style="position:absolute;top:623px;left:106px;white-space:nowrap" class="ft3181"><b>1.</b></p>
<p style="position:absolute;top:623px;left:148px;white-space:nowrap" class="ft3181"><b>What Humira is and what it is used for</b></p>
<p style="position:absolute;top:661px;left:106px;white-space:nowrap" class="ft3182">Humira contains the active substance adalimumab.</p>
<p style="position:absolute;top:699px;left:106px;white-space:nowrap" class="ft3182">Humira is&#160;intended for&#160;the&#160;treatment of&#160;the inflammatory diseases described below:</p>
<p style="position:absolute;top:717px;left:133px;white-space:nowrap" class="ft3186">&#160;Polyarticular juvenile idiopathic arthritis</p>
<p style="position:absolute;top:738px;left:133px;white-space:nowrap" class="ft3186">&#160;Enthesitis-related&#160;arthritis</p>
<p style="position:absolute;top:758px;left:133px;white-space:nowrap" class="ft3186">&#160;Paediatric plaque psoriasis</p>
<p style="position:absolute;top:778px;left:133px;white-space:nowrap" class="ft3186">&#160;Paediatric Crohn’s disease</p>
<p style="position:absolute;top:798px;left:133px;white-space:nowrap" class="ft3186">&#160;Paediatric uveitis</p>
<p style="position:absolute;top:838px;left:106px;white-space:nowrap" class="ft3184">The active ingredient&#160;in Humira, adalimumab, is a&#160;human&#160;monoclonal antibody. Monoclonal antibodies&#160;<br/>are&#160;proteins that&#160;attach to a specific target.</p>
<p style="position:absolute;top:895px;left:106px;white-space:nowrap" class="ft3184">The target of&#160;adalimumab&#160;is a&#160;protein&#160;called&#160;tumour necrosis factor&#160;(TNFα), which&#160;is involved in the&#160;<br/>immune (defence) system and&#160;is present at increased levels in&#160;the&#160;inflammatory diseases&#160;listed above.&#160;By&#160;<br/>attaching to&#160;TNFα, Humira decreases the process of inflammation in these diseases.</p>
<p style="position:absolute;top:971px;left:106px;white-space:nowrap" class="ft3182">Polyarticular juvenile idiopathic arthritis</p>
<p style="position:absolute;top:1008px;left:106px;white-space:nowrap" class="ft3184">Polyarticular juvenile idiopathic arthritis is an inflammatory disease of the joints&#160;that usually first appears&#160;<br/>in childhood.</p>
</div>
<!-- Page 319 -->
<a name="319"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page319-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3190">319</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft3194">Humira is used to treat polyarticular juvenile idiopathic arthritis in&#160;patients from 2&#160;years of age.&#160;Your child&#160;<br/>may first be given other disease-modifying medicines, such as methotrexate.&#160;If&#160;these medicines&#160;do not&#160;<br/>work&#160;well enough,&#160;your child&#160;will be given&#160;Humira&#160;to treat&#160;his/her&#160;polyarticular juvenile idiopathic&#160;<br/>arthritis.</p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft3192">Your doctor will decide if Humira should be used with methotrexate or alone.</p>
<p style="position:absolute;top:219px;left:106px;white-space:nowrap" class="ft3192">Enthesitis-related arthritis</p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft3194">Enthesitis-related arthritis is an inflammatory disease of the joints and the places where tendons join the&#160;<br/>bone.</p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft3194">Humira is used to treat enthesitis-related arthritis in patients from 6&#160;years of age.&#160;Your child&#160;may first be&#160;<br/>given other disease-modifying medicines, such as methotrexate.&#160;If&#160;these&#160;medicines&#160;do not&#160;work&#160;well&#160;<br/>enough,&#160;your child&#160;will be given&#160;Humira&#160;to treat&#160;his/her&#160;enthesitis-related&#160;arthritis.</p>
<p style="position:absolute;top:390px;left:106px;white-space:nowrap" class="ft3192">Paediatric plaque psoriasis</p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft3194">Plaque psoriasis is a skin condition that causes red, flaky, crusty patches of skin covered with silvery&#160;<br/>scales.&#160;Plaque psoriasis can also affect the nails, causing them to crumble, become thickened and lift away&#160;<br/>from&#160;the nail bed which can be painful. Psoriasis is believed to be caused by a problem with the body’s&#160;<br/>immune system that leads to an increased production of skin cells.</p>
<p style="position:absolute;top:522px;left:106px;white-space:nowrap" class="ft3194">Humira is used to treat severe chronic plaque psoriasis in children and adolescents aged 4 to 17&#160;years for&#160;<br/>whom topical therapy and phototherapies have either not worked very well or are not suitable.</p>
<p style="position:absolute;top:579px;left:106px;white-space:nowrap" class="ft3192">Paediatric&#160;Crohn’s disease</p>
<p style="position:absolute;top:617px;left:106px;white-space:nowrap" class="ft3192">Crohn’s disease is an inflammatory disease of the digestive tract.</p>
<p style="position:absolute;top:655px;left:106px;white-space:nowrap" class="ft3192">Humira is used to treat moderate to severe&#160;Crohn’s disease in children and adolescents aged 6 to 17&#160;years.</p>
<p style="position:absolute;top:693px;left:106px;white-space:nowrap" class="ft3194">Your child may first be given other medicines.&#160;If&#160;these medicines&#160;do not&#160;work&#160;well enough,&#160;your child<br/>will be given&#160;Humira&#160;to reduce the signs and symptoms of&#160;his/her&#160;disease.</p>
<p style="position:absolute;top:750px;left:106px;white-space:nowrap" class="ft3192">Paediatric&#160;uveitis</p>
<p style="position:absolute;top:788px;left:106px;white-space:nowrap" class="ft3192">Non-infectious uveitis is an inflammatory disease affecting certain parts of the eye.</p>
<p style="position:absolute;top:826px;left:106px;white-space:nowrap" class="ft3194">Humira is used to treat&#160;children&#160;with chronic non-infectious uveitis from 2&#160;years of age with inflammation&#160;<br/>affecting&#160;the front of&#160;the&#160;eye</p>
<p style="position:absolute;top:883px;left:106px;white-space:nowrap" class="ft3194">This inflammation&#160;may&#160;lead to a decrease of vision and/or the presence of floaters in the&#160;eye&#160;(black dots or&#160;<br/>wispy lines that move across the field of vision). Humira works by reducing this inflammation.</p>
<p style="position:absolute;top:940px;left:106px;white-space:nowrap" class="ft3194">Your child may&#160;first be given other medicines.&#160;If&#160;these medicines&#160;do&#160;not&#160;work&#160;well enough,&#160;your child<br/>will be given&#160;Humira&#160;to reduce the signs and symptoms of&#160;his/her&#160;disease.</p>
</div>
<!-- Page 320 -->
<a name="320"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page320-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3200">320</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft3201"><b>2.</b></p>
<p style="position:absolute;top:86px;left:148px;white-space:nowrap" class="ft3201"><b>What you need to know before your child uses Humira</b></p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft3201"><b>Do not use Humira:</b></p>
<p style="position:absolute;top:161px;left:133px;white-space:nowrap" class="ft3206">&#160;If your child is allergic to adalimumab or any of the other ingredients of this medicine (listed in&#160;</p>
<p style="position:absolute;top:182px;left:160px;white-space:nowrap" class="ft3202">section 6).&#160;</p>
<p style="position:absolute;top:219px;left:133px;white-space:nowrap" class="ft3206">&#160;If your child has active tuberculosis or other severe infections (see “Warnings and precautions”).&#160;</p>
<p style="position:absolute;top:240px;left:160px;white-space:nowrap" class="ft3204">It is important that you tell your doctor if your child has symptoms of infections, for example,&#160;<br/>fever, wounds, feeling tired, dental problems.</p>
<p style="position:absolute;top:296px;left:133px;white-space:nowrap" class="ft3206">&#160;If your child has moderate or severe heart failure. It is important to tell your doctor if your child&#160;</p>
<p style="position:absolute;top:317px;left:160px;white-space:nowrap" class="ft3202">has had or has a serious heart condition (see “Warnings and precautions”).</p>
<p style="position:absolute;top:355px;left:106px;white-space:nowrap" class="ft3201"><b>Warnings and precautions</b></p>
<p style="position:absolute;top:393px;left:106px;white-space:nowrap" class="ft3202">Talk to your doctor or pharmacist before using Humira.</p>
<p style="position:absolute;top:431px;left:106px;white-space:nowrap" class="ft3202">Allergic reactions</p>
<p style="position:absolute;top:468px;left:133px;white-space:nowrap" class="ft3206">&#160;If your child gets allergic reactions with symptoms such as chest tightness, wheezing, dizziness,&#160;</p>
<p style="position:absolute;top:489px;left:160px;white-space:nowrap" class="ft3205">swelling or rash do not inject more Humira and contact your doctor immediately&#160;since, in rare&#160;<br/>cases, these reactions can be life threatening.</p>
<p style="position:absolute;top:546px;left:106px;white-space:nowrap" class="ft3202">Infections</p>
<p style="position:absolute;top:583px;left:133px;white-space:nowrap" class="ft3206">&#160;If your child has an infection, including long-term&#160;infection or an infection in one part of the body&#160;</p>
<p style="position:absolute;top:604px;left:160px;white-space:nowrap" class="ft3204">(for example, leg ulcer) consult your doctor before starting Humira. If you are unsure, contact&#160;<br/>your doctor.&#160;</p>
<p style="position:absolute;top:661px;left:133px;white-space:nowrap" class="ft3206">&#160;Your child might get infections more easily while he/she is receiving Humira treatment. This risk&#160;</p>
<p style="position:absolute;top:681px;left:160px;white-space:nowrap" class="ft3204">may increase&#160;if your child has problems with his/her lungs. These infections may be serious and&#160;<br/>include:&#160;</p>
<p style="position:absolute;top:718px;left:187px;white-space:nowrap" class="ft3206">&#160;tuberculosis</p>
<p style="position:absolute;top:739px;left:187px;white-space:nowrap" class="ft3206">&#160;infections caused by viruses, fungi, parasites or bacteria</p>
<p style="position:absolute;top:759px;left:187px;white-space:nowrap" class="ft3206">&#160;severe infection in the blood (sepsis)</p>
<p style="position:absolute;top:798px;left:160px;white-space:nowrap" class="ft3204">In rare cases, these infections can be life-threatening. It is important to tell your doctor if your&#160;<br/>child gets symptoms such as fever, wounds, feeling tired or dental problems. Your doctor may tell&#160;<br/>you to stop using Humira for some time.</p>
<p style="position:absolute;top:874px;left:133px;white-space:nowrap" class="ft3206">&#160;Tell your doctor if your child lives or travels in regions where fungal infections (for example,&#160;</p>
<p style="position:absolute;top:895px;left:160px;white-space:nowrap" class="ft3202">histoplasmosis, coccidioidomycosis or blastomycosis) are very common.</p>
<p style="position:absolute;top:932px;left:133px;white-space:nowrap" class="ft3206">&#160;Tell your doctor if your child has had infections which keep coming back or other conditions that&#160;</p>
<p style="position:absolute;top:953px;left:160px;white-space:nowrap" class="ft3202">increase the risk of infections.</p>
<p style="position:absolute;top:990px;left:133px;white-space:nowrap" class="ft3206">&#160;Your child and his/her doctor should pay special attention to signs of infection while your child is&#160;</p>
<p style="position:absolute;top:1011px;left:160px;white-space:nowrap" class="ft3204">being treated with Humira. It is important to tell your doctor if your child gets symptoms of&#160;<br/>infections, such as fever, wounds, feeling tired or dental problems.</p>
</div>
<!-- Page 321 -->
<a name="321"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page321-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3210">321</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft3212">Tuberculosis</p>
<p style="position:absolute;top:123px;left:131px;white-space:nowrap" class="ft3216">&#160;As cases of tuberculosis have been reported in patients treated with Humira, your doctor will&#160;</p>
<p style="position:absolute;top:144px;left:158px;white-space:nowrap" class="ft3215">check your child for signs and symptoms of tuberculosis before starting Humira. This will include&#160;<br/>a thorough medical evaluation including your child’s medical history and appropriate screening&#160;<br/>tests (for example, chest X-ray and a tuberculin test). The conduct and results of these tests should&#160;<br/>be recorded&#160;on your child’s&#160;<b>Patient Reminder Card</b>.&#160;</p>
<p style="position:absolute;top:238px;left:191px;white-space:nowrap" class="ft3216">&#160;It is very important that you tell your doctor if your child has ever had tuberculosis, or if&#160;</p>
<p style="position:absolute;top:259px;left:212px;white-space:nowrap" class="ft3215">your child has been in close contact with someone who has had tuberculosis. If your child&#160;<br/>has active tuberculosis, do not&#160;use Humira.</p>
<p style="position:absolute;top:296px;left:191px;white-space:nowrap" class="ft3216">&#160;Tuberculosis can develop during therapy even if your child has received treatment for the&#160;</p>
<p style="position:absolute;top:317px;left:212px;white-space:nowrap" class="ft3212">prevention of tuberculosis.&#160;</p>
<p style="position:absolute;top:335px;left:191px;white-space:nowrap" class="ft3216">&#160;If symptoms of tuberculosis (for example, cough that does not go away, weight loss, lack&#160;</p>
<p style="position:absolute;top:356px;left:212px;white-space:nowrap" class="ft3214">of&#160;energy, mild fever), or any other infection appear during or after therapy tell your&#160;<br/>doctor immediately.</p>
<p style="position:absolute;top:413px;left:106px;white-space:nowrap" class="ft3212">Hepatitis B</p>
<p style="position:absolute;top:451px;left:133px;white-space:nowrap" class="ft3216">&#160;Tell your doctor if your child is a carrier of the hepatitis B virus (HBV), if he/she has active HBV&#160;</p>
<p style="position:absolute;top:471px;left:160px;white-space:nowrap" class="ft3212">or if you think he/she might be at risk of getting HBV.&#160;</p>
<p style="position:absolute;top:490px;left:187px;white-space:nowrap" class="ft3216">&#160;Your doctor&#160;should test your child for HBV. In people who carry HBV, Humira can cause&#160;</p>
<p style="position:absolute;top:510px;left:214px;white-space:nowrap" class="ft3212">the virus to become active again.</p>
<p style="position:absolute;top:529px;left:187px;white-space:nowrap" class="ft3216">&#160;In some rare cases, especially if your child is taking other medicines that suppress the&#160;</p>
<p style="position:absolute;top:550px;left:214px;white-space:nowrap" class="ft3212">immune system, reactivation of HBV can be life-threatening. &#160;</p>
<p style="position:absolute;top:588px;left:106px;white-space:nowrap" class="ft3212">Surgery&#160;or dental procedure</p>
<p style="position:absolute;top:625px;left:133px;white-space:nowrap" class="ft3216">&#160;If your child is about to have surgery or dental procedures please inform your doctor that your&#160;</p>
<p style="position:absolute;top:646px;left:160px;white-space:nowrap" class="ft3212">child is taking Humira. Your doctor may recommend temporary discontinuation of Humira.&#160;</p>
<p style="position:absolute;top:684px;left:106px;white-space:nowrap" class="ft3212">Demyelinating disease</p>
<p style="position:absolute;top:721px;left:133px;white-space:nowrap" class="ft3216">&#160;If your child has or develops&#160;a&#160;demyelinating disease&#160;(a disease that affects the insulating layer&#160;</p>
<p style="position:absolute;top:742px;left:160px;white-space:nowrap" class="ft3214">around the nerves,&#160;such as multiple sclerosis), your doctor will decide if he/she should receive or&#160;<br/>continue to receive Humira. Tell your doctor immediately&#160;if&#160;your child experiences symptoms like&#160;<br/>changes in vision, weakness in arms or legs or numbness or tingling in any part of the body.</p>
<p style="position:absolute;top:818px;left:106px;white-space:nowrap" class="ft3212">Vaccinations</p>
<p style="position:absolute;top:855px;left:133px;white-space:nowrap" class="ft3216">&#160;Certain vaccines may cause infections and should not be given while receiving Humira.&#160;</p>
<p style="position:absolute;top:894px;left:187px;white-space:nowrap" class="ft3216">&#160;Check with your doctor before your child receives any vaccines.&#160;</p>
<p style="position:absolute;top:914px;left:187px;white-space:nowrap" class="ft3216">&#160;It is recommended that children, if possible, be&#160;given all the scheduled vaccinations for&#160;</p>
<p style="position:absolute;top:935px;left:214px;white-space:nowrap" class="ft3212">their age before they start treatment&#160;with Humira.</p>
<p style="position:absolute;top:953px;left:187px;white-space:nowrap" class="ft3216">&#160;If your child received Humira while she was pregnant, her baby may be at higher risk for&#160;</p>
<p style="position:absolute;top:974px;left:214px;white-space:nowrap" class="ft3214">getting such an infection for up to approximately five months after the last Humira dose&#160;<br/>she received during pregnancy.&#160;It is&#160;important that you tell her baby's doctors and other&#160;<br/>health care professionals about your child’s Humira use during her pregnancy so they can&#160;<br/>decide when her baby should receive any vaccine.</p>
</div>
<!-- Page 322 -->
<a name="322"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page322-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3220">322</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft3222">Heart&#160;failure</p>
<p style="position:absolute;top:123px;left:133px;white-space:nowrap" class="ft3226">&#160;If your child&#160;has&#160;mild heart failure and&#160;is&#160;being treated with&#160;Humira,&#160;his/her&#160;heart failure&#160;status&#160;</p>
<p style="position:absolute;top:144px;left:160px;white-space:nowrap" class="ft3225">must be closely monitored by your doctor. It is important to tell your doctor if your child&#160;has&#160;had&#160;<br/>or has&#160;a serious heart condition. If&#160;he/she&#160;develops&#160;new or worsening symptoms of heart failure&#160;<br/>(e.g. shortness of breath, or swelling of your feet), you must contact your doctor immediately.&#160;<br/>Your doctor will decide if your child&#160;should receive&#160;Humira.</p>
<p style="position:absolute;top:239px;left:106px;white-space:nowrap" class="ft3222">Fever, bruising, bleeding&#160;or looking&#160;pale</p>
<p style="position:absolute;top:276px;left:133px;white-space:nowrap" class="ft3226">&#160;In some patients the body may fail to produce enough of the blood cells&#160;that&#160;fight off infections or&#160;</p>
<p style="position:absolute;top:297px;left:160px;white-space:nowrap" class="ft3224">help your child to stop bleeding. Your doctor may decide to stop treatment.&#160;If your child&#160;develops<br/>a fever that does not go away,&#160;develops light&#160;bruises&#160;or bleeds&#160;very&#160;easily or looks&#160;very pale, call&#160;<br/>your doctor right away.</p>
<p style="position:absolute;top:373px;left:106px;white-space:nowrap" class="ft3222">Cancer</p>
<p style="position:absolute;top:410px;left:133px;white-space:nowrap" class="ft3226">&#160;There have been very rare cases of certain kinds of cancer in children and adult patients taking&#160;</p>
<p style="position:absolute;top:431px;left:160px;white-space:nowrap" class="ft3222">Humira or other TNF blockers. &#160;</p>
<p style="position:absolute;top:468px;left:187px;white-space:nowrap" class="ft3226">&#160;People with more serious rheumatoid arthritis that have had the disease for a long time&#160;</p>
<p style="position:absolute;top:489px;left:214px;white-space:nowrap" class="ft3225">may have a higher than average risk&#160;of&#160;getting lymphoma (a cancer&#160;that affects the lymph&#160;<br/>system)&#160;and leukaemia (a cancer that affects the blood and bone marrow).</p>
<p style="position:absolute;top:526px;left:187px;white-space:nowrap" class="ft3226">&#160;If your child takes Humira the risk of getting lymphoma, leukaemia, or other cancers may&#160;</p>
<p style="position:absolute;top:547px;left:214px;white-space:nowrap" class="ft3224">increase.&#160;On rare occasions, an uncommon&#160;and severe type of lymphoma, has been seen in&#160;<br/>patients taking Humira. Some of those patients were also treated with azathioprine or 6-<br/>mercaptopurine.</p>
<p style="position:absolute;top:604px;left:187px;white-space:nowrap" class="ft3226">&#160;Tell your doctor if your child is taking azathioprine or 6-mercaptopurine with Humira.&#160;</p>
<p style="position:absolute;top:624px;left:187px;white-space:nowrap" class="ft3226">&#160;Cases of non-melanoma skin cancer have been observed in patients taking Humira.&#160;</p>
<p style="position:absolute;top:644px;left:187px;white-space:nowrap" class="ft3226">&#160;If new skin lesions appear during or after therapy or if existing lesions change appearance,&#160;</p>
<p style="position:absolute;top:665px;left:214px;white-space:nowrap" class="ft3222">tell your doctor.</p>
<p style="position:absolute;top:702px;left:133px;white-space:nowrap" class="ft3226">&#160;There have been cases of cancers, other than lymphoma in patients with a specific type of lung&#160;</p>
<p style="position:absolute;top:723px;left:160px;white-space:nowrap" class="ft3224">disease called Chronic Obstructive Pulmonary Disease (COPD) treated with another TNF blocker.&#160;<br/>If your child has COPD, or is a heavy smoker, you should discuss with your doctor whether&#160;<br/>treatment with a TNF blocker is appropriate for your child.</p>
<p style="position:absolute;top:798px;left:106px;white-space:nowrap" class="ft3222">Autoimmune disease</p>
<p style="position:absolute;top:836px;left:133px;white-space:nowrap" class="ft3226">&#160;On rare occasions, treatment with Humira could result in lupus-like syndrome. Contact your&#160;</p>
<p style="position:absolute;top:857px;left:160px;white-space:nowrap" class="ft3222">doctor if symptoms such as persistent unexplained rash, fever, joint pain or tiredness&#160;occur.</p>
<p style="position:absolute;top:895px;left:106px;white-space:nowrap" class="ft3221"><b>Other medicines and Humira</b></p>
<p style="position:absolute;top:933px;left:106px;white-space:nowrap" class="ft3225">Tell your doctor&#160;or pharmacist if your child is taking, has recently taken or might take any other&#160;<br/>medicines.</p>
<p style="position:absolute;top:990px;left:106px;white-space:nowrap" class="ft3225">Your child should not take Humira with medicines containing the following active substances due to&#160;<br/>increased risk of serious infection:</p>
<p style="position:absolute;top:1027px;left:133px;white-space:nowrap" class="ft3226">&#160;anakinra</p>
<p style="position:absolute;top:1047px;left:133px;white-space:nowrap" class="ft3226">&#160;abatacept.</p>
</div>
<!-- Page 323 -->
<a name="323"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page323-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3230">323</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft3232">Humira can be taken together with:</p>
<p style="position:absolute;top:104px;left:133px;white-space:nowrap" class="ft3236">&#160;methotrexate</p>
<p style="position:absolute;top:124px;left:133px;white-space:nowrap" class="ft3236">&#160;certain disease-modifying anti-rheumatic agents (for example, sulfasalazine, hydroxychloroquine,&#160;</p>
<p style="position:absolute;top:145px;left:147px;white-space:nowrap" class="ft3232">leflunomide and injectable gold preparations)</p>
<p style="position:absolute;top:163px;left:133px;white-space:nowrap" class="ft3236">&#160;steroids or pain medications including non-steroidal anti-inflammatory&#160;drugs (NSAIDs).</p>
<p style="position:absolute;top:203px;left:106px;white-space:nowrap" class="ft3232">If you have questions, please ask your doctor.</p>
<p style="position:absolute;top:241px;left:106px;white-space:nowrap" class="ft3231"><b>Pregnancy and breast-feeding</b></p>
<p style="position:absolute;top:279px;left:132px;white-space:nowrap" class="ft3236">&#160;Your child&#160;should consider the&#160;use&#160;of&#160;adequate contraception&#160;to prevent pregnancy&#160;and&#160;continue&#160;</p>
<p style="position:absolute;top:300px;left:159px;white-space:nowrap" class="ft3232">its use&#160;for at least 5 months after the last Humira treatment.</p>
<p style="position:absolute;top:318px;left:132px;white-space:nowrap" class="ft3236">&#160;If&#160;your child is pregnant, thinks she may be pregnant or is planning to have a baby, ask her doctor&#160;</p>
<p style="position:absolute;top:338px;left:159px;white-space:nowrap" class="ft3232">for advice about taking this medicine.</p>
<p style="position:absolute;top:357px;left:132px;white-space:nowrap" class="ft3236">&#160;Humira should only be used during a pregnancy if needed.</p>
<p style="position:absolute;top:377px;left:132px;white-space:nowrap" class="ft3236">&#160;According to a pregnancy study, there was no higher risk of&#160;birth defects when the mother had&#160;</p>
<p style="position:absolute;top:398px;left:159px;white-space:nowrap" class="ft3234">received Humira during pregnancy compared&#160;with&#160;mothers with the same disease who did not&#160;<br/>receive Humira.</p>
<p style="position:absolute;top:435px;left:132px;white-space:nowrap" class="ft3236">&#160;Humira can be used during breast-feeding.</p>
<p style="position:absolute;top:455px;left:132px;white-space:nowrap" class="ft3236">&#160;If your child received&#160;Humira during her pregnancy, her baby may have a higher risk for getting&#160;</p>
<p style="position:absolute;top:476px;left:159px;white-space:nowrap" class="ft3232">an infection.</p>
<p style="position:absolute;top:494px;left:132px;white-space:nowrap" class="ft3236">&#160;It is important that you tell her baby’s doctor and other health care professionals about her Humira&#160;</p>
<p style="position:absolute;top:515px;left:159px;white-space:nowrap" class="ft3234">use during her pregnancy before the baby receives any vaccine. For more information on vaccines&#160;<br/>see the “Warnings and precautions” section.</p>
<p style="position:absolute;top:572px;left:106px;white-space:nowrap" class="ft3231"><b>Driving and using machines</b></p>
<p style="position:absolute;top:610px;left:106px;white-space:nowrap" class="ft3235">Humira may have a small effect on your child’s ability to drive, cycle or use machines. Room spinning&#160;<br/>sensation and vision disturbances may occur after taking Humira.</p>
<p style="position:absolute;top:686px;left:106px;white-space:nowrap" class="ft3231"><b>3.</b></p>
<p style="position:absolute;top:686px;left:148px;white-space:nowrap" class="ft3231"><b>How to use Humira</b></p>
<p style="position:absolute;top:724px;left:106px;white-space:nowrap" class="ft3234">Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or&#160;<br/>pharmacist if you are not sure.&#160;</p>
<p style="position:absolute;top:781px;left:106px;white-space:nowrap" class="ft3234">The recommended doses for Humira in each of the approved uses are shown in the following table. Your&#160;<br/>doctor may prescribe another strength of Humira if your child needs a different dose.</p>
<p style="position:absolute;top:838px;left:114px;white-space:nowrap" class="ft32319"><b>Polyarticular juvenile idiopathic arthritis<br/>Age or body weight</b></p>
<p style="position:absolute;top:858px;left:346px;white-space:nowrap" class="ft32319"><b>How much and how often to&#160;<br/>take?</b></p>
<p style="position:absolute;top:858px;left:579px;white-space:nowrap" class="ft3231"><b>Notes</b></p>
<p style="position:absolute;top:897px;left:114px;white-space:nowrap" class="ft3234">Children, adolescents and adults&#160;<br/>from 2 years of age weighing 30&#160;<br/>kg or more</p>
<p style="position:absolute;top:897px;left:346px;white-space:nowrap" class="ft3232">40 mg&#160;every other week</p>
<p style="position:absolute;top:897px;left:579px;white-space:nowrap" class="ft3232">Not applicable</p>
<p style="position:absolute;top:955px;left:114px;white-space:nowrap" class="ft3234">Children and adolescents from 2&#160;<br/>years of age weighing 10 kg to&#160;<br/>less than 30 kg</p>
<p style="position:absolute;top:955px;left:346px;white-space:nowrap" class="ft3232">20 mg every other week</p>
<p style="position:absolute;top:955px;left:579px;white-space:nowrap" class="ft3232">Not applicable</p>
<p style="position:absolute;top:1032px;left:114px;white-space:nowrap" class="ft32319"><b>Enthesitis-related arthritis<br/>Age or body weight</b></p>
<p style="position:absolute;top:1052px;left:346px;white-space:nowrap" class="ft32319"><b>How much and how often to&#160;<br/>take?</b></p>
<p style="position:absolute;top:1052px;left:579px;white-space:nowrap" class="ft3231"><b>Notes</b></p>
</div>
<!-- Page 324 -->
<a name="324"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page324-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3240">324</p>
<p style="position:absolute;top:87px;left:114px;white-space:nowrap" class="ft3245">Children,&#160;adolescents and adults&#160;<br/>from 6 years of age weighing 30&#160;<br/>kg or more</p>
<p style="position:absolute;top:87px;left:346px;white-space:nowrap" class="ft3242">40 mg every other week</p>
<p style="position:absolute;top:87px;left:579px;white-space:nowrap" class="ft3242">Not applicable</p>
<p style="position:absolute;top:144px;left:114px;white-space:nowrap" class="ft3245">Children and adolescents from 6&#160;<br/>years of age weighing 15 kg to&#160;<br/>less than 30 kg</p>
<p style="position:absolute;top:144px;left:346px;white-space:nowrap" class="ft3242">20 mg every other week</p>
<p style="position:absolute;top:144px;left:579px;white-space:nowrap" class="ft3242">Not applicable</p>
<p style="position:absolute;top:222px;left:114px;white-space:nowrap" class="ft32419"><b>Paediatric plaque psoriasis<br/>Age&#160;or body weight</b></p>
<p style="position:absolute;top:242px;left:346px;white-space:nowrap" class="ft32419"><b>How much and how often to&#160;<br/>take?</b></p>
<p style="position:absolute;top:242px;left:579px;white-space:nowrap" class="ft3241"><b>Notes</b></p>
<p style="position:absolute;top:280px;left:114px;white-space:nowrap" class="ft3244">Children and adolescents from 4&#160;<br/>to 17 years of age weighing 30&#160;<br/>kg or more</p>
<p style="position:absolute;top:280px;left:346px;white-space:nowrap" class="ft3244">First dose of 40 mg, followed by&#160;<br/>40 mg one week later.</p>
<p style="position:absolute;top:337px;left:346px;white-space:nowrap" class="ft3244">Thereafter, the usual dose is 40&#160;<br/>mg&#160;every other week.</p>
<p style="position:absolute;top:280px;left:579px;white-space:nowrap" class="ft3242">Not applicable</p>
<p style="position:absolute;top:376px;left:114px;white-space:nowrap" class="ft3245">Children and adolescents from 4&#160;<br/>to 17 years of age weighing 15&#160;<br/>kg to less than 30 kg</p>
<p style="position:absolute;top:376px;left:346px;white-space:nowrap" class="ft3244">First dose of 20 mg, followed by&#160;<br/>20 mg one week later.</p>
<p style="position:absolute;top:433px;left:346px;white-space:nowrap" class="ft3244">Thereafter, the usual dose is 20&#160;<br/>mg&#160;every other week.</p>
<p style="position:absolute;top:376px;left:579px;white-space:nowrap" class="ft3242">Not applicable</p>
<p style="position:absolute;top:491px;left:114px;white-space:nowrap" class="ft32419"><b>Paediatric Crohn’s disease<br/>Age or body&#160;weight</b></p>
<p style="position:absolute;top:511px;left:346px;white-space:nowrap" class="ft32419"><b>How much and how often to&#160;<br/>take?</b></p>
<p style="position:absolute;top:511px;left:579px;white-space:nowrap" class="ft3241"><b>Notes</b></p>
<p style="position:absolute;top:550px;left:114px;white-space:nowrap" class="ft3244">Children and adolescents from 6&#160;<br/>to 17 years of age weighing 40&#160;<br/>kg or more</p>
<p style="position:absolute;top:550px;left:346px;white-space:nowrap" class="ft3245">First dose of 80 mg, followed by&#160;<br/>40 mg two weeks later.</p>
<p style="position:absolute;top:607px;left:346px;white-space:nowrap" class="ft3244">If a faster response is required,&#160;<br/>your child’s doctor may&#160;<br/>prescribe a first&#160;dose&#160;of 160 mg,&#160;<br/>followed by 80 mg two weeks&#160;<br/>later.</p>
<p style="position:absolute;top:720px;left:346px;white-space:nowrap" class="ft3244">Thereafter, the usual dose is 40&#160;<br/>mg&#160;every other week.</p>
<p style="position:absolute;top:550px;left:579px;white-space:nowrap" class="ft3244">Your child’s doctor may&#160;<br/>increase the dosage to 40 mg&#160;<br/>every week&#160;or 80 mg every&#160;<br/>other week.</p>
<p style="position:absolute;top:759px;left:114px;white-space:nowrap" class="ft3244">Children and adolescents from 6&#160;<br/>to 17 years of age weighing less&#160;<br/>than 40 kg</p>
<p style="position:absolute;top:759px;left:346px;white-space:nowrap" class="ft3244">First dose of 40 mg, followed by&#160;<br/>20 mg two weeks later.&#160;</p>
<p style="position:absolute;top:816px;left:346px;white-space:nowrap" class="ft3244">If a faster response is required,&#160;<br/>the doctor may prescribe a first&#160;<br/>dose of 80 mg, followed by 40&#160;<br/>mg two weeks later.</p>
<p style="position:absolute;top:911px;left:346px;white-space:nowrap" class="ft3244">Thereafter, the usual dose is 20&#160;<br/>mg&#160;every other week.</p>
<p style="position:absolute;top:759px;left:579px;white-space:nowrap" class="ft3244">Your child’s doctor may&#160;<br/>increase the dose frequency to&#160;<br/>20 mg every week.</p>
</div>
<!-- Page 325 -->
<a name="325"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page325-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3250">325</p>
<p style="position:absolute;top:87px;left:114px;white-space:nowrap" class="ft32519"><b>Paediatric uveitis<br/>Age or body weight</b></p>
<p style="position:absolute;top:107px;left:346px;white-space:nowrap" class="ft32515"><b>How much&#160;and&#160;how often to&#160;<br/>take?</b></p>
<p style="position:absolute;top:107px;left:579px;white-space:nowrap" class="ft3251"><b>Notes</b></p>
<p style="position:absolute;top:145px;left:114px;white-space:nowrap" class="ft3254">Children and adolescents from&#160;<br/>2&#160;years of age weighing less&#160;<br/>than 30&#160;kg</p>
<p style="position:absolute;top:145px;left:346px;white-space:nowrap" class="ft3252">20&#160;mg&#160;every other week</p>
<p style="position:absolute;top:145px;left:579px;white-space:nowrap" class="ft3254">Your doctor may prescribe an&#160;<br/>initial dose of 40&#160;mg to be&#160;<br/>administered one week prior to&#160;<br/>the start of the usual dose of&#160;<br/>20&#160;mg&#160;every other week.&#160;<br/>Humira&#160;is&#160;recommended&#160;for&#160;use&#160;<br/>in combination with&#160;<br/>methotrexate.</p>
<p style="position:absolute;top:298px;left:114px;white-space:nowrap" class="ft3255">Children and adolescents from&#160;<br/>2&#160;years of age weighing 30&#160;kg&#160;<br/>or more</p>
<p style="position:absolute;top:298px;left:346px;white-space:nowrap" class="ft3252">40&#160;mg&#160;every other week&#160;</p>
<p style="position:absolute;top:298px;left:579px;white-space:nowrap" class="ft3254">Your doctor may prescribe an&#160;<br/>initial dose of 80&#160;mg to be&#160;<br/>administered one week prior to&#160;<br/>the start of the usual dose of&#160;<br/>40&#160;mg&#160;every other week.<br/>Humira&#160;is&#160;recommended&#160;for&#160;use&#160;<br/>in combination with&#160;<br/>methotrexate.</p>
<p style="position:absolute;top:469px;left:106px;white-space:nowrap" class="ft3251"><b>Method and route of administration</b></p>
<p style="position:absolute;top:507px;left:106px;white-space:nowrap" class="ft3252">Humira is administered by injection under the skin (by subcutaneous injection).</p>
<p style="position:absolute;top:545px;left:106px;white-space:nowrap" class="ft3251"><b>Detailed instructions on how to inject Humira are provided in section 7 ‘Injecting Humira’.</b></p>
<p style="position:absolute;top:583px;left:106px;white-space:nowrap" class="ft3251"><b>If you use more&#160;Humira&#160;than you should</b></p>
<p style="position:absolute;top:621px;left:106px;white-space:nowrap" class="ft3255">If you accidentally inject Humira more frequently than told to by your doctor or pharmacist, call your&#160;<br/>doctor or pharmacist&#160;and tell them that your child has taken more. Always take the outer carton of the&#160;<br/>medicine with you, even if it is empty.&#160;</p>
<p style="position:absolute;top:697px;left:106px;white-space:nowrap" class="ft3251"><b>If you forget to use Humira</b></p>
<p style="position:absolute;top:735px;left:106px;white-space:nowrap" class="ft3254">If you forget to give your child an injection, you should inject the next dose of Humira as soon as you&#160;<br/>remember. Then give your child’s next dose as you would have on the originally scheduled day, had you&#160;<br/>not forgotten a dose.&#160;</p>
<p style="position:absolute;top:811px;left:106px;white-space:nowrap" class="ft3251"><b>If you&#160;stop using Humira</b></p>
<p style="position:absolute;top:849px;left:106px;white-space:nowrap" class="ft3254">The&#160;decision to stop using Humira should be discussed with your doctor. Your child’s symptoms may&#160;<br/>return if you stop using Humira.</p>
<p style="position:absolute;top:905px;left:106px;white-space:nowrap" class="ft3252">If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
<p style="position:absolute;top:963px;left:106px;white-space:nowrap" class="ft3251"><b>4.</b></p>
<p style="position:absolute;top:963px;left:148px;white-space:nowrap" class="ft3251"><b>Possible side effects</b></p>
<p style="position:absolute;top:1000px;left:106px;white-space:nowrap" class="ft3255">Like all medicines, this medicine can cause side effects, although not everybody gets them. Most side&#160;<br/>effects are mild to moderate. However, some may be serious and require treatment. Side effects may occur&#160;<br/>at least up to 4 months after&#160;the&#160;last Humira injection.&#160;</p>
</div>
<!-- Page 326 -->
<a name="326"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page326-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3260">326</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft3261"><b>Tell your doctor immediately if you notice any of the following</b></p>
<p style="position:absolute;top:123px;left:106px;white-space:nowrap" class="ft3266">&#160;severe rash, hives or other signs of allergic reaction&#160;</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft3266">&#160;swollen face, hands, feet</p>
<p style="position:absolute;top:163px;left:106px;white-space:nowrap" class="ft3266">&#160;trouble breathing, swallowing</p>
<p style="position:absolute;top:184px;left:106px;white-space:nowrap" class="ft3266">&#160;shortness of breath with physical activity or upon&#160;lying down or swelling of the feet</p>
<p style="position:absolute;top:224px;left:106px;white-space:nowrap" class="ft3261"><b>Tell your doctor as soon as possible if you notice any of the following</b></p>
<p style="position:absolute;top:261px;left:106px;white-space:nowrap" class="ft3266">&#160;signs of infection such as fever, feeling sick, wounds, dental problems, burning on urination</p>
<p style="position:absolute;top:281px;left:106px;white-space:nowrap" class="ft3266">&#160;feeling weak or tired</p>
<p style="position:absolute;top:301px;left:106px;white-space:nowrap" class="ft3266">&#160;coughing</p>
<p style="position:absolute;top:321px;left:106px;white-space:nowrap" class="ft3266">&#160;tingling</p>
<p style="position:absolute;top:342px;left:106px;white-space:nowrap" class="ft3266">&#160;numbness</p>
<p style="position:absolute;top:362px;left:106px;white-space:nowrap" class="ft3266">&#160;double vision</p>
<p style="position:absolute;top:382px;left:106px;white-space:nowrap" class="ft3266">&#160;arm&#160;or leg weakness</p>
<p style="position:absolute;top:402px;left:106px;white-space:nowrap" class="ft3266">&#160;a bump or open sore that doesn't heal</p>
<p style="position:absolute;top:422px;left:106px;white-space:nowrap" class="ft3266">&#160;signs and symptoms suggestive of blood disorders such as persistent fever, bruising, bleeding,&#160;</p>
<p style="position:absolute;top:443px;left:133px;white-space:nowrap" class="ft3262">paleness</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft3265">The symptoms described above can be signs of the below listed side effects, which&#160;have been observed&#160;<br/>with Humira.</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft3261"><b>Very common&#160;</b>(may&#160;affect more than 1 in 10 people)<i>&#160;&#160;</i></p>
<p style="position:absolute;top:575px;left:106px;white-space:nowrap" class="ft3266"></p>
<p style="position:absolute;top:577px;left:147px;white-space:nowrap" class="ft3262">injection site reactions (including pain, swelling, redness or itching)</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft3266"></p>
<p style="position:absolute;top:597px;left:147px;white-space:nowrap" class="ft3262">respiratory tract infections (including cold, runny nose, sinus infection, pneumonia)</p>
<p style="position:absolute;top:615px;left:106px;white-space:nowrap" class="ft3266"></p>
<p style="position:absolute;top:617px;left:147px;white-space:nowrap" class="ft3262">headache</p>
<p style="position:absolute;top:635px;left:106px;white-space:nowrap" class="ft3266"></p>
<p style="position:absolute;top:637px;left:147px;white-space:nowrap" class="ft3262">abdominal pain</p>
<p style="position:absolute;top:655px;left:106px;white-space:nowrap" class="ft3266"></p>
<p style="position:absolute;top:657px;left:147px;white-space:nowrap" class="ft3262">nausea and vomiting</p>
<p style="position:absolute;top:676px;left:106px;white-space:nowrap" class="ft3266"></p>
<p style="position:absolute;top:678px;left:147px;white-space:nowrap" class="ft3262">rash</p>
<p style="position:absolute;top:696px;left:106px;white-space:nowrap" class="ft3266"></p>
<p style="position:absolute;top:698px;left:147px;white-space:nowrap" class="ft3262">musculoskeletal pain</p>
<p style="position:absolute;top:736px;left:106px;white-space:nowrap" class="ft3261"><b>Common&#160;</b>(may&#160;affect up to 1 in 10 people)</p>
<p style="position:absolute;top:773px;left:106px;white-space:nowrap" class="ft3266"></p>
<p style="position:absolute;top:775px;left:147px;white-space:nowrap" class="ft3262">serious infections (including blood poisoning and influenza)</p>
<p style="position:absolute;top:793px;left:106px;white-space:nowrap" class="ft3266"></p>
<p style="position:absolute;top:795px;left:147px;white-space:nowrap" class="ft3262">intestinal infections&#160;(including gastroenteritis)</p>
<p style="position:absolute;top:813px;left:106px;white-space:nowrap" class="ft3266"></p>
<p style="position:absolute;top:815px;left:147px;white-space:nowrap" class="ft3262">skin infections (including cellulitis and shingles)</p>
<p style="position:absolute;top:833px;left:106px;white-space:nowrap" class="ft3266"></p>
<p style="position:absolute;top:835px;left:147px;white-space:nowrap" class="ft3262">ear infections</p>
<p style="position:absolute;top:853px;left:106px;white-space:nowrap" class="ft3266"></p>
<p style="position:absolute;top:855px;left:147px;white-space:nowrap" class="ft3262">oral infections (including tooth infections and cold sores)</p>
<p style="position:absolute;top:874px;left:106px;white-space:nowrap" class="ft3266"></p>
<p style="position:absolute;top:876px;left:147px;white-space:nowrap" class="ft3262">reproductive tract infections</p>
<p style="position:absolute;top:894px;left:106px;white-space:nowrap" class="ft3266"></p>
<p style="position:absolute;top:896px;left:147px;white-space:nowrap" class="ft3262">urinary tract infection</p>
<p style="position:absolute;top:914px;left:106px;white-space:nowrap" class="ft3266"></p>
<p style="position:absolute;top:916px;left:147px;white-space:nowrap" class="ft3262">fungal infections</p>
<p style="position:absolute;top:934px;left:106px;white-space:nowrap" class="ft3266"></p>
<p style="position:absolute;top:936px;left:147px;white-space:nowrap" class="ft3262">joint infections</p>
<p style="position:absolute;top:954px;left:106px;white-space:nowrap" class="ft3266"></p>
<p style="position:absolute;top:956px;left:147px;white-space:nowrap" class="ft3262">benign tumours</p>
<p style="position:absolute;top:974px;left:106px;white-space:nowrap" class="ft3266"></p>
<p style="position:absolute;top:976px;left:147px;white-space:nowrap" class="ft3262">skin cancer</p>
<p style="position:absolute;top:995px;left:106px;white-space:nowrap" class="ft3266"></p>
<p style="position:absolute;top:996px;left:147px;white-space:nowrap" class="ft3262">allergic reactions (including seasonal allergy)</p>
<p style="position:absolute;top:1015px;left:106px;white-space:nowrap" class="ft3266"></p>
<p style="position:absolute;top:1017px;left:147px;white-space:nowrap" class="ft3262">dehydration</p>
<p style="position:absolute;top:1035px;left:106px;white-space:nowrap" class="ft3266"></p>
<p style="position:absolute;top:1037px;left:147px;white-space:nowrap" class="ft3262">mood swings (including depression)</p>
<p style="position:absolute;top:1055px;left:106px;white-space:nowrap" class="ft3266"></p>
<p style="position:absolute;top:1057px;left:147px;white-space:nowrap" class="ft3262">anxiety</p>
<p style="position:absolute;top:1075px;left:106px;white-space:nowrap" class="ft3266"></p>
<p style="position:absolute;top:1077px;left:147px;white-space:nowrap" class="ft3262">difficulty sleeping</p>
</div>
<!-- Page 327 -->
<a name="327"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page327-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3270">327</p>
<p style="position:absolute;top:85px;left:106px;white-space:nowrap" class="ft3276"></p>
<p style="position:absolute;top:87px;left:147px;white-space:nowrap" class="ft3272">sensation disorders such as tingling, prickling or numbness</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft3276"></p>
<p style="position:absolute;top:107px;left:147px;white-space:nowrap" class="ft3272">migraine</p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft3276"></p>
<p style="position:absolute;top:127px;left:147px;white-space:nowrap" class="ft3272">nerve root compression (including low back pain and leg pain)</p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft3276"></p>
<p style="position:absolute;top:148px;left:147px;white-space:nowrap" class="ft3272">vision disturbances</p>
<p style="position:absolute;top:166px;left:106px;white-space:nowrap" class="ft3276"></p>
<p style="position:absolute;top:168px;left:147px;white-space:nowrap" class="ft3272">eye&#160;inflammation</p>
<p style="position:absolute;top:186px;left:106px;white-space:nowrap" class="ft3276"></p>
<p style="position:absolute;top:188px;left:147px;white-space:nowrap" class="ft3272">inflammation&#160;of the eye lid and eye swelling</p>
<p style="position:absolute;top:206px;left:106px;white-space:nowrap" class="ft3276"></p>
<p style="position:absolute;top:208px;left:147px;white-space:nowrap" class="ft3272">vertigo (feeling of dizziness or spinning)</p>
<p style="position:absolute;top:226px;left:106px;white-space:nowrap" class="ft3276"></p>
<p style="position:absolute;top:228px;left:147px;white-space:nowrap" class="ft3272">sensation of heart beating rapidly</p>
<p style="position:absolute;top:247px;left:106px;white-space:nowrap" class="ft3276"></p>
<p style="position:absolute;top:248px;left:147px;white-space:nowrap" class="ft3272">high blood pressure</p>
<p style="position:absolute;top:267px;left:106px;white-space:nowrap" class="ft3276"></p>
<p style="position:absolute;top:269px;left:147px;white-space:nowrap" class="ft3272">flushing</p>
<p style="position:absolute;top:287px;left:106px;white-space:nowrap" class="ft3276"></p>
<p style="position:absolute;top:289px;left:147px;white-space:nowrap" class="ft3272">haematoma (collection of blood outside of blood vessels)</p>
<p style="position:absolute;top:307px;left:106px;white-space:nowrap" class="ft3276"></p>
<p style="position:absolute;top:309px;left:147px;white-space:nowrap" class="ft3272">cough</p>
<p style="position:absolute;top:327px;left:106px;white-space:nowrap" class="ft3276"></p>
<p style="position:absolute;top:329px;left:147px;white-space:nowrap" class="ft3272">asthma</p>
<p style="position:absolute;top:347px;left:106px;white-space:nowrap" class="ft3276"></p>
<p style="position:absolute;top:349px;left:147px;white-space:nowrap" class="ft3272">shortness of breath</p>
<p style="position:absolute;top:367px;left:106px;white-space:nowrap" class="ft3276"></p>
<p style="position:absolute;top:369px;left:147px;white-space:nowrap" class="ft3272">gastrointestinal bleeding</p>
<p style="position:absolute;top:388px;left:106px;white-space:nowrap" class="ft3276"></p>
<p style="position:absolute;top:390px;left:147px;white-space:nowrap" class="ft3272">dyspepsia (indigestion, bloating, heart burn)</p>
<p style="position:absolute;top:408px;left:106px;white-space:nowrap" class="ft3276"></p>
<p style="position:absolute;top:410px;left:147px;white-space:nowrap" class="ft3272">acid reflux disease</p>
<p style="position:absolute;top:428px;left:106px;white-space:nowrap" class="ft3276"></p>
<p style="position:absolute;top:430px;left:147px;white-space:nowrap" class="ft3272">sicca syndrome (including dry eyes and dry mouth)</p>
<p style="position:absolute;top:448px;left:106px;white-space:nowrap" class="ft3276"></p>
<p style="position:absolute;top:450px;left:147px;white-space:nowrap" class="ft3272">itching</p>
<p style="position:absolute;top:468px;left:106px;white-space:nowrap" class="ft3276"></p>
<p style="position:absolute;top:470px;left:147px;white-space:nowrap" class="ft3272">itchy rash</p>
<p style="position:absolute;top:488px;left:106px;white-space:nowrap" class="ft3276"></p>
<p style="position:absolute;top:490px;left:147px;white-space:nowrap" class="ft3272">bruising</p>
<p style="position:absolute;top:509px;left:106px;white-space:nowrap" class="ft3276"></p>
<p style="position:absolute;top:510px;left:147px;white-space:nowrap" class="ft3272">inflammation of the skin (such as eczema)</p>
<p style="position:absolute;top:529px;left:106px;white-space:nowrap" class="ft3276"></p>
<p style="position:absolute;top:531px;left:147px;white-space:nowrap" class="ft3272">breaking of finger nails and toe nails</p>
<p style="position:absolute;top:549px;left:106px;white-space:nowrap" class="ft3276"></p>
<p style="position:absolute;top:551px;left:147px;white-space:nowrap" class="ft3272">increased sweating</p>
<p style="position:absolute;top:569px;left:106px;white-space:nowrap" class="ft3276"></p>
<p style="position:absolute;top:571px;left:147px;white-space:nowrap" class="ft3272">hair loss</p>
<p style="position:absolute;top:589px;left:106px;white-space:nowrap" class="ft3276"></p>
<p style="position:absolute;top:591px;left:147px;white-space:nowrap" class="ft3272">new&#160;onset or worsening of psoriasis</p>
<p style="position:absolute;top:609px;left:106px;white-space:nowrap" class="ft3276"></p>
<p style="position:absolute;top:611px;left:147px;white-space:nowrap" class="ft3272">muscle spasms</p>
<p style="position:absolute;top:630px;left:106px;white-space:nowrap" class="ft3276"></p>
<p style="position:absolute;top:631px;left:147px;white-space:nowrap" class="ft3272">blood in urine</p>
<p style="position:absolute;top:650px;left:106px;white-space:nowrap" class="ft3276"></p>
<p style="position:absolute;top:652px;left:147px;white-space:nowrap" class="ft3272">kidney problems</p>
<p style="position:absolute;top:670px;left:106px;white-space:nowrap" class="ft3276"></p>
<p style="position:absolute;top:672px;left:147px;white-space:nowrap" class="ft3272">chest pain</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft3276"></p>
<p style="position:absolute;top:692px;left:147px;white-space:nowrap" class="ft3272">oedema (swelling)</p>
<p style="position:absolute;top:710px;left:106px;white-space:nowrap" class="ft3276"></p>
<p style="position:absolute;top:712px;left:147px;white-space:nowrap" class="ft3272">fever</p>
<p style="position:absolute;top:730px;left:106px;white-space:nowrap" class="ft3276"></p>
<p style="position:absolute;top:732px;left:147px;white-space:nowrap" class="ft3272">reduction in blood platelets which increases risk of bleeding or bruising</p>
<p style="position:absolute;top:751px;left:106px;white-space:nowrap" class="ft3276"></p>
<p style="position:absolute;top:752px;left:147px;white-space:nowrap" class="ft3272">impaired healing</p>
<p style="position:absolute;top:790px;left:106px;white-space:nowrap" class="ft3271"><b>Uncommon&#160;</b>(may&#160;affect up to 1 in 100 people) &#160;</p>
<p style="position:absolute;top:828px;left:106px;white-space:nowrap" class="ft3276"></p>
<p style="position:absolute;top:829px;left:147px;white-space:nowrap" class="ft3274">opportunistic infections (which include tuberculosis and other infections that occur when resistance&#160;<br/>to disease is lowered)</p>
<p style="position:absolute;top:867px;left:106px;white-space:nowrap" class="ft3276"></p>
<p style="position:absolute;top:869px;left:147px;white-space:nowrap" class="ft3272">neurological infections (including viral meningitis)</p>
<p style="position:absolute;top:887px;left:106px;white-space:nowrap" class="ft3276"></p>
<p style="position:absolute;top:889px;left:147px;white-space:nowrap" class="ft3272">eye&#160;infections</p>
<p style="position:absolute;top:907px;left:106px;white-space:nowrap" class="ft3276"></p>
<p style="position:absolute;top:909px;left:147px;white-space:nowrap" class="ft3272">bacterial infections</p>
<p style="position:absolute;top:927px;left:106px;white-space:nowrap" class="ft3276"></p>
<p style="position:absolute;top:929px;left:147px;white-space:nowrap" class="ft3272">diverticulitis (inflammation and infection of the large intestine)</p>
<p style="position:absolute;top:947px;left:106px;white-space:nowrap" class="ft3276"></p>
<p style="position:absolute;top:949px;left:147px;white-space:nowrap" class="ft3272">cancer</p>
<p style="position:absolute;top:968px;left:106px;white-space:nowrap" class="ft3276"></p>
<p style="position:absolute;top:969px;left:147px;white-space:nowrap" class="ft3272">cancer that affects the lymph system</p>
<p style="position:absolute;top:988px;left:106px;white-space:nowrap" class="ft3276"></p>
<p style="position:absolute;top:990px;left:147px;white-space:nowrap" class="ft3272">melanoma</p>
<p style="position:absolute;top:1008px;left:106px;white-space:nowrap" class="ft3276"></p>
<p style="position:absolute;top:1010px;left:147px;white-space:nowrap" class="ft3275">immune disorders that could affect the lungs, skin and lymph nodes (most commonly presenting as&#160;<br/>sarcoidosis)</p>
<p style="position:absolute;top:1047px;left:106px;white-space:nowrap" class="ft3276"></p>
<p style="position:absolute;top:1049px;left:147px;white-space:nowrap" class="ft3272">vasculitis (inflammation of blood vessels)</p>
<p style="position:absolute;top:1067px;left:106px;white-space:nowrap" class="ft3276"></p>
<p style="position:absolute;top:1069px;left:147px;white-space:nowrap" class="ft3272">tremor (shaking)</p>
</div>
<!-- Page 328 -->
<a name="328"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page328-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3280">328</p>
<p style="position:absolute;top:85px;left:106px;white-space:nowrap" class="ft3286"></p>
<p style="position:absolute;top:87px;left:147px;white-space:nowrap" class="ft3282">neuropathy&#160;(disorder of the nerves)</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft3286"></p>
<p style="position:absolute;top:107px;left:147px;white-space:nowrap" class="ft3282">stroke</p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft3286"></p>
<p style="position:absolute;top:127px;left:147px;white-space:nowrap" class="ft3282">hearing loss, buzzing</p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft3286"></p>
<p style="position:absolute;top:148px;left:147px;white-space:nowrap" class="ft3282">sensation of heart beating irregularly such as skipped beats</p>
<p style="position:absolute;top:166px;left:106px;white-space:nowrap" class="ft3286"></p>
<p style="position:absolute;top:168px;left:147px;white-space:nowrap" class="ft3282">heart problems that can cause shortness of breath or ankle swelling</p>
<p style="position:absolute;top:186px;left:106px;white-space:nowrap" class="ft3286"></p>
<p style="position:absolute;top:188px;left:147px;white-space:nowrap" class="ft3282">heart attack</p>
<p style="position:absolute;top:206px;left:106px;white-space:nowrap" class="ft3286"></p>
<p style="position:absolute;top:208px;left:147px;white-space:nowrap" class="ft3282">a sac in the wall of a major artery, inflammation and clot of a vein, blockage of a blood vessel</p>
<p style="position:absolute;top:226px;left:106px;white-space:nowrap" class="ft3286"></p>
<p style="position:absolute;top:228px;left:147px;white-space:nowrap" class="ft3282">lung diseases causing shortness of breath (including inflammation)</p>
<p style="position:absolute;top:247px;left:106px;white-space:nowrap" class="ft3286"></p>
<p style="position:absolute;top:248px;left:147px;white-space:nowrap" class="ft3282">pulmonary embolism (blockage in an artery of the lung)</p>
<p style="position:absolute;top:267px;left:106px;white-space:nowrap" class="ft3286"></p>
<p style="position:absolute;top:269px;left:147px;white-space:nowrap" class="ft3282">pleural effusion (abnormal collection of fluid in the pleural space)</p>
<p style="position:absolute;top:287px;left:106px;white-space:nowrap" class="ft3286"></p>
<p style="position:absolute;top:289px;left:147px;white-space:nowrap" class="ft3282">inflammation of the pancreas&#160;which causes severe pain in the abdomen and back</p>
<p style="position:absolute;top:307px;left:106px;white-space:nowrap" class="ft3286"></p>
<p style="position:absolute;top:309px;left:147px;white-space:nowrap" class="ft3282">difficulty in swallowing</p>
<p style="position:absolute;top:327px;left:106px;white-space:nowrap" class="ft3286"></p>
<p style="position:absolute;top:329px;left:147px;white-space:nowrap" class="ft3282">facial oedema (swelling of the face)</p>
<p style="position:absolute;top:347px;left:106px;white-space:nowrap" class="ft3286"></p>
<p style="position:absolute;top:349px;left:147px;white-space:nowrap" class="ft3282">gallbladder inflammation, gallbladder stones</p>
<p style="position:absolute;top:367px;left:106px;white-space:nowrap" class="ft3286"></p>
<p style="position:absolute;top:369px;left:147px;white-space:nowrap" class="ft3282">fatty liver</p>
<p style="position:absolute;top:388px;left:106px;white-space:nowrap" class="ft3286"></p>
<p style="position:absolute;top:390px;left:147px;white-space:nowrap" class="ft3282">night sweats</p>
<p style="position:absolute;top:408px;left:106px;white-space:nowrap" class="ft3286"></p>
<p style="position:absolute;top:410px;left:147px;white-space:nowrap" class="ft3282">scar</p>
<p style="position:absolute;top:428px;left:106px;white-space:nowrap" class="ft3286"></p>
<p style="position:absolute;top:430px;left:147px;white-space:nowrap" class="ft3282">abnormal&#160;muscle breakdown</p>
<p style="position:absolute;top:448px;left:106px;white-space:nowrap" class="ft3286"></p>
<p style="position:absolute;top:450px;left:147px;white-space:nowrap" class="ft3284">systemic lupus erythematosus (including&#160;inflammation of skin, heart, lung, joints and other organ&#160;<br/>systems)</p>
<p style="position:absolute;top:487px;left:106px;white-space:nowrap" class="ft3286"></p>
<p style="position:absolute;top:489px;left:147px;white-space:nowrap" class="ft3282">sleep interruptions</p>
<p style="position:absolute;top:508px;left:106px;white-space:nowrap" class="ft3286"></p>
<p style="position:absolute;top:509px;left:147px;white-space:nowrap" class="ft3282">impotence</p>
<p style="position:absolute;top:528px;left:106px;white-space:nowrap" class="ft3286"></p>
<p style="position:absolute;top:530px;left:147px;white-space:nowrap" class="ft3282">inflammations</p>
<p style="position:absolute;top:567px;left:106px;white-space:nowrap" class="ft3281"><b>Rare&#160;</b>(may affect up to 1 in 1,000 people)</p>
<p style="position:absolute;top:605px;left:106px;white-space:nowrap" class="ft3286"></p>
<p style="position:absolute;top:607px;left:147px;white-space:nowrap" class="ft3282">leukaemia (cancer affecting the blood and bone marrow)</p>
<p style="position:absolute;top:625px;left:106px;white-space:nowrap" class="ft3286"></p>
<p style="position:absolute;top:627px;left:147px;white-space:nowrap" class="ft3282">severe allergic reaction with shock</p>
<p style="position:absolute;top:645px;left:106px;white-space:nowrap" class="ft3286"></p>
<p style="position:absolute;top:647px;left:147px;white-space:nowrap" class="ft3282">multiple&#160;sclerosis</p>
<p style="position:absolute;top:665px;left:106px;white-space:nowrap" class="ft3286"></p>
<p style="position:absolute;top:667px;left:147px;white-space:nowrap" class="ft3285">nerve disorders (such as eye nerve inflammation and Guillain-Barré syndrome that may cause&#160;<br/>muscle weakness, abnormal sensations, tingling in the arms and upper body)</p>
<p style="position:absolute;top:704px;left:106px;white-space:nowrap" class="ft3286"></p>
<p style="position:absolute;top:706px;left:147px;white-space:nowrap" class="ft3282">heart stops pumping</p>
<p style="position:absolute;top:724px;left:106px;white-space:nowrap" class="ft3286"></p>
<p style="position:absolute;top:726px;left:147px;white-space:nowrap" class="ft3282">pulmonary fibrosis (scarring of the lung)</p>
<p style="position:absolute;top:744px;left:106px;white-space:nowrap" class="ft3286"></p>
<p style="position:absolute;top:746px;left:147px;white-space:nowrap" class="ft3282">intestinal perforation (hole in the intestine)</p>
<p style="position:absolute;top:765px;left:106px;white-space:nowrap" class="ft3286"></p>
<p style="position:absolute;top:766px;left:147px;white-space:nowrap" class="ft3282">hepatitis</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft3286"></p>
<p style="position:absolute;top:787px;left:147px;white-space:nowrap" class="ft3282">reactivation of hepatitis B</p>
<p style="position:absolute;top:805px;left:106px;white-space:nowrap" class="ft3286"></p>
<p style="position:absolute;top:807px;left:147px;white-space:nowrap" class="ft3282">autoimmune hepatitis (inflammation of the liver caused by the body's own immune system)</p>
<p style="position:absolute;top:825px;left:106px;white-space:nowrap" class="ft3286"></p>
<p style="position:absolute;top:827px;left:147px;white-space:nowrap" class="ft3282">cutaneous vasculitis (inflammation of blood vessels in the skin)</p>
<p style="position:absolute;top:845px;left:106px;white-space:nowrap" class="ft3286"></p>
<p style="position:absolute;top:847px;left:147px;white-space:nowrap" class="ft3282">Stevens-Johnson syndrome (early symptoms include malaise, fever, headache and rash)</p>
<p style="position:absolute;top:865px;left:106px;white-space:nowrap" class="ft3286"></p>
<p style="position:absolute;top:867px;left:147px;white-space:nowrap" class="ft3282">facial oedema (swelling of the face) associated with allergic reactions</p>
<p style="position:absolute;top:886px;left:106px;white-space:nowrap" class="ft3286"></p>
<p style="position:absolute;top:887px;left:147px;white-space:nowrap" class="ft3282">erythema multiforme (inflammatory skin rash)</p>
<p style="position:absolute;top:906px;left:106px;white-space:nowrap" class="ft3286"></p>
<p style="position:absolute;top:908px;left:147px;white-space:nowrap" class="ft3282">lupus-like syndrome</p>
<p style="position:absolute;top:926px;left:106px;white-space:nowrap" class="ft3286"></p>
<p style="position:absolute;top:928px;left:147px;white-space:nowrap" class="ft3282">angioedema (localized swelling of the skin)</p>
<p style="position:absolute;top:946px;left:106px;white-space:nowrap" class="ft3286"></p>
<p style="position:absolute;top:948px;left:147px;white-space:nowrap" class="ft3282">lichenoid skin reaction&#160;(itchy reddish-purple skin rash)</p>
<p style="position:absolute;top:986px;left:106px;white-space:nowrap" class="ft3281"><b>Not known&#160;</b>(frequency cannot be estimated from the available data)</p>
<p style="position:absolute;top:1023px;left:106px;white-space:nowrap" class="ft3286">&#160;hepatosplenic T-cell lymphoma (a rare blood cancer that is often fatal)</p>
<p style="position:absolute;top:1043px;left:106px;white-space:nowrap" class="ft3286">&#160;Merkel cell carcinoma (a type of skin cancer)</p>
</div>
<!-- Page 329 -->
<a name="329"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page329-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3290">329</p>
<p style="position:absolute;top:85px;left:106px;white-space:nowrap" class="ft3296">&#160;Kaposi’s sarcoma, a rare cancer related to infection with human herpes virus 8. Kaposi’s sarcoma&#160;</p>
<p style="position:absolute;top:106px;left:133px;white-space:nowrap" class="ft3292">most commonly appears as purple lesions on the skin</p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft3296">&#160;liver failure</p>
<p style="position:absolute;top:145px;left:106px;white-space:nowrap" class="ft3296">&#160;worsening of a condition called dermatomyositis (seen as a skin rash accompanying muscle weakness)</p>
<p style="position:absolute;top:165px;left:106px;white-space:nowrap" class="ft3296">&#160;weight gain (for most patients,&#160;the weight gain was small)</p>
<p style="position:absolute;top:204px;left:106px;white-space:nowrap" class="ft3294">Some side effects observed with Humira may not have symptoms and may only be discovered through&#160;<br/>blood tests. These include:</p>
<p style="position:absolute;top:261px;left:106px;white-space:nowrap" class="ft3291"><b>Very common&#160;</b>(may&#160;affect more than 1 in 10 people)</p>
<p style="position:absolute;top:299px;left:106px;white-space:nowrap" class="ft3296"></p>
<p style="position:absolute;top:301px;left:147px;white-space:nowrap" class="ft3292">low blood measurements for white blood cells</p>
<p style="position:absolute;top:319px;left:106px;white-space:nowrap" class="ft3296"></p>
<p style="position:absolute;top:321px;left:147px;white-space:nowrap" class="ft3292">low&#160;blood measurements for red blood cells</p>
<p style="position:absolute;top:339px;left:106px;white-space:nowrap" class="ft3296"></p>
<p style="position:absolute;top:341px;left:147px;white-space:nowrap" class="ft3292">increased lipids in the blood</p>
<p style="position:absolute;top:359px;left:106px;white-space:nowrap" class="ft3296"></p>
<p style="position:absolute;top:361px;left:147px;white-space:nowrap" class="ft3292">elevated liver enzymes</p>
<p style="position:absolute;top:399px;left:106px;white-space:nowrap" class="ft3291"><b>Common&#160;</b>(may&#160;affect up to 1 in 10 people)</p>
<p style="position:absolute;top:436px;left:106px;white-space:nowrap" class="ft3296"></p>
<p style="position:absolute;top:438px;left:147px;white-space:nowrap" class="ft3292">high blood measurements for white blood cells</p>
<p style="position:absolute;top:456px;left:106px;white-space:nowrap" class="ft3296"></p>
<p style="position:absolute;top:458px;left:147px;white-space:nowrap" class="ft3292">low blood measurements for platelets</p>
<p style="position:absolute;top:477px;left:106px;white-space:nowrap" class="ft3296"></p>
<p style="position:absolute;top:478px;left:147px;white-space:nowrap" class="ft3292">increased uric acid in the blood</p>
<p style="position:absolute;top:497px;left:106px;white-space:nowrap" class="ft3296"></p>
<p style="position:absolute;top:499px;left:147px;white-space:nowrap" class="ft3292">abnormal blood measurements for sodium</p>
<p style="position:absolute;top:517px;left:106px;white-space:nowrap" class="ft3296"></p>
<p style="position:absolute;top:519px;left:147px;white-space:nowrap" class="ft3292">low blood measurements for calcium</p>
<p style="position:absolute;top:537px;left:106px;white-space:nowrap" class="ft3296"></p>
<p style="position:absolute;top:539px;left:147px;white-space:nowrap" class="ft3292">low blood measurements for phosphate</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft3296"></p>
<p style="position:absolute;top:559px;left:147px;white-space:nowrap" class="ft3292">high blood sugar</p>
<p style="position:absolute;top:577px;left:106px;white-space:nowrap" class="ft3296"></p>
<p style="position:absolute;top:579px;left:147px;white-space:nowrap" class="ft3292">high blood measurements for lactate dehydrogenase</p>
<p style="position:absolute;top:598px;left:106px;white-space:nowrap" class="ft3296"></p>
<p style="position:absolute;top:599px;left:147px;white-space:nowrap" class="ft3292">autoantibodies present in the blood</p>
<p style="position:absolute;top:618px;left:106px;white-space:nowrap" class="ft3296"></p>
<p style="position:absolute;top:620px;left:147px;white-space:nowrap" class="ft3292">low blood potassium</p>
<p style="position:absolute;top:657px;left:106px;white-space:nowrap" class="ft3291"><b>Uncommon&#160;</b>(may&#160;affect&#160;up to 1 in 100 people)&#160;</p>
<p style="position:absolute;top:695px;left:106px;white-space:nowrap" class="ft3296"></p>
<p style="position:absolute;top:697px;left:147px;white-space:nowrap" class="ft3292">elevated bilirubin measurement (liver blood test)</p>
<p style="position:absolute;top:735px;left:106px;white-space:nowrap" class="ft3291"><b>Rare&#160;</b>(may affect up to 1 in 1,000 people)</p>
<p style="position:absolute;top:772px;left:106px;white-space:nowrap" class="ft3296"></p>
<p style="position:absolute;top:774px;left:147px;white-space:nowrap" class="ft3292">low blood measurements for white blood cells, red blood cells and platelet count</p>
<p style="position:absolute;top:812px;left:106px;white-space:nowrap" class="ft3295"><b>Reporting of side effects<br/></b>If your child gets any side&#160;effects, talk to your doctor or pharmacist. This includes any possible side&#160;<br/>effects not listed in this leaflet.&#160;You can also report side effects directly via&#160;the national reporting system&#160;<br/><a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">listed in&#160;Appendix V.&#160;</a>By reporting side effects, you can help provide more information on the safety of&#160;<br/>this medicine.&#160;</p>
<p style="position:absolute;top:945px;left:106px;white-space:nowrap" class="ft3291"><b>5.</b></p>
<p style="position:absolute;top:945px;left:148px;white-space:nowrap" class="ft3291"><b>How to store Humira</b></p>
<p style="position:absolute;top:982px;left:106px;white-space:nowrap" class="ft3292">Keep this medicine out of the sight and reach of children.&#160;</p>
<p style="position:absolute;top:1020px;left:106px;white-space:nowrap" class="ft3292">Do not use this medicine after the expiry date stated on the label/blister/carton after EXP.&#160;</p>
<p style="position:absolute;top:1059px;left:106px;white-space:nowrap" class="ft3292">Store in a refrigerator (2</p>
<p style="position:absolute;top:1058px;left:266px;white-space:nowrap" class="ft3296">C&#160;–&#160;8C). Do not freeze.&#160;</p>
</div>
<!-- Page 330 -->
<a name="330"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page330-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3300">330</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft3302">Keep the pre-filled syringe in the outer carton in order to protect from light. &#160;</p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft3302">Alternative Storage:</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft33019">When needed (for example, when you are travelling), a single Humira pre-filled syringe may be stored at&#160;<br/>room temperature (up to 25°C) for a maximum period of 14 days&#160;–&#160;be sure to protect it from light. Once&#160;<br/>removed from the refrigerator for room temperature storage, the syringe&#160;<b>must be used within 14 days&#160;or&#160;<br/>discarded</b>, even if it is returned to the refrigerator. &#160;</p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft3304">You should record the date when the syringe is first removed from refrigerator and the date after which it&#160;<br/>should be discarded.</p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft3304">Do not throw away&#160;any medicines via wastewater or household waste. Ask your doctor or pharmacist how&#160;<br/>to throw away medicines you no longer use. These measures will help protect the environment.</p>
<p style="position:absolute;top:390px;left:106px;white-space:nowrap" class="ft3301"><b>6.</b></p>
<p style="position:absolute;top:390px;left:148px;white-space:nowrap" class="ft3301"><b>Contents of the pack and other information</b></p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft3301"><b>What Humira contains</b></p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft3304">The active substance is adalimumab.<br/>The&#160;other ingredients are mannitol, polysorbate 80 and water for injections.</p>
<p style="position:absolute;top:522px;left:106px;white-space:nowrap" class="ft3301"><b>What the Humira&#160;pre-filled syringe looks like and contents of the pack</b></p>
<p style="position:absolute;top:560px;left:106px;white-space:nowrap" class="ft3304">Humira 20&#160;mg solution for injection in pre-filled syringe for paediatric use&#160;is supplied as a sterile solution&#160;<br/>of 20&#160;mg adalimumab dissolved in 0.2&#160;ml solution.</p>
<p style="position:absolute;top:617px;left:106px;white-space:nowrap" class="ft3302">The Humira pre-filled syringe is a glass syringe containing a solution of adalimumab. &#160;</p>
<p style="position:absolute;top:655px;left:106px;white-space:nowrap" class="ft3302">The Humira pre-filled syringe is available in a pack containing 2 pre-filled&#160;syringes&#160;with 2 alcohol pads.&#160;&#160;</p>
<p style="position:absolute;top:693px;left:106px;white-space:nowrap" class="ft3302">Humira may be available as a vial, a pre-filled syringe and/or a pre-filled pen.</p>
<p style="position:absolute;top:731px;left:106px;white-space:nowrap" class="ft3301"><b>Marketing Authorisation Holder</b></p>
<p style="position:absolute;top:769px;left:106px;white-space:nowrap" class="ft3305">AbbVie Deutschland GmbH &amp; Co. KG<br/>Knollstrasse<br/>67061 Ludwigshafen<br/>Germany</p>
<p style="position:absolute;top:864px;left:106px;white-space:nowrap" class="ft3301"><b>Manufacturer&#160;</b></p>
<p style="position:absolute;top:902px;left:106px;white-space:nowrap" class="ft3304">AbbVie Biotechnology GmbH<br/>Knollstrasse<br/>67061 Ludwigshafen<br/>Germany</p>
</div>
<!-- Page 331 -->
<a name="331"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page331-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3310">331</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft3315">For any information about this medicine, please contact the local representative of the Marketing&#160;<br/>Authorisation Holder:</p>
<p style="position:absolute;top:145px;left:114px;white-space:nowrap" class="ft3314"><b>België/Belgique/Belgien<br/></b>AbbVie SA<br/>Tél/Tel: +32 10&#160;&#160;477811</p>
<p style="position:absolute;top:145px;left:462px;white-space:nowrap" class="ft3314"><b>Lietuva<br/></b>AbbVie UAB&#160;<br/>Tel:&#160;+370 5 205 3023</p>
<p style="position:absolute;top:202px;left:114px;white-space:nowrap" class="ft3314"><b>България<br/></b>АбВи ЕООД<br/>Тел.:+359 2 90 30 430</p>
<p style="position:absolute;top:202px;left:462px;white-space:nowrap" class="ft3315"><b>Luxembourg/Luxemburg<br/></b>AbbVie SA<br/>Belgique/Belgien<br/>Tél/Tel: +32 10 477811</p>
<p style="position:absolute;top:278px;left:114px;white-space:nowrap" class="ft3315"><b>Česká republika<br/></b>AbbVie s.r.o.&#160;<br/>Tel: +420 233 098 111</p>
<p style="position:absolute;top:278px;left:462px;white-space:nowrap" class="ft3315"><b>Magyarország<br/></b>AbbVie Kft.<br/>Tel.:+36 1 455 8600</p>
<p style="position:absolute;top:335px;left:114px;white-space:nowrap" class="ft3314"><b>Danmark<br/></b>AbbVie A/S<br/>Tlf:&#160;+45 72 30-20-28</p>
<p style="position:absolute;top:335px;left:462px;white-space:nowrap" class="ft3314"><b>Malta<br/></b>V.J.Salomone Pharma Limited&#160;<br/>Tel: +356 22983201</p>
<p style="position:absolute;top:392px;left:114px;white-space:nowrap" class="ft3315"><b>Deutschland<br/></b>AbbVie Deutschland&#160;GmbH &amp; Co. KG<br/>Tel: 00800 222843 33 (gebührenfrei)<br/>Tel: +49 (0) 611&#160;/&#160;1720-0</p>
<p style="position:absolute;top:392px;left:462px;white-space:nowrap" class="ft3314"><b>Nederland<br/></b>AbbVie B.V.<br/>Tel: &#160;+31 (0)88 322 2843</p>
<p style="position:absolute;top:468px;left:114px;white-space:nowrap" class="ft3314"><b>Eesti<br/></b>AbbVie&#160;OÜ<br/>Tel: +372&#160;623 1011</p>
<p style="position:absolute;top:468px;left:462px;white-space:nowrap" class="ft3314"><b>Norge<br/></b>AbbVie AS<br/>Tlf: +47 67 81 80 00</p>
<p style="position:absolute;top:525px;left:114px;white-space:nowrap" class="ft3314"><b>Ελλάδα<br/></b>AbbVie&#160;ΦΑΡΜΑΚΕΥΤΙΚΗ Α.Ε.<br/>Τηλ: +30&#160;214 4165 555</p>
<p style="position:absolute;top:525px;left:462px;white-space:nowrap" class="ft3314"><b>Österreich<br/></b>AbbVie GmbH&#160;<br/>Tel: +43 1 20589-0</p>
<p style="position:absolute;top:592px;left:114px;white-space:nowrap" class="ft3315"><b>España<br/></b>AbbVie Spain, S.L.U.<br/>Tel: &#160;+34 91 384 09 10</p>
<p style="position:absolute;top:592px;left:462px;white-space:nowrap" class="ft3315"><b>Polska<br/></b>AbbVie Sp. z o.o.<br/>Tel.: +48 22&#160;372 78 00&#160;</p>
<p style="position:absolute;top:649px;left:114px;white-space:nowrap" class="ft3315"><b>France<br/></b>AbbVie<br/>Tél: +33 (0) 1 45 60 13 00</p>
<p style="position:absolute;top:649px;left:462px;white-space:nowrap" class="ft3315"><b>Portugal<br/></b>AbbVie, Lda.&#160;<br/>Tel: +351 (0)21 1908400</p>
<p style="position:absolute;top:706px;left:114px;white-space:nowrap" class="ft3314"><b>Hrvatska&#160;<br/></b>AbbVie d.o.o.<br/>Tel + 385 (0)1&#160;5625 501</p>
<p style="position:absolute;top:706px;left:462px;white-space:nowrap" class="ft3314"><b>România<br/></b>AbbVie S.R.L.<br/>Tel: +40 21 529 30 35</p>
<p style="position:absolute;top:762px;left:114px;white-space:nowrap" class="ft3314"><b>Ireland<br/></b>AbbVie Limited&#160;<br/>Tel: +353 (0)1 4287900</p>
<p style="position:absolute;top:762px;left:462px;white-space:nowrap" class="ft3314"><b>Slovenija<br/></b>AbbVie&#160;Biofarmacevtska družba d.o.o.<br/>Tel: +386 (1)32 08 060</p>
<p style="position:absolute;top:819px;left:114px;white-space:nowrap" class="ft3314"><b>Ísland<br/></b>Vistor hf.<br/>Tel: +354 535 7000</p>
<p style="position:absolute;top:819px;left:462px;white-space:nowrap" class="ft3314"><b>Slovenská republika<br/></b>AbbVie s.r.o.<br/>Tel: +421 2 5050 0777</p>
<p style="position:absolute;top:876px;left:114px;white-space:nowrap" class="ft3314"><b>Italia<br/></b>AbbVie S.r.l.&#160;<br/>Tel: +39 06 928921</p>
<p style="position:absolute;top:876px;left:462px;white-space:nowrap" class="ft3314"><b>Suomi/Finland<br/></b>AbbVie Oy&#160;<br/>Puh/Tel: &#160;+358 (0)10 2411 200</p>
<p style="position:absolute;top:934px;left:114px;white-space:nowrap" class="ft3314"><b>Κύπρος<br/></b>Lifepharma (Z.A.M.) Ltd<br/>Τηλ.: +357 22 34 74 40</p>
<p style="position:absolute;top:934px;left:462px;white-space:nowrap" class="ft3314"><b>Sverige<br/></b>AbbVie AB<br/>Tel: &#160;+46 (0)8 684 44 600</p>
<p style="position:absolute;top:991px;left:114px;white-space:nowrap" class="ft3314"><b>Latvija<br/></b>AbbVie SIA&#160;<br/>Tel: +371 67605000</p>
<p style="position:absolute;top:991px;left:462px;white-space:nowrap" class="ft3314"><b>United Kingdom&#160;(Northern Ireland)<br/></b>AbbVie Deutschland GmbH &amp; Co. KG<br/>Tel: +44 (0)1628 561090</p>
<p style="position:absolute;top:1067px;left:106px;white-space:nowrap" class="ft3311"><b>This leaflet was last revised&#160;in</b></p>
</div>
<!-- Page 332 -->
<a name="332"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page332-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3320">332</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft3324">Detailed information on this medicine is available on the European Medicines Agency web site:&#160;<br/><a href="http://www.ema.europa.eu/">http://www.ema.europa.eu.</a></p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft33215"><b>To listen to or request a copy of this leaflet in&#160;&lt;Braille&gt;, &lt;large print&gt; or &lt;audio&gt;, please contact the&#160;<br/>local representative of the Marketing Authorisation Holder.</b></p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft3321"><b>7.</b></p>
<p style="position:absolute;top:238px;left:148px;white-space:nowrap" class="ft3321"><b>Injecting Humira</b></p>
<p style="position:absolute;top:275px;left:133px;white-space:nowrap" class="ft3326">&#160;The following instructions explain how to give your child a subcutaneous injection of Humira&#160;</p>
<p style="position:absolute;top:296px;left:160px;white-space:nowrap" class="ft3324">using the pre-filled syringe. First read all the instructions carefully and then follow them step by&#160;<br/>step.&#160;</p>
<p style="position:absolute;top:352px;left:133px;white-space:nowrap" class="ft3326">&#160;You will be instructed by your doctor, nurse or pharmacist on the technique of injection.&#160;</p>
<p style="position:absolute;top:391px;left:133px;white-space:nowrap" class="ft3326">&#160;Do not attempt to inject your child until you are sure that you understand how to prepare and give&#160;</p>
<p style="position:absolute;top:412px;left:160px;white-space:nowrap" class="ft3322">the injection.&#160;</p>
<p style="position:absolute;top:449px;left:133px;white-space:nowrap" class="ft3326">&#160;After proper training, the injection can be given by your child or given by another person, for&#160;</p>
<p style="position:absolute;top:470px;left:160px;white-space:nowrap" class="ft3322">example, a family member or friend. &#160;</p>
<p style="position:absolute;top:508px;left:133px;white-space:nowrap" class="ft3326">&#160;Only use each pre-filled syringe for one injection.</p>
<p style="position:absolute;top:547px;left:106px;white-space:nowrap" class="ft3321"><b>Humira Pre-filled Syringe</b></p>
<p style="position:absolute;top:585px;left:214px;white-space:nowrap" class="ft3321"><b>&#160; &#160; &#160; &#160;&#160;Plunger</b></p>
<p style="position:absolute;top:585px;left:376px;white-space:nowrap" class="ft3321"><b>&#160; &#160; &#160; &#160; &#160; &#160;Finger Grip</b></p>
<p style="position:absolute;top:585px;left:538px;white-space:nowrap" class="ft3321"><b>&#160; &#160; &#160; &#160;&#160;Needle Cover</b></p>
<p style="position:absolute;top:798px;left:114px;white-space:nowrap" class="ft3321"><b>Do not use the pre-filled syringe and call your doctor or pharmacist if the</b></p>
<p style="position:absolute;top:836px;left:133px;white-space:nowrap" class="ft3326">&#160;liquid is cloudy, discoloured, or has flakes or particles in it</p>
<p style="position:absolute;top:856px;left:133px;white-space:nowrap" class="ft3326">&#160;expiry (EXP) date has passed</p>
<p style="position:absolute;top:876px;left:133px;white-space:nowrap" class="ft3326">&#160;liquid has been frozen or left in direct sunlight</p>
<p style="position:absolute;top:896px;left:133px;white-space:nowrap" class="ft3326">&#160;pre-filled syringe has been dropped or crushed</p>
<p style="position:absolute;top:936px;left:106px;white-space:nowrap" class="ft33215"><b>Do not remove the needle cover until just before injection. Keep&#160;Humira out of the sight and reach&#160;<br/>of children.</b></p>
<p style="position:absolute;top:994px;left:114px;white-space:nowrap" class="ft3321"><b>STEP 1</b></p>
<p style="position:absolute;top:1032px;left:114px;white-space:nowrap" class="ft3322">Take Humira out of the refrigerator.</p>
<p style="position:absolute;top:1070px;left:114px;white-space:nowrap" class="ft3322">Leave Humira at room temperature for&#160;<b>15 to 30 minutes&#160;</b>before injecting.</p>
</div>
<!-- Page 333 -->
<a name="333"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page333-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3330">333</p>
<p style="position:absolute;top:105px;left:141px;white-space:nowrap" class="ft3336">&#160;<b>Do not&#160;</b>remove the needle cover while allowing Humira to reach room temperature</p>
<p style="position:absolute;top:125px;left:141px;white-space:nowrap" class="ft3336">&#160;<b>Do not&#160;</b>warm Humira in any other way. For example,&#160;<b>do not&#160;</b>warm it in a microwave or in hot&#160;</p>
<p style="position:absolute;top:146px;left:168px;white-space:nowrap" class="ft3332">water</p>
<p style="position:absolute;top:166px;left:114px;white-space:nowrap" class="ft3331"><b>STEP 2&#160;</b></p>
<p style="position:absolute;top:206px;left:114px;white-space:nowrap" class="ft3331"><b>&#160; &#160; &#160; &#160; &#160; &#160;Syringe</b></p>
<p style="position:absolute;top:468px;left:114px;white-space:nowrap" class="ft3331"><b>&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;Pad</b></p>
<p style="position:absolute;top:166px;left:392px;white-space:nowrap" class="ft3334">Check the expiry (EXP) date.&#160;<b>Do not&#160;</b>use the pre-filled&#160;<br/>syringe if expiry (EXP) date has passed.</p>
<p style="position:absolute;top:222px;left:392px;white-space:nowrap" class="ft3332">Place the following&#160;on a clean, flat surface</p>
<p style="position:absolute;top:260px;left:422px;white-space:nowrap" class="ft3336">&#160;1 single-use pre-filled syringe and&#160;</p>
<p style="position:absolute;top:280px;left:422px;white-space:nowrap" class="ft3336">&#160;1 alcohol pad</p>
<p style="position:absolute;top:320px;left:392px;white-space:nowrap" class="ft3332">Wash and dry your hands.</p>
<p style="position:absolute;top:487px;left:114px;white-space:nowrap" class="ft3331"><b>STEP 3</b></p>
<p style="position:absolute;top:525px;left:114px;white-space:nowrap" class="ft3331"><b>Injectable Areas</b></p>
<p style="position:absolute;top:826px;left:114px;white-space:nowrap" class="ft3332">&#160; &#160; &#160;<b>Injectable Areas</b></p>
<p style="position:absolute;top:487px;left:392px;white-space:nowrap" class="ft3332">Choose an injection site:</p>
<p style="position:absolute;top:525px;left:422px;white-space:nowrap" class="ft3336">&#160;On the front of your child’s thighs or</p>
<p style="position:absolute;top:545px;left:422px;white-space:nowrap" class="ft3336">&#160;Your child’s belly (abdomen) at&#160;least 5&#160;cm from&#160;</p>
<p style="position:absolute;top:566px;left:449px;white-space:nowrap" class="ft3332">his/her belly button (navel)</p>
<p style="position:absolute;top:584px;left:422px;white-space:nowrap" class="ft3336">&#160;At least 3&#160;cm from your child’s last injection site</p>
<p style="position:absolute;top:624px;left:392px;white-space:nowrap" class="ft3335">Wipe the injection site in a circular motion with the alcohol&#160;<br/>pad.</p>
<p style="position:absolute;top:680px;left:422px;white-space:nowrap" class="ft3336">&#160;<b>Do not&#160;</b>inject through clothes</p>
<p style="position:absolute;top:700px;left:422px;white-space:nowrap" class="ft3336">&#160;<b>Do not&#160;</b>inject into skin that is sore, bruised, red,&#160;</p>
<p style="position:absolute;top:721px;left:449px;white-space:nowrap" class="ft3335">hard, scarred, has stretch marks, or areas with&#160;<br/>psoriasis plaques</p>
</div>
<!-- Page 334 -->
<a name="334"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page334-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3340">334</p>
<p style="position:absolute;top:87px;left:114px;white-space:nowrap" class="ft3341"><b>STEP 4</b></p>
<p style="position:absolute;top:87px;left:392px;white-space:nowrap" class="ft3342">Hold the pre-filled syringe in one hand.</p>
<p style="position:absolute;top:125px;left:392px;white-space:nowrap" class="ft3342">Check the liquid in the pre-filled syringe.</p>
<p style="position:absolute;top:162px;left:425px;white-space:nowrap" class="ft3346">&#160;Make sure the liquid is clear and colourless</p>
<p style="position:absolute;top:182px;left:425px;white-space:nowrap" class="ft3346">&#160;<b>Do not&#160;</b>use the pre-filled syringe if the liquid is&#160;</p>
<p style="position:absolute;top:203px;left:452px;white-space:nowrap" class="ft3342">cloudy or has particles</p>
<p style="position:absolute;top:221px;left:425px;white-space:nowrap" class="ft3346">&#160;<b>Do not&#160;</b>use the pre-filled syringe if it has been&#160;</p>
<p style="position:absolute;top:242px;left:452px;white-space:nowrap" class="ft3342">dropped or crushed</p>
<p style="position:absolute;top:280px;left:392px;white-space:nowrap" class="ft3345">Gently pull the needle cover straight off with the other hand.&#160;<br/>Throw the needle cover away. Do not recap.</p>
<p style="position:absolute;top:336px;left:425px;white-space:nowrap" class="ft3346">&#160;<b>Do not&#160;</b>touch the needle with your fingers or let the&#160;</p>
<p style="position:absolute;top:357px;left:452px;white-space:nowrap" class="ft3342">needle touch anything</p>
<p style="position:absolute;top:396px;left:114px;white-space:nowrap" class="ft3341"><b>STEP 5</b></p>
<p style="position:absolute;top:396px;left:392px;white-space:nowrap" class="ft3342">Hold the pre-filled syringe with the needle&#160;facing up.</p>
<p style="position:absolute;top:433px;left:425px;white-space:nowrap" class="ft3346">&#160;Hold the pre-filled syringe at eye level with one&#160;</p>
<p style="position:absolute;top:454px;left:452px;white-space:nowrap" class="ft3342">hand so you can see the air in the pre-filled syringe</p>
<p style="position:absolute;top:492px;left:392px;white-space:nowrap" class="ft3344">Slowly push the plunger in to push the air out through the&#160;<br/>needle.&#160;</p>
<p style="position:absolute;top:548px;left:425px;white-space:nowrap" class="ft3346">&#160;It is normal to see a drop of liquid at the end of the&#160;</p>
<p style="position:absolute;top:569px;left:452px;white-space:nowrap" class="ft3342">needle</p>
<p style="position:absolute;top:648px;left:114px;white-space:nowrap" class="ft3341"><b>STEP 6</b></p>
<p style="position:absolute;top:648px;left:392px;white-space:nowrap" class="ft3344">Hold the body of the pre-filled syringe in one hand between&#160;<br/>the thumb and index fingers, like you would a pencil.</p>
<p style="position:absolute;top:705px;left:392px;white-space:nowrap" class="ft3344">Squeeze the skin at your child’s injection site with your&#160;<br/>other hand to make a raised area and hold it firmly.</p>
</div>
<!-- Page 335 -->
<a name="335"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page335-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3350">335</p>
<p style="position:absolute;top:87px;left:114px;white-space:nowrap" class="ft3351"><b>STEP 7</b></p>
<p style="position:absolute;top:87px;left:392px;white-space:nowrap" class="ft3354">Insert the needle all the way into the skin at about a&#160;<br/>45-degree angle with one quick, short motion.</p>
<p style="position:absolute;top:143px;left:425px;white-space:nowrap" class="ft3356">&#160;After the needle is in, let go&#160;of the skin you are&#160;</p>
<p style="position:absolute;top:164px;left:452px;white-space:nowrap" class="ft3352">holding</p>
<p style="position:absolute;top:202px;left:392px;white-space:nowrap" class="ft3354">Slowly push the plunger all the way in until all of the liquid&#160;<br/>is injected and the pre-filled syringe is empty.</p>
<p style="position:absolute;top:443px;left:114px;white-space:nowrap" class="ft3351"><b>STEP 8</b></p>
<p style="position:absolute;top:730px;left:114px;white-space:nowrap" class="ft3351"><b>&#160; &#160; &#160;&#160;&#160; &#160; &#160; &#160;&#160;Cotton Ball</b></p>
<p style="position:absolute;top:443px;left:392px;white-space:nowrap" class="ft3354">When the injection is completed, slowly pull the needle out&#160;<br/>of the skin&#160;while keeping the pre-filled syringe at the same&#160;<br/>angle.</p>
<p style="position:absolute;top:519px;left:392px;white-space:nowrap" class="ft3354">After completing the injection, place a cotton ball or gauze&#160;<br/>pad on the skin over the injection site.</p>
<p style="position:absolute;top:575px;left:433px;white-space:nowrap" class="ft3356">&#160;<b>Do not&#160;</b>rub</p>
<p style="position:absolute;top:595px;left:433px;white-space:nowrap" class="ft3356">&#160;Slight bleeding at the injection site is normal</p>
<p style="position:absolute;top:770px;left:114px;white-space:nowrap" class="ft3351"><b>STEP 9</b></p>
<p style="position:absolute;top:808px;left:114px;white-space:nowrap" class="ft3354">Throw away the used pre-filled syringe in a special disposal container as instructed by your doctor,&#160;<br/>nurse or pharmacist.&#160;<b>Never&#160;</b>recap a needle.</p>
<p style="position:absolute;top:864px;left:141px;white-space:nowrap" class="ft3356">&#160;<b>Do not&#160;</b>recycle or throw the pre-filled syringe in the household waste</p>
<p style="position:absolute;top:884px;left:141px;white-space:nowrap" class="ft3356">&#160;<b>Always&#160;</b>keep the pre-filled syringe and the special disposal container out of the sight and&#160;</p>
<p style="position:absolute;top:905px;left:168px;white-space:nowrap" class="ft3352">reach of children</p>
<p style="position:absolute;top:943px;left:114px;white-space:nowrap" class="ft3355">The&#160;needle cover, alcohol pad, cotton ball or gauze pad, blister and packaging may be put in your&#160;<br/>household waste.</p>
</div>
<!-- Page 336 -->
<a name="336"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page336-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3360">336</p>
<p style="position:absolute;top:86px;left:310px;white-space:nowrap" class="ft3361"><b>Package leaflet: Information for the patient</b></p>
<p style="position:absolute;top:124px;left:309px;white-space:nowrap" class="ft3361"><b>Humira&#160;40&#160;mg/0.8&#160;ml&#160;solution for injection</b></p>
<p style="position:absolute;top:143px;left:418px;white-space:nowrap" class="ft3362">adalimumab</p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft33619"><b>Read all of this leaflet carefully before your child starts using this medicine because it contains&#160;<br/>important information.</b></p>
<p style="position:absolute;top:218px;left:106px;white-space:nowrap" class="ft3366"></p>
<p style="position:absolute;top:220px;left:148px;white-space:nowrap" class="ft3362">Keep this leaflet. You may need to read it again.</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft3366"></p>
<p style="position:absolute;top:240px;left:148px;white-space:nowrap" class="ft3365">Your doctor will&#160;also give you a&#160;<b>Patient Reminder Card</b>, which contains important safety&#160;<br/>information that you need to be aware of before your child is given Humira and during treatment&#160;<br/>with Humira. Keep this&#160;<b>Patient Reminder Card&#160;</b>with you or your child.</p>
<p style="position:absolute;top:296px;left:106px;white-space:nowrap" class="ft3366"></p>
<p style="position:absolute;top:298px;left:148px;white-space:nowrap" class="ft3362">If you have any further questions, please ask your doctor or pharmacist.</p>
<p style="position:absolute;top:316px;left:106px;white-space:nowrap" class="ft3366"></p>
<p style="position:absolute;top:318px;left:148px;white-space:nowrap" class="ft3364">This medicine has been prescribed for your child only. Do not pass it on to others. It may harm&#160;<br/>them, even if their signs of illness are the same as your child's.</p>
<p style="position:absolute;top:356px;left:106px;white-space:nowrap" class="ft3366"></p>
<p style="position:absolute;top:357px;left:148px;white-space:nowrap" class="ft3364">If your child gets any side effects, talk to your child’s doctor or pharmacist. This includes any&#160;<br/>possible side effects not listed in this leaflet (see section 4).</p>
<p style="position:absolute;top:414px;left:106px;white-space:nowrap" class="ft33619"><b>What is in this leaflet<br/></b>1.</p>
<p style="position:absolute;top:433px;left:148px;white-space:nowrap" class="ft3362">What Humira is and what it is used for</p>
<p style="position:absolute;top:453px;left:106px;white-space:nowrap" class="ft3362">2.</p>
<p style="position:absolute;top:453px;left:148px;white-space:nowrap" class="ft3362">What you need to know before your child uses Humira</p>
<p style="position:absolute;top:471px;left:106px;white-space:nowrap" class="ft3362">3.</p>
<p style="position:absolute;top:471px;left:148px;white-space:nowrap" class="ft3362">How to&#160;use Humira</p>
<p style="position:absolute;top:490px;left:106px;white-space:nowrap" class="ft3362">4.</p>
<p style="position:absolute;top:490px;left:148px;white-space:nowrap" class="ft3362">Possible side effects</p>
<p style="position:absolute;top:509px;left:106px;white-space:nowrap" class="ft3362">5.</p>
<p style="position:absolute;top:509px;left:148px;white-space:nowrap" class="ft3362">How to store Humira</p>
<p style="position:absolute;top:528px;left:106px;white-space:nowrap" class="ft3362">6.</p>
<p style="position:absolute;top:528px;left:148px;white-space:nowrap" class="ft3362">Contents of the pack and other information</p>
<p style="position:absolute;top:585px;left:106px;white-space:nowrap" class="ft3361"><b>1.</b></p>
<p style="position:absolute;top:585px;left:148px;white-space:nowrap" class="ft3361"><b>What Humira is and what it is used for</b></p>
<p style="position:absolute;top:604px;left:106px;white-space:nowrap" class="ft3362">Humira contains the active substance adalimumab.</p>
<p style="position:absolute;top:642px;left:106px;white-space:nowrap" class="ft3362">Humira is&#160;intended for&#160;the&#160;treatment of&#160;the inflammatory diseases described below:</p>
<p style="position:absolute;top:661px;left:133px;white-space:nowrap" class="ft3366">&#160;Polyarticular juvenile idiopathic arthritis</p>
<p style="position:absolute;top:681px;left:133px;white-space:nowrap" class="ft3366">&#160;Enthesitis-related arthritis</p>
<p style="position:absolute;top:701px;left:133px;white-space:nowrap" class="ft3366">&#160;Paediatric plaque psoriasis</p>
<p style="position:absolute;top:721px;left:133px;white-space:nowrap" class="ft3366">&#160;Adolescent hidradenitis suppurativa</p>
<p style="position:absolute;top:741px;left:133px;white-space:nowrap" class="ft3366">&#160;Paediatric Crohn’s disease</p>
<p style="position:absolute;top:761px;left:133px;white-space:nowrap" class="ft3366">&#160;Paediatric ulcerative colitis</p>
<p style="position:absolute;top:781px;left:133px;white-space:nowrap" class="ft3366">&#160;Paediatric uveitis</p>
<p style="position:absolute;top:821px;left:106px;white-space:nowrap" class="ft3364">The active ingredient&#160;in Humira, adalimumab, is a&#160;human&#160;monoclonal antibody. Monoclonal antibodies&#160;<br/>are&#160;proteins that&#160;attach to a specific target.</p>
<p style="position:absolute;top:878px;left:106px;white-space:nowrap" class="ft3364">The target of&#160;adalimumab&#160;is a&#160;protein&#160;called&#160;tumour necrosis factor&#160;(TNFα), which&#160;is involved in the&#160;<br/>immune (defence) system and&#160;is present at increased levels in&#160;the&#160;inflammatory diseases&#160;listed above.&#160;By&#160;<br/>attaching to&#160;TNFα, Humira decreases the process of inflammation in these diseases.</p>
<p style="position:absolute;top:954px;left:106px;white-space:nowrap" class="ft3362">Polyarticular juvenile idiopathic arthritis and&#160;enthesitis-related arthritis</p>
<p style="position:absolute;top:992px;left:106px;white-space:nowrap" class="ft3362">Polyarticular juvenile idiopathic arthritis and enthesitis-related arthritis are inflammatory diseases.</p>
<p style="position:absolute;top:1030px;left:106px;white-space:nowrap" class="ft3365">Humira is used to treat polyarticular juvenile idiopathic arthritis and enthesitis-related arthritis.&#160;Your child<br/>may first be given other disease-modifying medicines, such as methotrexate.&#160;If&#160;these medicines&#160;do not&#160;</p>
</div>
<!-- Page 337 -->
<a name="337"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page337-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3370">337</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft3375">work&#160;well enough,&#160;your child&#160;will be given&#160;Humira&#160;to treat&#160;his/her&#160;polyarticular juvenile idiopathic&#160;<br/>arthritis or enthesitis-related arthritis.</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft3372">Paediatric plaque&#160;psoriasis</p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft3375">Plaque psoriasis is a skin condition that causes red, flaky, crusty patches of skin covered with silvery&#160;<br/>scales.&#160;Plaque psoriasis can also affect the nails, causing them to crumble, become thickened and lift away&#160;<br/>from the nail bed which can be&#160;painful. Psoriasis is believed to be caused by a problem with the body’s&#160;<br/>immune system that leads to an increased production of skin cells.</p>
<p style="position:absolute;top:276px;left:106px;white-space:nowrap" class="ft3374">Humira is used to treat severe plaque psoriasis in children and adolescents aged 4 to 17 years in whom&#160;<br/>topical therapy and phototherapies have either not worked very well or are not suitable. &#160;</p>
<p style="position:absolute;top:333px;left:106px;white-space:nowrap" class="ft3372">Adolescent hidradenitis suppurativa</p>
<p style="position:absolute;top:370px;left:106px;white-space:nowrap" class="ft3375">Hidradenitis suppurativa&#160;(sometimes called acne inversa) is a chronic and often painful inflammatory skin&#160;<br/>disease.&#160;Symptoms may include tender nodules (lumps) and abscesses (boils) that may leak pus. It most&#160;<br/><a href="http://en.wikipedia.org/wiki/Inframammary_fold">commonly affects specific areas of the skin, such as&#160;under the breasts, the armpits, inner thighs, groin and&#160;<br/></a>buttocks.&#160;Scarring may also occur in affected areas.</p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft3374">Humira is used to treat hidradenitis suppurativa in adolescents from 12 years of age.&#160;Humira can reduce&#160;<br/>the number of nodules and abscesses you have and the pain that is often associated with the disease. You&#160;<br/>may first be given other medicines. If you do not respond well enough to these medicines, you will be&#160;<br/>given Humira.</p>
<p style="position:absolute;top:560px;left:106px;white-space:nowrap" class="ft3372">Paediatric Crohn's disease&#160;</p>
<p style="position:absolute;top:598px;left:106px;white-space:nowrap" class="ft3374">Crohn’s disease is an inflammatory disease of&#160;the&#160;digestive tract.&#160;Humira is indicated for the treatment of&#160;<br/>Crohn's disease in children aged 6 to 17&#160;years.&#160;Your child&#160;may&#160;first be given other medicines.&#160;If&#160;these&#160;<br/>medicines&#160;do not&#160;work&#160;well enough,&#160;your child&#160;will be given&#160;Humira&#160;to reduce the signs and symptoms of&#160;<br/>his/her&#160;disease.</p>
<p style="position:absolute;top:693px;left:106px;white-space:nowrap" class="ft3372">Paediatric&#160;ulcerative colitis</p>
<p style="position:absolute;top:731px;left:106px;white-space:nowrap" class="ft3374">Ulcerative colitis is an inflammatory disease of the&#160;large intestine.&#160;Humira is used to treat&#160;moderate to&#160;<br/>severe&#160;ulcerative colitis in&#160;children aged 6 to 17 years.&#160;Your child may first be given&#160;other medicines. If&#160;<br/>these medicines do not work&#160;well enough, your child&#160;will be given Humira to reduce the signs and&#160;<br/>symptoms of&#160;his/her&#160;disease.</p>
<p style="position:absolute;top:826px;left:106px;white-space:nowrap" class="ft3372">Paediatric&#160;uveitis</p>
<p style="position:absolute;top:864px;left:106px;white-space:nowrap" class="ft3372">Non-infectious uveitis is an&#160;inflammatory disease affecting certain parts of the eye.</p>
<p style="position:absolute;top:902px;left:106px;white-space:nowrap" class="ft3374">Humira is used to treat children from 2&#160;years of age with chronic non-infectious uveitis with inflammation&#160;<br/>affecting the front of the eye. This inflammation may lead to a decrease of vision and/or the presence of&#160;<br/>floaters in the eye (black dots or wispy lines that move across the field of vision). Humira works by&#160;<br/>reducing this inflammation.</p>
<p style="position:absolute;top:1016px;left:106px;white-space:nowrap" class="ft3371"><b>2.</b></p>
<p style="position:absolute;top:1016px;left:148px;white-space:nowrap" class="ft3371"><b>What you need to know before your child uses Humira</b></p>
<p style="position:absolute;top:1054px;left:106px;white-space:nowrap" class="ft3371"><b>Do not use&#160;Humira</b></p>
</div>
<!-- Page 338 -->
<a name="338"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page338-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3380">338</p>
<p style="position:absolute;top:85px;left:133px;white-space:nowrap" class="ft3386">&#160;If your child is allergic to adalimumab or any of the other ingredients of this medicine (listed in&#160;</p>
<p style="position:absolute;top:106px;left:160px;white-space:nowrap" class="ft3382">section 6).&#160;</p>
<p style="position:absolute;top:143px;left:133px;white-space:nowrap" class="ft3386">&#160;If your child has a severe infection, including active tuberculosis (see “Warnings and&#160;</p>
<p style="position:absolute;top:164px;left:160px;white-space:nowrap" class="ft3384">precautions”). It is important that you tell your doctor if your child has symptoms of infections,&#160;<br/>e.g. fever, wounds, feeling tired, dental problems.</p>
<p style="position:absolute;top:221px;left:133px;white-space:nowrap" class="ft3386">&#160;If your child has moderate or severe heart failure. It is important to tell your doctor if your child&#160;</p>
<p style="position:absolute;top:241px;left:160px;white-space:nowrap" class="ft3382">has had or has a serious heart condition (see “Warnings and precautions”).</p>
<p style="position:absolute;top:279px;left:106px;white-space:nowrap" class="ft3381"><b>Warnings and precautions</b></p>
<p style="position:absolute;top:317px;left:106px;white-space:nowrap" class="ft3382">Talk to your child’s doctor or pharmacist before using Humira</p>
<p style="position:absolute;top:355px;left:133px;white-space:nowrap" class="ft3386">&#160;If your child experiences allergic reactions with symptoms such as chest tightness, wheezing,&#160;</p>
<p style="position:absolute;top:375px;left:160px;white-space:nowrap" class="ft3385">dizziness, swelling or rash do not inject more Humira&#160;and contact your doctor immediately since,&#160;<br/>in rare cases, these reactions can be life threatening.</p>
<p style="position:absolute;top:432px;left:133px;white-space:nowrap" class="ft3386">&#160;If your child has an infection, including long-term&#160;or localized infection (for example, leg ulcer)&#160;</p>
<p style="position:absolute;top:453px;left:160px;white-space:nowrap" class="ft3382">consult your doctor before starting Humira. If you are unsure, contact your doctor.&#160;</p>
<p style="position:absolute;top:490px;left:133px;white-space:nowrap" class="ft3386">&#160;Your child might get infections more easily while receiving Humira treatment. This risk may&#160;</p>
<p style="position:absolute;top:510px;left:160px;white-space:nowrap" class="ft3384">increase if his/her lung function is impaired. These infections may be serious and include&#160;<br/>tuberculosis, infections caused by viruses,&#160;fungi, parasites or bacteria, or other opportunistic&#160;<br/>infections and sepsis that may, in rare cases, be life-threatening. It is important to tell your doctor&#160;<br/>if your child gets symptoms such as fever, wounds, feeling tired or dental problems. Your doctor&#160;<br/>may&#160;recommend temporary discontinuation of Humira.</p>
<p style="position:absolute;top:624px;left:133px;white-space:nowrap" class="ft3386">&#160;As cases of tuberculosis have been reported in patients treated with Humira, your doctor will&#160;</p>
<p style="position:absolute;top:644px;left:160px;white-space:nowrap" class="ft3384">check your child for signs and symptoms of tuberculosis before starting Humira. This will include&#160;<br/>a thorough medical evaluation including your child’s medical history and appropriate screening&#160;<br/>tests (for example chest X-ray and a tuberculin test). The conduct and results of these tests should&#160;<br/>be recorded on your child's&#160;<b>Patient Reminder Card</b>. It is very important that you tell your doctor&#160;<br/>if your child has ever had tuberculosis, or if he/she has been in close contact with someone who&#160;<br/>has had tuberculosis. Tuberculosis can develop during therapy even if your child has received&#160;<br/>preventative treatment for tuberculosis.&#160;If symptoms of tuberculosis (persistent cough, weight&#160;<br/>loss, listlessness, mild fever), or any other infection appear during or after therapy tell your doctor&#160;<br/>immediately.</p>
<p style="position:absolute;top:834px;left:133px;white-space:nowrap" class="ft3386">&#160;Advise your doctor if your child resides or travels in regions where fungal infections such as&#160;</p>
<p style="position:absolute;top:854px;left:160px;white-space:nowrap" class="ft3382">histoplasmosis, coccidioidomycosis or blastomycosis are endemic.</p>
<p style="position:absolute;top:892px;left:133px;white-space:nowrap" class="ft3386">&#160;Advise your doctor if your child has a history of recurrent infections or other conditions that&#160;</p>
<p style="position:absolute;top:913px;left:160px;white-space:nowrap" class="ft3382">increase the risk of infections.</p>
<p style="position:absolute;top:950px;left:133px;white-space:nowrap" class="ft3386">&#160;Advise your doctor if your child is a carrier of&#160;the hepatitis B virus (HBV), if he/she has active&#160;</p>
<p style="position:absolute;top:971px;left:160px;white-space:nowrap" class="ft3384">HBV or if you think he/she might be at risk of contracting HBV. Your child’s doctor should test&#160;<br/>your child for HBV. Humira can cause reactivation of HBV in people who carry this virus. In&#160;<br/>some rare cases,&#160;especially if your child is taking other medicines that suppress the immune&#160;<br/>system, reactivation of HBV can be life-threatening.&#160;</p>
</div>
<!-- Page 339 -->
<a name="339"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page339-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3390">339</p>
<p style="position:absolute;top:85px;left:133px;white-space:nowrap" class="ft3396">&#160;It is important to tell your doctor if your child gets symptoms of infections, such as fever, wounds,&#160;</p>
<p style="position:absolute;top:106px;left:160px;white-space:nowrap" class="ft3392">feeling tired or dental&#160;problems.</p>
<p style="position:absolute;top:143px;left:133px;white-space:nowrap" class="ft3396">&#160;If your child is about to undergo surgery or dental procedures please inform your doctor that&#160;</p>
<p style="position:absolute;top:164px;left:160px;white-space:nowrap" class="ft3392">he/she is taking Humira. Your doctor may recommend temporary discontinuation.</p>
<p style="position:absolute;top:202px;left:133px;white-space:nowrap" class="ft3396">&#160;If your child has or develops a demyelinating disease such as multiple&#160;sclerosis, your doctor will&#160;</p>
<p style="position:absolute;top:222px;left:160px;white-space:nowrap" class="ft3394">decide if he/she should receive or continue to receive Humira. Tell your doctor immediately if&#160;<br/>your child experiences symptoms like changes in vision, weakness in arms or legs or numbness or&#160;<br/>tingling in any part of the body.</p>
<p style="position:absolute;top:298px;left:133px;white-space:nowrap" class="ft3396">&#160;Certain vaccines may cause infections and should not be given while receiving Humira. &#160;Please&#160;</p>
<p style="position:absolute;top:318px;left:160px;white-space:nowrap" class="ft3394">check with your doctor before your child receives any vaccines. It is recommended that children,&#160;<br/>if possible, be brought up to date with all immunisations in agreement with current immunisation&#160;<br/>guidelines prior to initiating Humira therapy. If you received Humira while you were pregnant,&#160;<br/>your baby may be at higher risk for getting such an infection for up to approximately five months&#160;<br/>after the last dose you received during pregnancy. It is important that you tell your baby's doctors&#160;<br/>and other health care professionals about your Humira use during your pregnancy so they can&#160;<br/>decide when your baby should receive any vaccine.</p>
<p style="position:absolute;top:469px;left:133px;white-space:nowrap" class="ft3396">&#160;If your child has mild heart failure and is&#160;being treated with Humira, his/her heart failure status&#160;</p>
<p style="position:absolute;top:490px;left:160px;white-space:nowrap" class="ft3394">must be closely monitored by your doctor. &#160;It is important to tell your doctor if your child has had&#160;<br/>or has a serious heart condition. &#160;If he/she develops new or worsening symptoms of heart failure&#160;<br/>(e.g. shortness of breath, or swelling of his/her feet), you must contact your doctor immediately.&#160;<br/>Your doctor will decide if your child should receive Humira. &#160;</p>
<p style="position:absolute;top:585px;left:133px;white-space:nowrap" class="ft3396">&#160;In some patients the body may fail to produce enough of the blood cells that help your child's</p>
<p style="position:absolute;top:606px;left:160px;white-space:nowrap" class="ft3394">body fight infections or help him/her to stop bleeding. &#160;If your child develops a fever that does not&#160;<br/>go away, bruises or bleeds very easily or looks very pale, call your doctor right away. Your doctor&#160;<br/>may decide to stop treatment.</p>
<p style="position:absolute;top:681px;left:133px;white-space:nowrap" class="ft3396">&#160;There have been very rare cases of certain kinds of cancer in children and adult patients taking&#160;</p>
<p style="position:absolute;top:701px;left:160px;white-space:nowrap" class="ft3394">Humira or other TNF blockers. People with more serious rheumatoid arthritis that have had the&#160;<br/>disease for a long time may have a higher than average risk of getting lymphoma (a cancer&#160;that&#160;<br/>affects the lymph system) and leukemia (a cancer that affects the blood and bone marrow). If your&#160;<br/>child takes Humira the risk of getting lymphoma, leukemia, or other cancers may increase. On&#160;<br/>rare occasions, a specific and severe type of lymphoma, has been observed in patients taking&#160;<br/>Humira. Some of those patients were also treated with azathioprine or 6-&#160;mercaptopurine. Tell&#160;<br/>your doctor if your child is taking azathioprine or 6-mercaptopurine with Humira. In addition&#160;<br/>cases of non-melanoma skin cancer have been observed in patients taking Humira. If new skin&#160;<br/>lesions appear during or after therapy or if existing lesions change appearance, tell your doctor.</p>
<p style="position:absolute;top:889px;left:133px;white-space:nowrap" class="ft3396">&#160;There have been cases of cancers,&#160;other than lymphoma in patients with a specific type of lung&#160;</p>
<p style="position:absolute;top:910px;left:160px;white-space:nowrap" class="ft3394">disease called Chronic Obstructive Pulmonary Disease (COPD) treated with another TNF blocker.&#160;<br/>If your child has COPD, or is a heavy smoker, you should discuss with your doctor whether&#160;<br/>treatment with a TNF blocker is appropriate for your child.</p>
<p style="position:absolute;top:985px;left:133px;white-space:nowrap" class="ft3396">&#160;On rare&#160;occasions, treatment with Humira could result in lupus-like syndrome. Contact your&#160;</p>
<p style="position:absolute;top:1005px;left:160px;white-space:nowrap" class="ft3392">doctor if symptoms such as persistent unexplained rash, fever, joint pain or tiredness&#160;occur.</p>
</div>
<!-- Page 340 -->
<a name="340"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft34035{font-size:17px;font-family:HORGHZ+TimesNewRoman;color:#1a1a1a;}
-->
</style>
<div id="page340-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3400">340</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft3401"><b>Other medicines and Humira</b></p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft3404">Tell your child’s doctor or pharmacist if your child is taking, has recently taken or might take any other&#160;<br/>medicines.</p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft3404">Humira can be taken together with methotrexate or certain disease-modifying anti-rheumatic agents&#160;<br/>(sulfasalazine, hydroxychloroquine, leflunomide and injectable gold preparations), steroids or pain&#160;<br/>medications including non-steroidal anti-inflammatory drugs (NSAIDs).</p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft3404">Your child should not take Humira with medicines containing the active substances&#160;anakinra or abatacept<br/>due to increased risk of serious infection. If you have questions,&#160;please ask your doctor.</p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft3401"><b>Pregnancy and breast-feeding</b></p>
<p style="position:absolute;top:351px;left:133px;white-space:nowrap" class="ft3406">&#160;Your child&#160;should consider the&#160;use&#160;of&#160;adequate contraception&#160;to prevent pregnancy&#160;and&#160;continue&#160;</p>
<p style="position:absolute;top:372px;left:160px;white-space:nowrap" class="ft3402">its use&#160;for at least 5 months after the last Humira treatment.</p>
<p style="position:absolute;top:390px;left:132px;white-space:nowrap" class="ft3406">&#160;If your child is pregnant, thinks she may be pregnant or is planning to have a baby, ask her doctor&#160;</p>
<p style="position:absolute;top:411px;left:159px;white-space:nowrap" class="ft34035">for advice about taking this medicine.</p>
<p style="position:absolute;top:429px;left:132px;white-space:nowrap" class="ft3406">&#160;Humira should only&#160;be used during a pregnancy if needed.</p>
<p style="position:absolute;top:449px;left:132px;white-space:nowrap" class="ft3406">&#160;According to a pregnancy study, there was no higher risk of birth defects when the mother had&#160;</p>
<p style="position:absolute;top:470px;left:159px;white-space:nowrap" class="ft3404">received&#160;Humira during pregnancy compared with mothers with the same disease who did not&#160;<br/>receive Humira.</p>
<p style="position:absolute;top:508px;left:132px;white-space:nowrap" class="ft3406">&#160;Humira can be used during breast-feeding.</p>
<p style="position:absolute;top:528px;left:133px;white-space:nowrap" class="ft3406">&#160;If your child&#160;receives&#160;Humira during&#160;her&#160;pregnancy,&#160;her&#160;baby may have a higher&#160;risk for getting&#160;</p>
<p style="position:absolute;top:548px;left:160px;white-space:nowrap" class="ft3402">an infection.</p>
<p style="position:absolute;top:567px;left:133px;white-space:nowrap" class="ft3406">&#160;It is important that you tell&#160;her&#160;baby’s doctor and other health care professionals about&#160;her&#160;Humira&#160;</p>
<p style="position:absolute;top:588px;left:160px;white-space:nowrap" class="ft3404">use during&#160;her&#160;pregnancy before the baby receives any vaccine.&#160;For more information on vaccines,&#160;<br/>see the “Warnings and precautions” section.</p>
<p style="position:absolute;top:644px;left:106px;white-space:nowrap" class="ft3401"><b>Driving and using machines</b></p>
<p style="position:absolute;top:683px;left:106px;white-space:nowrap" class="ft3405">Humira may have a minor influence on the ability to drive, cycle or use machines. Room spinning&#160;<br/>sensation and vision disturbances may occur after taking Humira.</p>
<p style="position:absolute;top:739px;left:106px;white-space:nowrap" class="ft3401"><b>Humira contains sodium</b></p>
<p style="position:absolute;top:777px;left:106px;white-space:nowrap" class="ft3404">This medicinal product contains less than 1&#160;mmol&#160;of&#160;sodium (23&#160;mg) per 0.8&#160;ml dose, i.e. essentially&#160;<br/>‘sodium-free’.</p>
<p style="position:absolute;top:853px;left:106px;white-space:nowrap" class="ft3401"><b>3.</b></p>
<p style="position:absolute;top:853px;left:148px;white-space:nowrap" class="ft3401"><b>How to use Humira</b></p>
<p style="position:absolute;top:891px;left:106px;white-space:nowrap" class="ft3404">Always use this medicine exactly as your child’s doctor or pharmacist has instructed. Check with your&#160;<br/>child’s doctor or pharmacist if you are not sure about any of the instructions or if you have any questions.&#160;<br/>Your doctor may prescribe another strength of&#160;Humira if your child needs a different dose.</p>
</div>
<!-- Page 341 -->
<a name="341"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page341-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3410">341</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft3412">Children&#160;and adolescents&#160;with polyarticular juvenile idiopathic arthritis</p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft3413"><i>Children and adolescents from 2&#160;years of age weighing 10&#160;kg to less than 30&#160;kg</i></p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft3412">The recommended dose of Humira is 20&#160;mg&#160;every other week.</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft3413"><i>Children and adolescents from 2&#160;years of age weighing 30&#160;kg or more</i></p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft3412">The recommended dose of Humira&#160;is 40&#160;mg&#160;every other week.</p>
<p style="position:absolute;top:276px;left:106px;white-space:nowrap" class="ft3412">Children,&#160;adolescents and adults&#160;with&#160;enthesitis-related arthritis</p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft3413"><i>Children and adolescents from 6&#160;years of age weighing&#160;15&#160;kg to less than 30&#160;kg</i></p>
<p style="position:absolute;top:352px;left:106px;white-space:nowrap" class="ft3412">The recommended dose of Humira is 20&#160;mg&#160;every other week.</p>
<p style="position:absolute;top:390px;left:106px;white-space:nowrap" class="ft3413"><i>Children, adolescents and adults from 6&#160;years of age weighing 30&#160;kg or more</i></p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft3412">The recommended dose of Humira is 40&#160;mg&#160;every other week.</p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft3412">Children&#160;and&#160;adolescents with&#160;psoriasis</p>
<p style="position:absolute;top:503px;left:106px;white-space:nowrap" class="ft3413"><i>Children and adolescents from 4 to 17&#160;years of age weighing 15&#160;kg to less than 30&#160;kg</i></p>
<p style="position:absolute;top:541px;left:106px;white-space:nowrap" class="ft3415">The recommended dose of Humira&#160;is an initial dose of 20&#160;mg, followed by 20&#160;mg&#160;one week later.&#160;<br/>Thereafter, the usual dose is 20&#160;mg every other week.</p>
<p style="position:absolute;top:598px;left:106px;white-space:nowrap" class="ft3413"><i>Children&#160;and adolescents from 4 to 17&#160;years of age weighing 30&#160;kg or more</i></p>
<p style="position:absolute;top:636px;left:106px;white-space:nowrap" class="ft3414">The recommended dose of Humira is an initial dose of 40&#160;mg, followed by 40&#160;mg&#160;one week later.&#160;<br/>Thereafter, the usual dose is 40&#160;mg every other week.</p>
<p style="position:absolute;top:693px;left:106px;white-space:nowrap" class="ft3412">Adolescents with hidradenitis suppurativa&#160;from 12&#160;to 17&#160;years of age, weighing&#160;30&#160;kg&#160;or more</p>
<p style="position:absolute;top:731px;left:106px;white-space:nowrap" class="ft3414">The recommended dose of Humira is&#160;an initial dose of 80&#160;mg&#160;(as&#160;two&#160;40&#160;mg&#160;injections in one day),&#160;<br/>followed by 40&#160;mg&#160;every other week starting one week later. If you have an inadequate response&#160;to&#160;<br/>Humira 40&#160;mg&#160;every other week, your doctor may increase the dosage to 40&#160;mg&#160;every week&#160;or 80&#160;mg&#160;<br/>every other week.</p>
<p style="position:absolute;top:826px;left:106px;white-space:nowrap" class="ft3412">It is recommended that you use an antiseptic wash daily on the affected areas.</p>
<p style="position:absolute;top:864px;left:106px;white-space:nowrap" class="ft3412">Children and adolescents with Crohn's disease</p>
<p style="position:absolute;top:902px;left:106px;white-space:nowrap" class="ft3413"><i>Children and adolescents from 6 to 17&#160;years of age weighing less than 40&#160;kg</i>&#160;&#160;</p>
<p style="position:absolute;top:940px;left:106px;white-space:nowrap" class="ft3414">The usual dose regimen is 40&#160;mg initially followed by 20&#160;mg two weeks later. If a faster response is&#160;<br/>required, your child’s doctor may prescribe an initial dose of 80&#160;mg (as two&#160;40&#160;mg&#160;injections in one day)&#160;<br/>followed by 40&#160;mg two weeks later.</p>
<p style="position:absolute;top:1016px;left:106px;white-space:nowrap" class="ft3414">Thereafter, the usual dose is 20&#160;mg every other week. Depending on your child’s response, your child’s&#160;<br/>doctor may increase the dose frequency to 20&#160;mg&#160;every week. &#160;</p>
<p style="position:absolute;top:1072px;left:106px;white-space:nowrap" class="ft3413"><i>Children and adolescents from 6 to&#160;17&#160;years of age weighing 40&#160;kg or more&#160;</i></p>
</div>
<!-- Page 342 -->
<a name="342"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page342-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3420">342</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft3424">The usual dose regimen is 80&#160;mg (as two&#160;40&#160;mg&#160;injections in one day) initially followed by 40&#160;mg two&#160;<br/>weeks later. If a faster response is required, your child’s doctor may prescribe an initial dose of 160&#160;mg&#160;<br/>initially (as four&#160;40&#160;mg&#160;injections in one day or two&#160;40&#160;mg&#160;injections per day for two consecutive days)&#160;<br/>followed by 80&#160;mg (as two&#160;40&#160;mg&#160;injections in one day) two weeks later.</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft3424">Thereafter, the usual dose is 40&#160;mg every other week. Depending on your child’s response, your child’s&#160;<br/>doctor may increase the dosage to 40&#160;mg every week&#160;or&#160;80&#160;mg&#160;every other week.</p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft3422">Children and adolescents with&#160;ulcerative colitis</p>
<p style="position:absolute;top:295px;left:106px;white-space:nowrap" class="ft3423"><i>Children and adolescents from 6 years of age weighing less than 40 kg</i></p>
<p style="position:absolute;top:333px;left:106px;white-space:nowrap" class="ft3424">The usual Humira dose is 80&#160;mg (as two 40 mg injections in one day) initially followed by 40 mg&#160;(as one&#160;<br/>40 mg injection)&#160;two weeks later. Thereafter, the usual dose is 40 mg every other week.&#160;</p>
<p style="position:absolute;top:390px;left:106px;white-space:nowrap" class="ft3422">Patients who turn 18&#160;years of age&#160;while on&#160;40 mg every other week,&#160;should continue their&#160;prescribed dose.</p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft3423"><i>Children and adolescents from 6 years of age weighing 40 kg or more</i></p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft3425">The usual Humira dose is 160 mg (as&#160;four 40 mg injections in one day or two 40 mg injections per day for&#160;<br/>two consecutive days) initially, followed by 80 mg (as&#160;two 40 mg&#160;injections in one day) two weeks later.&#160;<br/>Thereafter the usual dose is 80 mg every other week.&#160;</p>
<p style="position:absolute;top:541px;left:106px;white-space:nowrap" class="ft3422">Patients who turn 18&#160;years of age&#160;while on&#160;80 mg every other week,&#160;should continue their prescribed dose.</p>
<p style="position:absolute;top:579px;left:106px;white-space:nowrap" class="ft3422">Children&#160;and adolescents&#160;with chronic non-infectious&#160;uveitis from 2&#160;years of age</p>
<p style="position:absolute;top:617px;left:106px;white-space:nowrap" class="ft34214"><i>Children and adolescents from 2&#160;years of age weighing less than 30&#160;kg<br/></i>The usual dose of Humira is 20&#160;mg&#160;every other week with methotrexate.</p>
<p style="position:absolute;top:674px;left:106px;white-space:nowrap" class="ft3425">Your child’s doctor may also prescribe an initial dose of 40&#160;mg which may be&#160;administered one week&#160;<br/>prior to the start of the&#160;usual dose.</p>
<p style="position:absolute;top:731px;left:106px;white-space:nowrap" class="ft3423"><i>Children and adolescents from 2&#160;years of age weighing 30&#160;kg or more</i></p>
<p style="position:absolute;top:769px;left:106px;white-space:nowrap" class="ft3422">The usual dose of Humira is 40&#160;mg&#160;every other week with methotrexate.</p>
<p style="position:absolute;top:807px;left:106px;white-space:nowrap" class="ft3425">Your child’s doctor may also prescribe an initial dose&#160;of 80&#160;mg which may be administered one week&#160;<br/>prior to the start of the&#160;usual dose.</p>
<p style="position:absolute;top:864px;left:106px;white-space:nowrap" class="ft3421"><b>Method and route of administration</b></p>
<p style="position:absolute;top:902px;left:106px;white-space:nowrap" class="ft3422">Humira is administered by injection under the skin (by subcutaneous injection).</p>
<p style="position:absolute;top:940px;left:106px;white-space:nowrap" class="ft3421"><b>Instructions for preparing and giving an injection of&#160;Humira</b></p>
<p style="position:absolute;top:978px;left:106px;white-space:nowrap" class="ft3424">The following instructions explain how to inject Humira. Please read the instructions carefully and follow&#160;<br/>them step by step. You will be instructed by your child's doctor or his/her assistant on the technique of&#160;<br/>injection and the amount to give to&#160;your child. Do not attempt to give your child an injection until you are&#160;<br/>sure that you understand how to prepare and give the injection. After proper training, the injection can be&#160;<br/>self-administered or given by another person, for example a family member&#160;or friend.</p>
</div>
<!-- Page 343 -->
<a name="343"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft34336{font-size:17px;font-family:HORGHZ+CourierNew;color:#000000;}
-->
</style>
<div id="page343-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3430">343</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft3435">Failure to perform the following steps as described may cause contamination which may lead to infection&#160;<br/>of&#160;your child.</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft3432">This injection should not be mixed in the same syringe or vial with any other medicine.</p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft3431"><b>1)&#160;</b></p>
<p style="position:absolute;top:181px;left:148px;white-space:nowrap" class="ft3431"><b>Setting up&#160;</b></p>
<p style="position:absolute;top:218px;left:106px;white-space:nowrap" class="ft3436"></p>
<p style="position:absolute;top:220px;left:147px;white-space:nowrap" class="ft3434">Make sure you know the proper amount (volume) needed for dosing. If you don’t know the amount,&#160;<br/><b>STOP HERE&#160;</b>and contact your doctor for further instruction.</p>
<p style="position:absolute;top:276px;left:106px;white-space:nowrap" class="ft3436"></p>
<p style="position:absolute;top:278px;left:150px;white-space:nowrap" class="ft3434">You will need a special container for waste, such as a sharps container or as instructed by your&#160;<br/>nurse, doctor or pharmacist. Place the container on your work surface.</p>
<p style="position:absolute;top:334px;left:106px;white-space:nowrap" class="ft3436"></p>
<p style="position:absolute;top:336px;left:150px;white-space:nowrap" class="ft3432">Wash your hands thoroughly</p>
<p style="position:absolute;top:374px;left:106px;white-space:nowrap" class="ft3436"></p>
<p style="position:absolute;top:375px;left:150px;white-space:nowrap" class="ft3434">Remove one box containing, one syringe, one vial adapter, one vial, two alcohol pads and one&#160;<br/>needle from the carton. If there is a second box in the carton for&#160;a future injection, place it back in&#160;<br/>the refrigerator immediately.</p>
<p style="position:absolute;top:451px;left:106px;white-space:nowrap" class="ft3436"></p>
<p style="position:absolute;top:453px;left:150px;white-space:nowrap" class="ft3435">Look at the expiry date on the box to be used.&#160;<b>DO NOT&#160;</b>use any item after the date shown on the&#160;<br/>box.</p>
<p style="position:absolute;top:509px;left:106px;white-space:nowrap" class="ft3436"></p>
<p style="position:absolute;top:510px;left:150px;white-space:nowrap" class="ft3434">Set up the following items on a clean surface,&#160;<b>DO NOT&#160;</b>take them out of their individual packaging&#160;<br/>yet.</p>
<p style="position:absolute;top:568px;left:148px;white-space:nowrap" class="ft34336">o</p>
<p style="position:absolute;top:567px;left:191px;white-space:nowrap" class="ft3432">One 1 ml syringe (1)&#160;</p>
<p style="position:absolute;top:587px;left:148px;white-space:nowrap" class="ft34336">o</p>
<p style="position:absolute;top:586px;left:191px;white-space:nowrap" class="ft3432">One&#160;vial adapter (2)&#160;</p>
<p style="position:absolute;top:606px;left:148px;white-space:nowrap" class="ft34336">o</p>
<p style="position:absolute;top:606px;left:191px;white-space:nowrap" class="ft3432">One&#160;vial for paediatric use of Humira for injection (3)</p>
<p style="position:absolute;top:625px;left:148px;white-space:nowrap" class="ft34336">o</p>
<p style="position:absolute;top:624px;left:191px;white-space:nowrap" class="ft3432">Two alcohol pads (4)</p>
<p style="position:absolute;top:644px;left:148px;white-space:nowrap" class="ft34336">o</p>
<p style="position:absolute;top:643px;left:191px;white-space:nowrap" class="ft3432">One&#160;needle (5)</p>
<p style="position:absolute;top:916px;left:106px;white-space:nowrap" class="ft3436"></p>
<p style="position:absolute;top:918px;left:150px;white-space:nowrap" class="ft3434">Humira is a liquid that is clear and colourless.&#160;<b>DO NOT&#160;</b>use if the liquid is cloudy, discoloured or&#160;<br/>has flakes or particles in it.</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft3431"><b>2)&#160;</b></p>
<p style="position:absolute;top:975px;left:148px;white-space:nowrap" class="ft3431"><b>Preparing the Humira dose for injection</b></p>
<p style="position:absolute;top:1013px;left:148px;white-space:nowrap" class="ft3432">General handling:&#160;<b>DO NOT&#160;</b>dispose of any waste items until after the injection is completed.</p>
</div>
<!-- Page 344 -->
<a name="344"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page344-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3440">344</p>
<p style="position:absolute;top:85px;left:106px;white-space:nowrap" class="ft3446"></p>
<p style="position:absolute;top:87px;left:147px;white-space:nowrap" class="ft3445">Prepare the needle by partially peeling&#160;the package open from the end closest to the yellow syringe&#160;<br/>connector. Peel the package just far enough to expose the yellow syringe connector.&#160;<br/>Set the package down with the clear side of the package facing up.</p>
<p style="position:absolute;top:417px;left:106px;white-space:nowrap" class="ft3446"></p>
<p style="position:absolute;top:419px;left:147px;white-space:nowrap" class="ft3442">Pop off the white plastic cap from the&#160;vial to see the top of the vial stopper.</p>
<p style="position:absolute;top:691px;left:106px;white-space:nowrap" class="ft3446"></p>
<p style="position:absolute;top:693px;left:147px;white-space:nowrap" class="ft3445">Use&#160;one of the alcohol pads to wipe the vial stopper. DO NOT touch the vial stopper after wiping&#160;<br/>with the alcohol pad.</p>
<p style="position:absolute;top:749px;left:106px;white-space:nowrap" class="ft3446"></p>
<p style="position:absolute;top:751px;left:147px;white-space:nowrap" class="ft3442">Peel the cover off the vial adapter package but do not take out the vial adapter. &#160;&#160;</p>
<p style="position:absolute;top:1020px;left:106px;white-space:nowrap" class="ft3446"></p>
<p style="position:absolute;top:1022px;left:147px;white-space:nowrap" class="ft3442">Hold the vial with the vial stopper facing up.</p>
<p style="position:absolute;top:1059px;left:106px;white-space:nowrap" class="ft3446"></p>
<p style="position:absolute;top:1061px;left:147px;white-space:nowrap" class="ft3445">With the vial adapter still in the clear package, attach it to the vial stopper by pushing down until the&#160;<br/>vial adapter snaps in place. &#160;</p>
</div>
<!-- Page 345 -->
<a name="345"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page345-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3450">345</p>
<p style="position:absolute;top:104px;left:106px;white-space:nowrap" class="ft3456"></p>
<p style="position:absolute;top:106px;left:147px;white-space:nowrap" class="ft3452">When you are sure the adapter is attached to the vial, lift off the package from the vial adapter.&#160;</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft3456"></p>
<p style="position:absolute;top:145px;left:147px;white-space:nowrap" class="ft3454">Gently set the vial with vial adapter down on your clean work surface. Be careful that it does not fall&#160;<br/>over.&#160;<b>DO NOT&#160;</b>touch the vial adapter.&#160;</p>
<p style="position:absolute;top:441px;left:106px;white-space:nowrap" class="ft3456"></p>
<p style="position:absolute;top:443px;left:147px;white-space:nowrap" class="ft3452">Prepare the syringe by partially peeling the package open from the end closest&#160;to white plunger rod.</p>
<p style="position:absolute;top:480px;left:106px;white-space:nowrap" class="ft3456"></p>
<p style="position:absolute;top:482px;left:147px;white-space:nowrap" class="ft3454">Peel the clear package just far enough to expose the white plunger rod, but do not take the syringe&#160;<br/>out of the package. &#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft3456"></p>
<p style="position:absolute;top:540px;left:147px;white-space:nowrap" class="ft3455">Hold the syringe package and&#160;<b>SLOWLY&#160;</b>pull the white plunger rod out to 0.1 ml beyond the&#160;<br/>prescribed dose (For example, if the prescribed dose is 0.5 ml, pull the white plunger rod to 0.6 ml).&#160;<br/><b>NEVER&#160;</b>pull past the 0.9 ml position regardless of prescribed dose.</p>
<p style="position:absolute;top:616px;left:106px;white-space:nowrap" class="ft3456"></p>
<p style="position:absolute;top:617px;left:147px;white-space:nowrap" class="ft3452">You will set the volume to the prescribed dose in a later step.</p>
<p style="position:absolute;top:655px;left:106px;white-space:nowrap" class="ft3456"></p>
<p style="position:absolute;top:657px;left:147px;white-space:nowrap" class="ft3451"><b>DO NOT&#160;</b>pull the white plunger rod completely out of the syringe.</p>
<p style="position:absolute;top:694px;left:106px;white-space:nowrap" class="ft3451"><b>NOTE</b>:&#160;</p>
<p style="position:absolute;top:732px;left:106px;white-space:nowrap" class="ft3454">If the white plunger rod is pulled completely out of the syringe, discard the syringe and contact your&#160;<br/>Humira provider for a replacement.&#160;<b>DO NOT&#160;</b>try to reinsert the white plunger rod.</p>
<p style="position:absolute;top:941px;left:462px;white-space:nowrap" class="ft3452">Dose + 0.1 ml</p>
<p style="position:absolute;top:1031px;left:106px;white-space:nowrap" class="ft3456"></p>
<p style="position:absolute;top:1033px;left:150px;white-space:nowrap" class="ft3454"><b>DO NOT&#160;</b>use the white plunger rod to remove the syringe from the package. Hold the syringe on&#160;<br/>the graduated area and pull the syringe from its package.&#160;<b>DO NOT&#160;</b>set the syringe down at any&#160;<br/>time.</p>
</div>
<!-- Page 346 -->
<a name="346"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page346-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3460">346</p>
<p style="position:absolute;top:104px;left:104px;white-space:nowrap" class="ft3466"></p>
<p style="position:absolute;top:106px;left:147px;white-space:nowrap" class="ft3465">While holding the vial adapter firmly, insert the syringe tip into the vial adapter and twist the&#160;<br/>syringe clockwise with one hand until firm.&#160;<b>DO NOT&#160;</b>over-tighten.&#160;</p>
<p style="position:absolute;top:393px;left:109px;white-space:nowrap" class="ft3466"></p>
<p style="position:absolute;top:395px;left:150px;white-space:nowrap" class="ft3462">While holding the vial, push the white plunger rod all the way down. This step is important to get&#160;</p>
<p style="position:absolute;top:414px;left:152px;white-space:nowrap" class="ft3462">the proper dose. Hold the white plunger rod in and turn the vial and syringe upside down.</p>
<p style="position:absolute;top:681px;left:109px;white-space:nowrap" class="ft3466"></p>
<p style="position:absolute;top:683px;left:150px;white-space:nowrap" class="ft3461"><b>SLOWLY&#160;</b>pull the white plunger rod out to 0.1 ml beyond the prescribed dose. This is important to&#160;</p>
<p style="position:absolute;top:702px;left:152px;white-space:nowrap" class="ft3464">get the proper dose. You will set the volume to the prescribed dose in step 4, Dose Preparation. If&#160;<br/>the prescribed dose is 0.5 ml, pull the white plunger rod out to 0.6 ml. You will see the liquid&#160;<br/>medication from the vial go into the syringe.</p>
<p style="position:absolute;top:1008px;left:100px;white-space:nowrap" class="ft3466"></p>
<p style="position:absolute;top:1010px;left:150px;white-space:nowrap" class="ft3464">Push the white plunger rod all the way back in to push the liquid medication back into the vial.&#160;<br/>Again,&#160;<b>SLOWLY&#160;</b>pull the white plunger rod out to 0.1 ml beyond the prescribed dose, this is&#160;<br/>important to get the proper dose and important in order to prevent air bubbles or air gaps in the&#160;<br/>liquid medication. You will set the&#160;volume to the prescribed dose in step 4, Dose Preparation.</p>
</div>
<!-- Page 347 -->
<a name="347"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page347-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3470">347</p>
<p style="position:absolute;top:339px;left:107px;white-space:nowrap" class="ft3476"></p>
<p style="position:absolute;top:341px;left:147px;white-space:nowrap" class="ft3474">If you see remaining air bubbles or air gaps in the liquid medication in the syringe, you may repeat&#160;<br/>this process up to 3 times.&#160;<b>DO NOT&#160;</b>shake the syringe.</p>
<p style="position:absolute;top:417px;left:106px;white-space:nowrap" class="ft3471"><b>NOTE</b>:&#160;</p>
<p style="position:absolute;top:455px;left:106px;white-space:nowrap" class="ft3475">If the white plunger rod is pulled completely out of the syringe, discard the syringe and contact your&#160;<br/>Humira provider for a replacement.&#160;<b>DO NOT&#160;</b>try to reinsert the white plunger rod.</p>
<p style="position:absolute;top:511px;left:106px;white-space:nowrap" class="ft3476"></p>
<p style="position:absolute;top:513px;left:147px;white-space:nowrap" class="ft3474">While still holding the syringe upright at the graduated area, remove the vial adapter with the vial by&#160;<br/>twisting the vial adapter off with the other hand. Be sure to remove the vial adapter with the vial&#160;<br/>from the syringe.&#160;<b>DO NOT&#160;</b>touch the tip of the syringe.</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft3476"></p>
<p style="position:absolute;top:825px;left:147px;white-space:nowrap" class="ft3472">If a large air bubble or air gap can be seen near the syringe tip,&#160;<b>SLOWLY&#160;</b>push the white plunger&#160;</p>
<p style="position:absolute;top:844px;left:150px;white-space:nowrap" class="ft3475">rod into&#160;the syringe until fluid begins to enter the syringe tip.&#160;<b>DO NOT&#160;</b>push the white plunger rod&#160;<br/>past the dose position.</p>
<p style="position:absolute;top:900px;left:106px;white-space:nowrap" class="ft3476"></p>
<p style="position:absolute;top:902px;left:147px;white-space:nowrap" class="ft3472">For example, if the prescribed dose is 0.5 ml,&#160;<b>DO NOT&#160;</b>push the white plunger rod past the 0.5 ml</p>
<p style="position:absolute;top:921px;left:150px;white-space:nowrap" class="ft3472">position.</p>
<p style="position:absolute;top:958px;left:106px;white-space:nowrap" class="ft3476"></p>
<p style="position:absolute;top:960px;left:147px;white-space:nowrap" class="ft3472">Check to see that the fluid remaining in the syringe is at least the prescribed dose volume. If the&#160;</p>
<p style="position:absolute;top:979px;left:150px;white-space:nowrap" class="ft3474">remaining volume is less than the prescribed dose volume,&#160;<b>DO NOT&#160;</b>use the syringe and contact&#160;<br/>your healthcare provider.</p>
<p style="position:absolute;top:1036px;left:106px;white-space:nowrap" class="ft3476"></p>
<p style="position:absolute;top:1038px;left:147px;white-space:nowrap" class="ft3472">With your free hand, pick&#160;up the needle package with the yellow syringe connector facing down.</p>
</div>
<!-- Page 348 -->
<a name="348"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page348-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3480">348</p>
<p style="position:absolute;top:85px;left:106px;white-space:nowrap" class="ft3486"></p>
<p style="position:absolute;top:87px;left:147px;white-space:nowrap" class="ft3482">Keeping the syringe up, insert the syringe tip into the yellow syringe connector and twist the syringe&#160;</p>
<p style="position:absolute;top:106px;left:150px;white-space:nowrap" class="ft3482">as indicated by the arrow in the picture until firm. The needle is now attached to&#160;the syringe.</p>
<p style="position:absolute;top:376px;left:106px;white-space:nowrap" class="ft3486"></p>
<p style="position:absolute;top:378px;left:147px;white-space:nowrap" class="ft3482">Pull the needle package off, but&#160;<b>DO NOT&#160;</b>remove the clear needle cap.</p>
<p style="position:absolute;top:415px;left:106px;white-space:nowrap" class="ft3486"></p>
<p style="position:absolute;top:417px;left:147px;white-space:nowrap" class="ft3485">Place the syringe on your clean work surface. Continue with injection site and dose preparation&#160;<br/>immediately.</p>
<p style="position:absolute;top:474px;left:106px;white-space:nowrap" class="ft3481"><b>3)&#160;</b></p>
<p style="position:absolute;top:474px;left:148px;white-space:nowrap" class="ft3481"><b>Choosing and preparing an injection site</b></p>
<p style="position:absolute;top:511px;left:106px;white-space:nowrap" class="ft3486"></p>
<p style="position:absolute;top:513px;left:147px;white-space:nowrap" class="ft3484">Choose a site on your thigh or stomach.&#160;<b>DO NOT&#160;</b>use the same site that was used for the last&#160;<br/>injection.</p>
<p style="position:absolute;top:550px;left:106px;white-space:nowrap" class="ft3486"></p>
<p style="position:absolute;top:552px;left:147px;white-space:nowrap" class="ft3482">The new injection site should be given at least 3&#160;cm from the last injection site.</p>
<p style="position:absolute;top:820px;left:106px;white-space:nowrap" class="ft3486"></p>
<p style="position:absolute;top:822px;left:147px;white-space:nowrap" class="ft3484"><b>DO NOT&#160;</b>inject in an area where the skin is reddened, bruised, or hard. This may mean there is an&#160;<br/>infection and therefore you should contact your doctor.</p>
<p style="position:absolute;top:859px;left:106px;white-space:nowrap" class="ft3486"></p>
<p style="position:absolute;top:861px;left:147px;white-space:nowrap" class="ft3485">To reduce the chance of infection, wipe the injection site with the other alcohol pad.&#160;<b>DO&#160;NOT&#160;</b>touch&#160;<br/>the area&#160;again before injecting.</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft3481"><b>4)&#160;</b></p>
<p style="position:absolute;top:918px;left:148px;white-space:nowrap" class="ft3481"><b>Dose Preparation&#160;</b></p>
<p style="position:absolute;top:964px;left:106px;white-space:nowrap" class="ft3486"></p>
<p style="position:absolute;top:966px;left:147px;white-space:nowrap" class="ft3482">Pick up the syringe with the needle pointing up.</p>
<p style="position:absolute;top:984px;left:106px;white-space:nowrap" class="ft3486"></p>
<p style="position:absolute;top:986px;left:147px;white-space:nowrap" class="ft3482">Use&#160;your other hand to flip the pink needle cover down toward the syringe.</p>
</div>
<!-- Page 349 -->
<a name="349"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page349-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3490">349</p>
<p style="position:absolute;top:339px;left:106px;white-space:nowrap" class="ft3496"></p>
<p style="position:absolute;top:341px;left:147px;white-space:nowrap" class="ft3492">Remove the clear needle cap by pulling it straight up with your other hand.</p>
<p style="position:absolute;top:611px;left:106px;white-space:nowrap" class="ft3496"></p>
<p style="position:absolute;top:613px;left:147px;white-space:nowrap" class="ft3492">The needle is clean.</p>
<p style="position:absolute;top:631px;left:106px;white-space:nowrap" class="ft3496"></p>
<p style="position:absolute;top:633px;left:147px;white-space:nowrap" class="ft3491"><b>DO NOT&#160;</b>touch the needle.</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft3496"></p>
<p style="position:absolute;top:653px;left:147px;white-space:nowrap" class="ft3491"><b>DO NOT&#160;</b>set the syringe down at any time after the clear needle cap is off.</p>
<p style="position:absolute;top:672px;left:106px;white-space:nowrap" class="ft3496"></p>
<p style="position:absolute;top:674px;left:147px;white-space:nowrap" class="ft3491"><b>DO NOT&#160;</b>try to put the clear needle cap back on the needle.</p>
<p style="position:absolute;top:711px;left:106px;white-space:nowrap" class="ft3496"></p>
<p style="position:absolute;top:712px;left:156px;white-space:nowrap" class="ft3494">Hold&#160;the&#160;syringe&#160;at&#160;eye-level&#160;with&#160;the&#160;needle&#160;pointing&#160;up&#160;to&#160;see&#160;the&#160;amount&#160;clearly.&#160;Be&#160;careful&#160;not&#160;<br/>to squirt the liquid medication into your eye.</p>
<p style="position:absolute;top:750px;left:106px;white-space:nowrap" class="ft3496"></p>
<p style="position:absolute;top:752px;left:156px;white-space:nowrap" class="ft3492">Recheck the prescribed medication amount.</p>
<p style="position:absolute;top:770px;left:106px;white-space:nowrap" class="ft3496"></p>
<p style="position:absolute;top:772px;left:156px;white-space:nowrap" class="ft34915">Push the white plunger rod gently into the syringe until the syringe contains the prescribed amount&#160;<br/>of liquid. Excess liquid may come out of&#160;the needle while the white plunger rod is being pushed.&#160;<b>DO&#160;<br/>NOT&#160;</b>wipe off the needle or the syringe.</p>
<p style="position:absolute;top:848px;left:106px;white-space:nowrap" class="ft3491"><b>5)</b></p>
<p style="position:absolute;top:848px;left:148px;white-space:nowrap" class="ft3491"><b>Injecting Humira</b></p>
<p style="position:absolute;top:885px;left:106px;white-space:nowrap" class="ft3496"></p>
<p style="position:absolute;top:887px;left:156px;white-space:nowrap" class="ft3492">With the free hand, gently grasp the cleaned area of skin and hold firmly.&#160;</p>
<p style="position:absolute;top:905px;left:106px;white-space:nowrap" class="ft3496"></p>
<p style="position:absolute;top:907px;left:156px;white-space:nowrap" class="ft3492">With the other hand, hold syringe at 45-degree angle to skin.&#160;</p>
<p style="position:absolute;top:925px;left:106px;white-space:nowrap" class="ft3496"></p>
<p style="position:absolute;top:927px;left:156px;white-space:nowrap" class="ft3492">With one quick, short motion, push needle all the way into skin.</p>
<p style="position:absolute;top:945px;left:106px;white-space:nowrap" class="ft3496"></p>
<p style="position:absolute;top:947px;left:156px;white-space:nowrap" class="ft3492">Let go of the skin in your hand.</p>
<p style="position:absolute;top:965px;left:106px;white-space:nowrap" class="ft3496"></p>
<p style="position:absolute;top:967px;left:156px;white-space:nowrap" class="ft3492">Push the white plunger rod to inject the liquid medication until the syringe is empty.</p>
<p style="position:absolute;top:986px;left:106px;white-space:nowrap" class="ft3496"></p>
<p style="position:absolute;top:987px;left:156px;white-space:nowrap" class="ft3494">When&#160;the&#160;syringe&#160;&#160;is&#160;empty,&#160;remove&#160;the&#160;&#160;needle&#160;from&#160;skin,&#160;being&#160;careful&#160;to&#160;pull&#160;it&#160;out&#160;at&#160;the&#160;same&#160;<br/>angle as when it was inserted.</p>
</div>
<!-- Page 350 -->
<a name="350"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page350-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3500">350</p>
<p style="position:absolute;top:321px;left:106px;white-space:nowrap" class="ft3506"></p>
<p style="position:absolute;top:323px;left:156px;white-space:nowrap" class="ft3504">Gently&#160;flip&#160;the&#160;pink&#160;needle&#160;cover&#160;up,&#160;over&#160;the&#160;needle&#160;and&#160;snap&#160;into&#160;place&#160;and&#160;set&#160;the&#160;syringe&#160;with&#160;<br/>needle on the work surface. DO NOT&#160;put the clear needle cap back on the needle.</p>
<p style="position:absolute;top:610px;left:106px;white-space:nowrap" class="ft3506"></p>
<p style="position:absolute;top:612px;left:156px;white-space:nowrap" class="ft3504">Using&#160;a piece of gauze, apply pressure over the&#160;injection site for 10 seconds. A little bleeding&#160;may&#160;<br/>occur.&#160;<b>DO NOT&#160;</b>rub the injection site. Use a plaster if you want to.&#160;</p>
<p style="position:absolute;top:669px;left:106px;white-space:nowrap" class="ft3501"><b>6)</b></p>
<p style="position:absolute;top:669px;left:148px;white-space:nowrap" class="ft3501"><b>Throwing away supplies</b></p>
<p style="position:absolute;top:706px;left:106px;white-space:nowrap" class="ft3506"></p>
<p style="position:absolute;top:708px;left:156px;white-space:nowrap" class="ft3504">You will need a special container for waste, such as&#160;a&#160;sharps container or as instructed by your nurse,&#160;<br/>doctor or pharmacist.</p>
<p style="position:absolute;top:745px;left:106px;white-space:nowrap" class="ft3506"></p>
<p style="position:absolute;top:747px;left:156px;white-space:nowrap" class="ft3505">Put the syringe with needle, vial and vial adapter into a special sharps container. DO NOT put these&#160;<br/>items into regular household waste.</p>
<p style="position:absolute;top:784px;left:106px;white-space:nowrap" class="ft3506"></p>
<p style="position:absolute;top:786px;left:156px;white-space:nowrap" class="ft3502">The syringe, needle, vial and vial adapter MUST NEVER be reused.</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft3506"></p>
<p style="position:absolute;top:806px;left:156px;white-space:nowrap" class="ft3502">Keep the special container out of the sight and reach of children at all times.</p>
<p style="position:absolute;top:824px;left:106px;white-space:nowrap" class="ft3506"></p>
<p style="position:absolute;top:826px;left:156px;white-space:nowrap" class="ft3502">Throw away all other used items into your regular household waste.</p>
<p style="position:absolute;top:864px;left:106px;white-space:nowrap" class="ft3501"><b>If you use more Humira than you should</b></p>
<p style="position:absolute;top:902px;left:106px;white-space:nowrap" class="ft3504">If&#160;you accidentally inject a larger amount of Humira liquid, or if you inject Humira more frequently than&#160;<br/>told to by your doctor, call your doctor&#160;and tell him/her that your child has taken more. Always take the&#160;<br/>outer carton or the vial of the medicine with you, even if it is empty.&#160;</p>
<p style="position:absolute;top:978px;left:106px;white-space:nowrap" class="ft3501"><b>If you use less Humira than you should</b></p>
<p style="position:absolute;top:1016px;left:106px;white-space:nowrap" class="ft3505">If you accidentally inject a smaller amount of Humira liquid, or if you inject Humira less frequently than&#160;<br/>told to by your child’s doctor or pharmacist, you should call your child’s doctor&#160;or pharmacist and tell&#160;<br/>him/her that your child has taken less. Always take the outer carton or the vial of the medicine with you,&#160;<br/>even if it is empty.</p>
</div>
<!-- Page 351 -->
<a name="351"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page351-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3510">351</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft3511"><b>If you forget to use Humira</b></p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft3515">If you forget to give your child a Humira injection, you should inject the Humira dose as soon as you&#160;<br/>remember. Then administer your child's next dose as you would have on the originally scheduled day, had&#160;<br/>you not forgotten a dose.&#160;</p>
<p style="position:absolute;top:219px;left:106px;white-space:nowrap" class="ft3511"><b>If your child stops using Humira</b></p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft3514">The&#160;decision to stop using Humira should be discussed with your child’s doctor. Your child’s symptoms&#160;<br/>may return upon discontinuation.</p>
<p style="position:absolute;top:312px;left:106px;white-space:nowrap" class="ft3512">If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
<p style="position:absolute;top:369px;left:106px;white-space:nowrap" class="ft3511"><b>4.</b></p>
<p style="position:absolute;top:369px;left:148px;white-space:nowrap" class="ft3511"><b>Possible side effects</b></p>
<p style="position:absolute;top:407px;left:106px;white-space:nowrap" class="ft3515">Like all medicines, this medicine can cause side effects, although not everybody gets them. Most side&#160;<br/>effects are mild to moderate. However, some may be serious and require treatment. Side effects may occur&#160;<br/>at least up to 4 months after the last Humira injection. &#160;</p>
<p style="position:absolute;top:483px;left:106px;white-space:nowrap" class="ft3512">Tell your doctor immediately if you notice any of the following</p>
<p style="position:absolute;top:520px;left:106px;white-space:nowrap" class="ft3516"></p>
<p style="position:absolute;top:522px;left:147px;white-space:nowrap" class="ft3512">severe rash, hives or other signs of allergic reaction;&#160;</p>
<p style="position:absolute;top:540px;left:106px;white-space:nowrap" class="ft3516"></p>
<p style="position:absolute;top:542px;left:147px;white-space:nowrap" class="ft3512">swollen face, hands, feet;</p>
<p style="position:absolute;top:560px;left:106px;white-space:nowrap" class="ft3516"></p>
<p style="position:absolute;top:562px;left:147px;white-space:nowrap" class="ft3512">trouble breathing, swallowing;</p>
<p style="position:absolute;top:580px;left:106px;white-space:nowrap" class="ft3516"></p>
<p style="position:absolute;top:582px;left:147px;white-space:nowrap" class="ft3512">shortness of breath with exertion or upon lying down&#160;or swelling of the feet.</p>
<p style="position:absolute;top:620px;left:106px;white-space:nowrap" class="ft3512">Tell your doctor as soon as possible if you notice any of the following</p>
<p style="position:absolute;top:658px;left:106px;white-space:nowrap" class="ft3516"></p>
<p style="position:absolute;top:660px;left:148px;white-space:nowrap" class="ft3512">signs of infection such as fever, feeling sick, wounds, dental problems, burning on urination;</p>
<p style="position:absolute;top:678px;left:106px;white-space:nowrap" class="ft3516"></p>
<p style="position:absolute;top:680px;left:147px;white-space:nowrap" class="ft3512">feeling weak or tired;</p>
<p style="position:absolute;top:698px;left:106px;white-space:nowrap" class="ft3516"></p>
<p style="position:absolute;top:700px;left:147px;white-space:nowrap" class="ft3512">coughing;</p>
<p style="position:absolute;top:718px;left:106px;white-space:nowrap" class="ft3516"></p>
<p style="position:absolute;top:720px;left:147px;white-space:nowrap" class="ft3512">tingling;</p>
<p style="position:absolute;top:738px;left:106px;white-space:nowrap" class="ft3516"></p>
<p style="position:absolute;top:740px;left:147px;white-space:nowrap" class="ft3512">numbness;</p>
<p style="position:absolute;top:758px;left:106px;white-space:nowrap" class="ft3516"></p>
<p style="position:absolute;top:760px;left:147px;white-space:nowrap" class="ft3512">double&#160;vision;</p>
<p style="position:absolute;top:779px;left:106px;white-space:nowrap" class="ft3516"></p>
<p style="position:absolute;top:780px;left:147px;white-space:nowrap" class="ft3512">arm&#160;or leg weakness;</p>
<p style="position:absolute;top:799px;left:106px;white-space:nowrap" class="ft3516"></p>
<p style="position:absolute;top:801px;left:147px;white-space:nowrap" class="ft3512">a&#160;bump or open sore that doesn't heal;</p>
<p style="position:absolute;top:819px;left:106px;white-space:nowrap" class="ft3516"></p>
<p style="position:absolute;top:821px;left:147px;white-space:nowrap" class="ft3515">signs and symptoms suggestive of blood disorders such as persistent fever, bruising, bleeding,&#160;<br/>paleness.</p>
<p style="position:absolute;top:878px;left:106px;white-space:nowrap" class="ft3515">The symptoms described above can be signs of the below listed side effects, which&#160;have been observed&#160;<br/>with Humira.</p>
<p style="position:absolute;top:935px;left:106px;white-space:nowrap" class="ft3512">Very common (may affect more than 1 in 10 people)</p>
<p style="position:absolute;top:972px;left:106px;white-space:nowrap" class="ft3516"></p>
<p style="position:absolute;top:973px;left:147px;white-space:nowrap" class="ft3512">injection site reactions (including pain, swelling, redness or itching);</p>
<p style="position:absolute;top:992px;left:105px;white-space:nowrap" class="ft3516"></p>
<p style="position:absolute;top:994px;left:150px;white-space:nowrap" class="ft3512">respiratory tract infections (including cold, runny nose, sinus infection, pneumonia);</p>
<p style="position:absolute;top:1012px;left:105px;white-space:nowrap" class="ft3516"></p>
<p style="position:absolute;top:1014px;left:150px;white-space:nowrap" class="ft3512">headache;</p>
<p style="position:absolute;top:1032px;left:105px;white-space:nowrap" class="ft3516"></p>
<p style="position:absolute;top:1034px;left:150px;white-space:nowrap" class="ft3512">abdominal pain;</p>
<p style="position:absolute;top:1052px;left:105px;white-space:nowrap" class="ft3516"></p>
<p style="position:absolute;top:1054px;left:150px;white-space:nowrap" class="ft3512">nausea and vomiting;</p>
<p style="position:absolute;top:1072px;left:105px;white-space:nowrap" class="ft3516"></p>
<p style="position:absolute;top:1074px;left:150px;white-space:nowrap" class="ft3512">rash;</p>
</div>
<!-- Page 352 -->
<a name="352"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page352-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3520">352</p>
<p style="position:absolute;top:85px;left:105px;white-space:nowrap" class="ft3526"></p>
<p style="position:absolute;top:87px;left:150px;white-space:nowrap" class="ft3522">musculoskeletal pain.</p>
<p style="position:absolute;top:125px;left:106px;white-space:nowrap" class="ft3522">Common (may affect up to 1 in 10 people)&#160;</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft3526"></p>
<p style="position:absolute;top:164px;left:147px;white-space:nowrap" class="ft3522">serious&#160;infections (including blood poisoning and influenza);</p>
<p style="position:absolute;top:182px;left:106px;white-space:nowrap" class="ft3526"></p>
<p style="position:absolute;top:184px;left:147px;white-space:nowrap" class="ft3522">intestinal infections&#160;(including gastroenteritis);</p>
<p style="position:absolute;top:203px;left:106px;white-space:nowrap" class="ft3526"></p>
<p style="position:absolute;top:204px;left:147px;white-space:nowrap" class="ft3522">skin infections (including&#160;cellulitis and shingles);</p>
<p style="position:absolute;top:223px;left:106px;white-space:nowrap" class="ft3526"></p>
<p style="position:absolute;top:225px;left:147px;white-space:nowrap" class="ft3522">ear infections;</p>
<p style="position:absolute;top:243px;left:106px;white-space:nowrap" class="ft3526"></p>
<p style="position:absolute;top:245px;left:147px;white-space:nowrap" class="ft3522">oral infections (including tooth infections and cold sores);</p>
<p style="position:absolute;top:263px;left:106px;white-space:nowrap" class="ft3526"></p>
<p style="position:absolute;top:265px;left:147px;white-space:nowrap" class="ft3522">reproductive tract infections;</p>
<p style="position:absolute;top:283px;left:106px;white-space:nowrap" class="ft3526"></p>
<p style="position:absolute;top:285px;left:147px;white-space:nowrap" class="ft3522">urinary tract infection;</p>
<p style="position:absolute;top:303px;left:106px;white-space:nowrap" class="ft3526"></p>
<p style="position:absolute;top:305px;left:147px;white-space:nowrap" class="ft3522">fungal infections;</p>
<p style="position:absolute;top:324px;left:106px;white-space:nowrap" class="ft3526"></p>
<p style="position:absolute;top:325px;left:147px;white-space:nowrap" class="ft3522">joint infections,</p>
<p style="position:absolute;top:344px;left:106px;white-space:nowrap" class="ft3526"></p>
<p style="position:absolute;top:346px;left:147px;white-space:nowrap" class="ft3522">benign tumours;</p>
<p style="position:absolute;top:364px;left:106px;white-space:nowrap" class="ft3526"></p>
<p style="position:absolute;top:366px;left:147px;white-space:nowrap" class="ft3522">skin cancer;</p>
<p style="position:absolute;top:384px;left:106px;white-space:nowrap" class="ft3526"></p>
<p style="position:absolute;top:386px;left:147px;white-space:nowrap" class="ft3522">allergic reactions (including&#160;seasonal allergy);</p>
<p style="position:absolute;top:404px;left:106px;white-space:nowrap" class="ft3526"></p>
<p style="position:absolute;top:406px;left:147px;white-space:nowrap" class="ft3522">dehydration;</p>
<p style="position:absolute;top:424px;left:106px;white-space:nowrap" class="ft3526"></p>
<p style="position:absolute;top:426px;left:147px;white-space:nowrap" class="ft3522">mood swings (including depression);</p>
<p style="position:absolute;top:445px;left:106px;white-space:nowrap" class="ft3526"></p>
<p style="position:absolute;top:446px;left:147px;white-space:nowrap" class="ft3522">anxiety;</p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft3526"></p>
<p style="position:absolute;top:467px;left:147px;white-space:nowrap" class="ft3522">difficulty sleeping;</p>
<p style="position:absolute;top:485px;left:106px;white-space:nowrap" class="ft3526"></p>
<p style="position:absolute;top:487px;left:147px;white-space:nowrap" class="ft3522">sensation disorders such as tingling, prickling or numbness;</p>
<p style="position:absolute;top:505px;left:106px;white-space:nowrap" class="ft3526"></p>
<p style="position:absolute;top:507px;left:147px;white-space:nowrap" class="ft3522">migraine;</p>
<p style="position:absolute;top:525px;left:106px;white-space:nowrap" class="ft3526"></p>
<p style="position:absolute;top:527px;left:147px;white-space:nowrap" class="ft3522">nerve root compression (including low back pain and leg pain);</p>
<p style="position:absolute;top:545px;left:106px;white-space:nowrap" class="ft3526"></p>
<p style="position:absolute;top:547px;left:147px;white-space:nowrap" class="ft3522">vision disturbances;&#160;</p>
<p style="position:absolute;top:565px;left:106px;white-space:nowrap" class="ft3526"></p>
<p style="position:absolute;top:567px;left:147px;white-space:nowrap" class="ft3522">eye&#160;inflammation;</p>
<p style="position:absolute;top:586px;left:106px;white-space:nowrap" class="ft3526"></p>
<p style="position:absolute;top:588px;left:147px;white-space:nowrap" class="ft3522">inflammation of the eye lid and eye swelling;</p>
<p style="position:absolute;top:606px;left:106px;white-space:nowrap" class="ft3526"></p>
<p style="position:absolute;top:608px;left:147px;white-space:nowrap" class="ft3522">vertigo;</p>
<p style="position:absolute;top:626px;left:106px;white-space:nowrap" class="ft3526"></p>
<p style="position:absolute;top:628px;left:147px;white-space:nowrap" class="ft3522">sensation of heart beating rapidly;</p>
<p style="position:absolute;top:646px;left:106px;white-space:nowrap" class="ft3526"></p>
<p style="position:absolute;top:648px;left:147px;white-space:nowrap" class="ft3522">high blood pressure;</p>
<p style="position:absolute;top:666px;left:106px;white-space:nowrap" class="ft3526"></p>
<p style="position:absolute;top:668px;left:147px;white-space:nowrap" class="ft3522">flushing;</p>
<p style="position:absolute;top:686px;left:106px;white-space:nowrap" class="ft3526"></p>
<p style="position:absolute;top:688px;left:147px;white-space:nowrap" class="ft3522">haematoma;</p>
<p style="position:absolute;top:707px;left:106px;white-space:nowrap" class="ft3526"></p>
<p style="position:absolute;top:708px;left:147px;white-space:nowrap" class="ft3522">cough;</p>
<p style="position:absolute;top:727px;left:106px;white-space:nowrap" class="ft3526"></p>
<p style="position:absolute;top:729px;left:147px;white-space:nowrap" class="ft3522">asthma;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft3526"></p>
<p style="position:absolute;top:749px;left:147px;white-space:nowrap" class="ft3522">shortness of breath;</p>
<p style="position:absolute;top:767px;left:106px;white-space:nowrap" class="ft3526"></p>
<p style="position:absolute;top:769px;left:147px;white-space:nowrap" class="ft3522">gastrointestinal bleeding;</p>
<p style="position:absolute;top:787px;left:106px;white-space:nowrap" class="ft3526"></p>
<p style="position:absolute;top:789px;left:147px;white-space:nowrap" class="ft3522">dyspepsia (indigestion, bloating, heart&#160;burn);</p>
<p style="position:absolute;top:807px;left:106px;white-space:nowrap" class="ft3526"></p>
<p style="position:absolute;top:809px;left:147px;white-space:nowrap" class="ft3522">acid reflux disease;</p>
<p style="position:absolute;top:828px;left:106px;white-space:nowrap" class="ft3526"></p>
<p style="position:absolute;top:829px;left:147px;white-space:nowrap" class="ft3522">sicca syndrome (including dry eyes and dry mouth);</p>
<p style="position:absolute;top:848px;left:106px;white-space:nowrap" class="ft3526"></p>
<p style="position:absolute;top:850px;left:147px;white-space:nowrap" class="ft3522">itching;</p>
<p style="position:absolute;top:868px;left:106px;white-space:nowrap" class="ft3526"></p>
<p style="position:absolute;top:870px;left:147px;white-space:nowrap" class="ft3522">itchy rash;</p>
<p style="position:absolute;top:888px;left:106px;white-space:nowrap" class="ft3526"></p>
<p style="position:absolute;top:890px;left:147px;white-space:nowrap" class="ft3522">bruising;</p>
<p style="position:absolute;top:908px;left:106px;white-space:nowrap" class="ft3526"></p>
<p style="position:absolute;top:910px;left:147px;white-space:nowrap" class="ft3522">inflammation of the skin (such as eczema);</p>
<p style="position:absolute;top:928px;left:106px;white-space:nowrap" class="ft3526"></p>
<p style="position:absolute;top:930px;left:147px;white-space:nowrap" class="ft3522">breaking of finger nails and toe nails;</p>
<p style="position:absolute;top:949px;left:106px;white-space:nowrap" class="ft3526"></p>
<p style="position:absolute;top:950px;left:147px;white-space:nowrap" class="ft3522">increased sweating;</p>
<p style="position:absolute;top:969px;left:106px;white-space:nowrap" class="ft3526"></p>
<p style="position:absolute;top:971px;left:147px;white-space:nowrap" class="ft3522">hair loss;</p>
<p style="position:absolute;top:989px;left:106px;white-space:nowrap" class="ft3526"></p>
<p style="position:absolute;top:991px;left:147px;white-space:nowrap" class="ft3522">new&#160;onset or worsening of psoriasis;</p>
<p style="position:absolute;top:1009px;left:106px;white-space:nowrap" class="ft3526"></p>
<p style="position:absolute;top:1011px;left:147px;white-space:nowrap" class="ft3522">muscle spasms;</p>
<p style="position:absolute;top:1029px;left:106px;white-space:nowrap" class="ft3526"></p>
<p style="position:absolute;top:1031px;left:147px;white-space:nowrap" class="ft3522">blood in urine;</p>
<p style="position:absolute;top:1049px;left:106px;white-space:nowrap" class="ft3526"></p>
<p style="position:absolute;top:1051px;left:147px;white-space:nowrap" class="ft3522">kidney problems;</p>
<p style="position:absolute;top:1069px;left:106px;white-space:nowrap" class="ft3526"></p>
<p style="position:absolute;top:1071px;left:147px;white-space:nowrap" class="ft3522">chest pain;</p>
</div>
<!-- Page 353 -->
<a name="353"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page353-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3530">353</p>
<p style="position:absolute;top:85px;left:106px;white-space:nowrap" class="ft3536"></p>
<p style="position:absolute;top:87px;left:147px;white-space:nowrap" class="ft3532">oedema;</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft3536"></p>
<p style="position:absolute;top:107px;left:147px;white-space:nowrap" class="ft3532">fever;</p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft3536"></p>
<p style="position:absolute;top:127px;left:147px;white-space:nowrap" class="ft3532">reduction in blood platelets which increases risk of bleeding or bruising;</p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft3536"></p>
<p style="position:absolute;top:148px;left:147px;white-space:nowrap" class="ft3532">impaired healing.</p>
<p style="position:absolute;top:185px;left:106px;white-space:nowrap" class="ft3532">Uncommon (may affect up to 1 in 100 people)</p>
<p style="position:absolute;top:223px;left:106px;white-space:nowrap" class="ft3536"></p>
<p style="position:absolute;top:225px;left:147px;white-space:nowrap" class="ft3534">opportunistic infections (which&#160;include tuberculosis and other infections that occur when resistance&#160;<br/>to disease is lowered);</p>
<p style="position:absolute;top:262px;left:106px;white-space:nowrap" class="ft3536"></p>
<p style="position:absolute;top:264px;left:147px;white-space:nowrap" class="ft3532">neurological infections (including viral meningitis);</p>
<p style="position:absolute;top:282px;left:106px;white-space:nowrap" class="ft3536"></p>
<p style="position:absolute;top:284px;left:147px;white-space:nowrap" class="ft3532">eye&#160;infections;</p>
<p style="position:absolute;top:302px;left:106px;white-space:nowrap" class="ft3536"></p>
<p style="position:absolute;top:304px;left:147px;white-space:nowrap" class="ft3532">bacterial infections;</p>
<p style="position:absolute;top:322px;left:106px;white-space:nowrap" class="ft3536"></p>
<p style="position:absolute;top:324px;left:147px;white-space:nowrap" class="ft3532">diverticulitis (inflammation and infection of the large intestine);</p>
<p style="position:absolute;top:343px;left:106px;white-space:nowrap" class="ft3536"></p>
<p style="position:absolute;top:345px;left:147px;white-space:nowrap" class="ft3532">cancer;&#160;</p>
<p style="position:absolute;top:363px;left:106px;white-space:nowrap" class="ft3536"></p>
<p style="position:absolute;top:365px;left:147px;white-space:nowrap" class="ft3532">cancer that affects the lymph system;</p>
<p style="position:absolute;top:383px;left:106px;white-space:nowrap" class="ft3536"></p>
<p style="position:absolute;top:385px;left:147px;white-space:nowrap" class="ft3532">melanoma;</p>
<p style="position:absolute;top:403px;left:106px;white-space:nowrap" class="ft3536"></p>
<p style="position:absolute;top:405px;left:147px;white-space:nowrap" class="ft3534">immune disorders that could affect the lungs, skin and lymph nodes ( most commonly presenting as&#160;<br/>sarcoidosis);</p>
<p style="position:absolute;top:442px;left:106px;white-space:nowrap" class="ft3536"></p>
<p style="position:absolute;top:444px;left:147px;white-space:nowrap" class="ft3532">vasculitis (inflammation of blood vessels);</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft3536"></p>
<p style="position:absolute;top:464px;left:147px;white-space:nowrap" class="ft3532">tremor;</p>
<p style="position:absolute;top:483px;left:106px;white-space:nowrap" class="ft3536"></p>
<p style="position:absolute;top:485px;left:147px;white-space:nowrap" class="ft3532">stroke;</p>
<p style="position:absolute;top:502px;left:106px;white-space:nowrap" class="ft3536"></p>
<p style="position:absolute;top:504px;left:147px;white-space:nowrap" class="ft3532">neuropathy;</p>
<p style="position:absolute;top:523px;left:106px;white-space:nowrap" class="ft3536"></p>
<p style="position:absolute;top:525px;left:147px;white-space:nowrap" class="ft3532">hearing loss, buzzing;</p>
<p style="position:absolute;top:543px;left:106px;white-space:nowrap" class="ft3536"></p>
<p style="position:absolute;top:545px;left:147px;white-space:nowrap" class="ft3532">sensation of heart beating irregularly such as skipped beats;</p>
<p style="position:absolute;top:563px;left:106px;white-space:nowrap" class="ft3536"></p>
<p style="position:absolute;top:565px;left:147px;white-space:nowrap" class="ft3532">heart problems that can cause shortness of breath or ankle swelling;</p>
<p style="position:absolute;top:583px;left:106px;white-space:nowrap" class="ft3536"></p>
<p style="position:absolute;top:585px;left:147px;white-space:nowrap" class="ft3532">heart attack;</p>
<p style="position:absolute;top:603px;left:106px;white-space:nowrap" class="ft3536"></p>
<p style="position:absolute;top:605px;left:147px;white-space:nowrap" class="ft3532">a sac in the wall of a major artery, inflammation and clot of a vein; blockage of a blood vessel;</p>
<p style="position:absolute;top:623px;left:106px;white-space:nowrap" class="ft3536"></p>
<p style="position:absolute;top:625px;left:147px;white-space:nowrap" class="ft3532">lung&#160;diseases causing shortness of breath (including inflammation);</p>
<p style="position:absolute;top:644px;left:106px;white-space:nowrap" class="ft3536"></p>
<p style="position:absolute;top:645px;left:147px;white-space:nowrap" class="ft3532">pulmonary embolism (blockage in an artery of the lung);</p>
<p style="position:absolute;top:664px;left:106px;white-space:nowrap" class="ft3536"></p>
<p style="position:absolute;top:666px;left:147px;white-space:nowrap" class="ft3532">pleural effusion (abnormal collection of fluid on the pleural space);</p>
<p style="position:absolute;top:684px;left:106px;white-space:nowrap" class="ft3536"></p>
<p style="position:absolute;top:686px;left:147px;white-space:nowrap" class="ft3532">inflammation of the pancreas which causes severe pain in the abdomen and back;</p>
<p style="position:absolute;top:704px;left:106px;white-space:nowrap" class="ft3536"></p>
<p style="position:absolute;top:706px;left:147px;white-space:nowrap" class="ft3532">difficulty in swallowing;</p>
<p style="position:absolute;top:724px;left:106px;white-space:nowrap" class="ft3536"></p>
<p style="position:absolute;top:726px;left:147px;white-space:nowrap" class="ft3532">facial oedema;</p>
<p style="position:absolute;top:744px;left:106px;white-space:nowrap" class="ft3536"></p>
<p style="position:absolute;top:746px;left:147px;white-space:nowrap" class="ft3532">gallbladder inflammation, gallbladder stones;</p>
<p style="position:absolute;top:765px;left:106px;white-space:nowrap" class="ft3536"></p>
<p style="position:absolute;top:766px;left:147px;white-space:nowrap" class="ft3532">fatty liver;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft3536"></p>
<p style="position:absolute;top:787px;left:147px;white-space:nowrap" class="ft3532">night sweats;</p>
<p style="position:absolute;top:805px;left:106px;white-space:nowrap" class="ft3536"></p>
<p style="position:absolute;top:807px;left:147px;white-space:nowrap" class="ft3532">scar;</p>
<p style="position:absolute;top:825px;left:106px;white-space:nowrap" class="ft3536"></p>
<p style="position:absolute;top:827px;left:147px;white-space:nowrap" class="ft3532">abnormal&#160;muscle breakdown;</p>
<p style="position:absolute;top:845px;left:106px;white-space:nowrap" class="ft3536"></p>
<p style="position:absolute;top:847px;left:147px;white-space:nowrap" class="ft3534">systemic lupus erythematosus (including inflammation of skin, heart, lung, joints and other organ<br/>systems);</p>
<p style="position:absolute;top:884px;left:106px;white-space:nowrap" class="ft3536"></p>
<p style="position:absolute;top:886px;left:147px;white-space:nowrap" class="ft3532">sleep interruptions;</p>
<p style="position:absolute;top:905px;left:106px;white-space:nowrap" class="ft3536"></p>
<p style="position:absolute;top:906px;left:147px;white-space:nowrap" class="ft3532">impotence;</p>
<p style="position:absolute;top:925px;left:106px;white-space:nowrap" class="ft3536"></p>
<p style="position:absolute;top:927px;left:147px;white-space:nowrap" class="ft3532">inflammations.</p>
<p style="position:absolute;top:964px;left:106px;white-space:nowrap" class="ft3532">Rare (may affect up to 1 in 1000 people)</p>
<p style="position:absolute;top:1002px;left:106px;white-space:nowrap" class="ft3536"></p>
<p style="position:absolute;top:1004px;left:147px;white-space:nowrap" class="ft3532">leukemia (cancer affecting the blood and bone marrow);</p>
<p style="position:absolute;top:1022px;left:106px;white-space:nowrap" class="ft3536"></p>
<p style="position:absolute;top:1024px;left:147px;white-space:nowrap" class="ft3532">severe allergic reaction with shock;</p>
<p style="position:absolute;top:1042px;left:106px;white-space:nowrap" class="ft3536"></p>
<p style="position:absolute;top:1044px;left:147px;white-space:nowrap" class="ft3532">multiple sclerosis;</p>
<p style="position:absolute;top:1062px;left:106px;white-space:nowrap" class="ft3536"></p>
<p style="position:absolute;top:1064px;left:147px;white-space:nowrap" class="ft3534">nerve disorders (such as eye nerve&#160;inflammation and Guillain-Barré syndrome that may cause&#160;<br/>muscle weakness, abnormal sensations, tingling in the arms and upper body);</p>
</div>
<!-- Page 354 -->
<a name="354"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page354-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3540">354</p>
<p style="position:absolute;top:85px;left:106px;white-space:nowrap" class="ft3546"></p>
<p style="position:absolute;top:87px;left:147px;white-space:nowrap" class="ft3542">heart stops pumping;</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft3546"></p>
<p style="position:absolute;top:107px;left:147px;white-space:nowrap" class="ft3542">pulmonary fibrosis (scarring of the lung);</p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft3546"></p>
<p style="position:absolute;top:127px;left:147px;white-space:nowrap" class="ft3542">intestinal perforation;</p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft3546"></p>
<p style="position:absolute;top:148px;left:147px;white-space:nowrap" class="ft3542">hepatitis;</p>
<p style="position:absolute;top:166px;left:106px;white-space:nowrap" class="ft3546"></p>
<p style="position:absolute;top:168px;left:147px;white-space:nowrap" class="ft3542">reactivation of hepatitis&#160;B;</p>
<p style="position:absolute;top:186px;left:106px;white-space:nowrap" class="ft3546"></p>
<p style="position:absolute;top:188px;left:147px;white-space:nowrap" class="ft3542">autoimmune hepatitis (inflammation of the liver caused by the body's own immune system);</p>
<p style="position:absolute;top:206px;left:106px;white-space:nowrap" class="ft3546"></p>
<p style="position:absolute;top:208px;left:147px;white-space:nowrap" class="ft3542">cutaneous vasculitis (inflammation of blood vessels in the skin);</p>
<p style="position:absolute;top:226px;left:106px;white-space:nowrap" class="ft3546"></p>
<p style="position:absolute;top:228px;left:147px;white-space:nowrap" class="ft3542">Stevens-Johnson syndrome (early symptoms include malaise, fever, headache and rash);</p>
<p style="position:absolute;top:247px;left:106px;white-space:nowrap" class="ft3546"></p>
<p style="position:absolute;top:248px;left:147px;white-space:nowrap" class="ft3542">facial oedema associated with allergic reactions;</p>
<p style="position:absolute;top:267px;left:106px;white-space:nowrap" class="ft3546"></p>
<p style="position:absolute;top:269px;left:147px;white-space:nowrap" class="ft3542">erythema multiforme (inflammatory skin rash);</p>
<p style="position:absolute;top:287px;left:106px;white-space:nowrap" class="ft3546"></p>
<p style="position:absolute;top:289px;left:147px;white-space:nowrap" class="ft3542">lupus-like syndrome;</p>
<p style="position:absolute;top:307px;left:106px;white-space:nowrap" class="ft3546"></p>
<p style="position:absolute;top:309px;left:147px;white-space:nowrap" class="ft3542">angioedema (localized swelling of the skin);</p>
<p style="position:absolute;top:327px;left:106px;white-space:nowrap" class="ft3546"></p>
<p style="position:absolute;top:329px;left:147px;white-space:nowrap" class="ft3542">lichenoid skin reaction (itchy reddish-purple skin&#160;rash).</p>
<p style="position:absolute;top:367px;left:106px;white-space:nowrap" class="ft3542">Not known (frequency cannot be estimated from available data)</p>
<p style="position:absolute;top:404px;left:106px;white-space:nowrap" class="ft3546">&#160;hepatosplenic T-cell lymphoma (a rare blood cancer that is often fatal);</p>
<p style="position:absolute;top:424px;left:106px;white-space:nowrap" class="ft3546">&#160;Merkel cell carcinoma (a type of skin cancer);</p>
<p style="position:absolute;top:445px;left:106px;white-space:nowrap" class="ft3546">&#160;Kaposi’s sarcoma, a rare cancer related to infection with human herpes virus 8. Kaposi’s sarcoma&#160;</p>
<p style="position:absolute;top:465px;left:133px;white-space:nowrap" class="ft3542">most commonly appears&#160;as purple lesions on the skin;</p>
<p style="position:absolute;top:484px;left:106px;white-space:nowrap" class="ft3546">&#160;liver failure;</p>
<p style="position:absolute;top:504px;left:106px;white-space:nowrap" class="ft3546">&#160;worsening of a condition called dermatomyositis (seen as a skin rash accompanying muscle&#160;</p>
<p style="position:absolute;top:525px;left:133px;white-space:nowrap" class="ft3542">weakness);</p>
<p style="position:absolute;top:543px;left:106px;white-space:nowrap" class="ft3546">&#160;weight gain (for most patients, the weight gain was small).</p>
<p style="position:absolute;top:583px;left:106px;white-space:nowrap" class="ft3544">Some side effects observed with Humira may not have&#160;symptoms and may only be discovered through&#160;<br/>blood tests. These include:</p>
<p style="position:absolute;top:640px;left:106px;white-space:nowrap" class="ft3542">Very common (may affect more than 1 in 10 people)</p>
<p style="position:absolute;top:677px;left:106px;white-space:nowrap" class="ft3546"></p>
<p style="position:absolute;top:679px;left:147px;white-space:nowrap" class="ft3542">low blood measurements for white blood cells;</p>
<p style="position:absolute;top:697px;left:106px;white-space:nowrap" class="ft3546"></p>
<p style="position:absolute;top:699px;left:147px;white-space:nowrap" class="ft3542">low blood measurements for red blood cells;</p>
<p style="position:absolute;top:717px;left:106px;white-space:nowrap" class="ft3546"></p>
<p style="position:absolute;top:719px;left:147px;white-space:nowrap" class="ft3542">increased lipids in the blood;</p>
<p style="position:absolute;top:738px;left:106px;white-space:nowrap" class="ft3546"></p>
<p style="position:absolute;top:739px;left:147px;white-space:nowrap" class="ft3542">elevated&#160;liver enzymes.</p>
<p style="position:absolute;top:777px;left:106px;white-space:nowrap" class="ft3542">Common (may affect up to 1 in 10 people)</p>
<p style="position:absolute;top:815px;left:106px;white-space:nowrap" class="ft3546"></p>
<p style="position:absolute;top:816px;left:147px;white-space:nowrap" class="ft3542">high blood measurements for white blood cells; &#160;</p>
<p style="position:absolute;top:835px;left:106px;white-space:nowrap" class="ft3546"></p>
<p style="position:absolute;top:837px;left:147px;white-space:nowrap" class="ft3542">low blood measurements for platelets;</p>
<p style="position:absolute;top:855px;left:106px;white-space:nowrap" class="ft3546"></p>
<p style="position:absolute;top:857px;left:147px;white-space:nowrap" class="ft3542">increased uric acid in the blood;</p>
<p style="position:absolute;top:875px;left:106px;white-space:nowrap" class="ft3546"></p>
<p style="position:absolute;top:877px;left:147px;white-space:nowrap" class="ft3542">abnormal blood measurements for sodium;</p>
<p style="position:absolute;top:895px;left:106px;white-space:nowrap" class="ft3546"></p>
<p style="position:absolute;top:897px;left:147px;white-space:nowrap" class="ft3542">low blood measurements for calcium;</p>
<p style="position:absolute;top:915px;left:106px;white-space:nowrap" class="ft3546"></p>
<p style="position:absolute;top:917px;left:147px;white-space:nowrap" class="ft3542">low blood measurements for phosphate;</p>
<p style="position:absolute;top:936px;left:106px;white-space:nowrap" class="ft3546"></p>
<p style="position:absolute;top:937px;left:147px;white-space:nowrap" class="ft3542">high blood sugar;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft3546"></p>
<p style="position:absolute;top:958px;left:147px;white-space:nowrap" class="ft3542">high blood measurements for lactate dehydrogenase;</p>
<p style="position:absolute;top:976px;left:106px;white-space:nowrap" class="ft3546"></p>
<p style="position:absolute;top:978px;left:147px;white-space:nowrap" class="ft3542">autoantibodies present in the blood;</p>
<p style="position:absolute;top:996px;left:106px;white-space:nowrap" class="ft3546"></p>
<p style="position:absolute;top:998px;left:147px;white-space:nowrap" class="ft3542">low blood potassium.</p>
<p style="position:absolute;top:1036px;left:106px;white-space:nowrap" class="ft3541"><b>Uncommon&#160;</b>(may&#160;affect up to 1 in 100 people)&#160;</p>
<p style="position:absolute;top:1073px;left:106px;white-space:nowrap" class="ft3546"></p>
<p style="position:absolute;top:1075px;left:147px;white-space:nowrap" class="ft3542">elevated bilirubin measurement (liver blood&#160;test).</p>
</div>
<!-- Page 355 -->
<a name="355"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page355-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3550">355</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft3552">Rare (may affect up to 1 in 1,000 people)</p>
<p style="position:absolute;top:142px;left:106px;white-space:nowrap" class="ft3556"></p>
<p style="position:absolute;top:144px;left:147px;white-space:nowrap" class="ft3552">low blood measurements for white blood cells, red blood cells and platelet count.</p>
<p style="position:absolute;top:182px;left:106px;white-space:nowrap" class="ft3555"><b>Reporting of side effects<br/></b>If your child gets any side effects, talk to your child’s doctor or pharmacist. This includes&#160;any possible&#160;<br/>side&#160;effects not listed in this leaflet.&#160;You can also report side effects directly via&#160;the national reporting&#160;<br/><a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">system listed in&#160;Appendix V.&#160;</a>By reporting side effects, you can help provide more information&#160;on the&#160;<br/>safety of this medicine.</p>
<p style="position:absolute;top:315px;left:106px;white-space:nowrap" class="ft3551"><b>5.</b></p>
<p style="position:absolute;top:315px;left:148px;white-space:nowrap" class="ft3551"><b>How to store Humira</b></p>
<p style="position:absolute;top:353px;left:106px;white-space:nowrap" class="ft3552">Keep this medicine out of the sight and reach of children.&#160;</p>
<p style="position:absolute;top:391px;left:106px;white-space:nowrap" class="ft3552">Do not use this medicine after the expiry date stated on the label/blister/carton after EXP.&#160;</p>
<p style="position:absolute;top:430px;left:106px;white-space:nowrap" class="ft3552">Store in a refrigerator (2</p>
<p style="position:absolute;top:428px;left:266px;white-space:nowrap" class="ft3556">C&#160;–&#160;8C). Do not freeze.&#160;</p>
<p style="position:absolute;top:468px;left:106px;white-space:nowrap" class="ft3552">Keep the vial in the outer carton in order to protect from light.</p>
<p style="position:absolute;top:506px;left:106px;white-space:nowrap" class="ft3554">Do not throw away any medicines via wastewater or household waste. Ask your doctor or pharmacist how&#160;<br/>to throw away medicines you no longer use. These measures will help protect the environment.</p>
<p style="position:absolute;top:582px;left:106px;white-space:nowrap" class="ft3551"><b>6.</b></p>
<p style="position:absolute;top:582px;left:148px;white-space:nowrap" class="ft3551"><b>Contents of the pack and other information</b></p>
<p style="position:absolute;top:620px;left:106px;white-space:nowrap" class="ft3551"><b>What Humira contains</b></p>
<p style="position:absolute;top:658px;left:106px;white-space:nowrap" class="ft3554">The active substance is adalimumab.<br/>The&#160;other ingredients are mannitol, citric acid monohydrate,&#160;sodium citrate, sodium dihydrogen phosphate&#160;<br/>dihydrate, disodium phosphate dihydrate, sodium chloride, polysorbate 80, sodium hydroxide and water&#160;<br/>for injections.</p>
<p style="position:absolute;top:752px;left:106px;white-space:nowrap" class="ft3551"><b>What the Humira vial looks like and contents of the pack</b></p>
<p style="position:absolute;top:791px;left:106px;white-space:nowrap" class="ft3555">Humira 40&#160;mg solution for injection&#160;in vials is supplied as a sterile solution of 40&#160;mg adalimumab&#160;<br/>dissolved in 0.8&#160;ml solution.</p>
<p style="position:absolute;top:847px;left:106px;white-space:nowrap" class="ft3555">The Humira vial is a glass vial containing a solution of adalimumab. One pack contains 2 boxes, each&#160;<br/>containing 1 vial, 1 empty sterile syringe, 1 needle, 1 vial&#160;adapter and 2 alcohol pads.</p>
<p style="position:absolute;top:904px;left:106px;white-space:nowrap" class="ft3552">Humira&#160;may be&#160;available as a&#160;vial, a&#160;pre-filled syringe&#160;and/or a pre-filled pen.</p>
<p style="position:absolute;top:942px;left:106px;white-space:nowrap" class="ft3551"><b>Marketing Authorisation Holder</b></p>
<p style="position:absolute;top:980px;left:106px;white-space:nowrap" class="ft3554">AbbVie Deutschland GmbH &amp; Co. KG<br/>Knollstrasse<br/>67061 Ludwigshafen<br/>Germany</p>
</div>
<!-- Page 356 -->
<a name="356"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page356-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3560">356</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft3561"><b>Manufacturer&#160;</b></p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft3565">AbbVie Biotechnology&#160;GmbH<br/>Knollstrasse<br/>67061 Ludwigshafen<br/>Germany</p>
<p style="position:absolute;top:219px;left:106px;white-space:nowrap" class="ft3565">For any information about this medicine, please contact the local representative of the Marketing&#160;<br/>Authorisation Holder.</p>
<p style="position:absolute;top:276px;left:114px;white-space:nowrap" class="ft3564"><b>België/Belgique/Belgien<br/></b>AbbVie SA<br/>Tél/Tel: +32 10&#160;&#160;477811</p>
<p style="position:absolute;top:276px;left:462px;white-space:nowrap" class="ft3565"><b>Lietuva<br/></b>AbbVie UAB&#160;<br/>Tel: +370&#160;5 205 3023</p>
<p style="position:absolute;top:353px;left:114px;white-space:nowrap" class="ft3564"><b>България<br/></b>АбВи ЕООД<br/>Тел.:+359 2 90 30 430</p>
<p style="position:absolute;top:353px;left:462px;white-space:nowrap" class="ft3564"><b>Luxembourg/Luxemburg<br/></b>AbbVie SA<br/>Belgique/Belgien<br/>Tél/Tel: +32 10 477811</p>
<p style="position:absolute;top:447px;left:114px;white-space:nowrap" class="ft3565"><b>Česká republika<br/></b>AbbVie s.r.o.&#160;<br/>Tel: +420 233 098 111</p>
<p style="position:absolute;top:447px;left:462px;white-space:nowrap" class="ft3565"><b>Magyarország<br/></b>AbbVie Kft.<br/>Tel.:+36 1 455 8600</p>
<p style="position:absolute;top:523px;left:114px;white-space:nowrap" class="ft3565"><b>Danmark<br/></b>AbbVie A/S<br/>Tlf: +45 72&#160;30-20-28</p>
<p style="position:absolute;top:523px;left:462px;white-space:nowrap" class="ft3565"><b>Malta<br/></b>V.J.Salomone Pharma Limited&#160;<br/>Tel: +356 22983201</p>
<p style="position:absolute;top:599px;left:114px;white-space:nowrap" class="ft3564"><b>Deutschland<br/></b>AbbVie Deutschland&#160;GmbH &amp; Co. KG<br/>Tel: 00800 222843 33 (gebührenfrei)<br/>Tel: +49 (0) 611&#160;/&#160;1720-0</p>
<p style="position:absolute;top:599px;left:462px;white-space:nowrap" class="ft3564"><b>Nederland<br/></b>AbbVie B.V.<br/>Tel: &#160;+31 (0)88 322 2843</p>
<p style="position:absolute;top:694px;left:114px;white-space:nowrap" class="ft3564"><b>Eesti<br/></b>AbbVie&#160;OÜ<br/>Tel: +372 623 1011</p>
<p style="position:absolute;top:694px;left:462px;white-space:nowrap" class="ft3564"><b>Norge<br/></b>AbbVie AS<br/>Tlf: +47 67 81 80 00</p>
<p style="position:absolute;top:770px;left:114px;white-space:nowrap" class="ft3565"><b>Ελλάδα<br/></b>AbbVie&#160;ΦΑΡΜΑΚΕΥΤΙΚΗ Α.Ε.<br/>Τηλ: +30&#160;214 4165 555</p>
<p style="position:absolute;top:770px;left:462px;white-space:nowrap" class="ft3565"><b>Österreich<br/></b>AbbVie GmbH&#160;<br/>Tel: +43 1 20589-0</p>
<p style="position:absolute;top:846px;left:114px;white-space:nowrap" class="ft3565"><b>España<br/></b>AbbVie Spain, S.L.U.<br/>Tel: &#160;+34 91 384 09 10</p>
<p style="position:absolute;top:846px;left:462px;white-space:nowrap" class="ft3565"><b>Polska<br/></b>AbbVie Sp. z o.o.<br/>Tel.: +48 22&#160;372 78 00&#160;</p>
<p style="position:absolute;top:922px;left:114px;white-space:nowrap" class="ft3564"><b>France<br/></b>AbbVie<br/>Tél: +33 (0) 1 45 60 13 00</p>
<p style="position:absolute;top:922px;left:462px;white-space:nowrap" class="ft3564"><b>Portugal<br/></b>AbbVie, Lda.&#160;<br/>Tel: +351 (0)21 1908400</p>
<p style="position:absolute;top:998px;left:114px;white-space:nowrap" class="ft3564"><b>Hrvatska&#160;<br/></b>AbbVie d.o.o.<br/>Tel + 385 (0)1&#160;5625 501</p>
<p style="position:absolute;top:998px;left:462px;white-space:nowrap" class="ft3564"><b>România<br/></b>AbbVie S.R.L.<br/>Tel: +40 21 529 30 35</p>
</div>
<!-- Page 357 -->
<a name="357"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page357-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3570">357</p>
<p style="position:absolute;top:86px;left:114px;white-space:nowrap" class="ft3574"><b>Ireland<br/></b>AbbVie Limited&#160;<br/>Tel: +353 (0)1 4287900</p>
<p style="position:absolute;top:86px;left:462px;white-space:nowrap" class="ft3574"><b>Slovenija<br/></b>AbbVie Biofarmacevtska družba&#160;d.o.o.<br/>Tel: +386 (1)32 08 060</p>
<p style="position:absolute;top:162px;left:114px;white-space:nowrap" class="ft3574"><b>Ísland<br/></b>Vistor hf.<br/>Tel: +354 535 7000</p>
<p style="position:absolute;top:162px;left:462px;white-space:nowrap" class="ft3574"><b>Slovenská republika<br/></b>AbbVie s.r.o.<br/>Tel: +421 2 5050 0777</p>
<p style="position:absolute;top:238px;left:114px;white-space:nowrap" class="ft3574"><b>Italia<br/></b>AbbVie S.r.l.&#160;<br/>Tel: +39 06 928921</p>
<p style="position:absolute;top:238px;left:462px;white-space:nowrap" class="ft3574"><b>Suomi/Finland<br/></b>AbbVie Oy&#160;<br/>Puh/Tel: &#160;+358 (0)10 2411 200</p>
<p style="position:absolute;top:314px;left:114px;white-space:nowrap" class="ft3574"><b>Κύπρος<br/></b>Lifepharma (Z.A.M.) Ltd<br/>Τηλ.: +357 22 34 74 40</p>
<p style="position:absolute;top:314px;left:462px;white-space:nowrap" class="ft3574"><b>Sverige<br/></b>AbbVie AB<br/>Tel: &#160;+46 (0)8 684 44 600</p>
<p style="position:absolute;top:390px;left:114px;white-space:nowrap" class="ft3575"><b>Latvija<br/></b>AbbVie SIA&#160;<br/>Tel: +371 67605000</p>
<p style="position:absolute;top:390px;left:462px;white-space:nowrap" class="ft3575"><b>United Kingdom&#160;(Northern Ireland)<br/></b>AbbVie Deutschland GmbH &amp; Co. KG<br/>Tel: +44 (0)1628 561090</p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft3571"><b>This leaflet was last revised in&#160;</b></p>
<p style="position:absolute;top:503px;left:106px;white-space:nowrap" class="ft3574">Detailed information on this medicine is available on the European Medicines Agency web site:&#160;<br/><a href="http://www.ema.europa.eu/">http://www.ema.europa.eu.</a></p>
<p style="position:absolute;top:560px;left:106px;white-space:nowrap" class="ft35719"><b>To listen to or request a copy of this leaflet in&#160;&lt;Braille&gt;, &lt;large print&gt; or &lt;audio&gt;, please&#160;contact the&#160;<br/>local representative of the Marketing Authorisation Holder.</b></p>
</div>
<!-- Page 358 -->
<a name="358"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page358-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3580">358</p>
<p style="position:absolute;top:86px;left:306px;white-space:nowrap" class="ft3581"><b>Package leaflet: Information for the patient</b></p>
<p style="position:absolute;top:124px;left:261px;white-space:nowrap" class="ft3581"><b>Humira&#160;40&#160;mg&#160;solution for injection in pre-filled syringe</b></p>
<p style="position:absolute;top:143px;left:418px;white-space:nowrap" class="ft3582">adalimumab</p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft35819"><b>Read all of this leaflet carefully before you start using this&#160;medicine because it contains important&#160;<br/>information for you.</b></p>
<p style="position:absolute;top:218px;left:106px;white-space:nowrap" class="ft3586"></p>
<p style="position:absolute;top:220px;left:148px;white-space:nowrap" class="ft3582">Keep this leaflet. You may need to read it again.</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft3586"></p>
<p style="position:absolute;top:240px;left:148px;white-space:nowrap" class="ft3585">Your doctor will also give you a&#160;<b>Patient Reminder Card</b>, which contains important safety&#160;<br/>information that you need to be aware of before you are given Humira and during treatment with&#160;<br/>Humira. Keep this&#160;<b>Patient Reminder Card&#160;</b>with you.&#160;</p>
<p style="position:absolute;top:296px;left:106px;white-space:nowrap" class="ft3586"></p>
<p style="position:absolute;top:298px;left:148px;white-space:nowrap" class="ft3582">If you have any further questions, please ask your doctor or pharmacist.</p>
<p style="position:absolute;top:316px;left:106px;white-space:nowrap" class="ft3586"></p>
<p style="position:absolute;top:318px;left:148px;white-space:nowrap" class="ft3584">This medicine has been prescribed for you only. Do not pass it on to others. It may harm them,&#160;even&#160;<br/>if their signs of illness are the same as yours.</p>
<p style="position:absolute;top:356px;left:106px;white-space:nowrap" class="ft3586"></p>
<p style="position:absolute;top:357px;left:148px;white-space:nowrap" class="ft3584">If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects&#160;<br/>not listed in this leaflet (see section 4).</p>
<p style="position:absolute;top:414px;left:106px;white-space:nowrap" class="ft35819"><b>What is in this leaflet<br/></b>1.</p>
<p style="position:absolute;top:433px;left:148px;white-space:nowrap" class="ft3582">What Humira is and what it is used for</p>
<p style="position:absolute;top:453px;left:106px;white-space:nowrap" class="ft3582">2.</p>
<p style="position:absolute;top:453px;left:148px;white-space:nowrap" class="ft3582">What you need to know before you use Humira</p>
<p style="position:absolute;top:471px;left:106px;white-space:nowrap" class="ft3582">3.</p>
<p style="position:absolute;top:471px;left:148px;white-space:nowrap" class="ft3582">How to use Humira</p>
<p style="position:absolute;top:490px;left:106px;white-space:nowrap" class="ft3582">4.</p>
<p style="position:absolute;top:490px;left:148px;white-space:nowrap" class="ft3582">Possible side effects</p>
<p style="position:absolute;top:509px;left:106px;white-space:nowrap" class="ft3582">5</p>
<p style="position:absolute;top:509px;left:148px;white-space:nowrap" class="ft3582">How to store Humira</p>
<p style="position:absolute;top:528px;left:106px;white-space:nowrap" class="ft3582">6.</p>
<p style="position:absolute;top:528px;left:148px;white-space:nowrap" class="ft3582">Contents of the pack and other information</p>
<p style="position:absolute;top:585px;left:106px;white-space:nowrap" class="ft3581"><b>1.</b></p>
<p style="position:absolute;top:585px;left:148px;white-space:nowrap" class="ft3581"><b>What Humira is and what it is used for</b></p>
<p style="position:absolute;top:623px;left:106px;white-space:nowrap" class="ft3582">Humira&#160;contains the active substance adalimumab.&#160;</p>
<p style="position:absolute;top:661px;left:106px;white-space:nowrap" class="ft3582">Humira&#160;is intended for&#160;the&#160;treatment of&#160;the inflammatory diseases described below:</p>
<p style="position:absolute;top:679px;left:106px;white-space:nowrap" class="ft3586">&#160;Rheumatoid arthritis,&#160;</p>
<p style="position:absolute;top:699px;left:106px;white-space:nowrap" class="ft3586">&#160;Polyarticular juvenile idiopathic arthritis,&#160;</p>
<p style="position:absolute;top:720px;left:106px;white-space:nowrap" class="ft3586">&#160;Enthesitis-related arthritis,&#160;</p>
<p style="position:absolute;top:740px;left:106px;white-space:nowrap" class="ft3586">&#160;Ankylosing spondylitis,&#160;</p>
<p style="position:absolute;top:760px;left:106px;white-space:nowrap" class="ft3586">&#160;Axial spondyloarthritis without radiographic evidence of ankylosing spondylitis,&#160;</p>
<p style="position:absolute;top:780px;left:106px;white-space:nowrap" class="ft3586">&#160;Psoriatic arthritis,&#160;</p>
<p style="position:absolute;top:800px;left:106px;white-space:nowrap" class="ft3586">&#160;Psoriasis,</p>
<p style="position:absolute;top:820px;left:106px;white-space:nowrap" class="ft3586">&#160;Hidradenitis suppurativa,&#160;</p>
<p style="position:absolute;top:841px;left:106px;white-space:nowrap" class="ft3586">&#160;Crohn’s disease,</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft3586">&#160;Ulcerative colitis&#160;and&#160;</p>
<p style="position:absolute;top:881px;left:106px;white-space:nowrap" class="ft3586">&#160;Non-infectious uveitis</p>
<p style="position:absolute;top:921px;left:106px;white-space:nowrap" class="ft3585">The active ingredient&#160;in Humira, adalimumab, is a&#160;human&#160;monoclonal antibody. Monoclonal antibodies&#160;<br/>are&#160;proteins that&#160;attach to a specific target.</p>
<p style="position:absolute;top:978px;left:106px;white-space:nowrap" class="ft3585">The target of&#160;adalimumab&#160;is a&#160;protein&#160;called&#160;tumour necrosis factor&#160;(TNFα), which&#160;is involved in the&#160;<br/>immune (defence) system and&#160;is present at increased levels in&#160;the&#160;inflammatory diseases&#160;listed above.&#160;By&#160;<br/>attaching to&#160;TNFα, Humira decreases the process of inflammation in these diseases.</p>
</div>
<!-- Page 359 -->
<a name="359"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page359-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3590">359</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft3592">Rheumatoid arthritis</p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft3592">Rheumatoid arthritis is an inflammatory disease of the joints.</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft3594">Humira is used to treat rheumatoid arthritis in adults. If you have moderate to severe active rheumatoid&#160;<br/>arthritis, you may first be given other disease-modifying medicines, such as methotrexate. If you do not&#160;<br/>respond well enough to these medicines, you will be given Humira to treat your rheumatoid arthritis. &#160;</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft3594">Humira can also be used to treat severe, active and progressive rheumatoid arthritis without previous&#160;<br/>methotrexate treatment.</p>
<p style="position:absolute;top:295px;left:106px;white-space:nowrap" class="ft3595">Humira has been shown to slow down the damage to the cartilage and bone&#160;of the joints caused by the&#160;<br/>disease and to improve physical function.</p>
<p style="position:absolute;top:352px;left:106px;white-space:nowrap" class="ft3595">Usually, Humira is used with methotrexate. If your doctor determines that methotrexate is inappropriate,&#160;<br/>Humira can be given alone.</p>
<p style="position:absolute;top:409px;left:106px;white-space:nowrap" class="ft3592">Polyarticular juvenile idiopathic arthritis and enthesitis-related arthritis</p>
<p style="position:absolute;top:446px;left:106px;white-space:nowrap" class="ft3592">Polyarticular juvenile idiopathic arthritis and enthesitis-related arthritis are inflammatory diseases.</p>
<p style="position:absolute;top:485px;left:106px;white-space:nowrap" class="ft3595">Humira is used to treat polyarticular juvenile idiopathic arthritis in children and adolescents aged 2 to 17&#160;<br/>years and enthesitis-related arthritis in children and adolescents aged 6 to 17 years. You may first be given&#160;<br/>other disease-modifying medicines, such as methotrexate. If you do not respond well enough to these&#160;<br/>medicines, you will be given Humira to treat your polyarticular juvenile idiopathic arthritis or enthesitis-<br/>related arthritis.</p>
<p style="position:absolute;top:598px;left:106px;white-space:nowrap" class="ft3595">Ankylosing spondylitis&#160;and axial spondyloarthritis without radiographic evidence of ankylosing&#160;<br/>spondylitis</p>
<p style="position:absolute;top:655px;left:106px;white-space:nowrap" class="ft3594">Ankylosing spondylitis and axial spondyloarthritis without radiographic evidence&#160;of ankylosing&#160;<br/>spondylitis, are inflammatory diseases of the spine.</p>
<p style="position:absolute;top:712px;left:106px;white-space:nowrap" class="ft3594">Humira is used to treat ankylosing spondylitis and axial spondyloarthritis without radiographic evidence of&#160;<br/>ankylosing spondylitis in adults. If you have ankylosing spondylitis or axial spondyloarthritis without&#160;<br/>radiographic evidence of ankylosing spondylitis, you will first be given other medicines. If you do not&#160;<br/>respond well enough to these medicines, you will be given Humira to reduce the signs and symptoms of&#160;<br/>your disease.</p>
<p style="position:absolute;top:826px;left:106px;white-space:nowrap" class="ft3592">Psoriatic arthritis</p>
<p style="position:absolute;top:864px;left:106px;white-space:nowrap" class="ft3592">Psoriatic arthritis is an inflammation of the joints associated with psoriasis.</p>
<p style="position:absolute;top:902px;left:106px;white-space:nowrap" class="ft3594">Humira is used to treat psoriatic arthritis in adults. Humira has been shown to slow down the damage to&#160;<br/>the cartilage and bone of the joints caused by the disease and&#160;to improve physical function.</p>
<p style="position:absolute;top:959px;left:106px;white-space:nowrap" class="ft3592">Plaque psoriasis in adults and children&#160;</p>
<p style="position:absolute;top:997px;left:106px;white-space:nowrap" class="ft3594">Plaque psoriasis is a skin condition that causes red, flaky, crusty patches of skin covered with silvery&#160;<br/>scales. Plaque psoriasis can also affect the nails, causing them to crumble,&#160;become thickened and lift away&#160;<br/>from the nail bed which can be painful. Psoriasis is believed to be caused by a problem with the body’s&#160;<br/>immune system that leads to an increased production of skin cells.</p>
</div>
<!-- Page 360 -->
<a name="360"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page360-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3600">360</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft3604">Humira is used to treat moderate to severe plaque psoriasis in adults.&#160;Humira is also used to treat severe&#160;<br/>plaque psoriasis in children and adolescents aged 4 to 17 years for whom topical therapy and&#160;<br/>phototherapies have either not worked very well or are not suitable.</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft3602">Hidradenitis suppurativa&#160;in adults and&#160;adolescents</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft3604">Hidradenitis suppurativa (sometimes called acne inversa) is a chronic and often painful inflammatory skin&#160;<br/>disease.&#160;Symptoms may include tender nodules (lumps) and abscesses (boils) that may leak pus. It most&#160;<br/>commonly affects specific areas of&#160;<a href="http://en.wikipedia.org/wiki/Inframammary_fold">the skin, such as&#160;under the breasts, the armpits, inner thighs, groin and&#160;<br/></a>buttocks.&#160;Scarring may also occur in affected areas.</p>
<p style="position:absolute;top:295px;left:106px;white-space:nowrap" class="ft3604">Humira is used to treat hidradenitis suppurativa in adults&#160;and&#160;adolescents from 12 years of age.&#160;Humira&#160;<br/>can reduce the number of nodules and abscesses you have and the pain that is often associated with the&#160;<br/>disease. You may first be given other medicines. If you do not respond well enough to these medicines,&#160;<br/>you will&#160;be&#160;given Humira.</p>
<p style="position:absolute;top:390px;left:106px;white-space:nowrap" class="ft3602">Crohn’s disease in adults and children</p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft3602">Crohn’s disease is an inflammatory disease of the digestive tract.</p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft3605">Humira is used to treat Crohn’s disease in adults&#160;and children aged 6 to 17 years. If you have Crohn’s&#160;<br/>disease you will first be given other medicines. If you do not respond well enough to these medicines, you&#160;<br/>will be given Humira to reduce the signs and symptoms of your Crohn’s disease.</p>
<p style="position:absolute;top:541px;left:106px;white-space:nowrap" class="ft3602">Ulcerative colitis&#160;in adults and children</p>
<p style="position:absolute;top:579px;left:106px;white-space:nowrap" class="ft3602">Ulcerative colitis is an inflammatory disease of the&#160;large intestine.</p>
<p style="position:absolute;top:617px;left:106px;white-space:nowrap" class="ft3604">Humira is used to treat&#160;moderate to severe&#160;ulcerative colitis in adults&#160;and children aged 6 to 17 years. If&#160;<br/>you have ulcerative colitis you&#160;may&#160;first be given other medicines. If you do not respond well enough to&#160;<br/>these medicines, you will&#160;be&#160;given Humira to reduce the signs and symptoms of your disease.</p>
<p style="position:absolute;top:693px;left:106px;white-space:nowrap" class="ft3602">Non-infectious uveitis&#160;in adults and children</p>
<p style="position:absolute;top:731px;left:106px;white-space:nowrap" class="ft3602">Non-infectious uveitis is an inflammatory disease affecting certain parts of the eye.</p>
<p style="position:absolute;top:769px;left:106px;white-space:nowrap" class="ft3602">Humira is used to treat&#160;</p>
<p style="position:absolute;top:787px;left:133px;white-space:nowrap" class="ft3606">&#160;Adults with non-infectious&#160;uveitis with inflammation affecting the back of the eye</p>
<p style="position:absolute;top:807px;left:133px;white-space:nowrap" class="ft3606">&#160;Children from 2&#160;years of age with chronic non-infectious uveitis with inflammation affecting the&#160;</p>
<p style="position:absolute;top:828px;left:160px;white-space:nowrap" class="ft3602">front of the eye&#160;</p>
<p style="position:absolute;top:866px;left:106px;white-space:nowrap" class="ft3604">This inflammation may lead to a decrease of vision and/or the presence of floaters in the eye (black dots or&#160;<br/>wispy lines that move across the field of vision). Humira works by reducing this inflammation.</p>
<p style="position:absolute;top:942px;left:106px;white-space:nowrap" class="ft3601"><b>2.</b></p>
<p style="position:absolute;top:942px;left:148px;white-space:nowrap" class="ft3601"><b>What you need to know before you use&#160;Humira</b></p>
<p style="position:absolute;top:980px;left:106px;white-space:nowrap" class="ft3601"><b>Do not use Humira</b></p>
<p style="position:absolute;top:1017px;left:133px;white-space:nowrap" class="ft3606">&#160;If you are allergic to adalimumab or any of the other ingredients of this medicine (listed in section&#160;</p>
<p style="position:absolute;top:1038px;left:160px;white-space:nowrap" class="ft3602">6).&#160;</p>
</div>
<!-- Page 361 -->
<a name="361"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page361-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3610">361</p>
<p style="position:absolute;top:85px;left:133px;white-space:nowrap" class="ft3616">&#160;If you have a severe infection, including active tuberculosis (see Warnings and precautions”). It is&#160;</p>
<p style="position:absolute;top:106px;left:160px;white-space:nowrap" class="ft3615">important that you tell your doctor if you have symptoms of infections, e.g. fever, wounds, feeling&#160;<br/>tired, dental&#160;problems.</p>
<p style="position:absolute;top:162px;left:133px;white-space:nowrap" class="ft3616">&#160;If you have moderate or severe heart failure. It is important to tell your doctor if you have had or&#160;</p>
<p style="position:absolute;top:183px;left:160px;white-space:nowrap" class="ft3612">have a serious heart condition (see “Warnings and precautions”).</p>
<p style="position:absolute;top:221px;left:106px;white-space:nowrap" class="ft3611"><b>Warnings and precautions</b></p>
<p style="position:absolute;top:259px;left:106px;white-space:nowrap" class="ft3612">Talk to your doctor or pharmacist before using&#160;Humira</p>
<p style="position:absolute;top:296px;left:133px;white-space:nowrap" class="ft3616">&#160;If you experience allergic reactions with symptoms such as chest tightness, wheezing, dizziness,&#160;</p>
<p style="position:absolute;top:317px;left:160px;white-space:nowrap" class="ft3614">swelling or rash do not inject more Humira and contact your doctor immediately since, in rare&#160;<br/>cases, these reactions can be life threatening.&#160;</p>
<p style="position:absolute;top:374px;left:133px;white-space:nowrap" class="ft3616">&#160;If you&#160;have an infection, including long-term&#160;or localized infection (for example, leg ulcer)&#160;</p>
<p style="position:absolute;top:394px;left:160px;white-space:nowrap" class="ft3612">consult your doctor before starting Humira. If you are unsure, contact your doctor.&#160;</p>
<p style="position:absolute;top:432px;left:133px;white-space:nowrap" class="ft3616">&#160;You might get infections more easily while you are receiving Humira treatment. This&#160;risk may&#160;</p>
<p style="position:absolute;top:453px;left:160px;white-space:nowrap" class="ft3615">increase if your lung function is impaired. These infections may be serious and include&#160;<br/>tuberculosis, infections caused by viruses, fungi, parasites or bacteria, or other opportunistic&#160;<br/>infections and sepsis that may, in rare cases, be life-threatening. It is important to tell your doctor&#160;<br/>if you get symptoms such as fever, wounds, feeling tired or dental problems. Your doctor may&#160;<br/>recommend temporary discontinuation of Humira.</p>
<p style="position:absolute;top:565px;left:133px;white-space:nowrap" class="ft3616">&#160;As cases of tuberculosis have been reported in patients treated with Humira, your doctor will&#160;</p>
<p style="position:absolute;top:586px;left:160px;white-space:nowrap" class="ft3614">check you for signs and symptoms of tuberculosis before starting Humira. This will include a&#160;<br/>thorough medical evaluation including your medical history and appropriate screening tests (for&#160;<br/>example chest X-ray and a tuberculin test). The conduct and results of these tests should be&#160;<br/>recorded on your&#160;<b>Patient Reminder Card</b>. It is very important that you tell your doctor if you&#160;<br/>have ever had tuberculosis, or if you have been in close contact with someone who has had&#160;<br/>tuberculosis. Tuberculosis can develop during therapy even if you have received preventative&#160;<br/>treatment for tuberculosis. If symptoms of tuberculosis (persistent cough, weight loss, listlessness,&#160;<br/>mild fever), or any other infection appear during or after therapy tell your doctor immediately.&#160;</p>
<p style="position:absolute;top:756px;left:133px;white-space:nowrap" class="ft3616">&#160;Advise your doctor if you reside or travel in regions where fungal infections such as&#160;</p>
<p style="position:absolute;top:777px;left:160px;white-space:nowrap" class="ft3612">histoplasmosis, coccidioidomycosis or blastomycosis are endemic.</p>
<p style="position:absolute;top:815px;left:133px;white-space:nowrap" class="ft3616">&#160;Advise your doctor if you have a history of recurrent infections or other conditions that&#160;increase&#160;</p>
<p style="position:absolute;top:836px;left:160px;white-space:nowrap" class="ft3612">the risk of infections.</p>
<p style="position:absolute;top:873px;left:133px;white-space:nowrap" class="ft3616">&#160;Advise your doctor if you are a carrier of the hepatitis B virus (HBV), if you have active HBV or&#160;</p>
<p style="position:absolute;top:894px;left:160px;white-space:nowrap" class="ft3614">if you think you might be at risk of contracting HBV. Your doctor should test you for HBV.&#160;<br/>Humira can cause reactivation of&#160;HBV in people who carry this virus. In some rare cases,&#160;<br/>especially if you are taking other medicines that suppress the immune system, reactivation of&#160;<br/>HBV can be life-threatening.&#160;</p>
<p style="position:absolute;top:988px;left:133px;white-space:nowrap" class="ft3616">&#160;If you are over 65 years you may be more susceptible to infections while taking Humira. You and&#160;</p>
<p style="position:absolute;top:1008px;left:160px;white-space:nowrap" class="ft3614">your doctor should pay special attention to signs of infection while you are being treated with&#160;<br/>Humira. It is important to tell your doctor if you get symptoms of infections, such as fever,&#160;<br/>wounds, feeling tired or dental problems.</p>
</div>
<!-- Page 362 -->
<a name="362"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page362-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3620">362</p>
<p style="position:absolute;top:85px;left:133px;white-space:nowrap" class="ft3626">&#160;If&#160;you are about to undergo surgery or dental procedures,&#160;please inform your doctor that you are&#160;</p>
<p style="position:absolute;top:106px;left:160px;white-space:nowrap" class="ft3622">taking Humira. Your doctor may recommend temporary discontinuation of Humira.</p>
<p style="position:absolute;top:143px;left:133px;white-space:nowrap" class="ft3626">&#160;If you have or develop demyelinating disease such as multiple sclerosis, your&#160;doctor will decide if&#160;</p>
<p style="position:absolute;top:164px;left:160px;white-space:nowrap" class="ft3624">you should receive or continue to receive Humira. Tell your doctor immediately if you experience&#160;<br/>symptoms like changes in your vision, weakness in your arms or legs or numbness or tingling in&#160;<br/>any part of your body.</p>
<p style="position:absolute;top:239px;left:133px;white-space:nowrap" class="ft3626">&#160;Certain vaccines may cause infections and should not be given while receiving Humira. Please&#160;</p>
<p style="position:absolute;top:260px;left:160px;white-space:nowrap" class="ft3625">check with your doctor before you receive any vaccines. It is recommended that children, if&#160;<br/>possible, be brought up to date with all immunisations in agreement with current immunisation&#160;<br/>guidelines prior to initiating Humira therapy. If you received Humira while you were pregnant,&#160;<br/>your baby may be at higher risk for getting such an infection for up to approximately five months&#160;<br/>after the last dose you received during pregnancy. It is important that you tell your baby's doctors&#160;<br/>and other health care professionals about your Humira use during your pregnancy so they can&#160;<br/>decide when your baby should receive any vaccine.</p>
<p style="position:absolute;top:411px;left:133px;white-space:nowrap" class="ft3626">&#160;If you have mild heart failure and you are being treated with Humira,&#160;your heart failure status&#160;</p>
<p style="position:absolute;top:432px;left:160px;white-space:nowrap" class="ft3624">must be closely monitored by your doctor. It is important to tell your doctor if you have had or&#160;<br/>have a serious heart condition. If you develop new or worsening symptoms of heart failure (e.g.&#160;<br/>shortness of breath, or swelling of your feet), you must contact your doctor immediately. Your&#160;<br/>doctor will decide if you should receive Humira.</p>
<p style="position:absolute;top:526px;left:133px;white-space:nowrap" class="ft3626">&#160;In some patients the body may fail to produce enough of the blood cells that help your body fight&#160;</p>
<p style="position:absolute;top:547px;left:160px;white-space:nowrap" class="ft3624">infections or help you to stop bleeding. If you develop a fever that does not go away, bruise or&#160;<br/>bleed very easily or look very pale, call your doctor right away. Your doctor may decide to stop&#160;<br/>treatment.</p>
<p style="position:absolute;top:622px;left:133px;white-space:nowrap" class="ft3626">&#160;There have been very rare cases of certain kinds of cancer in children and adult patients taking&#160;</p>
<p style="position:absolute;top:643px;left:160px;white-space:nowrap" class="ft3624">Humira or other TNF blockers. People with more serious rheumatoid arthritis that have had the&#160;<br/>disease for a long time may have a higher than average risk of getting lymphoma (a cancer that&#160;<br/>affects the lymph system) and leukemia (a cancer that affects the blood and bone marrow). If you&#160;<br/>take Humira the risk of getting lymphoma, leukemia, or other cancers may increase. On rare&#160;<br/>occasions, a specific and severe type of lymphoma has been observed in patients taking Humira.&#160;<br/>Some of those patients were also treated with&#160;azathioprine or 6-&#160;mercaptopurine. Tell your doctor&#160;<br/>if you are taking azathioprine or 6-mercaptopurine with Humira. In addition,&#160;cases of non-<br/>melanoma skin cancer have been observed in patients taking Humira. If new skin lesions appear&#160;<br/>during or after therapy or if existing lesions change appearance, tell your doctor.</p>
<p style="position:absolute;top:830px;left:133px;white-space:nowrap" class="ft3626">&#160;There have been cases of cancers,&#160;other than lymphoma in patients with a specific type of lung&#160;</p>
<p style="position:absolute;top:851px;left:160px;white-space:nowrap" class="ft3624">disease called Chronic Obstructive Pulmonary Disease (COPD) treated with another TNF blocker.&#160;<br/>If you have COPD, or are a heavy smoker, you should discuss with your doctor whether treatment&#160;<br/>with&#160;a TNF blocker is appropriate for you.</p>
<p style="position:absolute;top:927px;left:133px;white-space:nowrap" class="ft3626">&#160;On rare occasions, treatment with Humira could result in lupus-like syndrome. Contact your&#160;</p>
<p style="position:absolute;top:948px;left:160px;white-space:nowrap" class="ft3622">doctor if symptoms such as persistent unexplained rash, fever, joint pain or tiredness&#160;occur.</p>
<p style="position:absolute;top:985px;left:106px;white-space:nowrap" class="ft3621"><b>Children and adolescents</b></p>
<p style="position:absolute;top:1023px;left:133px;white-space:nowrap" class="ft3626">&#160;Vaccinations: if possible,&#160;children should be up to date with all vaccinations before using Humira.</p>
<p style="position:absolute;top:1043px;left:133px;white-space:nowrap" class="ft3626">&#160;Do not give Humira to children with polyarticular juvenile idiopathic arthritis below the age of 2&#160;</p>
<p style="position:absolute;top:1064px;left:160px;white-space:nowrap" class="ft3622">years.</p>
</div>
<!-- Page 363 -->
<a name="363"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page363-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3630">363</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft3631"><b>Other medicines and Humira</b></p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft3632">Tell your doctor or&#160;pharmacist if you are taking, have recently taken or might take any other medicines.</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft3634">Humira can be taken together with methotrexate or certain disease-modifying anti-rheumatic agents&#160;<br/>(sulfasalazine, hydroxychloroquine, leflunomide and injectable gold preparations), steroids or pain&#160;<br/>medications including non-steroidal anti-inflammatory drugs (NSAIDs).</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft3634">You should not take Humira with medicines containing the active substances&#160;anakinra or abatacept&#160;due to&#160;<br/>increased risk of serious infection. If you have questions, please ask your doctor.&#160;</p>
<p style="position:absolute;top:295px;left:106px;white-space:nowrap" class="ft3631"><b>Pregnancy and breast-feeding</b></p>
<p style="position:absolute;top:332px;left:133px;white-space:nowrap" class="ft3636">&#160;You&#160;should consider the&#160;use&#160;of&#160;adequate contraception&#160;to prevent pregnancy&#160;and&#160;continue its use&#160;</p>
<p style="position:absolute;top:353px;left:160px;white-space:nowrap" class="ft3632">for at least 5 months after the last Humira treatment.</p>
<p style="position:absolute;top:371px;left:133px;white-space:nowrap" class="ft3636">&#160;If you are pregnant, think you may be&#160;pregnant or are planning to have a baby, ask your doctor for&#160;</p>
<p style="position:absolute;top:392px;left:160px;white-space:nowrap" class="ft3632">advice about taking this medicine.</p>
<p style="position:absolute;top:410px;left:133px;white-space:nowrap" class="ft3636">&#160;Humira should only be used during a pregnancy if needed.</p>
<p style="position:absolute;top:430px;left:133px;white-space:nowrap" class="ft3636">&#160;According to a pregnancy study, there was no higher risk of birth defects when the mother had&#160;</p>
<p style="position:absolute;top:451px;left:160px;white-space:nowrap" class="ft3634">received&#160;Humira during pregnancy compared with mothers with the same disease&#160;who did not&#160;<br/>receive Humira.</p>
<p style="position:absolute;top:488px;left:133px;white-space:nowrap" class="ft3636">&#160;Humira can be used during breast-feeding</p>
<p style="position:absolute;top:509px;left:133px;white-space:nowrap" class="ft3636">&#160;If you receive Humira during your pregnancy, your baby may have a higher risk&#160;for getting an&#160;</p>
<p style="position:absolute;top:530px;left:160px;white-space:nowrap" class="ft3632">infection.</p>
<p style="position:absolute;top:548px;left:133px;white-space:nowrap" class="ft3636">&#160;It is important&#160;that you tell your baby’s doctors and other health care professionals about your&#160;</p>
<p style="position:absolute;top:568px;left:160px;white-space:nowrap" class="ft3634">Humira use during your pregnancy before the baby receives any vaccine (for more information&#160;on&#160;<br/>vaccines&#160;see&#160;the&#160;“Warnings and precautions”&#160;section).</p>
<p style="position:absolute;top:626px;left:106px;white-space:nowrap" class="ft3631"><b>Driving and using machines</b></p>
<p style="position:absolute;top:663px;left:106px;white-space:nowrap" class="ft3634">Humira may have a minor influence on your ability to drive, cycle or use machines. Room spinning&#160;<br/>sensation and vision disturbances may occur after taking Humira.</p>
<p style="position:absolute;top:720px;left:106px;white-space:nowrap" class="ft3631"><b>Humira contains sodium</b></p>
<p style="position:absolute;top:758px;left:106px;white-space:nowrap" class="ft3634">This medicinal product contains less than 1&#160;mmol&#160;of sodium (23&#160;mg) per 0.8&#160;ml dose, i.e. essentially&#160;<br/>‘sodium-free’.</p>
<p style="position:absolute;top:834px;left:106px;white-space:nowrap" class="ft3631"><b>3.</b></p>
<p style="position:absolute;top:834px;left:148px;white-space:nowrap" class="ft3631"><b>How to use Humira</b></p>
<p style="position:absolute;top:872px;left:106px;white-space:nowrap" class="ft3634">Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or&#160;<br/>pharmacist if you are not sure.&#160;Your doctor may prescribe another strength of&#160;Humira if you need a&#160;<br/>different dose.</p>
<p style="position:absolute;top:948px;left:106px;white-space:nowrap" class="ft3634">Adults with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis or axial spondyloarthritis&#160;<br/>without radiographic evidence of ankylosing spondylitis</p>
<p style="position:absolute;top:1005px;left:106px;white-space:nowrap" class="ft3634">Humira is injected under the skin (subcutaneous use). The usual dose for adults with rheumatoid arthritis,&#160;<br/>ankylosing spondylitis, axial spondyloarthritis without radiographic evidence of ankylosing spondylitis&#160;<br/>and for patients with psoriatic arthritis is 40&#160;mg adalimumab given every other week as a single dose. &#160;</p>
</div>
<!-- Page 364 -->
<a name="364"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page364-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3640">364</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft3645">In rheumatoid arthritis, methotrexate is continued while using Humira. If your doctor determines that&#160;<br/>methotrexate is inappropriate, Humira can be given alone.&#160;</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft3644">If you have rheumatoid arthritis and you do not receive methotrexate with your Humira therapy, your&#160;<br/>doctor may decide to give 40&#160;mg adalimumab every week&#160;or 80&#160;mg&#160;every other week.</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft3642">Children, adolescents and adults&#160;with polyarticular juvenile idiopathic arthritis</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft3643"><i>Children and adolescents from 2&#160;years of age weighing 10&#160;kg to less than 30&#160;kg</i></p>
<p style="position:absolute;top:276px;left:106px;white-space:nowrap" class="ft3642">The recommended dose of Humira is 20&#160;mg&#160;every other week.</p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft3643"><i>Children, adolescents and adults from 2&#160;years of age weighing 30&#160;kg or more</i></p>
<p style="position:absolute;top:352px;left:106px;white-space:nowrap" class="ft3642">The recommended dose of Humira is 40&#160;mg&#160;every other week.</p>
<p style="position:absolute;top:390px;left:106px;white-space:nowrap" class="ft3642">Children, adolescents and adults&#160;with&#160;enthesitis-related arthritis</p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft3643"><i>Children and adolescents from 6&#160;years of age weighing 15&#160;kg to less than 30&#160;kg</i></p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft3642">The recommended dose of Humira is 20&#160;mg&#160;every other week.</p>
<p style="position:absolute;top:503px;left:106px;white-space:nowrap" class="ft3643"><i>Children, adolescents and adults from 6&#160;years of age weighing 30&#160;kg or more</i></p>
<p style="position:absolute;top:541px;left:106px;white-space:nowrap" class="ft3642">The recommended dose of Humira&#160;is 40&#160;mg&#160;every other week.</p>
<p style="position:absolute;top:579px;left:106px;white-space:nowrap" class="ft3642">Adults with psoriasis</p>
<p style="position:absolute;top:617px;left:106px;white-space:nowrap" class="ft3644">The usual dose for adults with psoriasis is an initial dose&#160;of 80&#160;mg&#160;(as two&#160;40&#160;mg&#160;injections in one day),&#160;<br/>followed by 40&#160;mg&#160;given every other week starting one week after the initial dose. You should continue to&#160;<br/>inject Humira for as long as your doctor has told you. Depending on your response, your doctor may&#160;<br/>increase the dosage&#160;to 40&#160;mg every week&#160;or 80&#160;mg&#160;every other week.</p>
<p style="position:absolute;top:712px;left:106px;white-space:nowrap" class="ft3642">Children&#160;and&#160;adolescents with plaque psoriasis</p>
<p style="position:absolute;top:750px;left:106px;white-space:nowrap" class="ft3643"><i>Children and adolescents from 4&#160;to 17&#160;years of age weighing 15&#160;kg to less than 30&#160;kg</i></p>
<p style="position:absolute;top:788px;left:106px;white-space:nowrap" class="ft3644">The recommended dose of Humira is an initial dose of 20&#160;mg, followed by 20&#160;mg&#160;one week later.&#160;<br/>Thereafter, the usual dose is 20&#160;mg every other week.</p>
<p style="position:absolute;top:845px;left:106px;white-space:nowrap" class="ft3643"><i>Children and adolescents from 4 to 17&#160;years of age weighing 30&#160;kg or more</i></p>
<p style="position:absolute;top:883px;left:106px;white-space:nowrap" class="ft3644">The recommended dose of Humira is an initial dose of 40&#160;mg, followed by 40&#160;mg&#160;one week later.&#160;<br/>Thereafter, the usual dose is 40&#160;mg every other week.</p>
<p style="position:absolute;top:940px;left:106px;white-space:nowrap" class="ft3642">Adults with hidradenitis suppurativa</p>
<p style="position:absolute;top:978px;left:106px;white-space:nowrap" class="ft3644">The usual dose regimen for hidradenitis suppurativa is an initial dose of 160&#160;mg (as&#160;four&#160;40&#160;mg&#160;injections&#160;<br/>in one day or&#160;two&#160;40&#160;mg&#160;injections per day for two consecutive days), followed by an 80&#160;mg dose (as&#160;two<br/>40&#160;mg&#160;injections&#160;in one&#160;day) two weeks later.&#160;After two further weeks, continue with a dose of 40&#160;mg&#160;<br/>every week&#160;or 80&#160;mg&#160;every other week,&#160;as prescribed by your doctor. It is recommended that you use an&#160;<br/>antiseptic wash daily on the affected areas.</p>
</div>
<!-- Page 365 -->
<a name="365"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page365-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3650">365</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft3652">Adolescents with hidradenitis suppurativa from 12&#160;to&#160;17&#160;years of age weighing&#160;30&#160;kg&#160;or more</p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft3655">The recommended dose of&#160;Humira is an initial dose of 80&#160;mg&#160;(as&#160;two&#160;40&#160;mg&#160;injections in one day),&#160;<br/>followed by 40&#160;mg&#160;every other week starting one week later. If you have an inadequate response&#160;to&#160;<br/>Humira 40&#160;mg&#160;every&#160;other week, your doctor may increase the dosage to 40&#160;mg&#160;every week&#160;or 80&#160;mg&#160;<br/>every other week.</p>
<p style="position:absolute;top:219px;left:106px;white-space:nowrap" class="ft3652">It is recommended that you use an antiseptic wash daily on the affected areas.</p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft3652">Adults with Crohn’s disease</p>
<p style="position:absolute;top:295px;left:106px;white-space:nowrap" class="ft3654">The usual dose regimen for Crohn’s disease is 80&#160;mg&#160;(as two&#160;40&#160;mg&#160;injections in one day)&#160;initially&#160;<br/>followed by 40&#160;mg&#160;every other week two weeks later. If &#160;a faster response is required your doctor may&#160;<br/>prescribe an initial dose of 160&#160;mg (as&#160;four&#160;40&#160;mg&#160;injections in one day or&#160;two&#160;40&#160;mg&#160;injections per day&#160;<br/>for two consecutive days), followed by 80&#160;mg&#160;(as two&#160;40&#160;mg&#160;injections in one day)&#160;two weeks later and&#160;<br/>thereafter as 40&#160;mg&#160;every other week. Depending on your response, your doctor may increase the dosage&#160;<br/>to&#160;40&#160;mg&#160;every week&#160;or 80&#160;mg&#160;every other week.</p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft3652">Children&#160;and&#160;adolescents with Crohn's disease</p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft3653"><i>Children and adolescents from 6 to 17&#160;years of age weighing less than 40&#160;kg &#160;</i></p>
<p style="position:absolute;top:503px;left:106px;white-space:nowrap" class="ft3654">The usual dose regimen is 40&#160;mg initially followed by 20&#160;mg two weeks later. If a faster response is&#160;<br/>required, your doctor may&#160;prescribe an initial dose of 80&#160;mg (as&#160;two&#160;40&#160;mg&#160;injections in&#160;one&#160;day)&#160;<br/>followed by 40&#160;mg two weeks later.</p>
<p style="position:absolute;top:579px;left:106px;white-space:nowrap" class="ft3654">Thereafter, the usual dose is 20&#160;mg every other week. Depending on your response, your doctor may&#160;<br/>increase the dose frequency to 20&#160;mg&#160;every week. &#160;</p>
<p style="position:absolute;top:636px;left:106px;white-space:nowrap" class="ft3654"><i>Children and adolescents from 6 to 17&#160;years of age weighing 40&#160;kg or more<br/></i>The usual dose regimen is 80&#160;mg&#160;(as two&#160;40&#160;mg&#160;injections in one day)&#160;initially followed by 40&#160;mg two&#160;<br/>weeks later. If a faster response is required, your doctor may prescribe an initial dose of 160&#160;mg (as&#160;four<br/>40&#160;mg&#160;injections in&#160;one&#160;day or as&#160;two&#160;40&#160;mg&#160;injections per day for&#160;two&#160;consecutive days) followed by&#160;<br/>80&#160;mg&#160;(as two&#160;40&#160;mg&#160;injections in one day)&#160;two weeks&#160;later.</p>
<p style="position:absolute;top:750px;left:106px;white-space:nowrap" class="ft3654">Thereafter, the usual dose is 40&#160;mg every other week. Depending on your response, your doctor may&#160;<br/>increase the dosage&#160;to 40&#160;mg every week&#160;or 80&#160;mg&#160;every other week.</p>
<p style="position:absolute;top:807px;left:106px;white-space:nowrap" class="ft3652">Adults with ulcerative colitis</p>
<p style="position:absolute;top:845px;left:106px;white-space:nowrap" class="ft3654">The usual Humira dose for adults with ulcerative colitis is 160&#160;mg&#160;(as four&#160;40&#160;mg&#160;injections in one day or&#160;<br/>two&#160;40&#160;mg&#160;injections per day for two consecutive days)&#160;at Week 0 and 80&#160;mg&#160;(as two&#160;40&#160;mg&#160;injections in&#160;<br/>one day)&#160;at Week 2 and thereafter 40&#160;mg&#160;every&#160;other week. Depending on your response, your doctor may&#160;<br/>increase the dosage to 40&#160;mg every week&#160;or 80&#160;mg&#160;every other week.&#160;</p>
<p style="position:absolute;top:940px;left:106px;white-space:nowrap" class="ft3652">Children and adolescents&#160;with ulcerative colitis</p>
<p style="position:absolute;top:978px;left:106px;white-space:nowrap" class="ft3653"><i>Children and adolescents from 6 years of age weighing less than 40 kg</i></p>
<p style="position:absolute;top:1016px;left:106px;white-space:nowrap" class="ft3654">The usual&#160;Humira dose is 80 mg (as two 40 mg injections in one day) initially followed by 40 mg&#160;(as one&#160;<br/>40 mg injection)&#160;two weeks later. Thereafter, the usual dose is 40 mg every other week.&#160;</p>
<p style="position:absolute;top:1072px;left:106px;white-space:nowrap" class="ft3652">Patients who turn 18&#160;years of age&#160;while on&#160;40 mg every other week,&#160;should continue their prescribed dose.</p>
</div>
<!-- Page 366 -->
<a name="366"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page366-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3660">366</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft3663"><i>Children and adolescents from 6 years of age weighing 40 kg or more</i></p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft3665">The usual Humira dose is 160 mg (as&#160;four 40 mg injections in one day or two 40 mg injections per day for&#160;<br/>two consecutive days) initially, followed&#160;by 80 mg (as&#160;two 40 mg injections in one day) two weeks later.&#160;<br/>Thereafter the usual dose is 80 mg every other week.&#160;</p>
<p style="position:absolute;top:219px;left:106px;white-space:nowrap" class="ft3662">Patients who turn 18&#160;years of age&#160;while on&#160;80 mg every other week,&#160;should continue their prescribed dose.</p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft3662">Adults with non-infectious uveitis</p>
<p style="position:absolute;top:295px;left:106px;white-space:nowrap" class="ft3664">The usual dose for adults with non-infectious uveitis is an initial dose of 80&#160;mg&#160;(as two injections in one&#160;<br/>day), followed by 40&#160;mg given every other week starting one week after the initial dose. You should&#160;<br/>continue to inject Humira for as long as your doctor has told you.</p>
<p style="position:absolute;top:370px;left:106px;white-space:nowrap" class="ft3664">In&#160;non-infectious uveitis, corticosteroids or other medicines that influence the immune system may be&#160;<br/>continued while using Humira. Humira can also be given alone.</p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft3662">Children&#160;and adolescents&#160;with chronic non-infectious uveitis from&#160;2&#160;years of age</p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft3663"><i>Children and adolescents from 2&#160;years of age weighing less than 30&#160;kg</i></p>
<p style="position:absolute;top:503px;left:106px;white-space:nowrap" class="ft3662">The usual dose of Humira is 20&#160;mg&#160;every other week with methotrexate.</p>
<p style="position:absolute;top:541px;left:106px;white-space:nowrap" class="ft3665">Your doctor may also prescribe an initial dose of 40&#160;mg which may be administered one week prior to the&#160;<br/>start of the&#160;usual dose.</p>
<p style="position:absolute;top:598px;left:106px;white-space:nowrap" class="ft3663"><i>Children and adolescents from 2&#160;years of age weighing 30&#160;kg or more</i></p>
<p style="position:absolute;top:636px;left:106px;white-space:nowrap" class="ft3662">The usual dose of Humira is 40&#160;mg&#160;every other week with methotrexate.</p>
<p style="position:absolute;top:674px;left:106px;white-space:nowrap" class="ft3665">Your doctor may also prescribe an initial dose of 80&#160;mg which may be administered&#160;one week prior to the&#160;<br/>start of the&#160;usual dose.</p>
<p style="position:absolute;top:731px;left:106px;white-space:nowrap" class="ft3661"><b>Method and route of administration</b></p>
<p style="position:absolute;top:769px;left:106px;white-space:nowrap" class="ft3662">Humira is administered by injection under the skin (by subcutaneous injection).</p>
<p style="position:absolute;top:807px;left:106px;white-space:nowrap" class="ft3661"><b>Instructions for preparing and giving an injection of Humira</b></p>
<p style="position:absolute;top:845px;left:106px;white-space:nowrap" class="ft3664">The following instructions explain how to inject Humira. Please read the instructions carefully and follow&#160;<br/>them step by step. You will be instructed by your doctor or his/her assistant on the technique of self-<br/>injection. Do not attempt to self-inject until you are sure that you understand how to prepare and give the&#160;<br/>injection. After proper training, the injection can be self-administered or given by another person, for&#160;<br/>example a family member or friend. &#160;</p>
<p style="position:absolute;top:959px;left:106px;white-space:nowrap" class="ft3662">This injection should not be mixed in the same syringe or vial with any other&#160;medicine.</p>
<p style="position:absolute;top:997px;left:106px;white-space:nowrap" class="ft3661"><b>1)&#160;</b></p>
<p style="position:absolute;top:997px;left:148px;white-space:nowrap" class="ft3661"><b>Setting up</b></p>
<p style="position:absolute;top:1035px;left:106px;white-space:nowrap" class="ft3664">Wash your hands thoroughly&#160;<br/>Set up the following items on a clean surface</p>
</div>
<!-- Page 367 -->
<a name="367"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page367-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3670">367</p>
<p style="position:absolute;top:87px;left:148px;white-space:nowrap" class="ft36736">o</p>
<p style="position:absolute;top:86px;left:191px;white-space:nowrap" class="ft3672">One pre-filled syringe of Humira for injection &#160; &#160;&#160;</p>
<p style="position:absolute;top:106px;left:148px;white-space:nowrap" class="ft36736">o</p>
<p style="position:absolute;top:105px;left:191px;white-space:nowrap" class="ft3672">One alcohol pad</p>
<p style="position:absolute;top:400px;left:106px;white-space:nowrap" class="ft3672">Look at the expiry date on the syringe. Do not use the product after the month and&#160;year shown.</p>
<p style="position:absolute;top:438px;left:106px;white-space:nowrap" class="ft3671"><b>2)</b></p>
<p style="position:absolute;top:438px;left:148px;white-space:nowrap" class="ft3671"><b>Choosing and preparing an injection site</b></p>
<p style="position:absolute;top:476px;left:106px;white-space:nowrap" class="ft3672">Choose a site on your thigh or stomach</p>
<p style="position:absolute;top:773px;left:106px;white-space:nowrap" class="ft3672">Each new injection should be given at least 3 cm from the last injection site.&#160;</p>
<p style="position:absolute;top:793px;left:148px;white-space:nowrap" class="ft36736">o</p>
<p style="position:absolute;top:792px;left:191px;white-space:nowrap" class="ft3674">Do not inject in an area where the skin is reddened, bruised, or hard.&#160;This may mean there is&#160;<br/>an infection.</p>
<p style="position:absolute;top:831px;left:148px;white-space:nowrap" class="ft36736">o</p>
<p style="position:absolute;top:830px;left:191px;white-space:nowrap" class="ft3672">Wipe the injection site with the enclosed alcohol pad, using a circular motion.</p>
<p style="position:absolute;top:849px;left:148px;white-space:nowrap" class="ft36736">o</p>
<p style="position:absolute;top:849px;left:191px;white-space:nowrap" class="ft3672">Do not touch the area again before injecting.</p>
<p style="position:absolute;top:887px;left:106px;white-space:nowrap" class="ft3671"><b>3)&#160;</b></p>
<p style="position:absolute;top:887px;left:148px;white-space:nowrap" class="ft3671"><b>Injecting Humira&#160;</b></p>
<p style="position:absolute;top:924px;left:106px;white-space:nowrap" class="ft3672">•</p>
<p style="position:absolute;top:924px;left:147px;white-space:nowrap" class="ft3672">Do NOT shake the syringe.</p>
<p style="position:absolute;top:944px;left:106px;white-space:nowrap" class="ft3672">•</p>
<p style="position:absolute;top:944px;left:147px;white-space:nowrap" class="ft3672">Remove cap from needle syringe, being careful not to touch the needle or let it touch any surface.</p>
<p style="position:absolute;top:962px;left:106px;white-space:nowrap" class="ft3672">•</p>
<p style="position:absolute;top:962px;left:148px;white-space:nowrap" class="ft3672">With one hand, gently grasp the cleaned areas of skin and hold firmly</p>
</div>
<!-- Page 368 -->
<a name="368"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page368-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3680">368</p>
<p style="position:absolute;top:336px;left:106px;white-space:nowrap" class="ft3686"></p>
<p style="position:absolute;top:338px;left:147px;white-space:nowrap" class="ft3682">With the other hand, hold syringe at 45-degree angle to skin, with the grooved side up.</p>
<p style="position:absolute;top:356px;left:106px;white-space:nowrap" class="ft3686"></p>
<p style="position:absolute;top:358px;left:147px;white-space:nowrap" class="ft3682">With one quick, short motion,&#160;push needle all the way into skin</p>
<p style="position:absolute;top:376px;left:106px;white-space:nowrap" class="ft3686"></p>
<p style="position:absolute;top:378px;left:147px;white-space:nowrap" class="ft3682">Release the skin with the first hand</p>
<p style="position:absolute;top:397px;left:106px;white-space:nowrap" class="ft3686"></p>
<p style="position:absolute;top:399px;left:147px;white-space:nowrap" class="ft3682">Push plunger to inject solution&#160;–&#160;it can take from 2 to 5 seconds to empty the syringe</p>
<p style="position:absolute;top:417px;left:106px;white-space:nowrap" class="ft3686"></p>
<p style="position:absolute;top:419px;left:147px;white-space:nowrap" class="ft3684">When the syringe is empty, remove the needle from skin, being careful to keep it at the same angle<br/>as when it was inserted</p>
<p style="position:absolute;top:456px;left:106px;white-space:nowrap" class="ft3686"></p>
<p style="position:absolute;top:458px;left:147px;white-space:nowrap" class="ft3684">Using&#160;your thumb or a piece of gauze, apply pressure over the injection site for 10 seconds. &#160;A little&#160;<br/>bleeding may occur. Do not rub the injection site. Use a plaster if you want to.</p>
<p style="position:absolute;top:515px;left:106px;white-space:nowrap" class="ft3681"><b>4)&#160;</b></p>
<p style="position:absolute;top:515px;left:148px;white-space:nowrap" class="ft3681"><b>Throwing away supplies</b></p>
<p style="position:absolute;top:552px;left:106px;white-space:nowrap" class="ft3686"></p>
<p style="position:absolute;top:554px;left:147px;white-space:nowrap" class="ft3682">The Humira syringe&#160;should NEVER be reused. NEVER recap a needle.</p>
<p style="position:absolute;top:572px;left:106px;white-space:nowrap" class="ft3686"></p>
<p style="position:absolute;top:574px;left:147px;white-space:nowrap" class="ft3685">After injecting Humira, immediately throw away the used syringe in a special container as&#160;<br/>instructed by your doctor, nurse or pharmacist.</p>
<p style="position:absolute;top:611px;left:106px;white-space:nowrap" class="ft3686"></p>
<p style="position:absolute;top:613px;left:147px;white-space:nowrap" class="ft3682">Keep this container out of the sight and reach of children</p>
<p style="position:absolute;top:651px;left:106px;white-space:nowrap" class="ft3681"><b>Instructions for preparing and giving an injection of Humira</b></p>
<p style="position:absolute;top:689px;left:106px;white-space:nowrap" class="ft3684">The following instructions explain how to inject Humira. Please read the instructions carefully and follow&#160;<br/>them step by step.&#160;You&#160;will be instructed by your doctor or his/her assistant on the technique of&#160;self-<br/>injection.&#160;Do&#160;not attempt to self-inject until you are sure that you understand how to prepare and give the&#160;<br/>injection.&#160;After proper training, the injection can be self-administered or given by another person, for&#160;<br/>example a family member or friend.</p>
<p style="position:absolute;top:803px;left:106px;white-space:nowrap" class="ft3682">This injection should not be mixed in the same syringe or vial with any other medicine.</p>
<p style="position:absolute;top:841px;left:106px;white-space:nowrap" class="ft3681"><b>1)&#160;</b></p>
<p style="position:absolute;top:841px;left:148px;white-space:nowrap" class="ft3681"><b>Setting up</b></p>
<p style="position:absolute;top:879px;left:106px;white-space:nowrap" class="ft3684">Wash your hands thoroughly&#160;<br/>Set up the following items on a clean surface</p>
<p style="position:absolute;top:935px;left:148px;white-space:nowrap" class="ft36836">o</p>
<p style="position:absolute;top:934px;left:191px;white-space:nowrap" class="ft3682">One pre-filled syringe of Humira for injection</p>
<p style="position:absolute;top:954px;left:148px;white-space:nowrap" class="ft36836">o</p>
<p style="position:absolute;top:953px;left:191px;white-space:nowrap" class="ft3682">One alcohol pad</p>
</div>
<!-- Page 369 -->
<a name="369"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page369-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3690">369</p>
<p style="position:absolute;top:307px;left:106px;white-space:nowrap" class="ft3692">Look at the expiry date on the syringe.&#160;Do not use the product after the month and year shown.</p>
<p style="position:absolute;top:345px;left:106px;white-space:nowrap" class="ft3691"><b>2)&#160;</b></p>
<p style="position:absolute;top:345px;left:148px;white-space:nowrap" class="ft3691"><b>Choosing and preparing an injection site</b></p>
<p style="position:absolute;top:383px;left:106px;white-space:nowrap" class="ft3692">Choose a site on your thigh or stomach</p>
<p style="position:absolute;top:592px;left:106px;white-space:nowrap" class="ft3692">Each new injection should be given at least 3&#160;cm from the last injection site.&#160;</p>
<p style="position:absolute;top:612px;left:148px;white-space:nowrap" class="ft36936">o</p>
<p style="position:absolute;top:611px;left:191px;white-space:nowrap" class="ft3695">Do not inject in an area where the skin is reddened, bruised, or hard. This may mean there is&#160;<br/>an infection.</p>
<p style="position:absolute;top:650px;left:148px;white-space:nowrap" class="ft36936">o</p>
<p style="position:absolute;top:649px;left:191px;white-space:nowrap" class="ft3692">Wipe the injection site with the enclosed alcohol pad, using a circular motion.</p>
<p style="position:absolute;top:669px;left:148px;white-space:nowrap" class="ft36936">o</p>
<p style="position:absolute;top:668px;left:191px;white-space:nowrap" class="ft3692">Do not touch the area again before injecting.</p>
<p style="position:absolute;top:706px;left:106px;white-space:nowrap" class="ft3691"><b>3)&#160;</b></p>
<p style="position:absolute;top:706px;left:148px;white-space:nowrap" class="ft3691"><b>Injecting Humira&#160;</b></p>
<p style="position:absolute;top:743px;left:106px;white-space:nowrap" class="ft3696"></p>
<p style="position:absolute;top:745px;left:147px;white-space:nowrap" class="ft3692">Do NOT shake the syringe.</p>
<p style="position:absolute;top:763px;left:106px;white-space:nowrap" class="ft3696"></p>
<p style="position:absolute;top:765px;left:147px;white-space:nowrap" class="ft3692">Remove cap from needle syringe, being careful not to touch the needle or let it touch any surface.</p>
<p style="position:absolute;top:783px;left:106px;white-space:nowrap" class="ft3696"></p>
<p style="position:absolute;top:785px;left:147px;white-space:nowrap" class="ft3692">With one hand, gently grasp the cleaned areas of&#160;skin and hold firmly</p>
<p style="position:absolute;top:1047px;left:106px;white-space:nowrap" class="ft3696"></p>
<p style="position:absolute;top:1049px;left:147px;white-space:nowrap" class="ft3692">With the other hand, hold syringe at 45-degree angle to skin, with the grooved side up.</p>
<p style="position:absolute;top:1067px;left:106px;white-space:nowrap" class="ft3696"></p>
<p style="position:absolute;top:1069px;left:147px;white-space:nowrap" class="ft3692">With one quick, short motion, push needle all the way into skin</p>
</div>
<!-- Page 370 -->
<a name="370"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page370-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3700">370</p>
<p style="position:absolute;top:85px;left:106px;white-space:nowrap" class="ft3706"></p>
<p style="position:absolute;top:87px;left:147px;white-space:nowrap" class="ft3702">Release the skin with the first hand</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft3706"></p>
<p style="position:absolute;top:107px;left:147px;white-space:nowrap" class="ft3702">Push plunger to inject&#160;solution&#160;–&#160;it can take from 2 to 5 seconds to empty the syringe</p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft3706"></p>
<p style="position:absolute;top:127px;left:147px;white-space:nowrap" class="ft3704">When the syringe is empty, remove the needle from skin, being careful to keep it at the same angle&#160;<br/>as when it was inserted</p>
<p style="position:absolute;top:165px;left:106px;white-space:nowrap" class="ft3706"></p>
<p style="position:absolute;top:167px;left:147px;white-space:nowrap" class="ft3705">Hold the syringe in one hand and with the other hand slide the outer&#160;protective shield over the&#160;<br/>exposed needle until it locks in place</p>
<p style="position:absolute;top:204px;left:106px;white-space:nowrap" class="ft3706"></p>
<p style="position:absolute;top:206px;left:147px;white-space:nowrap" class="ft3704">Using&#160;your thumb or a piece of gauze, apply pressure over the injection site for 10 seconds.&#160;&#160;A little&#160;<br/>bleeding may occur.&#160;Do not rub the injection site. Use a plaster if you want to.</p>
<p style="position:absolute;top:263px;left:106px;white-space:nowrap" class="ft3701"><b>4)</b></p>
<p style="position:absolute;top:263px;left:148px;white-space:nowrap" class="ft3701"><b>Throwing away supplies</b></p>
<p style="position:absolute;top:300px;left:106px;white-space:nowrap" class="ft3706"></p>
<p style="position:absolute;top:302px;left:147px;white-space:nowrap" class="ft3702">The Humira syringe should NEVER be reused. NEVER recap a needle</p>
<p style="position:absolute;top:320px;left:106px;white-space:nowrap" class="ft3706"></p>
<p style="position:absolute;top:322px;left:147px;white-space:nowrap" class="ft3704">After injecting Humira, immediately throw away the used syringe in a special container as&#160;<br/>instructed by your doctor, nurse or pharmacist.</p>
<p style="position:absolute;top:360px;left:106px;white-space:nowrap" class="ft3702">Keep this container out of the sight and reach of children</p>
<p style="position:absolute;top:398px;left:106px;white-space:nowrap" class="ft3701"><b>If you use more Humira than you should</b></p>
<p style="position:absolute;top:436px;left:106px;white-space:nowrap" class="ft3704">If you accidentally inject Humira more frequently than told to by your doctor or pharmacist, call your&#160;<br/>doctor or pharmacist&#160;and tell him/her that you have taken more. Always take the outer&#160;carton of the&#160;<br/>medicine with you, even if it is empty.&#160;</p>
<p style="position:absolute;top:512px;left:106px;white-space:nowrap" class="ft3701"><b>If you forget to use Humira</b></p>
<p style="position:absolute;top:550px;left:106px;white-space:nowrap" class="ft3704">If you forget to give yourself an injection, you should inject the next dose of Humira as soon as you&#160;<br/>remember. Then take your next dose as you would have on your originally scheduled day, had you not&#160;<br/>forgotten a dose.&#160;</p>
<p style="position:absolute;top:626px;left:106px;white-space:nowrap" class="ft3701"><b>If you stop using Humira</b></p>
<p style="position:absolute;top:663px;left:106px;white-space:nowrap" class="ft3704">The&#160;decision to stop using Humira should be discussed with your doctor. Your symptoms may return upon&#160;<br/>discontinuation.</p>
<p style="position:absolute;top:720px;left:106px;white-space:nowrap" class="ft3702">If you have any further questions on the use of this&#160;product, ask your doctor or pharmacist.</p>
<p style="position:absolute;top:777px;left:106px;white-space:nowrap" class="ft3701"><b>4.</b></p>
<p style="position:absolute;top:777px;left:148px;white-space:nowrap" class="ft3701"><b>Possible side effects</b></p>
<p style="position:absolute;top:815px;left:106px;white-space:nowrap" class="ft3704">Like all medicines, this medicine can cause side effects, although not everybody gets them. Most side&#160;<br/>effects are mild to moderate. However, some may be serious and require treatment. Side effects may occur&#160;<br/>at least up to 4 months after the last Humira injection. &#160;</p>
<p style="position:absolute;top:891px;left:106px;white-space:nowrap" class="ft3702">Tell your doctor immediately if you notice any of the following&#160;</p>
<p style="position:absolute;top:909px;left:106px;white-space:nowrap" class="ft3706"></p>
<p style="position:absolute;top:911px;left:147px;white-space:nowrap" class="ft3702">severe rash, hives or other signs of allergic reaction;&#160;</p>
<p style="position:absolute;top:929px;left:106px;white-space:nowrap" class="ft3706"></p>
<p style="position:absolute;top:931px;left:147px;white-space:nowrap" class="ft3702">swollen face, hands, feet;</p>
<p style="position:absolute;top:950px;left:106px;white-space:nowrap" class="ft3706"></p>
<p style="position:absolute;top:951px;left:147px;white-space:nowrap" class="ft3702">trouble breathing, swallowing;</p>
<p style="position:absolute;top:970px;left:106px;white-space:nowrap" class="ft3706"></p>
<p style="position:absolute;top:972px;left:147px;white-space:nowrap" class="ft3702">shortness of breath with exertion or upon lying down or swelling&#160;of the feet.</p>
<p style="position:absolute;top:1010px;left:106px;white-space:nowrap" class="ft3702">Tell your doctor as soon as possible if you notice any of the following&#160;</p>
<p style="position:absolute;top:1028px;left:106px;white-space:nowrap" class="ft3706"></p>
<p style="position:absolute;top:1030px;left:147px;white-space:nowrap" class="ft3702">signs of infection such as fever, feeling sick, wounds, dental problems, burning on urination;</p>
<p style="position:absolute;top:1048px;left:106px;white-space:nowrap" class="ft3706"></p>
<p style="position:absolute;top:1050px;left:147px;white-space:nowrap" class="ft3702">feeling weak or tired;</p>
<p style="position:absolute;top:1068px;left:106px;white-space:nowrap" class="ft3706"></p>
<p style="position:absolute;top:1070px;left:147px;white-space:nowrap" class="ft3702">coughing;</p>
</div>
<!-- Page 371 -->
<a name="371"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page371-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3710">371</p>
<p style="position:absolute;top:85px;left:106px;white-space:nowrap" class="ft3716"></p>
<p style="position:absolute;top:87px;left:147px;white-space:nowrap" class="ft3712">tingling;</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft3716"></p>
<p style="position:absolute;top:107px;left:147px;white-space:nowrap" class="ft3712">numbness;</p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft3716"></p>
<p style="position:absolute;top:127px;left:147px;white-space:nowrap" class="ft3712">double vision;</p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft3716"></p>
<p style="position:absolute;top:148px;left:147px;white-space:nowrap" class="ft3712">arm&#160;or&#160;leg&#160;weakness;</p>
<p style="position:absolute;top:166px;left:106px;white-space:nowrap" class="ft3716"></p>
<p style="position:absolute;top:168px;left:147px;white-space:nowrap" class="ft3712">a&#160;bump or open sore that doesn't heal;</p>
<p style="position:absolute;top:186px;left:106px;white-space:nowrap" class="ft3716"></p>
<p style="position:absolute;top:188px;left:147px;white-space:nowrap" class="ft3714">signs and symptoms suggestive of blood disorders such as persistent fever, bruising, bleeding,&#160;<br/>paleness.</p>
<p style="position:absolute;top:245px;left:106px;white-space:nowrap" class="ft3714">The symptoms described above can be signs of the below listed side effects, which have been observed&#160;<br/>with Humira.</p>
<p style="position:absolute;top:302px;left:106px;white-space:nowrap" class="ft3712">Very common (may affect more than 1 in 10 people) &#160;</p>
<p style="position:absolute;top:339px;left:106px;white-space:nowrap" class="ft3716"></p>
<p style="position:absolute;top:341px;left:147px;white-space:nowrap" class="ft3712">injection site reactions (including pain, swelling, redness or itching);</p>
<p style="position:absolute;top:359px;left:106px;white-space:nowrap" class="ft3716"></p>
<p style="position:absolute;top:361px;left:147px;white-space:nowrap" class="ft3712">respiratory tract infections (including cold, runny nose, sinus infection, pneumonia);</p>
<p style="position:absolute;top:379px;left:106px;white-space:nowrap" class="ft3716"></p>
<p style="position:absolute;top:381px;left:147px;white-space:nowrap" class="ft3712">headache;</p>
<p style="position:absolute;top:400px;left:106px;white-space:nowrap" class="ft3716"></p>
<p style="position:absolute;top:401px;left:147px;white-space:nowrap" class="ft3712">abdominal&#160;pain;</p>
<p style="position:absolute;top:420px;left:106px;white-space:nowrap" class="ft3716"></p>
<p style="position:absolute;top:422px;left:147px;white-space:nowrap" class="ft3712">nausea and vomiting;</p>
<p style="position:absolute;top:440px;left:106px;white-space:nowrap" class="ft3716"></p>
<p style="position:absolute;top:442px;left:147px;white-space:nowrap" class="ft3712">rash;</p>
<p style="position:absolute;top:460px;left:106px;white-space:nowrap" class="ft3716"></p>
<p style="position:absolute;top:462px;left:147px;white-space:nowrap" class="ft3712">musculoskeletal pain.</p>
<p style="position:absolute;top:498px;left:106px;white-space:nowrap" class="ft3712">Common (may affect up to 1 in 10&#160;people)</p>
<p style="position:absolute;top:535px;left:106px;white-space:nowrap" class="ft3716"></p>
<p style="position:absolute;top:537px;left:147px;white-space:nowrap" class="ft3712">serious&#160;infections (including blood poisoning and influenza);</p>
<p style="position:absolute;top:555px;left:106px;white-space:nowrap" class="ft3716"></p>
<p style="position:absolute;top:557px;left:147px;white-space:nowrap" class="ft3712">intestinal infections&#160;(including gastroenteritis);</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft3716"></p>
<p style="position:absolute;top:577px;left:147px;white-space:nowrap" class="ft3712">skin infections (including cellulitis and&#160;shingles);</p>
<p style="position:absolute;top:596px;left:106px;white-space:nowrap" class="ft3716"></p>
<p style="position:absolute;top:598px;left:147px;white-space:nowrap" class="ft3712">ear infections;</p>
<p style="position:absolute;top:616px;left:106px;white-space:nowrap" class="ft3716"></p>
<p style="position:absolute;top:618px;left:147px;white-space:nowrap" class="ft3712">oral infections (including tooth infections and cold sores);</p>
<p style="position:absolute;top:636px;left:106px;white-space:nowrap" class="ft3716"></p>
<p style="position:absolute;top:638px;left:147px;white-space:nowrap" class="ft3712">reproductive tract infections;</p>
<p style="position:absolute;top:656px;left:106px;white-space:nowrap" class="ft3716"></p>
<p style="position:absolute;top:658px;left:147px;white-space:nowrap" class="ft3712">urinary tract infection;</p>
<p style="position:absolute;top:676px;left:106px;white-space:nowrap" class="ft3716"></p>
<p style="position:absolute;top:678px;left:147px;white-space:nowrap" class="ft3712">fungal infections;</p>
<p style="position:absolute;top:697px;left:106px;white-space:nowrap" class="ft3716"></p>
<p style="position:absolute;top:698px;left:147px;white-space:nowrap" class="ft3712">joint infections;</p>
<p style="position:absolute;top:717px;left:106px;white-space:nowrap" class="ft3716"></p>
<p style="position:absolute;top:719px;left:147px;white-space:nowrap" class="ft3712">benign tumours;</p>
<p style="position:absolute;top:737px;left:106px;white-space:nowrap" class="ft3716"></p>
<p style="position:absolute;top:739px;left:147px;white-space:nowrap" class="ft3712">skin cancer;</p>
<p style="position:absolute;top:757px;left:106px;white-space:nowrap" class="ft3716"></p>
<p style="position:absolute;top:759px;left:147px;white-space:nowrap" class="ft3712">allergic reactions (including seasonal&#160;allergy);</p>
<p style="position:absolute;top:777px;left:106px;white-space:nowrap" class="ft3716"></p>
<p style="position:absolute;top:779px;left:147px;white-space:nowrap" class="ft3712">dehydration;</p>
<p style="position:absolute;top:797px;left:106px;white-space:nowrap" class="ft3716"></p>
<p style="position:absolute;top:799px;left:147px;white-space:nowrap" class="ft3712">mood swings (including depression);</p>
<p style="position:absolute;top:817px;left:106px;white-space:nowrap" class="ft3716"></p>
<p style="position:absolute;top:819px;left:147px;white-space:nowrap" class="ft3712">anxiety;</p>
<p style="position:absolute;top:838px;left:106px;white-space:nowrap" class="ft3716"></p>
<p style="position:absolute;top:840px;left:147px;white-space:nowrap" class="ft3712">difficulty sleeping;</p>
<p style="position:absolute;top:858px;left:106px;white-space:nowrap" class="ft3716"></p>
<p style="position:absolute;top:860px;left:147px;white-space:nowrap" class="ft3712">sensation disorders such as tingling, prickling or numbness;</p>
<p style="position:absolute;top:878px;left:106px;white-space:nowrap" class="ft3716"></p>
<p style="position:absolute;top:880px;left:147px;white-space:nowrap" class="ft3712">migraine;</p>
<p style="position:absolute;top:898px;left:106px;white-space:nowrap" class="ft3716"></p>
<p style="position:absolute;top:900px;left:147px;white-space:nowrap" class="ft3712">nerve root compression (including low back pain and leg pain);</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft3716"></p>
<p style="position:absolute;top:920px;left:147px;white-space:nowrap" class="ft3712">vision disturbances;&#160;</p>
<p style="position:absolute;top:938px;left:106px;white-space:nowrap" class="ft3716"></p>
<p style="position:absolute;top:940px;left:147px;white-space:nowrap" class="ft3712">eye&#160;inflammation;</p>
<p style="position:absolute;top:959px;left:106px;white-space:nowrap" class="ft3716"></p>
<p style="position:absolute;top:960px;left:147px;white-space:nowrap" class="ft3712">inflammation of the eye lid and eye swelling;</p>
<p style="position:absolute;top:979px;left:106px;white-space:nowrap" class="ft3716"></p>
<p style="position:absolute;top:981px;left:147px;white-space:nowrap" class="ft3712">vertigo;</p>
<p style="position:absolute;top:999px;left:106px;white-space:nowrap" class="ft3716"></p>
<p style="position:absolute;top:1001px;left:147px;white-space:nowrap" class="ft3712">sensation of heart beating rapidly;</p>
<p style="position:absolute;top:1019px;left:106px;white-space:nowrap" class="ft3716"></p>
<p style="position:absolute;top:1021px;left:147px;white-space:nowrap" class="ft3712">high blood pressure;</p>
<p style="position:absolute;top:1039px;left:106px;white-space:nowrap" class="ft3716"></p>
<p style="position:absolute;top:1041px;left:147px;white-space:nowrap" class="ft3712">flushing;</p>
<p style="position:absolute;top:1059px;left:106px;white-space:nowrap" class="ft3716"></p>
<p style="position:absolute;top:1061px;left:147px;white-space:nowrap" class="ft3712">haematoma;</p>
<p style="position:absolute;top:1080px;left:106px;white-space:nowrap" class="ft3716"></p>
<p style="position:absolute;top:1081px;left:147px;white-space:nowrap" class="ft3712">cough;</p>
</div>
<!-- Page 372 -->
<a name="372"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page372-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3720">372</p>
<p style="position:absolute;top:85px;left:106px;white-space:nowrap" class="ft3726"></p>
<p style="position:absolute;top:87px;left:147px;white-space:nowrap" class="ft3722">asthma;</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft3726"></p>
<p style="position:absolute;top:107px;left:147px;white-space:nowrap" class="ft3722">shortness of breath;</p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft3726"></p>
<p style="position:absolute;top:127px;left:147px;white-space:nowrap" class="ft3722">gastrointestinal bleeding;</p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft3726"></p>
<p style="position:absolute;top:148px;left:147px;white-space:nowrap" class="ft3722">dyspepsia (indigestion, bloating, heart burn);</p>
<p style="position:absolute;top:166px;left:106px;white-space:nowrap" class="ft3726"></p>
<p style="position:absolute;top:168px;left:147px;white-space:nowrap" class="ft3722">acid&#160;reflux disease;</p>
<p style="position:absolute;top:186px;left:106px;white-space:nowrap" class="ft3726"></p>
<p style="position:absolute;top:188px;left:147px;white-space:nowrap" class="ft3722">sicca syndrome (including dry eyes and dry mouth);</p>
<p style="position:absolute;top:206px;left:106px;white-space:nowrap" class="ft3726"></p>
<p style="position:absolute;top:208px;left:147px;white-space:nowrap" class="ft3722">itching;</p>
<p style="position:absolute;top:226px;left:106px;white-space:nowrap" class="ft3726"></p>
<p style="position:absolute;top:228px;left:147px;white-space:nowrap" class="ft3722">itchy rash;</p>
<p style="position:absolute;top:247px;left:106px;white-space:nowrap" class="ft3726"></p>
<p style="position:absolute;top:248px;left:147px;white-space:nowrap" class="ft3722">bruising;</p>
<p style="position:absolute;top:267px;left:106px;white-space:nowrap" class="ft3726"></p>
<p style="position:absolute;top:269px;left:147px;white-space:nowrap" class="ft3722">inflammation of the skin (such as eczema);</p>
<p style="position:absolute;top:287px;left:106px;white-space:nowrap" class="ft3726"></p>
<p style="position:absolute;top:289px;left:147px;white-space:nowrap" class="ft3722">breaking of finger nails and toe nails;</p>
<p style="position:absolute;top:307px;left:106px;white-space:nowrap" class="ft3726"></p>
<p style="position:absolute;top:309px;left:147px;white-space:nowrap" class="ft3722">increased sweating;</p>
<p style="position:absolute;top:327px;left:106px;white-space:nowrap" class="ft3726"></p>
<p style="position:absolute;top:329px;left:147px;white-space:nowrap" class="ft3722">hair loss;</p>
<p style="position:absolute;top:347px;left:106px;white-space:nowrap" class="ft3726"></p>
<p style="position:absolute;top:349px;left:147px;white-space:nowrap" class="ft3722">new&#160;onset or worsening of psoriasis;</p>
<p style="position:absolute;top:367px;left:106px;white-space:nowrap" class="ft3726"></p>
<p style="position:absolute;top:369px;left:147px;white-space:nowrap" class="ft3722">muscle&#160;spasms;</p>
<p style="position:absolute;top:388px;left:106px;white-space:nowrap" class="ft3726"></p>
<p style="position:absolute;top:390px;left:147px;white-space:nowrap" class="ft3722">blood in urine;</p>
<p style="position:absolute;top:408px;left:106px;white-space:nowrap" class="ft3726"></p>
<p style="position:absolute;top:410px;left:147px;white-space:nowrap" class="ft3722">kidney problems;</p>
<p style="position:absolute;top:428px;left:106px;white-space:nowrap" class="ft3726"></p>
<p style="position:absolute;top:430px;left:147px;white-space:nowrap" class="ft3722">chest pain;</p>
<p style="position:absolute;top:448px;left:106px;white-space:nowrap" class="ft3726"></p>
<p style="position:absolute;top:450px;left:147px;white-space:nowrap" class="ft3722">oedema;</p>
<p style="position:absolute;top:468px;left:106px;white-space:nowrap" class="ft3726"></p>
<p style="position:absolute;top:470px;left:147px;white-space:nowrap" class="ft3722">fever;</p>
<p style="position:absolute;top:488px;left:106px;white-space:nowrap" class="ft3726"></p>
<p style="position:absolute;top:490px;left:147px;white-space:nowrap" class="ft3722">reduction in blood platelets which increases risk of bleeding or bruising;</p>
<p style="position:absolute;top:509px;left:106px;white-space:nowrap" class="ft3726"></p>
<p style="position:absolute;top:510px;left:147px;white-space:nowrap" class="ft3722">impaired healing.</p>
<p style="position:absolute;top:548px;left:106px;white-space:nowrap" class="ft3722">Uncommon (may affect up to 1 in 100 people)</p>
<p style="position:absolute;top:586px;left:106px;white-space:nowrap" class="ft3726"></p>
<p style="position:absolute;top:588px;left:147px;white-space:nowrap" class="ft3724">opportunistic infections (which include&#160;tuberculosis and other infections that occur when resistance&#160;<br/>to disease is lowered);</p>
<p style="position:absolute;top:625px;left:106px;white-space:nowrap" class="ft3726"></p>
<p style="position:absolute;top:627px;left:147px;white-space:nowrap" class="ft3722">neurological infections (including viral meningitis);</p>
<p style="position:absolute;top:645px;left:106px;white-space:nowrap" class="ft3726"></p>
<p style="position:absolute;top:647px;left:147px;white-space:nowrap" class="ft3722">eye&#160;infections;</p>
<p style="position:absolute;top:665px;left:106px;white-space:nowrap" class="ft3726"></p>
<p style="position:absolute;top:667px;left:147px;white-space:nowrap" class="ft3722">bacterial infections;</p>
<p style="position:absolute;top:685px;left:106px;white-space:nowrap" class="ft3726"></p>
<p style="position:absolute;top:687px;left:147px;white-space:nowrap" class="ft3722">diverticulitis (inflammation and infection of the large intestine);</p>
<p style="position:absolute;top:706px;left:106px;white-space:nowrap" class="ft3726"></p>
<p style="position:absolute;top:707px;left:147px;white-space:nowrap" class="ft3722">cancer;</p>
<p style="position:absolute;top:726px;left:106px;white-space:nowrap" class="ft3726"></p>
<p style="position:absolute;top:728px;left:147px;white-space:nowrap" class="ft3722">cancer that affects the lymph system;</p>
<p style="position:absolute;top:746px;left:106px;white-space:nowrap" class="ft3726"></p>
<p style="position:absolute;top:748px;left:147px;white-space:nowrap" class="ft3722">melanoma;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft3726"></p>
<p style="position:absolute;top:768px;left:147px;white-space:nowrap" class="ft3725">immune disorders that could affect the lungs, skin and lymph nodes (most commonly presenting as&#160;<br/>sarcoidosis);</p>
<p style="position:absolute;top:805px;left:106px;white-space:nowrap" class="ft3726"></p>
<p style="position:absolute;top:807px;left:147px;white-space:nowrap" class="ft3722">vasculitis (inflammation of blood vessels);</p>
<p style="position:absolute;top:825px;left:106px;white-space:nowrap" class="ft3726"></p>
<p style="position:absolute;top:827px;left:147px;white-space:nowrap" class="ft3722">tremor;</p>
<p style="position:absolute;top:845px;left:106px;white-space:nowrap" class="ft3726"></p>
<p style="position:absolute;top:847px;left:147px;white-space:nowrap" class="ft3722">neuropathy;</p>
<p style="position:absolute;top:865px;left:106px;white-space:nowrap" class="ft3726"></p>
<p style="position:absolute;top:867px;left:147px;white-space:nowrap" class="ft3722">stroke;</p>
<p style="position:absolute;top:886px;left:106px;white-space:nowrap" class="ft3726"></p>
<p style="position:absolute;top:887px;left:147px;white-space:nowrap" class="ft3722">hearing loss, buzzing;</p>
<p style="position:absolute;top:906px;left:106px;white-space:nowrap" class="ft3726"></p>
<p style="position:absolute;top:908px;left:147px;white-space:nowrap" class="ft3722">sensation of heart beating irregularly such as skipped beats;</p>
<p style="position:absolute;top:926px;left:106px;white-space:nowrap" class="ft3726"></p>
<p style="position:absolute;top:928px;left:147px;white-space:nowrap" class="ft3722">heart problems that can cause shortness of breath or ankle swelling;</p>
<p style="position:absolute;top:946px;left:106px;white-space:nowrap" class="ft3726"></p>
<p style="position:absolute;top:948px;left:147px;white-space:nowrap" class="ft3722">heart attack;</p>
<p style="position:absolute;top:966px;left:106px;white-space:nowrap" class="ft3726"></p>
<p style="position:absolute;top:968px;left:147px;white-space:nowrap" class="ft3722">a sac in the wall of a major artery, inflammation and clot of a vein; blockage of a blood vessel;</p>
<p style="position:absolute;top:986px;left:106px;white-space:nowrap" class="ft3726"></p>
<p style="position:absolute;top:988px;left:147px;white-space:nowrap" class="ft3722">lung diseases causing shortness of breath (including inflammation);</p>
<p style="position:absolute;top:1006px;left:106px;white-space:nowrap" class="ft3726"></p>
<p style="position:absolute;top:1008px;left:147px;white-space:nowrap" class="ft3722">pulmonary embolism (blockage in an artery of the lung);</p>
<p style="position:absolute;top:1027px;left:106px;white-space:nowrap" class="ft3726"></p>
<p style="position:absolute;top:1029px;left:147px;white-space:nowrap" class="ft3722">pleural effusion (abnormal collection of fluid in the pleural space);</p>
<p style="position:absolute;top:1047px;left:106px;white-space:nowrap" class="ft3726"></p>
<p style="position:absolute;top:1049px;left:147px;white-space:nowrap" class="ft3722">inflammation of the pancreas which causes severe pain in the abdomen and back;</p>
<p style="position:absolute;top:1067px;left:106px;white-space:nowrap" class="ft3726"></p>
<p style="position:absolute;top:1069px;left:147px;white-space:nowrap" class="ft3722">difficulty in swallowing;</p>
</div>
<!-- Page 373 -->
<a name="373"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page373-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3730">373</p>
<p style="position:absolute;top:85px;left:106px;white-space:nowrap" class="ft3736"></p>
<p style="position:absolute;top:87px;left:147px;white-space:nowrap" class="ft3732">facial oedema;</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft3736"></p>
<p style="position:absolute;top:107px;left:147px;white-space:nowrap" class="ft3732">gallbladder inflammation, gallbladder stones;</p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft3736"></p>
<p style="position:absolute;top:127px;left:147px;white-space:nowrap" class="ft3732">fatty liver;</p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft3736"></p>
<p style="position:absolute;top:148px;left:147px;white-space:nowrap" class="ft3732">night sweats;</p>
<p style="position:absolute;top:166px;left:106px;white-space:nowrap" class="ft3736"></p>
<p style="position:absolute;top:168px;left:147px;white-space:nowrap" class="ft3732">scar;</p>
<p style="position:absolute;top:186px;left:106px;white-space:nowrap" class="ft3736"></p>
<p style="position:absolute;top:188px;left:147px;white-space:nowrap" class="ft3732">abnormal&#160;muscle breakdown;</p>
<p style="position:absolute;top:206px;left:106px;white-space:nowrap" class="ft3736"></p>
<p style="position:absolute;top:208px;left:147px;white-space:nowrap" class="ft3734">systemic lupus erythematosus (including inflammation of skin, heart, lung, joints and other organ&#160;<br/>systems);</p>
<p style="position:absolute;top:245px;left:106px;white-space:nowrap" class="ft3736"></p>
<p style="position:absolute;top:247px;left:147px;white-space:nowrap" class="ft3732">sleep interruptions;</p>
<p style="position:absolute;top:266px;left:106px;white-space:nowrap" class="ft3736"></p>
<p style="position:absolute;top:267px;left:147px;white-space:nowrap" class="ft3732">impotence;</p>
<p style="position:absolute;top:286px;left:106px;white-space:nowrap" class="ft3736"></p>
<p style="position:absolute;top:288px;left:147px;white-space:nowrap" class="ft3732">inflammations.</p>
<p style="position:absolute;top:325px;left:106px;white-space:nowrap" class="ft3732">Rare (may affect up to 1 in 1,000 people)</p>
<p style="position:absolute;top:363px;left:106px;white-space:nowrap" class="ft3736"></p>
<p style="position:absolute;top:365px;left:147px;white-space:nowrap" class="ft3732">leukaemia (cancer affecting the blood and bone marrow);</p>
<p style="position:absolute;top:383px;left:106px;white-space:nowrap" class="ft3736"></p>
<p style="position:absolute;top:385px;left:147px;white-space:nowrap" class="ft3732">Severe allergic reaction with shock;</p>
<p style="position:absolute;top:403px;left:106px;white-space:nowrap" class="ft3736"></p>
<p style="position:absolute;top:405px;left:147px;white-space:nowrap" class="ft3732">multiple sclerosis;</p>
<p style="position:absolute;top:423px;left:106px;white-space:nowrap" class="ft3736"></p>
<p style="position:absolute;top:425px;left:147px;white-space:nowrap" class="ft3734">nerve disorders (such as eye nerve inflammation and&#160;Guillain-Barré syndrome that may cause&#160;<br/>muscle weakness, abnormal sensations, tingling in the arms and upper body);</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft3736"></p>
<p style="position:absolute;top:464px;left:147px;white-space:nowrap" class="ft3732">heart stops pumping;&#160;</p>
<p style="position:absolute;top:483px;left:106px;white-space:nowrap" class="ft3736"></p>
<p style="position:absolute;top:485px;left:147px;white-space:nowrap" class="ft3732">pulmonary fibrosis (scarring of the lung);</p>
<p style="position:absolute;top:502px;left:106px;white-space:nowrap" class="ft3736"></p>
<p style="position:absolute;top:504px;left:147px;white-space:nowrap" class="ft3732">intestinal perforation;</p>
<p style="position:absolute;top:523px;left:106px;white-space:nowrap" class="ft3736"></p>
<p style="position:absolute;top:525px;left:147px;white-space:nowrap" class="ft3732">hepatitis;</p>
<p style="position:absolute;top:543px;left:106px;white-space:nowrap" class="ft3736"></p>
<p style="position:absolute;top:545px;left:147px;white-space:nowrap" class="ft3732">reactivation of hepatitis B;</p>
<p style="position:absolute;top:563px;left:106px;white-space:nowrap" class="ft3736"></p>
<p style="position:absolute;top:565px;left:147px;white-space:nowrap" class="ft3732">autoimmune hepatitis (inflammation of the liver caused by the body's own immune system);</p>
<p style="position:absolute;top:583px;left:106px;white-space:nowrap" class="ft3736"></p>
<p style="position:absolute;top:585px;left:147px;white-space:nowrap" class="ft3732">cutaneous vasculitis (inflammation of blood vessels in the skin);</p>
<p style="position:absolute;top:603px;left:106px;white-space:nowrap" class="ft3736"></p>
<p style="position:absolute;top:605px;left:147px;white-space:nowrap" class="ft3732">Stevens-Johnson syndrome (early symptoms include malaise, fever, headache and rash);</p>
<p style="position:absolute;top:623px;left:106px;white-space:nowrap" class="ft3736"></p>
<p style="position:absolute;top:625px;left:147px;white-space:nowrap" class="ft3732">facial oedema associated with allergic reactions;</p>
<p style="position:absolute;top:644px;left:106px;white-space:nowrap" class="ft3736"></p>
<p style="position:absolute;top:645px;left:147px;white-space:nowrap" class="ft3732">erythema multiforme (inflammatory skin rash);</p>
<p style="position:absolute;top:664px;left:106px;white-space:nowrap" class="ft3736"></p>
<p style="position:absolute;top:666px;left:147px;white-space:nowrap" class="ft3732">lupus-like syndrome;</p>
<p style="position:absolute;top:684px;left:106px;white-space:nowrap" class="ft3736"></p>
<p style="position:absolute;top:686px;left:147px;white-space:nowrap" class="ft3732">angioedema (localized swelling of the skin);</p>
<p style="position:absolute;top:704px;left:106px;white-space:nowrap" class="ft3736"></p>
<p style="position:absolute;top:706px;left:147px;white-space:nowrap" class="ft3732">lichenoid skin reaction (itchy reddish-purple skin&#160;rash).</p>
<p style="position:absolute;top:744px;left:106px;white-space:nowrap" class="ft3732">Not known (frequency cannot be estimated from available data)</p>
<p style="position:absolute;top:781px;left:106px;white-space:nowrap" class="ft3736">&#160;hepatosplenic T-cell lymphoma (a rare blood cancer that is often fatal);</p>
<p style="position:absolute;top:802px;left:106px;white-space:nowrap" class="ft3736">&#160;Merkel cell carcinoma (a type of skin cancer);</p>
<p style="position:absolute;top:822px;left:106px;white-space:nowrap" class="ft3736">&#160;Kaposi’s sarcoma, a rare cancer related to infection with human herpes virus 8. Kaposi’s sarcoma&#160;</p>
<p style="position:absolute;top:842px;left:133px;white-space:nowrap" class="ft3732">most commonly appears as purple lesions&#160;on the skin;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft3736">&#160;liver failure;</p>
<p style="position:absolute;top:881px;left:106px;white-space:nowrap" class="ft3736">&#160;worsening of a condition called dermatomyositis (seen as a skin rash accompanying muscle&#160;</p>
<p style="position:absolute;top:902px;left:133px;white-space:nowrap" class="ft3732">weakness);</p>
<p style="position:absolute;top:920px;left:106px;white-space:nowrap" class="ft3736">&#160;weight gain (for most patients, the weight gain was small).</p>
<p style="position:absolute;top:960px;left:106px;white-space:nowrap" class="ft3734">Some side effects observed with Humira may not have symptoms and&#160;may&#160;only be discovered through&#160;<br/>blood tests. These include:</p>
<p style="position:absolute;top:1017px;left:106px;white-space:nowrap" class="ft3732">Very common (may affect more than 1 in 10 people)&#160;</p>
<p style="position:absolute;top:1054px;left:106px;white-space:nowrap" class="ft3736"></p>
<p style="position:absolute;top:1056px;left:147px;white-space:nowrap" class="ft3732">low blood measurements for white blood cells;</p>
<p style="position:absolute;top:1074px;left:106px;white-space:nowrap" class="ft3736"></p>
<p style="position:absolute;top:1076px;left:147px;white-space:nowrap" class="ft3732">low blood measurements for red blood cells;</p>
</div>
<!-- Page 374 -->
<a name="374"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page374-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3740">374</p>
<p style="position:absolute;top:85px;left:106px;white-space:nowrap" class="ft3746"></p>
<p style="position:absolute;top:87px;left:147px;white-space:nowrap" class="ft3742">increased lipids in the blood;</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft3746"></p>
<p style="position:absolute;top:107px;left:147px;white-space:nowrap" class="ft3742">elevated liver enzymes.</p>
<p style="position:absolute;top:145px;left:106px;white-space:nowrap" class="ft3742">Common (may affect up to 1 in 10 people)</p>
<p style="position:absolute;top:182px;left:106px;white-space:nowrap" class="ft3746"></p>
<p style="position:absolute;top:184px;left:147px;white-space:nowrap" class="ft3742">high blood measurements for white blood cells; &#160;</p>
<p style="position:absolute;top:203px;left:106px;white-space:nowrap" class="ft3746"></p>
<p style="position:absolute;top:204px;left:147px;white-space:nowrap" class="ft3742">low blood measurements for platelets;</p>
<p style="position:absolute;top:223px;left:106px;white-space:nowrap" class="ft3746"></p>
<p style="position:absolute;top:225px;left:147px;white-space:nowrap" class="ft3742">increased uric acid in the blood;</p>
<p style="position:absolute;top:243px;left:106px;white-space:nowrap" class="ft3746"></p>
<p style="position:absolute;top:245px;left:147px;white-space:nowrap" class="ft3742">abnormal blood measurements for sodium;</p>
<p style="position:absolute;top:263px;left:106px;white-space:nowrap" class="ft3746"></p>
<p style="position:absolute;top:265px;left:147px;white-space:nowrap" class="ft3742">low blood measurements for calcium;</p>
<p style="position:absolute;top:283px;left:106px;white-space:nowrap" class="ft3746"></p>
<p style="position:absolute;top:285px;left:147px;white-space:nowrap" class="ft3742">low blood measurements for phosphate;</p>
<p style="position:absolute;top:303px;left:106px;white-space:nowrap" class="ft3746"></p>
<p style="position:absolute;top:305px;left:147px;white-space:nowrap" class="ft3742">high blood sugar;</p>
<p style="position:absolute;top:324px;left:106px;white-space:nowrap" class="ft3746"></p>
<p style="position:absolute;top:325px;left:147px;white-space:nowrap" class="ft3742">high blood measurements for lactate dehydrogenase;</p>
<p style="position:absolute;top:344px;left:106px;white-space:nowrap" class="ft3746"></p>
<p style="position:absolute;top:346px;left:147px;white-space:nowrap" class="ft3742">autoantibodies present in the blood;</p>
<p style="position:absolute;top:364px;left:106px;white-space:nowrap" class="ft3746"></p>
<p style="position:absolute;top:366px;left:147px;white-space:nowrap" class="ft3742">low blood potassium.</p>
<p style="position:absolute;top:404px;left:106px;white-space:nowrap" class="ft3742">Uncommon&#160;(may&#160;affect up to 1 in 100 people)&#160;</p>
<p style="position:absolute;top:441px;left:106px;white-space:nowrap" class="ft3746"></p>
<p style="position:absolute;top:443px;left:147px;white-space:nowrap" class="ft3742">elevated bilirubin measurement (liver blood test).</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft3742">Rare&#160;(may affect up to 1 in 1,000 people)</p>
<p style="position:absolute;top:518px;left:106px;white-space:nowrap" class="ft3746"></p>
<p style="position:absolute;top:520px;left:147px;white-space:nowrap" class="ft3742">low blood measurements for white blood cells, red blood cells and platelet count.</p>
<p style="position:absolute;top:558px;left:106px;white-space:nowrap" class="ft3744"><b>Reporting of side effects<br/></b>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not&#160;<br/>listed in this leaflet. You can also report side effects directly via&#160;the national reporting system listed in&#160;<br/><a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix V.&#160;</a>By reporting side effects, you can help provide more information&#160;on the safety of this&#160;<br/>medicine.</p>
<p style="position:absolute;top:691px;left:106px;white-space:nowrap" class="ft3741"><b>5.</b></p>
<p style="position:absolute;top:691px;left:148px;white-space:nowrap" class="ft3741"><b>How to store Humira</b></p>
<p style="position:absolute;top:729px;left:106px;white-space:nowrap" class="ft3742">Keep this medicine out of the sight and reach of children.&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft3742">Do not use this medicine after the expiry date stated on the label/blister/carton after EXP.&#160;</p>
<p style="position:absolute;top:806px;left:106px;white-space:nowrap" class="ft3742">Store in a refrigerator (2</p>
<p style="position:absolute;top:804px;left:266px;white-space:nowrap" class="ft3746">C&#160;–&#160;8C). Do not freeze.&#160;</p>
<p style="position:absolute;top:844px;left:106px;white-space:nowrap" class="ft3742">Keep the pre-filled syringe in the outer carton in order to protect from light. &#160;</p>
<p style="position:absolute;top:882px;left:106px;white-space:nowrap" class="ft3742">Alternative Storage:</p>
<p style="position:absolute;top:920px;left:106px;white-space:nowrap" class="ft37419">When needed (for example when you are travelling), a single Humira pre-filled syringe may be stored at&#160;<br/>room temperature (up to 25°C) for a maximum period of 14 days&#160;–&#160;be sure to protect it from light. Once&#160;<br/>removed from the refrigerator for room temperature&#160;storage, the syringe&#160;<b>must be used within 14 days&#160;or&#160;<br/>discarded</b>, even if it is returned to the refrigerator. &#160;</p>
<p style="position:absolute;top:1014px;left:106px;white-space:nowrap" class="ft3744">You should record the date when the syringe is first removed from refrigerator and the date after which it&#160;<br/>should be discarded. &#160;</p>
</div>
<!-- Page 375 -->
<a name="375"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page375-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3750">375</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft3755">Do not throw away any medicines via wastewater or household waste. Ask your doctor or pharmacist how&#160;<br/>to throw away medicines you no longer use. These measures will help protect the environment.</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft3751"><b>6.</b></p>
<p style="position:absolute;top:162px;left:148px;white-space:nowrap" class="ft3751"><b>Contents of the pack and other information</b></p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft3751"><b>What Humira contains</b></p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft3754">The&#160;active substance is adalimumab.<br/>The&#160;other ingredients are mannitol, citric acid monohydrate, sodium citrate, sodium dihydrogen phosphate&#160;<br/>dihydrate, disodium phosphate dihydrate, sodium chloride, polysorbate 80, sodium hydroxide and water&#160;<br/>for injections.</p>
<p style="position:absolute;top:333px;left:106px;white-space:nowrap" class="ft3751"><b>What the Humira pre-filled syringe looks like and contents of the pack</b></p>
<p style="position:absolute;top:370px;left:106px;white-space:nowrap" class="ft3754">Humira 40&#160;mg solution for injection in pre-filled syringe is supplied as a sterile solution of 40&#160;mg&#160;<br/>adalimumab dissolved in 0.8&#160;ml solution.</p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft3754">The Humira pre-filled syringe is a glass&#160;syringe containing a solution of adalimumab. Each pack contains&#160;<br/>1, 2, 4 or 6 pre-filled syringes for patient use with 1, 2, 4 or 6 alcohol pads, respectively. &#160;</p>
<p style="position:absolute;top:485px;left:106px;white-space:nowrap" class="ft3752">Not all pack sizes may be marketed.</p>
<p style="position:absolute;top:522px;left:106px;white-space:nowrap" class="ft3752">Humira&#160;may be&#160;available as a vial, a pre-filled syringe and/or&#160;a pre-filled pen.</p>
<p style="position:absolute;top:560px;left:106px;white-space:nowrap" class="ft3751"><b>Marketing Authorisation Holder</b></p>
<p style="position:absolute;top:598px;left:106px;white-space:nowrap" class="ft3754">AbbVie Deutschland GmbH &amp; Co. KG<br/>Knollstrasse<br/>67061 Ludwigshafen<br/>Germany</p>
<p style="position:absolute;top:693px;left:106px;white-space:nowrap" class="ft3751"><b>Manufacturer</b></p>
<p style="position:absolute;top:731px;left:106px;white-space:nowrap" class="ft3754">AbbVie Biotechnology GmbH<br/>Knollstrasse<br/>67061 Ludwigshafen<br/>Germany</p>
<p style="position:absolute;top:826px;left:106px;white-space:nowrap" class="ft3754">For any information about this medicine,&#160;please contact the local representative of the Marketing&#160;<br/>Authorisation Holder.</p>
<p style="position:absolute;top:885px;left:114px;white-space:nowrap" class="ft3754"><b>België/Belgique/Belgien<br/></b>AbbVie SA<br/>Tél/Tel: +32 10&#160;&#160;477811</p>
<p style="position:absolute;top:885px;left:462px;white-space:nowrap" class="ft3754"><b>Lietuva<br/></b>AbbVie UAB&#160;<br/>Tel: +370 5 205 3023</p>
<p style="position:absolute;top:962px;left:114px;white-space:nowrap" class="ft3755"><b>България<br/></b>АбВи ЕООД<br/>Тел.:+359 2 90 30 430</p>
<p style="position:absolute;top:962px;left:462px;white-space:nowrap" class="ft3754"><b>Luxembourg/Luxemburg<br/></b>AbbVie SA<br/>Belgique/Belgien<br/>Tél/Tel: +32 10 477811</p>
</div>
<!-- Page 376 -->
<a name="376"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page376-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3760">376</p>
<p style="position:absolute;top:86px;left:114px;white-space:nowrap" class="ft3764"><b>Česká republika<br/></b>AbbVie s.r.o.&#160;<br/>Tel: +420 233 098 111</p>
<p style="position:absolute;top:86px;left:462px;white-space:nowrap" class="ft3764"><b>Magyarország<br/></b>AbbVie Kft.<br/>Tel.:+36 1 455 8600</p>
<p style="position:absolute;top:162px;left:114px;white-space:nowrap" class="ft3764"><b>Danmark<br/></b>AbbVie A/S<br/>Tlf: +45 72 30-20-28</p>
<p style="position:absolute;top:162px;left:462px;white-space:nowrap" class="ft3764"><b>Malta<br/></b>V.J.Salomone Pharma Limited&#160;<br/>Tel: +356 22983201</p>
<p style="position:absolute;top:238px;left:114px;white-space:nowrap" class="ft3764"><b>Deutschland<br/></b>AbbVie Deutschland&#160;GmbH &amp; Co. KG<br/>Tel: 00800 222843 33 (gebührenfrei)<br/>Tel: +49 (0) 611&#160;/&#160;1720-0</p>
<p style="position:absolute;top:238px;left:462px;white-space:nowrap" class="ft3764"><b>Nederland<br/></b>AbbVie B.V.<br/>Tel: &#160;+31 (0)88 322 2843</p>
<p style="position:absolute;top:333px;left:114px;white-space:nowrap" class="ft3765"><b>Eesti<br/></b>AbbVie&#160;OÜ<br/>Tel: +372 623 1011</p>
<p style="position:absolute;top:333px;left:462px;white-space:nowrap" class="ft3765"><b>Norge<br/></b>AbbVie AS<br/>Tlf: +47 67 81 80 00</p>
<p style="position:absolute;top:409px;left:114px;white-space:nowrap" class="ft3764"><b>Ελλάδα<br/></b>AbbVie&#160;ΦΑΡΜΑΚΕΥΤΙΚΗ Α.Ε.<br/>Τηλ: +30&#160;214 4165 555</p>
<p style="position:absolute;top:409px;left:462px;white-space:nowrap" class="ft3764"><b>Österreich<br/></b>AbbVie GmbH&#160;<br/>Tel: +43 1 20589-0</p>
<p style="position:absolute;top:485px;left:114px;white-space:nowrap" class="ft3764"><b>España<br/></b>AbbVie Spain, S.L.U.<br/>Tel: &#160;+34 91 384 09 10</p>
<p style="position:absolute;top:485px;left:462px;white-space:nowrap" class="ft3764"><b>Polska<br/></b>AbbVie Sp. z o.o.<br/>Tel.: +48 22&#160;372 78 00&#160;</p>
<p style="position:absolute;top:560px;left:114px;white-space:nowrap" class="ft3764"><b>France<br/></b>AbbVie<br/>Tél: +33 (0) 1 45 60 13 00</p>
<p style="position:absolute;top:560px;left:462px;white-space:nowrap" class="ft3764"><b>Portugal<br/></b>AbbVie, Lda.&#160;<br/>Tel: +351 (0)21&#160;1908400</p>
<p style="position:absolute;top:636px;left:114px;white-space:nowrap" class="ft3764"><b>Hrvatska&#160;<br/></b>AbbVie d.o.o.<br/>Tel + 385 (0)1&#160;5625 501</p>
<p style="position:absolute;top:636px;left:462px;white-space:nowrap" class="ft3764"><b>România<br/></b>AbbVie S.R.L.<br/>Tel: +40 21 529 30 35</p>
<p style="position:absolute;top:712px;left:114px;white-space:nowrap" class="ft3765"><b>Ireland<br/></b>AbbVie Limited&#160;<br/>Tel: +353 (0)1 4287900</p>
<p style="position:absolute;top:712px;left:462px;white-space:nowrap" class="ft3765"><b>Slovenija<br/></b>AbbVie Biofarmacevtska družba d.o.o.<br/>Tel: +386 (1)32 08 060</p>
<p style="position:absolute;top:788px;left:114px;white-space:nowrap" class="ft3765"><b>Ísland<br/></b>Vistor hf.<br/>Tel: +354 535&#160;7000</p>
<p style="position:absolute;top:788px;left:462px;white-space:nowrap" class="ft3765"><b>Slovenská republika<br/></b>AbbVie s.r.o.<br/>Tel: +421 2 5050 0777</p>
<p style="position:absolute;top:864px;left:114px;white-space:nowrap" class="ft3764"><b>Italia<br/></b>AbbVie S.r.l.&#160;<br/>Tel: +39 06 928921</p>
<p style="position:absolute;top:864px;left:462px;white-space:nowrap" class="ft3764"><b>Suomi/Finland<br/></b>AbbVie Oy&#160;<br/>Puh/Tel: &#160;+358 (0)10 2411 200</p>
<p style="position:absolute;top:941px;left:114px;white-space:nowrap" class="ft3765"><b>Κύπρος<br/></b>Lifepharma (Z.A.M.) Ltd<br/>Τηλ.: +357 22 34 74 40</p>
<p style="position:absolute;top:941px;left:462px;white-space:nowrap" class="ft3765"><b>Sverige<br/></b>AbbVie AB<br/>Tel: &#160;+46 (0)8 684 44&#160;600</p>
<p style="position:absolute;top:1017px;left:114px;white-space:nowrap" class="ft3764"><b>Latvija<br/></b>AbbVie SIA&#160;<br/>Tel: +371 67605000</p>
<p style="position:absolute;top:1017px;left:462px;white-space:nowrap" class="ft3764"><b>United Kingdom&#160;(Northern Ireland)<br/></b>AbbVie Deutschland GmbH &amp; Co. KG<br/>Tel: +44 (0)1628 561090</p>
</div>
<!-- Page 377 -->
<a name="377"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page377-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3770">377</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft3771"><b>This leaflet was last revised in</b></p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft3774">Detailed information on this medicine is available on the European Medicines Agency web site:&#160;<br/><a href="http://www.ema.europa.eu/">http://www.ema.europa.eu.</a></p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft37719"><b>To listen to or request a copy of this leaflet in&#160;&lt;Braille&gt;, &lt;large print&gt; or &lt;audio&gt;, please&#160;contact the&#160;<br/>local representative of the Marketing Authorisation Holder.</b></p>
</div>
<!-- Page 378 -->
<a name="378"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page378-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3780">378</p>
<p style="position:absolute;top:86px;left:306px;white-space:nowrap" class="ft3781"><b>Package leaflet: Information for the patient</b></p>
<p style="position:absolute;top:124px;left:274px;white-space:nowrap" class="ft3781"><b>Humira&#160;40&#160;mg&#160;solution for injection in pre-filled pen</b></p>
<p style="position:absolute;top:143px;left:418px;white-space:nowrap" class="ft3782">adalimumab</p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft37819"><b>Read all of this leaflet carefully before you start using this&#160;medicine because it contains important&#160;<br/>information for you.</b></p>
<p style="position:absolute;top:218px;left:106px;white-space:nowrap" class="ft3786"></p>
<p style="position:absolute;top:220px;left:148px;white-space:nowrap" class="ft3782">Keep this leaflet. You may need to read it again.</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft3786"></p>
<p style="position:absolute;top:240px;left:148px;white-space:nowrap" class="ft3785">Your doctor will also give you a&#160;<b>Patient Reminder Card</b>, which contains important safety&#160;<br/>information that you need to be aware of before you are given Humira and during treatment with&#160;<br/>Humira. Keep this&#160;<b>Patient Reminder Card&#160;</b>with you.</p>
<p style="position:absolute;top:296px;left:106px;white-space:nowrap" class="ft3786"></p>
<p style="position:absolute;top:298px;left:148px;white-space:nowrap" class="ft3782">If you have any further questions, ask your doctor or pharmacist.</p>
<p style="position:absolute;top:316px;left:106px;white-space:nowrap" class="ft3786"></p>
<p style="position:absolute;top:318px;left:148px;white-space:nowrap" class="ft3784">This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even&#160;<br/>if&#160;their signs of illness are the same as yours.</p>
<p style="position:absolute;top:356px;left:106px;white-space:nowrap" class="ft3786"></p>
<p style="position:absolute;top:357px;left:148px;white-space:nowrap" class="ft3784">If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects&#160;<br/>not listed in this leaflet (see section 4).</p>
<p style="position:absolute;top:414px;left:106px;white-space:nowrap" class="ft37819"><b>What is in this leaflet<br/></b>1.</p>
<p style="position:absolute;top:433px;left:148px;white-space:nowrap" class="ft3782">What Humira is and what it is used for</p>
<p style="position:absolute;top:453px;left:106px;white-space:nowrap" class="ft3782">2.</p>
<p style="position:absolute;top:453px;left:148px;white-space:nowrap" class="ft3782">What you need to know before you use Humira</p>
<p style="position:absolute;top:471px;left:106px;white-space:nowrap" class="ft3782">3.</p>
<p style="position:absolute;top:471px;left:148px;white-space:nowrap" class="ft3782">How to use Humira</p>
<p style="position:absolute;top:490px;left:106px;white-space:nowrap" class="ft3782">4.</p>
<p style="position:absolute;top:490px;left:148px;white-space:nowrap" class="ft3782">Possible side effects</p>
<p style="position:absolute;top:509px;left:106px;white-space:nowrap" class="ft3782">5</p>
<p style="position:absolute;top:509px;left:148px;white-space:nowrap" class="ft3782">How to store Humira</p>
<p style="position:absolute;top:528px;left:106px;white-space:nowrap" class="ft3782">6.</p>
<p style="position:absolute;top:528px;left:148px;white-space:nowrap" class="ft3782">Contents of the pack and other information</p>
<p style="position:absolute;top:585px;left:106px;white-space:nowrap" class="ft3781"><b>1.</b></p>
<p style="position:absolute;top:585px;left:148px;white-space:nowrap" class="ft3781"><b>What Humira is and what it is used for</b></p>
<p style="position:absolute;top:623px;left:106px;white-space:nowrap" class="ft3782">Humira&#160;contains the active substance adalimumab.&#160;</p>
<p style="position:absolute;top:661px;left:106px;white-space:nowrap" class="ft3782">Humira&#160;is intended for&#160;the&#160;treatment of&#160;the inflammatory diseases described below:</p>
<p style="position:absolute;top:679px;left:106px;white-space:nowrap" class="ft3786">&#160;Rheumatoid arthritis,&#160;</p>
<p style="position:absolute;top:699px;left:106px;white-space:nowrap" class="ft3786">&#160;Polyarticular juvenile idiopathic arthritis,&#160;</p>
<p style="position:absolute;top:720px;left:106px;white-space:nowrap" class="ft3786">&#160;Enthesitis-related arthritis,&#160;</p>
<p style="position:absolute;top:740px;left:106px;white-space:nowrap" class="ft3786">&#160;Ankylosing spondylitis,&#160;</p>
<p style="position:absolute;top:760px;left:106px;white-space:nowrap" class="ft3786">&#160;Axial spondyloarthritis without radiographic evidence of ankylosing spondylitis,&#160;</p>
<p style="position:absolute;top:780px;left:106px;white-space:nowrap" class="ft3786">&#160;Psoriatic arthritis,&#160;</p>
<p style="position:absolute;top:800px;left:106px;white-space:nowrap" class="ft3786">&#160;Psoriasis,</p>
<p style="position:absolute;top:820px;left:106px;white-space:nowrap" class="ft3786">&#160;Hidradenitis suppurativa,&#160;</p>
<p style="position:absolute;top:841px;left:106px;white-space:nowrap" class="ft3786">&#160;Crohn’s disease,</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft3786">&#160;Ulcerative colitis&#160;and&#160;</p>
<p style="position:absolute;top:881px;left:106px;white-space:nowrap" class="ft3786">&#160;Non-infectious uveitis</p>
<p style="position:absolute;top:921px;left:106px;white-space:nowrap" class="ft3785">The active ingredient&#160;in Humira, adalimumab, is a&#160;human&#160;monoclonal antibody. Monoclonal antibodies&#160;<br/>are&#160;proteins that&#160;attach to a specific target.</p>
<p style="position:absolute;top:978px;left:106px;white-space:nowrap" class="ft3785">The target of&#160;adalimumab&#160;is a&#160;protein&#160;called&#160;tumour necrosis factor&#160;(TNFα), which&#160;is involved in the&#160;<br/>immune (defence) system and&#160;is present at increased levels in&#160;the&#160;inflammatory diseases&#160;listed above.&#160;By&#160;<br/>attaching to&#160;TNFα, Humira decreases the process of inflammation in these diseases.</p>
</div>
<!-- Page 379 -->
<a name="379"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page379-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3790">379</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft3792">Rheumatoid arthritis</p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft3792">Rheumatoid arthritis is an inflammatory disease of the joints.</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft3794">Humira is used to treat rheumatoid arthritis in adults. If you have moderate to severe active rheumatoid&#160;<br/>arthritis, you may first be given other disease-modifying medicines, such as methotrexate. If you do not&#160;<br/>respond well enough to these medicines, you will be given Humira to treat your rheumatoid arthritis. &#160;</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft3794">Humira can also be used to treat severe, active and progressive rheumatoid arthritis without previous&#160;<br/>methotrexate treatment.</p>
<p style="position:absolute;top:295px;left:106px;white-space:nowrap" class="ft3794">Humira has been shown to slow down the damage to the cartilage and bone&#160;of the joints caused by the&#160;<br/>disease and to improve physical function.&#160;<br/>Usually, Humira is used with methotrexate. If your doctor determines that methotrexate is inappropriate,&#160;<br/>Humira can be given alone.&#160;</p>
<p style="position:absolute;top:390px;left:106px;white-space:nowrap" class="ft3792">Polyarticular juvenile idiopathic arthritis and enthesitis-related arthritis</p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft3792">Polyarticular juvenile idiopathic arthritis and enthesitis-related arthritis are inflammatory diseases.</p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft3794">Humira is used to treat polyarticular juvenile idiopathic arthritis in children and adolescents aged 2 to 17&#160;<br/>years and enthesitis-related arthritis in children and adolescents aged 6 to 17 years. You may first be given&#160;<br/>other disease-modifying medicines, such as methotrexate. If you do not respond well enough to these&#160;<br/>medicines, you will be given Humira to treat your polyarticular juvenile idiopathic arthritis or enthesitis-<br/>related arthritis.</p>
<p style="position:absolute;top:579px;left:106px;white-space:nowrap" class="ft3794">Ankylosing spondylitis&#160;and axial spondyloarthritis without radiographic evidence of ankylosing&#160;<br/>spondylitis</p>
<p style="position:absolute;top:636px;left:106px;white-space:nowrap" class="ft3794">Ankylosing spondylitis and axial spondyloarthritis without radiographic evidence&#160;of ankylosing&#160;<br/>spondylitis, are inflammatory diseases of the spine.</p>
<p style="position:absolute;top:693px;left:106px;white-space:nowrap" class="ft3794">Humira is used to treat ankylosing spondylitis and axial spondyloarthritis without radiographic evidence of&#160;<br/>ankylosing spondylitis in adults. If you have ankylosing spondylitis or axial spondyloarthritis without&#160;<br/>radiographic evidence of ankylosing spondylitis, you will first be given other medicines. If you do not&#160;<br/>respond well enough to these medicines, you will be given Humira to reduce the signs and symptoms of&#160;<br/>your disease.</p>
<p style="position:absolute;top:807px;left:106px;white-space:nowrap" class="ft3792">Psoriatic arthritis</p>
<p style="position:absolute;top:845px;left:106px;white-space:nowrap" class="ft3792">Psoriatic arthritis is an inflammation of the joints associated with psoriasis.</p>
<p style="position:absolute;top:883px;left:106px;white-space:nowrap" class="ft3794">Humira is used to treat psoriatic arthritis in adults. Humira has been shown to slow down the damage to&#160;<br/>the cartilage and bone of the joints caused by the disease&#160;and to improve physical function.</p>
<p style="position:absolute;top:940px;left:106px;white-space:nowrap" class="ft3792">Plaque psoriasis in adults and children&#160;</p>
<p style="position:absolute;top:978px;left:106px;white-space:nowrap" class="ft3794">Plaque psoriasis is a skin condition that causes red, flaky, crusty patches of skin covered with silvery&#160;<br/>scales. Plaque psoriasis can also affect the nails, causing them to crumble, become thickened and lift away&#160;<br/>from the nail bed which can be painful. Psoriasis is believed to be caused by a problem with the body’s&#160;<br/>immune system that leads to an increased production of skin cells.</p>
</div>
<!-- Page 380 -->
<a name="380"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page380-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3800">380</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft3804">Humira is used to treat moderate to severe plaque&#160;psoriasis in adults.&#160;Humira is also used to treat severe&#160;<br/>plaque psoriasis in children and adolescents aged 4 to 17 years for whom topical therapy and&#160;<br/>phototherapies have either not worked very well or are not suitable.</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft3802">Hidradenitis suppurativa&#160;in adults and adolescents</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft3804">Hidradenitis suppurativa (sometimes called acne inversa) is a chronic and often painful inflammatory skin&#160;<br/>disease.&#160;Symptoms may include tender nodules (lumps) and abscesses (boils) that may leak pus. It most&#160;<br/>commonly affects specific areas&#160;<a href="http://en.wikipedia.org/wiki/Inframammary_fold">of the skin, such as&#160;under the breasts, the armpits, inner thighs, groin and&#160;<br/></a>buttocks.&#160;Scarring may also occur in affected areas.</p>
<p style="position:absolute;top:295px;left:106px;white-space:nowrap" class="ft3804">Humira is used to treat hidradenitis suppurativa in adults&#160;and&#160;adolescents from 12 years of age.&#160;Humira&#160;<br/>can reduce the number of nodules and abscesses you have and the pain that is often associated with the&#160;<br/>disease. You may first be given other medicines. If you do not respond well enough to these medicines,&#160;<br/>you will be given Humira.</p>
<p style="position:absolute;top:390px;left:106px;white-space:nowrap" class="ft3802">Crohn’s disease in adults and children</p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft3802">Crohn’s disease is an inflammatory disease of the digestive tract.</p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft3805">Humira is used to treat Crohn’s disease in adults and children aged 6 to 17 years.&#160;If you have Crohn’s&#160;<br/>disease you will first be&#160;given other medicines. If you do not respond well enough to these medicines, you&#160;<br/>will be given Humira to reduce the signs and symptoms of your Crohn’s disease.</p>
<p style="position:absolute;top:541px;left:106px;white-space:nowrap" class="ft3802">Ulcerative colitis&#160;in adults and children</p>
<p style="position:absolute;top:579px;left:106px;white-space:nowrap" class="ft3802">Ulcerative colitis is an inflammatory disease of the&#160;large intestine.</p>
<p style="position:absolute;top:617px;left:106px;white-space:nowrap" class="ft3804">Humira is used to treat&#160;moderate to severe&#160;ulcerative colitis in adults&#160;and children aged 6 to 17 years. If&#160;<br/>you have ulcerative colitis you&#160;may&#160;first be given other medicines. If you do not respond well enough to&#160;<br/>these medicines, you will be given Humira to reduce the signs and symptoms of your disease.</p>
<p style="position:absolute;top:693px;left:106px;white-space:nowrap" class="ft3802">Non-infectious uveitis&#160;in adults and children</p>
<p style="position:absolute;top:731px;left:106px;white-space:nowrap" class="ft3802">Non-infectious uveitis is an inflammatory disease&#160;affecting certain parts of the eye.</p>
<p style="position:absolute;top:769px;left:106px;white-space:nowrap" class="ft3802">Humira is used to treat&#160;</p>
<p style="position:absolute;top:787px;left:133px;white-space:nowrap" class="ft3806">&#160;Adults with non-infectious uveitis with inflammation affecting the back of the eye&#160;</p>
<p style="position:absolute;top:807px;left:133px;white-space:nowrap" class="ft3806">&#160;Children from 2&#160;years of age with chronic non-infectious uveitis with inflammation affecting the&#160;</p>
<p style="position:absolute;top:828px;left:160px;white-space:nowrap" class="ft3802">front of&#160;the eye</p>
<p style="position:absolute;top:866px;left:106px;white-space:nowrap" class="ft3804">This inflammation may lead to a decrease of vision and/or the presence of floaters in the eye (black dots or&#160;<br/>wispy lines that move across the field of vision). Humira works by reducing this inflammation.</p>
<p style="position:absolute;top:942px;left:106px;white-space:nowrap" class="ft3801"><b>2.</b></p>
<p style="position:absolute;top:942px;left:148px;white-space:nowrap" class="ft3801"><b>What you need to know before you use Humira</b></p>
<p style="position:absolute;top:980px;left:106px;white-space:nowrap" class="ft3801"><b>Do not use Humira</b></p>
<p style="position:absolute;top:1017px;left:133px;white-space:nowrap" class="ft3806">&#160;If you are allergic to adalimumab or any of the other ingredients of this medicine (listed in section&#160;</p>
<p style="position:absolute;top:1038px;left:160px;white-space:nowrap" class="ft3802">6).&#160;</p>
</div>
<!-- Page 381 -->
<a name="381"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page381-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3810">381</p>
<p style="position:absolute;top:85px;left:133px;white-space:nowrap" class="ft3816">&#160;If you have a severe infection, including active tuberculosis (see “Warnings and precautions”). It&#160;</p>
<p style="position:absolute;top:106px;left:160px;white-space:nowrap" class="ft3815">is important that you tell your doctor if you have symptoms of infections, e.g. fever, wounds,&#160;<br/>feeling tired, dental problems.</p>
<p style="position:absolute;top:162px;left:133px;white-space:nowrap" class="ft3816">&#160;If you have moderate or severe heart failure. It is important to tell your doctor if you have had or&#160;</p>
<p style="position:absolute;top:183px;left:160px;white-space:nowrap" class="ft3812">have a serious heart condition (see “Warnings and&#160;precautions”).</p>
<p style="position:absolute;top:221px;left:106px;white-space:nowrap" class="ft3811"><b>Warnings and precautions</b></p>
<p style="position:absolute;top:259px;left:106px;white-space:nowrap" class="ft3812">Talk to your doctor or pharmacist before using Humira</p>
<p style="position:absolute;top:296px;left:133px;white-space:nowrap" class="ft3816">&#160;If you experience allergic reactions with symptoms such as chest tightness, wheezing, dizziness,&#160;</p>
<p style="position:absolute;top:317px;left:160px;white-space:nowrap" class="ft3814">swelling or rash do not inject more Humira and contact your&#160;doctor immediately since, in rare&#160;<br/>cases, these reactions can be life threatening.</p>
<p style="position:absolute;top:374px;left:133px;white-space:nowrap" class="ft3816">&#160;If you have an infection, including long-term&#160;or localized infection (for example, leg ulcer)&#160;</p>
<p style="position:absolute;top:394px;left:160px;white-space:nowrap" class="ft3812">consult your doctor before starting Humira. If you are unsure, contact your doctor.&#160;</p>
<p style="position:absolute;top:432px;left:133px;white-space:nowrap" class="ft3816">&#160;You might get infections more easily while you are receiving Humira treatment. This risk may&#160;</p>
<p style="position:absolute;top:453px;left:160px;white-space:nowrap" class="ft3815">increase if your lung function is impaired. These infections may be serious and include&#160;<br/>tuberculosis, infections caused by viruses, fungi, parasites or bacteria, or other opportunistic&#160;<br/>infections and sepsis that may, in rare cases, be life-threatening. It is important to tell your doctor&#160;<br/>if you get symptoms such as fever, wounds, feeling tired or dental problems. Your doctor may&#160;<br/>recommend temporary discontinuation of Humira.</p>
<p style="position:absolute;top:565px;left:133px;white-space:nowrap" class="ft3816">&#160;As cases of tuberculosis have been reported in patients treated with Humira, your doctor will&#160;</p>
<p style="position:absolute;top:586px;left:160px;white-space:nowrap" class="ft3814">check you for signs and symptoms of tuberculosis before starting Humira. This will include a&#160;<br/>thorough medical evaluation including your medical&#160;history and appropriate screening tests (for&#160;<br/>example chest X-ray and a tuberculin test). The conduct and results of these tests should be&#160;<br/>recorded on your&#160;<b>Patient Reminder Card</b>. It is very important that you tell your doctor if you&#160;<br/>have ever had tuberculosis, or if you have been in close contact with someone who has had&#160;<br/>tuberculosis. Tuberculosis can develop during therapy even if you have received preventative&#160;<br/>treatment for tuberculosis. If symptoms of tuberculosis (persistent cough, weight loss, listlessness,&#160;<br/>mild fever), or any other infection appear during or after therapy tell your doctor immediately.</p>
<p style="position:absolute;top:756px;left:133px;white-space:nowrap" class="ft3816">&#160;Advise your doctor if you reside or travel in regions where fungal infections such as&#160;</p>
<p style="position:absolute;top:777px;left:160px;white-space:nowrap" class="ft3812">histoplasmosis, coccidioidomycosis or blastomycosis are endemic.</p>
<p style="position:absolute;top:815px;left:133px;white-space:nowrap" class="ft3816">&#160;Advise your doctor if you have a history of recurrent infections or other conditions that increase&#160;</p>
<p style="position:absolute;top:836px;left:160px;white-space:nowrap" class="ft3812">the risk of infections.</p>
<p style="position:absolute;top:873px;left:133px;white-space:nowrap" class="ft3816">&#160;Advise your doctor if you are a carrier of the hepatitis B virus (HBV), if you have active HBV or&#160;</p>
<p style="position:absolute;top:894px;left:160px;white-space:nowrap" class="ft3814">if you think you might be at risk of contracting HBV. Your doctor should test you for HBV.&#160;<br/>Humira can cause reactivation of HBV in people who carry this virus. In some rare cases,&#160;<br/>especially if you are taking other medicines that suppress the immune system, reactivation of&#160;<br/>HBV can be life-threatening. &#160;</p>
<p style="position:absolute;top:988px;left:133px;white-space:nowrap" class="ft3816">&#160;If you are over 65 years you may be more susceptible to infections while taking Humira. You and&#160;</p>
<p style="position:absolute;top:1008px;left:160px;white-space:nowrap" class="ft3814">your doctor should pay special attention to signs of infection while you are being treated with&#160;<br/>Humira. It is important to tell your doctor if you get symptoms of infections, such as fever,&#160;<br/>wounds, feeling tired or dental problems.</p>
</div>
<!-- Page 382 -->
<a name="382"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page382-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3820">382</p>
<p style="position:absolute;top:85px;left:133px;white-space:nowrap" class="ft3826">&#160;If you are about to undergo surgery or dental procedures,&#160;please inform your doctor that you are&#160;</p>
<p style="position:absolute;top:106px;left:160px;white-space:nowrap" class="ft3822">taking Humira. Your doctor may recommend temporary discontinuation of Humira.&#160;</p>
<p style="position:absolute;top:143px;left:133px;white-space:nowrap" class="ft3826">&#160;If you have or develop demyelinating disease such as multiple sclerosis, your doctor will decide if&#160;</p>
<p style="position:absolute;top:164px;left:160px;white-space:nowrap" class="ft3824">you should receive or continue to receive Humira. Tell your doctor immediately if you experience&#160;<br/>symptoms like changes in your vision, weakness in&#160;your arms or legs or numbness or tingling in&#160;<br/>any part of your body.</p>
<p style="position:absolute;top:239px;left:133px;white-space:nowrap" class="ft3826">&#160;Certain vaccines may cause infections and should not be given while receiving Humira. Please&#160;</p>
<p style="position:absolute;top:260px;left:160px;white-space:nowrap" class="ft3825">check with your doctor before you receive any vaccines. It is recommended that children, if&#160;<br/>possible, be brought up to date with all immunisations in agreement with current immunisation&#160;<br/>guidelines prior to initiating Humira therapy. If you received Humira while you were pregnant,&#160;<br/>your baby may be at higher risk for getting such an infection for up&#160;to approximately five months&#160;<br/>after the last dose you received during pregnancy. It is important that you tell your baby's doctors&#160;<br/>and other health care professionals about your Humira use during your pregnancy so they can&#160;<br/>decide when your baby should receive any vaccine.</p>
<p style="position:absolute;top:411px;left:133px;white-space:nowrap" class="ft3826">&#160;If you have mild heart failure and you are being treated with Humira, your heart failure status&#160;</p>
<p style="position:absolute;top:432px;left:160px;white-space:nowrap" class="ft3824">must be closely monitored by your doctor. It is important to tell your doctor if you have had or&#160;<br/>have a serious heart condition. If you develop&#160;new&#160;or worsening symptoms of heart failure (e.g.&#160;<br/>shortness of breath, or swelling of your feet), you must contact your doctor immediately. Your&#160;<br/>doctor will decide if you should receive Humira.</p>
<p style="position:absolute;top:526px;left:133px;white-space:nowrap" class="ft3826">&#160;In some patients the body may fail to produce enough of the blood cells that help your body fight&#160;</p>
<p style="position:absolute;top:547px;left:160px;white-space:nowrap" class="ft3824">infections or help you to stop bleeding. If you develop a fever that does not go away, bruise or&#160;<br/>bleed very easily or look very pale, call your doctor right away. Your doctor may decide to stop&#160;<br/>treatment.</p>
<p style="position:absolute;top:622px;left:133px;white-space:nowrap" class="ft3826">&#160;There have been&#160;very rare cases of certain kinds of cancer in children and adult patients taking&#160;</p>
<p style="position:absolute;top:643px;left:160px;white-space:nowrap" class="ft3824">Humira or other TNF blockers. People with more serious rheumatoid arthritis that have had the&#160;<br/>disease for a long time may have a higher than average risk of getting lymphoma (a cancer that&#160;<br/>affects the lymph system) and leukemia (a cancer that affects the blood and bone marrow). If you&#160;<br/>take Humira the risk of getting lymphoma, leukemia, or other cancers may increase. On rare&#160;<br/>occasions, a specific and severe type of lymphoma has been observed in patients taking Humira.&#160;<br/>Some of those patients were also treated with azathioprine or 6-&#160;mercaptopurine. Tell your doctor&#160;<br/>if you are taking azathioprine or 6-mercaptopurine with Humira. In addition,&#160;cases of non-<br/>melanoma skin cancer have been observed in patients taking Humira. If new skin lesions appear&#160;<br/>during or after therapy or if existing lesions change appearance, tell your doctor.</p>
<p style="position:absolute;top:832px;left:133px;white-space:nowrap" class="ft3826">&#160;There have been cases of cancers, other than lymphoma in patients with a specific type of lung&#160;</p>
<p style="position:absolute;top:853px;left:160px;white-space:nowrap" class="ft3825">disease called Chronic Obstructive Pulmonary Disease (COPD) treated with another TNF blocker.&#160;<br/>If you have COPD, or are a heavy smoker, you should discuss with your doctor whether treatment&#160;<br/>with a TNF blocker is appropriate for you.</p>
<p style="position:absolute;top:928px;left:133px;white-space:nowrap" class="ft3826">&#160;On rare occasions, treatment&#160;with Humira could result in lupus-like syndrome. Contact your&#160;</p>
<p style="position:absolute;top:949px;left:160px;white-space:nowrap" class="ft3822">doctor if symptoms such as persistent unexplained rash, fever, joint pain or tiredness&#160;occur.</p>
<p style="position:absolute;top:987px;left:106px;white-space:nowrap" class="ft3821"><b>Children and adolescents</b></p>
<p style="position:absolute;top:1024px;left:133px;white-space:nowrap" class="ft3826">&#160;Vaccinations: if possible,&#160;children should be up to date with all vaccinations before using Humira.</p>
<p style="position:absolute;top:1045px;left:133px;white-space:nowrap" class="ft3826">&#160;Do not give Humira to children with polyarticular juvenile idiopathic arthritis below the age of 2&#160;</p>
<p style="position:absolute;top:1066px;left:160px;white-space:nowrap" class="ft3822">years.</p>
</div>
<!-- Page 383 -->
<a name="383"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page383-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3830">383</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft3831"><b>Other medicines and Humira</b></p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft3832">Tell your doctor or pharmacist if you are taking, have recently taken or might take any other&#160;medicines.</p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft3834">Humira can be taken together with methotrexate or certain disease-modifying anti-rheumatic agents&#160;<br/>(sulfasalazine, hydroxychloroquine, leflunomide and injectable gold preparations), steroids or pain&#160;<br/>medications including non-steroidal&#160;anti-inflammatory drugs (NSAIDs).</p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft3834">You should not take Humira with medicines containing the active substances&#160;anakinra or abatacept&#160;due to&#160;<br/>increased risk of serious infection. If you have questions, please ask your doctor.</p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft3831"><b>Pregnancy and breast-feeding</b></p>
<p style="position:absolute;top:351px;left:133px;white-space:nowrap" class="ft3836">&#160;You&#160;should consider the&#160;use&#160;of&#160;adequate contraception&#160;to prevent pregnancy&#160;and&#160;continue its use&#160;</p>
<p style="position:absolute;top:372px;left:160px;white-space:nowrap" class="ft3832">for at least 5 months after the last Humira treatment.</p>
<p style="position:absolute;top:390px;left:133px;white-space:nowrap" class="ft3836">&#160;If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for&#160;</p>
<p style="position:absolute;top:411px;left:160px;white-space:nowrap" class="ft3832">advice&#160;about taking this medicine.</p>
<p style="position:absolute;top:429px;left:133px;white-space:nowrap" class="ft3836">&#160;Humira should only be used during a pregnancy if needed.</p>
<p style="position:absolute;top:449px;left:133px;white-space:nowrap" class="ft3836">&#160;According to a pregnancy study, there was no higher risk of birth defects when the mother had&#160;</p>
<p style="position:absolute;top:470px;left:160px;white-space:nowrap" class="ft3834">received Humira during pregnancy compared with mothers with the same disease&#160;who&#160;did not&#160;<br/>receive Humira.</p>
<p style="position:absolute;top:508px;left:133px;white-space:nowrap" class="ft3836">&#160;Humira can be used during breast-feeding.</p>
<p style="position:absolute;top:528px;left:133px;white-space:nowrap" class="ft3836">&#160;If you receive Humira during your pregnancy, your baby may have a higher risk for getting an&#160;</p>
<p style="position:absolute;top:548px;left:160px;white-space:nowrap" class="ft3832">infection.</p>
<p style="position:absolute;top:567px;left:133px;white-space:nowrap" class="ft3836">&#160;It is important that you tell your baby’s doctors and other health care professionals about your&#160;</p>
<p style="position:absolute;top:588px;left:160px;white-space:nowrap" class="ft3834">Humira use during your pregnancy before the baby receives any vaccine.&#160;&#160;For more information&#160;<br/>on vaccines&#160;see&#160;the “Warnings and precautions”&#160;section).</p>
<p style="position:absolute;top:644px;left:106px;white-space:nowrap" class="ft3831"><b>Driving and using machines</b></p>
<p style="position:absolute;top:683px;left:106px;white-space:nowrap" class="ft3835">Humira may have a minor influence on your ability to drive, cycle&#160;or use machines. Room spinning&#160;<br/>sensation and vision disturbances may occur after taking Humira.</p>
<p style="position:absolute;top:739px;left:106px;white-space:nowrap" class="ft3831"><b>Humira contains sodium</b></p>
<p style="position:absolute;top:777px;left:106px;white-space:nowrap" class="ft3834">This medicinal product contains less than 1&#160;mmol&#160;of sodium (23&#160;mg) per 0.8&#160;ml dose, i.e. essentially&#160;<br/>‘sodium-free’.</p>
<p style="position:absolute;top:853px;left:106px;white-space:nowrap" class="ft3831"><b>3.</b></p>
<p style="position:absolute;top:853px;left:148px;white-space:nowrap" class="ft3831"><b>How to use&#160;Humira</b></p>
<p style="position:absolute;top:891px;left:106px;white-space:nowrap" class="ft3834">Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or&#160;<br/>pharmacist if you are not sure.&#160;Your doctor may prescribe another strength of Humira if you need a&#160;<br/>different dose.</p>
<p style="position:absolute;top:967px;left:106px;white-space:nowrap" class="ft3834">Adults with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis or axial spondyloarthritis&#160;<br/>without radiographic evidence of ankylosing spondylitis</p>
<p style="position:absolute;top:1024px;left:106px;white-space:nowrap" class="ft3834">Humira is injected under the skin (subcutaneous use). The usual dose for adults with rheumatoid arthritis,&#160;<br/>ankylosing spondylitis, axial spondyloarthritis without radiographic evidence of ankylosing spondylitis&#160;<br/>and for patients with psoriatic arthritis is 40&#160;mg adalimumab given every other week as a single dose. &#160;</p>
</div>
<!-- Page 384 -->
<a name="384"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page384-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3840">384</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft3845">In rheumatoid arthritis, methotrexate is continued while using&#160;Humira. If your doctor determines that&#160;<br/>methotrexate is inappropriate, Humira can be given alone.&#160;</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft3844">If you have rheumatoid arthritis and you do not receive methotrexate with your Humira therapy, your&#160;<br/>doctor may decide to give 40&#160;mg adalimumab every week&#160;or&#160;80&#160;mg&#160;every other week.</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft3842">Children, adolescents and adults&#160;with polyarticular juvenile idiopathic arthritis</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft3843"><i>Children and adolescents from 2&#160;years of age weighing 10&#160;kg to less than 30&#160;kg</i></p>
<p style="position:absolute;top:276px;left:106px;white-space:nowrap" class="ft3842">The recommended dose of Humira is 20&#160;mg&#160;every other week.</p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft3843"><i>Children, adolescents and adults from 2&#160;years of age weighing 30&#160;kg or more</i></p>
<p style="position:absolute;top:352px;left:106px;white-space:nowrap" class="ft3842">The recommended dose of Humira is 40&#160;mg&#160;every other week.</p>
<p style="position:absolute;top:390px;left:106px;white-space:nowrap" class="ft3842">Children, adolescents and adults&#160;with&#160;enthesitis-related arthritis</p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft3843"><i>Children and adolescents from 6&#160;years of age weighing 15&#160;kg&#160;to less than 30&#160;kg</i></p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft3842">The recommended dose of Humira is 20&#160;mg&#160;every other week.</p>
<p style="position:absolute;top:503px;left:106px;white-space:nowrap" class="ft3843"><i>Children, adolescents and adults from 6years of age weighing 30&#160;kg or more</i></p>
<p style="position:absolute;top:541px;left:106px;white-space:nowrap" class="ft3842">The recommended dose of Humira is 40&#160;mg&#160;every other week.</p>
<p style="position:absolute;top:579px;left:106px;white-space:nowrap" class="ft3842">Adults with psoriasis</p>
<p style="position:absolute;top:617px;left:106px;white-space:nowrap" class="ft3844">The usual dose for&#160;adults with psoriasis is an initial dose&#160;of 80&#160;mg&#160;(as two&#160;40&#160;mg&#160;injections in one day),&#160;<br/>followed by 40&#160;mg&#160;given every other week starting one week after the initial dose. You should continue to&#160;<br/>inject Humira for as long as your doctor has told you. Depending on your response, your doctor may&#160;<br/>increase the dosage&#160;to 40&#160;mg every week&#160;or 80&#160;mg&#160;every other week.</p>
<p style="position:absolute;top:712px;left:106px;white-space:nowrap" class="ft3842">Children&#160;and&#160;adolescents with plaque psoriasis</p>
<p style="position:absolute;top:750px;left:106px;white-space:nowrap" class="ft3843"><i>Children and adolescents from 4 to 17&#160;years of age weighing 15&#160;kg to less than 30&#160;kg</i></p>
<p style="position:absolute;top:788px;left:106px;white-space:nowrap" class="ft3844">The recommended&#160;dose of Humira is an initial dose of 20&#160;mg, followed by 20&#160;mg&#160;one week later.&#160;<br/>Thereafter, the usual dose is 20&#160;mg every other week.</p>
<p style="position:absolute;top:845px;left:106px;white-space:nowrap" class="ft3843"><i>Children and adolescents from 4 to 17&#160;years of age weighing 30&#160;kg or more</i></p>
<p style="position:absolute;top:883px;left:106px;white-space:nowrap" class="ft3844">The recommended dose of Humira is an initial&#160;dose of 40&#160;mg, followed by 40&#160;mg&#160;one week later.&#160;<br/>Thereafter, the usual dose is 40&#160;mg every other week.</p>
<p style="position:absolute;top:940px;left:106px;white-space:nowrap" class="ft3842">Adults with hidradenitis suppurativa</p>
<p style="position:absolute;top:978px;left:106px;white-space:nowrap" class="ft3844">The usual dose regimen for hidradenitis suppurativa is an initial dose of 160&#160;mg (as&#160;four&#160;40&#160;mg&#160;injections&#160;<br/>in one&#160;day or&#160;two&#160;40&#160;mg&#160;injections per day for two consecutive days), followed by an 80&#160;mg dose (as&#160;two<br/>40&#160;mg&#160;injections&#160;in one&#160;day) two weeks later. After two further weeks, continue with a dosage&#160;of 40&#160;mg&#160;<br/>every week&#160;or 80&#160;mg&#160;every other week,&#160;as prescribed by your doctor. It is recommended that you use an&#160;<br/>antiseptic wash daily on the affected areas.</p>
</div>
<!-- Page 385 -->
<a name="385"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page385-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3850">385</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft3852">Adolescents with hidradenitis suppurativa from 12&#160;to 17&#160;years of age weighing 30&#160;kg&#160;or more</p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft3855">The recommended dose of&#160;Humira is an initial dose of 80&#160;mg&#160;(as&#160;two&#160;40&#160;mg&#160;injections in one day),&#160;<br/>followed by 40&#160;mg&#160;every other week starting one week later. If you have an inadequate response&#160;to&#160;<br/>Humira 40&#160;mg&#160;every other week, your doctor may increase the dosage&#160;to&#160;40&#160;mg&#160;every week&#160;or 80&#160;mg&#160;<br/>every other week.</p>
<p style="position:absolute;top:219px;left:106px;white-space:nowrap" class="ft3852">It is recommended that you use an antiseptic wash daily on the affected areas.</p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft3852">Adults with Crohn’s disease</p>
<p style="position:absolute;top:295px;left:106px;white-space:nowrap" class="ft3854">The usual dose regimen for Crohn’s disease is 80&#160;mg&#160;(as two&#160;40&#160;mg&#160;injections in one day)&#160;initially&#160;<br/>followed by 40&#160;mg&#160;every other week two weeks later. If a faster&#160;response is required your doctor may&#160;<br/>prescribe an initial dose of 160&#160;mg (as&#160;four&#160;40&#160;mg&#160;injections in one day or&#160;two&#160;40mg&#160;injections per day for&#160;<br/>two consecutive days), followed by 80&#160;mg&#160;(as two&#160;40&#160;mg&#160;injections in one day)&#160;two weeks later and&#160;<br/>thereafter as&#160;40&#160;mg&#160;every other week. Depending on your response, your doctor may increase the dosage&#160;<br/>to 40&#160;mg&#160;every week&#160;or 80&#160;mg&#160;every other week.</p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft3852">Children&#160;and&#160;adolescents with Crohn's disease</p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft3853"><i>Children and adolescents from 6 to 17&#160;years of age weighing less than 40&#160;kg</i>&#160;&#160;</p>
<p style="position:absolute;top:503px;left:106px;white-space:nowrap" class="ft3854">The usual dose regimen is 40&#160;mg initially followed by 20&#160;mg two weeks later. If a faster response is&#160;<br/>required, your doctor may&#160;prescribe an initial dose of 80&#160;mg (as&#160;two&#160;40&#160;mg&#160;injections in&#160;one&#160;day)&#160;<br/>followed by 40&#160;mg two weeks later.</p>
<p style="position:absolute;top:579px;left:106px;white-space:nowrap" class="ft3854">Thereafter, the usual dose is 20&#160;mg every other week. Depending on your response, your doctor may&#160;<br/>increase the dose frequency to 20&#160;mg&#160;every week. &#160;</p>
<p style="position:absolute;top:636px;left:106px;white-space:nowrap" class="ft3853"><i>Children and adolescents from 6 to 17&#160;years of age weighing 40&#160;kg or more</i></p>
<p style="position:absolute;top:674px;left:106px;white-space:nowrap" class="ft3854">The usual dose regimen is 80&#160;mg&#160;(as two&#160;40&#160;mg&#160;injections in one day)&#160;initially followed by 40&#160;mg two&#160;<br/>weeks later. &#160;If a faster response is required, your doctor may prescribe an initial dose of 160&#160;mg (as&#160;four<br/>40&#160;mg&#160;injections in&#160;one&#160;day or as&#160;two&#160;40&#160;mg&#160;injections per day for&#160;two&#160;consecutive days)&#160;followed by&#160;<br/>80&#160;mg&#160;(as two&#160;40&#160;mg&#160;injections in one day)&#160;two weeks later.</p>
<p style="position:absolute;top:769px;left:106px;white-space:nowrap" class="ft3854">Thereafter, the usual dose is 40&#160;mg every other week. &#160;Depending on your response, your doctor may&#160;<br/>increase the dosage to 40&#160;mg every week&#160;or 80&#160;mg&#160;every other week.</p>
<p style="position:absolute;top:826px;left:106px;white-space:nowrap" class="ft3852">Adults with ulcerative colitis</p>
<p style="position:absolute;top:864px;left:106px;white-space:nowrap" class="ft3854">The usual Humira dose for adults with ulcerative colitis is 160&#160;mg&#160;(as four&#160;40&#160;mg&#160;injections in one day or&#160;<br/>two&#160;40&#160;mg&#160;injections per day for two consecutive days)&#160;at Week 0 and 80&#160;mg&#160;(as two&#160;40&#160;mg&#160;injections in&#160;<br/>one day)&#160;at Week 2 and thereafter 40&#160;mg&#160;every other week. Depending on your response, your doctor may&#160;<br/>increase the dosage to 40&#160;mg every week&#160;or 80&#160;mg&#160;every other week. &#160; &#160;</p>
<p style="position:absolute;top:959px;left:106px;white-space:nowrap" class="ft3852">Children and adolescents&#160;with ulcerative colitis</p>
<p style="position:absolute;top:997px;left:106px;white-space:nowrap" class="ft3853"><i>Children and adolescents from 6 years of age weighing less&#160;than 40 kg</i></p>
<p style="position:absolute;top:1035px;left:106px;white-space:nowrap" class="ft3854">The usual Humira dose is 80 mg (as two 40 mg injections in one day) initially followed by 40 mg&#160;(as one&#160;<br/>40 mg injection)&#160;two weeks later. Thereafter, the usual dose is 40 mg every other week.&#160;</p>
</div>
<!-- Page 386 -->
<a name="386"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page386-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3860">386</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft3862">Patients who turn 18&#160;years of age&#160;while on&#160;40 mg every other week,&#160;should continue their prescribed dose.</p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft3863"><i>Children and adolescents from 6 years of age weighing 40 kg or more</i></p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft3864">The usual Humira dose is 160 mg (as&#160;four 40 mg injections in one day or two 40 mg injections per day for&#160;<br/>two consecutive days) initially, followed by 80 mg (as&#160;two 40 mg injections in one day) two weeks later.&#160;<br/>Thereafter the usual dose is 80 mg every other week.&#160;</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft3862">Patients who turn 18&#160;years of age&#160;while on&#160;80 mg every other week,&#160;should continue their prescribed dose.</p>
<p style="position:absolute;top:276px;left:106px;white-space:nowrap" class="ft3862">Adults&#160;with non-infectious uveitis</p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft3864">The usual dose for adults with non-infectious uveitis is an initial dose of 80&#160;mg&#160;(as two injections in one&#160;<br/>day), followed by 40&#160;mg given every other week starting one week after the initial dose. You should&#160;<br/>continue to inject&#160;Humira for as long as your doctor has told you.</p>
<p style="position:absolute;top:390px;left:106px;white-space:nowrap" class="ft3864">In&#160;non-infectious uveitis, corticosteroids or other medicines that influence the immune system may be&#160;<br/>continued while using Humira. Humira can also be given alone.</p>
<p style="position:absolute;top:446px;left:106px;white-space:nowrap" class="ft3862">Children&#160;and adolescents&#160;with chronic non-infectious uveitis from 2&#160;years of age</p>
<p style="position:absolute;top:485px;left:106px;white-space:nowrap" class="ft3863"><i>Children and adolescents from 2&#160;years of age weighing less than 30&#160;kg</i></p>
<p style="position:absolute;top:522px;left:106px;white-space:nowrap" class="ft3862">The usual dose of Humira is 20&#160;mg&#160;every other week with methotrexate.</p>
<p style="position:absolute;top:560px;left:106px;white-space:nowrap" class="ft3864">Your doctor may also prescribe an initial dose of 40&#160;mg which may be&#160;administered one week prior to the&#160;<br/>start of the&#160;usual dose.</p>
<p style="position:absolute;top:617px;left:106px;white-space:nowrap" class="ft3863"><i>Children and adolescents from 2&#160;years of age weighing 30&#160;kg or more</i></p>
<p style="position:absolute;top:655px;left:106px;white-space:nowrap" class="ft3862">The usual dose of Humira is 40&#160;mg&#160;every other week with methotrexate.</p>
<p style="position:absolute;top:693px;left:106px;white-space:nowrap" class="ft3864">Your doctor may also prescribe an initial dose of 80&#160;mg&#160;which may be administered one week prior to the&#160;<br/>start of the&#160;usual dose.</p>
<p style="position:absolute;top:750px;left:106px;white-space:nowrap" class="ft3861"><b>Method and route of administration</b></p>
<p style="position:absolute;top:788px;left:106px;white-space:nowrap" class="ft3862">Humira is administered by injection under the skin (by subcutaneous injection).</p>
<p style="position:absolute;top:826px;left:106px;white-space:nowrap" class="ft3861"><b>Injecting Humira yourself</b></p>
<p style="position:absolute;top:864px;left:106px;white-space:nowrap" class="ft3865">The following instructions explain how to give yourself an injection of Humira using the pre-filled pen.&#160;<br/>Please read the instructions carefully and follow them step by step. You will be instructed by your doctor&#160;<br/>or his/her assistant on the technique of self-injection. Do not attempt to self-inject until you are sure that&#160;<br/>you understand how to prepare and give the injection. After proper training, the injection can be self-<br/>administered or given by another person, for example a family member or friend.</p>
<p style="position:absolute;top:978px;left:106px;white-space:nowrap" class="ft3861"><b>What should I do before I give myself a subcutaneous injection of Humira?</b></p>
</div>
<!-- Page 387 -->
<a name="387"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page387-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3870">387</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft3872">1.</p>
<p style="position:absolute;top:86px;left:147px;white-space:nowrap" class="ft3872">Wash your hands thoroughly.&#160;</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft3872">2.&#160;</p>
<p style="position:absolute;top:105px;left:147px;white-space:nowrap" class="ft3872">Take one dose tray containing a pre-filled pen of Humira from the refrigerator.&#160;</p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft3872">3.&#160;</p>
<p style="position:absolute;top:124px;left:147px;white-space:nowrap" class="ft3872">Do not shake or drop the pre-filled pen.</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft3872">4.&#160;</p>
<p style="position:absolute;top:143px;left:147px;white-space:nowrap" class="ft3872">Set up the following items on a clean surface.</p>
<p style="position:absolute;top:181px;left:147px;white-space:nowrap" class="ft3874">One&#160;pre-filled pen of Humira<br/>One alcohol pad</p>
<p style="position:absolute;top:276px;left:467px;white-space:nowrap" class="ft3872">Pad</p>
<p style="position:absolute;top:333px;left:467px;white-space:nowrap" class="ft3872">Window</p>
<p style="position:absolute;top:446px;left:106px;white-space:nowrap" class="ft3872">5.&#160;</p>
<p style="position:absolute;top:446px;left:147px;white-space:nowrap" class="ft3874">Check the expiry date on the pre-filled pen label&#160;(EXP:)&#160;Do not use the product if the date has&#160;<br/>passed the month and year shown.</p>
<p style="position:absolute;top:503px;left:106px;white-space:nowrap" class="ft3872">6.&#160;</p>
<p style="position:absolute;top:503px;left:147px;white-space:nowrap" class="ft3874">Hold the pre-filled pen with the grey cap (labelled ‘1’)&#160;pointing up. Check the appearance of the&#160;<br/>Humira solution through the window on the sides of the pre-filled pen. It must be clear and&#160;<br/>colourless. If it is cloudy or discoloured or has flakes or particles in it, you must not use it. Do not&#160;<br/>use a pre-filled&#160;pen that is frozen or if it has been left in direct sunlight. Only remove both the grey&#160;<br/>cap and the plum cap&#160;<b>immediately&#160;</b>before injection</p>
<p style="position:absolute;top:674px;left:462px;white-space:nowrap" class="ft3872">Window</p>
<p style="position:absolute;top:712px;left:462px;white-space:nowrap" class="ft3872">Clear Liquid in Syringe</p>
<p style="position:absolute;top:848px;left:106px;white-space:nowrap" class="ft3871"><b>Where should I give my injection?&#160;</b></p>
<p style="position:absolute;top:886px;left:106px;white-space:nowrap" class="ft3872">1.&#160;</p>
<p style="position:absolute;top:886px;left:147px;white-space:nowrap" class="ft3872">Choose a site on the top of your&#160;thigh or stomach (except the area around the navel).</p>
</div>
<!-- Page 388 -->
<a name="388"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page388-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3880">388</p>
<p style="position:absolute;top:318px;left:106px;white-space:nowrap" class="ft3882">2.&#160;</p>
<p style="position:absolute;top:318px;left:147px;white-space:nowrap" class="ft3885">Change the place that you inject each time so that you do not become sore in one area. Each new&#160;<br/>injection should be given at least 3&#160;cm from the last injection site.&#160;</p>
<p style="position:absolute;top:374px;left:106px;white-space:nowrap" class="ft3882">3.&#160;</p>
<p style="position:absolute;top:374px;left:147px;white-space:nowrap" class="ft3884">Do not inject in an area where the skin is reddened, bruised, or hard. This may mean there is an&#160;<br/>infection. &#160;</p>
<p style="position:absolute;top:431px;left:106px;white-space:nowrap" class="ft3881"><b>How do I give my injection?</b></p>
<p style="position:absolute;top:469px;left:106px;white-space:nowrap" class="ft3882">1.&#160;</p>
<p style="position:absolute;top:469px;left:147px;white-space:nowrap" class="ft3884">Wipe your skin by using the enclosed alcohol pad, using a circular motion. Do not touch the area&#160;<br/>again before injecting. &#160;</p>
<p style="position:absolute;top:526px;left:106px;white-space:nowrap" class="ft3882">2.</p>
<p style="position:absolute;top:526px;left:147px;white-space:nowrap" class="ft3884">Only remove both the grey cap and the plum cap&#160;<b>immediately&#160;</b>before injection. Hold the grey body&#160;<br/>of the pre-filled pen with one hand. Place hand on the middle of the pen so that neither the grey cap&#160;<br/>(1) nor the plum cap (2) is covered. Hold the pre-filled pen&#160;with the grey cap (1) pointing up. With&#160;<br/>your other hand, pull the grey cap (1) straight off, check that the small black needle cover of the&#160;<br/>syringe has been removed with the cap, then discard cap. If a few small drops of liquid come out of&#160;<br/>the needle, that is okay. The white needle sleeve will now be exposed. Do not try to touch the needle&#160;<br/>housed in the barrel.&#160;<b>DO NOT RECAP&#160;</b>as you may damage the needle inside.&#160;</p>
<p style="position:absolute;top:935px;left:106px;white-space:nowrap" class="ft3882">3.&#160;</p>
<p style="position:absolute;top:935px;left:147px;white-space:nowrap" class="ft38819">Pull the plum safety cap (labelled ‘2’) straight off to expose the plum coloured activation button.&#160;<br/>The pre-filled pen is now ready to use. Do not press the plum activation button until properly&#160;<br/>positioned as this will result in discharge of medication.&#160;<b>DO NOT RECAP as this could cause the&#160;<br/>unit to discharge.</b></p>
</div>
<!-- Page 389 -->
<a name="389"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page389-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3890">389</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft3891"><b>Giving the injection</b></p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft3892">1.&#160;</p>
<p style="position:absolute;top:124px;left:147px;white-space:nowrap" class="ft3894">With&#160;your free hand, gently grasp a sizable area of the cleaned skin at the injection site and hold&#160;<br/>firmly (see below). &#160;</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft3892">2. &#160;</p>
<p style="position:absolute;top:162px;left:147px;white-space:nowrap" class="ft3895">Place the white end of the pre-filled pen at a right angle (90 degrees) to the skin, so that you can see&#160;<br/>the window. The presence of one&#160;or more bubbles in the window is normal.</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft3892">3.&#160;</p>
<p style="position:absolute;top:200px;left:147px;white-space:nowrap" class="ft3894">Holding the barrel of the pre-filled pen, press down slightly onto the injection site (holding in place&#160;<br/>without moving).&#160;</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft3892">4.&#160;</p>
<p style="position:absolute;top:238px;left:147px;white-space:nowrap" class="ft3894">With your index finger or your thumb, press the plum coloured button on top once you are ready to&#160;<br/>begin the injection (see below). You will then hear a loud ‘click’ as the needle is released and you&#160;<br/>will feel a small prick as the needle advances.&#160;</p>
<p style="position:absolute;top:295px;left:106px;white-space:nowrap" class="ft3892">5.&#160;</p>
<p style="position:absolute;top:295px;left:147px;white-space:nowrap" class="ft3894">Keep pressing and continue to hold the pre-filled pen with steady pressure in place for about&#160;<b>10&#160;<br/>seconds to ensure a complete injection.&#160;</b>Do&#160;not remove the pre-filled pen while the injection is&#160;<br/>being given.&#160;</p>
<p style="position:absolute;top:584px;left:106px;white-space:nowrap" class="ft3892">6.&#160;</p>
<p style="position:absolute;top:584px;left:148px;white-space:nowrap" class="ft3894">You will see a yellow indicator move into the window during the injection. The injection is&#160;<br/>complete when the yellow indicator stops moving. The yellow indicator is part of the plunger of the&#160;<br/>pre-filled pen. If the yellow indicator is not shown in the window, the plunger has not advanced&#160;<br/>adequately and the injection is not complete. &#160;</p>
<p style="position:absolute;top:679px;left:106px;white-space:nowrap" class="ft3892">7.&#160;</p>
<p style="position:absolute;top:679px;left:147px;white-space:nowrap" class="ft3894">Lift the pre-filled pen straight up from the injection site. The white needle sleeve will move down&#160;<br/>over the needle and lock into place over the needle tip. Do not try to&#160;touch the needle. The white&#160;<br/>needle sleeve is there to protect you from touching the needle. &#160;&#160;</p>
<p style="position:absolute;top:774px;left:328px;white-space:nowrap" class="ft3894">White Needle<br/>Sleeve</p>
<p style="position:absolute;top:811px;left:677px;white-space:nowrap" class="ft3892">Window</p>
<p style="position:absolute;top:850px;left:677px;white-space:nowrap" class="ft3894">Yellow Indicator&#160;<br/>Visible</p>
<p style="position:absolute;top:969px;left:106px;white-space:nowrap" class="ft3892">8.&#160;</p>
<p style="position:absolute;top:969px;left:147px;white-space:nowrap" class="ft3894">You may notice a spot of blood at the injection site. You can press a cotton ball or a&#160;piece of gauze&#160;<br/>over the injection site for 10 seconds. Do not rub the injection site. Use a plaster if you want to.</p>
<p style="position:absolute;top:1026px;left:106px;white-space:nowrap" class="ft3891"><b>Throwing away supplies</b></p>
<p style="position:absolute;top:1064px;left:106px;white-space:nowrap" class="ft3892">Only use each pre-filled pen for one injection. Do not put either of the caps back on the pre-filled pen.</p>
</div>
<!-- Page 390 -->
<a name="390"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page390-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3900">390</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft3904">After injecting Humira, immediately throw away the used pre-filled pen in a special container as&#160;<br/>instructed by your doctor, nurse or pharmacist<br/>Keep this container out of the sight and reach of children</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft3901"><b>If you use more&#160;Humira&#160;than you should</b></p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft3905">If you accidentally inject Humira more frequently than told to by your doctor or pharmacist, call your&#160;<br/>doctor or pharmacist&#160;and tell him/her that you have taken more. Always take the outer carton of the&#160;<br/>medicine with you, even if it is empty.&#160;</p>
<p style="position:absolute;top:276px;left:106px;white-space:nowrap" class="ft3901"><b>If you forget to use Humira</b></p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft3904">If you forget to give yourself an injection, you should inject the next dose of Humira as soon as you&#160;<br/>remember. Then take your next dose as you would have on your originally scheduled day, had you not&#160;<br/>forgotten a dose.&#160;</p>
<p style="position:absolute;top:390px;left:106px;white-space:nowrap" class="ft3901"><b>If you stop using&#160;Humira</b></p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft3904">The&#160;decision to stop using Humira should be discussed with your doctor. Your symptoms may return upon&#160;<br/>discontinuation.</p>
<p style="position:absolute;top:485px;left:106px;white-space:nowrap" class="ft3902">If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
<p style="position:absolute;top:541px;left:106px;white-space:nowrap" class="ft3901"><b>4.</b></p>
<p style="position:absolute;top:541px;left:148px;white-space:nowrap" class="ft3901"><b>Possible side effects</b></p>
<p style="position:absolute;top:579px;left:106px;white-space:nowrap" class="ft3905">Like all&#160;medicines, this medicine can cause side effects, although not everybody gets them. Most side&#160;<br/>effects are mild to moderate. However, some may be serious and require treatment. Side effects may occur&#160;<br/>at least up to 4 months after the last Humira injection.</p>
<p style="position:absolute;top:655px;left:106px;white-space:nowrap" class="ft3902">Tell your doctor immediately if you notice any of the following&#160;</p>
<p style="position:absolute;top:673px;left:106px;white-space:nowrap" class="ft3906"></p>
<p style="position:absolute;top:675px;left:147px;white-space:nowrap" class="ft3902">severe rash, hives or other signs of allergic reaction;&#160;</p>
<p style="position:absolute;top:694px;left:106px;white-space:nowrap" class="ft3906"></p>
<p style="position:absolute;top:696px;left:147px;white-space:nowrap" class="ft3902">swollen face, hands, feet;</p>
<p style="position:absolute;top:714px;left:106px;white-space:nowrap" class="ft3906"></p>
<p style="position:absolute;top:716px;left:147px;white-space:nowrap" class="ft3902">trouble breathing, swallowing;</p>
<p style="position:absolute;top:734px;left:106px;white-space:nowrap" class="ft3906"></p>
<p style="position:absolute;top:736px;left:147px;white-space:nowrap" class="ft3902">shortness of breath with exertion or upon lying down or swelling of the&#160;feet.</p>
<p style="position:absolute;top:774px;left:106px;white-space:nowrap" class="ft3902">Tell your doctor as soon as possible if you notice any of the following</p>
<p style="position:absolute;top:792px;left:106px;white-space:nowrap" class="ft3906"></p>
<p style="position:absolute;top:794px;left:147px;white-space:nowrap" class="ft3902">signs of infection such as fever, feeling sick, wounds, dental problems, burning on urination;</p>
<p style="position:absolute;top:812px;left:106px;white-space:nowrap" class="ft3906"></p>
<p style="position:absolute;top:814px;left:147px;white-space:nowrap" class="ft3902">feeling weak or tired;</p>
<p style="position:absolute;top:832px;left:106px;white-space:nowrap" class="ft3906"></p>
<p style="position:absolute;top:834px;left:147px;white-space:nowrap" class="ft3902">coughing;</p>
<p style="position:absolute;top:852px;left:106px;white-space:nowrap" class="ft3906"></p>
<p style="position:absolute;top:854px;left:147px;white-space:nowrap" class="ft3902">tingling;</p>
<p style="position:absolute;top:873px;left:106px;white-space:nowrap" class="ft3906"></p>
<p style="position:absolute;top:874px;left:147px;white-space:nowrap" class="ft3902">numbness;</p>
<p style="position:absolute;top:893px;left:106px;white-space:nowrap" class="ft3906"></p>
<p style="position:absolute;top:895px;left:147px;white-space:nowrap" class="ft3902">double vision;</p>
<p style="position:absolute;top:913px;left:106px;white-space:nowrap" class="ft3906"></p>
<p style="position:absolute;top:915px;left:147px;white-space:nowrap" class="ft3902">arm&#160;or leg&#160;weakness;</p>
<p style="position:absolute;top:933px;left:106px;white-space:nowrap" class="ft3906"></p>
<p style="position:absolute;top:935px;left:147px;white-space:nowrap" class="ft3902">a&#160;bump or open sore that doesn't heal;</p>
<p style="position:absolute;top:953px;left:106px;white-space:nowrap" class="ft3906"></p>
<p style="position:absolute;top:955px;left:147px;white-space:nowrap" class="ft3904">signs and symptoms suggestive of blood disorders such as persistent fever, bruising, bleeding,&#160;<br/>paleness.</p>
<p style="position:absolute;top:1012px;left:106px;white-space:nowrap" class="ft3904">The symptoms described above can be signs of the below listed side effects, which have been observed&#160;<br/>with Humira.</p>
</div>
<!-- Page 391 -->
<a name="391"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page391-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3910">391</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft3912">Very common (may affect more than 1 in 10 people)</p>
<p style="position:absolute;top:123px;left:106px;white-space:nowrap" class="ft3916"></p>
<p style="position:absolute;top:125px;left:147px;white-space:nowrap" class="ft3912">injection site reactions (including pain, swelling, redness or itching);</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft3916"></p>
<p style="position:absolute;top:145px;left:147px;white-space:nowrap" class="ft3912">respiratory tract infections (including cold, runny nose, sinus infection, pneumonia);</p>
<p style="position:absolute;top:163px;left:106px;white-space:nowrap" class="ft3916"></p>
<p style="position:absolute;top:165px;left:147px;white-space:nowrap" class="ft3912">headache;</p>
<p style="position:absolute;top:184px;left:106px;white-space:nowrap" class="ft3916"></p>
<p style="position:absolute;top:185px;left:147px;white-space:nowrap" class="ft3912">abdominal pain;</p>
<p style="position:absolute;top:204px;left:106px;white-space:nowrap" class="ft3916"></p>
<p style="position:absolute;top:206px;left:147px;white-space:nowrap" class="ft3912">nausea and vomiting;</p>
<p style="position:absolute;top:224px;left:106px;white-space:nowrap" class="ft3916"></p>
<p style="position:absolute;top:226px;left:147px;white-space:nowrap" class="ft3912">rash;</p>
<p style="position:absolute;top:244px;left:106px;white-space:nowrap" class="ft3916"></p>
<p style="position:absolute;top:246px;left:147px;white-space:nowrap" class="ft3912">musculoskeletal pain.</p>
<p style="position:absolute;top:284px;left:106px;white-space:nowrap" class="ft3912">Common (may affect up to 1 in 10 people)</p>
<p style="position:absolute;top:321px;left:106px;white-space:nowrap" class="ft3916"></p>
<p style="position:absolute;top:323px;left:147px;white-space:nowrap" class="ft3912">serious&#160;infections (including blood poisoning and influenza);</p>
<p style="position:absolute;top:342px;left:106px;white-space:nowrap" class="ft3916"></p>
<p style="position:absolute;top:343px;left:147px;white-space:nowrap" class="ft3912">intestinal infections (including gastroenteritis);</p>
<p style="position:absolute;top:362px;left:106px;white-space:nowrap" class="ft3916"></p>
<p style="position:absolute;top:364px;left:147px;white-space:nowrap" class="ft3912">skin infections (including cellulitis and shingles);</p>
<p style="position:absolute;top:382px;left:106px;white-space:nowrap" class="ft3916"></p>
<p style="position:absolute;top:384px;left:147px;white-space:nowrap" class="ft3912">ear infections;</p>
<p style="position:absolute;top:402px;left:106px;white-space:nowrap" class="ft3916"></p>
<p style="position:absolute;top:404px;left:147px;white-space:nowrap" class="ft3912">oral infections (including tooth infections and cold sores);</p>
<p style="position:absolute;top:422px;left:106px;white-space:nowrap" class="ft3916"></p>
<p style="position:absolute;top:424px;left:147px;white-space:nowrap" class="ft3912">reproductive tract infections;</p>
<p style="position:absolute;top:442px;left:106px;white-space:nowrap" class="ft3916"></p>
<p style="position:absolute;top:444px;left:147px;white-space:nowrap" class="ft3912">urinary tract infection;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft3916"></p>
<p style="position:absolute;top:464px;left:147px;white-space:nowrap" class="ft3912">fungal infections;</p>
<p style="position:absolute;top:483px;left:106px;white-space:nowrap" class="ft3916"></p>
<p style="position:absolute;top:485px;left:147px;white-space:nowrap" class="ft3912">joint infections;</p>
<p style="position:absolute;top:502px;left:106px;white-space:nowrap" class="ft3916"></p>
<p style="position:absolute;top:504px;left:147px;white-space:nowrap" class="ft3912">benign tumours;</p>
<p style="position:absolute;top:523px;left:106px;white-space:nowrap" class="ft3916"></p>
<p style="position:absolute;top:525px;left:147px;white-space:nowrap" class="ft3912">skin cancer;</p>
<p style="position:absolute;top:543px;left:106px;white-space:nowrap" class="ft3916"></p>
<p style="position:absolute;top:545px;left:147px;white-space:nowrap" class="ft3912">allergic reactions (including seasonal allergy);</p>
<p style="position:absolute;top:563px;left:106px;white-space:nowrap" class="ft3916"></p>
<p style="position:absolute;top:565px;left:147px;white-space:nowrap" class="ft3912">dehydration;</p>
<p style="position:absolute;top:583px;left:106px;white-space:nowrap" class="ft3916"></p>
<p style="position:absolute;top:585px;left:147px;white-space:nowrap" class="ft3912">mood swings (including depression);</p>
<p style="position:absolute;top:603px;left:106px;white-space:nowrap" class="ft3916"></p>
<p style="position:absolute;top:605px;left:147px;white-space:nowrap" class="ft3912">anxiety;</p>
<p style="position:absolute;top:623px;left:106px;white-space:nowrap" class="ft3916"></p>
<p style="position:absolute;top:625px;left:147px;white-space:nowrap" class="ft3912">difficulty sleeping;</p>
<p style="position:absolute;top:644px;left:106px;white-space:nowrap" class="ft3916"></p>
<p style="position:absolute;top:645px;left:147px;white-space:nowrap" class="ft3912">sensation disorders such as tingling, prickling or numbness;</p>
<p style="position:absolute;top:664px;left:106px;white-space:nowrap" class="ft3916"></p>
<p style="position:absolute;top:666px;left:147px;white-space:nowrap" class="ft3912">migraine;</p>
<p style="position:absolute;top:684px;left:106px;white-space:nowrap" class="ft3916"></p>
<p style="position:absolute;top:686px;left:147px;white-space:nowrap" class="ft3912">nerve root compression (including low back pain and leg pain);</p>
<p style="position:absolute;top:704px;left:106px;white-space:nowrap" class="ft3916"></p>
<p style="position:absolute;top:706px;left:147px;white-space:nowrap" class="ft3912">vision disturbances;&#160;</p>
<p style="position:absolute;top:724px;left:106px;white-space:nowrap" class="ft3916"></p>
<p style="position:absolute;top:726px;left:147px;white-space:nowrap" class="ft3912">eye&#160;inflammation;</p>
<p style="position:absolute;top:744px;left:106px;white-space:nowrap" class="ft3916"></p>
<p style="position:absolute;top:746px;left:147px;white-space:nowrap" class="ft3912">inflammation of the eye lid and eye swelling;</p>
<p style="position:absolute;top:765px;left:106px;white-space:nowrap" class="ft3916"></p>
<p style="position:absolute;top:766px;left:147px;white-space:nowrap" class="ft3912">vertigo;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft3916"></p>
<p style="position:absolute;top:787px;left:147px;white-space:nowrap" class="ft3912">sensation of heart beating rapidly;</p>
<p style="position:absolute;top:805px;left:106px;white-space:nowrap" class="ft3916"></p>
<p style="position:absolute;top:807px;left:147px;white-space:nowrap" class="ft3912">high blood pressure;</p>
<p style="position:absolute;top:825px;left:106px;white-space:nowrap" class="ft3916"></p>
<p style="position:absolute;top:827px;left:147px;white-space:nowrap" class="ft3912">flushing;</p>
<p style="position:absolute;top:845px;left:106px;white-space:nowrap" class="ft3916"></p>
<p style="position:absolute;top:847px;left:147px;white-space:nowrap" class="ft3912">haematoma;</p>
<p style="position:absolute;top:865px;left:106px;white-space:nowrap" class="ft3916"></p>
<p style="position:absolute;top:867px;left:147px;white-space:nowrap" class="ft3912">cough;</p>
<p style="position:absolute;top:886px;left:106px;white-space:nowrap" class="ft3916"></p>
<p style="position:absolute;top:887px;left:147px;white-space:nowrap" class="ft3912">asthma;</p>
<p style="position:absolute;top:906px;left:106px;white-space:nowrap" class="ft3916"></p>
<p style="position:absolute;top:908px;left:147px;white-space:nowrap" class="ft3912">shortness of breath;</p>
<p style="position:absolute;top:926px;left:106px;white-space:nowrap" class="ft3916"></p>
<p style="position:absolute;top:928px;left:147px;white-space:nowrap" class="ft3912">gastrointestinal bleeding;</p>
<p style="position:absolute;top:946px;left:106px;white-space:nowrap" class="ft3916"></p>
<p style="position:absolute;top:948px;left:147px;white-space:nowrap" class="ft3912">dyspepsia (indigestion, bloating, heart burn);</p>
<p style="position:absolute;top:966px;left:106px;white-space:nowrap" class="ft3916"></p>
<p style="position:absolute;top:968px;left:147px;white-space:nowrap" class="ft3912">acid reflux disease;</p>
<p style="position:absolute;top:986px;left:106px;white-space:nowrap" class="ft3916"></p>
<p style="position:absolute;top:988px;left:147px;white-space:nowrap" class="ft3912">sicca syndrome (including dry eyes and dry mouth);</p>
<p style="position:absolute;top:1006px;left:106px;white-space:nowrap" class="ft3916"></p>
<p style="position:absolute;top:1008px;left:147px;white-space:nowrap" class="ft3912">itching;</p>
<p style="position:absolute;top:1027px;left:106px;white-space:nowrap" class="ft3916"></p>
<p style="position:absolute;top:1029px;left:147px;white-space:nowrap" class="ft3912">itchy rash;</p>
<p style="position:absolute;top:1047px;left:106px;white-space:nowrap" class="ft3916"></p>
<p style="position:absolute;top:1049px;left:147px;white-space:nowrap" class="ft3912">bruising;</p>
<p style="position:absolute;top:1067px;left:106px;white-space:nowrap" class="ft3916"></p>
<p style="position:absolute;top:1069px;left:147px;white-space:nowrap" class="ft3912">inflammation of the skin (such as eczema);</p>
</div>
<!-- Page 392 -->
<a name="392"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page392-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3920">392</p>
<p style="position:absolute;top:85px;left:106px;white-space:nowrap" class="ft3926"></p>
<p style="position:absolute;top:87px;left:147px;white-space:nowrap" class="ft3922">breaking of finger nails and toe nails;</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft3926"></p>
<p style="position:absolute;top:107px;left:147px;white-space:nowrap" class="ft3922">increased sweating;</p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft3926"></p>
<p style="position:absolute;top:127px;left:147px;white-space:nowrap" class="ft3922">hair loss;</p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft3926"></p>
<p style="position:absolute;top:148px;left:147px;white-space:nowrap" class="ft3922">new&#160;onset or worsening of psoriasis;</p>
<p style="position:absolute;top:166px;left:106px;white-space:nowrap" class="ft3926"></p>
<p style="position:absolute;top:168px;left:147px;white-space:nowrap" class="ft3922">muscle spasms;</p>
<p style="position:absolute;top:186px;left:106px;white-space:nowrap" class="ft3926"></p>
<p style="position:absolute;top:188px;left:147px;white-space:nowrap" class="ft3922">blood in urine;</p>
<p style="position:absolute;top:206px;left:106px;white-space:nowrap" class="ft3926"></p>
<p style="position:absolute;top:208px;left:147px;white-space:nowrap" class="ft3922">kidney problems;</p>
<p style="position:absolute;top:226px;left:106px;white-space:nowrap" class="ft3926"></p>
<p style="position:absolute;top:228px;left:147px;white-space:nowrap" class="ft3922">chest pain;</p>
<p style="position:absolute;top:247px;left:106px;white-space:nowrap" class="ft3926"></p>
<p style="position:absolute;top:248px;left:147px;white-space:nowrap" class="ft3922">oedema;</p>
<p style="position:absolute;top:267px;left:106px;white-space:nowrap" class="ft3926"></p>
<p style="position:absolute;top:269px;left:147px;white-space:nowrap" class="ft3922">fever;</p>
<p style="position:absolute;top:287px;left:106px;white-space:nowrap" class="ft3926"></p>
<p style="position:absolute;top:289px;left:147px;white-space:nowrap" class="ft3922">reduction in blood platelets which increases risk of bleeding or bruising;</p>
<p style="position:absolute;top:307px;left:106px;white-space:nowrap" class="ft3926"></p>
<p style="position:absolute;top:309px;left:147px;white-space:nowrap" class="ft3922">impaired healing.</p>
<p style="position:absolute;top:347px;left:106px;white-space:nowrap" class="ft3922">Uncommon (may affect up to 1 in 100 people)&#160;</p>
<p style="position:absolute;top:384px;left:106px;white-space:nowrap" class="ft3926"></p>
<p style="position:absolute;top:386px;left:147px;white-space:nowrap" class="ft3924">opportunistic infections (which include tuberculosis and&#160;other infections that occur when resistance&#160;<br/>to disease is lowered);</p>
<p style="position:absolute;top:423px;left:106px;white-space:nowrap" class="ft3926"></p>
<p style="position:absolute;top:425px;left:147px;white-space:nowrap" class="ft3922">neurological infections (including viral meningitis);</p>
<p style="position:absolute;top:443px;left:106px;white-space:nowrap" class="ft3926"></p>
<p style="position:absolute;top:445px;left:147px;white-space:nowrap" class="ft3922">eye&#160;infections;</p>
<p style="position:absolute;top:464px;left:106px;white-space:nowrap" class="ft3926"></p>
<p style="position:absolute;top:465px;left:147px;white-space:nowrap" class="ft3922">bacterial infections;</p>
<p style="position:absolute;top:484px;left:106px;white-space:nowrap" class="ft3926"></p>
<p style="position:absolute;top:486px;left:147px;white-space:nowrap" class="ft3922">diverticulitis (inflammation and infection of the large intestine);</p>
<p style="position:absolute;top:504px;left:106px;white-space:nowrap" class="ft3926"></p>
<p style="position:absolute;top:506px;left:147px;white-space:nowrap" class="ft3922">cancer;</p>
<p style="position:absolute;top:524px;left:106px;white-space:nowrap" class="ft3926"></p>
<p style="position:absolute;top:526px;left:147px;white-space:nowrap" class="ft3922">cancer that affects&#160;the lymph system;</p>
<p style="position:absolute;top:544px;left:106px;white-space:nowrap" class="ft3926"></p>
<p style="position:absolute;top:546px;left:147px;white-space:nowrap" class="ft3922">melanoma;</p>
<p style="position:absolute;top:564px;left:106px;white-space:nowrap" class="ft3926"></p>
<p style="position:absolute;top:566px;left:147px;white-space:nowrap" class="ft3925">immune disorders that could affect the lungs, skin and lymph nodes (most commonly presenting as&#160;<br/>sarcoidosis);</p>
<p style="position:absolute;top:603px;left:106px;white-space:nowrap" class="ft3926"></p>
<p style="position:absolute;top:605px;left:147px;white-space:nowrap" class="ft3922">vasculitis (inflammation of blood vessels);</p>
<p style="position:absolute;top:623px;left:106px;white-space:nowrap" class="ft3926"></p>
<p style="position:absolute;top:625px;left:147px;white-space:nowrap" class="ft3922">tremor;</p>
<p style="position:absolute;top:644px;left:106px;white-space:nowrap" class="ft3926"></p>
<p style="position:absolute;top:645px;left:147px;white-space:nowrap" class="ft3922">neuropathy;</p>
<p style="position:absolute;top:664px;left:106px;white-space:nowrap" class="ft3926"></p>
<p style="position:absolute;top:666px;left:147px;white-space:nowrap" class="ft3922">stroke;</p>
<p style="position:absolute;top:684px;left:106px;white-space:nowrap" class="ft3926"></p>
<p style="position:absolute;top:686px;left:147px;white-space:nowrap" class="ft3922">hearing loss, buzzing;</p>
<p style="position:absolute;top:704px;left:106px;white-space:nowrap" class="ft3926"></p>
<p style="position:absolute;top:706px;left:147px;white-space:nowrap" class="ft3922">sensation of heart beating irregularly such as skipped beats;</p>
<p style="position:absolute;top:724px;left:106px;white-space:nowrap" class="ft3926"></p>
<p style="position:absolute;top:726px;left:147px;white-space:nowrap" class="ft3922">heart problems that can cause shortness of breath or ankle swelling;</p>
<p style="position:absolute;top:744px;left:106px;white-space:nowrap" class="ft3926"></p>
<p style="position:absolute;top:746px;left:147px;white-space:nowrap" class="ft3922">heart attack;</p>
<p style="position:absolute;top:765px;left:106px;white-space:nowrap" class="ft3926"></p>
<p style="position:absolute;top:766px;left:147px;white-space:nowrap" class="ft3922">a sac in the wall of a major artery, inflammation and clot of a vein, blockage of a blood vessel;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft3926"></p>
<p style="position:absolute;top:787px;left:147px;white-space:nowrap" class="ft3922">lung diseases causing shortness of&#160;breath (including inflammation);</p>
<p style="position:absolute;top:805px;left:106px;white-space:nowrap" class="ft3926"></p>
<p style="position:absolute;top:807px;left:147px;white-space:nowrap" class="ft3922">pulmonary embolism (blockage in an artery of the lung);</p>
<p style="position:absolute;top:825px;left:106px;white-space:nowrap" class="ft3926"></p>
<p style="position:absolute;top:827px;left:147px;white-space:nowrap" class="ft3922">pleural effusion (abnormal collection of fluid in the pleural space);</p>
<p style="position:absolute;top:845px;left:106px;white-space:nowrap" class="ft3926"></p>
<p style="position:absolute;top:847px;left:147px;white-space:nowrap" class="ft3922">inflammation of the pancreas which causes severe pain in the abdomen and back;</p>
<p style="position:absolute;top:865px;left:106px;white-space:nowrap" class="ft3926"></p>
<p style="position:absolute;top:867px;left:147px;white-space:nowrap" class="ft3922">difficulty in swallowing;</p>
<p style="position:absolute;top:886px;left:106px;white-space:nowrap" class="ft3926"></p>
<p style="position:absolute;top:887px;left:147px;white-space:nowrap" class="ft3922">facial oedema;</p>
<p style="position:absolute;top:906px;left:106px;white-space:nowrap" class="ft3926"></p>
<p style="position:absolute;top:908px;left:147px;white-space:nowrap" class="ft3922">gallbladder inflammation, gallbladder stones;</p>
<p style="position:absolute;top:926px;left:106px;white-space:nowrap" class="ft3926"></p>
<p style="position:absolute;top:928px;left:147px;white-space:nowrap" class="ft3922">fatty liver;</p>
<p style="position:absolute;top:946px;left:106px;white-space:nowrap" class="ft3926"></p>
<p style="position:absolute;top:948px;left:147px;white-space:nowrap" class="ft3922">night sweats;</p>
<p style="position:absolute;top:966px;left:106px;white-space:nowrap" class="ft3926"></p>
<p style="position:absolute;top:968px;left:147px;white-space:nowrap" class="ft3922">scar;</p>
<p style="position:absolute;top:986px;left:106px;white-space:nowrap" class="ft3926"></p>
<p style="position:absolute;top:988px;left:147px;white-space:nowrap" class="ft3922">abnormal&#160;muscle breakdown;</p>
<p style="position:absolute;top:1006px;left:106px;white-space:nowrap" class="ft3926"></p>
<p style="position:absolute;top:1008px;left:147px;white-space:nowrap" class="ft3924">systemic lupus erythematosus (including inflammation of skin, heart, lung, joints and other organ&#160;<br/>systems);</p>
<p style="position:absolute;top:1046px;left:106px;white-space:nowrap" class="ft3926"></p>
<p style="position:absolute;top:1048px;left:147px;white-space:nowrap" class="ft3922">sleep interruptions;</p>
<p style="position:absolute;top:1066px;left:106px;white-space:nowrap" class="ft3926"></p>
<p style="position:absolute;top:1068px;left:147px;white-space:nowrap" class="ft3922">impotence;</p>
</div>
<!-- Page 393 -->
<a name="393"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page393-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3930">393</p>
<p style="position:absolute;top:85px;left:106px;white-space:nowrap" class="ft3936"></p>
<p style="position:absolute;top:87px;left:147px;white-space:nowrap" class="ft3932">inflammations.</p>
<p style="position:absolute;top:125px;left:106px;white-space:nowrap" class="ft3932">Rare (may affect up to 1 in 1,000 people)</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft3936"></p>
<p style="position:absolute;top:164px;left:147px;white-space:nowrap" class="ft3932">leukemia (cancer affecting the blood and bone marrow);</p>
<p style="position:absolute;top:182px;left:106px;white-space:nowrap" class="ft3936"></p>
<p style="position:absolute;top:184px;left:147px;white-space:nowrap" class="ft3932">severe allergic reaction with shock;</p>
<p style="position:absolute;top:203px;left:106px;white-space:nowrap" class="ft3936"></p>
<p style="position:absolute;top:204px;left:147px;white-space:nowrap" class="ft3932">multiple sclerosis;</p>
<p style="position:absolute;top:223px;left:106px;white-space:nowrap" class="ft3936"></p>
<p style="position:absolute;top:225px;left:147px;white-space:nowrap" class="ft3934">nerve disorders (such as eye nerve inflammation and Guillain-Barré syndrome that may cause&#160;<br/>muscle weakness, abnormal sensations, tingling in the arms and upper body);</p>
<p style="position:absolute;top:262px;left:106px;white-space:nowrap" class="ft3936"></p>
<p style="position:absolute;top:264px;left:147px;white-space:nowrap" class="ft3932">heart stops pumping;</p>
<p style="position:absolute;top:282px;left:106px;white-space:nowrap" class="ft3936"></p>
<p style="position:absolute;top:284px;left:147px;white-space:nowrap" class="ft3932">pulmonary fibrosis (scarring of the lung);</p>
<p style="position:absolute;top:302px;left:106px;white-space:nowrap" class="ft3936"></p>
<p style="position:absolute;top:304px;left:147px;white-space:nowrap" class="ft3932">intestinal perforation;</p>
<p style="position:absolute;top:322px;left:106px;white-space:nowrap" class="ft3936"></p>
<p style="position:absolute;top:324px;left:147px;white-space:nowrap" class="ft3932">hepatitis;</p>
<p style="position:absolute;top:343px;left:106px;white-space:nowrap" class="ft3936"></p>
<p style="position:absolute;top:345px;left:147px;white-space:nowrap" class="ft3932">reactivation of hepatitis B;</p>
<p style="position:absolute;top:363px;left:106px;white-space:nowrap" class="ft3936"></p>
<p style="position:absolute;top:365px;left:147px;white-space:nowrap" class="ft3932">autoimmune hepatitis&#160;(inflammation of the liver caused by the body's own immune system);</p>
<p style="position:absolute;top:383px;left:106px;white-space:nowrap" class="ft3936"></p>
<p style="position:absolute;top:385px;left:147px;white-space:nowrap" class="ft3932">cutaneous vasculitis (inflammation of blood vessels in the skin);</p>
<p style="position:absolute;top:403px;left:106px;white-space:nowrap" class="ft3936"></p>
<p style="position:absolute;top:405px;left:147px;white-space:nowrap" class="ft3932">Stevens-Johnson syndrome (early symptoms include malaise, fever, headache and rash);</p>
<p style="position:absolute;top:423px;left:106px;white-space:nowrap" class="ft3936"></p>
<p style="position:absolute;top:425px;left:147px;white-space:nowrap" class="ft3932">facial oedema associated with allergic reactions;</p>
<p style="position:absolute;top:443px;left:106px;white-space:nowrap" class="ft3936"></p>
<p style="position:absolute;top:445px;left:147px;white-space:nowrap" class="ft3932">erythema multiforme (inflammatory skin rash);</p>
<p style="position:absolute;top:464px;left:106px;white-space:nowrap" class="ft3936"></p>
<p style="position:absolute;top:465px;left:147px;white-space:nowrap" class="ft3932">lupus-like syndrome;</p>
<p style="position:absolute;top:484px;left:106px;white-space:nowrap" class="ft3936"></p>
<p style="position:absolute;top:486px;left:147px;white-space:nowrap" class="ft3932">angioedema (localized swelling of the skin);</p>
<p style="position:absolute;top:504px;left:106px;white-space:nowrap" class="ft3936"></p>
<p style="position:absolute;top:506px;left:147px;white-space:nowrap" class="ft3932">lichenoid skin reaction (itchy reddish-purple skin&#160;rash).</p>
<p style="position:absolute;top:544px;left:106px;white-space:nowrap" class="ft3932">Not known (frequency cannot be estimated from available data)</p>
<p style="position:absolute;top:581px;left:106px;white-space:nowrap" class="ft3936"></p>
<p style="position:absolute;top:583px;left:147px;white-space:nowrap" class="ft3932">hepatosplenic T-cell lymphoma (a rare blood cancer that is often fatal);</p>
<p style="position:absolute;top:601px;left:106px;white-space:nowrap" class="ft3936"></p>
<p style="position:absolute;top:603px;left:147px;white-space:nowrap" class="ft3932">Merkel cell carcinoma (a type of skin cancer);</p>
<p style="position:absolute;top:621px;left:106px;white-space:nowrap" class="ft3936"></p>
<p style="position:absolute;top:623px;left:147px;white-space:nowrap" class="ft3934">Kaposi’s sarcoma, a rare cancer related to infection with human herpes virus 8. Kaposi’s sarcoma&#160;<br/>most commonly appears as purple lesions&#160;on the skin;</p>
<p style="position:absolute;top:661px;left:106px;white-space:nowrap" class="ft3936"></p>
<p style="position:absolute;top:662px;left:147px;white-space:nowrap" class="ft3932">liver failure;</p>
<p style="position:absolute;top:681px;left:106px;white-space:nowrap" class="ft3936"></p>
<p style="position:absolute;top:683px;left:147px;white-space:nowrap" class="ft3935">worsening of a condition called dermatomyositis (seen as a skin rash accompanying muscle&#160;<br/>weakness);</p>
<p style="position:absolute;top:720px;left:106px;white-space:nowrap" class="ft3936"></p>
<p style="position:absolute;top:721px;left:147px;white-space:nowrap" class="ft3932">weight gain (for most patients, the weight gain was small).</p>
<p style="position:absolute;top:760px;left:106px;white-space:nowrap" class="ft3935">Some side effects observed with Humira may not have symptoms and&#160;may&#160;only be discovered through&#160;<br/>blood tests. These include:</p>
<p style="position:absolute;top:816px;left:106px;white-space:nowrap" class="ft3932">Very common (may affect more than 1 in 10 people)</p>
<p style="position:absolute;top:853px;left:106px;white-space:nowrap" class="ft3936"></p>
<p style="position:absolute;top:855px;left:147px;white-space:nowrap" class="ft3932">low blood measurements for white blood cells;</p>
<p style="position:absolute;top:874px;left:106px;white-space:nowrap" class="ft3936"></p>
<p style="position:absolute;top:876px;left:147px;white-space:nowrap" class="ft3932">low blood measurements for red blood cells;</p>
<p style="position:absolute;top:894px;left:106px;white-space:nowrap" class="ft3936"></p>
<p style="position:absolute;top:896px;left:147px;white-space:nowrap" class="ft3932">increased lipids in the blood;</p>
<p style="position:absolute;top:914px;left:106px;white-space:nowrap" class="ft3936"></p>
<p style="position:absolute;top:916px;left:147px;white-space:nowrap" class="ft3932">elevated liver enzymes.</p>
<p style="position:absolute;top:954px;left:106px;white-space:nowrap" class="ft3932">Common (may affect up to 1 in 10 people)</p>
<p style="position:absolute;top:991px;left:106px;white-space:nowrap" class="ft3936"></p>
<p style="position:absolute;top:993px;left:147px;white-space:nowrap" class="ft3932">high blood measurements for white blood cells; &#160;</p>
<p style="position:absolute;top:1012px;left:106px;white-space:nowrap" class="ft3936"></p>
<p style="position:absolute;top:1013px;left:147px;white-space:nowrap" class="ft3932">low blood measurements for platelets;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft3936"></p>
<p style="position:absolute;top:1034px;left:147px;white-space:nowrap" class="ft3932">increased uric acid in the blood;</p>
<p style="position:absolute;top:1052px;left:106px;white-space:nowrap" class="ft3936"></p>
<p style="position:absolute;top:1054px;left:147px;white-space:nowrap" class="ft3932">abnormal blood measurements for sodium;</p>
<p style="position:absolute;top:1072px;left:106px;white-space:nowrap" class="ft3936"></p>
<p style="position:absolute;top:1074px;left:147px;white-space:nowrap" class="ft3932">low blood measurements for calcium;</p>
</div>
<!-- Page 394 -->
<a name="394"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page394-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3940">394</p>
<p style="position:absolute;top:85px;left:106px;white-space:nowrap" class="ft3946"></p>
<p style="position:absolute;top:87px;left:147px;white-space:nowrap" class="ft3942">low blood measurements for phosphate;</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft3946"></p>
<p style="position:absolute;top:107px;left:147px;white-space:nowrap" class="ft3942">high blood sugar;</p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft3946"></p>
<p style="position:absolute;top:127px;left:147px;white-space:nowrap" class="ft3942">high blood measurements for lactate dehydrogenase;</p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft3946"></p>
<p style="position:absolute;top:148px;left:147px;white-space:nowrap" class="ft3942">autoantibodies present in the blood;</p>
<p style="position:absolute;top:166px;left:106px;white-space:nowrap" class="ft3946"></p>
<p style="position:absolute;top:168px;left:147px;white-space:nowrap" class="ft3942">low blood potassium.</p>
<p style="position:absolute;top:206px;left:106px;white-space:nowrap" class="ft3942">Uncommon&#160;(may affect up to 1 in 100 people)</p>
<p style="position:absolute;top:243px;left:106px;white-space:nowrap" class="ft3946"></p>
<p style="position:absolute;top:245px;left:147px;white-space:nowrap" class="ft3942">elevated bilirubin measurement (liver blood test).</p>
<p style="position:absolute;top:283px;left:106px;white-space:nowrap" class="ft3942">Rare (may&#160;affect up to 1 in 1,000 people)</p>
<p style="position:absolute;top:320px;left:106px;white-space:nowrap" class="ft3946"></p>
<p style="position:absolute;top:322px;left:147px;white-space:nowrap" class="ft3942">low blood measurements for white blood cells, red blood cells and platelet count.</p>
<p style="position:absolute;top:360px;left:106px;white-space:nowrap" class="ft3945"><b>Reporting of side effects<br/></b>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not&#160;<br/>listed in this leaflet.&#160;You can also report side effects directly via&#160;the national reporting system listed in&#160;<br/><a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix V.&#160;</a>By reporting side effects, you can help provide more information on the safety of this&#160;<br/>medicine.&#160;</p>
<p style="position:absolute;top:493px;left:106px;white-space:nowrap" class="ft3941"><b>5.</b></p>
<p style="position:absolute;top:493px;left:148px;white-space:nowrap" class="ft3941"><b>How to store Humira</b></p>
<p style="position:absolute;top:531px;left:106px;white-space:nowrap" class="ft3942">Keep this medicine out of the sight and reach of&#160;children.</p>
<p style="position:absolute;top:568px;left:106px;white-space:nowrap" class="ft3942">Do not use this medicine after the expiry date stated on the&#160;label/blister/carton after EXP.</p>
<p style="position:absolute;top:608px;left:106px;white-space:nowrap" class="ft3942">Store in a refrigerator (2</p>
<p style="position:absolute;top:606px;left:266px;white-space:nowrap" class="ft3946">C&#160;–&#160;8C). Do not freeze.</p>
<p style="position:absolute;top:646px;left:106px;white-space:nowrap" class="ft3942">Keep the pre-filled pen in the outer carton in order to protect from light.</p>
<p style="position:absolute;top:684px;left:106px;white-space:nowrap" class="ft3942">Alternative Storage:</p>
<p style="position:absolute;top:721px;left:106px;white-space:nowrap" class="ft39419">When needed (for example when you are travelling), a single Humira pre-filled pen may be stored at room&#160;<br/>temperature (up to 25°C) for a maximum period of 14 days&#160;–&#160;be sure to protect it from light. Once&#160;<br/>removed from the refrigerator for room temperature storage, the pen&#160;<b>must be used within 14 days&#160;or&#160;<br/>discarded</b>, even if it is returned to the refrigerator. &#160;</p>
<p style="position:absolute;top:816px;left:106px;white-space:nowrap" class="ft3944">You should record the date when the pen is first removed from refrigerator and the date after which it&#160;<br/>should be discarded.</p>
<p style="position:absolute;top:873px;left:106px;white-space:nowrap" class="ft3944">Do not throw away any medicines via wastewater or household waste. Ask your doctor or pharmacist how&#160;<br/>to throw away medicines you no longer use. These measures will help protect the environment.</p>
<p style="position:absolute;top:949px;left:106px;white-space:nowrap" class="ft3941"><b>6.</b></p>
<p style="position:absolute;top:949px;left:148px;white-space:nowrap" class="ft3941"><b>Contents of the pack and other information</b></p>
<p style="position:absolute;top:987px;left:106px;white-space:nowrap" class="ft3941"><b>What Humira contains</b></p>
<p style="position:absolute;top:1025px;left:106px;white-space:nowrap" class="ft3944">The active substance is adalimumab.<br/>The&#160;other ingredients are mannitol, citric acid monohydrate, sodium citrate, sodium dihydrogen phosphate&#160;<br/>dihydrate, disodium phosphate dihydrate, sodium chloride, polysorbate 80, sodium hydroxide and water&#160;<br/>for injections.</p>
</div>
<!-- Page 395 -->
<a name="395"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page395-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3950">395</p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft3951"><b>What the&#160;Humira pre-filled pen looks like and contents of the pack</b></p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft3955">Humira 40&#160;mg solution for injection in pre-filled pen is supplied as a sterile solution of 40&#160;mg adalimumab&#160;<br/>dissolved in 0.8&#160;ml solution.</p>
<p style="position:absolute;top:219px;left:106px;white-space:nowrap" class="ft3954">The Humira pre-filled pen is a single-use grey and plum-coloured pen which contains a glass syringe with&#160;<br/>Humira. There are two caps&#160;–&#160;one is grey and labelled ‘1’ and the other is plum and labelled ‘2’. There is a&#160;<br/>window on each side of the pen through which you can see the Humira solution inside the syringe. &#160;</p>
<p style="position:absolute;top:295px;left:106px;white-space:nowrap" class="ft3954">The Humira pre-filled pen is available in packs containing 1, 2, 4 and 6 pre-filled pens.&#160;The 1 pre-filled&#160;<br/>pen pack comes with 2 alcohol pads (1 spare). For the 2, 4 and 6 pre-filled pen packs, each&#160;pre-filled pen&#160;<br/>comes with 1 alcohol pad.&#160;&#160;</p>
<p style="position:absolute;top:370px;left:106px;white-space:nowrap" class="ft3952">Not all pack sizes may be marketed. &#160;</p>
<p style="position:absolute;top:409px;left:106px;white-space:nowrap" class="ft3952">Humira&#160;may be&#160;available as a vial, a pre-filled syringe and/or&#160;a pre-filled pen.</p>
<p style="position:absolute;top:446px;left:106px;white-space:nowrap" class="ft3951"><b>Marketing Authorisation Holder</b></p>
<p style="position:absolute;top:485px;left:106px;white-space:nowrap" class="ft3954">AbbVie Deutschland GmbH &amp; Co. KG<br/>Knollstrasse<br/>67061 Ludwigshafen<br/>Germany</p>
<p style="position:absolute;top:579px;left:106px;white-space:nowrap" class="ft3951"><b>Manufacturer&#160;</b></p>
<p style="position:absolute;top:617px;left:106px;white-space:nowrap" class="ft3954">AbbVie Biotechnology GmbH<br/>Knollstrasse<br/>67061 Ludwigshafen<br/>Germany</p>
<p style="position:absolute;top:712px;left:106px;white-space:nowrap" class="ft3954">For any information about this medicine, please contact the local representative of the Marketing&#160;<br/>Authorisation Holder.</p>
<p style="position:absolute;top:771px;left:114px;white-space:nowrap" class="ft3954"><b>België/Belgique/Belgien<br/></b>AbbVie SA<br/>Tél/Tel: +32 10&#160;&#160;477811</p>
<p style="position:absolute;top:771px;left:462px;white-space:nowrap" class="ft3955"><b>Lietuva<br/></b>AbbVie UAB&#160;<br/>Tel: +370 5 205 3023</p>
<p style="position:absolute;top:848px;left:114px;white-space:nowrap" class="ft3954"><b>България<br/></b>АбВи ЕООД<br/>Тел.:+359 2 90 30 430</p>
<p style="position:absolute;top:848px;left:462px;white-space:nowrap" class="ft3954"><b>Luxembourg/Luxemburg<br/></b>AbbVie SA<br/>Belgique/Belgien<br/>Tél/Tel: +32 10 477811</p>
<p style="position:absolute;top:942px;left:114px;white-space:nowrap" class="ft3954"><b>Česká republika<br/></b>AbbVie s.r.o.&#160;<br/>Tel: +420 233 098 111</p>
<p style="position:absolute;top:942px;left:462px;white-space:nowrap" class="ft3954"><b>Magyarország<br/></b>AbbVie&#160;Kft.<br/>Tel.:+36 1 455 8600</p>
<p style="position:absolute;top:1018px;left:114px;white-space:nowrap" class="ft3955"><b>Danmark<br/></b>AbbVie A/S<br/>Tlf: +45 72 30-20-28</p>
<p style="position:absolute;top:1018px;left:462px;white-space:nowrap" class="ft3955"><b>Malta<br/></b>V.J.Salomone Pharma Limited&#160;<br/>Tel: +356 22983201</p>
</div>
<!-- Page 396 -->
<a name="396"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page396-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3960">396</p>
<p style="position:absolute;top:86px;left:114px;white-space:nowrap" class="ft3964"><b>Deutschland<br/></b>AbbVie Deutschland&#160;GmbH &amp; Co. KG<br/>Tel: 00800 222843 33 (gebührenfrei)<br/>Tel: +49 (0) 611&#160;/&#160;1720-0</p>
<p style="position:absolute;top:86px;left:462px;white-space:nowrap" class="ft3964"><b>Nederland<br/></b>AbbVie B.V.<br/>Tel:&#160;&#160;+31 (0)88 322 2843</p>
<p style="position:absolute;top:181px;left:114px;white-space:nowrap" class="ft3964"><b>Eesti<br/></b>AbbVie&#160;OÜ<br/>Tel: +372 623 1011</p>
<p style="position:absolute;top:181px;left:462px;white-space:nowrap" class="ft3964"><b>Norge<br/></b>AbbVie AS<br/>Tlf: +47 67 81 80 00</p>
<p style="position:absolute;top:257px;left:114px;white-space:nowrap" class="ft3964"><b>Ελλάδα<br/></b>AbbVie&#160;ΦΑΡΜΑΚΕΥΤΙΚΗ Α.Ε.<br/>Τηλ: +30&#160;214 4165 555</p>
<p style="position:absolute;top:257px;left:462px;white-space:nowrap" class="ft3964"><b>Österreich<br/></b>AbbVie GmbH&#160;<br/>Tel: +43 1 20589-0</p>
<p style="position:absolute;top:324px;left:114px;white-space:nowrap" class="ft3964"><b>España<br/></b>AbbVie Spain, S.L.U.<br/>Tel: &#160;+34 91 384 09 10</p>
<p style="position:absolute;top:324px;left:462px;white-space:nowrap" class="ft3964"><b>Polska<br/></b>AbbVie Sp. z o.o.<br/>Tel.: +48 22&#160;372 78 00&#160;</p>
<p style="position:absolute;top:400px;left:114px;white-space:nowrap" class="ft3964"><b>France<br/></b>AbbVie<br/>Tél: +33 (0) 1 45 60 13 00</p>
<p style="position:absolute;top:400px;left:462px;white-space:nowrap" class="ft3964"><b>Portugal<br/></b>AbbVie, Lda.&#160;<br/>Tel: +351 (0)21 1908400</p>
<p style="position:absolute;top:474px;left:114px;white-space:nowrap" class="ft3964"><b>Hrvatska&#160;<br/></b>AbbVie d.o.o.<br/>Tel + 385 (0)1&#160;5625 501</p>
<p style="position:absolute;top:474px;left:462px;white-space:nowrap" class="ft3964"><b>România<br/></b>AbbVie S.R.L.<br/>Tel: +40 21 529 30 35</p>
<p style="position:absolute;top:550px;left:114px;white-space:nowrap" class="ft3964"><b>Ireland<br/></b>AbbVie Limited&#160;<br/>Tel:&#160;+353 (0)1 4287900</p>
<p style="position:absolute;top:550px;left:462px;white-space:nowrap" class="ft3964"><b>Slovenija<br/></b>AbbVie Biofarmacevtska družba d.o.o.<br/>Tel: +386 (1)32 08 060</p>
<p style="position:absolute;top:626px;left:114px;white-space:nowrap" class="ft3964"><b>Ísland<br/></b>Vistor hf.<br/>Tel: +354 535 7000</p>
<p style="position:absolute;top:626px;left:462px;white-space:nowrap" class="ft3964"><b>Slovenská republika<br/></b>AbbVie s.r.o.<br/>Tel: +421 2 5050 0777</p>
<p style="position:absolute;top:702px;left:114px;white-space:nowrap" class="ft3964"><b>Italia<br/></b>AbbVie S.r.l.&#160;<br/>Tel: +39 06 928921</p>
<p style="position:absolute;top:702px;left:462px;white-space:nowrap" class="ft3965"><b>Suomi/Finland<br/></b>AbbVie Oy&#160;<br/>Puh/Tel: &#160;+358 (0)10 2411 200</p>
<p style="position:absolute;top:779px;left:114px;white-space:nowrap" class="ft3964"><b>Κύπρος<br/></b>Lifepharma (Z.A.M.) Ltd<br/>Τηλ.: +357 22 34 74 40</p>
<p style="position:absolute;top:779px;left:462px;white-space:nowrap" class="ft3964"><b>Sverige<br/></b>AbbVie AB<br/>Tel: &#160;+46 (0)8 684 44 600</p>
<p style="position:absolute;top:855px;left:114px;white-space:nowrap" class="ft3964"><b>Latvija<br/></b>AbbVie SIA&#160;<br/>Tel: +371 67605000</p>
<p style="position:absolute;top:855px;left:462px;white-space:nowrap" class="ft3964"><b>United Kingdom&#160;(Northern Ireland)<br/></b>AbbVie Deutschland GmbH &amp; Co. KG<br/>Tel: +44 (0)1628&#160;561090</p>
<p style="position:absolute;top:931px;left:106px;white-space:nowrap" class="ft3961"><b>This leaflet was last revised in</b></p>
<p style="position:absolute;top:969px;left:106px;white-space:nowrap" class="ft3964">Detailed information on this medicine is available on the European Medicines Agency web site:&#160;<br/><a href="http://www.ema.europa.eu./">http://www.ema.europa.eu.</a></p>
<p style="position:absolute;top:1026px;left:106px;white-space:nowrap" class="ft39619"><b>To listen to or request a copy of this leaflet in&#160;&lt;Braille&gt;, &lt;large print&gt; or &lt;audio&gt;, please contact the&#160;<br/>local representative of the Marketing Authorisation Holder.</b></p>
</div>
<!-- Page 397 -->
<a name="397"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page397-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3970">397</p>
<p style="position:absolute;top:86px;left:306px;white-space:nowrap" class="ft3971"><b>Package leaflet: Information for the patient</b></p>
<p style="position:absolute;top:124px;left:261px;white-space:nowrap" class="ft3971"><b>Humira 40&#160;mg&#160;solution for injection in pre-filled syringe</b></p>
<p style="position:absolute;top:143px;left:418px;white-space:nowrap" class="ft3972">adalimumab</p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft39719"><b>Read all of this&#160;leaflet carefully before you start using this medicine because it contains important&#160;<br/>information for you.</b></p>
<p style="position:absolute;top:218px;left:106px;white-space:nowrap" class="ft3976"></p>
<p style="position:absolute;top:220px;left:148px;white-space:nowrap" class="ft3972">Keep this leaflet. You may need to read it again.</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft3976"></p>
<p style="position:absolute;top:240px;left:148px;white-space:nowrap" class="ft3975">Your doctor will also give you a&#160;<b>Patient Reminder Card</b>, which contains important safety&#160;<br/>information that you need to be aware of before you begin using Humira and during treatment with&#160;<br/>Humira. Keep this&#160;<b>Patient Reminder Card&#160;</b>with you.</p>
<p style="position:absolute;top:296px;left:106px;white-space:nowrap" class="ft3976"></p>
<p style="position:absolute;top:298px;left:148px;white-space:nowrap" class="ft3972">If you have any questions, ask your doctor or pharmacist.</p>
<p style="position:absolute;top:316px;left:106px;white-space:nowrap" class="ft3976"></p>
<p style="position:absolute;top:318px;left:148px;white-space:nowrap" class="ft3974">This medicine has&#160;been prescribed for you only. Do not pass it on to others. It may harm them, even&#160;<br/>if their signs of illness are the same as yours.</p>
<p style="position:absolute;top:356px;left:106px;white-space:nowrap" class="ft3976"></p>
<p style="position:absolute;top:357px;left:148px;white-space:nowrap" class="ft3974">If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects&#160;<br/>not listed in this leaflet. See section 4.</p>
<p style="position:absolute;top:414px;left:106px;white-space:nowrap" class="ft39719"><b>What is in this leaflet<br/></b>1.</p>
<p style="position:absolute;top:433px;left:148px;white-space:nowrap" class="ft3972">What Humira is and what it is used for</p>
<p style="position:absolute;top:453px;left:106px;white-space:nowrap" class="ft3972">2.</p>
<p style="position:absolute;top:453px;left:148px;white-space:nowrap" class="ft3972">What you need to know before you use Humira</p>
<p style="position:absolute;top:471px;left:106px;white-space:nowrap" class="ft3972">3.</p>
<p style="position:absolute;top:471px;left:148px;white-space:nowrap" class="ft3972">How to use Humira</p>
<p style="position:absolute;top:490px;left:106px;white-space:nowrap" class="ft3972">4.</p>
<p style="position:absolute;top:490px;left:148px;white-space:nowrap" class="ft3972">Possible side effects</p>
<p style="position:absolute;top:509px;left:106px;white-space:nowrap" class="ft3972">5</p>
<p style="position:absolute;top:509px;left:148px;white-space:nowrap" class="ft3972">How to store Humira</p>
<p style="position:absolute;top:528px;left:106px;white-space:nowrap" class="ft3972">6.</p>
<p style="position:absolute;top:528px;left:148px;white-space:nowrap" class="ft3972">Contents of the pack and other information</p>
<p style="position:absolute;top:547px;left:106px;white-space:nowrap" class="ft3972">7.</p>
<p style="position:absolute;top:547px;left:148px;white-space:nowrap" class="ft3972">Injecting Humira</p>
<p style="position:absolute;top:604px;left:106px;white-space:nowrap" class="ft3971"><b>1.</b></p>
<p style="position:absolute;top:604px;left:148px;white-space:nowrap" class="ft3971"><b>What Humira is and what it is used for</b></p>
<p style="position:absolute;top:642px;left:106px;white-space:nowrap" class="ft3972">Humira contains the active substance adalimumab.</p>
<p style="position:absolute;top:680px;left:106px;white-space:nowrap" class="ft3972">Humira is used to treat</p>
<p style="position:absolute;top:698px;left:133px;white-space:nowrap" class="ft3976">&#160;Rheumatoid arthritis</p>
<p style="position:absolute;top:718px;left:133px;white-space:nowrap" class="ft3976">&#160;Polyarticular juvenile idiopathic arthritis</p>
<p style="position:absolute;top:739px;left:133px;white-space:nowrap" class="ft3976">&#160;Enthesitis-related arthritis</p>
<p style="position:absolute;top:759px;left:133px;white-space:nowrap" class="ft3976">&#160;Ankylosing spondylitis</p>
<p style="position:absolute;top:779px;left:133px;white-space:nowrap" class="ft3976">&#160;Axial spondyloarthritis without radiographic evidence of ankylosing spondylitis</p>
<p style="position:absolute;top:799px;left:133px;white-space:nowrap" class="ft3976">&#160;Psoriatic arthritis</p>
<p style="position:absolute;top:819px;left:133px;white-space:nowrap" class="ft3976">&#160;Plaque psoriasis</p>
<p style="position:absolute;top:839px;left:133px;white-space:nowrap" class="ft3976">&#160;Hidradenitis suppurativa</p>
<p style="position:absolute;top:860px;left:133px;white-space:nowrap" class="ft3976">&#160;Crohn’s disease</p>
<p style="position:absolute;top:880px;left:133px;white-space:nowrap" class="ft3976">&#160;Ulcerative colitis</p>
<p style="position:absolute;top:900px;left:133px;white-space:nowrap" class="ft3976">&#160;Non-infectious uveitis</p>
<p style="position:absolute;top:940px;left:106px;white-space:nowrap" class="ft3974">The active ingredient in Humira, adalimumab, is a human&#160;monoclonal antibody. Monoclonal antibodies&#160;<br/>are&#160;proteins that attach to a specific target.</p>
<p style="position:absolute;top:997px;left:106px;white-space:nowrap" class="ft3974">The target of adalimumab is a protein called tumour necrosis factor (TNFα), which is involved in the&#160;<br/>immune (defence) system and is present at increased levels in the&#160;inflammatory diseases listed above. By&#160;<br/>attaching to TNFα, Humira decreases the process of inflammation in these diseases.</p>
</div>
<!-- Page 398 -->
<a name="398"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page398-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3980">398</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft3981"><b>Rheumatoid arthritis</b></p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft3982">Rheumatoid arthritis is an inflammatory disease of the joints.</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft3984">Humira is used to treat moderate to severe&#160;rheumatoid arthritis in adults. You may first be given other&#160;<br/>disease-modifying medicines, such as methotrexate. If you do not respond well enough to these medicines,&#160;<br/>you will be given Humira.</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft3984">Humira can also be used to treat severe, active and progressive&#160;rheumatoid arthritis without previous&#160;<br/>methotrexate treatment.</p>
<p style="position:absolute;top:295px;left:106px;white-space:nowrap" class="ft3985">Humira can slow down the damage to the joints caused by the inflammatory disease and can help them&#160;<br/>move&#160;more freely.&#160;</p>
<p style="position:absolute;top:352px;left:106px;white-space:nowrap" class="ft3982">Your doctor will decide if&#160;Humira&#160;should be&#160;used with methotrexate&#160;or&#160;alone.</p>
<p style="position:absolute;top:390px;left:106px;white-space:nowrap" class="ft3981"><b>Polyarticular juvenile idiopathic arthritis</b></p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft3982">Polyarticular juvenile idiopathic arthritis is an inflammatory disease of the joints.</p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft3985">Humira is used to treat polyarticular juvenile idiopathic arthritis in patients from 2 years of age. You may&#160;<br/>first be&#160;given other disease-modifying medicines, such as methotrexate. If you do not respond well enough&#160;<br/>to these medicines, you will be given Humira.</p>
<p style="position:absolute;top:541px;left:106px;white-space:nowrap" class="ft3982">Your doctor will decide if Humira should be used with methotrexate or alone.</p>
<p style="position:absolute;top:579px;left:106px;white-space:nowrap" class="ft3981"><b>Enthesitis-related arthritis</b></p>
<p style="position:absolute;top:617px;left:106px;white-space:nowrap" class="ft3984">Enthesitis-related arthritis is an inflammatory disease of the joints and the places where tendons join the&#160;<br/>bone.</p>
<p style="position:absolute;top:674px;left:106px;white-space:nowrap" class="ft3984">Humira is used to treat enthesitis-related arthritis in patients from 6 years of age. You may first be given&#160;<br/>other disease-modifying medicines,&#160;such as methotrexate. If you do not respond well enough to these&#160;<br/>medicines, you will be given Humira.</p>
<p style="position:absolute;top:750px;left:106px;white-space:nowrap" class="ft39819"><b>Ankylosing spondylitis and axial spondyloarthritis without radiographic evidence of ankylosing&#160;<br/>spondylitis&#160;</b></p>
<p style="position:absolute;top:807px;left:106px;white-space:nowrap" class="ft3985">Ankylosing spondylitis and axial&#160;spondyloarthritis without radiographic evidence of ankylosing&#160;<br/>spondylitis are inflammatory diseases of the spine.</p>
<p style="position:absolute;top:864px;left:106px;white-space:nowrap" class="ft3984">Humira is used to treat severe ankylosing spondylitis and axial spondyloarthritis without radiographic&#160;<br/>evidence of ankylosing spondylitis in&#160;adults. You may&#160;first be given other medicines. If you do not&#160;<br/>respond well enough to these medicines, you will be given Humira.</p>
<p style="position:absolute;top:940px;left:106px;white-space:nowrap" class="ft3981"><b>Psoriatic arthritis</b></p>
<p style="position:absolute;top:978px;left:106px;white-space:nowrap" class="ft3982">Psoriatic arthritis is an inflammatory disease of the joints that is usually associated with psoriasis.</p>
<p style="position:absolute;top:1016px;left:106px;white-space:nowrap" class="ft3984">Humira is used to treat psoriatic arthritis in adults. Humira can slow down the damage to the joints caused&#160;<br/>by the disease and can help them move more freely. You may first be given other medicines. If you do not&#160;<br/>respond well enough to these medicines, you&#160;will be given Humira.</p>
</div>
<!-- Page 399 -->
<a name="399"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page399-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft3990">399</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft3991"><b>Plaque psoriasis&#160;</b></p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft3994">Plaque psoriasis is a skin condition that causes red, flaky, crusty patches of skin covered with silvery&#160;<br/>scales. Plaque psoriasis can also affect the nails, causing them to crumble, become thickened and lift away&#160;<br/>from&#160;the&#160;nail bed which can be painful.</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft3992">Humira is used to treat</p>
<p style="position:absolute;top:218px;left:133px;white-space:nowrap" class="ft3996">&#160;moderate to severe chronic plaque psoriasis in adults and&#160;</p>
<p style="position:absolute;top:238px;left:133px;white-space:nowrap" class="ft3996">&#160;severe&#160;chronic&#160;plaque psoriasis in children and adolescents aged 4 to 17 years for whom topical&#160;</p>
<p style="position:absolute;top:259px;left:160px;white-space:nowrap" class="ft3992">therapy and phototherapies have either not worked very well or are not suitable.</p>
<p style="position:absolute;top:297px;left:106px;white-space:nowrap" class="ft3991"><b>Hidradenitis suppurativa</b></p>
<p style="position:absolute;top:335px;left:106px;white-space:nowrap" class="ft3994">Hidradenitis suppurativa (sometimes called acne inversa) is a chronic and often painful inflammatory skin&#160;<br/>disease. Symptoms may include tender nodules (lumps) and abscesses (boils) that may leak pus. It most&#160;<br/>commonly affects specific areas of the skin, suc<a href="http://en.wikipedia.org/wiki/Inframammary_fold">h as&#160;under the breasts, the armpits, inner thighs, groin and&#160;<br/></a>buttocks.&#160;Scarring may also occur in affected areas.</p>
<p style="position:absolute;top:430px;left:106px;white-space:nowrap" class="ft3992">Humira is used to treat&#160;</p>
<p style="position:absolute;top:448px;left:133px;white-space:nowrap" class="ft3996">&#160;moderate to severe hidradenitis suppurativa in adults&#160;and</p>
<p style="position:absolute;top:468px;left:133px;white-space:nowrap" class="ft3996">&#160;moderate to severe hidradenitis suppurativa in adolescents aged 12 to 17&#160;years.</p>
<p style="position:absolute;top:508px;left:106px;white-space:nowrap" class="ft3994">Humira can reduce the number of nodules and abscesses caused by the disease and the pain that is often&#160;<br/>associated with the disease.&#160;You may first be given other medicines. If you do not respond well enough to&#160;<br/>these medicines, you will be given Humira.</p>
<p style="position:absolute;top:584px;left:106px;white-space:nowrap" class="ft3991"><b>Crohn’s disease&#160;</b></p>
<p style="position:absolute;top:622px;left:106px;white-space:nowrap" class="ft3992">Crohn’s disease is an inflammatory disease of the digestive tract.</p>
<p style="position:absolute;top:660px;left:106px;white-space:nowrap" class="ft3992">Humira is used to treat</p>
<p style="position:absolute;top:678px;left:133px;white-space:nowrap" class="ft3996">&#160;moderate to severe Crohn’s disease in adults and&#160;</p>
<p style="position:absolute;top:698px;left:133px;white-space:nowrap" class="ft3996">&#160;moderate to&#160;severe Crohn’s disease in children and adolescents aged 6 to 17 years</p>
<p style="position:absolute;top:738px;left:106px;white-space:nowrap" class="ft3994">You may&#160;first be given other medicines. If you do not respond well enough to these medicines, you will be&#160;<br/>given Humira.</p>
<p style="position:absolute;top:795px;left:106px;white-space:nowrap" class="ft3991"><b>Ulcerative colitis</b></p>
<p style="position:absolute;top:833px;left:106px;white-space:nowrap" class="ft3992">Ulcerative colitis is an inflammatory&#160;disease of the large intestine.</p>
<p style="position:absolute;top:871px;left:106px;white-space:nowrap" class="ft3992">Humira is used to treat&#160;</p>
<p style="position:absolute;top:889px;left:133px;white-space:nowrap" class="ft3996">&#160;moderate to severe ulcerative colitis in adults&#160;and</p>
<p style="position:absolute;top:909px;left:133px;white-space:nowrap" class="ft3996">&#160;moderate to severe ulcerative colitis in children and adolescents aged 6 to 17 years.</p>
<p style="position:absolute;top:949px;left:106px;white-space:nowrap" class="ft3995">You may&#160;first be given other medicines. If you do not respond well enough to these medicines, you will be&#160;<br/>given Humira.</p>
<p style="position:absolute;top:1006px;left:106px;white-space:nowrap" class="ft3991"><b>Non-infectious uveitis</b></p>
<p style="position:absolute;top:1044px;left:106px;white-space:nowrap" class="ft3992">Non-infectious uveitis is an inflammatory disease affecting certain parts of the eye.</p>
<p style="position:absolute;top:1082px;left:106px;white-space:nowrap" class="ft3992">Humira is used to treat&#160;</p>
</div>
<!-- Page 400 -->
<a name="400"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page400-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4000">400</p>
<p style="position:absolute;top:85px;left:133px;white-space:nowrap" class="ft4006">&#160;adults&#160;with non-infectious uveitis with inflammation affecting the back of the eye</p>
<p style="position:absolute;top:105px;left:133px;white-space:nowrap" class="ft4006">&#160;children&#160;with chronic non-infectious uveitis&#160;from 2&#160;years of age&#160;with inflammation affecting the&#160;</p>
<p style="position:absolute;top:126px;left:160px;white-space:nowrap" class="ft4002">front of the eye</p>
<p style="position:absolute;top:164px;left:106px;white-space:nowrap" class="ft4004">This inflammation may lead to a decrease of vision and/or the presence of floaters in the eye (black dots or&#160;<br/>wispy&#160;lines that move across the field of vision). Humira works by reducing this inflammation.</p>
<p style="position:absolute;top:221px;left:106px;white-space:nowrap" class="ft4004">You may first be given other medicines. If you do not respond well enough to these medicines, you will be&#160;<br/>given Humira.</p>
<p style="position:absolute;top:297px;left:106px;white-space:nowrap" class="ft4001"><b>2.</b></p>
<p style="position:absolute;top:297px;left:148px;white-space:nowrap" class="ft4001"><b>What you need to know before you use Humira</b></p>
<p style="position:absolute;top:335px;left:106px;white-space:nowrap" class="ft4001"><b>Do not use Humira:</b></p>
<p style="position:absolute;top:372px;left:133px;white-space:nowrap" class="ft4006">&#160;If you are allergic to adalimumab or any of the other ingredients of this medicine (listed in section&#160;</p>
<p style="position:absolute;top:393px;left:160px;white-space:nowrap" class="ft4002">6).&#160;</p>
<p style="position:absolute;top:430px;left:133px;white-space:nowrap" class="ft4006">&#160;If you have active tuberculosis or other severe infections (see “Warnings and precautions”). It is&#160;</p>
<p style="position:absolute;top:451px;left:160px;white-space:nowrap" class="ft4004">important that you tell&#160;your doctor if you have symptoms of infections, for example, fever,&#160;<br/>wounds, feeling tired, dental problems.</p>
<p style="position:absolute;top:508px;left:133px;white-space:nowrap" class="ft4006">&#160;If you have moderate or severe heart failure. It is important to tell your doctor if you have had or&#160;</p>
<p style="position:absolute;top:528px;left:160px;white-space:nowrap" class="ft4002">have a serious heart condition (see “Warnings&#160;and precautions”).</p>
<p style="position:absolute;top:566px;left:106px;white-space:nowrap" class="ft4001"><b>Warnings and precautions</b></p>
<p style="position:absolute;top:604px;left:106px;white-space:nowrap" class="ft4002">Talk to your doctor or pharmacist before using Humira.</p>
<p style="position:absolute;top:642px;left:106px;white-space:nowrap" class="ft4002">Allergic reactions</p>
<p style="position:absolute;top:679px;left:133px;white-space:nowrap" class="ft4006">&#160;If you get allergic reactions with symptoms such as chest tightness, wheezing, dizziness, swelling&#160;</p>
<p style="position:absolute;top:700px;left:160px;white-space:nowrap" class="ft4004">or rash do not inject more Humira and contact your doctor immediately since, in rare cases, these&#160;<br/>reactions can be life threatening.</p>
<p style="position:absolute;top:757px;left:106px;white-space:nowrap" class="ft4002">Infections</p>
<p style="position:absolute;top:794px;left:133px;white-space:nowrap" class="ft4006">&#160;If you have an infection, including long-term&#160;infection or an infection in one part of the body (for&#160;</p>
<p style="position:absolute;top:815px;left:160px;white-space:nowrap" class="ft4005">example, leg ulcer) consult your doctor before starting Humira. If you are unsure, contact your&#160;<br/>doctor.&#160;</p>
<p style="position:absolute;top:871px;left:133px;white-space:nowrap" class="ft4006">&#160;You might get infections more easily while you are receiving Humira treatment. This risk may&#160;</p>
<p style="position:absolute;top:892px;left:160px;white-space:nowrap" class="ft4002">increase if you have problems with your lungs. These infections may be serious and include:&#160;</p>
<p style="position:absolute;top:911px;left:187px;white-space:nowrap" class="ft4006">&#160;tuberculosis</p>
<p style="position:absolute;top:931px;left:187px;white-space:nowrap" class="ft4006">&#160;infections caused by viruses, fungi, parasites or bacteria</p>
<p style="position:absolute;top:951px;left:187px;white-space:nowrap" class="ft4006">&#160;severe infection in the blood (sepsis)</p>
<p style="position:absolute;top:991px;left:160px;white-space:nowrap" class="ft4005">In rare&#160;cases, these infections can be life-threatening. It is important to tell your doctor if you get&#160;<br/>symptoms such as fever, wounds, feeling tired or dental problems. Your doctor may tell you to&#160;<br/>stop using Humira for some time.</p>
</div>
<!-- Page 401 -->
<a name="401"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page401-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4010">401</p>
<p style="position:absolute;top:85px;left:133px;white-space:nowrap" class="ft4016">&#160;Tell your doctor if you live or&#160;travel in regions where&#160;fungal infections&#160;(for example,&#160;</p>
<p style="position:absolute;top:106px;left:160px;white-space:nowrap" class="ft4012">histoplasmosis, coccidioidomycosis or blastomycosis) are very common.</p>
<p style="position:absolute;top:143px;left:133px;white-space:nowrap" class="ft4016">&#160;Tell your doctor if you have had infections which keep coming back or other conditions that&#160;</p>
<p style="position:absolute;top:164px;left:160px;white-space:nowrap" class="ft4012">increase the risk of infections.</p>
<p style="position:absolute;top:202px;left:133px;white-space:nowrap" class="ft4016">&#160;If&#160;you are over 65 years you may be more likely to get infections while taking Humira. You and&#160;</p>
<p style="position:absolute;top:222px;left:160px;white-space:nowrap" class="ft4014">your doctor should pay special attention to signs of infection while you are being treated with&#160;<br/>Humira. It is important to tell your doctor if you get symptoms of&#160;infections, such as fever,&#160;<br/>wounds, feeling tired or dental problems.</p>
<p style="position:absolute;top:298px;left:106px;white-space:nowrap" class="ft4012">Tuberculosis</p>
<p style="position:absolute;top:335px;left:133px;white-space:nowrap" class="ft4016">&#160;It is very important that you tell your doctor if you have ever had tuberculosis, or if you have been&#160;</p>
<p style="position:absolute;top:356px;left:160px;white-space:nowrap" class="ft4014">in close contact with someone who has had tuberculosis.&#160;If you have&#160;active tuberculosis, do not&#160;<br/>use Humira.</p>
<p style="position:absolute;top:412px;left:187px;white-space:nowrap" class="ft4016">&#160;As cases of tuberculosis have been reported in patients treated with Humira, your doctor&#160;</p>
<p style="position:absolute;top:433px;left:214px;white-space:nowrap" class="ft4014">will check you for signs and symptoms of tuberculosis before starting Humira. This will&#160;<br/>include a thorough medical evaluation&#160;including your medical history and appropriate&#160;<br/>screening tests (for example, chest X-ray and a tuberculin test). The conduct and results of&#160;<br/>these tests should be recorded on your&#160;<b>Patient Reminder Card</b>.&#160;</p>
<p style="position:absolute;top:509px;left:187px;white-space:nowrap" class="ft4016">&#160;Tuberculosis can develop during therapy even if you have&#160;received treatment for the&#160;</p>
<p style="position:absolute;top:530px;left:214px;white-space:nowrap" class="ft4012">prevention of tuberculosis.&#160;</p>
<p style="position:absolute;top:548px;left:187px;white-space:nowrap" class="ft4016">&#160;If symptoms of tuberculosis (for example, cough that does not go away, weight loss, lack&#160;</p>
<p style="position:absolute;top:568px;left:214px;white-space:nowrap" class="ft4014">of&#160;energy, mild fever), or any other infection appear during or after therapy tell your&#160;<br/>doctor immediately.</p>
<p style="position:absolute;top:626px;left:106px;white-space:nowrap" class="ft4012">Hepatitis B</p>
<p style="position:absolute;top:663px;left:133px;white-space:nowrap" class="ft4016">&#160;Tell your doctor if you are a carrier of the hepatitis B virus (HBV), if you have active HBV or if&#160;</p>
<p style="position:absolute;top:684px;left:160px;white-space:nowrap" class="ft4012">you think you might be at risk of getting HBV.&#160;</p>
<p style="position:absolute;top:702px;left:187px;white-space:nowrap" class="ft4016">&#160;Your doctor should test you for HBV. In people who carry HBV, Humira can cause the&#160;</p>
<p style="position:absolute;top:723px;left:214px;white-space:nowrap" class="ft4012">virus to become active again.</p>
<p style="position:absolute;top:741px;left:187px;white-space:nowrap" class="ft4016">&#160;In some rare cases, especially if you are taking other medicines that suppress the immune&#160;</p>
<p style="position:absolute;top:762px;left:214px;white-space:nowrap" class="ft4012">system, reactivation of HBV can be life-threatening. &#160;</p>
<p style="position:absolute;top:800px;left:106px;white-space:nowrap" class="ft4012">Surgery&#160;or dental procedure</p>
<p style="position:absolute;top:837px;left:133px;white-space:nowrap" class="ft4016">&#160;If you are about to have surgery or dental procedures,&#160;please&#160;inform your doctor that you are&#160;</p>
<p style="position:absolute;top:858px;left:160px;white-space:nowrap" class="ft4012">taking Humira. Your doctor may recommend temporary discontinuation of Humira.&#160;</p>
<p style="position:absolute;top:896px;left:106px;white-space:nowrap" class="ft4012">Demyelinating disease</p>
<p style="position:absolute;top:933px;left:133px;white-space:nowrap" class="ft4016">&#160;If you have or develop&#160;a&#160;demyelinating disease&#160;(a disease that affects the insulating layer around&#160;</p>
<p style="position:absolute;top:954px;left:160px;white-space:nowrap" class="ft4015">the nerves,&#160;such as&#160;multiple sclerosis), your doctor will decide if you should receive or continue to&#160;<br/>receive Humira. Tell your doctor immediately if you experience symptoms like changes in your&#160;<br/>vision, weakness in your arms or legs or numbness or tingling in any part of your&#160;body.</p>
<p style="position:absolute;top:1030px;left:106px;white-space:nowrap" class="ft4012">Vaccinations</p>
<p style="position:absolute;top:1067px;left:133px;white-space:nowrap" class="ft4016">&#160;Certain vaccines may cause infections and should not be given while receiving Humira.&#160;</p>
</div>
<!-- Page 402 -->
<a name="402"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page402-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4020">402</p>
<p style="position:absolute;top:104px;left:187px;white-space:nowrap" class="ft4026">&#160;Check with your doctor before you receive any vaccines.</p>
<p style="position:absolute;top:124px;left:187px;white-space:nowrap" class="ft4026">&#160;It is recommended that children, if possible, be&#160;given all the scheduled vaccinations for</p>
<p style="position:absolute;top:145px;left:214px;white-space:nowrap" class="ft4022">their age before they start treatment&#160;with Humira.</p>
<p style="position:absolute;top:163px;left:187px;white-space:nowrap" class="ft4026">&#160;If you received Humira while you were pregnant, your baby may be at higher risk for&#160;</p>
<p style="position:absolute;top:184px;left:214px;white-space:nowrap" class="ft4025">getting such an infection for up to approximately five months after the last&#160;Humira&#160;dose&#160;<br/>you received during pregnancy.&#160;It is&#160;important that you tell your baby's doctors and other&#160;<br/>health care professionals about your Humira use during your pregnancy so they can&#160;<br/>decide when your baby should receive any vaccine.</p>
<p style="position:absolute;top:279px;left:106px;white-space:nowrap" class="ft4022">Heart failure</p>
<p style="position:absolute;top:316px;left:133px;white-space:nowrap" class="ft4026">&#160;If you have mild heart failure and are being treated with Humira, your heart failure status must be&#160;</p>
<p style="position:absolute;top:337px;left:160px;white-space:nowrap" class="ft4025">closely monitored by your doctor. It is important to tell your doctor if you have had or have a&#160;<br/>serious heart condition. If you develop new or worsening symptoms of heart failure (e.g. shortness&#160;<br/>of breath, or swelling of your feet), you must contact your doctor immediately. Your doctor will&#160;<br/>decide if you should receive Humira.</p>
<p style="position:absolute;top:432px;left:106px;white-space:nowrap" class="ft4022">Fever, bruising, bleeding or looking pale</p>
<p style="position:absolute;top:469px;left:133px;white-space:nowrap" class="ft4026">&#160;In some patients the body may fail to produce enough of the blood cells that fight off infections or&#160;</p>
<p style="position:absolute;top:490px;left:160px;white-space:nowrap" class="ft4025">help you to stop bleeding. Your doctor may decide to stop treatment.&#160;If you develop a fever that&#160;<br/>does not go away,&#160;develop light bruises&#160;or bleed very easily or look very pale, call your doctor&#160;<br/>right away.</p>
<p style="position:absolute;top:566px;left:106px;white-space:nowrap" class="ft4022">Cancer</p>
<p style="position:absolute;top:604px;left:133px;white-space:nowrap" class="ft4026">&#160;There have been very rare cases of certain kinds of cancer in children and adult patients taking&#160;</p>
<p style="position:absolute;top:624px;left:160px;white-space:nowrap" class="ft4022">Humira or other TNF blockers. &#160;</p>
<p style="position:absolute;top:662px;left:187px;white-space:nowrap" class="ft4026">&#160;People with more serious rheumatoid arthritis that have had the disease for a long time&#160;</p>
<p style="position:absolute;top:683px;left:214px;white-space:nowrap" class="ft4025">may have a higher than average risk of getting lymphoma (a cancer that affects the lymph&#160;<br/>system) and leukaemia (a cancer that affects the blood and bone marrow).</p>
<p style="position:absolute;top:720px;left:187px;white-space:nowrap" class="ft4026">&#160;If you take Humira the risk of getting lymphoma, leukaemia, or other cancers may&#160;</p>
<p style="position:absolute;top:741px;left:214px;white-space:nowrap" class="ft4025">increase.&#160;On rare occasions,&#160;an uncommon&#160;and severe type of lymphoma,&#160;has been&#160;seen&#160;in&#160;<br/>patients taking Humira. Some of those patients were also treated with azathioprine or 6-<br/>mercaptopurine.</p>
<p style="position:absolute;top:797px;left:187px;white-space:nowrap" class="ft4026">&#160;Tell your doctor if you are taking azathioprine or 6-mercaptopurine with Humira.&#160;</p>
<p style="position:absolute;top:817px;left:187px;white-space:nowrap" class="ft4026">&#160;Cases&#160;of non-melanoma skin cancer have been observed in patients taking Humira.</p>
<p style="position:absolute;top:837px;left:187px;white-space:nowrap" class="ft4026">&#160;If new skin lesions appear during or after therapy or if existing lesions change appearance,&#160;</p>
<p style="position:absolute;top:858px;left:214px;white-space:nowrap" class="ft4022">tell your doctor.</p>
<p style="position:absolute;top:895px;left:133px;white-space:nowrap" class="ft4026">&#160;There have been cases of cancers,&#160;other than lymphoma in patients with a specific type of lung&#160;</p>
<p style="position:absolute;top:916px;left:160px;white-space:nowrap" class="ft4024">disease called Chronic Obstructive Pulmonary Disease (COPD) treated with another TNF blocker.&#160;<br/>If you have COPD, or are a heavy smoker, you should discuss with your doctor whether treatment&#160;<br/>with a&#160;TNF blocker is appropriate for you.</p>
<p style="position:absolute;top:992px;left:106px;white-space:nowrap" class="ft4022">Autoimmune disease</p>
<p style="position:absolute;top:1029px;left:133px;white-space:nowrap" class="ft4026">&#160;On rare occasions, treatment with Humira could result in lupus-like syndrome. Contact your&#160;</p>
<p style="position:absolute;top:1050px;left:160px;white-space:nowrap" class="ft4022">doctor if symptoms such as persistent unexplained rash, fever, joint pain or tiredness&#160;occur.</p>
</div>
<!-- Page 403 -->
<a name="403"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page403-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4030">403</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft4031"><b>Children and&#160;adolescents</b></p>
<p style="position:absolute;top:123px;left:133px;white-space:nowrap" class="ft4036">&#160;Vaccinations: if possible,&#160;children should be up to date with all vaccinations before using Humira.</p>
<p style="position:absolute;top:163px;left:106px;white-space:nowrap" class="ft4031"><b>Other medicines and Humira</b></p>
<p style="position:absolute;top:201px;left:106px;white-space:nowrap" class="ft4032">Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p>
<p style="position:absolute;top:239px;left:106px;white-space:nowrap" class="ft4035">You should not take Humira with medicines containing the following active substances&#160;due to increased&#160;<br/>risk of serious infection:</p>
<p style="position:absolute;top:276px;left:133px;white-space:nowrap" class="ft4036">&#160;anakinra</p>
<p style="position:absolute;top:296px;left:133px;white-space:nowrap" class="ft4036">&#160;abatacept.</p>
<p style="position:absolute;top:336px;left:106px;white-space:nowrap" class="ft4032">Humira can be taken together with:</p>
<p style="position:absolute;top:355px;left:133px;white-space:nowrap" class="ft4036">&#160;methotrexate</p>
<p style="position:absolute;top:375px;left:133px;white-space:nowrap" class="ft4036">&#160;certain disease-modifying anti-rheumatic agents (for example, sulfasalazine, hydroxychloroquine,&#160;</p>
<p style="position:absolute;top:395px;left:147px;white-space:nowrap" class="ft4032">leflunomide and injectable gold preparations)</p>
<p style="position:absolute;top:414px;left:133px;white-space:nowrap" class="ft4036">&#160;steroids or pain medications including non-steroidal anti-inflammatory drugs (NSAIDs).</p>
<p style="position:absolute;top:454px;left:106px;white-space:nowrap" class="ft4032">If you have questions, please ask your doctor.</p>
<p style="position:absolute;top:491px;left:106px;white-space:nowrap" class="ft4031"><b>Pregnancy and breast-feeding</b></p>
<p style="position:absolute;top:529px;left:133px;white-space:nowrap" class="ft4036">&#160;You&#160;should consider the&#160;use&#160;of&#160;adequate contraception&#160;to prevent pregnancy&#160;and&#160;continue its use&#160;</p>
<p style="position:absolute;top:550px;left:160px;white-space:nowrap" class="ft4032">for at least 5 months after the last Humira treatment.</p>
<p style="position:absolute;top:568px;left:133px;white-space:nowrap" class="ft4036">&#160;If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for&#160;</p>
<p style="position:absolute;top:589px;left:160px;white-space:nowrap" class="ft4032">advice about taking this medicine.</p>
<p style="position:absolute;top:607px;left:133px;white-space:nowrap" class="ft4036">&#160;Humira should only be used during a pregnancy if needed.</p>
<p style="position:absolute;top:627px;left:133px;white-space:nowrap" class="ft4036">&#160;According to a pregnancy study, there was no higher risk of birth defects when the mother had&#160;</p>
<p style="position:absolute;top:648px;left:160px;white-space:nowrap" class="ft4034">received Humira during pregnancy compared with mothers with the same disease&#160;who&#160;did not&#160;<br/>receive Humira.</p>
<p style="position:absolute;top:685px;left:133px;white-space:nowrap" class="ft4036">&#160;Humira can be used during breast-feeding.</p>
<p style="position:absolute;top:706px;left:133px;white-space:nowrap" class="ft4036">&#160;If you receive Humira during your pregnancy, your baby may have a higher&#160;risk for getting an&#160;</p>
<p style="position:absolute;top:726px;left:160px;white-space:nowrap" class="ft4032">infection.</p>
<p style="position:absolute;top:744px;left:133px;white-space:nowrap" class="ft4036">&#160;It is important that you tell your baby’s doctors and other health care professionals&#160;about your&#160;</p>
<p style="position:absolute;top:765px;left:160px;white-space:nowrap" class="ft4034">Humira use during your pregnancy before the baby receives any vaccine. For more information&#160;on&#160;<br/>vaccines&#160;see&#160;the&#160;“Warnings and precautions”&#160;section.</p>
<p style="position:absolute;top:822px;left:106px;white-space:nowrap" class="ft4031"><b>Driving and using machines</b></p>
<p style="position:absolute;top:860px;left:106px;white-space:nowrap" class="ft4035">Humira may have a small effect on your ability to drive, cycle or use&#160;machines. Room spinning sensation&#160;<br/>and vision disturbances may occur after taking Humira.</p>
<p style="position:absolute;top:936px;left:106px;white-space:nowrap" class="ft4031"><b>3.</b></p>
<p style="position:absolute;top:936px;left:148px;white-space:nowrap" class="ft4031"><b>How to use Humira</b></p>
<p style="position:absolute;top:974px;left:106px;white-space:nowrap" class="ft4034">Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or&#160;<br/>pharmacist if you are not sure.&#160;</p>
<p style="position:absolute;top:1031px;left:106px;white-space:nowrap" class="ft4034">The&#160;recommended doses for Humira in each of the approved uses are shown in the following table.&#160;Your&#160;<br/>doctor may prescribe another strength of Humira if you need a different dose.</p>
</div>
<!-- Page 404 -->
<a name="404"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page404-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4040">404</p>
<p style="position:absolute;top:87px;left:122px;white-space:nowrap" class="ft40419"><b>Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis or axial spondyloarthritis&#160;<br/>without radiographic evidence of ankylosing spondylitis<br/>Age or body weight</b></p>
<p style="position:absolute;top:125px;left:355px;white-space:nowrap" class="ft40419"><b>How much and how often to&#160;<br/>take?</b></p>
<p style="position:absolute;top:125px;left:587px;white-space:nowrap" class="ft4041"><b>Notes</b></p>
<p style="position:absolute;top:164px;left:122px;white-space:nowrap" class="ft4042">Adults&#160;</p>
<p style="position:absolute;top:164px;left:355px;white-space:nowrap" class="ft4042">40 mg every other week</p>
<p style="position:absolute;top:164px;left:587px;white-space:nowrap" class="ft4045">In rheumatoid arthritis,&#160;<br/>methotrexate is continued while&#160;<br/>using Humira. If your doctor&#160;<br/>decides&#160;that methotrexate is&#160;<br/>inappropriate, Humira can be&#160;<br/>given alone.</p>
<p style="position:absolute;top:297px;left:587px;white-space:nowrap" class="ft4044">If you have rheumatoid arthritis&#160;<br/>and you do not receive&#160;<br/>methotrexate with your Humira&#160;<br/>therapy, your doctor may decide&#160;<br/>to give Humira 40 mg every&#160;<br/>week&#160;or 80 mg every other&#160;<br/>week.&#160;</p>
<p style="position:absolute;top:450px;left:122px;white-space:nowrap" class="ft40419"><b>Polyarticular juvenile idiopathic arthritis<br/>Age or body weight</b></p>
<p style="position:absolute;top:470px;left:355px;white-space:nowrap" class="ft40419"><b>How much and how often to&#160;<br/>take?</b></p>
<p style="position:absolute;top:470px;left:587px;white-space:nowrap" class="ft4041"><b>Notes</b></p>
<p style="position:absolute;top:509px;left:122px;white-space:nowrap" class="ft4045">Children, adolescents and adults&#160;<br/>from 2 years of age weighing 30&#160;<br/>kg or more</p>
<p style="position:absolute;top:509px;left:355px;white-space:nowrap" class="ft4042">40 mg every other week</p>
<p style="position:absolute;top:509px;left:587px;white-space:nowrap" class="ft4042">Not applicable</p>
<p style="position:absolute;top:566px;left:122px;white-space:nowrap" class="ft4045">Children and adolescents from 2&#160;<br/>years of age&#160;weighing 10 kg to&#160;<br/>less than 30 kg</p>
<p style="position:absolute;top:566px;left:355px;white-space:nowrap" class="ft4042">20 mg every other week&#160;</p>
<p style="position:absolute;top:566px;left:587px;white-space:nowrap" class="ft4042">Not applicable</p>
<p style="position:absolute;top:644px;left:122px;white-space:nowrap" class="ft40419"><b>Enthesitis-related arthritis<br/>Age or body weight</b></p>
<p style="position:absolute;top:663px;left:355px;white-space:nowrap" class="ft40419"><b>How much and how often to&#160;<br/>take?</b></p>
<p style="position:absolute;top:663px;left:587px;white-space:nowrap" class="ft4041"><b>Notes</b></p>
<p style="position:absolute;top:702px;left:122px;white-space:nowrap" class="ft4044">Children, adolescents and adults&#160;<br/>from 6 years of age weighing 30&#160;<br/>kg or more</p>
<p style="position:absolute;top:702px;left:355px;white-space:nowrap" class="ft4042">40 mg every other week&#160;</p>
<p style="position:absolute;top:702px;left:587px;white-space:nowrap" class="ft4042">Not applicable</p>
<p style="position:absolute;top:760px;left:122px;white-space:nowrap" class="ft4044">Children and adolescents from 6&#160;<br/>years of age weighing 15 kg to&#160;<br/>less than 30 kg</p>
<p style="position:absolute;top:760px;left:355px;white-space:nowrap" class="ft4042">20 mg every other week</p>
<p style="position:absolute;top:760px;left:587px;white-space:nowrap" class="ft4042">Not applicable</p>
<p style="position:absolute;top:837px;left:122px;white-space:nowrap" class="ft40419"><b>Plaque psoriasis<br/>Age or body weight</b></p>
<p style="position:absolute;top:857px;left:355px;white-space:nowrap" class="ft40419"><b>How much and how often to&#160;<br/>take?</b></p>
<p style="position:absolute;top:857px;left:587px;white-space:nowrap" class="ft4041"><b>Notes</b></p>
<p style="position:absolute;top:896px;left:122px;white-space:nowrap" class="ft4042">Adults&#160;</p>
<p style="position:absolute;top:896px;left:355px;white-space:nowrap" class="ft4044">First dose&#160;of 80 mg (two 40 mg&#160;<br/>injections in one day), followed&#160;<br/>by 40 mg every other week&#160;<br/>starting one week after the first&#160;<br/>dose.</p>
<p style="position:absolute;top:896px;left:587px;white-space:nowrap" class="ft4044">If you have an inadequate&#160;<br/>response, your doctor may&#160;<br/>increase the&#160;dosage&#160;to 40 mg&#160;<br/>every week&#160;or 80 mg every&#160;<br/>other week.</p>
<p style="position:absolute;top:1010px;left:122px;white-space:nowrap" class="ft4045">Children and adolescents from 4&#160;<br/>to 17 years of age weighing 30&#160;<br/>kg or more</p>
<p style="position:absolute;top:1010px;left:355px;white-space:nowrap" class="ft4044">First dose of 40 mg, followed by&#160;<br/>40 mg one week later.</p>
<p style="position:absolute;top:1010px;left:587px;white-space:nowrap" class="ft4042">Not applicable</p>
</div>
<!-- Page 405 -->
<a name="405"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page405-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4050">405</p>
<p style="position:absolute;top:87px;left:355px;white-space:nowrap" class="ft4054">Thereafter, the usual dose is 40&#160;<br/>mg&#160;every other week.</p>
<p style="position:absolute;top:125px;left:122px;white-space:nowrap" class="ft4054">Children and adolescents from 4&#160;<br/>to 17 years of age weighing 15&#160;<br/>kg to&#160;less than 30 kg</p>
<p style="position:absolute;top:125px;left:355px;white-space:nowrap" class="ft4054">First dose of 20 mg, followed by&#160;<br/>20 mg one week later.</p>
<p style="position:absolute;top:182px;left:355px;white-space:nowrap" class="ft4054">Thereafter, the usual dose is 20&#160;<br/>mg&#160;every other week.</p>
<p style="position:absolute;top:125px;left:587px;white-space:nowrap" class="ft4052">Not applicable</p>
<p style="position:absolute;top:241px;left:122px;white-space:nowrap" class="ft40519"><b>Hidradenitis suppurativa<br/>Age or body weight</b></p>
<p style="position:absolute;top:261px;left:355px;white-space:nowrap" class="ft40515"><b>How much and how often to&#160;<br/>take?</b></p>
<p style="position:absolute;top:261px;left:587px;white-space:nowrap" class="ft4051"><b>Notes</b></p>
<p style="position:absolute;top:299px;left:122px;white-space:nowrap" class="ft4052">Adults&#160;</p>
<p style="position:absolute;top:299px;left:355px;white-space:nowrap" class="ft4054">First dose of 160&#160;mg&#160;(four 40&#160;<br/>mg&#160;injections in one day or two&#160;<br/>40 mg injections per day for two&#160;<br/>consecutive days), followed by&#160;<br/>an 80&#160;mg dose (two 40 mg&#160;<br/>injections in one day) two&#160;<br/>weeks later. After two further&#160;<br/>weeks, continue with a dose of&#160;<br/>40 mg every week&#160;or 80 mg&#160;<br/>every other&#160;week, as prescribed&#160;<br/>by your doctor. &#160;</p>
<p style="position:absolute;top:299px;left:587px;white-space:nowrap" class="ft4055">It is recommended that you use&#160;<br/>an antiseptic wash daily on the&#160;<br/>affected areas.</p>
<p style="position:absolute;top:509px;left:122px;white-space:nowrap" class="ft4054">Adolescents from 12 to 17 years&#160;<br/>of age weighing 30 kg or more</p>
<p style="position:absolute;top:509px;left:355px;white-space:nowrap" class="ft4054">First dose of 80 mg (two 40 mg&#160;<br/>injections in one day), followed&#160;<br/>by 40 mg every other week&#160;<br/>starting one week later. &#160;</p>
<p style="position:absolute;top:509px;left:587px;white-space:nowrap" class="ft4055">If you have an inadequate&#160;<br/>response&#160;to Humira 40 mg every&#160;<br/>other week, your doctor may&#160;<br/>increase the&#160;dosage&#160;to 40 mg&#160;<br/>every week&#160;or 80 mg every&#160;<br/>other week.<br/>It is recommended that you use&#160;<br/>an antiseptic wash daily on&#160;the&#160;<br/>affected areas.</p>
<p style="position:absolute;top:719px;left:122px;white-space:nowrap" class="ft40519"><b>Crohn’s disease<br/>Age or body weight</b></p>
<p style="position:absolute;top:739px;left:355px;white-space:nowrap" class="ft40515"><b>How much and how often to&#160;<br/>take?</b></p>
<p style="position:absolute;top:739px;left:587px;white-space:nowrap" class="ft4051"><b>Notes</b></p>
<p style="position:absolute;top:777px;left:122px;white-space:nowrap" class="ft4055">Children, adolescents and adults&#160;<br/>from 6 years of age weighing 40&#160;<br/>kg or more</p>
<p style="position:absolute;top:777px;left:355px;white-space:nowrap" class="ft4055">First dose of 80 mg (two 40 mg&#160;<br/>injections in one day), followed&#160;<br/>by 40 mg two weeks&#160;later.</p>
<p style="position:absolute;top:853px;left:355px;white-space:nowrap" class="ft4054">If a faster response is required,&#160;<br/>the doctor may prescribe a first&#160;<br/>dose of 160 mg (four 40 mg&#160;<br/>injections in one day or two 40&#160;<br/>mg&#160;injections per day for two&#160;<br/>consecutive days), followed by&#160;<br/>80 mg (two 40 mg injections in&#160;<br/>one day) two weeks later.</p>
<p style="position:absolute;top:1024px;left:355px;white-space:nowrap" class="ft4054">Thereafter, the usual dose is 40&#160;<br/>mg&#160;every other week.</p>
<p style="position:absolute;top:777px;left:587px;white-space:nowrap" class="ft4055">Your doctor may increase the&#160;<br/>dosage&#160;to 40 mg every week&#160;or&#160;<br/>80 mg every other week.</p>
</div>
<!-- Page 406 -->
<a name="406"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page406-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4060">406</p>
<p style="position:absolute;top:87px;left:122px;white-space:nowrap" class="ft4065">Children and adolescents from 6&#160;<br/>to 17 years of age weighing less&#160;<br/>than 40 kg</p>
<p style="position:absolute;top:87px;left:355px;white-space:nowrap" class="ft4064">First dose of 40 mg, followed by&#160;<br/>20 mg two&#160;weeks later.&#160;</p>
<p style="position:absolute;top:144px;left:355px;white-space:nowrap" class="ft4064">If a faster response is required,&#160;<br/>the doctor may prescribe a first&#160;<br/>dose of 80 mg (two 40 mg&#160;<br/>injections in one day), followed&#160;<br/>by 40 mg two weeks later.</p>
<p style="position:absolute;top:257px;left:355px;white-space:nowrap" class="ft4064">Thereafter, the usual dose is 20&#160;<br/>mg&#160;every other week.</p>
<p style="position:absolute;top:87px;left:587px;white-space:nowrap" class="ft4065">Your doctor may increase the&#160;<br/>dose&#160;frequency to 20 mg every&#160;<br/>week.</p>
<p style="position:absolute;top:316px;left:122px;white-space:nowrap" class="ft40619"><b>Ulcerative colitis<br/>Age or body weight</b></p>
<p style="position:absolute;top:336px;left:355px;white-space:nowrap" class="ft40619"><b>How much and how often to&#160;<br/>take?</b></p>
<p style="position:absolute;top:336px;left:587px;white-space:nowrap" class="ft4061"><b>Notes</b></p>
<p style="position:absolute;top:374px;left:122px;white-space:nowrap" class="ft4062">Adults</p>
<p style="position:absolute;top:374px;left:355px;white-space:nowrap" class="ft4065">First dose of 160 mg (four 40&#160;<br/>mg&#160;injections in one day or two&#160;<br/>40 mg injections per day for two&#160;<br/>consecutive days), followed by&#160;<br/>80 mg (two&#160;40 mg injections in&#160;<br/>one day) two weeks later.</p>
<p style="position:absolute;top:507px;left:355px;white-space:nowrap" class="ft4065">Thereafter, the usual dose is 40&#160;<br/>mg&#160;every other week.</p>
<p style="position:absolute;top:374px;left:587px;white-space:nowrap" class="ft4064">Your doctor may increase the&#160;<br/>dosage&#160;to 40 mg every week&#160;or&#160;<br/>80 mg every other week.</p>
<p style="position:absolute;top:546px;left:122px;white-space:nowrap" class="ft4064">Children&#160;and adolescents from&#160;6<br/>years of age weighing less than&#160;<br/>40 kg</p>
<p style="position:absolute;top:546px;left:355px;white-space:nowrap" class="ft4065">First dose of 80 mg&#160;(two 40 mg&#160;<br/>injections&#160;in one&#160;day), followed&#160;<br/>by 40 mg&#160;(one 40 mg injection)&#160;<br/>two weeks later.</p>
<p style="position:absolute;top:641px;left:355px;white-space:nowrap" class="ft4065">Thereafter, the usual dose is 40&#160;<br/>mg&#160;every&#160;other week.</p>
<p style="position:absolute;top:546px;left:587px;white-space:nowrap" class="ft4064">You should continue taking&#160;<br/>Humira at your usual dose, even&#160;<br/>after turning 18 years of age.</p>
<p style="position:absolute;top:679px;left:122px;white-space:nowrap" class="ft4064">Children and adolescents from&#160;6<br/>years of age weighing 40 kg or&#160;<br/>more</p>
<p style="position:absolute;top:679px;left:355px;white-space:nowrap" class="ft4064">First dose of 160 mg (four 40&#160;<br/>mg&#160;injections in one day or two&#160;<br/>40 mg injections per day for two&#160;<br/>consecutive days), followed by&#160;<br/>80 mg (two 40 mg injections in&#160;<br/>one day) two weeks later.</p>
<p style="position:absolute;top:812px;left:355px;white-space:nowrap" class="ft4064">Thereafter, the usual dose is 80&#160;<br/>mg&#160;every other week.</p>
<p style="position:absolute;top:679px;left:587px;white-space:nowrap" class="ft4064">You should continue taking&#160;<br/>Humira at your usual dose, even&#160;<br/>after turning 18 years of age.</p>
</div>
<!-- Page 407 -->
<a name="407"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page407-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4070">407</p>
<p style="position:absolute;top:87px;left:122px;white-space:nowrap" class="ft40719"><b>Non-infectious uveitis<br/>Age or body weight</b></p>
<p style="position:absolute;top:107px;left:355px;white-space:nowrap" class="ft40715"><b>How much and how often to&#160;<br/>take?</b></p>
<p style="position:absolute;top:107px;left:587px;white-space:nowrap" class="ft4071"><b>Notes</b></p>
<p style="position:absolute;top:145px;left:122px;white-space:nowrap" class="ft4072">Adults</p>
<p style="position:absolute;top:145px;left:355px;white-space:nowrap" class="ft4074">First dose of 80 mg&#160;(two 40 mg&#160;<br/>injections in one day), followed&#160;<br/>by 40 mg every other week&#160;<br/>starting one week after the first&#160;<br/>dose.</p>
<p style="position:absolute;top:145px;left:587px;white-space:nowrap" class="ft4074">Corticosteroids or other&#160;<br/>medicines that influence the&#160;<br/>immune system may be&#160;<br/>continued while using Humira.&#160;<br/>Humira can also be given alone.</p>
<p style="position:absolute;top:241px;left:122px;white-space:nowrap" class="ft4074">Children&#160;and adolescents from&#160;<br/>2&#160;years of age weighing less&#160;<br/>than 30&#160;kg</p>
<p style="position:absolute;top:241px;left:355px;white-space:nowrap" class="ft4072">20&#160;mg&#160;every other week</p>
<p style="position:absolute;top:241px;left:587px;white-space:nowrap" class="ft4074">Your doctor may prescribe an&#160;<br/>initial dose of 40&#160;mg to be&#160;<br/>administered one week prior to&#160;<br/>the start of the usual dose of&#160;<br/>20&#160;mg&#160;every other week.&#160;<br/>Humira is recommended for use&#160;<br/>in combination with&#160;<br/>methotrexate.</p>
<p style="position:absolute;top:393px;left:122px;white-space:nowrap" class="ft4074">Children and adolescents from&#160;<br/>2&#160;years of age weighing at least&#160;<br/>30&#160;kg</p>
<p style="position:absolute;top:393px;left:355px;white-space:nowrap" class="ft4072">40&#160;mg&#160;every other week&#160;</p>
<p style="position:absolute;top:393px;left:587px;white-space:nowrap" class="ft4075">Your doctor may prescribe an&#160;<br/>initial dose of 80&#160;mg to be&#160;<br/>administered one week prior to&#160;<br/>the start of the usual dose of&#160;<br/>40&#160;mg&#160;every other week.&#160;<br/>Humira is recommended for use&#160;<br/>in combination with&#160;<br/>methotrexate.</p>
<p style="position:absolute;top:565px;left:106px;white-space:nowrap" class="ft4071"><b>Method and route of administration</b></p>
<p style="position:absolute;top:603px;left:106px;white-space:nowrap" class="ft4072">Humira is administered by injection under the skin (by subcutaneous injection).</p>
<p style="position:absolute;top:641px;left:106px;white-space:nowrap" class="ft4071"><b>Detailed instructions on how to inject Humira are&#160;provided in section 7 ‘Injecting Humira’.</b></p>
<p style="position:absolute;top:679px;left:106px;white-space:nowrap" class="ft4071"><b>If you use more&#160;Humira&#160;than you should</b></p>
<p style="position:absolute;top:717px;left:106px;white-space:nowrap" class="ft4074">If you accidentally inject Humira more frequently than told to by your doctor or pharmacist, call your&#160;<br/>doctor or pharmacist&#160;and tell them that you have taken more. Always take the outer carton of the medicine&#160;<br/>with you, even if it is empty.&#160;</p>
<p style="position:absolute;top:792px;left:106px;white-space:nowrap" class="ft4071"><b>If you forget to use Humira</b></p>
<p style="position:absolute;top:831px;left:106px;white-space:nowrap" class="ft4074">If you forget to give yourself an injection, you should inject the next dose of Humira as soon as you&#160;<br/>remember. Then take your next dose as you would have on&#160;your originally scheduled day, had you not&#160;<br/>forgotten a dose.&#160;</p>
<p style="position:absolute;top:906px;left:106px;white-space:nowrap" class="ft4071"><b>If you stop using Humira</b></p>
<p style="position:absolute;top:944px;left:106px;white-space:nowrap" class="ft4074">The&#160;decision to stop using Humira should be discussed with your doctor. Your symptoms may return if&#160;<br/>you stop using Humira.</p>
<p style="position:absolute;top:1001px;left:106px;white-space:nowrap" class="ft4072">If you have any further questions on the use&#160;of this medicine, ask your doctor or pharmacist.</p>
</div>
<!-- Page 408 -->
<a name="408"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page408-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4080">408</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft4081"><b>4.</b></p>
<p style="position:absolute;top:86px;left:148px;white-space:nowrap" class="ft4081"><b>Possible side effects</b></p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft4084">Like all medicines, this medicine can cause side effects, although not everybody gets them. Most side&#160;<br/>effects are mild to moderate. However, some may be serious and require treatment. Side effects may occur&#160;<br/>at least up to 4 months after the last Humira injection.&#160;</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft4081"><b>Tell your doctor immediately if you notice any of the following</b></p>
<p style="position:absolute;top:237px;left:106px;white-space:nowrap" class="ft4086">&#160;severe rash, hives or other signs of allergic reaction&#160;</p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft4086">&#160;swollen face, hands, feet</p>
<p style="position:absolute;top:277px;left:106px;white-space:nowrap" class="ft4086">&#160;trouble breathing, swallowing</p>
<p style="position:absolute;top:298px;left:106px;white-space:nowrap" class="ft4086">&#160;shortness of breath with physical activity or upon lying down or&#160;swelling of the feet</p>
<p style="position:absolute;top:337px;left:106px;white-space:nowrap" class="ft4081"><b>Tell your doctor as soon as possible if you notice any of the following</b></p>
<p style="position:absolute;top:375px;left:106px;white-space:nowrap" class="ft4086">&#160;signs of infection such as fever, feeling sick, wounds, dental problems, burning on urination</p>
<p style="position:absolute;top:395px;left:106px;white-space:nowrap" class="ft4086">&#160;feeling weak or tired</p>
<p style="position:absolute;top:415px;left:106px;white-space:nowrap" class="ft4086">&#160;coughing</p>
<p style="position:absolute;top:435px;left:106px;white-space:nowrap" class="ft4086">&#160;tingling</p>
<p style="position:absolute;top:455px;left:106px;white-space:nowrap" class="ft4086">&#160;numbness</p>
<p style="position:absolute;top:475px;left:106px;white-space:nowrap" class="ft4086">&#160;double vision</p>
<p style="position:absolute;top:496px;left:106px;white-space:nowrap" class="ft4086">&#160;arm&#160;or leg weakness</p>
<p style="position:absolute;top:516px;left:106px;white-space:nowrap" class="ft4086">&#160;a bump or open sore that doesn't heal</p>
<p style="position:absolute;top:536px;left:106px;white-space:nowrap" class="ft4086">&#160;signs and symptoms suggestive of blood disorders such as persistent fever, bruising, bleeding,&#160;</p>
<p style="position:absolute;top:557px;left:133px;white-space:nowrap" class="ft4082">paleness</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft4084">The symptoms described above can be signs of the below listed side effects, which have been observed&#160;<br/>with Humira.</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft4081"><b>Very common&#160;</b>(may&#160;affect more than 1 in 10 people)<i>&#160;&#160;</i></p>
<p style="position:absolute;top:689px;left:106px;white-space:nowrap" class="ft4086">&#160;injection site reactions (including pain, swelling, redness or itching)</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft4086">&#160;respiratory tract infections (including cold, runny nose, sinus infection, pneumonia)</p>
<p style="position:absolute;top:729px;left:106px;white-space:nowrap" class="ft4086">&#160;headache</p>
<p style="position:absolute;top:749px;left:106px;white-space:nowrap" class="ft4086">&#160;abdominal pain</p>
<p style="position:absolute;top:770px;left:106px;white-space:nowrap" class="ft4086">&#160;nausea and vomiting</p>
<p style="position:absolute;top:790px;left:106px;white-space:nowrap" class="ft4086">&#160;rash</p>
<p style="position:absolute;top:810px;left:106px;white-space:nowrap" class="ft4086">&#160;musculoskeletal pain</p>
<p style="position:absolute;top:848px;left:106px;white-space:nowrap" class="ft4081"><b>Common&#160;</b>(may&#160;affect up to 1 in 10 people)&#160;</p>
<p style="position:absolute;top:885px;left:106px;white-space:nowrap" class="ft4086">&#160;serious&#160;infections (including blood poisoning and influenza)</p>
<p style="position:absolute;top:905px;left:106px;white-space:nowrap" class="ft4086">&#160;intestinal infections (including gastroenteritis)</p>
<p style="position:absolute;top:925px;left:106px;white-space:nowrap" class="ft4086">&#160;skin infections (including cellulitis and shingles)</p>
<p style="position:absolute;top:946px;left:106px;white-space:nowrap" class="ft4086">&#160;ear&#160;infections</p>
<p style="position:absolute;top:966px;left:106px;white-space:nowrap" class="ft4086">&#160;oral infections (including tooth infections and cold sores)</p>
<p style="position:absolute;top:986px;left:106px;white-space:nowrap" class="ft4086">&#160;reproductive tract infections</p>
<p style="position:absolute;top:1006px;left:106px;white-space:nowrap" class="ft4086">&#160;urinary tract infection</p>
<p style="position:absolute;top:1026px;left:106px;white-space:nowrap" class="ft4086">&#160;fungal infections</p>
<p style="position:absolute;top:1046px;left:106px;white-space:nowrap" class="ft4086">&#160;joint infections</p>
<p style="position:absolute;top:1067px;left:106px;white-space:nowrap" class="ft4086">&#160;benign tumours</p>
</div>
<!-- Page 409 -->
<a name="409"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page409-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4090">409</p>
<p style="position:absolute;top:85px;left:106px;white-space:nowrap" class="ft4096">&#160;skin cancer</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft4096">&#160;allergic reactions (including seasonal allergy)</p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft4096">&#160;dehydration</p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft4096">&#160;mood swings (including depression)</p>
<p style="position:absolute;top:166px;left:106px;white-space:nowrap" class="ft4096">&#160;anxiety</p>
<p style="position:absolute;top:186px;left:106px;white-space:nowrap" class="ft4096">&#160;difficulty sleeping</p>
<p style="position:absolute;top:206px;left:106px;white-space:nowrap" class="ft4096">&#160;sensation disorders such as tingling, prickling or numbness</p>
<p style="position:absolute;top:226px;left:106px;white-space:nowrap" class="ft4096">&#160;migraine</p>
<p style="position:absolute;top:247px;left:106px;white-space:nowrap" class="ft4096">&#160;nerve root compression (including low back pain and leg pain)</p>
<p style="position:absolute;top:267px;left:106px;white-space:nowrap" class="ft4096">&#160;vision disturbances</p>
<p style="position:absolute;top:287px;left:106px;white-space:nowrap" class="ft4096">&#160;eye&#160;inflammation</p>
<p style="position:absolute;top:307px;left:106px;white-space:nowrap" class="ft4096">&#160;inflammation of the eye lid and&#160;eye swelling</p>
<p style="position:absolute;top:327px;left:106px;white-space:nowrap" class="ft4096">&#160;vertigo (feeling of dizziness or spinning)</p>
<p style="position:absolute;top:347px;left:106px;white-space:nowrap" class="ft4096">&#160;sensation of heart beating rapidly</p>
<p style="position:absolute;top:367px;left:106px;white-space:nowrap" class="ft4096">&#160;high blood pressure</p>
<p style="position:absolute;top:388px;left:106px;white-space:nowrap" class="ft4096">&#160;flushing</p>
<p style="position:absolute;top:408px;left:106px;white-space:nowrap" class="ft4096">&#160;haematoma (collection of blood outside of blood vessels)</p>
<p style="position:absolute;top:428px;left:106px;white-space:nowrap" class="ft4096">&#160;cough</p>
<p style="position:absolute;top:448px;left:106px;white-space:nowrap" class="ft4096">&#160;asthma</p>
<p style="position:absolute;top:468px;left:106px;white-space:nowrap" class="ft4096">&#160;shortness of breath</p>
<p style="position:absolute;top:488px;left:106px;white-space:nowrap" class="ft4096">&#160;gastrointestinal bleeding</p>
<p style="position:absolute;top:509px;left:106px;white-space:nowrap" class="ft4096">&#160;dyspepsia (indigestion, bloating, heart burn)</p>
<p style="position:absolute;top:529px;left:106px;white-space:nowrap" class="ft4096">&#160;acid reflux disease</p>
<p style="position:absolute;top:549px;left:106px;white-space:nowrap" class="ft4096">&#160;sicca syndrome (including dry eyes and dry mouth)</p>
<p style="position:absolute;top:569px;left:106px;white-space:nowrap" class="ft4096">&#160;itching</p>
<p style="position:absolute;top:589px;left:106px;white-space:nowrap" class="ft4096">&#160;itchy rash</p>
<p style="position:absolute;top:609px;left:106px;white-space:nowrap" class="ft4096">&#160;bruising</p>
<p style="position:absolute;top:630px;left:106px;white-space:nowrap" class="ft4096">&#160;inflammation of the skin (such as eczema)</p>
<p style="position:absolute;top:650px;left:106px;white-space:nowrap" class="ft4096">&#160;breaking of finger nails and toe nails</p>
<p style="position:absolute;top:670px;left:106px;white-space:nowrap" class="ft4096">&#160;increased sweating</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft4096">&#160;hair loss</p>
<p style="position:absolute;top:710px;left:106px;white-space:nowrap" class="ft4096">&#160;new&#160;onset or worsening&#160;of psoriasis</p>
<p style="position:absolute;top:730px;left:106px;white-space:nowrap" class="ft4096">&#160;muscle spasms</p>
<p style="position:absolute;top:751px;left:106px;white-space:nowrap" class="ft4096">&#160;blood in urine</p>
<p style="position:absolute;top:771px;left:106px;white-space:nowrap" class="ft4096">&#160;kidney problems</p>
<p style="position:absolute;top:791px;left:106px;white-space:nowrap" class="ft4096">&#160;chest pain</p>
<p style="position:absolute;top:811px;left:106px;white-space:nowrap" class="ft4096">&#160;oedema (swelling)</p>
<p style="position:absolute;top:831px;left:106px;white-space:nowrap" class="ft4096">&#160;fever</p>
<p style="position:absolute;top:851px;left:106px;white-space:nowrap" class="ft4096">&#160;reduction in blood platelets which increases risk of bleeding or bruising</p>
<p style="position:absolute;top:871px;left:106px;white-space:nowrap" class="ft4096">&#160;impaired healing</p>
<p style="position:absolute;top:911px;left:106px;white-space:nowrap" class="ft4091"><b>Uncommon&#160;</b>(may&#160;affect up to 1 in 100 people) &#160;</p>
<p style="position:absolute;top:949px;left:106px;white-space:nowrap" class="ft4096">&#160;opportunistic infections (which include tuberculosis and other infections that occur when resistance to&#160;</p>
<p style="position:absolute;top:969px;left:133px;white-space:nowrap" class="ft4092">disease is lowered)</p>
<p style="position:absolute;top:988px;left:106px;white-space:nowrap" class="ft4096">&#160;neurological infections (including viral meningitis)</p>
<p style="position:absolute;top:1008px;left:106px;white-space:nowrap" class="ft4096">&#160;eye&#160;infections</p>
<p style="position:absolute;top:1028px;left:106px;white-space:nowrap" class="ft4096">&#160;bacterial infections</p>
<p style="position:absolute;top:1048px;left:106px;white-space:nowrap" class="ft4096">&#160;diverticulitis (inflammation and infection of the large intestine)</p>
<p style="position:absolute;top:1068px;left:106px;white-space:nowrap" class="ft4096">&#160;cancer</p>
</div>
<!-- Page 410 -->
<a name="410"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page410-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4100">410</p>
<p style="position:absolute;top:85px;left:106px;white-space:nowrap" class="ft4106">&#160;cancer that affects the lymph system</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft4106">&#160;melanoma</p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft4106">&#160;immune disorders that could affect the lungs, skin and lymph nodes (most commonly presenting as&#160;</p>
<p style="position:absolute;top:147px;left:133px;white-space:nowrap" class="ft4102">sarcoidosis)</p>
<p style="position:absolute;top:165px;left:106px;white-space:nowrap" class="ft4106">&#160;vasculitis (inflammation of blood vessels)</p>
<p style="position:absolute;top:185px;left:106px;white-space:nowrap" class="ft4106">&#160;tremor (shaking)</p>
<p style="position:absolute;top:205px;left:106px;white-space:nowrap" class="ft4106">&#160;neuropathy (disorder of the nerves)</p>
<p style="position:absolute;top:225px;left:106px;white-space:nowrap" class="ft4106">&#160;stroke</p>
<p style="position:absolute;top:245px;left:106px;white-space:nowrap" class="ft4106">&#160;hearing loss, buzzing</p>
<p style="position:absolute;top:266px;left:106px;white-space:nowrap" class="ft4106">&#160;sensation of heart beating irregularly such as skipped beats</p>
<p style="position:absolute;top:286px;left:106px;white-space:nowrap" class="ft4106">&#160;heart problems that can cause shortness of breath or ankle swelling</p>
<p style="position:absolute;top:306px;left:106px;white-space:nowrap" class="ft4106">&#160;heart attack</p>
<p style="position:absolute;top:326px;left:106px;white-space:nowrap" class="ft4106">&#160;a sac in the wall of a major artery, inflammation and clot of a vein, blockage of&#160;a blood vessel</p>
<p style="position:absolute;top:346px;left:106px;white-space:nowrap" class="ft4106">&#160;lung diseases causing shortness of breath (including inflammation)</p>
<p style="position:absolute;top:366px;left:106px;white-space:nowrap" class="ft4106">&#160;pulmonary embolism (blockage in an artery of the lung)</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft4106">&#160;pleural effusion (abnormal collection of fluid in the pleural space)</p>
<p style="position:absolute;top:407px;left:106px;white-space:nowrap" class="ft4106">&#160;inflammation of the pancreas which causes severe pain in the abdomen and back</p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft4106">&#160;difficulty in swallowing</p>
<p style="position:absolute;top:447px;left:106px;white-space:nowrap" class="ft4106">&#160;facial oedema (swelling of the face)</p>
<p style="position:absolute;top:467px;left:106px;white-space:nowrap" class="ft4106">&#160;gallbladder inflammation, gallbladder stones</p>
<p style="position:absolute;top:487px;left:106px;white-space:nowrap" class="ft4106">&#160;fatty liver</p>
<p style="position:absolute;top:508px;left:106px;white-space:nowrap" class="ft4106">&#160;night sweats</p>
<p style="position:absolute;top:528px;left:106px;white-space:nowrap" class="ft4106">&#160;scar</p>
<p style="position:absolute;top:548px;left:106px;white-space:nowrap" class="ft4106">&#160;abnormal&#160;muscle breakdown</p>
<p style="position:absolute;top:568px;left:106px;white-space:nowrap" class="ft4106">&#160;systemic lupus erythematosus (including inflammation of skin,&#160;heart, lung, joints and other organ&#160;</p>
<p style="position:absolute;top:589px;left:133px;white-space:nowrap" class="ft4102">systems)</p>
<p style="position:absolute;top:607px;left:106px;white-space:nowrap" class="ft4106">&#160;sleep interruptions</p>
<p style="position:absolute;top:627px;left:106px;white-space:nowrap" class="ft4106">&#160;impotence</p>
<p style="position:absolute;top:647px;left:106px;white-space:nowrap" class="ft4106">&#160;inflammations</p>
<p style="position:absolute;top:687px;left:106px;white-space:nowrap" class="ft4101"><b>Rare&#160;</b>(may affect up to 1 in 1,000 people)</p>
<p style="position:absolute;top:724px;left:106px;white-space:nowrap" class="ft4106">&#160;leukaemia (cancer affecting the blood and bone marrow)</p>
<p style="position:absolute;top:744px;left:106px;white-space:nowrap" class="ft4106">&#160;severe allergic reaction with shock</p>
<p style="position:absolute;top:765px;left:106px;white-space:nowrap" class="ft4106">&#160;multiple sclerosis</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft4106">&#160;nerve&#160;disorders (such as eye nerve inflammation and Guillain-Barré syndrome that may cause muscle&#160;</p>
<p style="position:absolute;top:806px;left:133px;white-space:nowrap" class="ft4102">weakness, abnormal sensations, tingling in the arms and upper body)</p>
<p style="position:absolute;top:824px;left:106px;white-space:nowrap" class="ft4106">&#160;heart stops pumping</p>
<p style="position:absolute;top:844px;left:106px;white-space:nowrap" class="ft4106">&#160;pulmonary fibrosis (scarring of the lung)</p>
<p style="position:absolute;top:864px;left:106px;white-space:nowrap" class="ft4106">&#160;intestinal perforation (hole in the intestine)</p>
<p style="position:absolute;top:884px;left:106px;white-space:nowrap" class="ft4106">&#160;hepatitis</p>
<p style="position:absolute;top:905px;left:106px;white-space:nowrap" class="ft4106">&#160;reactivation of hepatitis B</p>
<p style="position:absolute;top:925px;left:106px;white-space:nowrap" class="ft4106">&#160;autoimmune hepatitis (inflammation of the liver caused by the body's own immune system)</p>
<p style="position:absolute;top:945px;left:106px;white-space:nowrap" class="ft4106">&#160;cutaneous vasculitis (inflammation of blood vessels in the skin)</p>
<p style="position:absolute;top:965px;left:106px;white-space:nowrap" class="ft4106">&#160;Stevens-Johnson syndrome (early symptoms include malaise, fever, headache and rash)</p>
<p style="position:absolute;top:985px;left:106px;white-space:nowrap" class="ft4106">&#160;facial oedema (swelling of the face) associated with allergic reactions</p>
<p style="position:absolute;top:1005px;left:106px;white-space:nowrap" class="ft4106">&#160;erythema multiforme (inflammatory skin rash)</p>
<p style="position:absolute;top:1026px;left:106px;white-space:nowrap" class="ft4106">&#160;lupus-like syndrome</p>
<p style="position:absolute;top:1046px;left:106px;white-space:nowrap" class="ft4106">&#160;angioedema (localized swelling of the skin)</p>
<p style="position:absolute;top:1066px;left:106px;white-space:nowrap" class="ft4106">&#160;lichenoid skin reaction (itchy reddish-purple skin&#160;rash)</p>
</div>
<!-- Page 411 -->
<a name="411"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page411-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4110">411</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft4111"><b>Not known&#160;</b>(frequency cannot be estimated from the available data)</p>
<p style="position:absolute;top:142px;left:106px;white-space:nowrap" class="ft4116">&#160;hepatosplenic T-cell lymphoma (a rare blood cancer that is often fatal)</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft4116">&#160;Merkel cell carcinoma (a type of skin cancer)</p>
<p style="position:absolute;top:182px;left:106px;white-space:nowrap" class="ft4116">&#160;Kaposi’s sarcoma, a rare cancer related to infection&#160;with human herpes virus 8. Kaposi’s sarcoma&#160;</p>
<p style="position:absolute;top:203px;left:133px;white-space:nowrap" class="ft4112">most commonly appears as purple lesions on the skin</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft4116">&#160;liver failure</p>
<p style="position:absolute;top:242px;left:106px;white-space:nowrap" class="ft4116">&#160;worsening of a condition called dermatomyositis (seen as a skin rash accompanying muscle weakness)</p>
<p style="position:absolute;top:262px;left:106px;white-space:nowrap" class="ft4116">&#160;weight gain (for most patients, the weight gain&#160;was small)</p>
<p style="position:absolute;top:302px;left:106px;white-space:nowrap" class="ft4114">Some side effects observed with Humira may not have symptoms and may only be discovered through&#160;<br/>blood tests. These include:</p>
<p style="position:absolute;top:359px;left:106px;white-space:nowrap" class="ft4111"><b>Very common&#160;</b>(may&#160;affect more than 1 in 10 people)</p>
<p style="position:absolute;top:396px;left:106px;white-space:nowrap" class="ft4116">&#160;low blood measurements for white blood cells</p>
<p style="position:absolute;top:416px;left:106px;white-space:nowrap" class="ft4116">&#160;low blood measurements&#160;for red blood cells</p>
<p style="position:absolute;top:436px;left:106px;white-space:nowrap" class="ft4116">&#160;increased lipids in the blood</p>
<p style="position:absolute;top:456px;left:106px;white-space:nowrap" class="ft4116">&#160;elevated liver enzymes</p>
<p style="position:absolute;top:496px;left:106px;white-space:nowrap" class="ft4111"><b>Common&#160;</b>(may&#160;affect up to 1 in 10 people)</p>
<p style="position:absolute;top:533px;left:106px;white-space:nowrap" class="ft4116">&#160;high blood measurements for white blood cells</p>
<p style="position:absolute;top:554px;left:106px;white-space:nowrap" class="ft4116">&#160;low blood measurements for platelets</p>
<p style="position:absolute;top:574px;left:106px;white-space:nowrap" class="ft4116">&#160;increased uric acid in the blood</p>
<p style="position:absolute;top:594px;left:106px;white-space:nowrap" class="ft4116">&#160;abnormal blood measurements for sodium</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft4116">&#160;low blood measurements for calcium</p>
<p style="position:absolute;top:634px;left:106px;white-space:nowrap" class="ft4116">&#160;low blood measurements for phosphate</p>
<p style="position:absolute;top:654px;left:106px;white-space:nowrap" class="ft4116">&#160;high blood sugar</p>
<p style="position:absolute;top:675px;left:106px;white-space:nowrap" class="ft4116">&#160;high blood measurements for lactate dehydrogenase</p>
<p style="position:absolute;top:695px;left:106px;white-space:nowrap" class="ft4116">&#160;autoantibodies present in the blood</p>
<p style="position:absolute;top:715px;left:106px;white-space:nowrap" class="ft4116">&#160;low blood potassium</p>
<p style="position:absolute;top:755px;left:106px;white-space:nowrap" class="ft4111"><b>Uncommon&#160;</b>(may&#160;affect up to 1 in 100 people)&#160;</p>
<p style="position:absolute;top:792px;left:106px;white-space:nowrap" class="ft4116">&#160;elevated bilirubin measurement (liver blood test)</p>
<p style="position:absolute;top:832px;left:106px;white-space:nowrap" class="ft4111"><b>Rare&#160;</b>(may affect up to 1 in 1,000 people)</p>
<p style="position:absolute;top:869px;left:106px;white-space:nowrap" class="ft4116">&#160;low blood measurements for white blood cells, red blood cells and platelet count</p>
<p style="position:absolute;top:909px;left:106px;white-space:nowrap" class="ft4114"><b>Reporting of side effects<br/></b>If you get any side effects, talk to your doctor or&#160;pharmacist. This includes any possible side effects not&#160;<br/>listed in this leaflet.&#160;You can also report side effects directly via&#160;the national reporting system listed in&#160;<br/><a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix V.&#160;</a>By reporting side effects, you can help provide more information&#160;on the safety of this&#160;<br/>medicine.</p>
<p style="position:absolute;top:1042px;left:106px;white-space:nowrap" class="ft4111"><b>5.</b></p>
<p style="position:absolute;top:1042px;left:148px;white-space:nowrap" class="ft4111"><b>How to store Humira</b></p>
<p style="position:absolute;top:1080px;left:106px;white-space:nowrap" class="ft4112">Keep this medicine out of the sight and reach of children.&#160;</p>
</div>
<!-- Page 412 -->
<a name="412"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page412-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4120">412</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft4122">Do not use this medicine after the expiry date stated on the label/blister/carton after EXP.&#160;</p>
<p style="position:absolute;top:144px;left:106px;white-space:nowrap" class="ft4122">Store in a refrigerator (2</p>
<p style="position:absolute;top:142px;left:266px;white-space:nowrap" class="ft4126">C&#160;–&#160;8C). Do not freeze.&#160;</p>
<p style="position:absolute;top:182px;left:106px;white-space:nowrap" class="ft4122">Keep the pre-filled syringe in the outer carton in order to protect from light.</p>
<p style="position:absolute;top:220px;left:106px;white-space:nowrap" class="ft4122">Alternative Storage:</p>
<p style="position:absolute;top:258px;left:106px;white-space:nowrap" class="ft41219">When needed (for example when you are travelling), a single Humira pre-filled syringe may be stored at&#160;<br/>room temperature (up to 25°C) for a maximum period of 14&#160;days&#160;–&#160;be sure to protect it from light. Once&#160;<br/>removed from the refrigerator for room temperature&#160;storage, the syringe&#160;<b>must be used within 14 days&#160;or&#160;<br/>discarded</b>, even if it is returned to the refrigerator. &#160;</p>
<p style="position:absolute;top:353px;left:106px;white-space:nowrap" class="ft4124">You should record the date when the syringe is first removed from refrigerator and the date after which it&#160;<br/>should be discarded.</p>
<p style="position:absolute;top:410px;left:106px;white-space:nowrap" class="ft4124">Do not throw away any medicines via wastewater or household waste. Ask your doctor or pharmacist how&#160;<br/>to throw away medicines you no longer use. These measures will help protect the environment.</p>
<p style="position:absolute;top:486px;left:106px;white-space:nowrap" class="ft4121"><b>6.</b></p>
<p style="position:absolute;top:486px;left:148px;white-space:nowrap" class="ft4121"><b>Contents of the pack and other information</b></p>
<p style="position:absolute;top:523px;left:106px;white-space:nowrap" class="ft4121"><b>What Humira contains</b></p>
<p style="position:absolute;top:562px;left:106px;white-space:nowrap" class="ft4124">The&#160;active substance is adalimumab.<br/>The&#160;other ingredients are mannitol, polysorbate 80 and water for injections.</p>
<p style="position:absolute;top:618px;left:106px;white-space:nowrap" class="ft4121"><b>What the Humira pre-filled&#160;syringe&#160;looks like and contents of the pack</b></p>
<p style="position:absolute;top:656px;left:106px;white-space:nowrap" class="ft4124">Humira 40&#160;mg solution for injection in pre-filled syringe is supplied as a&#160;sterile solution of 40&#160;mg&#160;<br/>adalimumab dissolved in 0.4&#160;ml solution.</p>
<p style="position:absolute;top:713px;left:106px;white-space:nowrap" class="ft4124">The Humira pre-filled&#160;syringe&#160;is a glass syringe containing&#160;a solution of adalimumab. Each pack contains&#160;<br/>1, 2, 4&#160;or&#160;6 pre-filled&#160;syringes for patient use with 1, 2, 4 or 6 alcohol pads,&#160;respectively.&#160;&#160;</p>
<p style="position:absolute;top:770px;left:106px;white-space:nowrap" class="ft4122">Not all pack sizes may be marketed. &#160;</p>
<p style="position:absolute;top:808px;left:106px;white-space:nowrap" class="ft4122">Humira may be available as a vial, a pre-filled syringe and/or a pre-filled pen.</p>
<p style="position:absolute;top:846px;left:106px;white-space:nowrap" class="ft4121"><b>Marketing Authorisation Holder</b></p>
<p style="position:absolute;top:884px;left:106px;white-space:nowrap" class="ft4124">AbbVie Deutschland GmbH &amp; Co. KG<br/>Knollstrasse<br/>67061 Ludwigshafen<br/>Germany</p>
</div>
<!-- Page 413 -->
<a name="413"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page413-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4130">413</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft4131"><b>Manufacturer&#160;</b></p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft4135">AbbVie Biotechnology GmbH<br/>Knollstrasse<br/>67061 Ludwigshafen<br/>Germany</p>
<p style="position:absolute;top:219px;left:106px;white-space:nowrap" class="ft4135">For any information about this medicine, please contact the local representative of the Marketing&#160;<br/>Authorisation Holder:</p>
<p style="position:absolute;top:276px;left:114px;white-space:nowrap" class="ft4134"><b>België/Belgique/Belgien<br/></b>AbbVie SA<br/>Tél/Tel: +32 10&#160;&#160;477811</p>
<p style="position:absolute;top:276px;left:462px;white-space:nowrap" class="ft4135"><b>Lietuva<br/></b>AbbVie UAB&#160;<br/>Tel: +370 5 205 3023</p>
<p style="position:absolute;top:353px;left:114px;white-space:nowrap" class="ft4134"><b>България<br/></b>АбВи ЕООД<br/>Тел.:+359 2 90 30 430</p>
<p style="position:absolute;top:353px;left:462px;white-space:nowrap" class="ft4134"><b>Luxembourg/Luxemburg<br/></b>AbbVie SA<br/>Belgique/Belgien<br/>Tél/Tel: +32 10 477811</p>
<p style="position:absolute;top:447px;left:114px;white-space:nowrap" class="ft4135"><b>Česká republika<br/></b>AbbVie s.r.o.&#160;<br/>Tel: +420 233 098 111</p>
<p style="position:absolute;top:447px;left:462px;white-space:nowrap" class="ft4135"><b>Magyarország<br/></b>AbbVie Kft.<br/>Tel.:+36 1&#160;455 8600</p>
<p style="position:absolute;top:523px;left:114px;white-space:nowrap" class="ft4135"><b>Danmark<br/></b>AbbVie A/S<br/>Tlf: +45 72 30-20-28</p>
<p style="position:absolute;top:523px;left:462px;white-space:nowrap" class="ft4135"><b>Malta<br/></b>V.J.Salomone Pharma Limited&#160;<br/>Tel: +356 22983201</p>
<p style="position:absolute;top:599px;left:114px;white-space:nowrap" class="ft4134"><b>Deutschland<br/></b>AbbVie Deutschland&#160;GmbH &amp; Co. KG<br/>Tel: 00800 222843 33 (gebührenfrei)<br/>Tel: +49 (0) 611&#160;/&#160;1720-0</p>
<p style="position:absolute;top:599px;left:462px;white-space:nowrap" class="ft4134"><b>Nederland<br/></b>AbbVie B.V.<br/>Tel: &#160;+31 (0)88 322&#160;2843</p>
<p style="position:absolute;top:694px;left:114px;white-space:nowrap" class="ft4134"><b>Eesti<br/></b>AbbVie&#160;OÜ<br/>Tel: +372 623 1011</p>
<p style="position:absolute;top:694px;left:462px;white-space:nowrap" class="ft4134"><b>Norge<br/></b>AbbVie AS<br/>Tlf: +47 67 81 80 00</p>
<p style="position:absolute;top:770px;left:114px;white-space:nowrap" class="ft4135"><b>Ελλάδα<br/></b>AbbVie&#160;ΦΑΡΜΑΚΕΥΤΙΚΗ Α.Ε.<br/>Τηλ: +30&#160;214 4165 555</p>
<p style="position:absolute;top:770px;left:462px;white-space:nowrap" class="ft4135"><b>Österreich<br/></b>AbbVie GmbH&#160;<br/>Tel: +43 1 20589-0</p>
<p style="position:absolute;top:846px;left:114px;white-space:nowrap" class="ft4135"><b>España<br/></b>AbbVie Spain, S.L.U.<br/>Tel: &#160;+34 91 384 09 10</p>
<p style="position:absolute;top:846px;left:462px;white-space:nowrap" class="ft4135"><b>Polska<br/></b>AbbVie Sp. z o.o.<br/>Tel.: +48 22&#160;372 78 00&#160;</p>
<p style="position:absolute;top:922px;left:114px;white-space:nowrap" class="ft4134"><b>France<br/></b>AbbVie<br/>Tél: +33 (0) 1 45 60 13 00</p>
<p style="position:absolute;top:922px;left:462px;white-space:nowrap" class="ft4134"><b>Portugal<br/></b>AbbVie, Lda.&#160;<br/>Tel: +351 (0)21 1908400</p>
<p style="position:absolute;top:996px;left:114px;white-space:nowrap" class="ft4134"><b>Hrvatska&#160;<br/></b>AbbVie d.o.o.<br/>Tel + 385 (0)1&#160;5625 501</p>
<p style="position:absolute;top:996px;left:462px;white-space:nowrap" class="ft4134"><b>România<br/></b>AbbVie S.R.L.<br/>Tel: +40 21 529 30 35</p>
</div>
<!-- Page 414 -->
<a name="414"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page414-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4140">414</p>
<p style="position:absolute;top:86px;left:114px;white-space:nowrap" class="ft4144"><b>Ireland<br/></b>AbbVie Limited&#160;<br/>Tel: +353 (0)1 4287900</p>
<p style="position:absolute;top:86px;left:462px;white-space:nowrap" class="ft4144"><b>Slovenija<br/></b>AbbVie Biofarmacevtska družba d.o.o.<br/>Tel: +386 (1)32 08 060</p>
<p style="position:absolute;top:162px;left:114px;white-space:nowrap" class="ft4144"><b>Ísland<br/></b>Vistor hf.<br/>Tel: +354 535 7000</p>
<p style="position:absolute;top:162px;left:462px;white-space:nowrap" class="ft4144"><b>Slovenská republika<br/></b>AbbVie s.r.o.<br/>Tel: +421 2 5050 0777</p>
<p style="position:absolute;top:238px;left:114px;white-space:nowrap" class="ft4144"><b>Italia<br/></b>AbbVie S.r.l.&#160;<br/>Tel: +39 06 928921</p>
<p style="position:absolute;top:238px;left:462px;white-space:nowrap" class="ft4144"><b>Suomi/Finland<br/></b>AbbVie Oy&#160;<br/>Puh/Tel: &#160;+358 (0)10&#160;2411 200</p>
<p style="position:absolute;top:315px;left:114px;white-space:nowrap" class="ft4144"><b>Κύπρος<br/></b>Lifepharma (Z.A.M.) Ltd<br/>Τηλ.: +357 22 34 74 40</p>
<p style="position:absolute;top:315px;left:462px;white-space:nowrap" class="ft4144"><b>Sverige<br/></b>AbbVie AB<br/>Tel: &#160;+46 (0)8 684 44 600</p>
<p style="position:absolute;top:391px;left:114px;white-space:nowrap" class="ft4144"><b>Latvija<br/></b>AbbVie SIA&#160;<br/>Tel: +371 67605000</p>
<p style="position:absolute;top:391px;left:462px;white-space:nowrap" class="ft4144"><b>United Kingdom&#160;(Northern Ireland)<br/></b>AbbVie Deutschland GmbH &amp; Co. KG<br/>Tel: +44 (0)1628 561090</p>
<p style="position:absolute;top:467px;left:106px;white-space:nowrap" class="ft4141"><b>This leaflet&#160;was last revised in</b></p>
<p style="position:absolute;top:505px;left:106px;white-space:nowrap" class="ft4145">Detailed information on this medicine is available on the European Medicines Agency web site:&#160;<br/><a href="http://www.ema.europa.eu/">http://www.ema.europa.eu.</a></p>
<p style="position:absolute;top:562px;left:106px;white-space:nowrap" class="ft41415"><b>To listen to or request a copy of this leaflet in&#160;&lt;Braille&gt;, &lt;large print&gt; or &lt;audio&gt;, please contact the&#160;<br/>local representative of the Marketing Authorisation Holder.</b></p>
<p style="position:absolute;top:638px;left:106px;white-space:nowrap" class="ft4141"><b>7.</b></p>
<p style="position:absolute;top:638px;left:148px;white-space:nowrap" class="ft4141"><b>Injecting Humira</b></p>
<p style="position:absolute;top:675px;left:133px;white-space:nowrap" class="ft4146">&#160;The following instructions explain how to give yourself a subcutaneous injection of Humira using&#160;</p>
<p style="position:absolute;top:696px;left:160px;white-space:nowrap" class="ft4142">the pre-filled syringe. First read all the instructions carefully and then follow them step by step.&#160;</p>
<p style="position:absolute;top:733px;left:133px;white-space:nowrap" class="ft4146">&#160;You will be instructed by your doctor, nurse or pharmacist on the technique of self-injection.&#160;</p>
<p style="position:absolute;top:772px;left:133px;white-space:nowrap" class="ft4146">&#160;Do not attempt to self-inject until you are sure that you understand how to prepare and give the&#160;</p>
<p style="position:absolute;top:793px;left:160px;white-space:nowrap" class="ft4142">injection.&#160;</p>
<p style="position:absolute;top:830px;left:133px;white-space:nowrap" class="ft4146">&#160;After proper training, the injection can be given&#160;by yourself or given by another person, for&#160;</p>
<p style="position:absolute;top:851px;left:160px;white-space:nowrap" class="ft4142">example, a family member or friend. &#160;</p>
<p style="position:absolute;top:888px;left:133px;white-space:nowrap" class="ft4146">&#160;Only use each pre-filled syringe for one injection.</p>
</div>
<!-- Page 415 -->
<a name="415"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page415-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4150">415</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft4151"><b>Humira Pre-filled Syringe</b></p>
<p style="position:absolute;top:124px;left:214px;white-space:nowrap" class="ft4151"><b>&#160; &#160; &#160; &#160;Plunger</b></p>
<p style="position:absolute;top:124px;left:376px;white-space:nowrap" class="ft4151"><b>&#160; &#160; &#160; &#160; &#160; &#160;Finger Grip</b></p>
<p style="position:absolute;top:124px;left:538px;white-space:nowrap" class="ft4151"><b>&#160; &#160; &#160; &#160; &#160;Needle Cover</b></p>
<p style="position:absolute;top:358px;left:106px;white-space:nowrap" class="ft4151"><b>Do not use the pre-filled&#160;syringe and call your doctor or pharmacist if the</b></p>
<p style="position:absolute;top:398px;left:133px;white-space:nowrap" class="ft4156">&#160;liquid is cloudy, discoloured, or has flakes or particles in it</p>
<p style="position:absolute;top:418px;left:133px;white-space:nowrap" class="ft4156">&#160;expiry (EXP) date has passed</p>
<p style="position:absolute;top:438px;left:133px;white-space:nowrap" class="ft4156">&#160;liquid has been frozen or left in direct sunlight</p>
<p style="position:absolute;top:458px;left:133px;white-space:nowrap" class="ft4156">&#160;pre-filled syringe has been dropped or crushed</p>
<p style="position:absolute;top:498px;left:106px;white-space:nowrap" class="ft41519"><b>Do not remove&#160;the needle cover until just before injection. Keep Humira out of the sight and reach&#160;<br/>of children.</b></p>
<p style="position:absolute;top:555px;left:114px;white-space:nowrap" class="ft4151"><b>STEP 1</b></p>
<p style="position:absolute;top:594px;left:114px;white-space:nowrap" class="ft4152">Take Humira out of the refrigerator.</p>
<p style="position:absolute;top:631px;left:114px;white-space:nowrap" class="ft4152">Leave Humira at room temperature for&#160;<b>15 to 30 minutes&#160;</b>before injecting.</p>
<p style="position:absolute;top:669px;left:141px;white-space:nowrap" class="ft4156">&#160;<b>Do not&#160;</b>remove the needle cover while allowing Humira to reach room temperature</p>
<p style="position:absolute;top:689px;left:141px;white-space:nowrap" class="ft4156">&#160;<b>Do not&#160;</b>warm Humira in any other way. For example,&#160;<b>do not&#160;</b>warm it in a microwave or in hot&#160;</p>
<p style="position:absolute;top:710px;left:168px;white-space:nowrap" class="ft4152">water</p>
<p style="position:absolute;top:729px;left:114px;white-space:nowrap" class="ft4151"><b>STEP 2&#160;</b></p>
<p style="position:absolute;top:769px;left:114px;white-space:nowrap" class="ft4151"><b>&#160; &#160; &#160; &#160; &#160; &#160;Syringe</b></p>
<p style="position:absolute;top:1022px;left:114px;white-space:nowrap" class="ft4151"><b>&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;Pad</b></p>
<p style="position:absolute;top:729px;left:392px;white-space:nowrap" class="ft4154">Check the expiry (EXP) date.&#160;<b>Do not&#160;</b>use the pre-filled&#160;<br/>syringe if expiry (EXP) date has passed.</p>
<p style="position:absolute;top:786px;left:392px;white-space:nowrap" class="ft4152">Place the following on a clean, flat surface</p>
<p style="position:absolute;top:824px;left:422px;white-space:nowrap" class="ft4156">&#160;1 single-use pre-filled syringe and&#160;</p>
<p style="position:absolute;top:844px;left:422px;white-space:nowrap" class="ft4156">&#160;1 alcohol pad</p>
<p style="position:absolute;top:884px;left:392px;white-space:nowrap" class="ft4152">Wash and dry your hands.</p>
</div>
<!-- Page 416 -->
<a name="416"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page416-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4160">416</p>
<p style="position:absolute;top:87px;left:114px;white-space:nowrap" class="ft4161"><b>STEP 3</b></p>
<p style="position:absolute;top:125px;left:114px;white-space:nowrap" class="ft4161"><b>Injectable Areas</b></p>
<p style="position:absolute;top:426px;left:114px;white-space:nowrap" class="ft4162">&#160; &#160; &#160;<b>Injectable Areas</b></p>
<p style="position:absolute;top:87px;left:392px;white-space:nowrap" class="ft4162">Choose an injection&#160;site:</p>
<p style="position:absolute;top:124px;left:422px;white-space:nowrap" class="ft4166">&#160;On the front of your thighs or</p>
<p style="position:absolute;top:144px;left:422px;white-space:nowrap" class="ft4166">&#160;Your belly (abdomen) at least 5 cm from your belly&#160;</p>
<p style="position:absolute;top:165px;left:449px;white-space:nowrap" class="ft4162">button (navel)</p>
<p style="position:absolute;top:183px;left:422px;white-space:nowrap" class="ft4166">&#160;At least 3 cm from your last injection site</p>
<p style="position:absolute;top:223px;left:392px;white-space:nowrap" class="ft4165">Wipe the injection site in a circular motion with the alcohol&#160;<br/>pad.</p>
<p style="position:absolute;top:279px;left:422px;white-space:nowrap" class="ft4166">&#160;<b>Do not&#160;</b>inject through clothes</p>
<p style="position:absolute;top:299px;left:422px;white-space:nowrap" class="ft4166">&#160;<b>Do not&#160;</b>inject into skin that is sore, bruised, red,&#160;</p>
<p style="position:absolute;top:320px;left:449px;white-space:nowrap" class="ft4165">hard, scarred, has stretch marks, or areas with&#160;<br/>psoriasis plaques</p>
<p style="position:absolute;top:445px;left:114px;white-space:nowrap" class="ft4161"><b>STEP 4</b></p>
<p style="position:absolute;top:445px;left:392px;white-space:nowrap" class="ft4162">Hold the pre-filled syringe in one hand.</p>
<p style="position:absolute;top:483px;left:392px;white-space:nowrap" class="ft4162">Check the liquid in the pre-filled syringe.</p>
<p style="position:absolute;top:520px;left:425px;white-space:nowrap" class="ft4166">&#160;Make sure the liquid is clear and colourless</p>
<p style="position:absolute;top:541px;left:425px;white-space:nowrap" class="ft4166">&#160;<b>Do not&#160;</b>use the pre-filled syringe if the liquid is&#160;</p>
<p style="position:absolute;top:561px;left:452px;white-space:nowrap" class="ft4162">cloudy or has particles</p>
<p style="position:absolute;top:580px;left:425px;white-space:nowrap" class="ft4166">&#160;<b>Do not&#160;</b>use the pre-filled syringe if it has been&#160;</p>
<p style="position:absolute;top:600px;left:452px;white-space:nowrap" class="ft4162">dropped or crushed</p>
<p style="position:absolute;top:638px;left:392px;white-space:nowrap" class="ft4164">Gently pull the needle cover straight off with the other hand.&#160;<br/>Throw the needle cover away. Do not recap.</p>
<p style="position:absolute;top:695px;left:425px;white-space:nowrap" class="ft4166">&#160;<b>Do&#160;not&#160;</b>touch the needle with your fingers or let the&#160;</p>
<p style="position:absolute;top:715px;left:452px;white-space:nowrap" class="ft4162">needle touch anything</p>
<p style="position:absolute;top:754px;left:114px;white-space:nowrap" class="ft4161"><b>STEP 5</b></p>
<p style="position:absolute;top:754px;left:392px;white-space:nowrap" class="ft4162">Hold the pre-filled syringe with the needle&#160;facing up.</p>
<p style="position:absolute;top:792px;left:425px;white-space:nowrap" class="ft4166">&#160;Hold the pre-filled syringe at eye level with one&#160;</p>
<p style="position:absolute;top:812px;left:452px;white-space:nowrap" class="ft4162">hand so you can see the air in the pre-filled syringe</p>
<p style="position:absolute;top:850px;left:392px;white-space:nowrap" class="ft4165">Slowly push the plunger in to push the air out through the&#160;<br/>needle.&#160;</p>
<p style="position:absolute;top:906px;left:425px;white-space:nowrap" class="ft4166">&#160;It is normal to see a drop of liquid at the end of the&#160;</p>
<p style="position:absolute;top:927px;left:452px;white-space:nowrap" class="ft4162">needle</p>
</div>
<!-- Page 417 -->
<a name="417"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page417-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4170">417</p>
<p style="position:absolute;top:87px;left:114px;white-space:nowrap" class="ft4171"><b>STEP 6</b></p>
<p style="position:absolute;top:87px;left:392px;white-space:nowrap" class="ft4174">Hold the body of the pre-filled syringe in one hand between&#160;<br/>the thumb and index fingers, like you would a pencil.</p>
<p style="position:absolute;top:144px;left:392px;white-space:nowrap" class="ft4174">Squeeze the skin at your injection site with your other hand&#160;<br/>to make a raised area and hold it firmly.</p>
<p style="position:absolute;top:380px;left:114px;white-space:nowrap" class="ft4171"><b>STEP 7</b></p>
<p style="position:absolute;top:380px;left:392px;white-space:nowrap" class="ft4175">Insert the needle all the way into the skin at about a 45-<br/>degree angle with one quick, short motion.</p>
<p style="position:absolute;top:436px;left:425px;white-space:nowrap" class="ft4176">&#160;After the needle is in, let go of the&#160;skin you are&#160;</p>
<p style="position:absolute;top:457px;left:452px;white-space:nowrap" class="ft4172">holding</p>
<p style="position:absolute;top:495px;left:392px;white-space:nowrap" class="ft4174">Slowly push the plunger all the way in until all of the liquid&#160;<br/>is injected and the pre-filled syringe is empty.</p>
<p style="position:absolute;top:738px;left:114px;white-space:nowrap" class="ft4171"><b>STEP 8</b></p>
<p style="position:absolute;top:1026px;left:114px;white-space:nowrap" class="ft4171"><b>&#160; &#160; &#160; &#160; &#160; &#160; &#160;Cotton Ball</b></p>
<p style="position:absolute;top:738px;left:392px;white-space:nowrap" class="ft4175">When the injection is completed, slowly pull the needle out&#160;<br/>of the skin while keeping&#160;the pre-filled syringe at the same&#160;<br/>angle.</p>
<p style="position:absolute;top:814px;left:392px;white-space:nowrap" class="ft4174">After completing the injection, place a cotton ball or gauze&#160;<br/>pad on the skin over the injection site.</p>
<p style="position:absolute;top:870px;left:433px;white-space:nowrap" class="ft4176">&#160;<b>Do not&#160;</b>rub</p>
<p style="position:absolute;top:890px;left:433px;white-space:nowrap" class="ft4176">&#160;Slight bleeding at the injection site is normal</p>
</div>
<!-- Page 418 -->
<a name="418"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page418-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4180">418</p>
<p style="position:absolute;top:87px;left:114px;white-space:nowrap" class="ft4181"><b>STEP 9</b></p>
<p style="position:absolute;top:125px;left:114px;white-space:nowrap" class="ft4184">Throw away the used pre-filled syringe in a special disposal container as instructed by your doctor,&#160;<br/>nurse or pharmacist.&#160;<b>Never&#160;</b>recap a needle.</p>
<p style="position:absolute;top:181px;left:141px;white-space:nowrap" class="ft4186">&#160;<b>Do not&#160;</b>recycle or throw the pre-filled syringe in the household waste</p>
<p style="position:absolute;top:201px;left:141px;white-space:nowrap" class="ft4186">&#160;<b>Always&#160;</b>keep the pre-filled syringe and the special disposal container out of the sight and&#160;</p>
<p style="position:absolute;top:222px;left:168px;white-space:nowrap" class="ft4182">reach of children</p>
<p style="position:absolute;top:260px;left:114px;white-space:nowrap" class="ft4185">The&#160;needle cover, alcohol pad, cotton ball or gauze pad, blister and packaging may be put in your&#160;<br/>household waste.</p>
</div>
<!-- Page 419 -->
<a name="419"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page419-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4190">419</p>
<p style="position:absolute;top:86px;left:306px;white-space:nowrap" class="ft4191"><b>Package leaflet: Information for the patient</b></p>
<p style="position:absolute;top:124px;left:274px;white-space:nowrap" class="ft4191"><b>Humira&#160;40&#160;mg&#160;solution&#160;for injection in pre-filled pen</b></p>
<p style="position:absolute;top:143px;left:418px;white-space:nowrap" class="ft4192">adalimumab</p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft41919"><b>Read all of this leaflet carefully before you start using this medicine because it contains important&#160;<br/>information for you.</b></p>
<p style="position:absolute;top:218px;left:106px;white-space:nowrap" class="ft4196"></p>
<p style="position:absolute;top:220px;left:148px;white-space:nowrap" class="ft4192">Keep this leaflet. You may need to read it again.</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft4196"></p>
<p style="position:absolute;top:240px;left:148px;white-space:nowrap" class="ft4195">Your doctor will also give you a&#160;<b>Patient Reminder Card</b>, which contains important safety&#160;<br/>information that you need to be aware of before you begin using Humira and during treatment with&#160;<br/>Humira. Keep this&#160;<b>Patient Reminder Card&#160;</b>with you.</p>
<p style="position:absolute;top:296px;left:106px;white-space:nowrap" class="ft4196"></p>
<p style="position:absolute;top:298px;left:148px;white-space:nowrap" class="ft4192">If you have any questions, ask your doctor or pharmacist.</p>
<p style="position:absolute;top:316px;left:106px;white-space:nowrap" class="ft4196"></p>
<p style="position:absolute;top:318px;left:148px;white-space:nowrap" class="ft4194">This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even&#160;<br/>if their signs of illness are the same as yours.</p>
<p style="position:absolute;top:356px;left:106px;white-space:nowrap" class="ft4196"></p>
<p style="position:absolute;top:357px;left:148px;white-space:nowrap" class="ft4194">If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects&#160;<br/>not listed in this leaflet. See section 4.</p>
<p style="position:absolute;top:414px;left:106px;white-space:nowrap" class="ft41919"><b>What is in this leaflet<br/></b>1.</p>
<p style="position:absolute;top:433px;left:148px;white-space:nowrap" class="ft4192">What Humira is and what it is used for</p>
<p style="position:absolute;top:453px;left:106px;white-space:nowrap" class="ft4192">2.</p>
<p style="position:absolute;top:453px;left:148px;white-space:nowrap" class="ft4192">What you need to know before you use Humira</p>
<p style="position:absolute;top:471px;left:106px;white-space:nowrap" class="ft4192">3.</p>
<p style="position:absolute;top:471px;left:148px;white-space:nowrap" class="ft4192">How to use Humira</p>
<p style="position:absolute;top:490px;left:106px;white-space:nowrap" class="ft4192">4.</p>
<p style="position:absolute;top:490px;left:148px;white-space:nowrap" class="ft4192">Possible side effects</p>
<p style="position:absolute;top:509px;left:106px;white-space:nowrap" class="ft4192">5</p>
<p style="position:absolute;top:509px;left:148px;white-space:nowrap" class="ft4192">How to store Humira</p>
<p style="position:absolute;top:528px;left:106px;white-space:nowrap" class="ft4192">6.</p>
<p style="position:absolute;top:528px;left:148px;white-space:nowrap" class="ft4192">Contents of the pack and other&#160;information</p>
<p style="position:absolute;top:547px;left:106px;white-space:nowrap" class="ft4192">7.</p>
<p style="position:absolute;top:547px;left:148px;white-space:nowrap" class="ft4192">Injecting Humira</p>
<p style="position:absolute;top:604px;left:106px;white-space:nowrap" class="ft4191"><b>1.</b></p>
<p style="position:absolute;top:604px;left:148px;white-space:nowrap" class="ft4191"><b>What Humira is and what it is used for</b></p>
<p style="position:absolute;top:642px;left:106px;white-space:nowrap" class="ft4192">Humira contains the active substance adalimumab.</p>
<p style="position:absolute;top:680px;left:106px;white-space:nowrap" class="ft4192">Humira is used to treat</p>
<p style="position:absolute;top:698px;left:133px;white-space:nowrap" class="ft4196">&#160;Rheumatoid arthritis</p>
<p style="position:absolute;top:718px;left:133px;white-space:nowrap" class="ft4196">&#160;Polyarticular juvenile idiopathic arthritis</p>
<p style="position:absolute;top:739px;left:133px;white-space:nowrap" class="ft4196">&#160;Enthesitis-related arthritis</p>
<p style="position:absolute;top:759px;left:133px;white-space:nowrap" class="ft4196">&#160;Ankylosing&#160;spondylitis</p>
<p style="position:absolute;top:779px;left:133px;white-space:nowrap" class="ft4196">&#160;Axial spondyloarthritis without radiographic evidence of ankylosing spondylitis</p>
<p style="position:absolute;top:799px;left:133px;white-space:nowrap" class="ft4196">&#160;Psoriatic arthritis</p>
<p style="position:absolute;top:819px;left:133px;white-space:nowrap" class="ft4196">&#160;Plaque psoriasis</p>
<p style="position:absolute;top:839px;left:133px;white-space:nowrap" class="ft4196">&#160;Hidradenitis suppurativa</p>
<p style="position:absolute;top:860px;left:133px;white-space:nowrap" class="ft4196">&#160;Crohn’s disease</p>
<p style="position:absolute;top:880px;left:133px;white-space:nowrap" class="ft4196">&#160;Ulcerative colitis</p>
<p style="position:absolute;top:900px;left:133px;white-space:nowrap" class="ft4196">&#160;Non-infectious uveitis</p>
<p style="position:absolute;top:940px;left:106px;white-space:nowrap" class="ft4194">The active ingredient&#160;in Humira,&#160;adalimumab, is a&#160;human&#160;monoclonal antibody. Monoclonal antibodies&#160;<br/>are&#160;proteins that&#160;attach to a specific target.</p>
<p style="position:absolute;top:997px;left:106px;white-space:nowrap" class="ft4194">The target of&#160;adalimumab&#160;is a&#160;protein&#160;called&#160;tumour necrosis factor&#160;(TNFα), which&#160;is involved in the&#160;<br/>immune (defence) system and&#160;is present at increased levels in&#160;the&#160;inflammatory diseases&#160;listed above.&#160;By&#160;<br/>attaching to&#160;TNFα, Humira decreases the process of inflammation in these diseases.</p>
</div>
<!-- Page 420 -->
<a name="420"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page420-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4200">420</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft4201"><b>Rheumatoid arthritis</b></p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft4202">Rheumatoid arthritis is an inflammatory disease of the joints.</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft4204">Humira is&#160;used to treat moderate to severe rheumatoid arthritis in adults. You may first be given other&#160;<br/>disease-modifying medicines, such as methotrexate. If you do not respond well enough to these medicines,&#160;<br/>you will be given Humira.</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft4204">Humira can also be used to treat severe, active and progressive rheumatoid arthritis without previous&#160;<br/>methotrexate treatment.</p>
<p style="position:absolute;top:295px;left:106px;white-space:nowrap" class="ft4205">Humira can slow down the damage to the joints caused by the inflammatory disease and can help them&#160;<br/>move&#160;more freely.&#160;</p>
<p style="position:absolute;top:352px;left:106px;white-space:nowrap" class="ft4202">Your doctor will decide if Humira should be used with methotrexate or alone.&#160;</p>
<p style="position:absolute;top:390px;left:106px;white-space:nowrap" class="ft4201"><b>Polyarticular juvenile idiopathic arthritis</b></p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft4202">Polyarticular juvenile idiopathic arthritis is an inflammatory disease of the joints.</p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft4205">Humira is used to treat polyarticular juvenile idiopathic arthritis in patients from&#160;2 years of age. You may&#160;<br/>first be given other disease-modifying medicines, such as methotrexate. If you do not respond well enough&#160;<br/>to these medicines, you will be given Humira.</p>
<p style="position:absolute;top:541px;left:106px;white-space:nowrap" class="ft4202">Your doctor will decide if Humira should be used with methotrexate or alone.</p>
<p style="position:absolute;top:579px;left:106px;white-space:nowrap" class="ft4201"><b>Enthesitis-related arthritis</b></p>
<p style="position:absolute;top:617px;left:106px;white-space:nowrap" class="ft4204">Enthesitis-related arthritis is an inflammatory disease of the joints and the places where tendons join the&#160;<br/>bone.</p>
<p style="position:absolute;top:674px;left:106px;white-space:nowrap" class="ft4204">Humira is used to treat enthesitis-related arthritis in patients from 6 years of age. You may first be given&#160;<br/>other disease-modifying medicines, such as methotrexate. If you do not respond well enough to these&#160;<br/>medicines, you will be given Humira.</p>
<p style="position:absolute;top:750px;left:106px;white-space:nowrap" class="ft42019"><b>Ankylosing spondylitis and axial spondyloarthritis without radiographic evidence of ankylosing&#160;<br/>spondylitis</b></p>
<p style="position:absolute;top:807px;left:106px;white-space:nowrap" class="ft4205">Ankylosing spondylitis and axial spondyloarthritis without radiographic evidence of ankylosing&#160;<br/>spondylitis are inflammatory diseases of the spine.</p>
<p style="position:absolute;top:864px;left:106px;white-space:nowrap" class="ft4204">Humira is used to treat severe ankylosing spondylitis and axial spondyloarthritis without radiographic&#160;<br/>evidence of&#160;ankylosing spondylitis in adults. You may first be given other medicines. If you do not&#160;<br/>respond well enough to these medicines, you will be given Humira.</p>
<p style="position:absolute;top:940px;left:106px;white-space:nowrap" class="ft4201"><b>Psoriatic arthritis</b></p>
<p style="position:absolute;top:978px;left:106px;white-space:nowrap" class="ft4202">Psoriatic arthritis is an inflammatory disease of the joints that is usually associated with psoriasis.</p>
<p style="position:absolute;top:1016px;left:106px;white-space:nowrap" class="ft4204">Humira is used to treat psoriatic arthritis in adults. Humira can slow down the damage to the joints caused&#160;<br/>by the disease and can help them move more freely. You may first be given other medicines. If you do not&#160;<br/>respond well enough to these medicines, you will be given Humira.</p>
</div>
<!-- Page 421 -->
<a name="421"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page421-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4210">421</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft4211"><b>Plaque psoriasis</b></p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft4214">Plaque psoriasis is a skin condition that causes red, flaky, crusty patches of skin covered with silvery&#160;<br/>scales. Plaque psoriasis can also affect the nails, causing them to crumble, become thickened and lift away&#160;<br/>from the nail bed which can be painful. &#160;</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft4212">Humira is used to treat</p>
<p style="position:absolute;top:218px;left:133px;white-space:nowrap" class="ft4216">&#160;moderate to severe chronic plaque psoriasis in adults and&#160;</p>
<p style="position:absolute;top:238px;left:133px;white-space:nowrap" class="ft4216">&#160;severe chronic plaque psoriasis in children and adolescents aged 4 to 17 years for whom topical&#160;</p>
<p style="position:absolute;top:259px;left:160px;white-space:nowrap" class="ft4212">therapy and phototherapies have either not worked very well or are not suitable.</p>
<p style="position:absolute;top:297px;left:106px;white-space:nowrap" class="ft4211"><b>Hidradenitis suppurativa</b></p>
<p style="position:absolute;top:335px;left:106px;white-space:nowrap" class="ft4214">Hidradenitis suppurativa (sometimes called acne inversa) is a chronic and often painful inflammatory skin&#160;<br/>disease. Symptoms may include tender nodules (lumps) and abscesses (boils) that may leak pus. It most&#160;<br/>commonly affects&#160;specific areas of the skin, such as under the breasts, the armpits, inner thighs, groin and&#160;<br/>buttocks.&#160;Scarring may also occur in affected areas.</p>
<p style="position:absolute;top:430px;left:106px;white-space:nowrap" class="ft4212">Humira is used to treat&#160;</p>
<p style="position:absolute;top:448px;left:133px;white-space:nowrap" class="ft4216">&#160;moderate to severe hidradenitis suppurativa in adults and</p>
<p style="position:absolute;top:468px;left:133px;white-space:nowrap" class="ft4216">&#160;moderate to severe hidradenitis suppurativa in adolescents&#160;aged&#160;12&#160;to 17&#160;years.</p>
<p style="position:absolute;top:508px;left:106px;white-space:nowrap" class="ft4214">Humira can reduce the number of nodules and abscesses caused by the disease and the pain that is often&#160;<br/>associated with the disease.&#160;You may first be given other medicines. If you do not respond well&#160;enough to&#160;<br/>these medicines, you will be given Humira.</p>
<p style="position:absolute;top:584px;left:106px;white-space:nowrap" class="ft4211"><b>Crohn’s disease</b></p>
<p style="position:absolute;top:622px;left:106px;white-space:nowrap" class="ft4212">Crohn’s disease is an inflammatory disease of the digestive tract.</p>
<p style="position:absolute;top:660px;left:106px;white-space:nowrap" class="ft4212">Humira is used to treat</p>
<p style="position:absolute;top:678px;left:133px;white-space:nowrap" class="ft4216">&#160;moderate to severe Crohn’s disease in adults and&#160;</p>
<p style="position:absolute;top:698px;left:133px;white-space:nowrap" class="ft4216">&#160;moderate to severe Crohn’s disease in&#160;children and adolescents aged 6 to 17 years</p>
<p style="position:absolute;top:738px;left:106px;white-space:nowrap" class="ft4214">You may first be given other medicines. If you do not respond well enough to these medicines, you will be&#160;<br/>given Humira.</p>
<p style="position:absolute;top:795px;left:106px;white-space:nowrap" class="ft4211"><b>Ulcerative colitis</b></p>
<p style="position:absolute;top:833px;left:106px;white-space:nowrap" class="ft4212">Ulcerative colitis is an inflammatory disease of the large intestine.</p>
<p style="position:absolute;top:871px;left:106px;white-space:nowrap" class="ft4212">Humira is used to treat&#160;</p>
<p style="position:absolute;top:889px;left:133px;white-space:nowrap" class="ft4216">&#160;moderate to severe ulcerative colitis in adults&#160;and</p>
<p style="position:absolute;top:909px;left:133px;white-space:nowrap" class="ft4216">&#160;moderate to severe ulcerative colitis in children and adolescents aged 6 to 17 years.</p>
<p style="position:absolute;top:949px;left:106px;white-space:nowrap" class="ft4215">You may first be given other medicines. If you do not respond well enough to these medicines, you will be&#160;<br/>given Humira.</p>
<p style="position:absolute;top:1006px;left:106px;white-space:nowrap" class="ft4211"><b>Non-infectious uveitis</b></p>
<p style="position:absolute;top:1044px;left:106px;white-space:nowrap" class="ft4212">Non-infectious uveitis is an inflammatory disease affecting certain parts of the eye.</p>
<p style="position:absolute;top:1082px;left:106px;white-space:nowrap" class="ft4212">Humira is used to treat&#160;</p>
</div>
<!-- Page 422 -->
<a name="422"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page422-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4220">422</p>
<p style="position:absolute;top:85px;left:133px;white-space:nowrap" class="ft4226">&#160;adults with non-infectious uveitis with inflammation affecting the back of the eye</p>
<p style="position:absolute;top:105px;left:133px;white-space:nowrap" class="ft4226">&#160;children&#160;with chronic non-infectious uveitis from 2&#160;years of age with inflammation affecting the&#160;</p>
<p style="position:absolute;top:126px;left:160px;white-space:nowrap" class="ft4222">front of the eye&#160;</p>
<p style="position:absolute;top:164px;left:106px;white-space:nowrap" class="ft4224">This inflammation may lead to a decrease of vision and/or the presence of floaters in the eye (black dots or&#160;<br/>wispy lines that move across the field of vision). Humira works by reducing this inflammation.</p>
<p style="position:absolute;top:221px;left:106px;white-space:nowrap" class="ft4224">You may first be given other medicines. If you do not respond well enough to these medicines, you will be&#160;<br/>given Humira.</p>
<p style="position:absolute;top:297px;left:106px;white-space:nowrap" class="ft4221"><b>2.</b></p>
<p style="position:absolute;top:297px;left:148px;white-space:nowrap" class="ft4221"><b>What you need to know before you use Humira</b></p>
<p style="position:absolute;top:335px;left:106px;white-space:nowrap" class="ft4221"><b>Do not use Humira:</b></p>
<p style="position:absolute;top:372px;left:133px;white-space:nowrap" class="ft4226">&#160;If you are allergic to adalimumab or any of the other ingredients of this medicine (listed in section&#160;</p>
<p style="position:absolute;top:393px;left:160px;white-space:nowrap" class="ft4222">6).&#160;</p>
<p style="position:absolute;top:430px;left:133px;white-space:nowrap" class="ft4226">&#160;If you have active tuberculosis or other severe infections (see “Warnings and precautions”). It is&#160;</p>
<p style="position:absolute;top:451px;left:160px;white-space:nowrap" class="ft4224">important that you tell your doctor if you have symptoms of infections, for example, fever,&#160;<br/>wounds, feeling tired, dental problems.</p>
<p style="position:absolute;top:508px;left:133px;white-space:nowrap" class="ft4226">&#160;If you have moderate or severe heart failure. It is important to tell your doctor if you have had or&#160;</p>
<p style="position:absolute;top:528px;left:160px;white-space:nowrap" class="ft4222">have a serious heart condition (see “Warnings and precautions”).</p>
<p style="position:absolute;top:566px;left:106px;white-space:nowrap" class="ft4221"><b>Warnings and precautions</b></p>
<p style="position:absolute;top:604px;left:106px;white-space:nowrap" class="ft4222">Talk to your doctor or pharmacist before using Humira.</p>
<p style="position:absolute;top:642px;left:106px;white-space:nowrap" class="ft4222">Allergic reactions</p>
<p style="position:absolute;top:679px;left:133px;white-space:nowrap" class="ft4226">&#160;If you get allergic reactions with symptoms such as chest tightness, wheezing, dizziness, swelling&#160;</p>
<p style="position:absolute;top:700px;left:160px;white-space:nowrap" class="ft4224">or rash do not inject more Humira and contact your doctor&#160;immediately since, in rare cases, these&#160;<br/>reactions can be life threatening.</p>
<p style="position:absolute;top:757px;left:106px;white-space:nowrap" class="ft4222">Infections</p>
<p style="position:absolute;top:794px;left:133px;white-space:nowrap" class="ft4226">&#160;If you have an infection, including long-term&#160;infection or an infection in one part of the body (for&#160;</p>
<p style="position:absolute;top:815px;left:160px;white-space:nowrap" class="ft4225">example, leg ulcer) consult your doctor before starting Humira. If&#160;you are unsure, contact your&#160;<br/>doctor.&#160;</p>
<p style="position:absolute;top:871px;left:133px;white-space:nowrap" class="ft4226">&#160;You might get infections more easily while you are receiving Humira treatment. This risk may&#160;</p>
<p style="position:absolute;top:892px;left:160px;white-space:nowrap" class="ft4222">increase if you have problems with your lungs. These infections may be serious and include:&#160;</p>
<p style="position:absolute;top:911px;left:187px;white-space:nowrap" class="ft4226">&#160;tuberculosis</p>
<p style="position:absolute;top:931px;left:187px;white-space:nowrap" class="ft4226">&#160;infections caused&#160;by viruses, fungi, parasites or bacteria</p>
<p style="position:absolute;top:951px;left:187px;white-space:nowrap" class="ft4226">&#160;severe infection in the blood (sepsis)</p>
<p style="position:absolute;top:991px;left:160px;white-space:nowrap" class="ft4225">In rare cases, these infections can be life-threatening. It is important to tell your doctor if you get&#160;<br/>symptoms such as fever, wounds, feeling tired or dental problems. Your&#160;doctor may tell you to&#160;<br/>stop using Humira for some time.</p>
</div>
<!-- Page 423 -->
<a name="423"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page423-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4230">423</p>
<p style="position:absolute;top:85px;left:133px;white-space:nowrap" class="ft4236">&#160;Tell your doctor if you live or travel in regions where&#160;fungal infections&#160;(for example,&#160;</p>
<p style="position:absolute;top:106px;left:160px;white-space:nowrap" class="ft4232">histoplasmosis, coccidioidomycosis or blastomycosis) are very common.</p>
<p style="position:absolute;top:143px;left:133px;white-space:nowrap" class="ft4236">&#160;Tell your doctor if you have had infections which keep coming back or other conditions that&#160;</p>
<p style="position:absolute;top:164px;left:160px;white-space:nowrap" class="ft4232">increase the risk of infections.</p>
<p style="position:absolute;top:202px;left:133px;white-space:nowrap" class="ft4236">&#160;If you are over 65 years you may be more likely to get infections while taking Humira. You and&#160;</p>
<p style="position:absolute;top:222px;left:160px;white-space:nowrap" class="ft4234">your doctor should pay special attention to signs of infection while you are being treated with&#160;<br/>Humira. It is important to tell your doctor if you get symptoms of infections, such as fever,&#160;<br/>wounds, feeling tired or dental problems.</p>
<p style="position:absolute;top:298px;left:106px;white-space:nowrap" class="ft4232">Tuberculosis</p>
<p style="position:absolute;top:335px;left:133px;white-space:nowrap" class="ft4236">&#160;It is very important that you tell your doctor if you have ever had tuberculosis, or&#160;if you have been&#160;</p>
<p style="position:absolute;top:356px;left:160px;white-space:nowrap" class="ft4234">in close contact with someone who has had tuberculosis. If you have active tuberculosis, do not&#160;<br/>use Humira.</p>
<p style="position:absolute;top:412px;left:187px;white-space:nowrap" class="ft4236">&#160;As cases of tuberculosis have been reported in patients treated with Humira, your doctor&#160;</p>
<p style="position:absolute;top:433px;left:214px;white-space:nowrap" class="ft4234">will check you for signs and symptoms of&#160;tuberculosis before starting Humira. This will&#160;<br/>include a thorough medical evaluation including your medical history and appropriate&#160;<br/>screening tests (for example, chest X-ray and a tuberculin test). The conduct and results of&#160;<br/>these tests should be recorded&#160;on&#160;your&#160;<b>Patient Reminder Card</b>.&#160;</p>
<p style="position:absolute;top:509px;left:187px;white-space:nowrap" class="ft4236">&#160;Tuberculosis can develop during therapy even if you have received treatment for the&#160;</p>
<p style="position:absolute;top:530px;left:214px;white-space:nowrap" class="ft4232">prevention of tuberculosis.&#160;</p>
<p style="position:absolute;top:548px;left:187px;white-space:nowrap" class="ft4236">&#160;If symptoms of tuberculosis (for example, cough that does not go away, weight loss, lack&#160;</p>
<p style="position:absolute;top:568px;left:214px;white-space:nowrap" class="ft4234">of&#160;energy, mild fever), or any other infection appear during or after therapy tell your&#160;<br/>doctor immediately.</p>
<p style="position:absolute;top:626px;left:106px;white-space:nowrap" class="ft4232">Hepatitis B</p>
<p style="position:absolute;top:663px;left:133px;white-space:nowrap" class="ft4236">&#160;Tell your doctor if you are a carrier of the hepatitis B virus (HBV), if you have active HBV or if&#160;</p>
<p style="position:absolute;top:684px;left:160px;white-space:nowrap" class="ft4232">you think you might be at risk of getting HBV.&#160;</p>
<p style="position:absolute;top:702px;left:187px;white-space:nowrap" class="ft4236">&#160;Your doctor should test you for HBV. In people who carry HBV, Humira can cause the&#160;</p>
<p style="position:absolute;top:723px;left:214px;white-space:nowrap" class="ft4232">virus to become active again.</p>
<p style="position:absolute;top:741px;left:187px;white-space:nowrap" class="ft4236">&#160;In some rare cases, especially if you are taking other medicines that suppress the immune&#160;</p>
<p style="position:absolute;top:762px;left:214px;white-space:nowrap" class="ft4232">system, reactivation of HBV can be life-threatening. &#160;</p>
<p style="position:absolute;top:800px;left:106px;white-space:nowrap" class="ft4232">Surgery&#160;or dental procedure</p>
<p style="position:absolute;top:837px;left:133px;white-space:nowrap" class="ft4236">&#160;If you are about to have surgery or dental procedures,&#160;please inform your doctor that you are&#160;</p>
<p style="position:absolute;top:858px;left:160px;white-space:nowrap" class="ft4232">taking Humira. Your doctor may recommend temporary discontinuation of Humira.&#160;</p>
<p style="position:absolute;top:896px;left:106px;white-space:nowrap" class="ft4232">Demyelinating disease</p>
<p style="position:absolute;top:933px;left:133px;white-space:nowrap" class="ft4236">&#160;If you have or develop&#160;a&#160;demyelinating disease&#160;(a disease that affects the insulating layer around&#160;</p>
<p style="position:absolute;top:954px;left:160px;white-space:nowrap" class="ft4235">the nerves,&#160;such as multiple sclerosis), your doctor will decide if you should receive or continue to&#160;<br/>receive Humira. Tell your doctor immediately if you experience symptoms like&#160;changes in your&#160;<br/>vision, weakness in your arms or legs or numbness or tingling in any part of your body.</p>
<p style="position:absolute;top:1030px;left:106px;white-space:nowrap" class="ft4232">Vaccinations</p>
<p style="position:absolute;top:1067px;left:133px;white-space:nowrap" class="ft4236">&#160;Certain vaccines may cause infections and should not be given while receiving Humira.&#160;</p>
</div>
<!-- Page 424 -->
<a name="424"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page424-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4240">424</p>
<p style="position:absolute;top:104px;left:187px;white-space:nowrap" class="ft4246">&#160;Check with your doctor before you receive any vaccines.&#160;</p>
<p style="position:absolute;top:124px;left:187px;white-space:nowrap" class="ft4246">&#160;It is recommended that children, if possible, be&#160;given all the scheduled vaccinations for&#160;</p>
<p style="position:absolute;top:145px;left:214px;white-space:nowrap" class="ft4242">their age before they start treatment&#160;with Humira.</p>
<p style="position:absolute;top:163px;left:187px;white-space:nowrap" class="ft4246">&#160;If you received Humira while you were pregnant, your baby may be at higher risk for&#160;</p>
<p style="position:absolute;top:184px;left:214px;white-space:nowrap" class="ft4245">getting such an infection for up to approximately five months after the last Humira dose&#160;<br/>you received during pregnancy.&#160;It is&#160;important that you tell your baby's doctors and other&#160;<br/>health care professionals about your Humira use during your pregnancy so they can&#160;<br/>decide when your&#160;baby should receive any vaccine.</p>
<p style="position:absolute;top:279px;left:106px;white-space:nowrap" class="ft4242">Heart&#160;failure</p>
<p style="position:absolute;top:316px;left:133px;white-space:nowrap" class="ft4246">&#160;If you have&#160;mild heart failure and&#160;are&#160;being treated with&#160;Humira,&#160;your&#160;heart failure status must be&#160;</p>
<p style="position:absolute;top:337px;left:160px;white-space:nowrap" class="ft4245">closely monitored by your doctor. It is important to tell your doctor if you&#160;have&#160;had or have a&#160;<br/>serious&#160;heart condition. If&#160;you&#160;develop new or worsening symptoms of heart failure (e.g. shortness&#160;<br/>of breath, or swelling of your feet), you must contact your doctor immediately. Your doctor will&#160;<br/>decide if you&#160;should receive Humira.</p>
<p style="position:absolute;top:432px;left:106px;white-space:nowrap" class="ft4242">Fever, bruising, bleeding&#160;or looking&#160;pale</p>
<p style="position:absolute;top:469px;left:170px;white-space:nowrap" class="ft4246">&#160;In some patients the body may fail to produce enough of the blood cells that fight&#160;off</p>
<p style="position:absolute;top:490px;left:197px;white-space:nowrap" class="ft4245">infections or help you to stop bleeding. Your doctor may decide to stop treatment.&#160;If you&#160;<br/>develop a fever that does not go away,&#160;develop light&#160;bruises&#160;or bleed very&#160;easily or look very&#160;<br/>pale, call your doctor right away.</p>
<p style="position:absolute;top:566px;left:106px;white-space:nowrap" class="ft4242">Cancer</p>
<p style="position:absolute;top:604px;left:133px;white-space:nowrap" class="ft4246">&#160;There have been very rare cases of certain kinds of cancer in children and adult patients taking&#160;</p>
<p style="position:absolute;top:624px;left:160px;white-space:nowrap" class="ft4242">Humira or other TNF blockers. &#160;</p>
<p style="position:absolute;top:662px;left:187px;white-space:nowrap" class="ft4246">&#160;People with more serious rheumatoid arthritis that have had the disease for a long time&#160;</p>
<p style="position:absolute;top:683px;left:214px;white-space:nowrap" class="ft4245">may have a higher than average risk of getting lymphoma (a cancer that affects the lymph&#160;<br/>system) and leukaemia (a cancer that affects the blood and bone marrow).</p>
<p style="position:absolute;top:720px;left:187px;white-space:nowrap" class="ft4246">&#160;If you take Humira the risk of getting lymphoma, leukaemia, or other cancers may&#160;</p>
<p style="position:absolute;top:741px;left:214px;white-space:nowrap" class="ft4245">increase.&#160;On rare occasions, an uncommon and severe type of lymphoma, has been seen in&#160;<br/>patients taking Humira. Some of those patients were also treated with azathioprine or 6-<br/>mercaptopurine.</p>
<p style="position:absolute;top:797px;left:187px;white-space:nowrap" class="ft4246">&#160;Tell your doctor if you are taking azathioprine or 6-mercaptopurine with Humira.&#160;</p>
<p style="position:absolute;top:817px;left:187px;white-space:nowrap" class="ft4246">&#160;Cases of non-melanoma skin cancer have been observed in patients taking Humira.&#160;</p>
<p style="position:absolute;top:837px;left:187px;white-space:nowrap" class="ft4246">&#160;If new skin lesions appear during or after therapy or if existing lesions change appearance,&#160;</p>
<p style="position:absolute;top:858px;left:214px;white-space:nowrap" class="ft4242">tell your doctor.</p>
<p style="position:absolute;top:895px;left:133px;white-space:nowrap" class="ft4246">&#160;There have been cases of cancers, other than lymphoma in patients with a specific type of lung&#160;</p>
<p style="position:absolute;top:916px;left:160px;white-space:nowrap" class="ft4244">disease called Chronic Obstructive Pulmonary Disease (COPD) treated with another TNF blocker.&#160;<br/>If you have COPD, or are a heavy smoker, you&#160;should discuss with your doctor whether treatment&#160;<br/>with a TNF blocker is appropriate for you.</p>
<p style="position:absolute;top:992px;left:106px;white-space:nowrap" class="ft4242">Autoimmune disease</p>
<p style="position:absolute;top:1029px;left:133px;white-space:nowrap" class="ft4246">&#160;On rare occasions, treatment with Humira could result in lupus-like syndrome. Contact your&#160;</p>
<p style="position:absolute;top:1050px;left:160px;white-space:nowrap" class="ft4242">doctor if symptoms such as persistent unexplained rash, fever, joint pain or tiredness&#160;occur.</p>
</div>
<!-- Page 425 -->
<a name="425"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page425-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4250">425</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft4251"><b>Children and adolescents</b></p>
<p style="position:absolute;top:123px;left:133px;white-space:nowrap" class="ft4256">&#160;Vaccinations: if possible,&#160;children should be up to date with all vaccinations before using Humira.</p>
<p style="position:absolute;top:163px;left:106px;white-space:nowrap" class="ft4251"><b>Other medicines and Humira</b></p>
<p style="position:absolute;top:201px;left:106px;white-space:nowrap" class="ft4252">Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p>
<p style="position:absolute;top:239px;left:106px;white-space:nowrap" class="ft4255">You should not take Humira with medicines containing the&#160;following&#160;active substances&#160;due to increased&#160;<br/>risk of serious infection:</p>
<p style="position:absolute;top:276px;left:133px;white-space:nowrap" class="ft4256">&#160;anakinra</p>
<p style="position:absolute;top:296px;left:133px;white-space:nowrap" class="ft4256">&#160;abatacept.</p>
<p style="position:absolute;top:336px;left:106px;white-space:nowrap" class="ft4252">Humira can be taken together with:</p>
<p style="position:absolute;top:355px;left:133px;white-space:nowrap" class="ft4256">&#160;methotrexate</p>
<p style="position:absolute;top:375px;left:133px;white-space:nowrap" class="ft4256">&#160;certain&#160;disease-modifying anti-rheumatic agents (for example, sulfasalazine, hydroxychloroquine,&#160;</p>
<p style="position:absolute;top:395px;left:147px;white-space:nowrap" class="ft4252">leflunomide and injectable gold preparations)</p>
<p style="position:absolute;top:414px;left:133px;white-space:nowrap" class="ft4256">&#160;steroids or pain medications including non-steroidal anti-inflammatory drugs (NSAIDs).</p>
<p style="position:absolute;top:454px;left:106px;white-space:nowrap" class="ft4252">If you have questions, please ask&#160;your doctor.</p>
<p style="position:absolute;top:491px;left:106px;white-space:nowrap" class="ft4251"><b>Pregnancy and breast-feeding</b></p>
<p style="position:absolute;top:529px;left:133px;white-space:nowrap" class="ft4256">&#160;You&#160;should consider the&#160;use&#160;of&#160;adequate contraception&#160;to prevent pregnancy&#160;and&#160;continue its use</p>
<p style="position:absolute;top:550px;left:160px;white-space:nowrap" class="ft4252">for at least 5 months after the last Humira treatment.</p>
<p style="position:absolute;top:568px;left:133px;white-space:nowrap" class="ft4256">&#160;If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for&#160;</p>
<p style="position:absolute;top:589px;left:160px;white-space:nowrap" class="ft4252">advice about taking this medicine.</p>
<p style="position:absolute;top:607px;left:133px;white-space:nowrap" class="ft4256">&#160;Humira should only be used during a pregnancy if needed.</p>
<p style="position:absolute;top:627px;left:133px;white-space:nowrap" class="ft4256">&#160;According to a pregnancy study, there was no higher risk of birth defects when the mother had&#160;</p>
<p style="position:absolute;top:648px;left:160px;white-space:nowrap" class="ft4254">received Humira during pregnancy compared with mothers with the same disease who did not&#160;<br/>receive Humira.</p>
<p style="position:absolute;top:685px;left:133px;white-space:nowrap" class="ft4256">&#160;Humira can be used during breast-feeding.</p>
<p style="position:absolute;top:706px;left:133px;white-space:nowrap" class="ft4256">&#160;If you receive Humira during your pregnancy, your baby may have a higher&#160;risk for getting an&#160;</p>
<p style="position:absolute;top:726px;left:160px;white-space:nowrap" class="ft4252">infection.</p>
<p style="position:absolute;top:744px;left:133px;white-space:nowrap" class="ft4256">&#160;It is important that you tell your baby’s doctors and other health care professionals about your&#160;</p>
<p style="position:absolute;top:765px;left:160px;white-space:nowrap" class="ft4254">Humira use during your pregnancy before the baby receives any vaccine. For more information&#160;on&#160;<br/>vaccines&#160;see&#160;the&#160;“Warnings and precautions”&#160;section.</p>
<p style="position:absolute;top:822px;left:106px;white-space:nowrap" class="ft4251"><b>Driving and using machines</b></p>
<p style="position:absolute;top:860px;left:106px;white-space:nowrap" class="ft4255">Humira may have a&#160;small effect on your ability to drive, cycle or use machines. Room spinning sensation&#160;<br/>and vision disturbances may occur after taking Humira.</p>
<p style="position:absolute;top:936px;left:106px;white-space:nowrap" class="ft4251"><b>3.</b></p>
<p style="position:absolute;top:936px;left:148px;white-space:nowrap" class="ft4251"><b>How to use Humira</b></p>
<p style="position:absolute;top:974px;left:106px;white-space:nowrap" class="ft4254">Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or&#160;<br/>pharmacist if you are not sure.&#160;</p>
<p style="position:absolute;top:1031px;left:106px;white-space:nowrap" class="ft4254">The recommended doses for Humira in each of the approved uses are shown in the following table.<br/>Your doctor may prescribe&#160;another strength of Humira if you need a different dose.</p>
</div>
<!-- Page 426 -->
<a name="426"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page426-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4260">426</p>
<p style="position:absolute;top:87px;left:114px;white-space:nowrap" class="ft42619"><b>Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis or axial spondyloarthritis&#160;<br/>without radiographic evidence of ankylosing spondylitis<br/>Age or body weight</b></p>
<p style="position:absolute;top:125px;left:346px;white-space:nowrap" class="ft42619"><b>How much and how often to&#160;<br/>take?</b></p>
<p style="position:absolute;top:125px;left:579px;white-space:nowrap" class="ft4261"><b>Notes</b></p>
<p style="position:absolute;top:164px;left:114px;white-space:nowrap" class="ft4262">Adults&#160;</p>
<p style="position:absolute;top:164px;left:346px;white-space:nowrap" class="ft4262">40 mg every other week</p>
<p style="position:absolute;top:164px;left:579px;white-space:nowrap" class="ft4265">In rheumatoid arthritis,&#160;<br/>methotrexate is continued while&#160;<br/>using Humira. If your doctor&#160;<br/>decides that methotrexate is&#160;<br/>inappropriate, Humira can be&#160;<br/>given alone.</p>
<p style="position:absolute;top:297px;left:579px;white-space:nowrap" class="ft4264">If you have rheumatoid arthritis&#160;<br/>and you do not&#160;receive&#160;<br/>methotrexate with your Humira&#160;<br/>therapy, your doctor may decide&#160;<br/>to give Humira 40 mg every&#160;<br/>week&#160;or 80 mg every other&#160;<br/>week.&#160;</p>
<p style="position:absolute;top:450px;left:114px;white-space:nowrap" class="ft42619"><b>Polyarticular juvenile idiopathic arthritis<br/>Age or body weight</b></p>
<p style="position:absolute;top:470px;left:346px;white-space:nowrap" class="ft42619"><b>How much and how often to&#160;<br/>take?</b></p>
<p style="position:absolute;top:470px;left:579px;white-space:nowrap" class="ft4261"><b>Notes</b></p>
<p style="position:absolute;top:509px;left:114px;white-space:nowrap" class="ft4265">Children, adolescents and adults&#160;<br/>from&#160;2&#160;years of age&#160;weighing 30&#160;<br/>kg or more</p>
<p style="position:absolute;top:509px;left:346px;white-space:nowrap" class="ft4262">40 mg every other week</p>
<p style="position:absolute;top:509px;left:579px;white-space:nowrap" class="ft4262">Not applicable</p>
<p style="position:absolute;top:566px;left:114px;white-space:nowrap" class="ft4265">Children&#160;and adolescents&#160;from 2&#160;<br/>years of age&#160;weighing 10 kg to&#160;<br/>less than 30 kg</p>
<p style="position:absolute;top:566px;left:346px;white-space:nowrap" class="ft4262">20 mg every other week</p>
<p style="position:absolute;top:566px;left:579px;white-space:nowrap" class="ft4262">Not applicable</p>
<p style="position:absolute;top:644px;left:114px;white-space:nowrap" class="ft42619"><b>Enthesitis-related arthritis<br/>Age or body weight</b></p>
<p style="position:absolute;top:663px;left:346px;white-space:nowrap" class="ft42619"><b>How much and how often to&#160;<br/>take?</b></p>
<p style="position:absolute;top:663px;left:579px;white-space:nowrap" class="ft4261"><b>Notes</b></p>
<p style="position:absolute;top:702px;left:114px;white-space:nowrap" class="ft4264">Children, adolescents and adults&#160;<br/>from 6 years of age&#160;weighing 30&#160;<br/>kg or more</p>
<p style="position:absolute;top:702px;left:346px;white-space:nowrap" class="ft4262">40 mg every other week</p>
<p style="position:absolute;top:702px;left:579px;white-space:nowrap" class="ft4262">Not applicable</p>
<p style="position:absolute;top:760px;left:114px;white-space:nowrap" class="ft4264">Children and adolescents from 6&#160;<br/>years of age weighing 15 kg to&#160;<br/>less than 30 kg</p>
<p style="position:absolute;top:760px;left:346px;white-space:nowrap" class="ft4262">20&#160;mg&#160;every other week</p>
<p style="position:absolute;top:760px;left:579px;white-space:nowrap" class="ft4262">Not applicable</p>
<p style="position:absolute;top:837px;left:114px;white-space:nowrap" class="ft42619"><b>Plaque psoriasis<br/>Age or body weight</b></p>
<p style="position:absolute;top:857px;left:346px;white-space:nowrap" class="ft42619"><b>How much and how often to&#160;<br/>take?</b></p>
<p style="position:absolute;top:857px;left:579px;white-space:nowrap" class="ft4261"><b>Notes</b></p>
<p style="position:absolute;top:896px;left:114px;white-space:nowrap" class="ft4262">Adults&#160;</p>
<p style="position:absolute;top:896px;left:346px;white-space:nowrap" class="ft4264">First dose of 80 mg (two 40 mg&#160;<br/>injections in one day), followed&#160;<br/>by 40 mg every other week&#160;<br/>starting one week after the first&#160;<br/>dose.</p>
<p style="position:absolute;top:896px;left:579px;white-space:nowrap" class="ft4264">If&#160;you have an inadequate&#160;<br/>response, your doctor may&#160;<br/>increase the dosage to 40 mg&#160;<br/>every week&#160;or 80 mg every&#160;<br/>other week.</p>
<p style="position:absolute;top:1010px;left:114px;white-space:nowrap" class="ft4265">Children and adolescents from 4<br/>to 17&#160;years of age&#160;weighing 30&#160;<br/>kg or more</p>
<p style="position:absolute;top:1010px;left:346px;white-space:nowrap" class="ft4264">First dose of 40 mg, followed by&#160;<br/>40 mg one week later.</p>
<p style="position:absolute;top:1010px;left:579px;white-space:nowrap" class="ft4262">Not applicable</p>
</div>
<!-- Page 427 -->
<a name="427"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page427-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4270">427</p>
<p style="position:absolute;top:87px;left:346px;white-space:nowrap" class="ft4274">Thereafter, the usual dose is 40&#160;<br/>mg&#160;every other week.</p>
<p style="position:absolute;top:125px;left:114px;white-space:nowrap" class="ft4274">Children and adolescents from 4&#160;<br/>to 17 years of age weighing 15&#160;<br/>kg to less than 30 kg</p>
<p style="position:absolute;top:125px;left:346px;white-space:nowrap" class="ft4274">First dose of 20 mg, followed by&#160;<br/>20 mg one week later.</p>
<p style="position:absolute;top:182px;left:346px;white-space:nowrap" class="ft4274">Thereafter, the usual dose is 20&#160;<br/>mg&#160;every&#160;other week.</p>
<p style="position:absolute;top:125px;left:579px;white-space:nowrap" class="ft4272">Not applicable</p>
<p style="position:absolute;top:241px;left:114px;white-space:nowrap" class="ft42719"><b>Hidradenitis suppurativa<br/>Age or body weight</b></p>
<p style="position:absolute;top:261px;left:346px;white-space:nowrap" class="ft42715"><b>How much and how often to&#160;<br/>take?</b></p>
<p style="position:absolute;top:261px;left:579px;white-space:nowrap" class="ft4271"><b>Notes</b></p>
<p style="position:absolute;top:299px;left:114px;white-space:nowrap" class="ft4272">Adults&#160;</p>
<p style="position:absolute;top:299px;left:346px;white-space:nowrap" class="ft4274">First dose of 160&#160;mg (four 40&#160;<br/>mg&#160;injections in one day or two&#160;<br/>40 mg injections per day for two&#160;<br/>consecutive days), followed by&#160;<br/>an 80&#160;mg&#160;dose (two 40 mg&#160;<br/>injections in one day) two&#160;<br/>weeks later. After two further&#160;<br/>weeks, continue with a dose of&#160;<br/>40 mg every week&#160;or 80 mg&#160;<br/>every other week, as prescribed&#160;<br/>by your doctor. &#160;</p>
<p style="position:absolute;top:299px;left:579px;white-space:nowrap" class="ft4275">It is recommended that you use&#160;<br/>an antiseptic wash daily on the&#160;<br/>affected&#160;areas.</p>
<p style="position:absolute;top:509px;left:114px;white-space:nowrap" class="ft4274">Adolescents from 12&#160;to 17&#160;years&#160;<br/>of age weighing 30 kg&#160;or more</p>
<p style="position:absolute;top:509px;left:346px;white-space:nowrap" class="ft4274">First dose of 80 mg (two 40 mg&#160;<br/>injections in one day), followed&#160;<br/>by 40 mg every other week&#160;<br/>starting one week later. &#160;</p>
<p style="position:absolute;top:509px;left:579px;white-space:nowrap" class="ft4275">If you have an inadequate&#160;<br/>response&#160;to Humira 40 mg every&#160;<br/>other week,&#160;your doctor may&#160;<br/>increase the dosage to 40 mg&#160;<br/>every week&#160;or 80 mg every&#160;<br/>other week.<br/>It is recommended that you use&#160;<br/>an antiseptic wash daily on the&#160;<br/>affected areas.</p>
<p style="position:absolute;top:719px;left:114px;white-space:nowrap" class="ft42719"><b>Crohn’s disease<br/>Age or body weight</b></p>
<p style="position:absolute;top:739px;left:346px;white-space:nowrap" class="ft42715"><b>How much and how often to&#160;<br/>take?</b></p>
<p style="position:absolute;top:739px;left:579px;white-space:nowrap" class="ft4271"><b>Notes</b></p>
<p style="position:absolute;top:777px;left:114px;white-space:nowrap" class="ft4275">Children,&#160;adolescents&#160;and adults&#160;<br/>from 6 years of age weighing 40&#160;<br/>kg or more</p>
<p style="position:absolute;top:777px;left:346px;white-space:nowrap" class="ft4275">First dose of 80 mg (two 40 mg&#160;<br/>injections in one day), followed&#160;<br/>by 40 mg two weeks later.</p>
<p style="position:absolute;top:853px;left:346px;white-space:nowrap" class="ft4274">If a faster response is required,&#160;<br/>the doctor may prescribe a first&#160;<br/>dose of 160 mg (four 40 mg&#160;<br/>injections in one day or two 40&#160;<br/>mg&#160;injections per day for two&#160;<br/>consecutive days), followed by&#160;<br/>80 mg (two 40 mg injections in&#160;<br/>one day) two weeks later.</p>
<p style="position:absolute;top:1024px;left:346px;white-space:nowrap" class="ft4274">Thereafter, the usual dose is 40&#160;<br/>mg&#160;every other week.</p>
<p style="position:absolute;top:777px;left:579px;white-space:nowrap" class="ft4275">Your doctor may increase the&#160;<br/>dosage to 40 mg every&#160;week&#160;or&#160;<br/>80 mg every other week.</p>
</div>
<!-- Page 428 -->
<a name="428"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page428-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4280">428</p>
<p style="position:absolute;top:87px;left:114px;white-space:nowrap" class="ft4285">Children and adolescents from 6<br/>to 17&#160;years of age weighing less&#160;<br/>than 40 kg</p>
<p style="position:absolute;top:87px;left:346px;white-space:nowrap" class="ft4284">First dose of 40 mg, followed by&#160;<br/>20 mg two weeks later.&#160;</p>
<p style="position:absolute;top:144px;left:346px;white-space:nowrap" class="ft4284">If a faster response is required,&#160;<br/>the doctor may prescribe a first&#160;<br/>dose of 80 mg (two 40&#160;mg&#160;<br/>injections in one day), followed&#160;<br/>by 40 mg two weeks later.</p>
<p style="position:absolute;top:257px;left:346px;white-space:nowrap" class="ft4284">Thereafter, the usual dose is 20&#160;<br/>mg&#160;every other week.</p>
<p style="position:absolute;top:87px;left:579px;white-space:nowrap" class="ft4285">Your doctor may increase the&#160;<br/>dose frequency to 20 mg every&#160;<br/>week.</p>
<p style="position:absolute;top:316px;left:114px;white-space:nowrap" class="ft42819"><b>Ulcerative colitis<br/>Age or body weight</b></p>
<p style="position:absolute;top:336px;left:346px;white-space:nowrap" class="ft42819"><b>How much and how often to&#160;<br/>take?</b></p>
<p style="position:absolute;top:336px;left:579px;white-space:nowrap" class="ft4281"><b>Notes</b></p>
<p style="position:absolute;top:374px;left:114px;white-space:nowrap" class="ft4282">Adults</p>
<p style="position:absolute;top:374px;left:346px;white-space:nowrap" class="ft4285">First dose of 160 mg (four 40&#160;<br/>mg&#160;injections in one day or two&#160;<br/>40 mg injections per day for two&#160;<br/>consecutive days), followed by&#160;<br/>80 mg (two 40 mg injections in&#160;<br/>one day) two weeks later.</p>
<p style="position:absolute;top:507px;left:346px;white-space:nowrap" class="ft4285">Thereafter, the usual dose is&#160;<br/>40&#160;mg&#160;every other week.</p>
<p style="position:absolute;top:374px;left:579px;white-space:nowrap" class="ft4284">Your doctor may increase the&#160;<br/>dosage to 40 mg every week&#160;or&#160;<br/>80 mg every other week.</p>
<p style="position:absolute;top:546px;left:114px;white-space:nowrap" class="ft4284">Children&#160;and adolescents from&#160;6<br/>years of age weighing less than&#160;<br/>40 kg</p>
<p style="position:absolute;top:546px;left:346px;white-space:nowrap" class="ft4285">First dose of 80 mg&#160;(two 40 mg&#160;<br/>injections&#160;in one&#160;day), followed&#160;<br/>by 40 mg&#160;(one 40 mg injection)&#160;<br/>two&#160;weeks later.</p>
<p style="position:absolute;top:641px;left:346px;white-space:nowrap" class="ft4285">Thereafter, the usual dose is 40&#160;<br/>mg&#160;every&#160;other week.</p>
<p style="position:absolute;top:546px;left:579px;white-space:nowrap" class="ft4284">You should continue taking&#160;<br/>Humira at your usual dose, even&#160;<br/>after turning 18 years of age.</p>
<p style="position:absolute;top:679px;left:114px;white-space:nowrap" class="ft4284">Children and adolescents from&#160;6<br/>years of age weighing 40 kg or&#160;<br/>more</p>
<p style="position:absolute;top:679px;left:346px;white-space:nowrap" class="ft4284">First dose of 160 mg (four 40<br/>mg&#160;injections in one day or two&#160;<br/>40 mg injections per day for two&#160;<br/>consecutive days), followed by&#160;<br/>80 mg (two 40 mg injections in&#160;<br/>one day) two weeks later.</p>
<p style="position:absolute;top:812px;left:346px;white-space:nowrap" class="ft4284">Thereafter, the usual dose is 80&#160;<br/>mg&#160;every other week.</p>
<p style="position:absolute;top:679px;left:579px;white-space:nowrap" class="ft4284">You should continue taking&#160;<br/>Humira at your usual&#160;dose, even&#160;<br/>after turning 18 years of age.</p>
</div>
<!-- Page 429 -->
<a name="429"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page429-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4290">429</p>
<p style="position:absolute;top:87px;left:114px;white-space:nowrap" class="ft42919"><b>Non-infectious uveitis<br/>Age or body weight</b></p>
<p style="position:absolute;top:107px;left:346px;white-space:nowrap" class="ft42915"><b>How much and how often to&#160;<br/>take?</b></p>
<p style="position:absolute;top:107px;left:579px;white-space:nowrap" class="ft4291"><b>Notes</b></p>
<p style="position:absolute;top:145px;left:114px;white-space:nowrap" class="ft4292">Adults</p>
<p style="position:absolute;top:145px;left:346px;white-space:nowrap" class="ft4294">First dose of 80 mg (two 40 mg&#160;<br/>injections in one day), followed&#160;<br/>by 40 mg every other week&#160;<br/>starting one week after the&#160;first&#160;<br/>dose.</p>
<p style="position:absolute;top:145px;left:579px;white-space:nowrap" class="ft4294">Corticosteroids or other&#160;<br/>medicines that influence the&#160;<br/>immune system may be&#160;<br/>continued while using Humira.&#160;<br/>Humira can also be given alone.</p>
<p style="position:absolute;top:241px;left:114px;white-space:nowrap" class="ft4294">Children&#160;and adolescents&#160;from&#160;<br/>2&#160;years of age weighing less&#160;<br/>than 30&#160;kg</p>
<p style="position:absolute;top:241px;left:346px;white-space:nowrap" class="ft4292">20&#160;mg&#160;every other week</p>
<p style="position:absolute;top:241px;left:579px;white-space:nowrap" class="ft4294">Your doctor&#160;may prescribe an&#160;<br/>initial dose of 40&#160;mg to be&#160;<br/>administered one week prior to&#160;<br/>the start of the usual dose of&#160;<br/>20&#160;mg&#160;every other week.&#160;<br/>Humira is recommended for use&#160;<br/>in combination with&#160;<br/>methotrexate.</p>
<p style="position:absolute;top:393px;left:114px;white-space:nowrap" class="ft4294">Children&#160;and adolescents&#160;from&#160;<br/>2&#160;years of age weighing at least&#160;<br/>30&#160;kg</p>
<p style="position:absolute;top:393px;left:346px;white-space:nowrap" class="ft4292">40&#160;mg&#160;every other week&#160;</p>
<p style="position:absolute;top:393px;left:579px;white-space:nowrap" class="ft4295">Your doctor may prescribe an&#160;<br/>initial dose of 80&#160;mg to be&#160;<br/>administered one week prior to&#160;<br/>the start of the usual dose of&#160;<br/>40&#160;mg&#160;every other week.&#160;<br/>Humira is recommended for use&#160;<br/>in combination with&#160;<br/>methotrexate.</p>
<p style="position:absolute;top:565px;left:106px;white-space:nowrap" class="ft4291"><b>Method and&#160;route of administration</b></p>
<p style="position:absolute;top:603px;left:106px;white-space:nowrap" class="ft4292">Humira is administered by injection under the skin (by subcutaneous injection).</p>
<p style="position:absolute;top:641px;left:106px;white-space:nowrap" class="ft4291"><b>Detailed instructions on how to inject Humira are provided in section 7 ‘Injecting Humira’.</b></p>
<p style="position:absolute;top:679px;left:106px;white-space:nowrap" class="ft4291"><b>If you use more&#160;Humira&#160;than you should</b></p>
<p style="position:absolute;top:717px;left:106px;white-space:nowrap" class="ft4294">If you accidentally inject Humira more frequently than told to by your doctor or pharmacist, call your&#160;<br/>doctor or pharmacist&#160;and tell them that you have taken more. Always take the outer carton of the medicine&#160;<br/>with you, even if it is empty.&#160;</p>
<p style="position:absolute;top:792px;left:106px;white-space:nowrap" class="ft4291"><b>If you forget&#160;to use Humira</b></p>
<p style="position:absolute;top:831px;left:106px;white-space:nowrap" class="ft4294">If you forget to give yourself an injection, you should inject the next dose of Humira as soon as you&#160;<br/>remember. Then take your next dose as you would have on your originally scheduled day, had you not&#160;<br/>forgotten a dose.&#160;</p>
<p style="position:absolute;top:906px;left:106px;white-space:nowrap" class="ft4291"><b>If you stop using Humira</b></p>
<p style="position:absolute;top:944px;left:106px;white-space:nowrap" class="ft4294">The&#160;decision to stop using Humira should be discussed with your doctor. Your symptoms may return if&#160;<br/>you stop using Humira.</p>
<p style="position:absolute;top:1001px;left:106px;white-space:nowrap" class="ft4292">If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
</div>
<!-- Page 430 -->
<a name="430"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page430-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4300">430</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft4301"><b>4.</b></p>
<p style="position:absolute;top:86px;left:148px;white-space:nowrap" class="ft4301"><b>Possible side effects</b></p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft4304">Like&#160;all medicines, this medicine can cause side effects, although not everybody gets them. Most side&#160;<br/>effects are mild to moderate. However, some may be serious and require treatment. Side effects may occur&#160;<br/>at least up to 4 months after the last Humira injection.&#160;</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft4301"><b>Tell your doctor immediately if you notice any of the following</b></p>
<p style="position:absolute;top:237px;left:106px;white-space:nowrap" class="ft4306">&#160;severe rash, hives or other signs of allergic reaction&#160;</p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft4306">&#160;swollen face, hands, feet</p>
<p style="position:absolute;top:277px;left:106px;white-space:nowrap" class="ft4306">&#160;trouble breathing, swallowing</p>
<p style="position:absolute;top:298px;left:106px;white-space:nowrap" class="ft4306">&#160;shortness of breath with physical activity or upon lying down or swelling&#160;of the feet</p>
<p style="position:absolute;top:337px;left:106px;white-space:nowrap" class="ft4301"><b>Tell your doctor as soon as possible if you notice any of the following</b></p>
<p style="position:absolute;top:375px;left:106px;white-space:nowrap" class="ft4306">&#160;signs of infection such as fever, feeling sick, wounds, dental problems, burning on urination</p>
<p style="position:absolute;top:395px;left:106px;white-space:nowrap" class="ft4306">&#160;feeling weak or tired</p>
<p style="position:absolute;top:415px;left:106px;white-space:nowrap" class="ft4306">&#160;coughing</p>
<p style="position:absolute;top:435px;left:106px;white-space:nowrap" class="ft4306">&#160;tingling</p>
<p style="position:absolute;top:455px;left:106px;white-space:nowrap" class="ft4306">&#160;numbness</p>
<p style="position:absolute;top:475px;left:106px;white-space:nowrap" class="ft4306">&#160;double vision</p>
<p style="position:absolute;top:496px;left:106px;white-space:nowrap" class="ft4306">&#160;arm&#160;or leg weakness</p>
<p style="position:absolute;top:516px;left:106px;white-space:nowrap" class="ft4306">&#160;a bump or open sore that doesn't heal</p>
<p style="position:absolute;top:536px;left:106px;white-space:nowrap" class="ft4306">&#160;signs and symptoms suggestive of blood disorders such as persistent fever, bruising, bleeding,&#160;</p>
<p style="position:absolute;top:557px;left:133px;white-space:nowrap" class="ft4302">paleness</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft4304">The symptoms described above can be signs of the below listed side effects, which have been observed&#160;<br/>with&#160;Humira.</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft4301"><b>Very common&#160;</b>(may&#160;affect more than 1 in 10 people)<i>&#160;&#160;</i></p>
<p style="position:absolute;top:689px;left:106px;white-space:nowrap" class="ft4306"></p>
<p style="position:absolute;top:691px;left:147px;white-space:nowrap" class="ft4302">injection site reactions (including pain, swelling, redness or itching)</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft4306"></p>
<p style="position:absolute;top:711px;left:147px;white-space:nowrap" class="ft4302">respiratory tract infections (including cold, runny nose, sinus infection, pneumonia)</p>
<p style="position:absolute;top:729px;left:106px;white-space:nowrap" class="ft4306"></p>
<p style="position:absolute;top:731px;left:147px;white-space:nowrap" class="ft4302">headache</p>
<p style="position:absolute;top:749px;left:106px;white-space:nowrap" class="ft4306"></p>
<p style="position:absolute;top:751px;left:147px;white-space:nowrap" class="ft4302">abdominal pain</p>
<p style="position:absolute;top:770px;left:106px;white-space:nowrap" class="ft4306"></p>
<p style="position:absolute;top:771px;left:147px;white-space:nowrap" class="ft4302">nausea and&#160;vomiting</p>
<p style="position:absolute;top:790px;left:106px;white-space:nowrap" class="ft4306"></p>
<p style="position:absolute;top:792px;left:147px;white-space:nowrap" class="ft4302">rash</p>
<p style="position:absolute;top:810px;left:106px;white-space:nowrap" class="ft4306"></p>
<p style="position:absolute;top:812px;left:147px;white-space:nowrap" class="ft4302">musculoskeletal pain</p>
<p style="position:absolute;top:850px;left:106px;white-space:nowrap" class="ft4301"><b>Common&#160;</b>(may&#160;affect up to 1 in 10 people)&#160;</p>
<p style="position:absolute;top:887px;left:106px;white-space:nowrap" class="ft4306"></p>
<p style="position:absolute;top:889px;left:147px;white-space:nowrap" class="ft4302">serious&#160;infections (including blood poisoning and influenza)</p>
<p style="position:absolute;top:907px;left:106px;white-space:nowrap" class="ft4306"></p>
<p style="position:absolute;top:909px;left:147px;white-space:nowrap" class="ft4302">intestinal infections&#160;(including gastroenteritis)</p>
<p style="position:absolute;top:927px;left:106px;white-space:nowrap" class="ft4306"></p>
<p style="position:absolute;top:929px;left:147px;white-space:nowrap" class="ft4302">skin infections (including cellulitis and shingles)</p>
<p style="position:absolute;top:947px;left:106px;white-space:nowrap" class="ft4306"></p>
<p style="position:absolute;top:949px;left:147px;white-space:nowrap" class="ft4302">ear infections</p>
<p style="position:absolute;top:968px;left:106px;white-space:nowrap" class="ft4306"></p>
<p style="position:absolute;top:969px;left:147px;white-space:nowrap" class="ft4302">oral infections (including tooth infections and cold sores)</p>
<p style="position:absolute;top:988px;left:106px;white-space:nowrap" class="ft4306"></p>
<p style="position:absolute;top:990px;left:147px;white-space:nowrap" class="ft4302">reproductive tract infections</p>
<p style="position:absolute;top:1008px;left:106px;white-space:nowrap" class="ft4306"></p>
<p style="position:absolute;top:1010px;left:147px;white-space:nowrap" class="ft4302">urinary tract infection</p>
<p style="position:absolute;top:1028px;left:106px;white-space:nowrap" class="ft4306"></p>
<p style="position:absolute;top:1030px;left:147px;white-space:nowrap" class="ft4302">fungal infections</p>
<p style="position:absolute;top:1048px;left:106px;white-space:nowrap" class="ft4306"></p>
<p style="position:absolute;top:1050px;left:147px;white-space:nowrap" class="ft4302">joint infections</p>
<p style="position:absolute;top:1068px;left:106px;white-space:nowrap" class="ft4306"></p>
<p style="position:absolute;top:1070px;left:147px;white-space:nowrap" class="ft4302">benign tumours</p>
</div>
<!-- Page 431 -->
<a name="431"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page431-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4310">431</p>
<p style="position:absolute;top:85px;left:106px;white-space:nowrap" class="ft4316"></p>
<p style="position:absolute;top:87px;left:147px;white-space:nowrap" class="ft4312">skin cancer</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft4316"></p>
<p style="position:absolute;top:107px;left:147px;white-space:nowrap" class="ft4312">allergic reactions (including seasonal allergy)</p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft4316"></p>
<p style="position:absolute;top:127px;left:147px;white-space:nowrap" class="ft4312">dehydration</p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft4316"></p>
<p style="position:absolute;top:148px;left:147px;white-space:nowrap" class="ft4312">mood swings&#160;(including depression)</p>
<p style="position:absolute;top:166px;left:106px;white-space:nowrap" class="ft4316"></p>
<p style="position:absolute;top:168px;left:147px;white-space:nowrap" class="ft4312">anxiety</p>
<p style="position:absolute;top:186px;left:106px;white-space:nowrap" class="ft4316"></p>
<p style="position:absolute;top:188px;left:147px;white-space:nowrap" class="ft4312">difficulty sleeping</p>
<p style="position:absolute;top:206px;left:106px;white-space:nowrap" class="ft4316"></p>
<p style="position:absolute;top:208px;left:147px;white-space:nowrap" class="ft4312">sensation disorders such as tingling, prickling or numbness</p>
<p style="position:absolute;top:226px;left:106px;white-space:nowrap" class="ft4316"></p>
<p style="position:absolute;top:228px;left:147px;white-space:nowrap" class="ft4312">migraine</p>
<p style="position:absolute;top:247px;left:106px;white-space:nowrap" class="ft4316"></p>
<p style="position:absolute;top:248px;left:147px;white-space:nowrap" class="ft4312">nerve root compression (including low back pain and leg pain)</p>
<p style="position:absolute;top:267px;left:106px;white-space:nowrap" class="ft4316"></p>
<p style="position:absolute;top:269px;left:147px;white-space:nowrap" class="ft4312">vision disturbances</p>
<p style="position:absolute;top:287px;left:106px;white-space:nowrap" class="ft4316"></p>
<p style="position:absolute;top:289px;left:147px;white-space:nowrap" class="ft4312">eye&#160;inflammation</p>
<p style="position:absolute;top:307px;left:106px;white-space:nowrap" class="ft4316"></p>
<p style="position:absolute;top:309px;left:147px;white-space:nowrap" class="ft4312">inflammation of the eye lid and eye swelling</p>
<p style="position:absolute;top:327px;left:106px;white-space:nowrap" class="ft4316"></p>
<p style="position:absolute;top:329px;left:147px;white-space:nowrap" class="ft4312">vertigo (feeling of dizziness or spinning)</p>
<p style="position:absolute;top:347px;left:106px;white-space:nowrap" class="ft4316"></p>
<p style="position:absolute;top:349px;left:147px;white-space:nowrap" class="ft4312">sensation of heart beating rapidly</p>
<p style="position:absolute;top:367px;left:106px;white-space:nowrap" class="ft4316"></p>
<p style="position:absolute;top:369px;left:147px;white-space:nowrap" class="ft4312">high blood pressure</p>
<p style="position:absolute;top:388px;left:106px;white-space:nowrap" class="ft4316"></p>
<p style="position:absolute;top:390px;left:147px;white-space:nowrap" class="ft4312">flushing</p>
<p style="position:absolute;top:408px;left:106px;white-space:nowrap" class="ft4316"></p>
<p style="position:absolute;top:410px;left:147px;white-space:nowrap" class="ft4312">haematoma (collection of blood outside of blood vessels)</p>
<p style="position:absolute;top:428px;left:106px;white-space:nowrap" class="ft4316"></p>
<p style="position:absolute;top:430px;left:147px;white-space:nowrap" class="ft4312">cough</p>
<p style="position:absolute;top:448px;left:106px;white-space:nowrap" class="ft4316"></p>
<p style="position:absolute;top:450px;left:147px;white-space:nowrap" class="ft4312">asthma</p>
<p style="position:absolute;top:468px;left:106px;white-space:nowrap" class="ft4316"></p>
<p style="position:absolute;top:470px;left:147px;white-space:nowrap" class="ft4312">shortness of breath</p>
<p style="position:absolute;top:488px;left:106px;white-space:nowrap" class="ft4316"></p>
<p style="position:absolute;top:490px;left:147px;white-space:nowrap" class="ft4312">gastrointestinal bleeding</p>
<p style="position:absolute;top:509px;left:106px;white-space:nowrap" class="ft4316"></p>
<p style="position:absolute;top:510px;left:147px;white-space:nowrap" class="ft4312">dyspepsia (indigestion, bloating, heart burn)</p>
<p style="position:absolute;top:529px;left:106px;white-space:nowrap" class="ft4316"></p>
<p style="position:absolute;top:531px;left:147px;white-space:nowrap" class="ft4312">acid reflux disease</p>
<p style="position:absolute;top:549px;left:106px;white-space:nowrap" class="ft4316"></p>
<p style="position:absolute;top:551px;left:147px;white-space:nowrap" class="ft4312">sicca syndrome (including dry eyes and dry mouth)</p>
<p style="position:absolute;top:569px;left:106px;white-space:nowrap" class="ft4316"></p>
<p style="position:absolute;top:571px;left:147px;white-space:nowrap" class="ft4312">itching</p>
<p style="position:absolute;top:589px;left:106px;white-space:nowrap" class="ft4316"></p>
<p style="position:absolute;top:591px;left:147px;white-space:nowrap" class="ft4312">itchy rash</p>
<p style="position:absolute;top:609px;left:106px;white-space:nowrap" class="ft4316"></p>
<p style="position:absolute;top:611px;left:147px;white-space:nowrap" class="ft4312">bruising</p>
<p style="position:absolute;top:630px;left:106px;white-space:nowrap" class="ft4316"></p>
<p style="position:absolute;top:631px;left:147px;white-space:nowrap" class="ft4312">inflammation of the skin (such as eczema)</p>
<p style="position:absolute;top:650px;left:106px;white-space:nowrap" class="ft4316"></p>
<p style="position:absolute;top:652px;left:147px;white-space:nowrap" class="ft4312">breaking of finger nails and toe nails</p>
<p style="position:absolute;top:670px;left:106px;white-space:nowrap" class="ft4316"></p>
<p style="position:absolute;top:672px;left:147px;white-space:nowrap" class="ft4312">increased sweating</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft4316"></p>
<p style="position:absolute;top:692px;left:147px;white-space:nowrap" class="ft4312">hair loss</p>
<p style="position:absolute;top:710px;left:106px;white-space:nowrap" class="ft4316"></p>
<p style="position:absolute;top:712px;left:147px;white-space:nowrap" class="ft4312">new&#160;onset or worsening of&#160;psoriasis</p>
<p style="position:absolute;top:730px;left:106px;white-space:nowrap" class="ft4316"></p>
<p style="position:absolute;top:732px;left:147px;white-space:nowrap" class="ft4312">muscle spasms</p>
<p style="position:absolute;top:751px;left:106px;white-space:nowrap" class="ft4316"></p>
<p style="position:absolute;top:752px;left:147px;white-space:nowrap" class="ft4312">blood in urine</p>
<p style="position:absolute;top:771px;left:106px;white-space:nowrap" class="ft4316"></p>
<p style="position:absolute;top:773px;left:147px;white-space:nowrap" class="ft4312">kidney problems</p>
<p style="position:absolute;top:791px;left:106px;white-space:nowrap" class="ft4316"></p>
<p style="position:absolute;top:793px;left:147px;white-space:nowrap" class="ft4312">chest pain</p>
<p style="position:absolute;top:811px;left:106px;white-space:nowrap" class="ft4316"></p>
<p style="position:absolute;top:813px;left:147px;white-space:nowrap" class="ft4312">oedema (swelling)</p>
<p style="position:absolute;top:831px;left:106px;white-space:nowrap" class="ft4316"></p>
<p style="position:absolute;top:833px;left:147px;white-space:nowrap" class="ft4312">fever</p>
<p style="position:absolute;top:851px;left:106px;white-space:nowrap" class="ft4316"></p>
<p style="position:absolute;top:853px;left:147px;white-space:nowrap" class="ft4312">reduction in blood platelets which increases risk of bleeding or bruising</p>
<p style="position:absolute;top:871px;left:106px;white-space:nowrap" class="ft4316"></p>
<p style="position:absolute;top:873px;left:147px;white-space:nowrap" class="ft4312">impaired healing</p>
<p style="position:absolute;top:911px;left:106px;white-space:nowrap" class="ft4311"><b>Uncommon&#160;</b>(may&#160;affect up to 1 in 100 people) &#160;</p>
<p style="position:absolute;top:949px;left:106px;white-space:nowrap" class="ft4316"></p>
<p style="position:absolute;top:950px;left:147px;white-space:nowrap" class="ft4314">opportunistic infections&#160;(which include tuberculosis and other infections that occur when resistance&#160;<br/>to disease is lowered)</p>
<p style="position:absolute;top:988px;left:106px;white-space:nowrap" class="ft4316"></p>
<p style="position:absolute;top:990px;left:147px;white-space:nowrap" class="ft4312">neurological infections (including viral meningitis)</p>
<p style="position:absolute;top:1008px;left:106px;white-space:nowrap" class="ft4316"></p>
<p style="position:absolute;top:1010px;left:147px;white-space:nowrap" class="ft4312">eye&#160;infections</p>
<p style="position:absolute;top:1028px;left:106px;white-space:nowrap" class="ft4316"></p>
<p style="position:absolute;top:1030px;left:147px;white-space:nowrap" class="ft4312">bacterial infections</p>
<p style="position:absolute;top:1048px;left:106px;white-space:nowrap" class="ft4316"></p>
<p style="position:absolute;top:1050px;left:147px;white-space:nowrap" class="ft4312">diverticulitis (inflammation and infection of the large intestine)</p>
<p style="position:absolute;top:1068px;left:106px;white-space:nowrap" class="ft4316"></p>
<p style="position:absolute;top:1070px;left:147px;white-space:nowrap" class="ft4312">cancer</p>
</div>
<!-- Page 432 -->
<a name="432"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page432-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4320">432</p>
<p style="position:absolute;top:85px;left:106px;white-space:nowrap" class="ft4326"></p>
<p style="position:absolute;top:87px;left:147px;white-space:nowrap" class="ft4322">cancer that affects the lymph system</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft4326"></p>
<p style="position:absolute;top:107px;left:147px;white-space:nowrap" class="ft4322">melanoma</p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft4326"></p>
<p style="position:absolute;top:127px;left:147px;white-space:nowrap" class="ft4324">immune disorders that could affect the lungs, skin and lymph nodes (most commonly presenting as&#160;<br/>sarcoidosis)</p>
<p style="position:absolute;top:165px;left:106px;white-space:nowrap" class="ft4326"></p>
<p style="position:absolute;top:167px;left:147px;white-space:nowrap" class="ft4322">vasculitis (inflammation of blood vessels)</p>
<p style="position:absolute;top:185px;left:106px;white-space:nowrap" class="ft4326"></p>
<p style="position:absolute;top:187px;left:147px;white-space:nowrap" class="ft4322">tremor (shaking)</p>
<p style="position:absolute;top:205px;left:106px;white-space:nowrap" class="ft4326"></p>
<p style="position:absolute;top:207px;left:147px;white-space:nowrap" class="ft4322">neuropathy (disorder of the nerves)</p>
<p style="position:absolute;top:225px;left:106px;white-space:nowrap" class="ft4326"></p>
<p style="position:absolute;top:227px;left:147px;white-space:nowrap" class="ft4322">stroke</p>
<p style="position:absolute;top:245px;left:106px;white-space:nowrap" class="ft4326"></p>
<p style="position:absolute;top:247px;left:147px;white-space:nowrap" class="ft4322">hearing loss, buzzing</p>
<p style="position:absolute;top:266px;left:106px;white-space:nowrap" class="ft4326"></p>
<p style="position:absolute;top:267px;left:147px;white-space:nowrap" class="ft4322">sensation of heart beating irregularly such as skipped beats</p>
<p style="position:absolute;top:286px;left:106px;white-space:nowrap" class="ft4326"></p>
<p style="position:absolute;top:288px;left:147px;white-space:nowrap" class="ft4322">heart problems that can cause shortness of breath or ankle swelling</p>
<p style="position:absolute;top:306px;left:106px;white-space:nowrap" class="ft4326"></p>
<p style="position:absolute;top:308px;left:147px;white-space:nowrap" class="ft4322">heart attack</p>
<p style="position:absolute;top:326px;left:106px;white-space:nowrap" class="ft4326"></p>
<p style="position:absolute;top:328px;left:147px;white-space:nowrap" class="ft4322">a sac in the wall of a major artery, inflammation and clot of a vein, blockage of a&#160;blood vessel</p>
<p style="position:absolute;top:346px;left:106px;white-space:nowrap" class="ft4326"></p>
<p style="position:absolute;top:348px;left:147px;white-space:nowrap" class="ft4322">lung diseases causing shortness of breath (including inflammation)</p>
<p style="position:absolute;top:366px;left:106px;white-space:nowrap" class="ft4326"></p>
<p style="position:absolute;top:368px;left:147px;white-space:nowrap" class="ft4322">pulmonary embolism (blockage in an artery of the lung)</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft4326"></p>
<p style="position:absolute;top:388px;left:147px;white-space:nowrap" class="ft4322">pleural effusion (abnormal collection of fluid in the pleural space)</p>
<p style="position:absolute;top:407px;left:106px;white-space:nowrap" class="ft4326"></p>
<p style="position:absolute;top:409px;left:147px;white-space:nowrap" class="ft4322">inflammation of the pancreas which causes severe pain&#160;in the abdomen and back</p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft4326"></p>
<p style="position:absolute;top:429px;left:147px;white-space:nowrap" class="ft4322">difficulty in swallowing</p>
<p style="position:absolute;top:447px;left:106px;white-space:nowrap" class="ft4326"></p>
<p style="position:absolute;top:449px;left:147px;white-space:nowrap" class="ft4322">facial oedema (swelling of the face)</p>
<p style="position:absolute;top:467px;left:106px;white-space:nowrap" class="ft4326"></p>
<p style="position:absolute;top:469px;left:147px;white-space:nowrap" class="ft4322">gallbladder inflammation, gallbladder stones</p>
<p style="position:absolute;top:487px;left:106px;white-space:nowrap" class="ft4326"></p>
<p style="position:absolute;top:489px;left:147px;white-space:nowrap" class="ft4322">fatty liver</p>
<p style="position:absolute;top:508px;left:106px;white-space:nowrap" class="ft4326"></p>
<p style="position:absolute;top:509px;left:147px;white-space:nowrap" class="ft4322">night sweats</p>
<p style="position:absolute;top:528px;left:106px;white-space:nowrap" class="ft4326"></p>
<p style="position:absolute;top:530px;left:147px;white-space:nowrap" class="ft4322">scar</p>
<p style="position:absolute;top:548px;left:106px;white-space:nowrap" class="ft4326"></p>
<p style="position:absolute;top:550px;left:147px;white-space:nowrap" class="ft4322">abnormal&#160;muscle breakdown</p>
<p style="position:absolute;top:568px;left:106px;white-space:nowrap" class="ft4326"></p>
<p style="position:absolute;top:570px;left:147px;white-space:nowrap" class="ft4325">systemic lupus erythematosus (including inflammation of skin, heart, lung, joints and other organ&#160;<br/>systems)</p>
<p style="position:absolute;top:607px;left:106px;white-space:nowrap" class="ft4326"></p>
<p style="position:absolute;top:609px;left:147px;white-space:nowrap" class="ft4322">sleep interruptions</p>
<p style="position:absolute;top:627px;left:106px;white-space:nowrap" class="ft4326"></p>
<p style="position:absolute;top:629px;left:147px;white-space:nowrap" class="ft4322">impotence</p>
<p style="position:absolute;top:647px;left:106px;white-space:nowrap" class="ft4326"></p>
<p style="position:absolute;top:649px;left:147px;white-space:nowrap" class="ft4322">inflammations</p>
<p style="position:absolute;top:687px;left:106px;white-space:nowrap" class="ft4321"><b>Rare&#160;</b>(may affect up to 1 in 1,000 people)</p>
<p style="position:absolute;top:724px;left:106px;white-space:nowrap" class="ft4326"></p>
<p style="position:absolute;top:726px;left:147px;white-space:nowrap" class="ft4322">leukaemia (cancer affecting the blood and bone marrow)</p>
<p style="position:absolute;top:744px;left:106px;white-space:nowrap" class="ft4326"></p>
<p style="position:absolute;top:746px;left:147px;white-space:nowrap" class="ft4322">severe allergic reaction with shock</p>
<p style="position:absolute;top:765px;left:106px;white-space:nowrap" class="ft4326"></p>
<p style="position:absolute;top:766px;left:147px;white-space:nowrap" class="ft4322">multiple sclerosis</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft4326"></p>
<p style="position:absolute;top:787px;left:147px;white-space:nowrap" class="ft4324">nerve disorders&#160;(such as eye nerve inflammation and Guillain-Barré syndrome that may cause&#160;<br/>muscle weakness, abnormal sensations, tingling in the arms and upper body)</p>
<p style="position:absolute;top:824px;left:106px;white-space:nowrap" class="ft4326"></p>
<p style="position:absolute;top:826px;left:147px;white-space:nowrap" class="ft4322">heart stops pumping</p>
<p style="position:absolute;top:844px;left:106px;white-space:nowrap" class="ft4326"></p>
<p style="position:absolute;top:846px;left:147px;white-space:nowrap" class="ft4322">pulmonary fibrosis (scarring of the lung)</p>
<p style="position:absolute;top:864px;left:106px;white-space:nowrap" class="ft4326"></p>
<p style="position:absolute;top:866px;left:147px;white-space:nowrap" class="ft4322">intestinal perforation (hole in the&#160;intestine)</p>
<p style="position:absolute;top:884px;left:106px;white-space:nowrap" class="ft4326"></p>
<p style="position:absolute;top:886px;left:147px;white-space:nowrap" class="ft4322">hepatitis</p>
<p style="position:absolute;top:905px;left:106px;white-space:nowrap" class="ft4326"></p>
<p style="position:absolute;top:906px;left:147px;white-space:nowrap" class="ft4322">reactivation of hepatitis B</p>
<p style="position:absolute;top:925px;left:106px;white-space:nowrap" class="ft4326"></p>
<p style="position:absolute;top:927px;left:147px;white-space:nowrap" class="ft4322">autoimmune hepatitis (inflammation of the liver caused by the body's own immune system)</p>
<p style="position:absolute;top:945px;left:106px;white-space:nowrap" class="ft4326"></p>
<p style="position:absolute;top:947px;left:147px;white-space:nowrap" class="ft4322">cutaneous vasculitis (inflammation of blood vessels in the skin)</p>
<p style="position:absolute;top:965px;left:106px;white-space:nowrap" class="ft4326"></p>
<p style="position:absolute;top:967px;left:147px;white-space:nowrap" class="ft4322">Stevens-Johnson syndrome (early symptoms include malaise, fever, headache and rash)</p>
<p style="position:absolute;top:985px;left:106px;white-space:nowrap" class="ft4326"></p>
<p style="position:absolute;top:987px;left:147px;white-space:nowrap" class="ft4322">facial oedema (swelling of the face) associated with allergic reactions</p>
<p style="position:absolute;top:1005px;left:106px;white-space:nowrap" class="ft4326"></p>
<p style="position:absolute;top:1007px;left:147px;white-space:nowrap" class="ft4322">erythema multiforme (inflammatory skin rash)</p>
<p style="position:absolute;top:1026px;left:106px;white-space:nowrap" class="ft4326"></p>
<p style="position:absolute;top:1027px;left:147px;white-space:nowrap" class="ft4322">lupus-like syndrome</p>
<p style="position:absolute;top:1046px;left:106px;white-space:nowrap" class="ft4326"></p>
<p style="position:absolute;top:1048px;left:147px;white-space:nowrap" class="ft4322">angioedema (localized swelling of the skin)</p>
<p style="position:absolute;top:1066px;left:106px;white-space:nowrap" class="ft4326"></p>
<p style="position:absolute;top:1068px;left:147px;white-space:nowrap" class="ft4322">lichenoid skin reaction (itchy reddish-purple&#160;skin&#160;rash)</p>
</div>
<!-- Page 433 -->
<a name="433"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page433-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4330">433</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft4331"><b>Not known&#160;</b>(frequency cannot be estimated from the available data)</p>
<p style="position:absolute;top:142px;left:106px;white-space:nowrap" class="ft4336">&#160;hepatosplenic T-cell lymphoma (a rare blood cancer that is often fatal)</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft4336">&#160;Merkel cell carcinoma (a type of skin cancer)</p>
<p style="position:absolute;top:182px;left:106px;white-space:nowrap" class="ft4336">&#160;Kaposi’s sarcoma, a rare cancer related to infection with&#160;human herpes virus 8. Kaposi’s sarcoma&#160;</p>
<p style="position:absolute;top:203px;left:133px;white-space:nowrap" class="ft4332">most commonly appears as purple lesions on the skin</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft4336">&#160;liver failure</p>
<p style="position:absolute;top:242px;left:106px;white-space:nowrap" class="ft4336">&#160;worsening of a condition called dermatomyositis (seen as a skin rash accompanying muscle weakness)</p>
<p style="position:absolute;top:262px;left:106px;white-space:nowrap" class="ft4336">&#160;weight gain (for most patients, the weight gain was&#160;small)</p>
<p style="position:absolute;top:302px;left:106px;white-space:nowrap" class="ft4334">Some side effects observed with Humira may not have symptoms and may only be discovered through&#160;<br/>blood tests. These include:</p>
<p style="position:absolute;top:359px;left:106px;white-space:nowrap" class="ft4331"><b>Very common&#160;</b>(may&#160;affect more than 1 in 10 people)</p>
<p style="position:absolute;top:396px;left:106px;white-space:nowrap" class="ft4336"></p>
<p style="position:absolute;top:398px;left:147px;white-space:nowrap" class="ft4332">low blood measurements for white blood cells</p>
<p style="position:absolute;top:416px;left:106px;white-space:nowrap" class="ft4336"></p>
<p style="position:absolute;top:418px;left:147px;white-space:nowrap" class="ft4332">low blood measurements for&#160;red blood cells</p>
<p style="position:absolute;top:436px;left:106px;white-space:nowrap" class="ft4336"></p>
<p style="position:absolute;top:438px;left:147px;white-space:nowrap" class="ft4332">increased lipids in the blood</p>
<p style="position:absolute;top:456px;left:106px;white-space:nowrap" class="ft4336"></p>
<p style="position:absolute;top:458px;left:147px;white-space:nowrap" class="ft4332">elevated liver enzymes</p>
<p style="position:absolute;top:496px;left:106px;white-space:nowrap" class="ft4331"><b>Common&#160;</b>(may&#160;affect up to 1 in 10 people)</p>
<p style="position:absolute;top:533px;left:106px;white-space:nowrap" class="ft4336"></p>
<p style="position:absolute;top:535px;left:147px;white-space:nowrap" class="ft4332">high blood measurements for white blood cells</p>
<p style="position:absolute;top:554px;left:106px;white-space:nowrap" class="ft4336"></p>
<p style="position:absolute;top:555px;left:147px;white-space:nowrap" class="ft4332">low blood measurements for platelets</p>
<p style="position:absolute;top:574px;left:106px;white-space:nowrap" class="ft4336"></p>
<p style="position:absolute;top:576px;left:147px;white-space:nowrap" class="ft4332">increased uric acid in the blood</p>
<p style="position:absolute;top:594px;left:106px;white-space:nowrap" class="ft4336"></p>
<p style="position:absolute;top:596px;left:147px;white-space:nowrap" class="ft4332">abnormal blood measurements&#160;for sodium</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft4336"></p>
<p style="position:absolute;top:616px;left:147px;white-space:nowrap" class="ft4332">low blood measurements for calcium</p>
<p style="position:absolute;top:634px;left:106px;white-space:nowrap" class="ft4336"></p>
<p style="position:absolute;top:636px;left:147px;white-space:nowrap" class="ft4332">low blood measurements for phosphate</p>
<p style="position:absolute;top:654px;left:106px;white-space:nowrap" class="ft4336"></p>
<p style="position:absolute;top:656px;left:147px;white-space:nowrap" class="ft4332">high blood sugar</p>
<p style="position:absolute;top:675px;left:106px;white-space:nowrap" class="ft4336"></p>
<p style="position:absolute;top:676px;left:147px;white-space:nowrap" class="ft4332">high blood measurements for lactate dehydrogenase</p>
<p style="position:absolute;top:695px;left:106px;white-space:nowrap" class="ft4336"></p>
<p style="position:absolute;top:697px;left:147px;white-space:nowrap" class="ft4332">autoantibodies present in the blood</p>
<p style="position:absolute;top:715px;left:106px;white-space:nowrap" class="ft4336"></p>
<p style="position:absolute;top:717px;left:147px;white-space:nowrap" class="ft4332">low blood potassium</p>
<p style="position:absolute;top:755px;left:106px;white-space:nowrap" class="ft4331"><b>Uncommon&#160;</b>(may&#160;affect up to 1 in 100 people)&#160;</p>
<p style="position:absolute;top:792px;left:106px;white-space:nowrap" class="ft4336"></p>
<p style="position:absolute;top:794px;left:148px;white-space:nowrap" class="ft4332">elevated bilirubin measurement (liver blood test)</p>
<p style="position:absolute;top:832px;left:106px;white-space:nowrap" class="ft4331"><b>Rare&#160;</b>(may affect up to 1 in 1,000 people)</p>
<p style="position:absolute;top:869px;left:106px;white-space:nowrap" class="ft4336"></p>
<p style="position:absolute;top:871px;left:147px;white-space:nowrap" class="ft4332">low blood measurements for white blood cells, red blood cells and platelet count</p>
<p style="position:absolute;top:909px;left:106px;white-space:nowrap" class="ft4334"><b>Reporting of side effects<br/></b>If you get any side effects, talk to your doctor or&#160;pharmacist. This includes any possible side effects not&#160;<br/>listed in this leaflet.&#160;You can also report side effects directly via&#160;the national reporting system listed in&#160;<br/><a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix V.</a>&#160;&#160;By reporting side effects, you can help provide more information&#160;on the safety of this&#160;<br/>medicine.</p>
<p style="position:absolute;top:1042px;left:106px;white-space:nowrap" class="ft4331"><b>5.</b></p>
<p style="position:absolute;top:1042px;left:148px;white-space:nowrap" class="ft4331"><b>How to&#160;store Humira</b></p>
<p style="position:absolute;top:1080px;left:106px;white-space:nowrap" class="ft4332">Keep this medicine out of the sight and reach of children.&#160;</p>
</div>
<!-- Page 434 -->
<a name="434"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page434-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4340">434</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft4342">Do not use this medicine after the expiry date stated on the label/blister/carton after EXP.&#160;</p>
<p style="position:absolute;top:144px;left:106px;white-space:nowrap" class="ft4342">Store in a refrigerator (2</p>
<p style="position:absolute;top:142px;left:266px;white-space:nowrap" class="ft4346">C&#160;–&#160;8C). Do not freeze.&#160;</p>
<p style="position:absolute;top:182px;left:106px;white-space:nowrap" class="ft4342">Keep the pre-filled pen in the outer carton in order to protect from light. &#160;</p>
<p style="position:absolute;top:220px;left:106px;white-space:nowrap" class="ft4342">Alternative Storage:</p>
<p style="position:absolute;top:258px;left:106px;white-space:nowrap" class="ft43419">When needed (for example, when you are travelling), a single Humira pre-filled pen may be stored at&#160;<br/>room temperature (up to 25°C) for a maximum period of 14 days&#160;–&#160;be sure to protect it from&#160;light. Once&#160;<br/>removed from the refrigerator for room temperature storage, the pen&#160;<b>must be used within 14 days&#160;or&#160;<br/>discarded</b>, even if it is returned to the refrigerator. &#160;</p>
<p style="position:absolute;top:353px;left:106px;white-space:nowrap" class="ft4344">You should record the date when the pen is first removed from refrigerator and the&#160;date after which it&#160;<br/>should be discarded.</p>
<p style="position:absolute;top:410px;left:106px;white-space:nowrap" class="ft4344">Do not throw away any medicines via wastewater or household waste. Ask your doctor or pharmacist how&#160;<br/>to throw away medicines you no longer use. These measures will help protect the environment.</p>
<p style="position:absolute;top:486px;left:106px;white-space:nowrap" class="ft4341"><b>6.</b></p>
<p style="position:absolute;top:486px;left:148px;white-space:nowrap" class="ft4341"><b>Contents of the&#160;pack and other information</b></p>
<p style="position:absolute;top:523px;left:106px;white-space:nowrap" class="ft4341"><b>What Humira contains</b></p>
<p style="position:absolute;top:562px;left:106px;white-space:nowrap" class="ft4344">The active substance is adalimumab.<br/>The&#160;other ingredients are mannitol, polysorbate 80 and water for injections.</p>
<p style="position:absolute;top:618px;left:106px;white-space:nowrap" class="ft4341"><b>What the Humira pre-filled pen looks like and contents of the pack</b></p>
<p style="position:absolute;top:656px;left:106px;white-space:nowrap" class="ft4344">Humira 40&#160;mg solution&#160;for injection in pre-filled pen is supplied as a sterile solution of 40&#160;mg adalimumab&#160;<br/>dissolved in 0.4&#160;ml solution.</p>
<p style="position:absolute;top:713px;left:106px;white-space:nowrap" class="ft4344">The Humira pre-filled pen is a single-use grey and plum-coloured pen which contains a glass syringe with&#160;<br/>Humira. There are two caps&#160;–&#160;one is grey and labelled ‘1’ and the other is plum and labelled ‘2’. There is a&#160;<br/>window on each side of the pen through which you can see the Humira solution inside the syringe. &#160;</p>
<p style="position:absolute;top:789px;left:106px;white-space:nowrap" class="ft4344">The Humira pre-filled pen is available in packs containing 1, 2, 4 and 6 pre-filled pens.&#160;The 1 pre-filled&#160;<br/>pen pack comes with 2 alcohol pads (1 spare). For the 2, 4 and 6 pre-filled pen packs, each pre-filled pen&#160;<br/>comes with 1 alcohol pad.&#160;&#160;</p>
<p style="position:absolute;top:865px;left:106px;white-space:nowrap" class="ft4342">Not all pack sizes may be marketed. &#160;</p>
<p style="position:absolute;top:903px;left:106px;white-space:nowrap" class="ft4342">Humira&#160;may be&#160;available as a vial, a pre-filled syringe and/or&#160;a pre-filled pen.</p>
<p style="position:absolute;top:941px;left:106px;white-space:nowrap" class="ft4341"><b>Marketing Authorisation Holder</b></p>
<p style="position:absolute;top:979px;left:106px;white-space:nowrap" class="ft4345">AbbVie Deutschland GmbH &amp; Co. KG<br/>Knollstrasse<br/>67061 Ludwigshafen<br/>Germany</p>
<p style="position:absolute;top:1074px;left:106px;white-space:nowrap" class="ft4341"><b>Manufacturer&#160;</b></p>
</div>
<!-- Page 435 -->
<a name="435"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page435-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4350">435</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft4354">AbbVie Biotechnology GmbH<br/>Knollstrasse<br/>67061 Ludwigshafen<br/>Germany</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft4354">For any information about this medicine, please contact the local representative of the Marketing&#160;<br/>Authorisation Holder:</p>
<p style="position:absolute;top:258px;left:114px;white-space:nowrap" class="ft4354"><b>België/Belgique/Belgien<br/></b>AbbVie SA<br/>Tél/Tel: +32 10&#160;&#160;477811</p>
<p style="position:absolute;top:258px;left:462px;white-space:nowrap" class="ft4355"><b>Lietuva<br/></b>AbbVie UAB&#160;<br/>Tel: +370 5 205 3023</p>
<p style="position:absolute;top:336px;left:114px;white-space:nowrap" class="ft4354"><b>България<br/></b>АбВи ЕООД<br/>Тел.:+359 2&#160;90 30 430</p>
<p style="position:absolute;top:336px;left:462px;white-space:nowrap" class="ft4354"><b>Luxembourg/Luxemburg<br/></b>AbbVie SA<br/>Belgique/Belgien<br/>Tél/Tel: +32 10 477811</p>
<p style="position:absolute;top:430px;left:114px;white-space:nowrap" class="ft4354"><b>Česká republika<br/></b>AbbVie s.r.o.&#160;<br/>Tel: +420 233 098 111</p>
<p style="position:absolute;top:430px;left:462px;white-space:nowrap" class="ft4354"><b>Magyarország<br/></b>AbbVie Kft.<br/>Tel.:+36 1 455 8600</p>
<p style="position:absolute;top:506px;left:114px;white-space:nowrap" class="ft4355"><b>Danmark<br/></b>AbbVie A/S<br/>Tlf: +45 72 30-20-28</p>
<p style="position:absolute;top:506px;left:462px;white-space:nowrap" class="ft4355"><b>Malta<br/></b>V.J.Salomone Pharma Limited&#160;<br/>Tel: +356 22983201</p>
<p style="position:absolute;top:582px;left:114px;white-space:nowrap" class="ft4354"><b>Deutschland<br/></b>AbbVie Deutschland&#160;GmbH &amp; Co. KG<br/>Tel: 00800 222843 33 (gebührenfrei)<br/>Tel: +49 (0) 611&#160;/&#160;1720-0</p>
<p style="position:absolute;top:582px;left:462px;white-space:nowrap" class="ft4355"><b>Nederland<br/></b>AbbVie B.V.<br/>Tel: &#160;+31 (0)88 322 2843</p>
<p style="position:absolute;top:677px;left:114px;white-space:nowrap" class="ft4354"><b>Eesti<br/></b>AbbVie&#160;OÜ<br/>Tel: +372 623 1011</p>
<p style="position:absolute;top:677px;left:462px;white-space:nowrap" class="ft4354"><b>Norge<br/></b>AbbVie AS<br/>Tlf: +47 67 81 80 00</p>
<p style="position:absolute;top:753px;left:114px;white-space:nowrap" class="ft4354"><b>Ελλάδα<br/></b>AbbVie&#160;ΦΑΡΜΑΚΕΥΤΙΚΗ Α.Ε.<br/>Τηλ: +30&#160;214 4165 555</p>
<p style="position:absolute;top:753px;left:462px;white-space:nowrap" class="ft4354"><b>Österreich<br/></b>AbbVie GmbH&#160;<br/>Tel: +43 1 20589-0</p>
<p style="position:absolute;top:820px;left:114px;white-space:nowrap" class="ft4355"><b>España<br/></b>AbbVie Spain, S.L.U.<br/>Tel: &#160;+34 91 384 09 10</p>
<p style="position:absolute;top:820px;left:462px;white-space:nowrap" class="ft4355"><b>Polska<br/></b>AbbVie Sp. z o.o.<br/>Tel.: +48 22&#160;372 78 00&#160;</p>
<p style="position:absolute;top:896px;left:114px;white-space:nowrap" class="ft4354"><b>France<br/></b>AbbVie<br/>Tél: +33 (0) 1 45&#160;60 13 00</p>
<p style="position:absolute;top:896px;left:462px;white-space:nowrap" class="ft4354"><b>Portugal<br/></b>AbbVie, Lda.&#160;<br/>Tel: +351 (0)21 1908400</p>
<p style="position:absolute;top:972px;left:114px;white-space:nowrap" class="ft4354"><b>Hrvatska&#160;<br/></b>AbbVie d.o.o.<br/>Tel + 385 (0)1&#160;5625 501</p>
<p style="position:absolute;top:972px;left:462px;white-space:nowrap" class="ft4354"><b>România<br/></b>AbbVie S.R.L.<br/>Tel: +40 21 529 30 35</p>
</div>
<!-- Page 436 -->
<a name="436"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page436-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4360">436</p>
<p style="position:absolute;top:86px;left:114px;white-space:nowrap" class="ft4364"><b>Ireland<br/></b>AbbVie Limited&#160;<br/>Tel: +353 (0)1 4287900</p>
<p style="position:absolute;top:86px;left:462px;white-space:nowrap" class="ft4364"><b>Slovenija<br/></b>AbbVie Biofarmacevtska družba d.o.o.<br/>Tel: +386&#160;(1)32 08 060</p>
<p style="position:absolute;top:162px;left:114px;white-space:nowrap" class="ft4364"><b>Ísland<br/></b>Vistor hf.<br/>Tel: +354 535 7000</p>
<p style="position:absolute;top:162px;left:462px;white-space:nowrap" class="ft4364"><b>Slovenská republika<br/></b>AbbVie s.r.o.<br/>Tel: +421 2 5050 0777</p>
<p style="position:absolute;top:238px;left:114px;white-space:nowrap" class="ft4364"><b>Italia<br/></b>AbbVie S.r.l.&#160;<br/>Tel: +39 06 928921</p>
<p style="position:absolute;top:238px;left:462px;white-space:nowrap" class="ft4364"><b>Suomi/Finland<br/></b>AbbVie Oy&#160;<br/>Puh/Tel: &#160;+358 (0)10 2411 200</p>
<p style="position:absolute;top:315px;left:114px;white-space:nowrap" class="ft4364"><b>Κύπρος<br/></b>Lifepharma (Z.A.M.) Ltd<br/>Τηλ.: +357 22 34&#160;74 40</p>
<p style="position:absolute;top:315px;left:462px;white-space:nowrap" class="ft4364"><b>Sverige<br/></b>AbbVie AB<br/>Tel: &#160;+46 (0)8 684 44 600</p>
<p style="position:absolute;top:391px;left:114px;white-space:nowrap" class="ft4364"><b>Latvija<br/></b>AbbVie SIA&#160;<br/>Tel: +371 67605000</p>
<p style="position:absolute;top:391px;left:462px;white-space:nowrap" class="ft4364"><b>United Kingdom&#160;(Northern Ireland)<br/></b>AbbVie Deutschland GmbH &amp; Co. KG<br/>Tel: +44 (0)1628 561090</p>
<p style="position:absolute;top:467px;left:106px;white-space:nowrap" class="ft4361"><b>This leaflet was last revised in</b></p>
<p style="position:absolute;top:505px;left:106px;white-space:nowrap" class="ft4365">Detailed information on this medicine is available on the European Medicines Agency web site:&#160;<br/><a href="http://www.ema.europa.eu/">http://www.ema.europa.eu.</a></p>
<p style="position:absolute;top:562px;left:106px;white-space:nowrap" class="ft43615"><b>To listen to or request a copy of this leaflet in&#160;&lt;Braille&gt;, &lt;large print&gt; or &lt;audio&gt;, please&#160;contact the&#160;<br/>local representative of the Marketing Authorisation Holder.</b></p>
<p style="position:absolute;top:638px;left:106px;white-space:nowrap" class="ft4361"><b>7.&#160;</b></p>
<p style="position:absolute;top:638px;left:148px;white-space:nowrap" class="ft4361"><b>Injecting Humira</b></p>
<p style="position:absolute;top:677px;left:133px;white-space:nowrap" class="ft4366">&#160;The following instructions explain how to give yourself a&#160;subcutaneous&#160;injection of Humira using&#160;</p>
<p style="position:absolute;top:698px;left:160px;white-space:nowrap" class="ft4362">the pre-filled pen. First read all the instructions carefully and then follow them step by step.&#160;</p>
<p style="position:absolute;top:735px;left:133px;white-space:nowrap" class="ft4366">&#160;You will be instructed by your doctor, nurse or pharmacist on the technique of self-injection.&#160;</p>
<p style="position:absolute;top:774px;left:133px;white-space:nowrap" class="ft4366">&#160;Do not attempt to self-inject until you are sure that you understand how to prepare and give the&#160;</p>
<p style="position:absolute;top:795px;left:160px;white-space:nowrap" class="ft4362">injection.&#160;</p>
<p style="position:absolute;top:832px;left:133px;white-space:nowrap" class="ft4366">&#160;After proper training, the injection can be given by yourself or given by another person, for&#160;</p>
<p style="position:absolute;top:853px;left:160px;white-space:nowrap" class="ft4362">example, a family member or friend.</p>
<p style="position:absolute;top:891px;left:133px;white-space:nowrap" class="ft4366">&#160;Only use each pre-filled pen for one injection.</p>
</div>
<!-- Page 437 -->
<a name="437"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page437-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4370">437</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft4371"><b>Humira Pre-filled Pen</b></p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft4371"><b>&#160; &#160;Grey Cap 1 &#160; &#160; White Needle Sleeve &#160; &#160; &#160;White Arrow &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;Plum-coloured Cap 2</b></p>
<p style="position:absolute;top:312px;left:106px;white-space:nowrap" class="ft43719"><b>&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160;Needle &#160; &#160; &#160; &#160; &#160; Inspection Window &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;Plum Activator Button &#160; &#160;&#160;<br/>&#160; &#160; &#160; &#160; &#160;&#160;&#160;<br/>Do not use the pre-filled pen and call your doctor or pharmacist if the</b></p>
<p style="position:absolute;top:387px;left:133px;white-space:nowrap" class="ft4376">&#160;liquid is cloudy, discoloured, or has flakes or particles in it</p>
<p style="position:absolute;top:407px;left:133px;white-space:nowrap" class="ft4376">&#160;expiry (EXP) date has passed</p>
<p style="position:absolute;top:428px;left:133px;white-space:nowrap" class="ft4376">&#160;liquid has been frozen or left in direct sunlight</p>
<p style="position:absolute;top:448px;left:133px;white-space:nowrap" class="ft4376">&#160;pre-filled pen has been dropped or&#160;crushed</p>
<p style="position:absolute;top:487px;left:106px;white-space:nowrap" class="ft43719"><b>Do not remove the caps until just before injection. Keep Humira out of the sight and reach of&#160;<br/>children.</b></p>
<p style="position:absolute;top:545px;left:114px;white-space:nowrap" class="ft4371"><b>STEP 1</b></p>
<p style="position:absolute;top:583px;left:114px;white-space:nowrap" class="ft4372">Take Humira out of the refrigerator.</p>
<p style="position:absolute;top:621px;left:114px;white-space:nowrap" class="ft4372">Leave Humira at room temperature for&#160;<b>15 to 30 minutes&#160;</b>before injecting.</p>
<p style="position:absolute;top:658px;left:141px;white-space:nowrap" class="ft4376">&#160;<b>Do not&#160;</b>remove the Grey or Plum-coloured Caps while allowing Humira to reach room&#160;</p>
<p style="position:absolute;top:679px;left:168px;white-space:nowrap" class="ft4372">temperature</p>
<p style="position:absolute;top:697px;left:141px;white-space:nowrap" class="ft4376">&#160;<b>Do not&#160;</b>warm Humira in any other way. For example,&#160;<b>do not&#160;</b>warm it in a microwave or in hot&#160;</p>
<p style="position:absolute;top:718px;left:168px;white-space:nowrap" class="ft4372">water</p>
</div>
<!-- Page 438 -->
<a name="438"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page438-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4380">438</p>
<p style="position:absolute;top:87px;left:114px;white-space:nowrap" class="ft4381"><b>STEP 2&#160;</b></p>
<p style="position:absolute;top:125px;left:114px;white-space:nowrap" class="ft4382">&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;<b>Pen</b></p>
<p style="position:absolute;top:435px;left:114px;white-space:nowrap" class="ft4381"><b>&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160;Pad</b></p>
<p style="position:absolute;top:106px;left:392px;white-space:nowrap" class="ft4385">Check expiry (EXP) date.&#160;<b>Do not&#160;</b>use the pre-filled pen if&#160;<br/>expiry (EXP) date has passed.</p>
<p style="position:absolute;top:163px;left:392px;white-space:nowrap" class="ft4382">Place the following on a clean, flat surface</p>
<p style="position:absolute;top:200px;left:422px;white-space:nowrap" class="ft4386">&#160;1 single-use pre-filled pen and&#160;</p>
<p style="position:absolute;top:220px;left:422px;white-space:nowrap" class="ft4386">&#160;1 alcohol pad</p>
<p style="position:absolute;top:260px;left:392px;white-space:nowrap" class="ft4382">Wash and dry your hands.</p>
<p style="position:absolute;top:455px;left:114px;white-space:nowrap" class="ft4381"><b>STEP 3</b></p>
<p style="position:absolute;top:493px;left:114px;white-space:nowrap" class="ft4381"><b>Injectable Areas</b></p>
<p style="position:absolute;top:793px;left:114px;white-space:nowrap" class="ft4382">&#160; &#160; &#160;<b>Injectable&#160;Areas</b></p>
<p style="position:absolute;top:474px;left:392px;white-space:nowrap" class="ft4382">Choose an injection site:</p>
<p style="position:absolute;top:511px;left:422px;white-space:nowrap" class="ft4386">&#160;On the front of your thighs or</p>
<p style="position:absolute;top:531px;left:422px;white-space:nowrap" class="ft4386">&#160;Your belly (abdomen) at least 5 cm from your belly&#160;</p>
<p style="position:absolute;top:552px;left:449px;white-space:nowrap" class="ft4382">button (navel)</p>
<p style="position:absolute;top:570px;left:422px;white-space:nowrap" class="ft4386">&#160;At least 3 cm from your last injection site</p>
<p style="position:absolute;top:610px;left:392px;white-space:nowrap" class="ft4384">Wipe the injection site in a circular motion with the alcohol&#160;<br/>pad.</p>
<p style="position:absolute;top:666px;left:422px;white-space:nowrap" class="ft4386">&#160;<b>Do not&#160;</b>inject through clothes</p>
<p style="position:absolute;top:686px;left:422px;white-space:nowrap" class="ft4386">&#160;<b>Do not&#160;</b>inject into skin that is sore, bruised, red,&#160;</p>
<p style="position:absolute;top:707px;left:449px;white-space:nowrap" class="ft4384">hard, scarred, has stretch marks, or areas with&#160;<br/>psoriasis plaques</p>
</div>
<!-- Page 439 -->
<a name="439"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page439-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4390">439</p>
<p style="position:absolute;top:87px;left:114px;white-space:nowrap" class="ft4391"><b>STEP 4</b></p>
<p style="position:absolute;top:106px;left:392px;white-space:nowrap" class="ft4392">Hold the pre-filled pen with the Grey Cap 1 pointing up.&#160;</p>
<p style="position:absolute;top:144px;left:392px;white-space:nowrap" class="ft4392">Check the inspection window.</p>
<p style="position:absolute;top:181px;left:422px;white-space:nowrap" class="ft4396">&#160;It is normal&#160;to see 1 or more bubbles in the window</p>
<p style="position:absolute;top:201px;left:422px;white-space:nowrap" class="ft4396">&#160;Make sure the liquid is clear and colourless</p>
<p style="position:absolute;top:221px;left:422px;white-space:nowrap" class="ft4396">&#160;<b>Do not&#160;</b>use the pre-filled pen if the liquid is cloudy&#160;</p>
<p style="position:absolute;top:242px;left:449px;white-space:nowrap" class="ft4392">or has particles</p>
<p style="position:absolute;top:260px;left:422px;white-space:nowrap" class="ft4396">&#160;<b>Do not&#160;</b>use the pre-filled pen if it has been dropped&#160;</p>
<p style="position:absolute;top:281px;left:449px;white-space:nowrap" class="ft4392">or crushed</p>
<p style="position:absolute;top:368px;left:114px;white-space:nowrap" class="ft4391"><b>STEP 5</b></p>
<p style="position:absolute;top:406px;left:118px;white-space:nowrap" class="ft4391"><b>Cap 1</b></p>
<p style="position:absolute;top:644px;left:114px;white-space:nowrap" class="ft4391"><b>&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160;Cap 2</b></p>
<p style="position:absolute;top:387px;left:392px;white-space:nowrap" class="ft4394">Pull the Grey Cap 1 straight off. Throw the cap away. Do&#160;<br/>not recap.</p>
<p style="position:absolute;top:443px;left:423px;white-space:nowrap" class="ft4396">&#160;Check that the small black needle cover of the&#160;</p>
<p style="position:absolute;top:464px;left:450px;white-space:nowrap" class="ft4392">syringe has been removed with the cap</p>
<p style="position:absolute;top:483px;left:423px;white-space:nowrap" class="ft4396">&#160;It is normal to see a few drops of liquid come out&#160;of&#160;</p>
<p style="position:absolute;top:504px;left:450px;white-space:nowrap" class="ft4392">the needle</p>
<p style="position:absolute;top:541px;left:392px;white-space:nowrap" class="ft4394">Pull the Plum-coloured Cap 2 straight off. Throw the cap&#160;<br/>away. Do not recap.</p>
<p style="position:absolute;top:598px;left:392px;white-space:nowrap" class="ft4392">The pre-filled pen is now ready to use.</p>
<p style="position:absolute;top:636px;left:392px;white-space:nowrap" class="ft4395">Turn&#160;the pre-filled pen so that the white arrow points toward&#160;<br/>the injection site.</p>
<p style="position:absolute;top:675px;left:114px;white-space:nowrap" class="ft4391"><b>STEP 6</b></p>
<p style="position:absolute;top:694px;left:392px;white-space:nowrap" class="ft4395">Squeeze the skin at your&#160;injection site with your other hand&#160;<br/>to make a raised area and hold it firmly&#160;until the injection is&#160;<br/>complete.</p>
<p style="position:absolute;top:770px;left:392px;white-space:nowrap" class="ft4394">Point the white arrow toward the injection site (thigh or&#160;<br/>abdomen).</p>
<p style="position:absolute;top:827px;left:392px;white-space:nowrap" class="ft4394">Place the white needle sleeve straight&#160;<b>(90˚ angle)&#160;</b>against the&#160;<br/>injection site.</p>
<p style="position:absolute;top:884px;left:392px;white-space:nowrap" class="ft4394">Hold&#160;the pre-filled pen so that you can see the inspection&#160;<br/>window.</p>
<p style="position:absolute;top:941px;left:392px;white-space:nowrap" class="ft4394"><b>Do not&#160;</b>press the plum activator button until you are ready to&#160;<br/>inject.</p>
</div>
<!-- Page 440 -->
<a name="440"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page440-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4400">440</p>
<p style="position:absolute;top:87px;left:114px;white-space:nowrap" class="ft4401"><b>STEP 7</b></p>
<p style="position:absolute;top:125px;left:114px;white-space:nowrap" class="ft4401"><b>&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;10 Seconds &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160;</b></p>
<p style="position:absolute;top:106px;left:392px;white-space:nowrap" class="ft4404"><b>Firmly&#160;push&#160;the pre-filled pen&#160;down&#160;</b>against the injection&#160;<br/>site&#160;before starting the injection.<br/><b>Keep pushing down&#160;</b>to prevent the pre-filled pen from&#160;<br/>moving away from the skin during the injection.</p>
<p style="position:absolute;top:201px;left:392px;white-space:nowrap" class="ft44019"><b>Press&#160;</b>the plum activator button and count slowly for&#160;<b>10&#160;<br/></b>seconds.</p>
<p style="position:absolute;top:257px;left:422px;white-space:nowrap" class="ft4406">&#160;A loud&#160;<b>“click”&#160;</b>will signal the start of the injection</p>
<p style="position:absolute;top:277px;left:422px;white-space:nowrap" class="ft4406">&#160;<b>Keep pushing&#160;</b>the pre-filled pen down&#160;<b>firmly</b></p>
<p style="position:absolute;top:298px;left:449px;white-space:nowrap" class="ft4404">against the injection site&#160;until the injection is&#160;<br/>complete.</p>
<p style="position:absolute;top:355px;left:392px;white-space:nowrap" class="ft4404">The injection is complete when the yellow indicator has&#160;<br/>stopped moving.</p>
<p style="position:absolute;top:494px;left:114px;white-space:nowrap" class="ft4401"><b>STEP 8</b></p>
<p style="position:absolute;top:513px;left:392px;white-space:nowrap" class="ft4404">When the injection is completed,&#160;slowly pull the pre-filled&#160;<br/>pen from the skin. The white needle sleeve will cover the&#160;<br/>needle tip.</p>
<p style="position:absolute;top:569px;left:422px;white-space:nowrap" class="ft4406">&#160;A small amount of liquid on the injection site is&#160;</p>
<p style="position:absolute;top:590px;left:449px;white-space:nowrap" class="ft4402">normal</p>
<p style="position:absolute;top:628px;left:392px;white-space:nowrap" class="ft4405">If there are more than a few drops of liquid on the injection&#160;<br/>site, contact your doctor, nurse or pharmacist.</p>
<p style="position:absolute;top:685px;left:392px;white-space:nowrap" class="ft4404">After completing the injection, place a cotton ball or gauze&#160;<br/>pad on the skin over the injection site.</p>
<p style="position:absolute;top:741px;left:422px;white-space:nowrap" class="ft4406">&#160;<b>Do not&#160;</b>rub</p>
<p style="position:absolute;top:761px;left:422px;white-space:nowrap" class="ft4406">&#160;Slight bleeding at the injection site is normal</p>
<p style="position:absolute;top:783px;left:114px;white-space:nowrap" class="ft4401"><b>STEP 9</b></p>
<p style="position:absolute;top:821px;left:114px;white-space:nowrap" class="ft4404">Throw away the used pre-filled pen in a special disposal container as&#160;instructed by your doctor, nurse&#160;<br/>or pharmacist.</p>
<p style="position:absolute;top:877px;left:141px;white-space:nowrap" class="ft4406">&#160;<b>Do not&#160;</b>recycle or throw the pre-filled pen in the household waste</p>
<p style="position:absolute;top:897px;left:141px;white-space:nowrap" class="ft4406">&#160;<b>Always&#160;</b>keep the pre-filled pen and the special disposal container out of the sight and reach of&#160;</p>
<p style="position:absolute;top:918px;left:168px;white-space:nowrap" class="ft4402">children</p>
<p style="position:absolute;top:956px;left:114px;white-space:nowrap" class="ft4404">The caps, alcohol pad, cotton ball&#160;or gauze pad, blister and packaging may be put in your household&#160;<br/>waste.</p>
</div>
<!-- Page 441 -->
<a name="441"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page441-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4410">441</p>
<p style="position:absolute;top:86px;left:306px;white-space:nowrap" class="ft4411"><b>Package leaflet: Information for the patient</b></p>
<p style="position:absolute;top:124px;left:261px;white-space:nowrap" class="ft4411"><b>Humira&#160;80&#160;mg&#160;solution for injection in pre-filled syringe</b></p>
<p style="position:absolute;top:143px;left:418px;white-space:nowrap" class="ft4412">adalimumab</p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft44119"><b>Read all of this leaflet carefully before you start using this&#160;medicine because it contains important&#160;<br/>information for you.</b></p>
<p style="position:absolute;top:218px;left:106px;white-space:nowrap" class="ft4416"></p>
<p style="position:absolute;top:220px;left:148px;white-space:nowrap" class="ft4412">Keep this leaflet. You may need to read it again.</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft4416"></p>
<p style="position:absolute;top:240px;left:148px;white-space:nowrap" class="ft4415">Your doctor will also give you a&#160;<b>Patient Reminder Card</b>, which contains important safety&#160;<br/>information that you need to be aware of before you begin&#160;using Humira and during treatment with&#160;<br/>Humira. Keep this&#160;<b>Patient Reminder Card&#160;</b>with you.&#160;</p>
<p style="position:absolute;top:296px;left:106px;white-space:nowrap" class="ft4416"></p>
<p style="position:absolute;top:298px;left:148px;white-space:nowrap" class="ft4412">If you have any questions, ask your doctor or pharmacist.</p>
<p style="position:absolute;top:316px;left:106px;white-space:nowrap" class="ft4416"></p>
<p style="position:absolute;top:318px;left:148px;white-space:nowrap" class="ft4414">This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even&#160;<br/>if their&#160;signs of illness are the same as yours.</p>
<p style="position:absolute;top:356px;left:106px;white-space:nowrap" class="ft4416"></p>
<p style="position:absolute;top:357px;left:148px;white-space:nowrap" class="ft4414">If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects&#160;<br/>not listed in this leaflet. See section 4.</p>
<p style="position:absolute;top:414px;left:106px;white-space:nowrap" class="ft44119"><b>What is in this leaflet<br/></b>1.</p>
<p style="position:absolute;top:433px;left:148px;white-space:nowrap" class="ft4412">What Humira is and what it is used for</p>
<p style="position:absolute;top:453px;left:106px;white-space:nowrap" class="ft4412">2.</p>
<p style="position:absolute;top:453px;left:148px;white-space:nowrap" class="ft4412">What you need to know before you use Humira</p>
<p style="position:absolute;top:471px;left:106px;white-space:nowrap" class="ft4412">3.</p>
<p style="position:absolute;top:471px;left:148px;white-space:nowrap" class="ft4412">How to use Humira</p>
<p style="position:absolute;top:490px;left:106px;white-space:nowrap" class="ft4412">4.</p>
<p style="position:absolute;top:490px;left:148px;white-space:nowrap" class="ft4412">Possible side effects</p>
<p style="position:absolute;top:509px;left:106px;white-space:nowrap" class="ft4412">5.</p>
<p style="position:absolute;top:509px;left:148px;white-space:nowrap" class="ft4412">How to store Humira</p>
<p style="position:absolute;top:528px;left:106px;white-space:nowrap" class="ft4412">6.</p>
<p style="position:absolute;top:528px;left:148px;white-space:nowrap" class="ft4412">Contents of the pack and other information</p>
<p style="position:absolute;top:547px;left:106px;white-space:nowrap" class="ft4412">7.</p>
<p style="position:absolute;top:547px;left:148px;white-space:nowrap" class="ft4412">Injecting Humira</p>
<p style="position:absolute;top:604px;left:106px;white-space:nowrap" class="ft4411"><b>1.</b></p>
<p style="position:absolute;top:604px;left:148px;white-space:nowrap" class="ft4411"><b>What Humira is and what it is used for</b></p>
<p style="position:absolute;top:642px;left:106px;white-space:nowrap" class="ft4412">Humira contains the active substance adalimumab.</p>
<p style="position:absolute;top:680px;left:106px;white-space:nowrap" class="ft4412">Humira is used to treat</p>
<p style="position:absolute;top:698px;left:133px;white-space:nowrap" class="ft4416">&#160;Rheumatoid arthritis</p>
<p style="position:absolute;top:718px;left:133px;white-space:nowrap" class="ft4416">&#160;Plaque psoriasis</p>
<p style="position:absolute;top:739px;left:133px;white-space:nowrap" class="ft4416">&#160;Hidradenitis suppurativa</p>
<p style="position:absolute;top:759px;left:133px;white-space:nowrap" class="ft4416">&#160;Crohn’s disease</p>
<p style="position:absolute;top:779px;left:133px;white-space:nowrap" class="ft4416">&#160;Ulcerative colitis</p>
<p style="position:absolute;top:799px;left:133px;white-space:nowrap" class="ft4416">&#160;Non-infectious uveitis</p>
<p style="position:absolute;top:839px;left:106px;white-space:nowrap" class="ft4414">The active ingredient&#160;in Humira, adalimumab, is a&#160;human&#160;monoclonal antibody. Monoclonal antibodies&#160;<br/>are&#160;proteins that&#160;attach to a specific target.</p>
<p style="position:absolute;top:896px;left:106px;white-space:nowrap" class="ft4414">The target of&#160;adalimumab&#160;is a&#160;protein&#160;called&#160;tumour necrosis factor&#160;(TNFα), which&#160;is involved in the&#160;<br/>immune (defence) system and&#160;is present at increased levels in&#160;the&#160;inflammatory diseases&#160;listed above.&#160;By&#160;<br/>attaching to&#160;TNFα, Humira decreases the process of inflammation in these diseases.</p>
<p style="position:absolute;top:972px;left:106px;white-space:nowrap" class="ft4411"><b>Rheumatoid arthritis</b></p>
<p style="position:absolute;top:1010px;left:106px;white-space:nowrap" class="ft4412">Rheumatoid arthritis is an inflammatory disease of the joints.</p>
</div>
<!-- Page 442 -->
<a name="442"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page442-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4420">442</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft4424">Humira is used to treat moderate to severe rheumatoid arthritis in adults. You may first be given other&#160;<br/>disease-modifying medicines, such as methotrexate. If you do not respond well enough to these medicines,&#160;<br/>you will be given Humira.</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft4425">Humira can also be used to treat severe, active and progressive&#160;rheumatoid arthritis without previous&#160;<br/>methotrexate treatment.</p>
<p style="position:absolute;top:219px;left:106px;white-space:nowrap" class="ft4425">Humira can slow down the damage to the joints caused by the inflammatory disease and can help them&#160;<br/>move&#160;more freely.&#160;</p>
<p style="position:absolute;top:276px;left:106px;white-space:nowrap" class="ft4422">Your doctor will decide if Humira should be used with methotrexate or&#160;alone.</p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft4421"><b>Plaque psoriasis</b></p>
<p style="position:absolute;top:352px;left:106px;white-space:nowrap" class="ft4424">Plaque psoriasis is a skin condition that causes red, flaky, crusty patches of skin covered with silvery&#160;<br/>scales. Plaque psoriasis can also affect the nails, causing them to crumble, become thickened and lift away&#160;<br/>from the nail bed which can be painful. &#160;</p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft4422">Humira is used to treat moderate to severe&#160;chronic&#160;plaque psoriasis in adults.&#160;&#160;</p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft4421"><b>Hidradenitis suppurativa</b></p>
<p style="position:absolute;top:503px;left:106px;white-space:nowrap" class="ft4425">Hidradenitis suppurativa (sometimes called acne inversa) is a chronic and often painful inflammatory skin&#160;<br/>disease.&#160;Symptoms may include tender nodules (lumps) and abscesses (boils) that may leak pus. It most&#160;<br/><a href="http://en.wikipedia.org/wiki/Inframammary_fold">commonly affects specific areas of the skin, such as&#160;under the breasts, the armpits, inner thighs, groin and&#160;<br/></a>buttocks.&#160;Scarring may also occur in affected areas.</p>
<p style="position:absolute;top:598px;left:106px;white-space:nowrap" class="ft4422">Humira is used to treat&#160;</p>
<p style="position:absolute;top:617px;left:133px;white-space:nowrap" class="ft4426">&#160;moderate to severe hidradenitis suppurativa in adults&#160;and</p>
<p style="position:absolute;top:637px;left:133px;white-space:nowrap" class="ft4426">&#160;moderate to severe hidradenitis suppurativa in adolescents&#160;aged&#160;12to 17&#160;years.</p>
<p style="position:absolute;top:676px;left:106px;white-space:nowrap" class="ft4424">Humira can reduce the number of nodules and abscesses caused by&#160;the disease and the pain that is often&#160;<br/>associated with the disease.&#160;You may first be given other medicines. If you do not respond well enough to&#160;<br/>these medicines, you will be given Humira.</p>
<p style="position:absolute;top:752px;left:106px;white-space:nowrap" class="ft4421"><b>Crohn’s disease</b></p>
<p style="position:absolute;top:790px;left:106px;white-space:nowrap" class="ft4422">Crohn’s disease is an inflammatory disease of the&#160;digestive tract.</p>
<p style="position:absolute;top:828px;left:106px;white-space:nowrap" class="ft4422">Humira is used to treat&#160;</p>
<p style="position:absolute;top:847px;left:133px;white-space:nowrap" class="ft4426">&#160;moderate to severe&#160;Crohn’s disease in adults&#160;and&#160;</p>
<p style="position:absolute;top:867px;left:133px;white-space:nowrap" class="ft4426">&#160;moderate to severe&#160;Crohn’s disease in children and adolescents aged 6 to 17&#160;years.</p>
<p style="position:absolute;top:906px;left:106px;white-space:nowrap" class="ft4424">You may first be given other medicines. If you do not respond well enough to&#160;these medicines, you will be&#160;<br/>given Humira.</p>
<p style="position:absolute;top:963px;left:106px;white-space:nowrap" class="ft4421"><b>Ulcerative colitis</b></p>
<p style="position:absolute;top:1002px;left:106px;white-space:nowrap" class="ft4422">Ulcerative colitis is an inflammatory disease of the large intestine.</p>
<p style="position:absolute;top:1039px;left:106px;white-space:nowrap" class="ft4422">Humira is used to treat&#160;</p>
<p style="position:absolute;top:1058px;left:133px;white-space:nowrap" class="ft4426">&#160;moderate to severe&#160;ulcerative colitis in adults&#160;and</p>
<p style="position:absolute;top:1078px;left:133px;white-space:nowrap" class="ft4426">&#160;moderate to severe ulcerative colitis in children and adolescents aged 6 to 17 years.</p>
</div>
<!-- Page 443 -->
<a name="443"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page443-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4430">443</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft4434">You may first be given other medicines. If you do not respond well enough to these medicines, you will be&#160;<br/>given Humira.</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft4431"><b>Non-infectious uveitis</b></p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft4432">Non-infectious uveitis is an inflammatory disease affecting certain&#160;parts of the eye.</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft4432">Humira is used to treat&#160;</p>
<p style="position:absolute;top:256px;left:133px;white-space:nowrap" class="ft4436">&#160;adults with non-infectious uveitis with inflammation affecting the back of the eye&#160;</p>
<p style="position:absolute;top:276px;left:133px;white-space:nowrap" class="ft4436">&#160;children with chronic non-infectious uveitis from 2&#160;years of age with inflammation affecting the&#160;</p>
<p style="position:absolute;top:297px;left:160px;white-space:nowrap" class="ft4432">front of the eye&#160;</p>
<p style="position:absolute;top:335px;left:106px;white-space:nowrap" class="ft4434">This inflammation may lead to a decrease of vision and/or the presence of floaters in the eye (black dots or&#160;<br/>wispy lines that move across the field of vision). Humira works by reducing this inflammation. You may&#160;<br/>first be given other medicines. If you do not respond well enough to these medicines, you will be given&#160;<br/>Humira.</p>
<p style="position:absolute;top:449px;left:106px;white-space:nowrap" class="ft4431"><b>2.</b></p>
<p style="position:absolute;top:449px;left:148px;white-space:nowrap" class="ft4431"><b>What you need to know before you use Humira</b></p>
<p style="position:absolute;top:487px;left:106px;white-space:nowrap" class="ft4431"><b>Do not use Humira:</b></p>
<p style="position:absolute;top:524px;left:133px;white-space:nowrap" class="ft4436">&#160;If you are allergic to adalimumab or any of the other ingredients of this medicine (listed in section&#160;</p>
<p style="position:absolute;top:545px;left:160px;white-space:nowrap" class="ft4432">6).&#160;</p>
<p style="position:absolute;top:582px;left:133px;white-space:nowrap" class="ft4436">&#160;If you have active&#160;tuberculosis or other severe infections (see “Warnings and precautions”). It is&#160;</p>
<p style="position:absolute;top:603px;left:160px;white-space:nowrap" class="ft4434">important that you tell your doctor if you have symptoms of infections, for example, fever,&#160;<br/>wounds, feeling tired, dental problems.</p>
<p style="position:absolute;top:659px;left:133px;white-space:nowrap" class="ft4436">&#160;If you have moderate or severe heart failure. It is important to tell your doctor if you have had or&#160;</p>
<p style="position:absolute;top:680px;left:160px;white-space:nowrap" class="ft4432">have a serious heart condition (see “Warnings and precautions”).</p>
<p style="position:absolute;top:718px;left:106px;white-space:nowrap" class="ft4431"><b>Warnings and precautions</b></p>
<p style="position:absolute;top:756px;left:106px;white-space:nowrap" class="ft4432">Talk to your doctor or pharmacist before using Humira.</p>
<p style="position:absolute;top:794px;left:106px;white-space:nowrap" class="ft4432">Allergic reactions</p>
<p style="position:absolute;top:831px;left:133px;white-space:nowrap" class="ft4436">&#160;If you get allergic reactions with symptoms such as chest tightness, wheezing, dizziness, swelling&#160;</p>
<p style="position:absolute;top:852px;left:160px;white-space:nowrap" class="ft4435">or rash do not inject more Humira and contact your doctor immediately since, in rare cases, these&#160;<br/>reactions can be life threatening.&#160;</p>
<p style="position:absolute;top:909px;left:106px;white-space:nowrap" class="ft4432">Infections</p>
<p style="position:absolute;top:946px;left:133px;white-space:nowrap" class="ft4436">&#160;If you have an infection, including long-term&#160;infection or an infection in one part of the body (for&#160;</p>
<p style="position:absolute;top:967px;left:160px;white-space:nowrap" class="ft4434">example, leg ulcer) consult your doctor before starting Humira. If you are unsure, contact your&#160;<br/>doctor.&#160;</p>
<p style="position:absolute;top:1023px;left:133px;white-space:nowrap" class="ft4436">&#160;You might get infections more easily while you are receiving Humira treatment. This risk may&#160;</p>
<p style="position:absolute;top:1044px;left:160px;white-space:nowrap" class="ft4432">increase if you have problems with your lungs. These infections may be serious and include:</p>
<p style="position:absolute;top:1062px;left:187px;white-space:nowrap" class="ft4436">&#160;tuberculosis</p>
</div>
<!-- Page 444 -->
<a name="444"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page444-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4440">444</p>
<p style="position:absolute;top:85px;left:187px;white-space:nowrap" class="ft4446">&#160;infections caused by viruses, fungi, parasites or bacteria</p>
<p style="position:absolute;top:105px;left:187px;white-space:nowrap" class="ft4446">&#160;severe infection in the blood (sepsis)</p>
<p style="position:absolute;top:145px;left:160px;white-space:nowrap" class="ft4444">In rare cases,&#160;these infections can be life-threatening. It is important to tell your doctor if you get&#160;<br/>symptoms such as fever, wounds, feeling tired or dental problems. Your doctor may tell you to&#160;<br/>stop using Humira for some time.</p>
<p style="position:absolute;top:221px;left:133px;white-space:nowrap" class="ft4446">&#160;Tell your doctor if you live or travel&#160;in regions where fungal infections (for example,&#160;</p>
<p style="position:absolute;top:241px;left:160px;white-space:nowrap" class="ft4442">histoplasmosis, coccidioidomycosis or blastomycosis) are very common.</p>
<p style="position:absolute;top:279px;left:133px;white-space:nowrap" class="ft4446">&#160;Tell your doctor if you have had infections which keep coming back or other conditions that&#160;</p>
<p style="position:absolute;top:300px;left:160px;white-space:nowrap" class="ft4442">increase the risk of infections.</p>
<p style="position:absolute;top:337px;left:133px;white-space:nowrap" class="ft4446">&#160;If you are&#160;over 65&#160;years you may be more likely to get infections while taking Humira. You and&#160;</p>
<p style="position:absolute;top:357px;left:160px;white-space:nowrap" class="ft4445">your doctor should pay special attention to signs of infection while you are being treated with&#160;<br/>Humira. It is important to tell your doctor if you get symptoms of infections, such as fever,&#160;<br/>wounds, feeling tired or dental problems.</p>
<p style="position:absolute;top:433px;left:106px;white-space:nowrap" class="ft4442">Tuberculosis</p>
<p style="position:absolute;top:471px;left:132px;white-space:nowrap" class="ft4446">&#160;It is very important that you tell your doctor if you have ever had tuberculosis, or if you have been&#160;</p>
<p style="position:absolute;top:491px;left:159px;white-space:nowrap" class="ft4444">in close contact with someone who has had tuberculosis. If you have active tuberculosis, do not&#160;<br/>use Humira.</p>
<p style="position:absolute;top:548px;left:187px;white-space:nowrap" class="ft4446">&#160;As cases of tuberculosis have been reported in patients treated with Humira, your doctor&#160;</p>
<p style="position:absolute;top:568px;left:214px;white-space:nowrap" class="ft4444">will check you for signs and symptoms of tuberculosis before starting Humira. This will&#160;<br/>include a thorough medical evaluation including&#160;your medical history and appropriate&#160;<br/>screening tests (for example, chest X-ray and a tuberculin test). The conduct and results of&#160;<br/>these tests should be recorded on your&#160;<b>Patient Reminder Card</b>. &#160;</p>
<p style="position:absolute;top:644px;left:187px;white-space:nowrap" class="ft4446">&#160;Tuberculosis can develop during therapy even if you have received treatment for the&#160;</p>
<p style="position:absolute;top:665px;left:214px;white-space:nowrap" class="ft4442">prevention of tuberculosis.&#160;</p>
<p style="position:absolute;top:683px;left:187px;white-space:nowrap" class="ft4446">&#160;If symptoms of tuberculosis (for example, cough that does not go away, weight loss, lack&#160;</p>
<p style="position:absolute;top:704px;left:214px;white-space:nowrap" class="ft4444">of&#160;energy, mild fever), or any other infection appear during or after therapy tell your&#160;<br/>doctor immediately.&#160;</p>
<p style="position:absolute;top:761px;left:106px;white-space:nowrap" class="ft4442">Hepatitis B</p>
<p style="position:absolute;top:798px;left:133px;white-space:nowrap" class="ft4446">&#160;Tell your doctor if you are a carrier of the hepatitis B virus (HBV), if you have active HBV or if&#160;</p>
<p style="position:absolute;top:819px;left:160px;white-space:nowrap" class="ft4442">you think you might be at risk of getting HBV. &#160;</p>
<p style="position:absolute;top:856px;left:187px;white-space:nowrap" class="ft4446">&#160;Your doctor should test you for HBV. In people who carry HBV, Humira can cause the&#160;</p>
<p style="position:absolute;top:877px;left:214px;white-space:nowrap" class="ft4442">virus to become active again.&#160;</p>
<p style="position:absolute;top:895px;left:187px;white-space:nowrap" class="ft4446">&#160;In some rare cases, especially if you are taking other medicines that suppress the immune&#160;</p>
<p style="position:absolute;top:916px;left:214px;white-space:nowrap" class="ft4442">system, reactivation of HBV can be life-threatening.</p>
<p style="position:absolute;top:954px;left:106px;white-space:nowrap" class="ft4442">Surgery&#160;or dental procedure</p>
<p style="position:absolute;top:991px;left:133px;white-space:nowrap" class="ft4446">&#160;If you are about to have surgery or dental procedures,&#160;please inform your doctor that you are&#160;</p>
<p style="position:absolute;top:1012px;left:160px;white-space:nowrap" class="ft4442">taking Humira. Your doctor may recommend temporary discontinuation of Humira.</p>
<p style="position:absolute;top:1050px;left:106px;white-space:nowrap" class="ft4442">Demyelinating disease</p>
</div>
<!-- Page 445 -->
<a name="445"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page445-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4450">445</p>
<p style="position:absolute;top:85px;left:133px;white-space:nowrap" class="ft4456">&#160;If you have or develop&#160;a&#160;demyelinating disease&#160;(a disease that affects the insulating layer around&#160;</p>
<p style="position:absolute;top:106px;left:160px;white-space:nowrap" class="ft4454">the nerves,&#160;such as multiple sclerosis), your doctor will decide if you should receive or continue to&#160;<br/>receive Humira. Tell your doctor immediately if you experience symptoms like changes in your&#160;<br/>vision, weakness in your arms or legs or numbness or tingling in any part of your body.</p>
<p style="position:absolute;top:182px;left:106px;white-space:nowrap" class="ft4452">Vaccinations</p>
<p style="position:absolute;top:219px;left:133px;white-space:nowrap" class="ft4456">&#160;Certain vaccines may cause infections and should not be given while receiving Humira. &#160;</p>
<p style="position:absolute;top:258px;left:187px;white-space:nowrap" class="ft4456">&#160;Check with your doctor before you receive any vaccines.&#160;</p>
<p style="position:absolute;top:279px;left:187px;white-space:nowrap" class="ft4456">&#160;It is recommended that children, if possible, be given all the scheduled vaccinations for&#160;</p>
<p style="position:absolute;top:300px;left:214px;white-space:nowrap" class="ft4452">their age before they start treatment with Humira.</p>
<p style="position:absolute;top:318px;left:187px;white-space:nowrap" class="ft4456">&#160;If you received Humira while you were pregnant, your baby&#160;may be at higher risk for&#160;</p>
<p style="position:absolute;top:338px;left:214px;white-space:nowrap" class="ft4455">getting such an infection for up to approximately five months after the last Humira dose&#160;<br/>you received during pregnancy. It is important that you tell your baby's doctors and other&#160;<br/>health care professionals about your Humira use during your pregnancy so they can&#160;<br/>decide when your baby should receive any vaccine.</p>
<p style="position:absolute;top:433px;left:106px;white-space:nowrap" class="ft4452">Heart&#160;failure</p>
<p style="position:absolute;top:471px;left:133px;white-space:nowrap" class="ft4456">&#160;If you have mild heart failure and are being treated with Humira, your heart failure status must be&#160;</p>
<p style="position:absolute;top:491px;left:160px;white-space:nowrap" class="ft4455">closely monitored by your doctor. It is important to tell&#160;your doctor if you have had or have a&#160;<br/>serious heart condition. If&#160;you develop new or worsening symptoms of heart failure (e.g. shortness&#160;<br/>of breath, or swelling of your feet), you must contact your doctor immediately. Your doctor will&#160;<br/>decide if you should receive Humira.</p>
<p style="position:absolute;top:586px;left:106px;white-space:nowrap" class="ft4452">Fever, bruising, bleeding&#160;or looking&#160;pale</p>
<p style="position:absolute;top:624px;left:133px;white-space:nowrap" class="ft4456">&#160;In some patients the body may fail to produce enough of the blood cells that fight&#160;off&#160;infections or&#160;</p>
<p style="position:absolute;top:644px;left:160px;white-space:nowrap" class="ft4454">help you to stop bleeding. Your doctor may decide to stop treatment.&#160;If you develop a fever that<br/>does not go away, develop light bruises or bleed very easily or look very pale, call your doctor&#160;<br/>right away.</p>
<p style="position:absolute;top:720px;left:106px;white-space:nowrap" class="ft4452">Cancer</p>
<p style="position:absolute;top:758px;left:133px;white-space:nowrap" class="ft4456">&#160;There have been very rare cases of certain kinds of cancer in children and adult patients taking&#160;</p>
<p style="position:absolute;top:778px;left:160px;white-space:nowrap" class="ft4452">Humira or other TNF blockers.&#160;</p>
<p style="position:absolute;top:816px;left:187px;white-space:nowrap" class="ft4456">&#160;People with more serious rheumatoid arthritis that have had the disease for a long time&#160;</p>
<p style="position:absolute;top:837px;left:214px;white-space:nowrap" class="ft4454">may have a higher than average risk of getting lymphoma (a cancer that affects the lymph&#160;<br/>system) and leukaemia (a cancer that affects the blood and bone marrow).&#160;</p>
<p style="position:absolute;top:874px;left:187px;white-space:nowrap" class="ft4456">&#160;If you take Humira the risk of getting lymphoma, leukaemia, or other cancers may&#160;</p>
<p style="position:absolute;top:895px;left:214px;white-space:nowrap" class="ft4454">increase. On rare occasions, an uncommon and severe type of lymphoma has been seen in&#160;<br/>patients taking Humira. Some of those patients were also treated with azathioprine or 6-<br/>mercaptopurine.&#160;</p>
<p style="position:absolute;top:951px;left:187px;white-space:nowrap" class="ft4456">&#160;Tell your doctor if you are taking azathioprine or 6-mercaptopurine with Humira.&#160;</p>
<p style="position:absolute;top:971px;left:187px;white-space:nowrap" class="ft4456">&#160;Cases of non-melanoma skin cancer have been observed in patients taking Humira.&#160;</p>
<p style="position:absolute;top:991px;left:187px;white-space:nowrap" class="ft4456">&#160;If new skin lesions appear during or after therapy or if existing lesions change&#160;appearance,&#160;</p>
<p style="position:absolute;top:1012px;left:214px;white-space:nowrap" class="ft4452">tell your doctor.</p>
<p style="position:absolute;top:1049px;left:133px;white-space:nowrap" class="ft4456">&#160;There have been cases of cancers, other than lymphoma in patients with a specific type of lung&#160;</p>
<p style="position:absolute;top:1070px;left:160px;white-space:nowrap" class="ft4452">disease called Chronic Obstructive Pulmonary Disease (COPD) treated with another TNF blocker.&#160;</p>
</div>
<!-- Page 446 -->
<a name="446"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page446-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4460">446</p>
<p style="position:absolute;top:86px;left:160px;white-space:nowrap" class="ft4465">If you have COPD, or are a heavy smoker, you should discuss with your doctor whether treatment&#160;<br/>with a TNF blocker is appropriate for you.</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft4462">Autoimmune disease</p>
<p style="position:absolute;top:180px;left:133px;white-space:nowrap" class="ft4466">&#160;On rare occasions, treatment with Humira could result in lupus-like syndrome. Contact your&#160;</p>
<p style="position:absolute;top:201px;left:160px;white-space:nowrap" class="ft4462">doctor if symptoms such as persistent&#160;unexplained rash, fever, joint pain or tiredness&#160;occur.</p>
<p style="position:absolute;top:239px;left:106px;white-space:nowrap" class="ft4461"><b>Children and adolescents</b></p>
<p style="position:absolute;top:276px;left:133px;white-space:nowrap" class="ft4466">&#160;Vaccinations: if possible,&#160;children should be up to date with all vaccinations before using Humira.</p>
<p style="position:absolute;top:316px;left:106px;white-space:nowrap" class="ft4461"><b>Other medicines and Humira</b></p>
<p style="position:absolute;top:354px;left:106px;white-space:nowrap" class="ft4462">Tell your doctor or pharmacist if you are&#160;taking, have recently taken or might take any other medicines.</p>
<p style="position:absolute;top:392px;left:106px;white-space:nowrap" class="ft4465">You should not take Humira with medicines containing the&#160;following&#160;active substances&#160;due to increased&#160;<br/>risk of serious infection:</p>
<p style="position:absolute;top:429px;left:133px;white-space:nowrap" class="ft4466">&#160;anakinra</p>
<p style="position:absolute;top:449px;left:133px;white-space:nowrap" class="ft4466">&#160;abatacept.</p>
<p style="position:absolute;top:489px;left:106px;white-space:nowrap" class="ft4462">Humira can be taken together with:</p>
<p style="position:absolute;top:508px;left:133px;white-space:nowrap" class="ft4466">&#160;methotrexate&#160;</p>
<p style="position:absolute;top:528px;left:133px;white-space:nowrap" class="ft4466">&#160;certain disease-modifying anti-rheumatic agents (for example, sulfasalazine, hydroxychloroquine,&#160;</p>
<p style="position:absolute;top:548px;left:147px;white-space:nowrap" class="ft4462">leflunomide and injectable gold preparations)</p>
<p style="position:absolute;top:567px;left:133px;white-space:nowrap" class="ft4466">&#160;steroids or pain medications including non-steroidal anti-inflammatory drugs (NSAIDs).</p>
<p style="position:absolute;top:607px;left:106px;white-space:nowrap" class="ft4462">If you have questions, please ask your doctor.&#160;</p>
<p style="position:absolute;top:644px;left:106px;white-space:nowrap" class="ft4461"><b>Pregnancy and breast-feeding</b></p>
<p style="position:absolute;top:682px;left:133px;white-space:nowrap" class="ft4466">&#160;You&#160;should consider the&#160;use&#160;of&#160;adequate contraception&#160;to prevent pregnancy&#160;and&#160;continue its use&#160;</p>
<p style="position:absolute;top:703px;left:160px;white-space:nowrap" class="ft4462">for at least 5&#160;months after the last Humira treatment.</p>
<p style="position:absolute;top:721px;left:133px;white-space:nowrap" class="ft4466">&#160;If you are pregnant, think you may be&#160;pregnant or are planning to have a baby, ask your doctor for&#160;</p>
<p style="position:absolute;top:742px;left:160px;white-space:nowrap" class="ft4462">advice about taking this medicine.</p>
<p style="position:absolute;top:760px;left:133px;white-space:nowrap" class="ft4466">&#160;Humira should only be used during a pregnancy if needed.</p>
<p style="position:absolute;top:780px;left:133px;white-space:nowrap" class="ft4466">&#160;According to a pregnancy study, there was no higher risk of birth defects when the mother had&#160;</p>
<p style="position:absolute;top:801px;left:160px;white-space:nowrap" class="ft4464">received&#160;Humira during pregnancy compared with mothers with the same disease&#160;who did not&#160;<br/>receive Humira.</p>
<p style="position:absolute;top:838px;left:133px;white-space:nowrap" class="ft4466">&#160;Humira can be used during breast-feeding.</p>
<p style="position:absolute;top:859px;left:133px;white-space:nowrap" class="ft4466">&#160;If you receive Humira during your pregnancy, your baby may have a higher&#160;risk for getting an&#160;</p>
<p style="position:absolute;top:879px;left:160px;white-space:nowrap" class="ft4462">infection.</p>
<p style="position:absolute;top:897px;left:133px;white-space:nowrap" class="ft4466">&#160;It is important that you tell your baby’s doctors and other health care professionals about your&#160;</p>
<p style="position:absolute;top:918px;left:160px;white-space:nowrap" class="ft4464">Humira use during your pregnancy before the baby receives any vaccine. &#160;For more information&#160;<br/>on vaccines&#160;see&#160;the “Warnings and precautions”&#160;section.</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft4461"><b>Driving and using machines</b></p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft4465">Humira may have a small effect on your ability to drive, cycle or use machines. Room spinning sensation&#160;<br/>and vision disturbances may occur after taking Humira.</p>
</div>
<!-- Page 447 -->
<a name="447"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page447-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4470">447</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft4471"><b>3.</b></p>
<p style="position:absolute;top:105px;left:148px;white-space:nowrap" class="ft4471"><b>How to use Humira</b></p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft4474">Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or&#160;<br/>pharmacist if you are not sure.&#160;</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft4474">The recommended doses for Humira in each of the approved uses are shown in the following table. Your&#160;<br/>doctor may prescribe another strength of Humira if you need a different dose.</p>
<p style="position:absolute;top:257px;left:114px;white-space:nowrap" class="ft44719"><b>Rheumatoid arthritis<br/>Age or body weight</b></p>
<p style="position:absolute;top:277px;left:346px;white-space:nowrap" class="ft44719"><b>How much and how often to&#160;<br/>take?</b></p>
<p style="position:absolute;top:277px;left:579px;white-space:nowrap" class="ft4471"><b>Notes</b></p>
<p style="position:absolute;top:316px;left:114px;white-space:nowrap" class="ft4472">Adults&#160;</p>
<p style="position:absolute;top:316px;left:346px;white-space:nowrap" class="ft4472">40 mg every other week</p>
<p style="position:absolute;top:316px;left:579px;white-space:nowrap" class="ft4474">In rheumatoid arthritis,&#160;<br/>methotrexate is continued while&#160;<br/>using Humira. If your doctor<br/>decides that methotrexate is&#160;<br/>inappropriate, Humira can be&#160;<br/>given alone.</p>
<p style="position:absolute;top:449px;left:579px;white-space:nowrap" class="ft4474">If you have rheumatoid arthritis&#160;<br/>and you do not receive&#160;<br/>methotrexate with your Humira&#160;<br/>therapy, your doctor may decide&#160;<br/>to give Humira 40 mg every&#160;<br/>week&#160;or 80 mg every other&#160;<br/>week.&#160;</p>
<p style="position:absolute;top:602px;left:114px;white-space:nowrap" class="ft44719"><b>Plaque psoriasis<br/>Age or body weight</b></p>
<p style="position:absolute;top:622px;left:346px;white-space:nowrap" class="ft44719"><b>How much and how often to&#160;<br/>take?</b></p>
<p style="position:absolute;top:622px;left:579px;white-space:nowrap" class="ft4471"><b>Notes</b></p>
<p style="position:absolute;top:660px;left:114px;white-space:nowrap" class="ft4472">Adults</p>
<p style="position:absolute;top:660px;left:346px;white-space:nowrap" class="ft4474">First dose of 80&#160;mg (one 80&#160;mg&#160;<br/>injection), followed by 40&#160;mg&#160;<br/>every other week starting one&#160;<br/>week after the first dose.</p>
<p style="position:absolute;top:660px;left:579px;white-space:nowrap" class="ft4475">If you have an inadequate&#160;<br/>response, your doctor may&#160;<br/>increase the dosage to 40&#160;mg&#160;<br/>every week&#160;or 80 mg every&#160;<br/>other week.</p>
</div>
<!-- Page 448 -->
<a name="448"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page448-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4480">448</p>
<p style="position:absolute;top:87px;left:114px;white-space:nowrap" class="ft44819"><b>Hidradenitis suppurativa<br/>Age or body weight</b></p>
<p style="position:absolute;top:107px;left:346px;white-space:nowrap" class="ft44815"><b>How much and how often to&#160;<br/>take?</b></p>
<p style="position:absolute;top:107px;left:579px;white-space:nowrap" class="ft4481"><b>Notes</b></p>
<p style="position:absolute;top:145px;left:114px;white-space:nowrap" class="ft4482">Adults</p>
<p style="position:absolute;top:145px;left:346px;white-space:nowrap" class="ft4484">First dose of 160&#160;mg (two&#160;<br/>80&#160;mg injections in one day or&#160;<br/>one 80&#160;mg&#160;injection per day for&#160;<br/>two&#160;consecutive days), followed&#160;<br/>by an 80&#160;mg dose (one 80&#160;mg&#160;<br/>injection) two weeks later. After&#160;<br/>two further weeks, continue&#160;<br/>with a dose of 40&#160;mg every&#160;<br/>week&#160;or 80 mg every other&#160;<br/>week, as prescribed by your&#160;<br/>doctor. &#160;</p>
<p style="position:absolute;top:145px;left:579px;white-space:nowrap" class="ft4484">It is recommended that you use&#160;<br/>an antiseptic&#160;wash daily on the&#160;<br/>affected areas.</p>
<p style="position:absolute;top:355px;left:114px;white-space:nowrap" class="ft4484">Adolescents from 12&#160;to 17&#160;years&#160;<br/>of age weighing 30 kg&#160;or more</p>
<p style="position:absolute;top:355px;left:346px;white-space:nowrap" class="ft4484">First dose of 80 mg (one 80 mg&#160;<br/>injection), followed by 40 mg&#160;<br/>every other week starting one&#160;<br/>week&#160;later. &#160;</p>
<p style="position:absolute;top:355px;left:579px;white-space:nowrap" class="ft4485">If you have an inadequate&#160;<br/>response&#160;to Humira 40 mg every&#160;<br/>other week, your doctor may&#160;<br/>increase the dosage to 40 mg&#160;<br/>every week&#160;or 80 mg every&#160;<br/>other week.</p>
<p style="position:absolute;top:487px;left:579px;white-space:nowrap" class="ft4485">It is recommended that you use&#160;<br/>an antiseptic wash daily on the&#160;<br/>affected areas.</p>
<p style="position:absolute;top:565px;left:114px;white-space:nowrap" class="ft44819"><b>Crohn’s disease<br/>Age or body weight</b></p>
<p style="position:absolute;top:585px;left:346px;white-space:nowrap" class="ft44815"><b>How much and how&#160;often to&#160;<br/>take?</b></p>
<p style="position:absolute;top:585px;left:579px;white-space:nowrap" class="ft4481"><b>Notes</b></p>
<p style="position:absolute;top:623px;left:114px;white-space:nowrap" class="ft4484">Children,&#160;adolescents&#160;and adults&#160;<br/>from 6 years of age weighing 40&#160;<br/>kg or more</p>
<p style="position:absolute;top:623px;left:346px;white-space:nowrap" class="ft4484">First dose of 80&#160;mg (one 80&#160;mg&#160;<br/>injection), followed by 40&#160;mg&#160;<br/>two weeks later.</p>
<p style="position:absolute;top:699px;left:346px;white-space:nowrap" class="ft4484">If a faster response is required,&#160;<br/>the doctor may prescribe a first&#160;<br/>dose of&#160;160&#160;mg (two 80&#160;mg&#160;<br/>injections in one day or one&#160;<br/>80&#160;mg injection per day for two&#160;<br/>consecutive days), followed by&#160;<br/>80&#160;mg (one 80&#160;mg injection)&#160;<br/>two weeks later.</p>
<p style="position:absolute;top:870px;left:346px;white-space:nowrap" class="ft4484">Thereafter, the usual dose is&#160;<br/>40&#160;mg&#160;every other week.</p>
<p style="position:absolute;top:623px;left:579px;white-space:nowrap" class="ft4484">Your doctor may increase the&#160;<br/>dosage to 40&#160;mg every week&#160;or&#160;<br/>80 mg every other week.</p>
</div>
<!-- Page 449 -->
<a name="449"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page449-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4490">449</p>
<p style="position:absolute;top:87px;left:114px;white-space:nowrap" class="ft4495">Children and adolescents from 6<br/>to 17&#160;years of age weighing less&#160;<br/>than 40 kg</p>
<p style="position:absolute;top:87px;left:346px;white-space:nowrap" class="ft4494">First dose of 40&#160;mg, followed by&#160;<br/>20&#160;mg two weeks later.&#160;</p>
<p style="position:absolute;top:144px;left:346px;white-space:nowrap" class="ft4494">If a faster response is required,&#160;<br/>the doctor may prescribe a first&#160;<br/>dose of 80&#160;mg&#160;(one 80&#160;mg&#160;<br/>injection), followed by 40&#160;mg&#160;<br/>two weeks later.</p>
<p style="position:absolute;top:257px;left:346px;white-space:nowrap" class="ft4494">Thereafter, the usual dose is&#160;<br/>20&#160;mg&#160;every other week.</p>
<p style="position:absolute;top:87px;left:579px;white-space:nowrap" class="ft4495">Your doctor may increase the&#160;<br/>dose frequency to 20&#160;mg&#160;every&#160;<br/>week.</p>
<p style="position:absolute;top:316px;left:114px;white-space:nowrap" class="ft44919"><b>Ulcerative colitis<br/>Age or body weight</b></p>
<p style="position:absolute;top:336px;left:346px;white-space:nowrap" class="ft44919"><b>How much and how often to&#160;<br/>take?</b></p>
<p style="position:absolute;top:336px;left:579px;white-space:nowrap" class="ft4491"><b>Notes</b></p>
<p style="position:absolute;top:374px;left:114px;white-space:nowrap" class="ft4492">Adults</p>
<p style="position:absolute;top:374px;left:346px;white-space:nowrap" class="ft4495">First dose of 160&#160;mg (two&#160;<br/>80&#160;mg injections in one day or&#160;<br/>one 80&#160;mg&#160;injection per day for&#160;<br/>two consecutive days), followed&#160;<br/>by 80&#160;mg (one 80&#160;mg injection)&#160;<br/>two weeks later.</p>
<p style="position:absolute;top:507px;left:346px;white-space:nowrap" class="ft4495">Thereafter, the usual dose is&#160;<br/>40&#160;mg&#160;every other week.</p>
<p style="position:absolute;top:374px;left:579px;white-space:nowrap" class="ft4494">Your doctor may&#160;increase the&#160;<br/>dosage to 40&#160;mg every week&#160;or&#160;<br/>80 mg every other week.</p>
<p style="position:absolute;top:546px;left:114px;white-space:nowrap" class="ft4494">Children&#160;and adolescents from&#160;6<br/>years of age weighing less than&#160;<br/>40 kg</p>
<p style="position:absolute;top:546px;left:346px;white-space:nowrap" class="ft4495">First dose of 80 mg&#160;(one 80 mg&#160;<br/>injection), followed by 40 mg<br/>(one 40 mg injection)&#160;two&#160;<br/>weeks later.</p>
<p style="position:absolute;top:641px;left:346px;white-space:nowrap" class="ft4495">Thereafter, the usual dose is 40&#160;<br/>mg&#160;every&#160;other week.</p>
<p style="position:absolute;top:546px;left:579px;white-space:nowrap" class="ft4494">You should continue taking&#160;<br/>Humira at your usual dose, even&#160;<br/>after turning 18 years of age.</p>
<p style="position:absolute;top:679px;left:114px;white-space:nowrap" class="ft4494">Children and adolescents from&#160;6<br/>years of age weighing 40 kg or&#160;<br/>more</p>
<p style="position:absolute;top:679px;left:346px;white-space:nowrap" class="ft4494">First dose of 160 mg (two&#160;80&#160;<br/>mg&#160;injections in one day or&#160;one<br/>80 mg injection per day for two&#160;<br/>consecutive days), followed by&#160;<br/>80 mg (one&#160;80 mg injection)&#160;<br/>two weeks later.</p>
<p style="position:absolute;top:812px;left:346px;white-space:nowrap" class="ft4494">Thereafter, the usual dose is 80&#160;<br/>mg&#160;every other week.</p>
<p style="position:absolute;top:679px;left:579px;white-space:nowrap" class="ft4494">You should continue taking&#160;<br/>Humira at your usual dose, even&#160;<br/>after turning 18 years of age.</p>
<p style="position:absolute;top:870px;left:114px;white-space:nowrap" class="ft44919"><b>Non-infectious uveitis<br/>Age or body weight</b></p>
<p style="position:absolute;top:890px;left:346px;white-space:nowrap" class="ft44919"><b>How much and how often to&#160;<br/>take?</b></p>
<p style="position:absolute;top:890px;left:579px;white-space:nowrap" class="ft4491"><b>Notes</b></p>
<p style="position:absolute;top:929px;left:114px;white-space:nowrap" class="ft4492">Adults</p>
<p style="position:absolute;top:929px;left:346px;white-space:nowrap" class="ft4494">First dose of 80 mg (one 80 mg&#160;<br/>injection), followed by 40 mg&#160;<br/>every other week starting one&#160;<br/>week after the first dose.</p>
<p style="position:absolute;top:929px;left:579px;white-space:nowrap" class="ft4495">Corticosteroids or other&#160;<br/>medicines that influence&#160;the&#160;<br/>immune system may be&#160;<br/>continued while using Humira.&#160;<br/>Humira can also be given alone.</p>
<p style="position:absolute;top:1025px;left:114px;white-space:nowrap" class="ft4494">Children&#160;and adolescents&#160;from&#160;<br/>2&#160;years of age weighing less&#160;<br/>than 30&#160;kg</p>
<p style="position:absolute;top:1025px;left:346px;white-space:nowrap" class="ft4492">20&#160;mg&#160;every other week</p>
<p style="position:absolute;top:1025px;left:579px;white-space:nowrap" class="ft4495">Your doctor may prescribe an&#160;<br/>initial dose of 40&#160;mg to be&#160;<br/>administered one&#160;week prior to&#160;<br/>the start of the usual dose of&#160;</p>
</div>
<!-- Page 450 -->
<a name="450"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page450-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4500">450</p>
<p style="position:absolute;top:87px;left:579px;white-space:nowrap" class="ft4504">20&#160;mg&#160;every other week.&#160;<br/>Humira is recommended for use&#160;<br/>in combination with&#160;<br/>methotrexate.</p>
<p style="position:absolute;top:163px;left:114px;white-space:nowrap" class="ft4504">Children&#160;and adolescents&#160;from&#160;<br/>2&#160;years of age weighing 30&#160;kg<br/>or more</p>
<p style="position:absolute;top:163px;left:346px;white-space:nowrap" class="ft4502">40&#160;mg&#160;every other week&#160;</p>
<p style="position:absolute;top:163px;left:579px;white-space:nowrap" class="ft4504">Your doctor may prescribe an<br/>initial dose of 80&#160;mg to be&#160;<br/>administered one week prior to&#160;<br/>the start of the usual dose of&#160;<br/>40&#160;mg&#160;every other week.&#160;<br/>Humira is recommended for use&#160;<br/>in combination with&#160;<br/>methotrexate.</p>
<p style="position:absolute;top:335px;left:106px;white-space:nowrap" class="ft4501"><b>Method and route of administration</b></p>
<p style="position:absolute;top:373px;left:106px;white-space:nowrap" class="ft4502">Humira is administered by injection under&#160;the skin (by subcutaneous injection).</p>
<p style="position:absolute;top:411px;left:106px;white-space:nowrap" class="ft4501"><b>Detailed instructions on how to inject Humira are provided in section 7 ‘Injecting Humira’.</b></p>
<p style="position:absolute;top:449px;left:106px;white-space:nowrap" class="ft4501"><b>If you use more Humira than you should</b></p>
<p style="position:absolute;top:487px;left:106px;white-space:nowrap" class="ft4505">If you accidentally inject Humira more frequently than told to by your doctor or&#160;pharmacist, call your&#160;<br/>doctor or pharmacist&#160;and tell them that you have taken more. Always take the outer carton of the medicine&#160;<br/>with you, even if it is empty.&#160;</p>
<p style="position:absolute;top:563px;left:106px;white-space:nowrap" class="ft4501"><b>If you forget to use Humira</b></p>
<p style="position:absolute;top:600px;left:106px;white-space:nowrap" class="ft4505">If you forget to give yourself an injection, you should inject the next dose of Humira as soon as you&#160;<br/>remember. Then take your next dose as you would have on your originally scheduled day, had you not&#160;<br/>forgotten a dose.&#160;</p>
<p style="position:absolute;top:676px;left:106px;white-space:nowrap" class="ft4501"><b>If you stop using Humira</b></p>
<p style="position:absolute;top:714px;left:106px;white-space:nowrap" class="ft4504">The&#160;decision to stop using Humira should be discussed with your doctor. Your symptoms may return if&#160;<br/>you stop using Humira.</p>
<p style="position:absolute;top:771px;left:106px;white-space:nowrap" class="ft4502">If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
<p style="position:absolute;top:828px;left:106px;white-space:nowrap" class="ft4501"><b>4.</b></p>
<p style="position:absolute;top:828px;left:148px;white-space:nowrap" class="ft4501"><b>Possible side effects</b></p>
<p style="position:absolute;top:866px;left:106px;white-space:nowrap" class="ft4505">Like all medicines,&#160;this medicine can cause side effects, although not everybody gets them. Most side&#160;<br/>effects are mild to moderate. However, some may be serious and require treatment. Side effects may occur&#160;<br/>at least up to 4&#160;months after the last Humira injection. &#160;</p>
<p style="position:absolute;top:942px;left:106px;white-space:nowrap" class="ft4501"><b>Tell your doctor immediately if you notice any of the following</b></p>
<p style="position:absolute;top:979px;left:106px;white-space:nowrap" class="ft4506"></p>
<p style="position:absolute;top:981px;left:147px;white-space:nowrap" class="ft4502">severe rash, hives or other signs of allergic reaction</p>
<p style="position:absolute;top:999px;left:106px;white-space:nowrap" class="ft4506"></p>
<p style="position:absolute;top:1001px;left:147px;white-space:nowrap" class="ft4502">swollen face, hands, feet</p>
<p style="position:absolute;top:1019px;left:106px;white-space:nowrap" class="ft4506"></p>
<p style="position:absolute;top:1021px;left:147px;white-space:nowrap" class="ft4502">trouble breathing, swallowing</p>
<p style="position:absolute;top:1040px;left:106px;white-space:nowrap" class="ft4506"></p>
<p style="position:absolute;top:1041px;left:147px;white-space:nowrap" class="ft4502">shortness of breath with physical activity or upon lying down or swelling of the feet</p>
</div>
<!-- Page 451 -->
<a name="451"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page451-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4510">451</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft4511"><b>Tell your doctor as soon as possible if you notice any of the following</b></p>
<p style="position:absolute;top:123px;left:106px;white-space:nowrap" class="ft4516"></p>
<p style="position:absolute;top:125px;left:147px;white-space:nowrap" class="ft4512">signs of infection such as fever, feeling sick, wounds, dental problems, burning on urination</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft4516"></p>
<p style="position:absolute;top:145px;left:147px;white-space:nowrap" class="ft4512">feeling weak or tired</p>
<p style="position:absolute;top:163px;left:106px;white-space:nowrap" class="ft4516"></p>
<p style="position:absolute;top:165px;left:147px;white-space:nowrap" class="ft4512">coughing</p>
<p style="position:absolute;top:184px;left:106px;white-space:nowrap" class="ft4516"></p>
<p style="position:absolute;top:185px;left:147px;white-space:nowrap" class="ft4512">tingling</p>
<p style="position:absolute;top:204px;left:106px;white-space:nowrap" class="ft4516"></p>
<p style="position:absolute;top:206px;left:147px;white-space:nowrap" class="ft4512">numbness</p>
<p style="position:absolute;top:224px;left:106px;white-space:nowrap" class="ft4516"></p>
<p style="position:absolute;top:226px;left:147px;white-space:nowrap" class="ft4512">double vision</p>
<p style="position:absolute;top:244px;left:106px;white-space:nowrap" class="ft4516"></p>
<p style="position:absolute;top:246px;left:147px;white-space:nowrap" class="ft4512">arm&#160;or leg weakness</p>
<p style="position:absolute;top:264px;left:106px;white-space:nowrap" class="ft4516"></p>
<p style="position:absolute;top:266px;left:147px;white-space:nowrap" class="ft4512">a bump&#160;or open sore that doesn't heal</p>
<p style="position:absolute;top:284px;left:106px;white-space:nowrap" class="ft4516"></p>
<p style="position:absolute;top:286px;left:147px;white-space:nowrap" class="ft4514">signs and symptoms suggestive of blood disorders such as persistent fever, bruising, bleeding,&#160;<br/>paleness</p>
<p style="position:absolute;top:343px;left:106px;white-space:nowrap" class="ft4515">The symptoms described above can be signs of the below listed side effects, which have been observed&#160;<br/>with Humira.</p>
<p style="position:absolute;top:400px;left:106px;white-space:nowrap" class="ft4511"><b>Very&#160;common&#160;</b>(may&#160;affect more than 1 in 10 people)&#160;</p>
<p style="position:absolute;top:437px;left:106px;white-space:nowrap" class="ft4516"></p>
<p style="position:absolute;top:439px;left:147px;white-space:nowrap" class="ft4512">injection site reactions (including pain, swelling, redness or itching)</p>
<p style="position:absolute;top:457px;left:106px;white-space:nowrap" class="ft4516"></p>
<p style="position:absolute;top:459px;left:147px;white-space:nowrap" class="ft4512">respiratory tract infections (including cold, runny nose, sinus infection, pneumonia)</p>
<p style="position:absolute;top:478px;left:106px;white-space:nowrap" class="ft4516"></p>
<p style="position:absolute;top:480px;left:147px;white-space:nowrap" class="ft4512">headache</p>
<p style="position:absolute;top:498px;left:106px;white-space:nowrap" class="ft4516"></p>
<p style="position:absolute;top:500px;left:147px;white-space:nowrap" class="ft4512">abdominal pain</p>
<p style="position:absolute;top:518px;left:106px;white-space:nowrap" class="ft4516"></p>
<p style="position:absolute;top:520px;left:147px;white-space:nowrap" class="ft4512">nausea and vomiting</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft4516"></p>
<p style="position:absolute;top:540px;left:147px;white-space:nowrap" class="ft4512">rash</p>
<p style="position:absolute;top:558px;left:106px;white-space:nowrap" class="ft4516"></p>
<p style="position:absolute;top:560px;left:147px;white-space:nowrap" class="ft4512">musculoskeletal pain</p>
<p style="position:absolute;top:597px;left:106px;white-space:nowrap" class="ft4511"><b>Common&#160;</b>(may&#160;affect up to 1 in 10 people)</p>
<p style="position:absolute;top:634px;left:106px;white-space:nowrap" class="ft4516"></p>
<p style="position:absolute;top:636px;left:147px;white-space:nowrap" class="ft4512">serious&#160;infections (including blood poisoning and influenza)</p>
<p style="position:absolute;top:654px;left:106px;white-space:nowrap" class="ft4516"></p>
<p style="position:absolute;top:656px;left:147px;white-space:nowrap" class="ft4512">intestinal infections (including gastroenteritis)</p>
<p style="position:absolute;top:674px;left:106px;white-space:nowrap" class="ft4516"></p>
<p style="position:absolute;top:676px;left:147px;white-space:nowrap" class="ft4512">skin infections (including cellulitis and shingles)</p>
<p style="position:absolute;top:694px;left:106px;white-space:nowrap" class="ft4516"></p>
<p style="position:absolute;top:696px;left:147px;white-space:nowrap" class="ft4512">ear infections</p>
<p style="position:absolute;top:715px;left:106px;white-space:nowrap" class="ft4516"></p>
<p style="position:absolute;top:716px;left:147px;white-space:nowrap" class="ft4512">oral infections (including tooth infections and cold sores)</p>
<p style="position:absolute;top:735px;left:106px;white-space:nowrap" class="ft4516"></p>
<p style="position:absolute;top:737px;left:147px;white-space:nowrap" class="ft4512">reproductive tract infections</p>
<p style="position:absolute;top:755px;left:106px;white-space:nowrap" class="ft4516"></p>
<p style="position:absolute;top:757px;left:147px;white-space:nowrap" class="ft4512">urinary tract infection</p>
<p style="position:absolute;top:775px;left:106px;white-space:nowrap" class="ft4516"></p>
<p style="position:absolute;top:777px;left:147px;white-space:nowrap" class="ft4512">fungal infections</p>
<p style="position:absolute;top:795px;left:106px;white-space:nowrap" class="ft4516"></p>
<p style="position:absolute;top:797px;left:147px;white-space:nowrap" class="ft4512">joint infections</p>
<p style="position:absolute;top:815px;left:106px;white-space:nowrap" class="ft4516"></p>
<p style="position:absolute;top:817px;left:147px;white-space:nowrap" class="ft4512">benign tumours</p>
<p style="position:absolute;top:835px;left:106px;white-space:nowrap" class="ft4516"></p>
<p style="position:absolute;top:837px;left:147px;white-space:nowrap" class="ft4512">skin cancer</p>
<p style="position:absolute;top:856px;left:106px;white-space:nowrap" class="ft4516"></p>
<p style="position:absolute;top:858px;left:147px;white-space:nowrap" class="ft4512">allergic reactions (including seasonal allergy)</p>
<p style="position:absolute;top:876px;left:106px;white-space:nowrap" class="ft4516"></p>
<p style="position:absolute;top:878px;left:147px;white-space:nowrap" class="ft4512">dehydration</p>
<p style="position:absolute;top:896px;left:106px;white-space:nowrap" class="ft4516"></p>
<p style="position:absolute;top:898px;left:147px;white-space:nowrap" class="ft4512">mood swings (including depression)</p>
<p style="position:absolute;top:916px;left:106px;white-space:nowrap" class="ft4516"></p>
<p style="position:absolute;top:918px;left:147px;white-space:nowrap" class="ft4512">anxiety</p>
<p style="position:absolute;top:936px;left:106px;white-space:nowrap" class="ft4516"></p>
<p style="position:absolute;top:938px;left:147px;white-space:nowrap" class="ft4512">difficulty sleeping</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft4516"></p>
<p style="position:absolute;top:958px;left:147px;white-space:nowrap" class="ft4512">sensation disorders such as tingling, prickling or numbness</p>
<p style="position:absolute;top:977px;left:106px;white-space:nowrap" class="ft4516"></p>
<p style="position:absolute;top:978px;left:147px;white-space:nowrap" class="ft4512">migraine</p>
<p style="position:absolute;top:997px;left:106px;white-space:nowrap" class="ft4516"></p>
<p style="position:absolute;top:999px;left:147px;white-space:nowrap" class="ft4512">nerve root compression (including low back pain and leg pain)</p>
<p style="position:absolute;top:1017px;left:106px;white-space:nowrap" class="ft4516"></p>
<p style="position:absolute;top:1019px;left:147px;white-space:nowrap" class="ft4512">vision disturbances</p>
<p style="position:absolute;top:1037px;left:106px;white-space:nowrap" class="ft4516"></p>
<p style="position:absolute;top:1039px;left:147px;white-space:nowrap" class="ft4512">eye&#160;inflammation</p>
<p style="position:absolute;top:1057px;left:106px;white-space:nowrap" class="ft4516"></p>
<p style="position:absolute;top:1059px;left:147px;white-space:nowrap" class="ft4512">inflammation of the eye lid and eye swelling</p>
<p style="position:absolute;top:1077px;left:106px;white-space:nowrap" class="ft4516"></p>
<p style="position:absolute;top:1079px;left:147px;white-space:nowrap" class="ft4512">vertigo (feeling of dizziness or spinning)</p>
</div>
<!-- Page 452 -->
<a name="452"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page452-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4520">452</p>
<p style="position:absolute;top:85px;left:106px;white-space:nowrap" class="ft4526"></p>
<p style="position:absolute;top:87px;left:147px;white-space:nowrap" class="ft4522">sensation of heart beating rapidly</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft4526"></p>
<p style="position:absolute;top:107px;left:147px;white-space:nowrap" class="ft4522">high blood pressure</p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft4526"></p>
<p style="position:absolute;top:127px;left:147px;white-space:nowrap" class="ft4522">flushing</p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft4526"></p>
<p style="position:absolute;top:148px;left:147px;white-space:nowrap" class="ft4522">haematoma (collection of blood outside of blood vessels)</p>
<p style="position:absolute;top:166px;left:106px;white-space:nowrap" class="ft4526"></p>
<p style="position:absolute;top:168px;left:147px;white-space:nowrap" class="ft4522">cough</p>
<p style="position:absolute;top:186px;left:106px;white-space:nowrap" class="ft4526"></p>
<p style="position:absolute;top:188px;left:147px;white-space:nowrap" class="ft4522">asthma</p>
<p style="position:absolute;top:206px;left:106px;white-space:nowrap" class="ft4526"></p>
<p style="position:absolute;top:208px;left:147px;white-space:nowrap" class="ft4522">shortness of breath</p>
<p style="position:absolute;top:226px;left:106px;white-space:nowrap" class="ft4526"></p>
<p style="position:absolute;top:228px;left:147px;white-space:nowrap" class="ft4522">gastrointestinal bleeding</p>
<p style="position:absolute;top:247px;left:106px;white-space:nowrap" class="ft4526"></p>
<p style="position:absolute;top:248px;left:147px;white-space:nowrap" class="ft4522">dyspepsia (indigestion, bloating, heart burn)</p>
<p style="position:absolute;top:267px;left:106px;white-space:nowrap" class="ft4526"></p>
<p style="position:absolute;top:269px;left:147px;white-space:nowrap" class="ft4522">acid reflux disease</p>
<p style="position:absolute;top:287px;left:106px;white-space:nowrap" class="ft4526"></p>
<p style="position:absolute;top:289px;left:147px;white-space:nowrap" class="ft4522">sicca syndrome (including dry eyes and dry mouth)</p>
<p style="position:absolute;top:307px;left:106px;white-space:nowrap" class="ft4526"></p>
<p style="position:absolute;top:309px;left:147px;white-space:nowrap" class="ft4522">itching</p>
<p style="position:absolute;top:327px;left:106px;white-space:nowrap" class="ft4526"></p>
<p style="position:absolute;top:329px;left:147px;white-space:nowrap" class="ft4522">itchy rash</p>
<p style="position:absolute;top:347px;left:106px;white-space:nowrap" class="ft4526"></p>
<p style="position:absolute;top:349px;left:147px;white-space:nowrap" class="ft4522">bruising</p>
<p style="position:absolute;top:367px;left:106px;white-space:nowrap" class="ft4526"></p>
<p style="position:absolute;top:369px;left:147px;white-space:nowrap" class="ft4522">inflammation of the skin (such as eczema)</p>
<p style="position:absolute;top:388px;left:106px;white-space:nowrap" class="ft4526"></p>
<p style="position:absolute;top:390px;left:147px;white-space:nowrap" class="ft4522">breaking of finger nails and toe nails</p>
<p style="position:absolute;top:408px;left:106px;white-space:nowrap" class="ft4526"></p>
<p style="position:absolute;top:410px;left:147px;white-space:nowrap" class="ft4522">increased sweating</p>
<p style="position:absolute;top:428px;left:106px;white-space:nowrap" class="ft4526"></p>
<p style="position:absolute;top:430px;left:147px;white-space:nowrap" class="ft4522">hair loss</p>
<p style="position:absolute;top:448px;left:106px;white-space:nowrap" class="ft4526"></p>
<p style="position:absolute;top:450px;left:147px;white-space:nowrap" class="ft4522">new&#160;onset or worsening of psoriasis</p>
<p style="position:absolute;top:468px;left:106px;white-space:nowrap" class="ft4526"></p>
<p style="position:absolute;top:470px;left:147px;white-space:nowrap" class="ft4522">muscle spasms</p>
<p style="position:absolute;top:488px;left:106px;white-space:nowrap" class="ft4526"></p>
<p style="position:absolute;top:490px;left:147px;white-space:nowrap" class="ft4522">blood in urine</p>
<p style="position:absolute;top:509px;left:106px;white-space:nowrap" class="ft4526"></p>
<p style="position:absolute;top:510px;left:147px;white-space:nowrap" class="ft4522">kidney problems</p>
<p style="position:absolute;top:529px;left:106px;white-space:nowrap" class="ft4526"></p>
<p style="position:absolute;top:531px;left:147px;white-space:nowrap" class="ft4522">chest pain</p>
<p style="position:absolute;top:549px;left:106px;white-space:nowrap" class="ft4526"></p>
<p style="position:absolute;top:551px;left:147px;white-space:nowrap" class="ft4522">oedema (swelling)</p>
<p style="position:absolute;top:569px;left:106px;white-space:nowrap" class="ft4526"></p>
<p style="position:absolute;top:571px;left:147px;white-space:nowrap" class="ft4522">fever</p>
<p style="position:absolute;top:589px;left:106px;white-space:nowrap" class="ft4526"></p>
<p style="position:absolute;top:591px;left:147px;white-space:nowrap" class="ft4522">reduction in blood platelets which increases risk of bleeding or bruising</p>
<p style="position:absolute;top:609px;left:106px;white-space:nowrap" class="ft4526"></p>
<p style="position:absolute;top:611px;left:147px;white-space:nowrap" class="ft4522">impaired healing</p>
<p style="position:absolute;top:649px;left:106px;white-space:nowrap" class="ft4521"><b>Uncommon&#160;</b>(may&#160;affect up to 1 in 100 people)</p>
<p style="position:absolute;top:686px;left:106px;white-space:nowrap" class="ft4526"></p>
<p style="position:absolute;top:688px;left:147px;white-space:nowrap" class="ft4524">opportunistic infections (which include&#160;tuberculosis and other infections that occur when resistance&#160;<br/>to disease is lowered)</p>
<p style="position:absolute;top:726px;left:106px;white-space:nowrap" class="ft4526"></p>
<p style="position:absolute;top:728px;left:147px;white-space:nowrap" class="ft4522">neurological infections (including viral meningitis)</p>
<p style="position:absolute;top:746px;left:106px;white-space:nowrap" class="ft4526"></p>
<p style="position:absolute;top:748px;left:147px;white-space:nowrap" class="ft4522">eye&#160;infections</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft4526"></p>
<p style="position:absolute;top:768px;left:147px;white-space:nowrap" class="ft4522">bacterial infections</p>
<p style="position:absolute;top:786px;left:106px;white-space:nowrap" class="ft4526"></p>
<p style="position:absolute;top:788px;left:147px;white-space:nowrap" class="ft4522">diverticulitis (inflammation and infection of the large intestine)</p>
<p style="position:absolute;top:806px;left:106px;white-space:nowrap" class="ft4526"></p>
<p style="position:absolute;top:808px;left:147px;white-space:nowrap" class="ft4522">cancer</p>
<p style="position:absolute;top:826px;left:106px;white-space:nowrap" class="ft4526"></p>
<p style="position:absolute;top:828px;left:147px;white-space:nowrap" class="ft4522">cancer that affects the lymph system</p>
<p style="position:absolute;top:847px;left:106px;white-space:nowrap" class="ft4526"></p>
<p style="position:absolute;top:849px;left:147px;white-space:nowrap" class="ft4522">melanoma</p>
<p style="position:absolute;top:867px;left:106px;white-space:nowrap" class="ft4526"></p>
<p style="position:absolute;top:869px;left:147px;white-space:nowrap" class="ft4525">immune disorders that could affect the lungs, skin and lymph nodes (most commonly presenting as&#160;<br/>sarcoidosis)</p>
<p style="position:absolute;top:906px;left:106px;white-space:nowrap" class="ft4526"></p>
<p style="position:absolute;top:908px;left:147px;white-space:nowrap" class="ft4522">vasculitis (inflammation of blood vessels)</p>
<p style="position:absolute;top:926px;left:106px;white-space:nowrap" class="ft4526"></p>
<p style="position:absolute;top:928px;left:147px;white-space:nowrap" class="ft4522">tremor (shaking)</p>
<p style="position:absolute;top:946px;left:106px;white-space:nowrap" class="ft4526"></p>
<p style="position:absolute;top:948px;left:147px;white-space:nowrap" class="ft4522">neuropathy (disorder of the nerves)</p>
<p style="position:absolute;top:966px;left:106px;white-space:nowrap" class="ft4526"></p>
<p style="position:absolute;top:968px;left:147px;white-space:nowrap" class="ft4522">stroke</p>
<p style="position:absolute;top:986px;left:106px;white-space:nowrap" class="ft4526"></p>
<p style="position:absolute;top:988px;left:147px;white-space:nowrap" class="ft4522">hearing&#160;loss, buzzing</p>
<p style="position:absolute;top:1006px;left:106px;white-space:nowrap" class="ft4526"></p>
<p style="position:absolute;top:1008px;left:147px;white-space:nowrap" class="ft4522">sensation of heart beating irregularly such as skipped beats</p>
<p style="position:absolute;top:1027px;left:106px;white-space:nowrap" class="ft4526"></p>
<p style="position:absolute;top:1029px;left:147px;white-space:nowrap" class="ft4522">heart problems that can cause shortness of breath or ankle swelling</p>
<p style="position:absolute;top:1047px;left:106px;white-space:nowrap" class="ft4526"></p>
<p style="position:absolute;top:1049px;left:147px;white-space:nowrap" class="ft4522">heart attack</p>
<p style="position:absolute;top:1067px;left:106px;white-space:nowrap" class="ft4526"></p>
<p style="position:absolute;top:1069px;left:147px;white-space:nowrap" class="ft4522">a sac in the wall of a major artery, inflammation and clot of a vein; blockage of a blood vessel</p>
</div>
<!-- Page 453 -->
<a name="453"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page453-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4530">453</p>
<p style="position:absolute;top:85px;left:106px;white-space:nowrap" class="ft4536"></p>
<p style="position:absolute;top:87px;left:147px;white-space:nowrap" class="ft4532">lung&#160;diseases causing shortness of breath (including inflammation)</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft4536"></p>
<p style="position:absolute;top:107px;left:147px;white-space:nowrap" class="ft4532">pulmonary embolism (blockage in an artery of the lung)</p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft4536"></p>
<p style="position:absolute;top:127px;left:147px;white-space:nowrap" class="ft4532">pleural effusion (abnormal collection of fluid in the pleural space)</p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft4536"></p>
<p style="position:absolute;top:148px;left:147px;white-space:nowrap" class="ft4532">inflammation of the pancreas which causes severe pain in the abdomen and back</p>
<p style="position:absolute;top:166px;left:106px;white-space:nowrap" class="ft4536"></p>
<p style="position:absolute;top:168px;left:147px;white-space:nowrap" class="ft4532">difficulty in swallowing</p>
<p style="position:absolute;top:186px;left:106px;white-space:nowrap" class="ft4536"></p>
<p style="position:absolute;top:188px;left:147px;white-space:nowrap" class="ft4532">facial oedema (swelling of the face)</p>
<p style="position:absolute;top:206px;left:106px;white-space:nowrap" class="ft4536"></p>
<p style="position:absolute;top:208px;left:147px;white-space:nowrap" class="ft4532">gallbladder inflammation, gallbladder stones</p>
<p style="position:absolute;top:226px;left:106px;white-space:nowrap" class="ft4536"></p>
<p style="position:absolute;top:228px;left:147px;white-space:nowrap" class="ft4532">fatty liver</p>
<p style="position:absolute;top:247px;left:106px;white-space:nowrap" class="ft4536"></p>
<p style="position:absolute;top:248px;left:147px;white-space:nowrap" class="ft4532">night sweats</p>
<p style="position:absolute;top:267px;left:106px;white-space:nowrap" class="ft4536"></p>
<p style="position:absolute;top:269px;left:147px;white-space:nowrap" class="ft4532">scar</p>
<p style="position:absolute;top:287px;left:106px;white-space:nowrap" class="ft4536"></p>
<p style="position:absolute;top:289px;left:147px;white-space:nowrap" class="ft4532">abnormal&#160;muscle breakdown</p>
<p style="position:absolute;top:307px;left:106px;white-space:nowrap" class="ft4536"></p>
<p style="position:absolute;top:309px;left:147px;white-space:nowrap" class="ft4534">systemic lupus erythematosus (including inflammation of skin, heart, lung, joints&#160;and other organ&#160;<br/>systems)</p>
<p style="position:absolute;top:346px;left:106px;white-space:nowrap" class="ft4536"></p>
<p style="position:absolute;top:348px;left:147px;white-space:nowrap" class="ft4532">sleep interruptions</p>
<p style="position:absolute;top:366px;left:106px;white-space:nowrap" class="ft4536"></p>
<p style="position:absolute;top:368px;left:147px;white-space:nowrap" class="ft4532">impotence</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft4536"></p>
<p style="position:absolute;top:388px;left:147px;white-space:nowrap" class="ft4532">inflammations</p>
<p style="position:absolute;top:426px;left:106px;white-space:nowrap" class="ft4531"><b>Rare&#160;</b>(may affect up to 1 in 1,000 people)</p>
<p style="position:absolute;top:464px;left:106px;white-space:nowrap" class="ft4536"></p>
<p style="position:absolute;top:465px;left:147px;white-space:nowrap" class="ft4532">leukaemia (cancer affecting the blood and bone marrow)</p>
<p style="position:absolute;top:484px;left:106px;white-space:nowrap" class="ft4536"></p>
<p style="position:absolute;top:486px;left:147px;white-space:nowrap" class="ft4532">severe allergic reaction with shock</p>
<p style="position:absolute;top:504px;left:106px;white-space:nowrap" class="ft4536"></p>
<p style="position:absolute;top:506px;left:147px;white-space:nowrap" class="ft4532">multiple sclerosis</p>
<p style="position:absolute;top:524px;left:106px;white-space:nowrap" class="ft4536"></p>
<p style="position:absolute;top:526px;left:147px;white-space:nowrap" class="ft4535">nerve disorders (such as eye nerve inflammation and Guillain-Barré syndrome that may cause&#160;<br/>muscle weakness, abnormal sensations, tingling in the arms and upper body)</p>
<p style="position:absolute;top:563px;left:106px;white-space:nowrap" class="ft4536"></p>
<p style="position:absolute;top:565px;left:147px;white-space:nowrap" class="ft4532">heart stops pumping</p>
<p style="position:absolute;top:583px;left:106px;white-space:nowrap" class="ft4536"></p>
<p style="position:absolute;top:585px;left:147px;white-space:nowrap" class="ft4532">pulmonary fibrosis (scarring of the lung)</p>
<p style="position:absolute;top:603px;left:106px;white-space:nowrap" class="ft4536"></p>
<p style="position:absolute;top:605px;left:147px;white-space:nowrap" class="ft4532">intestinal perforation (hole in the intestine)</p>
<p style="position:absolute;top:623px;left:106px;white-space:nowrap" class="ft4536"></p>
<p style="position:absolute;top:625px;left:147px;white-space:nowrap" class="ft4532">hepatitis</p>
<p style="position:absolute;top:644px;left:106px;white-space:nowrap" class="ft4536"></p>
<p style="position:absolute;top:645px;left:147px;white-space:nowrap" class="ft4532">reactivation of hepatitis B</p>
<p style="position:absolute;top:664px;left:106px;white-space:nowrap" class="ft4536"></p>
<p style="position:absolute;top:666px;left:147px;white-space:nowrap" class="ft4532">autoimmune hepatitis (inflammation of the liver caused by the body's own immune system)</p>
<p style="position:absolute;top:684px;left:106px;white-space:nowrap" class="ft4536"></p>
<p style="position:absolute;top:686px;left:147px;white-space:nowrap" class="ft4532">cutaneous vasculitis (inflammation of blood vessels in the skin)</p>
<p style="position:absolute;top:704px;left:106px;white-space:nowrap" class="ft4536"></p>
<p style="position:absolute;top:706px;left:147px;white-space:nowrap" class="ft4532">Stevens-Johnson syndrome (early symptoms include malaise, fever, headache and rash)</p>
<p style="position:absolute;top:724px;left:106px;white-space:nowrap" class="ft4536"></p>
<p style="position:absolute;top:726px;left:147px;white-space:nowrap" class="ft4532">facial oedema (swelling of the face) associated with allergic reactions</p>
<p style="position:absolute;top:744px;left:106px;white-space:nowrap" class="ft4536"></p>
<p style="position:absolute;top:746px;left:147px;white-space:nowrap" class="ft4532">erythema multiforme (inflammatory skin rash)</p>
<p style="position:absolute;top:765px;left:106px;white-space:nowrap" class="ft4536"></p>
<p style="position:absolute;top:766px;left:147px;white-space:nowrap" class="ft4532">lupus-like syndrome</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft4536"></p>
<p style="position:absolute;top:787px;left:147px;white-space:nowrap" class="ft4532">angioedema (localized swelling of the skin)</p>
<p style="position:absolute;top:805px;left:106px;white-space:nowrap" class="ft4536"></p>
<p style="position:absolute;top:807px;left:147px;white-space:nowrap" class="ft4532">lichenoid skin reaction (itchy reddish-purple skin&#160;rash)</p>
<p style="position:absolute;top:845px;left:106px;white-space:nowrap" class="ft4531"><b>Not known&#160;</b>(frequency cannot be estimated from the available data)</p>
<p style="position:absolute;top:882px;left:106px;white-space:nowrap" class="ft4536">&#160;hepatosplenic T-cell lymphoma (a rare blood cancer that is often fatal)</p>
<p style="position:absolute;top:902px;left:106px;white-space:nowrap" class="ft4536">&#160;Merkel cell carcinoma (a type of skin cancer)</p>
<p style="position:absolute;top:922px;left:106px;white-space:nowrap" class="ft4536">&#160;Kaposi’s sarcoma, a rare cancer related to infection with human herpes virus 8.&#160;Kaposi’s sarcoma&#160;</p>
<p style="position:absolute;top:943px;left:133px;white-space:nowrap" class="ft4532">most commonly appears as purple lesions on the skin</p>
<p style="position:absolute;top:961px;left:106px;white-space:nowrap" class="ft4536">&#160;liver failure</p>
<p style="position:absolute;top:982px;left:106px;white-space:nowrap" class="ft4536">&#160;worsening of a condition called dermatomyositis (seen as a skin rash accompanying muscle weakness)</p>
<p style="position:absolute;top:1002px;left:106px;white-space:nowrap" class="ft4536">&#160;weight gain (for most patients, the weight gain was small)</p>
<p style="position:absolute;top:1042px;left:106px;white-space:nowrap" class="ft4535">Some side&#160;effects observed with Humira may not have symptoms and may only be discovered through&#160;<br/>blood tests. These include:</p>
</div>
<!-- Page 454 -->
<a name="454"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page454-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4540">454</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft4541"><b>Very common&#160;</b>(may&#160;affect more than 1 in 10 people)&#160;</p>
<p style="position:absolute;top:123px;left:106px;white-space:nowrap" class="ft4546"></p>
<p style="position:absolute;top:125px;left:147px;white-space:nowrap" class="ft4542">low blood measurements for white blood cells</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft4546"></p>
<p style="position:absolute;top:145px;left:147px;white-space:nowrap" class="ft4542">low blood measurements for red blood cells</p>
<p style="position:absolute;top:163px;left:106px;white-space:nowrap" class="ft4546"></p>
<p style="position:absolute;top:165px;left:147px;white-space:nowrap" class="ft4542">increased lipids in the blood</p>
<p style="position:absolute;top:184px;left:106px;white-space:nowrap" class="ft4546"></p>
<p style="position:absolute;top:185px;left:147px;white-space:nowrap" class="ft4542">elevated liver enzymes</p>
<p style="position:absolute;top:224px;left:106px;white-space:nowrap" class="ft4541"><b>Common&#160;</b>(may&#160;affect up to 1 in 10 people)</p>
<p style="position:absolute;top:261px;left:106px;white-space:nowrap" class="ft4546"></p>
<p style="position:absolute;top:263px;left:147px;white-space:nowrap" class="ft4542">high blood measurements for white blood cells &#160;</p>
<p style="position:absolute;top:281px;left:106px;white-space:nowrap" class="ft4546"></p>
<p style="position:absolute;top:283px;left:147px;white-space:nowrap" class="ft4542">low blood measurements for platelets</p>
<p style="position:absolute;top:301px;left:106px;white-space:nowrap" class="ft4546"></p>
<p style="position:absolute;top:303px;left:147px;white-space:nowrap" class="ft4542">increased uric acid in the blood</p>
<p style="position:absolute;top:321px;left:106px;white-space:nowrap" class="ft4546"></p>
<p style="position:absolute;top:323px;left:147px;white-space:nowrap" class="ft4542">abnormal blood measurements for sodium</p>
<p style="position:absolute;top:342px;left:106px;white-space:nowrap" class="ft4546"></p>
<p style="position:absolute;top:343px;left:147px;white-space:nowrap" class="ft4542">low&#160;blood measurements for calcium</p>
<p style="position:absolute;top:362px;left:106px;white-space:nowrap" class="ft4546"></p>
<p style="position:absolute;top:364px;left:147px;white-space:nowrap" class="ft4542">low blood measurements for phosphate</p>
<p style="position:absolute;top:382px;left:106px;white-space:nowrap" class="ft4546"></p>
<p style="position:absolute;top:384px;left:147px;white-space:nowrap" class="ft4542">high blood sugar</p>
<p style="position:absolute;top:402px;left:106px;white-space:nowrap" class="ft4546"></p>
<p style="position:absolute;top:404px;left:147px;white-space:nowrap" class="ft4542">high blood measurements for lactate dehydrogenase</p>
<p style="position:absolute;top:422px;left:106px;white-space:nowrap" class="ft4546"></p>
<p style="position:absolute;top:424px;left:147px;white-space:nowrap" class="ft4542">autoantibodies present in the blood</p>
<p style="position:absolute;top:442px;left:106px;white-space:nowrap" class="ft4546"></p>
<p style="position:absolute;top:444px;left:147px;white-space:nowrap" class="ft4542">low blood potassium</p>
<p style="position:absolute;top:482px;left:106px;white-space:nowrap" class="ft4541"><b>Uncommon&#160;</b>(may&#160;affect up to 1 in 100 people)&#160;</p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft4546"></p>
<p style="position:absolute;top:521px;left:147px;white-space:nowrap" class="ft4542">elevated&#160;bilirubin measurement (liver blood test)</p>
<p style="position:absolute;top:559px;left:106px;white-space:nowrap" class="ft4541"><b>Rare&#160;</b>(may affect up to 1 in 1,000 people)</p>
<p style="position:absolute;top:596px;left:106px;white-space:nowrap" class="ft4546"></p>
<p style="position:absolute;top:598px;left:147px;white-space:nowrap" class="ft4542">low blood measurements for white blood cells, red blood cells and platelet count</p>
<p style="position:absolute;top:636px;left:106px;white-space:nowrap" class="ft4544"><b>Reporting of side effects<br/></b>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not&#160;<br/>listed in this leaflet. You can also report side effects directly via&#160;the national reporting system listed in&#160;<br/><a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix V.&#160;</a>By reporting side effects, you can help provide more information&#160;on the safety of this&#160;<br/>medicine.</p>
<p style="position:absolute;top:769px;left:106px;white-space:nowrap" class="ft4541"><b>5.</b></p>
<p style="position:absolute;top:769px;left:148px;white-space:nowrap" class="ft4541"><b>How to store Humira</b></p>
<p style="position:absolute;top:807px;left:106px;white-space:nowrap" class="ft4542">Keep this medicine out of the sight and reach of&#160;children.&#160;</p>
<p style="position:absolute;top:845px;left:106px;white-space:nowrap" class="ft4542">Do not use this medicine after the expiry date stated on the label/blister/carton after EXP.&#160;</p>
<p style="position:absolute;top:884px;left:106px;white-space:nowrap" class="ft4542">Store in a refrigerator (2</p>
<p style="position:absolute;top:882px;left:266px;white-space:nowrap" class="ft4546">C&#160;–&#160;8C). Do not freeze.&#160;</p>
<p style="position:absolute;top:922px;left:106px;white-space:nowrap" class="ft4542">Keep the pre-filled syringe in the outer carton in order to protect from light.</p>
<p style="position:absolute;top:960px;left:106px;white-space:nowrap" class="ft4542">Alternative&#160;Storage:</p>
<p style="position:absolute;top:998px;left:106px;white-space:nowrap" class="ft45419">When needed (for example when you are travelling), a single Humira pre-filled syringe may be stored at&#160;<br/>room temperature (up to 25°C) for a maximum period of 14&#160;days&#160;–&#160;be sure to protect it from light. Once&#160;<br/>removed from the refrigerator for room temperature storage, the syringe&#160;<b>must be used within 14&#160;days&#160;or&#160;<br/>discarded</b>, even if it is returned to the refrigerator. &#160;</p>
</div>
<!-- Page 455 -->
<a name="455"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page455-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4550">455</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft4555">You should record the date when the syringe is first removed from refrigerator and the date after which it&#160;<br/>should be discarded. &#160;</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft4554">Do&#160;not throw away any medicines via wastewater or household waste. Ask your doctor or pharmacist how&#160;<br/>to throw away medicines you no longer use. These measures will help protect the environment.</p>
<p style="position:absolute;top:219px;left:106px;white-space:nowrap" class="ft4551"><b>6.</b></p>
<p style="position:absolute;top:219px;left:148px;white-space:nowrap" class="ft4551"><b>Contents of the pack and other information</b></p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft4551"><b>What Humira contains</b></p>
<p style="position:absolute;top:295px;left:106px;white-space:nowrap" class="ft4555">The active substance is adalimumab.<br/>The&#160;other ingredients are mannitol, polysorbate 80 and water for injections.</p>
<p style="position:absolute;top:352px;left:106px;white-space:nowrap" class="ft4551"><b>What the Humira pre-filled syringe looks like and contents of the pack</b></p>
<p style="position:absolute;top:390px;left:106px;white-space:nowrap" class="ft4554">Humira 80&#160;mg solution for injection in pre-filled syringe is&#160;supplied as a sterile solution of 80&#160;mg&#160;<br/>adalimumab dissolved in 0.8&#160;ml solution.</p>
<p style="position:absolute;top:446px;left:106px;white-space:nowrap" class="ft4552">The Humira pre-filled syringe is a glass syringe containing a solution of adalimumab.&#160;</p>
<p style="position:absolute;top:485px;left:106px;white-space:nowrap" class="ft4555">The Humira pre-filled syringe is available in a pack containing 1 pre-filled syringe for patient use with 1&#160;<br/>alcohol pad. &#160;</p>
<p style="position:absolute;top:541px;left:106px;white-space:nowrap" class="ft4552">Humira&#160;may be&#160;available as a vial, a pre-filled syringe and/or&#160;a pre-filled pen.</p>
<p style="position:absolute;top:579px;left:106px;white-space:nowrap" class="ft4551"><b>Marketing Authorisation Holder</b></p>
<p style="position:absolute;top:617px;left:106px;white-space:nowrap" class="ft4554">AbbVie Deutschland GmbH &amp; Co. KG<br/>Knollstrasse<br/>67061 Ludwigshafen<br/>Germany</p>
<p style="position:absolute;top:712px;left:106px;white-space:nowrap" class="ft4551"><b>Manufacturer&#160;</b></p>
<p style="position:absolute;top:750px;left:106px;white-space:nowrap" class="ft4554">AbbVie&#160;Biotechnology GmbH<br/>Knollstrasse<br/>67061 Ludwigshafen<br/>Germany</p>
<p style="position:absolute;top:845px;left:106px;white-space:nowrap" class="ft4554">For any information about this medicine, please contact the local representative of the Marketing&#160;<br/>Authorisation Holder:</p>
<p style="position:absolute;top:904px;left:114px;white-space:nowrap" class="ft4554"><b>België/Belgique/Belgien<br/></b>AbbVie SA<br/>Tél/Tel: +32 10 &#160;477811</p>
<p style="position:absolute;top:904px;left:462px;white-space:nowrap" class="ft4555"><b>Lietuva<br/></b>AbbVie UAB&#160;<br/>Tel: +370 5 205 3023</p>
</div>
<!-- Page 456 -->
<a name="456"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page456-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4560">456</p>
<p style="position:absolute;top:86px;left:114px;white-space:nowrap" class="ft4564"><b>България<br/></b>АбВи ЕООД<br/>Тел.:+359 2 90 30 430</p>
<p style="position:absolute;top:86px;left:462px;white-space:nowrap" class="ft4564"><b>Luxembourg/Luxemburg<br/></b>AbbVie SA<br/>Belgique/Belgien<br/>Tél/Tel: +32 10 477811</p>
<p style="position:absolute;top:181px;left:114px;white-space:nowrap" class="ft4564"><b>Česká republika<br/></b>AbbVie s.r.o.&#160;<br/>Tel: +420 233 098 111</p>
<p style="position:absolute;top:181px;left:462px;white-space:nowrap" class="ft4564"><b>Magyarország<br/></b>AbbVie Kft.<br/>Tel.:+36 1 455 8600</p>
<p style="position:absolute;top:257px;left:114px;white-space:nowrap" class="ft4564"><b>Danmark<br/></b>AbbVie A/S<br/>Tlf: +45 72 30-20-28</p>
<p style="position:absolute;top:257px;left:462px;white-space:nowrap" class="ft4564"><b>Malta<br/></b>V.J.Salomone Pharma Limited&#160;<br/>Tel: +356 22983201</p>
<p style="position:absolute;top:333px;left:114px;white-space:nowrap" class="ft4564"><b>Deutschland<br/></b>AbbVie Deutschland GmbH &amp; Co. KG<br/>Tel: 00800 222843 33 (gebührenfrei)<br/>Tel: +49 (0) 611&#160;/&#160;1720-0</p>
<p style="position:absolute;top:333px;left:462px;white-space:nowrap" class="ft4565"><b>Nederland<br/></b>AbbVie B.V.<br/>Tel: &#160;+31 (0)88 322 2843</p>
<p style="position:absolute;top:427px;left:114px;white-space:nowrap" class="ft4564"><b>Eesti<br/></b>AbbVie&#160;OÜ<br/>Tel: +372 623 1011</p>
<p style="position:absolute;top:427px;left:462px;white-space:nowrap" class="ft4564"><b>Norge<br/></b>AbbVie AS<br/>Tlf: +47 67 81 80 00</p>
<p style="position:absolute;top:503px;left:114px;white-space:nowrap" class="ft4564"><b>Ελλάδα<br/></b>AbbVie&#160;ΦΑΡΜΑΚΕΥΤΙΚΗ Α.Ε.<br/>Τηλ: +30&#160;214 4165 555</p>
<p style="position:absolute;top:503px;left:462px;white-space:nowrap" class="ft4564"><b>Österreich<br/></b>AbbVie GmbH&#160;<br/>Tel: +43 1 20589-0</p>
<p style="position:absolute;top:579px;left:114px;white-space:nowrap" class="ft4565"><b>España<br/></b>AbbVie Spain, S.L.U.<br/>Tel: &#160;+34 91 384 09 10</p>
<p style="position:absolute;top:579px;left:462px;white-space:nowrap" class="ft4565"><b>Polska<br/></b>AbbVie Sp. z o.o.<br/>Tel.: +48 22&#160;372 78 00&#160;</p>
<p style="position:absolute;top:655px;left:114px;white-space:nowrap" class="ft4565"><b>France<br/></b>AbbVie<br/>Tél: +33 (0) 1 45 60 13 00</p>
<p style="position:absolute;top:655px;left:462px;white-space:nowrap" class="ft4565"><b>Portugal<br/></b>AbbVie, Lda.&#160;<br/>Tel: +351 (0)21 1908400</p>
<p style="position:absolute;top:729px;left:114px;white-space:nowrap" class="ft4565"><b>Hrvatska&#160;<br/></b>AbbVie d.o.o.<br/>Tel + 385 (0)1&#160;5625 501</p>
<p style="position:absolute;top:729px;left:462px;white-space:nowrap" class="ft4565"><b>România<br/></b>AbbVie S.R.L.<br/>Tel: +40 21 529 30 35</p>
<p style="position:absolute;top:805px;left:114px;white-space:nowrap" class="ft4564"><b>Ireland<br/></b>AbbVie Limited&#160;<br/>Tel: +353 (0)1 4287900</p>
<p style="position:absolute;top:805px;left:462px;white-space:nowrap" class="ft4564"><b>Slovenija<br/></b>AbbVie Biofarmacevtska družba d.o.o.<br/>Tel: +386 (1)32 08 060</p>
<p style="position:absolute;top:881px;left:114px;white-space:nowrap" class="ft4564"><b>Ísland<br/></b>Vistor hf.<br/>Tel: +354 535 7000</p>
<p style="position:absolute;top:881px;left:462px;white-space:nowrap" class="ft4564"><b>Slovenská republika<br/></b>AbbVie s.r.o.<br/>Tel: +421 2 5050 0777</p>
<p style="position:absolute;top:957px;left:114px;white-space:nowrap" class="ft4564"><b>Italia<br/></b>AbbVie S.r.l.&#160;<br/>Tel: +39 06 928921</p>
<p style="position:absolute;top:957px;left:462px;white-space:nowrap" class="ft4564"><b>Suomi/Finland<br/></b>AbbVie Oy&#160;<br/>Puh/Tel: &#160;+358 (0)10&#160;2411 200</p>
<p style="position:absolute;top:1035px;left:114px;white-space:nowrap" class="ft4564"><b>Κύπρος<br/></b>Lifepharma (Z.A.M.) Ltd<br/>Τηλ.: +357 22 34 74 40</p>
<p style="position:absolute;top:1035px;left:462px;white-space:nowrap" class="ft4564"><b>Sverige<br/></b>AbbVie AB<br/>Tel: &#160;+46 (0)8 684 44 600</p>
</div>
<!-- Page 457 -->
<a name="457"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page457-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4570">457</p>
<p style="position:absolute;top:105px;left:114px;white-space:nowrap" class="ft4574"><b>Latvija<br/></b>AbbVie SIA&#160;<br/>Tel: +371 67605000</p>
<p style="position:absolute;top:105px;left:462px;white-space:nowrap" class="ft4574"><b>United Kingdom&#160;(Northern Ireland)<br/></b>AbbVie Deutschland GmbH &amp; Co. KG<br/>Tel: +44 (0)1628 561090</p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft4571"><b>This leaflet was last revised in&#160;</b></p>
<p style="position:absolute;top:219px;left:106px;white-space:nowrap" class="ft4575">Detailed information on this medicine is available on the European Medicines Agency web site:&#160;<br/><a href="http://www.ema.europa.eu/">http://www.ema.europa.eu.</a></p>
<p style="position:absolute;top:276px;left:106px;white-space:nowrap" class="ft45719"><b>To listen to or request a copy of this leaflet in&#160;&lt;Braille&gt;, &lt;large print&gt; or &lt;audio&gt;, please contact the&#160;<br/>local representative of the Marketing Authorisation Holder.</b></p>
<p style="position:absolute;top:356px;left:106px;white-space:nowrap" class="ft4571"><b>7.</b></p>
<p style="position:absolute;top:356px;left:148px;white-space:nowrap" class="ft4571"><b>Injecting Humira</b></p>
<p style="position:absolute;top:393px;left:133px;white-space:nowrap" class="ft4576">&#160;The following instructions explain how to give yourself a subcutaneous injection of Humira using&#160;</p>
<p style="position:absolute;top:414px;left:160px;white-space:nowrap" class="ft4572">the pre-filled syringe. First read all the instructions carefully and then follow them step by step.&#160;</p>
<p style="position:absolute;top:451px;left:133px;white-space:nowrap" class="ft4576">&#160;You will be instructed by your doctor, nurse or pharmacist on the technique of self-injection.&#160;</p>
<p style="position:absolute;top:490px;left:133px;white-space:nowrap" class="ft4576">&#160;Do not attempt to self-inject until you are sure that you understand how to prepare and give the&#160;</p>
<p style="position:absolute;top:511px;left:160px;white-space:nowrap" class="ft4572">injection.&#160;</p>
<p style="position:absolute;top:548px;left:133px;white-space:nowrap" class="ft4576">&#160;After proper training, the injection can be given by yourself or given by another person, for&#160;</p>
<p style="position:absolute;top:569px;left:160px;white-space:nowrap" class="ft4572">example, a family member or friend. &#160;</p>
<p style="position:absolute;top:606px;left:133px;white-space:nowrap" class="ft4576">&#160;Only use each&#160;pre-filled syringe for one injection.</p>
<p style="position:absolute;top:646px;left:106px;white-space:nowrap" class="ft4571"><b>Humira Pre-filled Syringe</b></p>
<p style="position:absolute;top:684px;left:214px;white-space:nowrap" class="ft4571"><b>&#160; &#160; &#160; &#160;Plunger</b></p>
<p style="position:absolute;top:684px;left:376px;white-space:nowrap" class="ft4571"><b>&#160; &#160; &#160; &#160; &#160; &#160;&#160;Finger Grip</b></p>
<p style="position:absolute;top:684px;left:538px;white-space:nowrap" class="ft4571"><b>&#160; &#160; &#160; &#160; &#160;Needle Cover</b></p>
<p style="position:absolute;top:919px;left:106px;white-space:nowrap" class="ft4571"><b>Do not use the pre-filled syringe and call your doctor or pharmacist if the</b></p>
<p style="position:absolute;top:958px;left:133px;white-space:nowrap" class="ft4576">&#160;liquid is cloudy, discoloured, or has flakes&#160;or particles in it</p>
<p style="position:absolute;top:978px;left:133px;white-space:nowrap" class="ft4576">&#160;expiry (EXP) date has passed</p>
<p style="position:absolute;top:998px;left:133px;white-space:nowrap" class="ft4576">&#160;liquid has been frozen or left in direct sunlight</p>
<p style="position:absolute;top:1018px;left:133px;white-space:nowrap" class="ft4576">&#160;pre-filled syringe has been dropped or crushed</p>
</div>
<!-- Page 458 -->
<a name="458"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page458-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4580">458</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft45815"><b>Do not remove the needle cover until just before injection. Keep Humira out of the sight and reach&#160;<br/>of&#160;children.</b></p>
<p style="position:absolute;top:144px;left:114px;white-space:nowrap" class="ft4581"><b>STEP 1</b></p>
<p style="position:absolute;top:181px;left:114px;white-space:nowrap" class="ft4582">Take Humira out of the refrigerator.</p>
<p style="position:absolute;top:220px;left:114px;white-space:nowrap" class="ft4582">Leave Humira at room temperature for&#160;<b>15 to 30 minutes&#160;</b>before injecting.</p>
<p style="position:absolute;top:257px;left:141px;white-space:nowrap" class="ft4586">&#160;<b>Do not&#160;</b>remove the needle cover while allowing Humira to reach room temperature</p>
<p style="position:absolute;top:277px;left:141px;white-space:nowrap" class="ft4586">&#160;<b>Do not&#160;</b>warm Humira in any other way. For example,&#160;<b>do not&#160;</b>warm it in a microwave or in hot&#160;</p>
<p style="position:absolute;top:298px;left:168px;white-space:nowrap" class="ft4582">water</p>
<p style="position:absolute;top:318px;left:114px;white-space:nowrap" class="ft4581"><b>STEP 2&#160;</b></p>
<p style="position:absolute;top:357px;left:114px;white-space:nowrap" class="ft4581"><b>&#160; &#160; &#160; &#160; &#160; &#160;Syringe</b></p>
<p style="position:absolute;top:620px;left:114px;white-space:nowrap" class="ft4581"><b>&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;Pad</b></p>
<p style="position:absolute;top:318px;left:392px;white-space:nowrap" class="ft4584">Check the expiry (EXP) date.&#160;<b>Do not&#160;</b>use the pre-filled&#160;<br/>syringe if expiry (EXP) date has passed.</p>
<p style="position:absolute;top:374px;left:392px;white-space:nowrap" class="ft4582">Place the following on a clean, flat surface</p>
<p style="position:absolute;top:412px;left:422px;white-space:nowrap" class="ft4586">&#160;1 single-use pre-filled syringe and&#160;</p>
<p style="position:absolute;top:432px;left:422px;white-space:nowrap" class="ft4586">&#160;1 alcohol pad</p>
<p style="position:absolute;top:472px;left:392px;white-space:nowrap" class="ft4582">Wash and dry your hands.</p>
<p style="position:absolute;top:639px;left:114px;white-space:nowrap" class="ft4581"><b>STEP 3</b></p>
<p style="position:absolute;top:677px;left:114px;white-space:nowrap" class="ft4581"><b>Injectable Areas</b></p>
<p style="position:absolute;top:978px;left:114px;white-space:nowrap" class="ft4582">&#160; &#160; &#160;<b>Injectable Areas</b></p>
<p style="position:absolute;top:639px;left:392px;white-space:nowrap" class="ft4582">Choose an injection site:</p>
<p style="position:absolute;top:676px;left:422px;white-space:nowrap" class="ft4586">&#160;On the front of your thighs or</p>
<p style="position:absolute;top:697px;left:422px;white-space:nowrap" class="ft4586">&#160;Your belly (abdomen) at least 5 cm from your belly&#160;</p>
<p style="position:absolute;top:717px;left:449px;white-space:nowrap" class="ft4582">button (navel)</p>
<p style="position:absolute;top:736px;left:422px;white-space:nowrap" class="ft4586">&#160;At&#160;least 3 cm from your last injection site</p>
<p style="position:absolute;top:775px;left:392px;white-space:nowrap" class="ft4584">Wipe the injection site in a circular motion with the alcohol&#160;<br/>pad.</p>
<p style="position:absolute;top:832px;left:422px;white-space:nowrap" class="ft4586">&#160;<b>Do not&#160;</b>inject through clothes</p>
<p style="position:absolute;top:852px;left:422px;white-space:nowrap" class="ft4586">&#160;<b>Do not&#160;</b>inject into skin that is sore, bruised, red,&#160;</p>
<p style="position:absolute;top:873px;left:449px;white-space:nowrap" class="ft4584">hard, scarred, has stretch marks, or areas with&#160;<br/>psoriasis&#160;plaques</p>
</div>
<!-- Page 459 -->
<a name="459"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page459-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4590">459</p>
<p style="position:absolute;top:87px;left:114px;white-space:nowrap" class="ft4591"><b>STEP 4</b></p>
<p style="position:absolute;top:87px;left:392px;white-space:nowrap" class="ft4592">Hold the pre-filled syringe in one hand.</p>
<p style="position:absolute;top:125px;left:392px;white-space:nowrap" class="ft4592">Check the liquid in the pre-filled syringe.</p>
<p style="position:absolute;top:162px;left:425px;white-space:nowrap" class="ft4596">&#160;Make sure the liquid is clear and colourless</p>
<p style="position:absolute;top:182px;left:425px;white-space:nowrap" class="ft4596">&#160;<b>Do not&#160;</b>use the pre-filled syringe if the liquid is&#160;</p>
<p style="position:absolute;top:203px;left:452px;white-space:nowrap" class="ft4592">cloudy or has particles</p>
<p style="position:absolute;top:221px;left:425px;white-space:nowrap" class="ft4596">&#160;<b>Do not&#160;</b>use the pre-filled&#160;syringe if it has been&#160;</p>
<p style="position:absolute;top:242px;left:452px;white-space:nowrap" class="ft4592">dropped or crushed</p>
<p style="position:absolute;top:280px;left:392px;white-space:nowrap" class="ft4595">Gently pull the needle cover straight off with the other hand.&#160;<br/>Throw the needle cover away. Do not recap.</p>
<p style="position:absolute;top:336px;left:425px;white-space:nowrap" class="ft4596">&#160;<b>Do not&#160;</b>touch the needle with your fingers or let the&#160;</p>
<p style="position:absolute;top:357px;left:452px;white-space:nowrap" class="ft4592">needle touch anything</p>
<p style="position:absolute;top:396px;left:114px;white-space:nowrap" class="ft4591"><b>STEP 5</b></p>
<p style="position:absolute;top:396px;left:392px;white-space:nowrap" class="ft4592">Hold the pre-filled syringe with the needle&#160;facing up.</p>
<p style="position:absolute;top:433px;left:425px;white-space:nowrap" class="ft4596">&#160;Hold the pre-filled syringe at eye level with one&#160;</p>
<p style="position:absolute;top:454px;left:452px;white-space:nowrap" class="ft4592">hand so you can see the air in the pre-filled syringe</p>
<p style="position:absolute;top:492px;left:392px;white-space:nowrap" class="ft4594">Slowly push the plunger in to push the air out through the&#160;<br/>needle.&#160;</p>
<p style="position:absolute;top:548px;left:425px;white-space:nowrap" class="ft4596">&#160;It is normal to see a drop&#160;of liquid at the end of the&#160;</p>
<p style="position:absolute;top:569px;left:452px;white-space:nowrap" class="ft4592">needle</p>
<p style="position:absolute;top:649px;left:114px;white-space:nowrap" class="ft4591"><b>STEP 6</b></p>
<p style="position:absolute;top:649px;left:392px;white-space:nowrap" class="ft4594">Hold the body of the pre-filled syringe in one hand between&#160;<br/>the thumb and index fingers, like you would a pencil.</p>
<p style="position:absolute;top:706px;left:392px;white-space:nowrap" class="ft4594">Squeeze the skin at your injection site with your other hand&#160;<br/>to make a raised area and hold&#160;it firmly.</p>
</div>
<!-- Page 460 -->
<a name="460"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page460-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4600">460</p>
<p style="position:absolute;top:87px;left:114px;white-space:nowrap" class="ft4601"><b>STEP 7</b></p>
<p style="position:absolute;top:87px;left:392px;white-space:nowrap" class="ft4604">Insert the needle all the way into the skin at about a 45-<br/>degree angle with one quick, short motion.</p>
<p style="position:absolute;top:143px;left:425px;white-space:nowrap" class="ft4606">&#160;After the needle is in, let go of the skin you are&#160;</p>
<p style="position:absolute;top:164px;left:452px;white-space:nowrap" class="ft4602">holding</p>
<p style="position:absolute;top:202px;left:392px;white-space:nowrap" class="ft4604">Slowly push the plunger all the way in until all of the liquid&#160;<br/>is&#160;injected and the pre-filled syringe is empty.</p>
<p style="position:absolute;top:445px;left:114px;white-space:nowrap" class="ft4601"><b>STEP 8</b></p>
<p style="position:absolute;top:732px;left:114px;white-space:nowrap" class="ft4601"><b>&#160; &#160; &#160; &#160; &#160; &#160; &#160;Cotton Ball</b></p>
<p style="position:absolute;top:445px;left:392px;white-space:nowrap" class="ft4604">When the injection is completed, slowly pull the needle out&#160;<br/>of the skin while keeping the pre-filled syringe at the same&#160;<br/>angle.</p>
<p style="position:absolute;top:521px;left:392px;white-space:nowrap" class="ft4604">After completing the injection, place a&#160;cotton ball or gauze&#160;<br/>pad on the skin over the injection site.</p>
<p style="position:absolute;top:577px;left:433px;white-space:nowrap" class="ft4606">&#160;<b>Do not&#160;</b>rub</p>
<p style="position:absolute;top:597px;left:433px;white-space:nowrap" class="ft4606">&#160;Slight bleeding at the injection site is normal</p>
<p style="position:absolute;top:771px;left:114px;white-space:nowrap" class="ft4601"><b>STEP 9</b></p>
<p style="position:absolute;top:810px;left:114px;white-space:nowrap" class="ft4605">Throw away the used pre-filled syringe in a special disposal container as instructed by your doctor,&#160;<br/>nurse or pharmacist.&#160;<b>Never&#160;</b>recap a needle.</p>
<p style="position:absolute;top:866px;left:141px;white-space:nowrap" class="ft4606">&#160;<b>Do not&#160;</b>recycle or throw the pre-filled syringe in the household waste</p>
<p style="position:absolute;top:886px;left:141px;white-space:nowrap" class="ft4606">&#160;<b>Always&#160;</b>keep the pre-filled syringe and the special disposal container out of the sight and&#160;</p>
<p style="position:absolute;top:907px;left:168px;white-space:nowrap" class="ft4602">reach of children</p>
<p style="position:absolute;top:945px;left:114px;white-space:nowrap" class="ft4604">The&#160;needle cover, alcohol pad, cotton ball or gauze&#160;pad, blister and packaging may be put in your&#160;<br/>household waste.</p>
</div>
<!-- Page 461 -->
<a name="461"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page461-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4610">461</p>
<p style="position:absolute;top:86px;left:306px;white-space:nowrap" class="ft4611"><b>Package leaflet: Information for the patient</b></p>
<p style="position:absolute;top:124px;left:274px;white-space:nowrap" class="ft4611"><b>Humira&#160;80&#160;mg&#160;solution for injection in pre-filled pen</b></p>
<p style="position:absolute;top:143px;left:418px;white-space:nowrap" class="ft4612">adalimumab</p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft46119"><b>Read all of this leaflet carefully before you start using this medicine&#160;because it contains important&#160;<br/>information for you.</b></p>
<p style="position:absolute;top:218px;left:106px;white-space:nowrap" class="ft4616"></p>
<p style="position:absolute;top:220px;left:148px;white-space:nowrap" class="ft4612">Keep this leaflet. You may need to read it again.</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft4616"></p>
<p style="position:absolute;top:240px;left:148px;white-space:nowrap" class="ft4615">Your doctor will also give you a&#160;<b>Patient Reminder Card</b>, which contains important safety&#160;<br/>information that you need to be aware of before you begin using Humira and during treatment with&#160;<br/>Humira. Keep this&#160;<b>Patient Reminder Card&#160;</b>with you.</p>
<p style="position:absolute;top:296px;left:106px;white-space:nowrap" class="ft4616"></p>
<p style="position:absolute;top:298px;left:148px;white-space:nowrap" class="ft4612">If you have any questions, ask your doctor or pharmacist.</p>
<p style="position:absolute;top:316px;left:106px;white-space:nowrap" class="ft4616"></p>
<p style="position:absolute;top:318px;left:148px;white-space:nowrap" class="ft4614">This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even&#160;<br/>if their signs of&#160;illness are the same as yours.</p>
<p style="position:absolute;top:356px;left:106px;white-space:nowrap" class="ft4616"></p>
<p style="position:absolute;top:357px;left:148px;white-space:nowrap" class="ft4614">If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects&#160;<br/>not listed in this leaflet. See section 4.</p>
<p style="position:absolute;top:414px;left:106px;white-space:nowrap" class="ft46119"><b>What is in this leaflet<br/></b>1.</p>
<p style="position:absolute;top:433px;left:148px;white-space:nowrap" class="ft4612">What Humira is and what it is used for</p>
<p style="position:absolute;top:453px;left:106px;white-space:nowrap" class="ft4612">2.</p>
<p style="position:absolute;top:453px;left:148px;white-space:nowrap" class="ft4612">What you need to know before you use Humira</p>
<p style="position:absolute;top:471px;left:106px;white-space:nowrap" class="ft4612">3.</p>
<p style="position:absolute;top:471px;left:148px;white-space:nowrap" class="ft4612">How to use Humira</p>
<p style="position:absolute;top:490px;left:106px;white-space:nowrap" class="ft4612">4.</p>
<p style="position:absolute;top:490px;left:148px;white-space:nowrap" class="ft4612">Possible side effects</p>
<p style="position:absolute;top:509px;left:106px;white-space:nowrap" class="ft4612">5</p>
<p style="position:absolute;top:509px;left:148px;white-space:nowrap" class="ft4612">How to store Humira</p>
<p style="position:absolute;top:528px;left:106px;white-space:nowrap" class="ft4612">6.</p>
<p style="position:absolute;top:528px;left:148px;white-space:nowrap" class="ft4612">Contents of the pack and other information</p>
<p style="position:absolute;top:547px;left:106px;white-space:nowrap" class="ft4612">7.</p>
<p style="position:absolute;top:547px;left:148px;white-space:nowrap" class="ft4612">Injecting Humira</p>
<p style="position:absolute;top:604px;left:106px;white-space:nowrap" class="ft4611"><b>1.</b></p>
<p style="position:absolute;top:604px;left:148px;white-space:nowrap" class="ft4611"><b>What Humira is and what it is used for</b></p>
<p style="position:absolute;top:642px;left:106px;white-space:nowrap" class="ft4612">Humira contains the active substance&#160;adalimumab.</p>
<p style="position:absolute;top:680px;left:106px;white-space:nowrap" class="ft4612">Humira is used to treat</p>
<p style="position:absolute;top:698px;left:133px;white-space:nowrap" class="ft4616">&#160;Rheumatoid arthritis</p>
<p style="position:absolute;top:718px;left:133px;white-space:nowrap" class="ft4616">&#160;Plaque psoriasis</p>
<p style="position:absolute;top:739px;left:133px;white-space:nowrap" class="ft4616">&#160;Hidradenitis suppurativa</p>
<p style="position:absolute;top:759px;left:133px;white-space:nowrap" class="ft4616">&#160;Crohn’s disease</p>
<p style="position:absolute;top:779px;left:133px;white-space:nowrap" class="ft4616">&#160;Ulcerative colitis</p>
<p style="position:absolute;top:799px;left:133px;white-space:nowrap" class="ft4616">&#160;Non-infectious uveitis</p>
<p style="position:absolute;top:839px;left:106px;white-space:nowrap" class="ft4614">The active ingredient&#160;in Humira, adalimumab, is a&#160;human&#160;monoclonal antibody. Monoclonal antibodies&#160;<br/>are&#160;proteins that&#160;attach to a specific target.</p>
<p style="position:absolute;top:896px;left:106px;white-space:nowrap" class="ft4614">The target of&#160;adalimumab&#160;is a&#160;protein&#160;called&#160;tumour necrosis factor&#160;(TNFα), which&#160;is involved in the&#160;<br/>immune (defence) system and&#160;is present at increased levels in&#160;the&#160;inflammatory diseases&#160;listed above.&#160;By&#160;<br/>attaching to&#160;TNFα, Humira decreases the process of inflammation in these diseases.</p>
<p style="position:absolute;top:972px;left:106px;white-space:nowrap" class="ft4611"><b>Rheumatoid arthritis</b></p>
<p style="position:absolute;top:1010px;left:106px;white-space:nowrap" class="ft4612">Rheumatoid arthritis is an inflammatory disease of the joints.</p>
</div>
<!-- Page 462 -->
<a name="462"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page462-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4620">462</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft4624">Humira is used to treat moderate to severe&#160;rheumatoid arthritis in adults. You may first be given other&#160;<br/>disease-modifying medicines, such as methotrexate. If you do not respond well enough to these medicines,&#160;<br/>you will be given Humira.</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft4625">Humira can also be used to treat severe, active and progressive&#160;rheumatoid arthritis without previous&#160;<br/>methotrexate treatment.</p>
<p style="position:absolute;top:219px;left:106px;white-space:nowrap" class="ft4625">Humira can slow down the damage to the joints caused by the inflammatory disease and can help them&#160;<br/>move&#160;more freely.&#160;</p>
<p style="position:absolute;top:276px;left:106px;white-space:nowrap" class="ft4622">Your doctor will decide if Humira should be used with methotrexate or&#160;alone.</p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft4621"><b>Plaque psoriasis</b></p>
<p style="position:absolute;top:352px;left:106px;white-space:nowrap" class="ft4624">Plaque psoriasis is a skin condition that causes red, flaky, crusty patches of skin covered with silvery&#160;<br/>scales. Plaque psoriasis can also affect the nails, causing them to crumble, become thickened and lift away&#160;<br/>from the nail bed&#160;which can be painful. &#160;</p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft4622">Humira is used to treat&#160;moderate to severe chronic plaque psoriasis in adults.</p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft4621"><b>Hidradenitis suppurativa</b></p>
<p style="position:absolute;top:503px;left:106px;white-space:nowrap" class="ft4625">Hidradenitis suppurativa (sometimes called acne inversa) is a chronic and often painful inflammatory skin&#160;<br/>disease. Symptoms&#160;may include tender nodules (lumps) and abscesses (boils) that may leak pus. It most&#160;<br/>commonly affects specific areas of the skin, such as under the breasts, the armpits, inner thighs, groin and&#160;<br/>buttocks.&#160;Scarring may also occur in affected areas.</p>
<p style="position:absolute;top:598px;left:106px;white-space:nowrap" class="ft4622">Humira is used to treat&#160;</p>
<p style="position:absolute;top:617px;left:133px;white-space:nowrap" class="ft4626">&#160;moderate to severe hidradenitis suppurativa in adults and</p>
<p style="position:absolute;top:637px;left:133px;white-space:nowrap" class="ft4626">&#160;moderate to severe hidradenitis suppurativa in adolescents aged 12 to 17 years.</p>
<p style="position:absolute;top:676px;left:106px;white-space:nowrap" class="ft4624">Humira can reduce the number of nodules and abscesses caused by the disease and the pain that is often&#160;<br/>associated with the disease.&#160;You may first be given other medicines. If you do not respond well enough to&#160;<br/>these medicines, you will be given Humira.</p>
<p style="position:absolute;top:752px;left:106px;white-space:nowrap" class="ft4621"><b>Crohn’s disease</b></p>
<p style="position:absolute;top:790px;left:106px;white-space:nowrap" class="ft4622">Crohn’s disease is an inflammatory disease of the digestive tract.</p>
<p style="position:absolute;top:828px;left:106px;white-space:nowrap" class="ft4622">Humira is used to treat</p>
<p style="position:absolute;top:847px;left:133px;white-space:nowrap" class="ft4626">&#160;moderate to severe Crohn’s disease in adults and&#160;</p>
<p style="position:absolute;top:867px;left:133px;white-space:nowrap" class="ft4626">&#160;moderate to severe Crohn’s disease in children and adolescents aged 6 to 17 years.</p>
<p style="position:absolute;top:906px;left:106px;white-space:nowrap" class="ft4624">You may first&#160;be given other medicines. If you do not respond well enough to these medicines, you will be&#160;<br/>given Humira.</p>
<p style="position:absolute;top:963px;left:106px;white-space:nowrap" class="ft4621"><b>Ulcerative colitis</b></p>
<p style="position:absolute;top:1002px;left:106px;white-space:nowrap" class="ft4622">Ulcerative colitis is an inflammatory disease of the large intestine.</p>
<p style="position:absolute;top:1039px;left:106px;white-space:nowrap" class="ft4622">Humira is used to treat&#160;</p>
<p style="position:absolute;top:1058px;left:133px;white-space:nowrap" class="ft4626">&#160;moderate to severe&#160;ulcerative colitis in adults&#160;and</p>
<p style="position:absolute;top:1078px;left:133px;white-space:nowrap" class="ft4626">&#160;moderate to severe ulcerative colitis in children and adolescents aged 6 to 17 years.</p>
</div>
<!-- Page 463 -->
<a name="463"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page463-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4630">463</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft4634">You may first be given other medicines. If you do not respond well enough to these medicines, you will be&#160;<br/>given Humira.</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft4631"><b>Non-infectious uveitis</b></p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft4632">Non-infectious uveitis is an inflammatory disease affecting certain parts of the eye.</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft4632">Humira is used to treat&#160;</p>
<p style="position:absolute;top:256px;left:133px;white-space:nowrap" class="ft4636">&#160;adults with non-infectious uveitis with inflammation affecting the back of the eye&#160;</p>
<p style="position:absolute;top:276px;left:133px;white-space:nowrap" class="ft4636">&#160;children with chronic non-infectious uveitis from 2&#160;years of&#160;age with inflammation affecting the&#160;</p>
<p style="position:absolute;top:297px;left:160px;white-space:nowrap" class="ft4632">front of the eye</p>
<p style="position:absolute;top:335px;left:106px;white-space:nowrap" class="ft4634">This inflammation may lead to a decrease of vision and/or the presence of floaters in the eye (black dots or&#160;<br/>wispy lines that move across the field of vision). Humira works by reducing this inflammation. You may&#160;<br/>first be given other medicines. If you do not respond well enough to these medicines, you will be given&#160;<br/>Humira.</p>
<p style="position:absolute;top:449px;left:106px;white-space:nowrap" class="ft4631"><b>2.</b></p>
<p style="position:absolute;top:449px;left:148px;white-space:nowrap" class="ft4631"><b>What you need to know before you use Humira</b></p>
<p style="position:absolute;top:487px;left:106px;white-space:nowrap" class="ft4631"><b>Do not use Humira:</b></p>
<p style="position:absolute;top:524px;left:133px;white-space:nowrap" class="ft4636">&#160;If you are allergic to adalimumab or any of the other ingredients of this medicine (listed in section&#160;</p>
<p style="position:absolute;top:545px;left:160px;white-space:nowrap" class="ft4632">6).&#160;</p>
<p style="position:absolute;top:582px;left:133px;white-space:nowrap" class="ft4636">&#160;If you have active tuberculosis or other severe infections (see “Warnings and precautions”). It is&#160;</p>
<p style="position:absolute;top:603px;left:160px;white-space:nowrap" class="ft4634">important that you tell your doctor if you have symptoms of infections, for example, fever,&#160;<br/>wounds, feeling tired, dental problems.</p>
<p style="position:absolute;top:659px;left:133px;white-space:nowrap" class="ft4636">&#160;If you have moderate or severe heart failure. It is important to tell your doctor if you have had or&#160;</p>
<p style="position:absolute;top:680px;left:160px;white-space:nowrap" class="ft4632">have a serious heart condition (see “Warnings and precautions”).</p>
<p style="position:absolute;top:718px;left:106px;white-space:nowrap" class="ft4631"><b>Warnings and precautions</b></p>
<p style="position:absolute;top:756px;left:106px;white-space:nowrap" class="ft4632">Talk to your doctor or pharmacist before&#160;using Humira.</p>
<p style="position:absolute;top:794px;left:106px;white-space:nowrap" class="ft4632">Allergic reactions</p>
<p style="position:absolute;top:831px;left:133px;white-space:nowrap" class="ft4636">&#160;If you get allergic reactions with symptoms such as chest tightness, wheezing, dizziness, swelling&#160;</p>
<p style="position:absolute;top:852px;left:160px;white-space:nowrap" class="ft4635">or rash do not inject more Humira and contact your doctor immediately since, in rare cases, these&#160;<br/>reactions can be life threatening.</p>
<p style="position:absolute;top:909px;left:106px;white-space:nowrap" class="ft4632">Infections</p>
<p style="position:absolute;top:946px;left:133px;white-space:nowrap" class="ft4636">&#160;If you have an infection, including long-term&#160;infection or an infection in one part of the body (for&#160;</p>
<p style="position:absolute;top:967px;left:160px;white-space:nowrap" class="ft4634">example, leg ulcer) consult your doctor before starting Humira. If you are unsure, contact your&#160;<br/>doctor.&#160;</p>
<p style="position:absolute;top:1023px;left:133px;white-space:nowrap" class="ft4636">&#160;You might get infections&#160;more easily while you are receiving Humira treatment. This risk may&#160;</p>
<p style="position:absolute;top:1044px;left:160px;white-space:nowrap" class="ft4632">increase if you have problems with your lungs. These infections may be serious and include:&#160;</p>
<p style="position:absolute;top:1062px;left:187px;white-space:nowrap" class="ft4636">&#160;tuberculosis</p>
</div>
<!-- Page 464 -->
<a name="464"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page464-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4640">464</p>
<p style="position:absolute;top:85px;left:187px;white-space:nowrap" class="ft4646">&#160;infections caused by viruses, fungi, parasites or bacteria</p>
<p style="position:absolute;top:105px;left:187px;white-space:nowrap" class="ft4646">&#160;severe infection in the&#160;blood (sepsis)</p>
<p style="position:absolute;top:145px;left:160px;white-space:nowrap" class="ft4644">In rare cases, these infections can be life-threatening. It is important to tell your doctor if you get&#160;<br/>symptoms such as fever, wounds, feeling tired or dental problems. Your doctor may tell you to&#160;<br/>stop using Humira for some time.</p>
<p style="position:absolute;top:221px;left:133px;white-space:nowrap" class="ft4646">&#160;Tell your doctor if you live or travel in regions where&#160;fungal infections&#160;(for example,&#160;</p>
<p style="position:absolute;top:241px;left:160px;white-space:nowrap" class="ft4642">histoplasmosis, coccidioidomycosis or blastomycosis) are very common.</p>
<p style="position:absolute;top:279px;left:133px;white-space:nowrap" class="ft4646">&#160;Tell your doctor if you have had infections which keep coming back or other conditions that&#160;</p>
<p style="position:absolute;top:300px;left:160px;white-space:nowrap" class="ft4642">increase the&#160;risk of infections.</p>
<p style="position:absolute;top:337px;left:133px;white-space:nowrap" class="ft4646">&#160;If you are over 65 years you may be more likely to get infections while taking Humira. You and&#160;</p>
<p style="position:absolute;top:357px;left:160px;white-space:nowrap" class="ft4645">your doctor should pay special attention to signs of infection while you are being treated with&#160;<br/>Humira. It is important to tell your doctor&#160;if you get symptoms of infections, such as fever,&#160;<br/>wounds, feeling tired or dental problems.</p>
<p style="position:absolute;top:433px;left:106px;white-space:nowrap" class="ft4642">Tuberculosis</p>
<p style="position:absolute;top:471px;left:133px;white-space:nowrap" class="ft4646">&#160;It is very important that you tell your doctor if you have ever had tuberculosis, or if you have been&#160;</p>
<p style="position:absolute;top:491px;left:160px;white-space:nowrap" class="ft4644">in close contact with someone who has had tuberculosis. If you have active tuberculosis, do not&#160;<br/>use Humira.</p>
<p style="position:absolute;top:548px;left:187px;white-space:nowrap" class="ft4646">&#160;As cases of tuberculosis have been reported in patients treated with Humira, your doctor&#160;</p>
<p style="position:absolute;top:568px;left:214px;white-space:nowrap" class="ft4644">will check you for signs and symptoms of tuberculosis before starting Humira. This will&#160;<br/>include a thorough medical evaluation including your medical history and appropriate&#160;<br/>screening tests (for example, chest X-ray and a tuberculin test). The conduct and results of&#160;<br/>these tests should be recorded on your&#160;<b>Patient Reminder Card</b>.&#160;</p>
<p style="position:absolute;top:644px;left:187px;white-space:nowrap" class="ft4646">&#160;Tuberculosis can develop during&#160;therapy even if you have received treatment for the&#160;</p>
<p style="position:absolute;top:665px;left:214px;white-space:nowrap" class="ft4642">prevention of tuberculosis.&#160;</p>
<p style="position:absolute;top:683px;left:187px;white-space:nowrap" class="ft4646">&#160;If symptoms of tuberculosis (for example, cough that does not go away, weight loss, lack&#160;</p>
<p style="position:absolute;top:704px;left:214px;white-space:nowrap" class="ft4644">of&#160;energy, mild fever), or any other infection appear during or after therapy tell your&#160;<br/>doctor immediately.</p>
<p style="position:absolute;top:761px;left:106px;white-space:nowrap" class="ft4642">Hepatitis B</p>
<p style="position:absolute;top:798px;left:133px;white-space:nowrap" class="ft4646">&#160;Tell your doctor if you are a carrier of the hepatitis B virus (HBV), if you have active HBV or if&#160;</p>
<p style="position:absolute;top:819px;left:160px;white-space:nowrap" class="ft4642">you think you might be at risk of getting HBV.&#160;</p>
<p style="position:absolute;top:837px;left:187px;white-space:nowrap" class="ft4646">&#160;Your doctor should test you for HBV. In people who carry HBV, Humira can&#160;cause the&#160;</p>
<p style="position:absolute;top:858px;left:214px;white-space:nowrap" class="ft4642">virus to become active again.</p>
<p style="position:absolute;top:876px;left:187px;white-space:nowrap" class="ft4646">&#160;In some rare cases, especially if you are taking other medicines that suppress the immune&#160;</p>
<p style="position:absolute;top:897px;left:214px;white-space:nowrap" class="ft4642">system, reactivation of HBV can be life-threatening. &#160;</p>
<p style="position:absolute;top:935px;left:106px;white-space:nowrap" class="ft4642">Surgery&#160;or dental procedure</p>
<p style="position:absolute;top:972px;left:133px;white-space:nowrap" class="ft4646">&#160;If you are about to have surgery or dental procedures please inform your doctor that you are taking&#160;</p>
<p style="position:absolute;top:993px;left:160px;white-space:nowrap" class="ft4642">Humira. Your doctor may recommend temporary discontinuation of Humira.&#160;</p>
<p style="position:absolute;top:1031px;left:106px;white-space:nowrap" class="ft4642">Demyelinating disease</p>
</div>
<!-- Page 465 -->
<a name="465"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page465-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4650">465</p>
<p style="position:absolute;top:85px;left:133px;white-space:nowrap" class="ft4656">&#160;If you have or develop&#160;a&#160;demyelinating disease&#160;(a disease that affects the insulating layer around&#160;</p>
<p style="position:absolute;top:106px;left:160px;white-space:nowrap" class="ft4654">the nerves,&#160;such as multiple sclerosis), your doctor will decide if you should receive or continue to&#160;<br/>receive Humira. Tell your doctor immediately if you experience symptoms like changes in your&#160;<br/>vision, weakness in&#160;your arms or legs or numbness or tingling in any part of your body.</p>
<p style="position:absolute;top:182px;left:106px;white-space:nowrap" class="ft4652">Vaccinations</p>
<p style="position:absolute;top:219px;left:133px;white-space:nowrap" class="ft4656">&#160;Certain vaccines may cause infections and should not be given while receiving Humira.&#160;</p>
<p style="position:absolute;top:258px;left:187px;white-space:nowrap" class="ft4656">&#160;Check with your doctor before you receive any vaccines.&#160;</p>
<p style="position:absolute;top:279px;left:187px;white-space:nowrap" class="ft4656">&#160;It is recommended that children, if possible, be&#160;given all the scheduled vaccinations for&#160;</p>
<p style="position:absolute;top:300px;left:214px;white-space:nowrap" class="ft4652">their age before they start treatment&#160;with Humira.</p>
<p style="position:absolute;top:318px;left:187px;white-space:nowrap" class="ft4656">&#160;If you received Humira while you were pregnant, your baby may be at higher risk for&#160;</p>
<p style="position:absolute;top:338px;left:214px;white-space:nowrap" class="ft4655">getting such an infection for up to approximately five months after the last Humira dose&#160;<br/>you received during pregnancy.&#160;It is&#160;important that you tell your baby's doctors and other&#160;<br/>health care professionals about your Humira use during your pregnancy so they can&#160;<br/>decide when your baby should receive any vaccine.</p>
<p style="position:absolute;top:433px;left:106px;white-space:nowrap" class="ft4652">Heart&#160;failure</p>
<p style="position:absolute;top:471px;left:133px;white-space:nowrap" class="ft4656">&#160;If you have mild heart failure and are being treated with Humira, your heart failure status must be&#160;</p>
<p style="position:absolute;top:491px;left:160px;white-space:nowrap" class="ft4655">closely monitored by your doctor. It is important to tell your doctor if you have had or have a&#160;<br/>serious heart condition. If&#160;you develop new or worsening symptoms of heart failure (e.g. shortness&#160;<br/>of breath, or swelling of your feet), you must contact your doctor immediately. Your doctor will&#160;<br/>decide if you should receive Humira.</p>
<p style="position:absolute;top:586px;left:106px;white-space:nowrap" class="ft4652">Fever, bruising, bleeding&#160;or looking&#160;pale</p>
<p style="position:absolute;top:624px;left:133px;white-space:nowrap" class="ft4656">&#160;In some patients the body may fail to produce&#160;enough of the blood cells that&#160;fight&#160;off&#160;infections or&#160;</p>
<p style="position:absolute;top:644px;left:160px;white-space:nowrap" class="ft4654">help you to stop bleeding. Your doctor may decide to stop treatment.&#160;If you&#160;develop a fever that&#160;<br/>does not go away,&#160;develop light&#160;bruises&#160;or bleed very easily or look very pale, call your doctor&#160;<br/>right away.</p>
<p style="position:absolute;top:720px;left:106px;white-space:nowrap" class="ft4652">Cancer</p>
<p style="position:absolute;top:758px;left:133px;white-space:nowrap" class="ft4656">&#160;There have been very rare cases of certain kinds of cancer in children and adult patients taking&#160;</p>
<p style="position:absolute;top:778px;left:160px;white-space:nowrap" class="ft4652">Humira or other TNF blockers. &#160;</p>
<p style="position:absolute;top:816px;left:187px;white-space:nowrap" class="ft4656">&#160;People with more serious rheumatoid arthritis that have had the disease&#160;for a long time&#160;</p>
<p style="position:absolute;top:837px;left:214px;white-space:nowrap" class="ft4654">may have a higher than average risk of getting lymphoma (a cancer that affects the lymph&#160;<br/>system) and leukaemia (a cancer that affects the blood and bone marrow).</p>
<p style="position:absolute;top:874px;left:187px;white-space:nowrap" class="ft4656">&#160;If you take Humira the risk of getting lymphoma, leukaemia, or other cancers may&#160;</p>
<p style="position:absolute;top:895px;left:214px;white-space:nowrap" class="ft4654">increase.&#160;On rare occasions, an uncommon and severe type of lymphoma, has been seen in&#160;<br/>patients taking Humira. Some of those patients were also treated with azathioprine or 6-<br/>mercaptopurine.</p>
<p style="position:absolute;top:951px;left:187px;white-space:nowrap" class="ft4656">&#160;Tell your doctor if you are taking azathioprine or 6-mercaptopurine with Humira.&#160;</p>
<p style="position:absolute;top:971px;left:187px;white-space:nowrap" class="ft4656">&#160;Cases of non-melanoma skin cancer have been observed in patients taking Humira.&#160;</p>
<p style="position:absolute;top:991px;left:187px;white-space:nowrap" class="ft4656">&#160;If new skin lesions appear during or after therapy or if existing lesions change appearance,&#160;</p>
<p style="position:absolute;top:1012px;left:214px;white-space:nowrap" class="ft4652">tell your doctor.</p>
<p style="position:absolute;top:1049px;left:133px;white-space:nowrap" class="ft4656">&#160;There have been cases of cancers, other than lymphoma in patients with a specific type of lung&#160;</p>
<p style="position:absolute;top:1070px;left:160px;white-space:nowrap" class="ft4652">disease called Chronic Obstructive Pulmonary Disease (COPD) treated with another TNF blocker.&#160;</p>
</div>
<!-- Page 466 -->
<a name="466"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page466-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4660">466</p>
<p style="position:absolute;top:86px;left:160px;white-space:nowrap" class="ft4665">If you have COPD, or are a heavy smoker, you should discuss with your doctor whether treatment&#160;<br/>with a TNF blocker is appropriate for you.</p>
<p style="position:absolute;top:143px;left:106px;white-space:nowrap" class="ft4662">Autoimmune disease</p>
<p style="position:absolute;top:180px;left:133px;white-space:nowrap" class="ft4666">&#160;On rare occasions, treatment with Humira could result in lupus-like syndrome. Contact your&#160;</p>
<p style="position:absolute;top:201px;left:160px;white-space:nowrap" class="ft4662">doctor if symptoms such as persistent unexplained rash, fever, joint pain&#160;or tiredness&#160;occur.</p>
<p style="position:absolute;top:239px;left:106px;white-space:nowrap" class="ft4661"><b>Children and adolescents</b></p>
<p style="position:absolute;top:276px;left:133px;white-space:nowrap" class="ft4666">&#160;Vaccinations: if possible,&#160;children should be up to date with all vaccinations before using Humira.</p>
<p style="position:absolute;top:316px;left:106px;white-space:nowrap" class="ft4661"><b>Other medicines and Humira</b></p>
<p style="position:absolute;top:354px;left:106px;white-space:nowrap" class="ft4662">Tell your doctor or pharmacist if you are taking, have recently taken or might&#160;take any other medicines.</p>
<p style="position:absolute;top:392px;left:106px;white-space:nowrap" class="ft4665">You should not take Humira with medicines containing the&#160;following&#160;active substances&#160;due to increased&#160;<br/>risk of serious infection:</p>
<p style="position:absolute;top:429px;left:133px;white-space:nowrap" class="ft4666">&#160;anakinra</p>
<p style="position:absolute;top:449px;left:133px;white-space:nowrap" class="ft4666">&#160;abatacept.</p>
<p style="position:absolute;top:489px;left:106px;white-space:nowrap" class="ft4662">Humira can be taken together with:</p>
<p style="position:absolute;top:508px;left:133px;white-space:nowrap" class="ft4666">&#160;methotrexate</p>
<p style="position:absolute;top:528px;left:133px;white-space:nowrap" class="ft4666">&#160;certain disease-modifying anti-rheumatic agents (for example, sulfasalazine, hydroxychloroquine,&#160;</p>
<p style="position:absolute;top:548px;left:160px;white-space:nowrap" class="ft4662">leflunomide and injectable gold preparations)</p>
<p style="position:absolute;top:567px;left:133px;white-space:nowrap" class="ft4666">&#160;steroids or pain medications including non-steroidal anti-inflammatory drugs (NSAIDs).</p>
<p style="position:absolute;top:607px;left:106px;white-space:nowrap" class="ft4662">If you have questions, please ask your doctor.</p>
<p style="position:absolute;top:644px;left:106px;white-space:nowrap" class="ft4661"><b>Pregnancy and breast-feeding</b></p>
<p style="position:absolute;top:682px;left:133px;white-space:nowrap" class="ft4666">&#160;You&#160;should consider the&#160;use&#160;of&#160;adequate contraception&#160;to prevent pregnancy&#160;and&#160;continue its use&#160;</p>
<p style="position:absolute;top:703px;left:160px;white-space:nowrap" class="ft4662">for at least 5 months after the last Humira treatment.</p>
<p style="position:absolute;top:721px;left:133px;white-space:nowrap" class="ft4666">&#160;If you are pregnant, think you may be pregnant or are planning to have a&#160;baby, ask your doctor for&#160;</p>
<p style="position:absolute;top:742px;left:160px;white-space:nowrap" class="ft4662">advice about taking this medicine.</p>
<p style="position:absolute;top:760px;left:133px;white-space:nowrap" class="ft4666">&#160;Humira should only be used during a pregnancy if needed.</p>
<p style="position:absolute;top:780px;left:133px;white-space:nowrap" class="ft4666">&#160;According to a pregnancy study, there was no higher risk of birth defects when the mother had&#160;</p>
<p style="position:absolute;top:801px;left:160px;white-space:nowrap" class="ft4664">received Humira during pregnancy compared with&#160;mothers with the same disease&#160;who did not&#160;<br/>receive Humira.</p>
<p style="position:absolute;top:838px;left:133px;white-space:nowrap" class="ft4666">&#160;Humira can be used during breast-feeding.</p>
<p style="position:absolute;top:859px;left:133px;white-space:nowrap" class="ft4666">&#160;If you receive Humira during your pregnancy, your baby may have a higher&#160;risk for getting an&#160;</p>
<p style="position:absolute;top:879px;left:160px;white-space:nowrap" class="ft4662">infection.</p>
<p style="position:absolute;top:897px;left:133px;white-space:nowrap" class="ft4666">&#160;It is important that you tell your baby’s doctors&#160;and other health care professionals about your&#160;</p>
<p style="position:absolute;top:918px;left:160px;white-space:nowrap" class="ft4664">Humira use during your pregnancy before the baby receives any vaccine. For more information&#160;on&#160;<br/>vaccines&#160;see&#160;the&#160;“Warnings and precautions”&#160;section.</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft4661"><b>Driving and using machines</b></p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft4665">Humira may have a small effect&#160;on your ability to drive, cycle or use machines. Room spinning sensation&#160;<br/>and vision disturbances may occur after taking Humira.</p>
</div>
<!-- Page 467 -->
<a name="467"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page467-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4670">467</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft4671"><b>3.</b></p>
<p style="position:absolute;top:86px;left:148px;white-space:nowrap" class="ft4671"><b>How to use Humira</b></p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft4674">Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or&#160;<br/>pharmacist if you are not sure.</p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft4674">The recommended doses for Humira in each of the approved uses are shown in the following table. Your&#160;<br/>doctor may prescribe another strength of Humira if you need a different dose.</p>
<p style="position:absolute;top:239px;left:114px;white-space:nowrap" class="ft46719"><b>Rheumatoid arthritis<br/>Age or body weight</b></p>
<p style="position:absolute;top:258px;left:346px;white-space:nowrap" class="ft46719"><b>How much and how often to&#160;<br/>take?</b></p>
<p style="position:absolute;top:258px;left:579px;white-space:nowrap" class="ft4671"><b>Notes</b></p>
<p style="position:absolute;top:297px;left:114px;white-space:nowrap" class="ft4672">Adults&#160;</p>
<p style="position:absolute;top:297px;left:346px;white-space:nowrap" class="ft4672">40 mg every other week</p>
<p style="position:absolute;top:297px;left:579px;white-space:nowrap" class="ft4675">In rheumatoid arthritis,&#160;<br/>methotrexate is continued while&#160;<br/>using Humira. If your doctor&#160;<br/>decides that methotrexate is&#160;<br/>inappropriate, Humira can be&#160;<br/>given alone.</p>
<p style="position:absolute;top:430px;left:579px;white-space:nowrap" class="ft4674">If you have rheumatoid&#160;arthritis&#160;<br/>and you do not receive&#160;<br/>methotrexate with your Humira&#160;<br/>therapy, your doctor may decide&#160;<br/>to give Humira 40 mg every&#160;<br/>week&#160;or 80 mg every other&#160;<br/>week.&#160;</p>
<p style="position:absolute;top:583px;left:114px;white-space:nowrap" class="ft46719"><b>Plaque psoriasis<br/>Age or body weight</b></p>
<p style="position:absolute;top:603px;left:346px;white-space:nowrap" class="ft46719"><b>How much and how often to&#160;<br/>take?</b></p>
<p style="position:absolute;top:603px;left:579px;white-space:nowrap" class="ft4671"><b>Notes</b></p>
<p style="position:absolute;top:642px;left:114px;white-space:nowrap" class="ft4672">Adults&#160;</p>
<p style="position:absolute;top:642px;left:346px;white-space:nowrap" class="ft4674">First dose of&#160;80 mg (one 80 mg&#160;<br/>injection), followed by 40 mg&#160;<br/>every other week starting one&#160;<br/>week after the first dose.</p>
<p style="position:absolute;top:642px;left:579px;white-space:nowrap" class="ft4674">If you have an inadequate&#160;<br/>response, your doctor may&#160;<br/>increase the dosage to 40 mg&#160;<br/>every week&#160;or 80 mg every&#160;<br/>other week.</p>
<p style="position:absolute;top:776px;left:114px;white-space:nowrap" class="ft46719"><b>Hidradenitis suppurativa<br/>Age&#160;or body weight</b></p>
<p style="position:absolute;top:796px;left:346px;white-space:nowrap" class="ft46715"><b>How much and how often to&#160;<br/>take?</b></p>
<p style="position:absolute;top:796px;left:579px;white-space:nowrap" class="ft4671"><b>Notes</b></p>
<p style="position:absolute;top:834px;left:114px;white-space:nowrap" class="ft4672">Adults&#160;</p>
<p style="position:absolute;top:834px;left:346px;white-space:nowrap" class="ft4674">First dose of 160&#160;mg (two 80&#160;<br/>mg&#160;injections in one day or one&#160;<br/>80 mg injection per day for two&#160;<br/>consecutive days), followed by&#160;<br/>an 80&#160;mg dose (one 80 mg&#160;<br/>injection) two weeks later. After&#160;<br/>two further&#160;weeks, continue&#160;<br/>with a dose of 40 mg every&#160;<br/>week&#160;or 80 mg every other&#160;<br/>week, as prescribed by your&#160;<br/>doctor. &#160;</p>
<p style="position:absolute;top:834px;left:579px;white-space:nowrap" class="ft4674">It is recommended that you use&#160;<br/>an antiseptic wash daily on the&#160;<br/>affected areas.</p>
</div>
<!-- Page 468 -->
<a name="468"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page468-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4680">468</p>
<p style="position:absolute;top:87px;left:114px;white-space:nowrap" class="ft4684">Adolescents from 12 to 17 years&#160;<br/>of age weighing 30 kg or more</p>
<p style="position:absolute;top:87px;left:346px;white-space:nowrap" class="ft4684">First dose of 80 mg (one 80 mg&#160;<br/>injection), followed by 40 mg&#160;<br/>every other week starting one&#160;<br/>week&#160;later. &#160;</p>
<p style="position:absolute;top:87px;left:579px;white-space:nowrap" class="ft4684">If you have an inadequate&#160;<br/>response&#160;to Humira 40 mg every&#160;<br/>other week, your doctor may&#160;<br/>increase the dosage to 40 mg&#160;<br/>every week&#160;or 80 mg every&#160;<br/>other week.<br/>It is recommended that you use&#160;<br/>an antiseptic wash daily on the&#160;<br/>affected areas.</p>
<p style="position:absolute;top:297px;left:114px;white-space:nowrap" class="ft46819"><b>Crohn’s disease<br/>Age or body weight</b></p>
<p style="position:absolute;top:317px;left:346px;white-space:nowrap" class="ft46815"><b>How much and how often to&#160;<br/>take?</b></p>
<p style="position:absolute;top:317px;left:579px;white-space:nowrap" class="ft4681"><b>Notes</b></p>
<p style="position:absolute;top:355px;left:114px;white-space:nowrap" class="ft4685">Children,&#160;adolescents&#160;and adults&#160;<br/>from 6 to 17 years of age&#160;<br/>weighing 40 kg or more</p>
<p style="position:absolute;top:355px;left:346px;white-space:nowrap" class="ft4685">First dose of&#160;80 mg (one 80 mg&#160;<br/>injection), followed by 40 mg&#160;<br/>two weeks later.</p>
<p style="position:absolute;top:431px;left:346px;white-space:nowrap" class="ft4684">If a faster response is required,&#160;<br/>the doctor may prescribe a first&#160;<br/>dose of 160 mg (two 80 mg&#160;<br/>injections in one day or one&#160;<br/>80&#160;mg injection per day for two&#160;<br/>consecutive days), followed by&#160;<br/>80 mg&#160;(one 80 mg injection)&#160;<br/>two weeks later.</p>
<p style="position:absolute;top:602px;left:346px;white-space:nowrap" class="ft4684">Thereafter, the usual dose is 40&#160;<br/>mg&#160;every other week.</p>
<p style="position:absolute;top:355px;left:579px;white-space:nowrap" class="ft4685">Your doctor may increase the&#160;<br/>dosage to 40 mg every week&#160;or&#160;<br/>80 mg every other week.</p>
<p style="position:absolute;top:641px;left:114px;white-space:nowrap" class="ft4684">Children and adolescents from 6&#160;<br/>to 17 years of age weighing less&#160;<br/>than 40 kg</p>
<p style="position:absolute;top:641px;left:346px;white-space:nowrap" class="ft4684">First dose of 40 mg, followed by&#160;<br/>20 mg two weeks later.&#160;<br/>If a faster response is required,&#160;<br/>the doctor may prescribe a first&#160;<br/>dose of 80 mg (one 80 mg&#160;<br/>injection), followed by 40 mg&#160;<br/>two weeks later.</p>
<p style="position:absolute;top:792px;left:346px;white-space:nowrap" class="ft4684">Thereafter, the usual dose is 20&#160;<br/>mg&#160;every other week.</p>
<p style="position:absolute;top:641px;left:579px;white-space:nowrap" class="ft4684">Your&#160;doctor may increase the&#160;<br/>dose frequency to 20 mg every&#160;<br/>week.</p>
<p style="position:absolute;top:851px;left:114px;white-space:nowrap" class="ft46819"><b>Ulcerative colitis<br/>Age or body weight</b></p>
<p style="position:absolute;top:870px;left:346px;white-space:nowrap" class="ft46819"><b>How much and how often to&#160;<br/>take?</b></p>
<p style="position:absolute;top:870px;left:579px;white-space:nowrap" class="ft4681"><b>Notes</b></p>
<p style="position:absolute;top:909px;left:114px;white-space:nowrap" class="ft4682">Adults</p>
<p style="position:absolute;top:909px;left:346px;white-space:nowrap" class="ft4685">First dose of 160 mg (two 80&#160;<br/>mg&#160;injections in one day or&#160;one&#160;<br/>80 mg injection&#160;per day for two&#160;<br/>consecutive&#160;days), followed by&#160;<br/>80 mg (one 80 mg injection)&#160;<br/>two weeks later.</p>
<p style="position:absolute;top:1042px;left:346px;white-space:nowrap" class="ft4684">Thereafter, the usual dose is 40&#160;<br/>mg&#160;every other week.</p>
<p style="position:absolute;top:909px;left:579px;white-space:nowrap" class="ft4685">Your doctor may increase the&#160;<br/>dosage to 40 mg every week&#160;or&#160;<br/>80 mg every other week.</p>
</div>
<!-- Page 469 -->
<a name="469"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page469-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4690">469</p>
<p style="position:absolute;top:87px;left:114px;white-space:nowrap" class="ft4695">Children&#160;and adolescents from&#160;6<br/>years of age weighing&#160;less than&#160;<br/>40 kg</p>
<p style="position:absolute;top:87px;left:346px;white-space:nowrap" class="ft4694">First dose of 80 mg&#160;(one 80 mg&#160;<br/>injection), followed by 40 mg<br/>(one 40 mg injection)&#160;two&#160;<br/>weeks later.</p>
<p style="position:absolute;top:181px;left:346px;white-space:nowrap" class="ft4694">Thereafter, the usual dose is 40&#160;<br/>mg&#160;every&#160;other week.</p>
<p style="position:absolute;top:87px;left:579px;white-space:nowrap" class="ft4695">You should continue taking&#160;<br/>Humira at your usual dose, even&#160;<br/>after turning 18 years&#160;of age.</p>
<p style="position:absolute;top:220px;left:114px;white-space:nowrap" class="ft4695">Children and adolescents from&#160;6<br/>years of age weighing 40 kg or&#160;<br/>more</p>
<p style="position:absolute;top:220px;left:346px;white-space:nowrap" class="ft4695">First dose of 160 mg (two&#160;80&#160;<br/>mg&#160;injections in one day or&#160;one<br/>80 mg injection per day for two&#160;<br/>consecutive days), followed by&#160;<br/>80 mg (one&#160;80 mg injection)&#160;<br/>two weeks later.</p>
<p style="position:absolute;top:353px;left:346px;white-space:nowrap" class="ft4694">Thereafter, the usual dose is 80&#160;<br/>mg&#160;every other week.</p>
<p style="position:absolute;top:220px;left:579px;white-space:nowrap" class="ft4695">You should continue taking&#160;<br/>Humira at your usual dose, even&#160;<br/>after turning 18 years of age.</p>
<p style="position:absolute;top:411px;left:114px;white-space:nowrap" class="ft46919"><b>Non-infectious uveitis<br/>Age or body weight</b></p>
<p style="position:absolute;top:431px;left:346px;white-space:nowrap" class="ft46919"><b>How much and how often to&#160;<br/>take?</b></p>
<p style="position:absolute;top:431px;left:579px;white-space:nowrap" class="ft4691"><b>Notes</b></p>
<p style="position:absolute;top:470px;left:114px;white-space:nowrap" class="ft4692">Adults</p>
<p style="position:absolute;top:470px;left:346px;white-space:nowrap" class="ft4695">First dose of 80 mg (one 80 mg&#160;<br/>injection), followed by 40 mg&#160;<br/>every other week starting one&#160;<br/>week after the first dose.</p>
<p style="position:absolute;top:470px;left:579px;white-space:nowrap" class="ft4694">Corticosteroids or other&#160;<br/>medicines that influence the&#160;<br/>immune system may be&#160;<br/>continued while using Humira.&#160;<br/>Humira can also be given alone.</p>
<p style="position:absolute;top:566px;left:114px;white-space:nowrap" class="ft4695">Children&#160;and adolescents&#160;from&#160;<br/>2&#160;years of age weighing less&#160;<br/>than 30&#160;kg</p>
<p style="position:absolute;top:566px;left:346px;white-space:nowrap" class="ft4692">20&#160;mg&#160;every other week</p>
<p style="position:absolute;top:566px;left:579px;white-space:nowrap" class="ft4694">Your doctor may prescribe an&#160;<br/>initial dose of 40&#160;mg to be&#160;<br/>administered one week prior to&#160;<br/>the start of the usual dose of&#160;<br/>20&#160;mg&#160;every other week.&#160;<br/>Humira is recommended for use&#160;<br/>in combination with&#160;<br/>methotrexate.</p>
<p style="position:absolute;top:718px;left:114px;white-space:nowrap" class="ft4694">Children&#160;and adolescents&#160;from&#160;<br/>2&#160;years of age weighing 30&#160;kg<br/>or more</p>
<p style="position:absolute;top:718px;left:346px;white-space:nowrap" class="ft4692">40&#160;mg&#160;every other week&#160;</p>
<p style="position:absolute;top:718px;left:579px;white-space:nowrap" class="ft4694">Your doctor may prescribe an&#160;<br/>initial dose of 80&#160;mg to be&#160;<br/>administered one week prior to&#160;<br/>the start of the usual dose of&#160;<br/>40&#160;mg&#160;every other&#160;week.&#160;<br/>Humira is recommended for use&#160;<br/>in combination with&#160;<br/>methotrexate.</p>
<p style="position:absolute;top:890px;left:106px;white-space:nowrap" class="ft4691"><b>Method and route of administration</b></p>
<p style="position:absolute;top:928px;left:106px;white-space:nowrap" class="ft4692">Humira is administered by injection under the skin (by subcutaneous injection).</p>
<p style="position:absolute;top:966px;left:106px;white-space:nowrap" class="ft4691"><b>Detailed instructions on how to inject Humira are provided in section&#160;7 ‘Injecting Humira’.</b></p>
<p style="position:absolute;top:1003px;left:106px;white-space:nowrap" class="ft4691"><b>If you use more&#160;Humira&#160;than you should</b></p>
</div>
<!-- Page 470 -->
<a name="470"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page470-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4700">470</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft4704">If you accidentally inject Humira more frequently than told to by your doctor or pharmacist, call your&#160;<br/>doctor or pharmacist&#160;and tell them that you have taken more. Always take the outer carton of the medicine&#160;<br/>with you, even if it is empty.&#160;</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft4701"><b>If you forget to use Humira</b></p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft4705">If you forget to give yourself an injection, you should inject the next dose of Humira as soon as you&#160;<br/>remember. Then take your next dose as you would have on your originally scheduled day, had you not&#160;<br/>forgotten a dose.&#160;</p>
<p style="position:absolute;top:276px;left:106px;white-space:nowrap" class="ft4701"><b>If you stop using Humira</b></p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft4704">The&#160;decision to stop using Humira should be discussed with your doctor. Your symptoms may return if&#160;<br/>you stop using Humira.</p>
<p style="position:absolute;top:370px;left:106px;white-space:nowrap" class="ft4702">If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft4701"><b>4.</b></p>
<p style="position:absolute;top:427px;left:148px;white-space:nowrap" class="ft4701"><b>Possible side effects</b></p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft4705">Like all medicines, this medicine can cause side effects, although not everybody gets them. Most side&#160;<br/>effects are mild to moderate. However, some may be serious and require treatment. Side effects may occur&#160;<br/>at least up to 4 months after the last Humira injection.&#160;</p>
<p style="position:absolute;top:541px;left:106px;white-space:nowrap" class="ft4701"><b>Tell your doctor immediately if you notice any of the following</b></p>
<p style="position:absolute;top:578px;left:106px;white-space:nowrap" class="ft4706">&#160;severe rash, hives or other signs of allergic reaction&#160;</p>
<p style="position:absolute;top:599px;left:106px;white-space:nowrap" class="ft4706">&#160;swollen face, hands, feet</p>
<p style="position:absolute;top:619px;left:106px;white-space:nowrap" class="ft4706">&#160;trouble breathing, swallowing</p>
<p style="position:absolute;top:639px;left:106px;white-space:nowrap" class="ft4706">&#160;shortness of breath with physical activity or upon lying down or swelling of the feet</p>
<p style="position:absolute;top:679px;left:106px;white-space:nowrap" class="ft4701"><b>Tell your doctor as soon as possible if you notice any of the following</b></p>
<p style="position:absolute;top:716px;left:106px;white-space:nowrap" class="ft4706">&#160;signs of infection such as fever, feeling sick, wounds, dental problems,&#160;burning on urination</p>
<p style="position:absolute;top:736px;left:106px;white-space:nowrap" class="ft4706">&#160;feeling weak or tired</p>
<p style="position:absolute;top:756px;left:106px;white-space:nowrap" class="ft4706">&#160;coughing</p>
<p style="position:absolute;top:776px;left:106px;white-space:nowrap" class="ft4706">&#160;tingling</p>
<p style="position:absolute;top:797px;left:106px;white-space:nowrap" class="ft4706">&#160;numbness</p>
<p style="position:absolute;top:817px;left:106px;white-space:nowrap" class="ft4706">&#160;double vision</p>
<p style="position:absolute;top:837px;left:106px;white-space:nowrap" class="ft4706">&#160;arm&#160;or leg weakness</p>
<p style="position:absolute;top:857px;left:106px;white-space:nowrap" class="ft4706">&#160;a bump or open sore that doesn't heal</p>
<p style="position:absolute;top:877px;left:106px;white-space:nowrap" class="ft4706">&#160;signs and symptoms suggestive of blood disorders such as persistent fever, bruising, bleeding,&#160;</p>
<p style="position:absolute;top:898px;left:133px;white-space:nowrap" class="ft4702">paleness</p>
<p style="position:absolute;top:936px;left:106px;white-space:nowrap" class="ft4705">The&#160;symptoms described above can be signs of the below listed side effects, which have been observed&#160;<br/>with Humira.</p>
<p style="position:absolute;top:993px;left:106px;white-space:nowrap" class="ft4701"><b>Very common&#160;</b>(may&#160;affect more than 1 in 10 people)<i>&#160;&#160;</i></p>
<p style="position:absolute;top:1030px;left:106px;white-space:nowrap" class="ft4706"></p>
<p style="position:absolute;top:1032px;left:147px;white-space:nowrap" class="ft4702">injection site reactions (including pain, swelling, redness or itching)</p>
<p style="position:absolute;top:1050px;left:106px;white-space:nowrap" class="ft4706"></p>
<p style="position:absolute;top:1052px;left:147px;white-space:nowrap" class="ft4702">respiratory tract infections (including cold, runny nose, sinus infection, pneumonia)</p>
<p style="position:absolute;top:1071px;left:106px;white-space:nowrap" class="ft4706"></p>
<p style="position:absolute;top:1072px;left:147px;white-space:nowrap" class="ft4702">headache</p>
</div>
<!-- Page 471 -->
<a name="471"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page471-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4710">471</p>
<p style="position:absolute;top:85px;left:106px;white-space:nowrap" class="ft4716"></p>
<p style="position:absolute;top:87px;left:147px;white-space:nowrap" class="ft4712">abdominal pain</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft4716"></p>
<p style="position:absolute;top:107px;left:147px;white-space:nowrap" class="ft4712">nausea and vomiting</p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft4716"></p>
<p style="position:absolute;top:127px;left:147px;white-space:nowrap" class="ft4712">rash</p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft4716"></p>
<p style="position:absolute;top:148px;left:147px;white-space:nowrap" class="ft4712">musculoskeletal pain</p>
<p style="position:absolute;top:185px;left:106px;white-space:nowrap" class="ft4711"><b>Common&#160;</b>(may&#160;affect up to 1 in 10 people)</p>
<p style="position:absolute;top:223px;left:106px;white-space:nowrap" class="ft4716"></p>
<p style="position:absolute;top:225px;left:147px;white-space:nowrap" class="ft4712">serious&#160;infections (including blood poisoning and influenza)</p>
<p style="position:absolute;top:243px;left:106px;white-space:nowrap" class="ft4716"></p>
<p style="position:absolute;top:245px;left:147px;white-space:nowrap" class="ft4712">intestinal&#160;infections&#160;(including gastroenteritis)</p>
<p style="position:absolute;top:263px;left:106px;white-space:nowrap" class="ft4716"></p>
<p style="position:absolute;top:265px;left:147px;white-space:nowrap" class="ft4712">skin infections (including cellulitis and shingles)</p>
<p style="position:absolute;top:283px;left:106px;white-space:nowrap" class="ft4716"></p>
<p style="position:absolute;top:285px;left:147px;white-space:nowrap" class="ft4712">ear infections</p>
<p style="position:absolute;top:303px;left:106px;white-space:nowrap" class="ft4716"></p>
<p style="position:absolute;top:305px;left:147px;white-space:nowrap" class="ft4712">oral infections (including tooth infections and cold sores)</p>
<p style="position:absolute;top:324px;left:106px;white-space:nowrap" class="ft4716"></p>
<p style="position:absolute;top:325px;left:147px;white-space:nowrap" class="ft4712">reproductive tract infections</p>
<p style="position:absolute;top:344px;left:106px;white-space:nowrap" class="ft4716"></p>
<p style="position:absolute;top:346px;left:147px;white-space:nowrap" class="ft4712">urinary tract infection</p>
<p style="position:absolute;top:364px;left:106px;white-space:nowrap" class="ft4716"></p>
<p style="position:absolute;top:366px;left:147px;white-space:nowrap" class="ft4712">fungal infections</p>
<p style="position:absolute;top:384px;left:106px;white-space:nowrap" class="ft4716"></p>
<p style="position:absolute;top:386px;left:147px;white-space:nowrap" class="ft4712">joint infections</p>
<p style="position:absolute;top:404px;left:106px;white-space:nowrap" class="ft4716"></p>
<p style="position:absolute;top:406px;left:147px;white-space:nowrap" class="ft4712">benign tumours</p>
<p style="position:absolute;top:424px;left:106px;white-space:nowrap" class="ft4716"></p>
<p style="position:absolute;top:426px;left:147px;white-space:nowrap" class="ft4712">skin cancer</p>
<p style="position:absolute;top:445px;left:106px;white-space:nowrap" class="ft4716"></p>
<p style="position:absolute;top:446px;left:147px;white-space:nowrap" class="ft4712">allergic reactions (including seasonal allergy)</p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft4716"></p>
<p style="position:absolute;top:467px;left:147px;white-space:nowrap" class="ft4712">dehydration</p>
<p style="position:absolute;top:485px;left:106px;white-space:nowrap" class="ft4716"></p>
<p style="position:absolute;top:487px;left:147px;white-space:nowrap" class="ft4712">mood swings (including depression)</p>
<p style="position:absolute;top:505px;left:106px;white-space:nowrap" class="ft4716"></p>
<p style="position:absolute;top:507px;left:147px;white-space:nowrap" class="ft4712">anxiety</p>
<p style="position:absolute;top:525px;left:106px;white-space:nowrap" class="ft4716"></p>
<p style="position:absolute;top:527px;left:147px;white-space:nowrap" class="ft4712">difficulty sleeping</p>
<p style="position:absolute;top:545px;left:106px;white-space:nowrap" class="ft4716"></p>
<p style="position:absolute;top:547px;left:147px;white-space:nowrap" class="ft4712">sensation disorders such as tingling, prickling or numbness</p>
<p style="position:absolute;top:565px;left:106px;white-space:nowrap" class="ft4716"></p>
<p style="position:absolute;top:567px;left:147px;white-space:nowrap" class="ft4712">migraine</p>
<p style="position:absolute;top:586px;left:106px;white-space:nowrap" class="ft4716"></p>
<p style="position:absolute;top:588px;left:147px;white-space:nowrap" class="ft4712">nerve root compression (including low&#160;back pain and leg pain)</p>
<p style="position:absolute;top:606px;left:106px;white-space:nowrap" class="ft4716"></p>
<p style="position:absolute;top:608px;left:147px;white-space:nowrap" class="ft4712">vision disturbances</p>
<p style="position:absolute;top:626px;left:106px;white-space:nowrap" class="ft4716"></p>
<p style="position:absolute;top:628px;left:147px;white-space:nowrap" class="ft4712">eye&#160;inflammation</p>
<p style="position:absolute;top:646px;left:106px;white-space:nowrap" class="ft4716"></p>
<p style="position:absolute;top:648px;left:147px;white-space:nowrap" class="ft4712">inflammation of the eye lid and eye swelling</p>
<p style="position:absolute;top:666px;left:106px;white-space:nowrap" class="ft4716"></p>
<p style="position:absolute;top:668px;left:147px;white-space:nowrap" class="ft4712">vertigo (feeling of dizziness or spinning)</p>
<p style="position:absolute;top:686px;left:106px;white-space:nowrap" class="ft4716"></p>
<p style="position:absolute;top:688px;left:147px;white-space:nowrap" class="ft4712">sensation of heart beating rapidly</p>
<p style="position:absolute;top:707px;left:106px;white-space:nowrap" class="ft4716"></p>
<p style="position:absolute;top:708px;left:147px;white-space:nowrap" class="ft4712">high blood pressure</p>
<p style="position:absolute;top:727px;left:106px;white-space:nowrap" class="ft4716"></p>
<p style="position:absolute;top:729px;left:147px;white-space:nowrap" class="ft4712">flushing</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft4716"></p>
<p style="position:absolute;top:749px;left:147px;white-space:nowrap" class="ft4712">haematoma (collection of blood outside of&#160;blood vessels)</p>
<p style="position:absolute;top:767px;left:106px;white-space:nowrap" class="ft4716"></p>
<p style="position:absolute;top:769px;left:147px;white-space:nowrap" class="ft4712">cough</p>
<p style="position:absolute;top:787px;left:106px;white-space:nowrap" class="ft4716"></p>
<p style="position:absolute;top:789px;left:147px;white-space:nowrap" class="ft4712">asthma</p>
<p style="position:absolute;top:807px;left:106px;white-space:nowrap" class="ft4716"></p>
<p style="position:absolute;top:809px;left:147px;white-space:nowrap" class="ft4712">shortness of breath</p>
<p style="position:absolute;top:828px;left:106px;white-space:nowrap" class="ft4716"></p>
<p style="position:absolute;top:829px;left:147px;white-space:nowrap" class="ft4712">gastrointestinal bleeding</p>
<p style="position:absolute;top:848px;left:106px;white-space:nowrap" class="ft4716"></p>
<p style="position:absolute;top:850px;left:147px;white-space:nowrap" class="ft4712">dyspepsia (indigestion, bloating, heart burn)</p>
<p style="position:absolute;top:868px;left:106px;white-space:nowrap" class="ft4716"></p>
<p style="position:absolute;top:870px;left:147px;white-space:nowrap" class="ft4712">acid reflux disease</p>
<p style="position:absolute;top:888px;left:106px;white-space:nowrap" class="ft4716"></p>
<p style="position:absolute;top:890px;left:147px;white-space:nowrap" class="ft4712">sicca syndrome (including dry eyes and dry mouth)</p>
<p style="position:absolute;top:908px;left:106px;white-space:nowrap" class="ft4716"></p>
<p style="position:absolute;top:910px;left:147px;white-space:nowrap" class="ft4712">itching</p>
<p style="position:absolute;top:928px;left:106px;white-space:nowrap" class="ft4716"></p>
<p style="position:absolute;top:930px;left:147px;white-space:nowrap" class="ft4712">itchy rash</p>
<p style="position:absolute;top:949px;left:106px;white-space:nowrap" class="ft4716"></p>
<p style="position:absolute;top:950px;left:147px;white-space:nowrap" class="ft4712">bruising</p>
<p style="position:absolute;top:969px;left:106px;white-space:nowrap" class="ft4716"></p>
<p style="position:absolute;top:971px;left:147px;white-space:nowrap" class="ft4712">inflammation of the skin (such as eczema)</p>
<p style="position:absolute;top:989px;left:106px;white-space:nowrap" class="ft4716"></p>
<p style="position:absolute;top:991px;left:147px;white-space:nowrap" class="ft4712">breaking of finger nails and toe nails</p>
<p style="position:absolute;top:1009px;left:106px;white-space:nowrap" class="ft4716"></p>
<p style="position:absolute;top:1011px;left:147px;white-space:nowrap" class="ft4712">increased sweating</p>
<p style="position:absolute;top:1029px;left:106px;white-space:nowrap" class="ft4716"></p>
<p style="position:absolute;top:1031px;left:147px;white-space:nowrap" class="ft4712">hair loss</p>
<p style="position:absolute;top:1049px;left:106px;white-space:nowrap" class="ft4716"></p>
<p style="position:absolute;top:1051px;left:147px;white-space:nowrap" class="ft4712">new&#160;onset or worsening of psoriasis</p>
<p style="position:absolute;top:1069px;left:106px;white-space:nowrap" class="ft4716"></p>
<p style="position:absolute;top:1071px;left:147px;white-space:nowrap" class="ft4712">muscle spasms</p>
</div>
<!-- Page 472 -->
<a name="472"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page472-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4720">472</p>
<p style="position:absolute;top:85px;left:106px;white-space:nowrap" class="ft4726"></p>
<p style="position:absolute;top:87px;left:147px;white-space:nowrap" class="ft4722">blood in urine</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft4726"></p>
<p style="position:absolute;top:107px;left:147px;white-space:nowrap" class="ft4722">kidney problems</p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft4726"></p>
<p style="position:absolute;top:127px;left:147px;white-space:nowrap" class="ft4722">chest pain</p>
<p style="position:absolute;top:146px;left:106px;white-space:nowrap" class="ft4726"></p>
<p style="position:absolute;top:148px;left:147px;white-space:nowrap" class="ft4722">oedema (swelling)</p>
<p style="position:absolute;top:166px;left:106px;white-space:nowrap" class="ft4726"></p>
<p style="position:absolute;top:168px;left:147px;white-space:nowrap" class="ft4722">fever</p>
<p style="position:absolute;top:186px;left:106px;white-space:nowrap" class="ft4726"></p>
<p style="position:absolute;top:188px;left:147px;white-space:nowrap" class="ft4722">reduction in blood platelets which increases risk of bleeding or&#160;bruising</p>
<p style="position:absolute;top:206px;left:106px;white-space:nowrap" class="ft4726"></p>
<p style="position:absolute;top:208px;left:147px;white-space:nowrap" class="ft4722">impaired healing</p>
<p style="position:absolute;top:246px;left:106px;white-space:nowrap" class="ft4721"><b>Uncommon&#160;</b>(may&#160;affect up to 1 in 100 people) &#160;</p>
<p style="position:absolute;top:283px;left:106px;white-space:nowrap" class="ft4726"></p>
<p style="position:absolute;top:285px;left:147px;white-space:nowrap" class="ft4724">opportunistic infections (which include tuberculosis and other infections that occur when resistance&#160;<br/>to disease is lowered)</p>
<p style="position:absolute;top:322px;left:106px;white-space:nowrap" class="ft4726"></p>
<p style="position:absolute;top:324px;left:147px;white-space:nowrap" class="ft4722">neurological infections (including viral meningitis)</p>
<p style="position:absolute;top:343px;left:106px;white-space:nowrap" class="ft4726"></p>
<p style="position:absolute;top:345px;left:147px;white-space:nowrap" class="ft4722">eye&#160;infections</p>
<p style="position:absolute;top:363px;left:106px;white-space:nowrap" class="ft4726"></p>
<p style="position:absolute;top:365px;left:147px;white-space:nowrap" class="ft4722">bacterial infections</p>
<p style="position:absolute;top:383px;left:106px;white-space:nowrap" class="ft4726"></p>
<p style="position:absolute;top:385px;left:147px;white-space:nowrap" class="ft4722">diverticulitis (inflammation and infection of the large intestine)</p>
<p style="position:absolute;top:403px;left:106px;white-space:nowrap" class="ft4726"></p>
<p style="position:absolute;top:405px;left:147px;white-space:nowrap" class="ft4722">cancer</p>
<p style="position:absolute;top:423px;left:106px;white-space:nowrap" class="ft4726"></p>
<p style="position:absolute;top:425px;left:147px;white-space:nowrap" class="ft4722">cancer that affects the lymph system</p>
<p style="position:absolute;top:443px;left:106px;white-space:nowrap" class="ft4726"></p>
<p style="position:absolute;top:445px;left:147px;white-space:nowrap" class="ft4722">melanoma</p>
<p style="position:absolute;top:464px;left:106px;white-space:nowrap" class="ft4726"></p>
<p style="position:absolute;top:465px;left:147px;white-space:nowrap" class="ft4724">immune disorders that could affect the lungs, skin and lymph nodes (most commonly presenting as&#160;<br/>sarcoidosis)</p>
<p style="position:absolute;top:502px;left:106px;white-space:nowrap" class="ft4726"></p>
<p style="position:absolute;top:504px;left:147px;white-space:nowrap" class="ft4722">vasculitis (inflammation of blood vessels)</p>
<p style="position:absolute;top:523px;left:106px;white-space:nowrap" class="ft4726"></p>
<p style="position:absolute;top:525px;left:147px;white-space:nowrap" class="ft4722">tremor (shaking)</p>
<p style="position:absolute;top:543px;left:106px;white-space:nowrap" class="ft4726"></p>
<p style="position:absolute;top:545px;left:147px;white-space:nowrap" class="ft4722">neuropathy (disorder of the nerves)</p>
<p style="position:absolute;top:563px;left:106px;white-space:nowrap" class="ft4726"></p>
<p style="position:absolute;top:565px;left:147px;white-space:nowrap" class="ft4722">stroke</p>
<p style="position:absolute;top:583px;left:106px;white-space:nowrap" class="ft4726"></p>
<p style="position:absolute;top:585px;left:147px;white-space:nowrap" class="ft4722">hearing loss, buzzing</p>
<p style="position:absolute;top:603px;left:106px;white-space:nowrap" class="ft4726"></p>
<p style="position:absolute;top:605px;left:147px;white-space:nowrap" class="ft4722">sensation of heart beating irregularly such as skipped beats</p>
<p style="position:absolute;top:623px;left:106px;white-space:nowrap" class="ft4726"></p>
<p style="position:absolute;top:625px;left:147px;white-space:nowrap" class="ft4722">heart problems that can cause shortness of breath or&#160;ankle swelling</p>
<p style="position:absolute;top:644px;left:106px;white-space:nowrap" class="ft4726"></p>
<p style="position:absolute;top:645px;left:147px;white-space:nowrap" class="ft4722">heart attack</p>
<p style="position:absolute;top:664px;left:106px;white-space:nowrap" class="ft4726"></p>
<p style="position:absolute;top:666px;left:147px;white-space:nowrap" class="ft4722">a sac in the wall of a major artery, inflammation and clot of a vein, blockage of a blood vessel</p>
<p style="position:absolute;top:684px;left:106px;white-space:nowrap" class="ft4726"></p>
<p style="position:absolute;top:686px;left:147px;white-space:nowrap" class="ft4722">lung diseases causing shortness of breath (including inflammation)</p>
<p style="position:absolute;top:704px;left:106px;white-space:nowrap" class="ft4726"></p>
<p style="position:absolute;top:706px;left:147px;white-space:nowrap" class="ft4722">pulmonary embolism (blockage in an artery of the lung)</p>
<p style="position:absolute;top:724px;left:106px;white-space:nowrap" class="ft4726"></p>
<p style="position:absolute;top:726px;left:147px;white-space:nowrap" class="ft4722">pleural effusion (abnormal collection of fluid in the pleural space)</p>
<p style="position:absolute;top:744px;left:106px;white-space:nowrap" class="ft4726"></p>
<p style="position:absolute;top:746px;left:147px;white-space:nowrap" class="ft4722">inflammation of the pancreas which causes severe pain in the abdomen and back</p>
<p style="position:absolute;top:765px;left:106px;white-space:nowrap" class="ft4726"></p>
<p style="position:absolute;top:766px;left:147px;white-space:nowrap" class="ft4722">difficulty in swallowing</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft4726"></p>
<p style="position:absolute;top:787px;left:147px;white-space:nowrap" class="ft4722">facial oedema (swelling of the face)</p>
<p style="position:absolute;top:805px;left:106px;white-space:nowrap" class="ft4726"></p>
<p style="position:absolute;top:807px;left:147px;white-space:nowrap" class="ft4722">gallbladder inflammation, gallbladder stones</p>
<p style="position:absolute;top:825px;left:106px;white-space:nowrap" class="ft4726"></p>
<p style="position:absolute;top:827px;left:147px;white-space:nowrap" class="ft4722">fatty liver</p>
<p style="position:absolute;top:845px;left:106px;white-space:nowrap" class="ft4726"></p>
<p style="position:absolute;top:847px;left:147px;white-space:nowrap" class="ft4722">night sweats</p>
<p style="position:absolute;top:865px;left:106px;white-space:nowrap" class="ft4726"></p>
<p style="position:absolute;top:867px;left:147px;white-space:nowrap" class="ft4722">scar</p>
<p style="position:absolute;top:886px;left:106px;white-space:nowrap" class="ft4726"></p>
<p style="position:absolute;top:887px;left:147px;white-space:nowrap" class="ft4722">abnormal&#160;muscle breakdown</p>
<p style="position:absolute;top:906px;left:106px;white-space:nowrap" class="ft4726"></p>
<p style="position:absolute;top:908px;left:147px;white-space:nowrap" class="ft4724">systemic lupus erythematosus (including inflammation of skin, heart, lung, joints and other organ&#160;<br/>systems)</p>
<p style="position:absolute;top:945px;left:106px;white-space:nowrap" class="ft4726"></p>
<p style="position:absolute;top:947px;left:147px;white-space:nowrap" class="ft4722">sleep interruptions</p>
<p style="position:absolute;top:965px;left:106px;white-space:nowrap" class="ft4726"></p>
<p style="position:absolute;top:967px;left:147px;white-space:nowrap" class="ft4722">impotence</p>
<p style="position:absolute;top:985px;left:106px;white-space:nowrap" class="ft4726"></p>
<p style="position:absolute;top:987px;left:147px;white-space:nowrap" class="ft4722">inflammations</p>
<p style="position:absolute;top:1025px;left:106px;white-space:nowrap" class="ft4721"><b>Rare&#160;</b>(may affect up to 1 in 1,000 people)</p>
<p style="position:absolute;top:1062px;left:106px;white-space:nowrap" class="ft4726"></p>
<p style="position:absolute;top:1064px;left:147px;white-space:nowrap" class="ft4722">leukaemia&#160;(cancer affecting the blood and bone marrow)</p>
</div>
<!-- Page 473 -->
<a name="473"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page473-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4730">473</p>
<p style="position:absolute;top:85px;left:106px;white-space:nowrap" class="ft4736"></p>
<p style="position:absolute;top:87px;left:147px;white-space:nowrap" class="ft4732">severe allergic reaction with shock</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft4736"></p>
<p style="position:absolute;top:107px;left:147px;white-space:nowrap" class="ft4732">multiple sclerosis</p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft4736"></p>
<p style="position:absolute;top:127px;left:147px;white-space:nowrap" class="ft4734">nerve disorders (such as eye nerve inflammation and Guillain-Barré syndrome that may cause&#160;<br/>muscle weakness, abnormal sensations, tingling in the arms and upper body)</p>
<p style="position:absolute;top:165px;left:106px;white-space:nowrap" class="ft4736"></p>
<p style="position:absolute;top:167px;left:147px;white-space:nowrap" class="ft4732">heart stops pumping</p>
<p style="position:absolute;top:185px;left:106px;white-space:nowrap" class="ft4736"></p>
<p style="position:absolute;top:187px;left:147px;white-space:nowrap" class="ft4732">pulmonary fibrosis (scarring of the lung)</p>
<p style="position:absolute;top:205px;left:106px;white-space:nowrap" class="ft4736"></p>
<p style="position:absolute;top:207px;left:147px;white-space:nowrap" class="ft4732">intestinal perforation (hole in the intestine)</p>
<p style="position:absolute;top:225px;left:106px;white-space:nowrap" class="ft4736"></p>
<p style="position:absolute;top:227px;left:147px;white-space:nowrap" class="ft4732">hepatitis</p>
<p style="position:absolute;top:245px;left:106px;white-space:nowrap" class="ft4736"></p>
<p style="position:absolute;top:247px;left:147px;white-space:nowrap" class="ft4732">reactivation of hepatitis B</p>
<p style="position:absolute;top:266px;left:106px;white-space:nowrap" class="ft4736"></p>
<p style="position:absolute;top:267px;left:147px;white-space:nowrap" class="ft4732">autoimmune hepatitis (inflammation of the liver caused by the body's own immune system)</p>
<p style="position:absolute;top:286px;left:106px;white-space:nowrap" class="ft4736"></p>
<p style="position:absolute;top:288px;left:147px;white-space:nowrap" class="ft4732">cutaneous vasculitis (inflammation of blood vessels in the skin)</p>
<p style="position:absolute;top:306px;left:106px;white-space:nowrap" class="ft4736"></p>
<p style="position:absolute;top:308px;left:147px;white-space:nowrap" class="ft4732">Stevens-Johnson syndrome (early symptoms include malaise, fever, headache and rash)</p>
<p style="position:absolute;top:326px;left:106px;white-space:nowrap" class="ft4736"></p>
<p style="position:absolute;top:328px;left:147px;white-space:nowrap" class="ft4732">facial oedema (swelling of the face) associated with allergic reactions</p>
<p style="position:absolute;top:346px;left:106px;white-space:nowrap" class="ft4736"></p>
<p style="position:absolute;top:348px;left:147px;white-space:nowrap" class="ft4732">erythema multiforme (inflammatory skin rash)</p>
<p style="position:absolute;top:366px;left:106px;white-space:nowrap" class="ft4736"></p>
<p style="position:absolute;top:368px;left:147px;white-space:nowrap" class="ft4732">lupus-like syndrome</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft4736"></p>
<p style="position:absolute;top:388px;left:147px;white-space:nowrap" class="ft4732">angioedema (localized swelling of the skin)</p>
<p style="position:absolute;top:407px;left:106px;white-space:nowrap" class="ft4736"></p>
<p style="position:absolute;top:409px;left:147px;white-space:nowrap" class="ft4732">lichenoid skin reaction (itchy reddish-purple skin&#160;rash)</p>
<p style="position:absolute;top:446px;left:106px;white-space:nowrap" class="ft4731"><b>Not known&#160;</b>(frequency cannot be estimated from the available data)</p>
<p style="position:absolute;top:484px;left:106px;white-space:nowrap" class="ft4736">&#160;hepatosplenic T-cell lymphoma (a rare blood cancer that is often&#160;fatal)</p>
<p style="position:absolute;top:504px;left:106px;white-space:nowrap" class="ft4736">&#160;Merkel cell carcinoma (a type of skin cancer)</p>
<p style="position:absolute;top:524px;left:106px;white-space:nowrap" class="ft4736">&#160;Kaposi’s sarcoma, a rare cancer related to infection with human herpes virus 8. Kaposi’s sarcoma&#160;</p>
<p style="position:absolute;top:545px;left:133px;white-space:nowrap" class="ft4732">most commonly appears as purple lesions on the skin</p>
<p style="position:absolute;top:563px;left:106px;white-space:nowrap" class="ft4736">&#160;liver failure</p>
<p style="position:absolute;top:583px;left:106px;white-space:nowrap" class="ft4736">&#160;worsening of a condition called dermatomyositis (seen as a skin rash accompanying muscle weakness)</p>
<p style="position:absolute;top:603px;left:106px;white-space:nowrap" class="ft4736">&#160;weight gain (for most patients, the weight gain was small)</p>
<p style="position:absolute;top:643px;left:106px;white-space:nowrap" class="ft4734">Some side effects observed with Humira may not have symptoms and may only be discovered through&#160;<br/>blood tests. These include:</p>
<p style="position:absolute;top:700px;left:106px;white-space:nowrap" class="ft4731"><b>Very common&#160;</b>(may&#160;affect more than 1 in 10 people)</p>
<p style="position:absolute;top:738px;left:106px;white-space:nowrap" class="ft4736"></p>
<p style="position:absolute;top:739px;left:147px;white-space:nowrap" class="ft4732">low blood measurements for white blood cells</p>
<p style="position:absolute;top:758px;left:106px;white-space:nowrap" class="ft4736"></p>
<p style="position:absolute;top:760px;left:147px;white-space:nowrap" class="ft4732">low blood measurements for red blood cells</p>
<p style="position:absolute;top:778px;left:106px;white-space:nowrap" class="ft4736"></p>
<p style="position:absolute;top:780px;left:147px;white-space:nowrap" class="ft4732">increased lipids in the blood</p>
<p style="position:absolute;top:798px;left:106px;white-space:nowrap" class="ft4736"></p>
<p style="position:absolute;top:800px;left:147px;white-space:nowrap" class="ft4732">elevated liver enzymes</p>
<p style="position:absolute;top:838px;left:106px;white-space:nowrap" class="ft4731"><b>Common&#160;</b>(may&#160;affect up to 1 in 10 people)</p>
<p style="position:absolute;top:875px;left:106px;white-space:nowrap" class="ft4736"></p>
<p style="position:absolute;top:877px;left:147px;white-space:nowrap" class="ft4732">high blood measurements for white&#160;blood cells</p>
<p style="position:absolute;top:895px;left:106px;white-space:nowrap" class="ft4736"></p>
<p style="position:absolute;top:897px;left:147px;white-space:nowrap" class="ft4732">low blood measurements for platelets</p>
<p style="position:absolute;top:915px;left:106px;white-space:nowrap" class="ft4736"></p>
<p style="position:absolute;top:917px;left:147px;white-space:nowrap" class="ft4732">increased uric acid in the blood</p>
<p style="position:absolute;top:936px;left:106px;white-space:nowrap" class="ft4736"></p>
<p style="position:absolute;top:937px;left:147px;white-space:nowrap" class="ft4732">abnormal blood measurements for sodium</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft4736"></p>
<p style="position:absolute;top:958px;left:147px;white-space:nowrap" class="ft4732">low blood measurements for calcium</p>
<p style="position:absolute;top:976px;left:106px;white-space:nowrap" class="ft4736"></p>
<p style="position:absolute;top:978px;left:147px;white-space:nowrap" class="ft4732">low blood measurements for phosphate</p>
<p style="position:absolute;top:996px;left:106px;white-space:nowrap" class="ft4736"></p>
<p style="position:absolute;top:998px;left:147px;white-space:nowrap" class="ft4732">high blood sugar</p>
<p style="position:absolute;top:1016px;left:106px;white-space:nowrap" class="ft4736"></p>
<p style="position:absolute;top:1018px;left:147px;white-space:nowrap" class="ft4732">high blood measurements for lactate dehydrogenase</p>
<p style="position:absolute;top:1036px;left:106px;white-space:nowrap" class="ft4736"></p>
<p style="position:absolute;top:1038px;left:147px;white-space:nowrap" class="ft4732">autoantibodies present in the blood</p>
<p style="position:absolute;top:1057px;left:106px;white-space:nowrap" class="ft4736"></p>
<p style="position:absolute;top:1058px;left:147px;white-space:nowrap" class="ft4732">low blood potassium</p>
</div>
<!-- Page 474 -->
<a name="474"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page474-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4740">474</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft4741"><b>Uncommon&#160;</b>(may&#160;affect up to 1 in 100 people)&#160;</p>
<p style="position:absolute;top:123px;left:106px;white-space:nowrap" class="ft4746"></p>
<p style="position:absolute;top:125px;left:147px;white-space:nowrap" class="ft4742">elevated bilirubin measurement (liver blood test)</p>
<p style="position:absolute;top:163px;left:106px;white-space:nowrap" class="ft4741"><b>Rare&#160;</b>(may affect up to 1 in 1,000 people)</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft4746"></p>
<p style="position:absolute;top:202px;left:147px;white-space:nowrap" class="ft4742">low blood measurements for white blood cells, red&#160;blood cells and platelet count</p>
<p style="position:absolute;top:240px;left:106px;white-space:nowrap" class="ft4744"><b>Reporting of side effects<br/></b>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not&#160;<br/>listed in this leaflet.&#160;You can also report side effects directly via&#160;the national reporting system listed in&#160;<br/><a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix V.&#160;</a>By reporting side effects, you can help provide more information on the safety&#160;of this&#160;<br/>medicine.</p>
<p style="position:absolute;top:373px;left:106px;white-space:nowrap" class="ft4741"><b>5.</b></p>
<p style="position:absolute;top:373px;left:148px;white-space:nowrap" class="ft4741"><b>How to store Humira</b></p>
<p style="position:absolute;top:411px;left:106px;white-space:nowrap" class="ft4742">Keep this medicine out of the sight and reach of children.&#160;</p>
<p style="position:absolute;top:449px;left:106px;white-space:nowrap" class="ft4742">Do not use this medicine after the expiry date stated on&#160;the label/blister/carton after EXP.&#160;</p>
<p style="position:absolute;top:488px;left:106px;white-space:nowrap" class="ft4742">Store in a refrigerator (2</p>
<p style="position:absolute;top:486px;left:266px;white-space:nowrap" class="ft4746">C&#160;–&#160;8C). Do not freeze.&#160;</p>
<p style="position:absolute;top:526px;left:106px;white-space:nowrap" class="ft4742">Keep the pre-filled pen in the outer carton in order to protect from light. &#160;</p>
<p style="position:absolute;top:564px;left:106px;white-space:nowrap" class="ft4742">Alternative Storage:</p>
<p style="position:absolute;top:602px;left:106px;white-space:nowrap" class="ft47419">When needed (for example, when you are travelling), a single Humira pre-filled pen may be stored at&#160;<br/>room temperature (up to 25°C) for a maximum period of 14 days&#160;–&#160;be sure to protect it from light. Once&#160;<br/>removed from the refrigerator for room temperature storage, the pen&#160;<b>must be used within 14 days&#160;or&#160;<br/>discarded</b>, even if it is returned to the refrigerator. &#160;</p>
<p style="position:absolute;top:697px;left:106px;white-space:nowrap" class="ft4744">You should record the date when the pen is first removed from refrigerator and the date after which it&#160;<br/>should be discarded.</p>
<p style="position:absolute;top:753px;left:106px;white-space:nowrap" class="ft4744">Do not throw away any medicines via wastewater or household waste. Ask your doctor or pharmacist how&#160;<br/>to throw away medicines you no longer use. These measures will help protect the environment.</p>
<p style="position:absolute;top:829px;left:106px;white-space:nowrap" class="ft4741"><b>6.</b></p>
<p style="position:absolute;top:829px;left:148px;white-space:nowrap" class="ft4741"><b>Contents of the pack and other information</b></p>
<p style="position:absolute;top:868px;left:106px;white-space:nowrap" class="ft4741"><b>What Humira contains</b></p>
<p style="position:absolute;top:905px;left:106px;white-space:nowrap" class="ft4744">The active substance is adalimumab.<br/>The&#160;other ingredients are mannitol, polysorbate 80 and water for injections.</p>
</div>
<!-- Page 475 -->
<a name="475"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page475-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4750">475</p>
<p style="position:absolute;top:86px;left:106px;white-space:nowrap" class="ft4751"><b>What the Humira pre-filled pen looks like and contents of the pack</b></p>
<p style="position:absolute;top:124px;left:106px;white-space:nowrap" class="ft4754">Humira 80&#160;mg solution for injection in pre-filled pen is supplied as a sterile solution of 80&#160;mg adalimumab&#160;<br/>dissolved in 0.8&#160;ml solution.</p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft4754">The Humira pre-filled pen is a single-use grey and plum-coloured pen which contains a glass syringe with&#160;<br/>Humira. There are two caps&#160;–&#160;one is grey and labelled ‘1’ and the other is plum and labelled ‘2’. There&#160;is a&#160;<br/>window on each side of the pen through which you can see the Humira solution inside the syringe.</p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft4752">The Humira pre-filled pen is available in packs&#160;containing:</p>
<p style="position:absolute;top:275px;left:133px;white-space:nowrap" class="ft4756">&#160;1&#160;pre-filled pen&#160;for patient use&#160;with 2 alcohol pads (1 spare)</p>
<p style="position:absolute;top:295px;left:133px;white-space:nowrap" class="ft4756">&#160;3 pre-filled pens for patient&#160;use with 4 alcohol pads (1 spare)</p>
<p style="position:absolute;top:335px;left:106px;white-space:nowrap" class="ft4752">Not all pack sizes may be marketed.</p>
<p style="position:absolute;top:392px;left:106px;white-space:nowrap" class="ft4752">Humira may be available as a vial, a pre-filled syringe and/or a pre-filled pen.</p>
<p style="position:absolute;top:430px;left:106px;white-space:nowrap" class="ft4751"><b>Marketing Authorisation Holder</b></p>
<p style="position:absolute;top:468px;left:106px;white-space:nowrap" class="ft4754">AbbVie Deutschland GmbH &amp; Co. KG<br/>Knollstrasse<br/>67061 Ludwigshafen<br/>Germany</p>
<p style="position:absolute;top:563px;left:106px;white-space:nowrap" class="ft4751"><b>Manufacturer&#160;</b></p>
<p style="position:absolute;top:600px;left:106px;white-space:nowrap" class="ft4755">AbbVie Biotechnology GmbH<br/>Knollstrasse<br/>67061 Ludwigshafen<br/>Germany</p>
<p style="position:absolute;top:696px;left:106px;white-space:nowrap" class="ft4754">For any information about this medicine, please contact the local representative of the Marketing&#160;<br/>Authorisation Holder:</p>
<p style="position:absolute;top:754px;left:114px;white-space:nowrap" class="ft4754"><b>België/Belgique/Belgien<br/></b>AbbVie SA<br/>Tél/Tel: +32 10&#160;&#160;477811</p>
<p style="position:absolute;top:754px;left:462px;white-space:nowrap" class="ft4754"><b>Lietuva<br/></b>AbbVie UAB&#160;<br/>Tel: +370 5 205 3023</p>
<p style="position:absolute;top:831px;left:114px;white-space:nowrap" class="ft4754"><b>България<br/></b>АбВи ЕООД<br/>Тел.:+359 2 90 30 430</p>
<p style="position:absolute;top:831px;left:462px;white-space:nowrap" class="ft4754"><b>Luxembourg/Luxemburg<br/></b>AbbVie SA<br/>Belgique/Belgien<br/>Tél/Tel: +32 10 477811</p>
<p style="position:absolute;top:926px;left:114px;white-space:nowrap" class="ft4755"><b>Česká republika<br/></b>AbbVie s.r.o.&#160;<br/>Tel: +420 233 098 111</p>
<p style="position:absolute;top:926px;left:462px;white-space:nowrap" class="ft4755"><b>Magyarország<br/></b>AbbVie&#160;Kft.<br/>Tel.:+36 1 455 8600</p>
<p style="position:absolute;top:1002px;left:114px;white-space:nowrap" class="ft4755"><b>Danmark<br/></b>AbbVie A/S<br/>Tlf: +45 72 30-20-28</p>
<p style="position:absolute;top:1002px;left:462px;white-space:nowrap" class="ft4755"><b>Malta<br/></b>V.J.Salomone Pharma Limited&#160;<br/>Tel: +356 22983201</p>
</div>
<!-- Page 476 -->
<a name="476"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page476-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4760">476</p>
<p style="position:absolute;top:86px;left:114px;white-space:nowrap" class="ft4764"><b>Deutschland<br/></b>AbbVie Deutschland&#160;GmbH &amp; Co. KG<br/>Tel: 00800 222843 33 (gebührenfrei)<br/>Tel: +49 (0) 611&#160;/&#160;1720-0</p>
<p style="position:absolute;top:86px;left:462px;white-space:nowrap" class="ft4764"><b>Nederland<br/></b>AbbVie B.V.<br/>Tel:&#160;&#160;+31 (0)88 322 2843</p>
<p style="position:absolute;top:181px;left:114px;white-space:nowrap" class="ft4764"><b>Eesti<br/></b>AbbVie&#160;OÜ<br/>Tel: +372 623 1011</p>
<p style="position:absolute;top:181px;left:462px;white-space:nowrap" class="ft4764"><b>Norge<br/></b>AbbVie AS<br/>Tlf: +47 67 81 80 00</p>
<p style="position:absolute;top:257px;left:114px;white-space:nowrap" class="ft4764"><b>Ελλάδα<br/></b>AbbVie&#160;ΦΑΡΜΑΚΕΥΤΙΚΗ Α.Ε.<br/>Τηλ: +30&#160;214 4165 555</p>
<p style="position:absolute;top:257px;left:462px;white-space:nowrap" class="ft4764"><b>Österreich<br/></b>AbbVie GmbH&#160;<br/>Tel: +43 1 20589-0</p>
<p style="position:absolute;top:324px;left:114px;white-space:nowrap" class="ft4764"><b>España<br/></b>AbbVie Spain, S.L.U.<br/>Tel: &#160;+34 91 384 09 10</p>
<p style="position:absolute;top:324px;left:462px;white-space:nowrap" class="ft4764"><b>Polska<br/></b>AbbVie Sp. z o.o.<br/>Tel.: +48 22&#160;372 78 00&#160;</p>
<p style="position:absolute;top:400px;left:114px;white-space:nowrap" class="ft4764"><b>France<br/></b>AbbVie<br/>Tél: +33 (0) 1 45 60 13 00</p>
<p style="position:absolute;top:400px;left:462px;white-space:nowrap" class="ft4764"><b>Portugal<br/></b>AbbVie, Lda.&#160;<br/>Tel: +351 (0)21 1908400</p>
<p style="position:absolute;top:476px;left:114px;white-space:nowrap" class="ft4764"><b>Hrvatska&#160;<br/></b>AbbVie d.o.o.<br/>Tel + 385 (0)1&#160;5625 501</p>
<p style="position:absolute;top:476px;left:462px;white-space:nowrap" class="ft4764"><b>România<br/></b>AbbVie S.R.L.<br/>Tel: +40 21 529 30 35</p>
<p style="position:absolute;top:552px;left:114px;white-space:nowrap" class="ft4764"><b>Ireland<br/></b>AbbVie Limited&#160;<br/>Tel:&#160;+353 (0)1 4287900</p>
<p style="position:absolute;top:552px;left:462px;white-space:nowrap" class="ft4764"><b>Slovenija<br/></b>AbbVie Biofarmacevtska družba d.o.o.<br/>Tel: +386 (1)32 08 060</p>
<p style="position:absolute;top:627px;left:114px;white-space:nowrap" class="ft4765"><b>Ísland<br/></b>Vistor hf.<br/>Tel: +354 535 7000</p>
<p style="position:absolute;top:627px;left:462px;white-space:nowrap" class="ft4765"><b>Slovenská republika<br/></b>AbbVie s.r.o.<br/>Tel: +421 2 5050 0777</p>
<p style="position:absolute;top:703px;left:114px;white-space:nowrap" class="ft4764"><b>Italia<br/></b>AbbVie S.r.l.&#160;<br/>Tel: +39 06 928921</p>
<p style="position:absolute;top:703px;left:462px;white-space:nowrap" class="ft4765"><b>Suomi/Finland<br/></b>AbbVie Oy&#160;<br/>Puh/Tel: &#160;+358 (0)10 2411 200</p>
<p style="position:absolute;top:781px;left:114px;white-space:nowrap" class="ft4765"><b>Κύπρος<br/></b>Lifepharma (Z.A.M.) Ltd<br/>Τηλ.: +357 22 34 74 40</p>
<p style="position:absolute;top:781px;left:462px;white-space:nowrap" class="ft4765"><b>Sverige<br/></b>AbbVie AB<br/>Tel: &#160;+46 (0)8 684 44 600</p>
<p style="position:absolute;top:857px;left:114px;white-space:nowrap" class="ft4765"><b>Latvija<br/></b>AbbVie SIA&#160;<br/>Tel: +371 67605000</p>
<p style="position:absolute;top:857px;left:462px;white-space:nowrap" class="ft4765"><b>United Kingdom&#160;(Northern Ireland)<br/></b>AbbVie Deutschland GmbH &amp; Co. KG<br/>Tel: +44 (0)1628&#160;561090</p>
<p style="position:absolute;top:942px;left:106px;white-space:nowrap" class="ft4761"><b>This leaflet was last revised in</b></p>
<p style="position:absolute;top:980px;left:106px;white-space:nowrap" class="ft4765">Detailed information on this medicine is available on the European Medicines Agency web site:&#160;<br/><a href="http://www.ema.europa.eu/">http://www.ema.europa.eu.</a></p>
<p style="position:absolute;top:1037px;left:106px;white-space:nowrap" class="ft47619"><b>To listen to or request a copy of this leaflet in&#160;&lt;Braille&gt;, &lt;large print&gt; or &lt;audio&gt;, please contact the&#160;<br/>local representative of the Marketing Authorisation Holder.</b></p>
</div>
<!-- Page 477 -->
<a name="477"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page477-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4770">477</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft4771"><b>7.&#160;</b></p>
<p style="position:absolute;top:105px;left:148px;white-space:nowrap" class="ft4771"><b>Injecting Humira</b></p>
<p style="position:absolute;top:144px;left:133px;white-space:nowrap" class="ft4776">&#160;The following instructions explain how to give yourself a subcutaneous injection of Humira using&#160;</p>
<p style="position:absolute;top:165px;left:160px;white-space:nowrap" class="ft4772">the pre-filled pen. First read all the instructions carefully and then follow them step by step.&#160;</p>
<p style="position:absolute;top:202px;left:133px;white-space:nowrap" class="ft4776">&#160;You will be instructed by your doctor, nurse or pharmacist on the technique of self-injection.&#160;</p>
<p style="position:absolute;top:241px;left:133px;white-space:nowrap" class="ft4776">&#160;Do not attempt to self-inject until you are sure that you understand how to prepare and give the&#160;</p>
<p style="position:absolute;top:262px;left:160px;white-space:nowrap" class="ft4772">injection.&#160;</p>
<p style="position:absolute;top:299px;left:133px;white-space:nowrap" class="ft4776">&#160;After proper training, the injection can be given by yourself or given by another person, for&#160;</p>
<p style="position:absolute;top:320px;left:160px;white-space:nowrap" class="ft4772">example, a family member or friend.</p>
<p style="position:absolute;top:358px;left:133px;white-space:nowrap" class="ft4776">&#160;Only use each pre-filled pen for one injection.</p>
<p style="position:absolute;top:397px;left:106px;white-space:nowrap" class="ft4771"><b>Humira Pre-filled Pen</b></p>
<p style="position:absolute;top:436px;left:106px;white-space:nowrap" class="ft4771"><b>&#160; &#160;Grey Cap 1 &#160; &#160; White Needle Sleeve &#160; &#160;White Arrow &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;Plum-coloured Cap 2</b></p>
<p style="position:absolute;top:624px;left:106px;white-space:nowrap" class="ft47715"><b>&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160;Needle &#160; &#160; &#160; &#160; &#160; Inspection Window &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;Plum Activator Button &#160; &#160;&#160;<br/>&#160; &#160; &#160; &#160; &#160; &#160;<br/>Do not use the pre-filled pen and call your doctor or pharmacist if the</b></p>
<p style="position:absolute;top:699px;left:133px;white-space:nowrap" class="ft4776">&#160;liquid is cloudy, discoloured, or has flakes or particles in it</p>
<p style="position:absolute;top:719px;left:133px;white-space:nowrap" class="ft4776">&#160;expiry (EXP) date has passed</p>
<p style="position:absolute;top:739px;left:133px;white-space:nowrap" class="ft4776">&#160;liquid has been frozen or&#160;left in direct sunlight</p>
<p style="position:absolute;top:759px;left:133px;white-space:nowrap" class="ft4776">&#160;pre-filled pen has been dropped or crushed</p>
<p style="position:absolute;top:799px;left:106px;white-space:nowrap" class="ft47719"><b>Do not remove the caps until just before injection. Keep Humira out of the sight and reach of&#160;<br/>children.</b></p>
<p style="position:absolute;top:857px;left:114px;white-space:nowrap" class="ft4771"><b>STEP 1</b></p>
<p style="position:absolute;top:895px;left:114px;white-space:nowrap" class="ft4772">Take Humira out of the refrigerator.</p>
<p style="position:absolute;top:932px;left:114px;white-space:nowrap" class="ft4772">Leave Humira at room temperature for&#160;<b>15 to 30 minutes&#160;</b>before injecting.</p>
<p style="position:absolute;top:970px;left:141px;white-space:nowrap" class="ft4776">&#160;<b>Do not&#160;</b>remove the Grey or Plum-coloured Caps while allowing Humira to reach room&#160;</p>
<p style="position:absolute;top:991px;left:168px;white-space:nowrap" class="ft4772">temperature</p>
<p style="position:absolute;top:1009px;left:141px;white-space:nowrap" class="ft4776">&#160;<b>Do not&#160;</b>warm Humira in any other way. For example,&#160;<b>do not&#160;</b>warm it in a microwave or in hot&#160;</p>
<p style="position:absolute;top:1030px;left:168px;white-space:nowrap" class="ft4772">water</p>
</div>
<!-- Page 478 -->
<a name="478"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page478-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4780">478</p>
<p style="position:absolute;top:87px;left:114px;white-space:nowrap" class="ft4781"><b>STEP 2&#160;</b></p>
<p style="position:absolute;top:125px;left:114px;white-space:nowrap" class="ft4782">&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;<b>Pen</b></p>
<p style="position:absolute;top:435px;left:114px;white-space:nowrap" class="ft4781"><b>&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160;Pad</b></p>
<p style="position:absolute;top:106px;left:392px;white-space:nowrap" class="ft4785">Check expiry (EXP) date.&#160;<b>Do not&#160;</b>use the pre-filled pen if&#160;<br/>expiry (EXP) date has passed.</p>
<p style="position:absolute;top:163px;left:392px;white-space:nowrap" class="ft4782">Place the following on a clean, flat surface</p>
<p style="position:absolute;top:200px;left:422px;white-space:nowrap" class="ft4786">&#160;1 single-use pre-filled pen and&#160;</p>
<p style="position:absolute;top:220px;left:422px;white-space:nowrap" class="ft4786">&#160;1 alcohol pad</p>
<p style="position:absolute;top:260px;left:392px;white-space:nowrap" class="ft4782">Wash and dry your hands.</p>
<p style="position:absolute;top:455px;left:114px;white-space:nowrap" class="ft4781"><b>STEP 3</b></p>
<p style="position:absolute;top:493px;left:114px;white-space:nowrap" class="ft4781"><b>Injectable Areas</b></p>
<p style="position:absolute;top:793px;left:114px;white-space:nowrap" class="ft4782">&#160; &#160; &#160;<b>Injectable Areas</b></p>
<p style="position:absolute;top:474px;left:392px;white-space:nowrap" class="ft4782">Choose an injection site:</p>
<p style="position:absolute;top:511px;left:422px;white-space:nowrap" class="ft4786">&#160;On the front of your thighs or</p>
<p style="position:absolute;top:531px;left:422px;white-space:nowrap" class="ft4786">&#160;Your belly (abdomen) at least 5 cm from your belly&#160;</p>
<p style="position:absolute;top:552px;left:449px;white-space:nowrap" class="ft4782">button (navel)</p>
<p style="position:absolute;top:570px;left:422px;white-space:nowrap" class="ft4786">&#160;At least 3 cm from your last injection site</p>
<p style="position:absolute;top:610px;left:392px;white-space:nowrap" class="ft4784">Wipe the injection site in a circular motion with the alcohol&#160;<br/>pad.</p>
<p style="position:absolute;top:666px;left:422px;white-space:nowrap" class="ft4786">&#160;<b>Do not&#160;</b>inject through clothes</p>
<p style="position:absolute;top:686px;left:422px;white-space:nowrap" class="ft4786">&#160;<b>Do not&#160;</b>inject into skin that is sore, bruised, red,&#160;</p>
<p style="position:absolute;top:707px;left:449px;white-space:nowrap" class="ft4784">hard, scarred, has stretch marks, or areas with&#160;<br/>psoriasis plaques</p>
</div>
<!-- Page 479 -->
<a name="479"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page479-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4790">479</p>
<p style="position:absolute;top:87px;left:114px;white-space:nowrap" class="ft4791"><b>STEP 4</b></p>
<p style="position:absolute;top:106px;left:392px;white-space:nowrap" class="ft4792">Hold the pre-filled pen with the Grey Cap 1 pointing up.&#160;</p>
<p style="position:absolute;top:144px;left:392px;white-space:nowrap" class="ft4792">Check the inspection window.</p>
<p style="position:absolute;top:181px;left:422px;white-space:nowrap" class="ft4796">&#160;It is normal to see 1 or more bubbles in the window</p>
<p style="position:absolute;top:201px;left:422px;white-space:nowrap" class="ft4796">&#160;Make sure the liquid is clear and colourless</p>
<p style="position:absolute;top:221px;left:422px;white-space:nowrap" class="ft4796">&#160;<b>Do not&#160;</b>use the pre-filled pen if the liquid is cloudy&#160;</p>
<p style="position:absolute;top:242px;left:449px;white-space:nowrap" class="ft4792">or has particles</p>
<p style="position:absolute;top:260px;left:422px;white-space:nowrap" class="ft4796">&#160;<b>Do not&#160;</b>use the pre-filled pen if it has been dropped&#160;</p>
<p style="position:absolute;top:281px;left:449px;white-space:nowrap" class="ft4792">or crushed</p>
<p style="position:absolute;top:368px;left:114px;white-space:nowrap" class="ft4791"><b>STEP 5</b></p>
<p style="position:absolute;top:406px;left:114px;white-space:nowrap" class="ft4791"><b>Cap 1</b></p>
<p style="position:absolute;top:644px;left:114px;white-space:nowrap" class="ft4791"><b>&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160;Cap 2</b></p>
<p style="position:absolute;top:387px;left:392px;white-space:nowrap" class="ft47919">Pull the Grey Cap 1 straight off. Throw the cap away.&#160;<b>Do&#160;<br/>not&#160;</b>recap.</p>
<p style="position:absolute;top:443px;left:423px;white-space:nowrap" class="ft4796">&#160;Check that the small black needle cover of the&#160;</p>
<p style="position:absolute;top:464px;left:450px;white-space:nowrap" class="ft4792">syringe has been removed with the cap</p>
<p style="position:absolute;top:483px;left:423px;white-space:nowrap" class="ft4796">&#160;It is normal to see a few drops of liquid come out&#160;of&#160;</p>
<p style="position:absolute;top:504px;left:450px;white-space:nowrap" class="ft4792">the needle</p>
<p style="position:absolute;top:541px;left:392px;white-space:nowrap" class="ft4794">Pull the Plum-coloured Cap 2 straight off. Throw the cap&#160;<br/>away.&#160;<b>Do not&#160;</b>recap.</p>
<p style="position:absolute;top:598px;left:392px;white-space:nowrap" class="ft4792">The pre-filled pen is now ready to use.</p>
<p style="position:absolute;top:636px;left:392px;white-space:nowrap" class="ft4795">Turn&#160;the pre-filled pen so that the white arrow points toward&#160;<br/>the injection site.</p>
<p style="position:absolute;top:675px;left:114px;white-space:nowrap" class="ft4791"><b>STEP 6</b></p>
<p style="position:absolute;top:694px;left:392px;white-space:nowrap" class="ft4795">Squeeze the skin at your&#160;injection site with your other hand&#160;<br/>to make a raised area and hold it firmly&#160;until the injection is&#160;<br/>complete.</p>
<p style="position:absolute;top:770px;left:392px;white-space:nowrap" class="ft4794">Point the white arrow toward the injection site (thigh or&#160;<br/>abdomen).</p>
<p style="position:absolute;top:827px;left:392px;white-space:nowrap" class="ft4794">Place the white needle sleeve straight&#160;<b>(90˚ angle)&#160;</b>against the&#160;<br/>injection site.</p>
<p style="position:absolute;top:884px;left:392px;white-space:nowrap" class="ft4794">Hold&#160;the pre-filled pen so that you can see the inspection&#160;<br/>window.</p>
<p style="position:absolute;top:941px;left:392px;white-space:nowrap" class="ft4794"><b>Do not&#160;</b>press the plum activator button until you are ready to&#160;<br/>inject.</p>
</div>
<!-- Page 480 -->
<a name="480"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page480-div" style="position:relative;width:918px;height:1188px;">
<p style="position:absolute;top:1121px;left:445px;white-space:nowrap" class="ft4800">480</p>
<p style="position:absolute;top:87px;left:114px;white-space:nowrap" class="ft4801"><b>STEP 7</b></p>
<p style="position:absolute;top:125px;left:114px;white-space:nowrap" class="ft4801"><b>&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;15 Seconds &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160;</b></p>
<p style="position:absolute;top:106px;left:392px;white-space:nowrap" class="ft4804"><b>Firmly&#160;push&#160;the pre-filled pen down&#160;</b>against the injection&#160;<br/>site&#160;before starting the injection.<br/><b>Keep pushing down&#160;</b>to prevent the pre-filled pen from&#160;<br/>moving away from the skin during the injection.</p>
<p style="position:absolute;top:201px;left:392px;white-space:nowrap" class="ft48019"><b>Press&#160;</b>the plum activator button and count slowly for&#160;<b>15&#160;<br/></b>seconds.</p>
<p style="position:absolute;top:257px;left:422px;white-space:nowrap" class="ft4806">&#160;A&#160;loud&#160;<b>“click”&#160;</b>will signal the start of the injection</p>
<p style="position:absolute;top:277px;left:422px;white-space:nowrap" class="ft4806">&#160;<b>Keep pushing&#160;</b>the pre-filled pen down&#160;<b>firmly&#160;</b></p>
<p style="position:absolute;top:298px;left:449px;white-space:nowrap" class="ft4804">against the injection site&#160;until the injection is&#160;<br/>complete.</p>
<p style="position:absolute;top:355px;left:392px;white-space:nowrap" class="ft4804">The injection is complete when the yellow indicator has&#160;<br/>stopped moving.</p>
<p style="position:absolute;top:478px;left:114px;white-space:nowrap" class="ft4801"><b>STEP 8</b></p>
<p style="position:absolute;top:497px;left:392px;white-space:nowrap" class="ft4805">When the&#160;injection is completed, slowly pull the pre-filled&#160;<br/>pen from the skin. The white needle sleeve will cover the&#160;<br/>needle tip.</p>
<p style="position:absolute;top:553px;left:422px;white-space:nowrap" class="ft4806">&#160;A small amount of liquid on the injection site is&#160;</p>
<p style="position:absolute;top:574px;left:449px;white-space:nowrap" class="ft4802">normal</p>
<p style="position:absolute;top:612px;left:392px;white-space:nowrap" class="ft4804">If there are more than a few drops of liquid on the injection&#160;<br/>site, contact your doctor, nurse or pharmacist.</p>
<p style="position:absolute;top:669px;left:392px;white-space:nowrap" class="ft4804">After completing the injection, place a cotton ball or gauze&#160;<br/>pad on the skin over the injection site.</p>
<p style="position:absolute;top:725px;left:422px;white-space:nowrap" class="ft4806">&#160;<b>Do not&#160;</b>rub</p>
<p style="position:absolute;top:745px;left:422px;white-space:nowrap" class="ft4806">&#160;Slight bleeding at the injection site is normal</p>
<p style="position:absolute;top:767px;left:114px;white-space:nowrap" class="ft4801"><b>STEP 9</b></p>
<p style="position:absolute;top:805px;left:114px;white-space:nowrap" class="ft4804">Throw away the used pre-filled pen in a special&#160;disposal container as instructed by your doctor, nurse&#160;<br/>or pharmacist.</p>
<p style="position:absolute;top:861px;left:141px;white-space:nowrap" class="ft4806">&#160;<b>Do not&#160;</b>recycle or throw the pre-filled pen in the household waste</p>
<p style="position:absolute;top:881px;left:141px;white-space:nowrap" class="ft4806">&#160;<b>Always&#160;</b>keep the pre-filled pen and the special disposal container out of the sight and reach of&#160;</p>
<p style="position:absolute;top:902px;left:168px;white-space:nowrap" class="ft4802">children</p>
<p style="position:absolute;top:940px;left:114px;white-space:nowrap" class="ft4805">The caps,&#160;alcohol pad, cotton ball or gauze pad, blister and packaging may be put in your household&#160;<br/>waste.</p>
</div>
<a name="outline"></a><h1>Document Outline</h1>
<ul>
<li><a href="humira-epar-product-information_en.html#1">SUMMARY OF PRODUCT CHARACTERISTICS</a></li>
<li><a href="humira-epar-product-information_en.html#265">A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE</a></li>
<li><a href="humira-epar-product-information_en.html#265">B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE</a></li>
<li><a href="humira-epar-product-information_en.html#265">C. &#160;OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION</a></li>
<li><a href="humira-epar-product-information_en.html#266">D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</a></li>
<li><a href="humira-epar-product-information_en.html#268">A. LABELLING</a></li>
<li><a href="humira-epar-product-information_en.html#317">B. PACKAGE LEAFLET</a></li>
</ul>
<hr/>
</body>
</html>
